{"docstore/data": {"f83e9682-a495-4a36-a4a8-4e014dbd92c8": {"__data__": {"id_": "f83e9682-a495-4a36-a4a8-4e014dbd92c8", "embedding": null, "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n04-Aug-2021  \nMcKesson Corp.   (MCK ) \nQ1 2022 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n04-Aug-2021  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d722b2c6-7573-48d7-9a60-f4b19a5e6cb3", "node_type": "4", "metadata": {"page_label": "1", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "efe455de270294df9c7814c802004b11805be4d1969b3fed5f84580030ea722f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ec128aed-3c4f-4f95-8b2f-d785c52e4ebb", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n04-Aug-2021  \nMcKesson Corp.   (MCK ) \nQ1 2022 Earnings Call    ", "original_text": "(MCK ) \nQ1 2022 Earnings Call    "}, "hash": "9d0967770510c3daf66fb545e7ab8c40ae4954e0f11f36f44d2b42e42979ea36", "class_name": "RelatedNodeInfo"}}, "text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n04-Aug-2021  \nMcKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 165, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ec128aed-3c4f-4f95-8b2f-d785c52e4ebb": {"__data__": {"id_": "ec128aed-3c4f-4f95-8b2f-d785c52e4ebb", "embedding": null, "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n04-Aug-2021  \nMcKesson Corp.   (MCK ) \nQ1 2022 Earnings Call    ", "original_text": "(MCK ) \nQ1 2022 Earnings Call    ", "page_label": "1", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d722b2c6-7573-48d7-9a60-f4b19a5e6cb3", "node_type": "4", "metadata": {"page_label": "1", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "efe455de270294df9c7814c802004b11805be4d1969b3fed5f84580030ea722f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f83e9682-a495-4a36-a4a8-4e014dbd92c8", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n04-Aug-2021  \nMcKesson Corp.   (MCK ) \nQ1 2022 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n04-Aug-2021  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3895a6612842a1670cd2ef8ca6ac7e8f5dd57c5e8bb79fccf2e16841c5ebdf22", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6582eba8-2152-47f3-8923-e4a7cc436a98", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A \nFinance, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "original_text": "McKesson Corp.  "}, "hash": "ae46665b834ba0e849865d4bf45b9a7ddf3ca48fa37458abc8757dea0f8f9a07", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2022 Earnings Call    ", "start_char_idx": 165, "end_char_idx": 198, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6582eba8-2152-47f3-8923-e4a7cc436a98": {"__data__": {"id_": "6582eba8-2152-47f3-8923-e4a7cc436a98", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A \nFinance, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6464c30c-9944-4870-b7fd-30474d3e4691", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "15906db17c0a214cdb7014edc7b71258980b09669b7c358d0c2d04d0357632cc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ec128aed-3c4f-4f95-8b2f-d785c52e4ebb", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n04-Aug-2021  \nMcKesson Corp.   (MCK ) \nQ1 2022 Earnings Call    ", "original_text": "(MCK ) \nQ1 2022 Earnings Call    ", "page_label": "1", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1f7b0b3621ffed0e7a505efb83c1cf05380684d50f6b37ef63d72ae22be5bd39", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c16b6ac7-9fb5-44b6-897c-c8bbbc105df6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A \nFinance, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A \nFinance, McKesson Corp.  \n"}, "hash": "a4ef592ba8b465643548ac84f66d5e0f48ce1fb4ad5121fd02040dddeaaa215b", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c16b6ac7-9fb5-44b6-897c-c8bbbc105df6": {"__data__": {"id_": "c16b6ac7-9fb5-44b6-897c-c8bbbc105df6", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A \nFinance, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A \nFinance, McKesson Corp.  \n", "page_label": "2", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6464c30c-9944-4870-b7fd-30474d3e4691", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "15906db17c0a214cdb7014edc7b71258980b09669b7c358d0c2d04d0357632cc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6582eba8-2152-47f3-8923-e4a7cc436a98", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A \nFinance, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a26b733d1547c45d9bc0fe598fdf2a982bdc78acc8ee8768c09806da021ca829", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31fdebb4-7161-4aa7-939a-87c79c7d7d8d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A \nFinance, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "original_text": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "d8a605ca4c2fc24598e9dec9aadfe9727bf7c10508742ca05d7742d019d1de29", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A \nFinance, McKesson Corp.  \n", "start_char_idx": 16, "end_char_idx": 313, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31fdebb4-7161-4aa7-939a-87c79c7d7d8d": {"__data__": {"id_": "31fdebb4-7161-4aa7-939a-87c79c7d7d8d", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A \nFinance, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "original_text": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6464c30c-9944-4870-b7fd-30474d3e4691", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "15906db17c0a214cdb7014edc7b71258980b09669b7c358d0c2d04d0357632cc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c16b6ac7-9fb5-44b6-897c-c8bbbc105df6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A \nFinance, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A \nFinance, McKesson Corp.  \n", "page_label": "2", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8956bdb755d6e8f162795e0c8dd0f4ac7f0cb0f6a0baf9bd6f7cab7408463cd8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "77750ec6-480d-4325-8aca-1cdeddb3ed3e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A \nFinance, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorga n Securities LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  Charles Rhyee  \nAnalyst, Cowen and Company  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n "}, "hash": "6c71aa6dc9ef8d45074910609a5a35397de53080f24b7de006c5aae6b21a277b", "class_name": "RelatedNodeInfo"}}, "text": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 313, "end_char_idx": 385, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "77750ec6-480d-4325-8aca-1cdeddb3ed3e": {"__data__": {"id_": "77750ec6-480d-4325-8aca-1cdeddb3ed3e", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A \nFinance, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorga n Securities LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  Charles Rhyee  \nAnalyst, Cowen and Company  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "page_label": "2", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6464c30c-9944-4870-b7fd-30474d3e4691", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "15906db17c0a214cdb7014edc7b71258980b09669b7c358d0c2d04d0357632cc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31fdebb4-7161-4aa7-939a-87c79c7d7d8d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A \nFinance, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "original_text": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4edd43f3b8d29e2908eb6e2f9cf2468265d56c36c624abed9a37504253b30aa1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b869698-0365-4461-8a32-c7c76314708c", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A \nFinance, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorga n Securities LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  Charles Rhyee  \nAnalyst, Cowen and Company  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nAdam Heussner  \nAnalyst, Credit Suisse Securities (USA) LLC  \n  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n"}, "hash": "7296cb0633fc2cc5d4bfad2b7e63e8679839c4c28e7be469a17051f10830130a", "class_name": "RelatedNodeInfo"}}, "text": "Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "start_char_idx": 385, "end_char_idx": 472, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b869698-0365-4461-8a32-c7c76314708c": {"__data__": {"id_": "3b869698-0365-4461-8a32-c7c76314708c", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A \nFinance, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorga n Securities LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  Charles Rhyee  \nAnalyst, Cowen and Company  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nAdam Heussner  \nAnalyst, Credit Suisse Securities (USA) LLC  \n  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n", "page_label": "2", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6464c30c-9944-4870-b7fd-30474d3e4691", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "15906db17c0a214cdb7014edc7b71258980b09669b7c358d0c2d04d0357632cc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "77750ec6-480d-4325-8aca-1cdeddb3ed3e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A \nFinance, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorga n Securities LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  Charles Rhyee  \nAnalyst, Cowen and Company  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "page_label": "2", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "86e1bdbd851c15efb52ed1231a3150a0779136d6604a477c3788e2042c202f38", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f696633f-3170-428f-a177-b1bc588b35c7", "node_type": "1", "metadata": {"window": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorga n Securities LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  Charles Rhyee  \nAnalyst, Cowen and Company  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nAdam Heussner  \nAnalyst, Credit Suisse Securities (USA) LLC  \n  ", "original_text": "Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n"}, "hash": "2077da3b877ea70b17f96a8e87858169fc39d7867c3fc4eec6311be93f83b0fd", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n", "start_char_idx": 472, "end_char_idx": 866, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f696633f-3170-428f-a177-b1bc588b35c7": {"__data__": {"id_": "f696633f-3170-428f-a177-b1bc588b35c7", "embedding": null, "metadata": {"window": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorga n Securities LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  Charles Rhyee  \nAnalyst, Cowen and Company  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nAdam Heussner  \nAnalyst, Credit Suisse Securities (USA) LLC  \n  ", "original_text": "Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "page_label": "2", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6464c30c-9944-4870-b7fd-30474d3e4691", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "15906db17c0a214cdb7014edc7b71258980b09669b7c358d0c2d04d0357632cc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b869698-0365-4461-8a32-c7c76314708c", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A \nFinance, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorga n Securities LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  Charles Rhyee  \nAnalyst, Cowen and Company  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nAdam Heussner  \nAnalyst, Credit Suisse Securities (USA) LLC  \n  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n", "page_label": "2", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f76c54d84305151459de70b5bbf871b385b133e2e05919c15b64b8ec7a3dc1e6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2893e45-a589-4373-8848-d928f97a1cf8", "node_type": "1", "metadata": {"window": "Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorga n Securities LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  Charles Rhyee  \nAnalyst, Cowen and Company  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nAdam Heussner  \nAnalyst, Credit Suisse Securities (USA) LLC  \n  ", "original_text": "Lisa C. Gill  \nAnalyst, JPMorga n Securities LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  Charles Rhyee  \nAnalyst, Cowen and Company  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. "}, "hash": "677af71cda6c67d1fc228bfc6835464def5cde352c55cda9c32b8bc83d3bbbfa", "class_name": "RelatedNodeInfo"}}, "text": "Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "start_char_idx": 866, "end_char_idx": 916, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2893e45-a589-4373-8848-d928f97a1cf8": {"__data__": {"id_": "b2893e45-a589-4373-8848-d928f97a1cf8", "embedding": null, "metadata": {"window": "Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorga n Securities LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  Charles Rhyee  \nAnalyst, Cowen and Company  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nAdam Heussner  \nAnalyst, Credit Suisse Securities (USA) LLC  \n  ", "original_text": "Lisa C. Gill  \nAnalyst, JPMorga n Securities LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  Charles Rhyee  \nAnalyst, Cowen and Company  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "2", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6464c30c-9944-4870-b7fd-30474d3e4691", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "15906db17c0a214cdb7014edc7b71258980b09669b7c358d0c2d04d0357632cc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f696633f-3170-428f-a177-b1bc588b35c7", "node_type": "1", "metadata": {"window": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorga n Securities LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  Charles Rhyee  \nAnalyst, Cowen and Company  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nAdam Heussner  \nAnalyst, Credit Suisse Securities (USA) LLC  \n  ", "original_text": "Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "page_label": "2", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b110762a8de5a1c6c817ebf8b8d72047368f5667f4d60134dbacb23533ceae9c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "edda169b-9d02-4c3a-81a0-81ed150dd0fc", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorga n Securities LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  Charles Rhyee  \nAnalyst, Cowen and Company  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nAdam Heussner  \nAnalyst, Credit Suisse Securities (USA) LLC  \n  ", "original_text": "LLC  \nAdam Heussner  \nAnalyst, Credit Suisse Securities (USA) LLC  \n  "}, "hash": "60796f507e7d6d0cff31c8fa4283dedd109832ee11dea5814954dfbcfe292d44", "class_name": "RelatedNodeInfo"}}, "text": "Lisa C. Gill  \nAnalyst, JPMorga n Securities LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  Charles Rhyee  \nAnalyst, Cowen and Company  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "start_char_idx": 916, "end_char_idx": 1157, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "edda169b-9d02-4c3a-81a0-81ed150dd0fc": {"__data__": {"id_": "edda169b-9d02-4c3a-81a0-81ed150dd0fc", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorga n Securities LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  Charles Rhyee  \nAnalyst, Cowen and Company  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nAdam Heussner  \nAnalyst, Credit Suisse Securities (USA) LLC  \n  ", "original_text": "LLC  \nAdam Heussner  \nAnalyst, Credit Suisse Securities (USA) LLC  \n  ", "page_label": "2", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6464c30c-9944-4870-b7fd-30474d3e4691", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "15906db17c0a214cdb7014edc7b71258980b09669b7c358d0c2d04d0357632cc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2893e45-a589-4373-8848-d928f97a1cf8", "node_type": "1", "metadata": {"window": "Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorga n Securities LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  Charles Rhyee  \nAnalyst, Cowen and Company  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nAdam Heussner  \nAnalyst, Credit Suisse Securities (USA) LLC  \n  ", "original_text": "Lisa C. Gill  \nAnalyst, JPMorga n Securities LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  Charles Rhyee  \nAnalyst, Cowen and Company  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "2", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "131debb9a4b4a0a32012a2925c4c94ec99fd1441435c634e0d558da605ab061e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99a8d6da-fe84-401a-8a6a-d044775aeef1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson's Q1 Earnings Call.  Today's conference is being recorded.  At this time, I \nwould like to turn the call over to Holly Weiss. ", "original_text": "McKesson Corp.  "}, "hash": "adb62ccc2736ebf9066257a8e0da1fe014ca8f885da61d89cd7d5fdfd7458220", "class_name": "RelatedNodeInfo"}}, "text": "LLC  \nAdam Heussner  \nAnalyst, Credit Suisse Securities (USA) LLC  \n  ", "start_char_idx": 1157, "end_char_idx": 1227, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99a8d6da-fe84-401a-8a6a-d044775aeef1": {"__data__": {"id_": "99a8d6da-fe84-401a-8a6a-d044775aeef1", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson's Q1 Earnings Call.  Today's conference is being recorded.  At this time, I \nwould like to turn the call over to Holly Weiss. ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a958f72cda9a0512e6189a1558dd95ed4a280e865dde43031e6356019193df41", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "edda169b-9d02-4c3a-81a0-81ed150dd0fc", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  \n Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n Lisa C. Gill  \nAnalyst, JPMorga n Securities LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  Charles Rhyee  \nAnalyst, Cowen and Company  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nAdam Heussner  \nAnalyst, Credit Suisse Securities (USA) LLC  \n  ", "original_text": "LLC  \nAdam Heussner  \nAnalyst, Credit Suisse Securities (USA) LLC  \n  ", "page_label": "2", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "70e5d8125af2a47f0fa73ce89ea178da7eea0593cdca6eb3d2dbc688dfd32dc9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d1d1419e-2bbb-4c5d-a5ed-9215f9c73a02", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson's Q1 Earnings Call.  Today's conference is being recorded.  At this time, I \nwould like to turn the call over to Holly Weiss.  Please go ahead.  \n ", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson's Q1 Earnings Call. "}, "hash": "2e614ac8386b2c81dc4a2cbf5a132678f6fc49aa814ae31f78657d18602e217c", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d1d1419e-2bbb-4c5d-a5ed-9215f9c73a02": {"__data__": {"id_": "d1d1419e-2bbb-4c5d-a5ed-9215f9c73a02", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson's Q1 Earnings Call.  Today's conference is being recorded.  At this time, I \nwould like to turn the call over to Holly Weiss.  Please go ahead.  \n ", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson's Q1 Earnings Call. ", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a958f72cda9a0512e6189a1558dd95ed4a280e865dde43031e6356019193df41", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99a8d6da-fe84-401a-8a6a-d044775aeef1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson's Q1 Earnings Call.  Today's conference is being recorded.  At this time, I \nwould like to turn the call over to Holly Weiss. ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "329489d5b17f6cbc73786a61a2e6908cf04b98119130fe33687c409306d180ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "457cf053-83a7-48a5-a713-b2f43607afea", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson's Q1 Earnings Call.  Today's conference is being recorded.  At this time, I \nwould like to turn the call over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n", "original_text": "Today's conference is being recorded. "}, "hash": "c8d8c16ca2a03d49b9ef6e2e77908b70cc6e255c2c70a57838204d5d598b1141", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson's Q1 Earnings Call. ", "start_char_idx": 16, "end_char_idx": 272, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "457cf053-83a7-48a5-a713-b2f43607afea": {"__data__": {"id_": "457cf053-83a7-48a5-a713-b2f43607afea", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson's Q1 Earnings Call.  Today's conference is being recorded.  At this time, I \nwould like to turn the call over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n", "original_text": "Today's conference is being recorded. ", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a958f72cda9a0512e6189a1558dd95ed4a280e865dde43031e6356019193df41", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d1d1419e-2bbb-4c5d-a5ed-9215f9c73a02", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson's Q1 Earnings Call.  Today's conference is being recorded.  At this time, I \nwould like to turn the call over to Holly Weiss.  Please go ahead.  \n ", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson's Q1 Earnings Call. ", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04dacb8632f6f5d31a1544857fc2e4a060f0dbd24e8e62008a94a610aea95eba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b98e6ce4-63ae-4c9e-946a-4b1ba6ae1e0b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson's Q1 Earnings Call.  Today's conference is being recorded.  At this time, I \nwould like to turn the call over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Jenny. ", "original_text": "At this time, I \nwould like to turn the call over to Holly Weiss. "}, "hash": "25822263c96778ba945c9affe2ecf0a725710291eadcfbca37c2689eeee72ade", "class_name": "RelatedNodeInfo"}}, "text": "Today's conference is being recorded. ", "start_char_idx": 272, "end_char_idx": 310, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b98e6ce4-63ae-4c9e-946a-4b1ba6ae1e0b": {"__data__": {"id_": "b98e6ce4-63ae-4c9e-946a-4b1ba6ae1e0b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson's Q1 Earnings Call.  Today's conference is being recorded.  At this time, I \nwould like to turn the call over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Jenny. ", "original_text": "At this time, I \nwould like to turn the call over to Holly Weiss. ", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a958f72cda9a0512e6189a1558dd95ed4a280e865dde43031e6356019193df41", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "457cf053-83a7-48a5-a713-b2f43607afea", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson's Q1 Earnings Call.  Today's conference is being recorded.  At this time, I \nwould like to turn the call over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n", "original_text": "Today's conference is being recorded. ", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b881101e795d2569f8fc48898885ce808309f7e46dd676cea5d88b5d682d70e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f523c120-2c37-4cc5-a00e-d79ecb49ec38", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson's Q1 Earnings Call.  Today's conference is being recorded.  At this time, I \nwould like to turn the call over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Jenny.  Good afternoon and welcome everyone to McKesson's First Quarter Fiscal 2021 Earnings \nCall. ", "original_text": "Please go ahead.  \n "}, "hash": "d29e472764f416938f1e6e211b09bba65157abce4a567d663657c609bf37d649", "class_name": "RelatedNodeInfo"}}, "text": "At this time, I \nwould like to turn the call over to Holly Weiss. ", "start_char_idx": 310, "end_char_idx": 376, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f523c120-2c37-4cc5-a00e-d79ecb49ec38": {"__data__": {"id_": "f523c120-2c37-4cc5-a00e-d79ecb49ec38", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson's Q1 Earnings Call.  Today's conference is being recorded.  At this time, I \nwould like to turn the call over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Jenny.  Good afternoon and welcome everyone to McKesson's First Quarter Fiscal 2021 Earnings \nCall. ", "original_text": "Please go ahead.  \n ", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a958f72cda9a0512e6189a1558dd95ed4a280e865dde43031e6356019193df41", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b98e6ce4-63ae-4c9e-946a-4b1ba6ae1e0b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson's Q1 Earnings Call.  Today's conference is being recorded.  At this time, I \nwould like to turn the call over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Jenny. ", "original_text": "At this time, I \nwould like to turn the call over to Holly Weiss. ", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af47ce42db44b2e72ba4c99bd32fe3398d472b396ea2217bdf1dcb8b4af5eaaa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f41daaa-f10a-48c8-9db0-a62861abacf2", "node_type": "1", "metadata": {"window": "Today's conference is being recorded.  At this time, I \nwould like to turn the call over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Jenny.  Good afternoon and welcome everyone to McKesson's First Quarter Fiscal 2021 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt  Vitalone, our Chief Financial Officer. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n"}, "hash": "82f2637c4208dd5ec93017a8cbd2cb447d2f71e268a1c4e0523588c93296d4d9", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 376, "end_char_idx": 396, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f41daaa-f10a-48c8-9db0-a62861abacf2": {"__data__": {"id_": "6f41daaa-f10a-48c8-9db0-a62861abacf2", "embedding": null, "metadata": {"window": "Today's conference is being recorded.  At this time, I \nwould like to turn the call over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Jenny.  Good afternoon and welcome everyone to McKesson's First Quarter Fiscal 2021 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt  Vitalone, our Chief Financial Officer. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a958f72cda9a0512e6189a1558dd95ed4a280e865dde43031e6356019193df41", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f523c120-2c37-4cc5-a00e-d79ecb49ec38", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson's Q1 Earnings Call.  Today's conference is being recorded.  At this time, I \nwould like to turn the call over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Jenny.  Good afternoon and welcome everyone to McKesson's First Quarter Fiscal 2021 Earnings \nCall. ", "original_text": "Please go ahead.  \n ", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48230a0fac0122ab49b529da870a2a413ba62022d597476d5ad6de8b5a74d667", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2cd79074-27cf-4109-80a0-8836a74cbd67", "node_type": "1", "metadata": {"window": "At this time, I \nwould like to turn the call over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Jenny.  Good afternoon and welcome everyone to McKesson's First Quarter Fiscal 2021 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt  Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "original_text": "Thank you, Jenny. "}, "hash": "4e60948df591409760ce98f1f8617b7fbefe505c4891865554b61c9b800817f9", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n", "start_char_idx": 396, "end_char_idx": 771, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2cd79074-27cf-4109-80a0-8836a74cbd67": {"__data__": {"id_": "2cd79074-27cf-4109-80a0-8836a74cbd67", "embedding": null, "metadata": {"window": "At this time, I \nwould like to turn the call over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Jenny.  Good afternoon and welcome everyone to McKesson's First Quarter Fiscal 2021 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt  Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "original_text": "Thank you, Jenny. ", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a958f72cda9a0512e6189a1558dd95ed4a280e865dde43031e6356019193df41", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f41daaa-f10a-48c8-9db0-a62861abacf2", "node_type": "1", "metadata": {"window": "Today's conference is being recorded.  At this time, I \nwould like to turn the call over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Jenny.  Good afternoon and welcome everyone to McKesson's First Quarter Fiscal 2021 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt  Vitalone, our Chief Financial Officer. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50ef7ed2cbf29d093722139ad5ee81ba9295fa9ef5b048b800394712b6d9f5bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ecf906c3-b20c-418a-94dd-244b93fba816", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Jenny.  Good afternoon and welcome everyone to McKesson's First Quarter Fiscal 2021 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt  Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts about McKesson's operations and \nfuture re sults. ", "original_text": "Good afternoon and welcome everyone to McKesson's First Quarter Fiscal 2021 Earnings \nCall. "}, "hash": "31c1ce93638f7cfddeab39f48eee8fd7aa23ec07c50f1745f70b2edd587d1cf7", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, Jenny. ", "start_char_idx": 771, "end_char_idx": 789, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ecf906c3-b20c-418a-94dd-244b93fba816": {"__data__": {"id_": "ecf906c3-b20c-418a-94dd-244b93fba816", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Jenny.  Good afternoon and welcome everyone to McKesson's First Quarter Fiscal 2021 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt  Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts about McKesson's operations and \nfuture re sults. ", "original_text": "Good afternoon and welcome everyone to McKesson's First Quarter Fiscal 2021 Earnings \nCall. ", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a958f72cda9a0512e6189a1558dd95ed4a280e865dde43031e6356019193df41", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2cd79074-27cf-4109-80a0-8836a74cbd67", "node_type": "1", "metadata": {"window": "At this time, I \nwould like to turn the call over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Jenny.  Good afternoon and welcome everyone to McKesson's First Quarter Fiscal 2021 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt  Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "original_text": "Thank you, Jenny. ", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ba3e9530aec875a0ae07c15c421203899ed8facf2392a2fb4f561dfa12aca34c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed2c0c07-5989-4f5c-b9b7-d3614c03ec97", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Jenny.  Good afternoon and welcome everyone to McKesson's First Quarter Fiscal 2021 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt  Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts about McKesson's operations and \nfuture re sults.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to mater ially differ from those in our forward -looking statements.  \n \n", "original_text": "Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt  Vitalone, our Chief Financial Officer. \n"}, "hash": "069693e86e50568e7bcdc7cec2bac47410d55ce1c0a4305c4d78e37194abbc7b", "class_name": "RelatedNodeInfo"}}, "text": "Good afternoon and welcome everyone to McKesson's First Quarter Fiscal 2021 Earnings \nCall. ", "start_char_idx": 789, "end_char_idx": 881, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed2c0c07-5989-4f5c-b9b7-d3614c03ec97": {"__data__": {"id_": "ed2c0c07-5989-4f5c-b9b7-d3614c03ec97", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Jenny.  Good afternoon and welcome everyone to McKesson's First Quarter Fiscal 2021 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt  Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts about McKesson's operations and \nfuture re sults.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to mater ially differ from those in our forward -looking statements.  \n \n", "original_text": "Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt  Vitalone, our Chief Financial Officer. \n", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a958f72cda9a0512e6189a1558dd95ed4a280e865dde43031e6356019193df41", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ecf906c3-b20c-418a-94dd-244b93fba816", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Jenny.  Good afternoon and welcome everyone to McKesson's First Quarter Fiscal 2021 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt  Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts about McKesson's operations and \nfuture re sults. ", "original_text": "Good afternoon and welcome everyone to McKesson's First Quarter Fiscal 2021 Earnings \nCall. ", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a2b57f04e03a48f66f06fdad57762aa5d52eabba046c253ae127b41d5852a89d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3dad2a05-56c1-4b3d-ae8a-2d117e128145", "node_type": "1", "metadata": {"window": "Thank you, Jenny.  Good afternoon and welcome everyone to McKesson's First Quarter Fiscal 2021 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt  Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts about McKesson's operations and \nfuture re sults.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to mater ially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures. ", "original_text": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n"}, "hash": "497b820379f5576aff9f538972e9afb12f2a780be2c54ad61b90a743391aff01", "class_name": "RelatedNodeInfo"}}, "text": "Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt  Vitalone, our Chief Financial Officer. \n", "start_char_idx": 881, "end_char_idx": 995, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3dad2a05-56c1-4b3d-ae8a-2d117e128145": {"__data__": {"id_": "3dad2a05-56c1-4b3d-ae8a-2d117e128145", "embedding": null, "metadata": {"window": "Thank you, Jenny.  Good afternoon and welcome everyone to McKesson's First Quarter Fiscal 2021 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt  Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts about McKesson's operations and \nfuture re sults.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to mater ially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures. ", "original_text": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a958f72cda9a0512e6189a1558dd95ed4a280e865dde43031e6356019193df41", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed2c0c07-5989-4f5c-b9b7-d3614c03ec97", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Jenny.  Good afternoon and welcome everyone to McKesson's First Quarter Fiscal 2021 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt  Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts about McKesson's operations and \nfuture re sults.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to mater ially differ from those in our forward -looking statements.  \n \n", "original_text": "Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt  Vitalone, our Chief Financial Officer. \n", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a95fa6712ac9b64976107996ce85c76cc25120a1a599e15b3cb759eb2cfad9b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de00f2ab-9af6-4fdc-9f32-3b3629b82c5b", "node_type": "1", "metadata": {"window": "Good afternoon and welcome everyone to McKesson's First Quarter Fiscal 2021 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt  Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts about McKesson's operations and \nfuture re sults.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to mater ially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n", "original_text": "Today's discussion will include forward -looking statements, such as forecasts about McKesson's operations and \nfuture re sults. "}, "hash": "1cf46ef2ff1fb437eb95f93d14d436e61225675557e3218a0c3ae48b9822625f", "class_name": "RelatedNodeInfo"}}, "text": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "start_char_idx": 995, "end_char_idx": 1096, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de00f2ab-9af6-4fdc-9f32-3b3629b82c5b": {"__data__": {"id_": "de00f2ab-9af6-4fdc-9f32-3b3629b82c5b", "embedding": null, "metadata": {"window": "Good afternoon and welcome everyone to McKesson's First Quarter Fiscal 2021 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt  Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts about McKesson's operations and \nfuture re sults.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to mater ially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n", "original_text": "Today's discussion will include forward -looking statements, such as forecasts about McKesson's operations and \nfuture re sults. ", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a958f72cda9a0512e6189a1558dd95ed4a280e865dde43031e6356019193df41", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3dad2a05-56c1-4b3d-ae8a-2d117e128145", "node_type": "1", "metadata": {"window": "Thank you, Jenny.  Good afternoon and welcome everyone to McKesson's First Quarter Fiscal 2021 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt  Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts about McKesson's operations and \nfuture re sults.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to mater ially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures. ", "original_text": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bdc474dd3fe51c05f4be293fb8981d325b0e1f184c65b774e0b38d9b476d2c0f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba88020a-3774-4150-95c0-eadbd35d6e34", "node_type": "1", "metadata": {"window": "Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt  Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts about McKesson's operations and \nfuture re sults.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to mater ially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n ", "original_text": "Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to mater ially differ from those in our forward -looking statements.  \n \n"}, "hash": "6c9666d68f6163416b94a43f1b77c608cb2b3da969e5df09f9e7e63cbb017064", "class_name": "RelatedNodeInfo"}}, "text": "Today's discussion will include forward -looking statements, such as forecasts about McKesson's operations and \nfuture re sults. ", "start_char_idx": 1096, "end_char_idx": 1225, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ba88020a-3774-4150-95c0-eadbd35d6e34": {"__data__": {"id_": "ba88020a-3774-4150-95c0-eadbd35d6e34", "embedding": null, "metadata": {"window": "Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt  Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts about McKesson's operations and \nfuture re sults.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to mater ially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n ", "original_text": "Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to mater ially differ from those in our forward -looking statements.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a958f72cda9a0512e6189a1558dd95ed4a280e865dde43031e6356019193df41", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de00f2ab-9af6-4fdc-9f32-3b3629b82c5b", "node_type": "1", "metadata": {"window": "Good afternoon and welcome everyone to McKesson's First Quarter Fiscal 2021 Earnings \nCall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt  Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts about McKesson's operations and \nfuture re sults.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to mater ially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n", "original_text": "Today's discussion will include forward -looking statements, such as forecasts about McKesson's operations and \nfuture re sults. ", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28957515021da0bd8c0fc6e313043d8082cce141e072cd0e569a5be693ad9166", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c0e8da74-71f3-4579-bb60-b4e2d22724dd", "node_type": "1", "metadata": {"window": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts about McKesson's operations and \nfuture re sults.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to mater ially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "During this call, we will discuss non -GAAP financial measures. "}, "hash": "843423f0eac4d2897f32fd2e7648e2a1a5e9f459652a35fb5989ab63c0e73661", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to mater ially differ from those in our forward -looking statements.  \n \n", "start_char_idx": 1225, "end_char_idx": 1541, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c0e8da74-71f3-4579-bb60-b4e2d22724dd": {"__data__": {"id_": "c0e8da74-71f3-4579-bb60-b4e2d22724dd", "embedding": null, "metadata": {"window": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts about McKesson's operations and \nfuture re sults.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to mater ially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "During this call, we will discuss non -GAAP financial measures. ", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a958f72cda9a0512e6189a1558dd95ed4a280e865dde43031e6356019193df41", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba88020a-3774-4150-95c0-eadbd35d6e34", "node_type": "1", "metadata": {"window": "Today, I'm joined by Brian Tyler, our Chief Executive Officer; and Britt  Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts about McKesson's operations and \nfuture re sults.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to mater ially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n ", "original_text": "Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to mater ially differ from those in our forward -looking statements.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e7a236bdaf1ba77170f1fc22f92826bcc88a22cae7a0cc5dbd8d526ebf44723", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e3fb905-c808-4c72-9988-092173fc332e", "node_type": "1", "metadata": {"window": "Today's discussion will include forward -looking statements, such as forecasts about McKesson's operations and \nfuture re sults.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to mater ially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good afternoon, everybody. ", "original_text": "Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n"}, "hash": "5b99f296a2e1d76b612c044c518ac30f5b48da1dfb93777a374f242e9c9d7911", "class_name": "RelatedNodeInfo"}}, "text": "During this call, we will discuss non -GAAP financial measures. ", "start_char_idx": 1541, "end_char_idx": 1605, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e3fb905-c808-4c72-9988-092173fc332e": {"__data__": {"id_": "7e3fb905-c808-4c72-9988-092173fc332e", "embedding": null, "metadata": {"window": "Today's discussion will include forward -looking statements, such as forecasts about McKesson's operations and \nfuture re sults.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to mater ially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good afternoon, everybody. ", "original_text": "Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a958f72cda9a0512e6189a1558dd95ed4a280e865dde43031e6356019193df41", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c0e8da74-71f3-4579-bb60-b4e2d22724dd", "node_type": "1", "metadata": {"window": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements, such as forecasts about McKesson's operations and \nfuture re sults.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to mater ially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "During this call, we will discuss non -GAAP financial measures. ", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da0f0dc47885b76149ebddd415259ce5b3dabe8b858dd83b4fbe2b9e690f9f8c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "075a7369-29b1-425f-9266-4eb3823cc4f3", "node_type": "1", "metadata": {"window": "Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to mater ially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good afternoon, everybody.  Thank you for joining us on our first quarter call today. ", "original_text": "With that, let me turn it over to Brian.  \n "}, "hash": "edbd261f02c630b549fe4154d7d12de519359f2a9f1aa22a25bdf7d24629c1d2", "class_name": "RelatedNodeInfo"}}, "text": "Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n", "start_char_idx": 1605, "end_char_idx": 1858, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "075a7369-29b1-425f-9266-4eb3823cc4f3": {"__data__": {"id_": "075a7369-29b1-425f-9266-4eb3823cc4f3", "embedding": null, "metadata": {"window": "Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to mater ially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good afternoon, everybody.  Thank you for joining us on our first quarter call today. ", "original_text": "With that, let me turn it over to Brian.  \n ", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a958f72cda9a0512e6189a1558dd95ed4a280e865dde43031e6356019193df41", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e3fb905-c808-4c72-9988-092173fc332e", "node_type": "1", "metadata": {"window": "Today's discussion will include forward -looking statements, such as forecasts about McKesson's operations and \nfuture re sults.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to mater ially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good afternoon, everybody. ", "original_text": "Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce70de6f852ba88f7f9a81fbee03423afb677069da96309ae8cfab81e83b8a46", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "762aa045-09df-4d7f-a3a2-746bcb0aa253", "node_type": "1", "metadata": {"window": "During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good afternoon, everybody.  Thank you for joining us on our first quarter call today.  We are \npleased to be reporting a strong start to our fiscal 2022, which reflects continued operating momentum across our \nbusinesses despite the fact that our markets are s till recovering from the impacts of COVID -19. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n"}, "hash": "515202cf527931a5f04fe997faff6ef322b88e5f5aa3a91c325e02a550c357f6", "class_name": "RelatedNodeInfo"}}, "text": "With that, let me turn it over to Brian.  \n ", "start_char_idx": 1858, "end_char_idx": 1902, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "762aa045-09df-4d7f-a3a2-746bcb0aa253": {"__data__": {"id_": "762aa045-09df-4d7f-a3a2-746bcb0aa253", "embedding": null, "metadata": {"window": "During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good afternoon, everybody.  Thank you for joining us on our first quarter call today.  We are \npleased to be reporting a strong start to our fiscal 2022, which reflects continued operating momentum across our \nbusinesses despite the fact that our markets are s till recovering from the impacts of COVID -19. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a958f72cda9a0512e6189a1558dd95ed4a280e865dde43031e6356019193df41", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "075a7369-29b1-425f-9266-4eb3823cc4f3", "node_type": "1", "metadata": {"window": "Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to mater ially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good afternoon, everybody.  Thank you for joining us on our first quarter call today. ", "original_text": "With that, let me turn it over to Brian.  \n ", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16ffe8cc0070c506f8b75a4ea4002777546a37f653bb5825cd62f1afeada98d4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e5a43be-5022-4053-b87e-1b7101db70da", "node_type": "1", "metadata": {"window": "Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good afternoon, everybody.  Thank you for joining us on our first quarter call today.  We are \npleased to be reporting a strong start to our fiscal 2022, which reflects continued operating momentum across our \nbusinesses despite the fact that our markets are s till recovering from the impacts of COVID -19.  We're also making \nsignificant progress against our strategic priorities and our commitment to do what's in the best interest of you, our \nshareholders.  \n \n", "original_text": "Thank you, Holly, and good afternoon, everybody. "}, "hash": "187cc768c5ebe247a4fec3ea5d9b98fdf8d9220c673343239adee38f8bd2b1a9", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "start_char_idx": 1902, "end_char_idx": 2247, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e5a43be-5022-4053-b87e-1b7101db70da": {"__data__": {"id_": "9e5a43be-5022-4053-b87e-1b7101db70da", "embedding": null, "metadata": {"window": "Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good afternoon, everybody.  Thank you for joining us on our first quarter call today.  We are \npleased to be reporting a strong start to our fiscal 2022, which reflects continued operating momentum across our \nbusinesses despite the fact that our markets are s till recovering from the impacts of COVID -19.  We're also making \nsignificant progress against our strategic priorities and our commitment to do what's in the best interest of you, our \nshareholders.  \n \n", "original_text": "Thank you, Holly, and good afternoon, everybody. ", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a958f72cda9a0512e6189a1558dd95ed4a280e865dde43031e6356019193df41", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "762aa045-09df-4d7f-a3a2-746bcb0aa253", "node_type": "1", "metadata": {"window": "During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good afternoon, everybody.  Thank you for joining us on our first quarter call today.  We are \npleased to be reporting a strong start to our fiscal 2022, which reflects continued operating momentum across our \nbusinesses despite the fact that our markets are s till recovering from the impacts of COVID -19. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f20444353b9a05ee26b9f21604f863f4535aed97eadc4b3b9470398ff8b658f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "788f3d9c-5f38-4fd4-9f1e-d710ab04a3c2", "node_type": "1", "metadata": {"window": "With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good afternoon, everybody.  Thank you for joining us on our first quarter call today.  We are \npleased to be reporting a strong start to our fiscal 2022, which reflects continued operating momentum across our \nbusinesses despite the fact that our markets are s till recovering from the impacts of COVID -19.  We're also making \nsignificant progress against our strategic priorities and our commitment to do what's in the best interest of you, our \nshareholders.  \n \n Before we get to our first quarter results, I want to prov ide an update on the progress made towards a broad \nresolution of governmental opioid -related claims. ", "original_text": "Thank you for joining us on our first quarter call today. "}, "hash": "866446c06ad65f9249f0fe0836257ecf493c5182476696d8afff4f9bf4ccc824", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, Holly, and good afternoon, everybody. ", "start_char_idx": 2247, "end_char_idx": 2296, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "788f3d9c-5f38-4fd4-9f1e-d710ab04a3c2": {"__data__": {"id_": "788f3d9c-5f38-4fd4-9f1e-d710ab04a3c2", "embedding": null, "metadata": {"window": "With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good afternoon, everybody.  Thank you for joining us on our first quarter call today.  We are \npleased to be reporting a strong start to our fiscal 2022, which reflects continued operating momentum across our \nbusinesses despite the fact that our markets are s till recovering from the impacts of COVID -19.  We're also making \nsignificant progress against our strategic priorities and our commitment to do what's in the best interest of you, our \nshareholders.  \n \n Before we get to our first quarter results, I want to prov ide an update on the progress made towards a broad \nresolution of governmental opioid -related claims. ", "original_text": "Thank you for joining us on our first quarter call today. ", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a958f72cda9a0512e6189a1558dd95ed4a280e865dde43031e6356019193df41", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e5a43be-5022-4053-b87e-1b7101db70da", "node_type": "1", "metadata": {"window": "Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good afternoon, everybody.  Thank you for joining us on our first quarter call today.  We are \npleased to be reporting a strong start to our fiscal 2022, which reflects continued operating momentum across our \nbusinesses despite the fact that our markets are s till recovering from the impacts of COVID -19.  We're also making \nsignificant progress against our strategic priorities and our commitment to do what's in the best interest of you, our \nshareholders.  \n \n", "original_text": "Thank you, Holly, and good afternoon, everybody. ", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b2a10b2d2a0519e94e763c371d3b804c9ba282618532e32dcf3500b88c9bc856", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a2a7d591-0172-4bea-b6bc-500673f85b8e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good afternoon, everybody.  Thank you for joining us on our first quarter call today.  We are \npleased to be reporting a strong start to our fiscal 2022, which reflects continued operating momentum across our \nbusinesses despite the fact that our markets are s till recovering from the impacts of COVID -19.  We're also making \nsignificant progress against our strategic priorities and our commitment to do what's in the best interest of you, our \nshareholders.  \n \n Before we get to our first quarter results, I want to prov ide an update on the progress made towards a broad \nresolution of governmental opioid -related claims.  On July 21, we announced that McKesson, along with two other \ndistributors, negotiated a comprehensive proposed settlement agreement, which, if all conditio ns are satisfied, \nwould result in a settlement of a substantial majority of opioid lawsuits filed by state and local governmental \nentities. ", "original_text": "We are \npleased to be reporting a strong start to our fiscal 2022, which reflects continued operating momentum across our \nbusinesses despite the fact that our markets are s till recovering from the impacts of COVID -19. "}, "hash": "0d4ed189b47b49ff3cb1175221670e46512dac1758cb68ef5c0dbf8b72cb49d7", "class_name": "RelatedNodeInfo"}}, "text": "Thank you for joining us on our first quarter call today. ", "start_char_idx": 2296, "end_char_idx": 2354, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a2a7d591-0172-4bea-b6bc-500673f85b8e": {"__data__": {"id_": "a2a7d591-0172-4bea-b6bc-500673f85b8e", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good afternoon, everybody.  Thank you for joining us on our first quarter call today.  We are \npleased to be reporting a strong start to our fiscal 2022, which reflects continued operating momentum across our \nbusinesses despite the fact that our markets are s till recovering from the impacts of COVID -19.  We're also making \nsignificant progress against our strategic priorities and our commitment to do what's in the best interest of you, our \nshareholders.  \n \n Before we get to our first quarter results, I want to prov ide an update on the progress made towards a broad \nresolution of governmental opioid -related claims.  On July 21, we announced that McKesson, along with two other \ndistributors, negotiated a comprehensive proposed settlement agreement, which, if all conditio ns are satisfied, \nwould result in a settlement of a substantial majority of opioid lawsuits filed by state and local governmental \nentities. ", "original_text": "We are \npleased to be reporting a strong start to our fiscal 2022, which reflects continued operating momentum across our \nbusinesses despite the fact that our markets are s till recovering from the impacts of COVID -19. ", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a958f72cda9a0512e6189a1558dd95ed4a280e865dde43031e6356019193df41", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "788f3d9c-5f38-4fd4-9f1e-d710ab04a3c2", "node_type": "1", "metadata": {"window": "With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good afternoon, everybody.  Thank you for joining us on our first quarter call today.  We are \npleased to be reporting a strong start to our fiscal 2022, which reflects continued operating momentum across our \nbusinesses despite the fact that our markets are s till recovering from the impacts of COVID -19.  We're also making \nsignificant progress against our strategic priorities and our commitment to do what's in the best interest of you, our \nshareholders.  \n \n Before we get to our first quarter results, I want to prov ide an update on the progress made towards a broad \nresolution of governmental opioid -related claims. ", "original_text": "Thank you for joining us on our first quarter call today. ", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16caeda25459d2060fd765dffd605711833d491ef3855d2e1b29062b8439f6e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "476329e1-aff9-4a14-b432-9980aab58668", "node_type": "1", "metadata": {"window": "Thank you, Holly, and good afternoon, everybody.  Thank you for joining us on our first quarter call today.  We are \npleased to be reporting a strong start to our fiscal 2022, which reflects continued operating momentum across our \nbusinesses despite the fact that our markets are s till recovering from the impacts of COVID -19.  We're also making \nsignificant progress against our strategic priorities and our commitment to do what's in the best interest of you, our \nshareholders.  \n \n Before we get to our first quarter results, I want to prov ide an update on the progress made towards a broad \nresolution of governmental opioid -related claims.  On July 21, we announced that McKesson, along with two other \ndistributors, negotiated a comprehensive proposed settlement agreement, which, if all conditio ns are satisfied, \nwould result in a settlement of a substantial majority of opioid lawsuits filed by state and local governmental \nentities.  If this broad resolution \u2013 if this broad agreement becomes effective, the agreement reached between the \ndistributors  and the state of New York and its participating subdivisions to settle opioid -related claims will become \npart of this broader settlement agreement.  \n \n", "original_text": "We're also making \nsignificant progress against our strategic priorities and our commitment to do what's in the best interest of you, our \nshareholders.  \n \n"}, "hash": "95d51fa3226ba7a318f04f8c2de7fedf3eb7779178fd25dcbe3858128ada0f27", "class_name": "RelatedNodeInfo"}}, "text": "We are \npleased to be reporting a strong start to our fiscal 2022, which reflects continued operating momentum across our \nbusinesses despite the fact that our markets are s till recovering from the impacts of COVID -19. ", "start_char_idx": 2354, "end_char_idx": 2575, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "476329e1-aff9-4a14-b432-9980aab58668": {"__data__": {"id_": "476329e1-aff9-4a14-b432-9980aab58668", "embedding": null, "metadata": {"window": "Thank you, Holly, and good afternoon, everybody.  Thank you for joining us on our first quarter call today.  We are \npleased to be reporting a strong start to our fiscal 2022, which reflects continued operating momentum across our \nbusinesses despite the fact that our markets are s till recovering from the impacts of COVID -19.  We're also making \nsignificant progress against our strategic priorities and our commitment to do what's in the best interest of you, our \nshareholders.  \n \n Before we get to our first quarter results, I want to prov ide an update on the progress made towards a broad \nresolution of governmental opioid -related claims.  On July 21, we announced that McKesson, along with two other \ndistributors, negotiated a comprehensive proposed settlement agreement, which, if all conditio ns are satisfied, \nwould result in a settlement of a substantial majority of opioid lawsuits filed by state and local governmental \nentities.  If this broad resolution \u2013 if this broad agreement becomes effective, the agreement reached between the \ndistributors  and the state of New York and its participating subdivisions to settle opioid -related claims will become \npart of this broader settlement agreement.  \n \n", "original_text": "We're also making \nsignificant progress against our strategic priorities and our commitment to do what's in the best interest of you, our \nshareholders.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a958f72cda9a0512e6189a1558dd95ed4a280e865dde43031e6356019193df41", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2a7d591-0172-4bea-b6bc-500673f85b8e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good afternoon, everybody.  Thank you for joining us on our first quarter call today.  We are \npleased to be reporting a strong start to our fiscal 2022, which reflects continued operating momentum across our \nbusinesses despite the fact that our markets are s till recovering from the impacts of COVID -19.  We're also making \nsignificant progress against our strategic priorities and our commitment to do what's in the best interest of you, our \nshareholders.  \n \n Before we get to our first quarter results, I want to prov ide an update on the progress made towards a broad \nresolution of governmental opioid -related claims.  On July 21, we announced that McKesson, along with two other \ndistributors, negotiated a comprehensive proposed settlement agreement, which, if all conditio ns are satisfied, \nwould result in a settlement of a substantial majority of opioid lawsuits filed by state and local governmental \nentities. ", "original_text": "We are \npleased to be reporting a strong start to our fiscal 2022, which reflects continued operating momentum across our \nbusinesses despite the fact that our markets are s till recovering from the impacts of COVID -19. ", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f50f8123263895d1c1cd9d6ef3139327a1f4ea3c4831a5c75146b1330478f2ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db397d6e-e0d5-4b2e-a6f9-aa9bfd9c1da9", "node_type": "1", "metadata": {"window": "Thank you for joining us on our first quarter call today.  We are \npleased to be reporting a strong start to our fiscal 2022, which reflects continued operating momentum across our \nbusinesses despite the fact that our markets are s till recovering from the impacts of COVID -19.  We're also making \nsignificant progress against our strategic priorities and our commitment to do what's in the best interest of you, our \nshareholders.  \n \n Before we get to our first quarter results, I want to prov ide an update on the progress made towards a broad \nresolution of governmental opioid -related claims.  On July 21, we announced that McKesson, along with two other \ndistributors, negotiated a comprehensive proposed settlement agreement, which, if all conditio ns are satisfied, \nwould result in a settlement of a substantial majority of opioid lawsuits filed by state and local governmental \nentities.  If this broad resolution \u2013 if this broad agreement becomes effective, the agreement reached between the \ndistributors  and the state of New York and its participating subdivisions to settle opioid -related claims will become \npart of this broader settlement agreement.  \n \n Under the negotiated proposed settlement agreement and subject to final state, territorial and political s ubdivision \nparticipation, McKesson will pay up to $7.9 billion over a period of 18 years. ", "original_text": "Before we get to our first quarter results, I want to prov ide an update on the progress made towards a broad \nresolution of governmental opioid -related claims. "}, "hash": "f064b8de985d36115518a4f5894083b0a8a6965c08f2227d6cff5f8709a89e2b", "class_name": "RelatedNodeInfo"}}, "text": "We're also making \nsignificant progress against our strategic priorities and our commitment to do what's in the best interest of you, our \nshareholders.  \n \n", "start_char_idx": 2575, "end_char_idx": 2732, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db397d6e-e0d5-4b2e-a6f9-aa9bfd9c1da9": {"__data__": {"id_": "db397d6e-e0d5-4b2e-a6f9-aa9bfd9c1da9", "embedding": null, "metadata": {"window": "Thank you for joining us on our first quarter call today.  We are \npleased to be reporting a strong start to our fiscal 2022, which reflects continued operating momentum across our \nbusinesses despite the fact that our markets are s till recovering from the impacts of COVID -19.  We're also making \nsignificant progress against our strategic priorities and our commitment to do what's in the best interest of you, our \nshareholders.  \n \n Before we get to our first quarter results, I want to prov ide an update on the progress made towards a broad \nresolution of governmental opioid -related claims.  On July 21, we announced that McKesson, along with two other \ndistributors, negotiated a comprehensive proposed settlement agreement, which, if all conditio ns are satisfied, \nwould result in a settlement of a substantial majority of opioid lawsuits filed by state and local governmental \nentities.  If this broad resolution \u2013 if this broad agreement becomes effective, the agreement reached between the \ndistributors  and the state of New York and its participating subdivisions to settle opioid -related claims will become \npart of this broader settlement agreement.  \n \n Under the negotiated proposed settlement agreement and subject to final state, territorial and political s ubdivision \nparticipation, McKesson will pay up to $7.9 billion over a period of 18 years. ", "original_text": "Before we get to our first quarter results, I want to prov ide an update on the progress made towards a broad \nresolution of governmental opioid -related claims. ", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a958f72cda9a0512e6189a1558dd95ed4a280e865dde43031e6356019193df41", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "476329e1-aff9-4a14-b432-9980aab58668", "node_type": "1", "metadata": {"window": "Thank you, Holly, and good afternoon, everybody.  Thank you for joining us on our first quarter call today.  We are \npleased to be reporting a strong start to our fiscal 2022, which reflects continued operating momentum across our \nbusinesses despite the fact that our markets are s till recovering from the impacts of COVID -19.  We're also making \nsignificant progress against our strategic priorities and our commitment to do what's in the best interest of you, our \nshareholders.  \n \n Before we get to our first quarter results, I want to prov ide an update on the progress made towards a broad \nresolution of governmental opioid -related claims.  On July 21, we announced that McKesson, along with two other \ndistributors, negotiated a comprehensive proposed settlement agreement, which, if all conditio ns are satisfied, \nwould result in a settlement of a substantial majority of opioid lawsuits filed by state and local governmental \nentities.  If this broad resolution \u2013 if this broad agreement becomes effective, the agreement reached between the \ndistributors  and the state of New York and its participating subdivisions to settle opioid -related claims will become \npart of this broader settlement agreement.  \n \n", "original_text": "We're also making \nsignificant progress against our strategic priorities and our commitment to do what's in the best interest of you, our \nshareholders.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2e3a2b4f41692412e780e0eaa91c2e74f58adef64a2644f6b787afa70dbdc52a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "700990cd-a583-49ec-a912-21367bdc88f2", "node_type": "1", "metadata": {"window": "We are \npleased to be reporting a strong start to our fiscal 2022, which reflects continued operating momentum across our \nbusinesses despite the fact that our markets are s till recovering from the impacts of COVID -19.  We're also making \nsignificant progress against our strategic priorities and our commitment to do what's in the best interest of you, our \nshareholders.  \n \n Before we get to our first quarter results, I want to prov ide an update on the progress made towards a broad \nresolution of governmental opioid -related claims.  On July 21, we announced that McKesson, along with two other \ndistributors, negotiated a comprehensive proposed settlement agreement, which, if all conditio ns are satisfied, \nwould result in a settlement of a substantial majority of opioid lawsuits filed by state and local governmental \nentities.  If this broad resolution \u2013 if this broad agreement becomes effective, the agreement reached between the \ndistributors  and the state of New York and its participating subdivisions to settle opioid -related claims will become \npart of this broader settlement agreement.  \n \n Under the negotiated proposed settlement agreement and subject to final state, territorial and political s ubdivision \nparticipation, McKesson will pay up to $7.9 billion over a period of 18 years.  Over the next several months, we will \nmonitor participation of the eligible governmental entities to determine if participation levels are sufficient to \nproceed. ", "original_text": "On July 21, we announced that McKesson, along with two other \ndistributors, negotiated a comprehensive proposed settlement agreement, which, if all conditio ns are satisfied, \nwould result in a settlement of a substantial majority of opioid lawsuits filed by state and local governmental \nentities. "}, "hash": "79a623e6c1b59c6092fc4b4df70303f7dde239485a824d0c4ce761b99b7704e1", "class_name": "RelatedNodeInfo"}}, "text": "Before we get to our first quarter results, I want to prov ide an update on the progress made towards a broad \nresolution of governmental opioid -related claims. ", "start_char_idx": 2732, "end_char_idx": 2894, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "700990cd-a583-49ec-a912-21367bdc88f2": {"__data__": {"id_": "700990cd-a583-49ec-a912-21367bdc88f2", "embedding": null, "metadata": {"window": "We are \npleased to be reporting a strong start to our fiscal 2022, which reflects continued operating momentum across our \nbusinesses despite the fact that our markets are s till recovering from the impacts of COVID -19.  We're also making \nsignificant progress against our strategic priorities and our commitment to do what's in the best interest of you, our \nshareholders.  \n \n Before we get to our first quarter results, I want to prov ide an update on the progress made towards a broad \nresolution of governmental opioid -related claims.  On July 21, we announced that McKesson, along with two other \ndistributors, negotiated a comprehensive proposed settlement agreement, which, if all conditio ns are satisfied, \nwould result in a settlement of a substantial majority of opioid lawsuits filed by state and local governmental \nentities.  If this broad resolution \u2013 if this broad agreement becomes effective, the agreement reached between the \ndistributors  and the state of New York and its participating subdivisions to settle opioid -related claims will become \npart of this broader settlement agreement.  \n \n Under the negotiated proposed settlement agreement and subject to final state, territorial and political s ubdivision \nparticipation, McKesson will pay up to $7.9 billion over a period of 18 years.  Over the next several months, we will \nmonitor participation of the eligible governmental entities to determine if participation levels are sufficient to \nproceed. ", "original_text": "On July 21, we announced that McKesson, along with two other \ndistributors, negotiated a comprehensive proposed settlement agreement, which, if all conditio ns are satisfied, \nwould result in a settlement of a substantial majority of opioid lawsuits filed by state and local governmental \nentities. ", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a958f72cda9a0512e6189a1558dd95ed4a280e865dde43031e6356019193df41", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db397d6e-e0d5-4b2e-a6f9-aa9bfd9c1da9", "node_type": "1", "metadata": {"window": "Thank you for joining us on our first quarter call today.  We are \npleased to be reporting a strong start to our fiscal 2022, which reflects continued operating momentum across our \nbusinesses despite the fact that our markets are s till recovering from the impacts of COVID -19.  We're also making \nsignificant progress against our strategic priorities and our commitment to do what's in the best interest of you, our \nshareholders.  \n \n Before we get to our first quarter results, I want to prov ide an update on the progress made towards a broad \nresolution of governmental opioid -related claims.  On July 21, we announced that McKesson, along with two other \ndistributors, negotiated a comprehensive proposed settlement agreement, which, if all conditio ns are satisfied, \nwould result in a settlement of a substantial majority of opioid lawsuits filed by state and local governmental \nentities.  If this broad resolution \u2013 if this broad agreement becomes effective, the agreement reached between the \ndistributors  and the state of New York and its participating subdivisions to settle opioid -related claims will become \npart of this broader settlement agreement.  \n \n Under the negotiated proposed settlement agreement and subject to final state, territorial and political s ubdivision \nparticipation, McKesson will pay up to $7.9 billion over a period of 18 years. ", "original_text": "Before we get to our first quarter results, I want to prov ide an update on the progress made towards a broad \nresolution of governmental opioid -related claims. ", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f87444f70347e125b997cf7af587d8fd45f0f917270ef821f28c71bcbf0d5b7f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d0d3edd-552b-489e-b875-74220e3d1196", "node_type": "1", "metadata": {"window": "We're also making \nsignificant progress against our strategic priorities and our commitment to do what's in the best interest of you, our \nshareholders.  \n \n Before we get to our first quarter results, I want to prov ide an update on the progress made towards a broad \nresolution of governmental opioid -related claims.  On July 21, we announced that McKesson, along with two other \ndistributors, negotiated a comprehensive proposed settlement agreement, which, if all conditio ns are satisfied, \nwould result in a settlement of a substantial majority of opioid lawsuits filed by state and local governmental \nentities.  If this broad resolution \u2013 if this broad agreement becomes effective, the agreement reached between the \ndistributors  and the state of New York and its participating subdivisions to settle opioid -related claims will become \npart of this broader settlement agreement.  \n \n Under the negotiated proposed settlement agreement and subject to final state, territorial and political s ubdivision \nparticipation, McKesson will pay up to $7.9 billion over a period of 18 years.  Over the next several months, we will \nmonitor participation of the eligible governmental entities to determine if participation levels are sufficient to \nproceed.  This  is an important development, and I am pleased with the progress we've made after years of \nnegotiations.  \n ", "original_text": "If this broad resolution \u2013 if this broad agreement becomes effective, the agreement reached between the \ndistributors  and the state of New York and its participating subdivisions to settle opioid -related claims will become \npart of this broader settlement agreement.  \n \n"}, "hash": "2cd469fef80754c0250e0332d76c203b8c8f9fa90ebf7ffa3c53a64e190c463a", "class_name": "RelatedNodeInfo"}}, "text": "On July 21, we announced that McKesson, along with two other \ndistributors, negotiated a comprehensive proposed settlement agreement, which, if all conditio ns are satisfied, \nwould result in a settlement of a substantial majority of opioid lawsuits filed by state and local governmental \nentities. ", "start_char_idx": 2894, "end_char_idx": 3193, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d0d3edd-552b-489e-b875-74220e3d1196": {"__data__": {"id_": "8d0d3edd-552b-489e-b875-74220e3d1196", "embedding": null, "metadata": {"window": "We're also making \nsignificant progress against our strategic priorities and our commitment to do what's in the best interest of you, our \nshareholders.  \n \n Before we get to our first quarter results, I want to prov ide an update on the progress made towards a broad \nresolution of governmental opioid -related claims.  On July 21, we announced that McKesson, along with two other \ndistributors, negotiated a comprehensive proposed settlement agreement, which, if all conditio ns are satisfied, \nwould result in a settlement of a substantial majority of opioid lawsuits filed by state and local governmental \nentities.  If this broad resolution \u2013 if this broad agreement becomes effective, the agreement reached between the \ndistributors  and the state of New York and its participating subdivisions to settle opioid -related claims will become \npart of this broader settlement agreement.  \n \n Under the negotiated proposed settlement agreement and subject to final state, territorial and political s ubdivision \nparticipation, McKesson will pay up to $7.9 billion over a period of 18 years.  Over the next several months, we will \nmonitor participation of the eligible governmental entities to determine if participation levels are sufficient to \nproceed.  This  is an important development, and I am pleased with the progress we've made after years of \nnegotiations.  \n ", "original_text": "If this broad resolution \u2013 if this broad agreement becomes effective, the agreement reached between the \ndistributors  and the state of New York and its participating subdivisions to settle opioid -related claims will become \npart of this broader settlement agreement.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a958f72cda9a0512e6189a1558dd95ed4a280e865dde43031e6356019193df41", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "700990cd-a583-49ec-a912-21367bdc88f2", "node_type": "1", "metadata": {"window": "We are \npleased to be reporting a strong start to our fiscal 2022, which reflects continued operating momentum across our \nbusinesses despite the fact that our markets are s till recovering from the impacts of COVID -19.  We're also making \nsignificant progress against our strategic priorities and our commitment to do what's in the best interest of you, our \nshareholders.  \n \n Before we get to our first quarter results, I want to prov ide an update on the progress made towards a broad \nresolution of governmental opioid -related claims.  On July 21, we announced that McKesson, along with two other \ndistributors, negotiated a comprehensive proposed settlement agreement, which, if all conditio ns are satisfied, \nwould result in a settlement of a substantial majority of opioid lawsuits filed by state and local governmental \nentities.  If this broad resolution \u2013 if this broad agreement becomes effective, the agreement reached between the \ndistributors  and the state of New York and its participating subdivisions to settle opioid -related claims will become \npart of this broader settlement agreement.  \n \n Under the negotiated proposed settlement agreement and subject to final state, territorial and political s ubdivision \nparticipation, McKesson will pay up to $7.9 billion over a period of 18 years.  Over the next several months, we will \nmonitor participation of the eligible governmental entities to determine if participation levels are sufficient to \nproceed. ", "original_text": "On July 21, we announced that McKesson, along with two other \ndistributors, negotiated a comprehensive proposed settlement agreement, which, if all conditio ns are satisfied, \nwould result in a settlement of a substantial majority of opioid lawsuits filed by state and local governmental \nentities. ", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3ede0850d644444ab61dda1a7a4b6785803a389a92157d5bf9144ebd6994d313", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d62f0f69-44e8-4529-bf6d-ba12c52478f0", "node_type": "1", "metadata": {"window": "Before we get to our first quarter results, I want to prov ide an update on the progress made towards a broad \nresolution of governmental opioid -related claims.  On July 21, we announced that McKesson, along with two other \ndistributors, negotiated a comprehensive proposed settlement agreement, which, if all conditio ns are satisfied, \nwould result in a settlement of a substantial majority of opioid lawsuits filed by state and local governmental \nentities.  If this broad resolution \u2013 if this broad agreement becomes effective, the agreement reached between the \ndistributors  and the state of New York and its participating subdivisions to settle opioid -related claims will become \npart of this broader settlement agreement.  \n \n Under the negotiated proposed settlement agreement and subject to final state, territorial and political s ubdivision \nparticipation, McKesson will pay up to $7.9 billion over a period of 18 years.  Over the next several months, we will \nmonitor participation of the eligible governmental entities to determine if participation levels are sufficient to \nproceed.  This  is an important development, and I am pleased with the progress we've made after years of \nnegotiations.  \n ", "original_text": "Under the negotiated proposed settlement agreement and subject to final state, territorial and political s ubdivision \nparticipation, McKesson will pay up to $7.9 billion over a period of 18 years. "}, "hash": "b9d461e82a32809e1fd6e364e6c1b3cf5721a5f0ef497e48592b926355458e15", "class_name": "RelatedNodeInfo"}}, "text": "If this broad resolution \u2013 if this broad agreement becomes effective, the agreement reached between the \ndistributors  and the state of New York and its participating subdivisions to settle opioid -related claims will become \npart of this broader settlement agreement.  \n \n", "start_char_idx": 3193, "end_char_idx": 3466, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d62f0f69-44e8-4529-bf6d-ba12c52478f0": {"__data__": {"id_": "d62f0f69-44e8-4529-bf6d-ba12c52478f0", "embedding": null, "metadata": {"window": "Before we get to our first quarter results, I want to prov ide an update on the progress made towards a broad \nresolution of governmental opioid -related claims.  On July 21, we announced that McKesson, along with two other \ndistributors, negotiated a comprehensive proposed settlement agreement, which, if all conditio ns are satisfied, \nwould result in a settlement of a substantial majority of opioid lawsuits filed by state and local governmental \nentities.  If this broad resolution \u2013 if this broad agreement becomes effective, the agreement reached between the \ndistributors  and the state of New York and its participating subdivisions to settle opioid -related claims will become \npart of this broader settlement agreement.  \n \n Under the negotiated proposed settlement agreement and subject to final state, territorial and political s ubdivision \nparticipation, McKesson will pay up to $7.9 billion over a period of 18 years.  Over the next several months, we will \nmonitor participation of the eligible governmental entities to determine if participation levels are sufficient to \nproceed.  This  is an important development, and I am pleased with the progress we've made after years of \nnegotiations.  \n ", "original_text": "Under the negotiated proposed settlement agreement and subject to final state, territorial and political s ubdivision \nparticipation, McKesson will pay up to $7.9 billion over a period of 18 years. ", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a958f72cda9a0512e6189a1558dd95ed4a280e865dde43031e6356019193df41", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d0d3edd-552b-489e-b875-74220e3d1196", "node_type": "1", "metadata": {"window": "We're also making \nsignificant progress against our strategic priorities and our commitment to do what's in the best interest of you, our \nshareholders.  \n \n Before we get to our first quarter results, I want to prov ide an update on the progress made towards a broad \nresolution of governmental opioid -related claims.  On July 21, we announced that McKesson, along with two other \ndistributors, negotiated a comprehensive proposed settlement agreement, which, if all conditio ns are satisfied, \nwould result in a settlement of a substantial majority of opioid lawsuits filed by state and local governmental \nentities.  If this broad resolution \u2013 if this broad agreement becomes effective, the agreement reached between the \ndistributors  and the state of New York and its participating subdivisions to settle opioid -related claims will become \npart of this broader settlement agreement.  \n \n Under the negotiated proposed settlement agreement and subject to final state, territorial and political s ubdivision \nparticipation, McKesson will pay up to $7.9 billion over a period of 18 years.  Over the next several months, we will \nmonitor participation of the eligible governmental entities to determine if participation levels are sufficient to \nproceed.  This  is an important development, and I am pleased with the progress we've made after years of \nnegotiations.  \n ", "original_text": "If this broad resolution \u2013 if this broad agreement becomes effective, the agreement reached between the \ndistributors  and the state of New York and its participating subdivisions to settle opioid -related claims will become \npart of this broader settlement agreement.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a30a5d377a7304ef15c3bbf8512964de4eadd36c580cbd3ebf9ed16ba8f14bd1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "684b5ed1-0fbd-42d2-b92b-f5e9518be79b", "node_type": "1", "metadata": {"window": "On July 21, we announced that McKesson, along with two other \ndistributors, negotiated a comprehensive proposed settlement agreement, which, if all conditio ns are satisfied, \nwould result in a settlement of a substantial majority of opioid lawsuits filed by state and local governmental \nentities.  If this broad resolution \u2013 if this broad agreement becomes effective, the agreement reached between the \ndistributors  and the state of New York and its participating subdivisions to settle opioid -related claims will become \npart of this broader settlement agreement.  \n \n Under the negotiated proposed settlement agreement and subject to final state, territorial and political s ubdivision \nparticipation, McKesson will pay up to $7.9 billion over a period of 18 years.  Over the next several months, we will \nmonitor participation of the eligible governmental entities to determine if participation levels are sufficient to \nproceed.  This  is an important development, and I am pleased with the progress we've made after years of \nnegotiations.  \n ", "original_text": "Over the next several months, we will \nmonitor participation of the eligible governmental entities to determine if participation levels are sufficient to \nproceed. "}, "hash": "308f7b217e4e774806ac5d078e96895c273a280f94d8f4747e013eff70c31839", "class_name": "RelatedNodeInfo"}}, "text": "Under the negotiated proposed settlement agreement and subject to final state, territorial and political s ubdivision \nparticipation, McKesson will pay up to $7.9 billion over a period of 18 years. ", "start_char_idx": 3466, "end_char_idx": 3664, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "684b5ed1-0fbd-42d2-b92b-f5e9518be79b": {"__data__": {"id_": "684b5ed1-0fbd-42d2-b92b-f5e9518be79b", "embedding": null, "metadata": {"window": "On July 21, we announced that McKesson, along with two other \ndistributors, negotiated a comprehensive proposed settlement agreement, which, if all conditio ns are satisfied, \nwould result in a settlement of a substantial majority of opioid lawsuits filed by state and local governmental \nentities.  If this broad resolution \u2013 if this broad agreement becomes effective, the agreement reached between the \ndistributors  and the state of New York and its participating subdivisions to settle opioid -related claims will become \npart of this broader settlement agreement.  \n \n Under the negotiated proposed settlement agreement and subject to final state, territorial and political s ubdivision \nparticipation, McKesson will pay up to $7.9 billion over a period of 18 years.  Over the next several months, we will \nmonitor participation of the eligible governmental entities to determine if participation levels are sufficient to \nproceed.  This  is an important development, and I am pleased with the progress we've made after years of \nnegotiations.  \n ", "original_text": "Over the next several months, we will \nmonitor participation of the eligible governmental entities to determine if participation levels are sufficient to \nproceed. ", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a958f72cda9a0512e6189a1558dd95ed4a280e865dde43031e6356019193df41", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d62f0f69-44e8-4529-bf6d-ba12c52478f0", "node_type": "1", "metadata": {"window": "Before we get to our first quarter results, I want to prov ide an update on the progress made towards a broad \nresolution of governmental opioid -related claims.  On July 21, we announced that McKesson, along with two other \ndistributors, negotiated a comprehensive proposed settlement agreement, which, if all conditio ns are satisfied, \nwould result in a settlement of a substantial majority of opioid lawsuits filed by state and local governmental \nentities.  If this broad resolution \u2013 if this broad agreement becomes effective, the agreement reached between the \ndistributors  and the state of New York and its participating subdivisions to settle opioid -related claims will become \npart of this broader settlement agreement.  \n \n Under the negotiated proposed settlement agreement and subject to final state, territorial and political s ubdivision \nparticipation, McKesson will pay up to $7.9 billion over a period of 18 years.  Over the next several months, we will \nmonitor participation of the eligible governmental entities to determine if participation levels are sufficient to \nproceed.  This  is an important development, and I am pleased with the progress we've made after years of \nnegotiations.  \n ", "original_text": "Under the negotiated proposed settlement agreement and subject to final state, territorial and political s ubdivision \nparticipation, McKesson will pay up to $7.9 billion over a period of 18 years. ", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5c06c8e026c92a4b4a2fa16d8829094655b8800c019b12d475bf8f653b1f7719", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7365827a-e44a-46fd-b8e0-51db5c52ef6c", "node_type": "1", "metadata": {"window": "If this broad resolution \u2013 if this broad agreement becomes effective, the agreement reached between the \ndistributors  and the state of New York and its participating subdivisions to settle opioid -related claims will become \npart of this broader settlement agreement.  \n \n Under the negotiated proposed settlement agreement and subject to final state, territorial and political s ubdivision \nparticipation, McKesson will pay up to $7.9 billion over a period of 18 years.  Over the next several months, we will \nmonitor participation of the eligible governmental entities to determine if participation levels are sufficient to \nproceed.  This  is an important development, and I am pleased with the progress we've made after years of \nnegotiations.  \n ", "original_text": "This  is an important development, and I am pleased with the progress we've made after years of \nnegotiations.  \n "}, "hash": "ee77c7a2a4ee51efe4038b0034c246a4962703ae16f8fce6a9f3ec4d1165d7f6", "class_name": "RelatedNodeInfo"}}, "text": "Over the next several months, we will \nmonitor participation of the eligible governmental entities to determine if participation levels are sufficient to \nproceed. ", "start_char_idx": 3664, "end_char_idx": 3828, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7365827a-e44a-46fd-b8e0-51db5c52ef6c": {"__data__": {"id_": "7365827a-e44a-46fd-b8e0-51db5c52ef6c", "embedding": null, "metadata": {"window": "If this broad resolution \u2013 if this broad agreement becomes effective, the agreement reached between the \ndistributors  and the state of New York and its participating subdivisions to settle opioid -related claims will become \npart of this broader settlement agreement.  \n \n Under the negotiated proposed settlement agreement and subject to final state, territorial and political s ubdivision \nparticipation, McKesson will pay up to $7.9 billion over a period of 18 years.  Over the next several months, we will \nmonitor participation of the eligible governmental entities to determine if participation levels are sufficient to \nproceed.  This  is an important development, and I am pleased with the progress we've made after years of \nnegotiations.  \n ", "original_text": "This  is an important development, and I am pleased with the progress we've made after years of \nnegotiations.  \n ", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a958f72cda9a0512e6189a1558dd95ed4a280e865dde43031e6356019193df41", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "684b5ed1-0fbd-42d2-b92b-f5e9518be79b", "node_type": "1", "metadata": {"window": "On July 21, we announced that McKesson, along with two other \ndistributors, negotiated a comprehensive proposed settlement agreement, which, if all conditio ns are satisfied, \nwould result in a settlement of a substantial majority of opioid lawsuits filed by state and local governmental \nentities.  If this broad resolution \u2013 if this broad agreement becomes effective, the agreement reached between the \ndistributors  and the state of New York and its participating subdivisions to settle opioid -related claims will become \npart of this broader settlement agreement.  \n \n Under the negotiated proposed settlement agreement and subject to final state, territorial and political s ubdivision \nparticipation, McKesson will pay up to $7.9 billion over a period of 18 years.  Over the next several months, we will \nmonitor participation of the eligible governmental entities to determine if participation levels are sufficient to \nproceed.  This  is an important development, and I am pleased with the progress we've made after years of \nnegotiations.  \n ", "original_text": "Over the next several months, we will \nmonitor participation of the eligible governmental entities to determine if participation levels are sufficient to \nproceed. ", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e59648fe0a9871c77af447119ee7bb0e824b7a893c9035bfa3c1e0cc64652e84", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce7ee229-8083-4fe9-82d3-a147aa02706c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nIf we're able to reach a final settlement, it would provide immediate relief to thousands of communities across the \nUnited States that have been impac ted by this public health crisis.  While we strongly dispute the allegations made \nin these lawsuits, we believe that bringing resolution to these outstanding claims is in the best interest of those \nimpacted by this crisis.  We also believe resolution is in t he best interest of our shareholders, and will allow us to \nfurther focus on the business and our role in protecting the safety and the integrity of the pharmaceutical supply \nchain.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "c59802c4124f1ac6d97fb072c19f4c4256a8bf57b2fdf21bf747b57f64842e05", "class_name": "RelatedNodeInfo"}}, "text": "This  is an important development, and I am pleased with the progress we've made after years of \nnegotiations.  \n ", "start_char_idx": 3828, "end_char_idx": 3942, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce7ee229-8083-4fe9-82d3-a147aa02706c": {"__data__": {"id_": "ce7ee229-8083-4fe9-82d3-a147aa02706c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nIf we're able to reach a final settlement, it would provide immediate relief to thousands of communities across the \nUnited States that have been impac ted by this public health crisis.  While we strongly dispute the allegations made \nin these lawsuits, we believe that bringing resolution to these outstanding claims is in the best interest of those \nimpacted by this crisis.  We also believe resolution is in t he best interest of our shareholders, and will allow us to \nfurther focus on the business and our role in protecting the safety and the integrity of the pharmaceutical supply \nchain.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "aab73de7-ebef-4918-a603-d86999a6bb6b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd1ba625e40547f387ed9f87e5863c4972d0e09d6489fa3c2949a93197be6035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7365827a-e44a-46fd-b8e0-51db5c52ef6c", "node_type": "1", "metadata": {"window": "If this broad resolution \u2013 if this broad agreement becomes effective, the agreement reached between the \ndistributors  and the state of New York and its participating subdivisions to settle opioid -related claims will become \npart of this broader settlement agreement.  \n \n Under the negotiated proposed settlement agreement and subject to final state, territorial and political s ubdivision \nparticipation, McKesson will pay up to $7.9 billion over a period of 18 years.  Over the next several months, we will \nmonitor participation of the eligible governmental entities to determine if participation levels are sufficient to \nproceed.  This  is an important development, and I am pleased with the progress we've made after years of \nnegotiations.  \n ", "original_text": "This  is an important development, and I am pleased with the progress we've made after years of \nnegotiations.  \n ", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9d3b4cec457baf48b87c5cb428f0342f670ba853f22669ffa672bbe847999c84", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "40738c12-5fb4-4b89-9afe-171b5bf4e61f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nIf we're able to reach a final settlement, it would provide immediate relief to thousands of communities across the \nUnited States that have been impac ted by this public health crisis.  While we strongly dispute the allegations made \nin these lawsuits, we believe that bringing resolution to these outstanding claims is in the best interest of those \nimpacted by this crisis.  We also believe resolution is in t he best interest of our shareholders, and will allow us to \nfurther focus on the business and our role in protecting the safety and the integrity of the pharmaceutical supply \nchain.  \n \n We remain committed to doing our part to fight against the opioid epidemic  through efforts to continuously \nenhance our anti -diversion programs and to advocate for reform at the state and national level. ", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nIf we're able to reach a final settlement, it would provide immediate relief to thousands of communities across the \nUnited States that have been impac ted by this public health crisis. "}, "hash": "c38b1c2c565af8259903626d94537afe4df85364e270d4c19cf985ae19e57252", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "40738c12-5fb4-4b89-9afe-171b5bf4e61f": {"__data__": {"id_": "40738c12-5fb4-4b89-9afe-171b5bf4e61f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nIf we're able to reach a final settlement, it would provide immediate relief to thousands of communities across the \nUnited States that have been impac ted by this public health crisis.  While we strongly dispute the allegations made \nin these lawsuits, we believe that bringing resolution to these outstanding claims is in the best interest of those \nimpacted by this crisis.  We also believe resolution is in t he best interest of our shareholders, and will allow us to \nfurther focus on the business and our role in protecting the safety and the integrity of the pharmaceutical supply \nchain.  \n \n We remain committed to doing our part to fight against the opioid epidemic  through efforts to continuously \nenhance our anti -diversion programs and to advocate for reform at the state and national level. ", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nIf we're able to reach a final settlement, it would provide immediate relief to thousands of communities across the \nUnited States that have been impac ted by this public health crisis. ", "page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "aab73de7-ebef-4918-a603-d86999a6bb6b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd1ba625e40547f387ed9f87e5863c4972d0e09d6489fa3c2949a93197be6035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce7ee229-8083-4fe9-82d3-a147aa02706c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nIf we're able to reach a final settlement, it would provide immediate relief to thousands of communities across the \nUnited States that have been impac ted by this public health crisis.  While we strongly dispute the allegations made \nin these lawsuits, we believe that bringing resolution to these outstanding claims is in the best interest of those \nimpacted by this crisis.  We also believe resolution is in t he best interest of our shareholders, and will allow us to \nfurther focus on the business and our role in protecting the safety and the integrity of the pharmaceutical supply \nchain.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d332bbcfbacb329f9c9f27818df9ea1543a818f1993315785109adc6cfb33b73", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8dbfb1e4-9b0c-4486-81d0-c72af5a1de1a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nIf we're able to reach a final settlement, it would provide immediate relief to thousands of communities across the \nUnited States that have been impac ted by this public health crisis.  While we strongly dispute the allegations made \nin these lawsuits, we believe that bringing resolution to these outstanding claims is in the best interest of those \nimpacted by this crisis.  We also believe resolution is in t he best interest of our shareholders, and will allow us to \nfurther focus on the business and our role in protecting the safety and the integrity of the pharmaceutical supply \nchain.  \n \n We remain committed to doing our part to fight against the opioid epidemic  through efforts to continuously \nenhance our anti -diversion programs and to advocate for reform at the state and national level.  If the settlement \ncannot be finalized or plaintiffs instead choose to pursue their claims in court, we are prepared to litigate  against \nthose claims, and we remain confident in our defenses.  \n \n", "original_text": "While we strongly dispute the allegations made \nin these lawsuits, we believe that bringing resolution to these outstanding claims is in the best interest of those \nimpacted by this crisis. "}, "hash": "1711b4226419945c7e7574660c1d01d7080d74f4f81a7bfe040ca16403a3436a", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nIf we're able to reach a final settlement, it would provide immediate relief to thousands of communities across the \nUnited States that have been impac ted by this public health crisis. ", "start_char_idx": 16, "end_char_idx": 366, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8dbfb1e4-9b0c-4486-81d0-c72af5a1de1a": {"__data__": {"id_": "8dbfb1e4-9b0c-4486-81d0-c72af5a1de1a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nIf we're able to reach a final settlement, it would provide immediate relief to thousands of communities across the \nUnited States that have been impac ted by this public health crisis.  While we strongly dispute the allegations made \nin these lawsuits, we believe that bringing resolution to these outstanding claims is in the best interest of those \nimpacted by this crisis.  We also believe resolution is in t he best interest of our shareholders, and will allow us to \nfurther focus on the business and our role in protecting the safety and the integrity of the pharmaceutical supply \nchain.  \n \n We remain committed to doing our part to fight against the opioid epidemic  through efforts to continuously \nenhance our anti -diversion programs and to advocate for reform at the state and national level.  If the settlement \ncannot be finalized or plaintiffs instead choose to pursue their claims in court, we are prepared to litigate  against \nthose claims, and we remain confident in our defenses.  \n \n", "original_text": "While we strongly dispute the allegations made \nin these lawsuits, we believe that bringing resolution to these outstanding claims is in the best interest of those \nimpacted by this crisis. ", "page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "aab73de7-ebef-4918-a603-d86999a6bb6b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd1ba625e40547f387ed9f87e5863c4972d0e09d6489fa3c2949a93197be6035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "40738c12-5fb4-4b89-9afe-171b5bf4e61f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nIf we're able to reach a final settlement, it would provide immediate relief to thousands of communities across the \nUnited States that have been impac ted by this public health crisis.  While we strongly dispute the allegations made \nin these lawsuits, we believe that bringing resolution to these outstanding claims is in the best interest of those \nimpacted by this crisis.  We also believe resolution is in t he best interest of our shareholders, and will allow us to \nfurther focus on the business and our role in protecting the safety and the integrity of the pharmaceutical supply \nchain.  \n \n We remain committed to doing our part to fight against the opioid epidemic  through efforts to continuously \nenhance our anti -diversion programs and to advocate for reform at the state and national level. ", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nIf we're able to reach a final settlement, it would provide immediate relief to thousands of communities across the \nUnited States that have been impac ted by this public health crisis. ", "page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65caac9018d3d0a371ae0af92c768078e30fbeeacb799b0bf32f7768bfb7e6bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b73a2fb4-dd1c-4380-a8c1-c0e82a86ba0e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nIf we're able to reach a final settlement, it would provide immediate relief to thousands of communities across the \nUnited States that have been impac ted by this public health crisis.  While we strongly dispute the allegations made \nin these lawsuits, we believe that bringing resolution to these outstanding claims is in the best interest of those \nimpacted by this crisis.  We also believe resolution is in t he best interest of our shareholders, and will allow us to \nfurther focus on the business and our role in protecting the safety and the integrity of the pharmaceutical supply \nchain.  \n \n We remain committed to doing our part to fight against the opioid epidemic  through efforts to continuously \nenhance our anti -diversion programs and to advocate for reform at the state and national level.  If the settlement \ncannot be finalized or plaintiffs instead choose to pursue their claims in court, we are prepared to litigate  against \nthose claims, and we remain confident in our defenses.  \n \n We also recently announced that we entered into an agreement to sell several of our McKesson Europe \nbusinesses to the PHOENIX Group, who we believe is the right and natural successor to McKesson and the ideal \nleader of these European businesses going forward. ", "original_text": "We also believe resolution is in t he best interest of our shareholders, and will allow us to \nfurther focus on the business and our role in protecting the safety and the integrity of the pharmaceutical supply \nchain.  \n \n"}, "hash": "3026f4297526920a83db7a848c226fd58ff5ef938827a408ab1d3c54eb1bebb1", "class_name": "RelatedNodeInfo"}}, "text": "While we strongly dispute the allegations made \nin these lawsuits, we believe that bringing resolution to these outstanding claims is in the best interest of those \nimpacted by this crisis. ", "start_char_idx": 366, "end_char_idx": 556, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b73a2fb4-dd1c-4380-a8c1-c0e82a86ba0e": {"__data__": {"id_": "b73a2fb4-dd1c-4380-a8c1-c0e82a86ba0e", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nIf we're able to reach a final settlement, it would provide immediate relief to thousands of communities across the \nUnited States that have been impac ted by this public health crisis.  While we strongly dispute the allegations made \nin these lawsuits, we believe that bringing resolution to these outstanding claims is in the best interest of those \nimpacted by this crisis.  We also believe resolution is in t he best interest of our shareholders, and will allow us to \nfurther focus on the business and our role in protecting the safety and the integrity of the pharmaceutical supply \nchain.  \n \n We remain committed to doing our part to fight against the opioid epidemic  through efforts to continuously \nenhance our anti -diversion programs and to advocate for reform at the state and national level.  If the settlement \ncannot be finalized or plaintiffs instead choose to pursue their claims in court, we are prepared to litigate  against \nthose claims, and we remain confident in our defenses.  \n \n We also recently announced that we entered into an agreement to sell several of our McKesson Europe \nbusinesses to the PHOENIX Group, who we believe is the right and natural successor to McKesson and the ideal \nleader of these European businesses going forward. ", "original_text": "We also believe resolution is in t he best interest of our shareholders, and will allow us to \nfurther focus on the business and our role in protecting the safety and the integrity of the pharmaceutical supply \nchain.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "aab73de7-ebef-4918-a603-d86999a6bb6b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd1ba625e40547f387ed9f87e5863c4972d0e09d6489fa3c2949a93197be6035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8dbfb1e4-9b0c-4486-81d0-c72af5a1de1a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nIf we're able to reach a final settlement, it would provide immediate relief to thousands of communities across the \nUnited States that have been impac ted by this public health crisis.  While we strongly dispute the allegations made \nin these lawsuits, we believe that bringing resolution to these outstanding claims is in the best interest of those \nimpacted by this crisis.  We also believe resolution is in t he best interest of our shareholders, and will allow us to \nfurther focus on the business and our role in protecting the safety and the integrity of the pharmaceutical supply \nchain.  \n \n We remain committed to doing our part to fight against the opioid epidemic  through efforts to continuously \nenhance our anti -diversion programs and to advocate for reform at the state and national level.  If the settlement \ncannot be finalized or plaintiffs instead choose to pursue their claims in court, we are prepared to litigate  against \nthose claims, and we remain confident in our defenses.  \n \n", "original_text": "While we strongly dispute the allegations made \nin these lawsuits, we believe that bringing resolution to these outstanding claims is in the best interest of those \nimpacted by this crisis. ", "page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "06d65caa869fd4f69a41ad1878cddd39ec7b7fe9f71b1cd50e594af9611c6983", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "287a00fc-2062-4d04-9545-f3a31d0fe8da", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nIf we're able to reach a final settlement, it would provide immediate relief to thousands of communities across the \nUnited States that have been impac ted by this public health crisis.  While we strongly dispute the allegations made \nin these lawsuits, we believe that bringing resolution to these outstanding claims is in the best interest of those \nimpacted by this crisis.  We also believe resolution is in t he best interest of our shareholders, and will allow us to \nfurther focus on the business and our role in protecting the safety and the integrity of the pharmaceutical supply \nchain.  \n \n We remain committed to doing our part to fight against the opioid epidemic  through efforts to continuously \nenhance our anti -diversion programs and to advocate for reform at the state and national level.  If the settlement \ncannot be finalized or plaintiffs instead choose to pursue their claims in court, we are prepared to litigate  against \nthose claims, and we remain confident in our defenses.  \n \n We also recently announced that we entered into an agreement to sell several of our McKesson Europe \nbusinesses to the PHOENIX Group, who we believe is the right and natural successor to McKesson and the ideal \nleader of these European businesses going forward.  The agreement includes our McKesson Europe businesses \nin France, Italy, Ireland, Portugal, Belgium and Slovenia as well as our German AG headquarters in Stuttgart, our \nshared service  center in Lithuania, our German wound care business and our equity stake in our joint venture in \nthe Netherlands. ", "original_text": "We remain committed to doing our part to fight against the opioid epidemic  through efforts to continuously \nenhance our anti -diversion programs and to advocate for reform at the state and national level. "}, "hash": "69b3141841a72b2f85cb92ec6efbdf94c53c256a8b962178739d825e529416f6", "class_name": "RelatedNodeInfo"}}, "text": "We also believe resolution is in t he best interest of our shareholders, and will allow us to \nfurther focus on the business and our role in protecting the safety and the integrity of the pharmaceutical supply \nchain.  \n \n", "start_char_idx": 556, "end_char_idx": 778, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "287a00fc-2062-4d04-9545-f3a31d0fe8da": {"__data__": {"id_": "287a00fc-2062-4d04-9545-f3a31d0fe8da", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nIf we're able to reach a final settlement, it would provide immediate relief to thousands of communities across the \nUnited States that have been impac ted by this public health crisis.  While we strongly dispute the allegations made \nin these lawsuits, we believe that bringing resolution to these outstanding claims is in the best interest of those \nimpacted by this crisis.  We also believe resolution is in t he best interest of our shareholders, and will allow us to \nfurther focus on the business and our role in protecting the safety and the integrity of the pharmaceutical supply \nchain.  \n \n We remain committed to doing our part to fight against the opioid epidemic  through efforts to continuously \nenhance our anti -diversion programs and to advocate for reform at the state and national level.  If the settlement \ncannot be finalized or plaintiffs instead choose to pursue their claims in court, we are prepared to litigate  against \nthose claims, and we remain confident in our defenses.  \n \n We also recently announced that we entered into an agreement to sell several of our McKesson Europe \nbusinesses to the PHOENIX Group, who we believe is the right and natural successor to McKesson and the ideal \nleader of these European businesses going forward.  The agreement includes our McKesson Europe businesses \nin France, Italy, Ireland, Portugal, Belgium and Slovenia as well as our German AG headquarters in Stuttgart, our \nshared service  center in Lithuania, our German wound care business and our equity stake in our joint venture in \nthe Netherlands. ", "original_text": "We remain committed to doing our part to fight against the opioid epidemic  through efforts to continuously \nenhance our anti -diversion programs and to advocate for reform at the state and national level. ", "page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "aab73de7-ebef-4918-a603-d86999a6bb6b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd1ba625e40547f387ed9f87e5863c4972d0e09d6489fa3c2949a93197be6035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b73a2fb4-dd1c-4380-a8c1-c0e82a86ba0e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nIf we're able to reach a final settlement, it would provide immediate relief to thousands of communities across the \nUnited States that have been impac ted by this public health crisis.  While we strongly dispute the allegations made \nin these lawsuits, we believe that bringing resolution to these outstanding claims is in the best interest of those \nimpacted by this crisis.  We also believe resolution is in t he best interest of our shareholders, and will allow us to \nfurther focus on the business and our role in protecting the safety and the integrity of the pharmaceutical supply \nchain.  \n \n We remain committed to doing our part to fight against the opioid epidemic  through efforts to continuously \nenhance our anti -diversion programs and to advocate for reform at the state and national level.  If the settlement \ncannot be finalized or plaintiffs instead choose to pursue their claims in court, we are prepared to litigate  against \nthose claims, and we remain confident in our defenses.  \n \n We also recently announced that we entered into an agreement to sell several of our McKesson Europe \nbusinesses to the PHOENIX Group, who we believe is the right and natural successor to McKesson and the ideal \nleader of these European businesses going forward. ", "original_text": "We also believe resolution is in t he best interest of our shareholders, and will allow us to \nfurther focus on the business and our role in protecting the safety and the integrity of the pharmaceutical supply \nchain.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7e865673486f497e4f2a33c33683a760e997fb43902aee81ca5f00d55df39170", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "60879f82-860d-40cc-8e6e-7646a7f4c04f", "node_type": "1", "metadata": {"window": "While we strongly dispute the allegations made \nin these lawsuits, we believe that bringing resolution to these outstanding claims is in the best interest of those \nimpacted by this crisis.  We also believe resolution is in t he best interest of our shareholders, and will allow us to \nfurther focus on the business and our role in protecting the safety and the integrity of the pharmaceutical supply \nchain.  \n \n We remain committed to doing our part to fight against the opioid epidemic  through efforts to continuously \nenhance our anti -diversion programs and to advocate for reform at the state and national level.  If the settlement \ncannot be finalized or plaintiffs instead choose to pursue their claims in court, we are prepared to litigate  against \nthose claims, and we remain confident in our defenses.  \n \n We also recently announced that we entered into an agreement to sell several of our McKesson Europe \nbusinesses to the PHOENIX Group, who we believe is the right and natural successor to McKesson and the ideal \nleader of these European businesses going forward.  The agreement includes our McKesson Europe businesses \nin France, Italy, Ireland, Portugal, Belgium and Slovenia as well as our German AG headquarters in Stuttgart, our \nshared service  center in Lithuania, our German wound care business and our equity stake in our joint venture in \nthe Netherlands.  This transaction is expected to close in fiscal 2023, subject to customary closing conditions, \nincluding the receipt of required regulatory a pprovals.  \n \n", "original_text": "If the settlement \ncannot be finalized or plaintiffs instead choose to pursue their claims in court, we are prepared to litigate  against \nthose claims, and we remain confident in our defenses.  \n \n"}, "hash": "046012f1038f126a19e21b1b6257917ec12338482167a523845d302f61eba5cb", "class_name": "RelatedNodeInfo"}}, "text": "We remain committed to doing our part to fight against the opioid epidemic  through efforts to continuously \nenhance our anti -diversion programs and to advocate for reform at the state and national level. ", "start_char_idx": 778, "end_char_idx": 984, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "60879f82-860d-40cc-8e6e-7646a7f4c04f": {"__data__": {"id_": "60879f82-860d-40cc-8e6e-7646a7f4c04f", "embedding": null, "metadata": {"window": "While we strongly dispute the allegations made \nin these lawsuits, we believe that bringing resolution to these outstanding claims is in the best interest of those \nimpacted by this crisis.  We also believe resolution is in t he best interest of our shareholders, and will allow us to \nfurther focus on the business and our role in protecting the safety and the integrity of the pharmaceutical supply \nchain.  \n \n We remain committed to doing our part to fight against the opioid epidemic  through efforts to continuously \nenhance our anti -diversion programs and to advocate for reform at the state and national level.  If the settlement \ncannot be finalized or plaintiffs instead choose to pursue their claims in court, we are prepared to litigate  against \nthose claims, and we remain confident in our defenses.  \n \n We also recently announced that we entered into an agreement to sell several of our McKesson Europe \nbusinesses to the PHOENIX Group, who we believe is the right and natural successor to McKesson and the ideal \nleader of these European businesses going forward.  The agreement includes our McKesson Europe businesses \nin France, Italy, Ireland, Portugal, Belgium and Slovenia as well as our German AG headquarters in Stuttgart, our \nshared service  center in Lithuania, our German wound care business and our equity stake in our joint venture in \nthe Netherlands.  This transaction is expected to close in fiscal 2023, subject to customary closing conditions, \nincluding the receipt of required regulatory a pprovals.  \n \n", "original_text": "If the settlement \ncannot be finalized or plaintiffs instead choose to pursue their claims in court, we are prepared to litigate  against \nthose claims, and we remain confident in our defenses.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "aab73de7-ebef-4918-a603-d86999a6bb6b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd1ba625e40547f387ed9f87e5863c4972d0e09d6489fa3c2949a93197be6035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "287a00fc-2062-4d04-9545-f3a31d0fe8da", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nIf we're able to reach a final settlement, it would provide immediate relief to thousands of communities across the \nUnited States that have been impac ted by this public health crisis.  While we strongly dispute the allegations made \nin these lawsuits, we believe that bringing resolution to these outstanding claims is in the best interest of those \nimpacted by this crisis.  We also believe resolution is in t he best interest of our shareholders, and will allow us to \nfurther focus on the business and our role in protecting the safety and the integrity of the pharmaceutical supply \nchain.  \n \n We remain committed to doing our part to fight against the opioid epidemic  through efforts to continuously \nenhance our anti -diversion programs and to advocate for reform at the state and national level.  If the settlement \ncannot be finalized or plaintiffs instead choose to pursue their claims in court, we are prepared to litigate  against \nthose claims, and we remain confident in our defenses.  \n \n We also recently announced that we entered into an agreement to sell several of our McKesson Europe \nbusinesses to the PHOENIX Group, who we believe is the right and natural successor to McKesson and the ideal \nleader of these European businesses going forward.  The agreement includes our McKesson Europe businesses \nin France, Italy, Ireland, Portugal, Belgium and Slovenia as well as our German AG headquarters in Stuttgart, our \nshared service  center in Lithuania, our German wound care business and our equity stake in our joint venture in \nthe Netherlands. ", "original_text": "We remain committed to doing our part to fight against the opioid epidemic  through efforts to continuously \nenhance our anti -diversion programs and to advocate for reform at the state and national level. ", "page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3adb48207736a0cd6c9bf94908be05e0a1fc9449065c0080973e6dd21d026c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6617c27-4688-48c7-addb-fbd8d2495fc1", "node_type": "1", "metadata": {"window": "We also believe resolution is in t he best interest of our shareholders, and will allow us to \nfurther focus on the business and our role in protecting the safety and the integrity of the pharmaceutical supply \nchain.  \n \n We remain committed to doing our part to fight against the opioid epidemic  through efforts to continuously \nenhance our anti -diversion programs and to advocate for reform at the state and national level.  If the settlement \ncannot be finalized or plaintiffs instead choose to pursue their claims in court, we are prepared to litigate  against \nthose claims, and we remain confident in our defenses.  \n \n We also recently announced that we entered into an agreement to sell several of our McKesson Europe \nbusinesses to the PHOENIX Group, who we believe is the right and natural successor to McKesson and the ideal \nleader of these European businesses going forward.  The agreement includes our McKesson Europe businesses \nin France, Italy, Ireland, Portugal, Belgium and Slovenia as well as our German AG headquarters in Stuttgart, our \nshared service  center in Lithuania, our German wound care business and our equity stake in our joint venture in \nthe Netherlands.  This transaction is expected to close in fiscal 2023, subject to customary closing conditions, \nincluding the receipt of required regulatory a pprovals.  \n \n Our remaining European businesses in the UK, Norway, Austria and Denmark were not included in this \ntransaction and will continue to be operated by McKesson. ", "original_text": "We also recently announced that we entered into an agreement to sell several of our McKesson Europe \nbusinesses to the PHOENIX Group, who we believe is the right and natural successor to McKesson and the ideal \nleader of these European businesses going forward. "}, "hash": "caba936244d4ea253f893053b42f43980496a462bcd6525236cca9b198a4d13e", "class_name": "RelatedNodeInfo"}}, "text": "If the settlement \ncannot be finalized or plaintiffs instead choose to pursue their claims in court, we are prepared to litigate  against \nthose claims, and we remain confident in our defenses.  \n \n", "start_char_idx": 984, "end_char_idx": 1182, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6617c27-4688-48c7-addb-fbd8d2495fc1": {"__data__": {"id_": "b6617c27-4688-48c7-addb-fbd8d2495fc1", "embedding": null, "metadata": {"window": "We also believe resolution is in t he best interest of our shareholders, and will allow us to \nfurther focus on the business and our role in protecting the safety and the integrity of the pharmaceutical supply \nchain.  \n \n We remain committed to doing our part to fight against the opioid epidemic  through efforts to continuously \nenhance our anti -diversion programs and to advocate for reform at the state and national level.  If the settlement \ncannot be finalized or plaintiffs instead choose to pursue their claims in court, we are prepared to litigate  against \nthose claims, and we remain confident in our defenses.  \n \n We also recently announced that we entered into an agreement to sell several of our McKesson Europe \nbusinesses to the PHOENIX Group, who we believe is the right and natural successor to McKesson and the ideal \nleader of these European businesses going forward.  The agreement includes our McKesson Europe businesses \nin France, Italy, Ireland, Portugal, Belgium and Slovenia as well as our German AG headquarters in Stuttgart, our \nshared service  center in Lithuania, our German wound care business and our equity stake in our joint venture in \nthe Netherlands.  This transaction is expected to close in fiscal 2023, subject to customary closing conditions, \nincluding the receipt of required regulatory a pprovals.  \n \n Our remaining European businesses in the UK, Norway, Austria and Denmark were not included in this \ntransaction and will continue to be operated by McKesson. ", "original_text": "We also recently announced that we entered into an agreement to sell several of our McKesson Europe \nbusinesses to the PHOENIX Group, who we believe is the right and natural successor to McKesson and the ideal \nleader of these European businesses going forward. ", "page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "aab73de7-ebef-4918-a603-d86999a6bb6b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd1ba625e40547f387ed9f87e5863c4972d0e09d6489fa3c2949a93197be6035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "60879f82-860d-40cc-8e6e-7646a7f4c04f", "node_type": "1", "metadata": {"window": "While we strongly dispute the allegations made \nin these lawsuits, we believe that bringing resolution to these outstanding claims is in the best interest of those \nimpacted by this crisis.  We also believe resolution is in t he best interest of our shareholders, and will allow us to \nfurther focus on the business and our role in protecting the safety and the integrity of the pharmaceutical supply \nchain.  \n \n We remain committed to doing our part to fight against the opioid epidemic  through efforts to continuously \nenhance our anti -diversion programs and to advocate for reform at the state and national level.  If the settlement \ncannot be finalized or plaintiffs instead choose to pursue their claims in court, we are prepared to litigate  against \nthose claims, and we remain confident in our defenses.  \n \n We also recently announced that we entered into an agreement to sell several of our McKesson Europe \nbusinesses to the PHOENIX Group, who we believe is the right and natural successor to McKesson and the ideal \nleader of these European businesses going forward.  The agreement includes our McKesson Europe businesses \nin France, Italy, Ireland, Portugal, Belgium and Slovenia as well as our German AG headquarters in Stuttgart, our \nshared service  center in Lithuania, our German wound care business and our equity stake in our joint venture in \nthe Netherlands.  This transaction is expected to close in fiscal 2023, subject to customary closing conditions, \nincluding the receipt of required regulatory a pprovals.  \n \n", "original_text": "If the settlement \ncannot be finalized or plaintiffs instead choose to pursue their claims in court, we are prepared to litigate  against \nthose claims, and we remain confident in our defenses.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ef5f38595bada2e84f4fcd74a0977433ceeff5144104749f24295c014870d82", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d38de659-b006-4b2b-925c-f77785825da3", "node_type": "1", "metadata": {"window": "We remain committed to doing our part to fight against the opioid epidemic  through efforts to continuously \nenhance our anti -diversion programs and to advocate for reform at the state and national level.  If the settlement \ncannot be finalized or plaintiffs instead choose to pursue their claims in court, we are prepared to litigate  against \nthose claims, and we remain confident in our defenses.  \n \n We also recently announced that we entered into an agreement to sell several of our McKesson Europe \nbusinesses to the PHOENIX Group, who we believe is the right and natural successor to McKesson and the ideal \nleader of these European businesses going forward.  The agreement includes our McKesson Europe businesses \nin France, Italy, Ireland, Portugal, Belgium and Slovenia as well as our German AG headquarters in Stuttgart, our \nshared service  center in Lithuania, our German wound care business and our equity stake in our joint venture in \nthe Netherlands.  This transaction is expected to close in fiscal 2023, subject to customary closing conditions, \nincluding the receipt of required regulatory a pprovals.  \n \n Our remaining European businesses in the UK, Norway, Austria and Denmark were not included in this \ntransaction and will continue to be operated by McKesson.  However, we are exploring strategic alternatives for \nthese remaining businesses as we al ign future investments to our growth strategies outside of Europe. ", "original_text": "The agreement includes our McKesson Europe businesses \nin France, Italy, Ireland, Portugal, Belgium and Slovenia as well as our German AG headquarters in Stuttgart, our \nshared service  center in Lithuania, our German wound care business and our equity stake in our joint venture in \nthe Netherlands. "}, "hash": "8c9325e5640fb6b8cc012024f8cd6cdf7aa762da15b5d8035c877295fbb8cc4e", "class_name": "RelatedNodeInfo"}}, "text": "We also recently announced that we entered into an agreement to sell several of our McKesson Europe \nbusinesses to the PHOENIX Group, who we believe is the right and natural successor to McKesson and the ideal \nleader of these European businesses going forward. ", "start_char_idx": 1182, "end_char_idx": 1444, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d38de659-b006-4b2b-925c-f77785825da3": {"__data__": {"id_": "d38de659-b006-4b2b-925c-f77785825da3", "embedding": null, "metadata": {"window": "We remain committed to doing our part to fight against the opioid epidemic  through efforts to continuously \nenhance our anti -diversion programs and to advocate for reform at the state and national level.  If the settlement \ncannot be finalized or plaintiffs instead choose to pursue their claims in court, we are prepared to litigate  against \nthose claims, and we remain confident in our defenses.  \n \n We also recently announced that we entered into an agreement to sell several of our McKesson Europe \nbusinesses to the PHOENIX Group, who we believe is the right and natural successor to McKesson and the ideal \nleader of these European businesses going forward.  The agreement includes our McKesson Europe businesses \nin France, Italy, Ireland, Portugal, Belgium and Slovenia as well as our German AG headquarters in Stuttgart, our \nshared service  center in Lithuania, our German wound care business and our equity stake in our joint venture in \nthe Netherlands.  This transaction is expected to close in fiscal 2023, subject to customary closing conditions, \nincluding the receipt of required regulatory a pprovals.  \n \n Our remaining European businesses in the UK, Norway, Austria and Denmark were not included in this \ntransaction and will continue to be operated by McKesson.  However, we are exploring strategic alternatives for \nthese remaining businesses as we al ign future investments to our growth strategies outside of Europe. ", "original_text": "The agreement includes our McKesson Europe businesses \nin France, Italy, Ireland, Portugal, Belgium and Slovenia as well as our German AG headquarters in Stuttgart, our \nshared service  center in Lithuania, our German wound care business and our equity stake in our joint venture in \nthe Netherlands. ", "page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "aab73de7-ebef-4918-a603-d86999a6bb6b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd1ba625e40547f387ed9f87e5863c4972d0e09d6489fa3c2949a93197be6035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6617c27-4688-48c7-addb-fbd8d2495fc1", "node_type": "1", "metadata": {"window": "We also believe resolution is in t he best interest of our shareholders, and will allow us to \nfurther focus on the business and our role in protecting the safety and the integrity of the pharmaceutical supply \nchain.  \n \n We remain committed to doing our part to fight against the opioid epidemic  through efforts to continuously \nenhance our anti -diversion programs and to advocate for reform at the state and national level.  If the settlement \ncannot be finalized or plaintiffs instead choose to pursue their claims in court, we are prepared to litigate  against \nthose claims, and we remain confident in our defenses.  \n \n We also recently announced that we entered into an agreement to sell several of our McKesson Europe \nbusinesses to the PHOENIX Group, who we believe is the right and natural successor to McKesson and the ideal \nleader of these European businesses going forward.  The agreement includes our McKesson Europe businesses \nin France, Italy, Ireland, Portugal, Belgium and Slovenia as well as our German AG headquarters in Stuttgart, our \nshared service  center in Lithuania, our German wound care business and our equity stake in our joint venture in \nthe Netherlands.  This transaction is expected to close in fiscal 2023, subject to customary closing conditions, \nincluding the receipt of required regulatory a pprovals.  \n \n Our remaining European businesses in the UK, Norway, Austria and Denmark were not included in this \ntransaction and will continue to be operated by McKesson. ", "original_text": "We also recently announced that we entered into an agreement to sell several of our McKesson Europe \nbusinesses to the PHOENIX Group, who we believe is the right and natural successor to McKesson and the ideal \nleader of these European businesses going forward. ", "page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "55897c33584e6f4f534fd68cf86e3348b3139084b698c735c81705ac60cc35a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3348ed2d-9eba-42fd-90d8-39141be3c4cd", "node_type": "1", "metadata": {"window": "If the settlement \ncannot be finalized or plaintiffs instead choose to pursue their claims in court, we are prepared to litigate  against \nthose claims, and we remain confident in our defenses.  \n \n We also recently announced that we entered into an agreement to sell several of our McKesson Europe \nbusinesses to the PHOENIX Group, who we believe is the right and natural successor to McKesson and the ideal \nleader of these European businesses going forward.  The agreement includes our McKesson Europe businesses \nin France, Italy, Ireland, Portugal, Belgium and Slovenia as well as our German AG headquarters in Stuttgart, our \nshared service  center in Lithuania, our German wound care business and our equity stake in our joint venture in \nthe Netherlands.  This transaction is expected to close in fiscal 2023, subject to customary closing conditions, \nincluding the receipt of required regulatory a pprovals.  \n \n Our remaining European businesses in the UK, Norway, Austria and Denmark were not included in this \ntransaction and will continue to be operated by McKesson.  However, we are exploring strategic alternatives for \nthese remaining businesses as we al ign future investments to our growth strategies outside of Europe.  We \nbelieve fully exiting Europe is another step towards becoming a more streamlined and efficient organization.  \n \n", "original_text": "This transaction is expected to close in fiscal 2023, subject to customary closing conditions, \nincluding the receipt of required regulatory a pprovals.  \n \n"}, "hash": "02900e77ff5e56591beb390473d160e9d2c4b416f03373902245a3f1450393b3", "class_name": "RelatedNodeInfo"}}, "text": "The agreement includes our McKesson Europe businesses \nin France, Italy, Ireland, Portugal, Belgium and Slovenia as well as our German AG headquarters in Stuttgart, our \nshared service  center in Lithuania, our German wound care business and our equity stake in our joint venture in \nthe Netherlands. ", "start_char_idx": 1444, "end_char_idx": 1745, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3348ed2d-9eba-42fd-90d8-39141be3c4cd": {"__data__": {"id_": "3348ed2d-9eba-42fd-90d8-39141be3c4cd", "embedding": null, "metadata": {"window": "If the settlement \ncannot be finalized or plaintiffs instead choose to pursue their claims in court, we are prepared to litigate  against \nthose claims, and we remain confident in our defenses.  \n \n We also recently announced that we entered into an agreement to sell several of our McKesson Europe \nbusinesses to the PHOENIX Group, who we believe is the right and natural successor to McKesson and the ideal \nleader of these European businesses going forward.  The agreement includes our McKesson Europe businesses \nin France, Italy, Ireland, Portugal, Belgium and Slovenia as well as our German AG headquarters in Stuttgart, our \nshared service  center in Lithuania, our German wound care business and our equity stake in our joint venture in \nthe Netherlands.  This transaction is expected to close in fiscal 2023, subject to customary closing conditions, \nincluding the receipt of required regulatory a pprovals.  \n \n Our remaining European businesses in the UK, Norway, Austria and Denmark were not included in this \ntransaction and will continue to be operated by McKesson.  However, we are exploring strategic alternatives for \nthese remaining businesses as we al ign future investments to our growth strategies outside of Europe.  We \nbelieve fully exiting Europe is another step towards becoming a more streamlined and efficient organization.  \n \n", "original_text": "This transaction is expected to close in fiscal 2023, subject to customary closing conditions, \nincluding the receipt of required regulatory a pprovals.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "aab73de7-ebef-4918-a603-d86999a6bb6b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd1ba625e40547f387ed9f87e5863c4972d0e09d6489fa3c2949a93197be6035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d38de659-b006-4b2b-925c-f77785825da3", "node_type": "1", "metadata": {"window": "We remain committed to doing our part to fight against the opioid epidemic  through efforts to continuously \nenhance our anti -diversion programs and to advocate for reform at the state and national level.  If the settlement \ncannot be finalized or plaintiffs instead choose to pursue their claims in court, we are prepared to litigate  against \nthose claims, and we remain confident in our defenses.  \n \n We also recently announced that we entered into an agreement to sell several of our McKesson Europe \nbusinesses to the PHOENIX Group, who we believe is the right and natural successor to McKesson and the ideal \nleader of these European businesses going forward.  The agreement includes our McKesson Europe businesses \nin France, Italy, Ireland, Portugal, Belgium and Slovenia as well as our German AG headquarters in Stuttgart, our \nshared service  center in Lithuania, our German wound care business and our equity stake in our joint venture in \nthe Netherlands.  This transaction is expected to close in fiscal 2023, subject to customary closing conditions, \nincluding the receipt of required regulatory a pprovals.  \n \n Our remaining European businesses in the UK, Norway, Austria and Denmark were not included in this \ntransaction and will continue to be operated by McKesson.  However, we are exploring strategic alternatives for \nthese remaining businesses as we al ign future investments to our growth strategies outside of Europe. ", "original_text": "The agreement includes our McKesson Europe businesses \nin France, Italy, Ireland, Portugal, Belgium and Slovenia as well as our German AG headquarters in Stuttgart, our \nshared service  center in Lithuania, our German wound care business and our equity stake in our joint venture in \nthe Netherlands. ", "page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4bb5f29c88b4b5cf62d8f4215390bac6c701dde81bb34b6a7fa5980030b7e1f5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "21e0f154-4ae3-452f-9f66-7559709e042e", "node_type": "1", "metadata": {"window": "We also recently announced that we entered into an agreement to sell several of our McKesson Europe \nbusinesses to the PHOENIX Group, who we believe is the right and natural successor to McKesson and the ideal \nleader of these European businesses going forward.  The agreement includes our McKesson Europe businesses \nin France, Italy, Ireland, Portugal, Belgium and Slovenia as well as our German AG headquarters in Stuttgart, our \nshared service  center in Lithuania, our German wound care business and our equity stake in our joint venture in \nthe Netherlands.  This transaction is expected to close in fiscal 2023, subject to customary closing conditions, \nincluding the receipt of required regulatory a pprovals.  \n \n Our remaining European businesses in the UK, Norway, Austria and Denmark were not included in this \ntransaction and will continue to be operated by McKesson.  However, we are exploring strategic alternatives for \nthese remaining businesses as we al ign future investments to our growth strategies outside of Europe.  We \nbelieve fully exiting Europe is another step towards becoming a more streamlined and efficient organization.  \n \n Let me turn now to our performance in the quarter. ", "original_text": "Our remaining European businesses in the UK, Norway, Austria and Denmark were not included in this \ntransaction and will continue to be operated by McKesson. "}, "hash": "ded70989cb0998f6a95c74933081a6ed108c08eea704145c70974df6aa45fe52", "class_name": "RelatedNodeInfo"}}, "text": "This transaction is expected to close in fiscal 2023, subject to customary closing conditions, \nincluding the receipt of required regulatory a pprovals.  \n \n", "start_char_idx": 1745, "end_char_idx": 1902, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "21e0f154-4ae3-452f-9f66-7559709e042e": {"__data__": {"id_": "21e0f154-4ae3-452f-9f66-7559709e042e", "embedding": null, "metadata": {"window": "We also recently announced that we entered into an agreement to sell several of our McKesson Europe \nbusinesses to the PHOENIX Group, who we believe is the right and natural successor to McKesson and the ideal \nleader of these European businesses going forward.  The agreement includes our McKesson Europe businesses \nin France, Italy, Ireland, Portugal, Belgium and Slovenia as well as our German AG headquarters in Stuttgart, our \nshared service  center in Lithuania, our German wound care business and our equity stake in our joint venture in \nthe Netherlands.  This transaction is expected to close in fiscal 2023, subject to customary closing conditions, \nincluding the receipt of required regulatory a pprovals.  \n \n Our remaining European businesses in the UK, Norway, Austria and Denmark were not included in this \ntransaction and will continue to be operated by McKesson.  However, we are exploring strategic alternatives for \nthese remaining businesses as we al ign future investments to our growth strategies outside of Europe.  We \nbelieve fully exiting Europe is another step towards becoming a more streamlined and efficient organization.  \n \n Let me turn now to our performance in the quarter. ", "original_text": "Our remaining European businesses in the UK, Norway, Austria and Denmark were not included in this \ntransaction and will continue to be operated by McKesson. ", "page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "aab73de7-ebef-4918-a603-d86999a6bb6b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd1ba625e40547f387ed9f87e5863c4972d0e09d6489fa3c2949a93197be6035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3348ed2d-9eba-42fd-90d8-39141be3c4cd", "node_type": "1", "metadata": {"window": "If the settlement \ncannot be finalized or plaintiffs instead choose to pursue their claims in court, we are prepared to litigate  against \nthose claims, and we remain confident in our defenses.  \n \n We also recently announced that we entered into an agreement to sell several of our McKesson Europe \nbusinesses to the PHOENIX Group, who we believe is the right and natural successor to McKesson and the ideal \nleader of these European businesses going forward.  The agreement includes our McKesson Europe businesses \nin France, Italy, Ireland, Portugal, Belgium and Slovenia as well as our German AG headquarters in Stuttgart, our \nshared service  center in Lithuania, our German wound care business and our equity stake in our joint venture in \nthe Netherlands.  This transaction is expected to close in fiscal 2023, subject to customary closing conditions, \nincluding the receipt of required regulatory a pprovals.  \n \n Our remaining European businesses in the UK, Norway, Austria and Denmark were not included in this \ntransaction and will continue to be operated by McKesson.  However, we are exploring strategic alternatives for \nthese remaining businesses as we al ign future investments to our growth strategies outside of Europe.  We \nbelieve fully exiting Europe is another step towards becoming a more streamlined and efficient organization.  \n \n", "original_text": "This transaction is expected to close in fiscal 2023, subject to customary closing conditions, \nincluding the receipt of required regulatory a pprovals.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9d95a7099f59392f78e9b6f1ac7b34dd22954adfc2b01b6a63469a26805c5530", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b02d88aa-a561-4588-be76-7f2bad2be6cf", "node_type": "1", "metadata": {"window": "The agreement includes our McKesson Europe businesses \nin France, Italy, Ireland, Portugal, Belgium and Slovenia as well as our German AG headquarters in Stuttgart, our \nshared service  center in Lithuania, our German wound care business and our equity stake in our joint venture in \nthe Netherlands.  This transaction is expected to close in fiscal 2023, subject to customary closing conditions, \nincluding the receipt of required regulatory a pprovals.  \n \n Our remaining European businesses in the UK, Norway, Austria and Denmark were not included in this \ntransaction and will continue to be operated by McKesson.  However, we are exploring strategic alternatives for \nthese remaining businesses as we al ign future investments to our growth strategies outside of Europe.  We \nbelieve fully exiting Europe is another step towards becoming a more streamlined and efficient organization.  \n \n Let me turn now to our performance in the quarter.  We are continuing to see the operating momentum we \ndiscussed on our fourth quarter fiscal 2021 earnings call. ", "original_text": "However, we are exploring strategic alternatives for \nthese remaining businesses as we al ign future investments to our growth strategies outside of Europe. "}, "hash": "4b525ef362d6fa9cf710845ebbb5f371363fb631f118223ad7ab6b7a2c19734a", "class_name": "RelatedNodeInfo"}}, "text": "Our remaining European businesses in the UK, Norway, Austria and Denmark were not included in this \ntransaction and will continue to be operated by McKesson. ", "start_char_idx": 1902, "end_char_idx": 2060, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b02d88aa-a561-4588-be76-7f2bad2be6cf": {"__data__": {"id_": "b02d88aa-a561-4588-be76-7f2bad2be6cf", "embedding": null, "metadata": {"window": "The agreement includes our McKesson Europe businesses \nin France, Italy, Ireland, Portugal, Belgium and Slovenia as well as our German AG headquarters in Stuttgart, our \nshared service  center in Lithuania, our German wound care business and our equity stake in our joint venture in \nthe Netherlands.  This transaction is expected to close in fiscal 2023, subject to customary closing conditions, \nincluding the receipt of required regulatory a pprovals.  \n \n Our remaining European businesses in the UK, Norway, Austria and Denmark were not included in this \ntransaction and will continue to be operated by McKesson.  However, we are exploring strategic alternatives for \nthese remaining businesses as we al ign future investments to our growth strategies outside of Europe.  We \nbelieve fully exiting Europe is another step towards becoming a more streamlined and efficient organization.  \n \n Let me turn now to our performance in the quarter.  We are continuing to see the operating momentum we \ndiscussed on our fourth quarter fiscal 2021 earnings call. ", "original_text": "However, we are exploring strategic alternatives for \nthese remaining businesses as we al ign future investments to our growth strategies outside of Europe. ", "page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "aab73de7-ebef-4918-a603-d86999a6bb6b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd1ba625e40547f387ed9f87e5863c4972d0e09d6489fa3c2949a93197be6035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "21e0f154-4ae3-452f-9f66-7559709e042e", "node_type": "1", "metadata": {"window": "We also recently announced that we entered into an agreement to sell several of our McKesson Europe \nbusinesses to the PHOENIX Group, who we believe is the right and natural successor to McKesson and the ideal \nleader of these European businesses going forward.  The agreement includes our McKesson Europe businesses \nin France, Italy, Ireland, Portugal, Belgium and Slovenia as well as our German AG headquarters in Stuttgart, our \nshared service  center in Lithuania, our German wound care business and our equity stake in our joint venture in \nthe Netherlands.  This transaction is expected to close in fiscal 2023, subject to customary closing conditions, \nincluding the receipt of required regulatory a pprovals.  \n \n Our remaining European businesses in the UK, Norway, Austria and Denmark were not included in this \ntransaction and will continue to be operated by McKesson.  However, we are exploring strategic alternatives for \nthese remaining businesses as we al ign future investments to our growth strategies outside of Europe.  We \nbelieve fully exiting Europe is another step towards becoming a more streamlined and efficient organization.  \n \n Let me turn now to our performance in the quarter. ", "original_text": "Our remaining European businesses in the UK, Norway, Austria and Denmark were not included in this \ntransaction and will continue to be operated by McKesson. ", "page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6469f8644cd021294e4424945a2baa842c53d521225d4e6cd0b73fd1133a4758", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a41e7c1-daf3-4602-b03e-372d076995bc", "node_type": "1", "metadata": {"window": "This transaction is expected to close in fiscal 2023, subject to customary closing conditions, \nincluding the receipt of required regulatory a pprovals.  \n \n Our remaining European businesses in the UK, Norway, Austria and Denmark were not included in this \ntransaction and will continue to be operated by McKesson.  However, we are exploring strategic alternatives for \nthese remaining businesses as we al ign future investments to our growth strategies outside of Europe.  We \nbelieve fully exiting Europe is another step towards becoming a more streamlined and efficient organization.  \n \n Let me turn now to our performance in the quarter.  We are continuing to see the operating momentum we \ndiscussed on our fourth quarter fiscal 2021 earnings call.  Today, we're reporting adjusted earnings per diluted \nshare of $5.56, ahead of our original expectations, resulting from the strength across our businesses and our \nroles in  the COVID -19 response efforts across the geographies in which we operate.  \n \n", "original_text": "We \nbelieve fully exiting Europe is another step towards becoming a more streamlined and efficient organization.  \n \n"}, "hash": "ae28cb576426c6d1e92cd41d8ec36e1303ad12faa364cf42284af8ab815494bc", "class_name": "RelatedNodeInfo"}}, "text": "However, we are exploring strategic alternatives for \nthese remaining businesses as we al ign future investments to our growth strategies outside of Europe. ", "start_char_idx": 2060, "end_char_idx": 2217, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a41e7c1-daf3-4602-b03e-372d076995bc": {"__data__": {"id_": "5a41e7c1-daf3-4602-b03e-372d076995bc", "embedding": null, "metadata": {"window": "This transaction is expected to close in fiscal 2023, subject to customary closing conditions, \nincluding the receipt of required regulatory a pprovals.  \n \n Our remaining European businesses in the UK, Norway, Austria and Denmark were not included in this \ntransaction and will continue to be operated by McKesson.  However, we are exploring strategic alternatives for \nthese remaining businesses as we al ign future investments to our growth strategies outside of Europe.  We \nbelieve fully exiting Europe is another step towards becoming a more streamlined and efficient organization.  \n \n Let me turn now to our performance in the quarter.  We are continuing to see the operating momentum we \ndiscussed on our fourth quarter fiscal 2021 earnings call.  Today, we're reporting adjusted earnings per diluted \nshare of $5.56, ahead of our original expectations, resulting from the strength across our businesses and our \nroles in  the COVID -19 response efforts across the geographies in which we operate.  \n \n", "original_text": "We \nbelieve fully exiting Europe is another step towards becoming a more streamlined and efficient organization.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "aab73de7-ebef-4918-a603-d86999a6bb6b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd1ba625e40547f387ed9f87e5863c4972d0e09d6489fa3c2949a93197be6035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b02d88aa-a561-4588-be76-7f2bad2be6cf", "node_type": "1", "metadata": {"window": "The agreement includes our McKesson Europe businesses \nin France, Italy, Ireland, Portugal, Belgium and Slovenia as well as our German AG headquarters in Stuttgart, our \nshared service  center in Lithuania, our German wound care business and our equity stake in our joint venture in \nthe Netherlands.  This transaction is expected to close in fiscal 2023, subject to customary closing conditions, \nincluding the receipt of required regulatory a pprovals.  \n \n Our remaining European businesses in the UK, Norway, Austria and Denmark were not included in this \ntransaction and will continue to be operated by McKesson.  However, we are exploring strategic alternatives for \nthese remaining businesses as we al ign future investments to our growth strategies outside of Europe.  We \nbelieve fully exiting Europe is another step towards becoming a more streamlined and efficient organization.  \n \n Let me turn now to our performance in the quarter.  We are continuing to see the operating momentum we \ndiscussed on our fourth quarter fiscal 2021 earnings call. ", "original_text": "However, we are exploring strategic alternatives for \nthese remaining businesses as we al ign future investments to our growth strategies outside of Europe. ", "page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "35248b335f764cbc39ca9b48463f8682fbf50aea91059ce7bae363686aac1d81", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c70e5224-e48b-4b44-9788-932c86458571", "node_type": "1", "metadata": {"window": "Our remaining European businesses in the UK, Norway, Austria and Denmark were not included in this \ntransaction and will continue to be operated by McKesson.  However, we are exploring strategic alternatives for \nthese remaining businesses as we al ign future investments to our growth strategies outside of Europe.  We \nbelieve fully exiting Europe is another step towards becoming a more streamlined and efficient organization.  \n \n Let me turn now to our performance in the quarter.  We are continuing to see the operating momentum we \ndiscussed on our fourth quarter fiscal 2021 earnings call.  Today, we're reporting adjusted earnings per diluted \nshare of $5.56, ahead of our original expectations, resulting from the strength across our businesses and our \nroles in  the COVID -19 response efforts across the geographies in which we operate.  \n \n Our US and international distribution businesses are playing an integral role in the pandemic response and our \noperational excellence and capabilities continue to be highlighted th rough our evolving partnership with the US \ngovernment's COVID -19 vaccine distribution efforts. ", "original_text": "Let me turn now to our performance in the quarter. "}, "hash": "ecff7de376ca7698622ca419987247a016511d52a285a7409645fcdaec19d78b", "class_name": "RelatedNodeInfo"}}, "text": "We \nbelieve fully exiting Europe is another step towards becoming a more streamlined and efficient organization.  \n \n", "start_char_idx": 2217, "end_char_idx": 2334, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c70e5224-e48b-4b44-9788-932c86458571": {"__data__": {"id_": "c70e5224-e48b-4b44-9788-932c86458571", "embedding": null, "metadata": {"window": "Our remaining European businesses in the UK, Norway, Austria and Denmark were not included in this \ntransaction and will continue to be operated by McKesson.  However, we are exploring strategic alternatives for \nthese remaining businesses as we al ign future investments to our growth strategies outside of Europe.  We \nbelieve fully exiting Europe is another step towards becoming a more streamlined and efficient organization.  \n \n Let me turn now to our performance in the quarter.  We are continuing to see the operating momentum we \ndiscussed on our fourth quarter fiscal 2021 earnings call.  Today, we're reporting adjusted earnings per diluted \nshare of $5.56, ahead of our original expectations, resulting from the strength across our businesses and our \nroles in  the COVID -19 response efforts across the geographies in which we operate.  \n \n Our US and international distribution businesses are playing an integral role in the pandemic response and our \noperational excellence and capabilities continue to be highlighted th rough our evolving partnership with the US \ngovernment's COVID -19 vaccine distribution efforts. ", "original_text": "Let me turn now to our performance in the quarter. ", "page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "aab73de7-ebef-4918-a603-d86999a6bb6b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd1ba625e40547f387ed9f87e5863c4972d0e09d6489fa3c2949a93197be6035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a41e7c1-daf3-4602-b03e-372d076995bc", "node_type": "1", "metadata": {"window": "This transaction is expected to close in fiscal 2023, subject to customary closing conditions, \nincluding the receipt of required regulatory a pprovals.  \n \n Our remaining European businesses in the UK, Norway, Austria and Denmark were not included in this \ntransaction and will continue to be operated by McKesson.  However, we are exploring strategic alternatives for \nthese remaining businesses as we al ign future investments to our growth strategies outside of Europe.  We \nbelieve fully exiting Europe is another step towards becoming a more streamlined and efficient organization.  \n \n Let me turn now to our performance in the quarter.  We are continuing to see the operating momentum we \ndiscussed on our fourth quarter fiscal 2021 earnings call.  Today, we're reporting adjusted earnings per diluted \nshare of $5.56, ahead of our original expectations, resulting from the strength across our businesses and our \nroles in  the COVID -19 response efforts across the geographies in which we operate.  \n \n", "original_text": "We \nbelieve fully exiting Europe is another step towards becoming a more streamlined and efficient organization.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05774308bb812ed1c1ea65ba2d68bbdf2cb70458aee77d71cd5c51396d7bd8bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2d48526-221e-4a5b-8e21-baf48fc1d8d9", "node_type": "1", "metadata": {"window": "However, we are exploring strategic alternatives for \nthese remaining businesses as we al ign future investments to our growth strategies outside of Europe.  We \nbelieve fully exiting Europe is another step towards becoming a more streamlined and efficient organization.  \n \n Let me turn now to our performance in the quarter.  We are continuing to see the operating momentum we \ndiscussed on our fourth quarter fiscal 2021 earnings call.  Today, we're reporting adjusted earnings per diluted \nshare of $5.56, ahead of our original expectations, resulting from the strength across our businesses and our \nroles in  the COVID -19 response efforts across the geographies in which we operate.  \n \n Our US and international distribution businesses are playing an integral role in the pandemic response and our \noperational excellence and capabilities continue to be highlighted th rough our evolving partnership with the US \ngovernment's COVID -19 vaccine distribution efforts.  Through July, our US pharmaceutical business has \nsuccessfully distributed over 185 million Moderna and J&J COVID -19 vaccines to administration sites across the \nUnited States, and our medical business has now assembled enough kits to support the administration of more \nthan 785 million doses for all vaccine types.  \n \n", "original_text": "We are continuing to see the operating momentum we \ndiscussed on our fourth quarter fiscal 2021 earnings call. "}, "hash": "3edb10385d0366fe22c5b28bad41f64d27ba256eaba3e038995f78235a7e9c91", "class_name": "RelatedNodeInfo"}}, "text": "Let me turn now to our performance in the quarter. ", "start_char_idx": 2334, "end_char_idx": 2385, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2d48526-221e-4a5b-8e21-baf48fc1d8d9": {"__data__": {"id_": "d2d48526-221e-4a5b-8e21-baf48fc1d8d9", "embedding": null, "metadata": {"window": "However, we are exploring strategic alternatives for \nthese remaining businesses as we al ign future investments to our growth strategies outside of Europe.  We \nbelieve fully exiting Europe is another step towards becoming a more streamlined and efficient organization.  \n \n Let me turn now to our performance in the quarter.  We are continuing to see the operating momentum we \ndiscussed on our fourth quarter fiscal 2021 earnings call.  Today, we're reporting adjusted earnings per diluted \nshare of $5.56, ahead of our original expectations, resulting from the strength across our businesses and our \nroles in  the COVID -19 response efforts across the geographies in which we operate.  \n \n Our US and international distribution businesses are playing an integral role in the pandemic response and our \noperational excellence and capabilities continue to be highlighted th rough our evolving partnership with the US \ngovernment's COVID -19 vaccine distribution efforts.  Through July, our US pharmaceutical business has \nsuccessfully distributed over 185 million Moderna and J&J COVID -19 vaccines to administration sites across the \nUnited States, and our medical business has now assembled enough kits to support the administration of more \nthan 785 million doses for all vaccine types.  \n \n", "original_text": "We are continuing to see the operating momentum we \ndiscussed on our fourth quarter fiscal 2021 earnings call. ", "page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "aab73de7-ebef-4918-a603-d86999a6bb6b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd1ba625e40547f387ed9f87e5863c4972d0e09d6489fa3c2949a93197be6035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c70e5224-e48b-4b44-9788-932c86458571", "node_type": "1", "metadata": {"window": "Our remaining European businesses in the UK, Norway, Austria and Denmark were not included in this \ntransaction and will continue to be operated by McKesson.  However, we are exploring strategic alternatives for \nthese remaining businesses as we al ign future investments to our growth strategies outside of Europe.  We \nbelieve fully exiting Europe is another step towards becoming a more streamlined and efficient organization.  \n \n Let me turn now to our performance in the quarter.  We are continuing to see the operating momentum we \ndiscussed on our fourth quarter fiscal 2021 earnings call.  Today, we're reporting adjusted earnings per diluted \nshare of $5.56, ahead of our original expectations, resulting from the strength across our businesses and our \nroles in  the COVID -19 response efforts across the geographies in which we operate.  \n \n Our US and international distribution businesses are playing an integral role in the pandemic response and our \noperational excellence and capabilities continue to be highlighted th rough our evolving partnership with the US \ngovernment's COVID -19 vaccine distribution efforts. ", "original_text": "Let me turn now to our performance in the quarter. ", "page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2055de93657d9a18dde840dbe3fa4bfd5c25819bf74097e430e77cf509839e87", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e702d4d-32a8-4918-8e7c-bf688c2c495d", "node_type": "1", "metadata": {"window": "We \nbelieve fully exiting Europe is another step towards becoming a more streamlined and efficient organization.  \n \n Let me turn now to our performance in the quarter.  We are continuing to see the operating momentum we \ndiscussed on our fourth quarter fiscal 2021 earnings call.  Today, we're reporting adjusted earnings per diluted \nshare of $5.56, ahead of our original expectations, resulting from the strength across our businesses and our \nroles in  the COVID -19 response efforts across the geographies in which we operate.  \n \n Our US and international distribution businesses are playing an integral role in the pandemic response and our \noperational excellence and capabilities continue to be highlighted th rough our evolving partnership with the US \ngovernment's COVID -19 vaccine distribution efforts.  Through July, our US pharmaceutical business has \nsuccessfully distributed over 185 million Moderna and J&J COVID -19 vaccines to administration sites across the \nUnited States, and our medical business has now assembled enough kits to support the administration of more \nthan 785 million doses for all vaccine types.  \n \n Also in the quarter, the US government asked McKesson to support their mission of sending millions of COVID -19 \nvaccines to countries in need all around the globe. ", "original_text": "Today, we're reporting adjusted earnings per diluted \nshare of $5.56, ahead of our original expectations, resulting from the strength across our businesses and our \nroles in  the COVID -19 response efforts across the geographies in which we operate.  \n \n"}, "hash": "edc5c4ed98cc19450e03ce7686bfa458d9ef11a4cd527ab3d70c84db92d05dd4", "class_name": "RelatedNodeInfo"}}, "text": "We are continuing to see the operating momentum we \ndiscussed on our fourth quarter fiscal 2021 earnings call. ", "start_char_idx": 2385, "end_char_idx": 2496, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e702d4d-32a8-4918-8e7c-bf688c2c495d": {"__data__": {"id_": "4e702d4d-32a8-4918-8e7c-bf688c2c495d", "embedding": null, "metadata": {"window": "We \nbelieve fully exiting Europe is another step towards becoming a more streamlined and efficient organization.  \n \n Let me turn now to our performance in the quarter.  We are continuing to see the operating momentum we \ndiscussed on our fourth quarter fiscal 2021 earnings call.  Today, we're reporting adjusted earnings per diluted \nshare of $5.56, ahead of our original expectations, resulting from the strength across our businesses and our \nroles in  the COVID -19 response efforts across the geographies in which we operate.  \n \n Our US and international distribution businesses are playing an integral role in the pandemic response and our \noperational excellence and capabilities continue to be highlighted th rough our evolving partnership with the US \ngovernment's COVID -19 vaccine distribution efforts.  Through July, our US pharmaceutical business has \nsuccessfully distributed over 185 million Moderna and J&J COVID -19 vaccines to administration sites across the \nUnited States, and our medical business has now assembled enough kits to support the administration of more \nthan 785 million doses for all vaccine types.  \n \n Also in the quarter, the US government asked McKesson to support their mission of sending millions of COVID -19 \nvaccines to countries in need all around the globe. ", "original_text": "Today, we're reporting adjusted earnings per diluted \nshare of $5.56, ahead of our original expectations, resulting from the strength across our businesses and our \nroles in  the COVID -19 response efforts across the geographies in which we operate.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "aab73de7-ebef-4918-a603-d86999a6bb6b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd1ba625e40547f387ed9f87e5863c4972d0e09d6489fa3c2949a93197be6035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2d48526-221e-4a5b-8e21-baf48fc1d8d9", "node_type": "1", "metadata": {"window": "However, we are exploring strategic alternatives for \nthese remaining businesses as we al ign future investments to our growth strategies outside of Europe.  We \nbelieve fully exiting Europe is another step towards becoming a more streamlined and efficient organization.  \n \n Let me turn now to our performance in the quarter.  We are continuing to see the operating momentum we \ndiscussed on our fourth quarter fiscal 2021 earnings call.  Today, we're reporting adjusted earnings per diluted \nshare of $5.56, ahead of our original expectations, resulting from the strength across our businesses and our \nroles in  the COVID -19 response efforts across the geographies in which we operate.  \n \n Our US and international distribution businesses are playing an integral role in the pandemic response and our \noperational excellence and capabilities continue to be highlighted th rough our evolving partnership with the US \ngovernment's COVID -19 vaccine distribution efforts.  Through July, our US pharmaceutical business has \nsuccessfully distributed over 185 million Moderna and J&J COVID -19 vaccines to administration sites across the \nUnited States, and our medical business has now assembled enough kits to support the administration of more \nthan 785 million doses for all vaccine types.  \n \n", "original_text": "We are continuing to see the operating momentum we \ndiscussed on our fourth quarter fiscal 2021 earnings call. ", "page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "99e4c32a6db47ef4581000966d99447667c6f4b4333677dc6a48056cfbca8208", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1dafb4f4-86c7-4132-9ef3-99abf227b352", "node_type": "1", "metadata": {"window": "Let me turn now to our performance in the quarter.  We are continuing to see the operating momentum we \ndiscussed on our fourth quarter fiscal 2021 earnings call.  Today, we're reporting adjusted earnings per diluted \nshare of $5.56, ahead of our original expectations, resulting from the strength across our businesses and our \nroles in  the COVID -19 response efforts across the geographies in which we operate.  \n \n Our US and international distribution businesses are playing an integral role in the pandemic response and our \noperational excellence and capabilities continue to be highlighted th rough our evolving partnership with the US \ngovernment's COVID -19 vaccine distribution efforts.  Through July, our US pharmaceutical business has \nsuccessfully distributed over 185 million Moderna and J&J COVID -19 vaccines to administration sites across the \nUnited States, and our medical business has now assembled enough kits to support the administration of more \nthan 785 million doses for all vaccine types.  \n \n Also in the quarter, the US government asked McKesson to support their mission of sending millions of COVID -19 \nvaccines to countries in need all around the globe.  We are picking and packing Moderna and Johnson & Johnson \nCOVID -19 vaccines into temperature -controlled coolers and preparing these vaccines for pickup by international \npartners, all at the direct ion of the US government.  \n \n", "original_text": "Our US and international distribution businesses are playing an integral role in the pandemic response and our \noperational excellence and capabilities continue to be highlighted th rough our evolving partnership with the US \ngovernment's COVID -19 vaccine distribution efforts. "}, "hash": "7f8f0974a3ddfb4114a1f2b279cdf379c436a3cf6f0cd8b72a8e8bf69273683a", "class_name": "RelatedNodeInfo"}}, "text": "Today, we're reporting adjusted earnings per diluted \nshare of $5.56, ahead of our original expectations, resulting from the strength across our businesses and our \nroles in  the COVID -19 response efforts across the geographies in which we operate.  \n \n", "start_char_idx": 2496, "end_char_idx": 2750, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1dafb4f4-86c7-4132-9ef3-99abf227b352": {"__data__": {"id_": "1dafb4f4-86c7-4132-9ef3-99abf227b352", "embedding": null, "metadata": {"window": "Let me turn now to our performance in the quarter.  We are continuing to see the operating momentum we \ndiscussed on our fourth quarter fiscal 2021 earnings call.  Today, we're reporting adjusted earnings per diluted \nshare of $5.56, ahead of our original expectations, resulting from the strength across our businesses and our \nroles in  the COVID -19 response efforts across the geographies in which we operate.  \n \n Our US and international distribution businesses are playing an integral role in the pandemic response and our \noperational excellence and capabilities continue to be highlighted th rough our evolving partnership with the US \ngovernment's COVID -19 vaccine distribution efforts.  Through July, our US pharmaceutical business has \nsuccessfully distributed over 185 million Moderna and J&J COVID -19 vaccines to administration sites across the \nUnited States, and our medical business has now assembled enough kits to support the administration of more \nthan 785 million doses for all vaccine types.  \n \n Also in the quarter, the US government asked McKesson to support their mission of sending millions of COVID -19 \nvaccines to countries in need all around the globe.  We are picking and packing Moderna and Johnson & Johnson \nCOVID -19 vaccines into temperature -controlled coolers and preparing these vaccines for pickup by international \npartners, all at the direct ion of the US government.  \n \n", "original_text": "Our US and international distribution businesses are playing an integral role in the pandemic response and our \noperational excellence and capabilities continue to be highlighted th rough our evolving partnership with the US \ngovernment's COVID -19 vaccine distribution efforts. ", "page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "aab73de7-ebef-4918-a603-d86999a6bb6b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd1ba625e40547f387ed9f87e5863c4972d0e09d6489fa3c2949a93197be6035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e702d4d-32a8-4918-8e7c-bf688c2c495d", "node_type": "1", "metadata": {"window": "We \nbelieve fully exiting Europe is another step towards becoming a more streamlined and efficient organization.  \n \n Let me turn now to our performance in the quarter.  We are continuing to see the operating momentum we \ndiscussed on our fourth quarter fiscal 2021 earnings call.  Today, we're reporting adjusted earnings per diluted \nshare of $5.56, ahead of our original expectations, resulting from the strength across our businesses and our \nroles in  the COVID -19 response efforts across the geographies in which we operate.  \n \n Our US and international distribution businesses are playing an integral role in the pandemic response and our \noperational excellence and capabilities continue to be highlighted th rough our evolving partnership with the US \ngovernment's COVID -19 vaccine distribution efforts.  Through July, our US pharmaceutical business has \nsuccessfully distributed over 185 million Moderna and J&J COVID -19 vaccines to administration sites across the \nUnited States, and our medical business has now assembled enough kits to support the administration of more \nthan 785 million doses for all vaccine types.  \n \n Also in the quarter, the US government asked McKesson to support their mission of sending millions of COVID -19 \nvaccines to countries in need all around the globe. ", "original_text": "Today, we're reporting adjusted earnings per diluted \nshare of $5.56, ahead of our original expectations, resulting from the strength across our businesses and our \nroles in  the COVID -19 response efforts across the geographies in which we operate.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50415b9e2acbe49126949ce04028ced6de003809002c7637dd489018928ab5f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94888eb3-2fd3-4d1f-afa9-13c4b8f347af", "node_type": "1", "metadata": {"window": "We are continuing to see the operating momentum we \ndiscussed on our fourth quarter fiscal 2021 earnings call.  Today, we're reporting adjusted earnings per diluted \nshare of $5.56, ahead of our original expectations, resulting from the strength across our businesses and our \nroles in  the COVID -19 response efforts across the geographies in which we operate.  \n \n Our US and international distribution businesses are playing an integral role in the pandemic response and our \noperational excellence and capabilities continue to be highlighted th rough our evolving partnership with the US \ngovernment's COVID -19 vaccine distribution efforts.  Through July, our US pharmaceutical business has \nsuccessfully distributed over 185 million Moderna and J&J COVID -19 vaccines to administration sites across the \nUnited States, and our medical business has now assembled enough kits to support the administration of more \nthan 785 million doses for all vaccine types.  \n \n Also in the quarter, the US government asked McKesson to support their mission of sending millions of COVID -19 \nvaccines to countries in need all around the globe.  We are picking and packing Moderna and Johnson & Johnson \nCOVID -19 vaccines into temperature -controlled coolers and preparing these vaccines for pickup by international \npartners, all at the direct ion of the US government.  \n \n McKesson is not managing the actual shipments of vaccines to other countries. ", "original_text": "Through July, our US pharmaceutical business has \nsuccessfully distributed over 185 million Moderna and J&J COVID -19 vaccines to administration sites across the \nUnited States, and our medical business has now assembled enough kits to support the administration of more \nthan 785 million doses for all vaccine types.  \n \n"}, "hash": "869e003dd28e1498a65bd821f49f03f2018b267f060fcef13e09d3822299f963", "class_name": "RelatedNodeInfo"}}, "text": "Our US and international distribution businesses are playing an integral role in the pandemic response and our \noperational excellence and capabilities continue to be highlighted th rough our evolving partnership with the US \ngovernment's COVID -19 vaccine distribution efforts. ", "start_char_idx": 2750, "end_char_idx": 3029, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94888eb3-2fd3-4d1f-afa9-13c4b8f347af": {"__data__": {"id_": "94888eb3-2fd3-4d1f-afa9-13c4b8f347af", "embedding": null, "metadata": {"window": "We are continuing to see the operating momentum we \ndiscussed on our fourth quarter fiscal 2021 earnings call.  Today, we're reporting adjusted earnings per diluted \nshare of $5.56, ahead of our original expectations, resulting from the strength across our businesses and our \nroles in  the COVID -19 response efforts across the geographies in which we operate.  \n \n Our US and international distribution businesses are playing an integral role in the pandemic response and our \noperational excellence and capabilities continue to be highlighted th rough our evolving partnership with the US \ngovernment's COVID -19 vaccine distribution efforts.  Through July, our US pharmaceutical business has \nsuccessfully distributed over 185 million Moderna and J&J COVID -19 vaccines to administration sites across the \nUnited States, and our medical business has now assembled enough kits to support the administration of more \nthan 785 million doses for all vaccine types.  \n \n Also in the quarter, the US government asked McKesson to support their mission of sending millions of COVID -19 \nvaccines to countries in need all around the globe.  We are picking and packing Moderna and Johnson & Johnson \nCOVID -19 vaccines into temperature -controlled coolers and preparing these vaccines for pickup by international \npartners, all at the direct ion of the US government.  \n \n McKesson is not managing the actual shipments of vaccines to other countries. ", "original_text": "Through July, our US pharmaceutical business has \nsuccessfully distributed over 185 million Moderna and J&J COVID -19 vaccines to administration sites across the \nUnited States, and our medical business has now assembled enough kits to support the administration of more \nthan 785 million doses for all vaccine types.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "aab73de7-ebef-4918-a603-d86999a6bb6b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd1ba625e40547f387ed9f87e5863c4972d0e09d6489fa3c2949a93197be6035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1dafb4f4-86c7-4132-9ef3-99abf227b352", "node_type": "1", "metadata": {"window": "Let me turn now to our performance in the quarter.  We are continuing to see the operating momentum we \ndiscussed on our fourth quarter fiscal 2021 earnings call.  Today, we're reporting adjusted earnings per diluted \nshare of $5.56, ahead of our original expectations, resulting from the strength across our businesses and our \nroles in  the COVID -19 response efforts across the geographies in which we operate.  \n \n Our US and international distribution businesses are playing an integral role in the pandemic response and our \noperational excellence and capabilities continue to be highlighted th rough our evolving partnership with the US \ngovernment's COVID -19 vaccine distribution efforts.  Through July, our US pharmaceutical business has \nsuccessfully distributed over 185 million Moderna and J&J COVID -19 vaccines to administration sites across the \nUnited States, and our medical business has now assembled enough kits to support the administration of more \nthan 785 million doses for all vaccine types.  \n \n Also in the quarter, the US government asked McKesson to support their mission of sending millions of COVID -19 \nvaccines to countries in need all around the globe.  We are picking and packing Moderna and Johnson & Johnson \nCOVID -19 vaccines into temperature -controlled coolers and preparing these vaccines for pickup by international \npartners, all at the direct ion of the US government.  \n \n", "original_text": "Our US and international distribution businesses are playing an integral role in the pandemic response and our \noperational excellence and capabilities continue to be highlighted th rough our evolving partnership with the US \ngovernment's COVID -19 vaccine distribution efforts. ", "page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66783dc267c1323888718a796f78d01a43c64eb9b549d91e7651837eb5f15590", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0eaa8fcd-51d6-4be5-b020-9c2b79628dd1", "node_type": "1", "metadata": {"window": "Today, we're reporting adjusted earnings per diluted \nshare of $5.56, ahead of our original expectations, resulting from the strength across our businesses and our \nroles in  the COVID -19 response efforts across the geographies in which we operate.  \n \n Our US and international distribution businesses are playing an integral role in the pandemic response and our \noperational excellence and capabilities continue to be highlighted th rough our evolving partnership with the US \ngovernment's COVID -19 vaccine distribution efforts.  Through July, our US pharmaceutical business has \nsuccessfully distributed over 185 million Moderna and J&J COVID -19 vaccines to administration sites across the \nUnited States, and our medical business has now assembled enough kits to support the administration of more \nthan 785 million doses for all vaccine types.  \n \n Also in the quarter, the US government asked McKesson to support their mission of sending millions of COVID -19 \nvaccines to countries in need all around the globe.  We are picking and packing Moderna and Johnson & Johnson \nCOVID -19 vaccines into temperature -controlled coolers and preparing these vaccines for pickup by international \npartners, all at the direct ion of the US government.  \n \n McKesson is not managing the actual shipments of vaccines to other countries.  Through July, we successfully \nprepared over 65 million COVID -19 vaccines for shipment abroad. ", "original_text": "Also in the quarter, the US government asked McKesson to support their mission of sending millions of COVID -19 \nvaccines to countries in need all around the globe. "}, "hash": "0c93ce95f3dafce695a74e423ea4161721b7d2fc88ab07c29d5907626a7ed185", "class_name": "RelatedNodeInfo"}}, "text": "Through July, our US pharmaceutical business has \nsuccessfully distributed over 185 million Moderna and J&J COVID -19 vaccines to administration sites across the \nUnited States, and our medical business has now assembled enough kits to support the administration of more \nthan 785 million doses for all vaccine types.  \n \n", "start_char_idx": 3029, "end_char_idx": 3351, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0eaa8fcd-51d6-4be5-b020-9c2b79628dd1": {"__data__": {"id_": "0eaa8fcd-51d6-4be5-b020-9c2b79628dd1", "embedding": null, "metadata": {"window": "Today, we're reporting adjusted earnings per diluted \nshare of $5.56, ahead of our original expectations, resulting from the strength across our businesses and our \nroles in  the COVID -19 response efforts across the geographies in which we operate.  \n \n Our US and international distribution businesses are playing an integral role in the pandemic response and our \noperational excellence and capabilities continue to be highlighted th rough our evolving partnership with the US \ngovernment's COVID -19 vaccine distribution efforts.  Through July, our US pharmaceutical business has \nsuccessfully distributed over 185 million Moderna and J&J COVID -19 vaccines to administration sites across the \nUnited States, and our medical business has now assembled enough kits to support the administration of more \nthan 785 million doses for all vaccine types.  \n \n Also in the quarter, the US government asked McKesson to support their mission of sending millions of COVID -19 \nvaccines to countries in need all around the globe.  We are picking and packing Moderna and Johnson & Johnson \nCOVID -19 vaccines into temperature -controlled coolers and preparing these vaccines for pickup by international \npartners, all at the direct ion of the US government.  \n \n McKesson is not managing the actual shipments of vaccines to other countries.  Through July, we successfully \nprepared over 65 million COVID -19 vaccines for shipment abroad. ", "original_text": "Also in the quarter, the US government asked McKesson to support their mission of sending millions of COVID -19 \nvaccines to countries in need all around the globe. ", "page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "aab73de7-ebef-4918-a603-d86999a6bb6b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd1ba625e40547f387ed9f87e5863c4972d0e09d6489fa3c2949a93197be6035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94888eb3-2fd3-4d1f-afa9-13c4b8f347af", "node_type": "1", "metadata": {"window": "We are continuing to see the operating momentum we \ndiscussed on our fourth quarter fiscal 2021 earnings call.  Today, we're reporting adjusted earnings per diluted \nshare of $5.56, ahead of our original expectations, resulting from the strength across our businesses and our \nroles in  the COVID -19 response efforts across the geographies in which we operate.  \n \n Our US and international distribution businesses are playing an integral role in the pandemic response and our \noperational excellence and capabilities continue to be highlighted th rough our evolving partnership with the US \ngovernment's COVID -19 vaccine distribution efforts.  Through July, our US pharmaceutical business has \nsuccessfully distributed over 185 million Moderna and J&J COVID -19 vaccines to administration sites across the \nUnited States, and our medical business has now assembled enough kits to support the administration of more \nthan 785 million doses for all vaccine types.  \n \n Also in the quarter, the US government asked McKesson to support their mission of sending millions of COVID -19 \nvaccines to countries in need all around the globe.  We are picking and packing Moderna and Johnson & Johnson \nCOVID -19 vaccines into temperature -controlled coolers and preparing these vaccines for pickup by international \npartners, all at the direct ion of the US government.  \n \n McKesson is not managing the actual shipments of vaccines to other countries. ", "original_text": "Through July, our US pharmaceutical business has \nsuccessfully distributed over 185 million Moderna and J&J COVID -19 vaccines to administration sites across the \nUnited States, and our medical business has now assembled enough kits to support the administration of more \nthan 785 million doses for all vaccine types.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c72ccc5c5826f11383b4bed10dd01ab0dfcbfc2073d0399e0c16bf5e84804c40", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb840545-f360-43c1-b029-4b461c5cae8d", "node_type": "1", "metadata": {"window": "Our US and international distribution businesses are playing an integral role in the pandemic response and our \noperational excellence and capabilities continue to be highlighted th rough our evolving partnership with the US \ngovernment's COVID -19 vaccine distribution efforts.  Through July, our US pharmaceutical business has \nsuccessfully distributed over 185 million Moderna and J&J COVID -19 vaccines to administration sites across the \nUnited States, and our medical business has now assembled enough kits to support the administration of more \nthan 785 million doses for all vaccine types.  \n \n Also in the quarter, the US government asked McKesson to support their mission of sending millions of COVID -19 \nvaccines to countries in need all around the globe.  We are picking and packing Moderna and Johnson & Johnson \nCOVID -19 vaccines into temperature -controlled coolers and preparing these vaccines for pickup by international \npartners, all at the direct ion of the US government.  \n \n McKesson is not managing the actual shipments of vaccines to other countries.  Through July, we successfully \nprepared over 65 million COVID -19 vaccines for shipment abroad.  We are humbled and honored to serve the US \ngovernment in this expanded role.  \n ", "original_text": "We are picking and packing Moderna and Johnson & Johnson \nCOVID -19 vaccines into temperature -controlled coolers and preparing these vaccines for pickup by international \npartners, all at the direct ion of the US government.  \n \n"}, "hash": "f0184496ae0e3f5cf40f116c62d930f149b2961306d6e8180cbb7bb5a6408827", "class_name": "RelatedNodeInfo"}}, "text": "Also in the quarter, the US government asked McKesson to support their mission of sending millions of COVID -19 \nvaccines to countries in need all around the globe. ", "start_char_idx": 3351, "end_char_idx": 3516, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb840545-f360-43c1-b029-4b461c5cae8d": {"__data__": {"id_": "fb840545-f360-43c1-b029-4b461c5cae8d", "embedding": null, "metadata": {"window": "Our US and international distribution businesses are playing an integral role in the pandemic response and our \noperational excellence and capabilities continue to be highlighted th rough our evolving partnership with the US \ngovernment's COVID -19 vaccine distribution efforts.  Through July, our US pharmaceutical business has \nsuccessfully distributed over 185 million Moderna and J&J COVID -19 vaccines to administration sites across the \nUnited States, and our medical business has now assembled enough kits to support the administration of more \nthan 785 million doses for all vaccine types.  \n \n Also in the quarter, the US government asked McKesson to support their mission of sending millions of COVID -19 \nvaccines to countries in need all around the globe.  We are picking and packing Moderna and Johnson & Johnson \nCOVID -19 vaccines into temperature -controlled coolers and preparing these vaccines for pickup by international \npartners, all at the direct ion of the US government.  \n \n McKesson is not managing the actual shipments of vaccines to other countries.  Through July, we successfully \nprepared over 65 million COVID -19 vaccines for shipment abroad.  We are humbled and honored to serve the US \ngovernment in this expanded role.  \n ", "original_text": "We are picking and packing Moderna and Johnson & Johnson \nCOVID -19 vaccines into temperature -controlled coolers and preparing these vaccines for pickup by international \npartners, all at the direct ion of the US government.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "aab73de7-ebef-4918-a603-d86999a6bb6b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd1ba625e40547f387ed9f87e5863c4972d0e09d6489fa3c2949a93197be6035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0eaa8fcd-51d6-4be5-b020-9c2b79628dd1", "node_type": "1", "metadata": {"window": "Today, we're reporting adjusted earnings per diluted \nshare of $5.56, ahead of our original expectations, resulting from the strength across our businesses and our \nroles in  the COVID -19 response efforts across the geographies in which we operate.  \n \n Our US and international distribution businesses are playing an integral role in the pandemic response and our \noperational excellence and capabilities continue to be highlighted th rough our evolving partnership with the US \ngovernment's COVID -19 vaccine distribution efforts.  Through July, our US pharmaceutical business has \nsuccessfully distributed over 185 million Moderna and J&J COVID -19 vaccines to administration sites across the \nUnited States, and our medical business has now assembled enough kits to support the administration of more \nthan 785 million doses for all vaccine types.  \n \n Also in the quarter, the US government asked McKesson to support their mission of sending millions of COVID -19 \nvaccines to countries in need all around the globe.  We are picking and packing Moderna and Johnson & Johnson \nCOVID -19 vaccines into temperature -controlled coolers and preparing these vaccines for pickup by international \npartners, all at the direct ion of the US government.  \n \n McKesson is not managing the actual shipments of vaccines to other countries.  Through July, we successfully \nprepared over 65 million COVID -19 vaccines for shipment abroad. ", "original_text": "Also in the quarter, the US government asked McKesson to support their mission of sending millions of COVID -19 \nvaccines to countries in need all around the globe. ", "page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "74d43c9aae2f8750ce14c9d3f168f56716129b2487e21724a264f9e1068c7b25", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43a700a0-c926-4ecc-aacf-00f3716eb136", "node_type": "1", "metadata": {"window": "Through July, our US pharmaceutical business has \nsuccessfully distributed over 185 million Moderna and J&J COVID -19 vaccines to administration sites across the \nUnited States, and our medical business has now assembled enough kits to support the administration of more \nthan 785 million doses for all vaccine types.  \n \n Also in the quarter, the US government asked McKesson to support their mission of sending millions of COVID -19 \nvaccines to countries in need all around the globe.  We are picking and packing Moderna and Johnson & Johnson \nCOVID -19 vaccines into temperature -controlled coolers and preparing these vaccines for pickup by international \npartners, all at the direct ion of the US government.  \n \n McKesson is not managing the actual shipments of vaccines to other countries.  Through July, we successfully \nprepared over 65 million COVID -19 vaccines for shipment abroad.  We are humbled and honored to serve the US \ngovernment in this expanded role.  \n ", "original_text": "McKesson is not managing the actual shipments of vaccines to other countries. "}, "hash": "3d046b5b1c7cd0a27e7755982e6364333fd8b73ef9564782d352b586732d89c5", "class_name": "RelatedNodeInfo"}}, "text": "We are picking and packing Moderna and Johnson & Johnson \nCOVID -19 vaccines into temperature -controlled coolers and preparing these vaccines for pickup by international \npartners, all at the direct ion of the US government.  \n \n", "start_char_idx": 3516, "end_char_idx": 3746, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43a700a0-c926-4ecc-aacf-00f3716eb136": {"__data__": {"id_": "43a700a0-c926-4ecc-aacf-00f3716eb136", "embedding": null, "metadata": {"window": "Through July, our US pharmaceutical business has \nsuccessfully distributed over 185 million Moderna and J&J COVID -19 vaccines to administration sites across the \nUnited States, and our medical business has now assembled enough kits to support the administration of more \nthan 785 million doses for all vaccine types.  \n \n Also in the quarter, the US government asked McKesson to support their mission of sending millions of COVID -19 \nvaccines to countries in need all around the globe.  We are picking and packing Moderna and Johnson & Johnson \nCOVID -19 vaccines into temperature -controlled coolers and preparing these vaccines for pickup by international \npartners, all at the direct ion of the US government.  \n \n McKesson is not managing the actual shipments of vaccines to other countries.  Through July, we successfully \nprepared over 65 million COVID -19 vaccines for shipment abroad.  We are humbled and honored to serve the US \ngovernment in this expanded role.  \n ", "original_text": "McKesson is not managing the actual shipments of vaccines to other countries. ", "page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "aab73de7-ebef-4918-a603-d86999a6bb6b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd1ba625e40547f387ed9f87e5863c4972d0e09d6489fa3c2949a93197be6035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb840545-f360-43c1-b029-4b461c5cae8d", "node_type": "1", "metadata": {"window": "Our US and international distribution businesses are playing an integral role in the pandemic response and our \noperational excellence and capabilities continue to be highlighted th rough our evolving partnership with the US \ngovernment's COVID -19 vaccine distribution efforts.  Through July, our US pharmaceutical business has \nsuccessfully distributed over 185 million Moderna and J&J COVID -19 vaccines to administration sites across the \nUnited States, and our medical business has now assembled enough kits to support the administration of more \nthan 785 million doses for all vaccine types.  \n \n Also in the quarter, the US government asked McKesson to support their mission of sending millions of COVID -19 \nvaccines to countries in need all around the globe.  We are picking and packing Moderna and Johnson & Johnson \nCOVID -19 vaccines into temperature -controlled coolers and preparing these vaccines for pickup by international \npartners, all at the direct ion of the US government.  \n \n McKesson is not managing the actual shipments of vaccines to other countries.  Through July, we successfully \nprepared over 65 million COVID -19 vaccines for shipment abroad.  We are humbled and honored to serve the US \ngovernment in this expanded role.  \n ", "original_text": "We are picking and packing Moderna and Johnson & Johnson \nCOVID -19 vaccines into temperature -controlled coolers and preparing these vaccines for pickup by international \npartners, all at the direct ion of the US government.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af17f0a794b5ff37f39eef2ce69c8bf386182b8f7fa9c3f1c74b56314c225819", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4ca7e15f-fdbc-491d-9d1b-74b999eadee9", "node_type": "1", "metadata": {"window": "Also in the quarter, the US government asked McKesson to support their mission of sending millions of COVID -19 \nvaccines to countries in need all around the globe.  We are picking and packing Moderna and Johnson & Johnson \nCOVID -19 vaccines into temperature -controlled coolers and preparing these vaccines for pickup by international \npartners, all at the direct ion of the US government.  \n \n McKesson is not managing the actual shipments of vaccines to other countries.  Through July, we successfully \nprepared over 65 million COVID -19 vaccines for shipment abroad.  We are humbled and honored to serve the US \ngovernment in this expanded role.  \n ", "original_text": "Through July, we successfully \nprepared over 65 million COVID -19 vaccines for shipment abroad. "}, "hash": "c38b211f4ad575a95565573da524650ebc57e26f94a8f25484f593237ba17079", "class_name": "RelatedNodeInfo"}}, "text": "McKesson is not managing the actual shipments of vaccines to other countries. ", "start_char_idx": 3746, "end_char_idx": 3824, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4ca7e15f-fdbc-491d-9d1b-74b999eadee9": {"__data__": {"id_": "4ca7e15f-fdbc-491d-9d1b-74b999eadee9", "embedding": null, "metadata": {"window": "Also in the quarter, the US government asked McKesson to support their mission of sending millions of COVID -19 \nvaccines to countries in need all around the globe.  We are picking and packing Moderna and Johnson & Johnson \nCOVID -19 vaccines into temperature -controlled coolers and preparing these vaccines for pickup by international \npartners, all at the direct ion of the US government.  \n \n McKesson is not managing the actual shipments of vaccines to other countries.  Through July, we successfully \nprepared over 65 million COVID -19 vaccines for shipment abroad.  We are humbled and honored to serve the US \ngovernment in this expanded role.  \n ", "original_text": "Through July, we successfully \nprepared over 65 million COVID -19 vaccines for shipment abroad. ", "page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "aab73de7-ebef-4918-a603-d86999a6bb6b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd1ba625e40547f387ed9f87e5863c4972d0e09d6489fa3c2949a93197be6035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43a700a0-c926-4ecc-aacf-00f3716eb136", "node_type": "1", "metadata": {"window": "Through July, our US pharmaceutical business has \nsuccessfully distributed over 185 million Moderna and J&J COVID -19 vaccines to administration sites across the \nUnited States, and our medical business has now assembled enough kits to support the administration of more \nthan 785 million doses for all vaccine types.  \n \n Also in the quarter, the US government asked McKesson to support their mission of sending millions of COVID -19 \nvaccines to countries in need all around the globe.  We are picking and packing Moderna and Johnson & Johnson \nCOVID -19 vaccines into temperature -controlled coolers and preparing these vaccines for pickup by international \npartners, all at the direct ion of the US government.  \n \n McKesson is not managing the actual shipments of vaccines to other countries.  Through July, we successfully \nprepared over 65 million COVID -19 vaccines for shipment abroad.  We are humbled and honored to serve the US \ngovernment in this expanded role.  \n ", "original_text": "McKesson is not managing the actual shipments of vaccines to other countries. ", "page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5eb13665ebad59237cfee5a1c45465a9031eb7cc8aadec911dcf2317222383be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "221fece3-216c-487e-8de4-c703341d76c5", "node_type": "1", "metadata": {"window": "We are picking and packing Moderna and Johnson & Johnson \nCOVID -19 vaccines into temperature -controlled coolers and preparing these vaccines for pickup by international \npartners, all at the direct ion of the US government.  \n \n McKesson is not managing the actual shipments of vaccines to other countries.  Through July, we successfully \nprepared over 65 million COVID -19 vaccines for shipment abroad.  We are humbled and honored to serve the US \ngovernment in this expanded role.  \n ", "original_text": "We are humbled and honored to serve the US \ngovernment in this expanded role.  \n "}, "hash": "0c6cc0a2a0e04269f6e3ae09e91cc854a06933754b73cae913e61988925e7168", "class_name": "RelatedNodeInfo"}}, "text": "Through July, we successfully \nprepared over 65 million COVID -19 vaccines for shipment abroad. ", "start_char_idx": 3824, "end_char_idx": 3920, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "221fece3-216c-487e-8de4-c703341d76c5": {"__data__": {"id_": "221fece3-216c-487e-8de4-c703341d76c5", "embedding": null, "metadata": {"window": "We are picking and packing Moderna and Johnson & Johnson \nCOVID -19 vaccines into temperature -controlled coolers and preparing these vaccines for pickup by international \npartners, all at the direct ion of the US government.  \n \n McKesson is not managing the actual shipments of vaccines to other countries.  Through July, we successfully \nprepared over 65 million COVID -19 vaccines for shipment abroad.  We are humbled and honored to serve the US \ngovernment in this expanded role.  \n ", "original_text": "We are humbled and honored to serve the US \ngovernment in this expanded role.  \n ", "page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "aab73de7-ebef-4918-a603-d86999a6bb6b", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd1ba625e40547f387ed9f87e5863c4972d0e09d6489fa3c2949a93197be6035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4ca7e15f-fdbc-491d-9d1b-74b999eadee9", "node_type": "1", "metadata": {"window": "Also in the quarter, the US government asked McKesson to support their mission of sending millions of COVID -19 \nvaccines to countries in need all around the globe.  We are picking and packing Moderna and Johnson & Johnson \nCOVID -19 vaccines into temperature -controlled coolers and preparing these vaccines for pickup by international \npartners, all at the direct ion of the US government.  \n \n McKesson is not managing the actual shipments of vaccines to other countries.  Through July, we successfully \nprepared over 65 million COVID -19 vaccines for shipment abroad.  We are humbled and honored to serve the US \ngovernment in this expanded role.  \n ", "original_text": "Through July, we successfully \nprepared over 65 million COVID -19 vaccines for shipment abroad. ", "page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cced6323b571f59c248f9373f8bb109c4f077f610bbed95e988369664aeb8d74", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc6e4c4d-ea59-4a1b-a600-56c8905f7595", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nOur roles in Europe and Canada are also continuing to evolve, and we're partnering with local governments to \ndistribute and administer COVID -19 vaccines there as well.  Through July, we've distributed over 45 million \nvaccines to adminis tration sites in select markets across these geographies.  \n \n Based on our first quarter results, our evolving roles in the COVID -19 response efforts and our confidence in our \noutlook for the remainder of our fiscal 2022, we are raising our adjusted earnings per diluted share guidance to \n$19.80 to $20.40 from a previous range of $18.85 to $19.45.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "185b5f694f3ee7799dbe996611e40a1017f34bc71cebd42246c8dc2f5acc3217", "class_name": "RelatedNodeInfo"}}, "text": "We are humbled and honored to serve the US \ngovernment in this expanded role.  \n ", "start_char_idx": 3920, "end_char_idx": 4001, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc6e4c4d-ea59-4a1b-a600-56c8905f7595": {"__data__": {"id_": "cc6e4c4d-ea59-4a1b-a600-56c8905f7595", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nOur roles in Europe and Canada are also continuing to evolve, and we're partnering with local governments to \ndistribute and administer COVID -19 vaccines there as well.  Through July, we've distributed over 45 million \nvaccines to adminis tration sites in select markets across these geographies.  \n \n Based on our first quarter results, our evolving roles in the COVID -19 response efforts and our confidence in our \noutlook for the remainder of our fiscal 2022, we are raising our adjusted earnings per diluted share guidance to \n$19.80 to $20.40 from a previous range of $18.85 to $19.45.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce4cf70f47aba08c6d8df52ea899482b0f6cfa03010b333fb31caf0734f9a1f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "221fece3-216c-487e-8de4-c703341d76c5", "node_type": "1", "metadata": {"window": "We are picking and packing Moderna and Johnson & Johnson \nCOVID -19 vaccines into temperature -controlled coolers and preparing these vaccines for pickup by international \npartners, all at the direct ion of the US government.  \n \n McKesson is not managing the actual shipments of vaccines to other countries.  Through July, we successfully \nprepared over 65 million COVID -19 vaccines for shipment abroad.  We are humbled and honored to serve the US \ngovernment in this expanded role.  \n ", "original_text": "We are humbled and honored to serve the US \ngovernment in this expanded role.  \n ", "page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9437f24e3fd4618123754357fdbe1b7f1e42777d6fbeb390e0d134e6ba942ab6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "543244ed-7423-4dab-90f7-26279a703bdb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nOur roles in Europe and Canada are also continuing to evolve, and we're partnering with local governments to \ndistribute and administer COVID -19 vaccines there as well.  Through July, we've distributed over 45 million \nvaccines to adminis tration sites in select markets across these geographies.  \n \n Based on our first quarter results, our evolving roles in the COVID -19 response efforts and our confidence in our \noutlook for the remainder of our fiscal 2022, we are raising our adjusted earnings per diluted share guidance to \n$19.80 to $20.40 from a previous range of $18.85 to $19.45.  \n \n As I mentioned in my opening remarks, we're making significant progress against our strategic priorities. ", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nOur roles in Europe and Canada are also continuing to evolve, and we're partnering with local governments to \ndistribute and administer COVID -19 vaccines there as well. "}, "hash": "484429f05f75c42c51e091c9ff4b2a086bd560e2c7337918e547ba220aa3d45f", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "543244ed-7423-4dab-90f7-26279a703bdb": {"__data__": {"id_": "543244ed-7423-4dab-90f7-26279a703bdb", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nOur roles in Europe and Canada are also continuing to evolve, and we're partnering with local governments to \ndistribute and administer COVID -19 vaccines there as well.  Through July, we've distributed over 45 million \nvaccines to adminis tration sites in select markets across these geographies.  \n \n Based on our first quarter results, our evolving roles in the COVID -19 response efforts and our confidence in our \noutlook for the remainder of our fiscal 2022, we are raising our adjusted earnings per diluted share guidance to \n$19.80 to $20.40 from a previous range of $18.85 to $19.45.  \n \n As I mentioned in my opening remarks, we're making significant progress against our strategic priorities. ", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nOur roles in Europe and Canada are also continuing to evolve, and we're partnering with local governments to \ndistribute and administer COVID -19 vaccines there as well. ", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce4cf70f47aba08c6d8df52ea899482b0f6cfa03010b333fb31caf0734f9a1f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc6e4c4d-ea59-4a1b-a600-56c8905f7595", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nOur roles in Europe and Canada are also continuing to evolve, and we're partnering with local governments to \ndistribute and administer COVID -19 vaccines there as well.  Through July, we've distributed over 45 million \nvaccines to adminis tration sites in select markets across these geographies.  \n \n Based on our first quarter results, our evolving roles in the COVID -19 response efforts and our confidence in our \noutlook for the remainder of our fiscal 2022, we are raising our adjusted earnings per diluted share guidance to \n$19.80 to $20.40 from a previous range of $18.85 to $19.45.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "39d497c6d05129acb8595d2e2c811e70f48ad186bfd216928b20c3bf4c630263", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1caf4599-4614-4f81-98aa-d6565c103aa5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nOur roles in Europe and Canada are also continuing to evolve, and we're partnering with local governments to \ndistribute and administer COVID -19 vaccines there as well.  Through July, we've distributed over 45 million \nvaccines to adminis tration sites in select markets across these geographies.  \n \n Based on our first quarter results, our evolving roles in the COVID -19 response efforts and our confidence in our \noutlook for the remainder of our fiscal 2022, we are raising our adjusted earnings per diluted share guidance to \n$19.80 to $20.40 from a previous range of $18.85 to $19.45.  \n \n As I mentioned in my opening remarks, we're making significant progress against our strategic priorities.  We're \nsimplifying the portfolio and increasing our focus on  areas where we have deep expertise and that are central to \nour long -term growth strategy. ", "original_text": "Through July, we've distributed over 45 million \nvaccines to adminis tration sites in select markets across these geographies.  \n \n"}, "hash": "fd3993296d4d0aa2cc53441083581fa178f20413eaf0bd9f60b1d2167480aac1", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nOur roles in Europe and Canada are also continuing to evolve, and we're partnering with local governments to \ndistribute and administer COVID -19 vaccines there as well. ", "start_char_idx": 16, "end_char_idx": 350, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1caf4599-4614-4f81-98aa-d6565c103aa5": {"__data__": {"id_": "1caf4599-4614-4f81-98aa-d6565c103aa5", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nOur roles in Europe and Canada are also continuing to evolve, and we're partnering with local governments to \ndistribute and administer COVID -19 vaccines there as well.  Through July, we've distributed over 45 million \nvaccines to adminis tration sites in select markets across these geographies.  \n \n Based on our first quarter results, our evolving roles in the COVID -19 response efforts and our confidence in our \noutlook for the remainder of our fiscal 2022, we are raising our adjusted earnings per diluted share guidance to \n$19.80 to $20.40 from a previous range of $18.85 to $19.45.  \n \n As I mentioned in my opening remarks, we're making significant progress against our strategic priorities.  We're \nsimplifying the portfolio and increasing our focus on  areas where we have deep expertise and that are central to \nour long -term growth strategy. ", "original_text": "Through July, we've distributed over 45 million \nvaccines to adminis tration sites in select markets across these geographies.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce4cf70f47aba08c6d8df52ea899482b0f6cfa03010b333fb31caf0734f9a1f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "543244ed-7423-4dab-90f7-26279a703bdb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nOur roles in Europe and Canada are also continuing to evolve, and we're partnering with local governments to \ndistribute and administer COVID -19 vaccines there as well.  Through July, we've distributed over 45 million \nvaccines to adminis tration sites in select markets across these geographies.  \n \n Based on our first quarter results, our evolving roles in the COVID -19 response efforts and our confidence in our \noutlook for the remainder of our fiscal 2022, we are raising our adjusted earnings per diluted share guidance to \n$19.80 to $20.40 from a previous range of $18.85 to $19.45.  \n \n As I mentioned in my opening remarks, we're making significant progress against our strategic priorities. ", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nOur roles in Europe and Canada are also continuing to evolve, and we're partnering with local governments to \ndistribute and administer COVID -19 vaccines there as well. ", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "499f9e42978eb4879097c6aa28523bed92db4a1cd7aa64bbbd4aca821851875a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b3f95cd-3f93-4837-b699-889e2a4bed89", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nOur roles in Europe and Canada are also continuing to evolve, and we're partnering with local governments to \ndistribute and administer COVID -19 vaccines there as well.  Through July, we've distributed over 45 million \nvaccines to adminis tration sites in select markets across these geographies.  \n \n Based on our first quarter results, our evolving roles in the COVID -19 response efforts and our confidence in our \noutlook for the remainder of our fiscal 2022, we are raising our adjusted earnings per diluted share guidance to \n$19.80 to $20.40 from a previous range of $18.85 to $19.45.  \n \n As I mentioned in my opening remarks, we're making significant progress against our strategic priorities.  We're \nsimplifying the portfolio and increasing our focus on  areas where we have deep expertise and that are central to \nour long -term growth strategy.  Our progress to -date is underpinned by execution against our top company \npriorities.  \n \n", "original_text": "Based on our first quarter results, our evolving roles in the COVID -19 response efforts and our confidence in our \noutlook for the remainder of our fiscal 2022, we are raising our adjusted earnings per diluted share guidance to \n$19.80 to $20.40 from a previous range of $18.85 to $19.45.  \n \n"}, "hash": "0335b719f6307ada3ddf88d6dc51e1ef2833a797ee317a71cdaddf0d85b3cf46", "class_name": "RelatedNodeInfo"}}, "text": "Through July, we've distributed over 45 million \nvaccines to adminis tration sites in select markets across these geographies.  \n \n", "start_char_idx": 350, "end_char_idx": 481, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b3f95cd-3f93-4837-b699-889e2a4bed89": {"__data__": {"id_": "1b3f95cd-3f93-4837-b699-889e2a4bed89", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nOur roles in Europe and Canada are also continuing to evolve, and we're partnering with local governments to \ndistribute and administer COVID -19 vaccines there as well.  Through July, we've distributed over 45 million \nvaccines to adminis tration sites in select markets across these geographies.  \n \n Based on our first quarter results, our evolving roles in the COVID -19 response efforts and our confidence in our \noutlook for the remainder of our fiscal 2022, we are raising our adjusted earnings per diluted share guidance to \n$19.80 to $20.40 from a previous range of $18.85 to $19.45.  \n \n As I mentioned in my opening remarks, we're making significant progress against our strategic priorities.  We're \nsimplifying the portfolio and increasing our focus on  areas where we have deep expertise and that are central to \nour long -term growth strategy.  Our progress to -date is underpinned by execution against our top company \npriorities.  \n \n", "original_text": "Based on our first quarter results, our evolving roles in the COVID -19 response efforts and our confidence in our \noutlook for the remainder of our fiscal 2022, we are raising our adjusted earnings per diluted share guidance to \n$19.80 to $20.40 from a previous range of $18.85 to $19.45.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce4cf70f47aba08c6d8df52ea899482b0f6cfa03010b333fb31caf0734f9a1f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1caf4599-4614-4f81-98aa-d6565c103aa5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nOur roles in Europe and Canada are also continuing to evolve, and we're partnering with local governments to \ndistribute and administer COVID -19 vaccines there as well.  Through July, we've distributed over 45 million \nvaccines to adminis tration sites in select markets across these geographies.  \n \n Based on our first quarter results, our evolving roles in the COVID -19 response efforts and our confidence in our \noutlook for the remainder of our fiscal 2022, we are raising our adjusted earnings per diluted share guidance to \n$19.80 to $20.40 from a previous range of $18.85 to $19.45.  \n \n As I mentioned in my opening remarks, we're making significant progress against our strategic priorities.  We're \nsimplifying the portfolio and increasing our focus on  areas where we have deep expertise and that are central to \nour long -term growth strategy. ", "original_text": "Through July, we've distributed over 45 million \nvaccines to adminis tration sites in select markets across these geographies.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d92ab0e7226bfb25e6fc063a1c9c970795117472e8667b54a45201e94c4a3636", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "089b2f5e-8390-4126-8c94-1975296141f3", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nOur roles in Europe and Canada are also continuing to evolve, and we're partnering with local governments to \ndistribute and administer COVID -19 vaccines there as well.  Through July, we've distributed over 45 million \nvaccines to adminis tration sites in select markets across these geographies.  \n \n Based on our first quarter results, our evolving roles in the COVID -19 response efforts and our confidence in our \noutlook for the remainder of our fiscal 2022, we are raising our adjusted earnings per diluted share guidance to \n$19.80 to $20.40 from a previous range of $18.85 to $19.45.  \n \n As I mentioned in my opening remarks, we're making significant progress against our strategic priorities.  We're \nsimplifying the portfolio and increasing our focus on  areas where we have deep expertise and that are central to \nour long -term growth strategy.  Our progress to -date is underpinned by execution against our top company \npriorities.  \n \n The first is a focus on the people and the culture. ", "original_text": "As I mentioned in my opening remarks, we're making significant progress against our strategic priorities. "}, "hash": "23492bfc435b366437b21abcad2658e9a6d7ca4167295bb8a9dbcb1a96a9ee91", "class_name": "RelatedNodeInfo"}}, "text": "Based on our first quarter results, our evolving roles in the COVID -19 response efforts and our confidence in our \noutlook for the remainder of our fiscal 2022, we are raising our adjusted earnings per diluted share guidance to \n$19.80 to $20.40 from a previous range of $18.85 to $19.45.  \n \n", "start_char_idx": 481, "end_char_idx": 775, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "089b2f5e-8390-4126-8c94-1975296141f3": {"__data__": {"id_": "089b2f5e-8390-4126-8c94-1975296141f3", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nOur roles in Europe and Canada are also continuing to evolve, and we're partnering with local governments to \ndistribute and administer COVID -19 vaccines there as well.  Through July, we've distributed over 45 million \nvaccines to adminis tration sites in select markets across these geographies.  \n \n Based on our first quarter results, our evolving roles in the COVID -19 response efforts and our confidence in our \noutlook for the remainder of our fiscal 2022, we are raising our adjusted earnings per diluted share guidance to \n$19.80 to $20.40 from a previous range of $18.85 to $19.45.  \n \n As I mentioned in my opening remarks, we're making significant progress against our strategic priorities.  We're \nsimplifying the portfolio and increasing our focus on  areas where we have deep expertise and that are central to \nour long -term growth strategy.  Our progress to -date is underpinned by execution against our top company \npriorities.  \n \n The first is a focus on the people and the culture. ", "original_text": "As I mentioned in my opening remarks, we're making significant progress against our strategic priorities. ", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce4cf70f47aba08c6d8df52ea899482b0f6cfa03010b333fb31caf0734f9a1f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b3f95cd-3f93-4837-b699-889e2a4bed89", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nOur roles in Europe and Canada are also continuing to evolve, and we're partnering with local governments to \ndistribute and administer COVID -19 vaccines there as well.  Through July, we've distributed over 45 million \nvaccines to adminis tration sites in select markets across these geographies.  \n \n Based on our first quarter results, our evolving roles in the COVID -19 response efforts and our confidence in our \noutlook for the remainder of our fiscal 2022, we are raising our adjusted earnings per diluted share guidance to \n$19.80 to $20.40 from a previous range of $18.85 to $19.45.  \n \n As I mentioned in my opening remarks, we're making significant progress against our strategic priorities.  We're \nsimplifying the portfolio and increasing our focus on  areas where we have deep expertise and that are central to \nour long -term growth strategy.  Our progress to -date is underpinned by execution against our top company \npriorities.  \n \n", "original_text": "Based on our first quarter results, our evolving roles in the COVID -19 response efforts and our confidence in our \noutlook for the remainder of our fiscal 2022, we are raising our adjusted earnings per diluted share guidance to \n$19.80 to $20.40 from a previous range of $18.85 to $19.45.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3ea2b46e865017583dc39eab538c09fa396ca3f2bda2fa808ea1abd6d3f84598", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd91253e-bdfc-4188-9b2d-8683ccfd507d", "node_type": "1", "metadata": {"window": "Through July, we've distributed over 45 million \nvaccines to adminis tration sites in select markets across these geographies.  \n \n Based on our first quarter results, our evolving roles in the COVID -19 response efforts and our confidence in our \noutlook for the remainder of our fiscal 2022, we are raising our adjusted earnings per diluted share guidance to \n$19.80 to $20.40 from a previous range of $18.85 to $19.45.  \n \n As I mentioned in my opening remarks, we're making significant progress against our strategic priorities.  We're \nsimplifying the portfolio and increasing our focus on  areas where we have deep expertise and that are central to \nour long -term growth strategy.  Our progress to -date is underpinned by execution against our top company \npriorities.  \n \n The first is a focus on the people and the culture.  The second is our commitmen t to strengthen the core \npharmaceutical and medical supply chain businesses. ", "original_text": "We're \nsimplifying the portfolio and increasing our focus on  areas where we have deep expertise and that are central to \nour long -term growth strategy. "}, "hash": "26fdda9a1eda53ff390e285df79f8f59d6eec2721839ad889bdd42a4b0328285", "class_name": "RelatedNodeInfo"}}, "text": "As I mentioned in my opening remarks, we're making significant progress against our strategic priorities. ", "start_char_idx": 775, "end_char_idx": 881, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd91253e-bdfc-4188-9b2d-8683ccfd507d": {"__data__": {"id_": "fd91253e-bdfc-4188-9b2d-8683ccfd507d", "embedding": null, "metadata": {"window": "Through July, we've distributed over 45 million \nvaccines to adminis tration sites in select markets across these geographies.  \n \n Based on our first quarter results, our evolving roles in the COVID -19 response efforts and our confidence in our \noutlook for the remainder of our fiscal 2022, we are raising our adjusted earnings per diluted share guidance to \n$19.80 to $20.40 from a previous range of $18.85 to $19.45.  \n \n As I mentioned in my opening remarks, we're making significant progress against our strategic priorities.  We're \nsimplifying the portfolio and increasing our focus on  areas where we have deep expertise and that are central to \nour long -term growth strategy.  Our progress to -date is underpinned by execution against our top company \npriorities.  \n \n The first is a focus on the people and the culture.  The second is our commitmen t to strengthen the core \npharmaceutical and medical supply chain businesses. ", "original_text": "We're \nsimplifying the portfolio and increasing our focus on  areas where we have deep expertise and that are central to \nour long -term growth strategy. ", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce4cf70f47aba08c6d8df52ea899482b0f6cfa03010b333fb31caf0734f9a1f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "089b2f5e-8390-4126-8c94-1975296141f3", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nOur roles in Europe and Canada are also continuing to evolve, and we're partnering with local governments to \ndistribute and administer COVID -19 vaccines there as well.  Through July, we've distributed over 45 million \nvaccines to adminis tration sites in select markets across these geographies.  \n \n Based on our first quarter results, our evolving roles in the COVID -19 response efforts and our confidence in our \noutlook for the remainder of our fiscal 2022, we are raising our adjusted earnings per diluted share guidance to \n$19.80 to $20.40 from a previous range of $18.85 to $19.45.  \n \n As I mentioned in my opening remarks, we're making significant progress against our strategic priorities.  We're \nsimplifying the portfolio and increasing our focus on  areas where we have deep expertise and that are central to \nour long -term growth strategy.  Our progress to -date is underpinned by execution against our top company \npriorities.  \n \n The first is a focus on the people and the culture. ", "original_text": "As I mentioned in my opening remarks, we're making significant progress against our strategic priorities. ", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1facf78615c344e17310e5e000264769c42f62b02f888cd53f59c6ac8ebb4828", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4448a8bc-4bd5-44f4-8519-7c4afc2ae657", "node_type": "1", "metadata": {"window": "Based on our first quarter results, our evolving roles in the COVID -19 response efforts and our confidence in our \noutlook for the remainder of our fiscal 2022, we are raising our adjusted earnings per diluted share guidance to \n$19.80 to $20.40 from a previous range of $18.85 to $19.45.  \n \n As I mentioned in my opening remarks, we're making significant progress against our strategic priorities.  We're \nsimplifying the portfolio and increasing our focus on  areas where we have deep expertise and that are central to \nour long -term growth strategy.  Our progress to -date is underpinned by execution against our top company \npriorities.  \n \n The first is a focus on the people and the culture.  The second is our commitmen t to strengthen the core \npharmaceutical and medical supply chain businesses.  The third, our intentional efforts to simplify and streamline \nthe business. ", "original_text": "Our progress to -date is underpinned by execution against our top company \npriorities.  \n \n"}, "hash": "17a382d4b52e717fbdfc80ffad8f81cf66f8542a77172e22f9bd7b962a08ad9e", "class_name": "RelatedNodeInfo"}}, "text": "We're \nsimplifying the portfolio and increasing our focus on  areas where we have deep expertise and that are central to \nour long -term growth strategy. ", "start_char_idx": 881, "end_char_idx": 1035, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4448a8bc-4bd5-44f4-8519-7c4afc2ae657": {"__data__": {"id_": "4448a8bc-4bd5-44f4-8519-7c4afc2ae657", "embedding": null, "metadata": {"window": "Based on our first quarter results, our evolving roles in the COVID -19 response efforts and our confidence in our \noutlook for the remainder of our fiscal 2022, we are raising our adjusted earnings per diluted share guidance to \n$19.80 to $20.40 from a previous range of $18.85 to $19.45.  \n \n As I mentioned in my opening remarks, we're making significant progress against our strategic priorities.  We're \nsimplifying the portfolio and increasing our focus on  areas where we have deep expertise and that are central to \nour long -term growth strategy.  Our progress to -date is underpinned by execution against our top company \npriorities.  \n \n The first is a focus on the people and the culture.  The second is our commitmen t to strengthen the core \npharmaceutical and medical supply chain businesses.  The third, our intentional efforts to simplify and streamline \nthe business. ", "original_text": "Our progress to -date is underpinned by execution against our top company \npriorities.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce4cf70f47aba08c6d8df52ea899482b0f6cfa03010b333fb31caf0734f9a1f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd91253e-bdfc-4188-9b2d-8683ccfd507d", "node_type": "1", "metadata": {"window": "Through July, we've distributed over 45 million \nvaccines to adminis tration sites in select markets across these geographies.  \n \n Based on our first quarter results, our evolving roles in the COVID -19 response efforts and our confidence in our \noutlook for the remainder of our fiscal 2022, we are raising our adjusted earnings per diluted share guidance to \n$19.80 to $20.40 from a previous range of $18.85 to $19.45.  \n \n As I mentioned in my opening remarks, we're making significant progress against our strategic priorities.  We're \nsimplifying the portfolio and increasing our focus on  areas where we have deep expertise and that are central to \nour long -term growth strategy.  Our progress to -date is underpinned by execution against our top company \npriorities.  \n \n The first is a focus on the people and the culture.  The second is our commitmen t to strengthen the core \npharmaceutical and medical supply chain businesses. ", "original_text": "We're \nsimplifying the portfolio and increasing our focus on  areas where we have deep expertise and that are central to \nour long -term growth strategy. ", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bf7fb17e929ff8089e22dc10c3969fc9f7b12191092cf72b813543a04ecbc48f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7bd764bb-a95a-455c-b9b0-afa598f3bc9d", "node_type": "1", "metadata": {"window": "As I mentioned in my opening remarks, we're making significant progress against our strategic priorities.  We're \nsimplifying the portfolio and increasing our focus on  areas where we have deep expertise and that are central to \nour long -term growth strategy.  Our progress to -date is underpinned by execution against our top company \npriorities.  \n \n The first is a focus on the people and the culture.  The second is our commitmen t to strengthen the core \npharmaceutical and medical supply chain businesses.  The third, our intentional efforts to simplify and streamline \nthe business.  And finally, to continue to invest to advance our differentiated oncology and biopharma services \necosys tems.  \n \n", "original_text": "The first is a focus on the people and the culture. "}, "hash": "968f58bf4b49df15faa5177c276f72a2b5cccd2d299c544085940b711e3b3056", "class_name": "RelatedNodeInfo"}}, "text": "Our progress to -date is underpinned by execution against our top company \npriorities.  \n \n", "start_char_idx": 1035, "end_char_idx": 1126, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7bd764bb-a95a-455c-b9b0-afa598f3bc9d": {"__data__": {"id_": "7bd764bb-a95a-455c-b9b0-afa598f3bc9d", "embedding": null, "metadata": {"window": "As I mentioned in my opening remarks, we're making significant progress against our strategic priorities.  We're \nsimplifying the portfolio and increasing our focus on  areas where we have deep expertise and that are central to \nour long -term growth strategy.  Our progress to -date is underpinned by execution against our top company \npriorities.  \n \n The first is a focus on the people and the culture.  The second is our commitmen t to strengthen the core \npharmaceutical and medical supply chain businesses.  The third, our intentional efforts to simplify and streamline \nthe business.  And finally, to continue to invest to advance our differentiated oncology and biopharma services \necosys tems.  \n \n", "original_text": "The first is a focus on the people and the culture. ", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce4cf70f47aba08c6d8df52ea899482b0f6cfa03010b333fb31caf0734f9a1f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4448a8bc-4bd5-44f4-8519-7c4afc2ae657", "node_type": "1", "metadata": {"window": "Based on our first quarter results, our evolving roles in the COVID -19 response efforts and our confidence in our \noutlook for the remainder of our fiscal 2022, we are raising our adjusted earnings per diluted share guidance to \n$19.80 to $20.40 from a previous range of $18.85 to $19.45.  \n \n As I mentioned in my opening remarks, we're making significant progress against our strategic priorities.  We're \nsimplifying the portfolio and increasing our focus on  areas where we have deep expertise and that are central to \nour long -term growth strategy.  Our progress to -date is underpinned by execution against our top company \npriorities.  \n \n The first is a focus on the people and the culture.  The second is our commitmen t to strengthen the core \npharmaceutical and medical supply chain businesses.  The third, our intentional efforts to simplify and streamline \nthe business. ", "original_text": "Our progress to -date is underpinned by execution against our top company \npriorities.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ba35071b9a8700efd20cfb944b0f3234b7d55453ec2bfefa8380a59d312852e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd48613f-d7c9-4b69-8d0e-3f3a788d9423", "node_type": "1", "metadata": {"window": "We're \nsimplifying the portfolio and increasing our focus on  areas where we have deep expertise and that are central to \nour long -term growth strategy.  Our progress to -date is underpinned by execution against our top company \npriorities.  \n \n The first is a focus on the people and the culture.  The second is our commitmen t to strengthen the core \npharmaceutical and medical supply chain businesses.  The third, our intentional efforts to simplify and streamline \nthe business.  And finally, to continue to invest to advance our differentiated oncology and biopharma services \necosys tems.  \n \n Let me now touch briefly on the progress we're making across each of these priorities. ", "original_text": "The second is our commitmen t to strengthen the core \npharmaceutical and medical supply chain businesses. "}, "hash": "d9e82cb5e1976c397db2f3381fcd9450cc4d27e2c97e988e6db88deac2ce62fd", "class_name": "RelatedNodeInfo"}}, "text": "The first is a focus on the people and the culture. ", "start_char_idx": 1126, "end_char_idx": 1178, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd48613f-d7c9-4b69-8d0e-3f3a788d9423": {"__data__": {"id_": "fd48613f-d7c9-4b69-8d0e-3f3a788d9423", "embedding": null, "metadata": {"window": "We're \nsimplifying the portfolio and increasing our focus on  areas where we have deep expertise and that are central to \nour long -term growth strategy.  Our progress to -date is underpinned by execution against our top company \npriorities.  \n \n The first is a focus on the people and the culture.  The second is our commitmen t to strengthen the core \npharmaceutical and medical supply chain businesses.  The third, our intentional efforts to simplify and streamline \nthe business.  And finally, to continue to invest to advance our differentiated oncology and biopharma services \necosys tems.  \n \n Let me now touch briefly on the progress we're making across each of these priorities. ", "original_text": "The second is our commitmen t to strengthen the core \npharmaceutical and medical supply chain businesses. ", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce4cf70f47aba08c6d8df52ea899482b0f6cfa03010b333fb31caf0734f9a1f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7bd764bb-a95a-455c-b9b0-afa598f3bc9d", "node_type": "1", "metadata": {"window": "As I mentioned in my opening remarks, we're making significant progress against our strategic priorities.  We're \nsimplifying the portfolio and increasing our focus on  areas where we have deep expertise and that are central to \nour long -term growth strategy.  Our progress to -date is underpinned by execution against our top company \npriorities.  \n \n The first is a focus on the people and the culture.  The second is our commitmen t to strengthen the core \npharmaceutical and medical supply chain businesses.  The third, our intentional efforts to simplify and streamline \nthe business.  And finally, to continue to invest to advance our differentiated oncology and biopharma services \necosys tems.  \n \n", "original_text": "The first is a focus on the people and the culture. ", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8bfb8daf0b4ba7ddc8ec0b529030be73c78eeef92b19e3549e787a22ff514c55", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ba3b3a7-0fe1-47c4-88e8-3e59534d9359", "node_type": "1", "metadata": {"window": "Our progress to -date is underpinned by execution against our top company \npriorities.  \n \n The first is a focus on the people and the culture.  The second is our commitmen t to strengthen the core \npharmaceutical and medical supply chain businesses.  The third, our intentional efforts to simplify and streamline \nthe business.  And finally, to continue to invest to advance our differentiated oncology and biopharma services \necosys tems.  \n \n Let me now touch briefly on the progress we're making across each of these priorities.  First and foremost, we're \nprioritizing our people and advancing our company's culture as we strive to be recognized as an impact -driven \norganization and the best place to work in healthcare. ", "original_text": "The third, our intentional efforts to simplify and streamline \nthe business. "}, "hash": "689bec08a875818ee8faca77e0076a4e402b425035870c52521686405578d671", "class_name": "RelatedNodeInfo"}}, "text": "The second is our commitmen t to strengthen the core \npharmaceutical and medical supply chain businesses. ", "start_char_idx": 1178, "end_char_idx": 1284, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ba3b3a7-0fe1-47c4-88e8-3e59534d9359": {"__data__": {"id_": "3ba3b3a7-0fe1-47c4-88e8-3e59534d9359", "embedding": null, "metadata": {"window": "Our progress to -date is underpinned by execution against our top company \npriorities.  \n \n The first is a focus on the people and the culture.  The second is our commitmen t to strengthen the core \npharmaceutical and medical supply chain businesses.  The third, our intentional efforts to simplify and streamline \nthe business.  And finally, to continue to invest to advance our differentiated oncology and biopharma services \necosys tems.  \n \n Let me now touch briefly on the progress we're making across each of these priorities.  First and foremost, we're \nprioritizing our people and advancing our company's culture as we strive to be recognized as an impact -driven \norganization and the best place to work in healthcare. ", "original_text": "The third, our intentional efforts to simplify and streamline \nthe business. ", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce4cf70f47aba08c6d8df52ea899482b0f6cfa03010b333fb31caf0734f9a1f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd48613f-d7c9-4b69-8d0e-3f3a788d9423", "node_type": "1", "metadata": {"window": "We're \nsimplifying the portfolio and increasing our focus on  areas where we have deep expertise and that are central to \nour long -term growth strategy.  Our progress to -date is underpinned by execution against our top company \npriorities.  \n \n The first is a focus on the people and the culture.  The second is our commitmen t to strengthen the core \npharmaceutical and medical supply chain businesses.  The third, our intentional efforts to simplify and streamline \nthe business.  And finally, to continue to invest to advance our differentiated oncology and biopharma services \necosys tems.  \n \n Let me now touch briefly on the progress we're making across each of these priorities. ", "original_text": "The second is our commitmen t to strengthen the core \npharmaceutical and medical supply chain businesses. ", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "86b1711ce8e13a3b68b9aa7e40ab13ec60d1b01a70460fd854094f720f49bdc1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ddf13f7-f253-4cd3-b214-bcd58b0c96a3", "node_type": "1", "metadata": {"window": "The first is a focus on the people and the culture.  The second is our commitmen t to strengthen the core \npharmaceutical and medical supply chain businesses.  The third, our intentional efforts to simplify and streamline \nthe business.  And finally, to continue to invest to advance our differentiated oncology and biopharma services \necosys tems.  \n \n Let me now touch briefly on the progress we're making across each of these priorities.  First and foremost, we're \nprioritizing our people and advancing our company's culture as we strive to be recognized as an impact -driven \norganization and the best place to work in healthcare.  We've been hard at work to transform and energize our \ncompany's culture. ", "original_text": "And finally, to continue to invest to advance our differentiated oncology and biopharma services \necosys tems.  \n \n"}, "hash": "e3ce89b4287edc4acf38d552b30b57bbb12747767ce4a5f0332f0fa61acb8b5a", "class_name": "RelatedNodeInfo"}}, "text": "The third, our intentional efforts to simplify and streamline \nthe business. ", "start_char_idx": 1284, "end_char_idx": 1361, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ddf13f7-f253-4cd3-b214-bcd58b0c96a3": {"__data__": {"id_": "7ddf13f7-f253-4cd3-b214-bcd58b0c96a3", "embedding": null, "metadata": {"window": "The first is a focus on the people and the culture.  The second is our commitmen t to strengthen the core \npharmaceutical and medical supply chain businesses.  The third, our intentional efforts to simplify and streamline \nthe business.  And finally, to continue to invest to advance our differentiated oncology and biopharma services \necosys tems.  \n \n Let me now touch briefly on the progress we're making across each of these priorities.  First and foremost, we're \nprioritizing our people and advancing our company's culture as we strive to be recognized as an impact -driven \norganization and the best place to work in healthcare.  We've been hard at work to transform and energize our \ncompany's culture. ", "original_text": "And finally, to continue to invest to advance our differentiated oncology and biopharma services \necosys tems.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce4cf70f47aba08c6d8df52ea899482b0f6cfa03010b333fb31caf0734f9a1f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ba3b3a7-0fe1-47c4-88e8-3e59534d9359", "node_type": "1", "metadata": {"window": "Our progress to -date is underpinned by execution against our top company \npriorities.  \n \n The first is a focus on the people and the culture.  The second is our commitmen t to strengthen the core \npharmaceutical and medical supply chain businesses.  The third, our intentional efforts to simplify and streamline \nthe business.  And finally, to continue to invest to advance our differentiated oncology and biopharma services \necosys tems.  \n \n Let me now touch briefly on the progress we're making across each of these priorities.  First and foremost, we're \nprioritizing our people and advancing our company's culture as we strive to be recognized as an impact -driven \norganization and the best place to work in healthcare. ", "original_text": "The third, our intentional efforts to simplify and streamline \nthe business. ", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "957bf98d1a3d64f6170ad9bf4aaeb7cc948456704cd297f03355491506db009f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2da63bf2-277a-4caf-b6d1-f3b6475f4e11", "node_type": "1", "metadata": {"window": "The second is our commitmen t to strengthen the core \npharmaceutical and medical supply chain businesses.  The third, our intentional efforts to simplify and streamline \nthe business.  And finally, to continue to invest to advance our differentiated oncology and biopharma services \necosys tems.  \n \n Let me now touch briefly on the progress we're making across each of these priorities.  First and foremost, we're \nprioritizing our people and advancing our company's culture as we strive to be recognized as an impact -driven \norganization and the best place to work in healthcare.  We've been hard at work to transform and energize our \ncompany's culture.  Our ICARE and ILEAD values serve as the foundation as we work toward our common goal, \nadvancing health outcomes for all.  \n \n", "original_text": "Let me now touch briefly on the progress we're making across each of these priorities. "}, "hash": "0058745f62478dc8b6b2332440ce4c000d03de9f1b403b9b1fda490ee5c7a732", "class_name": "RelatedNodeInfo"}}, "text": "And finally, to continue to invest to advance our differentiated oncology and biopharma services \necosys tems.  \n \n", "start_char_idx": 1361, "end_char_idx": 1476, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2da63bf2-277a-4caf-b6d1-f3b6475f4e11": {"__data__": {"id_": "2da63bf2-277a-4caf-b6d1-f3b6475f4e11", "embedding": null, "metadata": {"window": "The second is our commitmen t to strengthen the core \npharmaceutical and medical supply chain businesses.  The third, our intentional efforts to simplify and streamline \nthe business.  And finally, to continue to invest to advance our differentiated oncology and biopharma services \necosys tems.  \n \n Let me now touch briefly on the progress we're making across each of these priorities.  First and foremost, we're \nprioritizing our people and advancing our company's culture as we strive to be recognized as an impact -driven \norganization and the best place to work in healthcare.  We've been hard at work to transform and energize our \ncompany's culture.  Our ICARE and ILEAD values serve as the foundation as we work toward our common goal, \nadvancing health outcomes for all.  \n \n", "original_text": "Let me now touch briefly on the progress we're making across each of these priorities. ", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce4cf70f47aba08c6d8df52ea899482b0f6cfa03010b333fb31caf0734f9a1f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ddf13f7-f253-4cd3-b214-bcd58b0c96a3", "node_type": "1", "metadata": {"window": "The first is a focus on the people and the culture.  The second is our commitmen t to strengthen the core \npharmaceutical and medical supply chain businesses.  The third, our intentional efforts to simplify and streamline \nthe business.  And finally, to continue to invest to advance our differentiated oncology and biopharma services \necosys tems.  \n \n Let me now touch briefly on the progress we're making across each of these priorities.  First and foremost, we're \nprioritizing our people and advancing our company's culture as we strive to be recognized as an impact -driven \norganization and the best place to work in healthcare.  We've been hard at work to transform and energize our \ncompany's culture. ", "original_text": "And finally, to continue to invest to advance our differentiated oncology and biopharma services \necosys tems.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad333c5463b32f2c3d0403b8cadfb0b1543eac5e9bae52f0a70ec08fc282a810", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "352a3560-d200-48d5-8ae8-294c72d1705b", "node_type": "1", "metadata": {"window": "The third, our intentional efforts to simplify and streamline \nthe business.  And finally, to continue to invest to advance our differentiated oncology and biopharma services \necosys tems.  \n \n Let me now touch briefly on the progress we're making across each of these priorities.  First and foremost, we're \nprioritizing our people and advancing our company's culture as we strive to be recognized as an impact -driven \norganization and the best place to work in healthcare.  We've been hard at work to transform and energize our \ncompany's culture.  Our ICARE and ILEAD values serve as the foundation as we work toward our common goal, \nadvancing health outcomes for all.  \n \n As an organization, we're commit ted to advancing diversity, equity and inclusion. ", "original_text": "First and foremost, we're \nprioritizing our people and advancing our company's culture as we strive to be recognized as an impact -driven \norganization and the best place to work in healthcare. "}, "hash": "5476a075fdb86a6a242c99490c9ea40b45650f4c3f6edbad993807df53de9c50", "class_name": "RelatedNodeInfo"}}, "text": "Let me now touch briefly on the progress we're making across each of these priorities. ", "start_char_idx": 1476, "end_char_idx": 1563, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "352a3560-d200-48d5-8ae8-294c72d1705b": {"__data__": {"id_": "352a3560-d200-48d5-8ae8-294c72d1705b", "embedding": null, "metadata": {"window": "The third, our intentional efforts to simplify and streamline \nthe business.  And finally, to continue to invest to advance our differentiated oncology and biopharma services \necosys tems.  \n \n Let me now touch briefly on the progress we're making across each of these priorities.  First and foremost, we're \nprioritizing our people and advancing our company's culture as we strive to be recognized as an impact -driven \norganization and the best place to work in healthcare.  We've been hard at work to transform and energize our \ncompany's culture.  Our ICARE and ILEAD values serve as the foundation as we work toward our common goal, \nadvancing health outcomes for all.  \n \n As an organization, we're commit ted to advancing diversity, equity and inclusion. ", "original_text": "First and foremost, we're \nprioritizing our people and advancing our company's culture as we strive to be recognized as an impact -driven \norganization and the best place to work in healthcare. ", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce4cf70f47aba08c6d8df52ea899482b0f6cfa03010b333fb31caf0734f9a1f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2da63bf2-277a-4caf-b6d1-f3b6475f4e11", "node_type": "1", "metadata": {"window": "The second is our commitmen t to strengthen the core \npharmaceutical and medical supply chain businesses.  The third, our intentional efforts to simplify and streamline \nthe business.  And finally, to continue to invest to advance our differentiated oncology and biopharma services \necosys tems.  \n \n Let me now touch briefly on the progress we're making across each of these priorities.  First and foremost, we're \nprioritizing our people and advancing our company's culture as we strive to be recognized as an impact -driven \norganization and the best place to work in healthcare.  We've been hard at work to transform and energize our \ncompany's culture.  Our ICARE and ILEAD values serve as the foundation as we work toward our common goal, \nadvancing health outcomes for all.  \n \n", "original_text": "Let me now touch briefly on the progress we're making across each of these priorities. ", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3dd3caf0e43621ebdfc824d00d3b4e65fe83190818efe993fa4017615193a04f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22d5cec0-b9d0-4421-9f09-1595c2ae18c4", "node_type": "1", "metadata": {"window": "And finally, to continue to invest to advance our differentiated oncology and biopharma services \necosys tems.  \n \n Let me now touch briefly on the progress we're making across each of these priorities.  First and foremost, we're \nprioritizing our people and advancing our company's culture as we strive to be recognized as an impact -driven \norganization and the best place to work in healthcare.  We've been hard at work to transform and energize our \ncompany's culture.  Our ICARE and ILEAD values serve as the foundation as we work toward our common goal, \nadvancing health outcomes for all.  \n \n As an organization, we're commit ted to advancing diversity, equity and inclusion.  For the sixth consecutive year, \nMcKesson was named a Best Place to Work for Disability Inclusion. ", "original_text": "We've been hard at work to transform and energize our \ncompany's culture. "}, "hash": "9446587b0f371b05bf86822e8fb7e9d46f8019c2a707bffdeef902577b86ded1", "class_name": "RelatedNodeInfo"}}, "text": "First and foremost, we're \nprioritizing our people and advancing our company's culture as we strive to be recognized as an impact -driven \norganization and the best place to work in healthcare. ", "start_char_idx": 1563, "end_char_idx": 1757, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22d5cec0-b9d0-4421-9f09-1595c2ae18c4": {"__data__": {"id_": "22d5cec0-b9d0-4421-9f09-1595c2ae18c4", "embedding": null, "metadata": {"window": "And finally, to continue to invest to advance our differentiated oncology and biopharma services \necosys tems.  \n \n Let me now touch briefly on the progress we're making across each of these priorities.  First and foremost, we're \nprioritizing our people and advancing our company's culture as we strive to be recognized as an impact -driven \norganization and the best place to work in healthcare.  We've been hard at work to transform and energize our \ncompany's culture.  Our ICARE and ILEAD values serve as the foundation as we work toward our common goal, \nadvancing health outcomes for all.  \n \n As an organization, we're commit ted to advancing diversity, equity and inclusion.  For the sixth consecutive year, \nMcKesson was named a Best Place to Work for Disability Inclusion. ", "original_text": "We've been hard at work to transform and energize our \ncompany's culture. ", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce4cf70f47aba08c6d8df52ea899482b0f6cfa03010b333fb31caf0734f9a1f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "352a3560-d200-48d5-8ae8-294c72d1705b", "node_type": "1", "metadata": {"window": "The third, our intentional efforts to simplify and streamline \nthe business.  And finally, to continue to invest to advance our differentiated oncology and biopharma services \necosys tems.  \n \n Let me now touch briefly on the progress we're making across each of these priorities.  First and foremost, we're \nprioritizing our people and advancing our company's culture as we strive to be recognized as an impact -driven \norganization and the best place to work in healthcare.  We've been hard at work to transform and energize our \ncompany's culture.  Our ICARE and ILEAD values serve as the foundation as we work toward our common goal, \nadvancing health outcomes for all.  \n \n As an organization, we're commit ted to advancing diversity, equity and inclusion. ", "original_text": "First and foremost, we're \nprioritizing our people and advancing our company's culture as we strive to be recognized as an impact -driven \norganization and the best place to work in healthcare. ", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e97d0d1848233826f676cfdba058e5d4a2661040690f198d510bb91db28b8423", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d078137-0358-4985-b56d-8a07fe6a6e67", "node_type": "1", "metadata": {"window": "Let me now touch briefly on the progress we're making across each of these priorities.  First and foremost, we're \nprioritizing our people and advancing our company's culture as we strive to be recognized as an impact -driven \norganization and the best place to work in healthcare.  We've been hard at work to transform and energize our \ncompany's culture.  Our ICARE and ILEAD values serve as the foundation as we work toward our common goal, \nadvancing health outcomes for all.  \n \n As an organization, we're commit ted to advancing diversity, equity and inclusion.  For the sixth consecutive year, \nMcKesson was named a Best Place to Work for Disability Inclusion.  McKesson earned a top -ranking score of 100 \non the 2021 Disability Equality Index.  \n \n", "original_text": "Our ICARE and ILEAD values serve as the foundation as we work toward our common goal, \nadvancing health outcomes for all.  \n \n"}, "hash": "6cbf0a937a7858efde900f43ea4d2b9bea4ad4a5bc0a7f6842252d1b087dc217", "class_name": "RelatedNodeInfo"}}, "text": "We've been hard at work to transform and energize our \ncompany's culture. ", "start_char_idx": 1757, "end_char_idx": 1831, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d078137-0358-4985-b56d-8a07fe6a6e67": {"__data__": {"id_": "2d078137-0358-4985-b56d-8a07fe6a6e67", "embedding": null, "metadata": {"window": "Let me now touch briefly on the progress we're making across each of these priorities.  First and foremost, we're \nprioritizing our people and advancing our company's culture as we strive to be recognized as an impact -driven \norganization and the best place to work in healthcare.  We've been hard at work to transform and energize our \ncompany's culture.  Our ICARE and ILEAD values serve as the foundation as we work toward our common goal, \nadvancing health outcomes for all.  \n \n As an organization, we're commit ted to advancing diversity, equity and inclusion.  For the sixth consecutive year, \nMcKesson was named a Best Place to Work for Disability Inclusion.  McKesson earned a top -ranking score of 100 \non the 2021 Disability Equality Index.  \n \n", "original_text": "Our ICARE and ILEAD values serve as the foundation as we work toward our common goal, \nadvancing health outcomes for all.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce4cf70f47aba08c6d8df52ea899482b0f6cfa03010b333fb31caf0734f9a1f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22d5cec0-b9d0-4421-9f09-1595c2ae18c4", "node_type": "1", "metadata": {"window": "And finally, to continue to invest to advance our differentiated oncology and biopharma services \necosys tems.  \n \n Let me now touch briefly on the progress we're making across each of these priorities.  First and foremost, we're \nprioritizing our people and advancing our company's culture as we strive to be recognized as an impact -driven \norganization and the best place to work in healthcare.  We've been hard at work to transform and energize our \ncompany's culture.  Our ICARE and ILEAD values serve as the foundation as we work toward our common goal, \nadvancing health outcomes for all.  \n \n As an organization, we're commit ted to advancing diversity, equity and inclusion.  For the sixth consecutive year, \nMcKesson was named a Best Place to Work for Disability Inclusion. ", "original_text": "We've been hard at work to transform and energize our \ncompany's culture. ", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e73111d6c04a1922cc3a29bf9a4aaff10512b99f3cfa80a276a6ab730953004", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b128367-34bf-4c37-b189-e2894cffad08", "node_type": "1", "metadata": {"window": "First and foremost, we're \nprioritizing our people and advancing our company's culture as we strive to be recognized as an impact -driven \norganization and the best place to work in healthcare.  We've been hard at work to transform and energize our \ncompany's culture.  Our ICARE and ILEAD values serve as the foundation as we work toward our common goal, \nadvancing health outcomes for all.  \n \n As an organization, we're commit ted to advancing diversity, equity and inclusion.  For the sixth consecutive year, \nMcKesson was named a Best Place to Work for Disability Inclusion.  McKesson earned a top -ranking score of 100 \non the 2021 Disability Equality Index.  \n \n In addition, we marked pr ogress in diverse representation in the US with female executive representation up 3% \nover the prior year and a 6% gain over the prior year in executive representation for persons of color. ", "original_text": "As an organization, we're commit ted to advancing diversity, equity and inclusion. "}, "hash": "93c6eb8942dfaee64bf5f509ac7693fa5b933a86865674d896d410f91b485989", "class_name": "RelatedNodeInfo"}}, "text": "Our ICARE and ILEAD values serve as the foundation as we work toward our common goal, \nadvancing health outcomes for all.  \n \n", "start_char_idx": 1831, "end_char_idx": 1957, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b128367-34bf-4c37-b189-e2894cffad08": {"__data__": {"id_": "2b128367-34bf-4c37-b189-e2894cffad08", "embedding": null, "metadata": {"window": "First and foremost, we're \nprioritizing our people and advancing our company's culture as we strive to be recognized as an impact -driven \norganization and the best place to work in healthcare.  We've been hard at work to transform and energize our \ncompany's culture.  Our ICARE and ILEAD values serve as the foundation as we work toward our common goal, \nadvancing health outcomes for all.  \n \n As an organization, we're commit ted to advancing diversity, equity and inclusion.  For the sixth consecutive year, \nMcKesson was named a Best Place to Work for Disability Inclusion.  McKesson earned a top -ranking score of 100 \non the 2021 Disability Equality Index.  \n \n In addition, we marked pr ogress in diverse representation in the US with female executive representation up 3% \nover the prior year and a 6% gain over the prior year in executive representation for persons of color. ", "original_text": "As an organization, we're commit ted to advancing diversity, equity and inclusion. ", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce4cf70f47aba08c6d8df52ea899482b0f6cfa03010b333fb31caf0734f9a1f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d078137-0358-4985-b56d-8a07fe6a6e67", "node_type": "1", "metadata": {"window": "Let me now touch briefly on the progress we're making across each of these priorities.  First and foremost, we're \nprioritizing our people and advancing our company's culture as we strive to be recognized as an impact -driven \norganization and the best place to work in healthcare.  We've been hard at work to transform and energize our \ncompany's culture.  Our ICARE and ILEAD values serve as the foundation as we work toward our common goal, \nadvancing health outcomes for all.  \n \n As an organization, we're commit ted to advancing diversity, equity and inclusion.  For the sixth consecutive year, \nMcKesson was named a Best Place to Work for Disability Inclusion.  McKesson earned a top -ranking score of 100 \non the 2021 Disability Equality Index.  \n \n", "original_text": "Our ICARE and ILEAD values serve as the foundation as we work toward our common goal, \nadvancing health outcomes for all.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b45bb7d4381e936dc23ff013a40bf115eacc4f440e4d212aa5c662a705bb23fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eefa3a66-b993-40e7-9efe-b5e9b6b76646", "node_type": "1", "metadata": {"window": "We've been hard at work to transform and energize our \ncompany's culture.  Our ICARE and ILEAD values serve as the foundation as we work toward our common goal, \nadvancing health outcomes for all.  \n \n As an organization, we're commit ted to advancing diversity, equity and inclusion.  For the sixth consecutive year, \nMcKesson was named a Best Place to Work for Disability Inclusion.  McKesson earned a top -ranking score of 100 \non the 2021 Disability Equality Index.  \n \n In addition, we marked pr ogress in diverse representation in the US with female executive representation up 3% \nover the prior year and a 6% gain over the prior year in executive representation for persons of color.  Our second \ncompany priority is to strengthen our core distribution  businesses where we have market -leading scale and \ncapabilities across North America. ", "original_text": "For the sixth consecutive year, \nMcKesson was named a Best Place to Work for Disability Inclusion. "}, "hash": "accbb3bdb237c820964e2afa840bd231f59affa97022a718e38f12558eb45054", "class_name": "RelatedNodeInfo"}}, "text": "As an organization, we're commit ted to advancing diversity, equity and inclusion. ", "start_char_idx": 1957, "end_char_idx": 2040, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eefa3a66-b993-40e7-9efe-b5e9b6b76646": {"__data__": {"id_": "eefa3a66-b993-40e7-9efe-b5e9b6b76646", "embedding": null, "metadata": {"window": "We've been hard at work to transform and energize our \ncompany's culture.  Our ICARE and ILEAD values serve as the foundation as we work toward our common goal, \nadvancing health outcomes for all.  \n \n As an organization, we're commit ted to advancing diversity, equity and inclusion.  For the sixth consecutive year, \nMcKesson was named a Best Place to Work for Disability Inclusion.  McKesson earned a top -ranking score of 100 \non the 2021 Disability Equality Index.  \n \n In addition, we marked pr ogress in diverse representation in the US with female executive representation up 3% \nover the prior year and a 6% gain over the prior year in executive representation for persons of color.  Our second \ncompany priority is to strengthen our core distribution  businesses where we have market -leading scale and \ncapabilities across North America. ", "original_text": "For the sixth consecutive year, \nMcKesson was named a Best Place to Work for Disability Inclusion. ", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce4cf70f47aba08c6d8df52ea899482b0f6cfa03010b333fb31caf0734f9a1f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b128367-34bf-4c37-b189-e2894cffad08", "node_type": "1", "metadata": {"window": "First and foremost, we're \nprioritizing our people and advancing our company's culture as we strive to be recognized as an impact -driven \norganization and the best place to work in healthcare.  We've been hard at work to transform and energize our \ncompany's culture.  Our ICARE and ILEAD values serve as the foundation as we work toward our common goal, \nadvancing health outcomes for all.  \n \n As an organization, we're commit ted to advancing diversity, equity and inclusion.  For the sixth consecutive year, \nMcKesson was named a Best Place to Work for Disability Inclusion.  McKesson earned a top -ranking score of 100 \non the 2021 Disability Equality Index.  \n \n In addition, we marked pr ogress in diverse representation in the US with female executive representation up 3% \nover the prior year and a 6% gain over the prior year in executive representation for persons of color. ", "original_text": "As an organization, we're commit ted to advancing diversity, equity and inclusion. ", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ead60cd4cf44543db6804479c399171b54d699e678efb2d24e84c1eb5905c91e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c27b8da1-4023-4672-a2eb-acdb504063fa", "node_type": "1", "metadata": {"window": "Our ICARE and ILEAD values serve as the foundation as we work toward our common goal, \nadvancing health outcomes for all.  \n \n As an organization, we're commit ted to advancing diversity, equity and inclusion.  For the sixth consecutive year, \nMcKesson was named a Best Place to Work for Disability Inclusion.  McKesson earned a top -ranking score of 100 \non the 2021 Disability Equality Index.  \n \n In addition, we marked pr ogress in diverse representation in the US with female executive representation up 3% \nover the prior year and a 6% gain over the prior year in executive representation for persons of color.  Our second \ncompany priority is to strengthen our core distribution  businesses where we have market -leading scale and \ncapabilities across North America.  Success in the core enables strong cash flow generation, which we in turn use \nto reinvest in the business and to return capital to our shareholders.  \n \n", "original_text": "McKesson earned a top -ranking score of 100 \non the 2021 Disability Equality Index.  \n \n"}, "hash": "73e5ec68e2b149d8709165d4b63c7c9b0c8de8cab29704871e8fba1161ef28a9", "class_name": "RelatedNodeInfo"}}, "text": "For the sixth consecutive year, \nMcKesson was named a Best Place to Work for Disability Inclusion. ", "start_char_idx": 2040, "end_char_idx": 2139, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c27b8da1-4023-4672-a2eb-acdb504063fa": {"__data__": {"id_": "c27b8da1-4023-4672-a2eb-acdb504063fa", "embedding": null, "metadata": {"window": "Our ICARE and ILEAD values serve as the foundation as we work toward our common goal, \nadvancing health outcomes for all.  \n \n As an organization, we're commit ted to advancing diversity, equity and inclusion.  For the sixth consecutive year, \nMcKesson was named a Best Place to Work for Disability Inclusion.  McKesson earned a top -ranking score of 100 \non the 2021 Disability Equality Index.  \n \n In addition, we marked pr ogress in diverse representation in the US with female executive representation up 3% \nover the prior year and a 6% gain over the prior year in executive representation for persons of color.  Our second \ncompany priority is to strengthen our core distribution  businesses where we have market -leading scale and \ncapabilities across North America.  Success in the core enables strong cash flow generation, which we in turn use \nto reinvest in the business and to return capital to our shareholders.  \n \n", "original_text": "McKesson earned a top -ranking score of 100 \non the 2021 Disability Equality Index.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce4cf70f47aba08c6d8df52ea899482b0f6cfa03010b333fb31caf0734f9a1f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eefa3a66-b993-40e7-9efe-b5e9b6b76646", "node_type": "1", "metadata": {"window": "We've been hard at work to transform and energize our \ncompany's culture.  Our ICARE and ILEAD values serve as the foundation as we work toward our common goal, \nadvancing health outcomes for all.  \n \n As an organization, we're commit ted to advancing diversity, equity and inclusion.  For the sixth consecutive year, \nMcKesson was named a Best Place to Work for Disability Inclusion.  McKesson earned a top -ranking score of 100 \non the 2021 Disability Equality Index.  \n \n In addition, we marked pr ogress in diverse representation in the US with female executive representation up 3% \nover the prior year and a 6% gain over the prior year in executive representation for persons of color.  Our second \ncompany priority is to strengthen our core distribution  businesses where we have market -leading scale and \ncapabilities across North America. ", "original_text": "For the sixth consecutive year, \nMcKesson was named a Best Place to Work for Disability Inclusion. ", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "420d22b015085e7c50fc4d81dc3b8829c91312a0f1f7de79191c87d3cfcd338a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2a816ea-df61-4499-bae7-07ad21468024", "node_type": "1", "metadata": {"window": "As an organization, we're commit ted to advancing diversity, equity and inclusion.  For the sixth consecutive year, \nMcKesson was named a Best Place to Work for Disability Inclusion.  McKesson earned a top -ranking score of 100 \non the 2021 Disability Equality Index.  \n \n In addition, we marked pr ogress in diverse representation in the US with female executive representation up 3% \nover the prior year and a 6% gain over the prior year in executive representation for persons of color.  Our second \ncompany priority is to strengthen our core distribution  businesses where we have market -leading scale and \ncapabilities across North America.  Success in the core enables strong cash flow generation, which we in turn use \nto reinvest in the business and to return capital to our shareholders.  \n \n In addition to our w ork to help our customers and government partners in their pandemic response efforts, our \npharmaceutical and medical surgical distribution businesses are continuing to improve and the recovery from the \neffects of the COVID -19 pandemic has been in line with  our expectations.  \n \n", "original_text": "In addition, we marked pr ogress in diverse representation in the US with female executive representation up 3% \nover the prior year and a 6% gain over the prior year in executive representation for persons of color. "}, "hash": "21bf02104c9f4960c3d5c89730a10866fba9c7a0af66c51d52f8feca4c311970", "class_name": "RelatedNodeInfo"}}, "text": "McKesson earned a top -ranking score of 100 \non the 2021 Disability Equality Index.  \n \n", "start_char_idx": 2139, "end_char_idx": 2227, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2a816ea-df61-4499-bae7-07ad21468024": {"__data__": {"id_": "b2a816ea-df61-4499-bae7-07ad21468024", "embedding": null, "metadata": {"window": "As an organization, we're commit ted to advancing diversity, equity and inclusion.  For the sixth consecutive year, \nMcKesson was named a Best Place to Work for Disability Inclusion.  McKesson earned a top -ranking score of 100 \non the 2021 Disability Equality Index.  \n \n In addition, we marked pr ogress in diverse representation in the US with female executive representation up 3% \nover the prior year and a 6% gain over the prior year in executive representation for persons of color.  Our second \ncompany priority is to strengthen our core distribution  businesses where we have market -leading scale and \ncapabilities across North America.  Success in the core enables strong cash flow generation, which we in turn use \nto reinvest in the business and to return capital to our shareholders.  \n \n In addition to our w ork to help our customers and government partners in their pandemic response efforts, our \npharmaceutical and medical surgical distribution businesses are continuing to improve and the recovery from the \neffects of the COVID -19 pandemic has been in line with  our expectations.  \n \n", "original_text": "In addition, we marked pr ogress in diverse representation in the US with female executive representation up 3% \nover the prior year and a 6% gain over the prior year in executive representation for persons of color. ", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce4cf70f47aba08c6d8df52ea899482b0f6cfa03010b333fb31caf0734f9a1f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c27b8da1-4023-4672-a2eb-acdb504063fa", "node_type": "1", "metadata": {"window": "Our ICARE and ILEAD values serve as the foundation as we work toward our common goal, \nadvancing health outcomes for all.  \n \n As an organization, we're commit ted to advancing diversity, equity and inclusion.  For the sixth consecutive year, \nMcKesson was named a Best Place to Work for Disability Inclusion.  McKesson earned a top -ranking score of 100 \non the 2021 Disability Equality Index.  \n \n In addition, we marked pr ogress in diverse representation in the US with female executive representation up 3% \nover the prior year and a 6% gain over the prior year in executive representation for persons of color.  Our second \ncompany priority is to strengthen our core distribution  businesses where we have market -leading scale and \ncapabilities across North America.  Success in the core enables strong cash flow generation, which we in turn use \nto reinvest in the business and to return capital to our shareholders.  \n \n", "original_text": "McKesson earned a top -ranking score of 100 \non the 2021 Disability Equality Index.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "70446851155f5d8181861ec442609fb86b82378c7fb08b655655592261c31901", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "caa2eb17-98b5-4f91-b9b0-30fc4331c39a", "node_type": "1", "metadata": {"window": "For the sixth consecutive year, \nMcKesson was named a Best Place to Work for Disability Inclusion.  McKesson earned a top -ranking score of 100 \non the 2021 Disability Equality Index.  \n \n In addition, we marked pr ogress in diverse representation in the US with female executive representation up 3% \nover the prior year and a 6% gain over the prior year in executive representation for persons of color.  Our second \ncompany priority is to strengthen our core distribution  businesses where we have market -leading scale and \ncapabilities across North America.  Success in the core enables strong cash flow generation, which we in turn use \nto reinvest in the business and to return capital to our shareholders.  \n \n In addition to our w ork to help our customers and government partners in their pandemic response efforts, our \npharmaceutical and medical surgical distribution businesses are continuing to improve and the recovery from the \neffects of the COVID -19 pandemic has been in line with  our expectations.  \n \n Elective procedures and primary care visits had improved throughout our first quarter and prescription volume \ntrends are showing signs of improvement as well. ", "original_text": "Our second \ncompany priority is to strengthen our core distribution  businesses where we have market -leading scale and \ncapabilities across North America. "}, "hash": "05ac28240267f53a1358bebc6fa7b6db0cc9327dbbf7d14baa8249b943391b68", "class_name": "RelatedNodeInfo"}}, "text": "In addition, we marked pr ogress in diverse representation in the US with female executive representation up 3% \nover the prior year and a 6% gain over the prior year in executive representation for persons of color. ", "start_char_idx": 2227, "end_char_idx": 2444, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "caa2eb17-98b5-4f91-b9b0-30fc4331c39a": {"__data__": {"id_": "caa2eb17-98b5-4f91-b9b0-30fc4331c39a", "embedding": null, "metadata": {"window": "For the sixth consecutive year, \nMcKesson was named a Best Place to Work for Disability Inclusion.  McKesson earned a top -ranking score of 100 \non the 2021 Disability Equality Index.  \n \n In addition, we marked pr ogress in diverse representation in the US with female executive representation up 3% \nover the prior year and a 6% gain over the prior year in executive representation for persons of color.  Our second \ncompany priority is to strengthen our core distribution  businesses where we have market -leading scale and \ncapabilities across North America.  Success in the core enables strong cash flow generation, which we in turn use \nto reinvest in the business and to return capital to our shareholders.  \n \n In addition to our w ork to help our customers and government partners in their pandemic response efforts, our \npharmaceutical and medical surgical distribution businesses are continuing to improve and the recovery from the \neffects of the COVID -19 pandemic has been in line with  our expectations.  \n \n Elective procedures and primary care visits had improved throughout our first quarter and prescription volume \ntrends are showing signs of improvement as well. ", "original_text": "Our second \ncompany priority is to strengthen our core distribution  businesses where we have market -leading scale and \ncapabilities across North America. ", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce4cf70f47aba08c6d8df52ea899482b0f6cfa03010b333fb31caf0734f9a1f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2a816ea-df61-4499-bae7-07ad21468024", "node_type": "1", "metadata": {"window": "As an organization, we're commit ted to advancing diversity, equity and inclusion.  For the sixth consecutive year, \nMcKesson was named a Best Place to Work for Disability Inclusion.  McKesson earned a top -ranking score of 100 \non the 2021 Disability Equality Index.  \n \n In addition, we marked pr ogress in diverse representation in the US with female executive representation up 3% \nover the prior year and a 6% gain over the prior year in executive representation for persons of color.  Our second \ncompany priority is to strengthen our core distribution  businesses where we have market -leading scale and \ncapabilities across North America.  Success in the core enables strong cash flow generation, which we in turn use \nto reinvest in the business and to return capital to our shareholders.  \n \n In addition to our w ork to help our customers and government partners in their pandemic response efforts, our \npharmaceutical and medical surgical distribution businesses are continuing to improve and the recovery from the \neffects of the COVID -19 pandemic has been in line with  our expectations.  \n \n", "original_text": "In addition, we marked pr ogress in diverse representation in the US with female executive representation up 3% \nover the prior year and a 6% gain over the prior year in executive representation for persons of color. ", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fb164a433916a41f43caa31b3bbc95d2ffba153891608c1ad7fd309f2a5be161", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b10b331-afd2-4b23-9764-08ded3d37185", "node_type": "1", "metadata": {"window": "McKesson earned a top -ranking score of 100 \non the 2021 Disability Equality Index.  \n \n In addition, we marked pr ogress in diverse representation in the US with female executive representation up 3% \nover the prior year and a 6% gain over the prior year in executive representation for persons of color.  Our second \ncompany priority is to strengthen our core distribution  businesses where we have market -leading scale and \ncapabilities across North America.  Success in the core enables strong cash flow generation, which we in turn use \nto reinvest in the business and to return capital to our shareholders.  \n \n In addition to our w ork to help our customers and government partners in their pandemic response efforts, our \npharmaceutical and medical surgical distribution businesses are continuing to improve and the recovery from the \neffects of the COVID -19 pandemic has been in line with  our expectations.  \n \n Elective procedures and primary care visits had improved throughout our first quarter and prescription volume \ntrends are showing signs of improvement as well.  Also positive are the trends we've seen across specialty and \noncology patient  visits, which were at or above pre -COVID baselines in the first quarter. ", "original_text": "Success in the core enables strong cash flow generation, which we in turn use \nto reinvest in the business and to return capital to our shareholders.  \n \n"}, "hash": "f99dbe9af4c91e5b71fb1502e73384ec68ddc5b982545acedcec1634b21ef79a", "class_name": "RelatedNodeInfo"}}, "text": "Our second \ncompany priority is to strengthen our core distribution  businesses where we have market -leading scale and \ncapabilities across North America. ", "start_char_idx": 2444, "end_char_idx": 2600, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b10b331-afd2-4b23-9764-08ded3d37185": {"__data__": {"id_": "1b10b331-afd2-4b23-9764-08ded3d37185", "embedding": null, "metadata": {"window": "McKesson earned a top -ranking score of 100 \non the 2021 Disability Equality Index.  \n \n In addition, we marked pr ogress in diverse representation in the US with female executive representation up 3% \nover the prior year and a 6% gain over the prior year in executive representation for persons of color.  Our second \ncompany priority is to strengthen our core distribution  businesses where we have market -leading scale and \ncapabilities across North America.  Success in the core enables strong cash flow generation, which we in turn use \nto reinvest in the business and to return capital to our shareholders.  \n \n In addition to our w ork to help our customers and government partners in their pandemic response efforts, our \npharmaceutical and medical surgical distribution businesses are continuing to improve and the recovery from the \neffects of the COVID -19 pandemic has been in line with  our expectations.  \n \n Elective procedures and primary care visits had improved throughout our first quarter and prescription volume \ntrends are showing signs of improvement as well.  Also positive are the trends we've seen across specialty and \noncology patient  visits, which were at or above pre -COVID baselines in the first quarter. ", "original_text": "Success in the core enables strong cash flow generation, which we in turn use \nto reinvest in the business and to return capital to our shareholders.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce4cf70f47aba08c6d8df52ea899482b0f6cfa03010b333fb31caf0734f9a1f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "caa2eb17-98b5-4f91-b9b0-30fc4331c39a", "node_type": "1", "metadata": {"window": "For the sixth consecutive year, \nMcKesson was named a Best Place to Work for Disability Inclusion.  McKesson earned a top -ranking score of 100 \non the 2021 Disability Equality Index.  \n \n In addition, we marked pr ogress in diverse representation in the US with female executive representation up 3% \nover the prior year and a 6% gain over the prior year in executive representation for persons of color.  Our second \ncompany priority is to strengthen our core distribution  businesses where we have market -leading scale and \ncapabilities across North America.  Success in the core enables strong cash flow generation, which we in turn use \nto reinvest in the business and to return capital to our shareholders.  \n \n In addition to our w ork to help our customers and government partners in their pandemic response efforts, our \npharmaceutical and medical surgical distribution businesses are continuing to improve and the recovery from the \neffects of the COVID -19 pandemic has been in line with  our expectations.  \n \n Elective procedures and primary care visits had improved throughout our first quarter and prescription volume \ntrends are showing signs of improvement as well. ", "original_text": "Our second \ncompany priority is to strengthen our core distribution  businesses where we have market -leading scale and \ncapabilities across North America. ", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6fdf1502b56fb88d2621cd388876d13b9779045e0db4868cd668da39b3c64916", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f7887e28-9c21-4773-b285-7627117ce47f", "node_type": "1", "metadata": {"window": "In addition, we marked pr ogress in diverse representation in the US with female executive representation up 3% \nover the prior year and a 6% gain over the prior year in executive representation for persons of color.  Our second \ncompany priority is to strengthen our core distribution  businesses where we have market -leading scale and \ncapabilities across North America.  Success in the core enables strong cash flow generation, which we in turn use \nto reinvest in the business and to return capital to our shareholders.  \n \n In addition to our w ork to help our customers and government partners in their pandemic response efforts, our \npharmaceutical and medical surgical distribution businesses are continuing to improve and the recovery from the \neffects of the COVID -19 pandemic has been in line with  our expectations.  \n \n Elective procedures and primary care visits had improved throughout our first quarter and prescription volume \ntrends are showing signs of improvement as well.  Also positive are the trends we've seen across specialty and \noncology patient  visits, which were at or above pre -COVID baselines in the first quarter.  And distribution volumes \nto our specialty provider customers continue to drive and support our growth.  \n \n", "original_text": "In addition to our w ork to help our customers and government partners in their pandemic response efforts, our \npharmaceutical and medical surgical distribution businesses are continuing to improve and the recovery from the \neffects of the COVID -19 pandemic has been in line with  our expectations.  \n \n"}, "hash": "1a6518461a8c648dea6dbd4516e5f3654c3f56bd63ac50bc3af4883da7004034", "class_name": "RelatedNodeInfo"}}, "text": "Success in the core enables strong cash flow generation, which we in turn use \nto reinvest in the business and to return capital to our shareholders.  \n \n", "start_char_idx": 2600, "end_char_idx": 2754, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f7887e28-9c21-4773-b285-7627117ce47f": {"__data__": {"id_": "f7887e28-9c21-4773-b285-7627117ce47f", "embedding": null, "metadata": {"window": "In addition, we marked pr ogress in diverse representation in the US with female executive representation up 3% \nover the prior year and a 6% gain over the prior year in executive representation for persons of color.  Our second \ncompany priority is to strengthen our core distribution  businesses where we have market -leading scale and \ncapabilities across North America.  Success in the core enables strong cash flow generation, which we in turn use \nto reinvest in the business and to return capital to our shareholders.  \n \n In addition to our w ork to help our customers and government partners in their pandemic response efforts, our \npharmaceutical and medical surgical distribution businesses are continuing to improve and the recovery from the \neffects of the COVID -19 pandemic has been in line with  our expectations.  \n \n Elective procedures and primary care visits had improved throughout our first quarter and prescription volume \ntrends are showing signs of improvement as well.  Also positive are the trends we've seen across specialty and \noncology patient  visits, which were at or above pre -COVID baselines in the first quarter.  And distribution volumes \nto our specialty provider customers continue to drive and support our growth.  \n \n", "original_text": "In addition to our w ork to help our customers and government partners in their pandemic response efforts, our \npharmaceutical and medical surgical distribution businesses are continuing to improve and the recovery from the \neffects of the COVID -19 pandemic has been in line with  our expectations.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce4cf70f47aba08c6d8df52ea899482b0f6cfa03010b333fb31caf0734f9a1f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b10b331-afd2-4b23-9764-08ded3d37185", "node_type": "1", "metadata": {"window": "McKesson earned a top -ranking score of 100 \non the 2021 Disability Equality Index.  \n \n In addition, we marked pr ogress in diverse representation in the US with female executive representation up 3% \nover the prior year and a 6% gain over the prior year in executive representation for persons of color.  Our second \ncompany priority is to strengthen our core distribution  businesses where we have market -leading scale and \ncapabilities across North America.  Success in the core enables strong cash flow generation, which we in turn use \nto reinvest in the business and to return capital to our shareholders.  \n \n In addition to our w ork to help our customers and government partners in their pandemic response efforts, our \npharmaceutical and medical surgical distribution businesses are continuing to improve and the recovery from the \neffects of the COVID -19 pandemic has been in line with  our expectations.  \n \n Elective procedures and primary care visits had improved throughout our first quarter and prescription volume \ntrends are showing signs of improvement as well.  Also positive are the trends we've seen across specialty and \noncology patient  visits, which were at or above pre -COVID baselines in the first quarter. ", "original_text": "Success in the core enables strong cash flow generation, which we in turn use \nto reinvest in the business and to return capital to our shareholders.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4aa39e77720d25e9a9a0e793fded32d54c5fdf8b89be73c89ecc39aa2f03066a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f930f83-4729-407d-8c0a-8ef339a66b43", "node_type": "1", "metadata": {"window": "Our second \ncompany priority is to strengthen our core distribution  businesses where we have market -leading scale and \ncapabilities across North America.  Success in the core enables strong cash flow generation, which we in turn use \nto reinvest in the business and to return capital to our shareholders.  \n \n In addition to our w ork to help our customers and government partners in their pandemic response efforts, our \npharmaceutical and medical surgical distribution businesses are continuing to improve and the recovery from the \neffects of the COVID -19 pandemic has been in line with  our expectations.  \n \n Elective procedures and primary care visits had improved throughout our first quarter and prescription volume \ntrends are showing signs of improvement as well.  Also positive are the trends we've seen across specialty and \noncology patient  visits, which were at or above pre -COVID baselines in the first quarter.  And distribution volumes \nto our specialty provider customers continue to drive and support our growth.  \n \n In our Canadian distribution business, our operational excellence and scale wa s recently recognized through a \nnew partnership with one of Canada's largest retailers as a primary distribution customer. ", "original_text": "Elective procedures and primary care visits had improved throughout our first quarter and prescription volume \ntrends are showing signs of improvement as well. "}, "hash": "05908c9506c98f11f0a3ed2cdf20a8ef0027885e341608bde58ea7c30dfb503c", "class_name": "RelatedNodeInfo"}}, "text": "In addition to our w ork to help our customers and government partners in their pandemic response efforts, our \npharmaceutical and medical surgical distribution businesses are continuing to improve and the recovery from the \neffects of the COVID -19 pandemic has been in line with  our expectations.  \n \n", "start_char_idx": 2754, "end_char_idx": 3058, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f930f83-4729-407d-8c0a-8ef339a66b43": {"__data__": {"id_": "9f930f83-4729-407d-8c0a-8ef339a66b43", "embedding": null, "metadata": {"window": "Our second \ncompany priority is to strengthen our core distribution  businesses where we have market -leading scale and \ncapabilities across North America.  Success in the core enables strong cash flow generation, which we in turn use \nto reinvest in the business and to return capital to our shareholders.  \n \n In addition to our w ork to help our customers and government partners in their pandemic response efforts, our \npharmaceutical and medical surgical distribution businesses are continuing to improve and the recovery from the \neffects of the COVID -19 pandemic has been in line with  our expectations.  \n \n Elective procedures and primary care visits had improved throughout our first quarter and prescription volume \ntrends are showing signs of improvement as well.  Also positive are the trends we've seen across specialty and \noncology patient  visits, which were at or above pre -COVID baselines in the first quarter.  And distribution volumes \nto our specialty provider customers continue to drive and support our growth.  \n \n In our Canadian distribution business, our operational excellence and scale wa s recently recognized through a \nnew partnership with one of Canada's largest retailers as a primary distribution customer. ", "original_text": "Elective procedures and primary care visits had improved throughout our first quarter and prescription volume \ntrends are showing signs of improvement as well. ", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce4cf70f47aba08c6d8df52ea899482b0f6cfa03010b333fb31caf0734f9a1f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f7887e28-9c21-4773-b285-7627117ce47f", "node_type": "1", "metadata": {"window": "In addition, we marked pr ogress in diverse representation in the US with female executive representation up 3% \nover the prior year and a 6% gain over the prior year in executive representation for persons of color.  Our second \ncompany priority is to strengthen our core distribution  businesses where we have market -leading scale and \ncapabilities across North America.  Success in the core enables strong cash flow generation, which we in turn use \nto reinvest in the business and to return capital to our shareholders.  \n \n In addition to our w ork to help our customers and government partners in their pandemic response efforts, our \npharmaceutical and medical surgical distribution businesses are continuing to improve and the recovery from the \neffects of the COVID -19 pandemic has been in line with  our expectations.  \n \n Elective procedures and primary care visits had improved throughout our first quarter and prescription volume \ntrends are showing signs of improvement as well.  Also positive are the trends we've seen across specialty and \noncology patient  visits, which were at or above pre -COVID baselines in the first quarter.  And distribution volumes \nto our specialty provider customers continue to drive and support our growth.  \n \n", "original_text": "In addition to our w ork to help our customers and government partners in their pandemic response efforts, our \npharmaceutical and medical surgical distribution businesses are continuing to improve and the recovery from the \neffects of the COVID -19 pandemic has been in line with  our expectations.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0664a0531af43c67da14950ff86dea0f71d13cdc0bcddb04ca887ef280a23dcb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "57a66c74-fecd-4fe9-80b0-6031c910a757", "node_type": "1", "metadata": {"window": "Success in the core enables strong cash flow generation, which we in turn use \nto reinvest in the business and to return capital to our shareholders.  \n \n In addition to our w ork to help our customers and government partners in their pandemic response efforts, our \npharmaceutical and medical surgical distribution businesses are continuing to improve and the recovery from the \neffects of the COVID -19 pandemic has been in line with  our expectations.  \n \n Elective procedures and primary care visits had improved throughout our first quarter and prescription volume \ntrends are showing signs of improvement as well.  Also positive are the trends we've seen across specialty and \noncology patient  visits, which were at or above pre -COVID baselines in the first quarter.  And distribution volumes \nto our specialty provider customers continue to drive and support our growth.  \n \n In our Canadian distribution business, our operational excellence and scale wa s recently recognized through a \nnew partnership with one of Canada's largest retailers as a primary distribution customer.  This is a testament to \nthe strength of our supply chain in Canada. ", "original_text": "Also positive are the trends we've seen across specialty and \noncology patient  visits, which were at or above pre -COVID baselines in the first quarter. "}, "hash": "048d34cf3c8b412727d374117bdea918b707926a53dc0fca748ae12fe40548c4", "class_name": "RelatedNodeInfo"}}, "text": "Elective procedures and primary care visits had improved throughout our first quarter and prescription volume \ntrends are showing signs of improvement as well. ", "start_char_idx": 3058, "end_char_idx": 3218, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "57a66c74-fecd-4fe9-80b0-6031c910a757": {"__data__": {"id_": "57a66c74-fecd-4fe9-80b0-6031c910a757", "embedding": null, "metadata": {"window": "Success in the core enables strong cash flow generation, which we in turn use \nto reinvest in the business and to return capital to our shareholders.  \n \n In addition to our w ork to help our customers and government partners in their pandemic response efforts, our \npharmaceutical and medical surgical distribution businesses are continuing to improve and the recovery from the \neffects of the COVID -19 pandemic has been in line with  our expectations.  \n \n Elective procedures and primary care visits had improved throughout our first quarter and prescription volume \ntrends are showing signs of improvement as well.  Also positive are the trends we've seen across specialty and \noncology patient  visits, which were at or above pre -COVID baselines in the first quarter.  And distribution volumes \nto our specialty provider customers continue to drive and support our growth.  \n \n In our Canadian distribution business, our operational excellence and scale wa s recently recognized through a \nnew partnership with one of Canada's largest retailers as a primary distribution customer.  This is a testament to \nthe strength of our supply chain in Canada. ", "original_text": "Also positive are the trends we've seen across specialty and \noncology patient  visits, which were at or above pre -COVID baselines in the first quarter. ", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce4cf70f47aba08c6d8df52ea899482b0f6cfa03010b333fb31caf0734f9a1f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f930f83-4729-407d-8c0a-8ef339a66b43", "node_type": "1", "metadata": {"window": "Our second \ncompany priority is to strengthen our core distribution  businesses where we have market -leading scale and \ncapabilities across North America.  Success in the core enables strong cash flow generation, which we in turn use \nto reinvest in the business and to return capital to our shareholders.  \n \n In addition to our w ork to help our customers and government partners in their pandemic response efforts, our \npharmaceutical and medical surgical distribution businesses are continuing to improve and the recovery from the \neffects of the COVID -19 pandemic has been in line with  our expectations.  \n \n Elective procedures and primary care visits had improved throughout our first quarter and prescription volume \ntrends are showing signs of improvement as well.  Also positive are the trends we've seen across specialty and \noncology patient  visits, which were at or above pre -COVID baselines in the first quarter.  And distribution volumes \nto our specialty provider customers continue to drive and support our growth.  \n \n In our Canadian distribution business, our operational excellence and scale wa s recently recognized through a \nnew partnership with one of Canada's largest retailers as a primary distribution customer. ", "original_text": "Elective procedures and primary care visits had improved throughout our first quarter and prescription volume \ntrends are showing signs of improvement as well. ", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6bf90d05755d41d96eb1e1518bab1bc7da83fd4987809dedb0c92dc8f661486d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2dc66ff7-a240-466f-a074-82012c59058f", "node_type": "1", "metadata": {"window": "In addition to our w ork to help our customers and government partners in their pandemic response efforts, our \npharmaceutical and medical surgical distribution businesses are continuing to improve and the recovery from the \neffects of the COVID -19 pandemic has been in line with  our expectations.  \n \n Elective procedures and primary care visits had improved throughout our first quarter and prescription volume \ntrends are showing signs of improvement as well.  Also positive are the trends we've seen across specialty and \noncology patient  visits, which were at or above pre -COVID baselines in the first quarter.  And distribution volumes \nto our specialty provider customers continue to drive and support our growth.  \n \n In our Canadian distribution business, our operational excellence and scale wa s recently recognized through a \nnew partnership with one of Canada's largest retailers as a primary distribution customer.  This is a testament to \nthe strength of our supply chain in Canada.  The renewed focus on growing the core has been enabled by our \ncomm itment to streamline the business over the past several years, efforts that go beyond our recent \nannouncement to exit the European region, which I commented on in my opening remarks.  ", "original_text": "And distribution volumes \nto our specialty provider customers continue to drive and support our growth.  \n \n"}, "hash": "6a2508cf0a2bd9a79fccafb3cb75a166c8594687680ac402298d7436f5287b69", "class_name": "RelatedNodeInfo"}}, "text": "Also positive are the trends we've seen across specialty and \noncology patient  visits, which were at or above pre -COVID baselines in the first quarter. ", "start_char_idx": 3218, "end_char_idx": 3372, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2dc66ff7-a240-466f-a074-82012c59058f": {"__data__": {"id_": "2dc66ff7-a240-466f-a074-82012c59058f", "embedding": null, "metadata": {"window": "In addition to our w ork to help our customers and government partners in their pandemic response efforts, our \npharmaceutical and medical surgical distribution businesses are continuing to improve and the recovery from the \neffects of the COVID -19 pandemic has been in line with  our expectations.  \n \n Elective procedures and primary care visits had improved throughout our first quarter and prescription volume \ntrends are showing signs of improvement as well.  Also positive are the trends we've seen across specialty and \noncology patient  visits, which were at or above pre -COVID baselines in the first quarter.  And distribution volumes \nto our specialty provider customers continue to drive and support our growth.  \n \n In our Canadian distribution business, our operational excellence and scale wa s recently recognized through a \nnew partnership with one of Canada's largest retailers as a primary distribution customer.  This is a testament to \nthe strength of our supply chain in Canada.  The renewed focus on growing the core has been enabled by our \ncomm itment to streamline the business over the past several years, efforts that go beyond our recent \nannouncement to exit the European region, which I commented on in my opening remarks.  ", "original_text": "And distribution volumes \nto our specialty provider customers continue to drive and support our growth.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce4cf70f47aba08c6d8df52ea899482b0f6cfa03010b333fb31caf0734f9a1f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "57a66c74-fecd-4fe9-80b0-6031c910a757", "node_type": "1", "metadata": {"window": "Success in the core enables strong cash flow generation, which we in turn use \nto reinvest in the business and to return capital to our shareholders.  \n \n In addition to our w ork to help our customers and government partners in their pandemic response efforts, our \npharmaceutical and medical surgical distribution businesses are continuing to improve and the recovery from the \neffects of the COVID -19 pandemic has been in line with  our expectations.  \n \n Elective procedures and primary care visits had improved throughout our first quarter and prescription volume \ntrends are showing signs of improvement as well.  Also positive are the trends we've seen across specialty and \noncology patient  visits, which were at or above pre -COVID baselines in the first quarter.  And distribution volumes \nto our specialty provider customers continue to drive and support our growth.  \n \n In our Canadian distribution business, our operational excellence and scale wa s recently recognized through a \nnew partnership with one of Canada's largest retailers as a primary distribution customer.  This is a testament to \nthe strength of our supply chain in Canada. ", "original_text": "Also positive are the trends we've seen across specialty and \noncology patient  visits, which were at or above pre -COVID baselines in the first quarter. ", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16868f0d562d2ba37b2577b526021705dc77132e820b4d4f2534138dc6e01c1f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de598687-e2df-469d-8641-513b680ff796", "node_type": "1", "metadata": {"window": "Elective procedures and primary care visits had improved throughout our first quarter and prescription volume \ntrends are showing signs of improvement as well.  Also positive are the trends we've seen across specialty and \noncology patient  visits, which were at or above pre -COVID baselines in the first quarter.  And distribution volumes \nto our specialty provider customers continue to drive and support our growth.  \n \n In our Canadian distribution business, our operational excellence and scale wa s recently recognized through a \nnew partnership with one of Canada's largest retailers as a primary distribution customer.  This is a testament to \nthe strength of our supply chain in Canada.  The renewed focus on growing the core has been enabled by our \ncomm itment to streamline the business over the past several years, efforts that go beyond our recent \nannouncement to exit the European region, which I commented on in my opening remarks.  ", "original_text": "In our Canadian distribution business, our operational excellence and scale wa s recently recognized through a \nnew partnership with one of Canada's largest retailers as a primary distribution customer. "}, "hash": "1bd56eb37b8124ef4adc021021bd00f0266653a694f6fb7c6cb47861e4a9e5ab", "class_name": "RelatedNodeInfo"}}, "text": "And distribution volumes \nto our specialty provider customers continue to drive and support our growth.  \n \n", "start_char_idx": 3372, "end_char_idx": 3480, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de598687-e2df-469d-8641-513b680ff796": {"__data__": {"id_": "de598687-e2df-469d-8641-513b680ff796", "embedding": null, "metadata": {"window": "Elective procedures and primary care visits had improved throughout our first quarter and prescription volume \ntrends are showing signs of improvement as well.  Also positive are the trends we've seen across specialty and \noncology patient  visits, which were at or above pre -COVID baselines in the first quarter.  And distribution volumes \nto our specialty provider customers continue to drive and support our growth.  \n \n In our Canadian distribution business, our operational excellence and scale wa s recently recognized through a \nnew partnership with one of Canada's largest retailers as a primary distribution customer.  This is a testament to \nthe strength of our supply chain in Canada.  The renewed focus on growing the core has been enabled by our \ncomm itment to streamline the business over the past several years, efforts that go beyond our recent \nannouncement to exit the European region, which I commented on in my opening remarks.  ", "original_text": "In our Canadian distribution business, our operational excellence and scale wa s recently recognized through a \nnew partnership with one of Canada's largest retailers as a primary distribution customer. ", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce4cf70f47aba08c6d8df52ea899482b0f6cfa03010b333fb31caf0734f9a1f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2dc66ff7-a240-466f-a074-82012c59058f", "node_type": "1", "metadata": {"window": "In addition to our w ork to help our customers and government partners in their pandemic response efforts, our \npharmaceutical and medical surgical distribution businesses are continuing to improve and the recovery from the \neffects of the COVID -19 pandemic has been in line with  our expectations.  \n \n Elective procedures and primary care visits had improved throughout our first quarter and prescription volume \ntrends are showing signs of improvement as well.  Also positive are the trends we've seen across specialty and \noncology patient  visits, which were at or above pre -COVID baselines in the first quarter.  And distribution volumes \nto our specialty provider customers continue to drive and support our growth.  \n \n In our Canadian distribution business, our operational excellence and scale wa s recently recognized through a \nnew partnership with one of Canada's largest retailers as a primary distribution customer.  This is a testament to \nthe strength of our supply chain in Canada.  The renewed focus on growing the core has been enabled by our \ncomm itment to streamline the business over the past several years, efforts that go beyond our recent \nannouncement to exit the European region, which I commented on in my opening remarks.  ", "original_text": "And distribution volumes \nto our specialty provider customers continue to drive and support our growth.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94a2f63b444f6324d5ad23982787c03430ca1b637cd595de1a33d480a481fdf2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca93a3be-8929-4588-9164-bf9165a43d6d", "node_type": "1", "metadata": {"window": "Also positive are the trends we've seen across specialty and \noncology patient  visits, which were at or above pre -COVID baselines in the first quarter.  And distribution volumes \nto our specialty provider customers continue to drive and support our growth.  \n \n In our Canadian distribution business, our operational excellence and scale wa s recently recognized through a \nnew partnership with one of Canada's largest retailers as a primary distribution customer.  This is a testament to \nthe strength of our supply chain in Canada.  The renewed focus on growing the core has been enabled by our \ncomm itment to streamline the business over the past several years, efforts that go beyond our recent \nannouncement to exit the European region, which I commented on in my opening remarks.  ", "original_text": "This is a testament to \nthe strength of our supply chain in Canada. "}, "hash": "590c0f6970a3e91d8a0a9b70a1138f8a29ef8b6613d33d118a559e1d78fcee07", "class_name": "RelatedNodeInfo"}}, "text": "In our Canadian distribution business, our operational excellence and scale wa s recently recognized through a \nnew partnership with one of Canada's largest retailers as a primary distribution customer. ", "start_char_idx": 3480, "end_char_idx": 3683, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca93a3be-8929-4588-9164-bf9165a43d6d": {"__data__": {"id_": "ca93a3be-8929-4588-9164-bf9165a43d6d", "embedding": null, "metadata": {"window": "Also positive are the trends we've seen across specialty and \noncology patient  visits, which were at or above pre -COVID baselines in the first quarter.  And distribution volumes \nto our specialty provider customers continue to drive and support our growth.  \n \n In our Canadian distribution business, our operational excellence and scale wa s recently recognized through a \nnew partnership with one of Canada's largest retailers as a primary distribution customer.  This is a testament to \nthe strength of our supply chain in Canada.  The renewed focus on growing the core has been enabled by our \ncomm itment to streamline the business over the past several years, efforts that go beyond our recent \nannouncement to exit the European region, which I commented on in my opening remarks.  ", "original_text": "This is a testament to \nthe strength of our supply chain in Canada. ", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce4cf70f47aba08c6d8df52ea899482b0f6cfa03010b333fb31caf0734f9a1f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de598687-e2df-469d-8641-513b680ff796", "node_type": "1", "metadata": {"window": "Elective procedures and primary care visits had improved throughout our first quarter and prescription volume \ntrends are showing signs of improvement as well.  Also positive are the trends we've seen across specialty and \noncology patient  visits, which were at or above pre -COVID baselines in the first quarter.  And distribution volumes \nto our specialty provider customers continue to drive and support our growth.  \n \n In our Canadian distribution business, our operational excellence and scale wa s recently recognized through a \nnew partnership with one of Canada's largest retailers as a primary distribution customer.  This is a testament to \nthe strength of our supply chain in Canada.  The renewed focus on growing the core has been enabled by our \ncomm itment to streamline the business over the past several years, efforts that go beyond our recent \nannouncement to exit the European region, which I commented on in my opening remarks.  ", "original_text": "In our Canadian distribution business, our operational excellence and scale wa s recently recognized through a \nnew partnership with one of Canada's largest retailers as a primary distribution customer. ", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e84c3d041142363b88b7f2d9fc3da49aa6fbf96a74924546c76e9d7b57e6317", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb9d3cfd-d7a4-4991-b9ce-96ec3fff4858", "node_type": "1", "metadata": {"window": "And distribution volumes \nto our specialty provider customers continue to drive and support our growth.  \n \n In our Canadian distribution business, our operational excellence and scale wa s recently recognized through a \nnew partnership with one of Canada's largest retailers as a primary distribution customer.  This is a testament to \nthe strength of our supply chain in Canada.  The renewed focus on growing the core has been enabled by our \ncomm itment to streamline the business over the past several years, efforts that go beyond our recent \nannouncement to exit the European region, which I commented on in my opening remarks.  ", "original_text": "The renewed focus on growing the core has been enabled by our \ncomm itment to streamline the business over the past several years, efforts that go beyond our recent \nannouncement to exit the European region, which I commented on in my opening remarks.  "}, "hash": "a95fbedca4d8987fd59af0204d63926e75f22cab1f8aea6c67ed35afd8e12b7a", "class_name": "RelatedNodeInfo"}}, "text": "This is a testament to \nthe strength of our supply chain in Canada. ", "start_char_idx": 3683, "end_char_idx": 3751, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb9d3cfd-d7a4-4991-b9ce-96ec3fff4858": {"__data__": {"id_": "fb9d3cfd-d7a4-4991-b9ce-96ec3fff4858", "embedding": null, "metadata": {"window": "And distribution volumes \nto our specialty provider customers continue to drive and support our growth.  \n \n In our Canadian distribution business, our operational excellence and scale wa s recently recognized through a \nnew partnership with one of Canada's largest retailers as a primary distribution customer.  This is a testament to \nthe strength of our supply chain in Canada.  The renewed focus on growing the core has been enabled by our \ncomm itment to streamline the business over the past several years, efforts that go beyond our recent \nannouncement to exit the European region, which I commented on in my opening remarks.  ", "original_text": "The renewed focus on growing the core has been enabled by our \ncomm itment to streamline the business over the past several years, efforts that go beyond our recent \nannouncement to exit the European region, which I commented on in my opening remarks.  ", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce4cf70f47aba08c6d8df52ea899482b0f6cfa03010b333fb31caf0734f9a1f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca93a3be-8929-4588-9164-bf9165a43d6d", "node_type": "1", "metadata": {"window": "Also positive are the trends we've seen across specialty and \noncology patient  visits, which were at or above pre -COVID baselines in the first quarter.  And distribution volumes \nto our specialty provider customers continue to drive and support our growth.  \n \n In our Canadian distribution business, our operational excellence and scale wa s recently recognized through a \nnew partnership with one of Canada's largest retailers as a primary distribution customer.  This is a testament to \nthe strength of our supply chain in Canada.  The renewed focus on growing the core has been enabled by our \ncomm itment to streamline the business over the past several years, efforts that go beyond our recent \nannouncement to exit the European region, which I commented on in my opening remarks.  ", "original_text": "This is a testament to \nthe strength of our supply chain in Canada. ", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "725d5ba5788786cfc761795684b10efc5c36dd9d0af17761fb6cff011805c758", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d160a25-bc44-4383-ac1b-0cf8af5c699d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOver the past several years, we've committed to transforming our operati ng model.  We've centralized back -office \nfunctions across North America and Europe to further rationalize costs through a reduction of our own retail \npharmacy footprint and a commitment to lower spend across the organization.  Throughout our enterprise, ther e's \nan initiative we call Spend Smart, which helped us achieve our three -year cost reduction target of $400 million to \n$500 million of annual cost savings by the end of our fiscal 2021.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "48b185609adc8c31af7ffc738bbce8c8c38d1718e8265b761e5ff89d37e35830", "class_name": "RelatedNodeInfo"}}, "text": "The renewed focus on growing the core has been enabled by our \ncomm itment to streamline the business over the past several years, efforts that go beyond our recent \nannouncement to exit the European region, which I commented on in my opening remarks.  ", "start_char_idx": 3751, "end_char_idx": 4004, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d160a25-bc44-4383-ac1b-0cf8af5c699d": {"__data__": {"id_": "2d160a25-bc44-4383-ac1b-0cf8af5c699d", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOver the past several years, we've committed to transforming our operati ng model.  We've centralized back -office \nfunctions across North America and Europe to further rationalize costs through a reduction of our own retail \npharmacy footprint and a commitment to lower spend across the organization.  Throughout our enterprise, ther e's \nan initiative we call Spend Smart, which helped us achieve our three -year cost reduction target of $400 million to \n$500 million of annual cost savings by the end of our fiscal 2021.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a8a9216-8deb-4e14-80bf-7ca55ba8e1b3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d86bca99cf03020665c8681e316da6076124daae4e5e026160542a31505695e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb9d3cfd-d7a4-4991-b9ce-96ec3fff4858", "node_type": "1", "metadata": {"window": "And distribution volumes \nto our specialty provider customers continue to drive and support our growth.  \n \n In our Canadian distribution business, our operational excellence and scale wa s recently recognized through a \nnew partnership with one of Canada's largest retailers as a primary distribution customer.  This is a testament to \nthe strength of our supply chain in Canada.  The renewed focus on growing the core has been enabled by our \ncomm itment to streamline the business over the past several years, efforts that go beyond our recent \nannouncement to exit the European region, which I commented on in my opening remarks.  ", "original_text": "The renewed focus on growing the core has been enabled by our \ncomm itment to streamline the business over the past several years, efforts that go beyond our recent \nannouncement to exit the European region, which I commented on in my opening remarks.  ", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c1e73c5778c2134463507b251da0b3e54d6aa1a823a43f427d6e2b439ef4c2ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bada9e6c-5064-49af-9b8a-2b492140a369", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOver the past several years, we've committed to transforming our operati ng model.  We've centralized back -office \nfunctions across North America and Europe to further rationalize costs through a reduction of our own retail \npharmacy footprint and a commitment to lower spend across the organization.  Throughout our enterprise, ther e's \nan initiative we call Spend Smart, which helped us achieve our three -year cost reduction target of $400 million to \n$500 million of annual cost savings by the end of our fiscal 2021.  \n \n Over time, we've identified businesses that are not central to McKess on's current strategic priorities or direction, \nas was the case in our exit of our position in Change Healthcare and the creation of a German wholesale joint \nventure with Walgreens Boots Alliance. ", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOver the past several years, we've committed to transforming our operati ng model. "}, "hash": "06c89709e2c0b3c8b22b5056ced4c940aa8cba61c9320d165de63117b565d0b4", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bada9e6c-5064-49af-9b8a-2b492140a369": {"__data__": {"id_": "bada9e6c-5064-49af-9b8a-2b492140a369", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOver the past several years, we've committed to transforming our operati ng model.  We've centralized back -office \nfunctions across North America and Europe to further rationalize costs through a reduction of our own retail \npharmacy footprint and a commitment to lower spend across the organization.  Throughout our enterprise, ther e's \nan initiative we call Spend Smart, which helped us achieve our three -year cost reduction target of $400 million to \n$500 million of annual cost savings by the end of our fiscal 2021.  \n \n Over time, we've identified businesses that are not central to McKess on's current strategic priorities or direction, \nas was the case in our exit of our position in Change Healthcare and the creation of a German wholesale joint \nventure with Walgreens Boots Alliance. ", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOver the past several years, we've committed to transforming our operati ng model. ", "page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a8a9216-8deb-4e14-80bf-7ca55ba8e1b3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d86bca99cf03020665c8681e316da6076124daae4e5e026160542a31505695e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d160a25-bc44-4383-ac1b-0cf8af5c699d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOver the past several years, we've committed to transforming our operati ng model.  We've centralized back -office \nfunctions across North America and Europe to further rationalize costs through a reduction of our own retail \npharmacy footprint and a commitment to lower spend across the organization.  Throughout our enterprise, ther e's \nan initiative we call Spend Smart, which helped us achieve our three -year cost reduction target of $400 million to \n$500 million of annual cost savings by the end of our fiscal 2021.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e6438a6b5a82210ebf9e4d7f59f6e4ac2d352886da0ce04449733682566be0b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8657a3d5-161c-4370-a5e0-5626426b9a9e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOver the past several years, we've committed to transforming our operati ng model.  We've centralized back -office \nfunctions across North America and Europe to further rationalize costs through a reduction of our own retail \npharmacy footprint and a commitment to lower spend across the organization.  Throughout our enterprise, ther e's \nan initiative we call Spend Smart, which helped us achieve our three -year cost reduction target of $400 million to \n$500 million of annual cost savings by the end of our fiscal 2021.  \n \n Over time, we've identified businesses that are not central to McKess on's current strategic priorities or direction, \nas was the case in our exit of our position in Change Healthcare and the creation of a German wholesale joint \nventure with Walgreens Boots Alliance.  We will continually review our portfolio to ensure tight an d focused \nalignment to our strategy.  \n \n", "original_text": "We've centralized back -office \nfunctions across North America and Europe to further rationalize costs through a reduction of our own retail \npharmacy footprint and a commitment to lower spend across the organization. "}, "hash": "1ba8e5a01f1fcc2bff478a3883c6af8cff1a81e1102cc27ce60f2c36115059a6", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOver the past several years, we've committed to transforming our operati ng model. ", "start_char_idx": 16, "end_char_idx": 265, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8657a3d5-161c-4370-a5e0-5626426b9a9e": {"__data__": {"id_": "8657a3d5-161c-4370-a5e0-5626426b9a9e", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOver the past several years, we've committed to transforming our operati ng model.  We've centralized back -office \nfunctions across North America and Europe to further rationalize costs through a reduction of our own retail \npharmacy footprint and a commitment to lower spend across the organization.  Throughout our enterprise, ther e's \nan initiative we call Spend Smart, which helped us achieve our three -year cost reduction target of $400 million to \n$500 million of annual cost savings by the end of our fiscal 2021.  \n \n Over time, we've identified businesses that are not central to McKess on's current strategic priorities or direction, \nas was the case in our exit of our position in Change Healthcare and the creation of a German wholesale joint \nventure with Walgreens Boots Alliance.  We will continually review our portfolio to ensure tight an d focused \nalignment to our strategy.  \n \n", "original_text": "We've centralized back -office \nfunctions across North America and Europe to further rationalize costs through a reduction of our own retail \npharmacy footprint and a commitment to lower spend across the organization. ", "page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a8a9216-8deb-4e14-80bf-7ca55ba8e1b3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d86bca99cf03020665c8681e316da6076124daae4e5e026160542a31505695e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bada9e6c-5064-49af-9b8a-2b492140a369", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOver the past several years, we've committed to transforming our operati ng model.  We've centralized back -office \nfunctions across North America and Europe to further rationalize costs through a reduction of our own retail \npharmacy footprint and a commitment to lower spend across the organization.  Throughout our enterprise, ther e's \nan initiative we call Spend Smart, which helped us achieve our three -year cost reduction target of $400 million to \n$500 million of annual cost savings by the end of our fiscal 2021.  \n \n Over time, we've identified businesses that are not central to McKess on's current strategic priorities or direction, \nas was the case in our exit of our position in Change Healthcare and the creation of a German wholesale joint \nventure with Walgreens Boots Alliance. ", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOver the past several years, we've committed to transforming our operati ng model. ", "page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d6a2dbca703f8cbd9845b8f89e6fc6406d9cdaaee8754c6c2d9b1a3e52262963", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "51e2f6e5-9386-4a0c-a3b7-63671cea186c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOver the past several years, we've committed to transforming our operati ng model.  We've centralized back -office \nfunctions across North America and Europe to further rationalize costs through a reduction of our own retail \npharmacy footprint and a commitment to lower spend across the organization.  Throughout our enterprise, ther e's \nan initiative we call Spend Smart, which helped us achieve our three -year cost reduction target of $400 million to \n$500 million of annual cost savings by the end of our fiscal 2021.  \n \n Over time, we've identified businesses that are not central to McKess on's current strategic priorities or direction, \nas was the case in our exit of our position in Change Healthcare and the creation of a German wholesale joint \nventure with Walgreens Boots Alliance.  We will continually review our portfolio to ensure tight an d focused \nalignment to our strategy.  \n \n All this work has enabled us to focus our time and investments on our strategic growth pillars, where we're \nworking to build connected ecosystems in the growth areas of oncology and biopharma services, which serve to \nadvance our already differentiated positions. ", "original_text": "Throughout our enterprise, ther e's \nan initiative we call Spend Smart, which helped us achieve our three -year cost reduction target of $400 million to \n$500 million of annual cost savings by the end of our fiscal 2021.  \n \n"}, "hash": "2a2fd43deee610142c411951482bd9d772a52c1e0196ad1fab1624185eaad93f", "class_name": "RelatedNodeInfo"}}, "text": "We've centralized back -office \nfunctions across North America and Europe to further rationalize costs through a reduction of our own retail \npharmacy footprint and a commitment to lower spend across the organization. ", "start_char_idx": 265, "end_char_idx": 483, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "51e2f6e5-9386-4a0c-a3b7-63671cea186c": {"__data__": {"id_": "51e2f6e5-9386-4a0c-a3b7-63671cea186c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOver the past several years, we've committed to transforming our operati ng model.  We've centralized back -office \nfunctions across North America and Europe to further rationalize costs through a reduction of our own retail \npharmacy footprint and a commitment to lower spend across the organization.  Throughout our enterprise, ther e's \nan initiative we call Spend Smart, which helped us achieve our three -year cost reduction target of $400 million to \n$500 million of annual cost savings by the end of our fiscal 2021.  \n \n Over time, we've identified businesses that are not central to McKess on's current strategic priorities or direction, \nas was the case in our exit of our position in Change Healthcare and the creation of a German wholesale joint \nventure with Walgreens Boots Alliance.  We will continually review our portfolio to ensure tight an d focused \nalignment to our strategy.  \n \n All this work has enabled us to focus our time and investments on our strategic growth pillars, where we're \nworking to build connected ecosystems in the growth areas of oncology and biopharma services, which serve to \nadvance our already differentiated positions. ", "original_text": "Throughout our enterprise, ther e's \nan initiative we call Spend Smart, which helped us achieve our three -year cost reduction target of $400 million to \n$500 million of annual cost savings by the end of our fiscal 2021.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a8a9216-8deb-4e14-80bf-7ca55ba8e1b3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d86bca99cf03020665c8681e316da6076124daae4e5e026160542a31505695e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8657a3d5-161c-4370-a5e0-5626426b9a9e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOver the past several years, we've committed to transforming our operati ng model.  We've centralized back -office \nfunctions across North America and Europe to further rationalize costs through a reduction of our own retail \npharmacy footprint and a commitment to lower spend across the organization.  Throughout our enterprise, ther e's \nan initiative we call Spend Smart, which helped us achieve our three -year cost reduction target of $400 million to \n$500 million of annual cost savings by the end of our fiscal 2021.  \n \n Over time, we've identified businesses that are not central to McKess on's current strategic priorities or direction, \nas was the case in our exit of our position in Change Healthcare and the creation of a German wholesale joint \nventure with Walgreens Boots Alliance.  We will continually review our portfolio to ensure tight an d focused \nalignment to our strategy.  \n \n", "original_text": "We've centralized back -office \nfunctions across North America and Europe to further rationalize costs through a reduction of our own retail \npharmacy footprint and a commitment to lower spend across the organization. ", "page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2bdd5bb6014853e633ad84bb9c47894ba86a8c7a9a747026d9e9f8799373e23a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95a1e65c-fc0e-4a06-afd2-c02a2d496a14", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOver the past several years, we've committed to transforming our operati ng model.  We've centralized back -office \nfunctions across North America and Europe to further rationalize costs through a reduction of our own retail \npharmacy footprint and a commitment to lower spend across the organization.  Throughout our enterprise, ther e's \nan initiative we call Spend Smart, which helped us achieve our three -year cost reduction target of $400 million to \n$500 million of annual cost savings by the end of our fiscal 2021.  \n \n Over time, we've identified businesses that are not central to McKess on's current strategic priorities or direction, \nas was the case in our exit of our position in Change Healthcare and the creation of a German wholesale joint \nventure with Walgreens Boots Alliance.  We will continually review our portfolio to ensure tight an d focused \nalignment to our strategy.  \n \n All this work has enabled us to focus our time and investments on our strategic growth pillars, where we're \nworking to build connected ecosystems in the growth areas of oncology and biopharma services, which serve to \nadvance our already differentiated positions.  We continue to be confident in the long -term outlook of businesses \nthat operate in these high -growth markets.  \n \n", "original_text": "Over time, we've identified businesses that are not central to McKess on's current strategic priorities or direction, \nas was the case in our exit of our position in Change Healthcare and the creation of a German wholesale joint \nventure with Walgreens Boots Alliance. "}, "hash": "904d73294f05b4da1932fdc1e06eded3add4bfb7d48f299309e0a153863d0cf3", "class_name": "RelatedNodeInfo"}}, "text": "Throughout our enterprise, ther e's \nan initiative we call Spend Smart, which helped us achieve our three -year cost reduction target of $400 million to \n$500 million of annual cost savings by the end of our fiscal 2021.  \n \n", "start_char_idx": 483, "end_char_idx": 708, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95a1e65c-fc0e-4a06-afd2-c02a2d496a14": {"__data__": {"id_": "95a1e65c-fc0e-4a06-afd2-c02a2d496a14", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOver the past several years, we've committed to transforming our operati ng model.  We've centralized back -office \nfunctions across North America and Europe to further rationalize costs through a reduction of our own retail \npharmacy footprint and a commitment to lower spend across the organization.  Throughout our enterprise, ther e's \nan initiative we call Spend Smart, which helped us achieve our three -year cost reduction target of $400 million to \n$500 million of annual cost savings by the end of our fiscal 2021.  \n \n Over time, we've identified businesses that are not central to McKess on's current strategic priorities or direction, \nas was the case in our exit of our position in Change Healthcare and the creation of a German wholesale joint \nventure with Walgreens Boots Alliance.  We will continually review our portfolio to ensure tight an d focused \nalignment to our strategy.  \n \n All this work has enabled us to focus our time and investments on our strategic growth pillars, where we're \nworking to build connected ecosystems in the growth areas of oncology and biopharma services, which serve to \nadvance our already differentiated positions.  We continue to be confident in the long -term outlook of businesses \nthat operate in these high -growth markets.  \n \n", "original_text": "Over time, we've identified businesses that are not central to McKess on's current strategic priorities or direction, \nas was the case in our exit of our position in Change Healthcare and the creation of a German wholesale joint \nventure with Walgreens Boots Alliance. ", "page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a8a9216-8deb-4e14-80bf-7ca55ba8e1b3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d86bca99cf03020665c8681e316da6076124daae4e5e026160542a31505695e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "51e2f6e5-9386-4a0c-a3b7-63671cea186c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOver the past several years, we've committed to transforming our operati ng model.  We've centralized back -office \nfunctions across North America and Europe to further rationalize costs through a reduction of our own retail \npharmacy footprint and a commitment to lower spend across the organization.  Throughout our enterprise, ther e's \nan initiative we call Spend Smart, which helped us achieve our three -year cost reduction target of $400 million to \n$500 million of annual cost savings by the end of our fiscal 2021.  \n \n Over time, we've identified businesses that are not central to McKess on's current strategic priorities or direction, \nas was the case in our exit of our position in Change Healthcare and the creation of a German wholesale joint \nventure with Walgreens Boots Alliance.  We will continually review our portfolio to ensure tight an d focused \nalignment to our strategy.  \n \n All this work has enabled us to focus our time and investments on our strategic growth pillars, where we're \nworking to build connected ecosystems in the growth areas of oncology and biopharma services, which serve to \nadvance our already differentiated positions. ", "original_text": "Throughout our enterprise, ther e's \nan initiative we call Spend Smart, which helped us achieve our three -year cost reduction target of $400 million to \n$500 million of annual cost savings by the end of our fiscal 2021.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab0d5f508bbcd97f131552954c5e99139307f6906b36e0c6bee8cf4a7733bb07", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38f7b1f1-6365-44a8-aab5-b59c4cb65b7e", "node_type": "1", "metadata": {"window": "We've centralized back -office \nfunctions across North America and Europe to further rationalize costs through a reduction of our own retail \npharmacy footprint and a commitment to lower spend across the organization.  Throughout our enterprise, ther e's \nan initiative we call Spend Smart, which helped us achieve our three -year cost reduction target of $400 million to \n$500 million of annual cost savings by the end of our fiscal 2021.  \n \n Over time, we've identified businesses that are not central to McKess on's current strategic priorities or direction, \nas was the case in our exit of our position in Change Healthcare and the creation of a German wholesale joint \nventure with Walgreens Boots Alliance.  We will continually review our portfolio to ensure tight an d focused \nalignment to our strategy.  \n \n All this work has enabled us to focus our time and investments on our strategic growth pillars, where we're \nworking to build connected ecosystems in the growth areas of oncology and biopharma services, which serve to \nadvance our already differentiated positions.  We continue to be confident in the long -term outlook of businesses \nthat operate in these high -growth markets.  \n \n Starting with oncology, an ecosystem that McKesson has strategically built over a period of nearly 1 5 years, \nbeginning with our acquisition of Oncology Therapeutics Network all the way back in 2007, which added, at that \ntime, core specialty distribution capabilities. ", "original_text": "We will continually review our portfolio to ensure tight an d focused \nalignment to our strategy.  \n \n"}, "hash": "450767e215377eb623fdec8c6130205aec5cfba0cbf9b59f8e1b7edf853903af", "class_name": "RelatedNodeInfo"}}, "text": "Over time, we've identified businesses that are not central to McKess on's current strategic priorities or direction, \nas was the case in our exit of our position in Change Healthcare and the creation of a German wholesale joint \nventure with Walgreens Boots Alliance. ", "start_char_idx": 708, "end_char_idx": 977, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38f7b1f1-6365-44a8-aab5-b59c4cb65b7e": {"__data__": {"id_": "38f7b1f1-6365-44a8-aab5-b59c4cb65b7e", "embedding": null, "metadata": {"window": "We've centralized back -office \nfunctions across North America and Europe to further rationalize costs through a reduction of our own retail \npharmacy footprint and a commitment to lower spend across the organization.  Throughout our enterprise, ther e's \nan initiative we call Spend Smart, which helped us achieve our three -year cost reduction target of $400 million to \n$500 million of annual cost savings by the end of our fiscal 2021.  \n \n Over time, we've identified businesses that are not central to McKess on's current strategic priorities or direction, \nas was the case in our exit of our position in Change Healthcare and the creation of a German wholesale joint \nventure with Walgreens Boots Alliance.  We will continually review our portfolio to ensure tight an d focused \nalignment to our strategy.  \n \n All this work has enabled us to focus our time and investments on our strategic growth pillars, where we're \nworking to build connected ecosystems in the growth areas of oncology and biopharma services, which serve to \nadvance our already differentiated positions.  We continue to be confident in the long -term outlook of businesses \nthat operate in these high -growth markets.  \n \n Starting with oncology, an ecosystem that McKesson has strategically built over a period of nearly 1 5 years, \nbeginning with our acquisition of Oncology Therapeutics Network all the way back in 2007, which added, at that \ntime, core specialty distribution capabilities. ", "original_text": "We will continually review our portfolio to ensure tight an d focused \nalignment to our strategy.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a8a9216-8deb-4e14-80bf-7ca55ba8e1b3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d86bca99cf03020665c8681e316da6076124daae4e5e026160542a31505695e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95a1e65c-fc0e-4a06-afd2-c02a2d496a14", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOver the past several years, we've committed to transforming our operati ng model.  We've centralized back -office \nfunctions across North America and Europe to further rationalize costs through a reduction of our own retail \npharmacy footprint and a commitment to lower spend across the organization.  Throughout our enterprise, ther e's \nan initiative we call Spend Smart, which helped us achieve our three -year cost reduction target of $400 million to \n$500 million of annual cost savings by the end of our fiscal 2021.  \n \n Over time, we've identified businesses that are not central to McKess on's current strategic priorities or direction, \nas was the case in our exit of our position in Change Healthcare and the creation of a German wholesale joint \nventure with Walgreens Boots Alliance.  We will continually review our portfolio to ensure tight an d focused \nalignment to our strategy.  \n \n All this work has enabled us to focus our time and investments on our strategic growth pillars, where we're \nworking to build connected ecosystems in the growth areas of oncology and biopharma services, which serve to \nadvance our already differentiated positions.  We continue to be confident in the long -term outlook of businesses \nthat operate in these high -growth markets.  \n \n", "original_text": "Over time, we've identified businesses that are not central to McKess on's current strategic priorities or direction, \nas was the case in our exit of our position in Change Healthcare and the creation of a German wholesale joint \nventure with Walgreens Boots Alliance. ", "page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e623d42be68fb283b78a321582c229abc7df3099808da675a44f497be2dd1ebf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f9d3cd1-3c01-4c9c-b614-861dab1fd871", "node_type": "1", "metadata": {"window": "Throughout our enterprise, ther e's \nan initiative we call Spend Smart, which helped us achieve our three -year cost reduction target of $400 million to \n$500 million of annual cost savings by the end of our fiscal 2021.  \n \n Over time, we've identified businesses that are not central to McKess on's current strategic priorities or direction, \nas was the case in our exit of our position in Change Healthcare and the creation of a German wholesale joint \nventure with Walgreens Boots Alliance.  We will continually review our portfolio to ensure tight an d focused \nalignment to our strategy.  \n \n All this work has enabled us to focus our time and investments on our strategic growth pillars, where we're \nworking to build connected ecosystems in the growth areas of oncology and biopharma services, which serve to \nadvance our already differentiated positions.  We continue to be confident in the long -term outlook of businesses \nthat operate in these high -growth markets.  \n \n Starting with oncology, an ecosystem that McKesson has strategically built over a period of nearly 1 5 years, \nbeginning with our acquisition of Oncology Therapeutics Network all the way back in 2007, which added, at that \ntime, core specialty distribution capabilities.  10 years ago, we deepened the breadth and the depth of our offering \nwith the acquisition  of US Oncology Network, which gave us practice management, site management for research \nand the iKnowMed EHR, which is one of the foundational pieces of Ontada.  \n \n", "original_text": "All this work has enabled us to focus our time and investments on our strategic growth pillars, where we're \nworking to build connected ecosystems in the growth areas of oncology and biopharma services, which serve to \nadvance our already differentiated positions. "}, "hash": "f0f1ab52ec4e4d9f9b44f7bd109c63ca661c2ce681d7570bb35cb6de33912e6d", "class_name": "RelatedNodeInfo"}}, "text": "We will continually review our portfolio to ensure tight an d focused \nalignment to our strategy.  \n \n", "start_char_idx": 977, "end_char_idx": 1079, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f9d3cd1-3c01-4c9c-b614-861dab1fd871": {"__data__": {"id_": "0f9d3cd1-3c01-4c9c-b614-861dab1fd871", "embedding": null, "metadata": {"window": "Throughout our enterprise, ther e's \nan initiative we call Spend Smart, which helped us achieve our three -year cost reduction target of $400 million to \n$500 million of annual cost savings by the end of our fiscal 2021.  \n \n Over time, we've identified businesses that are not central to McKess on's current strategic priorities or direction, \nas was the case in our exit of our position in Change Healthcare and the creation of a German wholesale joint \nventure with Walgreens Boots Alliance.  We will continually review our portfolio to ensure tight an d focused \nalignment to our strategy.  \n \n All this work has enabled us to focus our time and investments on our strategic growth pillars, where we're \nworking to build connected ecosystems in the growth areas of oncology and biopharma services, which serve to \nadvance our already differentiated positions.  We continue to be confident in the long -term outlook of businesses \nthat operate in these high -growth markets.  \n \n Starting with oncology, an ecosystem that McKesson has strategically built over a period of nearly 1 5 years, \nbeginning with our acquisition of Oncology Therapeutics Network all the way back in 2007, which added, at that \ntime, core specialty distribution capabilities.  10 years ago, we deepened the breadth and the depth of our offering \nwith the acquisition  of US Oncology Network, which gave us practice management, site management for research \nand the iKnowMed EHR, which is one of the foundational pieces of Ontada.  \n \n", "original_text": "All this work has enabled us to focus our time and investments on our strategic growth pillars, where we're \nworking to build connected ecosystems in the growth areas of oncology and biopharma services, which serve to \nadvance our already differentiated positions. ", "page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a8a9216-8deb-4e14-80bf-7ca55ba8e1b3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d86bca99cf03020665c8681e316da6076124daae4e5e026160542a31505695e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38f7b1f1-6365-44a8-aab5-b59c4cb65b7e", "node_type": "1", "metadata": {"window": "We've centralized back -office \nfunctions across North America and Europe to further rationalize costs through a reduction of our own retail \npharmacy footprint and a commitment to lower spend across the organization.  Throughout our enterprise, ther e's \nan initiative we call Spend Smart, which helped us achieve our three -year cost reduction target of $400 million to \n$500 million of annual cost savings by the end of our fiscal 2021.  \n \n Over time, we've identified businesses that are not central to McKess on's current strategic priorities or direction, \nas was the case in our exit of our position in Change Healthcare and the creation of a German wholesale joint \nventure with Walgreens Boots Alliance.  We will continually review our portfolio to ensure tight an d focused \nalignment to our strategy.  \n \n All this work has enabled us to focus our time and investments on our strategic growth pillars, where we're \nworking to build connected ecosystems in the growth areas of oncology and biopharma services, which serve to \nadvance our already differentiated positions.  We continue to be confident in the long -term outlook of businesses \nthat operate in these high -growth markets.  \n \n Starting with oncology, an ecosystem that McKesson has strategically built over a period of nearly 1 5 years, \nbeginning with our acquisition of Oncology Therapeutics Network all the way back in 2007, which added, at that \ntime, core specialty distribution capabilities. ", "original_text": "We will continually review our portfolio to ensure tight an d focused \nalignment to our strategy.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fde225e15bd97e38283f165030598aa9a50f1d3e49860e9423cf7ebe412618df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4001fd35-e2f0-4aaa-ac87-264600899c43", "node_type": "1", "metadata": {"window": "Over time, we've identified businesses that are not central to McKess on's current strategic priorities or direction, \nas was the case in our exit of our position in Change Healthcare and the creation of a German wholesale joint \nventure with Walgreens Boots Alliance.  We will continually review our portfolio to ensure tight an d focused \nalignment to our strategy.  \n \n All this work has enabled us to focus our time and investments on our strategic growth pillars, where we're \nworking to build connected ecosystems in the growth areas of oncology and biopharma services, which serve to \nadvance our already differentiated positions.  We continue to be confident in the long -term outlook of businesses \nthat operate in these high -growth markets.  \n \n Starting with oncology, an ecosystem that McKesson has strategically built over a period of nearly 1 5 years, \nbeginning with our acquisition of Oncology Therapeutics Network all the way back in 2007, which added, at that \ntime, core specialty distribution capabilities.  10 years ago, we deepened the breadth and the depth of our offering \nwith the acquisition  of US Oncology Network, which gave us practice management, site management for research \nand the iKnowMed EHR, which is one of the foundational pieces of Ontada.  \n \n Fast-forward to today and we're now supporting over 14,000 specialty physicians through distr ibution and GPO \nservices. ", "original_text": "We continue to be confident in the long -term outlook of businesses \nthat operate in these high -growth markets.  \n \n"}, "hash": "5dcb2945b5c3beb8e7bc4c75351d8c7ccc6c91850d08162c5c1045ad529fef3b", "class_name": "RelatedNodeInfo"}}, "text": "All this work has enabled us to focus our time and investments on our strategic growth pillars, where we're \nworking to build connected ecosystems in the growth areas of oncology and biopharma services, which serve to \nadvance our already differentiated positions. ", "start_char_idx": 1079, "end_char_idx": 1344, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4001fd35-e2f0-4aaa-ac87-264600899c43": {"__data__": {"id_": "4001fd35-e2f0-4aaa-ac87-264600899c43", "embedding": null, "metadata": {"window": "Over time, we've identified businesses that are not central to McKess on's current strategic priorities or direction, \nas was the case in our exit of our position in Change Healthcare and the creation of a German wholesale joint \nventure with Walgreens Boots Alliance.  We will continually review our portfolio to ensure tight an d focused \nalignment to our strategy.  \n \n All this work has enabled us to focus our time and investments on our strategic growth pillars, where we're \nworking to build connected ecosystems in the growth areas of oncology and biopharma services, which serve to \nadvance our already differentiated positions.  We continue to be confident in the long -term outlook of businesses \nthat operate in these high -growth markets.  \n \n Starting with oncology, an ecosystem that McKesson has strategically built over a period of nearly 1 5 years, \nbeginning with our acquisition of Oncology Therapeutics Network all the way back in 2007, which added, at that \ntime, core specialty distribution capabilities.  10 years ago, we deepened the breadth and the depth of our offering \nwith the acquisition  of US Oncology Network, which gave us practice management, site management for research \nand the iKnowMed EHR, which is one of the foundational pieces of Ontada.  \n \n Fast-forward to today and we're now supporting over 14,000 specialty physicians through distr ibution and GPO \nservices. ", "original_text": "We continue to be confident in the long -term outlook of businesses \nthat operate in these high -growth markets.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a8a9216-8deb-4e14-80bf-7ca55ba8e1b3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d86bca99cf03020665c8681e316da6076124daae4e5e026160542a31505695e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f9d3cd1-3c01-4c9c-b614-861dab1fd871", "node_type": "1", "metadata": {"window": "Throughout our enterprise, ther e's \nan initiative we call Spend Smart, which helped us achieve our three -year cost reduction target of $400 million to \n$500 million of annual cost savings by the end of our fiscal 2021.  \n \n Over time, we've identified businesses that are not central to McKess on's current strategic priorities or direction, \nas was the case in our exit of our position in Change Healthcare and the creation of a German wholesale joint \nventure with Walgreens Boots Alliance.  We will continually review our portfolio to ensure tight an d focused \nalignment to our strategy.  \n \n All this work has enabled us to focus our time and investments on our strategic growth pillars, where we're \nworking to build connected ecosystems in the growth areas of oncology and biopharma services, which serve to \nadvance our already differentiated positions.  We continue to be confident in the long -term outlook of businesses \nthat operate in these high -growth markets.  \n \n Starting with oncology, an ecosystem that McKesson has strategically built over a period of nearly 1 5 years, \nbeginning with our acquisition of Oncology Therapeutics Network all the way back in 2007, which added, at that \ntime, core specialty distribution capabilities.  10 years ago, we deepened the breadth and the depth of our offering \nwith the acquisition  of US Oncology Network, which gave us practice management, site management for research \nand the iKnowMed EHR, which is one of the foundational pieces of Ontada.  \n \n", "original_text": "All this work has enabled us to focus our time and investments on our strategic growth pillars, where we're \nworking to build connected ecosystems in the growth areas of oncology and biopharma services, which serve to \nadvance our already differentiated positions. ", "page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9d706f0e73d59a7d0c86d963960724519508ce7f89f4065c8deb19a57ccf7b95", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "21d36668-ce01-4fda-b10c-6aada7e8db93", "node_type": "1", "metadata": {"window": "We will continually review our portfolio to ensure tight an d focused \nalignment to our strategy.  \n \n All this work has enabled us to focus our time and investments on our strategic growth pillars, where we're \nworking to build connected ecosystems in the growth areas of oncology and biopharma services, which serve to \nadvance our already differentiated positions.  We continue to be confident in the long -term outlook of businesses \nthat operate in these high -growth markets.  \n \n Starting with oncology, an ecosystem that McKesson has strategically built over a period of nearly 1 5 years, \nbeginning with our acquisition of Oncology Therapeutics Network all the way back in 2007, which added, at that \ntime, core specialty distribution capabilities.  10 years ago, we deepened the breadth and the depth of our offering \nwith the acquisition  of US Oncology Network, which gave us practice management, site management for research \nand the iKnowMed EHR, which is one of the foundational pieces of Ontada.  \n \n Fast-forward to today and we're now supporting over 14,000 specialty physicians through distr ibution and GPO \nservices.  We're also the leading distributor in community oncology space and have over 1,400 physicians in the \nUS Oncology Network spread over approximately 600 sites of care in the US.  \n \n", "original_text": "Starting with oncology, an ecosystem that McKesson has strategically built over a period of nearly 1 5 years, \nbeginning with our acquisition of Oncology Therapeutics Network all the way back in 2007, which added, at that \ntime, core specialty distribution capabilities. "}, "hash": "fd1def1dcb2af9ec705398ef3ff3a080b3373f2bf2dca382a72213b909a2f553", "class_name": "RelatedNodeInfo"}}, "text": "We continue to be confident in the long -term outlook of businesses \nthat operate in these high -growth markets.  \n \n", "start_char_idx": 1344, "end_char_idx": 1461, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "21d36668-ce01-4fda-b10c-6aada7e8db93": {"__data__": {"id_": "21d36668-ce01-4fda-b10c-6aada7e8db93", "embedding": null, "metadata": {"window": "We will continually review our portfolio to ensure tight an d focused \nalignment to our strategy.  \n \n All this work has enabled us to focus our time and investments on our strategic growth pillars, where we're \nworking to build connected ecosystems in the growth areas of oncology and biopharma services, which serve to \nadvance our already differentiated positions.  We continue to be confident in the long -term outlook of businesses \nthat operate in these high -growth markets.  \n \n Starting with oncology, an ecosystem that McKesson has strategically built over a period of nearly 1 5 years, \nbeginning with our acquisition of Oncology Therapeutics Network all the way back in 2007, which added, at that \ntime, core specialty distribution capabilities.  10 years ago, we deepened the breadth and the depth of our offering \nwith the acquisition  of US Oncology Network, which gave us practice management, site management for research \nand the iKnowMed EHR, which is one of the foundational pieces of Ontada.  \n \n Fast-forward to today and we're now supporting over 14,000 specialty physicians through distr ibution and GPO \nservices.  We're also the leading distributor in community oncology space and have over 1,400 physicians in the \nUS Oncology Network spread over approximately 600 sites of care in the US.  \n \n", "original_text": "Starting with oncology, an ecosystem that McKesson has strategically built over a period of nearly 1 5 years, \nbeginning with our acquisition of Oncology Therapeutics Network all the way back in 2007, which added, at that \ntime, core specialty distribution capabilities. ", "page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a8a9216-8deb-4e14-80bf-7ca55ba8e1b3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d86bca99cf03020665c8681e316da6076124daae4e5e026160542a31505695e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4001fd35-e2f0-4aaa-ac87-264600899c43", "node_type": "1", "metadata": {"window": "Over time, we've identified businesses that are not central to McKess on's current strategic priorities or direction, \nas was the case in our exit of our position in Change Healthcare and the creation of a German wholesale joint \nventure with Walgreens Boots Alliance.  We will continually review our portfolio to ensure tight an d focused \nalignment to our strategy.  \n \n All this work has enabled us to focus our time and investments on our strategic growth pillars, where we're \nworking to build connected ecosystems in the growth areas of oncology and biopharma services, which serve to \nadvance our already differentiated positions.  We continue to be confident in the long -term outlook of businesses \nthat operate in these high -growth markets.  \n \n Starting with oncology, an ecosystem that McKesson has strategically built over a period of nearly 1 5 years, \nbeginning with our acquisition of Oncology Therapeutics Network all the way back in 2007, which added, at that \ntime, core specialty distribution capabilities.  10 years ago, we deepened the breadth and the depth of our offering \nwith the acquisition  of US Oncology Network, which gave us practice management, site management for research \nand the iKnowMed EHR, which is one of the foundational pieces of Ontada.  \n \n Fast-forward to today and we're now supporting over 14,000 specialty physicians through distr ibution and GPO \nservices. ", "original_text": "We continue to be confident in the long -term outlook of businesses \nthat operate in these high -growth markets.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2d6fd3014c3cf2b25d7d5ba9242bcef14902e7602127fa6563be6a6370bf5b71", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "964226ba-ff1a-4103-a704-8bc624ea1e3a", "node_type": "1", "metadata": {"window": "All this work has enabled us to focus our time and investments on our strategic growth pillars, where we're \nworking to build connected ecosystems in the growth areas of oncology and biopharma services, which serve to \nadvance our already differentiated positions.  We continue to be confident in the long -term outlook of businesses \nthat operate in these high -growth markets.  \n \n Starting with oncology, an ecosystem that McKesson has strategically built over a period of nearly 1 5 years, \nbeginning with our acquisition of Oncology Therapeutics Network all the way back in 2007, which added, at that \ntime, core specialty distribution capabilities.  10 years ago, we deepened the breadth and the depth of our offering \nwith the acquisition  of US Oncology Network, which gave us practice management, site management for research \nand the iKnowMed EHR, which is one of the foundational pieces of Ontada.  \n \n Fast-forward to today and we're now supporting over 14,000 specialty physicians through distr ibution and GPO \nservices.  We're also the leading distributor in community oncology space and have over 1,400 physicians in the \nUS Oncology Network spread over approximately 600 sites of care in the US.  \n \n As innovative specialty therapies come to market, our  leading position in oncology distribution enables us to grow \nour connected oncology ecosystem in parallel. ", "original_text": "10 years ago, we deepened the breadth and the depth of our offering \nwith the acquisition  of US Oncology Network, which gave us practice management, site management for research \nand the iKnowMed EHR, which is one of the foundational pieces of Ontada.  \n \n"}, "hash": "79d836a4109ee815c8208119fb9475395ced6862d9f18a3cf8f4baaeb7ffd404", "class_name": "RelatedNodeInfo"}}, "text": "Starting with oncology, an ecosystem that McKesson has strategically built over a period of nearly 1 5 years, \nbeginning with our acquisition of Oncology Therapeutics Network all the way back in 2007, which added, at that \ntime, core specialty distribution capabilities. ", "start_char_idx": 1461, "end_char_idx": 1732, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "964226ba-ff1a-4103-a704-8bc624ea1e3a": {"__data__": {"id_": "964226ba-ff1a-4103-a704-8bc624ea1e3a", "embedding": null, "metadata": {"window": "All this work has enabled us to focus our time and investments on our strategic growth pillars, where we're \nworking to build connected ecosystems in the growth areas of oncology and biopharma services, which serve to \nadvance our already differentiated positions.  We continue to be confident in the long -term outlook of businesses \nthat operate in these high -growth markets.  \n \n Starting with oncology, an ecosystem that McKesson has strategically built over a period of nearly 1 5 years, \nbeginning with our acquisition of Oncology Therapeutics Network all the way back in 2007, which added, at that \ntime, core specialty distribution capabilities.  10 years ago, we deepened the breadth and the depth of our offering \nwith the acquisition  of US Oncology Network, which gave us practice management, site management for research \nand the iKnowMed EHR, which is one of the foundational pieces of Ontada.  \n \n Fast-forward to today and we're now supporting over 14,000 specialty physicians through distr ibution and GPO \nservices.  We're also the leading distributor in community oncology space and have over 1,400 physicians in the \nUS Oncology Network spread over approximately 600 sites of care in the US.  \n \n As innovative specialty therapies come to market, our  leading position in oncology distribution enables us to grow \nour connected oncology ecosystem in parallel. ", "original_text": "10 years ago, we deepened the breadth and the depth of our offering \nwith the acquisition  of US Oncology Network, which gave us practice management, site management for research \nand the iKnowMed EHR, which is one of the foundational pieces of Ontada.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a8a9216-8deb-4e14-80bf-7ca55ba8e1b3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d86bca99cf03020665c8681e316da6076124daae4e5e026160542a31505695e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "21d36668-ce01-4fda-b10c-6aada7e8db93", "node_type": "1", "metadata": {"window": "We will continually review our portfolio to ensure tight an d focused \nalignment to our strategy.  \n \n All this work has enabled us to focus our time and investments on our strategic growth pillars, where we're \nworking to build connected ecosystems in the growth areas of oncology and biopharma services, which serve to \nadvance our already differentiated positions.  We continue to be confident in the long -term outlook of businesses \nthat operate in these high -growth markets.  \n \n Starting with oncology, an ecosystem that McKesson has strategically built over a period of nearly 1 5 years, \nbeginning with our acquisition of Oncology Therapeutics Network all the way back in 2007, which added, at that \ntime, core specialty distribution capabilities.  10 years ago, we deepened the breadth and the depth of our offering \nwith the acquisition  of US Oncology Network, which gave us practice management, site management for research \nand the iKnowMed EHR, which is one of the foundational pieces of Ontada.  \n \n Fast-forward to today and we're now supporting over 14,000 specialty physicians through distr ibution and GPO \nservices.  We're also the leading distributor in community oncology space and have over 1,400 physicians in the \nUS Oncology Network spread over approximately 600 sites of care in the US.  \n \n", "original_text": "Starting with oncology, an ecosystem that McKesson has strategically built over a period of nearly 1 5 years, \nbeginning with our acquisition of Oncology Therapeutics Network all the way back in 2007, which added, at that \ntime, core specialty distribution capabilities. ", "page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "60c5f817d35b359711d8f0099cfc0ce2314dcbd78faffbe86c3817e289537a74", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b5381bcc-f224-4128-a1e1-8fdf7c4ddd26", "node_type": "1", "metadata": {"window": "We continue to be confident in the long -term outlook of businesses \nthat operate in these high -growth markets.  \n \n Starting with oncology, an ecosystem that McKesson has strategically built over a period of nearly 1 5 years, \nbeginning with our acquisition of Oncology Therapeutics Network all the way back in 2007, which added, at that \ntime, core specialty distribution capabilities.  10 years ago, we deepened the breadth and the depth of our offering \nwith the acquisition  of US Oncology Network, which gave us practice management, site management for research \nand the iKnowMed EHR, which is one of the foundational pieces of Ontada.  \n \n Fast-forward to today and we're now supporting over 14,000 specialty physicians through distr ibution and GPO \nservices.  We're also the leading distributor in community oncology space and have over 1,400 physicians in the \nUS Oncology Network spread over approximately 600 sites of care in the US.  \n \n As innovative specialty therapies come to market, our  leading position in oncology distribution enables us to grow \nour connected oncology ecosystem in parallel.  As we grow our non -affiliated and our US oncology provider basis, \nwe accelerate the growth of our oncology assets, such as GPO services, practice ma nagement, site management \nfor clinical research, specialty pharmacy and our value proposition for Ontada, where we're providing real -world \ninsight to both manufacturers and providers.  \n \n", "original_text": "Fast-forward to today and we're now supporting over 14,000 specialty physicians through distr ibution and GPO \nservices. "}, "hash": "766dd6aa01d615f7c7807c5bf564d8e4b46c1cabcf159fc198c5250e1ec09e3d", "class_name": "RelatedNodeInfo"}}, "text": "10 years ago, we deepened the breadth and the depth of our offering \nwith the acquisition  of US Oncology Network, which gave us practice management, site management for research \nand the iKnowMed EHR, which is one of the foundational pieces of Ontada.  \n \n", "start_char_idx": 1732, "end_char_idx": 1989, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b5381bcc-f224-4128-a1e1-8fdf7c4ddd26": {"__data__": {"id_": "b5381bcc-f224-4128-a1e1-8fdf7c4ddd26", "embedding": null, "metadata": {"window": "We continue to be confident in the long -term outlook of businesses \nthat operate in these high -growth markets.  \n \n Starting with oncology, an ecosystem that McKesson has strategically built over a period of nearly 1 5 years, \nbeginning with our acquisition of Oncology Therapeutics Network all the way back in 2007, which added, at that \ntime, core specialty distribution capabilities.  10 years ago, we deepened the breadth and the depth of our offering \nwith the acquisition  of US Oncology Network, which gave us practice management, site management for research \nand the iKnowMed EHR, which is one of the foundational pieces of Ontada.  \n \n Fast-forward to today and we're now supporting over 14,000 specialty physicians through distr ibution and GPO \nservices.  We're also the leading distributor in community oncology space and have over 1,400 physicians in the \nUS Oncology Network spread over approximately 600 sites of care in the US.  \n \n As innovative specialty therapies come to market, our  leading position in oncology distribution enables us to grow \nour connected oncology ecosystem in parallel.  As we grow our non -affiliated and our US oncology provider basis, \nwe accelerate the growth of our oncology assets, such as GPO services, practice ma nagement, site management \nfor clinical research, specialty pharmacy and our value proposition for Ontada, where we're providing real -world \ninsight to both manufacturers and providers.  \n \n", "original_text": "Fast-forward to today and we're now supporting over 14,000 specialty physicians through distr ibution and GPO \nservices. ", "page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a8a9216-8deb-4e14-80bf-7ca55ba8e1b3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d86bca99cf03020665c8681e316da6076124daae4e5e026160542a31505695e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "964226ba-ff1a-4103-a704-8bc624ea1e3a", "node_type": "1", "metadata": {"window": "All this work has enabled us to focus our time and investments on our strategic growth pillars, where we're \nworking to build connected ecosystems in the growth areas of oncology and biopharma services, which serve to \nadvance our already differentiated positions.  We continue to be confident in the long -term outlook of businesses \nthat operate in these high -growth markets.  \n \n Starting with oncology, an ecosystem that McKesson has strategically built over a period of nearly 1 5 years, \nbeginning with our acquisition of Oncology Therapeutics Network all the way back in 2007, which added, at that \ntime, core specialty distribution capabilities.  10 years ago, we deepened the breadth and the depth of our offering \nwith the acquisition  of US Oncology Network, which gave us practice management, site management for research \nand the iKnowMed EHR, which is one of the foundational pieces of Ontada.  \n \n Fast-forward to today and we're now supporting over 14,000 specialty physicians through distr ibution and GPO \nservices.  We're also the leading distributor in community oncology space and have over 1,400 physicians in the \nUS Oncology Network spread over approximately 600 sites of care in the US.  \n \n As innovative specialty therapies come to market, our  leading position in oncology distribution enables us to grow \nour connected oncology ecosystem in parallel. ", "original_text": "10 years ago, we deepened the breadth and the depth of our offering \nwith the acquisition  of US Oncology Network, which gave us practice management, site management for research \nand the iKnowMed EHR, which is one of the foundational pieces of Ontada.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "09f23300682d1163c8c93aa313377da83473acfc730b9bdb700b71a769f71387", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c80097b2-1e43-40c6-8e5d-3583c33167c7", "node_type": "1", "metadata": {"window": "Starting with oncology, an ecosystem that McKesson has strategically built over a period of nearly 1 5 years, \nbeginning with our acquisition of Oncology Therapeutics Network all the way back in 2007, which added, at that \ntime, core specialty distribution capabilities.  10 years ago, we deepened the breadth and the depth of our offering \nwith the acquisition  of US Oncology Network, which gave us practice management, site management for research \nand the iKnowMed EHR, which is one of the foundational pieces of Ontada.  \n \n Fast-forward to today and we're now supporting over 14,000 specialty physicians through distr ibution and GPO \nservices.  We're also the leading distributor in community oncology space and have over 1,400 physicians in the \nUS Oncology Network spread over approximately 600 sites of care in the US.  \n \n As innovative specialty therapies come to market, our  leading position in oncology distribution enables us to grow \nour connected oncology ecosystem in parallel.  As we grow our non -affiliated and our US oncology provider basis, \nwe accelerate the growth of our oncology assets, such as GPO services, practice ma nagement, site management \nfor clinical research, specialty pharmacy and our value proposition for Ontada, where we're providing real -world \ninsight to both manufacturers and providers.  \n \n Although in its infancy, Ontada's value is being recognized through exp anded partnerships with manufacturers \nsuch as Amgen and its leading role in a large -scale real -world research study known as MYLUNG, which aims to \nimprove treatments and outcomes for non -small cell lung cancer.  \n \n", "original_text": "We're also the leading distributor in community oncology space and have over 1,400 physicians in the \nUS Oncology Network spread over approximately 600 sites of care in the US.  \n \n"}, "hash": "41f784acf1cedbc548673e8940573f87341206cfeac4dad53d1035a51b14651b", "class_name": "RelatedNodeInfo"}}, "text": "Fast-forward to today and we're now supporting over 14,000 specialty physicians through distr ibution and GPO \nservices. ", "start_char_idx": 1989, "end_char_idx": 2110, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c80097b2-1e43-40c6-8e5d-3583c33167c7": {"__data__": {"id_": "c80097b2-1e43-40c6-8e5d-3583c33167c7", "embedding": null, "metadata": {"window": "Starting with oncology, an ecosystem that McKesson has strategically built over a period of nearly 1 5 years, \nbeginning with our acquisition of Oncology Therapeutics Network all the way back in 2007, which added, at that \ntime, core specialty distribution capabilities.  10 years ago, we deepened the breadth and the depth of our offering \nwith the acquisition  of US Oncology Network, which gave us practice management, site management for research \nand the iKnowMed EHR, which is one of the foundational pieces of Ontada.  \n \n Fast-forward to today and we're now supporting over 14,000 specialty physicians through distr ibution and GPO \nservices.  We're also the leading distributor in community oncology space and have over 1,400 physicians in the \nUS Oncology Network spread over approximately 600 sites of care in the US.  \n \n As innovative specialty therapies come to market, our  leading position in oncology distribution enables us to grow \nour connected oncology ecosystem in parallel.  As we grow our non -affiliated and our US oncology provider basis, \nwe accelerate the growth of our oncology assets, such as GPO services, practice ma nagement, site management \nfor clinical research, specialty pharmacy and our value proposition for Ontada, where we're providing real -world \ninsight to both manufacturers and providers.  \n \n Although in its infancy, Ontada's value is being recognized through exp anded partnerships with manufacturers \nsuch as Amgen and its leading role in a large -scale real -world research study known as MYLUNG, which aims to \nimprove treatments and outcomes for non -small cell lung cancer.  \n \n", "original_text": "We're also the leading distributor in community oncology space and have over 1,400 physicians in the \nUS Oncology Network spread over approximately 600 sites of care in the US.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a8a9216-8deb-4e14-80bf-7ca55ba8e1b3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d86bca99cf03020665c8681e316da6076124daae4e5e026160542a31505695e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b5381bcc-f224-4128-a1e1-8fdf7c4ddd26", "node_type": "1", "metadata": {"window": "We continue to be confident in the long -term outlook of businesses \nthat operate in these high -growth markets.  \n \n Starting with oncology, an ecosystem that McKesson has strategically built over a period of nearly 1 5 years, \nbeginning with our acquisition of Oncology Therapeutics Network all the way back in 2007, which added, at that \ntime, core specialty distribution capabilities.  10 years ago, we deepened the breadth and the depth of our offering \nwith the acquisition  of US Oncology Network, which gave us practice management, site management for research \nand the iKnowMed EHR, which is one of the foundational pieces of Ontada.  \n \n Fast-forward to today and we're now supporting over 14,000 specialty physicians through distr ibution and GPO \nservices.  We're also the leading distributor in community oncology space and have over 1,400 physicians in the \nUS Oncology Network spread over approximately 600 sites of care in the US.  \n \n As innovative specialty therapies come to market, our  leading position in oncology distribution enables us to grow \nour connected oncology ecosystem in parallel.  As we grow our non -affiliated and our US oncology provider basis, \nwe accelerate the growth of our oncology assets, such as GPO services, practice ma nagement, site management \nfor clinical research, specialty pharmacy and our value proposition for Ontada, where we're providing real -world \ninsight to both manufacturers and providers.  \n \n", "original_text": "Fast-forward to today and we're now supporting over 14,000 specialty physicians through distr ibution and GPO \nservices. ", "page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "effb6d664de7a7e1e8d62c5ac1eefc785ca61d729663bcb90322d262180b1723", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bbff9dfb-5a22-4188-b5ae-c4e0fd77c695", "node_type": "1", "metadata": {"window": "10 years ago, we deepened the breadth and the depth of our offering \nwith the acquisition  of US Oncology Network, which gave us practice management, site management for research \nand the iKnowMed EHR, which is one of the foundational pieces of Ontada.  \n \n Fast-forward to today and we're now supporting over 14,000 specialty physicians through distr ibution and GPO \nservices.  We're also the leading distributor in community oncology space and have over 1,400 physicians in the \nUS Oncology Network spread over approximately 600 sites of care in the US.  \n \n As innovative specialty therapies come to market, our  leading position in oncology distribution enables us to grow \nour connected oncology ecosystem in parallel.  As we grow our non -affiliated and our US oncology provider basis, \nwe accelerate the growth of our oncology assets, such as GPO services, practice ma nagement, site management \nfor clinical research, specialty pharmacy and our value proposition for Ontada, where we're providing real -world \ninsight to both manufacturers and providers.  \n \n Although in its infancy, Ontada's value is being recognized through exp anded partnerships with manufacturers \nsuch as Amgen and its leading role in a large -scale real -world research study known as MYLUNG, which aims to \nimprove treatments and outcomes for non -small cell lung cancer.  \n \n New therapies coming to market can also prov ide additional challenges for patients, providers and our biopharma \npartners. ", "original_text": "As innovative specialty therapies come to market, our  leading position in oncology distribution enables us to grow \nour connected oncology ecosystem in parallel. "}, "hash": "d8a1c2e15fc0f253392269587268869dda9072cc18ca9d076742277216f8c2b6", "class_name": "RelatedNodeInfo"}}, "text": "We're also the leading distributor in community oncology space and have over 1,400 physicians in the \nUS Oncology Network spread over approximately 600 sites of care in the US.  \n \n", "start_char_idx": 2110, "end_char_idx": 2291, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bbff9dfb-5a22-4188-b5ae-c4e0fd77c695": {"__data__": {"id_": "bbff9dfb-5a22-4188-b5ae-c4e0fd77c695", "embedding": null, "metadata": {"window": "10 years ago, we deepened the breadth and the depth of our offering \nwith the acquisition  of US Oncology Network, which gave us practice management, site management for research \nand the iKnowMed EHR, which is one of the foundational pieces of Ontada.  \n \n Fast-forward to today and we're now supporting over 14,000 specialty physicians through distr ibution and GPO \nservices.  We're also the leading distributor in community oncology space and have over 1,400 physicians in the \nUS Oncology Network spread over approximately 600 sites of care in the US.  \n \n As innovative specialty therapies come to market, our  leading position in oncology distribution enables us to grow \nour connected oncology ecosystem in parallel.  As we grow our non -affiliated and our US oncology provider basis, \nwe accelerate the growth of our oncology assets, such as GPO services, practice ma nagement, site management \nfor clinical research, specialty pharmacy and our value proposition for Ontada, where we're providing real -world \ninsight to both manufacturers and providers.  \n \n Although in its infancy, Ontada's value is being recognized through exp anded partnerships with manufacturers \nsuch as Amgen and its leading role in a large -scale real -world research study known as MYLUNG, which aims to \nimprove treatments and outcomes for non -small cell lung cancer.  \n \n New therapies coming to market can also prov ide additional challenges for patients, providers and our biopharma \npartners. ", "original_text": "As innovative specialty therapies come to market, our  leading position in oncology distribution enables us to grow \nour connected oncology ecosystem in parallel. ", "page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a8a9216-8deb-4e14-80bf-7ca55ba8e1b3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d86bca99cf03020665c8681e316da6076124daae4e5e026160542a31505695e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c80097b2-1e43-40c6-8e5d-3583c33167c7", "node_type": "1", "metadata": {"window": "Starting with oncology, an ecosystem that McKesson has strategically built over a period of nearly 1 5 years, \nbeginning with our acquisition of Oncology Therapeutics Network all the way back in 2007, which added, at that \ntime, core specialty distribution capabilities.  10 years ago, we deepened the breadth and the depth of our offering \nwith the acquisition  of US Oncology Network, which gave us practice management, site management for research \nand the iKnowMed EHR, which is one of the foundational pieces of Ontada.  \n \n Fast-forward to today and we're now supporting over 14,000 specialty physicians through distr ibution and GPO \nservices.  We're also the leading distributor in community oncology space and have over 1,400 physicians in the \nUS Oncology Network spread over approximately 600 sites of care in the US.  \n \n As innovative specialty therapies come to market, our  leading position in oncology distribution enables us to grow \nour connected oncology ecosystem in parallel.  As we grow our non -affiliated and our US oncology provider basis, \nwe accelerate the growth of our oncology assets, such as GPO services, practice ma nagement, site management \nfor clinical research, specialty pharmacy and our value proposition for Ontada, where we're providing real -world \ninsight to both manufacturers and providers.  \n \n Although in its infancy, Ontada's value is being recognized through exp anded partnerships with manufacturers \nsuch as Amgen and its leading role in a large -scale real -world research study known as MYLUNG, which aims to \nimprove treatments and outcomes for non -small cell lung cancer.  \n \n", "original_text": "We're also the leading distributor in community oncology space and have over 1,400 physicians in the \nUS Oncology Network spread over approximately 600 sites of care in the US.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8e9c0f2229474c106c18511dc51146b6d929ece9d221829419eae2b0bd00bce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f846f458-8638-4a22-aef0-138ba1cf2c30", "node_type": "1", "metadata": {"window": "Fast-forward to today and we're now supporting over 14,000 specialty physicians through distr ibution and GPO \nservices.  We're also the leading distributor in community oncology space and have over 1,400 physicians in the \nUS Oncology Network spread over approximately 600 sites of care in the US.  \n \n As innovative specialty therapies come to market, our  leading position in oncology distribution enables us to grow \nour connected oncology ecosystem in parallel.  As we grow our non -affiliated and our US oncology provider basis, \nwe accelerate the growth of our oncology assets, such as GPO services, practice ma nagement, site management \nfor clinical research, specialty pharmacy and our value proposition for Ontada, where we're providing real -world \ninsight to both manufacturers and providers.  \n \n Although in its infancy, Ontada's value is being recognized through exp anded partnerships with manufacturers \nsuch as Amgen and its leading role in a large -scale real -world research study known as MYLUNG, which aims to \nimprove treatments and outcomes for non -small cell lung cancer.  \n \n New therapies coming to market can also prov ide additional challenges for patients, providers and our biopharma \npartners.  Our Prescription Technology Solutions business invests in innovation and aims to provide access, \nadherence and affordability solutions for over 500 brands across nearly every the rapeutic area. ", "original_text": "As we grow our non -affiliated and our US oncology provider basis, \nwe accelerate the growth of our oncology assets, such as GPO services, practice ma nagement, site management \nfor clinical research, specialty pharmacy and our value proposition for Ontada, where we're providing real -world \ninsight to both manufacturers and providers.  \n \n"}, "hash": "019585c8f19ab2369ed2ea69d47c52409bba0e85928f244ba8b994f7eea5a5a4", "class_name": "RelatedNodeInfo"}}, "text": "As innovative specialty therapies come to market, our  leading position in oncology distribution enables us to grow \nour connected oncology ecosystem in parallel. ", "start_char_idx": 2291, "end_char_idx": 2454, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f846f458-8638-4a22-aef0-138ba1cf2c30": {"__data__": {"id_": "f846f458-8638-4a22-aef0-138ba1cf2c30", "embedding": null, "metadata": {"window": "Fast-forward to today and we're now supporting over 14,000 specialty physicians through distr ibution and GPO \nservices.  We're also the leading distributor in community oncology space and have over 1,400 physicians in the \nUS Oncology Network spread over approximately 600 sites of care in the US.  \n \n As innovative specialty therapies come to market, our  leading position in oncology distribution enables us to grow \nour connected oncology ecosystem in parallel.  As we grow our non -affiliated and our US oncology provider basis, \nwe accelerate the growth of our oncology assets, such as GPO services, practice ma nagement, site management \nfor clinical research, specialty pharmacy and our value proposition for Ontada, where we're providing real -world \ninsight to both manufacturers and providers.  \n \n Although in its infancy, Ontada's value is being recognized through exp anded partnerships with manufacturers \nsuch as Amgen and its leading role in a large -scale real -world research study known as MYLUNG, which aims to \nimprove treatments and outcomes for non -small cell lung cancer.  \n \n New therapies coming to market can also prov ide additional challenges for patients, providers and our biopharma \npartners.  Our Prescription Technology Solutions business invests in innovation and aims to provide access, \nadherence and affordability solutions for over 500 brands across nearly every the rapeutic area. ", "original_text": "As we grow our non -affiliated and our US oncology provider basis, \nwe accelerate the growth of our oncology assets, such as GPO services, practice ma nagement, site management \nfor clinical research, specialty pharmacy and our value proposition for Ontada, where we're providing real -world \ninsight to both manufacturers and providers.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a8a9216-8deb-4e14-80bf-7ca55ba8e1b3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d86bca99cf03020665c8681e316da6076124daae4e5e026160542a31505695e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bbff9dfb-5a22-4188-b5ae-c4e0fd77c695", "node_type": "1", "metadata": {"window": "10 years ago, we deepened the breadth and the depth of our offering \nwith the acquisition  of US Oncology Network, which gave us practice management, site management for research \nand the iKnowMed EHR, which is one of the foundational pieces of Ontada.  \n \n Fast-forward to today and we're now supporting over 14,000 specialty physicians through distr ibution and GPO \nservices.  We're also the leading distributor in community oncology space and have over 1,400 physicians in the \nUS Oncology Network spread over approximately 600 sites of care in the US.  \n \n As innovative specialty therapies come to market, our  leading position in oncology distribution enables us to grow \nour connected oncology ecosystem in parallel.  As we grow our non -affiliated and our US oncology provider basis, \nwe accelerate the growth of our oncology assets, such as GPO services, practice ma nagement, site management \nfor clinical research, specialty pharmacy and our value proposition for Ontada, where we're providing real -world \ninsight to both manufacturers and providers.  \n \n Although in its infancy, Ontada's value is being recognized through exp anded partnerships with manufacturers \nsuch as Amgen and its leading role in a large -scale real -world research study known as MYLUNG, which aims to \nimprove treatments and outcomes for non -small cell lung cancer.  \n \n New therapies coming to market can also prov ide additional challenges for patients, providers and our biopharma \npartners. ", "original_text": "As innovative specialty therapies come to market, our  leading position in oncology distribution enables us to grow \nour connected oncology ecosystem in parallel. ", "page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c1312990bb53927c9a0aed6156742e8e4c3599903996cf1a404de98f2083442b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d467cb1-15e7-417b-8119-d204f425b266", "node_type": "1", "metadata": {"window": "We're also the leading distributor in community oncology space and have over 1,400 physicians in the \nUS Oncology Network spread over approximately 600 sites of care in the US.  \n \n As innovative specialty therapies come to market, our  leading position in oncology distribution enables us to grow \nour connected oncology ecosystem in parallel.  As we grow our non -affiliated and our US oncology provider basis, \nwe accelerate the growth of our oncology assets, such as GPO services, practice ma nagement, site management \nfor clinical research, specialty pharmacy and our value proposition for Ontada, where we're providing real -world \ninsight to both manufacturers and providers.  \n \n Although in its infancy, Ontada's value is being recognized through exp anded partnerships with manufacturers \nsuch as Amgen and its leading role in a large -scale real -world research study known as MYLUNG, which aims to \nimprove treatments and outcomes for non -small cell lung cancer.  \n \n New therapies coming to market can also prov ide additional challenges for patients, providers and our biopharma \npartners.  Our Prescription Technology Solutions business invests in innovation and aims to provide access, \nadherence and affordability solutions for over 500 brands across nearly every the rapeutic area.  Our connectivity \nto over 50,000 pharmacies, 750,000 providers and 75% of EHRs in the US helps enable over $5 billion of \nprescription savings for patients each year.  \n \n", "original_text": "Although in its infancy, Ontada's value is being recognized through exp anded partnerships with manufacturers \nsuch as Amgen and its leading role in a large -scale real -world research study known as MYLUNG, which aims to \nimprove treatments and outcomes for non -small cell lung cancer.  \n \n"}, "hash": "805544a55ec265e604e86746065f6ff11bc3cef803be45e0075219b372610b01", "class_name": "RelatedNodeInfo"}}, "text": "As we grow our non -affiliated and our US oncology provider basis, \nwe accelerate the growth of our oncology assets, such as GPO services, practice ma nagement, site management \nfor clinical research, specialty pharmacy and our value proposition for Ontada, where we're providing real -world \ninsight to both manufacturers and providers.  \n \n", "start_char_idx": 2454, "end_char_idx": 2796, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d467cb1-15e7-417b-8119-d204f425b266": {"__data__": {"id_": "3d467cb1-15e7-417b-8119-d204f425b266", "embedding": null, "metadata": {"window": "We're also the leading distributor in community oncology space and have over 1,400 physicians in the \nUS Oncology Network spread over approximately 600 sites of care in the US.  \n \n As innovative specialty therapies come to market, our  leading position in oncology distribution enables us to grow \nour connected oncology ecosystem in parallel.  As we grow our non -affiliated and our US oncology provider basis, \nwe accelerate the growth of our oncology assets, such as GPO services, practice ma nagement, site management \nfor clinical research, specialty pharmacy and our value proposition for Ontada, where we're providing real -world \ninsight to both manufacturers and providers.  \n \n Although in its infancy, Ontada's value is being recognized through exp anded partnerships with manufacturers \nsuch as Amgen and its leading role in a large -scale real -world research study known as MYLUNG, which aims to \nimprove treatments and outcomes for non -small cell lung cancer.  \n \n New therapies coming to market can also prov ide additional challenges for patients, providers and our biopharma \npartners.  Our Prescription Technology Solutions business invests in innovation and aims to provide access, \nadherence and affordability solutions for over 500 brands across nearly every the rapeutic area.  Our connectivity \nto over 50,000 pharmacies, 750,000 providers and 75% of EHRs in the US helps enable over $5 billion of \nprescription savings for patients each year.  \n \n", "original_text": "Although in its infancy, Ontada's value is being recognized through exp anded partnerships with manufacturers \nsuch as Amgen and its leading role in a large -scale real -world research study known as MYLUNG, which aims to \nimprove treatments and outcomes for non -small cell lung cancer.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a8a9216-8deb-4e14-80bf-7ca55ba8e1b3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d86bca99cf03020665c8681e316da6076124daae4e5e026160542a31505695e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f846f458-8638-4a22-aef0-138ba1cf2c30", "node_type": "1", "metadata": {"window": "Fast-forward to today and we're now supporting over 14,000 specialty physicians through distr ibution and GPO \nservices.  We're also the leading distributor in community oncology space and have over 1,400 physicians in the \nUS Oncology Network spread over approximately 600 sites of care in the US.  \n \n As innovative specialty therapies come to market, our  leading position in oncology distribution enables us to grow \nour connected oncology ecosystem in parallel.  As we grow our non -affiliated and our US oncology provider basis, \nwe accelerate the growth of our oncology assets, such as GPO services, practice ma nagement, site management \nfor clinical research, specialty pharmacy and our value proposition for Ontada, where we're providing real -world \ninsight to both manufacturers and providers.  \n \n Although in its infancy, Ontada's value is being recognized through exp anded partnerships with manufacturers \nsuch as Amgen and its leading role in a large -scale real -world research study known as MYLUNG, which aims to \nimprove treatments and outcomes for non -small cell lung cancer.  \n \n New therapies coming to market can also prov ide additional challenges for patients, providers and our biopharma \npartners.  Our Prescription Technology Solutions business invests in innovation and aims to provide access, \nadherence and affordability solutions for over 500 brands across nearly every the rapeutic area. ", "original_text": "As we grow our non -affiliated and our US oncology provider basis, \nwe accelerate the growth of our oncology assets, such as GPO services, practice ma nagement, site management \nfor clinical research, specialty pharmacy and our value proposition for Ontada, where we're providing real -world \ninsight to both manufacturers and providers.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "62157c7562b4839dc0b6f66978baa12eaa0829b42834761155d3ff0223f9bd83", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b51c955-0d17-4316-91e8-75b0a700d21d", "node_type": "1", "metadata": {"window": "As innovative specialty therapies come to market, our  leading position in oncology distribution enables us to grow \nour connected oncology ecosystem in parallel.  As we grow our non -affiliated and our US oncology provider basis, \nwe accelerate the growth of our oncology assets, such as GPO services, practice ma nagement, site management \nfor clinical research, specialty pharmacy and our value proposition for Ontada, where we're providing real -world \ninsight to both manufacturers and providers.  \n \n Although in its infancy, Ontada's value is being recognized through exp anded partnerships with manufacturers \nsuch as Amgen and its leading role in a large -scale real -world research study known as MYLUNG, which aims to \nimprove treatments and outcomes for non -small cell lung cancer.  \n \n New therapies coming to market can also prov ide additional challenges for patients, providers and our biopharma \npartners.  Our Prescription Technology Solutions business invests in innovation and aims to provide access, \nadherence and affordability solutions for over 500 brands across nearly every the rapeutic area.  Our connectivity \nto over 50,000 pharmacies, 750,000 providers and 75% of EHRs in the US helps enable over $5 billion of \nprescription savings for patients each year.  \n \n Prescription Technology Solutions ended fiscal 2021 with solid momentum. ", "original_text": "New therapies coming to market can also prov ide additional challenges for patients, providers and our biopharma \npartners. "}, "hash": "b82e78fcd7fe8fffd71ad979cf7167677cca093248a9a55019cb7335b7d56586", "class_name": "RelatedNodeInfo"}}, "text": "Although in its infancy, Ontada's value is being recognized through exp anded partnerships with manufacturers \nsuch as Amgen and its leading role in a large -scale real -world research study known as MYLUNG, which aims to \nimprove treatments and outcomes for non -small cell lung cancer.  \n \n", "start_char_idx": 2796, "end_char_idx": 3088, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b51c955-0d17-4316-91e8-75b0a700d21d": {"__data__": {"id_": "3b51c955-0d17-4316-91e8-75b0a700d21d", "embedding": null, "metadata": {"window": "As innovative specialty therapies come to market, our  leading position in oncology distribution enables us to grow \nour connected oncology ecosystem in parallel.  As we grow our non -affiliated and our US oncology provider basis, \nwe accelerate the growth of our oncology assets, such as GPO services, practice ma nagement, site management \nfor clinical research, specialty pharmacy and our value proposition for Ontada, where we're providing real -world \ninsight to both manufacturers and providers.  \n \n Although in its infancy, Ontada's value is being recognized through exp anded partnerships with manufacturers \nsuch as Amgen and its leading role in a large -scale real -world research study known as MYLUNG, which aims to \nimprove treatments and outcomes for non -small cell lung cancer.  \n \n New therapies coming to market can also prov ide additional challenges for patients, providers and our biopharma \npartners.  Our Prescription Technology Solutions business invests in innovation and aims to provide access, \nadherence and affordability solutions for over 500 brands across nearly every the rapeutic area.  Our connectivity \nto over 50,000 pharmacies, 750,000 providers and 75% of EHRs in the US helps enable over $5 billion of \nprescription savings for patients each year.  \n \n Prescription Technology Solutions ended fiscal 2021 with solid momentum. ", "original_text": "New therapies coming to market can also prov ide additional challenges for patients, providers and our biopharma \npartners. ", "page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a8a9216-8deb-4e14-80bf-7ca55ba8e1b3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d86bca99cf03020665c8681e316da6076124daae4e5e026160542a31505695e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d467cb1-15e7-417b-8119-d204f425b266", "node_type": "1", "metadata": {"window": "We're also the leading distributor in community oncology space and have over 1,400 physicians in the \nUS Oncology Network spread over approximately 600 sites of care in the US.  \n \n As innovative specialty therapies come to market, our  leading position in oncology distribution enables us to grow \nour connected oncology ecosystem in parallel.  As we grow our non -affiliated and our US oncology provider basis, \nwe accelerate the growth of our oncology assets, such as GPO services, practice ma nagement, site management \nfor clinical research, specialty pharmacy and our value proposition for Ontada, where we're providing real -world \ninsight to both manufacturers and providers.  \n \n Although in its infancy, Ontada's value is being recognized through exp anded partnerships with manufacturers \nsuch as Amgen and its leading role in a large -scale real -world research study known as MYLUNG, which aims to \nimprove treatments and outcomes for non -small cell lung cancer.  \n \n New therapies coming to market can also prov ide additional challenges for patients, providers and our biopharma \npartners.  Our Prescription Technology Solutions business invests in innovation and aims to provide access, \nadherence and affordability solutions for over 500 brands across nearly every the rapeutic area.  Our connectivity \nto over 50,000 pharmacies, 750,000 providers and 75% of EHRs in the US helps enable over $5 billion of \nprescription savings for patients each year.  \n \n", "original_text": "Although in its infancy, Ontada's value is being recognized through exp anded partnerships with manufacturers \nsuch as Amgen and its leading role in a large -scale real -world research study known as MYLUNG, which aims to \nimprove treatments and outcomes for non -small cell lung cancer.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c5d2610b69703bf6c3bf4879c63e55a828c101db90d251c30660cb6b647670dd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bda6271b-2ebe-4f41-8a68-eb6d43a87a3b", "node_type": "1", "metadata": {"window": "As we grow our non -affiliated and our US oncology provider basis, \nwe accelerate the growth of our oncology assets, such as GPO services, practice ma nagement, site management \nfor clinical research, specialty pharmacy and our value proposition for Ontada, where we're providing real -world \ninsight to both manufacturers and providers.  \n \n Although in its infancy, Ontada's value is being recognized through exp anded partnerships with manufacturers \nsuch as Amgen and its leading role in a large -scale real -world research study known as MYLUNG, which aims to \nimprove treatments and outcomes for non -small cell lung cancer.  \n \n New therapies coming to market can also prov ide additional challenges for patients, providers and our biopharma \npartners.  Our Prescription Technology Solutions business invests in innovation and aims to provide access, \nadherence and affordability solutions for over 500 brands across nearly every the rapeutic area.  Our connectivity \nto over 50,000 pharmacies, 750,000 providers and 75% of EHRs in the US helps enable over $5 billion of \nprescription savings for patients each year.  \n \n Prescription Technology Solutions ended fiscal 2021 with solid momentum.  In  the first quarter of fiscal 2022, we \nsaw organic growth in the business and encouraging signs that patient engagement levels and prescription \nvolume trends are continuing to improve. ", "original_text": "Our Prescription Technology Solutions business invests in innovation and aims to provide access, \nadherence and affordability solutions for over 500 brands across nearly every the rapeutic area. "}, "hash": "d776c9f8f225142f59de911c162304857750c20276e36ccac033ee952db14836", "class_name": "RelatedNodeInfo"}}, "text": "New therapies coming to market can also prov ide additional challenges for patients, providers and our biopharma \npartners. ", "start_char_idx": 3088, "end_char_idx": 3212, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bda6271b-2ebe-4f41-8a68-eb6d43a87a3b": {"__data__": {"id_": "bda6271b-2ebe-4f41-8a68-eb6d43a87a3b", "embedding": null, "metadata": {"window": "As we grow our non -affiliated and our US oncology provider basis, \nwe accelerate the growth of our oncology assets, such as GPO services, practice ma nagement, site management \nfor clinical research, specialty pharmacy and our value proposition for Ontada, where we're providing real -world \ninsight to both manufacturers and providers.  \n \n Although in its infancy, Ontada's value is being recognized through exp anded partnerships with manufacturers \nsuch as Amgen and its leading role in a large -scale real -world research study known as MYLUNG, which aims to \nimprove treatments and outcomes for non -small cell lung cancer.  \n \n New therapies coming to market can also prov ide additional challenges for patients, providers and our biopharma \npartners.  Our Prescription Technology Solutions business invests in innovation and aims to provide access, \nadherence and affordability solutions for over 500 brands across nearly every the rapeutic area.  Our connectivity \nto over 50,000 pharmacies, 750,000 providers and 75% of EHRs in the US helps enable over $5 billion of \nprescription savings for patients each year.  \n \n Prescription Technology Solutions ended fiscal 2021 with solid momentum.  In  the first quarter of fiscal 2022, we \nsaw organic growth in the business and encouraging signs that patient engagement levels and prescription \nvolume trends are continuing to improve. ", "original_text": "Our Prescription Technology Solutions business invests in innovation and aims to provide access, \nadherence and affordability solutions for over 500 brands across nearly every the rapeutic area. ", "page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a8a9216-8deb-4e14-80bf-7ca55ba8e1b3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d86bca99cf03020665c8681e316da6076124daae4e5e026160542a31505695e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b51c955-0d17-4316-91e8-75b0a700d21d", "node_type": "1", "metadata": {"window": "As innovative specialty therapies come to market, our  leading position in oncology distribution enables us to grow \nour connected oncology ecosystem in parallel.  As we grow our non -affiliated and our US oncology provider basis, \nwe accelerate the growth of our oncology assets, such as GPO services, practice ma nagement, site management \nfor clinical research, specialty pharmacy and our value proposition for Ontada, where we're providing real -world \ninsight to both manufacturers and providers.  \n \n Although in its infancy, Ontada's value is being recognized through exp anded partnerships with manufacturers \nsuch as Amgen and its leading role in a large -scale real -world research study known as MYLUNG, which aims to \nimprove treatments and outcomes for non -small cell lung cancer.  \n \n New therapies coming to market can also prov ide additional challenges for patients, providers and our biopharma \npartners.  Our Prescription Technology Solutions business invests in innovation and aims to provide access, \nadherence and affordability solutions for over 500 brands across nearly every the rapeutic area.  Our connectivity \nto over 50,000 pharmacies, 750,000 providers and 75% of EHRs in the US helps enable over $5 billion of \nprescription savings for patients each year.  \n \n Prescription Technology Solutions ended fiscal 2021 with solid momentum. ", "original_text": "New therapies coming to market can also prov ide additional challenges for patients, providers and our biopharma \npartners. ", "page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "339c6dca400f414a38df30b446dc8ecce445931b00daa96fe2dce403e1184f02", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76b30c8c-481a-4e93-a72d-8b2beaf7c138", "node_type": "1", "metadata": {"window": "Although in its infancy, Ontada's value is being recognized through exp anded partnerships with manufacturers \nsuch as Amgen and its leading role in a large -scale real -world research study known as MYLUNG, which aims to \nimprove treatments and outcomes for non -small cell lung cancer.  \n \n New therapies coming to market can also prov ide additional challenges for patients, providers and our biopharma \npartners.  Our Prescription Technology Solutions business invests in innovation and aims to provide access, \nadherence and affordability solutions for over 500 brands across nearly every the rapeutic area.  Our connectivity \nto over 50,000 pharmacies, 750,000 providers and 75% of EHRs in the US helps enable over $5 billion of \nprescription savings for patients each year.  \n \n Prescription Technology Solutions ended fiscal 2021 with solid momentum.  In  the first quarter of fiscal 2022, we \nsaw organic growth in the business and encouraging signs that patient engagement levels and prescription \nvolume trends are continuing to improve.  Our market -leading technology offerings are helping patients get access \nto therapies they need more quickly and efficiently and stay on those therapies longer to get better health \noutcomes.  ", "original_text": "Our connectivity \nto over 50,000 pharmacies, 750,000 providers and 75% of EHRs in the US helps enable over $5 billion of \nprescription savings for patients each year.  \n \n"}, "hash": "39be6279759765fdee7212d08d1249c662ef700c2531315db038d630172edf28", "class_name": "RelatedNodeInfo"}}, "text": "Our Prescription Technology Solutions business invests in innovation and aims to provide access, \nadherence and affordability solutions for over 500 brands across nearly every the rapeutic area. ", "start_char_idx": 3212, "end_char_idx": 3407, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "76b30c8c-481a-4e93-a72d-8b2beaf7c138": {"__data__": {"id_": "76b30c8c-481a-4e93-a72d-8b2beaf7c138", "embedding": null, "metadata": {"window": "Although in its infancy, Ontada's value is being recognized through exp anded partnerships with manufacturers \nsuch as Amgen and its leading role in a large -scale real -world research study known as MYLUNG, which aims to \nimprove treatments and outcomes for non -small cell lung cancer.  \n \n New therapies coming to market can also prov ide additional challenges for patients, providers and our biopharma \npartners.  Our Prescription Technology Solutions business invests in innovation and aims to provide access, \nadherence and affordability solutions for over 500 brands across nearly every the rapeutic area.  Our connectivity \nto over 50,000 pharmacies, 750,000 providers and 75% of EHRs in the US helps enable over $5 billion of \nprescription savings for patients each year.  \n \n Prescription Technology Solutions ended fiscal 2021 with solid momentum.  In  the first quarter of fiscal 2022, we \nsaw organic growth in the business and encouraging signs that patient engagement levels and prescription \nvolume trends are continuing to improve.  Our market -leading technology offerings are helping patients get access \nto therapies they need more quickly and efficiently and stay on those therapies longer to get better health \noutcomes.  ", "original_text": "Our connectivity \nto over 50,000 pharmacies, 750,000 providers and 75% of EHRs in the US helps enable over $5 billion of \nprescription savings for patients each year.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a8a9216-8deb-4e14-80bf-7ca55ba8e1b3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d86bca99cf03020665c8681e316da6076124daae4e5e026160542a31505695e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bda6271b-2ebe-4f41-8a68-eb6d43a87a3b", "node_type": "1", "metadata": {"window": "As we grow our non -affiliated and our US oncology provider basis, \nwe accelerate the growth of our oncology assets, such as GPO services, practice ma nagement, site management \nfor clinical research, specialty pharmacy and our value proposition for Ontada, where we're providing real -world \ninsight to both manufacturers and providers.  \n \n Although in its infancy, Ontada's value is being recognized through exp anded partnerships with manufacturers \nsuch as Amgen and its leading role in a large -scale real -world research study known as MYLUNG, which aims to \nimprove treatments and outcomes for non -small cell lung cancer.  \n \n New therapies coming to market can also prov ide additional challenges for patients, providers and our biopharma \npartners.  Our Prescription Technology Solutions business invests in innovation and aims to provide access, \nadherence and affordability solutions for over 500 brands across nearly every the rapeutic area.  Our connectivity \nto over 50,000 pharmacies, 750,000 providers and 75% of EHRs in the US helps enable over $5 billion of \nprescription savings for patients each year.  \n \n Prescription Technology Solutions ended fiscal 2021 with solid momentum.  In  the first quarter of fiscal 2022, we \nsaw organic growth in the business and encouraging signs that patient engagement levels and prescription \nvolume trends are continuing to improve. ", "original_text": "Our Prescription Technology Solutions business invests in innovation and aims to provide access, \nadherence and affordability solutions for over 500 brands across nearly every the rapeutic area. ", "page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc5142cda15dc16002cb20114ea82f7fc534f439a33330353dec3dc0d466f735", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ad863a7-ba66-4131-b0c6-ecdf9e8dc175", "node_type": "1", "metadata": {"window": "New therapies coming to market can also prov ide additional challenges for patients, providers and our biopharma \npartners.  Our Prescription Technology Solutions business invests in innovation and aims to provide access, \nadherence and affordability solutions for over 500 brands across nearly every the rapeutic area.  Our connectivity \nto over 50,000 pharmacies, 750,000 providers and 75% of EHRs in the US helps enable over $5 billion of \nprescription savings for patients each year.  \n \n Prescription Technology Solutions ended fiscal 2021 with solid momentum.  In  the first quarter of fiscal 2022, we \nsaw organic growth in the business and encouraging signs that patient engagement levels and prescription \nvolume trends are continuing to improve.  Our market -leading technology offerings are helping patients get access \nto therapies they need more quickly and efficiently and stay on those therapies longer to get better health \noutcomes.  ", "original_text": "Prescription Technology Solutions ended fiscal 2021 with solid momentum. "}, "hash": "70d6dd0f0b6e79e7d1024d489a7641e65378e6c9f6b704d03b73708796ecc2ac", "class_name": "RelatedNodeInfo"}}, "text": "Our connectivity \nto over 50,000 pharmacies, 750,000 providers and 75% of EHRs in the US helps enable over $5 billion of \nprescription savings for patients each year.  \n \n", "start_char_idx": 3407, "end_char_idx": 3578, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ad863a7-ba66-4131-b0c6-ecdf9e8dc175": {"__data__": {"id_": "9ad863a7-ba66-4131-b0c6-ecdf9e8dc175", "embedding": null, "metadata": {"window": "New therapies coming to market can also prov ide additional challenges for patients, providers and our biopharma \npartners.  Our Prescription Technology Solutions business invests in innovation and aims to provide access, \nadherence and affordability solutions for over 500 brands across nearly every the rapeutic area.  Our connectivity \nto over 50,000 pharmacies, 750,000 providers and 75% of EHRs in the US helps enable over $5 billion of \nprescription savings for patients each year.  \n \n Prescription Technology Solutions ended fiscal 2021 with solid momentum.  In  the first quarter of fiscal 2022, we \nsaw organic growth in the business and encouraging signs that patient engagement levels and prescription \nvolume trends are continuing to improve.  Our market -leading technology offerings are helping patients get access \nto therapies they need more quickly and efficiently and stay on those therapies longer to get better health \noutcomes.  ", "original_text": "Prescription Technology Solutions ended fiscal 2021 with solid momentum. ", "page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a8a9216-8deb-4e14-80bf-7ca55ba8e1b3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d86bca99cf03020665c8681e316da6076124daae4e5e026160542a31505695e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76b30c8c-481a-4e93-a72d-8b2beaf7c138", "node_type": "1", "metadata": {"window": "Although in its infancy, Ontada's value is being recognized through exp anded partnerships with manufacturers \nsuch as Amgen and its leading role in a large -scale real -world research study known as MYLUNG, which aims to \nimprove treatments and outcomes for non -small cell lung cancer.  \n \n New therapies coming to market can also prov ide additional challenges for patients, providers and our biopharma \npartners.  Our Prescription Technology Solutions business invests in innovation and aims to provide access, \nadherence and affordability solutions for over 500 brands across nearly every the rapeutic area.  Our connectivity \nto over 50,000 pharmacies, 750,000 providers and 75% of EHRs in the US helps enable over $5 billion of \nprescription savings for patients each year.  \n \n Prescription Technology Solutions ended fiscal 2021 with solid momentum.  In  the first quarter of fiscal 2022, we \nsaw organic growth in the business and encouraging signs that patient engagement levels and prescription \nvolume trends are continuing to improve.  Our market -leading technology offerings are helping patients get access \nto therapies they need more quickly and efficiently and stay on those therapies longer to get better health \noutcomes.  ", "original_text": "Our connectivity \nto over 50,000 pharmacies, 750,000 providers and 75% of EHRs in the US helps enable over $5 billion of \nprescription savings for patients each year.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d95f989058e8038ac9a7d0dd5aba1efd06c0a3996e2af24fd893a05d2fba40f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "67c33a4a-a5e7-4ce6-b6b1-5832565b8945", "node_type": "1", "metadata": {"window": "Our Prescription Technology Solutions business invests in innovation and aims to provide access, \nadherence and affordability solutions for over 500 brands across nearly every the rapeutic area.  Our connectivity \nto over 50,000 pharmacies, 750,000 providers and 75% of EHRs in the US helps enable over $5 billion of \nprescription savings for patients each year.  \n \n Prescription Technology Solutions ended fiscal 2021 with solid momentum.  In  the first quarter of fiscal 2022, we \nsaw organic growth in the business and encouraging signs that patient engagement levels and prescription \nvolume trends are continuing to improve.  Our market -leading technology offerings are helping patients get access \nto therapies they need more quickly and efficiently and stay on those therapies longer to get better health \noutcomes.  ", "original_text": "In  the first quarter of fiscal 2022, we \nsaw organic growth in the business and encouraging signs that patient engagement levels and prescription \nvolume trends are continuing to improve. "}, "hash": "2ecda87d2f24d858eed90d8052b27bab8784b5cfb42816f853454c7aef6e82a6", "class_name": "RelatedNodeInfo"}}, "text": "Prescription Technology Solutions ended fiscal 2021 with solid momentum. ", "start_char_idx": 3578, "end_char_idx": 3651, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "67c33a4a-a5e7-4ce6-b6b1-5832565b8945": {"__data__": {"id_": "67c33a4a-a5e7-4ce6-b6b1-5832565b8945", "embedding": null, "metadata": {"window": "Our Prescription Technology Solutions business invests in innovation and aims to provide access, \nadherence and affordability solutions for over 500 brands across nearly every the rapeutic area.  Our connectivity \nto over 50,000 pharmacies, 750,000 providers and 75% of EHRs in the US helps enable over $5 billion of \nprescription savings for patients each year.  \n \n Prescription Technology Solutions ended fiscal 2021 with solid momentum.  In  the first quarter of fiscal 2022, we \nsaw organic growth in the business and encouraging signs that patient engagement levels and prescription \nvolume trends are continuing to improve.  Our market -leading technology offerings are helping patients get access \nto therapies they need more quickly and efficiently and stay on those therapies longer to get better health \noutcomes.  ", "original_text": "In  the first quarter of fiscal 2022, we \nsaw organic growth in the business and encouraging signs that patient engagement levels and prescription \nvolume trends are continuing to improve. ", "page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a8a9216-8deb-4e14-80bf-7ca55ba8e1b3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d86bca99cf03020665c8681e316da6076124daae4e5e026160542a31505695e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ad863a7-ba66-4131-b0c6-ecdf9e8dc175", "node_type": "1", "metadata": {"window": "New therapies coming to market can also prov ide additional challenges for patients, providers and our biopharma \npartners.  Our Prescription Technology Solutions business invests in innovation and aims to provide access, \nadherence and affordability solutions for over 500 brands across nearly every the rapeutic area.  Our connectivity \nto over 50,000 pharmacies, 750,000 providers and 75% of EHRs in the US helps enable over $5 billion of \nprescription savings for patients each year.  \n \n Prescription Technology Solutions ended fiscal 2021 with solid momentum.  In  the first quarter of fiscal 2022, we \nsaw organic growth in the business and encouraging signs that patient engagement levels and prescription \nvolume trends are continuing to improve.  Our market -leading technology offerings are helping patients get access \nto therapies they need more quickly and efficiently and stay on those therapies longer to get better health \noutcomes.  ", "original_text": "Prescription Technology Solutions ended fiscal 2021 with solid momentum. ", "page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45555f4a066f57255c2505c67c290343de5a7c6d9ac32e8be50da24e6fe9e942", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a2a34d8-231a-4c63-adb9-c0a3dbff2693", "node_type": "1", "metadata": {"window": "Our connectivity \nto over 50,000 pharmacies, 750,000 providers and 75% of EHRs in the US helps enable over $5 billion of \nprescription savings for patients each year.  \n \n Prescription Technology Solutions ended fiscal 2021 with solid momentum.  In  the first quarter of fiscal 2022, we \nsaw organic growth in the business and encouraging signs that patient engagement levels and prescription \nvolume trends are continuing to improve.  Our market -leading technology offerings are helping patients get access \nto therapies they need more quickly and efficiently and stay on those therapies longer to get better health \noutcomes.  ", "original_text": "Our market -leading technology offerings are helping patients get access \nto therapies they need more quickly and efficiently and stay on those therapies longer to get better health \noutcomes.  "}, "hash": "1b88bd53f059938cedce176e224ea399ac5a0d2c1ca694bcd4445d343e9fee05", "class_name": "RelatedNodeInfo"}}, "text": "In  the first quarter of fiscal 2022, we \nsaw organic growth in the business and encouraging signs that patient engagement levels and prescription \nvolume trends are continuing to improve. ", "start_char_idx": 3651, "end_char_idx": 3840, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a2a34d8-231a-4c63-adb9-c0a3dbff2693": {"__data__": {"id_": "0a2a34d8-231a-4c63-adb9-c0a3dbff2693", "embedding": null, "metadata": {"window": "Our connectivity \nto over 50,000 pharmacies, 750,000 providers and 75% of EHRs in the US helps enable over $5 billion of \nprescription savings for patients each year.  \n \n Prescription Technology Solutions ended fiscal 2021 with solid momentum.  In  the first quarter of fiscal 2022, we \nsaw organic growth in the business and encouraging signs that patient engagement levels and prescription \nvolume trends are continuing to improve.  Our market -leading technology offerings are helping patients get access \nto therapies they need more quickly and efficiently and stay on those therapies longer to get better health \noutcomes.  ", "original_text": "Our market -leading technology offerings are helping patients get access \nto therapies they need more quickly and efficiently and stay on those therapies longer to get better health \noutcomes.  ", "page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5a8a9216-8deb-4e14-80bf-7ca55ba8e1b3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d86bca99cf03020665c8681e316da6076124daae4e5e026160542a31505695e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "67c33a4a-a5e7-4ce6-b6b1-5832565b8945", "node_type": "1", "metadata": {"window": "Our Prescription Technology Solutions business invests in innovation and aims to provide access, \nadherence and affordability solutions for over 500 brands across nearly every the rapeutic area.  Our connectivity \nto over 50,000 pharmacies, 750,000 providers and 75% of EHRs in the US helps enable over $5 billion of \nprescription savings for patients each year.  \n \n Prescription Technology Solutions ended fiscal 2021 with solid momentum.  In  the first quarter of fiscal 2022, we \nsaw organic growth in the business and encouraging signs that patient engagement levels and prescription \nvolume trends are continuing to improve.  Our market -leading technology offerings are helping patients get access \nto therapies they need more quickly and efficiently and stay on those therapies longer to get better health \noutcomes.  ", "original_text": "In  the first quarter of fiscal 2022, we \nsaw organic growth in the business and encouraging signs that patient engagement levels and prescription \nvolume trends are continuing to improve. ", "page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ed09f62a4e79cf268a9459b368076d11a1326ad998073b2d4a2a338740966ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b1c75a6-e455-4acb-8d86-cc1e6d8cbf12", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn closing, we believe that we've made significant strides against our strategic priorities of strengthening the core, \nsimplifying the bu siness and investing in our growth areas of oncology and biopharma services.  Announcing the \nproposed opioid settlement agreement is an important development.  In addition, our strategic intent to exit the \nEuropean region positions us to become a more focuse d and agile company. ", "original_text": "McKesson Corp.  "}, "hash": "22c3d4bc9937b1f6be5ed01d984bcf23e56e5cb176bbd1017c3b09b058380b26", "class_name": "RelatedNodeInfo"}}, "text": "Our market -leading technology offerings are helping patients get access \nto therapies they need more quickly and efficiently and stay on those therapies longer to get better health \noutcomes.  ", "start_char_idx": 3840, "end_char_idx": 4034, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b1c75a6-e455-4acb-8d86-cc1e6d8cbf12": {"__data__": {"id_": "3b1c75a6-e455-4acb-8d86-cc1e6d8cbf12", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn closing, we believe that we've made significant strides against our strategic priorities of strengthening the core, \nsimplifying the bu siness and investing in our growth areas of oncology and biopharma services.  Announcing the \nproposed opioid settlement agreement is an important development.  In addition, our strategic intent to exit the \nEuropean region positions us to become a more focuse d and agile company. ", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c73484e1-29f7-4a39-9410-ade1661a5493", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f7e64d1d6ebff2efb420af7bea56de8b6f298f4d8ee26f1e8eb50023e721ab8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a2a34d8-231a-4c63-adb9-c0a3dbff2693", "node_type": "1", "metadata": {"window": "Our connectivity \nto over 50,000 pharmacies, 750,000 providers and 75% of EHRs in the US helps enable over $5 billion of \nprescription savings for patients each year.  \n \n Prescription Technology Solutions ended fiscal 2021 with solid momentum.  In  the first quarter of fiscal 2022, we \nsaw organic growth in the business and encouraging signs that patient engagement levels and prescription \nvolume trends are continuing to improve.  Our market -leading technology offerings are helping patients get access \nto therapies they need more quickly and efficiently and stay on those therapies longer to get better health \noutcomes.  ", "original_text": "Our market -leading technology offerings are helping patients get access \nto therapies they need more quickly and efficiently and stay on those therapies longer to get better health \noutcomes.  ", "page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9abd8630d51fd370a8edbed00f8c978e99ef03f3359fcf4b07ee84a2ab2ae73b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11235ed8-81e7-4e6a-b0b7-46dbb2e45934", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn closing, we believe that we've made significant strides against our strategic priorities of strengthening the core, \nsimplifying the bu siness and investing in our growth areas of oncology and biopharma services.  Announcing the \nproposed opioid settlement agreement is an important development.  In addition, our strategic intent to exit the \nEuropean region positions us to become a more focuse d and agile company.  We believe both are in the best \ninterest of our employees, in the best interest of our customers and in the best interest of our shareholders.  \n \n", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn closing, we believe that we've made significant strides against our strategic priorities of strengthening the core, \nsimplifying the bu siness and investing in our growth areas of oncology and biopharma services. "}, "hash": "21db4724b4dfe7abecd2d8cf7fb64ee07c201b5b61cbb502f1a289b14f195b10", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "11235ed8-81e7-4e6a-b0b7-46dbb2e45934": {"__data__": {"id_": "11235ed8-81e7-4e6a-b0b7-46dbb2e45934", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn closing, we believe that we've made significant strides against our strategic priorities of strengthening the core, \nsimplifying the bu siness and investing in our growth areas of oncology and biopharma services.  Announcing the \nproposed opioid settlement agreement is an important development.  In addition, our strategic intent to exit the \nEuropean region positions us to become a more focuse d and agile company.  We believe both are in the best \ninterest of our employees, in the best interest of our customers and in the best interest of our shareholders.  \n \n", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn closing, we believe that we've made significant strides against our strategic priorities of strengthening the core, \nsimplifying the bu siness and investing in our growth areas of oncology and biopharma services. ", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c73484e1-29f7-4a39-9410-ade1661a5493", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f7e64d1d6ebff2efb420af7bea56de8b6f298f4d8ee26f1e8eb50023e721ab8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b1c75a6-e455-4acb-8d86-cc1e6d8cbf12", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn closing, we believe that we've made significant strides against our strategic priorities of strengthening the core, \nsimplifying the bu siness and investing in our growth areas of oncology and biopharma services.  Announcing the \nproposed opioid settlement agreement is an important development.  In addition, our strategic intent to exit the \nEuropean region positions us to become a more focuse d and agile company. ", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c4fce2e4b3b873d598733f62f58ab71c598920bd6be2bb4fdc82223f905725c6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ea4d31c-ac5f-48b9-a0d0-cd928e8e4852", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn closing, we believe that we've made significant strides against our strategic priorities of strengthening the core, \nsimplifying the bu siness and investing in our growth areas of oncology and biopharma services.  Announcing the \nproposed opioid settlement agreement is an important development.  In addition, our strategic intent to exit the \nEuropean region positions us to become a more focuse d and agile company.  We believe both are in the best \ninterest of our employees, in the best interest of our customers and in the best interest of our shareholders.  \n \n While it's early in the fiscal year and the pandemic continues to present unknowns, I'm con fident in the \nfundamentals of the business and believe we are positioned well for long -term growth. ", "original_text": "Announcing the \nproposed opioid settlement agreement is an important development. "}, "hash": "20e99f40e7da4cc5c54f1236e09abf429d222edcb98857302b3ce92671b553cf", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn closing, we believe that we've made significant strides against our strategic priorities of strengthening the core, \nsimplifying the bu siness and investing in our growth areas of oncology and biopharma services. ", "start_char_idx": 16, "end_char_idx": 398, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ea4d31c-ac5f-48b9-a0d0-cd928e8e4852": {"__data__": {"id_": "6ea4d31c-ac5f-48b9-a0d0-cd928e8e4852", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn closing, we believe that we've made significant strides against our strategic priorities of strengthening the core, \nsimplifying the bu siness and investing in our growth areas of oncology and biopharma services.  Announcing the \nproposed opioid settlement agreement is an important development.  In addition, our strategic intent to exit the \nEuropean region positions us to become a more focuse d and agile company.  We believe both are in the best \ninterest of our employees, in the best interest of our customers and in the best interest of our shareholders.  \n \n While it's early in the fiscal year and the pandemic continues to present unknowns, I'm con fident in the \nfundamentals of the business and believe we are positioned well for long -term growth. ", "original_text": "Announcing the \nproposed opioid settlement agreement is an important development. ", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c73484e1-29f7-4a39-9410-ade1661a5493", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f7e64d1d6ebff2efb420af7bea56de8b6f298f4d8ee26f1e8eb50023e721ab8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "11235ed8-81e7-4e6a-b0b7-46dbb2e45934", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn closing, we believe that we've made significant strides against our strategic priorities of strengthening the core, \nsimplifying the bu siness and investing in our growth areas of oncology and biopharma services.  Announcing the \nproposed opioid settlement agreement is an important development.  In addition, our strategic intent to exit the \nEuropean region positions us to become a more focuse d and agile company.  We believe both are in the best \ninterest of our employees, in the best interest of our customers and in the best interest of our shareholders.  \n \n", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn closing, we believe that we've made significant strides against our strategic priorities of strengthening the core, \nsimplifying the bu siness and investing in our growth areas of oncology and biopharma services. ", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "58e3b76c95705138543cce1bf86edcd26626c9adf4f26409968055dec9463306", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f57362bb-e9da-44b4-9ea7-45dc118ed78f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn closing, we believe that we've made significant strides against our strategic priorities of strengthening the core, \nsimplifying the bu siness and investing in our growth areas of oncology and biopharma services.  Announcing the \nproposed opioid settlement agreement is an important development.  In addition, our strategic intent to exit the \nEuropean region positions us to become a more focuse d and agile company.  We believe both are in the best \ninterest of our employees, in the best interest of our customers and in the best interest of our shareholders.  \n \n While it's early in the fiscal year and the pandemic continues to present unknowns, I'm con fident in the \nfundamentals of the business and believe we are positioned well for long -term growth.  And we'll look to build upon \nthis momentum over the remainder of our fiscal 2022. ", "original_text": "In addition, our strategic intent to exit the \nEuropean region positions us to become a more focuse d and agile company. "}, "hash": "cb1dfc2ea917280d84ad87ba174623f0f38c80d80a133713d9942789e4135254", "class_name": "RelatedNodeInfo"}}, "text": "Announcing the \nproposed opioid settlement agreement is an important development. ", "start_char_idx": 398, "end_char_idx": 480, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f57362bb-e9da-44b4-9ea7-45dc118ed78f": {"__data__": {"id_": "f57362bb-e9da-44b4-9ea7-45dc118ed78f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn closing, we believe that we've made significant strides against our strategic priorities of strengthening the core, \nsimplifying the bu siness and investing in our growth areas of oncology and biopharma services.  Announcing the \nproposed opioid settlement agreement is an important development.  In addition, our strategic intent to exit the \nEuropean region positions us to become a more focuse d and agile company.  We believe both are in the best \ninterest of our employees, in the best interest of our customers and in the best interest of our shareholders.  \n \n While it's early in the fiscal year and the pandemic continues to present unknowns, I'm con fident in the \nfundamentals of the business and believe we are positioned well for long -term growth.  And we'll look to build upon \nthis momentum over the remainder of our fiscal 2022. ", "original_text": "In addition, our strategic intent to exit the \nEuropean region positions us to become a more focuse d and agile company. ", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c73484e1-29f7-4a39-9410-ade1661a5493", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f7e64d1d6ebff2efb420af7bea56de8b6f298f4d8ee26f1e8eb50023e721ab8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ea4d31c-ac5f-48b9-a0d0-cd928e8e4852", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn closing, we believe that we've made significant strides against our strategic priorities of strengthening the core, \nsimplifying the bu siness and investing in our growth areas of oncology and biopharma services.  Announcing the \nproposed opioid settlement agreement is an important development.  In addition, our strategic intent to exit the \nEuropean region positions us to become a more focuse d and agile company.  We believe both are in the best \ninterest of our employees, in the best interest of our customers and in the best interest of our shareholders.  \n \n While it's early in the fiscal year and the pandemic continues to present unknowns, I'm con fident in the \nfundamentals of the business and believe we are positioned well for long -term growth. ", "original_text": "Announcing the \nproposed opioid settlement agreement is an important development. ", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f6e5b8009b788fa83e11516a4c7246befb492bc79709de1bfdbe512846bf909", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d74b1fd4-9f27-4ea3-b33e-d67b4a8da2dc", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn closing, we believe that we've made significant strides against our strategic priorities of strengthening the core, \nsimplifying the bu siness and investing in our growth areas of oncology and biopharma services.  Announcing the \nproposed opioid settlement agreement is an important development.  In addition, our strategic intent to exit the \nEuropean region positions us to become a more focuse d and agile company.  We believe both are in the best \ninterest of our employees, in the best interest of our customers and in the best interest of our shareholders.  \n \n While it's early in the fiscal year and the pandemic continues to present unknowns, I'm con fident in the \nfundamentals of the business and believe we are positioned well for long -term growth.  And we'll look to build upon \nthis momentum over the remainder of our fiscal 2022.  Thank you for your time.  \n \n", "original_text": "We believe both are in the best \ninterest of our employees, in the best interest of our customers and in the best interest of our shareholders.  \n \n"}, "hash": "0e515e3f48b140b525fea5340b40d16c28dd5bb29aec5b47368f92c7b889fcbf", "class_name": "RelatedNodeInfo"}}, "text": "In addition, our strategic intent to exit the \nEuropean region positions us to become a more focuse d and agile company. ", "start_char_idx": 480, "end_char_idx": 601, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d74b1fd4-9f27-4ea3-b33e-d67b4a8da2dc": {"__data__": {"id_": "d74b1fd4-9f27-4ea3-b33e-d67b4a8da2dc", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn closing, we believe that we've made significant strides against our strategic priorities of strengthening the core, \nsimplifying the bu siness and investing in our growth areas of oncology and biopharma services.  Announcing the \nproposed opioid settlement agreement is an important development.  In addition, our strategic intent to exit the \nEuropean region positions us to become a more focuse d and agile company.  We believe both are in the best \ninterest of our employees, in the best interest of our customers and in the best interest of our shareholders.  \n \n While it's early in the fiscal year and the pandemic continues to present unknowns, I'm con fident in the \nfundamentals of the business and believe we are positioned well for long -term growth.  And we'll look to build upon \nthis momentum over the remainder of our fiscal 2022.  Thank you for your time.  \n \n", "original_text": "We believe both are in the best \ninterest of our employees, in the best interest of our customers and in the best interest of our shareholders.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c73484e1-29f7-4a39-9410-ade1661a5493", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f7e64d1d6ebff2efb420af7bea56de8b6f298f4d8ee26f1e8eb50023e721ab8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f57362bb-e9da-44b4-9ea7-45dc118ed78f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn closing, we believe that we've made significant strides against our strategic priorities of strengthening the core, \nsimplifying the bu siness and investing in our growth areas of oncology and biopharma services.  Announcing the \nproposed opioid settlement agreement is an important development.  In addition, our strategic intent to exit the \nEuropean region positions us to become a more focuse d and agile company.  We believe both are in the best \ninterest of our employees, in the best interest of our customers and in the best interest of our shareholders.  \n \n While it's early in the fiscal year and the pandemic continues to present unknowns, I'm con fident in the \nfundamentals of the business and believe we are positioned well for long -term growth.  And we'll look to build upon \nthis momentum over the remainder of our fiscal 2022. ", "original_text": "In addition, our strategic intent to exit the \nEuropean region positions us to become a more focuse d and agile company. ", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e67eb19a79511005421477f4d1de2cecb2a9ff97bb2c8b3921dab5e3fe6beee2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b762a92a-1fd7-4fc5-bfc3-b0558bba8e83", "node_type": "1", "metadata": {"window": "Announcing the \nproposed opioid settlement agreement is an important development.  In addition, our strategic intent to exit the \nEuropean region positions us to become a more focuse d and agile company.  We believe both are in the best \ninterest of our employees, in the best interest of our customers and in the best interest of our shareholders.  \n \n While it's early in the fiscal year and the pandemic continues to present unknowns, I'm con fident in the \nfundamentals of the business and believe we are positioned well for long -term growth.  And we'll look to build upon \nthis momentum over the remainder of our fiscal 2022.  Thank you for your time.  \n \n And with that, I'll turn it over to you, Britt, for a few additional comments.  \n ", "original_text": "While it's early in the fiscal year and the pandemic continues to present unknowns, I'm con fident in the \nfundamentals of the business and believe we are positioned well for long -term growth. "}, "hash": "019b450f7faa4be6fa94669c02856548215ffe2dbacf66ca12cdb6883db62749", "class_name": "RelatedNodeInfo"}}, "text": "We believe both are in the best \ninterest of our employees, in the best interest of our customers and in the best interest of our shareholders.  \n \n", "start_char_idx": 601, "end_char_idx": 749, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b762a92a-1fd7-4fc5-bfc3-b0558bba8e83": {"__data__": {"id_": "b762a92a-1fd7-4fc5-bfc3-b0558bba8e83", "embedding": null, "metadata": {"window": "Announcing the \nproposed opioid settlement agreement is an important development.  In addition, our strategic intent to exit the \nEuropean region positions us to become a more focuse d and agile company.  We believe both are in the best \ninterest of our employees, in the best interest of our customers and in the best interest of our shareholders.  \n \n While it's early in the fiscal year and the pandemic continues to present unknowns, I'm con fident in the \nfundamentals of the business and believe we are positioned well for long -term growth.  And we'll look to build upon \nthis momentum over the remainder of our fiscal 2022.  Thank you for your time.  \n \n And with that, I'll turn it over to you, Britt, for a few additional comments.  \n ", "original_text": "While it's early in the fiscal year and the pandemic continues to present unknowns, I'm con fident in the \nfundamentals of the business and believe we are positioned well for long -term growth. ", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c73484e1-29f7-4a39-9410-ade1661a5493", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f7e64d1d6ebff2efb420af7bea56de8b6f298f4d8ee26f1e8eb50023e721ab8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d74b1fd4-9f27-4ea3-b33e-d67b4a8da2dc", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn closing, we believe that we've made significant strides against our strategic priorities of strengthening the core, \nsimplifying the bu siness and investing in our growth areas of oncology and biopharma services.  Announcing the \nproposed opioid settlement agreement is an important development.  In addition, our strategic intent to exit the \nEuropean region positions us to become a more focuse d and agile company.  We believe both are in the best \ninterest of our employees, in the best interest of our customers and in the best interest of our shareholders.  \n \n While it's early in the fiscal year and the pandemic continues to present unknowns, I'm con fident in the \nfundamentals of the business and believe we are positioned well for long -term growth.  And we'll look to build upon \nthis momentum over the remainder of our fiscal 2022.  Thank you for your time.  \n \n", "original_text": "We believe both are in the best \ninterest of our employees, in the best interest of our customers and in the best interest of our shareholders.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65aaebf4bb3bed83288ee3674c5f832657fc73862fd8d4978dbbf3b23325ecfe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d7a845d7-b00c-4a62-8085-ebacf58be99a", "node_type": "1", "metadata": {"window": "In addition, our strategic intent to exit the \nEuropean region positions us to become a more focuse d and agile company.  We believe both are in the best \ninterest of our employees, in the best interest of our customers and in the best interest of our shareholders.  \n \n While it's early in the fiscal year and the pandemic continues to present unknowns, I'm con fident in the \nfundamentals of the business and believe we are positioned well for long -term growth.  And we'll look to build upon \nthis momentum over the remainder of our fiscal 2022.  Thank you for your time.  \n \n And with that, I'll turn it over to you, Britt, for a few additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n", "original_text": "And we'll look to build upon \nthis momentum over the remainder of our fiscal 2022. "}, "hash": "b508bfe6efed704bdafb0aa226809a8852655e189ff69124455053abc6104bf4", "class_name": "RelatedNodeInfo"}}, "text": "While it's early in the fiscal year and the pandemic continues to present unknowns, I'm con fident in the \nfundamentals of the business and believe we are positioned well for long -term growth. ", "start_char_idx": 749, "end_char_idx": 943, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d7a845d7-b00c-4a62-8085-ebacf58be99a": {"__data__": {"id_": "d7a845d7-b00c-4a62-8085-ebacf58be99a", "embedding": null, "metadata": {"window": "In addition, our strategic intent to exit the \nEuropean region positions us to become a more focuse d and agile company.  We believe both are in the best \ninterest of our employees, in the best interest of our customers and in the best interest of our shareholders.  \n \n While it's early in the fiscal year and the pandemic continues to present unknowns, I'm con fident in the \nfundamentals of the business and believe we are positioned well for long -term growth.  And we'll look to build upon \nthis momentum over the remainder of our fiscal 2022.  Thank you for your time.  \n \n And with that, I'll turn it over to you, Britt, for a few additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n", "original_text": "And we'll look to build upon \nthis momentum over the remainder of our fiscal 2022. ", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c73484e1-29f7-4a39-9410-ade1661a5493", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f7e64d1d6ebff2efb420af7bea56de8b6f298f4d8ee26f1e8eb50023e721ab8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b762a92a-1fd7-4fc5-bfc3-b0558bba8e83", "node_type": "1", "metadata": {"window": "Announcing the \nproposed opioid settlement agreement is an important development.  In addition, our strategic intent to exit the \nEuropean region positions us to become a more focuse d and agile company.  We believe both are in the best \ninterest of our employees, in the best interest of our customers and in the best interest of our shareholders.  \n \n While it's early in the fiscal year and the pandemic continues to present unknowns, I'm con fident in the \nfundamentals of the business and believe we are positioned well for long -term growth.  And we'll look to build upon \nthis momentum over the remainder of our fiscal 2022.  Thank you for your time.  \n \n And with that, I'll turn it over to you, Britt, for a few additional comments.  \n ", "original_text": "While it's early in the fiscal year and the pandemic continues to present unknowns, I'm con fident in the \nfundamentals of the business and believe we are positioned well for long -term growth. ", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "390892e3a2d3c917c72d484155444c7554547bd72d39aa41ad30ade81f8c228e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e63e32ae-6671-47db-9ea8-25eff69ebc10", "node_type": "1", "metadata": {"window": "We believe both are in the best \ninterest of our employees, in the best interest of our customers and in the best interest of our shareholders.  \n \n While it's early in the fiscal year and the pandemic continues to present unknowns, I'm con fident in the \nfundamentals of the business and believe we are positioned well for long -term growth.  And we'll look to build upon \nthis momentum over the remainder of our fiscal 2022.  Thank you for your time.  \n \n And with that, I'll turn it over to you, Britt, for a few additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone. ", "original_text": "Thank you for your time.  \n \n"}, "hash": "4cef8b9d61efbf2158ceb77022257f6f79084ab9ee7a57aead20bf7bc404ebcd", "class_name": "RelatedNodeInfo"}}, "text": "And we'll look to build upon \nthis momentum over the remainder of our fiscal 2022. ", "start_char_idx": 943, "end_char_idx": 1026, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e63e32ae-6671-47db-9ea8-25eff69ebc10": {"__data__": {"id_": "e63e32ae-6671-47db-9ea8-25eff69ebc10", "embedding": null, "metadata": {"window": "We believe both are in the best \ninterest of our employees, in the best interest of our customers and in the best interest of our shareholders.  \n \n While it's early in the fiscal year and the pandemic continues to present unknowns, I'm con fident in the \nfundamentals of the business and believe we are positioned well for long -term growth.  And we'll look to build upon \nthis momentum over the remainder of our fiscal 2022.  Thank you for your time.  \n \n And with that, I'll turn it over to you, Britt, for a few additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone. ", "original_text": "Thank you for your time.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c73484e1-29f7-4a39-9410-ade1661a5493", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f7e64d1d6ebff2efb420af7bea56de8b6f298f4d8ee26f1e8eb50023e721ab8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d7a845d7-b00c-4a62-8085-ebacf58be99a", "node_type": "1", "metadata": {"window": "In addition, our strategic intent to exit the \nEuropean region positions us to become a more focuse d and agile company.  We believe both are in the best \ninterest of our employees, in the best interest of our customers and in the best interest of our shareholders.  \n \n While it's early in the fiscal year and the pandemic continues to present unknowns, I'm con fident in the \nfundamentals of the business and believe we are positioned well for long -term growth.  And we'll look to build upon \nthis momentum over the remainder of our fiscal 2022.  Thank you for your time.  \n \n And with that, I'll turn it over to you, Britt, for a few additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n", "original_text": "And we'll look to build upon \nthis momentum over the remainder of our fiscal 2022. ", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e344447e1723c8815f2ec899df207bb15a3b9d67239a544bddaec1a8329807c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74474007-e75e-41f1-87cb-72d693461369", "node_type": "1", "metadata": {"window": "While it's early in the fiscal year and the pandemic continues to present unknowns, I'm con fident in the \nfundamentals of the business and believe we are positioned well for long -term growth.  And we'll look to build upon \nthis momentum over the remainder of our fiscal 2022.  Thank you for your time.  \n \n And with that, I'll turn it over to you, Britt, for a few additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone.  I'm pleased to speak with you today about our strong first \nquarter results, which reflect the importance of the products and services McKesson delivers, the execution and \nmomentum across our business, which includes supporting the US government's COVID -19 domestic and \ninternational vaccine and kitting efforts, and the recovery of prescription v olumes and patient visits impacted by \nthe COVID pandemic in the prior year.  \n \n", "original_text": "And with that, I'll turn it over to you, Britt, for a few additional comments.  \n "}, "hash": "61f68b5341c09abedba79de43ea7656c987ddf1905cb46bb6462b425f919a274", "class_name": "RelatedNodeInfo"}}, "text": "Thank you for your time.  \n \n", "start_char_idx": 1026, "end_char_idx": 1055, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74474007-e75e-41f1-87cb-72d693461369": {"__data__": {"id_": "74474007-e75e-41f1-87cb-72d693461369", "embedding": null, "metadata": {"window": "While it's early in the fiscal year and the pandemic continues to present unknowns, I'm con fident in the \nfundamentals of the business and believe we are positioned well for long -term growth.  And we'll look to build upon \nthis momentum over the remainder of our fiscal 2022.  Thank you for your time.  \n \n And with that, I'll turn it over to you, Britt, for a few additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone.  I'm pleased to speak with you today about our strong first \nquarter results, which reflect the importance of the products and services McKesson delivers, the execution and \nmomentum across our business, which includes supporting the US government's COVID -19 domestic and \ninternational vaccine and kitting efforts, and the recovery of prescription v olumes and patient visits impacted by \nthe COVID pandemic in the prior year.  \n \n", "original_text": "And with that, I'll turn it over to you, Britt, for a few additional comments.  \n ", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c73484e1-29f7-4a39-9410-ade1661a5493", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f7e64d1d6ebff2efb420af7bea56de8b6f298f4d8ee26f1e8eb50023e721ab8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e63e32ae-6671-47db-9ea8-25eff69ebc10", "node_type": "1", "metadata": {"window": "We believe both are in the best \ninterest of our employees, in the best interest of our customers and in the best interest of our shareholders.  \n \n While it's early in the fiscal year and the pandemic continues to present unknowns, I'm con fident in the \nfundamentals of the business and believe we are positioned well for long -term growth.  And we'll look to build upon \nthis momentum over the remainder of our fiscal 2022.  Thank you for your time.  \n \n And with that, I'll turn it over to you, Britt, for a few additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone. ", "original_text": "Thank you for your time.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6696058af25b1cd9ad7e3a16f4a09030c23b4eb4ebf0d05df82cb2453a8279f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29e97fdc-769c-4074-b2ec-ab82326ac8ee", "node_type": "1", "metadata": {"window": "And we'll look to build upon \nthis momentum over the remainder of our fiscal 2022.  Thank you for your time.  \n \n And with that, I'll turn it over to you, Britt, for a few additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone.  I'm pleased to speak with you today about our strong first \nquarter results, which reflect the importance of the products and services McKesson delivers, the execution and \nmomentum across our business, which includes supporting the US government's COVID -19 domestic and \ninternational vaccine and kitting efforts, and the recovery of prescription v olumes and patient visits impacted by \nthe COVID pandemic in the prior year.  \n \n I'll begin my remarks today by sharing an update on our European businesses, followed by our first quarter \nresults, and I'll close with an update for our fiscal 2022 outlook. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n"}, "hash": "42da0e605ace4ad3f39200655b6dc4fda3080a02bc9c7d86cc45e7e63f1214d0", "class_name": "RelatedNodeInfo"}}, "text": "And with that, I'll turn it over to you, Britt, for a few additional comments.  \n ", "start_char_idx": 1055, "end_char_idx": 1137, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29e97fdc-769c-4074-b2ec-ab82326ac8ee": {"__data__": {"id_": "29e97fdc-769c-4074-b2ec-ab82326ac8ee", "embedding": null, "metadata": {"window": "And we'll look to build upon \nthis momentum over the remainder of our fiscal 2022.  Thank you for your time.  \n \n And with that, I'll turn it over to you, Britt, for a few additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone.  I'm pleased to speak with you today about our strong first \nquarter results, which reflect the importance of the products and services McKesson delivers, the execution and \nmomentum across our business, which includes supporting the US government's COVID -19 domestic and \ninternational vaccine and kitting efforts, and the recovery of prescription v olumes and patient visits impacted by \nthe COVID pandemic in the prior year.  \n \n I'll begin my remarks today by sharing an update on our European businesses, followed by our first quarter \nresults, and I'll close with an update for our fiscal 2022 outlook. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c73484e1-29f7-4a39-9410-ade1661a5493", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f7e64d1d6ebff2efb420af7bea56de8b6f298f4d8ee26f1e8eb50023e721ab8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74474007-e75e-41f1-87cb-72d693461369", "node_type": "1", "metadata": {"window": "While it's early in the fiscal year and the pandemic continues to present unknowns, I'm con fident in the \nfundamentals of the business and believe we are positioned well for long -term growth.  And we'll look to build upon \nthis momentum over the remainder of our fiscal 2022.  Thank you for your time.  \n \n And with that, I'll turn it over to you, Britt, for a few additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone.  I'm pleased to speak with you today about our strong first \nquarter results, which reflect the importance of the products and services McKesson delivers, the execution and \nmomentum across our business, which includes supporting the US government's COVID -19 domestic and \ninternational vaccine and kitting efforts, and the recovery of prescription v olumes and patient visits impacted by \nthe COVID pandemic in the prior year.  \n \n", "original_text": "And with that, I'll turn it over to you, Britt, for a few additional comments.  \n ", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc2f739a06ace558e63daa5817a20ce792ee4347a58d2ae2ccb300e66da76aa0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c49c284b-892a-489d-a78c-edcabd441a3e", "node_type": "1", "metadata": {"window": "Thank you for your time.  \n \n And with that, I'll turn it over to you, Britt, for a few additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone.  I'm pleased to speak with you today about our strong first \nquarter results, which reflect the importance of the products and services McKesson delivers, the execution and \nmomentum across our business, which includes supporting the US government's COVID -19 domestic and \ninternational vaccine and kitting efforts, and the recovery of prescription v olumes and patient visits impacted by \nthe COVID pandemic in the prior year.  \n \n I'll begin my remarks today by sharing an update on our European businesses, followed by our first quarter \nresults, and I'll close with an update for our fiscal 2022 outlook.  The summary of our first quarter results and \nupdated guidance assumptions can be found in our earnings slide presentation, which is posted on the Investors \nsection of our website.  \n \n", "original_text": "Thank you, Brian, and good afternoon, everyone. "}, "hash": "4bd3271c1f08ad041fb6407f6abf2fddba450e3404b32ce6cdb52b1920325f03", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n", "start_char_idx": 1137, "end_char_idx": 1495, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c49c284b-892a-489d-a78c-edcabd441a3e": {"__data__": {"id_": "c49c284b-892a-489d-a78c-edcabd441a3e", "embedding": null, "metadata": {"window": "Thank you for your time.  \n \n And with that, I'll turn it over to you, Britt, for a few additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone.  I'm pleased to speak with you today about our strong first \nquarter results, which reflect the importance of the products and services McKesson delivers, the execution and \nmomentum across our business, which includes supporting the US government's COVID -19 domestic and \ninternational vaccine and kitting efforts, and the recovery of prescription v olumes and patient visits impacted by \nthe COVID pandemic in the prior year.  \n \n I'll begin my remarks today by sharing an update on our European businesses, followed by our first quarter \nresults, and I'll close with an update for our fiscal 2022 outlook.  The summary of our first quarter results and \nupdated guidance assumptions can be found in our earnings slide presentation, which is posted on the Investors \nsection of our website.  \n \n", "original_text": "Thank you, Brian, and good afternoon, everyone. ", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c73484e1-29f7-4a39-9410-ade1661a5493", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f7e64d1d6ebff2efb420af7bea56de8b6f298f4d8ee26f1e8eb50023e721ab8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29e97fdc-769c-4074-b2ec-ab82326ac8ee", "node_type": "1", "metadata": {"window": "And we'll look to build upon \nthis momentum over the remainder of our fiscal 2022.  Thank you for your time.  \n \n And with that, I'll turn it over to you, Britt, for a few additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone.  I'm pleased to speak with you today about our strong first \nquarter results, which reflect the importance of the products and services McKesson delivers, the execution and \nmomentum across our business, which includes supporting the US government's COVID -19 domestic and \ninternational vaccine and kitting efforts, and the recovery of prescription v olumes and patient visits impacted by \nthe COVID pandemic in the prior year.  \n \n I'll begin my remarks today by sharing an update on our European businesses, followed by our first quarter \nresults, and I'll close with an update for our fiscal 2022 outlook. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "01949af6fc50f1c532a46ea4fa9071ea82b5a53188ed5f8ee955d96f5812567d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fbc8833c-9f50-4b42-9162-234f8eff4809", "node_type": "1", "metadata": {"window": "And with that, I'll turn it over to you, Britt, for a few additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone.  I'm pleased to speak with you today about our strong first \nquarter results, which reflect the importance of the products and services McKesson delivers, the execution and \nmomentum across our business, which includes supporting the US government's COVID -19 domestic and \ninternational vaccine and kitting efforts, and the recovery of prescription v olumes and patient visits impacted by \nthe COVID pandemic in the prior year.  \n \n I'll begin my remarks today by sharing an update on our European businesses, followed by our first quarter \nresults, and I'll close with an update for our fiscal 2022 outlook.  The summary of our first quarter results and \nupdated guidance assumptions can be found in our earnings slide presentation, which is posted on the Investors \nsection of our website.  \n \n In early July, we announced an agreement to sell our European businesses in Fra nce, Italy, Ireland, Portugal, \nBelgium and Slovenia to the PHOENIX Group. ", "original_text": "I'm pleased to speak with you today about our strong first \nquarter results, which reflect the importance of the products and services McKesson delivers, the execution and \nmomentum across our business, which includes supporting the US government's COVID -19 domestic and \ninternational vaccine and kitting efforts, and the recovery of prescription v olumes and patient visits impacted by \nthe COVID pandemic in the prior year.  \n \n"}, "hash": "e44027371499611778fb7dea99721c4db47f9bfef5d7bc82f68ccc15c732cb75", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, Brian, and good afternoon, everyone. ", "start_char_idx": 1495, "end_char_idx": 1543, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fbc8833c-9f50-4b42-9162-234f8eff4809": {"__data__": {"id_": "fbc8833c-9f50-4b42-9162-234f8eff4809", "embedding": null, "metadata": {"window": "And with that, I'll turn it over to you, Britt, for a few additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone.  I'm pleased to speak with you today about our strong first \nquarter results, which reflect the importance of the products and services McKesson delivers, the execution and \nmomentum across our business, which includes supporting the US government's COVID -19 domestic and \ninternational vaccine and kitting efforts, and the recovery of prescription v olumes and patient visits impacted by \nthe COVID pandemic in the prior year.  \n \n I'll begin my remarks today by sharing an update on our European businesses, followed by our first quarter \nresults, and I'll close with an update for our fiscal 2022 outlook.  The summary of our first quarter results and \nupdated guidance assumptions can be found in our earnings slide presentation, which is posted on the Investors \nsection of our website.  \n \n In early July, we announced an agreement to sell our European businesses in Fra nce, Italy, Ireland, Portugal, \nBelgium and Slovenia to the PHOENIX Group. ", "original_text": "I'm pleased to speak with you today about our strong first \nquarter results, which reflect the importance of the products and services McKesson delivers, the execution and \nmomentum across our business, which includes supporting the US government's COVID -19 domestic and \ninternational vaccine and kitting efforts, and the recovery of prescription v olumes and patient visits impacted by \nthe COVID pandemic in the prior year.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c73484e1-29f7-4a39-9410-ade1661a5493", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f7e64d1d6ebff2efb420af7bea56de8b6f298f4d8ee26f1e8eb50023e721ab8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c49c284b-892a-489d-a78c-edcabd441a3e", "node_type": "1", "metadata": {"window": "Thank you for your time.  \n \n And with that, I'll turn it over to you, Britt, for a few additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone.  I'm pleased to speak with you today about our strong first \nquarter results, which reflect the importance of the products and services McKesson delivers, the execution and \nmomentum across our business, which includes supporting the US government's COVID -19 domestic and \ninternational vaccine and kitting efforts, and the recovery of prescription v olumes and patient visits impacted by \nthe COVID pandemic in the prior year.  \n \n I'll begin my remarks today by sharing an update on our European businesses, followed by our first quarter \nresults, and I'll close with an update for our fiscal 2022 outlook.  The summary of our first quarter results and \nupdated guidance assumptions can be found in our earnings slide presentation, which is posted on the Investors \nsection of our website.  \n \n", "original_text": "Thank you, Brian, and good afternoon, everyone. ", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c39a9e5e99f70c1b6111d55ba432276dd8029221769981fa36981c13afad43ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e7ebb4a-23cf-488e-96a9-b51104f3dc14", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone.  I'm pleased to speak with you today about our strong first \nquarter results, which reflect the importance of the products and services McKesson delivers, the execution and \nmomentum across our business, which includes supporting the US government's COVID -19 domestic and \ninternational vaccine and kitting efforts, and the recovery of prescription v olumes and patient visits impacted by \nthe COVID pandemic in the prior year.  \n \n I'll begin my remarks today by sharing an update on our European businesses, followed by our first quarter \nresults, and I'll close with an update for our fiscal 2022 outlook.  The summary of our first quarter results and \nupdated guidance assumptions can be found in our earnings slide presentation, which is posted on the Investors \nsection of our website.  \n \n In early July, we announced an agreement to sell our European businesses in Fra nce, Italy, Ireland, Portugal, \nBelgium and Slovenia to the PHOENIX Group.  This transaction includes our German AG headquarters in \nStuttgart and our European shared service center in Lithuania. ", "original_text": "I'll begin my remarks today by sharing an update on our European businesses, followed by our first quarter \nresults, and I'll close with an update for our fiscal 2022 outlook. "}, "hash": "80028182d7b81f70b0d8ab61b85f43af84b2f7c82f91c97df444b0e03de1b14b", "class_name": "RelatedNodeInfo"}}, "text": "I'm pleased to speak with you today about our strong first \nquarter results, which reflect the importance of the products and services McKesson delivers, the execution and \nmomentum across our business, which includes supporting the US government's COVID -19 domestic and \ninternational vaccine and kitting efforts, and the recovery of prescription v olumes and patient visits impacted by \nthe COVID pandemic in the prior year.  \n \n", "start_char_idx": 1543, "end_char_idx": 1975, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e7ebb4a-23cf-488e-96a9-b51104f3dc14": {"__data__": {"id_": "7e7ebb4a-23cf-488e-96a9-b51104f3dc14", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone.  I'm pleased to speak with you today about our strong first \nquarter results, which reflect the importance of the products and services McKesson delivers, the execution and \nmomentum across our business, which includes supporting the US government's COVID -19 domestic and \ninternational vaccine and kitting efforts, and the recovery of prescription v olumes and patient visits impacted by \nthe COVID pandemic in the prior year.  \n \n I'll begin my remarks today by sharing an update on our European businesses, followed by our first quarter \nresults, and I'll close with an update for our fiscal 2022 outlook.  The summary of our first quarter results and \nupdated guidance assumptions can be found in our earnings slide presentation, which is posted on the Investors \nsection of our website.  \n \n In early July, we announced an agreement to sell our European businesses in Fra nce, Italy, Ireland, Portugal, \nBelgium and Slovenia to the PHOENIX Group.  This transaction includes our German AG headquarters in \nStuttgart and our European shared service center in Lithuania. ", "original_text": "I'll begin my remarks today by sharing an update on our European businesses, followed by our first quarter \nresults, and I'll close with an update for our fiscal 2022 outlook. ", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c73484e1-29f7-4a39-9410-ade1661a5493", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f7e64d1d6ebff2efb420af7bea56de8b6f298f4d8ee26f1e8eb50023e721ab8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fbc8833c-9f50-4b42-9162-234f8eff4809", "node_type": "1", "metadata": {"window": "And with that, I'll turn it over to you, Britt, for a few additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone.  I'm pleased to speak with you today about our strong first \nquarter results, which reflect the importance of the products and services McKesson delivers, the execution and \nmomentum across our business, which includes supporting the US government's COVID -19 domestic and \ninternational vaccine and kitting efforts, and the recovery of prescription v olumes and patient visits impacted by \nthe COVID pandemic in the prior year.  \n \n I'll begin my remarks today by sharing an update on our European businesses, followed by our first quarter \nresults, and I'll close with an update for our fiscal 2022 outlook.  The summary of our first quarter results and \nupdated guidance assumptions can be found in our earnings slide presentation, which is posted on the Investors \nsection of our website.  \n \n In early July, we announced an agreement to sell our European businesses in Fra nce, Italy, Ireland, Portugal, \nBelgium and Slovenia to the PHOENIX Group. ", "original_text": "I'm pleased to speak with you today about our strong first \nquarter results, which reflect the importance of the products and services McKesson delivers, the execution and \nmomentum across our business, which includes supporting the US government's COVID -19 domestic and \ninternational vaccine and kitting efforts, and the recovery of prescription v olumes and patient visits impacted by \nthe COVID pandemic in the prior year.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "123e68f91eb013f2372d0381887eb066f5dd5c6049f9b6816a0287ce885c6159", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97d296fb-c5a7-4ecb-9bba-e6c8ef339995", "node_type": "1", "metadata": {"window": "Thank you, Brian, and good afternoon, everyone.  I'm pleased to speak with you today about our strong first \nquarter results, which reflect the importance of the products and services McKesson delivers, the execution and \nmomentum across our business, which includes supporting the US government's COVID -19 domestic and \ninternational vaccine and kitting efforts, and the recovery of prescription v olumes and patient visits impacted by \nthe COVID pandemic in the prior year.  \n \n I'll begin my remarks today by sharing an update on our European businesses, followed by our first quarter \nresults, and I'll close with an update for our fiscal 2022 outlook.  The summary of our first quarter results and \nupdated guidance assumptions can be found in our earnings slide presentation, which is posted on the Investors \nsection of our website.  \n \n In early July, we announced an agreement to sell our European businesses in Fra nce, Italy, Ireland, Portugal, \nBelgium and Slovenia to the PHOENIX Group.  This transaction includes our German AG headquarters in \nStuttgart and our European shared service center in Lithuania.  The purchase price for the transaction is \napproximately US$1.5 billion. ", "original_text": "The summary of our first quarter results and \nupdated guidance assumptions can be found in our earnings slide presentation, which is posted on the Investors \nsection of our website.  \n \n"}, "hash": "3fb247bc5bb0fcad8d6c4b683966064a254afff12e3330bbad15a5df0590ca8b", "class_name": "RelatedNodeInfo"}}, "text": "I'll begin my remarks today by sharing an update on our European businesses, followed by our first quarter \nresults, and I'll close with an update for our fiscal 2022 outlook. ", "start_char_idx": 1975, "end_char_idx": 2151, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "97d296fb-c5a7-4ecb-9bba-e6c8ef339995": {"__data__": {"id_": "97d296fb-c5a7-4ecb-9bba-e6c8ef339995", "embedding": null, "metadata": {"window": "Thank you, Brian, and good afternoon, everyone.  I'm pleased to speak with you today about our strong first \nquarter results, which reflect the importance of the products and services McKesson delivers, the execution and \nmomentum across our business, which includes supporting the US government's COVID -19 domestic and \ninternational vaccine and kitting efforts, and the recovery of prescription v olumes and patient visits impacted by \nthe COVID pandemic in the prior year.  \n \n I'll begin my remarks today by sharing an update on our European businesses, followed by our first quarter \nresults, and I'll close with an update for our fiscal 2022 outlook.  The summary of our first quarter results and \nupdated guidance assumptions can be found in our earnings slide presentation, which is posted on the Investors \nsection of our website.  \n \n In early July, we announced an agreement to sell our European businesses in Fra nce, Italy, Ireland, Portugal, \nBelgium and Slovenia to the PHOENIX Group.  This transaction includes our German AG headquarters in \nStuttgart and our European shared service center in Lithuania.  The purchase price for the transaction is \napproximately US$1.5 billion. ", "original_text": "The summary of our first quarter results and \nupdated guidance assumptions can be found in our earnings slide presentation, which is posted on the Investors \nsection of our website.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c73484e1-29f7-4a39-9410-ade1661a5493", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f7e64d1d6ebff2efb420af7bea56de8b6f298f4d8ee26f1e8eb50023e721ab8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e7ebb4a-23cf-488e-96a9-b51104f3dc14", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone.  I'm pleased to speak with you today about our strong first \nquarter results, which reflect the importance of the products and services McKesson delivers, the execution and \nmomentum across our business, which includes supporting the US government's COVID -19 domestic and \ninternational vaccine and kitting efforts, and the recovery of prescription v olumes and patient visits impacted by \nthe COVID pandemic in the prior year.  \n \n I'll begin my remarks today by sharing an update on our European businesses, followed by our first quarter \nresults, and I'll close with an update for our fiscal 2022 outlook.  The summary of our first quarter results and \nupdated guidance assumptions can be found in our earnings slide presentation, which is posted on the Investors \nsection of our website.  \n \n In early July, we announced an agreement to sell our European businesses in Fra nce, Italy, Ireland, Portugal, \nBelgium and Slovenia to the PHOENIX Group.  This transaction includes our German AG headquarters in \nStuttgart and our European shared service center in Lithuania. ", "original_text": "I'll begin my remarks today by sharing an update on our European businesses, followed by our first quarter \nresults, and I'll close with an update for our fiscal 2022 outlook. ", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "304f72ef3e0b9d6a1838c3a0e55d9668c59833fc80548230d4dc703a55d53bfe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6968186c-3690-4b61-a640-38113eddee23", "node_type": "1", "metadata": {"window": "I'm pleased to speak with you today about our strong first \nquarter results, which reflect the importance of the products and services McKesson delivers, the execution and \nmomentum across our business, which includes supporting the US government's COVID -19 domestic and \ninternational vaccine and kitting efforts, and the recovery of prescription v olumes and patient visits impacted by \nthe COVID pandemic in the prior year.  \n \n I'll begin my remarks today by sharing an update on our European businesses, followed by our first quarter \nresults, and I'll close with an update for our fiscal 2022 outlook.  The summary of our first quarter results and \nupdated guidance assumptions can be found in our earnings slide presentation, which is posted on the Investors \nsection of our website.  \n \n In early July, we announced an agreement to sell our European businesses in Fra nce, Italy, Ireland, Portugal, \nBelgium and Slovenia to the PHOENIX Group.  This transaction includes our German AG headquarters in \nStuttgart and our European shared service center in Lithuania.  The purchase price for the transaction is \napproximately US$1.5 billion.  The ultimate proceeds from this transaction are subject to certain adjustments \nunder the agreement. ", "original_text": "In early July, we announced an agreement to sell our European businesses in Fra nce, Italy, Ireland, Portugal, \nBelgium and Slovenia to the PHOENIX Group. "}, "hash": "b9afe4df07826d6b4b8b6bdb1034017d1b9830740061feb5695f399ccd705589", "class_name": "RelatedNodeInfo"}}, "text": "The summary of our first quarter results and \nupdated guidance assumptions can be found in our earnings slide presentation, which is posted on the Investors \nsection of our website.  \n \n", "start_char_idx": 2151, "end_char_idx": 2337, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6968186c-3690-4b61-a640-38113eddee23": {"__data__": {"id_": "6968186c-3690-4b61-a640-38113eddee23", "embedding": null, "metadata": {"window": "I'm pleased to speak with you today about our strong first \nquarter results, which reflect the importance of the products and services McKesson delivers, the execution and \nmomentum across our business, which includes supporting the US government's COVID -19 domestic and \ninternational vaccine and kitting efforts, and the recovery of prescription v olumes and patient visits impacted by \nthe COVID pandemic in the prior year.  \n \n I'll begin my remarks today by sharing an update on our European businesses, followed by our first quarter \nresults, and I'll close with an update for our fiscal 2022 outlook.  The summary of our first quarter results and \nupdated guidance assumptions can be found in our earnings slide presentation, which is posted on the Investors \nsection of our website.  \n \n In early July, we announced an agreement to sell our European businesses in Fra nce, Italy, Ireland, Portugal, \nBelgium and Slovenia to the PHOENIX Group.  This transaction includes our German AG headquarters in \nStuttgart and our European shared service center in Lithuania.  The purchase price for the transaction is \napproximately US$1.5 billion.  The ultimate proceeds from this transaction are subject to certain adjustments \nunder the agreement. ", "original_text": "In early July, we announced an agreement to sell our European businesses in Fra nce, Italy, Ireland, Portugal, \nBelgium and Slovenia to the PHOENIX Group. ", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c73484e1-29f7-4a39-9410-ade1661a5493", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f7e64d1d6ebff2efb420af7bea56de8b6f298f4d8ee26f1e8eb50023e721ab8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97d296fb-c5a7-4ecb-9bba-e6c8ef339995", "node_type": "1", "metadata": {"window": "Thank you, Brian, and good afternoon, everyone.  I'm pleased to speak with you today about our strong first \nquarter results, which reflect the importance of the products and services McKesson delivers, the execution and \nmomentum across our business, which includes supporting the US government's COVID -19 domestic and \ninternational vaccine and kitting efforts, and the recovery of prescription v olumes and patient visits impacted by \nthe COVID pandemic in the prior year.  \n \n I'll begin my remarks today by sharing an update on our European businesses, followed by our first quarter \nresults, and I'll close with an update for our fiscal 2022 outlook.  The summary of our first quarter results and \nupdated guidance assumptions can be found in our earnings slide presentation, which is posted on the Investors \nsection of our website.  \n \n In early July, we announced an agreement to sell our European businesses in Fra nce, Italy, Ireland, Portugal, \nBelgium and Slovenia to the PHOENIX Group.  This transaction includes our German AG headquarters in \nStuttgart and our European shared service center in Lithuania.  The purchase price for the transaction is \napproximately US$1.5 billion. ", "original_text": "The summary of our first quarter results and \nupdated guidance assumptions can be found in our earnings slide presentation, which is posted on the Investors \nsection of our website.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f843d069dca8783ebe1bacb249f140ac865482472b6404bacc7f0f323ab886f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "116cbcdc-4bee-44d4-8041-afe9be4e1272", "node_type": "1", "metadata": {"window": "I'll begin my remarks today by sharing an update on our European businesses, followed by our first quarter \nresults, and I'll close with an update for our fiscal 2022 outlook.  The summary of our first quarter results and \nupdated guidance assumptions can be found in our earnings slide presentation, which is posted on the Investors \nsection of our website.  \n \n In early July, we announced an agreement to sell our European businesses in Fra nce, Italy, Ireland, Portugal, \nBelgium and Slovenia to the PHOENIX Group.  This transaction includes our German AG headquarters in \nStuttgart and our European shared service center in Lithuania.  The purchase price for the transaction is \napproximately US$1.5 billion.  The ultimate proceeds from this transaction are subject to certain adjustments \nunder the agreement.  Therefore, the proceeds may differ from the purchase price.  \n \n", "original_text": "This transaction includes our German AG headquarters in \nStuttgart and our European shared service center in Lithuania. "}, "hash": "aa70addc799e5be417820b426528687f8332385cf216e84d9c9c4d19350f86a7", "class_name": "RelatedNodeInfo"}}, "text": "In early July, we announced an agreement to sell our European businesses in Fra nce, Italy, Ireland, Portugal, \nBelgium and Slovenia to the PHOENIX Group. ", "start_char_idx": 2337, "end_char_idx": 2492, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "116cbcdc-4bee-44d4-8041-afe9be4e1272": {"__data__": {"id_": "116cbcdc-4bee-44d4-8041-afe9be4e1272", "embedding": null, "metadata": {"window": "I'll begin my remarks today by sharing an update on our European businesses, followed by our first quarter \nresults, and I'll close with an update for our fiscal 2022 outlook.  The summary of our first quarter results and \nupdated guidance assumptions can be found in our earnings slide presentation, which is posted on the Investors \nsection of our website.  \n \n In early July, we announced an agreement to sell our European businesses in Fra nce, Italy, Ireland, Portugal, \nBelgium and Slovenia to the PHOENIX Group.  This transaction includes our German AG headquarters in \nStuttgart and our European shared service center in Lithuania.  The purchase price for the transaction is \napproximately US$1.5 billion.  The ultimate proceeds from this transaction are subject to certain adjustments \nunder the agreement.  Therefore, the proceeds may differ from the purchase price.  \n \n", "original_text": "This transaction includes our German AG headquarters in \nStuttgart and our European shared service center in Lithuania. ", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c73484e1-29f7-4a39-9410-ade1661a5493", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f7e64d1d6ebff2efb420af7bea56de8b6f298f4d8ee26f1e8eb50023e721ab8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6968186c-3690-4b61-a640-38113eddee23", "node_type": "1", "metadata": {"window": "I'm pleased to speak with you today about our strong first \nquarter results, which reflect the importance of the products and services McKesson delivers, the execution and \nmomentum across our business, which includes supporting the US government's COVID -19 domestic and \ninternational vaccine and kitting efforts, and the recovery of prescription v olumes and patient visits impacted by \nthe COVID pandemic in the prior year.  \n \n I'll begin my remarks today by sharing an update on our European businesses, followed by our first quarter \nresults, and I'll close with an update for our fiscal 2022 outlook.  The summary of our first quarter results and \nupdated guidance assumptions can be found in our earnings slide presentation, which is posted on the Investors \nsection of our website.  \n \n In early July, we announced an agreement to sell our European businesses in Fra nce, Italy, Ireland, Portugal, \nBelgium and Slovenia to the PHOENIX Group.  This transaction includes our German AG headquarters in \nStuttgart and our European shared service center in Lithuania.  The purchase price for the transaction is \napproximately US$1.5 billion.  The ultimate proceeds from this transaction are subject to certain adjustments \nunder the agreement. ", "original_text": "In early July, we announced an agreement to sell our European businesses in Fra nce, Italy, Ireland, Portugal, \nBelgium and Slovenia to the PHOENIX Group. ", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "917122f9d858645e88b233eb8217d9cc85696cd183668f176f3aaba687e26dbd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e2c87cc3-9b9c-4f73-b1d0-aff1e10807c4", "node_type": "1", "metadata": {"window": "The summary of our first quarter results and \nupdated guidance assumptions can be found in our earnings slide presentation, which is posted on the Investors \nsection of our website.  \n \n In early July, we announced an agreement to sell our European businesses in Fra nce, Italy, Ireland, Portugal, \nBelgium and Slovenia to the PHOENIX Group.  This transaction includes our German AG headquarters in \nStuttgart and our European shared service center in Lithuania.  The purchase price for the transaction is \napproximately US$1.5 billion.  The ultimate proceeds from this transaction are subject to certain adjustments \nunder the agreement.  Therefore, the proceeds may differ from the purchase price.  \n \n The assets involved in this transaction contributed approximately $12 billion in reven ue and $75 million in \nadjusted operating profit in fiscal 2021. ", "original_text": "The purchase price for the transaction is \napproximately US$1.5 billion. "}, "hash": "c2fa607f4aff30b1c83692ef46d58bb4587377650db5b6cdef0bbd96e01a4bd8", "class_name": "RelatedNodeInfo"}}, "text": "This transaction includes our German AG headquarters in \nStuttgart and our European shared service center in Lithuania. ", "start_char_idx": 2492, "end_char_idx": 2612, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e2c87cc3-9b9c-4f73-b1d0-aff1e10807c4": {"__data__": {"id_": "e2c87cc3-9b9c-4f73-b1d0-aff1e10807c4", "embedding": null, "metadata": {"window": "The summary of our first quarter results and \nupdated guidance assumptions can be found in our earnings slide presentation, which is posted on the Investors \nsection of our website.  \n \n In early July, we announced an agreement to sell our European businesses in Fra nce, Italy, Ireland, Portugal, \nBelgium and Slovenia to the PHOENIX Group.  This transaction includes our German AG headquarters in \nStuttgart and our European shared service center in Lithuania.  The purchase price for the transaction is \napproximately US$1.5 billion.  The ultimate proceeds from this transaction are subject to certain adjustments \nunder the agreement.  Therefore, the proceeds may differ from the purchase price.  \n \n The assets involved in this transaction contributed approximately $12 billion in reven ue and $75 million in \nadjusted operating profit in fiscal 2021. ", "original_text": "The purchase price for the transaction is \napproximately US$1.5 billion. ", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c73484e1-29f7-4a39-9410-ade1661a5493", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f7e64d1d6ebff2efb420af7bea56de8b6f298f4d8ee26f1e8eb50023e721ab8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "116cbcdc-4bee-44d4-8041-afe9be4e1272", "node_type": "1", "metadata": {"window": "I'll begin my remarks today by sharing an update on our European businesses, followed by our first quarter \nresults, and I'll close with an update for our fiscal 2022 outlook.  The summary of our first quarter results and \nupdated guidance assumptions can be found in our earnings slide presentation, which is posted on the Investors \nsection of our website.  \n \n In early July, we announced an agreement to sell our European businesses in Fra nce, Italy, Ireland, Portugal, \nBelgium and Slovenia to the PHOENIX Group.  This transaction includes our German AG headquarters in \nStuttgart and our European shared service center in Lithuania.  The purchase price for the transaction is \napproximately US$1.5 billion.  The ultimate proceeds from this transaction are subject to certain adjustments \nunder the agreement.  Therefore, the proceeds may differ from the purchase price.  \n \n", "original_text": "This transaction includes our German AG headquarters in \nStuttgart and our European shared service center in Lithuania. ", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4c443bdbb2fcb9cb772d25dfe9d64098d6a8243fd4fc5c12cf7a8a0d6e71d41", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71502514-5dd9-478f-97f0-41468b22eb06", "node_type": "1", "metadata": {"window": "In early July, we announced an agreement to sell our European businesses in Fra nce, Italy, Ireland, Portugal, \nBelgium and Slovenia to the PHOENIX Group.  This transaction includes our German AG headquarters in \nStuttgart and our European shared service center in Lithuania.  The purchase price for the transaction is \napproximately US$1.5 billion.  The ultimate proceeds from this transaction are subject to certain adjustments \nunder the agreement.  Therefore, the proceeds may differ from the purchase price.  \n \n The assets involved in this transaction contributed approximately $12 billion in reven ue and $75 million in \nadjusted operating profit in fiscal 2021.  We've determined that this transaction shall not qualify for discontinued \noperations. ", "original_text": "The ultimate proceeds from this transaction are subject to certain adjustments \nunder the agreement. "}, "hash": "2e5f584c7f91ce6e7970a1317bc3425d2c683c97f1a8ebb7c075a0f83dbecb4f", "class_name": "RelatedNodeInfo"}}, "text": "The purchase price for the transaction is \napproximately US$1.5 billion. ", "start_char_idx": 2612, "end_char_idx": 2685, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71502514-5dd9-478f-97f0-41468b22eb06": {"__data__": {"id_": "71502514-5dd9-478f-97f0-41468b22eb06", "embedding": null, "metadata": {"window": "In early July, we announced an agreement to sell our European businesses in Fra nce, Italy, Ireland, Portugal, \nBelgium and Slovenia to the PHOENIX Group.  This transaction includes our German AG headquarters in \nStuttgart and our European shared service center in Lithuania.  The purchase price for the transaction is \napproximately US$1.5 billion.  The ultimate proceeds from this transaction are subject to certain adjustments \nunder the agreement.  Therefore, the proceeds may differ from the purchase price.  \n \n The assets involved in this transaction contributed approximately $12 billion in reven ue and $75 million in \nadjusted operating profit in fiscal 2021.  We've determined that this transaction shall not qualify for discontinued \noperations. ", "original_text": "The ultimate proceeds from this transaction are subject to certain adjustments \nunder the agreement. ", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c73484e1-29f7-4a39-9410-ade1661a5493", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f7e64d1d6ebff2efb420af7bea56de8b6f298f4d8ee26f1e8eb50023e721ab8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e2c87cc3-9b9c-4f73-b1d0-aff1e10807c4", "node_type": "1", "metadata": {"window": "The summary of our first quarter results and \nupdated guidance assumptions can be found in our earnings slide presentation, which is posted on the Investors \nsection of our website.  \n \n In early July, we announced an agreement to sell our European businesses in Fra nce, Italy, Ireland, Portugal, \nBelgium and Slovenia to the PHOENIX Group.  This transaction includes our German AG headquarters in \nStuttgart and our European shared service center in Lithuania.  The purchase price for the transaction is \napproximately US$1.5 billion.  The ultimate proceeds from this transaction are subject to certain adjustments \nunder the agreement.  Therefore, the proceeds may differ from the purchase price.  \n \n The assets involved in this transaction contributed approximately $12 billion in reven ue and $75 million in \nadjusted operating profit in fiscal 2021. ", "original_text": "The purchase price for the transaction is \napproximately US$1.5 billion. ", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "76a7adc65908b0c8c4b0688f2a11002649068fe6a9a8b5e0c7f16c08d788118b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bcd066fa-aecd-434f-a73c-e50f98492cfa", "node_type": "1", "metadata": {"window": "This transaction includes our German AG headquarters in \nStuttgart and our European shared service center in Lithuania.  The purchase price for the transaction is \napproximately US$1.5 billion.  The ultimate proceeds from this transaction are subject to certain adjustments \nunder the agreement.  Therefore, the proceeds may differ from the purchase price.  \n \n The assets involved in this transaction contributed approximately $12 billion in reven ue and $75 million in \nadjusted operating profit in fiscal 2021.  We've determined that this transaction shall not qualify for discontinued \noperations.  The net assets included in the transaction we've classified as held for sale. ", "original_text": "Therefore, the proceeds may differ from the purchase price.  \n \n"}, "hash": "6cbc8428de9094fd73fa684b1c4b4e0288f10de354e1c19833044149fc5c3d80", "class_name": "RelatedNodeInfo"}}, "text": "The ultimate proceeds from this transaction are subject to certain adjustments \nunder the agreement. ", "start_char_idx": 2685, "end_char_idx": 2786, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bcd066fa-aecd-434f-a73c-e50f98492cfa": {"__data__": {"id_": "bcd066fa-aecd-434f-a73c-e50f98492cfa", "embedding": null, "metadata": {"window": "This transaction includes our German AG headquarters in \nStuttgart and our European shared service center in Lithuania.  The purchase price for the transaction is \napproximately US$1.5 billion.  The ultimate proceeds from this transaction are subject to certain adjustments \nunder the agreement.  Therefore, the proceeds may differ from the purchase price.  \n \n The assets involved in this transaction contributed approximately $12 billion in reven ue and $75 million in \nadjusted operating profit in fiscal 2021.  We've determined that this transaction shall not qualify for discontinued \noperations.  The net assets included in the transaction we've classified as held for sale. ", "original_text": "Therefore, the proceeds may differ from the purchase price.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c73484e1-29f7-4a39-9410-ade1661a5493", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f7e64d1d6ebff2efb420af7bea56de8b6f298f4d8ee26f1e8eb50023e721ab8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71502514-5dd9-478f-97f0-41468b22eb06", "node_type": "1", "metadata": {"window": "In early July, we announced an agreement to sell our European businesses in Fra nce, Italy, Ireland, Portugal, \nBelgium and Slovenia to the PHOENIX Group.  This transaction includes our German AG headquarters in \nStuttgart and our European shared service center in Lithuania.  The purchase price for the transaction is \napproximately US$1.5 billion.  The ultimate proceeds from this transaction are subject to certain adjustments \nunder the agreement.  Therefore, the proceeds may differ from the purchase price.  \n \n The assets involved in this transaction contributed approximately $12 billion in reven ue and $75 million in \nadjusted operating profit in fiscal 2021.  We've determined that this transaction shall not qualify for discontinued \noperations. ", "original_text": "The ultimate proceeds from this transaction are subject to certain adjustments \nunder the agreement. ", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d67d4c82964f573086317c00e212c54695059f419e3caa148326defbbf1ed09", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d951b41-9c17-42f8-9a9f-16d8774cc151", "node_type": "1", "metadata": {"window": "The purchase price for the transaction is \napproximately US$1.5 billion.  The ultimate proceeds from this transaction are subject to certain adjustments \nunder the agreement.  Therefore, the proceeds may differ from the purchase price.  \n \n The assets involved in this transaction contributed approximately $12 billion in reven ue and $75 million in \nadjusted operating profit in fiscal 2021.  We've determined that this transaction shall not qualify for discontinued \noperations.  The net assets included in the transaction we've classified as held for sale.  The held -for-sale \naccounting  is effective at the start of our second quarter of this fiscal year.  \n \n", "original_text": "The assets involved in this transaction contributed approximately $12 billion in reven ue and $75 million in \nadjusted operating profit in fiscal 2021. "}, "hash": "be8875917be34a2f81d1467a0e8fdc030c18111a67489a5d5bc7c8df04e0c105", "class_name": "RelatedNodeInfo"}}, "text": "Therefore, the proceeds may differ from the purchase price.  \n \n", "start_char_idx": 2786, "end_char_idx": 2850, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d951b41-9c17-42f8-9a9f-16d8774cc151": {"__data__": {"id_": "5d951b41-9c17-42f8-9a9f-16d8774cc151", "embedding": null, "metadata": {"window": "The purchase price for the transaction is \napproximately US$1.5 billion.  The ultimate proceeds from this transaction are subject to certain adjustments \nunder the agreement.  Therefore, the proceeds may differ from the purchase price.  \n \n The assets involved in this transaction contributed approximately $12 billion in reven ue and $75 million in \nadjusted operating profit in fiscal 2021.  We've determined that this transaction shall not qualify for discontinued \noperations.  The net assets included in the transaction we've classified as held for sale.  The held -for-sale \naccounting  is effective at the start of our second quarter of this fiscal year.  \n \n", "original_text": "The assets involved in this transaction contributed approximately $12 billion in reven ue and $75 million in \nadjusted operating profit in fiscal 2021. ", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c73484e1-29f7-4a39-9410-ade1661a5493", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f7e64d1d6ebff2efb420af7bea56de8b6f298f4d8ee26f1e8eb50023e721ab8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bcd066fa-aecd-434f-a73c-e50f98492cfa", "node_type": "1", "metadata": {"window": "This transaction includes our German AG headquarters in \nStuttgart and our European shared service center in Lithuania.  The purchase price for the transaction is \napproximately US$1.5 billion.  The ultimate proceeds from this transaction are subject to certain adjustments \nunder the agreement.  Therefore, the proceeds may differ from the purchase price.  \n \n The assets involved in this transaction contributed approximately $12 billion in reven ue and $75 million in \nadjusted operating profit in fiscal 2021.  We've determined that this transaction shall not qualify for discontinued \noperations.  The net assets included in the transaction we've classified as held for sale. ", "original_text": "Therefore, the proceeds may differ from the purchase price.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57d581b1a0957aac49d46af284498ec4908529a67ffae586874f28b99d0cb2de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "669e40df-56a7-406e-bdb6-78911d59393d", "node_type": "1", "metadata": {"window": "The ultimate proceeds from this transaction are subject to certain adjustments \nunder the agreement.  Therefore, the proceeds may differ from the purchase price.  \n \n The assets involved in this transaction contributed approximately $12 billion in reven ue and $75 million in \nadjusted operating profit in fiscal 2021.  We've determined that this transaction shall not qualify for discontinued \noperations.  The net assets included in the transaction we've classified as held for sale.  The held -for-sale \naccounting  is effective at the start of our second quarter of this fiscal year.  \n \n We will re -measure the net assets to the lower carrying amount or fair value, less cost to sell, and we estimate \nthat this will result in a GAAP -only charge of between $500 million to $ 700 million in our second quarter of fiscal \n2022. ", "original_text": "We've determined that this transaction shall not qualify for discontinued \noperations. "}, "hash": "f8b58e1c0a922c2f74065e7e00f606e7bfa98075dc33d38d35b1884190ad5c5f", "class_name": "RelatedNodeInfo"}}, "text": "The assets involved in this transaction contributed approximately $12 billion in reven ue and $75 million in \nadjusted operating profit in fiscal 2021. ", "start_char_idx": 2850, "end_char_idx": 3002, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "669e40df-56a7-406e-bdb6-78911d59393d": {"__data__": {"id_": "669e40df-56a7-406e-bdb6-78911d59393d", "embedding": null, "metadata": {"window": "The ultimate proceeds from this transaction are subject to certain adjustments \nunder the agreement.  Therefore, the proceeds may differ from the purchase price.  \n \n The assets involved in this transaction contributed approximately $12 billion in reven ue and $75 million in \nadjusted operating profit in fiscal 2021.  We've determined that this transaction shall not qualify for discontinued \noperations.  The net assets included in the transaction we've classified as held for sale.  The held -for-sale \naccounting  is effective at the start of our second quarter of this fiscal year.  \n \n We will re -measure the net assets to the lower carrying amount or fair value, less cost to sell, and we estimate \nthat this will result in a GAAP -only charge of between $500 million to $ 700 million in our second quarter of fiscal \n2022. ", "original_text": "We've determined that this transaction shall not qualify for discontinued \noperations. ", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c73484e1-29f7-4a39-9410-ade1661a5493", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f7e64d1d6ebff2efb420af7bea56de8b6f298f4d8ee26f1e8eb50023e721ab8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d951b41-9c17-42f8-9a9f-16d8774cc151", "node_type": "1", "metadata": {"window": "The purchase price for the transaction is \napproximately US$1.5 billion.  The ultimate proceeds from this transaction are subject to certain adjustments \nunder the agreement.  Therefore, the proceeds may differ from the purchase price.  \n \n The assets involved in this transaction contributed approximately $12 billion in reven ue and $75 million in \nadjusted operating profit in fiscal 2021.  We've determined that this transaction shall not qualify for discontinued \noperations.  The net assets included in the transaction we've classified as held for sale.  The held -for-sale \naccounting  is effective at the start of our second quarter of this fiscal year.  \n \n", "original_text": "The assets involved in this transaction contributed approximately $12 billion in reven ue and $75 million in \nadjusted operating profit in fiscal 2021. ", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "157690d0576e52ca786148c7e66068c6b8843fa581b0d80154906c91eb2e890a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4a3ccbd-9dd1-4171-82d3-2646896a0e56", "node_type": "1", "metadata": {"window": "Therefore, the proceeds may differ from the purchase price.  \n \n The assets involved in this transaction contributed approximately $12 billion in reven ue and $75 million in \nadjusted operating profit in fiscal 2021.  We've determined that this transaction shall not qualify for discontinued \noperations.  The net assets included in the transaction we've classified as held for sale.  The held -for-sale \naccounting  is effective at the start of our second quarter of this fiscal year.  \n \n We will re -measure the net assets to the lower carrying amount or fair value, less cost to sell, and we estimate \nthat this will result in a GAAP -only charge of between $500 million to $ 700 million in our second quarter of fiscal \n2022.  Due to held -for-sale accounting treatment, we'll discontinue recording depreciation and amortization on the \nassets involved in the transaction.  \n \n", "original_text": "The net assets included in the transaction we've classified as held for sale. "}, "hash": "d97eb3a0814cd6459fe0e81bd3d83499f3af21d68c2748411f0ef1bd99bcfe48", "class_name": "RelatedNodeInfo"}}, "text": "We've determined that this transaction shall not qualify for discontinued \noperations. ", "start_char_idx": 3002, "end_char_idx": 3089, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4a3ccbd-9dd1-4171-82d3-2646896a0e56": {"__data__": {"id_": "a4a3ccbd-9dd1-4171-82d3-2646896a0e56", "embedding": null, "metadata": {"window": "Therefore, the proceeds may differ from the purchase price.  \n \n The assets involved in this transaction contributed approximately $12 billion in reven ue and $75 million in \nadjusted operating profit in fiscal 2021.  We've determined that this transaction shall not qualify for discontinued \noperations.  The net assets included in the transaction we've classified as held for sale.  The held -for-sale \naccounting  is effective at the start of our second quarter of this fiscal year.  \n \n We will re -measure the net assets to the lower carrying amount or fair value, less cost to sell, and we estimate \nthat this will result in a GAAP -only charge of between $500 million to $ 700 million in our second quarter of fiscal \n2022.  Due to held -for-sale accounting treatment, we'll discontinue recording depreciation and amortization on the \nassets involved in the transaction.  \n \n", "original_text": "The net assets included in the transaction we've classified as held for sale. ", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c73484e1-29f7-4a39-9410-ade1661a5493", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f7e64d1d6ebff2efb420af7bea56de8b6f298f4d8ee26f1e8eb50023e721ab8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "669e40df-56a7-406e-bdb6-78911d59393d", "node_type": "1", "metadata": {"window": "The ultimate proceeds from this transaction are subject to certain adjustments \nunder the agreement.  Therefore, the proceeds may differ from the purchase price.  \n \n The assets involved in this transaction contributed approximately $12 billion in reven ue and $75 million in \nadjusted operating profit in fiscal 2021.  We've determined that this transaction shall not qualify for discontinued \noperations.  The net assets included in the transaction we've classified as held for sale.  The held -for-sale \naccounting  is effective at the start of our second quarter of this fiscal year.  \n \n We will re -measure the net assets to the lower carrying amount or fair value, less cost to sell, and we estimate \nthat this will result in a GAAP -only charge of between $500 million to $ 700 million in our second quarter of fiscal \n2022. ", "original_text": "We've determined that this transaction shall not qualify for discontinued \noperations. ", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1540419341f1efb32b4bdffd7e8761c09a1765e5b20b0bf6c67bb22c4395e99c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "52a70626-1056-4609-87cb-0b2648aa166e", "node_type": "1", "metadata": {"window": "The assets involved in this transaction contributed approximately $12 billion in reven ue and $75 million in \nadjusted operating profit in fiscal 2021.  We've determined that this transaction shall not qualify for discontinued \noperations.  The net assets included in the transaction we've classified as held for sale.  The held -for-sale \naccounting  is effective at the start of our second quarter of this fiscal year.  \n \n We will re -measure the net assets to the lower carrying amount or fair value, less cost to sell, and we estimate \nthat this will result in a GAAP -only charge of between $500 million to $ 700 million in our second quarter of fiscal \n2022.  Due to held -for-sale accounting treatment, we'll discontinue recording depreciation and amortization on the \nassets involved in the transaction.  \n \n As a result of the held -for-sale accounting, we would guide t o approximately $0.26 adjusted earnings accretion in \nfiscal 2022. ", "original_text": "The held -for-sale \naccounting  is effective at the start of our second quarter of this fiscal year.  \n \n"}, "hash": "92ecb132094c1a082e5a072fe6d7d993e73291b04fbefe6ca7d506b938073636", "class_name": "RelatedNodeInfo"}}, "text": "The net assets included in the transaction we've classified as held for sale. ", "start_char_idx": 3089, "end_char_idx": 3167, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "52a70626-1056-4609-87cb-0b2648aa166e": {"__data__": {"id_": "52a70626-1056-4609-87cb-0b2648aa166e", "embedding": null, "metadata": {"window": "The assets involved in this transaction contributed approximately $12 billion in reven ue and $75 million in \nadjusted operating profit in fiscal 2021.  We've determined that this transaction shall not qualify for discontinued \noperations.  The net assets included in the transaction we've classified as held for sale.  The held -for-sale \naccounting  is effective at the start of our second quarter of this fiscal year.  \n \n We will re -measure the net assets to the lower carrying amount or fair value, less cost to sell, and we estimate \nthat this will result in a GAAP -only charge of between $500 million to $ 700 million in our second quarter of fiscal \n2022.  Due to held -for-sale accounting treatment, we'll discontinue recording depreciation and amortization on the \nassets involved in the transaction.  \n \n As a result of the held -for-sale accounting, we would guide t o approximately $0.26 adjusted earnings accretion in \nfiscal 2022. ", "original_text": "The held -for-sale \naccounting  is effective at the start of our second quarter of this fiscal year.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c73484e1-29f7-4a39-9410-ade1661a5493", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f7e64d1d6ebff2efb420af7bea56de8b6f298f4d8ee26f1e8eb50023e721ab8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4a3ccbd-9dd1-4171-82d3-2646896a0e56", "node_type": "1", "metadata": {"window": "Therefore, the proceeds may differ from the purchase price.  \n \n The assets involved in this transaction contributed approximately $12 billion in reven ue and $75 million in \nadjusted operating profit in fiscal 2021.  We've determined that this transaction shall not qualify for discontinued \noperations.  The net assets included in the transaction we've classified as held for sale.  The held -for-sale \naccounting  is effective at the start of our second quarter of this fiscal year.  \n \n We will re -measure the net assets to the lower carrying amount or fair value, less cost to sell, and we estimate \nthat this will result in a GAAP -only charge of between $500 million to $ 700 million in our second quarter of fiscal \n2022.  Due to held -for-sale accounting treatment, we'll discontinue recording depreciation and amortization on the \nassets involved in the transaction.  \n \n", "original_text": "The net assets included in the transaction we've classified as held for sale. ", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cfe91232b94253231a223b0d1b21b444b4e476fd0bf548982bdd313362fda5a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e798b718-8dc1-4e3a-a001-c3458b9f0809", "node_type": "1", "metadata": {"window": "We've determined that this transaction shall not qualify for discontinued \noperations.  The net assets included in the transaction we've classified as held for sale.  The held -for-sale \naccounting  is effective at the start of our second quarter of this fiscal year.  \n \n We will re -measure the net assets to the lower carrying amount or fair value, less cost to sell, and we estimate \nthat this will result in a GAAP -only charge of between $500 million to $ 700 million in our second quarter of fiscal \n2022.  Due to held -for-sale accounting treatment, we'll discontinue recording depreciation and amortization on the \nassets involved in the transaction.  \n \n As a result of the held -for-sale accounting, we would guide t o approximately $0.26 adjusted earnings accretion in \nfiscal 2022.  This will be included in our updated outlook, and I'll outline those later in my remarks. ", "original_text": "We will re -measure the net assets to the lower carrying amount or fair value, less cost to sell, and we estimate \nthat this will result in a GAAP -only charge of between $500 million to $ 700 million in our second quarter of fiscal \n2022. "}, "hash": "dff3a08e84cc2aa2a700c19b8f049dacf0d8c32f2e5e81a71974bc44dbf3633d", "class_name": "RelatedNodeInfo"}}, "text": "The held -for-sale \naccounting  is effective at the start of our second quarter of this fiscal year.  \n \n", "start_char_idx": 3167, "end_char_idx": 3272, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e798b718-8dc1-4e3a-a001-c3458b9f0809": {"__data__": {"id_": "e798b718-8dc1-4e3a-a001-c3458b9f0809", "embedding": null, "metadata": {"window": "We've determined that this transaction shall not qualify for discontinued \noperations.  The net assets included in the transaction we've classified as held for sale.  The held -for-sale \naccounting  is effective at the start of our second quarter of this fiscal year.  \n \n We will re -measure the net assets to the lower carrying amount or fair value, less cost to sell, and we estimate \nthat this will result in a GAAP -only charge of between $500 million to $ 700 million in our second quarter of fiscal \n2022.  Due to held -for-sale accounting treatment, we'll discontinue recording depreciation and amortization on the \nassets involved in the transaction.  \n \n As a result of the held -for-sale accounting, we would guide t o approximately $0.26 adjusted earnings accretion in \nfiscal 2022.  This will be included in our updated outlook, and I'll outline those later in my remarks. ", "original_text": "We will re -measure the net assets to the lower carrying amount or fair value, less cost to sell, and we estimate \nthat this will result in a GAAP -only charge of between $500 million to $ 700 million in our second quarter of fiscal \n2022. ", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c73484e1-29f7-4a39-9410-ade1661a5493", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f7e64d1d6ebff2efb420af7bea56de8b6f298f4d8ee26f1e8eb50023e721ab8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "52a70626-1056-4609-87cb-0b2648aa166e", "node_type": "1", "metadata": {"window": "The assets involved in this transaction contributed approximately $12 billion in reven ue and $75 million in \nadjusted operating profit in fiscal 2021.  We've determined that this transaction shall not qualify for discontinued \noperations.  The net assets included in the transaction we've classified as held for sale.  The held -for-sale \naccounting  is effective at the start of our second quarter of this fiscal year.  \n \n We will re -measure the net assets to the lower carrying amount or fair value, less cost to sell, and we estimate \nthat this will result in a GAAP -only charge of between $500 million to $ 700 million in our second quarter of fiscal \n2022.  Due to held -for-sale accounting treatment, we'll discontinue recording depreciation and amortization on the \nassets involved in the transaction.  \n \n As a result of the held -for-sale accounting, we would guide t o approximately $0.26 adjusted earnings accretion in \nfiscal 2022. ", "original_text": "The held -for-sale \naccounting  is effective at the start of our second quarter of this fiscal year.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d491518b97dbe3d6a9fe3ea5a674be662eefa98cfdad600f24072a575aa5083c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb502cf6-9c2d-4506-9e91-20b68970e9d4", "node_type": "1", "metadata": {"window": "The net assets included in the transaction we've classified as held for sale.  The held -for-sale \naccounting  is effective at the start of our second quarter of this fiscal year.  \n \n We will re -measure the net assets to the lower carrying amount or fair value, less cost to sell, and we estimate \nthat this will result in a GAAP -only charge of between $500 million to $ 700 million in our second quarter of fiscal \n2022.  Due to held -for-sale accounting treatment, we'll discontinue recording depreciation and amortization on the \nassets involved in the transaction.  \n \n As a result of the held -for-sale accounting, we would guide t o approximately $0.26 adjusted earnings accretion in \nfiscal 2022.  This will be included in our updated outlook, and I'll outline those later in my remarks.  McKesson will \noperate these businesses and record revenue and income until the transaction is closed , which is expected to \noccur in fiscal 2023. ", "original_text": "Due to held -for-sale accounting treatment, we'll discontinue recording depreciation and amortization on the \nassets involved in the transaction.  \n \n"}, "hash": "520c18849acbe68799836cddbd12e069dc7a040bd8f3beb722daffbabcf12342", "class_name": "RelatedNodeInfo"}}, "text": "We will re -measure the net assets to the lower carrying amount or fair value, less cost to sell, and we estimate \nthat this will result in a GAAP -only charge of between $500 million to $ 700 million in our second quarter of fiscal \n2022. ", "start_char_idx": 3272, "end_char_idx": 3512, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb502cf6-9c2d-4506-9e91-20b68970e9d4": {"__data__": {"id_": "cb502cf6-9c2d-4506-9e91-20b68970e9d4", "embedding": null, "metadata": {"window": "The net assets included in the transaction we've classified as held for sale.  The held -for-sale \naccounting  is effective at the start of our second quarter of this fiscal year.  \n \n We will re -measure the net assets to the lower carrying amount or fair value, less cost to sell, and we estimate \nthat this will result in a GAAP -only charge of between $500 million to $ 700 million in our second quarter of fiscal \n2022.  Due to held -for-sale accounting treatment, we'll discontinue recording depreciation and amortization on the \nassets involved in the transaction.  \n \n As a result of the held -for-sale accounting, we would guide t o approximately $0.26 adjusted earnings accretion in \nfiscal 2022.  This will be included in our updated outlook, and I'll outline those later in my remarks.  McKesson will \noperate these businesses and record revenue and income until the transaction is closed , which is expected to \noccur in fiscal 2023. ", "original_text": "Due to held -for-sale accounting treatment, we'll discontinue recording depreciation and amortization on the \nassets involved in the transaction.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c73484e1-29f7-4a39-9410-ade1661a5493", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f7e64d1d6ebff2efb420af7bea56de8b6f298f4d8ee26f1e8eb50023e721ab8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e798b718-8dc1-4e3a-a001-c3458b9f0809", "node_type": "1", "metadata": {"window": "We've determined that this transaction shall not qualify for discontinued \noperations.  The net assets included in the transaction we've classified as held for sale.  The held -for-sale \naccounting  is effective at the start of our second quarter of this fiscal year.  \n \n We will re -measure the net assets to the lower carrying amount or fair value, less cost to sell, and we estimate \nthat this will result in a GAAP -only charge of between $500 million to $ 700 million in our second quarter of fiscal \n2022.  Due to held -for-sale accounting treatment, we'll discontinue recording depreciation and amortization on the \nassets involved in the transaction.  \n \n As a result of the held -for-sale accounting, we would guide t o approximately $0.26 adjusted earnings accretion in \nfiscal 2022.  This will be included in our updated outlook, and I'll outline those later in my remarks. ", "original_text": "We will re -measure the net assets to the lower carrying amount or fair value, less cost to sell, and we estimate \nthat this will result in a GAAP -only charge of between $500 million to $ 700 million in our second quarter of fiscal \n2022. ", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b398f2045f84f92ce2ef2124c2e67ac1177c6ac754e1af9a0aed6576ce1eb195", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "443ebb30-f426-4b10-8cda-a17a945f0421", "node_type": "1", "metadata": {"window": "The held -for-sale \naccounting  is effective at the start of our second quarter of this fiscal year.  \n \n We will re -measure the net assets to the lower carrying amount or fair value, less cost to sell, and we estimate \nthat this will result in a GAAP -only charge of between $500 million to $ 700 million in our second quarter of fiscal \n2022.  Due to held -for-sale accounting treatment, we'll discontinue recording depreciation and amortization on the \nassets involved in the transaction.  \n \n As a result of the held -for-sale accounting, we would guide t o approximately $0.26 adjusted earnings accretion in \nfiscal 2022.  This will be included in our updated outlook, and I'll outline those later in my remarks.  McKesson will \noperate these businesses and record revenue and income until the transaction is closed , which is expected to \noccur in fiscal 2023.  We're committed to exploring strategic alternatives for our remaining European businesses, \nand we'll provide details on the plans for the remaining businesses as they become available.  \n ", "original_text": "As a result of the held -for-sale accounting, we would guide t o approximately $0.26 adjusted earnings accretion in \nfiscal 2022. "}, "hash": "40b69f33d72cef70a1fe5c202e761538cce20bd23138c9e7c66d6f27edef2541", "class_name": "RelatedNodeInfo"}}, "text": "Due to held -for-sale accounting treatment, we'll discontinue recording depreciation and amortization on the \nassets involved in the transaction.  \n \n", "start_char_idx": 3512, "end_char_idx": 3662, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "443ebb30-f426-4b10-8cda-a17a945f0421": {"__data__": {"id_": "443ebb30-f426-4b10-8cda-a17a945f0421", "embedding": null, "metadata": {"window": "The held -for-sale \naccounting  is effective at the start of our second quarter of this fiscal year.  \n \n We will re -measure the net assets to the lower carrying amount or fair value, less cost to sell, and we estimate \nthat this will result in a GAAP -only charge of between $500 million to $ 700 million in our second quarter of fiscal \n2022.  Due to held -for-sale accounting treatment, we'll discontinue recording depreciation and amortization on the \nassets involved in the transaction.  \n \n As a result of the held -for-sale accounting, we would guide t o approximately $0.26 adjusted earnings accretion in \nfiscal 2022.  This will be included in our updated outlook, and I'll outline those later in my remarks.  McKesson will \noperate these businesses and record revenue and income until the transaction is closed , which is expected to \noccur in fiscal 2023.  We're committed to exploring strategic alternatives for our remaining European businesses, \nand we'll provide details on the plans for the remaining businesses as they become available.  \n ", "original_text": "As a result of the held -for-sale accounting, we would guide t o approximately $0.26 adjusted earnings accretion in \nfiscal 2022. ", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c73484e1-29f7-4a39-9410-ade1661a5493", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f7e64d1d6ebff2efb420af7bea56de8b6f298f4d8ee26f1e8eb50023e721ab8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb502cf6-9c2d-4506-9e91-20b68970e9d4", "node_type": "1", "metadata": {"window": "The net assets included in the transaction we've classified as held for sale.  The held -for-sale \naccounting  is effective at the start of our second quarter of this fiscal year.  \n \n We will re -measure the net assets to the lower carrying amount or fair value, less cost to sell, and we estimate \nthat this will result in a GAAP -only charge of between $500 million to $ 700 million in our second quarter of fiscal \n2022.  Due to held -for-sale accounting treatment, we'll discontinue recording depreciation and amortization on the \nassets involved in the transaction.  \n \n As a result of the held -for-sale accounting, we would guide t o approximately $0.26 adjusted earnings accretion in \nfiscal 2022.  This will be included in our updated outlook, and I'll outline those later in my remarks.  McKesson will \noperate these businesses and record revenue and income until the transaction is closed , which is expected to \noccur in fiscal 2023. ", "original_text": "Due to held -for-sale accounting treatment, we'll discontinue recording depreciation and amortization on the \nassets involved in the transaction.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "babe94ec85f79fcafbc54040d304c6a6f09a79df49558f65c2077511a81482d1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ec8581dc-743f-432b-b4b1-17e57d47661c", "node_type": "1", "metadata": {"window": "We will re -measure the net assets to the lower carrying amount or fair value, less cost to sell, and we estimate \nthat this will result in a GAAP -only charge of between $500 million to $ 700 million in our second quarter of fiscal \n2022.  Due to held -for-sale accounting treatment, we'll discontinue recording depreciation and amortization on the \nassets involved in the transaction.  \n \n As a result of the held -for-sale accounting, we would guide t o approximately $0.26 adjusted earnings accretion in \nfiscal 2022.  This will be included in our updated outlook, and I'll outline those later in my remarks.  McKesson will \noperate these businesses and record revenue and income until the transaction is closed , which is expected to \noccur in fiscal 2023.  We're committed to exploring strategic alternatives for our remaining European businesses, \nand we'll provide details on the plans for the remaining businesses as they become available.  \n ", "original_text": "This will be included in our updated outlook, and I'll outline those later in my remarks. "}, "hash": "2138b2a644451390bba065f9118da24f119478d23999d38eaf58866eab7503bb", "class_name": "RelatedNodeInfo"}}, "text": "As a result of the held -for-sale accounting, we would guide t o approximately $0.26 adjusted earnings accretion in \nfiscal 2022. ", "start_char_idx": 3662, "end_char_idx": 3792, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ec8581dc-743f-432b-b4b1-17e57d47661c": {"__data__": {"id_": "ec8581dc-743f-432b-b4b1-17e57d47661c", "embedding": null, "metadata": {"window": "We will re -measure the net assets to the lower carrying amount or fair value, less cost to sell, and we estimate \nthat this will result in a GAAP -only charge of between $500 million to $ 700 million in our second quarter of fiscal \n2022.  Due to held -for-sale accounting treatment, we'll discontinue recording depreciation and amortization on the \nassets involved in the transaction.  \n \n As a result of the held -for-sale accounting, we would guide t o approximately $0.26 adjusted earnings accretion in \nfiscal 2022.  This will be included in our updated outlook, and I'll outline those later in my remarks.  McKesson will \noperate these businesses and record revenue and income until the transaction is closed , which is expected to \noccur in fiscal 2023.  We're committed to exploring strategic alternatives for our remaining European businesses, \nand we'll provide details on the plans for the remaining businesses as they become available.  \n ", "original_text": "This will be included in our updated outlook, and I'll outline those later in my remarks. ", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c73484e1-29f7-4a39-9410-ade1661a5493", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f7e64d1d6ebff2efb420af7bea56de8b6f298f4d8ee26f1e8eb50023e721ab8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "443ebb30-f426-4b10-8cda-a17a945f0421", "node_type": "1", "metadata": {"window": "The held -for-sale \naccounting  is effective at the start of our second quarter of this fiscal year.  \n \n We will re -measure the net assets to the lower carrying amount or fair value, less cost to sell, and we estimate \nthat this will result in a GAAP -only charge of between $500 million to $ 700 million in our second quarter of fiscal \n2022.  Due to held -for-sale accounting treatment, we'll discontinue recording depreciation and amortization on the \nassets involved in the transaction.  \n \n As a result of the held -for-sale accounting, we would guide t o approximately $0.26 adjusted earnings accretion in \nfiscal 2022.  This will be included in our updated outlook, and I'll outline those later in my remarks.  McKesson will \noperate these businesses and record revenue and income until the transaction is closed , which is expected to \noccur in fiscal 2023.  We're committed to exploring strategic alternatives for our remaining European businesses, \nand we'll provide details on the plans for the remaining businesses as they become available.  \n ", "original_text": "As a result of the held -for-sale accounting, we would guide t o approximately $0.26 adjusted earnings accretion in \nfiscal 2022. ", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7d58d82853ec80651c8cfe76e1f3cb5993529fd3c03fb9b3dbacfeabdbd9230d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e7c870c4-92cd-4ce5-8190-5a61dc744bed", "node_type": "1", "metadata": {"window": "Due to held -for-sale accounting treatment, we'll discontinue recording depreciation and amortization on the \nassets involved in the transaction.  \n \n As a result of the held -for-sale accounting, we would guide t o approximately $0.26 adjusted earnings accretion in \nfiscal 2022.  This will be included in our updated outlook, and I'll outline those later in my remarks.  McKesson will \noperate these businesses and record revenue and income until the transaction is closed , which is expected to \noccur in fiscal 2023.  We're committed to exploring strategic alternatives for our remaining European businesses, \nand we'll provide details on the plans for the remaining businesses as they become available.  \n ", "original_text": "McKesson will \noperate these businesses and record revenue and income until the transaction is closed , which is expected to \noccur in fiscal 2023. "}, "hash": "fddd181c7624bfdfaa3aba2a416407e046cca8c82c82d45bebc73074e6b3e4b6", "class_name": "RelatedNodeInfo"}}, "text": "This will be included in our updated outlook, and I'll outline those later in my remarks. ", "start_char_idx": 3792, "end_char_idx": 3882, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e7c870c4-92cd-4ce5-8190-5a61dc744bed": {"__data__": {"id_": "e7c870c4-92cd-4ce5-8190-5a61dc744bed", "embedding": null, "metadata": {"window": "Due to held -for-sale accounting treatment, we'll discontinue recording depreciation and amortization on the \nassets involved in the transaction.  \n \n As a result of the held -for-sale accounting, we would guide t o approximately $0.26 adjusted earnings accretion in \nfiscal 2022.  This will be included in our updated outlook, and I'll outline those later in my remarks.  McKesson will \noperate these businesses and record revenue and income until the transaction is closed , which is expected to \noccur in fiscal 2023.  We're committed to exploring strategic alternatives for our remaining European businesses, \nand we'll provide details on the plans for the remaining businesses as they become available.  \n ", "original_text": "McKesson will \noperate these businesses and record revenue and income until the transaction is closed , which is expected to \noccur in fiscal 2023. ", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c73484e1-29f7-4a39-9410-ade1661a5493", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f7e64d1d6ebff2efb420af7bea56de8b6f298f4d8ee26f1e8eb50023e721ab8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ec8581dc-743f-432b-b4b1-17e57d47661c", "node_type": "1", "metadata": {"window": "We will re -measure the net assets to the lower carrying amount or fair value, less cost to sell, and we estimate \nthat this will result in a GAAP -only charge of between $500 million to $ 700 million in our second quarter of fiscal \n2022.  Due to held -for-sale accounting treatment, we'll discontinue recording depreciation and amortization on the \nassets involved in the transaction.  \n \n As a result of the held -for-sale accounting, we would guide t o approximately $0.26 adjusted earnings accretion in \nfiscal 2022.  This will be included in our updated outlook, and I'll outline those later in my remarks.  McKesson will \noperate these businesses and record revenue and income until the transaction is closed , which is expected to \noccur in fiscal 2023.  We're committed to exploring strategic alternatives for our remaining European businesses, \nand we'll provide details on the plans for the remaining businesses as they become available.  \n ", "original_text": "This will be included in our updated outlook, and I'll outline those later in my remarks. ", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "42bc30750566841903b8f1114cbc755f5bd375690b835401abfe6ce96f654750", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f01b621c-8781-4678-9567-44f6e6f9a89d", "node_type": "1", "metadata": {"window": "As a result of the held -for-sale accounting, we would guide t o approximately $0.26 adjusted earnings accretion in \nfiscal 2022.  This will be included in our updated outlook, and I'll outline those later in my remarks.  McKesson will \noperate these businesses and record revenue and income until the transaction is closed , which is expected to \noccur in fiscal 2023.  We're committed to exploring strategic alternatives for our remaining European businesses, \nand we'll provide details on the plans for the remaining businesses as they become available.  \n ", "original_text": "We're committed to exploring strategic alternatives for our remaining European businesses, \nand we'll provide details on the plans for the remaining businesses as they become available.  \n "}, "hash": "78a29805a38555049cb9d32b50f71b74b64da9c901dbc8ac0743c36b2de056ef", "class_name": "RelatedNodeInfo"}}, "text": "McKesson will \noperate these businesses and record revenue and income until the transaction is closed , which is expected to \noccur in fiscal 2023. ", "start_char_idx": 3882, "end_char_idx": 4030, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f01b621c-8781-4678-9567-44f6e6f9a89d": {"__data__": {"id_": "f01b621c-8781-4678-9567-44f6e6f9a89d", "embedding": null, "metadata": {"window": "As a result of the held -for-sale accounting, we would guide t o approximately $0.26 adjusted earnings accretion in \nfiscal 2022.  This will be included in our updated outlook, and I'll outline those later in my remarks.  McKesson will \noperate these businesses and record revenue and income until the transaction is closed , which is expected to \noccur in fiscal 2023.  We're committed to exploring strategic alternatives for our remaining European businesses, \nand we'll provide details on the plans for the remaining businesses as they become available.  \n ", "original_text": "We're committed to exploring strategic alternatives for our remaining European businesses, \nand we'll provide details on the plans for the remaining businesses as they become available.  \n ", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c73484e1-29f7-4a39-9410-ade1661a5493", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f7e64d1d6ebff2efb420af7bea56de8b6f298f4d8ee26f1e8eb50023e721ab8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e7c870c4-92cd-4ce5-8190-5a61dc744bed", "node_type": "1", "metadata": {"window": "Due to held -for-sale accounting treatment, we'll discontinue recording depreciation and amortization on the \nassets involved in the transaction.  \n \n As a result of the held -for-sale accounting, we would guide t o approximately $0.26 adjusted earnings accretion in \nfiscal 2022.  This will be included in our updated outlook, and I'll outline those later in my remarks.  McKesson will \noperate these businesses and record revenue and income until the transaction is closed , which is expected to \noccur in fiscal 2023.  We're committed to exploring strategic alternatives for our remaining European businesses, \nand we'll provide details on the plans for the remaining businesses as they become available.  \n ", "original_text": "McKesson will \noperate these businesses and record revenue and income until the transaction is closed , which is expected to \noccur in fiscal 2023. ", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c3f5abb6225567272481d3be2f0608be1cba6db4197f28486912354b18c59b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c2931d9-3cf4-4efe-97b8-583682dedfe5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nExiting Europe at this time is the right course of action for McKesson and our shareholders, and it will sharpen the \nfocus on our growth strategies of oncology and biopharma services as we develop and grow a connected \necosystem.  \n \n Let me now turn to our first quarter results.  Before I provide more details on our first quarter adjusted results, I \nwant to point out two items that impacted our GAAP -only results in the quarter. ", "original_text": "McKesson Corp.  "}, "hash": "1a4eccab3daecfb71d100a020757f17e2f99089f31ed987a595acc407026c66d", "class_name": "RelatedNodeInfo"}}, "text": "We're committed to exploring strategic alternatives for our remaining European businesses, \nand we'll provide details on the plans for the remaining businesses as they become available.  \n ", "start_char_idx": 4030, "end_char_idx": 4219, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4c2931d9-3cf4-4efe-97b8-583682dedfe5": {"__data__": {"id_": "4c2931d9-3cf4-4efe-97b8-583682dedfe5", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nExiting Europe at this time is the right course of action for McKesson and our shareholders, and it will sharpen the \nfocus on our growth strategies of oncology and biopharma services as we develop and grow a connected \necosystem.  \n \n Let me now turn to our first quarter results.  Before I provide more details on our first quarter adjusted results, I \nwant to point out two items that impacted our GAAP -only results in the quarter. ", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f814064c-e4e4-4a0c-a559-30de71f2b69b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85a65a04cccabac635df21aab89fbbd2add3315c874738d8ae84667c676b0625", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f01b621c-8781-4678-9567-44f6e6f9a89d", "node_type": "1", "metadata": {"window": "As a result of the held -for-sale accounting, we would guide t o approximately $0.26 adjusted earnings accretion in \nfiscal 2022.  This will be included in our updated outlook, and I'll outline those later in my remarks.  McKesson will \noperate these businesses and record revenue and income until the transaction is closed , which is expected to \noccur in fiscal 2023.  We're committed to exploring strategic alternatives for our remaining European businesses, \nand we'll provide details on the plans for the remaining businesses as they become available.  \n ", "original_text": "We're committed to exploring strategic alternatives for our remaining European businesses, \nand we'll provide details on the plans for the remaining businesses as they become available.  \n ", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "108473a018275ef0285acd40bc2042ea21b45a6e652efa09abd36c5e3f17003c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "52d0dbe8-ff4d-4fa6-b0b3-33702bc0805d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nExiting Europe at this time is the right course of action for McKesson and our shareholders, and it will sharpen the \nfocus on our growth strategies of oncology and biopharma services as we develop and grow a connected \necosystem.  \n \n Let me now turn to our first quarter results.  Before I provide more details on our first quarter adjusted results, I \nwant to point out two items that impacted our GAAP -only results in the quarter.  First, during the June quarter, we \ncommitted to donate certain personal protective equipment and related products to charitable organizations to \nassist in COVID -19 recovery efforts. ", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nExiting Europe at this time is the right course of action for McKesson and our shareholders, and it will sharpen the \nfocus on our growth strategies of oncology and biopharma services as we develop and grow a connected \necosystem.  \n \n"}, "hash": "0f5fddd987e2f5690c9b39e2855311c77fad272db7d3a8c4f3f1684ad9e927c9", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "52d0dbe8-ff4d-4fa6-b0b3-33702bc0805d": {"__data__": {"id_": "52d0dbe8-ff4d-4fa6-b0b3-33702bc0805d", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nExiting Europe at this time is the right course of action for McKesson and our shareholders, and it will sharpen the \nfocus on our growth strategies of oncology and biopharma services as we develop and grow a connected \necosystem.  \n \n Let me now turn to our first quarter results.  Before I provide more details on our first quarter adjusted results, I \nwant to point out two items that impacted our GAAP -only results in the quarter.  First, during the June quarter, we \ncommitted to donate certain personal protective equipment and related products to charitable organizations to \nassist in COVID -19 recovery efforts. ", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nExiting Europe at this time is the right course of action for McKesson and our shareholders, and it will sharpen the \nfocus on our growth strategies of oncology and biopharma services as we develop and grow a connected \necosystem.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f814064c-e4e4-4a0c-a559-30de71f2b69b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85a65a04cccabac635df21aab89fbbd2add3315c874738d8ae84667c676b0625", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4c2931d9-3cf4-4efe-97b8-583682dedfe5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nExiting Europe at this time is the right course of action for McKesson and our shareholders, and it will sharpen the \nfocus on our growth strategies of oncology and biopharma services as we develop and grow a connected \necosystem.  \n \n Let me now turn to our first quarter results.  Before I provide more details on our first quarter adjusted results, I \nwant to point out two items that impacted our GAAP -only results in the quarter. ", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "816e1227d4bce79abbd2147cfbd224b5b58f4fb065d3d4e0bf12fff84651178a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "45a50a94-d594-4356-90eb-c05ad720b1c2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nExiting Europe at this time is the right course of action for McKesson and our shareholders, and it will sharpen the \nfocus on our growth strategies of oncology and biopharma services as we develop and grow a connected \necosystem.  \n \n Let me now turn to our first quarter results.  Before I provide more details on our first quarter adjusted results, I \nwant to point out two items that impacted our GAAP -only results in the quarter.  First, during the June quarter, we \ncommitted to donate certain personal protective equipment and related products to charitable organizations to \nassist in COVID -19 recovery efforts.  In the quarter, we recorded $155 million of pre -tax inventory charges within \nour Medical Surgical Solutions segment for inventory, which we no longer intend to sell and will inste ad direct to \npreviously -mentioned charitable organizations.  \n \n", "original_text": "Let me now turn to our first quarter results. "}, "hash": "1a856c30007f92b95f6560040cd13303a625b2a367a52c7977fab27e6961cc40", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nExiting Europe at this time is the right course of action for McKesson and our shareholders, and it will sharpen the \nfocus on our growth strategies of oncology and biopharma services as we develop and grow a connected \necosystem.  \n \n", "start_char_idx": 16, "end_char_idx": 415, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "45a50a94-d594-4356-90eb-c05ad720b1c2": {"__data__": {"id_": "45a50a94-d594-4356-90eb-c05ad720b1c2", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nExiting Europe at this time is the right course of action for McKesson and our shareholders, and it will sharpen the \nfocus on our growth strategies of oncology and biopharma services as we develop and grow a connected \necosystem.  \n \n Let me now turn to our first quarter results.  Before I provide more details on our first quarter adjusted results, I \nwant to point out two items that impacted our GAAP -only results in the quarter.  First, during the June quarter, we \ncommitted to donate certain personal protective equipment and related products to charitable organizations to \nassist in COVID -19 recovery efforts.  In the quarter, we recorded $155 million of pre -tax inventory charges within \nour Medical Surgical Solutions segment for inventory, which we no longer intend to sell and will inste ad direct to \npreviously -mentioned charitable organizations.  \n \n", "original_text": "Let me now turn to our first quarter results. ", "page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f814064c-e4e4-4a0c-a559-30de71f2b69b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85a65a04cccabac635df21aab89fbbd2add3315c874738d8ae84667c676b0625", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "52d0dbe8-ff4d-4fa6-b0b3-33702bc0805d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nExiting Europe at this time is the right course of action for McKesson and our shareholders, and it will sharpen the \nfocus on our growth strategies of oncology and biopharma services as we develop and grow a connected \necosystem.  \n \n Let me now turn to our first quarter results.  Before I provide more details on our first quarter adjusted results, I \nwant to point out two items that impacted our GAAP -only results in the quarter.  First, during the June quarter, we \ncommitted to donate certain personal protective equipment and related products to charitable organizations to \nassist in COVID -19 recovery efforts. ", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nExiting Europe at this time is the right course of action for McKesson and our shareholders, and it will sharpen the \nfocus on our growth strategies of oncology and biopharma services as we develop and grow a connected \necosystem.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "71177b4984324ab76b37f083b17f59952ef97fc5f68e9afa57e6f7c10f2039ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0116716d-2282-4700-ac1f-86230ff9c21e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nExiting Europe at this time is the right course of action for McKesson and our shareholders, and it will sharpen the \nfocus on our growth strategies of oncology and biopharma services as we develop and grow a connected \necosystem.  \n \n Let me now turn to our first quarter results.  Before I provide more details on our first quarter adjusted results, I \nwant to point out two items that impacted our GAAP -only results in the quarter.  First, during the June quarter, we \ncommitted to donate certain personal protective equipment and related products to charitable organizations to \nassist in COVID -19 recovery efforts.  In the quarter, we recorded $155 million of pre -tax inventory charges within \nour Medical Surgical Solutions segment for inventory, which we no longer intend to sell and will inste ad direct to \npreviously -mentioned charitable organizations.  \n \n And secondly, on our May 6 earnings call, we outlined an initiative to rationalize office space in North America to \nincrease efficiencies and support increased employee flexibility. ", "original_text": "Before I provide more details on our first quarter adjusted results, I \nwant to point out two items that impacted our GAAP -only results in the quarter. "}, "hash": "95455cfad801e5028b2589fbc5adfa3d5320629e7b8d0cebbb67cf10bbc8768f", "class_name": "RelatedNodeInfo"}}, "text": "Let me now turn to our first quarter results. ", "start_char_idx": 415, "end_char_idx": 461, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0116716d-2282-4700-ac1f-86230ff9c21e": {"__data__": {"id_": "0116716d-2282-4700-ac1f-86230ff9c21e", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nExiting Europe at this time is the right course of action for McKesson and our shareholders, and it will sharpen the \nfocus on our growth strategies of oncology and biopharma services as we develop and grow a connected \necosystem.  \n \n Let me now turn to our first quarter results.  Before I provide more details on our first quarter adjusted results, I \nwant to point out two items that impacted our GAAP -only results in the quarter.  First, during the June quarter, we \ncommitted to donate certain personal protective equipment and related products to charitable organizations to \nassist in COVID -19 recovery efforts.  In the quarter, we recorded $155 million of pre -tax inventory charges within \nour Medical Surgical Solutions segment for inventory, which we no longer intend to sell and will inste ad direct to \npreviously -mentioned charitable organizations.  \n \n And secondly, on our May 6 earnings call, we outlined an initiative to rationalize office space in North America to \nincrease efficiencies and support increased employee flexibility. ", "original_text": "Before I provide more details on our first quarter adjusted results, I \nwant to point out two items that impacted our GAAP -only results in the quarter. ", "page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f814064c-e4e4-4a0c-a559-30de71f2b69b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85a65a04cccabac635df21aab89fbbd2add3315c874738d8ae84667c676b0625", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "45a50a94-d594-4356-90eb-c05ad720b1c2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nExiting Europe at this time is the right course of action for McKesson and our shareholders, and it will sharpen the \nfocus on our growth strategies of oncology and biopharma services as we develop and grow a connected \necosystem.  \n \n Let me now turn to our first quarter results.  Before I provide more details on our first quarter adjusted results, I \nwant to point out two items that impacted our GAAP -only results in the quarter.  First, during the June quarter, we \ncommitted to donate certain personal protective equipment and related products to charitable organizations to \nassist in COVID -19 recovery efforts.  In the quarter, we recorded $155 million of pre -tax inventory charges within \nour Medical Surgical Solutions segment for inventory, which we no longer intend to sell and will inste ad direct to \npreviously -mentioned charitable organizations.  \n \n", "original_text": "Let me now turn to our first quarter results. ", "page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5fb7651ab7093acde8d4aca46db0f09cc8abc6723f8ae85037d8d81b0578d358", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "597f608c-38e6-4583-9e05-882aa761432a", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nExiting Europe at this time is the right course of action for McKesson and our shareholders, and it will sharpen the \nfocus on our growth strategies of oncology and biopharma services as we develop and grow a connected \necosystem.  \n \n Let me now turn to our first quarter results.  Before I provide more details on our first quarter adjusted results, I \nwant to point out two items that impacted our GAAP -only results in the quarter.  First, during the June quarter, we \ncommitted to donate certain personal protective equipment and related products to charitable organizations to \nassist in COVID -19 recovery efforts.  In the quarter, we recorded $155 million of pre -tax inventory charges within \nour Medical Surgical Solutions segment for inventory, which we no longer intend to sell and will inste ad direct to \npreviously -mentioned charitable organizations.  \n \n And secondly, on our May 6 earnings call, we outlined an initiative to rationalize office space in North America to \nincrease efficiencies and support increased employee flexibility.  These actions  will result in the realization of \nannual operating expense savings of approximately $60 million to $80 million when fully implemented. ", "original_text": "First, during the June quarter, we \ncommitted to donate certain personal protective equipment and related products to charitable organizations to \nassist in COVID -19 recovery efforts. "}, "hash": "25d4edb30d8876446ad236a355ab8806f338db830747c0b3632c41c0faf9758f", "class_name": "RelatedNodeInfo"}}, "text": "Before I provide more details on our first quarter adjusted results, I \nwant to point out two items that impacted our GAAP -only results in the quarter. ", "start_char_idx": 461, "end_char_idx": 614, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "597f608c-38e6-4583-9e05-882aa761432a": {"__data__": {"id_": "597f608c-38e6-4583-9e05-882aa761432a", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nExiting Europe at this time is the right course of action for McKesson and our shareholders, and it will sharpen the \nfocus on our growth strategies of oncology and biopharma services as we develop and grow a connected \necosystem.  \n \n Let me now turn to our first quarter results.  Before I provide more details on our first quarter adjusted results, I \nwant to point out two items that impacted our GAAP -only results in the quarter.  First, during the June quarter, we \ncommitted to donate certain personal protective equipment and related products to charitable organizations to \nassist in COVID -19 recovery efforts.  In the quarter, we recorded $155 million of pre -tax inventory charges within \nour Medical Surgical Solutions segment for inventory, which we no longer intend to sell and will inste ad direct to \npreviously -mentioned charitable organizations.  \n \n And secondly, on our May 6 earnings call, we outlined an initiative to rationalize office space in North America to \nincrease efficiencies and support increased employee flexibility.  These actions  will result in the realization of \nannual operating expense savings of approximately $60 million to $80 million when fully implemented. ", "original_text": "First, during the June quarter, we \ncommitted to donate certain personal protective equipment and related products to charitable organizations to \nassist in COVID -19 recovery efforts. ", "page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f814064c-e4e4-4a0c-a559-30de71f2b69b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85a65a04cccabac635df21aab89fbbd2add3315c874738d8ae84667c676b0625", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0116716d-2282-4700-ac1f-86230ff9c21e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nExiting Europe at this time is the right course of action for McKesson and our shareholders, and it will sharpen the \nfocus on our growth strategies of oncology and biopharma services as we develop and grow a connected \necosystem.  \n \n Let me now turn to our first quarter results.  Before I provide more details on our first quarter adjusted results, I \nwant to point out two items that impacted our GAAP -only results in the quarter.  First, during the June quarter, we \ncommitted to donate certain personal protective equipment and related products to charitable organizations to \nassist in COVID -19 recovery efforts.  In the quarter, we recorded $155 million of pre -tax inventory charges within \nour Medical Surgical Solutions segment for inventory, which we no longer intend to sell and will inste ad direct to \npreviously -mentioned charitable organizations.  \n \n And secondly, on our May 6 earnings call, we outlined an initiative to rationalize office space in North America to \nincrease efficiencies and support increased employee flexibility. ", "original_text": "Before I provide more details on our first quarter adjusted results, I \nwant to point out two items that impacted our GAAP -only results in the quarter. ", "page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0241893377e4edd15c6302e3a3d15efb26ce06c60253cb073f75bd817392b755", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e25868c-67ef-4e9c-affa-cd2e590021f6", "node_type": "1", "metadata": {"window": "Let me now turn to our first quarter results.  Before I provide more details on our first quarter adjusted results, I \nwant to point out two items that impacted our GAAP -only results in the quarter.  First, during the June quarter, we \ncommitted to donate certain personal protective equipment and related products to charitable organizations to \nassist in COVID -19 recovery efforts.  In the quarter, we recorded $155 million of pre -tax inventory charges within \nour Medical Surgical Solutions segment for inventory, which we no longer intend to sell and will inste ad direct to \npreviously -mentioned charitable organizations.  \n \n And secondly, on our May 6 earnings call, we outlined an initiative to rationalize office space in North America to \nincrease efficiencies and support increased employee flexibility.  These actions  will result in the realization of \nannual operating expense savings of approximately $60 million to $80 million when fully implemented.  Our \nguidance does not assume a material benefit in fiscal 2022. ", "original_text": "In the quarter, we recorded $155 million of pre -tax inventory charges within \nour Medical Surgical Solutions segment for inventory, which we no longer intend to sell and will inste ad direct to \npreviously -mentioned charitable organizations.  \n \n"}, "hash": "3d2e4d4dae2dd70e3f3b08c59906196725f470a792ce0c5ad4727c19cd7e3417", "class_name": "RelatedNodeInfo"}}, "text": "First, during the June quarter, we \ncommitted to donate certain personal protective equipment and related products to charitable organizations to \nassist in COVID -19 recovery efforts. ", "start_char_idx": 614, "end_char_idx": 799, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e25868c-67ef-4e9c-affa-cd2e590021f6": {"__data__": {"id_": "5e25868c-67ef-4e9c-affa-cd2e590021f6", "embedding": null, "metadata": {"window": "Let me now turn to our first quarter results.  Before I provide more details on our first quarter adjusted results, I \nwant to point out two items that impacted our GAAP -only results in the quarter.  First, during the June quarter, we \ncommitted to donate certain personal protective equipment and related products to charitable organizations to \nassist in COVID -19 recovery efforts.  In the quarter, we recorded $155 million of pre -tax inventory charges within \nour Medical Surgical Solutions segment for inventory, which we no longer intend to sell and will inste ad direct to \npreviously -mentioned charitable organizations.  \n \n And secondly, on our May 6 earnings call, we outlined an initiative to rationalize office space in North America to \nincrease efficiencies and support increased employee flexibility.  These actions  will result in the realization of \nannual operating expense savings of approximately $60 million to $80 million when fully implemented.  Our \nguidance does not assume a material benefit in fiscal 2022. ", "original_text": "In the quarter, we recorded $155 million of pre -tax inventory charges within \nour Medical Surgical Solutions segment for inventory, which we no longer intend to sell and will inste ad direct to \npreviously -mentioned charitable organizations.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f814064c-e4e4-4a0c-a559-30de71f2b69b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85a65a04cccabac635df21aab89fbbd2add3315c874738d8ae84667c676b0625", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "597f608c-38e6-4583-9e05-882aa761432a", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nExiting Europe at this time is the right course of action for McKesson and our shareholders, and it will sharpen the \nfocus on our growth strategies of oncology and biopharma services as we develop and grow a connected \necosystem.  \n \n Let me now turn to our first quarter results.  Before I provide more details on our first quarter adjusted results, I \nwant to point out two items that impacted our GAAP -only results in the quarter.  First, during the June quarter, we \ncommitted to donate certain personal protective equipment and related products to charitable organizations to \nassist in COVID -19 recovery efforts.  In the quarter, we recorded $155 million of pre -tax inventory charges within \nour Medical Surgical Solutions segment for inventory, which we no longer intend to sell and will inste ad direct to \npreviously -mentioned charitable organizations.  \n \n And secondly, on our May 6 earnings call, we outlined an initiative to rationalize office space in North America to \nincrease efficiencies and support increased employee flexibility.  These actions  will result in the realization of \nannual operating expense savings of approximately $60 million to $80 million when fully implemented. ", "original_text": "First, during the June quarter, we \ncommitted to donate certain personal protective equipment and related products to charitable organizations to \nassist in COVID -19 recovery efforts. ", "page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c976d48b51fda4fcfc8d8ba3dfa10a91fc0f6a763c273cb0829e8a8a22291ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ef39308c-9ff4-4fa6-8d8b-7f34e656556c", "node_type": "1", "metadata": {"window": "Before I provide more details on our first quarter adjusted results, I \nwant to point out two items that impacted our GAAP -only results in the quarter.  First, during the June quarter, we \ncommitted to donate certain personal protective equipment and related products to charitable organizations to \nassist in COVID -19 recovery efforts.  In the quarter, we recorded $155 million of pre -tax inventory charges within \nour Medical Surgical Solutions segment for inventory, which we no longer intend to sell and will inste ad direct to \npreviously -mentioned charitable organizations.  \n \n And secondly, on our May 6 earnings call, we outlined an initiative to rationalize office space in North America to \nincrease efficiencies and support increased employee flexibility.  These actions  will result in the realization of \nannual operating expense savings of approximately $60 million to $80 million when fully implemented.  Our \nguidance does not assume a material benefit in fiscal 2022.  In the June quarter, we reported approximately $95 \nmillion of charges associated with this initiative.  \n \n", "original_text": "And secondly, on our May 6 earnings call, we outlined an initiative to rationalize office space in North America to \nincrease efficiencies and support increased employee flexibility. "}, "hash": "ced42edc4542363171cb298540c018efa994d3cc57d35a0e02af9f5200a190e6", "class_name": "RelatedNodeInfo"}}, "text": "In the quarter, we recorded $155 million of pre -tax inventory charges within \nour Medical Surgical Solutions segment for inventory, which we no longer intend to sell and will inste ad direct to \npreviously -mentioned charitable organizations.  \n \n", "start_char_idx": 799, "end_char_idx": 1047, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ef39308c-9ff4-4fa6-8d8b-7f34e656556c": {"__data__": {"id_": "ef39308c-9ff4-4fa6-8d8b-7f34e656556c", "embedding": null, "metadata": {"window": "Before I provide more details on our first quarter adjusted results, I \nwant to point out two items that impacted our GAAP -only results in the quarter.  First, during the June quarter, we \ncommitted to donate certain personal protective equipment and related products to charitable organizations to \nassist in COVID -19 recovery efforts.  In the quarter, we recorded $155 million of pre -tax inventory charges within \nour Medical Surgical Solutions segment for inventory, which we no longer intend to sell and will inste ad direct to \npreviously -mentioned charitable organizations.  \n \n And secondly, on our May 6 earnings call, we outlined an initiative to rationalize office space in North America to \nincrease efficiencies and support increased employee flexibility.  These actions  will result in the realization of \nannual operating expense savings of approximately $60 million to $80 million when fully implemented.  Our \nguidance does not assume a material benefit in fiscal 2022.  In the June quarter, we reported approximately $95 \nmillion of charges associated with this initiative.  \n \n", "original_text": "And secondly, on our May 6 earnings call, we outlined an initiative to rationalize office space in North America to \nincrease efficiencies and support increased employee flexibility. ", "page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f814064c-e4e4-4a0c-a559-30de71f2b69b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85a65a04cccabac635df21aab89fbbd2add3315c874738d8ae84667c676b0625", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e25868c-67ef-4e9c-affa-cd2e590021f6", "node_type": "1", "metadata": {"window": "Let me now turn to our first quarter results.  Before I provide more details on our first quarter adjusted results, I \nwant to point out two items that impacted our GAAP -only results in the quarter.  First, during the June quarter, we \ncommitted to donate certain personal protective equipment and related products to charitable organizations to \nassist in COVID -19 recovery efforts.  In the quarter, we recorded $155 million of pre -tax inventory charges within \nour Medical Surgical Solutions segment for inventory, which we no longer intend to sell and will inste ad direct to \npreviously -mentioned charitable organizations.  \n \n And secondly, on our May 6 earnings call, we outlined an initiative to rationalize office space in North America to \nincrease efficiencies and support increased employee flexibility.  These actions  will result in the realization of \nannual operating expense savings of approximately $60 million to $80 million when fully implemented.  Our \nguidance does not assume a material benefit in fiscal 2022. ", "original_text": "In the quarter, we recorded $155 million of pre -tax inventory charges within \nour Medical Surgical Solutions segment for inventory, which we no longer intend to sell and will inste ad direct to \npreviously -mentioned charitable organizations.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "994a2376c8ee9951441cb97f7e4584b70593f4dbf73cc0e27a61812511039498", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d0d8edf-12da-4f67-a7dd-9fb5126558a3", "node_type": "1", "metadata": {"window": "First, during the June quarter, we \ncommitted to donate certain personal protective equipment and related products to charitable organizations to \nassist in COVID -19 recovery efforts.  In the quarter, we recorded $155 million of pre -tax inventory charges within \nour Medical Surgical Solutions segment for inventory, which we no longer intend to sell and will inste ad direct to \npreviously -mentioned charitable organizations.  \n \n And secondly, on our May 6 earnings call, we outlined an initiative to rationalize office space in North America to \nincrease efficiencies and support increased employee flexibility.  These actions  will result in the realization of \nannual operating expense savings of approximately $60 million to $80 million when fully implemented.  Our \nguidance does not assume a material benefit in fiscal 2022.  In the June quarter, we reported approximately $95 \nmillion of charges associated with this initiative.  \n \n Moving now to our adjusted results for the first quarter, beginning with our consolidated results, which can be \nfound on slide 7. ", "original_text": "These actions  will result in the realization of \nannual operating expense savings of approximately $60 million to $80 million when fully implemented. "}, "hash": "6f0e0dff9e975a2782fd1ba481e4331969627b8ef77a5b3591f55b1b90c5ee5d", "class_name": "RelatedNodeInfo"}}, "text": "And secondly, on our May 6 earnings call, we outlined an initiative to rationalize office space in North America to \nincrease efficiencies and support increased employee flexibility. ", "start_char_idx": 1047, "end_char_idx": 1230, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d0d8edf-12da-4f67-a7dd-9fb5126558a3": {"__data__": {"id_": "5d0d8edf-12da-4f67-a7dd-9fb5126558a3", "embedding": null, "metadata": {"window": "First, during the June quarter, we \ncommitted to donate certain personal protective equipment and related products to charitable organizations to \nassist in COVID -19 recovery efforts.  In the quarter, we recorded $155 million of pre -tax inventory charges within \nour Medical Surgical Solutions segment for inventory, which we no longer intend to sell and will inste ad direct to \npreviously -mentioned charitable organizations.  \n \n And secondly, on our May 6 earnings call, we outlined an initiative to rationalize office space in North America to \nincrease efficiencies and support increased employee flexibility.  These actions  will result in the realization of \nannual operating expense savings of approximately $60 million to $80 million when fully implemented.  Our \nguidance does not assume a material benefit in fiscal 2022.  In the June quarter, we reported approximately $95 \nmillion of charges associated with this initiative.  \n \n Moving now to our adjusted results for the first quarter, beginning with our consolidated results, which can be \nfound on slide 7. ", "original_text": "These actions  will result in the realization of \nannual operating expense savings of approximately $60 million to $80 million when fully implemented. ", "page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f814064c-e4e4-4a0c-a559-30de71f2b69b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85a65a04cccabac635df21aab89fbbd2add3315c874738d8ae84667c676b0625", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef39308c-9ff4-4fa6-8d8b-7f34e656556c", "node_type": "1", "metadata": {"window": "Before I provide more details on our first quarter adjusted results, I \nwant to point out two items that impacted our GAAP -only results in the quarter.  First, during the June quarter, we \ncommitted to donate certain personal protective equipment and related products to charitable organizations to \nassist in COVID -19 recovery efforts.  In the quarter, we recorded $155 million of pre -tax inventory charges within \nour Medical Surgical Solutions segment for inventory, which we no longer intend to sell and will inste ad direct to \npreviously -mentioned charitable organizations.  \n \n And secondly, on our May 6 earnings call, we outlined an initiative to rationalize office space in North America to \nincrease efficiencies and support increased employee flexibility.  These actions  will result in the realization of \nannual operating expense savings of approximately $60 million to $80 million when fully implemented.  Our \nguidance does not assume a material benefit in fiscal 2022.  In the June quarter, we reported approximately $95 \nmillion of charges associated with this initiative.  \n \n", "original_text": "And secondly, on our May 6 earnings call, we outlined an initiative to rationalize office space in North America to \nincrease efficiencies and support increased employee flexibility. ", "page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d755b9a26f7ecabae1482f4b0ede0ecb4092e48923bab5c55439b1fdba1a9fbb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36b4135b-069b-434d-aca5-dc6d397e8928", "node_type": "1", "metadata": {"window": "In the quarter, we recorded $155 million of pre -tax inventory charges within \nour Medical Surgical Solutions segment for inventory, which we no longer intend to sell and will inste ad direct to \npreviously -mentioned charitable organizations.  \n \n And secondly, on our May 6 earnings call, we outlined an initiative to rationalize office space in North America to \nincrease efficiencies and support increased employee flexibility.  These actions  will result in the realization of \nannual operating expense savings of approximately $60 million to $80 million when fully implemented.  Our \nguidance does not assume a material benefit in fiscal 2022.  In the June quarter, we reported approximately $95 \nmillion of charges associated with this initiative.  \n \n Moving now to our adjusted results for the first quarter, beginning with our consolidated results, which can be \nfound on slide 7.  First quarter adjusted earnings per diluted share was $5.56, an increase of 10 1% compared to \nthe prior year. ", "original_text": "Our \nguidance does not assume a material benefit in fiscal 2022. "}, "hash": "7765de4ffeceef3198d09a96d0e357758b286295846116d75dd2cd9a0584391a", "class_name": "RelatedNodeInfo"}}, "text": "These actions  will result in the realization of \nannual operating expense savings of approximately $60 million to $80 million when fully implemented. ", "start_char_idx": 1230, "end_char_idx": 1381, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36b4135b-069b-434d-aca5-dc6d397e8928": {"__data__": {"id_": "36b4135b-069b-434d-aca5-dc6d397e8928", "embedding": null, "metadata": {"window": "In the quarter, we recorded $155 million of pre -tax inventory charges within \nour Medical Surgical Solutions segment for inventory, which we no longer intend to sell and will inste ad direct to \npreviously -mentioned charitable organizations.  \n \n And secondly, on our May 6 earnings call, we outlined an initiative to rationalize office space in North America to \nincrease efficiencies and support increased employee flexibility.  These actions  will result in the realization of \nannual operating expense savings of approximately $60 million to $80 million when fully implemented.  Our \nguidance does not assume a material benefit in fiscal 2022.  In the June quarter, we reported approximately $95 \nmillion of charges associated with this initiative.  \n \n Moving now to our adjusted results for the first quarter, beginning with our consolidated results, which can be \nfound on slide 7.  First quarter adjusted earnings per diluted share was $5.56, an increase of 10 1% compared to \nthe prior year. ", "original_text": "Our \nguidance does not assume a material benefit in fiscal 2022. ", "page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f814064c-e4e4-4a0c-a559-30de71f2b69b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85a65a04cccabac635df21aab89fbbd2add3315c874738d8ae84667c676b0625", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d0d8edf-12da-4f67-a7dd-9fb5126558a3", "node_type": "1", "metadata": {"window": "First, during the June quarter, we \ncommitted to donate certain personal protective equipment and related products to charitable organizations to \nassist in COVID -19 recovery efforts.  In the quarter, we recorded $155 million of pre -tax inventory charges within \nour Medical Surgical Solutions segment for inventory, which we no longer intend to sell and will inste ad direct to \npreviously -mentioned charitable organizations.  \n \n And secondly, on our May 6 earnings call, we outlined an initiative to rationalize office space in North America to \nincrease efficiencies and support increased employee flexibility.  These actions  will result in the realization of \nannual operating expense savings of approximately $60 million to $80 million when fully implemented.  Our \nguidance does not assume a material benefit in fiscal 2022.  In the June quarter, we reported approximately $95 \nmillion of charges associated with this initiative.  \n \n Moving now to our adjusted results for the first quarter, beginning with our consolidated results, which can be \nfound on slide 7. ", "original_text": "These actions  will result in the realization of \nannual operating expense savings of approximately $60 million to $80 million when fully implemented. ", "page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "541c0d96ede9cbdcfcc6a3520cba171f4c1417922567c30abfd9003e78eb9497", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f1dc62f2-bad7-4809-b510-aaf9d5715f1c", "node_type": "1", "metadata": {"window": "And secondly, on our May 6 earnings call, we outlined an initiative to rationalize office space in North America to \nincrease efficiencies and support increased employee flexibility.  These actions  will result in the realization of \nannual operating expense savings of approximately $60 million to $80 million when fully implemented.  Our \nguidance does not assume a material benefit in fiscal 2022.  In the June quarter, we reported approximately $95 \nmillion of charges associated with this initiative.  \n \n Moving now to our adjusted results for the first quarter, beginning with our consolidated results, which can be \nfound on slide 7.  First quarter adjusted earnings per diluted share was $5.56, an increase of 10 1% compared to \nthe prior year.  This result was driven by the recovery of prescription volumes and primary care patient visits from \nthe COVID -19 pandemic, as we lapped the most significant pandemic impacts from lockdowns in Q1 of fiscal \n2021. ", "original_text": "In the June quarter, we reported approximately $95 \nmillion of charges associated with this initiative.  \n \n"}, "hash": "4059d7ac783ea173d415525ec07712732c5f8dc36c4d7583d8ecd7187ac4bafa", "class_name": "RelatedNodeInfo"}}, "text": "Our \nguidance does not assume a material benefit in fiscal 2022. ", "start_char_idx": 1381, "end_char_idx": 1446, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f1dc62f2-bad7-4809-b510-aaf9d5715f1c": {"__data__": {"id_": "f1dc62f2-bad7-4809-b510-aaf9d5715f1c", "embedding": null, "metadata": {"window": "And secondly, on our May 6 earnings call, we outlined an initiative to rationalize office space in North America to \nincrease efficiencies and support increased employee flexibility.  These actions  will result in the realization of \nannual operating expense savings of approximately $60 million to $80 million when fully implemented.  Our \nguidance does not assume a material benefit in fiscal 2022.  In the June quarter, we reported approximately $95 \nmillion of charges associated with this initiative.  \n \n Moving now to our adjusted results for the first quarter, beginning with our consolidated results, which can be \nfound on slide 7.  First quarter adjusted earnings per diluted share was $5.56, an increase of 10 1% compared to \nthe prior year.  This result was driven by the recovery of prescription volumes and primary care patient visits from \nthe COVID -19 pandemic, as we lapped the most significant pandemic impacts from lockdowns in Q1 of fiscal \n2021. ", "original_text": "In the June quarter, we reported approximately $95 \nmillion of charges associated with this initiative.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f814064c-e4e4-4a0c-a559-30de71f2b69b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85a65a04cccabac635df21aab89fbbd2add3315c874738d8ae84667c676b0625", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36b4135b-069b-434d-aca5-dc6d397e8928", "node_type": "1", "metadata": {"window": "In the quarter, we recorded $155 million of pre -tax inventory charges within \nour Medical Surgical Solutions segment for inventory, which we no longer intend to sell and will inste ad direct to \npreviously -mentioned charitable organizations.  \n \n And secondly, on our May 6 earnings call, we outlined an initiative to rationalize office space in North America to \nincrease efficiencies and support increased employee flexibility.  These actions  will result in the realization of \nannual operating expense savings of approximately $60 million to $80 million when fully implemented.  Our \nguidance does not assume a material benefit in fiscal 2022.  In the June quarter, we reported approximately $95 \nmillion of charges associated with this initiative.  \n \n Moving now to our adjusted results for the first quarter, beginning with our consolidated results, which can be \nfound on slide 7.  First quarter adjusted earnings per diluted share was $5.56, an increase of 10 1% compared to \nthe prior year. ", "original_text": "Our \nguidance does not assume a material benefit in fiscal 2022. ", "page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5635247efbed88d4d6afa574f6a2b1b2144a6fbe591e47d8dd54f72144eba266", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d751b42-3569-4fbf-ac88-4025dd074770", "node_type": "1", "metadata": {"window": "These actions  will result in the realization of \nannual operating expense savings of approximately $60 million to $80 million when fully implemented.  Our \nguidance does not assume a material benefit in fiscal 2022.  In the June quarter, we reported approximately $95 \nmillion of charges associated with this initiative.  \n \n Moving now to our adjusted results for the first quarter, beginning with our consolidated results, which can be \nfound on slide 7.  First quarter adjusted earnings per diluted share was $5.56, an increase of 10 1% compared to \nthe prior year.  This result was driven by the recovery of prescription volumes and primary care patient visits from \nthe COVID -19 pandemic, as we lapped the most significant pandemic impacts from lockdowns in Q1 of fiscal \n2021.  It also includ ed a lower tax rate and the contribution from COVID -19 vaccine distribution and kitting \nprograms with the US government,  \n \nConsolidated revenues of $62.7 billion increased 13% from the prior year, driven by growth in the US \nPharmaceutical segment, largely d ue to higher volumes from retail national account customers and price \nincreases on branded and specialty pharmaceuticals, which is partially offset by branded to generic conversions.  \n \n", "original_text": "Moving now to our adjusted results for the first quarter, beginning with our consolidated results, which can be \nfound on slide 7. "}, "hash": "a1cd62718f5f4a1c33ccee0cb1f9a47b1dab028c21c249281f2bf5ab5304067b", "class_name": "RelatedNodeInfo"}}, "text": "In the June quarter, we reported approximately $95 \nmillion of charges associated with this initiative.  \n \n", "start_char_idx": 1446, "end_char_idx": 1554, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d751b42-3569-4fbf-ac88-4025dd074770": {"__data__": {"id_": "8d751b42-3569-4fbf-ac88-4025dd074770", "embedding": null, "metadata": {"window": "These actions  will result in the realization of \nannual operating expense savings of approximately $60 million to $80 million when fully implemented.  Our \nguidance does not assume a material benefit in fiscal 2022.  In the June quarter, we reported approximately $95 \nmillion of charges associated with this initiative.  \n \n Moving now to our adjusted results for the first quarter, beginning with our consolidated results, which can be \nfound on slide 7.  First quarter adjusted earnings per diluted share was $5.56, an increase of 10 1% compared to \nthe prior year.  This result was driven by the recovery of prescription volumes and primary care patient visits from \nthe COVID -19 pandemic, as we lapped the most significant pandemic impacts from lockdowns in Q1 of fiscal \n2021.  It also includ ed a lower tax rate and the contribution from COVID -19 vaccine distribution and kitting \nprograms with the US government,  \n \nConsolidated revenues of $62.7 billion increased 13% from the prior year, driven by growth in the US \nPharmaceutical segment, largely d ue to higher volumes from retail national account customers and price \nincreases on branded and specialty pharmaceuticals, which is partially offset by branded to generic conversions.  \n \n", "original_text": "Moving now to our adjusted results for the first quarter, beginning with our consolidated results, which can be \nfound on slide 7. ", "page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f814064c-e4e4-4a0c-a559-30de71f2b69b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85a65a04cccabac635df21aab89fbbd2add3315c874738d8ae84667c676b0625", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f1dc62f2-bad7-4809-b510-aaf9d5715f1c", "node_type": "1", "metadata": {"window": "And secondly, on our May 6 earnings call, we outlined an initiative to rationalize office space in North America to \nincrease efficiencies and support increased employee flexibility.  These actions  will result in the realization of \nannual operating expense savings of approximately $60 million to $80 million when fully implemented.  Our \nguidance does not assume a material benefit in fiscal 2022.  In the June quarter, we reported approximately $95 \nmillion of charges associated with this initiative.  \n \n Moving now to our adjusted results for the first quarter, beginning with our consolidated results, which can be \nfound on slide 7.  First quarter adjusted earnings per diluted share was $5.56, an increase of 10 1% compared to \nthe prior year.  This result was driven by the recovery of prescription volumes and primary care patient visits from \nthe COVID -19 pandemic, as we lapped the most significant pandemic impacts from lockdowns in Q1 of fiscal \n2021. ", "original_text": "In the June quarter, we reported approximately $95 \nmillion of charges associated with this initiative.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c021005163e64384352bd6e0c8ba4e8c4fc9f231fc3db2149671e0b2e77763e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "712ed9c8-cc23-4712-bb19-0963a9341340", "node_type": "1", "metadata": {"window": "Our \nguidance does not assume a material benefit in fiscal 2022.  In the June quarter, we reported approximately $95 \nmillion of charges associated with this initiative.  \n \n Moving now to our adjusted results for the first quarter, beginning with our consolidated results, which can be \nfound on slide 7.  First quarter adjusted earnings per diluted share was $5.56, an increase of 10 1% compared to \nthe prior year.  This result was driven by the recovery of prescription volumes and primary care patient visits from \nthe COVID -19 pandemic, as we lapped the most significant pandemic impacts from lockdowns in Q1 of fiscal \n2021.  It also includ ed a lower tax rate and the contribution from COVID -19 vaccine distribution and kitting \nprograms with the US government,  \n \nConsolidated revenues of $62.7 billion increased 13% from the prior year, driven by growth in the US \nPharmaceutical segment, largely d ue to higher volumes from retail national account customers and price \nincreases on branded and specialty pharmaceuticals, which is partially offset by branded to generic conversions.  \n \n Adjusted gross profit was $3.1 billion for the quarter, up 19% compared to the prior year. ", "original_text": "First quarter adjusted earnings per diluted share was $5.56, an increase of 10 1% compared to \nthe prior year. "}, "hash": "711d43209b5ece9cf8ec3781d491160b3ba4ccaec56780c204ae71f4c2292ba7", "class_name": "RelatedNodeInfo"}}, "text": "Moving now to our adjusted results for the first quarter, beginning with our consolidated results, which can be \nfound on slide 7. ", "start_char_idx": 1554, "end_char_idx": 1685, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "712ed9c8-cc23-4712-bb19-0963a9341340": {"__data__": {"id_": "712ed9c8-cc23-4712-bb19-0963a9341340", "embedding": null, "metadata": {"window": "Our \nguidance does not assume a material benefit in fiscal 2022.  In the June quarter, we reported approximately $95 \nmillion of charges associated with this initiative.  \n \n Moving now to our adjusted results for the first quarter, beginning with our consolidated results, which can be \nfound on slide 7.  First quarter adjusted earnings per diluted share was $5.56, an increase of 10 1% compared to \nthe prior year.  This result was driven by the recovery of prescription volumes and primary care patient visits from \nthe COVID -19 pandemic, as we lapped the most significant pandemic impacts from lockdowns in Q1 of fiscal \n2021.  It also includ ed a lower tax rate and the contribution from COVID -19 vaccine distribution and kitting \nprograms with the US government,  \n \nConsolidated revenues of $62.7 billion increased 13% from the prior year, driven by growth in the US \nPharmaceutical segment, largely d ue to higher volumes from retail national account customers and price \nincreases on branded and specialty pharmaceuticals, which is partially offset by branded to generic conversions.  \n \n Adjusted gross profit was $3.1 billion for the quarter, up 19% compared to the prior year. ", "original_text": "First quarter adjusted earnings per diluted share was $5.56, an increase of 10 1% compared to \nthe prior year. ", "page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f814064c-e4e4-4a0c-a559-30de71f2b69b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85a65a04cccabac635df21aab89fbbd2add3315c874738d8ae84667c676b0625", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d751b42-3569-4fbf-ac88-4025dd074770", "node_type": "1", "metadata": {"window": "These actions  will result in the realization of \nannual operating expense savings of approximately $60 million to $80 million when fully implemented.  Our \nguidance does not assume a material benefit in fiscal 2022.  In the June quarter, we reported approximately $95 \nmillion of charges associated with this initiative.  \n \n Moving now to our adjusted results for the first quarter, beginning with our consolidated results, which can be \nfound on slide 7.  First quarter adjusted earnings per diluted share was $5.56, an increase of 10 1% compared to \nthe prior year.  This result was driven by the recovery of prescription volumes and primary care patient visits from \nthe COVID -19 pandemic, as we lapped the most significant pandemic impacts from lockdowns in Q1 of fiscal \n2021.  It also includ ed a lower tax rate and the contribution from COVID -19 vaccine distribution and kitting \nprograms with the US government,  \n \nConsolidated revenues of $62.7 billion increased 13% from the prior year, driven by growth in the US \nPharmaceutical segment, largely d ue to higher volumes from retail national account customers and price \nincreases on branded and specialty pharmaceuticals, which is partially offset by branded to generic conversions.  \n \n", "original_text": "Moving now to our adjusted results for the first quarter, beginning with our consolidated results, which can be \nfound on slide 7. ", "page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a111e75f10c90cce4ab67292a9384eda0dbb8123f1c923d465b428472ac496fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fdcdf3c8-7100-47e6-a0eb-b575ef16f355", "node_type": "1", "metadata": {"window": "In the June quarter, we reported approximately $95 \nmillion of charges associated with this initiative.  \n \n Moving now to our adjusted results for the first quarter, beginning with our consolidated results, which can be \nfound on slide 7.  First quarter adjusted earnings per diluted share was $5.56, an increase of 10 1% compared to \nthe prior year.  This result was driven by the recovery of prescription volumes and primary care patient visits from \nthe COVID -19 pandemic, as we lapped the most significant pandemic impacts from lockdowns in Q1 of fiscal \n2021.  It also includ ed a lower tax rate and the contribution from COVID -19 vaccine distribution and kitting \nprograms with the US government,  \n \nConsolidated revenues of $62.7 billion increased 13% from the prior year, driven by growth in the US \nPharmaceutical segment, largely d ue to higher volumes from retail national account customers and price \nincreases on branded and specialty pharmaceuticals, which is partially offset by branded to generic conversions.  \n \n Adjusted gross profit was $3.1 billion for the quarter, up 19% compared to the prior year.  Adjusted operating \nexpenses in the quarter increased 6% year -over-year, led by higher operating expenses to support growth in our \ncore businesses and strategic investments, partially offset by the contribution of our German wholesale bus iness \nto the joint venture with Walgreens Boots Alliance.  \n \n", "original_text": "This result was driven by the recovery of prescription volumes and primary care patient visits from \nthe COVID -19 pandemic, as we lapped the most significant pandemic impacts from lockdowns in Q1 of fiscal \n2021. "}, "hash": "fe09c1f68cb40bc20413d5f9b6d37dd7b4bcc52094583c0cb702238b6e1d0054", "class_name": "RelatedNodeInfo"}}, "text": "First quarter adjusted earnings per diluted share was $5.56, an increase of 10 1% compared to \nthe prior year. ", "start_char_idx": 1685, "end_char_idx": 1796, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fdcdf3c8-7100-47e6-a0eb-b575ef16f355": {"__data__": {"id_": "fdcdf3c8-7100-47e6-a0eb-b575ef16f355", "embedding": null, "metadata": {"window": "In the June quarter, we reported approximately $95 \nmillion of charges associated with this initiative.  \n \n Moving now to our adjusted results for the first quarter, beginning with our consolidated results, which can be \nfound on slide 7.  First quarter adjusted earnings per diluted share was $5.56, an increase of 10 1% compared to \nthe prior year.  This result was driven by the recovery of prescription volumes and primary care patient visits from \nthe COVID -19 pandemic, as we lapped the most significant pandemic impacts from lockdowns in Q1 of fiscal \n2021.  It also includ ed a lower tax rate and the contribution from COVID -19 vaccine distribution and kitting \nprograms with the US government,  \n \nConsolidated revenues of $62.7 billion increased 13% from the prior year, driven by growth in the US \nPharmaceutical segment, largely d ue to higher volumes from retail national account customers and price \nincreases on branded and specialty pharmaceuticals, which is partially offset by branded to generic conversions.  \n \n Adjusted gross profit was $3.1 billion for the quarter, up 19% compared to the prior year.  Adjusted operating \nexpenses in the quarter increased 6% year -over-year, led by higher operating expenses to support growth in our \ncore businesses and strategic investments, partially offset by the contribution of our German wholesale bus iness \nto the joint venture with Walgreens Boots Alliance.  \n \n", "original_text": "This result was driven by the recovery of prescription volumes and primary care patient visits from \nthe COVID -19 pandemic, as we lapped the most significant pandemic impacts from lockdowns in Q1 of fiscal \n2021. ", "page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f814064c-e4e4-4a0c-a559-30de71f2b69b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85a65a04cccabac635df21aab89fbbd2add3315c874738d8ae84667c676b0625", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "712ed9c8-cc23-4712-bb19-0963a9341340", "node_type": "1", "metadata": {"window": "Our \nguidance does not assume a material benefit in fiscal 2022.  In the June quarter, we reported approximately $95 \nmillion of charges associated with this initiative.  \n \n Moving now to our adjusted results for the first quarter, beginning with our consolidated results, which can be \nfound on slide 7.  First quarter adjusted earnings per diluted share was $5.56, an increase of 10 1% compared to \nthe prior year.  This result was driven by the recovery of prescription volumes and primary care patient visits from \nthe COVID -19 pandemic, as we lapped the most significant pandemic impacts from lockdowns in Q1 of fiscal \n2021.  It also includ ed a lower tax rate and the contribution from COVID -19 vaccine distribution and kitting \nprograms with the US government,  \n \nConsolidated revenues of $62.7 billion increased 13% from the prior year, driven by growth in the US \nPharmaceutical segment, largely d ue to higher volumes from retail national account customers and price \nincreases on branded and specialty pharmaceuticals, which is partially offset by branded to generic conversions.  \n \n Adjusted gross profit was $3.1 billion for the quarter, up 19% compared to the prior year. ", "original_text": "First quarter adjusted earnings per diluted share was $5.56, an increase of 10 1% compared to \nthe prior year. ", "page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "26de1221b9207a8c2b3bd5e6bcca30fc3013a650d8dc3c8f6f56e6e6f15f64f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7457408c-9af1-49d5-acdf-08e8c9fd1f38", "node_type": "1", "metadata": {"window": "Moving now to our adjusted results for the first quarter, beginning with our consolidated results, which can be \nfound on slide 7.  First quarter adjusted earnings per diluted share was $5.56, an increase of 10 1% compared to \nthe prior year.  This result was driven by the recovery of prescription volumes and primary care patient visits from \nthe COVID -19 pandemic, as we lapped the most significant pandemic impacts from lockdowns in Q1 of fiscal \n2021.  It also includ ed a lower tax rate and the contribution from COVID -19 vaccine distribution and kitting \nprograms with the US government,  \n \nConsolidated revenues of $62.7 billion increased 13% from the prior year, driven by growth in the US \nPharmaceutical segment, largely d ue to higher volumes from retail national account customers and price \nincreases on branded and specialty pharmaceuticals, which is partially offset by branded to generic conversions.  \n \n Adjusted gross profit was $3.1 billion for the quarter, up 19% compared to the prior year.  Adjusted operating \nexpenses in the quarter increased 6% year -over-year, led by higher operating expenses to support growth in our \ncore businesses and strategic investments, partially offset by the contribution of our German wholesale bus iness \nto the joint venture with Walgreens Boots Alliance.  \n \n Adjusted operating profit was $1.1 billion for the quarter, an increase of 55% compared to the prior year, which \nreflects double -digit growth in each segment. ", "original_text": "It also includ ed a lower tax rate and the contribution from COVID -19 vaccine distribution and kitting \nprograms with the US government,  \n \nConsolidated revenues of $62.7 billion increased 13% from the prior year, driven by growth in the US \nPharmaceutical segment, largely d ue to higher volumes from retail national account customers and price \nincreases on branded and specialty pharmaceuticals, which is partially offset by branded to generic conversions.  \n \n"}, "hash": "c6e5f0b7f5ca7cb811ab8e62c78d7b4c0a447bb51a2fac04c75cfa7f9b9adf85", "class_name": "RelatedNodeInfo"}}, "text": "This result was driven by the recovery of prescription volumes and primary care patient visits from \nthe COVID -19 pandemic, as we lapped the most significant pandemic impacts from lockdowns in Q1 of fiscal \n2021. ", "start_char_idx": 1796, "end_char_idx": 2010, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7457408c-9af1-49d5-acdf-08e8c9fd1f38": {"__data__": {"id_": "7457408c-9af1-49d5-acdf-08e8c9fd1f38", "embedding": null, "metadata": {"window": "Moving now to our adjusted results for the first quarter, beginning with our consolidated results, which can be \nfound on slide 7.  First quarter adjusted earnings per diluted share was $5.56, an increase of 10 1% compared to \nthe prior year.  This result was driven by the recovery of prescription volumes and primary care patient visits from \nthe COVID -19 pandemic, as we lapped the most significant pandemic impacts from lockdowns in Q1 of fiscal \n2021.  It also includ ed a lower tax rate and the contribution from COVID -19 vaccine distribution and kitting \nprograms with the US government,  \n \nConsolidated revenues of $62.7 billion increased 13% from the prior year, driven by growth in the US \nPharmaceutical segment, largely d ue to higher volumes from retail national account customers and price \nincreases on branded and specialty pharmaceuticals, which is partially offset by branded to generic conversions.  \n \n Adjusted gross profit was $3.1 billion for the quarter, up 19% compared to the prior year.  Adjusted operating \nexpenses in the quarter increased 6% year -over-year, led by higher operating expenses to support growth in our \ncore businesses and strategic investments, partially offset by the contribution of our German wholesale bus iness \nto the joint venture with Walgreens Boots Alliance.  \n \n Adjusted operating profit was $1.1 billion for the quarter, an increase of 55% compared to the prior year, which \nreflects double -digit growth in each segment. ", "original_text": "It also includ ed a lower tax rate and the contribution from COVID -19 vaccine distribution and kitting \nprograms with the US government,  \n \nConsolidated revenues of $62.7 billion increased 13% from the prior year, driven by growth in the US \nPharmaceutical segment, largely d ue to higher volumes from retail national account customers and price \nincreases on branded and specialty pharmaceuticals, which is partially offset by branded to generic conversions.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f814064c-e4e4-4a0c-a559-30de71f2b69b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85a65a04cccabac635df21aab89fbbd2add3315c874738d8ae84667c676b0625", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fdcdf3c8-7100-47e6-a0eb-b575ef16f355", "node_type": "1", "metadata": {"window": "In the June quarter, we reported approximately $95 \nmillion of charges associated with this initiative.  \n \n Moving now to our adjusted results for the first quarter, beginning with our consolidated results, which can be \nfound on slide 7.  First quarter adjusted earnings per diluted share was $5.56, an increase of 10 1% compared to \nthe prior year.  This result was driven by the recovery of prescription volumes and primary care patient visits from \nthe COVID -19 pandemic, as we lapped the most significant pandemic impacts from lockdowns in Q1 of fiscal \n2021.  It also includ ed a lower tax rate and the contribution from COVID -19 vaccine distribution and kitting \nprograms with the US government,  \n \nConsolidated revenues of $62.7 billion increased 13% from the prior year, driven by growth in the US \nPharmaceutical segment, largely d ue to higher volumes from retail national account customers and price \nincreases on branded and specialty pharmaceuticals, which is partially offset by branded to generic conversions.  \n \n Adjusted gross profit was $3.1 billion for the quarter, up 19% compared to the prior year.  Adjusted operating \nexpenses in the quarter increased 6% year -over-year, led by higher operating expenses to support growth in our \ncore businesses and strategic investments, partially offset by the contribution of our German wholesale bus iness \nto the joint venture with Walgreens Boots Alliance.  \n \n", "original_text": "This result was driven by the recovery of prescription volumes and primary care patient visits from \nthe COVID -19 pandemic, as we lapped the most significant pandemic impacts from lockdowns in Q1 of fiscal \n2021. ", "page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7d59b7e1a7a39e00388b5b64afa1172868cdf7fb59f1d9518498509d85181f73", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93126888-687d-45e6-a1b0-b1aa390e640b", "node_type": "1", "metadata": {"window": "First quarter adjusted earnings per diluted share was $5.56, an increase of 10 1% compared to \nthe prior year.  This result was driven by the recovery of prescription volumes and primary care patient visits from \nthe COVID -19 pandemic, as we lapped the most significant pandemic impacts from lockdowns in Q1 of fiscal \n2021.  It also includ ed a lower tax rate and the contribution from COVID -19 vaccine distribution and kitting \nprograms with the US government,  \n \nConsolidated revenues of $62.7 billion increased 13% from the prior year, driven by growth in the US \nPharmaceutical segment, largely d ue to higher volumes from retail national account customers and price \nincreases on branded and specialty pharmaceuticals, which is partially offset by branded to generic conversions.  \n \n Adjusted gross profit was $3.1 billion for the quarter, up 19% compared to the prior year.  Adjusted operating \nexpenses in the quarter increased 6% year -over-year, led by higher operating expenses to support growth in our \ncore businesses and strategic investments, partially offset by the contribution of our German wholesale bus iness \nto the joint venture with Walgreens Boots Alliance.  \n \n Adjusted operating profit was $1.1 billion for the quarter, an increase of 55% compared to the prior year, which \nreflects double -digit growth in each segment.  Interest expense was $49 million in th e quarter, a decline of 18% \ncompared to the prior year, driven by the retirement of approximately $1 billion of long -term debt in fiscal 2021. \n", "original_text": "Adjusted gross profit was $3.1 billion for the quarter, up 19% compared to the prior year. "}, "hash": "69ed7ad65da60daf94a935fce8589be09f7c1d3d8294a778de46dd357c034d95", "class_name": "RelatedNodeInfo"}}, "text": "It also includ ed a lower tax rate and the contribution from COVID -19 vaccine distribution and kitting \nprograms with the US government,  \n \nConsolidated revenues of $62.7 billion increased 13% from the prior year, driven by growth in the US \nPharmaceutical segment, largely d ue to higher volumes from retail national account customers and price \nincreases on branded and specialty pharmaceuticals, which is partially offset by branded to generic conversions.  \n \n", "start_char_idx": 2010, "end_char_idx": 2476, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93126888-687d-45e6-a1b0-b1aa390e640b": {"__data__": {"id_": "93126888-687d-45e6-a1b0-b1aa390e640b", "embedding": null, "metadata": {"window": "First quarter adjusted earnings per diluted share was $5.56, an increase of 10 1% compared to \nthe prior year.  This result was driven by the recovery of prescription volumes and primary care patient visits from \nthe COVID -19 pandemic, as we lapped the most significant pandemic impacts from lockdowns in Q1 of fiscal \n2021.  It also includ ed a lower tax rate and the contribution from COVID -19 vaccine distribution and kitting \nprograms with the US government,  \n \nConsolidated revenues of $62.7 billion increased 13% from the prior year, driven by growth in the US \nPharmaceutical segment, largely d ue to higher volumes from retail national account customers and price \nincreases on branded and specialty pharmaceuticals, which is partially offset by branded to generic conversions.  \n \n Adjusted gross profit was $3.1 billion for the quarter, up 19% compared to the prior year.  Adjusted operating \nexpenses in the quarter increased 6% year -over-year, led by higher operating expenses to support growth in our \ncore businesses and strategic investments, partially offset by the contribution of our German wholesale bus iness \nto the joint venture with Walgreens Boots Alliance.  \n \n Adjusted operating profit was $1.1 billion for the quarter, an increase of 55% compared to the prior year, which \nreflects double -digit growth in each segment.  Interest expense was $49 million in th e quarter, a decline of 18% \ncompared to the prior year, driven by the retirement of approximately $1 billion of long -term debt in fiscal 2021. \n", "original_text": "Adjusted gross profit was $3.1 billion for the quarter, up 19% compared to the prior year. ", "page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f814064c-e4e4-4a0c-a559-30de71f2b69b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85a65a04cccabac635df21aab89fbbd2add3315c874738d8ae84667c676b0625", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7457408c-9af1-49d5-acdf-08e8c9fd1f38", "node_type": "1", "metadata": {"window": "Moving now to our adjusted results for the first quarter, beginning with our consolidated results, which can be \nfound on slide 7.  First quarter adjusted earnings per diluted share was $5.56, an increase of 10 1% compared to \nthe prior year.  This result was driven by the recovery of prescription volumes and primary care patient visits from \nthe COVID -19 pandemic, as we lapped the most significant pandemic impacts from lockdowns in Q1 of fiscal \n2021.  It also includ ed a lower tax rate and the contribution from COVID -19 vaccine distribution and kitting \nprograms with the US government,  \n \nConsolidated revenues of $62.7 billion increased 13% from the prior year, driven by growth in the US \nPharmaceutical segment, largely d ue to higher volumes from retail national account customers and price \nincreases on branded and specialty pharmaceuticals, which is partially offset by branded to generic conversions.  \n \n Adjusted gross profit was $3.1 billion for the quarter, up 19% compared to the prior year.  Adjusted operating \nexpenses in the quarter increased 6% year -over-year, led by higher operating expenses to support growth in our \ncore businesses and strategic investments, partially offset by the contribution of our German wholesale bus iness \nto the joint venture with Walgreens Boots Alliance.  \n \n Adjusted operating profit was $1.1 billion for the quarter, an increase of 55% compared to the prior year, which \nreflects double -digit growth in each segment. ", "original_text": "It also includ ed a lower tax rate and the contribution from COVID -19 vaccine distribution and kitting \nprograms with the US government,  \n \nConsolidated revenues of $62.7 billion increased 13% from the prior year, driven by growth in the US \nPharmaceutical segment, largely d ue to higher volumes from retail national account customers and price \nincreases on branded and specialty pharmaceuticals, which is partially offset by branded to generic conversions.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "15e8c48453b1f85e7cf7f63c4d3a2a62598801cddb018a04ccd588786f835b3c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38da15b6-9a60-4634-83b4-55ef267e4f15", "node_type": "1", "metadata": {"window": "This result was driven by the recovery of prescription volumes and primary care patient visits from \nthe COVID -19 pandemic, as we lapped the most significant pandemic impacts from lockdowns in Q1 of fiscal \n2021.  It also includ ed a lower tax rate and the contribution from COVID -19 vaccine distribution and kitting \nprograms with the US government,  \n \nConsolidated revenues of $62.7 billion increased 13% from the prior year, driven by growth in the US \nPharmaceutical segment, largely d ue to higher volumes from retail national account customers and price \nincreases on branded and specialty pharmaceuticals, which is partially offset by branded to generic conversions.  \n \n Adjusted gross profit was $3.1 billion for the quarter, up 19% compared to the prior year.  Adjusted operating \nexpenses in the quarter increased 6% year -over-year, led by higher operating expenses to support growth in our \ncore businesses and strategic investments, partially offset by the contribution of our German wholesale bus iness \nto the joint venture with Walgreens Boots Alliance.  \n \n Adjusted operating profit was $1.1 billion for the quarter, an increase of 55% compared to the prior year, which \nreflects double -digit growth in each segment.  Interest expense was $49 million in th e quarter, a decline of 18% \ncompared to the prior year, driven by the retirement of approximately $1 billion of long -term debt in fiscal 2021. \n Our adjusted tax rate was 11.3% for the quarter due to discrete tax items that were recorded during the quarter.  \n \n", "original_text": "Adjusted operating \nexpenses in the quarter increased 6% year -over-year, led by higher operating expenses to support growth in our \ncore businesses and strategic investments, partially offset by the contribution of our German wholesale bus iness \nto the joint venture with Walgreens Boots Alliance.  \n \n"}, "hash": "b7a978917c4a0703737801692c6685eeaa1d2e65771ac53982b3a7e4e6792e57", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted gross profit was $3.1 billion for the quarter, up 19% compared to the prior year. ", "start_char_idx": 2476, "end_char_idx": 2567, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38da15b6-9a60-4634-83b4-55ef267e4f15": {"__data__": {"id_": "38da15b6-9a60-4634-83b4-55ef267e4f15", "embedding": null, "metadata": {"window": "This result was driven by the recovery of prescription volumes and primary care patient visits from \nthe COVID -19 pandemic, as we lapped the most significant pandemic impacts from lockdowns in Q1 of fiscal \n2021.  It also includ ed a lower tax rate and the contribution from COVID -19 vaccine distribution and kitting \nprograms with the US government,  \n \nConsolidated revenues of $62.7 billion increased 13% from the prior year, driven by growth in the US \nPharmaceutical segment, largely d ue to higher volumes from retail national account customers and price \nincreases on branded and specialty pharmaceuticals, which is partially offset by branded to generic conversions.  \n \n Adjusted gross profit was $3.1 billion for the quarter, up 19% compared to the prior year.  Adjusted operating \nexpenses in the quarter increased 6% year -over-year, led by higher operating expenses to support growth in our \ncore businesses and strategic investments, partially offset by the contribution of our German wholesale bus iness \nto the joint venture with Walgreens Boots Alliance.  \n \n Adjusted operating profit was $1.1 billion for the quarter, an increase of 55% compared to the prior year, which \nreflects double -digit growth in each segment.  Interest expense was $49 million in th e quarter, a decline of 18% \ncompared to the prior year, driven by the retirement of approximately $1 billion of long -term debt in fiscal 2021. \n Our adjusted tax rate was 11.3% for the quarter due to discrete tax items that were recorded during the quarter.  \n \n", "original_text": "Adjusted operating \nexpenses in the quarter increased 6% year -over-year, led by higher operating expenses to support growth in our \ncore businesses and strategic investments, partially offset by the contribution of our German wholesale bus iness \nto the joint venture with Walgreens Boots Alliance.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f814064c-e4e4-4a0c-a559-30de71f2b69b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85a65a04cccabac635df21aab89fbbd2add3315c874738d8ae84667c676b0625", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93126888-687d-45e6-a1b0-b1aa390e640b", "node_type": "1", "metadata": {"window": "First quarter adjusted earnings per diluted share was $5.56, an increase of 10 1% compared to \nthe prior year.  This result was driven by the recovery of prescription volumes and primary care patient visits from \nthe COVID -19 pandemic, as we lapped the most significant pandemic impacts from lockdowns in Q1 of fiscal \n2021.  It also includ ed a lower tax rate and the contribution from COVID -19 vaccine distribution and kitting \nprograms with the US government,  \n \nConsolidated revenues of $62.7 billion increased 13% from the prior year, driven by growth in the US \nPharmaceutical segment, largely d ue to higher volumes from retail national account customers and price \nincreases on branded and specialty pharmaceuticals, which is partially offset by branded to generic conversions.  \n \n Adjusted gross profit was $3.1 billion for the quarter, up 19% compared to the prior year.  Adjusted operating \nexpenses in the quarter increased 6% year -over-year, led by higher operating expenses to support growth in our \ncore businesses and strategic investments, partially offset by the contribution of our German wholesale bus iness \nto the joint venture with Walgreens Boots Alliance.  \n \n Adjusted operating profit was $1.1 billion for the quarter, an increase of 55% compared to the prior year, which \nreflects double -digit growth in each segment.  Interest expense was $49 million in th e quarter, a decline of 18% \ncompared to the prior year, driven by the retirement of approximately $1 billion of long -term debt in fiscal 2021. \n", "original_text": "Adjusted gross profit was $3.1 billion for the quarter, up 19% compared to the prior year. ", "page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7834924f6eed9b34ed28efb07af7d8d9be16a4f2f5bd4704c3dac9651e1ad3e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e98bf018-66b5-4995-8749-b0d96ab85252", "node_type": "1", "metadata": {"window": "It also includ ed a lower tax rate and the contribution from COVID -19 vaccine distribution and kitting \nprograms with the US government,  \n \nConsolidated revenues of $62.7 billion increased 13% from the prior year, driven by growth in the US \nPharmaceutical segment, largely d ue to higher volumes from retail national account customers and price \nincreases on branded and specialty pharmaceuticals, which is partially offset by branded to generic conversions.  \n \n Adjusted gross profit was $3.1 billion for the quarter, up 19% compared to the prior year.  Adjusted operating \nexpenses in the quarter increased 6% year -over-year, led by higher operating expenses to support growth in our \ncore businesses and strategic investments, partially offset by the contribution of our German wholesale bus iness \nto the joint venture with Walgreens Boots Alliance.  \n \n Adjusted operating profit was $1.1 billion for the quarter, an increase of 55% compared to the prior year, which \nreflects double -digit growth in each segment.  Interest expense was $49 million in th e quarter, a decline of 18% \ncompared to the prior year, driven by the retirement of approximately $1 billion of long -term debt in fiscal 2021. \n Our adjusted tax rate was 11.3% for the quarter due to discrete tax items that were recorded during the quarter.  \n \n Our full year adjusted effective tax rate guidance of 18% to 19% remains unchanged. ", "original_text": "Adjusted operating profit was $1.1 billion for the quarter, an increase of 55% compared to the prior year, which \nreflects double -digit growth in each segment. "}, "hash": "813a0e1987e31fd8f56a2ad9c17cb75a39b043cb1587dc69c6f156179054c72e", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating \nexpenses in the quarter increased 6% year -over-year, led by higher operating expenses to support growth in our \ncore businesses and strategic investments, partially offset by the contribution of our German wholesale bus iness \nto the joint venture with Walgreens Boots Alliance.  \n \n", "start_char_idx": 2567, "end_char_idx": 2871, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e98bf018-66b5-4995-8749-b0d96ab85252": {"__data__": {"id_": "e98bf018-66b5-4995-8749-b0d96ab85252", "embedding": null, "metadata": {"window": "It also includ ed a lower tax rate and the contribution from COVID -19 vaccine distribution and kitting \nprograms with the US government,  \n \nConsolidated revenues of $62.7 billion increased 13% from the prior year, driven by growth in the US \nPharmaceutical segment, largely d ue to higher volumes from retail national account customers and price \nincreases on branded and specialty pharmaceuticals, which is partially offset by branded to generic conversions.  \n \n Adjusted gross profit was $3.1 billion for the quarter, up 19% compared to the prior year.  Adjusted operating \nexpenses in the quarter increased 6% year -over-year, led by higher operating expenses to support growth in our \ncore businesses and strategic investments, partially offset by the contribution of our German wholesale bus iness \nto the joint venture with Walgreens Boots Alliance.  \n \n Adjusted operating profit was $1.1 billion for the quarter, an increase of 55% compared to the prior year, which \nreflects double -digit growth in each segment.  Interest expense was $49 million in th e quarter, a decline of 18% \ncompared to the prior year, driven by the retirement of approximately $1 billion of long -term debt in fiscal 2021. \n Our adjusted tax rate was 11.3% for the quarter due to discrete tax items that were recorded during the quarter.  \n \n Our full year adjusted effective tax rate guidance of 18% to 19% remains unchanged. ", "original_text": "Adjusted operating profit was $1.1 billion for the quarter, an increase of 55% compared to the prior year, which \nreflects double -digit growth in each segment. ", "page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f814064c-e4e4-4a0c-a559-30de71f2b69b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85a65a04cccabac635df21aab89fbbd2add3315c874738d8ae84667c676b0625", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38da15b6-9a60-4634-83b4-55ef267e4f15", "node_type": "1", "metadata": {"window": "This result was driven by the recovery of prescription volumes and primary care patient visits from \nthe COVID -19 pandemic, as we lapped the most significant pandemic impacts from lockdowns in Q1 of fiscal \n2021.  It also includ ed a lower tax rate and the contribution from COVID -19 vaccine distribution and kitting \nprograms with the US government,  \n \nConsolidated revenues of $62.7 billion increased 13% from the prior year, driven by growth in the US \nPharmaceutical segment, largely d ue to higher volumes from retail national account customers and price \nincreases on branded and specialty pharmaceuticals, which is partially offset by branded to generic conversions.  \n \n Adjusted gross profit was $3.1 billion for the quarter, up 19% compared to the prior year.  Adjusted operating \nexpenses in the quarter increased 6% year -over-year, led by higher operating expenses to support growth in our \ncore businesses and strategic investments, partially offset by the contribution of our German wholesale bus iness \nto the joint venture with Walgreens Boots Alliance.  \n \n Adjusted operating profit was $1.1 billion for the quarter, an increase of 55% compared to the prior year, which \nreflects double -digit growth in each segment.  Interest expense was $49 million in th e quarter, a decline of 18% \ncompared to the prior year, driven by the retirement of approximately $1 billion of long -term debt in fiscal 2021. \n Our adjusted tax rate was 11.3% for the quarter due to discrete tax items that were recorded during the quarter.  \n \n", "original_text": "Adjusted operating \nexpenses in the quarter increased 6% year -over-year, led by higher operating expenses to support growth in our \ncore businesses and strategic investments, partially offset by the contribution of our German wholesale bus iness \nto the joint venture with Walgreens Boots Alliance.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3da685e365ff6d78b2e8b277fe0bd8af9fc4ac44173e3f214d46938fada65057", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a86b5497-f5ba-40b4-b33e-ea586b11cee7", "node_type": "1", "metadata": {"window": "Adjusted gross profit was $3.1 billion for the quarter, up 19% compared to the prior year.  Adjusted operating \nexpenses in the quarter increased 6% year -over-year, led by higher operating expenses to support growth in our \ncore businesses and strategic investments, partially offset by the contribution of our German wholesale bus iness \nto the joint venture with Walgreens Boots Alliance.  \n \n Adjusted operating profit was $1.1 billion for the quarter, an increase of 55% compared to the prior year, which \nreflects double -digit growth in each segment.  Interest expense was $49 million in th e quarter, a decline of 18% \ncompared to the prior year, driven by the retirement of approximately $1 billion of long -term debt in fiscal 2021. \n Our adjusted tax rate was 11.3% for the quarter due to discrete tax items that were recorded during the quarter.  \n \n Our full year adjusted effective tax rate guidance of 18% to 19% remains unchanged.  And our first quarter diluted \nweighted average shares were 158 million, a decrease of 3% year -over-year driven by $1 billion of shares \nrepurchased in the first quarter.  \n \n", "original_text": "Interest expense was $49 million in th e quarter, a decline of 18% \ncompared to the prior year, driven by the retirement of approximately $1 billion of long -term debt in fiscal 2021. \n"}, "hash": "d012efd24f1fadf633e346ea3a4a58104033df77279e4ebbe8a59b88dc984404", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating profit was $1.1 billion for the quarter, an increase of 55% compared to the prior year, which \nreflects double -digit growth in each segment. ", "start_char_idx": 2871, "end_char_idx": 3032, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a86b5497-f5ba-40b4-b33e-ea586b11cee7": {"__data__": {"id_": "a86b5497-f5ba-40b4-b33e-ea586b11cee7", "embedding": null, "metadata": {"window": "Adjusted gross profit was $3.1 billion for the quarter, up 19% compared to the prior year.  Adjusted operating \nexpenses in the quarter increased 6% year -over-year, led by higher operating expenses to support growth in our \ncore businesses and strategic investments, partially offset by the contribution of our German wholesale bus iness \nto the joint venture with Walgreens Boots Alliance.  \n \n Adjusted operating profit was $1.1 billion for the quarter, an increase of 55% compared to the prior year, which \nreflects double -digit growth in each segment.  Interest expense was $49 million in th e quarter, a decline of 18% \ncompared to the prior year, driven by the retirement of approximately $1 billion of long -term debt in fiscal 2021. \n Our adjusted tax rate was 11.3% for the quarter due to discrete tax items that were recorded during the quarter.  \n \n Our full year adjusted effective tax rate guidance of 18% to 19% remains unchanged.  And our first quarter diluted \nweighted average shares were 158 million, a decrease of 3% year -over-year driven by $1 billion of shares \nrepurchased in the first quarter.  \n \n", "original_text": "Interest expense was $49 million in th e quarter, a decline of 18% \ncompared to the prior year, driven by the retirement of approximately $1 billion of long -term debt in fiscal 2021. \n", "page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f814064c-e4e4-4a0c-a559-30de71f2b69b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85a65a04cccabac635df21aab89fbbd2add3315c874738d8ae84667c676b0625", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e98bf018-66b5-4995-8749-b0d96ab85252", "node_type": "1", "metadata": {"window": "It also includ ed a lower tax rate and the contribution from COVID -19 vaccine distribution and kitting \nprograms with the US government,  \n \nConsolidated revenues of $62.7 billion increased 13% from the prior year, driven by growth in the US \nPharmaceutical segment, largely d ue to higher volumes from retail national account customers and price \nincreases on branded and specialty pharmaceuticals, which is partially offset by branded to generic conversions.  \n \n Adjusted gross profit was $3.1 billion for the quarter, up 19% compared to the prior year.  Adjusted operating \nexpenses in the quarter increased 6% year -over-year, led by higher operating expenses to support growth in our \ncore businesses and strategic investments, partially offset by the contribution of our German wholesale bus iness \nto the joint venture with Walgreens Boots Alliance.  \n \n Adjusted operating profit was $1.1 billion for the quarter, an increase of 55% compared to the prior year, which \nreflects double -digit growth in each segment.  Interest expense was $49 million in th e quarter, a decline of 18% \ncompared to the prior year, driven by the retirement of approximately $1 billion of long -term debt in fiscal 2021. \n Our adjusted tax rate was 11.3% for the quarter due to discrete tax items that were recorded during the quarter.  \n \n Our full year adjusted effective tax rate guidance of 18% to 19% remains unchanged. ", "original_text": "Adjusted operating profit was $1.1 billion for the quarter, an increase of 55% compared to the prior year, which \nreflects double -digit growth in each segment. ", "page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28b43de5aa63a1895f4b444acdbff72ad9e207fd1990f8a725990d8f3ac7c675", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "698e1d7d-cd12-43e2-a5c0-4c9a01158a41", "node_type": "1", "metadata": {"window": "Adjusted operating \nexpenses in the quarter increased 6% year -over-year, led by higher operating expenses to support growth in our \ncore businesses and strategic investments, partially offset by the contribution of our German wholesale bus iness \nto the joint venture with Walgreens Boots Alliance.  \n \n Adjusted operating profit was $1.1 billion for the quarter, an increase of 55% compared to the prior year, which \nreflects double -digit growth in each segment.  Interest expense was $49 million in th e quarter, a decline of 18% \ncompared to the prior year, driven by the retirement of approximately $1 billion of long -term debt in fiscal 2021. \n Our adjusted tax rate was 11.3% for the quarter due to discrete tax items that were recorded during the quarter.  \n \n Our full year adjusted effective tax rate guidance of 18% to 19% remains unchanged.  And our first quarter diluted \nweighted average shares were 158 million, a decrease of 3% year -over-year driven by $1 billion of shares \nrepurchased in the first quarter.  \n \n Moving now to our first quarter segment results, which can be found on slides 8 through 12, and I'll start with US \nPharmaceutical. ", "original_text": "Our adjusted tax rate was 11.3% for the quarter due to discrete tax items that were recorded during the quarter.  \n \n"}, "hash": "63b68e54e2351977ad3b99e01d9e3ed358d8420aa99fb4ef55d15d2ba3bb9f9d", "class_name": "RelatedNodeInfo"}}, "text": "Interest expense was $49 million in th e quarter, a decline of 18% \ncompared to the prior year, driven by the retirement of approximately $1 billion of long -term debt in fiscal 2021. \n", "start_char_idx": 3032, "end_char_idx": 3217, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "698e1d7d-cd12-43e2-a5c0-4c9a01158a41": {"__data__": {"id_": "698e1d7d-cd12-43e2-a5c0-4c9a01158a41", "embedding": null, "metadata": {"window": "Adjusted operating \nexpenses in the quarter increased 6% year -over-year, led by higher operating expenses to support growth in our \ncore businesses and strategic investments, partially offset by the contribution of our German wholesale bus iness \nto the joint venture with Walgreens Boots Alliance.  \n \n Adjusted operating profit was $1.1 billion for the quarter, an increase of 55% compared to the prior year, which \nreflects double -digit growth in each segment.  Interest expense was $49 million in th e quarter, a decline of 18% \ncompared to the prior year, driven by the retirement of approximately $1 billion of long -term debt in fiscal 2021. \n Our adjusted tax rate was 11.3% for the quarter due to discrete tax items that were recorded during the quarter.  \n \n Our full year adjusted effective tax rate guidance of 18% to 19% remains unchanged.  And our first quarter diluted \nweighted average shares were 158 million, a decrease of 3% year -over-year driven by $1 billion of shares \nrepurchased in the first quarter.  \n \n Moving now to our first quarter segment results, which can be found on slides 8 through 12, and I'll start with US \nPharmaceutical. ", "original_text": "Our adjusted tax rate was 11.3% for the quarter due to discrete tax items that were recorded during the quarter.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f814064c-e4e4-4a0c-a559-30de71f2b69b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85a65a04cccabac635df21aab89fbbd2add3315c874738d8ae84667c676b0625", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a86b5497-f5ba-40b4-b33e-ea586b11cee7", "node_type": "1", "metadata": {"window": "Adjusted gross profit was $3.1 billion for the quarter, up 19% compared to the prior year.  Adjusted operating \nexpenses in the quarter increased 6% year -over-year, led by higher operating expenses to support growth in our \ncore businesses and strategic investments, partially offset by the contribution of our German wholesale bus iness \nto the joint venture with Walgreens Boots Alliance.  \n \n Adjusted operating profit was $1.1 billion for the quarter, an increase of 55% compared to the prior year, which \nreflects double -digit growth in each segment.  Interest expense was $49 million in th e quarter, a decline of 18% \ncompared to the prior year, driven by the retirement of approximately $1 billion of long -term debt in fiscal 2021. \n Our adjusted tax rate was 11.3% for the quarter due to discrete tax items that were recorded during the quarter.  \n \n Our full year adjusted effective tax rate guidance of 18% to 19% remains unchanged.  And our first quarter diluted \nweighted average shares were 158 million, a decrease of 3% year -over-year driven by $1 billion of shares \nrepurchased in the first quarter.  \n \n", "original_text": "Interest expense was $49 million in th e quarter, a decline of 18% \ncompared to the prior year, driven by the retirement of approximately $1 billion of long -term debt in fiscal 2021. \n", "page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7bf566a122b57d8fba6e8a9bd11d46fdc85aaaefa103ee16a27768a75348385a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba756eba-0b19-4a36-a4a1-c4d9105ffba6", "node_type": "1", "metadata": {"window": "Adjusted operating profit was $1.1 billion for the quarter, an increase of 55% compared to the prior year, which \nreflects double -digit growth in each segment.  Interest expense was $49 million in th e quarter, a decline of 18% \ncompared to the prior year, driven by the retirement of approximately $1 billion of long -term debt in fiscal 2021. \n Our adjusted tax rate was 11.3% for the quarter due to discrete tax items that were recorded during the quarter.  \n \n Our full year adjusted effective tax rate guidance of 18% to 19% remains unchanged.  And our first quarter diluted \nweighted average shares were 158 million, a decrease of 3% year -over-year driven by $1 billion of shares \nrepurchased in the first quarter.  \n \n Moving now to our first quarter segment results, which can be found on slides 8 through 12, and I'll start with US \nPharmaceutical.  Revenues were $50 billion, an increase of 12%, driven by higher volumes from retail national \naccount customers and price incre ases on branded and specialty pharmaceuticals, partially offset by branded to \ngeneric conversions.  \n ", "original_text": "Our full year adjusted effective tax rate guidance of 18% to 19% remains unchanged. "}, "hash": "cd97d211ada5f05f84f0613415e841a5061e2fd15c9ad519f57a69eba3ec8125", "class_name": "RelatedNodeInfo"}}, "text": "Our adjusted tax rate was 11.3% for the quarter due to discrete tax items that were recorded during the quarter.  \n \n", "start_char_idx": 3217, "end_char_idx": 3334, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ba756eba-0b19-4a36-a4a1-c4d9105ffba6": {"__data__": {"id_": "ba756eba-0b19-4a36-a4a1-c4d9105ffba6", "embedding": null, "metadata": {"window": "Adjusted operating profit was $1.1 billion for the quarter, an increase of 55% compared to the prior year, which \nreflects double -digit growth in each segment.  Interest expense was $49 million in th e quarter, a decline of 18% \ncompared to the prior year, driven by the retirement of approximately $1 billion of long -term debt in fiscal 2021. \n Our adjusted tax rate was 11.3% for the quarter due to discrete tax items that were recorded during the quarter.  \n \n Our full year adjusted effective tax rate guidance of 18% to 19% remains unchanged.  And our first quarter diluted \nweighted average shares were 158 million, a decrease of 3% year -over-year driven by $1 billion of shares \nrepurchased in the first quarter.  \n \n Moving now to our first quarter segment results, which can be found on slides 8 through 12, and I'll start with US \nPharmaceutical.  Revenues were $50 billion, an increase of 12%, driven by higher volumes from retail national \naccount customers and price incre ases on branded and specialty pharmaceuticals, partially offset by branded to \ngeneric conversions.  \n ", "original_text": "Our full year adjusted effective tax rate guidance of 18% to 19% remains unchanged. ", "page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f814064c-e4e4-4a0c-a559-30de71f2b69b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85a65a04cccabac635df21aab89fbbd2add3315c874738d8ae84667c676b0625", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "698e1d7d-cd12-43e2-a5c0-4c9a01158a41", "node_type": "1", "metadata": {"window": "Adjusted operating \nexpenses in the quarter increased 6% year -over-year, led by higher operating expenses to support growth in our \ncore businesses and strategic investments, partially offset by the contribution of our German wholesale bus iness \nto the joint venture with Walgreens Boots Alliance.  \n \n Adjusted operating profit was $1.1 billion for the quarter, an increase of 55% compared to the prior year, which \nreflects double -digit growth in each segment.  Interest expense was $49 million in th e quarter, a decline of 18% \ncompared to the prior year, driven by the retirement of approximately $1 billion of long -term debt in fiscal 2021. \n Our adjusted tax rate was 11.3% for the quarter due to discrete tax items that were recorded during the quarter.  \n \n Our full year adjusted effective tax rate guidance of 18% to 19% remains unchanged.  And our first quarter diluted \nweighted average shares were 158 million, a decrease of 3% year -over-year driven by $1 billion of shares \nrepurchased in the first quarter.  \n \n Moving now to our first quarter segment results, which can be found on slides 8 through 12, and I'll start with US \nPharmaceutical. ", "original_text": "Our adjusted tax rate was 11.3% for the quarter due to discrete tax items that were recorded during the quarter.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2eb7aaca262523d95f6d8745d8666a8f62fc097eb6b89326b7346f2b78d96c29", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6633cdd7-1e1c-47af-8a7d-136e6b475dfe", "node_type": "1", "metadata": {"window": "Interest expense was $49 million in th e quarter, a decline of 18% \ncompared to the prior year, driven by the retirement of approximately $1 billion of long -term debt in fiscal 2021. \n Our adjusted tax rate was 11.3% for the quarter due to discrete tax items that were recorded during the quarter.  \n \n Our full year adjusted effective tax rate guidance of 18% to 19% remains unchanged.  And our first quarter diluted \nweighted average shares were 158 million, a decrease of 3% year -over-year driven by $1 billion of shares \nrepurchased in the first quarter.  \n \n Moving now to our first quarter segment results, which can be found on slides 8 through 12, and I'll start with US \nPharmaceutical.  Revenues were $50 billion, an increase of 12%, driven by higher volumes from retail national \naccount customers and price incre ases on branded and specialty pharmaceuticals, partially offset by branded to \ngeneric conversions.  \n ", "original_text": "And our first quarter diluted \nweighted average shares were 158 million, a decrease of 3% year -over-year driven by $1 billion of shares \nrepurchased in the first quarter.  \n \n"}, "hash": "0cd518b7832cc620056c3b44815e29bbe8dc13ddf82f4d8cdaba022bb1f86d56", "class_name": "RelatedNodeInfo"}}, "text": "Our full year adjusted effective tax rate guidance of 18% to 19% remains unchanged. ", "start_char_idx": 3334, "end_char_idx": 3418, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6633cdd7-1e1c-47af-8a7d-136e6b475dfe": {"__data__": {"id_": "6633cdd7-1e1c-47af-8a7d-136e6b475dfe", "embedding": null, "metadata": {"window": "Interest expense was $49 million in th e quarter, a decline of 18% \ncompared to the prior year, driven by the retirement of approximately $1 billion of long -term debt in fiscal 2021. \n Our adjusted tax rate was 11.3% for the quarter due to discrete tax items that were recorded during the quarter.  \n \n Our full year adjusted effective tax rate guidance of 18% to 19% remains unchanged.  And our first quarter diluted \nweighted average shares were 158 million, a decrease of 3% year -over-year driven by $1 billion of shares \nrepurchased in the first quarter.  \n \n Moving now to our first quarter segment results, which can be found on slides 8 through 12, and I'll start with US \nPharmaceutical.  Revenues were $50 billion, an increase of 12%, driven by higher volumes from retail national \naccount customers and price incre ases on branded and specialty pharmaceuticals, partially offset by branded to \ngeneric conversions.  \n ", "original_text": "And our first quarter diluted \nweighted average shares were 158 million, a decrease of 3% year -over-year driven by $1 billion of shares \nrepurchased in the first quarter.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f814064c-e4e4-4a0c-a559-30de71f2b69b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85a65a04cccabac635df21aab89fbbd2add3315c874738d8ae84667c676b0625", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba756eba-0b19-4a36-a4a1-c4d9105ffba6", "node_type": "1", "metadata": {"window": "Adjusted operating profit was $1.1 billion for the quarter, an increase of 55% compared to the prior year, which \nreflects double -digit growth in each segment.  Interest expense was $49 million in th e quarter, a decline of 18% \ncompared to the prior year, driven by the retirement of approximately $1 billion of long -term debt in fiscal 2021. \n Our adjusted tax rate was 11.3% for the quarter due to discrete tax items that were recorded during the quarter.  \n \n Our full year adjusted effective tax rate guidance of 18% to 19% remains unchanged.  And our first quarter diluted \nweighted average shares were 158 million, a decrease of 3% year -over-year driven by $1 billion of shares \nrepurchased in the first quarter.  \n \n Moving now to our first quarter segment results, which can be found on slides 8 through 12, and I'll start with US \nPharmaceutical.  Revenues were $50 billion, an increase of 12%, driven by higher volumes from retail national \naccount customers and price incre ases on branded and specialty pharmaceuticals, partially offset by branded to \ngeneric conversions.  \n ", "original_text": "Our full year adjusted effective tax rate guidance of 18% to 19% remains unchanged. ", "page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1c3e838f67f1e6b940dd8387b2868f44f4a189dbdd865018cdf0554b9f27ecc5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f093c09-42b6-4a5a-8b8d-cc0a3901fe00", "node_type": "1", "metadata": {"window": "Our adjusted tax rate was 11.3% for the quarter due to discrete tax items that were recorded during the quarter.  \n \n Our full year adjusted effective tax rate guidance of 18% to 19% remains unchanged.  And our first quarter diluted \nweighted average shares were 158 million, a decrease of 3% year -over-year driven by $1 billion of shares \nrepurchased in the first quarter.  \n \n Moving now to our first quarter segment results, which can be found on slides 8 through 12, and I'll start with US \nPharmaceutical.  Revenues were $50 billion, an increase of 12%, driven by higher volumes from retail national \naccount customers and price incre ases on branded and specialty pharmaceuticals, partially offset by branded to \ngeneric conversions.  \n ", "original_text": "Moving now to our first quarter segment results, which can be found on slides 8 through 12, and I'll start with US \nPharmaceutical. "}, "hash": "a2aeceeb5bd94a43a9308996362d03e9b183689c4d4fcf29be6dca455a90ab8b", "class_name": "RelatedNodeInfo"}}, "text": "And our first quarter diluted \nweighted average shares were 158 million, a decrease of 3% year -over-year driven by $1 billion of shares \nrepurchased in the first quarter.  \n \n", "start_char_idx": 3418, "end_char_idx": 3594, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f093c09-42b6-4a5a-8b8d-cc0a3901fe00": {"__data__": {"id_": "8f093c09-42b6-4a5a-8b8d-cc0a3901fe00", "embedding": null, "metadata": {"window": "Our adjusted tax rate was 11.3% for the quarter due to discrete tax items that were recorded during the quarter.  \n \n Our full year adjusted effective tax rate guidance of 18% to 19% remains unchanged.  And our first quarter diluted \nweighted average shares were 158 million, a decrease of 3% year -over-year driven by $1 billion of shares \nrepurchased in the first quarter.  \n \n Moving now to our first quarter segment results, which can be found on slides 8 through 12, and I'll start with US \nPharmaceutical.  Revenues were $50 billion, an increase of 12%, driven by higher volumes from retail national \naccount customers and price incre ases on branded and specialty pharmaceuticals, partially offset by branded to \ngeneric conversions.  \n ", "original_text": "Moving now to our first quarter segment results, which can be found on slides 8 through 12, and I'll start with US \nPharmaceutical. ", "page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f814064c-e4e4-4a0c-a559-30de71f2b69b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85a65a04cccabac635df21aab89fbbd2add3315c874738d8ae84667c676b0625", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6633cdd7-1e1c-47af-8a7d-136e6b475dfe", "node_type": "1", "metadata": {"window": "Interest expense was $49 million in th e quarter, a decline of 18% \ncompared to the prior year, driven by the retirement of approximately $1 billion of long -term debt in fiscal 2021. \n Our adjusted tax rate was 11.3% for the quarter due to discrete tax items that were recorded during the quarter.  \n \n Our full year adjusted effective tax rate guidance of 18% to 19% remains unchanged.  And our first quarter diluted \nweighted average shares were 158 million, a decrease of 3% year -over-year driven by $1 billion of shares \nrepurchased in the first quarter.  \n \n Moving now to our first quarter segment results, which can be found on slides 8 through 12, and I'll start with US \nPharmaceutical.  Revenues were $50 billion, an increase of 12%, driven by higher volumes from retail national \naccount customers and price incre ases on branded and specialty pharmaceuticals, partially offset by branded to \ngeneric conversions.  \n ", "original_text": "And our first quarter diluted \nweighted average shares were 158 million, a decrease of 3% year -over-year driven by $1 billion of shares \nrepurchased in the first quarter.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cef43d76c9cfb87abacffedaaa4523a41effaaa1f564b9beb2cbfe7103b09a26", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db21c0dd-2673-403e-9089-f127cfb23285", "node_type": "1", "metadata": {"window": "Our full year adjusted effective tax rate guidance of 18% to 19% remains unchanged.  And our first quarter diluted \nweighted average shares were 158 million, a decrease of 3% year -over-year driven by $1 billion of shares \nrepurchased in the first quarter.  \n \n Moving now to our first quarter segment results, which can be found on slides 8 through 12, and I'll start with US \nPharmaceutical.  Revenues were $50 billion, an increase of 12%, driven by higher volumes from retail national \naccount customers and price incre ases on branded and specialty pharmaceuticals, partially offset by branded to \ngeneric conversions.  \n ", "original_text": "Revenues were $50 billion, an increase of 12%, driven by higher volumes from retail national \naccount customers and price incre ases on branded and specialty pharmaceuticals, partially offset by branded to \ngeneric conversions.  \n "}, "hash": "2e43053ba8bbad711399a8da3fe79d87de667679d08a20501d388e757783f7ac", "class_name": "RelatedNodeInfo"}}, "text": "Moving now to our first quarter segment results, which can be found on slides 8 through 12, and I'll start with US \nPharmaceutical. ", "start_char_idx": 3594, "end_char_idx": 3726, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db21c0dd-2673-403e-9089-f127cfb23285": {"__data__": {"id_": "db21c0dd-2673-403e-9089-f127cfb23285", "embedding": null, "metadata": {"window": "Our full year adjusted effective tax rate guidance of 18% to 19% remains unchanged.  And our first quarter diluted \nweighted average shares were 158 million, a decrease of 3% year -over-year driven by $1 billion of shares \nrepurchased in the first quarter.  \n \n Moving now to our first quarter segment results, which can be found on slides 8 through 12, and I'll start with US \nPharmaceutical.  Revenues were $50 billion, an increase of 12%, driven by higher volumes from retail national \naccount customers and price incre ases on branded and specialty pharmaceuticals, partially offset by branded to \ngeneric conversions.  \n ", "original_text": "Revenues were $50 billion, an increase of 12%, driven by higher volumes from retail national \naccount customers and price incre ases on branded and specialty pharmaceuticals, partially offset by branded to \ngeneric conversions.  \n ", "page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f814064c-e4e4-4a0c-a559-30de71f2b69b", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85a65a04cccabac635df21aab89fbbd2add3315c874738d8ae84667c676b0625", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f093c09-42b6-4a5a-8b8d-cc0a3901fe00", "node_type": "1", "metadata": {"window": "Our adjusted tax rate was 11.3% for the quarter due to discrete tax items that were recorded during the quarter.  \n \n Our full year adjusted effective tax rate guidance of 18% to 19% remains unchanged.  And our first quarter diluted \nweighted average shares were 158 million, a decrease of 3% year -over-year driven by $1 billion of shares \nrepurchased in the first quarter.  \n \n Moving now to our first quarter segment results, which can be found on slides 8 through 12, and I'll start with US \nPharmaceutical.  Revenues were $50 billion, an increase of 12%, driven by higher volumes from retail national \naccount customers and price incre ases on branded and specialty pharmaceuticals, partially offset by branded to \ngeneric conversions.  \n ", "original_text": "Moving now to our first quarter segment results, which can be found on slides 8 through 12, and I'll start with US \nPharmaceutical. ", "page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "901a6ca259557f7bdf40c3af8d870f79d7c266934c202b4cb719868c2d31ba0c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a90312b1-5ff9-4ef0-ae6a-5c8796ea43f6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit in the quarter increased 16% to $682 million, driven by the contribution from COVID -19 \nvaccine distribution and growth in specialt y products distribution to our providers and health care systems, which \nwas partially offset by higher operating costs in support of the company's oncology growth initiative.  \n \n Turning to Prescription Technology Solutions, we're very pleased with the strong  growth and scale that we're \nbuilding in this higher -margin segment.  The drivers for our Prescription Technology Solutions businesses continue \nto move in the right direction. ", "original_text": "McKesson Corp.  "}, "hash": "adda09aaa84719aa6567e9e3484e331a1b41805e5f95158a8c975de775ca4558", "class_name": "RelatedNodeInfo"}}, "text": "Revenues were $50 billion, an increase of 12%, driven by higher volumes from retail national \naccount customers and price incre ases on branded and specialty pharmaceuticals, partially offset by branded to \ngeneric conversions.  \n ", "start_char_idx": 3726, "end_char_idx": 3957, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a90312b1-5ff9-4ef0-ae6a-5c8796ea43f6": {"__data__": {"id_": "a90312b1-5ff9-4ef0-ae6a-5c8796ea43f6", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit in the quarter increased 16% to $682 million, driven by the contribution from COVID -19 \nvaccine distribution and growth in specialt y products distribution to our providers and health care systems, which \nwas partially offset by higher operating costs in support of the company's oncology growth initiative.  \n \n Turning to Prescription Technology Solutions, we're very pleased with the strong  growth and scale that we're \nbuilding in this higher -margin segment.  The drivers for our Prescription Technology Solutions businesses continue \nto move in the right direction. ", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "538e5af4-2c9f-4709-9ba0-f8be11c81f27", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8a4e26d803b2ff0d7de8095683cc2fc111a7d70f8b99b535df32135e202e2822", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db21c0dd-2673-403e-9089-f127cfb23285", "node_type": "1", "metadata": {"window": "Our full year adjusted effective tax rate guidance of 18% to 19% remains unchanged.  And our first quarter diluted \nweighted average shares were 158 million, a decrease of 3% year -over-year driven by $1 billion of shares \nrepurchased in the first quarter.  \n \n Moving now to our first quarter segment results, which can be found on slides 8 through 12, and I'll start with US \nPharmaceutical.  Revenues were $50 billion, an increase of 12%, driven by higher volumes from retail national \naccount customers and price incre ases on branded and specialty pharmaceuticals, partially offset by branded to \ngeneric conversions.  \n ", "original_text": "Revenues were $50 billion, an increase of 12%, driven by higher volumes from retail national \naccount customers and price incre ases on branded and specialty pharmaceuticals, partially offset by branded to \ngeneric conversions.  \n ", "page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7019fcfc34320346bd0dc94ef66b2e9aa8c4fd6915f49cd53036b875a14fff9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f566e4cc-3fad-49a4-899d-7a65ab8d5ab7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit in the quarter increased 16% to $682 million, driven by the contribution from COVID -19 \nvaccine distribution and growth in specialt y products distribution to our providers and health care systems, which \nwas partially offset by higher operating costs in support of the company's oncology growth initiative.  \n \n Turning to Prescription Technology Solutions, we're very pleased with the strong  growth and scale that we're \nbuilding in this higher -margin segment.  The drivers for our Prescription Technology Solutions businesses continue \nto move in the right direction.  First, we're seeing expansion in many of our services businesses as we continue t o \nadd more manufacturing partners and programs for our existing solutions such as electronic prior authorization, \nour access and adherence services and 3PL.  \n \n", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit in the quarter increased 16% to $682 million, driven by the contribution from COVID -19 \nvaccine distribution and growth in specialt y products distribution to our providers and health care systems, which \nwas partially offset by higher operating costs in support of the company's oncology growth initiative.  \n \n"}, "hash": "9a8a758950ed05ee6b784e46f23b55fc49319da953fd2fb89e5719cdb613fd9d", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f566e4cc-3fad-49a4-899d-7a65ab8d5ab7": {"__data__": {"id_": "f566e4cc-3fad-49a4-899d-7a65ab8d5ab7", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit in the quarter increased 16% to $682 million, driven by the contribution from COVID -19 \nvaccine distribution and growth in specialt y products distribution to our providers and health care systems, which \nwas partially offset by higher operating costs in support of the company's oncology growth initiative.  \n \n Turning to Prescription Technology Solutions, we're very pleased with the strong  growth and scale that we're \nbuilding in this higher -margin segment.  The drivers for our Prescription Technology Solutions businesses continue \nto move in the right direction.  First, we're seeing expansion in many of our services businesses as we continue t o \nadd more manufacturing partners and programs for our existing solutions such as electronic prior authorization, \nour access and adherence services and 3PL.  \n \n", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit in the quarter increased 16% to $682 million, driven by the contribution from COVID -19 \nvaccine distribution and growth in specialt y products distribution to our providers and health care systems, which \nwas partially offset by higher operating costs in support of the company's oncology growth initiative.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "538e5af4-2c9f-4709-9ba0-f8be11c81f27", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8a4e26d803b2ff0d7de8095683cc2fc111a7d70f8b99b535df32135e202e2822", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a90312b1-5ff9-4ef0-ae6a-5c8796ea43f6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit in the quarter increased 16% to $682 million, driven by the contribution from COVID -19 \nvaccine distribution and growth in specialt y products distribution to our providers and health care systems, which \nwas partially offset by higher operating costs in support of the company's oncology growth initiative.  \n \n Turning to Prescription Technology Solutions, we're very pleased with the strong  growth and scale that we're \nbuilding in this higher -margin segment.  The drivers for our Prescription Technology Solutions businesses continue \nto move in the right direction. ", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e949d2ffd8a45e44d72fe9047f8ec9e53fdd05bbb390e74e055b57b7ca0f966f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f32526a7-936e-4ff0-a791-9324a6177977", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit in the quarter increased 16% to $682 million, driven by the contribution from COVID -19 \nvaccine distribution and growth in specialt y products distribution to our providers and health care systems, which \nwas partially offset by higher operating costs in support of the company's oncology growth initiative.  \n \n Turning to Prescription Technology Solutions, we're very pleased with the strong  growth and scale that we're \nbuilding in this higher -margin segment.  The drivers for our Prescription Technology Solutions businesses continue \nto move in the right direction.  First, we're seeing expansion in many of our services businesses as we continue t o \nadd more manufacturing partners and programs for our existing solutions such as electronic prior authorization, \nour access and adherence services and 3PL.  \n \n Second, our technology -based platforms, like RelayHealth, support 19 billion clinical and financia l transactions \nannually, from claims routing in the growing discount card market to alerts and edits to make the practice of \npharmacy clinically safer and administratively more efficient. ", "original_text": "Turning to Prescription Technology Solutions, we're very pleased with the strong  growth and scale that we're \nbuilding in this higher -margin segment. "}, "hash": "02de96e9c6969260cedca01526f55a8b31abaf0b877d7533f0443b017065ff5a", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit in the quarter increased 16% to $682 million, driven by the contribution from COVID -19 \nvaccine distribution and growth in specialt y products distribution to our providers and health care systems, which \nwas partially offset by higher operating costs in support of the company's oncology growth initiative.  \n \n", "start_char_idx": 16, "end_char_idx": 519, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f32526a7-936e-4ff0-a791-9324a6177977": {"__data__": {"id_": "f32526a7-936e-4ff0-a791-9324a6177977", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit in the quarter increased 16% to $682 million, driven by the contribution from COVID -19 \nvaccine distribution and growth in specialt y products distribution to our providers and health care systems, which \nwas partially offset by higher operating costs in support of the company's oncology growth initiative.  \n \n Turning to Prescription Technology Solutions, we're very pleased with the strong  growth and scale that we're \nbuilding in this higher -margin segment.  The drivers for our Prescription Technology Solutions businesses continue \nto move in the right direction.  First, we're seeing expansion in many of our services businesses as we continue t o \nadd more manufacturing partners and programs for our existing solutions such as electronic prior authorization, \nour access and adherence services and 3PL.  \n \n Second, our technology -based platforms, like RelayHealth, support 19 billion clinical and financia l transactions \nannually, from claims routing in the growing discount card market to alerts and edits to make the practice of \npharmacy clinically safer and administratively more efficient. ", "original_text": "Turning to Prescription Technology Solutions, we're very pleased with the strong  growth and scale that we're \nbuilding in this higher -margin segment. ", "page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "538e5af4-2c9f-4709-9ba0-f8be11c81f27", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8a4e26d803b2ff0d7de8095683cc2fc111a7d70f8b99b535df32135e202e2822", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f566e4cc-3fad-49a4-899d-7a65ab8d5ab7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit in the quarter increased 16% to $682 million, driven by the contribution from COVID -19 \nvaccine distribution and growth in specialt y products distribution to our providers and health care systems, which \nwas partially offset by higher operating costs in support of the company's oncology growth initiative.  \n \n Turning to Prescription Technology Solutions, we're very pleased with the strong  growth and scale that we're \nbuilding in this higher -margin segment.  The drivers for our Prescription Technology Solutions businesses continue \nto move in the right direction.  First, we're seeing expansion in many of our services businesses as we continue t o \nadd more manufacturing partners and programs for our existing solutions such as electronic prior authorization, \nour access and adherence services and 3PL.  \n \n", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit in the quarter increased 16% to $682 million, driven by the contribution from COVID -19 \nvaccine distribution and growth in specialt y products distribution to our providers and health care systems, which \nwas partially offset by higher operating costs in support of the company's oncology growth initiative.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff845eaf535f8882f679261c561475d81e1f1136ce2c91040644ce5d41a2a512", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d382a1e-6038-4aeb-83f9-2454c8408fe6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit in the quarter increased 16% to $682 million, driven by the contribution from COVID -19 \nvaccine distribution and growth in specialt y products distribution to our providers and health care systems, which \nwas partially offset by higher operating costs in support of the company's oncology growth initiative.  \n \n Turning to Prescription Technology Solutions, we're very pleased with the strong  growth and scale that we're \nbuilding in this higher -margin segment.  The drivers for our Prescription Technology Solutions businesses continue \nto move in the right direction.  First, we're seeing expansion in many of our services businesses as we continue t o \nadd more manufacturing partners and programs for our existing solutions such as electronic prior authorization, \nour access and adherence services and 3PL.  \n \n Second, our technology -based platforms, like RelayHealth, support 19 billion clinical and financia l transactions \nannually, from claims routing in the growing discount card market to alerts and edits to make the practice of \npharmacy clinically safer and administratively more efficient.  And we continue to invest and innovate to build a \nconnected ecosyste m of biopharma services, our next -generation access and adherence solution, AMP, is \nshowing accelerated adoption and growth with new brands. ", "original_text": "The drivers for our Prescription Technology Solutions businesses continue \nto move in the right direction. "}, "hash": "ccc562e321a6145592d9d7f3daf7e1b4be4203b7415fc933acfde99eb91c1e21", "class_name": "RelatedNodeInfo"}}, "text": "Turning to Prescription Technology Solutions, we're very pleased with the strong  growth and scale that we're \nbuilding in this higher -margin segment. ", "start_char_idx": 519, "end_char_idx": 671, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d382a1e-6038-4aeb-83f9-2454c8408fe6": {"__data__": {"id_": "8d382a1e-6038-4aeb-83f9-2454c8408fe6", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit in the quarter increased 16% to $682 million, driven by the contribution from COVID -19 \nvaccine distribution and growth in specialt y products distribution to our providers and health care systems, which \nwas partially offset by higher operating costs in support of the company's oncology growth initiative.  \n \n Turning to Prescription Technology Solutions, we're very pleased with the strong  growth and scale that we're \nbuilding in this higher -margin segment.  The drivers for our Prescription Technology Solutions businesses continue \nto move in the right direction.  First, we're seeing expansion in many of our services businesses as we continue t o \nadd more manufacturing partners and programs for our existing solutions such as electronic prior authorization, \nour access and adherence services and 3PL.  \n \n Second, our technology -based platforms, like RelayHealth, support 19 billion clinical and financia l transactions \nannually, from claims routing in the growing discount card market to alerts and edits to make the practice of \npharmacy clinically safer and administratively more efficient.  And we continue to invest and innovate to build a \nconnected ecosyste m of biopharma services, our next -generation access and adherence solution, AMP, is \nshowing accelerated adoption and growth with new brands. ", "original_text": "The drivers for our Prescription Technology Solutions businesses continue \nto move in the right direction. ", "page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "538e5af4-2c9f-4709-9ba0-f8be11c81f27", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8a4e26d803b2ff0d7de8095683cc2fc111a7d70f8b99b535df32135e202e2822", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f32526a7-936e-4ff0-a791-9324a6177977", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit in the quarter increased 16% to $682 million, driven by the contribution from COVID -19 \nvaccine distribution and growth in specialt y products distribution to our providers and health care systems, which \nwas partially offset by higher operating costs in support of the company's oncology growth initiative.  \n \n Turning to Prescription Technology Solutions, we're very pleased with the strong  growth and scale that we're \nbuilding in this higher -margin segment.  The drivers for our Prescription Technology Solutions businesses continue \nto move in the right direction.  First, we're seeing expansion in many of our services businesses as we continue t o \nadd more manufacturing partners and programs for our existing solutions such as electronic prior authorization, \nour access and adherence services and 3PL.  \n \n Second, our technology -based platforms, like RelayHealth, support 19 billion clinical and financia l transactions \nannually, from claims routing in the growing discount card market to alerts and edits to make the practice of \npharmacy clinically safer and administratively more efficient. ", "original_text": "Turning to Prescription Technology Solutions, we're very pleased with the strong  growth and scale that we're \nbuilding in this higher -margin segment. ", "page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc9ca1047b5511d0222f9d69d5bcda477638b0c4e13e6bca18b9a60ea933c55d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49e135f0-05c0-4100-97f2-505cb130e0cb", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit in the quarter increased 16% to $682 million, driven by the contribution from COVID -19 \nvaccine distribution and growth in specialt y products distribution to our providers and health care systems, which \nwas partially offset by higher operating costs in support of the company's oncology growth initiative.  \n \n Turning to Prescription Technology Solutions, we're very pleased with the strong  growth and scale that we're \nbuilding in this higher -margin segment.  The drivers for our Prescription Technology Solutions businesses continue \nto move in the right direction.  First, we're seeing expansion in many of our services businesses as we continue t o \nadd more manufacturing partners and programs for our existing solutions such as electronic prior authorization, \nour access and adherence services and 3PL.  \n \n Second, our technology -based platforms, like RelayHealth, support 19 billion clinical and financia l transactions \nannually, from claims routing in the growing discount card market to alerts and edits to make the practice of \npharmacy clinically safer and administratively more efficient.  And we continue to invest and innovate to build a \nconnected ecosyste m of biopharma services, our next -generation access and adherence solution, AMP, is \nshowing accelerated adoption and growth with new brands.  This year, AMP is bringing its network -enabled \napproach to hub services and the support for oncology and specialty drugs covered under the medical benefit.  \n \n", "original_text": "First, we're seeing expansion in many of our services businesses as we continue t o \nadd more manufacturing partners and programs for our existing solutions such as electronic prior authorization, \nour access and adherence services and 3PL.  \n \n"}, "hash": "a8a027c65f438d7d850fa4fd983f3880acb7c887086e64aac7865a5952ce2413", "class_name": "RelatedNodeInfo"}}, "text": "The drivers for our Prescription Technology Solutions businesses continue \nto move in the right direction. ", "start_char_idx": 671, "end_char_idx": 778, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49e135f0-05c0-4100-97f2-505cb130e0cb": {"__data__": {"id_": "49e135f0-05c0-4100-97f2-505cb130e0cb", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit in the quarter increased 16% to $682 million, driven by the contribution from COVID -19 \nvaccine distribution and growth in specialt y products distribution to our providers and health care systems, which \nwas partially offset by higher operating costs in support of the company's oncology growth initiative.  \n \n Turning to Prescription Technology Solutions, we're very pleased with the strong  growth and scale that we're \nbuilding in this higher -margin segment.  The drivers for our Prescription Technology Solutions businesses continue \nto move in the right direction.  First, we're seeing expansion in many of our services businesses as we continue t o \nadd more manufacturing partners and programs for our existing solutions such as electronic prior authorization, \nour access and adherence services and 3PL.  \n \n Second, our technology -based platforms, like RelayHealth, support 19 billion clinical and financia l transactions \nannually, from claims routing in the growing discount card market to alerts and edits to make the practice of \npharmacy clinically safer and administratively more efficient.  And we continue to invest and innovate to build a \nconnected ecosyste m of biopharma services, our next -generation access and adherence solution, AMP, is \nshowing accelerated adoption and growth with new brands.  This year, AMP is bringing its network -enabled \napproach to hub services and the support for oncology and specialty drugs covered under the medical benefit.  \n \n", "original_text": "First, we're seeing expansion in many of our services businesses as we continue t o \nadd more manufacturing partners and programs for our existing solutions such as electronic prior authorization, \nour access and adherence services and 3PL.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "538e5af4-2c9f-4709-9ba0-f8be11c81f27", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8a4e26d803b2ff0d7de8095683cc2fc111a7d70f8b99b535df32135e202e2822", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d382a1e-6038-4aeb-83f9-2454c8408fe6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit in the quarter increased 16% to $682 million, driven by the contribution from COVID -19 \nvaccine distribution and growth in specialt y products distribution to our providers and health care systems, which \nwas partially offset by higher operating costs in support of the company's oncology growth initiative.  \n \n Turning to Prescription Technology Solutions, we're very pleased with the strong  growth and scale that we're \nbuilding in this higher -margin segment.  The drivers for our Prescription Technology Solutions businesses continue \nto move in the right direction.  First, we're seeing expansion in many of our services businesses as we continue t o \nadd more manufacturing partners and programs for our existing solutions such as electronic prior authorization, \nour access and adherence services and 3PL.  \n \n Second, our technology -based platforms, like RelayHealth, support 19 billion clinical and financia l transactions \nannually, from claims routing in the growing discount card market to alerts and edits to make the practice of \npharmacy clinically safer and administratively more efficient.  And we continue to invest and innovate to build a \nconnected ecosyste m of biopharma services, our next -generation access and adherence solution, AMP, is \nshowing accelerated adoption and growth with new brands. ", "original_text": "The drivers for our Prescription Technology Solutions businesses continue \nto move in the right direction. ", "page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73ae10e461db349c6487ab39dbdf67d74b0aa94909a3610675f00db429541b17", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae865361-eca3-4b03-8fde-163603c226b6", "node_type": "1", "metadata": {"window": "Turning to Prescription Technology Solutions, we're very pleased with the strong  growth and scale that we're \nbuilding in this higher -margin segment.  The drivers for our Prescription Technology Solutions businesses continue \nto move in the right direction.  First, we're seeing expansion in many of our services businesses as we continue t o \nadd more manufacturing partners and programs for our existing solutions such as electronic prior authorization, \nour access and adherence services and 3PL.  \n \n Second, our technology -based platforms, like RelayHealth, support 19 billion clinical and financia l transactions \nannually, from claims routing in the growing discount card market to alerts and edits to make the practice of \npharmacy clinically safer and administratively more efficient.  And we continue to invest and innovate to build a \nconnected ecosyste m of biopharma services, our next -generation access and adherence solution, AMP, is \nshowing accelerated adoption and growth with new brands.  This year, AMP is bringing its network -enabled \napproach to hub services and the support for oncology and specialty drugs covered under the medical benefit.  \n \n We also continue to expand our clinical decision support capabilities in provider office workflow across every \nmajor EHR. ", "original_text": "Second, our technology -based platforms, like RelayHealth, support 19 billion clinical and financia l transactions \nannually, from claims routing in the growing discount card market to alerts and edits to make the practice of \npharmacy clinically safer and administratively more efficient. "}, "hash": "74c138b7272bbb9a5ec0f1a5e87ac82d1b616685dbf9db6750e96a1d8c3c7090", "class_name": "RelatedNodeInfo"}}, "text": "First, we're seeing expansion in many of our services businesses as we continue t o \nadd more manufacturing partners and programs for our existing solutions such as electronic prior authorization, \nour access and adherence services and 3PL.  \n \n", "start_char_idx": 778, "end_char_idx": 1023, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae865361-eca3-4b03-8fde-163603c226b6": {"__data__": {"id_": "ae865361-eca3-4b03-8fde-163603c226b6", "embedding": null, "metadata": {"window": "Turning to Prescription Technology Solutions, we're very pleased with the strong  growth and scale that we're \nbuilding in this higher -margin segment.  The drivers for our Prescription Technology Solutions businesses continue \nto move in the right direction.  First, we're seeing expansion in many of our services businesses as we continue t o \nadd more manufacturing partners and programs for our existing solutions such as electronic prior authorization, \nour access and adherence services and 3PL.  \n \n Second, our technology -based platforms, like RelayHealth, support 19 billion clinical and financia l transactions \nannually, from claims routing in the growing discount card market to alerts and edits to make the practice of \npharmacy clinically safer and administratively more efficient.  And we continue to invest and innovate to build a \nconnected ecosyste m of biopharma services, our next -generation access and adherence solution, AMP, is \nshowing accelerated adoption and growth with new brands.  This year, AMP is bringing its network -enabled \napproach to hub services and the support for oncology and specialty drugs covered under the medical benefit.  \n \n We also continue to expand our clinical decision support capabilities in provider office workflow across every \nmajor EHR. ", "original_text": "Second, our technology -based platforms, like RelayHealth, support 19 billion clinical and financia l transactions \nannually, from claims routing in the growing discount card market to alerts and edits to make the practice of \npharmacy clinically safer and administratively more efficient. ", "page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "538e5af4-2c9f-4709-9ba0-f8be11c81f27", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8a4e26d803b2ff0d7de8095683cc2fc111a7d70f8b99b535df32135e202e2822", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49e135f0-05c0-4100-97f2-505cb130e0cb", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit in the quarter increased 16% to $682 million, driven by the contribution from COVID -19 \nvaccine distribution and growth in specialt y products distribution to our providers and health care systems, which \nwas partially offset by higher operating costs in support of the company's oncology growth initiative.  \n \n Turning to Prescription Technology Solutions, we're very pleased with the strong  growth and scale that we're \nbuilding in this higher -margin segment.  The drivers for our Prescription Technology Solutions businesses continue \nto move in the right direction.  First, we're seeing expansion in many of our services businesses as we continue t o \nadd more manufacturing partners and programs for our existing solutions such as electronic prior authorization, \nour access and adherence services and 3PL.  \n \n Second, our technology -based platforms, like RelayHealth, support 19 billion clinical and financia l transactions \nannually, from claims routing in the growing discount card market to alerts and edits to make the practice of \npharmacy clinically safer and administratively more efficient.  And we continue to invest and innovate to build a \nconnected ecosyste m of biopharma services, our next -generation access and adherence solution, AMP, is \nshowing accelerated adoption and growth with new brands.  This year, AMP is bringing its network -enabled \napproach to hub services and the support for oncology and specialty drugs covered under the medical benefit.  \n \n", "original_text": "First, we're seeing expansion in many of our services businesses as we continue t o \nadd more manufacturing partners and programs for our existing solutions such as electronic prior authorization, \nour access and adherence services and 3PL.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "affea92873fda93f9ce9b0fc760394d1345c8cadb53817a508a7aaee07beb19a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab6a8c2e-6ea9-4a48-9d0b-74cc3454b4f9", "node_type": "1", "metadata": {"window": "The drivers for our Prescription Technology Solutions businesses continue \nto move in the right direction.  First, we're seeing expansion in many of our services businesses as we continue t o \nadd more manufacturing partners and programs for our existing solutions such as electronic prior authorization, \nour access and adherence services and 3PL.  \n \n Second, our technology -based platforms, like RelayHealth, support 19 billion clinical and financia l transactions \nannually, from claims routing in the growing discount card market to alerts and edits to make the practice of \npharmacy clinically safer and administratively more efficient.  And we continue to invest and innovate to build a \nconnected ecosyste m of biopharma services, our next -generation access and adherence solution, AMP, is \nshowing accelerated adoption and growth with new brands.  This year, AMP is bringing its network -enabled \napproach to hub services and the support for oncology and specialty drugs covered under the medical benefit.  \n \n We also continue to expand our clinical decision support capabilities in provider office workflow across every \nmajor EHR.  Our technology network spans every touch point in the patient journey, from doctor's office to benefit \nverification to dispensing pharmacy, which allows us to address barriers in the patient journey by adding unique \nautomation that accelerates time to therapy and lowers patients' out -of-pocket costs.  \n \n", "original_text": "And we continue to invest and innovate to build a \nconnected ecosyste m of biopharma services, our next -generation access and adherence solution, AMP, is \nshowing accelerated adoption and growth with new brands. "}, "hash": "192236e6b32aff67e44359d74e15fb7beb2d53c558531071653613ad6eea6a44", "class_name": "RelatedNodeInfo"}}, "text": "Second, our technology -based platforms, like RelayHealth, support 19 billion clinical and financia l transactions \nannually, from claims routing in the growing discount card market to alerts and edits to make the practice of \npharmacy clinically safer and administratively more efficient. ", "start_char_idx": 1023, "end_char_idx": 1313, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab6a8c2e-6ea9-4a48-9d0b-74cc3454b4f9": {"__data__": {"id_": "ab6a8c2e-6ea9-4a48-9d0b-74cc3454b4f9", "embedding": null, "metadata": {"window": "The drivers for our Prescription Technology Solutions businesses continue \nto move in the right direction.  First, we're seeing expansion in many of our services businesses as we continue t o \nadd more manufacturing partners and programs for our existing solutions such as electronic prior authorization, \nour access and adherence services and 3PL.  \n \n Second, our technology -based platforms, like RelayHealth, support 19 billion clinical and financia l transactions \nannually, from claims routing in the growing discount card market to alerts and edits to make the practice of \npharmacy clinically safer and administratively more efficient.  And we continue to invest and innovate to build a \nconnected ecosyste m of biopharma services, our next -generation access and adherence solution, AMP, is \nshowing accelerated adoption and growth with new brands.  This year, AMP is bringing its network -enabled \napproach to hub services and the support for oncology and specialty drugs covered under the medical benefit.  \n \n We also continue to expand our clinical decision support capabilities in provider office workflow across every \nmajor EHR.  Our technology network spans every touch point in the patient journey, from doctor's office to benefit \nverification to dispensing pharmacy, which allows us to address barriers in the patient journey by adding unique \nautomation that accelerates time to therapy and lowers patients' out -of-pocket costs.  \n \n", "original_text": "And we continue to invest and innovate to build a \nconnected ecosyste m of biopharma services, our next -generation access and adherence solution, AMP, is \nshowing accelerated adoption and growth with new brands. ", "page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "538e5af4-2c9f-4709-9ba0-f8be11c81f27", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8a4e26d803b2ff0d7de8095683cc2fc111a7d70f8b99b535df32135e202e2822", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae865361-eca3-4b03-8fde-163603c226b6", "node_type": "1", "metadata": {"window": "Turning to Prescription Technology Solutions, we're very pleased with the strong  growth and scale that we're \nbuilding in this higher -margin segment.  The drivers for our Prescription Technology Solutions businesses continue \nto move in the right direction.  First, we're seeing expansion in many of our services businesses as we continue t o \nadd more manufacturing partners and programs for our existing solutions such as electronic prior authorization, \nour access and adherence services and 3PL.  \n \n Second, our technology -based platforms, like RelayHealth, support 19 billion clinical and financia l transactions \nannually, from claims routing in the growing discount card market to alerts and edits to make the practice of \npharmacy clinically safer and administratively more efficient.  And we continue to invest and innovate to build a \nconnected ecosyste m of biopharma services, our next -generation access and adherence solution, AMP, is \nshowing accelerated adoption and growth with new brands.  This year, AMP is bringing its network -enabled \napproach to hub services and the support for oncology and specialty drugs covered under the medical benefit.  \n \n We also continue to expand our clinical decision support capabilities in provider office workflow across every \nmajor EHR. ", "original_text": "Second, our technology -based platforms, like RelayHealth, support 19 billion clinical and financia l transactions \nannually, from claims routing in the growing discount card market to alerts and edits to make the practice of \npharmacy clinically safer and administratively more efficient. ", "page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28ef84c75bc9dd3326147e958679511aec3e212b95b6f73e54aae1f36a5514fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ebf078f5-b2d7-483b-ac2d-0176db9b45b6", "node_type": "1", "metadata": {"window": "First, we're seeing expansion in many of our services businesses as we continue t o \nadd more manufacturing partners and programs for our existing solutions such as electronic prior authorization, \nour access and adherence services and 3PL.  \n \n Second, our technology -based platforms, like RelayHealth, support 19 billion clinical and financia l transactions \nannually, from claims routing in the growing discount card market to alerts and edits to make the practice of \npharmacy clinically safer and administratively more efficient.  And we continue to invest and innovate to build a \nconnected ecosyste m of biopharma services, our next -generation access and adherence solution, AMP, is \nshowing accelerated adoption and growth with new brands.  This year, AMP is bringing its network -enabled \napproach to hub services and the support for oncology and specialty drugs covered under the medical benefit.  \n \n We also continue to expand our clinical decision support capabilities in provider office workflow across every \nmajor EHR.  Our technology network spans every touch point in the patient journey, from doctor's office to benefit \nverification to dispensing pharmacy, which allows us to address barriers in the patient journey by adding unique \nautomation that accelerates time to therapy and lowers patients' out -of-pocket costs.  \n \n In the June quarter, revenues were $881 milli on, an increase of 34%. ", "original_text": "This year, AMP is bringing its network -enabled \napproach to hub services and the support for oncology and specialty drugs covered under the medical benefit.  \n \n"}, "hash": "8c3fb85a633dd6ccae8e54797111147d25d7324a72c6eb2a5720e21f35fb6358", "class_name": "RelatedNodeInfo"}}, "text": "And we continue to invest and innovate to build a \nconnected ecosyste m of biopharma services, our next -generation access and adherence solution, AMP, is \nshowing accelerated adoption and growth with new brands. ", "start_char_idx": 1313, "end_char_idx": 1526, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ebf078f5-b2d7-483b-ac2d-0176db9b45b6": {"__data__": {"id_": "ebf078f5-b2d7-483b-ac2d-0176db9b45b6", "embedding": null, "metadata": {"window": "First, we're seeing expansion in many of our services businesses as we continue t o \nadd more manufacturing partners and programs for our existing solutions such as electronic prior authorization, \nour access and adherence services and 3PL.  \n \n Second, our technology -based platforms, like RelayHealth, support 19 billion clinical and financia l transactions \nannually, from claims routing in the growing discount card market to alerts and edits to make the practice of \npharmacy clinically safer and administratively more efficient.  And we continue to invest and innovate to build a \nconnected ecosyste m of biopharma services, our next -generation access and adherence solution, AMP, is \nshowing accelerated adoption and growth with new brands.  This year, AMP is bringing its network -enabled \napproach to hub services and the support for oncology and specialty drugs covered under the medical benefit.  \n \n We also continue to expand our clinical decision support capabilities in provider office workflow across every \nmajor EHR.  Our technology network spans every touch point in the patient journey, from doctor's office to benefit \nverification to dispensing pharmacy, which allows us to address barriers in the patient journey by adding unique \nautomation that accelerates time to therapy and lowers patients' out -of-pocket costs.  \n \n In the June quarter, revenues were $881 milli on, an increase of 34%. ", "original_text": "This year, AMP is bringing its network -enabled \napproach to hub services and the support for oncology and specialty drugs covered under the medical benefit.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "538e5af4-2c9f-4709-9ba0-f8be11c81f27", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8a4e26d803b2ff0d7de8095683cc2fc111a7d70f8b99b535df32135e202e2822", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab6a8c2e-6ea9-4a48-9d0b-74cc3454b4f9", "node_type": "1", "metadata": {"window": "The drivers for our Prescription Technology Solutions businesses continue \nto move in the right direction.  First, we're seeing expansion in many of our services businesses as we continue t o \nadd more manufacturing partners and programs for our existing solutions such as electronic prior authorization, \nour access and adherence services and 3PL.  \n \n Second, our technology -based platforms, like RelayHealth, support 19 billion clinical and financia l transactions \nannually, from claims routing in the growing discount card market to alerts and edits to make the practice of \npharmacy clinically safer and administratively more efficient.  And we continue to invest and innovate to build a \nconnected ecosyste m of biopharma services, our next -generation access and adherence solution, AMP, is \nshowing accelerated adoption and growth with new brands.  This year, AMP is bringing its network -enabled \napproach to hub services and the support for oncology and specialty drugs covered under the medical benefit.  \n \n We also continue to expand our clinical decision support capabilities in provider office workflow across every \nmajor EHR.  Our technology network spans every touch point in the patient journey, from doctor's office to benefit \nverification to dispensing pharmacy, which allows us to address barriers in the patient journey by adding unique \nautomation that accelerates time to therapy and lowers patients' out -of-pocket costs.  \n \n", "original_text": "And we continue to invest and innovate to build a \nconnected ecosyste m of biopharma services, our next -generation access and adherence solution, AMP, is \nshowing accelerated adoption and growth with new brands. ", "page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2199a6073348afad2e928f8c6f9ea6e6b233a2d8bc211ec625ff09749b76e727", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa80c09d-22e5-41b8-9fe2-368efcc71eeb", "node_type": "1", "metadata": {"window": "Second, our technology -based platforms, like RelayHealth, support 19 billion clinical and financia l transactions \nannually, from claims routing in the growing discount card market to alerts and edits to make the practice of \npharmacy clinically safer and administratively more efficient.  And we continue to invest and innovate to build a \nconnected ecosyste m of biopharma services, our next -generation access and adherence solution, AMP, is \nshowing accelerated adoption and growth with new brands.  This year, AMP is bringing its network -enabled \napproach to hub services and the support for oncology and specialty drugs covered under the medical benefit.  \n \n We also continue to expand our clinical decision support capabilities in provider office workflow across every \nmajor EHR.  Our technology network spans every touch point in the patient journey, from doctor's office to benefit \nverification to dispensing pharmacy, which allows us to address barriers in the patient journey by adding unique \nautomation that accelerates time to therapy and lowers patients' out -of-pocket costs.  \n \n In the June quarter, revenues were $881 milli on, an increase of 34%.  And adjusted operating profit increased \n62% to $139 million, driven by higher volumes of technology and service offerings to support biopharma \ncustomers, organic growth from access and adherence solutions and recovery of prescriptio n volumes from the \nCOVID -19 pandemic.  \n \n", "original_text": "We also continue to expand our clinical decision support capabilities in provider office workflow across every \nmajor EHR. "}, "hash": "92bc9e344e7a04d8f284c13c82e4c5c22bc6d4498e0f24d7dc6570ee6f4d737f", "class_name": "RelatedNodeInfo"}}, "text": "This year, AMP is bringing its network -enabled \napproach to hub services and the support for oncology and specialty drugs covered under the medical benefit.  \n \n", "start_char_idx": 1526, "end_char_idx": 1688, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa80c09d-22e5-41b8-9fe2-368efcc71eeb": {"__data__": {"id_": "aa80c09d-22e5-41b8-9fe2-368efcc71eeb", "embedding": null, "metadata": {"window": "Second, our technology -based platforms, like RelayHealth, support 19 billion clinical and financia l transactions \nannually, from claims routing in the growing discount card market to alerts and edits to make the practice of \npharmacy clinically safer and administratively more efficient.  And we continue to invest and innovate to build a \nconnected ecosyste m of biopharma services, our next -generation access and adherence solution, AMP, is \nshowing accelerated adoption and growth with new brands.  This year, AMP is bringing its network -enabled \napproach to hub services and the support for oncology and specialty drugs covered under the medical benefit.  \n \n We also continue to expand our clinical decision support capabilities in provider office workflow across every \nmajor EHR.  Our technology network spans every touch point in the patient journey, from doctor's office to benefit \nverification to dispensing pharmacy, which allows us to address barriers in the patient journey by adding unique \nautomation that accelerates time to therapy and lowers patients' out -of-pocket costs.  \n \n In the June quarter, revenues were $881 milli on, an increase of 34%.  And adjusted operating profit increased \n62% to $139 million, driven by higher volumes of technology and service offerings to support biopharma \ncustomers, organic growth from access and adherence solutions and recovery of prescriptio n volumes from the \nCOVID -19 pandemic.  \n \n", "original_text": "We also continue to expand our clinical decision support capabilities in provider office workflow across every \nmajor EHR. ", "page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "538e5af4-2c9f-4709-9ba0-f8be11c81f27", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8a4e26d803b2ff0d7de8095683cc2fc111a7d70f8b99b535df32135e202e2822", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ebf078f5-b2d7-483b-ac2d-0176db9b45b6", "node_type": "1", "metadata": {"window": "First, we're seeing expansion in many of our services businesses as we continue t o \nadd more manufacturing partners and programs for our existing solutions such as electronic prior authorization, \nour access and adherence services and 3PL.  \n \n Second, our technology -based platforms, like RelayHealth, support 19 billion clinical and financia l transactions \nannually, from claims routing in the growing discount card market to alerts and edits to make the practice of \npharmacy clinically safer and administratively more efficient.  And we continue to invest and innovate to build a \nconnected ecosyste m of biopharma services, our next -generation access and adherence solution, AMP, is \nshowing accelerated adoption and growth with new brands.  This year, AMP is bringing its network -enabled \napproach to hub services and the support for oncology and specialty drugs covered under the medical benefit.  \n \n We also continue to expand our clinical decision support capabilities in provider office workflow across every \nmajor EHR.  Our technology network spans every touch point in the patient journey, from doctor's office to benefit \nverification to dispensing pharmacy, which allows us to address barriers in the patient journey by adding unique \nautomation that accelerates time to therapy and lowers patients' out -of-pocket costs.  \n \n In the June quarter, revenues were $881 milli on, an increase of 34%. ", "original_text": "This year, AMP is bringing its network -enabled \napproach to hub services and the support for oncology and specialty drugs covered under the medical benefit.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "27d9016eee2951eb88dda2dec0d78f2e5acbd9982fc2488023f53b5d9ddc3ee5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e9bdfdb4-41a6-472a-9c5b-15bc6758ca01", "node_type": "1", "metadata": {"window": "And we continue to invest and innovate to build a \nconnected ecosyste m of biopharma services, our next -generation access and adherence solution, AMP, is \nshowing accelerated adoption and growth with new brands.  This year, AMP is bringing its network -enabled \napproach to hub services and the support for oncology and specialty drugs covered under the medical benefit.  \n \n We also continue to expand our clinical decision support capabilities in provider office workflow across every \nmajor EHR.  Our technology network spans every touch point in the patient journey, from doctor's office to benefit \nverification to dispensing pharmacy, which allows us to address barriers in the patient journey by adding unique \nautomation that accelerates time to therapy and lowers patients' out -of-pocket costs.  \n \n In the June quarter, revenues were $881 milli on, an increase of 34%.  And adjusted operating profit increased \n62% to $139 million, driven by higher volumes of technology and service offerings to support biopharma \ncustomers, organic growth from access and adherence solutions and recovery of prescriptio n volumes from the \nCOVID -19 pandemic.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.5 billion in the quarter, up 40%, driven by \nimprovements in primary care patient visits and increased sales of COVID -19 tests. ", "original_text": "Our technology network spans every touch point in the patient journey, from doctor's office to benefit \nverification to dispensing pharmacy, which allows us to address barriers in the patient journey by adding unique \nautomation that accelerates time to therapy and lowers patients' out -of-pocket costs.  \n \n"}, "hash": "fbc0cd3703a7403167fd9e0c96d5d7d9148e16eeda12ddaa953df60fcbacf249", "class_name": "RelatedNodeInfo"}}, "text": "We also continue to expand our clinical decision support capabilities in provider office workflow across every \nmajor EHR. ", "start_char_idx": 1688, "end_char_idx": 1811, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e9bdfdb4-41a6-472a-9c5b-15bc6758ca01": {"__data__": {"id_": "e9bdfdb4-41a6-472a-9c5b-15bc6758ca01", "embedding": null, "metadata": {"window": "And we continue to invest and innovate to build a \nconnected ecosyste m of biopharma services, our next -generation access and adherence solution, AMP, is \nshowing accelerated adoption and growth with new brands.  This year, AMP is bringing its network -enabled \napproach to hub services and the support for oncology and specialty drugs covered under the medical benefit.  \n \n We also continue to expand our clinical decision support capabilities in provider office workflow across every \nmajor EHR.  Our technology network spans every touch point in the patient journey, from doctor's office to benefit \nverification to dispensing pharmacy, which allows us to address barriers in the patient journey by adding unique \nautomation that accelerates time to therapy and lowers patients' out -of-pocket costs.  \n \n In the June quarter, revenues were $881 milli on, an increase of 34%.  And adjusted operating profit increased \n62% to $139 million, driven by higher volumes of technology and service offerings to support biopharma \ncustomers, organic growth from access and adherence solutions and recovery of prescriptio n volumes from the \nCOVID -19 pandemic.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.5 billion in the quarter, up 40%, driven by \nimprovements in primary care patient visits and increased sales of COVID -19 tests. ", "original_text": "Our technology network spans every touch point in the patient journey, from doctor's office to benefit \nverification to dispensing pharmacy, which allows us to address barriers in the patient journey by adding unique \nautomation that accelerates time to therapy and lowers patients' out -of-pocket costs.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "538e5af4-2c9f-4709-9ba0-f8be11c81f27", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8a4e26d803b2ff0d7de8095683cc2fc111a7d70f8b99b535df32135e202e2822", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa80c09d-22e5-41b8-9fe2-368efcc71eeb", "node_type": "1", "metadata": {"window": "Second, our technology -based platforms, like RelayHealth, support 19 billion clinical and financia l transactions \nannually, from claims routing in the growing discount card market to alerts and edits to make the practice of \npharmacy clinically safer and administratively more efficient.  And we continue to invest and innovate to build a \nconnected ecosyste m of biopharma services, our next -generation access and adherence solution, AMP, is \nshowing accelerated adoption and growth with new brands.  This year, AMP is bringing its network -enabled \napproach to hub services and the support for oncology and specialty drugs covered under the medical benefit.  \n \n We also continue to expand our clinical decision support capabilities in provider office workflow across every \nmajor EHR.  Our technology network spans every touch point in the patient journey, from doctor's office to benefit \nverification to dispensing pharmacy, which allows us to address barriers in the patient journey by adding unique \nautomation that accelerates time to therapy and lowers patients' out -of-pocket costs.  \n \n In the June quarter, revenues were $881 milli on, an increase of 34%.  And adjusted operating profit increased \n62% to $139 million, driven by higher volumes of technology and service offerings to support biopharma \ncustomers, organic growth from access and adherence solutions and recovery of prescriptio n volumes from the \nCOVID -19 pandemic.  \n \n", "original_text": "We also continue to expand our clinical decision support capabilities in provider office workflow across every \nmajor EHR. ", "page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "24320e8add7626ec1969b0e15316291af62b2fb5edf983fe5a18d24e8e312841", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "adfbc5c6-dbec-434e-b607-3781ca9b0e3d", "node_type": "1", "metadata": {"window": "This year, AMP is bringing its network -enabled \napproach to hub services and the support for oncology and specialty drugs covered under the medical benefit.  \n \n We also continue to expand our clinical decision support capabilities in provider office workflow across every \nmajor EHR.  Our technology network spans every touch point in the patient journey, from doctor's office to benefit \nverification to dispensing pharmacy, which allows us to address barriers in the patient journey by adding unique \nautomation that accelerates time to therapy and lowers patients' out -of-pocket costs.  \n \n In the June quarter, revenues were $881 milli on, an increase of 34%.  And adjusted operating profit increased \n62% to $139 million, driven by higher volumes of technology and service offerings to support biopharma \ncustomers, organic growth from access and adherence solutions and recovery of prescriptio n volumes from the \nCOVID -19 pandemic.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.5 billion in the quarter, up 40%, driven by \nimprovements in primary care patient visits and increased sales of COVID -19 tests.  The contribution from our \ncontr act with US government to prepare and distribute ancillary supplies related to the COVID -19 vaccine \nprovided a benefit of approximately $0.25 in the quarter and were above our original expectations.  \n \n", "original_text": "In the June quarter, revenues were $881 milli on, an increase of 34%. "}, "hash": "2799ba6e36d30f6b9514685ed2da6ec27eb3d89ebdb3afa94a81d03cedf73c7e", "class_name": "RelatedNodeInfo"}}, "text": "Our technology network spans every touch point in the patient journey, from doctor's office to benefit \nverification to dispensing pharmacy, which allows us to address barriers in the patient journey by adding unique \nautomation that accelerates time to therapy and lowers patients' out -of-pocket costs.  \n \n", "start_char_idx": 1811, "end_char_idx": 2120, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "adfbc5c6-dbec-434e-b607-3781ca9b0e3d": {"__data__": {"id_": "adfbc5c6-dbec-434e-b607-3781ca9b0e3d", "embedding": null, "metadata": {"window": "This year, AMP is bringing its network -enabled \napproach to hub services and the support for oncology and specialty drugs covered under the medical benefit.  \n \n We also continue to expand our clinical decision support capabilities in provider office workflow across every \nmajor EHR.  Our technology network spans every touch point in the patient journey, from doctor's office to benefit \nverification to dispensing pharmacy, which allows us to address barriers in the patient journey by adding unique \nautomation that accelerates time to therapy and lowers patients' out -of-pocket costs.  \n \n In the June quarter, revenues were $881 milli on, an increase of 34%.  And adjusted operating profit increased \n62% to $139 million, driven by higher volumes of technology and service offerings to support biopharma \ncustomers, organic growth from access and adherence solutions and recovery of prescriptio n volumes from the \nCOVID -19 pandemic.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.5 billion in the quarter, up 40%, driven by \nimprovements in primary care patient visits and increased sales of COVID -19 tests.  The contribution from our \ncontr act with US government to prepare and distribute ancillary supplies related to the COVID -19 vaccine \nprovided a benefit of approximately $0.25 in the quarter and were above our original expectations.  \n \n", "original_text": "In the June quarter, revenues were $881 milli on, an increase of 34%. ", "page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "538e5af4-2c9f-4709-9ba0-f8be11c81f27", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8a4e26d803b2ff0d7de8095683cc2fc111a7d70f8b99b535df32135e202e2822", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e9bdfdb4-41a6-472a-9c5b-15bc6758ca01", "node_type": "1", "metadata": {"window": "And we continue to invest and innovate to build a \nconnected ecosyste m of biopharma services, our next -generation access and adherence solution, AMP, is \nshowing accelerated adoption and growth with new brands.  This year, AMP is bringing its network -enabled \napproach to hub services and the support for oncology and specialty drugs covered under the medical benefit.  \n \n We also continue to expand our clinical decision support capabilities in provider office workflow across every \nmajor EHR.  Our technology network spans every touch point in the patient journey, from doctor's office to benefit \nverification to dispensing pharmacy, which allows us to address barriers in the patient journey by adding unique \nautomation that accelerates time to therapy and lowers patients' out -of-pocket costs.  \n \n In the June quarter, revenues were $881 milli on, an increase of 34%.  And adjusted operating profit increased \n62% to $139 million, driven by higher volumes of technology and service offerings to support biopharma \ncustomers, organic growth from access and adherence solutions and recovery of prescriptio n volumes from the \nCOVID -19 pandemic.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.5 billion in the quarter, up 40%, driven by \nimprovements in primary care patient visits and increased sales of COVID -19 tests. ", "original_text": "Our technology network spans every touch point in the patient journey, from doctor's office to benefit \nverification to dispensing pharmacy, which allows us to address barriers in the patient journey by adding unique \nautomation that accelerates time to therapy and lowers patients' out -of-pocket costs.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5e6f47dfcc9d65c31f20c2439fc091208ab0103614bc053e793189cd16b97720", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b868dc91-776d-413c-b5ef-2a69250b4110", "node_type": "1", "metadata": {"window": "We also continue to expand our clinical decision support capabilities in provider office workflow across every \nmajor EHR.  Our technology network spans every touch point in the patient journey, from doctor's office to benefit \nverification to dispensing pharmacy, which allows us to address barriers in the patient journey by adding unique \nautomation that accelerates time to therapy and lowers patients' out -of-pocket costs.  \n \n In the June quarter, revenues were $881 milli on, an increase of 34%.  And adjusted operating profit increased \n62% to $139 million, driven by higher volumes of technology and service offerings to support biopharma \ncustomers, organic growth from access and adherence solutions and recovery of prescriptio n volumes from the \nCOVID -19 pandemic.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.5 billion in the quarter, up 40%, driven by \nimprovements in primary care patient visits and increased sales of COVID -19 tests.  The contribution from our \ncontr act with US government to prepare and distribute ancillary supplies related to the COVID -19 vaccine \nprovided a benefit of approximately $0.25 in the quarter and were above our original expectations.  \n \n For the quarter, adjusted operating profit increased 107 % to $257 million, driven by improvements in primary care \npatient visits and the contribution from kitting and distribution of ancillary supplies for the US government's \nCOVID -19 vaccine program.  \n \n", "original_text": "And adjusted operating profit increased \n62% to $139 million, driven by higher volumes of technology and service offerings to support biopharma \ncustomers, organic growth from access and adherence solutions and recovery of prescriptio n volumes from the \nCOVID -19 pandemic.  \n \n"}, "hash": "a9389cac9ee35de5b9bc94229dfb07943f73ee9b5bf566c36bb82c9a74e186c7", "class_name": "RelatedNodeInfo"}}, "text": "In the June quarter, revenues were $881 milli on, an increase of 34%. ", "start_char_idx": 2120, "end_char_idx": 2190, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b868dc91-776d-413c-b5ef-2a69250b4110": {"__data__": {"id_": "b868dc91-776d-413c-b5ef-2a69250b4110", "embedding": null, "metadata": {"window": "We also continue to expand our clinical decision support capabilities in provider office workflow across every \nmajor EHR.  Our technology network spans every touch point in the patient journey, from doctor's office to benefit \nverification to dispensing pharmacy, which allows us to address barriers in the patient journey by adding unique \nautomation that accelerates time to therapy and lowers patients' out -of-pocket costs.  \n \n In the June quarter, revenues were $881 milli on, an increase of 34%.  And adjusted operating profit increased \n62% to $139 million, driven by higher volumes of technology and service offerings to support biopharma \ncustomers, organic growth from access and adherence solutions and recovery of prescriptio n volumes from the \nCOVID -19 pandemic.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.5 billion in the quarter, up 40%, driven by \nimprovements in primary care patient visits and increased sales of COVID -19 tests.  The contribution from our \ncontr act with US government to prepare and distribute ancillary supplies related to the COVID -19 vaccine \nprovided a benefit of approximately $0.25 in the quarter and were above our original expectations.  \n \n For the quarter, adjusted operating profit increased 107 % to $257 million, driven by improvements in primary care \npatient visits and the contribution from kitting and distribution of ancillary supplies for the US government's \nCOVID -19 vaccine program.  \n \n", "original_text": "And adjusted operating profit increased \n62% to $139 million, driven by higher volumes of technology and service offerings to support biopharma \ncustomers, organic growth from access and adherence solutions and recovery of prescriptio n volumes from the \nCOVID -19 pandemic.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "538e5af4-2c9f-4709-9ba0-f8be11c81f27", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8a4e26d803b2ff0d7de8095683cc2fc111a7d70f8b99b535df32135e202e2822", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "adfbc5c6-dbec-434e-b607-3781ca9b0e3d", "node_type": "1", "metadata": {"window": "This year, AMP is bringing its network -enabled \napproach to hub services and the support for oncology and specialty drugs covered under the medical benefit.  \n \n We also continue to expand our clinical decision support capabilities in provider office workflow across every \nmajor EHR.  Our technology network spans every touch point in the patient journey, from doctor's office to benefit \nverification to dispensing pharmacy, which allows us to address barriers in the patient journey by adding unique \nautomation that accelerates time to therapy and lowers patients' out -of-pocket costs.  \n \n In the June quarter, revenues were $881 milli on, an increase of 34%.  And adjusted operating profit increased \n62% to $139 million, driven by higher volumes of technology and service offerings to support biopharma \ncustomers, organic growth from access and adherence solutions and recovery of prescriptio n volumes from the \nCOVID -19 pandemic.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.5 billion in the quarter, up 40%, driven by \nimprovements in primary care patient visits and increased sales of COVID -19 tests.  The contribution from our \ncontr act with US government to prepare and distribute ancillary supplies related to the COVID -19 vaccine \nprovided a benefit of approximately $0.25 in the quarter and were above our original expectations.  \n \n", "original_text": "In the June quarter, revenues were $881 milli on, an increase of 34%. ", "page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e227e4f735ecccc405e228d46d56c1a1f1278364a6614fc4a77cd655d878089c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f455dcc5-044c-4b2d-8b19-e3e2b1298a25", "node_type": "1", "metadata": {"window": "Our technology network spans every touch point in the patient journey, from doctor's office to benefit \nverification to dispensing pharmacy, which allows us to address barriers in the patient journey by adding unique \nautomation that accelerates time to therapy and lowers patients' out -of-pocket costs.  \n \n In the June quarter, revenues were $881 milli on, an increase of 34%.  And adjusted operating profit increased \n62% to $139 million, driven by higher volumes of technology and service offerings to support biopharma \ncustomers, organic growth from access and adherence solutions and recovery of prescriptio n volumes from the \nCOVID -19 pandemic.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.5 billion in the quarter, up 40%, driven by \nimprovements in primary care patient visits and increased sales of COVID -19 tests.  The contribution from our \ncontr act with US government to prepare and distribute ancillary supplies related to the COVID -19 vaccine \nprovided a benefit of approximately $0.25 in the quarter and were above our original expectations.  \n \n For the quarter, adjusted operating profit increased 107 % to $257 million, driven by improvements in primary care \npatient visits and the contribution from kitting and distribution of ancillary supplies for the US government's \nCOVID -19 vaccine program.  \n \n Next, let me speak about International. ", "original_text": "Moving now to Medical -Surgical Solutions, revenues were $2.5 billion in the quarter, up 40%, driven by \nimprovements in primary care patient visits and increased sales of COVID -19 tests. "}, "hash": "4b2c78357cdfc48b99be512581c96475776f9432785019e28b1f3c039b7ebb7f", "class_name": "RelatedNodeInfo"}}, "text": "And adjusted operating profit increased \n62% to $139 million, driven by higher volumes of technology and service offerings to support biopharma \ncustomers, organic growth from access and adherence solutions and recovery of prescriptio n volumes from the \nCOVID -19 pandemic.  \n \n", "start_char_idx": 2190, "end_char_idx": 2469, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f455dcc5-044c-4b2d-8b19-e3e2b1298a25": {"__data__": {"id_": "f455dcc5-044c-4b2d-8b19-e3e2b1298a25", "embedding": null, "metadata": {"window": "Our technology network spans every touch point in the patient journey, from doctor's office to benefit \nverification to dispensing pharmacy, which allows us to address barriers in the patient journey by adding unique \nautomation that accelerates time to therapy and lowers patients' out -of-pocket costs.  \n \n In the June quarter, revenues were $881 milli on, an increase of 34%.  And adjusted operating profit increased \n62% to $139 million, driven by higher volumes of technology and service offerings to support biopharma \ncustomers, organic growth from access and adherence solutions and recovery of prescriptio n volumes from the \nCOVID -19 pandemic.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.5 billion in the quarter, up 40%, driven by \nimprovements in primary care patient visits and increased sales of COVID -19 tests.  The contribution from our \ncontr act with US government to prepare and distribute ancillary supplies related to the COVID -19 vaccine \nprovided a benefit of approximately $0.25 in the quarter and were above our original expectations.  \n \n For the quarter, adjusted operating profit increased 107 % to $257 million, driven by improvements in primary care \npatient visits and the contribution from kitting and distribution of ancillary supplies for the US government's \nCOVID -19 vaccine program.  \n \n Next, let me speak about International. ", "original_text": "Moving now to Medical -Surgical Solutions, revenues were $2.5 billion in the quarter, up 40%, driven by \nimprovements in primary care patient visits and increased sales of COVID -19 tests. ", "page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "538e5af4-2c9f-4709-9ba0-f8be11c81f27", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8a4e26d803b2ff0d7de8095683cc2fc111a7d70f8b99b535df32135e202e2822", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b868dc91-776d-413c-b5ef-2a69250b4110", "node_type": "1", "metadata": {"window": "We also continue to expand our clinical decision support capabilities in provider office workflow across every \nmajor EHR.  Our technology network spans every touch point in the patient journey, from doctor's office to benefit \nverification to dispensing pharmacy, which allows us to address barriers in the patient journey by adding unique \nautomation that accelerates time to therapy and lowers patients' out -of-pocket costs.  \n \n In the June quarter, revenues were $881 milli on, an increase of 34%.  And adjusted operating profit increased \n62% to $139 million, driven by higher volumes of technology and service offerings to support biopharma \ncustomers, organic growth from access and adherence solutions and recovery of prescriptio n volumes from the \nCOVID -19 pandemic.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.5 billion in the quarter, up 40%, driven by \nimprovements in primary care patient visits and increased sales of COVID -19 tests.  The contribution from our \ncontr act with US government to prepare and distribute ancillary supplies related to the COVID -19 vaccine \nprovided a benefit of approximately $0.25 in the quarter and were above our original expectations.  \n \n For the quarter, adjusted operating profit increased 107 % to $257 million, driven by improvements in primary care \npatient visits and the contribution from kitting and distribution of ancillary supplies for the US government's \nCOVID -19 vaccine program.  \n \n", "original_text": "And adjusted operating profit increased \n62% to $139 million, driven by higher volumes of technology and service offerings to support biopharma \ncustomers, organic growth from access and adherence solutions and recovery of prescriptio n volumes from the \nCOVID -19 pandemic.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "31fb79e2cd8dccf004f65a22c106277de398aafcfc796331ba20a2b9289a24f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a94bbe6-a393-4f47-a964-15c6c06f066f", "node_type": "1", "metadata": {"window": "In the June quarter, revenues were $881 milli on, an increase of 34%.  And adjusted operating profit increased \n62% to $139 million, driven by higher volumes of technology and service offerings to support biopharma \ncustomers, organic growth from access and adherence solutions and recovery of prescriptio n volumes from the \nCOVID -19 pandemic.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.5 billion in the quarter, up 40%, driven by \nimprovements in primary care patient visits and increased sales of COVID -19 tests.  The contribution from our \ncontr act with US government to prepare and distribute ancillary supplies related to the COVID -19 vaccine \nprovided a benefit of approximately $0.25 in the quarter and were above our original expectations.  \n \n For the quarter, adjusted operating profit increased 107 % to $257 million, driven by improvements in primary care \npatient visits and the contribution from kitting and distribution of ancillary supplies for the US government's \nCOVID -19 vaccine program.  \n \n Next, let me speak about International.  Revenues in the quarter were $9.2 billion, an increase of 8% year -over-\nyear. ", "original_text": "The contribution from our \ncontr act with US government to prepare and distribute ancillary supplies related to the COVID -19 vaccine \nprovided a benefit of approximately $0.25 in the quarter and were above our original expectations.  \n \n"}, "hash": "391c20b0802f58103a5d44d20432c023fcc8952805cd8c6c5c412fc58368c0b5", "class_name": "RelatedNodeInfo"}}, "text": "Moving now to Medical -Surgical Solutions, revenues were $2.5 billion in the quarter, up 40%, driven by \nimprovements in primary care patient visits and increased sales of COVID -19 tests. ", "start_char_idx": 2469, "end_char_idx": 2658, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a94bbe6-a393-4f47-a964-15c6c06f066f": {"__data__": {"id_": "2a94bbe6-a393-4f47-a964-15c6c06f066f", "embedding": null, "metadata": {"window": "In the June quarter, revenues were $881 milli on, an increase of 34%.  And adjusted operating profit increased \n62% to $139 million, driven by higher volumes of technology and service offerings to support biopharma \ncustomers, organic growth from access and adherence solutions and recovery of prescriptio n volumes from the \nCOVID -19 pandemic.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.5 billion in the quarter, up 40%, driven by \nimprovements in primary care patient visits and increased sales of COVID -19 tests.  The contribution from our \ncontr act with US government to prepare and distribute ancillary supplies related to the COVID -19 vaccine \nprovided a benefit of approximately $0.25 in the quarter and were above our original expectations.  \n \n For the quarter, adjusted operating profit increased 107 % to $257 million, driven by improvements in primary care \npatient visits and the contribution from kitting and distribution of ancillary supplies for the US government's \nCOVID -19 vaccine program.  \n \n Next, let me speak about International.  Revenues in the quarter were $9.2 billion, an increase of 8% year -over-\nyear. ", "original_text": "The contribution from our \ncontr act with US government to prepare and distribute ancillary supplies related to the COVID -19 vaccine \nprovided a benefit of approximately $0.25 in the quarter and were above our original expectations.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "538e5af4-2c9f-4709-9ba0-f8be11c81f27", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8a4e26d803b2ff0d7de8095683cc2fc111a7d70f8b99b535df32135e202e2822", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f455dcc5-044c-4b2d-8b19-e3e2b1298a25", "node_type": "1", "metadata": {"window": "Our technology network spans every touch point in the patient journey, from doctor's office to benefit \nverification to dispensing pharmacy, which allows us to address barriers in the patient journey by adding unique \nautomation that accelerates time to therapy and lowers patients' out -of-pocket costs.  \n \n In the June quarter, revenues were $881 milli on, an increase of 34%.  And adjusted operating profit increased \n62% to $139 million, driven by higher volumes of technology and service offerings to support biopharma \ncustomers, organic growth from access and adherence solutions and recovery of prescriptio n volumes from the \nCOVID -19 pandemic.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.5 billion in the quarter, up 40%, driven by \nimprovements in primary care patient visits and increased sales of COVID -19 tests.  The contribution from our \ncontr act with US government to prepare and distribute ancillary supplies related to the COVID -19 vaccine \nprovided a benefit of approximately $0.25 in the quarter and were above our original expectations.  \n \n For the quarter, adjusted operating profit increased 107 % to $257 million, driven by improvements in primary care \npatient visits and the contribution from kitting and distribution of ancillary supplies for the US government's \nCOVID -19 vaccine program.  \n \n Next, let me speak about International. ", "original_text": "Moving now to Medical -Surgical Solutions, revenues were $2.5 billion in the quarter, up 40%, driven by \nimprovements in primary care patient visits and increased sales of COVID -19 tests. ", "page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3faa73755279c27701152003935425c615cf6aa929d7e0886611c57c53327368", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "33605712-7f2e-4f96-a16c-c9b734cee2ee", "node_type": "1", "metadata": {"window": "And adjusted operating profit increased \n62% to $139 million, driven by higher volumes of technology and service offerings to support biopharma \ncustomers, organic growth from access and adherence solutions and recovery of prescriptio n volumes from the \nCOVID -19 pandemic.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.5 billion in the quarter, up 40%, driven by \nimprovements in primary care patient visits and increased sales of COVID -19 tests.  The contribution from our \ncontr act with US government to prepare and distribute ancillary supplies related to the COVID -19 vaccine \nprovided a benefit of approximately $0.25 in the quarter and were above our original expectations.  \n \n For the quarter, adjusted operating profit increased 107 % to $257 million, driven by improvements in primary care \npatient visits and the contribution from kitting and distribution of ancillary supplies for the US government's \nCOVID -19 vaccine program.  \n \n Next, let me speak about International.  Revenues in the quarter were $9.2 billion, an increase of 8% year -over-\nyear.  Excluding the impact from the divestiture of our German wholesale business, segment revenue increased \n28% year -over-year and was up 14% on an FX -adjusted basis. ", "original_text": "For the quarter, adjusted operating profit increased 107 % to $257 million, driven by improvements in primary care \npatient visits and the contribution from kitting and distribution of ancillary supplies for the US government's \nCOVID -19 vaccine program.  \n \n"}, "hash": "699f09670c591871538bbee7b13dde093acf760b605ef0ea3c00a1aca7467e97", "class_name": "RelatedNodeInfo"}}, "text": "The contribution from our \ncontr act with US government to prepare and distribute ancillary supplies related to the COVID -19 vaccine \nprovided a benefit of approximately $0.25 in the quarter and were above our original expectations.  \n \n", "start_char_idx": 2658, "end_char_idx": 2896, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "33605712-7f2e-4f96-a16c-c9b734cee2ee": {"__data__": {"id_": "33605712-7f2e-4f96-a16c-c9b734cee2ee", "embedding": null, "metadata": {"window": "And adjusted operating profit increased \n62% to $139 million, driven by higher volumes of technology and service offerings to support biopharma \ncustomers, organic growth from access and adherence solutions and recovery of prescriptio n volumes from the \nCOVID -19 pandemic.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.5 billion in the quarter, up 40%, driven by \nimprovements in primary care patient visits and increased sales of COVID -19 tests.  The contribution from our \ncontr act with US government to prepare and distribute ancillary supplies related to the COVID -19 vaccine \nprovided a benefit of approximately $0.25 in the quarter and were above our original expectations.  \n \n For the quarter, adjusted operating profit increased 107 % to $257 million, driven by improvements in primary care \npatient visits and the contribution from kitting and distribution of ancillary supplies for the US government's \nCOVID -19 vaccine program.  \n \n Next, let me speak about International.  Revenues in the quarter were $9.2 billion, an increase of 8% year -over-\nyear.  Excluding the impact from the divestiture of our German wholesale business, segment revenue increased \n28% year -over-year and was up 14% on an FX -adjusted basis. ", "original_text": "For the quarter, adjusted operating profit increased 107 % to $257 million, driven by improvements in primary care \npatient visits and the contribution from kitting and distribution of ancillary supplies for the US government's \nCOVID -19 vaccine program.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "538e5af4-2c9f-4709-9ba0-f8be11c81f27", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8a4e26d803b2ff0d7de8095683cc2fc111a7d70f8b99b535df32135e202e2822", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a94bbe6-a393-4f47-a964-15c6c06f066f", "node_type": "1", "metadata": {"window": "In the June quarter, revenues were $881 milli on, an increase of 34%.  And adjusted operating profit increased \n62% to $139 million, driven by higher volumes of technology and service offerings to support biopharma \ncustomers, organic growth from access and adherence solutions and recovery of prescriptio n volumes from the \nCOVID -19 pandemic.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.5 billion in the quarter, up 40%, driven by \nimprovements in primary care patient visits and increased sales of COVID -19 tests.  The contribution from our \ncontr act with US government to prepare and distribute ancillary supplies related to the COVID -19 vaccine \nprovided a benefit of approximately $0.25 in the quarter and were above our original expectations.  \n \n For the quarter, adjusted operating profit increased 107 % to $257 million, driven by improvements in primary care \npatient visits and the contribution from kitting and distribution of ancillary supplies for the US government's \nCOVID -19 vaccine program.  \n \n Next, let me speak about International.  Revenues in the quarter were $9.2 billion, an increase of 8% year -over-\nyear. ", "original_text": "The contribution from our \ncontr act with US government to prepare and distribute ancillary supplies related to the COVID -19 vaccine \nprovided a benefit of approximately $0.25 in the quarter and were above our original expectations.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94e1559d694517223f725ae14f4112900cd35fdc7fb4dd9a28e8b1941ce7940f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb245d20-4b69-4b34-8665-f263cfbdabdf", "node_type": "1", "metadata": {"window": "Moving now to Medical -Surgical Solutions, revenues were $2.5 billion in the quarter, up 40%, driven by \nimprovements in primary care patient visits and increased sales of COVID -19 tests.  The contribution from our \ncontr act with US government to prepare and distribute ancillary supplies related to the COVID -19 vaccine \nprovided a benefit of approximately $0.25 in the quarter and were above our original expectations.  \n \n For the quarter, adjusted operating profit increased 107 % to $257 million, driven by improvements in primary care \npatient visits and the contribution from kitting and distribution of ancillary supplies for the US government's \nCOVID -19 vaccine program.  \n \n Next, let me speak about International.  Revenues in the quarter were $9.2 billion, an increase of 8% year -over-\nyear.  Excluding the impact from the divestiture of our German wholesale business, segment revenue increased \n28% year -over-year and was up 14% on an FX -adjusted basis.  Revenue was primarily driven by th e contribution \nof our German wholesale business to the joint venture with Walgreens Boots Alliance, which was completed \nduring the third quarter of fiscal 2021, and the recovery of pharmaceutical distribution and retail pharmacy \nvolumes from the COVID -19 pandemic.  \n \n", "original_text": "Next, let me speak about International. "}, "hash": "7acfcd5e20b97985b707280b5aef8bd501b4248ef1e0fc29c4aa0045b92f3f90", "class_name": "RelatedNodeInfo"}}, "text": "For the quarter, adjusted operating profit increased 107 % to $257 million, driven by improvements in primary care \npatient visits and the contribution from kitting and distribution of ancillary supplies for the US government's \nCOVID -19 vaccine program.  \n \n", "start_char_idx": 2896, "end_char_idx": 3156, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb245d20-4b69-4b34-8665-f263cfbdabdf": {"__data__": {"id_": "bb245d20-4b69-4b34-8665-f263cfbdabdf", "embedding": null, "metadata": {"window": "Moving now to Medical -Surgical Solutions, revenues were $2.5 billion in the quarter, up 40%, driven by \nimprovements in primary care patient visits and increased sales of COVID -19 tests.  The contribution from our \ncontr act with US government to prepare and distribute ancillary supplies related to the COVID -19 vaccine \nprovided a benefit of approximately $0.25 in the quarter and were above our original expectations.  \n \n For the quarter, adjusted operating profit increased 107 % to $257 million, driven by improvements in primary care \npatient visits and the contribution from kitting and distribution of ancillary supplies for the US government's \nCOVID -19 vaccine program.  \n \n Next, let me speak about International.  Revenues in the quarter were $9.2 billion, an increase of 8% year -over-\nyear.  Excluding the impact from the divestiture of our German wholesale business, segment revenue increased \n28% year -over-year and was up 14% on an FX -adjusted basis.  Revenue was primarily driven by th e contribution \nof our German wholesale business to the joint venture with Walgreens Boots Alliance, which was completed \nduring the third quarter of fiscal 2021, and the recovery of pharmaceutical distribution and retail pharmacy \nvolumes from the COVID -19 pandemic.  \n \n", "original_text": "Next, let me speak about International. ", "page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "538e5af4-2c9f-4709-9ba0-f8be11c81f27", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8a4e26d803b2ff0d7de8095683cc2fc111a7d70f8b99b535df32135e202e2822", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "33605712-7f2e-4f96-a16c-c9b734cee2ee", "node_type": "1", "metadata": {"window": "And adjusted operating profit increased \n62% to $139 million, driven by higher volumes of technology and service offerings to support biopharma \ncustomers, organic growth from access and adherence solutions and recovery of prescriptio n volumes from the \nCOVID -19 pandemic.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.5 billion in the quarter, up 40%, driven by \nimprovements in primary care patient visits and increased sales of COVID -19 tests.  The contribution from our \ncontr act with US government to prepare and distribute ancillary supplies related to the COVID -19 vaccine \nprovided a benefit of approximately $0.25 in the quarter and were above our original expectations.  \n \n For the quarter, adjusted operating profit increased 107 % to $257 million, driven by improvements in primary care \npatient visits and the contribution from kitting and distribution of ancillary supplies for the US government's \nCOVID -19 vaccine program.  \n \n Next, let me speak about International.  Revenues in the quarter were $9.2 billion, an increase of 8% year -over-\nyear.  Excluding the impact from the divestiture of our German wholesale business, segment revenue increased \n28% year -over-year and was up 14% on an FX -adjusted basis. ", "original_text": "For the quarter, adjusted operating profit increased 107 % to $257 million, driven by improvements in primary care \npatient visits and the contribution from kitting and distribution of ancillary supplies for the US government's \nCOVID -19 vaccine program.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d21aeb3f37ad0ffa7858a052b7269abd765b98ad2cd280df45a73d4013646337", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f2b8289-1be7-4d70-ae36-6a127ab3cb8f", "node_type": "1", "metadata": {"window": "The contribution from our \ncontr act with US government to prepare and distribute ancillary supplies related to the COVID -19 vaccine \nprovided a benefit of approximately $0.25 in the quarter and were above our original expectations.  \n \n For the quarter, adjusted operating profit increased 107 % to $257 million, driven by improvements in primary care \npatient visits and the contribution from kitting and distribution of ancillary supplies for the US government's \nCOVID -19 vaccine program.  \n \n Next, let me speak about International.  Revenues in the quarter were $9.2 billion, an increase of 8% year -over-\nyear.  Excluding the impact from the divestiture of our German wholesale business, segment revenue increased \n28% year -over-year and was up 14% on an FX -adjusted basis.  Revenue was primarily driven by th e contribution \nof our German wholesale business to the joint venture with Walgreens Boots Alliance, which was completed \nduring the third quarter of fiscal 2021, and the recovery of pharmaceutical distribution and retail pharmacy \nvolumes from the COVID -19 pandemic.  \n \n First quarter adjusted operating profit increased 133% year -over-year to $170 million. ", "original_text": "Revenues in the quarter were $9.2 billion, an increase of 8% year -over-\nyear. "}, "hash": "49af0c7634fe7095292623fe9ece6d7862ed4fdc59a10724bdd45752906baed0", "class_name": "RelatedNodeInfo"}}, "text": "Next, let me speak about International. ", "start_char_idx": 3156, "end_char_idx": 3196, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f2b8289-1be7-4d70-ae36-6a127ab3cb8f": {"__data__": {"id_": "2f2b8289-1be7-4d70-ae36-6a127ab3cb8f", "embedding": null, "metadata": {"window": "The contribution from our \ncontr act with US government to prepare and distribute ancillary supplies related to the COVID -19 vaccine \nprovided a benefit of approximately $0.25 in the quarter and were above our original expectations.  \n \n For the quarter, adjusted operating profit increased 107 % to $257 million, driven by improvements in primary care \npatient visits and the contribution from kitting and distribution of ancillary supplies for the US government's \nCOVID -19 vaccine program.  \n \n Next, let me speak about International.  Revenues in the quarter were $9.2 billion, an increase of 8% year -over-\nyear.  Excluding the impact from the divestiture of our German wholesale business, segment revenue increased \n28% year -over-year and was up 14% on an FX -adjusted basis.  Revenue was primarily driven by th e contribution \nof our German wholesale business to the joint venture with Walgreens Boots Alliance, which was completed \nduring the third quarter of fiscal 2021, and the recovery of pharmaceutical distribution and retail pharmacy \nvolumes from the COVID -19 pandemic.  \n \n First quarter adjusted operating profit increased 133% year -over-year to $170 million. ", "original_text": "Revenues in the quarter were $9.2 billion, an increase of 8% year -over-\nyear. ", "page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "538e5af4-2c9f-4709-9ba0-f8be11c81f27", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8a4e26d803b2ff0d7de8095683cc2fc111a7d70f8b99b535df32135e202e2822", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb245d20-4b69-4b34-8665-f263cfbdabdf", "node_type": "1", "metadata": {"window": "Moving now to Medical -Surgical Solutions, revenues were $2.5 billion in the quarter, up 40%, driven by \nimprovements in primary care patient visits and increased sales of COVID -19 tests.  The contribution from our \ncontr act with US government to prepare and distribute ancillary supplies related to the COVID -19 vaccine \nprovided a benefit of approximately $0.25 in the quarter and were above our original expectations.  \n \n For the quarter, adjusted operating profit increased 107 % to $257 million, driven by improvements in primary care \npatient visits and the contribution from kitting and distribution of ancillary supplies for the US government's \nCOVID -19 vaccine program.  \n \n Next, let me speak about International.  Revenues in the quarter were $9.2 billion, an increase of 8% year -over-\nyear.  Excluding the impact from the divestiture of our German wholesale business, segment revenue increased \n28% year -over-year and was up 14% on an FX -adjusted basis.  Revenue was primarily driven by th e contribution \nof our German wholesale business to the joint venture with Walgreens Boots Alliance, which was completed \nduring the third quarter of fiscal 2021, and the recovery of pharmaceutical distribution and retail pharmacy \nvolumes from the COVID -19 pandemic.  \n \n", "original_text": "Next, let me speak about International. ", "page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f73756e63777f7aa4ecfc49829cc4be4552fa712fe1755c09f4fd0cbd26b9348", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc543d3d-679d-40f2-aade-bfc909a38cd0", "node_type": "1", "metadata": {"window": "For the quarter, adjusted operating profit increased 107 % to $257 million, driven by improvements in primary care \npatient visits and the contribution from kitting and distribution of ancillary supplies for the US government's \nCOVID -19 vaccine program.  \n \n Next, let me speak about International.  Revenues in the quarter were $9.2 billion, an increase of 8% year -over-\nyear.  Excluding the impact from the divestiture of our German wholesale business, segment revenue increased \n28% year -over-year and was up 14% on an FX -adjusted basis.  Revenue was primarily driven by th e contribution \nof our German wholesale business to the joint venture with Walgreens Boots Alliance, which was completed \nduring the third quarter of fiscal 2021, and the recovery of pharmaceutical distribution and retail pharmacy \nvolumes from the COVID -19 pandemic.  \n \n First quarter adjusted operating profit increased 133% year -over-year to $170 million.  On an FX -adjusted basis, \nadjusted operating profit increased 107% to $151 million, led by the recovery of pharmaceutical distribution and \nretail pharmacy volum es from the COVID -19 pandemic and distribution of COVID -19 vaccines and test kits in \nEurope and Canada.  \n ", "original_text": "Excluding the impact from the divestiture of our German wholesale business, segment revenue increased \n28% year -over-year and was up 14% on an FX -adjusted basis. "}, "hash": "26c963872c3f8dddc54accf831ff9e61e032fba4cafd9e948f13c67a2837901d", "class_name": "RelatedNodeInfo"}}, "text": "Revenues in the quarter were $9.2 billion, an increase of 8% year -over-\nyear. ", "start_char_idx": 3196, "end_char_idx": 3275, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc543d3d-679d-40f2-aade-bfc909a38cd0": {"__data__": {"id_": "fc543d3d-679d-40f2-aade-bfc909a38cd0", "embedding": null, "metadata": {"window": "For the quarter, adjusted operating profit increased 107 % to $257 million, driven by improvements in primary care \npatient visits and the contribution from kitting and distribution of ancillary supplies for the US government's \nCOVID -19 vaccine program.  \n \n Next, let me speak about International.  Revenues in the quarter were $9.2 billion, an increase of 8% year -over-\nyear.  Excluding the impact from the divestiture of our German wholesale business, segment revenue increased \n28% year -over-year and was up 14% on an FX -adjusted basis.  Revenue was primarily driven by th e contribution \nof our German wholesale business to the joint venture with Walgreens Boots Alliance, which was completed \nduring the third quarter of fiscal 2021, and the recovery of pharmaceutical distribution and retail pharmacy \nvolumes from the COVID -19 pandemic.  \n \n First quarter adjusted operating profit increased 133% year -over-year to $170 million.  On an FX -adjusted basis, \nadjusted operating profit increased 107% to $151 million, led by the recovery of pharmaceutical distribution and \nretail pharmacy volum es from the COVID -19 pandemic and distribution of COVID -19 vaccines and test kits in \nEurope and Canada.  \n ", "original_text": "Excluding the impact from the divestiture of our German wholesale business, segment revenue increased \n28% year -over-year and was up 14% on an FX -adjusted basis. ", "page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "538e5af4-2c9f-4709-9ba0-f8be11c81f27", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8a4e26d803b2ff0d7de8095683cc2fc111a7d70f8b99b535df32135e202e2822", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f2b8289-1be7-4d70-ae36-6a127ab3cb8f", "node_type": "1", "metadata": {"window": "The contribution from our \ncontr act with US government to prepare and distribute ancillary supplies related to the COVID -19 vaccine \nprovided a benefit of approximately $0.25 in the quarter and were above our original expectations.  \n \n For the quarter, adjusted operating profit increased 107 % to $257 million, driven by improvements in primary care \npatient visits and the contribution from kitting and distribution of ancillary supplies for the US government's \nCOVID -19 vaccine program.  \n \n Next, let me speak about International.  Revenues in the quarter were $9.2 billion, an increase of 8% year -over-\nyear.  Excluding the impact from the divestiture of our German wholesale business, segment revenue increased \n28% year -over-year and was up 14% on an FX -adjusted basis.  Revenue was primarily driven by th e contribution \nof our German wholesale business to the joint venture with Walgreens Boots Alliance, which was completed \nduring the third quarter of fiscal 2021, and the recovery of pharmaceutical distribution and retail pharmacy \nvolumes from the COVID -19 pandemic.  \n \n First quarter adjusted operating profit increased 133% year -over-year to $170 million. ", "original_text": "Revenues in the quarter were $9.2 billion, an increase of 8% year -over-\nyear. ", "page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57d1333f9bc0c259d5dc0a2f6dba5f3b498654b29bf0a2f9e4980742fcdc5785", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c672f9e-cde1-4448-9341-4167c1fa9644", "node_type": "1", "metadata": {"window": "Next, let me speak about International.  Revenues in the quarter were $9.2 billion, an increase of 8% year -over-\nyear.  Excluding the impact from the divestiture of our German wholesale business, segment revenue increased \n28% year -over-year and was up 14% on an FX -adjusted basis.  Revenue was primarily driven by th e contribution \nof our German wholesale business to the joint venture with Walgreens Boots Alliance, which was completed \nduring the third quarter of fiscal 2021, and the recovery of pharmaceutical distribution and retail pharmacy \nvolumes from the COVID -19 pandemic.  \n \n First quarter adjusted operating profit increased 133% year -over-year to $170 million.  On an FX -adjusted basis, \nadjusted operating profit increased 107% to $151 million, led by the recovery of pharmaceutical distribution and \nretail pharmacy volum es from the COVID -19 pandemic and distribution of COVID -19 vaccines and test kits in \nEurope and Canada.  \n ", "original_text": "Revenue was primarily driven by th e contribution \nof our German wholesale business to the joint venture with Walgreens Boots Alliance, which was completed \nduring the third quarter of fiscal 2021, and the recovery of pharmaceutical distribution and retail pharmacy \nvolumes from the COVID -19 pandemic.  \n \n"}, "hash": "152d0e5cb13c860cfb1d87f1d0f17ee93b07a307bfb4934c058bfcf2758baa8d", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the impact from the divestiture of our German wholesale business, segment revenue increased \n28% year -over-year and was up 14% on an FX -adjusted basis. ", "start_char_idx": 3275, "end_char_idx": 3439, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c672f9e-cde1-4448-9341-4167c1fa9644": {"__data__": {"id_": "5c672f9e-cde1-4448-9341-4167c1fa9644", "embedding": null, "metadata": {"window": "Next, let me speak about International.  Revenues in the quarter were $9.2 billion, an increase of 8% year -over-\nyear.  Excluding the impact from the divestiture of our German wholesale business, segment revenue increased \n28% year -over-year and was up 14% on an FX -adjusted basis.  Revenue was primarily driven by th e contribution \nof our German wholesale business to the joint venture with Walgreens Boots Alliance, which was completed \nduring the third quarter of fiscal 2021, and the recovery of pharmaceutical distribution and retail pharmacy \nvolumes from the COVID -19 pandemic.  \n \n First quarter adjusted operating profit increased 133% year -over-year to $170 million.  On an FX -adjusted basis, \nadjusted operating profit increased 107% to $151 million, led by the recovery of pharmaceutical distribution and \nretail pharmacy volum es from the COVID -19 pandemic and distribution of COVID -19 vaccines and test kits in \nEurope and Canada.  \n ", "original_text": "Revenue was primarily driven by th e contribution \nof our German wholesale business to the joint venture with Walgreens Boots Alliance, which was completed \nduring the third quarter of fiscal 2021, and the recovery of pharmaceutical distribution and retail pharmacy \nvolumes from the COVID -19 pandemic.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "538e5af4-2c9f-4709-9ba0-f8be11c81f27", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8a4e26d803b2ff0d7de8095683cc2fc111a7d70f8b99b535df32135e202e2822", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc543d3d-679d-40f2-aade-bfc909a38cd0", "node_type": "1", "metadata": {"window": "For the quarter, adjusted operating profit increased 107 % to $257 million, driven by improvements in primary care \npatient visits and the contribution from kitting and distribution of ancillary supplies for the US government's \nCOVID -19 vaccine program.  \n \n Next, let me speak about International.  Revenues in the quarter were $9.2 billion, an increase of 8% year -over-\nyear.  Excluding the impact from the divestiture of our German wholesale business, segment revenue increased \n28% year -over-year and was up 14% on an FX -adjusted basis.  Revenue was primarily driven by th e contribution \nof our German wholesale business to the joint venture with Walgreens Boots Alliance, which was completed \nduring the third quarter of fiscal 2021, and the recovery of pharmaceutical distribution and retail pharmacy \nvolumes from the COVID -19 pandemic.  \n \n First quarter adjusted operating profit increased 133% year -over-year to $170 million.  On an FX -adjusted basis, \nadjusted operating profit increased 107% to $151 million, led by the recovery of pharmaceutical distribution and \nretail pharmacy volum es from the COVID -19 pandemic and distribution of COVID -19 vaccines and test kits in \nEurope and Canada.  \n ", "original_text": "Excluding the impact from the divestiture of our German wholesale business, segment revenue increased \n28% year -over-year and was up 14% on an FX -adjusted basis. ", "page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ddcbfb29ccf76481d8c4dcd2701aeac390d82bc04702eaf6d662590e671f344", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd68e987-f384-44aa-9b8c-c406714340bf", "node_type": "1", "metadata": {"window": "Revenues in the quarter were $9.2 billion, an increase of 8% year -over-\nyear.  Excluding the impact from the divestiture of our German wholesale business, segment revenue increased \n28% year -over-year and was up 14% on an FX -adjusted basis.  Revenue was primarily driven by th e contribution \nof our German wholesale business to the joint venture with Walgreens Boots Alliance, which was completed \nduring the third quarter of fiscal 2021, and the recovery of pharmaceutical distribution and retail pharmacy \nvolumes from the COVID -19 pandemic.  \n \n First quarter adjusted operating profit increased 133% year -over-year to $170 million.  On an FX -adjusted basis, \nadjusted operating profit increased 107% to $151 million, led by the recovery of pharmaceutical distribution and \nretail pharmacy volum es from the COVID -19 pandemic and distribution of COVID -19 vaccines and test kits in \nEurope and Canada.  \n ", "original_text": "First quarter adjusted operating profit increased 133% year -over-year to $170 million. "}, "hash": "c056ff96a6a6edd5eee937ad6b7a8946ab05a737e05b646e0b737932dfa410ee", "class_name": "RelatedNodeInfo"}}, "text": "Revenue was primarily driven by th e contribution \nof our German wholesale business to the joint venture with Walgreens Boots Alliance, which was completed \nduring the third quarter of fiscal 2021, and the recovery of pharmaceutical distribution and retail pharmacy \nvolumes from the COVID -19 pandemic.  \n \n", "start_char_idx": 3439, "end_char_idx": 3747, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd68e987-f384-44aa-9b8c-c406714340bf": {"__data__": {"id_": "bd68e987-f384-44aa-9b8c-c406714340bf", "embedding": null, "metadata": {"window": "Revenues in the quarter were $9.2 billion, an increase of 8% year -over-\nyear.  Excluding the impact from the divestiture of our German wholesale business, segment revenue increased \n28% year -over-year and was up 14% on an FX -adjusted basis.  Revenue was primarily driven by th e contribution \nof our German wholesale business to the joint venture with Walgreens Boots Alliance, which was completed \nduring the third quarter of fiscal 2021, and the recovery of pharmaceutical distribution and retail pharmacy \nvolumes from the COVID -19 pandemic.  \n \n First quarter adjusted operating profit increased 133% year -over-year to $170 million.  On an FX -adjusted basis, \nadjusted operating profit increased 107% to $151 million, led by the recovery of pharmaceutical distribution and \nretail pharmacy volum es from the COVID -19 pandemic and distribution of COVID -19 vaccines and test kits in \nEurope and Canada.  \n ", "original_text": "First quarter adjusted operating profit increased 133% year -over-year to $170 million. ", "page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "538e5af4-2c9f-4709-9ba0-f8be11c81f27", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8a4e26d803b2ff0d7de8095683cc2fc111a7d70f8b99b535df32135e202e2822", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c672f9e-cde1-4448-9341-4167c1fa9644", "node_type": "1", "metadata": {"window": "Next, let me speak about International.  Revenues in the quarter were $9.2 billion, an increase of 8% year -over-\nyear.  Excluding the impact from the divestiture of our German wholesale business, segment revenue increased \n28% year -over-year and was up 14% on an FX -adjusted basis.  Revenue was primarily driven by th e contribution \nof our German wholesale business to the joint venture with Walgreens Boots Alliance, which was completed \nduring the third quarter of fiscal 2021, and the recovery of pharmaceutical distribution and retail pharmacy \nvolumes from the COVID -19 pandemic.  \n \n First quarter adjusted operating profit increased 133% year -over-year to $170 million.  On an FX -adjusted basis, \nadjusted operating profit increased 107% to $151 million, led by the recovery of pharmaceutical distribution and \nretail pharmacy volum es from the COVID -19 pandemic and distribution of COVID -19 vaccines and test kits in \nEurope and Canada.  \n ", "original_text": "Revenue was primarily driven by th e contribution \nof our German wholesale business to the joint venture with Walgreens Boots Alliance, which was completed \nduring the third quarter of fiscal 2021, and the recovery of pharmaceutical distribution and retail pharmacy \nvolumes from the COVID -19 pandemic.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f2c6ce4c1b5ef22a1ee0f5e6aa13a3dcccd906798b3e1602b3f041e7659f87df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4aa2dd7-7928-4ced-8b15-461867784303", "node_type": "1", "metadata": {"window": "Excluding the impact from the divestiture of our German wholesale business, segment revenue increased \n28% year -over-year and was up 14% on an FX -adjusted basis.  Revenue was primarily driven by th e contribution \nof our German wholesale business to the joint venture with Walgreens Boots Alliance, which was completed \nduring the third quarter of fiscal 2021, and the recovery of pharmaceutical distribution and retail pharmacy \nvolumes from the COVID -19 pandemic.  \n \n First quarter adjusted operating profit increased 133% year -over-year to $170 million.  On an FX -adjusted basis, \nadjusted operating profit increased 107% to $151 million, led by the recovery of pharmaceutical distribution and \nretail pharmacy volum es from the COVID -19 pandemic and distribution of COVID -19 vaccines and test kits in \nEurope and Canada.  \n ", "original_text": "On an FX -adjusted basis, \nadjusted operating profit increased 107% to $151 million, led by the recovery of pharmaceutical distribution and \nretail pharmacy volum es from the COVID -19 pandemic and distribution of COVID -19 vaccines and test kits in \nEurope and Canada.  \n "}, "hash": "ca2300ae1bfa335d8961c3c7cfa4ebec33ab0f932196ddbed1822033affb83e0", "class_name": "RelatedNodeInfo"}}, "text": "First quarter adjusted operating profit increased 133% year -over-year to $170 million. ", "start_char_idx": 3747, "end_char_idx": 3835, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4aa2dd7-7928-4ced-8b15-461867784303": {"__data__": {"id_": "a4aa2dd7-7928-4ced-8b15-461867784303", "embedding": null, "metadata": {"window": "Excluding the impact from the divestiture of our German wholesale business, segment revenue increased \n28% year -over-year and was up 14% on an FX -adjusted basis.  Revenue was primarily driven by th e contribution \nof our German wholesale business to the joint venture with Walgreens Boots Alliance, which was completed \nduring the third quarter of fiscal 2021, and the recovery of pharmaceutical distribution and retail pharmacy \nvolumes from the COVID -19 pandemic.  \n \n First quarter adjusted operating profit increased 133% year -over-year to $170 million.  On an FX -adjusted basis, \nadjusted operating profit increased 107% to $151 million, led by the recovery of pharmaceutical distribution and \nretail pharmacy volum es from the COVID -19 pandemic and distribution of COVID -19 vaccines and test kits in \nEurope and Canada.  \n ", "original_text": "On an FX -adjusted basis, \nadjusted operating profit increased 107% to $151 million, led by the recovery of pharmaceutical distribution and \nretail pharmacy volum es from the COVID -19 pandemic and distribution of COVID -19 vaccines and test kits in \nEurope and Canada.  \n ", "page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "538e5af4-2c9f-4709-9ba0-f8be11c81f27", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8a4e26d803b2ff0d7de8095683cc2fc111a7d70f8b99b535df32135e202e2822", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd68e987-f384-44aa-9b8c-c406714340bf", "node_type": "1", "metadata": {"window": "Revenues in the quarter were $9.2 billion, an increase of 8% year -over-\nyear.  Excluding the impact from the divestiture of our German wholesale business, segment revenue increased \n28% year -over-year and was up 14% on an FX -adjusted basis.  Revenue was primarily driven by th e contribution \nof our German wholesale business to the joint venture with Walgreens Boots Alliance, which was completed \nduring the third quarter of fiscal 2021, and the recovery of pharmaceutical distribution and retail pharmacy \nvolumes from the COVID -19 pandemic.  \n \n First quarter adjusted operating profit increased 133% year -over-year to $170 million.  On an FX -adjusted basis, \nadjusted operating profit increased 107% to $151 million, led by the recovery of pharmaceutical distribution and \nretail pharmacy volum es from the COVID -19 pandemic and distribution of COVID -19 vaccines and test kits in \nEurope and Canada.  \n ", "original_text": "First quarter adjusted operating profit increased 133% year -over-year to $170 million. ", "page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c40defe75c11e0243cd699715353ee5fca941fa2ea9588108e94a49300da326", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce896aa3-9b23-46fb-a57b-566f587f7376", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nMoving on to Corporate, for the quarter, adjusted corporate expenses were $154 million, a decrease of 7% year -\nover-year, driven by decreased opioid lit igation expenses.  We reported opioid -related litigation expenses of $35 \nmillion for the first quarter.  We continue to estimate fiscal 2022 opioid -related litigation expenses to approximate \n$155 million.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "2a18dc14c9274880564b20558d15b0789456ff018c5cb717c5701c8b84faaa67", "class_name": "RelatedNodeInfo"}}, "text": "On an FX -adjusted basis, \nadjusted operating profit increased 107% to $151 million, led by the recovery of pharmaceutical distribution and \nretail pharmacy volum es from the COVID -19 pandemic and distribution of COVID -19 vaccines and test kits in \nEurope and Canada.  \n ", "start_char_idx": 3835, "end_char_idx": 4108, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce896aa3-9b23-46fb-a57b-566f587f7376": {"__data__": {"id_": "ce896aa3-9b23-46fb-a57b-566f587f7376", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nMoving on to Corporate, for the quarter, adjusted corporate expenses were $154 million, a decrease of 7% year -\nover-year, driven by decreased opioid lit igation expenses.  We reported opioid -related litigation expenses of $35 \nmillion for the first quarter.  We continue to estimate fiscal 2022 opioid -related litigation expenses to approximate \n$155 million.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b1599fc327c32617d492de23bfdfcc95592645274780378ad1d16e9c944d1bd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4aa2dd7-7928-4ced-8b15-461867784303", "node_type": "1", "metadata": {"window": "Excluding the impact from the divestiture of our German wholesale business, segment revenue increased \n28% year -over-year and was up 14% on an FX -adjusted basis.  Revenue was primarily driven by th e contribution \nof our German wholesale business to the joint venture with Walgreens Boots Alliance, which was completed \nduring the third quarter of fiscal 2021, and the recovery of pharmaceutical distribution and retail pharmacy \nvolumes from the COVID -19 pandemic.  \n \n First quarter adjusted operating profit increased 133% year -over-year to $170 million.  On an FX -adjusted basis, \nadjusted operating profit increased 107% to $151 million, led by the recovery of pharmaceutical distribution and \nretail pharmacy volum es from the COVID -19 pandemic and distribution of COVID -19 vaccines and test kits in \nEurope and Canada.  \n ", "original_text": "On an FX -adjusted basis, \nadjusted operating profit increased 107% to $151 million, led by the recovery of pharmaceutical distribution and \nretail pharmacy volum es from the COVID -19 pandemic and distribution of COVID -19 vaccines and test kits in \nEurope and Canada.  \n ", "page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b59a9d3a9d20e9708ec17e48495adc0bb6a168f17a8e3ff4c111be6fa4aba23b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c1f172f1-849d-4980-83a0-8c58864b2ab3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nMoving on to Corporate, for the quarter, adjusted corporate expenses were $154 million, a decrease of 7% year -\nover-year, driven by decreased opioid lit igation expenses.  We reported opioid -related litigation expenses of $35 \nmillion for the first quarter.  We continue to estimate fiscal 2022 opioid -related litigation expenses to approximate \n$155 million.  \n \n I would remind you that while we've negotiated a com prehensive proposed settlement agreement, until we know \nthe scope of participation in proposed settlement, we are not in a position to revise our opioid litigation expenses \noutlook.  \n \n", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nMoving on to Corporate, for the quarter, adjusted corporate expenses were $154 million, a decrease of 7% year -\nover-year, driven by decreased opioid lit igation expenses. "}, "hash": "3294b9db0ae0c7a6a68419ba48274eaf473bbaca0c1000dd990aec5e2b40dcef", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c1f172f1-849d-4980-83a0-8c58864b2ab3": {"__data__": {"id_": "c1f172f1-849d-4980-83a0-8c58864b2ab3", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nMoving on to Corporate, for the quarter, adjusted corporate expenses were $154 million, a decrease of 7% year -\nover-year, driven by decreased opioid lit igation expenses.  We reported opioid -related litigation expenses of $35 \nmillion for the first quarter.  We continue to estimate fiscal 2022 opioid -related litigation expenses to approximate \n$155 million.  \n \n I would remind you that while we've negotiated a com prehensive proposed settlement agreement, until we know \nthe scope of participation in proposed settlement, we are not in a position to revise our opioid litigation expenses \noutlook.  \n \n", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nMoving on to Corporate, for the quarter, adjusted corporate expenses were $154 million, a decrease of 7% year -\nover-year, driven by decreased opioid lit igation expenses. ", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b1599fc327c32617d492de23bfdfcc95592645274780378ad1d16e9c944d1bd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce896aa3-9b23-46fb-a57b-566f587f7376", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nMoving on to Corporate, for the quarter, adjusted corporate expenses were $154 million, a decrease of 7% year -\nover-year, driven by decreased opioid lit igation expenses.  We reported opioid -related litigation expenses of $35 \nmillion for the first quarter.  We continue to estimate fiscal 2022 opioid -related litigation expenses to approximate \n$155 million.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "92203ea608ca41cb2147dcfea9401b8e4752a3420e0b78e3a156324d6e7af841", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "779bb085-8bbf-4741-9f5a-ee58a195a3ee", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nMoving on to Corporate, for the quarter, adjusted corporate expenses were $154 million, a decrease of 7% year -\nover-year, driven by decreased opioid lit igation expenses.  We reported opioid -related litigation expenses of $35 \nmillion for the first quarter.  We continue to estimate fiscal 2022 opioid -related litigation expenses to approximate \n$155 million.  \n \n I would remind you that while we've negotiated a com prehensive proposed settlement agreement, until we know \nthe scope of participation in proposed settlement, we are not in a position to revise our opioid litigation expenses \noutlook.  \n \n Let me now turn to our cash position, which can be found on slide 14. ", "original_text": "We reported opioid -related litigation expenses of $35 \nmillion for the first quarter. "}, "hash": "0b7900b6ee7c0dfbf3e7b0f62d56c8d5426eb6ff2b0357348eaa8d18e87c6831", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nMoving on to Corporate, for the quarter, adjusted corporate expenses were $154 million, a decrease of 7% year -\nover-year, driven by decreased opioid lit igation expenses. ", "start_char_idx": 16, "end_char_idx": 353, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "779bb085-8bbf-4741-9f5a-ee58a195a3ee": {"__data__": {"id_": "779bb085-8bbf-4741-9f5a-ee58a195a3ee", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nMoving on to Corporate, for the quarter, adjusted corporate expenses were $154 million, a decrease of 7% year -\nover-year, driven by decreased opioid lit igation expenses.  We reported opioid -related litigation expenses of $35 \nmillion for the first quarter.  We continue to estimate fiscal 2022 opioid -related litigation expenses to approximate \n$155 million.  \n \n I would remind you that while we've negotiated a com prehensive proposed settlement agreement, until we know \nthe scope of participation in proposed settlement, we are not in a position to revise our opioid litigation expenses \noutlook.  \n \n Let me now turn to our cash position, which can be found on slide 14. ", "original_text": "We reported opioid -related litigation expenses of $35 \nmillion for the first quarter. ", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b1599fc327c32617d492de23bfdfcc95592645274780378ad1d16e9c944d1bd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c1f172f1-849d-4980-83a0-8c58864b2ab3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nMoving on to Corporate, for the quarter, adjusted corporate expenses were $154 million, a decrease of 7% year -\nover-year, driven by decreased opioid lit igation expenses.  We reported opioid -related litigation expenses of $35 \nmillion for the first quarter.  We continue to estimate fiscal 2022 opioid -related litigation expenses to approximate \n$155 million.  \n \n I would remind you that while we've negotiated a com prehensive proposed settlement agreement, until we know \nthe scope of participation in proposed settlement, we are not in a position to revise our opioid litigation expenses \noutlook.  \n \n", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nMoving on to Corporate, for the quarter, adjusted corporate expenses were $154 million, a decrease of 7% year -\nover-year, driven by decreased opioid lit igation expenses. ", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d910651d30d3c8e0a960aa1723c693426c0edf5bf8c2d04a25ca2e0b76384a97", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "025d43a6-8a49-4858-864d-46bf7e71044b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nMoving on to Corporate, for the quarter, adjusted corporate expenses were $154 million, a decrease of 7% year -\nover-year, driven by decreased opioid lit igation expenses.  We reported opioid -related litigation expenses of $35 \nmillion for the first quarter.  We continue to estimate fiscal 2022 opioid -related litigation expenses to approximate \n$155 million.  \n \n I would remind you that while we've negotiated a com prehensive proposed settlement agreement, until we know \nthe scope of participation in proposed settlement, we are not in a position to revise our opioid litigation expenses \noutlook.  \n \n Let me now turn to our cash position, which can be found on slide 14.  We ended the quarter with a cash balance \nof $2.4 billion. ", "original_text": "We continue to estimate fiscal 2022 opioid -related litigation expenses to approximate \n$155 million.  \n \n"}, "hash": "b028d0d0e6d1c18f0abde64a09f46fa7c97bc699aac8a735c7114925087f6cfc", "class_name": "RelatedNodeInfo"}}, "text": "We reported opioid -related litigation expenses of $35 \nmillion for the first quarter. ", "start_char_idx": 353, "end_char_idx": 440, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "025d43a6-8a49-4858-864d-46bf7e71044b": {"__data__": {"id_": "025d43a6-8a49-4858-864d-46bf7e71044b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nMoving on to Corporate, for the quarter, adjusted corporate expenses were $154 million, a decrease of 7% year -\nover-year, driven by decreased opioid lit igation expenses.  We reported opioid -related litigation expenses of $35 \nmillion for the first quarter.  We continue to estimate fiscal 2022 opioid -related litigation expenses to approximate \n$155 million.  \n \n I would remind you that while we've negotiated a com prehensive proposed settlement agreement, until we know \nthe scope of participation in proposed settlement, we are not in a position to revise our opioid litigation expenses \noutlook.  \n \n Let me now turn to our cash position, which can be found on slide 14.  We ended the quarter with a cash balance \nof $2.4 billion. ", "original_text": "We continue to estimate fiscal 2022 opioid -related litigation expenses to approximate \n$155 million.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b1599fc327c32617d492de23bfdfcc95592645274780378ad1d16e9c944d1bd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "779bb085-8bbf-4741-9f5a-ee58a195a3ee", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nMoving on to Corporate, for the quarter, adjusted corporate expenses were $154 million, a decrease of 7% year -\nover-year, driven by decreased opioid lit igation expenses.  We reported opioid -related litigation expenses of $35 \nmillion for the first quarter.  We continue to estimate fiscal 2022 opioid -related litigation expenses to approximate \n$155 million.  \n \n I would remind you that while we've negotiated a com prehensive proposed settlement agreement, until we know \nthe scope of participation in proposed settlement, we are not in a position to revise our opioid litigation expenses \noutlook.  \n \n Let me now turn to our cash position, which can be found on slide 14. ", "original_text": "We reported opioid -related litigation expenses of $35 \nmillion for the first quarter. ", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0108a353840da437b9ced95bde59df19eddcfbfbb619e7fa9e7dc92856755390", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6a0b1ae-9c8a-4a19-b917-8318e1763e9b", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nMoving on to Corporate, for the quarter, adjusted corporate expenses were $154 million, a decrease of 7% year -\nover-year, driven by decreased opioid lit igation expenses.  We reported opioid -related litigation expenses of $35 \nmillion for the first quarter.  We continue to estimate fiscal 2022 opioid -related litigation expenses to approximate \n$155 million.  \n \n I would remind you that while we've negotiated a com prehensive proposed settlement agreement, until we know \nthe scope of participation in proposed settlement, we are not in a position to revise our opioid litigation expenses \noutlook.  \n \n Let me now turn to our cash position, which can be found on slide 14.  We ended the quarter with a cash balance \nof $2.4 billion.  During the quarter, we had negative free cash flow of $1.8 billion. ", "original_text": "I would remind you that while we've negotiated a com prehensive proposed settlement agreement, until we know \nthe scope of participation in proposed settlement, we are not in a position to revise our opioid litigation expenses \noutlook.  \n \n"}, "hash": "2d8ab27ece9e57b8996e468ab41bfddc4a26c400d568916c8454fcce6f45d24c", "class_name": "RelatedNodeInfo"}}, "text": "We continue to estimate fiscal 2022 opioid -related litigation expenses to approximate \n$155 million.  \n \n", "start_char_idx": 440, "end_char_idx": 546, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6a0b1ae-9c8a-4a19-b917-8318e1763e9b": {"__data__": {"id_": "a6a0b1ae-9c8a-4a19-b917-8318e1763e9b", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nMoving on to Corporate, for the quarter, adjusted corporate expenses were $154 million, a decrease of 7% year -\nover-year, driven by decreased opioid lit igation expenses.  We reported opioid -related litigation expenses of $35 \nmillion for the first quarter.  We continue to estimate fiscal 2022 opioid -related litigation expenses to approximate \n$155 million.  \n \n I would remind you that while we've negotiated a com prehensive proposed settlement agreement, until we know \nthe scope of participation in proposed settlement, we are not in a position to revise our opioid litigation expenses \noutlook.  \n \n Let me now turn to our cash position, which can be found on slide 14.  We ended the quarter with a cash balance \nof $2.4 billion.  During the quarter, we had negative free cash flow of $1.8 billion. ", "original_text": "I would remind you that while we've negotiated a com prehensive proposed settlement agreement, until we know \nthe scope of participation in proposed settlement, we are not in a position to revise our opioid litigation expenses \noutlook.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b1599fc327c32617d492de23bfdfcc95592645274780378ad1d16e9c944d1bd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "025d43a6-8a49-4858-864d-46bf7e71044b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nMoving on to Corporate, for the quarter, adjusted corporate expenses were $154 million, a decrease of 7% year -\nover-year, driven by decreased opioid lit igation expenses.  We reported opioid -related litigation expenses of $35 \nmillion for the first quarter.  We continue to estimate fiscal 2022 opioid -related litigation expenses to approximate \n$155 million.  \n \n I would remind you that while we've negotiated a com prehensive proposed settlement agreement, until we know \nthe scope of participation in proposed settlement, we are not in a position to revise our opioid litigation expenses \noutlook.  \n \n Let me now turn to our cash position, which can be found on slide 14.  We ended the quarter with a cash balance \nof $2.4 billion. ", "original_text": "We continue to estimate fiscal 2022 opioid -related litigation expenses to approximate \n$155 million.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eadd6a309611c98905ddaf53fa87f379775b5f4ae6f7dcdfdffdfd3f670f7209", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2a2ffae-0a6a-443a-b2f9-f0769c2eb74c", "node_type": "1", "metadata": {"window": "We reported opioid -related litigation expenses of $35 \nmillion for the first quarter.  We continue to estimate fiscal 2022 opioid -related litigation expenses to approximate \n$155 million.  \n \n I would remind you that while we've negotiated a com prehensive proposed settlement agreement, until we know \nthe scope of participation in proposed settlement, we are not in a position to revise our opioid litigation expenses \noutlook.  \n \n Let me now turn to our cash position, which can be found on slide 14.  We ended the quarter with a cash balance \nof $2.4 billion.  During the quarter, we had negative free cash flow of $1.8 billion.  As a reminder, our working \ncapital metrics and resulting free cash flow vary from quarter -to-quarter and are impacted by timing, incl uding the \nday and week that marks the close of a given quarter.  \n \n", "original_text": "Let me now turn to our cash position, which can be found on slide 14. "}, "hash": "9b6e3461b33ea4a26f3ce37bf071fc99040dba305d2b931bb6d97a7a2135014a", "class_name": "RelatedNodeInfo"}}, "text": "I would remind you that while we've negotiated a com prehensive proposed settlement agreement, until we know \nthe scope of participation in proposed settlement, we are not in a position to revise our opioid litigation expenses \noutlook.  \n \n", "start_char_idx": 546, "end_char_idx": 787, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2a2ffae-0a6a-443a-b2f9-f0769c2eb74c": {"__data__": {"id_": "d2a2ffae-0a6a-443a-b2f9-f0769c2eb74c", "embedding": null, "metadata": {"window": "We reported opioid -related litigation expenses of $35 \nmillion for the first quarter.  We continue to estimate fiscal 2022 opioid -related litigation expenses to approximate \n$155 million.  \n \n I would remind you that while we've negotiated a com prehensive proposed settlement agreement, until we know \nthe scope of participation in proposed settlement, we are not in a position to revise our opioid litigation expenses \noutlook.  \n \n Let me now turn to our cash position, which can be found on slide 14.  We ended the quarter with a cash balance \nof $2.4 billion.  During the quarter, we had negative free cash flow of $1.8 billion.  As a reminder, our working \ncapital metrics and resulting free cash flow vary from quarter -to-quarter and are impacted by timing, incl uding the \nday and week that marks the close of a given quarter.  \n \n", "original_text": "Let me now turn to our cash position, which can be found on slide 14. ", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b1599fc327c32617d492de23bfdfcc95592645274780378ad1d16e9c944d1bd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6a0b1ae-9c8a-4a19-b917-8318e1763e9b", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nMoving on to Corporate, for the quarter, adjusted corporate expenses were $154 million, a decrease of 7% year -\nover-year, driven by decreased opioid lit igation expenses.  We reported opioid -related litigation expenses of $35 \nmillion for the first quarter.  We continue to estimate fiscal 2022 opioid -related litigation expenses to approximate \n$155 million.  \n \n I would remind you that while we've negotiated a com prehensive proposed settlement agreement, until we know \nthe scope of participation in proposed settlement, we are not in a position to revise our opioid litigation expenses \noutlook.  \n \n Let me now turn to our cash position, which can be found on slide 14.  We ended the quarter with a cash balance \nof $2.4 billion.  During the quarter, we had negative free cash flow of $1.8 billion. ", "original_text": "I would remind you that while we've negotiated a com prehensive proposed settlement agreement, until we know \nthe scope of participation in proposed settlement, we are not in a position to revise our opioid litigation expenses \noutlook.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "beda519c340149aa76858e6f7a01ea15012090677b23d549c2e11f413b75d1ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e7969e38-6897-4eed-ac3c-bbfd6d365bc0", "node_type": "1", "metadata": {"window": "We continue to estimate fiscal 2022 opioid -related litigation expenses to approximate \n$155 million.  \n \n I would remind you that while we've negotiated a com prehensive proposed settlement agreement, until we know \nthe scope of participation in proposed settlement, we are not in a position to revise our opioid litigation expenses \noutlook.  \n \n Let me now turn to our cash position, which can be found on slide 14.  We ended the quarter with a cash balance \nof $2.4 billion.  During the quarter, we had negative free cash flow of $1.8 billion.  As a reminder, our working \ncapital metrics and resulting free cash flow vary from quarter -to-quarter and are impacted by timing, incl uding the \nday and week that marks the close of a given quarter.  \n \n We made $159 million of capital expenditures in the quarter, which includes investments in technology, data and \nanalytics to support our strategic initiatives of oncology and biopharma servic es. ", "original_text": "We ended the quarter with a cash balance \nof $2.4 billion. "}, "hash": "b7153edb9bf210b32d7dae5bfeced5e275a29d76106046751e70090c87ad2f62", "class_name": "RelatedNodeInfo"}}, "text": "Let me now turn to our cash position, which can be found on slide 14. ", "start_char_idx": 787, "end_char_idx": 857, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e7969e38-6897-4eed-ac3c-bbfd6d365bc0": {"__data__": {"id_": "e7969e38-6897-4eed-ac3c-bbfd6d365bc0", "embedding": null, "metadata": {"window": "We continue to estimate fiscal 2022 opioid -related litigation expenses to approximate \n$155 million.  \n \n I would remind you that while we've negotiated a com prehensive proposed settlement agreement, until we know \nthe scope of participation in proposed settlement, we are not in a position to revise our opioid litigation expenses \noutlook.  \n \n Let me now turn to our cash position, which can be found on slide 14.  We ended the quarter with a cash balance \nof $2.4 billion.  During the quarter, we had negative free cash flow of $1.8 billion.  As a reminder, our working \ncapital metrics and resulting free cash flow vary from quarter -to-quarter and are impacted by timing, incl uding the \nday and week that marks the close of a given quarter.  \n \n We made $159 million of capital expenditures in the quarter, which includes investments in technology, data and \nanalytics to support our strategic initiatives of oncology and biopharma servic es. ", "original_text": "We ended the quarter with a cash balance \nof $2.4 billion. ", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b1599fc327c32617d492de23bfdfcc95592645274780378ad1d16e9c944d1bd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2a2ffae-0a6a-443a-b2f9-f0769c2eb74c", "node_type": "1", "metadata": {"window": "We reported opioid -related litigation expenses of $35 \nmillion for the first quarter.  We continue to estimate fiscal 2022 opioid -related litigation expenses to approximate \n$155 million.  \n \n I would remind you that while we've negotiated a com prehensive proposed settlement agreement, until we know \nthe scope of participation in proposed settlement, we are not in a position to revise our opioid litigation expenses \noutlook.  \n \n Let me now turn to our cash position, which can be found on slide 14.  We ended the quarter with a cash balance \nof $2.4 billion.  During the quarter, we had negative free cash flow of $1.8 billion.  As a reminder, our working \ncapital metrics and resulting free cash flow vary from quarter -to-quarter and are impacted by timing, incl uding the \nday and week that marks the close of a given quarter.  \n \n", "original_text": "Let me now turn to our cash position, which can be found on slide 14. ", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "08cde3fca78bfe3270c75154efba5aa3a57a98bae9d7069a6696b00a5c300fd0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b902883b-949b-4192-a66e-5cc6f058d548", "node_type": "1", "metadata": {"window": "I would remind you that while we've negotiated a com prehensive proposed settlement agreement, until we know \nthe scope of participation in proposed settlement, we are not in a position to revise our opioid litigation expenses \noutlook.  \n \n Let me now turn to our cash position, which can be found on slide 14.  We ended the quarter with a cash balance \nof $2.4 billion.  During the quarter, we had negative free cash flow of $1.8 billion.  As a reminder, our working \ncapital metrics and resulting free cash flow vary from quarter -to-quarter and are impacted by timing, incl uding the \nday and week that marks the close of a given quarter.  \n \n We made $159 million of capital expenditures in the quarter, which includes investments in technology, data and \nanalytics to support our strategic initiatives of oncology and biopharma servic es.  As our business performed at a \nvery high level, we were also able to return $1.1 billion of cash to our shareholders in the June quarter. ", "original_text": "During the quarter, we had negative free cash flow of $1.8 billion. "}, "hash": "108f8d62fdb1523f5a3d7c9372dc945846a45e9d42e433bbe3cecf7087145fe7", "class_name": "RelatedNodeInfo"}}, "text": "We ended the quarter with a cash balance \nof $2.4 billion. ", "start_char_idx": 857, "end_char_idx": 916, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b902883b-949b-4192-a66e-5cc6f058d548": {"__data__": {"id_": "b902883b-949b-4192-a66e-5cc6f058d548", "embedding": null, "metadata": {"window": "I would remind you that while we've negotiated a com prehensive proposed settlement agreement, until we know \nthe scope of participation in proposed settlement, we are not in a position to revise our opioid litigation expenses \noutlook.  \n \n Let me now turn to our cash position, which can be found on slide 14.  We ended the quarter with a cash balance \nof $2.4 billion.  During the quarter, we had negative free cash flow of $1.8 billion.  As a reminder, our working \ncapital metrics and resulting free cash flow vary from quarter -to-quarter and are impacted by timing, incl uding the \nday and week that marks the close of a given quarter.  \n \n We made $159 million of capital expenditures in the quarter, which includes investments in technology, data and \nanalytics to support our strategic initiatives of oncology and biopharma servic es.  As our business performed at a \nvery high level, we were also able to return $1.1 billion of cash to our shareholders in the June quarter. ", "original_text": "During the quarter, we had negative free cash flow of $1.8 billion. ", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b1599fc327c32617d492de23bfdfcc95592645274780378ad1d16e9c944d1bd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e7969e38-6897-4eed-ac3c-bbfd6d365bc0", "node_type": "1", "metadata": {"window": "We continue to estimate fiscal 2022 opioid -related litigation expenses to approximate \n$155 million.  \n \n I would remind you that while we've negotiated a com prehensive proposed settlement agreement, until we know \nthe scope of participation in proposed settlement, we are not in a position to revise our opioid litigation expenses \noutlook.  \n \n Let me now turn to our cash position, which can be found on slide 14.  We ended the quarter with a cash balance \nof $2.4 billion.  During the quarter, we had negative free cash flow of $1.8 billion.  As a reminder, our working \ncapital metrics and resulting free cash flow vary from quarter -to-quarter and are impacted by timing, incl uding the \nday and week that marks the close of a given quarter.  \n \n We made $159 million of capital expenditures in the quarter, which includes investments in technology, data and \nanalytics to support our strategic initiatives of oncology and biopharma servic es. ", "original_text": "We ended the quarter with a cash balance \nof $2.4 billion. ", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fce1147b0bd79ecfdb62c6c2bbaadf7b026859870bb9b21dfa21cd96820ae2b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03bd78a2-2916-4196-a725-8a2f53984deb", "node_type": "1", "metadata": {"window": "Let me now turn to our cash position, which can be found on slide 14.  We ended the quarter with a cash balance \nof $2.4 billion.  During the quarter, we had negative free cash flow of $1.8 billion.  As a reminder, our working \ncapital metrics and resulting free cash flow vary from quarter -to-quarter and are impacted by timing, incl uding the \nday and week that marks the close of a given quarter.  \n \n We made $159 million of capital expenditures in the quarter, which includes investments in technology, data and \nanalytics to support our strategic initiatives of oncology and biopharma servic es.  As our business performed at a \nvery high level, we were also able to return $1.1 billion of cash to our shareholders in the June quarter.  This \nincluded $1 billion of share repurchases, pursuant to an accelerated share repurchase program, which resulted  in \nan initial delivery of 4.3 million shares in the quarter.  \n \n", "original_text": "As a reminder, our working \ncapital metrics and resulting free cash flow vary from quarter -to-quarter and are impacted by timing, incl uding the \nday and week that marks the close of a given quarter.  \n \n"}, "hash": "2026cf0f1780b26105c0b21f878b15cda395ee2e4c171b5879903ca562f6b66b", "class_name": "RelatedNodeInfo"}}, "text": "During the quarter, we had negative free cash flow of $1.8 billion. ", "start_char_idx": 916, "end_char_idx": 984, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03bd78a2-2916-4196-a725-8a2f53984deb": {"__data__": {"id_": "03bd78a2-2916-4196-a725-8a2f53984deb", "embedding": null, "metadata": {"window": "Let me now turn to our cash position, which can be found on slide 14.  We ended the quarter with a cash balance \nof $2.4 billion.  During the quarter, we had negative free cash flow of $1.8 billion.  As a reminder, our working \ncapital metrics and resulting free cash flow vary from quarter -to-quarter and are impacted by timing, incl uding the \nday and week that marks the close of a given quarter.  \n \n We made $159 million of capital expenditures in the quarter, which includes investments in technology, data and \nanalytics to support our strategic initiatives of oncology and biopharma servic es.  As our business performed at a \nvery high level, we were also able to return $1.1 billion of cash to our shareholders in the June quarter.  This \nincluded $1 billion of share repurchases, pursuant to an accelerated share repurchase program, which resulted  in \nan initial delivery of 4.3 million shares in the quarter.  \n \n", "original_text": "As a reminder, our working \ncapital metrics and resulting free cash flow vary from quarter -to-quarter and are impacted by timing, incl uding the \nday and week that marks the close of a given quarter.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b1599fc327c32617d492de23bfdfcc95592645274780378ad1d16e9c944d1bd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b902883b-949b-4192-a66e-5cc6f058d548", "node_type": "1", "metadata": {"window": "I would remind you that while we've negotiated a com prehensive proposed settlement agreement, until we know \nthe scope of participation in proposed settlement, we are not in a position to revise our opioid litigation expenses \noutlook.  \n \n Let me now turn to our cash position, which can be found on slide 14.  We ended the quarter with a cash balance \nof $2.4 billion.  During the quarter, we had negative free cash flow of $1.8 billion.  As a reminder, our working \ncapital metrics and resulting free cash flow vary from quarter -to-quarter and are impacted by timing, incl uding the \nday and week that marks the close of a given quarter.  \n \n We made $159 million of capital expenditures in the quarter, which includes investments in technology, data and \nanalytics to support our strategic initiatives of oncology and biopharma servic es.  As our business performed at a \nvery high level, we were also able to return $1.1 billion of cash to our shareholders in the June quarter. ", "original_text": "During the quarter, we had negative free cash flow of $1.8 billion. ", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3569f669f2e6b53c328f616210e81b240af083a5de4576881432e724fa4e0f16", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2113b4e-48dc-445a-81fb-6b2d550eaa9b", "node_type": "1", "metadata": {"window": "We ended the quarter with a cash balance \nof $2.4 billion.  During the quarter, we had negative free cash flow of $1.8 billion.  As a reminder, our working \ncapital metrics and resulting free cash flow vary from quarter -to-quarter and are impacted by timing, incl uding the \nday and week that marks the close of a given quarter.  \n \n We made $159 million of capital expenditures in the quarter, which includes investments in technology, data and \nanalytics to support our strategic initiatives of oncology and biopharma servic es.  As our business performed at a \nvery high level, we were also able to return $1.1 billion of cash to our shareholders in the June quarter.  This \nincluded $1 billion of share repurchases, pursuant to an accelerated share repurchase program, which resulted  in \nan initial delivery of 4.3 million shares in the quarter.  \n \n Additionally, we paid $69 million in dividends. ", "original_text": "We made $159 million of capital expenditures in the quarter, which includes investments in technology, data and \nanalytics to support our strategic initiatives of oncology and biopharma servic es. "}, "hash": "e4e2490c5cc536ddb75f0d912e0702627636ff1364ba6788f5fc5f1576ead605", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, our working \ncapital metrics and resulting free cash flow vary from quarter -to-quarter and are impacted by timing, incl uding the \nday and week that marks the close of a given quarter.  \n \n", "start_char_idx": 984, "end_char_idx": 1189, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2113b4e-48dc-445a-81fb-6b2d550eaa9b": {"__data__": {"id_": "c2113b4e-48dc-445a-81fb-6b2d550eaa9b", "embedding": null, "metadata": {"window": "We ended the quarter with a cash balance \nof $2.4 billion.  During the quarter, we had negative free cash flow of $1.8 billion.  As a reminder, our working \ncapital metrics and resulting free cash flow vary from quarter -to-quarter and are impacted by timing, incl uding the \nday and week that marks the close of a given quarter.  \n \n We made $159 million of capital expenditures in the quarter, which includes investments in technology, data and \nanalytics to support our strategic initiatives of oncology and biopharma servic es.  As our business performed at a \nvery high level, we were also able to return $1.1 billion of cash to our shareholders in the June quarter.  This \nincluded $1 billion of share repurchases, pursuant to an accelerated share repurchase program, which resulted  in \nan initial delivery of 4.3 million shares in the quarter.  \n \n Additionally, we paid $69 million in dividends. ", "original_text": "We made $159 million of capital expenditures in the quarter, which includes investments in technology, data and \nanalytics to support our strategic initiatives of oncology and biopharma servic es. ", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b1599fc327c32617d492de23bfdfcc95592645274780378ad1d16e9c944d1bd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03bd78a2-2916-4196-a725-8a2f53984deb", "node_type": "1", "metadata": {"window": "Let me now turn to our cash position, which can be found on slide 14.  We ended the quarter with a cash balance \nof $2.4 billion.  During the quarter, we had negative free cash flow of $1.8 billion.  As a reminder, our working \ncapital metrics and resulting free cash flow vary from quarter -to-quarter and are impacted by timing, incl uding the \nday and week that marks the close of a given quarter.  \n \n We made $159 million of capital expenditures in the quarter, which includes investments in technology, data and \nanalytics to support our strategic initiatives of oncology and biopharma servic es.  As our business performed at a \nvery high level, we were also able to return $1.1 billion of cash to our shareholders in the June quarter.  This \nincluded $1 billion of share repurchases, pursuant to an accelerated share repurchase program, which resulted  in \nan initial delivery of 4.3 million shares in the quarter.  \n \n", "original_text": "As a reminder, our working \ncapital metrics and resulting free cash flow vary from quarter -to-quarter and are impacted by timing, incl uding the \nday and week that marks the close of a given quarter.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9446add60e237ec71d1e99743c3655b64a732e6314b263dabad5cf5497d390af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "06a3276a-9792-4e8f-b620-f4a2e6d0a49f", "node_type": "1", "metadata": {"window": "During the quarter, we had negative free cash flow of $1.8 billion.  As a reminder, our working \ncapital metrics and resulting free cash flow vary from quarter -to-quarter and are impacted by timing, incl uding the \nday and week that marks the close of a given quarter.  \n \n We made $159 million of capital expenditures in the quarter, which includes investments in technology, data and \nanalytics to support our strategic initiatives of oncology and biopharma servic es.  As our business performed at a \nvery high level, we were also able to return $1.1 billion of cash to our shareholders in the June quarter.  This \nincluded $1 billion of share repurchases, pursuant to an accelerated share repurchase program, which resulted  in \nan initial delivery of 4.3 million shares in the quarter.  \n \n Additionally, we paid $69 million in dividends.  We have $1.8 billion remaining on our share repurchase \nauthorization and we're updating our guidance for diluted weighted shares outstanding to r ange from 154 million \nto 156 million for fiscal 2022, which incorporates plans to repurchase an additional $1 billion of stock over the \nremainder of the fiscal year.  \n \n", "original_text": "As our business performed at a \nvery high level, we were also able to return $1.1 billion of cash to our shareholders in the June quarter. "}, "hash": "c4b702abbf01fa5662a13fa946b3e104afcb41f7ffc68203137fb7e6949fb462", "class_name": "RelatedNodeInfo"}}, "text": "We made $159 million of capital expenditures in the quarter, which includes investments in technology, data and \nanalytics to support our strategic initiatives of oncology and biopharma servic es. ", "start_char_idx": 1189, "end_char_idx": 1386, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "06a3276a-9792-4e8f-b620-f4a2e6d0a49f": {"__data__": {"id_": "06a3276a-9792-4e8f-b620-f4a2e6d0a49f", "embedding": null, "metadata": {"window": "During the quarter, we had negative free cash flow of $1.8 billion.  As a reminder, our working \ncapital metrics and resulting free cash flow vary from quarter -to-quarter and are impacted by timing, incl uding the \nday and week that marks the close of a given quarter.  \n \n We made $159 million of capital expenditures in the quarter, which includes investments in technology, data and \nanalytics to support our strategic initiatives of oncology and biopharma servic es.  As our business performed at a \nvery high level, we were also able to return $1.1 billion of cash to our shareholders in the June quarter.  This \nincluded $1 billion of share repurchases, pursuant to an accelerated share repurchase program, which resulted  in \nan initial delivery of 4.3 million shares in the quarter.  \n \n Additionally, we paid $69 million in dividends.  We have $1.8 billion remaining on our share repurchase \nauthorization and we're updating our guidance for diluted weighted shares outstanding to r ange from 154 million \nto 156 million for fiscal 2022, which incorporates plans to repurchase an additional $1 billion of stock over the \nremainder of the fiscal year.  \n \n", "original_text": "As our business performed at a \nvery high level, we were also able to return $1.1 billion of cash to our shareholders in the June quarter. ", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b1599fc327c32617d492de23bfdfcc95592645274780378ad1d16e9c944d1bd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2113b4e-48dc-445a-81fb-6b2d550eaa9b", "node_type": "1", "metadata": {"window": "We ended the quarter with a cash balance \nof $2.4 billion.  During the quarter, we had negative free cash flow of $1.8 billion.  As a reminder, our working \ncapital metrics and resulting free cash flow vary from quarter -to-quarter and are impacted by timing, incl uding the \nday and week that marks the close of a given quarter.  \n \n We made $159 million of capital expenditures in the quarter, which includes investments in technology, data and \nanalytics to support our strategic initiatives of oncology and biopharma servic es.  As our business performed at a \nvery high level, we were also able to return $1.1 billion of cash to our shareholders in the June quarter.  This \nincluded $1 billion of share repurchases, pursuant to an accelerated share repurchase program, which resulted  in \nan initial delivery of 4.3 million shares in the quarter.  \n \n Additionally, we paid $69 million in dividends. ", "original_text": "We made $159 million of capital expenditures in the quarter, which includes investments in technology, data and \nanalytics to support our strategic initiatives of oncology and biopharma servic es. ", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8b60d16b355ec336d7b10ee3d4c865b798d729c4d6c29cedb37b18062391a37", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "992ffcc9-8f04-4da0-8b9a-4714540a8873", "node_type": "1", "metadata": {"window": "As a reminder, our working \ncapital metrics and resulting free cash flow vary from quarter -to-quarter and are impacted by timing, incl uding the \nday and week that marks the close of a given quarter.  \n \n We made $159 million of capital expenditures in the quarter, which includes investments in technology, data and \nanalytics to support our strategic initiatives of oncology and biopharma servic es.  As our business performed at a \nvery high level, we were also able to return $1.1 billion of cash to our shareholders in the June quarter.  This \nincluded $1 billion of share repurchases, pursuant to an accelerated share repurchase program, which resulted  in \nan initial delivery of 4.3 million shares in the quarter.  \n \n Additionally, we paid $69 million in dividends.  We have $1.8 billion remaining on our share repurchase \nauthorization and we're updating our guidance for diluted weighted shares outstanding to r ange from 154 million \nto 156 million for fiscal 2022, which incorporates plans to repurchase an additional $1 billion of stock over the \nremainder of the fiscal year.  \n \n Let me transition and speak to our outlook for the balance of fiscal 2022. ", "original_text": "This \nincluded $1 billion of share repurchases, pursuant to an accelerated share repurchase program, which resulted  in \nan initial delivery of 4.3 million shares in the quarter.  \n \n"}, "hash": "337066186c69e7f543e565fb7db9d35657cef96197d42c7101fb8bd69995246a", "class_name": "RelatedNodeInfo"}}, "text": "As our business performed at a \nvery high level, we were also able to return $1.1 billion of cash to our shareholders in the June quarter. ", "start_char_idx": 1386, "end_char_idx": 1525, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "992ffcc9-8f04-4da0-8b9a-4714540a8873": {"__data__": {"id_": "992ffcc9-8f04-4da0-8b9a-4714540a8873", "embedding": null, "metadata": {"window": "As a reminder, our working \ncapital metrics and resulting free cash flow vary from quarter -to-quarter and are impacted by timing, incl uding the \nday and week that marks the close of a given quarter.  \n \n We made $159 million of capital expenditures in the quarter, which includes investments in technology, data and \nanalytics to support our strategic initiatives of oncology and biopharma servic es.  As our business performed at a \nvery high level, we were also able to return $1.1 billion of cash to our shareholders in the June quarter.  This \nincluded $1 billion of share repurchases, pursuant to an accelerated share repurchase program, which resulted  in \nan initial delivery of 4.3 million shares in the quarter.  \n \n Additionally, we paid $69 million in dividends.  We have $1.8 billion remaining on our share repurchase \nauthorization and we're updating our guidance for diluted weighted shares outstanding to r ange from 154 million \nto 156 million for fiscal 2022, which incorporates plans to repurchase an additional $1 billion of stock over the \nremainder of the fiscal year.  \n \n Let me transition and speak to our outlook for the balance of fiscal 2022. ", "original_text": "This \nincluded $1 billion of share repurchases, pursuant to an accelerated share repurchase program, which resulted  in \nan initial delivery of 4.3 million shares in the quarter.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b1599fc327c32617d492de23bfdfcc95592645274780378ad1d16e9c944d1bd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "06a3276a-9792-4e8f-b620-f4a2e6d0a49f", "node_type": "1", "metadata": {"window": "During the quarter, we had negative free cash flow of $1.8 billion.  As a reminder, our working \ncapital metrics and resulting free cash flow vary from quarter -to-quarter and are impacted by timing, incl uding the \nday and week that marks the close of a given quarter.  \n \n We made $159 million of capital expenditures in the quarter, which includes investments in technology, data and \nanalytics to support our strategic initiatives of oncology and biopharma servic es.  As our business performed at a \nvery high level, we were also able to return $1.1 billion of cash to our shareholders in the June quarter.  This \nincluded $1 billion of share repurchases, pursuant to an accelerated share repurchase program, which resulted  in \nan initial delivery of 4.3 million shares in the quarter.  \n \n Additionally, we paid $69 million in dividends.  We have $1.8 billion remaining on our share repurchase \nauthorization and we're updating our guidance for diluted weighted shares outstanding to r ange from 154 million \nto 156 million for fiscal 2022, which incorporates plans to repurchase an additional $1 billion of stock over the \nremainder of the fiscal year.  \n \n", "original_text": "As our business performed at a \nvery high level, we were also able to return $1.1 billion of cash to our shareholders in the June quarter. ", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bad9d8298a73d5e105053e2ba06cc0d697cc4db49ea47b3102a8024d6ab41f65", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f45aeb1f-690b-4c44-b3aa-4116fd82a479", "node_type": "1", "metadata": {"window": "We made $159 million of capital expenditures in the quarter, which includes investments in technology, data and \nanalytics to support our strategic initiatives of oncology and biopharma servic es.  As our business performed at a \nvery high level, we were also able to return $1.1 billion of cash to our shareholders in the June quarter.  This \nincluded $1 billion of share repurchases, pursuant to an accelerated share repurchase program, which resulted  in \nan initial delivery of 4.3 million shares in the quarter.  \n \n Additionally, we paid $69 million in dividends.  We have $1.8 billion remaining on our share repurchase \nauthorization and we're updating our guidance for diluted weighted shares outstanding to r ange from 154 million \nto 156 million for fiscal 2022, which incorporates plans to repurchase an additional $1 billion of stock over the \nremainder of the fiscal year.  \n \n Let me transition and speak to our outlook for the balance of fiscal 2022.  For a full lis t of fiscal 2022 assumptions, \nplease refer to slide 16 through 19 in our supplemental slide presentation. ", "original_text": "Additionally, we paid $69 million in dividends. "}, "hash": "31e9da9a6a27d7309f7fe668c6a07928ce8bfd2e526e3d871d56fe17199c6676", "class_name": "RelatedNodeInfo"}}, "text": "This \nincluded $1 billion of share repurchases, pursuant to an accelerated share repurchase program, which resulted  in \nan initial delivery of 4.3 million shares in the quarter.  \n \n", "start_char_idx": 1525, "end_char_idx": 1708, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f45aeb1f-690b-4c44-b3aa-4116fd82a479": {"__data__": {"id_": "f45aeb1f-690b-4c44-b3aa-4116fd82a479", "embedding": null, "metadata": {"window": "We made $159 million of capital expenditures in the quarter, which includes investments in technology, data and \nanalytics to support our strategic initiatives of oncology and biopharma servic es.  As our business performed at a \nvery high level, we were also able to return $1.1 billion of cash to our shareholders in the June quarter.  This \nincluded $1 billion of share repurchases, pursuant to an accelerated share repurchase program, which resulted  in \nan initial delivery of 4.3 million shares in the quarter.  \n \n Additionally, we paid $69 million in dividends.  We have $1.8 billion remaining on our share repurchase \nauthorization and we're updating our guidance for diluted weighted shares outstanding to r ange from 154 million \nto 156 million for fiscal 2022, which incorporates plans to repurchase an additional $1 billion of stock over the \nremainder of the fiscal year.  \n \n Let me transition and speak to our outlook for the balance of fiscal 2022.  For a full lis t of fiscal 2022 assumptions, \nplease refer to slide 16 through 19 in our supplemental slide presentation. ", "original_text": "Additionally, we paid $69 million in dividends. ", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b1599fc327c32617d492de23bfdfcc95592645274780378ad1d16e9c944d1bd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "992ffcc9-8f04-4da0-8b9a-4714540a8873", "node_type": "1", "metadata": {"window": "As a reminder, our working \ncapital metrics and resulting free cash flow vary from quarter -to-quarter and are impacted by timing, incl uding the \nday and week that marks the close of a given quarter.  \n \n We made $159 million of capital expenditures in the quarter, which includes investments in technology, data and \nanalytics to support our strategic initiatives of oncology and biopharma servic es.  As our business performed at a \nvery high level, we were also able to return $1.1 billion of cash to our shareholders in the June quarter.  This \nincluded $1 billion of share repurchases, pursuant to an accelerated share repurchase program, which resulted  in \nan initial delivery of 4.3 million shares in the quarter.  \n \n Additionally, we paid $69 million in dividends.  We have $1.8 billion remaining on our share repurchase \nauthorization and we're updating our guidance for diluted weighted shares outstanding to r ange from 154 million \nto 156 million for fiscal 2022, which incorporates plans to repurchase an additional $1 billion of stock over the \nremainder of the fiscal year.  \n \n Let me transition and speak to our outlook for the balance of fiscal 2022. ", "original_text": "This \nincluded $1 billion of share repurchases, pursuant to an accelerated share repurchase program, which resulted  in \nan initial delivery of 4.3 million shares in the quarter.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "39db7750dc5929dd1a6c01a8a2b34469eba3dc6c87694cd3554cc52d0c033208", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6dd44dac-b214-4bd3-923c-d5fea3d07c50", "node_type": "1", "metadata": {"window": "As our business performed at a \nvery high level, we were also able to return $1.1 billion of cash to our shareholders in the June quarter.  This \nincluded $1 billion of share repurchases, pursuant to an accelerated share repurchase program, which resulted  in \nan initial delivery of 4.3 million shares in the quarter.  \n \n Additionally, we paid $69 million in dividends.  We have $1.8 billion remaining on our share repurchase \nauthorization and we're updating our guidance for diluted weighted shares outstanding to r ange from 154 million \nto 156 million for fiscal 2022, which incorporates plans to repurchase an additional $1 billion of stock over the \nremainder of the fiscal year.  \n \n Let me transition and speak to our outlook for the balance of fiscal 2022.  For a full lis t of fiscal 2022 assumptions, \nplease refer to slide 16 through 19 in our supplemental slide presentation.  I'll begin by reiterating a couple of key \nmacro -level assumptions that underpin our fiscal 2022 outlook. ", "original_text": "We have $1.8 billion remaining on our share repurchase \nauthorization and we're updating our guidance for diluted weighted shares outstanding to r ange from 154 million \nto 156 million for fiscal 2022, which incorporates plans to repurchase an additional $1 billion of stock over the \nremainder of the fiscal year.  \n \n"}, "hash": "36d692628ca62edd869139c82b17d590809f74095964588883e1a4862d1cfae6", "class_name": "RelatedNodeInfo"}}, "text": "Additionally, we paid $69 million in dividends. ", "start_char_idx": 1708, "end_char_idx": 1756, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6dd44dac-b214-4bd3-923c-d5fea3d07c50": {"__data__": {"id_": "6dd44dac-b214-4bd3-923c-d5fea3d07c50", "embedding": null, "metadata": {"window": "As our business performed at a \nvery high level, we were also able to return $1.1 billion of cash to our shareholders in the June quarter.  This \nincluded $1 billion of share repurchases, pursuant to an accelerated share repurchase program, which resulted  in \nan initial delivery of 4.3 million shares in the quarter.  \n \n Additionally, we paid $69 million in dividends.  We have $1.8 billion remaining on our share repurchase \nauthorization and we're updating our guidance for diluted weighted shares outstanding to r ange from 154 million \nto 156 million for fiscal 2022, which incorporates plans to repurchase an additional $1 billion of stock over the \nremainder of the fiscal year.  \n \n Let me transition and speak to our outlook for the balance of fiscal 2022.  For a full lis t of fiscal 2022 assumptions, \nplease refer to slide 16 through 19 in our supplemental slide presentation.  I'll begin by reiterating a couple of key \nmacro -level assumptions that underpin our fiscal 2022 outlook. ", "original_text": "We have $1.8 billion remaining on our share repurchase \nauthorization and we're updating our guidance for diluted weighted shares outstanding to r ange from 154 million \nto 156 million for fiscal 2022, which incorporates plans to repurchase an additional $1 billion of stock over the \nremainder of the fiscal year.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b1599fc327c32617d492de23bfdfcc95592645274780378ad1d16e9c944d1bd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f45aeb1f-690b-4c44-b3aa-4116fd82a479", "node_type": "1", "metadata": {"window": "We made $159 million of capital expenditures in the quarter, which includes investments in technology, data and \nanalytics to support our strategic initiatives of oncology and biopharma servic es.  As our business performed at a \nvery high level, we were also able to return $1.1 billion of cash to our shareholders in the June quarter.  This \nincluded $1 billion of share repurchases, pursuant to an accelerated share repurchase program, which resulted  in \nan initial delivery of 4.3 million shares in the quarter.  \n \n Additionally, we paid $69 million in dividends.  We have $1.8 billion remaining on our share repurchase \nauthorization and we're updating our guidance for diluted weighted shares outstanding to r ange from 154 million \nto 156 million for fiscal 2022, which incorporates plans to repurchase an additional $1 billion of stock over the \nremainder of the fiscal year.  \n \n Let me transition and speak to our outlook for the balance of fiscal 2022.  For a full lis t of fiscal 2022 assumptions, \nplease refer to slide 16 through 19 in our supplemental slide presentation. ", "original_text": "Additionally, we paid $69 million in dividends. ", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "effbab2ea2faecad7a3b7433943061b350457b20b7d2b9e1d34d53a79e11dc81", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55783554-8357-4aee-8b99-0ec801ae2e52", "node_type": "1", "metadata": {"window": "This \nincluded $1 billion of share repurchases, pursuant to an accelerated share repurchase program, which resulted  in \nan initial delivery of 4.3 million shares in the quarter.  \n \n Additionally, we paid $69 million in dividends.  We have $1.8 billion remaining on our share repurchase \nauthorization and we're updating our guidance for diluted weighted shares outstanding to r ange from 154 million \nto 156 million for fiscal 2022, which incorporates plans to repurchase an additional $1 billion of stock over the \nremainder of the fiscal year.  \n \n Let me transition and speak to our outlook for the balance of fiscal 2022.  For a full lis t of fiscal 2022 assumptions, \nplease refer to slide 16 through 19 in our supplemental slide presentation.  I'll begin by reiterating a couple of key \nmacro -level assumptions that underpin our fiscal 2022 outlook.  We expect prescription and patient engagement  \nvolumes will demonstrate steady improvement from the levels at the end of our fiscal 2021 through the first half of \nour fiscal 2022 and returned to pre -COVID levels in the second half of our fiscal 2022.  \n \n", "original_text": "Let me transition and speak to our outlook for the balance of fiscal 2022. "}, "hash": "2842bbbfd9f78c6f71735a7107ca038a0769d0c496067fcde82660f3060066fd", "class_name": "RelatedNodeInfo"}}, "text": "We have $1.8 billion remaining on our share repurchase \nauthorization and we're updating our guidance for diluted weighted shares outstanding to r ange from 154 million \nto 156 million for fiscal 2022, which incorporates plans to repurchase an additional $1 billion of stock over the \nremainder of the fiscal year.  \n \n", "start_char_idx": 1756, "end_char_idx": 2075, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "55783554-8357-4aee-8b99-0ec801ae2e52": {"__data__": {"id_": "55783554-8357-4aee-8b99-0ec801ae2e52", "embedding": null, "metadata": {"window": "This \nincluded $1 billion of share repurchases, pursuant to an accelerated share repurchase program, which resulted  in \nan initial delivery of 4.3 million shares in the quarter.  \n \n Additionally, we paid $69 million in dividends.  We have $1.8 billion remaining on our share repurchase \nauthorization and we're updating our guidance for diluted weighted shares outstanding to r ange from 154 million \nto 156 million for fiscal 2022, which incorporates plans to repurchase an additional $1 billion of stock over the \nremainder of the fiscal year.  \n \n Let me transition and speak to our outlook for the balance of fiscal 2022.  For a full lis t of fiscal 2022 assumptions, \nplease refer to slide 16 through 19 in our supplemental slide presentation.  I'll begin by reiterating a couple of key \nmacro -level assumptions that underpin our fiscal 2022 outlook.  We expect prescription and patient engagement  \nvolumes will demonstrate steady improvement from the levels at the end of our fiscal 2021 through the first half of \nour fiscal 2022 and returned to pre -COVID levels in the second half of our fiscal 2022.  \n \n", "original_text": "Let me transition and speak to our outlook for the balance of fiscal 2022. ", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b1599fc327c32617d492de23bfdfcc95592645274780378ad1d16e9c944d1bd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6dd44dac-b214-4bd3-923c-d5fea3d07c50", "node_type": "1", "metadata": {"window": "As our business performed at a \nvery high level, we were also able to return $1.1 billion of cash to our shareholders in the June quarter.  This \nincluded $1 billion of share repurchases, pursuant to an accelerated share repurchase program, which resulted  in \nan initial delivery of 4.3 million shares in the quarter.  \n \n Additionally, we paid $69 million in dividends.  We have $1.8 billion remaining on our share repurchase \nauthorization and we're updating our guidance for diluted weighted shares outstanding to r ange from 154 million \nto 156 million for fiscal 2022, which incorporates plans to repurchase an additional $1 billion of stock over the \nremainder of the fiscal year.  \n \n Let me transition and speak to our outlook for the balance of fiscal 2022.  For a full lis t of fiscal 2022 assumptions, \nplease refer to slide 16 through 19 in our supplemental slide presentation.  I'll begin by reiterating a couple of key \nmacro -level assumptions that underpin our fiscal 2022 outlook. ", "original_text": "We have $1.8 billion remaining on our share repurchase \nauthorization and we're updating our guidance for diluted weighted shares outstanding to r ange from 154 million \nto 156 million for fiscal 2022, which incorporates plans to repurchase an additional $1 billion of stock over the \nremainder of the fiscal year.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f24fa802b39ca742918df5fab194e0494bc44e2aa4e6833cee0a131d8216e257", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "087fe09a-eca9-47b8-8932-76d49386680e", "node_type": "1", "metadata": {"window": "Additionally, we paid $69 million in dividends.  We have $1.8 billion remaining on our share repurchase \nauthorization and we're updating our guidance for diluted weighted shares outstanding to r ange from 154 million \nto 156 million for fiscal 2022, which incorporates plans to repurchase an additional $1 billion of stock over the \nremainder of the fiscal year.  \n \n Let me transition and speak to our outlook for the balance of fiscal 2022.  For a full lis t of fiscal 2022 assumptions, \nplease refer to slide 16 through 19 in our supplemental slide presentation.  I'll begin by reiterating a couple of key \nmacro -level assumptions that underpin our fiscal 2022 outlook.  We expect prescription and patient engagement  \nvolumes will demonstrate steady improvement from the levels at the end of our fiscal 2021 through the first half of \nour fiscal 2022 and returned to pre -COVID levels in the second half of our fiscal 2022.  \n \n For fiscal 2022, our updated guidance for adjusted  earnings per diluted share is a range of $19.80 to $20.40, up \nfrom our previous range of $18.85 to $19.45, approximately equally split between our first and second half of the \nfiscal year. ", "original_text": "For a full lis t of fiscal 2022 assumptions, \nplease refer to slide 16 through 19 in our supplemental slide presentation. "}, "hash": "6e94c82da4d30dd1825967f6aa3b680bdec0392f4198027672c8cebaf87af161", "class_name": "RelatedNodeInfo"}}, "text": "Let me transition and speak to our outlook for the balance of fiscal 2022. ", "start_char_idx": 2075, "end_char_idx": 2150, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "087fe09a-eca9-47b8-8932-76d49386680e": {"__data__": {"id_": "087fe09a-eca9-47b8-8932-76d49386680e", "embedding": null, "metadata": {"window": "Additionally, we paid $69 million in dividends.  We have $1.8 billion remaining on our share repurchase \nauthorization and we're updating our guidance for diluted weighted shares outstanding to r ange from 154 million \nto 156 million for fiscal 2022, which incorporates plans to repurchase an additional $1 billion of stock over the \nremainder of the fiscal year.  \n \n Let me transition and speak to our outlook for the balance of fiscal 2022.  For a full lis t of fiscal 2022 assumptions, \nplease refer to slide 16 through 19 in our supplemental slide presentation.  I'll begin by reiterating a couple of key \nmacro -level assumptions that underpin our fiscal 2022 outlook.  We expect prescription and patient engagement  \nvolumes will demonstrate steady improvement from the levels at the end of our fiscal 2021 through the first half of \nour fiscal 2022 and returned to pre -COVID levels in the second half of our fiscal 2022.  \n \n For fiscal 2022, our updated guidance for adjusted  earnings per diluted share is a range of $19.80 to $20.40, up \nfrom our previous range of $18.85 to $19.45, approximately equally split between our first and second half of the \nfiscal year. ", "original_text": "For a full lis t of fiscal 2022 assumptions, \nplease refer to slide 16 through 19 in our supplemental slide presentation. ", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b1599fc327c32617d492de23bfdfcc95592645274780378ad1d16e9c944d1bd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55783554-8357-4aee-8b99-0ec801ae2e52", "node_type": "1", "metadata": {"window": "This \nincluded $1 billion of share repurchases, pursuant to an accelerated share repurchase program, which resulted  in \nan initial delivery of 4.3 million shares in the quarter.  \n \n Additionally, we paid $69 million in dividends.  We have $1.8 billion remaining on our share repurchase \nauthorization and we're updating our guidance for diluted weighted shares outstanding to r ange from 154 million \nto 156 million for fiscal 2022, which incorporates plans to repurchase an additional $1 billion of stock over the \nremainder of the fiscal year.  \n \n Let me transition and speak to our outlook for the balance of fiscal 2022.  For a full lis t of fiscal 2022 assumptions, \nplease refer to slide 16 through 19 in our supplemental slide presentation.  I'll begin by reiterating a couple of key \nmacro -level assumptions that underpin our fiscal 2022 outlook.  We expect prescription and patient engagement  \nvolumes will demonstrate steady improvement from the levels at the end of our fiscal 2021 through the first half of \nour fiscal 2022 and returned to pre -COVID levels in the second half of our fiscal 2022.  \n \n", "original_text": "Let me transition and speak to our outlook for the balance of fiscal 2022. ", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c291bb2803f97fa1b00ba6c2d4434c5647166f4bb74332fa8d9a8386f633330e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9102f105-2ebe-42a7-8f78-c941fb5a431b", "node_type": "1", "metadata": {"window": "We have $1.8 billion remaining on our share repurchase \nauthorization and we're updating our guidance for diluted weighted shares outstanding to r ange from 154 million \nto 156 million for fiscal 2022, which incorporates plans to repurchase an additional $1 billion of stock over the \nremainder of the fiscal year.  \n \n Let me transition and speak to our outlook for the balance of fiscal 2022.  For a full lis t of fiscal 2022 assumptions, \nplease refer to slide 16 through 19 in our supplemental slide presentation.  I'll begin by reiterating a couple of key \nmacro -level assumptions that underpin our fiscal 2022 outlook.  We expect prescription and patient engagement  \nvolumes will demonstrate steady improvement from the levels at the end of our fiscal 2021 through the first half of \nour fiscal 2022 and returned to pre -COVID levels in the second half of our fiscal 2022.  \n \n For fiscal 2022, our updated guidance for adjusted  earnings per diluted share is a range of $19.80 to $20.40, up \nfrom our previous range of $18.85 to $19.45, approximately equally split between our first and second half of the \nfiscal year.  Our updated outlook for adjusted earnings per diluted share reflec ts 15% to 18.5% growth from the \nprior year and our guidance assumes core growth across all of our segments.  \n \n", "original_text": "I'll begin by reiterating a couple of key \nmacro -level assumptions that underpin our fiscal 2022 outlook. "}, "hash": "610285c098f2039a1b01a17764887ada4b2f0ec42e3345d10bfbcdba4da0fc0c", "class_name": "RelatedNodeInfo"}}, "text": "For a full lis t of fiscal 2022 assumptions, \nplease refer to slide 16 through 19 in our supplemental slide presentation. ", "start_char_idx": 2150, "end_char_idx": 2272, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9102f105-2ebe-42a7-8f78-c941fb5a431b": {"__data__": {"id_": "9102f105-2ebe-42a7-8f78-c941fb5a431b", "embedding": null, "metadata": {"window": "We have $1.8 billion remaining on our share repurchase \nauthorization and we're updating our guidance for diluted weighted shares outstanding to r ange from 154 million \nto 156 million for fiscal 2022, which incorporates plans to repurchase an additional $1 billion of stock over the \nremainder of the fiscal year.  \n \n Let me transition and speak to our outlook for the balance of fiscal 2022.  For a full lis t of fiscal 2022 assumptions, \nplease refer to slide 16 through 19 in our supplemental slide presentation.  I'll begin by reiterating a couple of key \nmacro -level assumptions that underpin our fiscal 2022 outlook.  We expect prescription and patient engagement  \nvolumes will demonstrate steady improvement from the levels at the end of our fiscal 2021 through the first half of \nour fiscal 2022 and returned to pre -COVID levels in the second half of our fiscal 2022.  \n \n For fiscal 2022, our updated guidance for adjusted  earnings per diluted share is a range of $19.80 to $20.40, up \nfrom our previous range of $18.85 to $19.45, approximately equally split between our first and second half of the \nfiscal year.  Our updated outlook for adjusted earnings per diluted share reflec ts 15% to 18.5% growth from the \nprior year and our guidance assumes core growth across all of our segments.  \n \n", "original_text": "I'll begin by reiterating a couple of key \nmacro -level assumptions that underpin our fiscal 2022 outlook. ", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b1599fc327c32617d492de23bfdfcc95592645274780378ad1d16e9c944d1bd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "087fe09a-eca9-47b8-8932-76d49386680e", "node_type": "1", "metadata": {"window": "Additionally, we paid $69 million in dividends.  We have $1.8 billion remaining on our share repurchase \nauthorization and we're updating our guidance for diluted weighted shares outstanding to r ange from 154 million \nto 156 million for fiscal 2022, which incorporates plans to repurchase an additional $1 billion of stock over the \nremainder of the fiscal year.  \n \n Let me transition and speak to our outlook for the balance of fiscal 2022.  For a full lis t of fiscal 2022 assumptions, \nplease refer to slide 16 through 19 in our supplemental slide presentation.  I'll begin by reiterating a couple of key \nmacro -level assumptions that underpin our fiscal 2022 outlook.  We expect prescription and patient engagement  \nvolumes will demonstrate steady improvement from the levels at the end of our fiscal 2021 through the first half of \nour fiscal 2022 and returned to pre -COVID levels in the second half of our fiscal 2022.  \n \n For fiscal 2022, our updated guidance for adjusted  earnings per diluted share is a range of $19.80 to $20.40, up \nfrom our previous range of $18.85 to $19.45, approximately equally split between our first and second half of the \nfiscal year. ", "original_text": "For a full lis t of fiscal 2022 assumptions, \nplease refer to slide 16 through 19 in our supplemental slide presentation. ", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20c2e406e0fa4acaa5fe7ad11f64e02b440f94dd3ff5ca562ac4bf57ac3e314e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd34f446-3c0a-4c5a-b182-8353067c7ae4", "node_type": "1", "metadata": {"window": "Let me transition and speak to our outlook for the balance of fiscal 2022.  For a full lis t of fiscal 2022 assumptions, \nplease refer to slide 16 through 19 in our supplemental slide presentation.  I'll begin by reiterating a couple of key \nmacro -level assumptions that underpin our fiscal 2022 outlook.  We expect prescription and patient engagement  \nvolumes will demonstrate steady improvement from the levels at the end of our fiscal 2021 through the first half of \nour fiscal 2022 and returned to pre -COVID levels in the second half of our fiscal 2022.  \n \n For fiscal 2022, our updated guidance for adjusted  earnings per diluted share is a range of $19.80 to $20.40, up \nfrom our previous range of $18.85 to $19.45, approximately equally split between our first and second half of the \nfiscal year.  Our updated outlook for adjusted earnings per diluted share reflec ts 15% to 18.5% growth from the \nprior year and our guidance assumes core growth across all of our segments.  \n \n In the US Pharmaceutical segment, we now expect revenue to increase 5% to 8% and adjusted operating profit to \ndeliver 4.5% to 7.5% growth over the prior year. ", "original_text": "We expect prescription and patient engagement  \nvolumes will demonstrate steady improvement from the levels at the end of our fiscal 2021 through the first half of \nour fiscal 2022 and returned to pre -COVID levels in the second half of our fiscal 2022.  \n \n"}, "hash": "3e6f87228e118508367f55a78030b6101aa19247bf0367772f2287e2456881bc", "class_name": "RelatedNodeInfo"}}, "text": "I'll begin by reiterating a couple of key \nmacro -level assumptions that underpin our fiscal 2022 outlook. ", "start_char_idx": 2272, "end_char_idx": 2379, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd34f446-3c0a-4c5a-b182-8353067c7ae4": {"__data__": {"id_": "cd34f446-3c0a-4c5a-b182-8353067c7ae4", "embedding": null, "metadata": {"window": "Let me transition and speak to our outlook for the balance of fiscal 2022.  For a full lis t of fiscal 2022 assumptions, \nplease refer to slide 16 through 19 in our supplemental slide presentation.  I'll begin by reiterating a couple of key \nmacro -level assumptions that underpin our fiscal 2022 outlook.  We expect prescription and patient engagement  \nvolumes will demonstrate steady improvement from the levels at the end of our fiscal 2021 through the first half of \nour fiscal 2022 and returned to pre -COVID levels in the second half of our fiscal 2022.  \n \n For fiscal 2022, our updated guidance for adjusted  earnings per diluted share is a range of $19.80 to $20.40, up \nfrom our previous range of $18.85 to $19.45, approximately equally split between our first and second half of the \nfiscal year.  Our updated outlook for adjusted earnings per diluted share reflec ts 15% to 18.5% growth from the \nprior year and our guidance assumes core growth across all of our segments.  \n \n In the US Pharmaceutical segment, we now expect revenue to increase 5% to 8% and adjusted operating profit to \ndeliver 4.5% to 7.5% growth over the prior year. ", "original_text": "We expect prescription and patient engagement  \nvolumes will demonstrate steady improvement from the levels at the end of our fiscal 2021 through the first half of \nour fiscal 2022 and returned to pre -COVID levels in the second half of our fiscal 2022.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b1599fc327c32617d492de23bfdfcc95592645274780378ad1d16e9c944d1bd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9102f105-2ebe-42a7-8f78-c941fb5a431b", "node_type": "1", "metadata": {"window": "We have $1.8 billion remaining on our share repurchase \nauthorization and we're updating our guidance for diluted weighted shares outstanding to r ange from 154 million \nto 156 million for fiscal 2022, which incorporates plans to repurchase an additional $1 billion of stock over the \nremainder of the fiscal year.  \n \n Let me transition and speak to our outlook for the balance of fiscal 2022.  For a full lis t of fiscal 2022 assumptions, \nplease refer to slide 16 through 19 in our supplemental slide presentation.  I'll begin by reiterating a couple of key \nmacro -level assumptions that underpin our fiscal 2022 outlook.  We expect prescription and patient engagement  \nvolumes will demonstrate steady improvement from the levels at the end of our fiscal 2021 through the first half of \nour fiscal 2022 and returned to pre -COVID levels in the second half of our fiscal 2022.  \n \n For fiscal 2022, our updated guidance for adjusted  earnings per diluted share is a range of $19.80 to $20.40, up \nfrom our previous range of $18.85 to $19.45, approximately equally split between our first and second half of the \nfiscal year.  Our updated outlook for adjusted earnings per diluted share reflec ts 15% to 18.5% growth from the \nprior year and our guidance assumes core growth across all of our segments.  \n \n", "original_text": "I'll begin by reiterating a couple of key \nmacro -level assumptions that underpin our fiscal 2022 outlook. ", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "173af5dcefbcbc06a4a2b41eb9447ffca1de0da903a3b0c871055eabcfdeee3b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36902320-6767-4852-a8fc-d5d87bb374a0", "node_type": "1", "metadata": {"window": "For a full lis t of fiscal 2022 assumptions, \nplease refer to slide 16 through 19 in our supplemental slide presentation.  I'll begin by reiterating a couple of key \nmacro -level assumptions that underpin our fiscal 2022 outlook.  We expect prescription and patient engagement  \nvolumes will demonstrate steady improvement from the levels at the end of our fiscal 2021 through the first half of \nour fiscal 2022 and returned to pre -COVID levels in the second half of our fiscal 2022.  \n \n For fiscal 2022, our updated guidance for adjusted  earnings per diluted share is a range of $19.80 to $20.40, up \nfrom our previous range of $18.85 to $19.45, approximately equally split between our first and second half of the \nfiscal year.  Our updated outlook for adjusted earnings per diluted share reflec ts 15% to 18.5% growth from the \nprior year and our guidance assumes core growth across all of our segments.  \n \n In the US Pharmaceutical segment, we now expect revenue to increase 5% to 8% and adjusted operating profit to \ndeliver 4.5% to 7.5% growth over the prior year.  Our US Pharmaceutical segment continues to exhibit stable \nfundamentals. ", "original_text": "For fiscal 2022, our updated guidance for adjusted  earnings per diluted share is a range of $19.80 to $20.40, up \nfrom our previous range of $18.85 to $19.45, approximately equally split between our first and second half of the \nfiscal year. "}, "hash": "001a86727002d0ebdf3d02746c4488fa5f8384f38f37a2cff0e056a7980ae02d", "class_name": "RelatedNodeInfo"}}, "text": "We expect prescription and patient engagement  \nvolumes will demonstrate steady improvement from the levels at the end of our fiscal 2021 through the first half of \nour fiscal 2022 and returned to pre -COVID levels in the second half of our fiscal 2022.  \n \n", "start_char_idx": 2379, "end_char_idx": 2637, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36902320-6767-4852-a8fc-d5d87bb374a0": {"__data__": {"id_": "36902320-6767-4852-a8fc-d5d87bb374a0", "embedding": null, "metadata": {"window": "For a full lis t of fiscal 2022 assumptions, \nplease refer to slide 16 through 19 in our supplemental slide presentation.  I'll begin by reiterating a couple of key \nmacro -level assumptions that underpin our fiscal 2022 outlook.  We expect prescription and patient engagement  \nvolumes will demonstrate steady improvement from the levels at the end of our fiscal 2021 through the first half of \nour fiscal 2022 and returned to pre -COVID levels in the second half of our fiscal 2022.  \n \n For fiscal 2022, our updated guidance for adjusted  earnings per diluted share is a range of $19.80 to $20.40, up \nfrom our previous range of $18.85 to $19.45, approximately equally split between our first and second half of the \nfiscal year.  Our updated outlook for adjusted earnings per diluted share reflec ts 15% to 18.5% growth from the \nprior year and our guidance assumes core growth across all of our segments.  \n \n In the US Pharmaceutical segment, we now expect revenue to increase 5% to 8% and adjusted operating profit to \ndeliver 4.5% to 7.5% growth over the prior year.  Our US Pharmaceutical segment continues to exhibit stable \nfundamentals. ", "original_text": "For fiscal 2022, our updated guidance for adjusted  earnings per diluted share is a range of $19.80 to $20.40, up \nfrom our previous range of $18.85 to $19.45, approximately equally split between our first and second half of the \nfiscal year. ", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b1599fc327c32617d492de23bfdfcc95592645274780378ad1d16e9c944d1bd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd34f446-3c0a-4c5a-b182-8353067c7ae4", "node_type": "1", "metadata": {"window": "Let me transition and speak to our outlook for the balance of fiscal 2022.  For a full lis t of fiscal 2022 assumptions, \nplease refer to slide 16 through 19 in our supplemental slide presentation.  I'll begin by reiterating a couple of key \nmacro -level assumptions that underpin our fiscal 2022 outlook.  We expect prescription and patient engagement  \nvolumes will demonstrate steady improvement from the levels at the end of our fiscal 2021 through the first half of \nour fiscal 2022 and returned to pre -COVID levels in the second half of our fiscal 2022.  \n \n For fiscal 2022, our updated guidance for adjusted  earnings per diluted share is a range of $19.80 to $20.40, up \nfrom our previous range of $18.85 to $19.45, approximately equally split between our first and second half of the \nfiscal year.  Our updated outlook for adjusted earnings per diluted share reflec ts 15% to 18.5% growth from the \nprior year and our guidance assumes core growth across all of our segments.  \n \n In the US Pharmaceutical segment, we now expect revenue to increase 5% to 8% and adjusted operating profit to \ndeliver 4.5% to 7.5% growth over the prior year. ", "original_text": "We expect prescription and patient engagement  \nvolumes will demonstrate steady improvement from the levels at the end of our fiscal 2021 through the first half of \nour fiscal 2022 and returned to pre -COVID levels in the second half of our fiscal 2022.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b598f429e9cdb4a186bec8dcf8464790640543e369a0265a88fda536d39d5ab9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b0874b41-fb24-4091-8550-9ca33823a115", "node_type": "1", "metadata": {"window": "I'll begin by reiterating a couple of key \nmacro -level assumptions that underpin our fiscal 2022 outlook.  We expect prescription and patient engagement  \nvolumes will demonstrate steady improvement from the levels at the end of our fiscal 2021 through the first half of \nour fiscal 2022 and returned to pre -COVID levels in the second half of our fiscal 2022.  \n \n For fiscal 2022, our updated guidance for adjusted  earnings per diluted share is a range of $19.80 to $20.40, up \nfrom our previous range of $18.85 to $19.45, approximately equally split between our first and second half of the \nfiscal year.  Our updated outlook for adjusted earnings per diluted share reflec ts 15% to 18.5% growth from the \nprior year and our guidance assumes core growth across all of our segments.  \n \n In the US Pharmaceutical segment, we now expect revenue to increase 5% to 8% and adjusted operating profit to \ndeliver 4.5% to 7.5% growth over the prior year.  Our US Pharmaceutical segment continues to exhibit stable \nfundamentals.  Our outlook for branded pharmaceutical pricing remains consistent with the prior year for mid -\nsingle -digits increases in fiscal 2022. ", "original_text": "Our updated outlook for adjusted earnings per diluted share reflec ts 15% to 18.5% growth from the \nprior year and our guidance assumes core growth across all of our segments.  \n \n"}, "hash": "e5c36ac59eb86b7362ba790ca822a7ff183f6f5005ae88e8c187e1b9cab6ab65", "class_name": "RelatedNodeInfo"}}, "text": "For fiscal 2022, our updated guidance for adjusted  earnings per diluted share is a range of $19.80 to $20.40, up \nfrom our previous range of $18.85 to $19.45, approximately equally split between our first and second half of the \nfiscal year. ", "start_char_idx": 2637, "end_char_idx": 2880, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b0874b41-fb24-4091-8550-9ca33823a115": {"__data__": {"id_": "b0874b41-fb24-4091-8550-9ca33823a115", "embedding": null, "metadata": {"window": "I'll begin by reiterating a couple of key \nmacro -level assumptions that underpin our fiscal 2022 outlook.  We expect prescription and patient engagement  \nvolumes will demonstrate steady improvement from the levels at the end of our fiscal 2021 through the first half of \nour fiscal 2022 and returned to pre -COVID levels in the second half of our fiscal 2022.  \n \n For fiscal 2022, our updated guidance for adjusted  earnings per diluted share is a range of $19.80 to $20.40, up \nfrom our previous range of $18.85 to $19.45, approximately equally split between our first and second half of the \nfiscal year.  Our updated outlook for adjusted earnings per diluted share reflec ts 15% to 18.5% growth from the \nprior year and our guidance assumes core growth across all of our segments.  \n \n In the US Pharmaceutical segment, we now expect revenue to increase 5% to 8% and adjusted operating profit to \ndeliver 4.5% to 7.5% growth over the prior year.  Our US Pharmaceutical segment continues to exhibit stable \nfundamentals.  Our outlook for branded pharmaceutical pricing remains consistent with the prior year for mid -\nsingle -digits increases in fiscal 2022. ", "original_text": "Our updated outlook for adjusted earnings per diluted share reflec ts 15% to 18.5% growth from the \nprior year and our guidance assumes core growth across all of our segments.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b1599fc327c32617d492de23bfdfcc95592645274780378ad1d16e9c944d1bd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36902320-6767-4852-a8fc-d5d87bb374a0", "node_type": "1", "metadata": {"window": "For a full lis t of fiscal 2022 assumptions, \nplease refer to slide 16 through 19 in our supplemental slide presentation.  I'll begin by reiterating a couple of key \nmacro -level assumptions that underpin our fiscal 2022 outlook.  We expect prescription and patient engagement  \nvolumes will demonstrate steady improvement from the levels at the end of our fiscal 2021 through the first half of \nour fiscal 2022 and returned to pre -COVID levels in the second half of our fiscal 2022.  \n \n For fiscal 2022, our updated guidance for adjusted  earnings per diluted share is a range of $19.80 to $20.40, up \nfrom our previous range of $18.85 to $19.45, approximately equally split between our first and second half of the \nfiscal year.  Our updated outlook for adjusted earnings per diluted share reflec ts 15% to 18.5% growth from the \nprior year and our guidance assumes core growth across all of our segments.  \n \n In the US Pharmaceutical segment, we now expect revenue to increase 5% to 8% and adjusted operating profit to \ndeliver 4.5% to 7.5% growth over the prior year.  Our US Pharmaceutical segment continues to exhibit stable \nfundamentals. ", "original_text": "For fiscal 2022, our updated guidance for adjusted  earnings per diluted share is a range of $19.80 to $20.40, up \nfrom our previous range of $18.85 to $19.45, approximately equally split between our first and second half of the \nfiscal year. ", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bdfbfce6ab2555c7335058bd8ca73681885574d110b3af7b6e009a8c53fedcb0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8b09b061-8d45-419b-8557-eaffb6eb7b0a", "node_type": "1", "metadata": {"window": "We expect prescription and patient engagement  \nvolumes will demonstrate steady improvement from the levels at the end of our fiscal 2021 through the first half of \nour fiscal 2022 and returned to pre -COVID levels in the second half of our fiscal 2022.  \n \n For fiscal 2022, our updated guidance for adjusted  earnings per diluted share is a range of $19.80 to $20.40, up \nfrom our previous range of $18.85 to $19.45, approximately equally split between our first and second half of the \nfiscal year.  Our updated outlook for adjusted earnings per diluted share reflec ts 15% to 18.5% growth from the \nprior year and our guidance assumes core growth across all of our segments.  \n \n In the US Pharmaceutical segment, we now expect revenue to increase 5% to 8% and adjusted operating profit to \ndeliver 4.5% to 7.5% growth over the prior year.  Our US Pharmaceutical segment continues to exhibit stable \nfundamentals.  Our outlook for branded pharmaceutical pricing remains consistent with the prior year for mid -\nsingle -digits increases in fiscal 2022.  And the generics market remains compet itive, yet stable, as volumes have \nshown signs of recovery.  \n \n", "original_text": "In the US Pharmaceutical segment, we now expect revenue to increase 5% to 8% and adjusted operating profit to \ndeliver 4.5% to 7.5% growth over the prior year. "}, "hash": "be6b1f1dadd90125eea4d261f7ec9a23c7202065633741061ed0d8eda62b5d90", "class_name": "RelatedNodeInfo"}}, "text": "Our updated outlook for adjusted earnings per diluted share reflec ts 15% to 18.5% growth from the \nprior year and our guidance assumes core growth across all of our segments.  \n \n", "start_char_idx": 2880, "end_char_idx": 3060, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8b09b061-8d45-419b-8557-eaffb6eb7b0a": {"__data__": {"id_": "8b09b061-8d45-419b-8557-eaffb6eb7b0a", "embedding": null, "metadata": {"window": "We expect prescription and patient engagement  \nvolumes will demonstrate steady improvement from the levels at the end of our fiscal 2021 through the first half of \nour fiscal 2022 and returned to pre -COVID levels in the second half of our fiscal 2022.  \n \n For fiscal 2022, our updated guidance for adjusted  earnings per diluted share is a range of $19.80 to $20.40, up \nfrom our previous range of $18.85 to $19.45, approximately equally split between our first and second half of the \nfiscal year.  Our updated outlook for adjusted earnings per diluted share reflec ts 15% to 18.5% growth from the \nprior year and our guidance assumes core growth across all of our segments.  \n \n In the US Pharmaceutical segment, we now expect revenue to increase 5% to 8% and adjusted operating profit to \ndeliver 4.5% to 7.5% growth over the prior year.  Our US Pharmaceutical segment continues to exhibit stable \nfundamentals.  Our outlook for branded pharmaceutical pricing remains consistent with the prior year for mid -\nsingle -digits increases in fiscal 2022.  And the generics market remains compet itive, yet stable, as volumes have \nshown signs of recovery.  \n \n", "original_text": "In the US Pharmaceutical segment, we now expect revenue to increase 5% to 8% and adjusted operating profit to \ndeliver 4.5% to 7.5% growth over the prior year. ", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b1599fc327c32617d492de23bfdfcc95592645274780378ad1d16e9c944d1bd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b0874b41-fb24-4091-8550-9ca33823a115", "node_type": "1", "metadata": {"window": "I'll begin by reiterating a couple of key \nmacro -level assumptions that underpin our fiscal 2022 outlook.  We expect prescription and patient engagement  \nvolumes will demonstrate steady improvement from the levels at the end of our fiscal 2021 through the first half of \nour fiscal 2022 and returned to pre -COVID levels in the second half of our fiscal 2022.  \n \n For fiscal 2022, our updated guidance for adjusted  earnings per diluted share is a range of $19.80 to $20.40, up \nfrom our previous range of $18.85 to $19.45, approximately equally split between our first and second half of the \nfiscal year.  Our updated outlook for adjusted earnings per diluted share reflec ts 15% to 18.5% growth from the \nprior year and our guidance assumes core growth across all of our segments.  \n \n In the US Pharmaceutical segment, we now expect revenue to increase 5% to 8% and adjusted operating profit to \ndeliver 4.5% to 7.5% growth over the prior year.  Our US Pharmaceutical segment continues to exhibit stable \nfundamentals.  Our outlook for branded pharmaceutical pricing remains consistent with the prior year for mid -\nsingle -digits increases in fiscal 2022. ", "original_text": "Our updated outlook for adjusted earnings per diluted share reflec ts 15% to 18.5% growth from the \nprior year and our guidance assumes core growth across all of our segments.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dd9c6beb4318eac96c963d954a1483baac579076109382fdb00af1862ec80f08", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6e28386-1eea-4693-82c6-b814edc05b35", "node_type": "1", "metadata": {"window": "For fiscal 2022, our updated guidance for adjusted  earnings per diluted share is a range of $19.80 to $20.40, up \nfrom our previous range of $18.85 to $19.45, approximately equally split between our first and second half of the \nfiscal year.  Our updated outlook for adjusted earnings per diluted share reflec ts 15% to 18.5% growth from the \nprior year and our guidance assumes core growth across all of our segments.  \n \n In the US Pharmaceutical segment, we now expect revenue to increase 5% to 8% and adjusted operating profit to \ndeliver 4.5% to 7.5% growth over the prior year.  Our US Pharmaceutical segment continues to exhibit stable \nfundamentals.  Our outlook for branded pharmaceutical pricing remains consistent with the prior year for mid -\nsingle -digits increases in fiscal 2022.  And the generics market remains compet itive, yet stable, as volumes have \nshown signs of recovery.  \n \n COVID -19 vaccine contribution contributed approximately $0.30 in the first quarter of fiscal 2022. ", "original_text": "Our US Pharmaceutical segment continues to exhibit stable \nfundamentals. "}, "hash": "87acc3899f14ee6321d8975e6886857e8ff98666e8157fac21954abdc5a481ae", "class_name": "RelatedNodeInfo"}}, "text": "In the US Pharmaceutical segment, we now expect revenue to increase 5% to 8% and adjusted operating profit to \ndeliver 4.5% to 7.5% growth over the prior year. ", "start_char_idx": 3060, "end_char_idx": 3220, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6e28386-1eea-4693-82c6-b814edc05b35": {"__data__": {"id_": "b6e28386-1eea-4693-82c6-b814edc05b35", "embedding": null, "metadata": {"window": "For fiscal 2022, our updated guidance for adjusted  earnings per diluted share is a range of $19.80 to $20.40, up \nfrom our previous range of $18.85 to $19.45, approximately equally split between our first and second half of the \nfiscal year.  Our updated outlook for adjusted earnings per diluted share reflec ts 15% to 18.5% growth from the \nprior year and our guidance assumes core growth across all of our segments.  \n \n In the US Pharmaceutical segment, we now expect revenue to increase 5% to 8% and adjusted operating profit to \ndeliver 4.5% to 7.5% growth over the prior year.  Our US Pharmaceutical segment continues to exhibit stable \nfundamentals.  Our outlook for branded pharmaceutical pricing remains consistent with the prior year for mid -\nsingle -digits increases in fiscal 2022.  And the generics market remains compet itive, yet stable, as volumes have \nshown signs of recovery.  \n \n COVID -19 vaccine contribution contributed approximately $0.30 in the first quarter of fiscal 2022. ", "original_text": "Our US Pharmaceutical segment continues to exhibit stable \nfundamentals. ", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b1599fc327c32617d492de23bfdfcc95592645274780378ad1d16e9c944d1bd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8b09b061-8d45-419b-8557-eaffb6eb7b0a", "node_type": "1", "metadata": {"window": "We expect prescription and patient engagement  \nvolumes will demonstrate steady improvement from the levels at the end of our fiscal 2021 through the first half of \nour fiscal 2022 and returned to pre -COVID levels in the second half of our fiscal 2022.  \n \n For fiscal 2022, our updated guidance for adjusted  earnings per diluted share is a range of $19.80 to $20.40, up \nfrom our previous range of $18.85 to $19.45, approximately equally split between our first and second half of the \nfiscal year.  Our updated outlook for adjusted earnings per diluted share reflec ts 15% to 18.5% growth from the \nprior year and our guidance assumes core growth across all of our segments.  \n \n In the US Pharmaceutical segment, we now expect revenue to increase 5% to 8% and adjusted operating profit to \ndeliver 4.5% to 7.5% growth over the prior year.  Our US Pharmaceutical segment continues to exhibit stable \nfundamentals.  Our outlook for branded pharmaceutical pricing remains consistent with the prior year for mid -\nsingle -digits increases in fiscal 2022.  And the generics market remains compet itive, yet stable, as volumes have \nshown signs of recovery.  \n \n", "original_text": "In the US Pharmaceutical segment, we now expect revenue to increase 5% to 8% and adjusted operating profit to \ndeliver 4.5% to 7.5% growth over the prior year. ", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c4d40b9787b2ea2854668b147e900e584433815f8ee62372d49565b0eb36787b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "172134b3-14e5-4af0-a415-d6950b22407b", "node_type": "1", "metadata": {"window": "Our updated outlook for adjusted earnings per diluted share reflec ts 15% to 18.5% growth from the \nprior year and our guidance assumes core growth across all of our segments.  \n \n In the US Pharmaceutical segment, we now expect revenue to increase 5% to 8% and adjusted operating profit to \ndeliver 4.5% to 7.5% growth over the prior year.  Our US Pharmaceutical segment continues to exhibit stable \nfundamentals.  Our outlook for branded pharmaceutical pricing remains consistent with the prior year for mid -\nsingle -digits increases in fiscal 2022.  And the generics market remains compet itive, yet stable, as volumes have \nshown signs of recovery.  \n \n COVID -19 vaccine contribution contributed approximately $0.30 in the first quarter of fiscal 2022.  We are updating \nour full year outlook to approximately $0.45 to $0.55. ", "original_text": "Our outlook for branded pharmaceutical pricing remains consistent with the prior year for mid -\nsingle -digits increases in fiscal 2022. "}, "hash": "673179fb47fd54fe9a59fb277e29be5cef3292851067c994f8081ce4abcb933a", "class_name": "RelatedNodeInfo"}}, "text": "Our US Pharmaceutical segment continues to exhibit stable \nfundamentals. ", "start_char_idx": 3220, "end_char_idx": 3293, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "172134b3-14e5-4af0-a415-d6950b22407b": {"__data__": {"id_": "172134b3-14e5-4af0-a415-d6950b22407b", "embedding": null, "metadata": {"window": "Our updated outlook for adjusted earnings per diluted share reflec ts 15% to 18.5% growth from the \nprior year and our guidance assumes core growth across all of our segments.  \n \n In the US Pharmaceutical segment, we now expect revenue to increase 5% to 8% and adjusted operating profit to \ndeliver 4.5% to 7.5% growth over the prior year.  Our US Pharmaceutical segment continues to exhibit stable \nfundamentals.  Our outlook for branded pharmaceutical pricing remains consistent with the prior year for mid -\nsingle -digits increases in fiscal 2022.  And the generics market remains compet itive, yet stable, as volumes have \nshown signs of recovery.  \n \n COVID -19 vaccine contribution contributed approximately $0.30 in the first quarter of fiscal 2022.  We are updating \nour full year outlook to approximately $0.45 to $0.55. ", "original_text": "Our outlook for branded pharmaceutical pricing remains consistent with the prior year for mid -\nsingle -digits increases in fiscal 2022. ", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b1599fc327c32617d492de23bfdfcc95592645274780378ad1d16e9c944d1bd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6e28386-1eea-4693-82c6-b814edc05b35", "node_type": "1", "metadata": {"window": "For fiscal 2022, our updated guidance for adjusted  earnings per diluted share is a range of $19.80 to $20.40, up \nfrom our previous range of $18.85 to $19.45, approximately equally split between our first and second half of the \nfiscal year.  Our updated outlook for adjusted earnings per diluted share reflec ts 15% to 18.5% growth from the \nprior year and our guidance assumes core growth across all of our segments.  \n \n In the US Pharmaceutical segment, we now expect revenue to increase 5% to 8% and adjusted operating profit to \ndeliver 4.5% to 7.5% growth over the prior year.  Our US Pharmaceutical segment continues to exhibit stable \nfundamentals.  Our outlook for branded pharmaceutical pricing remains consistent with the prior year for mid -\nsingle -digits increases in fiscal 2022.  And the generics market remains compet itive, yet stable, as volumes have \nshown signs of recovery.  \n \n COVID -19 vaccine contribution contributed approximately $0.30 in the first quarter of fiscal 2022. ", "original_text": "Our US Pharmaceutical segment continues to exhibit stable \nfundamentals. ", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20e48b24db9567f2abf7d0c366a129caa0791889d8e05dfd3e87cd71ec8c0219", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd6bcc59-a4d9-445e-b645-c1e5ee85e6ab", "node_type": "1", "metadata": {"window": "In the US Pharmaceutical segment, we now expect revenue to increase 5% to 8% and adjusted operating profit to \ndeliver 4.5% to 7.5% growth over the prior year.  Our US Pharmaceutical segment continues to exhibit stable \nfundamentals.  Our outlook for branded pharmaceutical pricing remains consistent with the prior year for mid -\nsingle -digits increases in fiscal 2022.  And the generics market remains compet itive, yet stable, as volumes have \nshown signs of recovery.  \n \n COVID -19 vaccine contribution contributed approximately $0.30 in the first quarter of fiscal 2022.  We are updating \nour full year outlook to approximately $0.45 to $0.55.  The $0.45 to $0.55 range reflects anticipated contribution of \nearnings for the fair value of services performed as the US government's centralized distributor of COVID -19 \nvaccines, including work preparing vaccines for international missions.  \n ", "original_text": "And the generics market remains compet itive, yet stable, as volumes have \nshown signs of recovery.  \n \n"}, "hash": "af7d4e4c932e2f819c4111b3f4dffdba9af99efc6b979ad3d3c38deb5d9eda92", "class_name": "RelatedNodeInfo"}}, "text": "Our outlook for branded pharmaceutical pricing remains consistent with the prior year for mid -\nsingle -digits increases in fiscal 2022. ", "start_char_idx": 3293, "end_char_idx": 3430, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd6bcc59-a4d9-445e-b645-c1e5ee85e6ab": {"__data__": {"id_": "cd6bcc59-a4d9-445e-b645-c1e5ee85e6ab", "embedding": null, "metadata": {"window": "In the US Pharmaceutical segment, we now expect revenue to increase 5% to 8% and adjusted operating profit to \ndeliver 4.5% to 7.5% growth over the prior year.  Our US Pharmaceutical segment continues to exhibit stable \nfundamentals.  Our outlook for branded pharmaceutical pricing remains consistent with the prior year for mid -\nsingle -digits increases in fiscal 2022.  And the generics market remains compet itive, yet stable, as volumes have \nshown signs of recovery.  \n \n COVID -19 vaccine contribution contributed approximately $0.30 in the first quarter of fiscal 2022.  We are updating \nour full year outlook to approximately $0.45 to $0.55.  The $0.45 to $0.55 range reflects anticipated contribution of \nearnings for the fair value of services performed as the US government's centralized distributor of COVID -19 \nvaccines, including work preparing vaccines for international missions.  \n ", "original_text": "And the generics market remains compet itive, yet stable, as volumes have \nshown signs of recovery.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b1599fc327c32617d492de23bfdfcc95592645274780378ad1d16e9c944d1bd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "172134b3-14e5-4af0-a415-d6950b22407b", "node_type": "1", "metadata": {"window": "Our updated outlook for adjusted earnings per diluted share reflec ts 15% to 18.5% growth from the \nprior year and our guidance assumes core growth across all of our segments.  \n \n In the US Pharmaceutical segment, we now expect revenue to increase 5% to 8% and adjusted operating profit to \ndeliver 4.5% to 7.5% growth over the prior year.  Our US Pharmaceutical segment continues to exhibit stable \nfundamentals.  Our outlook for branded pharmaceutical pricing remains consistent with the prior year for mid -\nsingle -digits increases in fiscal 2022.  And the generics market remains compet itive, yet stable, as volumes have \nshown signs of recovery.  \n \n COVID -19 vaccine contribution contributed approximately $0.30 in the first quarter of fiscal 2022.  We are updating \nour full year outlook to approximately $0.45 to $0.55. ", "original_text": "Our outlook for branded pharmaceutical pricing remains consistent with the prior year for mid -\nsingle -digits increases in fiscal 2022. ", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48f110e684a3db34208aab29b63ff98cfefcf6d4942a335f829f2161832ee9da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54e1d588-7cb2-4f29-85ba-fb959a796e8b", "node_type": "1", "metadata": {"window": "Our US Pharmaceutical segment continues to exhibit stable \nfundamentals.  Our outlook for branded pharmaceutical pricing remains consistent with the prior year for mid -\nsingle -digits increases in fiscal 2022.  And the generics market remains compet itive, yet stable, as volumes have \nshown signs of recovery.  \n \n COVID -19 vaccine contribution contributed approximately $0.30 in the first quarter of fiscal 2022.  We are updating \nour full year outlook to approximately $0.45 to $0.55.  The $0.45 to $0.55 range reflects anticipated contribution of \nearnings for the fair value of services performed as the US government's centralized distributor of COVID -19 \nvaccines, including work preparing vaccines for international missions.  \n ", "original_text": "COVID -19 vaccine contribution contributed approximately $0.30 in the first quarter of fiscal 2022. "}, "hash": "2badd5bbd9e2d3742eb0bee2f5f20f7452c80a1fc208b324c04a7d672ea08318", "class_name": "RelatedNodeInfo"}}, "text": "And the generics market remains compet itive, yet stable, as volumes have \nshown signs of recovery.  \n \n", "start_char_idx": 3430, "end_char_idx": 3534, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54e1d588-7cb2-4f29-85ba-fb959a796e8b": {"__data__": {"id_": "54e1d588-7cb2-4f29-85ba-fb959a796e8b", "embedding": null, "metadata": {"window": "Our US Pharmaceutical segment continues to exhibit stable \nfundamentals.  Our outlook for branded pharmaceutical pricing remains consistent with the prior year for mid -\nsingle -digits increases in fiscal 2022.  And the generics market remains compet itive, yet stable, as volumes have \nshown signs of recovery.  \n \n COVID -19 vaccine contribution contributed approximately $0.30 in the first quarter of fiscal 2022.  We are updating \nour full year outlook to approximately $0.45 to $0.55.  The $0.45 to $0.55 range reflects anticipated contribution of \nearnings for the fair value of services performed as the US government's centralized distributor of COVID -19 \nvaccines, including work preparing vaccines for international missions.  \n ", "original_text": "COVID -19 vaccine contribution contributed approximately $0.30 in the first quarter of fiscal 2022. ", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b1599fc327c32617d492de23bfdfcc95592645274780378ad1d16e9c944d1bd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd6bcc59-a4d9-445e-b645-c1e5ee85e6ab", "node_type": "1", "metadata": {"window": "In the US Pharmaceutical segment, we now expect revenue to increase 5% to 8% and adjusted operating profit to \ndeliver 4.5% to 7.5% growth over the prior year.  Our US Pharmaceutical segment continues to exhibit stable \nfundamentals.  Our outlook for branded pharmaceutical pricing remains consistent with the prior year for mid -\nsingle -digits increases in fiscal 2022.  And the generics market remains compet itive, yet stable, as volumes have \nshown signs of recovery.  \n \n COVID -19 vaccine contribution contributed approximately $0.30 in the first quarter of fiscal 2022.  We are updating \nour full year outlook to approximately $0.45 to $0.55.  The $0.45 to $0.55 range reflects anticipated contribution of \nearnings for the fair value of services performed as the US government's centralized distributor of COVID -19 \nvaccines, including work preparing vaccines for international missions.  \n ", "original_text": "And the generics market remains compet itive, yet stable, as volumes have \nshown signs of recovery.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db8e72fee13d23dd78b07e6599fd87ab5a6f3521b05f2057191486511a8c457a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a68a17a3-fd8c-44e5-b790-ca16f9609a3f", "node_type": "1", "metadata": {"window": "Our outlook for branded pharmaceutical pricing remains consistent with the prior year for mid -\nsingle -digits increases in fiscal 2022.  And the generics market remains compet itive, yet stable, as volumes have \nshown signs of recovery.  \n \n COVID -19 vaccine contribution contributed approximately $0.30 in the first quarter of fiscal 2022.  We are updating \nour full year outlook to approximately $0.45 to $0.55.  The $0.45 to $0.55 range reflects anticipated contribution of \nearnings for the fair value of services performed as the US government's centralized distributor of COVID -19 \nvaccines, including work preparing vaccines for international missions.  \n ", "original_text": "We are updating \nour full year outlook to approximately $0.45 to $0.55. "}, "hash": "aef91a98f86fce017824e81c93682adf971903b257f540bef30f7e6cddf781b0", "class_name": "RelatedNodeInfo"}}, "text": "COVID -19 vaccine contribution contributed approximately $0.30 in the first quarter of fiscal 2022. ", "start_char_idx": 3534, "end_char_idx": 3634, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a68a17a3-fd8c-44e5-b790-ca16f9609a3f": {"__data__": {"id_": "a68a17a3-fd8c-44e5-b790-ca16f9609a3f", "embedding": null, "metadata": {"window": "Our outlook for branded pharmaceutical pricing remains consistent with the prior year for mid -\nsingle -digits increases in fiscal 2022.  And the generics market remains compet itive, yet stable, as volumes have \nshown signs of recovery.  \n \n COVID -19 vaccine contribution contributed approximately $0.30 in the first quarter of fiscal 2022.  We are updating \nour full year outlook to approximately $0.45 to $0.55.  The $0.45 to $0.55 range reflects anticipated contribution of \nearnings for the fair value of services performed as the US government's centralized distributor of COVID -19 \nvaccines, including work preparing vaccines for international missions.  \n ", "original_text": "We are updating \nour full year outlook to approximately $0.45 to $0.55. ", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b1599fc327c32617d492de23bfdfcc95592645274780378ad1d16e9c944d1bd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54e1d588-7cb2-4f29-85ba-fb959a796e8b", "node_type": "1", "metadata": {"window": "Our US Pharmaceutical segment continues to exhibit stable \nfundamentals.  Our outlook for branded pharmaceutical pricing remains consistent with the prior year for mid -\nsingle -digits increases in fiscal 2022.  And the generics market remains compet itive, yet stable, as volumes have \nshown signs of recovery.  \n \n COVID -19 vaccine contribution contributed approximately $0.30 in the first quarter of fiscal 2022.  We are updating \nour full year outlook to approximately $0.45 to $0.55.  The $0.45 to $0.55 range reflects anticipated contribution of \nearnings for the fair value of services performed as the US government's centralized distributor of COVID -19 \nvaccines, including work preparing vaccines for international missions.  \n ", "original_text": "COVID -19 vaccine contribution contributed approximately $0.30 in the first quarter of fiscal 2022. ", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "010a32f533dd1df8b3777d2032904739296a03c730575a25d4c41cfeaf1fe76c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bfb56051-6816-483f-8451-ec0dac69e7e1", "node_type": "1", "metadata": {"window": "And the generics market remains compet itive, yet stable, as volumes have \nshown signs of recovery.  \n \n COVID -19 vaccine contribution contributed approximately $0.30 in the first quarter of fiscal 2022.  We are updating \nour full year outlook to approximately $0.45 to $0.55.  The $0.45 to $0.55 range reflects anticipated contribution of \nearnings for the fair value of services performed as the US government's centralized distributor of COVID -19 \nvaccines, including work preparing vaccines for international missions.  \n ", "original_text": "The $0.45 to $0.55 range reflects anticipated contribution of \nearnings for the fair value of services performed as the US government's centralized distributor of COVID -19 \nvaccines, including work preparing vaccines for international missions.  \n "}, "hash": "61f2535dfde9deab5d93289d4b0814d39198aad771052f6d5537e4eca989ec25", "class_name": "RelatedNodeInfo"}}, "text": "We are updating \nour full year outlook to approximately $0.45 to $0.55. ", "start_char_idx": 3634, "end_char_idx": 3706, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bfb56051-6816-483f-8451-ec0dac69e7e1": {"__data__": {"id_": "bfb56051-6816-483f-8451-ec0dac69e7e1", "embedding": null, "metadata": {"window": "And the generics market remains compet itive, yet stable, as volumes have \nshown signs of recovery.  \n \n COVID -19 vaccine contribution contributed approximately $0.30 in the first quarter of fiscal 2022.  We are updating \nour full year outlook to approximately $0.45 to $0.55.  The $0.45 to $0.55 range reflects anticipated contribution of \nearnings for the fair value of services performed as the US government's centralized distributor of COVID -19 \nvaccines, including work preparing vaccines for international missions.  \n ", "original_text": "The $0.45 to $0.55 range reflects anticipated contribution of \nearnings for the fair value of services performed as the US government's centralized distributor of COVID -19 \nvaccines, including work preparing vaccines for international missions.  \n ", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b1599fc327c32617d492de23bfdfcc95592645274780378ad1d16e9c944d1bd5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a68a17a3-fd8c-44e5-b790-ca16f9609a3f", "node_type": "1", "metadata": {"window": "Our outlook for branded pharmaceutical pricing remains consistent with the prior year for mid -\nsingle -digits increases in fiscal 2022.  And the generics market remains compet itive, yet stable, as volumes have \nshown signs of recovery.  \n \n COVID -19 vaccine contribution contributed approximately $0.30 in the first quarter of fiscal 2022.  We are updating \nour full year outlook to approximately $0.45 to $0.55.  The $0.45 to $0.55 range reflects anticipated contribution of \nearnings for the fair value of services performed as the US government's centralized distributor of COVID -19 \nvaccines, including work preparing vaccines for international missions.  \n ", "original_text": "We are updating \nour full year outlook to approximately $0.45 to $0.55. ", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c03ab6ae563a50f7ed10a238d09ac7c464d15103ef7a4739a9ebf17d6480ae3b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32583cc3-92c0-47ba-a5fb-7988407ecf89", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nOur current outlook remains aligned t o the volume distribution schedule provided by the CDC and the US \ngovernment, which excludes booster shots and vaccines for pediatrics, which have not been approved by the \nFDA.  We will continue to invest in our leading and differentiated position in oncolo gy.  These investments will \nrepresent an approximate $0.20 headwind in fiscal 2022. ", "original_text": "McKesson Corp.  "}, "hash": "ca458ad166ab0c2e0b901eb69664bd19e6a0200b219754bda74a34c5001becb3", "class_name": "RelatedNodeInfo"}}, "text": "The $0.45 to $0.55 range reflects anticipated contribution of \nearnings for the fair value of services performed as the US government's centralized distributor of COVID -19 \nvaccines, including work preparing vaccines for international missions.  \n ", "start_char_idx": 3706, "end_char_idx": 3955, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "32583cc3-92c0-47ba-a5fb-7988407ecf89": {"__data__": {"id_": "32583cc3-92c0-47ba-a5fb-7988407ecf89", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nOur current outlook remains aligned t o the volume distribution schedule provided by the CDC and the US \ngovernment, which excludes booster shots and vaccines for pediatrics, which have not been approved by the \nFDA.  We will continue to invest in our leading and differentiated position in oncolo gy.  These investments will \nrepresent an approximate $0.20 headwind in fiscal 2022. ", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5627115a-c77a-423f-83db-5f873b473ef8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5855f621b735261b660edf52eb998c2f3544cc4fcfe589098400743018e36076", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bfb56051-6816-483f-8451-ec0dac69e7e1", "node_type": "1", "metadata": {"window": "And the generics market remains compet itive, yet stable, as volumes have \nshown signs of recovery.  \n \n COVID -19 vaccine contribution contributed approximately $0.30 in the first quarter of fiscal 2022.  We are updating \nour full year outlook to approximately $0.45 to $0.55.  The $0.45 to $0.55 range reflects anticipated contribution of \nearnings for the fair value of services performed as the US government's centralized distributor of COVID -19 \nvaccines, including work preparing vaccines for international missions.  \n ", "original_text": "The $0.45 to $0.55 range reflects anticipated contribution of \nearnings for the fair value of services performed as the US government's centralized distributor of COVID -19 \nvaccines, including work preparing vaccines for international missions.  \n ", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "15e39569b9e7504f695203c78ade358ca8d50783dbe517bf87c41db4ab59bf1a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e94e47a-8c6e-4b5b-8958-39d384676f79", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nOur current outlook remains aligned t o the volume distribution schedule provided by the CDC and the US \ngovernment, which excludes booster shots and vaccines for pediatrics, which have not been approved by the \nFDA.  We will continue to invest in our leading and differentiated position in oncolo gy.  These investments will \nrepresent an approximate $0.20 headwind in fiscal 2022.  Normalizing for the COVID -19 vaccine distribution and \nour ongoing growth investments, we continue to expect approximately 5% to 8% core adjusted operating profit \ngrowth.  \n \n", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nOur current outlook remains aligned t o the volume distribution schedule provided by the CDC and the US \ngovernment, which excludes booster shots and vaccines for pediatrics, which have not been approved by the \nFDA. "}, "hash": "a8cab7448ec78d6610753fcd79bc379929108018b055d3d5acaa0621bdf51967", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e94e47a-8c6e-4b5b-8958-39d384676f79": {"__data__": {"id_": "8e94e47a-8c6e-4b5b-8958-39d384676f79", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nOur current outlook remains aligned t o the volume distribution schedule provided by the CDC and the US \ngovernment, which excludes booster shots and vaccines for pediatrics, which have not been approved by the \nFDA.  We will continue to invest in our leading and differentiated position in oncolo gy.  These investments will \nrepresent an approximate $0.20 headwind in fiscal 2022.  Normalizing for the COVID -19 vaccine distribution and \nour ongoing growth investments, we continue to expect approximately 5% to 8% core adjusted operating profit \ngrowth.  \n \n", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nOur current outlook remains aligned t o the volume distribution schedule provided by the CDC and the US \ngovernment, which excludes booster shots and vaccines for pediatrics, which have not been approved by the \nFDA. ", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5627115a-c77a-423f-83db-5f873b473ef8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5855f621b735261b660edf52eb998c2f3544cc4fcfe589098400743018e36076", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32583cc3-92c0-47ba-a5fb-7988407ecf89", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nOur current outlook remains aligned t o the volume distribution schedule provided by the CDC and the US \ngovernment, which excludes booster shots and vaccines for pediatrics, which have not been approved by the \nFDA.  We will continue to invest in our leading and differentiated position in oncolo gy.  These investments will \nrepresent an approximate $0.20 headwind in fiscal 2022. ", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "780307fdbe61db4e7943bb4d3037fda3274b5d055900617969a037c0c92ec9f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c7c31d7-67b0-4635-b0d8-a0a2c8887652", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nOur current outlook remains aligned t o the volume distribution schedule provided by the CDC and the US \ngovernment, which excludes booster shots and vaccines for pediatrics, which have not been approved by the \nFDA.  We will continue to invest in our leading and differentiated position in oncolo gy.  These investments will \nrepresent an approximate $0.20 headwind in fiscal 2022.  Normalizing for the COVID -19 vaccine distribution and \nour ongoing growth investments, we continue to expect approximately 5% to 8% core adjusted operating profit \ngrowth.  \n \n In our Prescription Technology Solutions segment, we see revenue growth of 20% to 25% and adjusted operating \nprofit growth of 17% to 22%. ", "original_text": "We will continue to invest in our leading and differentiated position in oncolo gy. "}, "hash": "799a77d0620699b65a19eb644f54f63dbff42ea5d3d186fa11dd9234f7c2cddc", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nOur current outlook remains aligned t o the volume distribution schedule provided by the CDC and the US \ngovernment, which excludes booster shots and vaccines for pediatrics, which have not been approved by the \nFDA. ", "start_char_idx": 16, "end_char_idx": 398, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c7c31d7-67b0-4635-b0d8-a0a2c8887652": {"__data__": {"id_": "1c7c31d7-67b0-4635-b0d8-a0a2c8887652", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nOur current outlook remains aligned t o the volume distribution schedule provided by the CDC and the US \ngovernment, which excludes booster shots and vaccines for pediatrics, which have not been approved by the \nFDA.  We will continue to invest in our leading and differentiated position in oncolo gy.  These investments will \nrepresent an approximate $0.20 headwind in fiscal 2022.  Normalizing for the COVID -19 vaccine distribution and \nour ongoing growth investments, we continue to expect approximately 5% to 8% core adjusted operating profit \ngrowth.  \n \n In our Prescription Technology Solutions segment, we see revenue growth of 20% to 25% and adjusted operating \nprofit growth of 17% to 22%. ", "original_text": "We will continue to invest in our leading and differentiated position in oncolo gy. ", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5627115a-c77a-423f-83db-5f873b473ef8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5855f621b735261b660edf52eb998c2f3544cc4fcfe589098400743018e36076", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e94e47a-8c6e-4b5b-8958-39d384676f79", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nOur current outlook remains aligned t o the volume distribution schedule provided by the CDC and the US \ngovernment, which excludes booster shots and vaccines for pediatrics, which have not been approved by the \nFDA.  We will continue to invest in our leading and differentiated position in oncolo gy.  These investments will \nrepresent an approximate $0.20 headwind in fiscal 2022.  Normalizing for the COVID -19 vaccine distribution and \nour ongoing growth investments, we continue to expect approximately 5% to 8% core adjusted operating profit \ngrowth.  \n \n", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nOur current outlook remains aligned t o the volume distribution schedule provided by the CDC and the US \ngovernment, which excludes booster shots and vaccines for pediatrics, which have not been approved by the \nFDA. ", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7aa1c0fb17444430c65de1dc0fbcd57bdb888a85a2a647e85555f6592f8f6fa0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a53ab538-2f74-4fd7-b6cf-d96e6396f066", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nOur current outlook remains aligned t o the volume distribution schedule provided by the CDC and the US \ngovernment, which excludes booster shots and vaccines for pediatrics, which have not been approved by the \nFDA.  We will continue to invest in our leading and differentiated position in oncolo gy.  These investments will \nrepresent an approximate $0.20 headwind in fiscal 2022.  Normalizing for the COVID -19 vaccine distribution and \nour ongoing growth investments, we continue to expect approximately 5% to 8% core adjusted operating profit \ngrowth.  \n \n In our Prescription Technology Solutions segment, we see revenue growth of 20% to 25% and adjusted operating \nprofit growth of 17% to 22%.  This growth reflects the opportunities we see to accelerate service and transaction \ncontributions benefiting from our te chnology platforms.  \n \n", "original_text": "These investments will \nrepresent an approximate $0.20 headwind in fiscal 2022. "}, "hash": "1bef478253fa9a23a43fcd434ac1326bc80c35415ac63eb3fe8d2f02374996d3", "class_name": "RelatedNodeInfo"}}, "text": "We will continue to invest in our leading and differentiated position in oncolo gy. ", "start_char_idx": 398, "end_char_idx": 482, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a53ab538-2f74-4fd7-b6cf-d96e6396f066": {"__data__": {"id_": "a53ab538-2f74-4fd7-b6cf-d96e6396f066", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nOur current outlook remains aligned t o the volume distribution schedule provided by the CDC and the US \ngovernment, which excludes booster shots and vaccines for pediatrics, which have not been approved by the \nFDA.  We will continue to invest in our leading and differentiated position in oncolo gy.  These investments will \nrepresent an approximate $0.20 headwind in fiscal 2022.  Normalizing for the COVID -19 vaccine distribution and \nour ongoing growth investments, we continue to expect approximately 5% to 8% core adjusted operating profit \ngrowth.  \n \n In our Prescription Technology Solutions segment, we see revenue growth of 20% to 25% and adjusted operating \nprofit growth of 17% to 22%.  This growth reflects the opportunities we see to accelerate service and transaction \ncontributions benefiting from our te chnology platforms.  \n \n", "original_text": "These investments will \nrepresent an approximate $0.20 headwind in fiscal 2022. ", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5627115a-c77a-423f-83db-5f873b473ef8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5855f621b735261b660edf52eb998c2f3544cc4fcfe589098400743018e36076", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c7c31d7-67b0-4635-b0d8-a0a2c8887652", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nOur current outlook remains aligned t o the volume distribution schedule provided by the CDC and the US \ngovernment, which excludes booster shots and vaccines for pediatrics, which have not been approved by the \nFDA.  We will continue to invest in our leading and differentiated position in oncolo gy.  These investments will \nrepresent an approximate $0.20 headwind in fiscal 2022.  Normalizing for the COVID -19 vaccine distribution and \nour ongoing growth investments, we continue to expect approximately 5% to 8% core adjusted operating profit \ngrowth.  \n \n In our Prescription Technology Solutions segment, we see revenue growth of 20% to 25% and adjusted operating \nprofit growth of 17% to 22%. ", "original_text": "We will continue to invest in our leading and differentiated position in oncolo gy. ", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "025c26cbc69ec784732c93ed921cdfc5daf36253e78d0008bc145be0a4275e37", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9eeb541e-feca-4edd-b8d1-f6e0a6cb7e4e", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nOur current outlook remains aligned t o the volume distribution schedule provided by the CDC and the US \ngovernment, which excludes booster shots and vaccines for pediatrics, which have not been approved by the \nFDA.  We will continue to invest in our leading and differentiated position in oncolo gy.  These investments will \nrepresent an approximate $0.20 headwind in fiscal 2022.  Normalizing for the COVID -19 vaccine distribution and \nour ongoing growth investments, we continue to expect approximately 5% to 8% core adjusted operating profit \ngrowth.  \n \n In our Prescription Technology Solutions segment, we see revenue growth of 20% to 25% and adjusted operating \nprofit growth of 17% to 22%.  This growth reflects the opportunities we see to accelerate service and transaction \ncontributions benefiting from our te chnology platforms.  \n \n Now, transitioning to Medical -Surgical, we continue to partner with the US government under our contract for the \nkitting and distribution of ancillary supplies and are updating our outlook to $0.35 to $0.45 of contribution in this \nsegm ent related to kitting and distribution. ", "original_text": "Normalizing for the COVID -19 vaccine distribution and \nour ongoing growth investments, we continue to expect approximately 5% to 8% core adjusted operating profit \ngrowth.  \n \n"}, "hash": "d1e66e4cf10dd61367e43d1350ea53d4b7010c67f10b226eb98ec181656673e3", "class_name": "RelatedNodeInfo"}}, "text": "These investments will \nrepresent an approximate $0.20 headwind in fiscal 2022. ", "start_char_idx": 482, "end_char_idx": 562, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9eeb541e-feca-4edd-b8d1-f6e0a6cb7e4e": {"__data__": {"id_": "9eeb541e-feca-4edd-b8d1-f6e0a6cb7e4e", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nOur current outlook remains aligned t o the volume distribution schedule provided by the CDC and the US \ngovernment, which excludes booster shots and vaccines for pediatrics, which have not been approved by the \nFDA.  We will continue to invest in our leading and differentiated position in oncolo gy.  These investments will \nrepresent an approximate $0.20 headwind in fiscal 2022.  Normalizing for the COVID -19 vaccine distribution and \nour ongoing growth investments, we continue to expect approximately 5% to 8% core adjusted operating profit \ngrowth.  \n \n In our Prescription Technology Solutions segment, we see revenue growth of 20% to 25% and adjusted operating \nprofit growth of 17% to 22%.  This growth reflects the opportunities we see to accelerate service and transaction \ncontributions benefiting from our te chnology platforms.  \n \n Now, transitioning to Medical -Surgical, we continue to partner with the US government under our contract for the \nkitting and distribution of ancillary supplies and are updating our outlook to $0.35 to $0.45 of contribution in this \nsegm ent related to kitting and distribution. ", "original_text": "Normalizing for the COVID -19 vaccine distribution and \nour ongoing growth investments, we continue to expect approximately 5% to 8% core adjusted operating profit \ngrowth.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5627115a-c77a-423f-83db-5f873b473ef8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5855f621b735261b660edf52eb998c2f3544cc4fcfe589098400743018e36076", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a53ab538-2f74-4fd7-b6cf-d96e6396f066", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nOur current outlook remains aligned t o the volume distribution schedule provided by the CDC and the US \ngovernment, which excludes booster shots and vaccines for pediatrics, which have not been approved by the \nFDA.  We will continue to invest in our leading and differentiated position in oncolo gy.  These investments will \nrepresent an approximate $0.20 headwind in fiscal 2022.  Normalizing for the COVID -19 vaccine distribution and \nour ongoing growth investments, we continue to expect approximately 5% to 8% core adjusted operating profit \ngrowth.  \n \n In our Prescription Technology Solutions segment, we see revenue growth of 20% to 25% and adjusted operating \nprofit growth of 17% to 22%.  This growth reflects the opportunities we see to accelerate service and transaction \ncontributions benefiting from our te chnology platforms.  \n \n", "original_text": "These investments will \nrepresent an approximate $0.20 headwind in fiscal 2022. ", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d6ad8a071411afad2c5ae98690ba90af60e0ba867085e70c1f3476cbf5bc936c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e5d6a8ed-1ff8-43ab-8e1a-a046db7be58d", "node_type": "1", "metadata": {"window": "We will continue to invest in our leading and differentiated position in oncolo gy.  These investments will \nrepresent an approximate $0.20 headwind in fiscal 2022.  Normalizing for the COVID -19 vaccine distribution and \nour ongoing growth investments, we continue to expect approximately 5% to 8% core adjusted operating profit \ngrowth.  \n \n In our Prescription Technology Solutions segment, we see revenue growth of 20% to 25% and adjusted operating \nprofit growth of 17% to 22%.  This growth reflects the opportunities we see to accelerate service and transaction \ncontributions benefiting from our te chnology platforms.  \n \n Now, transitioning to Medical -Surgical, we continue to partner with the US government under our contract for the \nkitting and distribution of ancillary supplies and are updating our outlook to $0.35 to $0.45 of contribution in this \nsegm ent related to kitting and distribution.  This program's scope and duration is evolving, and our updated \nassumptions reflects the current outlook provided by the US government.  \n \n", "original_text": "In our Prescription Technology Solutions segment, we see revenue growth of 20% to 25% and adjusted operating \nprofit growth of 17% to 22%. "}, "hash": "402bb10d9fe7a1faad5e2a3cfa121aa25a6a85601f0e7d8e014f5f1b27b91418", "class_name": "RelatedNodeInfo"}}, "text": "Normalizing for the COVID -19 vaccine distribution and \nour ongoing growth investments, we continue to expect approximately 5% to 8% core adjusted operating profit \ngrowth.  \n \n", "start_char_idx": 562, "end_char_idx": 739, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e5d6a8ed-1ff8-43ab-8e1a-a046db7be58d": {"__data__": {"id_": "e5d6a8ed-1ff8-43ab-8e1a-a046db7be58d", "embedding": null, "metadata": {"window": "We will continue to invest in our leading and differentiated position in oncolo gy.  These investments will \nrepresent an approximate $0.20 headwind in fiscal 2022.  Normalizing for the COVID -19 vaccine distribution and \nour ongoing growth investments, we continue to expect approximately 5% to 8% core adjusted operating profit \ngrowth.  \n \n In our Prescription Technology Solutions segment, we see revenue growth of 20% to 25% and adjusted operating \nprofit growth of 17% to 22%.  This growth reflects the opportunities we see to accelerate service and transaction \ncontributions benefiting from our te chnology platforms.  \n \n Now, transitioning to Medical -Surgical, we continue to partner with the US government under our contract for the \nkitting and distribution of ancillary supplies and are updating our outlook to $0.35 to $0.45 of contribution in this \nsegm ent related to kitting and distribution.  This program's scope and duration is evolving, and our updated \nassumptions reflects the current outlook provided by the US government.  \n \n", "original_text": "In our Prescription Technology Solutions segment, we see revenue growth of 20% to 25% and adjusted operating \nprofit growth of 17% to 22%. ", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5627115a-c77a-423f-83db-5f873b473ef8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5855f621b735261b660edf52eb998c2f3544cc4fcfe589098400743018e36076", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9eeb541e-feca-4edd-b8d1-f6e0a6cb7e4e", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nOur current outlook remains aligned t o the volume distribution schedule provided by the CDC and the US \ngovernment, which excludes booster shots and vaccines for pediatrics, which have not been approved by the \nFDA.  We will continue to invest in our leading and differentiated position in oncolo gy.  These investments will \nrepresent an approximate $0.20 headwind in fiscal 2022.  Normalizing for the COVID -19 vaccine distribution and \nour ongoing growth investments, we continue to expect approximately 5% to 8% core adjusted operating profit \ngrowth.  \n \n In our Prescription Technology Solutions segment, we see revenue growth of 20% to 25% and adjusted operating \nprofit growth of 17% to 22%.  This growth reflects the opportunities we see to accelerate service and transaction \ncontributions benefiting from our te chnology platforms.  \n \n Now, transitioning to Medical -Surgical, we continue to partner with the US government under our contract for the \nkitting and distribution of ancillary supplies and are updating our outlook to $0.35 to $0.45 of contribution in this \nsegm ent related to kitting and distribution. ", "original_text": "Normalizing for the COVID -19 vaccine distribution and \nour ongoing growth investments, we continue to expect approximately 5% to 8% core adjusted operating profit \ngrowth.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "efe9ffa2a5e32a712ba3d52371ea9b0f56993b2ce902861f77cfd01cc5d72c78", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e941ba15-f36d-49f7-9b05-f9b4df94518e", "node_type": "1", "metadata": {"window": "These investments will \nrepresent an approximate $0.20 headwind in fiscal 2022.  Normalizing for the COVID -19 vaccine distribution and \nour ongoing growth investments, we continue to expect approximately 5% to 8% core adjusted operating profit \ngrowth.  \n \n In our Prescription Technology Solutions segment, we see revenue growth of 20% to 25% and adjusted operating \nprofit growth of 17% to 22%.  This growth reflects the opportunities we see to accelerate service and transaction \ncontributions benefiting from our te chnology platforms.  \n \n Now, transitioning to Medical -Surgical, we continue to partner with the US government under our contract for the \nkitting and distribution of ancillary supplies and are updating our outlook to $0.35 to $0.45 of contribution in this \nsegm ent related to kitting and distribution.  This program's scope and duration is evolving, and our updated \nassumptions reflects the current outlook provided by the US government.  \n \n Our revenue outlook assumes a 3% decline to 3% growth, and adjusted operating profit to deliver 6% to 12% \ngrowth over the prior year. ", "original_text": "This growth reflects the opportunities we see to accelerate service and transaction \ncontributions benefiting from our te chnology platforms.  \n \n"}, "hash": "9b4734baf935763c2e31691bad198f7692f8facd6afc4b64b4ca9868b9c84a11", "class_name": "RelatedNodeInfo"}}, "text": "In our Prescription Technology Solutions segment, we see revenue growth of 20% to 25% and adjusted operating \nprofit growth of 17% to 22%. ", "start_char_idx": 739, "end_char_idx": 878, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e941ba15-f36d-49f7-9b05-f9b4df94518e": {"__data__": {"id_": "e941ba15-f36d-49f7-9b05-f9b4df94518e", "embedding": null, "metadata": {"window": "These investments will \nrepresent an approximate $0.20 headwind in fiscal 2022.  Normalizing for the COVID -19 vaccine distribution and \nour ongoing growth investments, we continue to expect approximately 5% to 8% core adjusted operating profit \ngrowth.  \n \n In our Prescription Technology Solutions segment, we see revenue growth of 20% to 25% and adjusted operating \nprofit growth of 17% to 22%.  This growth reflects the opportunities we see to accelerate service and transaction \ncontributions benefiting from our te chnology platforms.  \n \n Now, transitioning to Medical -Surgical, we continue to partner with the US government under our contract for the \nkitting and distribution of ancillary supplies and are updating our outlook to $0.35 to $0.45 of contribution in this \nsegm ent related to kitting and distribution.  This program's scope and duration is evolving, and our updated \nassumptions reflects the current outlook provided by the US government.  \n \n Our revenue outlook assumes a 3% decline to 3% growth, and adjusted operating profit to deliver 6% to 12% \ngrowth over the prior year. ", "original_text": "This growth reflects the opportunities we see to accelerate service and transaction \ncontributions benefiting from our te chnology platforms.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5627115a-c77a-423f-83db-5f873b473ef8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5855f621b735261b660edf52eb998c2f3544cc4fcfe589098400743018e36076", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e5d6a8ed-1ff8-43ab-8e1a-a046db7be58d", "node_type": "1", "metadata": {"window": "We will continue to invest in our leading and differentiated position in oncolo gy.  These investments will \nrepresent an approximate $0.20 headwind in fiscal 2022.  Normalizing for the COVID -19 vaccine distribution and \nour ongoing growth investments, we continue to expect approximately 5% to 8% core adjusted operating profit \ngrowth.  \n \n In our Prescription Technology Solutions segment, we see revenue growth of 20% to 25% and adjusted operating \nprofit growth of 17% to 22%.  This growth reflects the opportunities we see to accelerate service and transaction \ncontributions benefiting from our te chnology platforms.  \n \n Now, transitioning to Medical -Surgical, we continue to partner with the US government under our contract for the \nkitting and distribution of ancillary supplies and are updating our outlook to $0.35 to $0.45 of contribution in this \nsegm ent related to kitting and distribution.  This program's scope and duration is evolving, and our updated \nassumptions reflects the current outlook provided by the US government.  \n \n", "original_text": "In our Prescription Technology Solutions segment, we see revenue growth of 20% to 25% and adjusted operating \nprofit growth of 17% to 22%. ", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5a8b3377b8123212f529fde864ca4ea72d703b9e49ee0f4452ba64ed7a3374e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "86bf8546-84d1-4e52-9226-00ea87b2cf09", "node_type": "1", "metadata": {"window": "Normalizing for the COVID -19 vaccine distribution and \nour ongoing growth investments, we continue to expect approximately 5% to 8% core adjusted operating profit \ngrowth.  \n \n In our Prescription Technology Solutions segment, we see revenue growth of 20% to 25% and adjusted operating \nprofit growth of 17% to 22%.  This growth reflects the opportunities we see to accelerate service and transaction \ncontributions benefiting from our te chnology platforms.  \n \n Now, transitioning to Medical -Surgical, we continue to partner with the US government under our contract for the \nkitting and distribution of ancillary supplies and are updating our outlook to $0.35 to $0.45 of contribution in this \nsegm ent related to kitting and distribution.  This program's scope and duration is evolving, and our updated \nassumptions reflects the current outlook provided by the US government.  \n \n Our revenue outlook assumes a 3% decline to 3% growth, and adjusted operating profit to deliver 6% to 12% \ngrowth over the prior year.  We continue to expect year -over-year core adjusted operating profit growth of \napproximately 10% to 16%.  \n \n", "original_text": "Now, transitioning to Medical -Surgical, we continue to partner with the US government under our contract for the \nkitting and distribution of ancillary supplies and are updating our outlook to $0.35 to $0.45 of contribution in this \nsegm ent related to kitting and distribution. "}, "hash": "a52e32201e4cec2d7aa6701fafef5b8367e39b65e41923c64cdafa644043824a", "class_name": "RelatedNodeInfo"}}, "text": "This growth reflects the opportunities we see to accelerate service and transaction \ncontributions benefiting from our te chnology platforms.  \n \n", "start_char_idx": 878, "end_char_idx": 1024, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "86bf8546-84d1-4e52-9226-00ea87b2cf09": {"__data__": {"id_": "86bf8546-84d1-4e52-9226-00ea87b2cf09", "embedding": null, "metadata": {"window": "Normalizing for the COVID -19 vaccine distribution and \nour ongoing growth investments, we continue to expect approximately 5% to 8% core adjusted operating profit \ngrowth.  \n \n In our Prescription Technology Solutions segment, we see revenue growth of 20% to 25% and adjusted operating \nprofit growth of 17% to 22%.  This growth reflects the opportunities we see to accelerate service and transaction \ncontributions benefiting from our te chnology platforms.  \n \n Now, transitioning to Medical -Surgical, we continue to partner with the US government under our contract for the \nkitting and distribution of ancillary supplies and are updating our outlook to $0.35 to $0.45 of contribution in this \nsegm ent related to kitting and distribution.  This program's scope and duration is evolving, and our updated \nassumptions reflects the current outlook provided by the US government.  \n \n Our revenue outlook assumes a 3% decline to 3% growth, and adjusted operating profit to deliver 6% to 12% \ngrowth over the prior year.  We continue to expect year -over-year core adjusted operating profit growth of \napproximately 10% to 16%.  \n \n", "original_text": "Now, transitioning to Medical -Surgical, we continue to partner with the US government under our contract for the \nkitting and distribution of ancillary supplies and are updating our outlook to $0.35 to $0.45 of contribution in this \nsegm ent related to kitting and distribution. ", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5627115a-c77a-423f-83db-5f873b473ef8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5855f621b735261b660edf52eb998c2f3544cc4fcfe589098400743018e36076", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e941ba15-f36d-49f7-9b05-f9b4df94518e", "node_type": "1", "metadata": {"window": "These investments will \nrepresent an approximate $0.20 headwind in fiscal 2022.  Normalizing for the COVID -19 vaccine distribution and \nour ongoing growth investments, we continue to expect approximately 5% to 8% core adjusted operating profit \ngrowth.  \n \n In our Prescription Technology Solutions segment, we see revenue growth of 20% to 25% and adjusted operating \nprofit growth of 17% to 22%.  This growth reflects the opportunities we see to accelerate service and transaction \ncontributions benefiting from our te chnology platforms.  \n \n Now, transitioning to Medical -Surgical, we continue to partner with the US government under our contract for the \nkitting and distribution of ancillary supplies and are updating our outlook to $0.35 to $0.45 of contribution in this \nsegm ent related to kitting and distribution.  This program's scope and duration is evolving, and our updated \nassumptions reflects the current outlook provided by the US government.  \n \n Our revenue outlook assumes a 3% decline to 3% growth, and adjusted operating profit to deliver 6% to 12% \ngrowth over the prior year. ", "original_text": "This growth reflects the opportunities we see to accelerate service and transaction \ncontributions benefiting from our te chnology platforms.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "291c65ef7e15be3d64babf1ea18a319a681bffd49c54d43a90985c527d29c6ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35eb249b-1d1d-41d9-b36a-9c25285b60b1", "node_type": "1", "metadata": {"window": "In our Prescription Technology Solutions segment, we see revenue growth of 20% to 25% and adjusted operating \nprofit growth of 17% to 22%.  This growth reflects the opportunities we see to accelerate service and transaction \ncontributions benefiting from our te chnology platforms.  \n \n Now, transitioning to Medical -Surgical, we continue to partner with the US government under our contract for the \nkitting and distribution of ancillary supplies and are updating our outlook to $0.35 to $0.45 of contribution in this \nsegm ent related to kitting and distribution.  This program's scope and duration is evolving, and our updated \nassumptions reflects the current outlook provided by the US government.  \n \n Our revenue outlook assumes a 3% decline to 3% growth, and adjusted operating profit to deliver 6% to 12% \ngrowth over the prior year.  We continue to expect year -over-year core adjusted operating profit growth of \napproximately 10% to 16%.  \n \n Finally, in the International segment, our revenue guidance is 1% decline to 4% growth as compa red to the prior \nyear. ", "original_text": "This program's scope and duration is evolving, and our updated \nassumptions reflects the current outlook provided by the US government.  \n \n"}, "hash": "cfde9b68a2841cc631d9874668effb6d08b48bc99c10fee1c32dee2961d1c6ba", "class_name": "RelatedNodeInfo"}}, "text": "Now, transitioning to Medical -Surgical, we continue to partner with the US government under our contract for the \nkitting and distribution of ancillary supplies and are updating our outlook to $0.35 to $0.45 of contribution in this \nsegm ent related to kitting and distribution. ", "start_char_idx": 1024, "end_char_idx": 1304, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35eb249b-1d1d-41d9-b36a-9c25285b60b1": {"__data__": {"id_": "35eb249b-1d1d-41d9-b36a-9c25285b60b1", "embedding": null, "metadata": {"window": "In our Prescription Technology Solutions segment, we see revenue growth of 20% to 25% and adjusted operating \nprofit growth of 17% to 22%.  This growth reflects the opportunities we see to accelerate service and transaction \ncontributions benefiting from our te chnology platforms.  \n \n Now, transitioning to Medical -Surgical, we continue to partner with the US government under our contract for the \nkitting and distribution of ancillary supplies and are updating our outlook to $0.35 to $0.45 of contribution in this \nsegm ent related to kitting and distribution.  This program's scope and duration is evolving, and our updated \nassumptions reflects the current outlook provided by the US government.  \n \n Our revenue outlook assumes a 3% decline to 3% growth, and adjusted operating profit to deliver 6% to 12% \ngrowth over the prior year.  We continue to expect year -over-year core adjusted operating profit growth of \napproximately 10% to 16%.  \n \n Finally, in the International segment, our revenue guidance is 1% decline to 4% growth as compa red to the prior \nyear. ", "original_text": "This program's scope and duration is evolving, and our updated \nassumptions reflects the current outlook provided by the US government.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5627115a-c77a-423f-83db-5f873b473ef8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5855f621b735261b660edf52eb998c2f3544cc4fcfe589098400743018e36076", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "86bf8546-84d1-4e52-9226-00ea87b2cf09", "node_type": "1", "metadata": {"window": "Normalizing for the COVID -19 vaccine distribution and \nour ongoing growth investments, we continue to expect approximately 5% to 8% core adjusted operating profit \ngrowth.  \n \n In our Prescription Technology Solutions segment, we see revenue growth of 20% to 25% and adjusted operating \nprofit growth of 17% to 22%.  This growth reflects the opportunities we see to accelerate service and transaction \ncontributions benefiting from our te chnology platforms.  \n \n Now, transitioning to Medical -Surgical, we continue to partner with the US government under our contract for the \nkitting and distribution of ancillary supplies and are updating our outlook to $0.35 to $0.45 of contribution in this \nsegm ent related to kitting and distribution.  This program's scope and duration is evolving, and our updated \nassumptions reflects the current outlook provided by the US government.  \n \n Our revenue outlook assumes a 3% decline to 3% growth, and adjusted operating profit to deliver 6% to 12% \ngrowth over the prior year.  We continue to expect year -over-year core adjusted operating profit growth of \napproximately 10% to 16%.  \n \n", "original_text": "Now, transitioning to Medical -Surgical, we continue to partner with the US government under our contract for the \nkitting and distribution of ancillary supplies and are updating our outlook to $0.35 to $0.45 of contribution in this \nsegm ent related to kitting and distribution. ", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "940789060b61ad8dfb7aac805e28187e05d50ff18d345ad564cba3ca6fc0bfab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3372fc1c-a3e7-4fc4-9d50-48514c50151e", "node_type": "1", "metadata": {"window": "This growth reflects the opportunities we see to accelerate service and transaction \ncontributions benefiting from our te chnology platforms.  \n \n Now, transitioning to Medical -Surgical, we continue to partner with the US government under our contract for the \nkitting and distribution of ancillary supplies and are updating our outlook to $0.35 to $0.45 of contribution in this \nsegm ent related to kitting and distribution.  This program's scope and duration is evolving, and our updated \nassumptions reflects the current outlook provided by the US government.  \n \n Our revenue outlook assumes a 3% decline to 3% growth, and adjusted operating profit to deliver 6% to 12% \ngrowth over the prior year.  We continue to expect year -over-year core adjusted operating profit growth of \napproximately 10% to 16%.  \n \n Finally, in the International segment, our revenue guidance is 1% decline to 4% growth as compa red to the prior \nyear.  And as a reminder, this reflects the contribution of our German wholesale business to the joint venture with \nWalgreens Boots Alliance. ", "original_text": "Our revenue outlook assumes a 3% decline to 3% growth, and adjusted operating profit to deliver 6% to 12% \ngrowth over the prior year. "}, "hash": "d9d17b34c6e7b9caabf29036193f4b8cd35b15266c33ef631317c92be8771509", "class_name": "RelatedNodeInfo"}}, "text": "This program's scope and duration is evolving, and our updated \nassumptions reflects the current outlook provided by the US government.  \n \n", "start_char_idx": 1304, "end_char_idx": 1444, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3372fc1c-a3e7-4fc4-9d50-48514c50151e": {"__data__": {"id_": "3372fc1c-a3e7-4fc4-9d50-48514c50151e", "embedding": null, "metadata": {"window": "This growth reflects the opportunities we see to accelerate service and transaction \ncontributions benefiting from our te chnology platforms.  \n \n Now, transitioning to Medical -Surgical, we continue to partner with the US government under our contract for the \nkitting and distribution of ancillary supplies and are updating our outlook to $0.35 to $0.45 of contribution in this \nsegm ent related to kitting and distribution.  This program's scope and duration is evolving, and our updated \nassumptions reflects the current outlook provided by the US government.  \n \n Our revenue outlook assumes a 3% decline to 3% growth, and adjusted operating profit to deliver 6% to 12% \ngrowth over the prior year.  We continue to expect year -over-year core adjusted operating profit growth of \napproximately 10% to 16%.  \n \n Finally, in the International segment, our revenue guidance is 1% decline to 4% growth as compa red to the prior \nyear.  And as a reminder, this reflects the contribution of our German wholesale business to the joint venture with \nWalgreens Boots Alliance. ", "original_text": "Our revenue outlook assumes a 3% decline to 3% growth, and adjusted operating profit to deliver 6% to 12% \ngrowth over the prior year. ", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5627115a-c77a-423f-83db-5f873b473ef8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5855f621b735261b660edf52eb998c2f3544cc4fcfe589098400743018e36076", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35eb249b-1d1d-41d9-b36a-9c25285b60b1", "node_type": "1", "metadata": {"window": "In our Prescription Technology Solutions segment, we see revenue growth of 20% to 25% and adjusted operating \nprofit growth of 17% to 22%.  This growth reflects the opportunities we see to accelerate service and transaction \ncontributions benefiting from our te chnology platforms.  \n \n Now, transitioning to Medical -Surgical, we continue to partner with the US government under our contract for the \nkitting and distribution of ancillary supplies and are updating our outlook to $0.35 to $0.45 of contribution in this \nsegm ent related to kitting and distribution.  This program's scope and duration is evolving, and our updated \nassumptions reflects the current outlook provided by the US government.  \n \n Our revenue outlook assumes a 3% decline to 3% growth, and adjusted operating profit to deliver 6% to 12% \ngrowth over the prior year.  We continue to expect year -over-year core adjusted operating profit growth of \napproximately 10% to 16%.  \n \n Finally, in the International segment, our revenue guidance is 1% decline to 4% growth as compa red to the prior \nyear. ", "original_text": "This program's scope and duration is evolving, and our updated \nassumptions reflects the current outlook provided by the US government.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa845830428a7a1114824cc08bcc9c830530e7cf9b6114a3a58bd3a02b3cb10b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dcfc7fd5-6d53-4c03-b02f-7cdcc9d5abc9", "node_type": "1", "metadata": {"window": "Now, transitioning to Medical -Surgical, we continue to partner with the US government under our contract for the \nkitting and distribution of ancillary supplies and are updating our outlook to $0.35 to $0.45 of contribution in this \nsegm ent related to kitting and distribution.  This program's scope and duration is evolving, and our updated \nassumptions reflects the current outlook provided by the US government.  \n \n Our revenue outlook assumes a 3% decline to 3% growth, and adjusted operating profit to deliver 6% to 12% \ngrowth over the prior year.  We continue to expect year -over-year core adjusted operating profit growth of \napproximately 10% to 16%.  \n \n Finally, in the International segment, our revenue guidance is 1% decline to 4% growth as compa red to the prior \nyear.  And as a reminder, this reflects the contribution of our German wholesale business to the joint venture with \nWalgreens Boots Alliance.  For adjusted operating profit, our guidance is growth in the segment of 26% to 30% \ndue to the prev iously mentioned benefit from the discontinuation of depreciation and amortization, which followed \nthe announcement of our agreement to sell certain European assets, our strong performance in the first quarter \nand the contribution from COVID -19 vaccine dis tribution in the segment.  \n \n", "original_text": "We continue to expect year -over-year core adjusted operating profit growth of \napproximately 10% to 16%.  \n \n"}, "hash": "d6589803fcda8d41fadf0d3c5b957fdbcf2e3c7e4dc2eb141f5a370fcc9417e9", "class_name": "RelatedNodeInfo"}}, "text": "Our revenue outlook assumes a 3% decline to 3% growth, and adjusted operating profit to deliver 6% to 12% \ngrowth over the prior year. ", "start_char_idx": 1444, "end_char_idx": 1579, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dcfc7fd5-6d53-4c03-b02f-7cdcc9d5abc9": {"__data__": {"id_": "dcfc7fd5-6d53-4c03-b02f-7cdcc9d5abc9", "embedding": null, "metadata": {"window": "Now, transitioning to Medical -Surgical, we continue to partner with the US government under our contract for the \nkitting and distribution of ancillary supplies and are updating our outlook to $0.35 to $0.45 of contribution in this \nsegm ent related to kitting and distribution.  This program's scope and duration is evolving, and our updated \nassumptions reflects the current outlook provided by the US government.  \n \n Our revenue outlook assumes a 3% decline to 3% growth, and adjusted operating profit to deliver 6% to 12% \ngrowth over the prior year.  We continue to expect year -over-year core adjusted operating profit growth of \napproximately 10% to 16%.  \n \n Finally, in the International segment, our revenue guidance is 1% decline to 4% growth as compa red to the prior \nyear.  And as a reminder, this reflects the contribution of our German wholesale business to the joint venture with \nWalgreens Boots Alliance.  For adjusted operating profit, our guidance is growth in the segment of 26% to 30% \ndue to the prev iously mentioned benefit from the discontinuation of depreciation and amortization, which followed \nthe announcement of our agreement to sell certain European assets, our strong performance in the first quarter \nand the contribution from COVID -19 vaccine dis tribution in the segment.  \n \n", "original_text": "We continue to expect year -over-year core adjusted operating profit growth of \napproximately 10% to 16%.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5627115a-c77a-423f-83db-5f873b473ef8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5855f621b735261b660edf52eb998c2f3544cc4fcfe589098400743018e36076", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3372fc1c-a3e7-4fc4-9d50-48514c50151e", "node_type": "1", "metadata": {"window": "This growth reflects the opportunities we see to accelerate service and transaction \ncontributions benefiting from our te chnology platforms.  \n \n Now, transitioning to Medical -Surgical, we continue to partner with the US government under our contract for the \nkitting and distribution of ancillary supplies and are updating our outlook to $0.35 to $0.45 of contribution in this \nsegm ent related to kitting and distribution.  This program's scope and duration is evolving, and our updated \nassumptions reflects the current outlook provided by the US government.  \n \n Our revenue outlook assumes a 3% decline to 3% growth, and adjusted operating profit to deliver 6% to 12% \ngrowth over the prior year.  We continue to expect year -over-year core adjusted operating profit growth of \napproximately 10% to 16%.  \n \n Finally, in the International segment, our revenue guidance is 1% decline to 4% growth as compa red to the prior \nyear.  And as a reminder, this reflects the contribution of our German wholesale business to the joint venture with \nWalgreens Boots Alliance. ", "original_text": "Our revenue outlook assumes a 3% decline to 3% growth, and adjusted operating profit to deliver 6% to 12% \ngrowth over the prior year. ", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c44ba55eaa9d84ed77bd9f07540bb1251f0568a419d088d4f74a0b0cd2ca449b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3a55486f-ef77-42ad-938a-53d8ed8499c7", "node_type": "1", "metadata": {"window": "This program's scope and duration is evolving, and our updated \nassumptions reflects the current outlook provided by the US government.  \n \n Our revenue outlook assumes a 3% decline to 3% growth, and adjusted operating profit to deliver 6% to 12% \ngrowth over the prior year.  We continue to expect year -over-year core adjusted operating profit growth of \napproximately 10% to 16%.  \n \n Finally, in the International segment, our revenue guidance is 1% decline to 4% growth as compa red to the prior \nyear.  And as a reminder, this reflects the contribution of our German wholesale business to the joint venture with \nWalgreens Boots Alliance.  For adjusted operating profit, our guidance is growth in the segment of 26% to 30% \ndue to the prev iously mentioned benefit from the discontinuation of depreciation and amortization, which followed \nthe announcement of our agreement to sell certain European assets, our strong performance in the first quarter \nand the contribution from COVID -19 vaccine dis tribution in the segment.  \n \n Turning now to the consolidated view, our guidance assumes 4% to 7% revenue growth and 7% to 10% adjusted \noperating profit growth compared to fiscal 2021. ", "original_text": "Finally, in the International segment, our revenue guidance is 1% decline to 4% growth as compa red to the prior \nyear. "}, "hash": "baa39b2bcbc197321d475566898b995f9261295aac886b8ea9514e0535d6e1a8", "class_name": "RelatedNodeInfo"}}, "text": "We continue to expect year -over-year core adjusted operating profit growth of \napproximately 10% to 16%.  \n \n", "start_char_idx": 1579, "end_char_idx": 1689, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3a55486f-ef77-42ad-938a-53d8ed8499c7": {"__data__": {"id_": "3a55486f-ef77-42ad-938a-53d8ed8499c7", "embedding": null, "metadata": {"window": "This program's scope and duration is evolving, and our updated \nassumptions reflects the current outlook provided by the US government.  \n \n Our revenue outlook assumes a 3% decline to 3% growth, and adjusted operating profit to deliver 6% to 12% \ngrowth over the prior year.  We continue to expect year -over-year core adjusted operating profit growth of \napproximately 10% to 16%.  \n \n Finally, in the International segment, our revenue guidance is 1% decline to 4% growth as compa red to the prior \nyear.  And as a reminder, this reflects the contribution of our German wholesale business to the joint venture with \nWalgreens Boots Alliance.  For adjusted operating profit, our guidance is growth in the segment of 26% to 30% \ndue to the prev iously mentioned benefit from the discontinuation of depreciation and amortization, which followed \nthe announcement of our agreement to sell certain European assets, our strong performance in the first quarter \nand the contribution from COVID -19 vaccine dis tribution in the segment.  \n \n Turning now to the consolidated view, our guidance assumes 4% to 7% revenue growth and 7% to 10% adjusted \noperating profit growth compared to fiscal 2021. ", "original_text": "Finally, in the International segment, our revenue guidance is 1% decline to 4% growth as compa red to the prior \nyear. ", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5627115a-c77a-423f-83db-5f873b473ef8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5855f621b735261b660edf52eb998c2f3544cc4fcfe589098400743018e36076", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dcfc7fd5-6d53-4c03-b02f-7cdcc9d5abc9", "node_type": "1", "metadata": {"window": "Now, transitioning to Medical -Surgical, we continue to partner with the US government under our contract for the \nkitting and distribution of ancillary supplies and are updating our outlook to $0.35 to $0.45 of contribution in this \nsegm ent related to kitting and distribution.  This program's scope and duration is evolving, and our updated \nassumptions reflects the current outlook provided by the US government.  \n \n Our revenue outlook assumes a 3% decline to 3% growth, and adjusted operating profit to deliver 6% to 12% \ngrowth over the prior year.  We continue to expect year -over-year core adjusted operating profit growth of \napproximately 10% to 16%.  \n \n Finally, in the International segment, our revenue guidance is 1% decline to 4% growth as compa red to the prior \nyear.  And as a reminder, this reflects the contribution of our German wholesale business to the joint venture with \nWalgreens Boots Alliance.  For adjusted operating profit, our guidance is growth in the segment of 26% to 30% \ndue to the prev iously mentioned benefit from the discontinuation of depreciation and amortization, which followed \nthe announcement of our agreement to sell certain European assets, our strong performance in the first quarter \nand the contribution from COVID -19 vaccine dis tribution in the segment.  \n \n", "original_text": "We continue to expect year -over-year core adjusted operating profit growth of \napproximately 10% to 16%.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "549a485284822c02e309d04e74923812ef6d6591a579caa8b0936a80f81965a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "005ed327-fe91-453a-b49e-b6074fe6487b", "node_type": "1", "metadata": {"window": "Our revenue outlook assumes a 3% decline to 3% growth, and adjusted operating profit to deliver 6% to 12% \ngrowth over the prior year.  We continue to expect year -over-year core adjusted operating profit growth of \napproximately 10% to 16%.  \n \n Finally, in the International segment, our revenue guidance is 1% decline to 4% growth as compa red to the prior \nyear.  And as a reminder, this reflects the contribution of our German wholesale business to the joint venture with \nWalgreens Boots Alliance.  For adjusted operating profit, our guidance is growth in the segment of 26% to 30% \ndue to the prev iously mentioned benefit from the discontinuation of depreciation and amortization, which followed \nthe announcement of our agreement to sell certain European assets, our strong performance in the first quarter \nand the contribution from COVID -19 vaccine dis tribution in the segment.  \n \n Turning now to the consolidated view, our guidance assumes 4% to 7% revenue growth and 7% to 10% adjusted \noperating profit growth compared to fiscal 2021.  And we continue to expect corporate expenses in the range of \n$670 million to $720 million.  \n \n", "original_text": "And as a reminder, this reflects the contribution of our German wholesale business to the joint venture with \nWalgreens Boots Alliance. "}, "hash": "11a870d35d7cfe090237bcdd029179df25ed187bfc43e05a92473c42fd5af699", "class_name": "RelatedNodeInfo"}}, "text": "Finally, in the International segment, our revenue guidance is 1% decline to 4% growth as compa red to the prior \nyear. ", "start_char_idx": 1689, "end_char_idx": 1809, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "005ed327-fe91-453a-b49e-b6074fe6487b": {"__data__": {"id_": "005ed327-fe91-453a-b49e-b6074fe6487b", "embedding": null, "metadata": {"window": "Our revenue outlook assumes a 3% decline to 3% growth, and adjusted operating profit to deliver 6% to 12% \ngrowth over the prior year.  We continue to expect year -over-year core adjusted operating profit growth of \napproximately 10% to 16%.  \n \n Finally, in the International segment, our revenue guidance is 1% decline to 4% growth as compa red to the prior \nyear.  And as a reminder, this reflects the contribution of our German wholesale business to the joint venture with \nWalgreens Boots Alliance.  For adjusted operating profit, our guidance is growth in the segment of 26% to 30% \ndue to the prev iously mentioned benefit from the discontinuation of depreciation and amortization, which followed \nthe announcement of our agreement to sell certain European assets, our strong performance in the first quarter \nand the contribution from COVID -19 vaccine dis tribution in the segment.  \n \n Turning now to the consolidated view, our guidance assumes 4% to 7% revenue growth and 7% to 10% adjusted \noperating profit growth compared to fiscal 2021.  And we continue to expect corporate expenses in the range of \n$670 million to $720 million.  \n \n", "original_text": "And as a reminder, this reflects the contribution of our German wholesale business to the joint venture with \nWalgreens Boots Alliance. ", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5627115a-c77a-423f-83db-5f873b473ef8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5855f621b735261b660edf52eb998c2f3544cc4fcfe589098400743018e36076", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a55486f-ef77-42ad-938a-53d8ed8499c7", "node_type": "1", "metadata": {"window": "This program's scope and duration is evolving, and our updated \nassumptions reflects the current outlook provided by the US government.  \n \n Our revenue outlook assumes a 3% decline to 3% growth, and adjusted operating profit to deliver 6% to 12% \ngrowth over the prior year.  We continue to expect year -over-year core adjusted operating profit growth of \napproximately 10% to 16%.  \n \n Finally, in the International segment, our revenue guidance is 1% decline to 4% growth as compa red to the prior \nyear.  And as a reminder, this reflects the contribution of our German wholesale business to the joint venture with \nWalgreens Boots Alliance.  For adjusted operating profit, our guidance is growth in the segment of 26% to 30% \ndue to the prev iously mentioned benefit from the discontinuation of depreciation and amortization, which followed \nthe announcement of our agreement to sell certain European assets, our strong performance in the first quarter \nand the contribution from COVID -19 vaccine dis tribution in the segment.  \n \n Turning now to the consolidated view, our guidance assumes 4% to 7% revenue growth and 7% to 10% adjusted \noperating profit growth compared to fiscal 2021. ", "original_text": "Finally, in the International segment, our revenue guidance is 1% decline to 4% growth as compa red to the prior \nyear. ", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41c281b6fc369c2fce913b85c4ddbb092a1cdeb3c6306571f22288f3c6339d61", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b642ea10-a4ca-47ff-8638-f51ef9585db9", "node_type": "1", "metadata": {"window": "We continue to expect year -over-year core adjusted operating profit growth of \napproximately 10% to 16%.  \n \n Finally, in the International segment, our revenue guidance is 1% decline to 4% growth as compa red to the prior \nyear.  And as a reminder, this reflects the contribution of our German wholesale business to the joint venture with \nWalgreens Boots Alliance.  For adjusted operating profit, our guidance is growth in the segment of 26% to 30% \ndue to the prev iously mentioned benefit from the discontinuation of depreciation and amortization, which followed \nthe announcement of our agreement to sell certain European assets, our strong performance in the first quarter \nand the contribution from COVID -19 vaccine dis tribution in the segment.  \n \n Turning now to the consolidated view, our guidance assumes 4% to 7% revenue growth and 7% to 10% adjusted \noperating profit growth compared to fiscal 2021.  And we continue to expect corporate expenses in the range of \n$670 million to $720 million.  \n \n Let me now turn to cash flow and capital deployment. ", "original_text": "For adjusted operating profit, our guidance is growth in the segment of 26% to 30% \ndue to the prev iously mentioned benefit from the discontinuation of depreciation and amortization, which followed \nthe announcement of our agreement to sell certain European assets, our strong performance in the first quarter \nand the contribution from COVID -19 vaccine dis tribution in the segment.  \n \n"}, "hash": "9f337bbeb5d0dcb64e650930a7df66553a83ed1c4f9d7fc21ad11ba84c151827", "class_name": "RelatedNodeInfo"}}, "text": "And as a reminder, this reflects the contribution of our German wholesale business to the joint venture with \nWalgreens Boots Alliance. ", "start_char_idx": 1809, "end_char_idx": 1945, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b642ea10-a4ca-47ff-8638-f51ef9585db9": {"__data__": {"id_": "b642ea10-a4ca-47ff-8638-f51ef9585db9", "embedding": null, "metadata": {"window": "We continue to expect year -over-year core adjusted operating profit growth of \napproximately 10% to 16%.  \n \n Finally, in the International segment, our revenue guidance is 1% decline to 4% growth as compa red to the prior \nyear.  And as a reminder, this reflects the contribution of our German wholesale business to the joint venture with \nWalgreens Boots Alliance.  For adjusted operating profit, our guidance is growth in the segment of 26% to 30% \ndue to the prev iously mentioned benefit from the discontinuation of depreciation and amortization, which followed \nthe announcement of our agreement to sell certain European assets, our strong performance in the first quarter \nand the contribution from COVID -19 vaccine dis tribution in the segment.  \n \n Turning now to the consolidated view, our guidance assumes 4% to 7% revenue growth and 7% to 10% adjusted \noperating profit growth compared to fiscal 2021.  And we continue to expect corporate expenses in the range of \n$670 million to $720 million.  \n \n Let me now turn to cash flow and capital deployment. ", "original_text": "For adjusted operating profit, our guidance is growth in the segment of 26% to 30% \ndue to the prev iously mentioned benefit from the discontinuation of depreciation and amortization, which followed \nthe announcement of our agreement to sell certain European assets, our strong performance in the first quarter \nand the contribution from COVID -19 vaccine dis tribution in the segment.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5627115a-c77a-423f-83db-5f873b473ef8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5855f621b735261b660edf52eb998c2f3544cc4fcfe589098400743018e36076", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "005ed327-fe91-453a-b49e-b6074fe6487b", "node_type": "1", "metadata": {"window": "Our revenue outlook assumes a 3% decline to 3% growth, and adjusted operating profit to deliver 6% to 12% \ngrowth over the prior year.  We continue to expect year -over-year core adjusted operating profit growth of \napproximately 10% to 16%.  \n \n Finally, in the International segment, our revenue guidance is 1% decline to 4% growth as compa red to the prior \nyear.  And as a reminder, this reflects the contribution of our German wholesale business to the joint venture with \nWalgreens Boots Alliance.  For adjusted operating profit, our guidance is growth in the segment of 26% to 30% \ndue to the prev iously mentioned benefit from the discontinuation of depreciation and amortization, which followed \nthe announcement of our agreement to sell certain European assets, our strong performance in the first quarter \nand the contribution from COVID -19 vaccine dis tribution in the segment.  \n \n Turning now to the consolidated view, our guidance assumes 4% to 7% revenue growth and 7% to 10% adjusted \noperating profit growth compared to fiscal 2021.  And we continue to expect corporate expenses in the range of \n$670 million to $720 million.  \n \n", "original_text": "And as a reminder, this reflects the contribution of our German wholesale business to the joint venture with \nWalgreens Boots Alliance. ", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da5141e5e7165d32493392d47c4ee82238bec5cb08509ae3f9ed9fee0952f4bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76268bb7-6aac-472d-b8e9-9eeef8acead7", "node_type": "1", "metadata": {"window": "Finally, in the International segment, our revenue guidance is 1% decline to 4% growth as compa red to the prior \nyear.  And as a reminder, this reflects the contribution of our German wholesale business to the joint venture with \nWalgreens Boots Alliance.  For adjusted operating profit, our guidance is growth in the segment of 26% to 30% \ndue to the prev iously mentioned benefit from the discontinuation of depreciation and amortization, which followed \nthe announcement of our agreement to sell certain European assets, our strong performance in the first quarter \nand the contribution from COVID -19 vaccine dis tribution in the segment.  \n \n Turning now to the consolidated view, our guidance assumes 4% to 7% revenue growth and 7% to 10% adjusted \noperating profit growth compared to fiscal 2021.  And we continue to expect corporate expenses in the range of \n$670 million to $720 million.  \n \n Let me now turn to cash flow and capital deployment.  We were pleased to recently announce the completion of a \ncash-funded upsized tender offer. ", "original_text": "Turning now to the consolidated view, our guidance assumes 4% to 7% revenue growth and 7% to 10% adjusted \noperating profit growth compared to fiscal 2021. "}, "hash": "d0a0bf95f97da618e13680fc3bc2843edb024606eac00f7c31caf05ec0cebdea", "class_name": "RelatedNodeInfo"}}, "text": "For adjusted operating profit, our guidance is growth in the segment of 26% to 30% \ndue to the prev iously mentioned benefit from the discontinuation of depreciation and amortization, which followed \nthe announcement of our agreement to sell certain European assets, our strong performance in the first quarter \nand the contribution from COVID -19 vaccine dis tribution in the segment.  \n \n", "start_char_idx": 1945, "end_char_idx": 2335, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "76268bb7-6aac-472d-b8e9-9eeef8acead7": {"__data__": {"id_": "76268bb7-6aac-472d-b8e9-9eeef8acead7", "embedding": null, "metadata": {"window": "Finally, in the International segment, our revenue guidance is 1% decline to 4% growth as compa red to the prior \nyear.  And as a reminder, this reflects the contribution of our German wholesale business to the joint venture with \nWalgreens Boots Alliance.  For adjusted operating profit, our guidance is growth in the segment of 26% to 30% \ndue to the prev iously mentioned benefit from the discontinuation of depreciation and amortization, which followed \nthe announcement of our agreement to sell certain European assets, our strong performance in the first quarter \nand the contribution from COVID -19 vaccine dis tribution in the segment.  \n \n Turning now to the consolidated view, our guidance assumes 4% to 7% revenue growth and 7% to 10% adjusted \noperating profit growth compared to fiscal 2021.  And we continue to expect corporate expenses in the range of \n$670 million to $720 million.  \n \n Let me now turn to cash flow and capital deployment.  We were pleased to recently announce the completion of a \ncash-funded upsized tender offer. ", "original_text": "Turning now to the consolidated view, our guidance assumes 4% to 7% revenue growth and 7% to 10% adjusted \noperating profit growth compared to fiscal 2021. ", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5627115a-c77a-423f-83db-5f873b473ef8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5855f621b735261b660edf52eb998c2f3544cc4fcfe589098400743018e36076", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b642ea10-a4ca-47ff-8638-f51ef9585db9", "node_type": "1", "metadata": {"window": "We continue to expect year -over-year core adjusted operating profit growth of \napproximately 10% to 16%.  \n \n Finally, in the International segment, our revenue guidance is 1% decline to 4% growth as compa red to the prior \nyear.  And as a reminder, this reflects the contribution of our German wholesale business to the joint venture with \nWalgreens Boots Alliance.  For adjusted operating profit, our guidance is growth in the segment of 26% to 30% \ndue to the prev iously mentioned benefit from the discontinuation of depreciation and amortization, which followed \nthe announcement of our agreement to sell certain European assets, our strong performance in the first quarter \nand the contribution from COVID -19 vaccine dis tribution in the segment.  \n \n Turning now to the consolidated view, our guidance assumes 4% to 7% revenue growth and 7% to 10% adjusted \noperating profit growth compared to fiscal 2021.  And we continue to expect corporate expenses in the range of \n$670 million to $720 million.  \n \n Let me now turn to cash flow and capital deployment. ", "original_text": "For adjusted operating profit, our guidance is growth in the segment of 26% to 30% \ndue to the prev iously mentioned benefit from the discontinuation of depreciation and amortization, which followed \nthe announcement of our agreement to sell certain European assets, our strong performance in the first quarter \nand the contribution from COVID -19 vaccine dis tribution in the segment.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d23b0ddf4e5136e863ad1ced90afaba4ac02c252e67c7aa4cf0b93efee238fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e7c7f9f2-999b-415e-bf5e-4772a9809177", "node_type": "1", "metadata": {"window": "And as a reminder, this reflects the contribution of our German wholesale business to the joint venture with \nWalgreens Boots Alliance.  For adjusted operating profit, our guidance is growth in the segment of 26% to 30% \ndue to the prev iously mentioned benefit from the discontinuation of depreciation and amortization, which followed \nthe announcement of our agreement to sell certain European assets, our strong performance in the first quarter \nand the contribution from COVID -19 vaccine dis tribution in the segment.  \n \n Turning now to the consolidated view, our guidance assumes 4% to 7% revenue growth and 7% to 10% adjusted \noperating profit growth compared to fiscal 2021.  And we continue to expect corporate expenses in the range of \n$670 million to $720 million.  \n \n Let me now turn to cash flow and capital deployment.  We were pleased to recently announce the completion of a \ncash-funded upsized tender offer.  This successful tender offer resulted in the early retirement of $922 million of \nour outstandi ng debt. ", "original_text": "And we continue to expect corporate expenses in the range of \n$670 million to $720 million.  \n \n"}, "hash": "7aff6c173660c06d38182d4e67485c7eda8bfce52dee2e6fb96a4dbcbf24e567", "class_name": "RelatedNodeInfo"}}, "text": "Turning now to the consolidated view, our guidance assumes 4% to 7% revenue growth and 7% to 10% adjusted \noperating profit growth compared to fiscal 2021. ", "start_char_idx": 2335, "end_char_idx": 2491, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e7c7f9f2-999b-415e-bf5e-4772a9809177": {"__data__": {"id_": "e7c7f9f2-999b-415e-bf5e-4772a9809177", "embedding": null, "metadata": {"window": "And as a reminder, this reflects the contribution of our German wholesale business to the joint venture with \nWalgreens Boots Alliance.  For adjusted operating profit, our guidance is growth in the segment of 26% to 30% \ndue to the prev iously mentioned benefit from the discontinuation of depreciation and amortization, which followed \nthe announcement of our agreement to sell certain European assets, our strong performance in the first quarter \nand the contribution from COVID -19 vaccine dis tribution in the segment.  \n \n Turning now to the consolidated view, our guidance assumes 4% to 7% revenue growth and 7% to 10% adjusted \noperating profit growth compared to fiscal 2021.  And we continue to expect corporate expenses in the range of \n$670 million to $720 million.  \n \n Let me now turn to cash flow and capital deployment.  We were pleased to recently announce the completion of a \ncash-funded upsized tender offer.  This successful tender offer resulted in the early retirement of $922 million of \nour outstandi ng debt. ", "original_text": "And we continue to expect corporate expenses in the range of \n$670 million to $720 million.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5627115a-c77a-423f-83db-5f873b473ef8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5855f621b735261b660edf52eb998c2f3544cc4fcfe589098400743018e36076", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76268bb7-6aac-472d-b8e9-9eeef8acead7", "node_type": "1", "metadata": {"window": "Finally, in the International segment, our revenue guidance is 1% decline to 4% growth as compa red to the prior \nyear.  And as a reminder, this reflects the contribution of our German wholesale business to the joint venture with \nWalgreens Boots Alliance.  For adjusted operating profit, our guidance is growth in the segment of 26% to 30% \ndue to the prev iously mentioned benefit from the discontinuation of depreciation and amortization, which followed \nthe announcement of our agreement to sell certain European assets, our strong performance in the first quarter \nand the contribution from COVID -19 vaccine dis tribution in the segment.  \n \n Turning now to the consolidated view, our guidance assumes 4% to 7% revenue growth and 7% to 10% adjusted \noperating profit growth compared to fiscal 2021.  And we continue to expect corporate expenses in the range of \n$670 million to $720 million.  \n \n Let me now turn to cash flow and capital deployment.  We were pleased to recently announce the completion of a \ncash-funded upsized tender offer. ", "original_text": "Turning now to the consolidated view, our guidance assumes 4% to 7% revenue growth and 7% to 10% adjusted \noperating profit growth compared to fiscal 2021. ", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "471b1f5545081f99cd4f7169562cdbc57d9dd0bcf0c9556448e3448ac45a6ac9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a5df632-896d-41e8-89f4-6e3c1efe2c3e", "node_type": "1", "metadata": {"window": "For adjusted operating profit, our guidance is growth in the segment of 26% to 30% \ndue to the prev iously mentioned benefit from the discontinuation of depreciation and amortization, which followed \nthe announcement of our agreement to sell certain European assets, our strong performance in the first quarter \nand the contribution from COVID -19 vaccine dis tribution in the segment.  \n \n Turning now to the consolidated view, our guidance assumes 4% to 7% revenue growth and 7% to 10% adjusted \noperating profit growth compared to fiscal 2021.  And we continue to expect corporate expenses in the range of \n$670 million to $720 million.  \n \n Let me now turn to cash flow and capital deployment.  We were pleased to recently announce the completion of a \ncash-funded upsized tender offer.  This successful tender offer resulted in the early retirement of $922 million of \nour outstandi ng debt.  Additionally, we announced the early retirement of a \u20ac600 million note for a total reduction \nin debt of approximately $1.6 billion. ", "original_text": "Let me now turn to cash flow and capital deployment. "}, "hash": "3322ce69b5f70ab450769c6553337927583c52d495e42c422b5725efcd354e55", "class_name": "RelatedNodeInfo"}}, "text": "And we continue to expect corporate expenses in the range of \n$670 million to $720 million.  \n \n", "start_char_idx": 2491, "end_char_idx": 2587, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a5df632-896d-41e8-89f4-6e3c1efe2c3e": {"__data__": {"id_": "8a5df632-896d-41e8-89f4-6e3c1efe2c3e", "embedding": null, "metadata": {"window": "For adjusted operating profit, our guidance is growth in the segment of 26% to 30% \ndue to the prev iously mentioned benefit from the discontinuation of depreciation and amortization, which followed \nthe announcement of our agreement to sell certain European assets, our strong performance in the first quarter \nand the contribution from COVID -19 vaccine dis tribution in the segment.  \n \n Turning now to the consolidated view, our guidance assumes 4% to 7% revenue growth and 7% to 10% adjusted \noperating profit growth compared to fiscal 2021.  And we continue to expect corporate expenses in the range of \n$670 million to $720 million.  \n \n Let me now turn to cash flow and capital deployment.  We were pleased to recently announce the completion of a \ncash-funded upsized tender offer.  This successful tender offer resulted in the early retirement of $922 million of \nour outstandi ng debt.  Additionally, we announced the early retirement of a \u20ac600 million note for a total reduction \nin debt of approximately $1.6 billion. ", "original_text": "Let me now turn to cash flow and capital deployment. ", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5627115a-c77a-423f-83db-5f873b473ef8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5855f621b735261b660edf52eb998c2f3544cc4fcfe589098400743018e36076", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e7c7f9f2-999b-415e-bf5e-4772a9809177", "node_type": "1", "metadata": {"window": "And as a reminder, this reflects the contribution of our German wholesale business to the joint venture with \nWalgreens Boots Alliance.  For adjusted operating profit, our guidance is growth in the segment of 26% to 30% \ndue to the prev iously mentioned benefit from the discontinuation of depreciation and amortization, which followed \nthe announcement of our agreement to sell certain European assets, our strong performance in the first quarter \nand the contribution from COVID -19 vaccine dis tribution in the segment.  \n \n Turning now to the consolidated view, our guidance assumes 4% to 7% revenue growth and 7% to 10% adjusted \noperating profit growth compared to fiscal 2021.  And we continue to expect corporate expenses in the range of \n$670 million to $720 million.  \n \n Let me now turn to cash flow and capital deployment.  We were pleased to recently announce the completion of a \ncash-funded upsized tender offer.  This successful tender offer resulted in the early retirement of $922 million of \nour outstandi ng debt. ", "original_text": "And we continue to expect corporate expenses in the range of \n$670 million to $720 million.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22b40905833b103934e5d27432dff1490c017bb62457c28b8c3f1ffb423af39f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b19518e1-b58c-47aa-9b26-c14e5cf6193a", "node_type": "1", "metadata": {"window": "Turning now to the consolidated view, our guidance assumes 4% to 7% revenue growth and 7% to 10% adjusted \noperating profit growth compared to fiscal 2021.  And we continue to expect corporate expenses in the range of \n$670 million to $720 million.  \n \n Let me now turn to cash flow and capital deployment.  We were pleased to recently announce the completion of a \ncash-funded upsized tender offer.  This successful tender offer resulted in the early retirement of $922 million of \nour outstandi ng debt.  Additionally, we announced the early retirement of a \u20ac600 million note for a total reduction \nin debt of approximately $1.6 billion.  These actions occurred during the beginning of our second quarter. ", "original_text": "We were pleased to recently announce the completion of a \ncash-funded upsized tender offer. "}, "hash": "1c2027fab78f1742134adced6ac9e27ee71b10e254430da645341407881eb07e", "class_name": "RelatedNodeInfo"}}, "text": "Let me now turn to cash flow and capital deployment. ", "start_char_idx": 2587, "end_char_idx": 2640, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b19518e1-b58c-47aa-9b26-c14e5cf6193a": {"__data__": {"id_": "b19518e1-b58c-47aa-9b26-c14e5cf6193a", "embedding": null, "metadata": {"window": "Turning now to the consolidated view, our guidance assumes 4% to 7% revenue growth and 7% to 10% adjusted \noperating profit growth compared to fiscal 2021.  And we continue to expect corporate expenses in the range of \n$670 million to $720 million.  \n \n Let me now turn to cash flow and capital deployment.  We were pleased to recently announce the completion of a \ncash-funded upsized tender offer.  This successful tender offer resulted in the early retirement of $922 million of \nour outstandi ng debt.  Additionally, we announced the early retirement of a \u20ac600 million note for a total reduction \nin debt of approximately $1.6 billion.  These actions occurred during the beginning of our second quarter. ", "original_text": "We were pleased to recently announce the completion of a \ncash-funded upsized tender offer. ", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5627115a-c77a-423f-83db-5f873b473ef8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5855f621b735261b660edf52eb998c2f3544cc4fcfe589098400743018e36076", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a5df632-896d-41e8-89f4-6e3c1efe2c3e", "node_type": "1", "metadata": {"window": "For adjusted operating profit, our guidance is growth in the segment of 26% to 30% \ndue to the prev iously mentioned benefit from the discontinuation of depreciation and amortization, which followed \nthe announcement of our agreement to sell certain European assets, our strong performance in the first quarter \nand the contribution from COVID -19 vaccine dis tribution in the segment.  \n \n Turning now to the consolidated view, our guidance assumes 4% to 7% revenue growth and 7% to 10% adjusted \noperating profit growth compared to fiscal 2021.  And we continue to expect corporate expenses in the range of \n$670 million to $720 million.  \n \n Let me now turn to cash flow and capital deployment.  We were pleased to recently announce the completion of a \ncash-funded upsized tender offer.  This successful tender offer resulted in the early retirement of $922 million of \nour outstandi ng debt.  Additionally, we announced the early retirement of a \u20ac600 million note for a total reduction \nin debt of approximately $1.6 billion. ", "original_text": "Let me now turn to cash flow and capital deployment. ", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46033012c932777583ce91ab576b732820df2341aa60b3a56ed31a8a55f8058f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "711bb4cf-c33b-4a13-b3be-b9b89d7a485c", "node_type": "1", "metadata": {"window": "And we continue to expect corporate expenses in the range of \n$670 million to $720 million.  \n \n Let me now turn to cash flow and capital deployment.  We were pleased to recently announce the completion of a \ncash-funded upsized tender offer.  This successful tender offer resulted in the early retirement of $922 million of \nour outstandi ng debt.  Additionally, we announced the early retirement of a \u20ac600 million note for a total reduction \nin debt of approximately $1.6 billion.  These actions occurred during the beginning of our second quarter.  It further \nstrengthened our balance sheet and fi nancial position and they are in line with our previously stated intent to \nmodestly delever.  \n \n", "original_text": "This successful tender offer resulted in the early retirement of $922 million of \nour outstandi ng debt. "}, "hash": "245fff169fc517fc1b3a86712b5d7fa21b85064b69dd575d0711d87934c86a37", "class_name": "RelatedNodeInfo"}}, "text": "We were pleased to recently announce the completion of a \ncash-funded upsized tender offer. ", "start_char_idx": 2640, "end_char_idx": 2732, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "711bb4cf-c33b-4a13-b3be-b9b89d7a485c": {"__data__": {"id_": "711bb4cf-c33b-4a13-b3be-b9b89d7a485c", "embedding": null, "metadata": {"window": "And we continue to expect corporate expenses in the range of \n$670 million to $720 million.  \n \n Let me now turn to cash flow and capital deployment.  We were pleased to recently announce the completion of a \ncash-funded upsized tender offer.  This successful tender offer resulted in the early retirement of $922 million of \nour outstandi ng debt.  Additionally, we announced the early retirement of a \u20ac600 million note for a total reduction \nin debt of approximately $1.6 billion.  These actions occurred during the beginning of our second quarter.  It further \nstrengthened our balance sheet and fi nancial position and they are in line with our previously stated intent to \nmodestly delever.  \n \n", "original_text": "This successful tender offer resulted in the early retirement of $922 million of \nour outstandi ng debt. ", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5627115a-c77a-423f-83db-5f873b473ef8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5855f621b735261b660edf52eb998c2f3544cc4fcfe589098400743018e36076", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b19518e1-b58c-47aa-9b26-c14e5cf6193a", "node_type": "1", "metadata": {"window": "Turning now to the consolidated view, our guidance assumes 4% to 7% revenue growth and 7% to 10% adjusted \noperating profit growth compared to fiscal 2021.  And we continue to expect corporate expenses in the range of \n$670 million to $720 million.  \n \n Let me now turn to cash flow and capital deployment.  We were pleased to recently announce the completion of a \ncash-funded upsized tender offer.  This successful tender offer resulted in the early retirement of $922 million of \nour outstandi ng debt.  Additionally, we announced the early retirement of a \u20ac600 million note for a total reduction \nin debt of approximately $1.6 billion.  These actions occurred during the beginning of our second quarter. ", "original_text": "We were pleased to recently announce the completion of a \ncash-funded upsized tender offer. ", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b52f50d88c12c3dcb743bb06f30863db9f529827f8e8552c4de05a728510f98c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d7233c4c-58e9-42bf-9819-0968bfaf78e9", "node_type": "1", "metadata": {"window": "Let me now turn to cash flow and capital deployment.  We were pleased to recently announce the completion of a \ncash-funded upsized tender offer.  This successful tender offer resulted in the early retirement of $922 million of \nour outstandi ng debt.  Additionally, we announced the early retirement of a \u20ac600 million note for a total reduction \nin debt of approximately $1.6 billion.  These actions occurred during the beginning of our second quarter.  It further \nstrengthened our balance sheet and fi nancial position and they are in line with our previously stated intent to \nmodestly delever.  \n \n And as a result of these actions, we're updating our interest expense guidance for fiscal 2022 to $180 million to \n$200 million. ", "original_text": "Additionally, we announced the early retirement of a \u20ac600 million note for a total reduction \nin debt of approximately $1.6 billion. "}, "hash": "0871dcf81b5f580862df629954be03d55226b33b5f2ceadd635113fca1debcdc", "class_name": "RelatedNodeInfo"}}, "text": "This successful tender offer resulted in the early retirement of $922 million of \nour outstandi ng debt. ", "start_char_idx": 2732, "end_char_idx": 2837, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d7233c4c-58e9-42bf-9819-0968bfaf78e9": {"__data__": {"id_": "d7233c4c-58e9-42bf-9819-0968bfaf78e9", "embedding": null, "metadata": {"window": "Let me now turn to cash flow and capital deployment.  We were pleased to recently announce the completion of a \ncash-funded upsized tender offer.  This successful tender offer resulted in the early retirement of $922 million of \nour outstandi ng debt.  Additionally, we announced the early retirement of a \u20ac600 million note for a total reduction \nin debt of approximately $1.6 billion.  These actions occurred during the beginning of our second quarter.  It further \nstrengthened our balance sheet and fi nancial position and they are in line with our previously stated intent to \nmodestly delever.  \n \n And as a result of these actions, we're updating our interest expense guidance for fiscal 2022 to $180 million to \n$200 million. ", "original_text": "Additionally, we announced the early retirement of a \u20ac600 million note for a total reduction \nin debt of approximately $1.6 billion. ", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5627115a-c77a-423f-83db-5f873b473ef8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5855f621b735261b660edf52eb998c2f3544cc4fcfe589098400743018e36076", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "711bb4cf-c33b-4a13-b3be-b9b89d7a485c", "node_type": "1", "metadata": {"window": "And we continue to expect corporate expenses in the range of \n$670 million to $720 million.  \n \n Let me now turn to cash flow and capital deployment.  We were pleased to recently announce the completion of a \ncash-funded upsized tender offer.  This successful tender offer resulted in the early retirement of $922 million of \nour outstandi ng debt.  Additionally, we announced the early retirement of a \u20ac600 million note for a total reduction \nin debt of approximately $1.6 billion.  These actions occurred during the beginning of our second quarter.  It further \nstrengthened our balance sheet and fi nancial position and they are in line with our previously stated intent to \nmodestly delever.  \n \n", "original_text": "This successful tender offer resulted in the early retirement of $922 million of \nour outstandi ng debt. ", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ed1bbd80784d77c9ff526606414e72e5bc4dfd80f53e5c5f1115b3b707887a63", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b456253-5279-40d1-b8a8-569c6b8da2b9", "node_type": "1", "metadata": {"window": "We were pleased to recently announce the completion of a \ncash-funded upsized tender offer.  This successful tender offer resulted in the early retirement of $922 million of \nour outstandi ng debt.  Additionally, we announced the early retirement of a \u20ac600 million note for a total reduction \nin debt of approximately $1.6 billion.  These actions occurred during the beginning of our second quarter.  It further \nstrengthened our balance sheet and fi nancial position and they are in line with our previously stated intent to \nmodestly delever.  \n \n And as a result of these actions, we're updating our interest expense guidance for fiscal 2022 to $180 million to \n$200 million.  We're also reiterating our free ca sh flow guidance from approximately $3.5 billion to $3.9 billion, \nwhich is net of property acquisitions and capitalized software expenses.  \n \n", "original_text": "These actions occurred during the beginning of our second quarter. "}, "hash": "bf287dad55fb5592926f8ad19b2260377fa966e760e7f69973e99e3f6056d28b", "class_name": "RelatedNodeInfo"}}, "text": "Additionally, we announced the early retirement of a \u20ac600 million note for a total reduction \nin debt of approximately $1.6 billion. ", "start_char_idx": 2837, "end_char_idx": 2970, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b456253-5279-40d1-b8a8-569c6b8da2b9": {"__data__": {"id_": "9b456253-5279-40d1-b8a8-569c6b8da2b9", "embedding": null, "metadata": {"window": "We were pleased to recently announce the completion of a \ncash-funded upsized tender offer.  This successful tender offer resulted in the early retirement of $922 million of \nour outstandi ng debt.  Additionally, we announced the early retirement of a \u20ac600 million note for a total reduction \nin debt of approximately $1.6 billion.  These actions occurred during the beginning of our second quarter.  It further \nstrengthened our balance sheet and fi nancial position and they are in line with our previously stated intent to \nmodestly delever.  \n \n And as a result of these actions, we're updating our interest expense guidance for fiscal 2022 to $180 million to \n$200 million.  We're also reiterating our free ca sh flow guidance from approximately $3.5 billion to $3.9 billion, \nwhich is net of property acquisitions and capitalized software expenses.  \n \n", "original_text": "These actions occurred during the beginning of our second quarter. ", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5627115a-c77a-423f-83db-5f873b473ef8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5855f621b735261b660edf52eb998c2f3544cc4fcfe589098400743018e36076", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d7233c4c-58e9-42bf-9819-0968bfaf78e9", "node_type": "1", "metadata": {"window": "Let me now turn to cash flow and capital deployment.  We were pleased to recently announce the completion of a \ncash-funded upsized tender offer.  This successful tender offer resulted in the early retirement of $922 million of \nour outstandi ng debt.  Additionally, we announced the early retirement of a \u20ac600 million note for a total reduction \nin debt of approximately $1.6 billion.  These actions occurred during the beginning of our second quarter.  It further \nstrengthened our balance sheet and fi nancial position and they are in line with our previously stated intent to \nmodestly delever.  \n \n And as a result of these actions, we're updating our interest expense guidance for fiscal 2022 to $180 million to \n$200 million. ", "original_text": "Additionally, we announced the early retirement of a \u20ac600 million note for a total reduction \nin debt of approximately $1.6 billion. ", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3b5e70fc4bf72e1e899bdbe739abd6733de4dfd409a5ae2c5acb1095a569e42", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e528031a-1144-44c2-851e-c4b0dbd99b26", "node_type": "1", "metadata": {"window": "This successful tender offer resulted in the early retirement of $922 million of \nour outstandi ng debt.  Additionally, we announced the early retirement of a \u20ac600 million note for a total reduction \nin debt of approximately $1.6 billion.  These actions occurred during the beginning of our second quarter.  It further \nstrengthened our balance sheet and fi nancial position and they are in line with our previously stated intent to \nmodestly delever.  \n \n And as a result of these actions, we're updating our interest expense guidance for fiscal 2022 to $180 million to \n$200 million.  We're also reiterating our free ca sh flow guidance from approximately $3.5 billion to $3.9 billion, \nwhich is net of property acquisitions and capitalized software expenses.  \n \n Last quarter, I mentioned that we anticipated a use of cash to purchase shares in McKesson Europe through \nexercises of a put rate option available to non -controlling shareholders that expired in June of fiscal 2022. ", "original_text": "It further \nstrengthened our balance sheet and fi nancial position and they are in line with our previously stated intent to \nmodestly delever.  \n \n"}, "hash": "289ec0f07f90f7217a4112523d06da650391d7359e02d65b0d51651eee8ea0d5", "class_name": "RelatedNodeInfo"}}, "text": "These actions occurred during the beginning of our second quarter. ", "start_char_idx": 2970, "end_char_idx": 3037, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e528031a-1144-44c2-851e-c4b0dbd99b26": {"__data__": {"id_": "e528031a-1144-44c2-851e-c4b0dbd99b26", "embedding": null, "metadata": {"window": "This successful tender offer resulted in the early retirement of $922 million of \nour outstandi ng debt.  Additionally, we announced the early retirement of a \u20ac600 million note for a total reduction \nin debt of approximately $1.6 billion.  These actions occurred during the beginning of our second quarter.  It further \nstrengthened our balance sheet and fi nancial position and they are in line with our previously stated intent to \nmodestly delever.  \n \n And as a result of these actions, we're updating our interest expense guidance for fiscal 2022 to $180 million to \n$200 million.  We're also reiterating our free ca sh flow guidance from approximately $3.5 billion to $3.9 billion, \nwhich is net of property acquisitions and capitalized software expenses.  \n \n Last quarter, I mentioned that we anticipated a use of cash to purchase shares in McKesson Europe through \nexercises of a put rate option available to non -controlling shareholders that expired in June of fiscal 2022. ", "original_text": "It further \nstrengthened our balance sheet and fi nancial position and they are in line with our previously stated intent to \nmodestly delever.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5627115a-c77a-423f-83db-5f873b473ef8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5855f621b735261b660edf52eb998c2f3544cc4fcfe589098400743018e36076", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b456253-5279-40d1-b8a8-569c6b8da2b9", "node_type": "1", "metadata": {"window": "We were pleased to recently announce the completion of a \ncash-funded upsized tender offer.  This successful tender offer resulted in the early retirement of $922 million of \nour outstandi ng debt.  Additionally, we announced the early retirement of a \u20ac600 million note for a total reduction \nin debt of approximately $1.6 billion.  These actions occurred during the beginning of our second quarter.  It further \nstrengthened our balance sheet and fi nancial position and they are in line with our previously stated intent to \nmodestly delever.  \n \n And as a result of these actions, we're updating our interest expense guidance for fiscal 2022 to $180 million to \n$200 million.  We're also reiterating our free ca sh flow guidance from approximately $3.5 billion to $3.9 billion, \nwhich is net of property acquisitions and capitalized software expenses.  \n \n", "original_text": "These actions occurred during the beginning of our second quarter. ", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ba36bc8de1eb5a66fbbea6baec5ed2be3fdeabad75007cfeff43085100cc5c37", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea6b1d55-c9cb-43d3-936d-136deaab3615", "node_type": "1", "metadata": {"window": "Additionally, we announced the early retirement of a \u20ac600 million note for a total reduction \nin debt of approximately $1.6 billion.  These actions occurred during the beginning of our second quarter.  It further \nstrengthened our balance sheet and fi nancial position and they are in line with our previously stated intent to \nmodestly delever.  \n \n And as a result of these actions, we're updating our interest expense guidance for fiscal 2022 to $180 million to \n$200 million.  We're also reiterating our free ca sh flow guidance from approximately $3.5 billion to $3.9 billion, \nwhich is net of property acquisitions and capitalized software expenses.  \n \n Last quarter, I mentioned that we anticipated a use of cash to purchase shares in McKesson Europe through \nexercises of a put rate option available to non -controlling shareholders that expired in June of fiscal 2022.  The \nremaining put rate options resulted in payments of approximately $1 billion in the quarter, which was generally in \nline with our expectations.  \n ", "original_text": "And as a result of these actions, we're updating our interest expense guidance for fiscal 2022 to $180 million to \n$200 million. "}, "hash": "4936eb5f0d4f2df382c162ab76294059f4aac7447912baad6e2d990a456f901e", "class_name": "RelatedNodeInfo"}}, "text": "It further \nstrengthened our balance sheet and fi nancial position and they are in line with our previously stated intent to \nmodestly delever.  \n \n", "start_char_idx": 3037, "end_char_idx": 3185, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea6b1d55-c9cb-43d3-936d-136deaab3615": {"__data__": {"id_": "ea6b1d55-c9cb-43d3-936d-136deaab3615", "embedding": null, "metadata": {"window": "Additionally, we announced the early retirement of a \u20ac600 million note for a total reduction \nin debt of approximately $1.6 billion.  These actions occurred during the beginning of our second quarter.  It further \nstrengthened our balance sheet and fi nancial position and they are in line with our previously stated intent to \nmodestly delever.  \n \n And as a result of these actions, we're updating our interest expense guidance for fiscal 2022 to $180 million to \n$200 million.  We're also reiterating our free ca sh flow guidance from approximately $3.5 billion to $3.9 billion, \nwhich is net of property acquisitions and capitalized software expenses.  \n \n Last quarter, I mentioned that we anticipated a use of cash to purchase shares in McKesson Europe through \nexercises of a put rate option available to non -controlling shareholders that expired in June of fiscal 2022.  The \nremaining put rate options resulted in payments of approximately $1 billion in the quarter, which was generally in \nline with our expectations.  \n ", "original_text": "And as a result of these actions, we're updating our interest expense guidance for fiscal 2022 to $180 million to \n$200 million. ", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5627115a-c77a-423f-83db-5f873b473ef8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5855f621b735261b660edf52eb998c2f3544cc4fcfe589098400743018e36076", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e528031a-1144-44c2-851e-c4b0dbd99b26", "node_type": "1", "metadata": {"window": "This successful tender offer resulted in the early retirement of $922 million of \nour outstandi ng debt.  Additionally, we announced the early retirement of a \u20ac600 million note for a total reduction \nin debt of approximately $1.6 billion.  These actions occurred during the beginning of our second quarter.  It further \nstrengthened our balance sheet and fi nancial position and they are in line with our previously stated intent to \nmodestly delever.  \n \n And as a result of these actions, we're updating our interest expense guidance for fiscal 2022 to $180 million to \n$200 million.  We're also reiterating our free ca sh flow guidance from approximately $3.5 billion to $3.9 billion, \nwhich is net of property acquisitions and capitalized software expenses.  \n \n Last quarter, I mentioned that we anticipated a use of cash to purchase shares in McKesson Europe through \nexercises of a put rate option available to non -controlling shareholders that expired in June of fiscal 2022. ", "original_text": "It further \nstrengthened our balance sheet and fi nancial position and they are in line with our previously stated intent to \nmodestly delever.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66b327e58bf1d4ca593e4a78242c3006352bf965e2dcfc7b8e0cf2daf5be20d4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "df49c8fb-a556-4bbb-b302-c0276d016f32", "node_type": "1", "metadata": {"window": "These actions occurred during the beginning of our second quarter.  It further \nstrengthened our balance sheet and fi nancial position and they are in line with our previously stated intent to \nmodestly delever.  \n \n And as a result of these actions, we're updating our interest expense guidance for fiscal 2022 to $180 million to \n$200 million.  We're also reiterating our free ca sh flow guidance from approximately $3.5 billion to $3.9 billion, \nwhich is net of property acquisitions and capitalized software expenses.  \n \n Last quarter, I mentioned that we anticipated a use of cash to purchase shares in McKesson Europe through \nexercises of a put rate option available to non -controlling shareholders that expired in June of fiscal 2022.  The \nremaining put rate options resulted in payments of approximately $1 billion in the quarter, which was generally in \nline with our expectations.  \n ", "original_text": "We're also reiterating our free ca sh flow guidance from approximately $3.5 billion to $3.9 billion, \nwhich is net of property acquisitions and capitalized software expenses.  \n \n"}, "hash": "879dc5d40bb3c10cc27926a4bd46bda7416ac5c6a09bd50a927e49f94294f767", "class_name": "RelatedNodeInfo"}}, "text": "And as a result of these actions, we're updating our interest expense guidance for fiscal 2022 to $180 million to \n$200 million. ", "start_char_idx": 3185, "end_char_idx": 3314, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "df49c8fb-a556-4bbb-b302-c0276d016f32": {"__data__": {"id_": "df49c8fb-a556-4bbb-b302-c0276d016f32", "embedding": null, "metadata": {"window": "These actions occurred during the beginning of our second quarter.  It further \nstrengthened our balance sheet and fi nancial position and they are in line with our previously stated intent to \nmodestly delever.  \n \n And as a result of these actions, we're updating our interest expense guidance for fiscal 2022 to $180 million to \n$200 million.  We're also reiterating our free ca sh flow guidance from approximately $3.5 billion to $3.9 billion, \nwhich is net of property acquisitions and capitalized software expenses.  \n \n Last quarter, I mentioned that we anticipated a use of cash to purchase shares in McKesson Europe through \nexercises of a put rate option available to non -controlling shareholders that expired in June of fiscal 2022.  The \nremaining put rate options resulted in payments of approximately $1 billion in the quarter, which was generally in \nline with our expectations.  \n ", "original_text": "We're also reiterating our free ca sh flow guidance from approximately $3.5 billion to $3.9 billion, \nwhich is net of property acquisitions and capitalized software expenses.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5627115a-c77a-423f-83db-5f873b473ef8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5855f621b735261b660edf52eb998c2f3544cc4fcfe589098400743018e36076", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea6b1d55-c9cb-43d3-936d-136deaab3615", "node_type": "1", "metadata": {"window": "Additionally, we announced the early retirement of a \u20ac600 million note for a total reduction \nin debt of approximately $1.6 billion.  These actions occurred during the beginning of our second quarter.  It further \nstrengthened our balance sheet and fi nancial position and they are in line with our previously stated intent to \nmodestly delever.  \n \n And as a result of these actions, we're updating our interest expense guidance for fiscal 2022 to $180 million to \n$200 million.  We're also reiterating our free ca sh flow guidance from approximately $3.5 billion to $3.9 billion, \nwhich is net of property acquisitions and capitalized software expenses.  \n \n Last quarter, I mentioned that we anticipated a use of cash to purchase shares in McKesson Europe through \nexercises of a put rate option available to non -controlling shareholders that expired in June of fiscal 2022.  The \nremaining put rate options resulted in payments of approximately $1 billion in the quarter, which was generally in \nline with our expectations.  \n ", "original_text": "And as a result of these actions, we're updating our interest expense guidance for fiscal 2022 to $180 million to \n$200 million. ", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7bc3b067422a77275332c620e6c455f0c0c744c7a75b1abfd0cbadf83859acb4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a8c55e7-8e5e-4d38-b242-e803471cd938", "node_type": "1", "metadata": {"window": "It further \nstrengthened our balance sheet and fi nancial position and they are in line with our previously stated intent to \nmodestly delever.  \n \n And as a result of these actions, we're updating our interest expense guidance for fiscal 2022 to $180 million to \n$200 million.  We're also reiterating our free ca sh flow guidance from approximately $3.5 billion to $3.9 billion, \nwhich is net of property acquisitions and capitalized software expenses.  \n \n Last quarter, I mentioned that we anticipated a use of cash to purchase shares in McKesson Europe through \nexercises of a put rate option available to non -controlling shareholders that expired in June of fiscal 2022.  The \nremaining put rate options resulted in payments of approximately $1 billion in the quarter, which was generally in \nline with our expectations.  \n ", "original_text": "Last quarter, I mentioned that we anticipated a use of cash to purchase shares in McKesson Europe through \nexercises of a put rate option available to non -controlling shareholders that expired in June of fiscal 2022. "}, "hash": "341ba7c3b0cb78661892f19770f10d3f44b63b783b48f7462f35ebdee43ef55b", "class_name": "RelatedNodeInfo"}}, "text": "We're also reiterating our free ca sh flow guidance from approximately $3.5 billion to $3.9 billion, \nwhich is net of property acquisitions and capitalized software expenses.  \n \n", "start_char_idx": 3314, "end_char_idx": 3493, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a8c55e7-8e5e-4d38-b242-e803471cd938": {"__data__": {"id_": "1a8c55e7-8e5e-4d38-b242-e803471cd938", "embedding": null, "metadata": {"window": "It further \nstrengthened our balance sheet and fi nancial position and they are in line with our previously stated intent to \nmodestly delever.  \n \n And as a result of these actions, we're updating our interest expense guidance for fiscal 2022 to $180 million to \n$200 million.  We're also reiterating our free ca sh flow guidance from approximately $3.5 billion to $3.9 billion, \nwhich is net of property acquisitions and capitalized software expenses.  \n \n Last quarter, I mentioned that we anticipated a use of cash to purchase shares in McKesson Europe through \nexercises of a put rate option available to non -controlling shareholders that expired in June of fiscal 2022.  The \nremaining put rate options resulted in payments of approximately $1 billion in the quarter, which was generally in \nline with our expectations.  \n ", "original_text": "Last quarter, I mentioned that we anticipated a use of cash to purchase shares in McKesson Europe through \nexercises of a put rate option available to non -controlling shareholders that expired in June of fiscal 2022. ", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5627115a-c77a-423f-83db-5f873b473ef8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5855f621b735261b660edf52eb998c2f3544cc4fcfe589098400743018e36076", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "df49c8fb-a556-4bbb-b302-c0276d016f32", "node_type": "1", "metadata": {"window": "These actions occurred during the beginning of our second quarter.  It further \nstrengthened our balance sheet and fi nancial position and they are in line with our previously stated intent to \nmodestly delever.  \n \n And as a result of these actions, we're updating our interest expense guidance for fiscal 2022 to $180 million to \n$200 million.  We're also reiterating our free ca sh flow guidance from approximately $3.5 billion to $3.9 billion, \nwhich is net of property acquisitions and capitalized software expenses.  \n \n Last quarter, I mentioned that we anticipated a use of cash to purchase shares in McKesson Europe through \nexercises of a put rate option available to non -controlling shareholders that expired in June of fiscal 2022.  The \nremaining put rate options resulted in payments of approximately $1 billion in the quarter, which was generally in \nline with our expectations.  \n ", "original_text": "We're also reiterating our free ca sh flow guidance from approximately $3.5 billion to $3.9 billion, \nwhich is net of property acquisitions and capitalized software expenses.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "24d85f1b27b18bf11e76749649812173cd982f5cc5d3a3b81d1b41cd970988fb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dbea9e38-8459-4ba4-8244-f328aba1bb3a", "node_type": "1", "metadata": {"window": "And as a result of these actions, we're updating our interest expense guidance for fiscal 2022 to $180 million to \n$200 million.  We're also reiterating our free ca sh flow guidance from approximately $3.5 billion to $3.9 billion, \nwhich is net of property acquisitions and capitalized software expenses.  \n \n Last quarter, I mentioned that we anticipated a use of cash to purchase shares in McKesson Europe through \nexercises of a put rate option available to non -controlling shareholders that expired in June of fiscal 2022.  The \nremaining put rate options resulted in payments of approximately $1 billion in the quarter, which was generally in \nline with our expectations.  \n ", "original_text": "The \nremaining put rate options resulted in payments of approximately $1 billion in the quarter, which was generally in \nline with our expectations.  \n "}, "hash": "228d661b81faa2d9ad1beb2b0a87139818e720d86c7f42fc3b113fb7c74b5643", "class_name": "RelatedNodeInfo"}}, "text": "Last quarter, I mentioned that we anticipated a use of cash to purchase shares in McKesson Europe through \nexercises of a put rate option available to non -controlling shareholders that expired in June of fiscal 2022. ", "start_char_idx": 3493, "end_char_idx": 3711, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dbea9e38-8459-4ba4-8244-f328aba1bb3a": {"__data__": {"id_": "dbea9e38-8459-4ba4-8244-f328aba1bb3a", "embedding": null, "metadata": {"window": "And as a result of these actions, we're updating our interest expense guidance for fiscal 2022 to $180 million to \n$200 million.  We're also reiterating our free ca sh flow guidance from approximately $3.5 billion to $3.9 billion, \nwhich is net of property acquisitions and capitalized software expenses.  \n \n Last quarter, I mentioned that we anticipated a use of cash to purchase shares in McKesson Europe through \nexercises of a put rate option available to non -controlling shareholders that expired in June of fiscal 2022.  The \nremaining put rate options resulted in payments of approximately $1 billion in the quarter, which was generally in \nline with our expectations.  \n ", "original_text": "The \nremaining put rate options resulted in payments of approximately $1 billion in the quarter, which was generally in \nline with our expectations.  \n ", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5627115a-c77a-423f-83db-5f873b473ef8", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5855f621b735261b660edf52eb998c2f3544cc4fcfe589098400743018e36076", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a8c55e7-8e5e-4d38-b242-e803471cd938", "node_type": "1", "metadata": {"window": "It further \nstrengthened our balance sheet and fi nancial position and they are in line with our previously stated intent to \nmodestly delever.  \n \n And as a result of these actions, we're updating our interest expense guidance for fiscal 2022 to $180 million to \n$200 million.  We're also reiterating our free ca sh flow guidance from approximately $3.5 billion to $3.9 billion, \nwhich is net of property acquisitions and capitalized software expenses.  \n \n Last quarter, I mentioned that we anticipated a use of cash to purchase shares in McKesson Europe through \nexercises of a put rate option available to non -controlling shareholders that expired in June of fiscal 2022.  The \nremaining put rate options resulted in payments of approximately $1 billion in the quarter, which was generally in \nline with our expectations.  \n ", "original_text": "Last quarter, I mentioned that we anticipated a use of cash to purchase shares in McKesson Europe through \nexercises of a put rate option available to non -controlling shareholders that expired in June of fiscal 2022. ", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eae39dc8711188d073e583b38c3820d0169e49cdd19ac9004795808b1274e2c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de566afb-e48f-432f-b50a-f7e263280ff8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAs a rem inder, this is reflected in the financing activities section of our cash flow statement.  As a result of this \nactivity, McKesson holds approximately 95% of McKesson Europe's outstanding common shares, and we \nanticipate income attributable to non -controlling  interest in the range of $175 million to $195 million in fiscal 2022.  \n \n Our commitment to return cash to shareholders through dividend and share repurchases was recently highlighted \nby our Board's approval of a 12% increase to our quarterly dividend to $0. ", "original_text": "McKesson Corp.  "}, "hash": "86a7189f55be73825c9defaeee5ea966cee5112b762352f4bf2fe36044a60d2a", "class_name": "RelatedNodeInfo"}}, "text": "The \nremaining put rate options resulted in payments of approximately $1 billion in the quarter, which was generally in \nline with our expectations.  \n ", "start_char_idx": 3711, "end_char_idx": 3863, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de566afb-e48f-432f-b50a-f7e263280ff8": {"__data__": {"id_": "de566afb-e48f-432f-b50a-f7e263280ff8", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAs a rem inder, this is reflected in the financing activities section of our cash flow statement.  As a result of this \nactivity, McKesson holds approximately 95% of McKesson Europe's outstanding common shares, and we \nanticipate income attributable to non -controlling  interest in the range of $175 million to $195 million in fiscal 2022.  \n \n Our commitment to return cash to shareholders through dividend and share repurchases was recently highlighted \nby our Board's approval of a 12% increase to our quarterly dividend to $0. ", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e0b8dec75ff27983ca96d4af55e0aea224e2447bb3be43e6e44c8a7e7b83eb5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dbea9e38-8459-4ba4-8244-f328aba1bb3a", "node_type": "1", "metadata": {"window": "And as a result of these actions, we're updating our interest expense guidance for fiscal 2022 to $180 million to \n$200 million.  We're also reiterating our free ca sh flow guidance from approximately $3.5 billion to $3.9 billion, \nwhich is net of property acquisitions and capitalized software expenses.  \n \n Last quarter, I mentioned that we anticipated a use of cash to purchase shares in McKesson Europe through \nexercises of a put rate option available to non -controlling shareholders that expired in June of fiscal 2022.  The \nremaining put rate options resulted in payments of approximately $1 billion in the quarter, which was generally in \nline with our expectations.  \n ", "original_text": "The \nremaining put rate options resulted in payments of approximately $1 billion in the quarter, which was generally in \nline with our expectations.  \n ", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5813f9dbf7702999cbba49fda5bd8dfc83fcecf6edf5d95346f4517e15d58380", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce96a2df-1e87-42cc-9805-873f31eca61c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAs a rem inder, this is reflected in the financing activities section of our cash flow statement.  As a result of this \nactivity, McKesson holds approximately 95% of McKesson Europe's outstanding common shares, and we \nanticipate income attributable to non -controlling  interest in the range of $175 million to $195 million in fiscal 2022.  \n \n Our commitment to return cash to shareholders through dividend and share repurchases was recently highlighted \nby our Board's approval of a 12% increase to our quarterly dividend to $0.  47 per share. ", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAs a rem inder, this is reflected in the financing activities section of our cash flow statement. "}, "hash": "7caf2a9c3a657b15100c22bfdeac6567b9c8f71fdca005c741f41e81fa93d065", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce96a2df-1e87-42cc-9805-873f31eca61c": {"__data__": {"id_": "ce96a2df-1e87-42cc-9805-873f31eca61c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAs a rem inder, this is reflected in the financing activities section of our cash flow statement.  As a result of this \nactivity, McKesson holds approximately 95% of McKesson Europe's outstanding common shares, and we \nanticipate income attributable to non -controlling  interest in the range of $175 million to $195 million in fiscal 2022.  \n \n Our commitment to return cash to shareholders through dividend and share repurchases was recently highlighted \nby our Board's approval of a 12% increase to our quarterly dividend to $0.  47 per share. ", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAs a rem inder, this is reflected in the financing activities section of our cash flow statement. ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e0b8dec75ff27983ca96d4af55e0aea224e2447bb3be43e6e44c8a7e7b83eb5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de566afb-e48f-432f-b50a-f7e263280ff8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAs a rem inder, this is reflected in the financing activities section of our cash flow statement.  As a result of this \nactivity, McKesson holds approximately 95% of McKesson Europe's outstanding common shares, and we \nanticipate income attributable to non -controlling  interest in the range of $175 million to $195 million in fiscal 2022.  \n \n Our commitment to return cash to shareholders through dividend and share repurchases was recently highlighted \nby our Board's approval of a 12% increase to our quarterly dividend to $0. ", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5c4472bf1fbc787f20f94bac47ac20925d48b0d984a79a860f7da8327b0883c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e08ae9b-3a34-4d84-a2d0-7192a116c0eb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAs a rem inder, this is reflected in the financing activities section of our cash flow statement.  As a result of this \nactivity, McKesson holds approximately 95% of McKesson Europe's outstanding common shares, and we \nanticipate income attributable to non -controlling  interest in the range of $175 million to $195 million in fiscal 2022.  \n \n Our commitment to return cash to shareholders through dividend and share repurchases was recently highlighted \nby our Board's approval of a 12% increase to our quarterly dividend to $0.  47 per share.  And our fiscal 2022 \nguidance continues to include share repurchases of approximately $2 billion for the full year.  \n \n", "original_text": "As a result of this \nactivity, McKesson holds approximately 95% of McKesson Europe's outstanding common shares, and we \nanticipate income attributable to non -controlling  interest in the range of $175 million to $195 million in fiscal 2022.  \n \n"}, "hash": "2a7931df4354f5151e878b9ced0ddc9cb8d77b6bbcdfa0f99e4cd806cacdb7a1", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAs a rem inder, this is reflected in the financing activities section of our cash flow statement. ", "start_char_idx": 16, "end_char_idx": 279, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e08ae9b-3a34-4d84-a2d0-7192a116c0eb": {"__data__": {"id_": "7e08ae9b-3a34-4d84-a2d0-7192a116c0eb", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAs a rem inder, this is reflected in the financing activities section of our cash flow statement.  As a result of this \nactivity, McKesson holds approximately 95% of McKesson Europe's outstanding common shares, and we \nanticipate income attributable to non -controlling  interest in the range of $175 million to $195 million in fiscal 2022.  \n \n Our commitment to return cash to shareholders through dividend and share repurchases was recently highlighted \nby our Board's approval of a 12% increase to our quarterly dividend to $0.  47 per share.  And our fiscal 2022 \nguidance continues to include share repurchases of approximately $2 billion for the full year.  \n \n", "original_text": "As a result of this \nactivity, McKesson holds approximately 95% of McKesson Europe's outstanding common shares, and we \nanticipate income attributable to non -controlling  interest in the range of $175 million to $195 million in fiscal 2022.  \n \n", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e0b8dec75ff27983ca96d4af55e0aea224e2447bb3be43e6e44c8a7e7b83eb5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce96a2df-1e87-42cc-9805-873f31eca61c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAs a rem inder, this is reflected in the financing activities section of our cash flow statement.  As a result of this \nactivity, McKesson holds approximately 95% of McKesson Europe's outstanding common shares, and we \nanticipate income attributable to non -controlling  interest in the range of $175 million to $195 million in fiscal 2022.  \n \n Our commitment to return cash to shareholders through dividend and share repurchases was recently highlighted \nby our Board's approval of a 12% increase to our quarterly dividend to $0.  47 per share. ", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAs a rem inder, this is reflected in the financing activities section of our cash flow statement. ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef06e3f744a2913883679b659156df1c96bd1735fed5cf2fab5360d69754a040", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fcd76f21-729d-4bb4-a4b2-36e02e9c58da", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAs a rem inder, this is reflected in the financing activities section of our cash flow statement.  As a result of this \nactivity, McKesson holds approximately 95% of McKesson Europe's outstanding common shares, and we \nanticipate income attributable to non -controlling  interest in the range of $175 million to $195 million in fiscal 2022.  \n \n Our commitment to return cash to shareholders through dividend and share repurchases was recently highlighted \nby our Board's approval of a 12% increase to our quarterly dividend to $0.  47 per share.  And our fiscal 2022 \nguidance continues to include share repurchases of approximately $2 billion for the full year.  \n \n In closing, we're pleased with the strong results of our first quarter. ", "original_text": "Our commitment to return cash to shareholders through dividend and share repurchases was recently highlighted \nby our Board's approval of a 12% increase to our quarterly dividend to $0. "}, "hash": "d173082005eecf9d364e72d7759226032a8b63781a05d1d710af91bfb44d0103", "class_name": "RelatedNodeInfo"}}, "text": "As a result of this \nactivity, McKesson holds approximately 95% of McKesson Europe's outstanding common shares, and we \nanticipate income attributable to non -controlling  interest in the range of $175 million to $195 million in fiscal 2022.  \n \n", "start_char_idx": 279, "end_char_idx": 525, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fcd76f21-729d-4bb4-a4b2-36e02e9c58da": {"__data__": {"id_": "fcd76f21-729d-4bb4-a4b2-36e02e9c58da", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAs a rem inder, this is reflected in the financing activities section of our cash flow statement.  As a result of this \nactivity, McKesson holds approximately 95% of McKesson Europe's outstanding common shares, and we \nanticipate income attributable to non -controlling  interest in the range of $175 million to $195 million in fiscal 2022.  \n \n Our commitment to return cash to shareholders through dividend and share repurchases was recently highlighted \nby our Board's approval of a 12% increase to our quarterly dividend to $0.  47 per share.  And our fiscal 2022 \nguidance continues to include share repurchases of approximately $2 billion for the full year.  \n \n In closing, we're pleased with the strong results of our first quarter. ", "original_text": "Our commitment to return cash to shareholders through dividend and share repurchases was recently highlighted \nby our Board's approval of a 12% increase to our quarterly dividend to $0. ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e0b8dec75ff27983ca96d4af55e0aea224e2447bb3be43e6e44c8a7e7b83eb5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e08ae9b-3a34-4d84-a2d0-7192a116c0eb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAs a rem inder, this is reflected in the financing activities section of our cash flow statement.  As a result of this \nactivity, McKesson holds approximately 95% of McKesson Europe's outstanding common shares, and we \nanticipate income attributable to non -controlling  interest in the range of $175 million to $195 million in fiscal 2022.  \n \n Our commitment to return cash to shareholders through dividend and share repurchases was recently highlighted \nby our Board's approval of a 12% increase to our quarterly dividend to $0.  47 per share.  And our fiscal 2022 \nguidance continues to include share repurchases of approximately $2 billion for the full year.  \n \n", "original_text": "As a result of this \nactivity, McKesson holds approximately 95% of McKesson Europe's outstanding common shares, and we \nanticipate income attributable to non -controlling  interest in the range of $175 million to $195 million in fiscal 2022.  \n \n", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8756a9492be30fa7b8a2b7299a6b4d4d65c27a2b6114edcc406ca27fe84acda0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "771f0825-9ede-447e-b427-a72336ab8db6", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAs a rem inder, this is reflected in the financing activities section of our cash flow statement.  As a result of this \nactivity, McKesson holds approximately 95% of McKesson Europe's outstanding common shares, and we \nanticipate income attributable to non -controlling  interest in the range of $175 million to $195 million in fiscal 2022.  \n \n Our commitment to return cash to shareholders through dividend and share repurchases was recently highlighted \nby our Board's approval of a 12% increase to our quarterly dividend to $0.  47 per share.  And our fiscal 2022 \nguidance continues to include share repurchases of approximately $2 billion for the full year.  \n \n In closing, we're pleased with the strong results of our first quarter.  We remain focused on driving growth as we \ninvest again st the strategic high -growth opportunities in oncology and biopharma services. ", "original_text": "47 per share. "}, "hash": "b847124ee75a0c0ad8f4727180441c7e44229d1ddd222c6a4e14875ff824b983", "class_name": "RelatedNodeInfo"}}, "text": "Our commitment to return cash to shareholders through dividend and share repurchases was recently highlighted \nby our Board's approval of a 12% increase to our quarterly dividend to $0. ", "start_char_idx": 525, "end_char_idx": 711, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "771f0825-9ede-447e-b427-a72336ab8db6": {"__data__": {"id_": "771f0825-9ede-447e-b427-a72336ab8db6", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAs a rem inder, this is reflected in the financing activities section of our cash flow statement.  As a result of this \nactivity, McKesson holds approximately 95% of McKesson Europe's outstanding common shares, and we \nanticipate income attributable to non -controlling  interest in the range of $175 million to $195 million in fiscal 2022.  \n \n Our commitment to return cash to shareholders through dividend and share repurchases was recently highlighted \nby our Board's approval of a 12% increase to our quarterly dividend to $0.  47 per share.  And our fiscal 2022 \nguidance continues to include share repurchases of approximately $2 billion for the full year.  \n \n In closing, we're pleased with the strong results of our first quarter.  We remain focused on driving growth as we \ninvest again st the strategic high -growth opportunities in oncology and biopharma services. ", "original_text": "47 per share. ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e0b8dec75ff27983ca96d4af55e0aea224e2447bb3be43e6e44c8a7e7b83eb5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fcd76f21-729d-4bb4-a4b2-36e02e9c58da", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAs a rem inder, this is reflected in the financing activities section of our cash flow statement.  As a result of this \nactivity, McKesson holds approximately 95% of McKesson Europe's outstanding common shares, and we \nanticipate income attributable to non -controlling  interest in the range of $175 million to $195 million in fiscal 2022.  \n \n Our commitment to return cash to shareholders through dividend and share repurchases was recently highlighted \nby our Board's approval of a 12% increase to our quarterly dividend to $0.  47 per share.  And our fiscal 2022 \nguidance continues to include share repurchases of approximately $2 billion for the full year.  \n \n In closing, we're pleased with the strong results of our first quarter. ", "original_text": "Our commitment to return cash to shareholders through dividend and share repurchases was recently highlighted \nby our Board's approval of a 12% increase to our quarterly dividend to $0. ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c71ad75f888ce7f075946cd0db2ea80683978b3e191c0f216a385f8f2642652c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0e92bf9-c418-45e4-b477-6f7a015ad158", "node_type": "1", "metadata": {"window": "As a result of this \nactivity, McKesson holds approximately 95% of McKesson Europe's outstanding common shares, and we \nanticipate income attributable to non -controlling  interest in the range of $175 million to $195 million in fiscal 2022.  \n \n Our commitment to return cash to shareholders through dividend and share repurchases was recently highlighted \nby our Board's approval of a 12% increase to our quarterly dividend to $0.  47 per share.  And our fiscal 2022 \nguidance continues to include share repurchases of approximately $2 billion for the full year.  \n \n In closing, we're pleased with the strong results of our first quarter.  We remain focused on driving growth as we \ninvest again st the strategic high -growth opportunities in oncology and biopharma services.  This focus, combined \nwith our commitment to further evolve the portfolio, will drive significant value to our customers, shareholders and \npatients. ", "original_text": "And our fiscal 2022 \nguidance continues to include share repurchases of approximately $2 billion for the full year.  \n \n"}, "hash": "458057abeb8bd47fbff16df46d5d0692ac3807be84f4fcb08981ccdb8b4c9ec9", "class_name": "RelatedNodeInfo"}}, "text": "47 per share. ", "start_char_idx": 711, "end_char_idx": 725, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0e92bf9-c418-45e4-b477-6f7a015ad158": {"__data__": {"id_": "d0e92bf9-c418-45e4-b477-6f7a015ad158", "embedding": null, "metadata": {"window": "As a result of this \nactivity, McKesson holds approximately 95% of McKesson Europe's outstanding common shares, and we \nanticipate income attributable to non -controlling  interest in the range of $175 million to $195 million in fiscal 2022.  \n \n Our commitment to return cash to shareholders through dividend and share repurchases was recently highlighted \nby our Board's approval of a 12% increase to our quarterly dividend to $0.  47 per share.  And our fiscal 2022 \nguidance continues to include share repurchases of approximately $2 billion for the full year.  \n \n In closing, we're pleased with the strong results of our first quarter.  We remain focused on driving growth as we \ninvest again st the strategic high -growth opportunities in oncology and biopharma services.  This focus, combined \nwith our commitment to further evolve the portfolio, will drive significant value to our customers, shareholders and \npatients. ", "original_text": "And our fiscal 2022 \nguidance continues to include share repurchases of approximately $2 billion for the full year.  \n \n", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e0b8dec75ff27983ca96d4af55e0aea224e2447bb3be43e6e44c8a7e7b83eb5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "771f0825-9ede-447e-b427-a72336ab8db6", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAs a rem inder, this is reflected in the financing activities section of our cash flow statement.  As a result of this \nactivity, McKesson holds approximately 95% of McKesson Europe's outstanding common shares, and we \nanticipate income attributable to non -controlling  interest in the range of $175 million to $195 million in fiscal 2022.  \n \n Our commitment to return cash to shareholders through dividend and share repurchases was recently highlighted \nby our Board's approval of a 12% increase to our quarterly dividend to $0.  47 per share.  And our fiscal 2022 \nguidance continues to include share repurchases of approximately $2 billion for the full year.  \n \n In closing, we're pleased with the strong results of our first quarter.  We remain focused on driving growth as we \ninvest again st the strategic high -growth opportunities in oncology and biopharma services. ", "original_text": "47 per share. ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2e0b86c410973444a5993e9572d7f7c241cb8ef448bc40b29dba3f0fd54c5fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c6506e4-3e3e-4640-91c9-2038d6b0d05b", "node_type": "1", "metadata": {"window": "Our commitment to return cash to shareholders through dividend and share repurchases was recently highlighted \nby our Board's approval of a 12% increase to our quarterly dividend to $0.  47 per share.  And our fiscal 2022 \nguidance continues to include share repurchases of approximately $2 billion for the full year.  \n \n In closing, we're pleased with the strong results of our first quarter.  We remain focused on driving growth as we \ninvest again st the strategic high -growth opportunities in oncology and biopharma services.  This focus, combined \nwith our commitment to further evolve the portfolio, will drive significant value to our customers, shareholders and \npatients.  Our outlook for fiscal 2022 r eflects this focus and execution with healthy adjusted operating profit and \nadjusted earnings per share growth and return of capital to our shareholders.  \n \n", "original_text": "In closing, we're pleased with the strong results of our first quarter. "}, "hash": "c4170cbcb204063ec5a0c8f36669366be3154f83d5111a2ee57664288054f526", "class_name": "RelatedNodeInfo"}}, "text": "And our fiscal 2022 \nguidance continues to include share repurchases of approximately $2 billion for the full year.  \n \n", "start_char_idx": 725, "end_char_idx": 845, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4c6506e4-3e3e-4640-91c9-2038d6b0d05b": {"__data__": {"id_": "4c6506e4-3e3e-4640-91c9-2038d6b0d05b", "embedding": null, "metadata": {"window": "Our commitment to return cash to shareholders through dividend and share repurchases was recently highlighted \nby our Board's approval of a 12% increase to our quarterly dividend to $0.  47 per share.  And our fiscal 2022 \nguidance continues to include share repurchases of approximately $2 billion for the full year.  \n \n In closing, we're pleased with the strong results of our first quarter.  We remain focused on driving growth as we \ninvest again st the strategic high -growth opportunities in oncology and biopharma services.  This focus, combined \nwith our commitment to further evolve the portfolio, will drive significant value to our customers, shareholders and \npatients.  Our outlook for fiscal 2022 r eflects this focus and execution with healthy adjusted operating profit and \nadjusted earnings per share growth and return of capital to our shareholders.  \n \n", "original_text": "In closing, we're pleased with the strong results of our first quarter. ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e0b8dec75ff27983ca96d4af55e0aea224e2447bb3be43e6e44c8a7e7b83eb5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0e92bf9-c418-45e4-b477-6f7a015ad158", "node_type": "1", "metadata": {"window": "As a result of this \nactivity, McKesson holds approximately 95% of McKesson Europe's outstanding common shares, and we \nanticipate income attributable to non -controlling  interest in the range of $175 million to $195 million in fiscal 2022.  \n \n Our commitment to return cash to shareholders through dividend and share repurchases was recently highlighted \nby our Board's approval of a 12% increase to our quarterly dividend to $0.  47 per share.  And our fiscal 2022 \nguidance continues to include share repurchases of approximately $2 billion for the full year.  \n \n In closing, we're pleased with the strong results of our first quarter.  We remain focused on driving growth as we \ninvest again st the strategic high -growth opportunities in oncology and biopharma services.  This focus, combined \nwith our commitment to further evolve the portfolio, will drive significant value to our customers, shareholders and \npatients. ", "original_text": "And our fiscal 2022 \nguidance continues to include share repurchases of approximately $2 billion for the full year.  \n \n", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f7d63a53fbe7bb83e4130398ca6e05468ac0f69b05b20be547d1389725ca73f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc8a2e9f-40e5-40b0-9903-2e573b4380f2", "node_type": "1", "metadata": {"window": "47 per share.  And our fiscal 2022 \nguidance continues to include share repurchases of approximately $2 billion for the full year.  \n \n In closing, we're pleased with the strong results of our first quarter.  We remain focused on driving growth as we \ninvest again st the strategic high -growth opportunities in oncology and biopharma services.  This focus, combined \nwith our commitment to further evolve the portfolio, will drive significant value to our customers, shareholders and \npatients.  Our outlook for fiscal 2022 r eflects this focus and execution with healthy adjusted operating profit and \nadjusted earnings per share growth and return of capital to our shareholders.  \n \n And with that, Holly, let me turn it back to you for Q&A.  \n ", "original_text": "We remain focused on driving growth as we \ninvest again st the strategic high -growth opportunities in oncology and biopharma services. "}, "hash": "75bff914eed545325fc902f862ffbd4c86be1ba461df2f11a24686b7b1d04c2f", "class_name": "RelatedNodeInfo"}}, "text": "In closing, we're pleased with the strong results of our first quarter. ", "start_char_idx": 845, "end_char_idx": 917, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc8a2e9f-40e5-40b0-9903-2e573b4380f2": {"__data__": {"id_": "fc8a2e9f-40e5-40b0-9903-2e573b4380f2", "embedding": null, "metadata": {"window": "47 per share.  And our fiscal 2022 \nguidance continues to include share repurchases of approximately $2 billion for the full year.  \n \n In closing, we're pleased with the strong results of our first quarter.  We remain focused on driving growth as we \ninvest again st the strategic high -growth opportunities in oncology and biopharma services.  This focus, combined \nwith our commitment to further evolve the portfolio, will drive significant value to our customers, shareholders and \npatients.  Our outlook for fiscal 2022 r eflects this focus and execution with healthy adjusted operating profit and \nadjusted earnings per share growth and return of capital to our shareholders.  \n \n And with that, Holly, let me turn it back to you for Q&A.  \n ", "original_text": "We remain focused on driving growth as we \ninvest again st the strategic high -growth opportunities in oncology and biopharma services. ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e0b8dec75ff27983ca96d4af55e0aea224e2447bb3be43e6e44c8a7e7b83eb5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4c6506e4-3e3e-4640-91c9-2038d6b0d05b", "node_type": "1", "metadata": {"window": "Our commitment to return cash to shareholders through dividend and share repurchases was recently highlighted \nby our Board's approval of a 12% increase to our quarterly dividend to $0.  47 per share.  And our fiscal 2022 \nguidance continues to include share repurchases of approximately $2 billion for the full year.  \n \n In closing, we're pleased with the strong results of our first quarter.  We remain focused on driving growth as we \ninvest again st the strategic high -growth opportunities in oncology and biopharma services.  This focus, combined \nwith our commitment to further evolve the portfolio, will drive significant value to our customers, shareholders and \npatients.  Our outlook for fiscal 2022 r eflects this focus and execution with healthy adjusted operating profit and \nadjusted earnings per share growth and return of capital to our shareholders.  \n \n", "original_text": "In closing, we're pleased with the strong results of our first quarter. ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bba964d76ea78800585253df84c4cc79ee16ce176dfc04b3e5d3dec0003f348e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3cf5e5fb-d0c1-4ed4-9f0a-ee62cc1b2bdf", "node_type": "1", "metadata": {"window": "And our fiscal 2022 \nguidance continues to include share repurchases of approximately $2 billion for the full year.  \n \n In closing, we're pleased with the strong results of our first quarter.  We remain focused on driving growth as we \ninvest again st the strategic high -growth opportunities in oncology and biopharma services.  This focus, combined \nwith our commitment to further evolve the portfolio, will drive significant value to our customers, shareholders and \npatients.  Our outlook for fiscal 2022 r eflects this focus and execution with healthy adjusted operating profit and \nadjusted earnings per share growth and return of capital to our shareholders.  \n \n And with that, Holly, let me turn it back to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investo r Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n", "original_text": "This focus, combined \nwith our commitment to further evolve the portfolio, will drive significant value to our customers, shareholders and \npatients. "}, "hash": "8dc0518e29d6fff8dbc7ffa9c097fc9171dc7795c1196e0aa0649abb03d62db0", "class_name": "RelatedNodeInfo"}}, "text": "We remain focused on driving growth as we \ninvest again st the strategic high -growth opportunities in oncology and biopharma services. ", "start_char_idx": 917, "end_char_idx": 1053, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3cf5e5fb-d0c1-4ed4-9f0a-ee62cc1b2bdf": {"__data__": {"id_": "3cf5e5fb-d0c1-4ed4-9f0a-ee62cc1b2bdf", "embedding": null, "metadata": {"window": "And our fiscal 2022 \nguidance continues to include share repurchases of approximately $2 billion for the full year.  \n \n In closing, we're pleased with the strong results of our first quarter.  We remain focused on driving growth as we \ninvest again st the strategic high -growth opportunities in oncology and biopharma services.  This focus, combined \nwith our commitment to further evolve the portfolio, will drive significant value to our customers, shareholders and \npatients.  Our outlook for fiscal 2022 r eflects this focus and execution with healthy adjusted operating profit and \nadjusted earnings per share growth and return of capital to our shareholders.  \n \n And with that, Holly, let me turn it back to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investo r Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n", "original_text": "This focus, combined \nwith our commitment to further evolve the portfolio, will drive significant value to our customers, shareholders and \npatients. ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e0b8dec75ff27983ca96d4af55e0aea224e2447bb3be43e6e44c8a7e7b83eb5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc8a2e9f-40e5-40b0-9903-2e573b4380f2", "node_type": "1", "metadata": {"window": "47 per share.  And our fiscal 2022 \nguidance continues to include share repurchases of approximately $2 billion for the full year.  \n \n In closing, we're pleased with the strong results of our first quarter.  We remain focused on driving growth as we \ninvest again st the strategic high -growth opportunities in oncology and biopharma services.  This focus, combined \nwith our commitment to further evolve the portfolio, will drive significant value to our customers, shareholders and \npatients.  Our outlook for fiscal 2022 r eflects this focus and execution with healthy adjusted operating profit and \nadjusted earnings per share growth and return of capital to our shareholders.  \n \n And with that, Holly, let me turn it back to you for Q&A.  \n ", "original_text": "We remain focused on driving growth as we \ninvest again st the strategic high -growth opportunities in oncology and biopharma services. ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4f744248a85068e3d54e38c2caf91161102e3347eb1574e7d78ba147b76bb33a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2288b7bf-e6a2-4263-9570-5ee9482101f3", "node_type": "1", "metadata": {"window": "In closing, we're pleased with the strong results of our first quarter.  We remain focused on driving growth as we \ninvest again st the strategic high -growth opportunities in oncology and biopharma services.  This focus, combined \nwith our commitment to further evolve the portfolio, will drive significant value to our customers, shareholders and \npatients.  Our outlook for fiscal 2022 r eflects this focus and execution with healthy adjusted operating profit and \nadjusted earnings per share growth and return of capital to our shareholders.  \n \n And with that, Holly, let me turn it back to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investo r Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Britt. ", "original_text": "Our outlook for fiscal 2022 r eflects this focus and execution with healthy adjusted operating profit and \nadjusted earnings per share growth and return of capital to our shareholders.  \n \n"}, "hash": "8026bf9b316352e7db6bb7ac5fde7d0b3d2f91f772bbe41c71334b380cbaf9df", "class_name": "RelatedNodeInfo"}}, "text": "This focus, combined \nwith our commitment to further evolve the portfolio, will drive significant value to our customers, shareholders and \npatients. ", "start_char_idx": 1053, "end_char_idx": 1203, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2288b7bf-e6a2-4263-9570-5ee9482101f3": {"__data__": {"id_": "2288b7bf-e6a2-4263-9570-5ee9482101f3", "embedding": null, "metadata": {"window": "In closing, we're pleased with the strong results of our first quarter.  We remain focused on driving growth as we \ninvest again st the strategic high -growth opportunities in oncology and biopharma services.  This focus, combined \nwith our commitment to further evolve the portfolio, will drive significant value to our customers, shareholders and \npatients.  Our outlook for fiscal 2022 r eflects this focus and execution with healthy adjusted operating profit and \nadjusted earnings per share growth and return of capital to our shareholders.  \n \n And with that, Holly, let me turn it back to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investo r Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Britt. ", "original_text": "Our outlook for fiscal 2022 r eflects this focus and execution with healthy adjusted operating profit and \nadjusted earnings per share growth and return of capital to our shareholders.  \n \n", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e0b8dec75ff27983ca96d4af55e0aea224e2447bb3be43e6e44c8a7e7b83eb5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3cf5e5fb-d0c1-4ed4-9f0a-ee62cc1b2bdf", "node_type": "1", "metadata": {"window": "And our fiscal 2022 \nguidance continues to include share repurchases of approximately $2 billion for the full year.  \n \n In closing, we're pleased with the strong results of our first quarter.  We remain focused on driving growth as we \ninvest again st the strategic high -growth opportunities in oncology and biopharma services.  This focus, combined \nwith our commitment to further evolve the portfolio, will drive significant value to our customers, shareholders and \npatients.  Our outlook for fiscal 2022 r eflects this focus and execution with healthy adjusted operating profit and \nadjusted earnings per share growth and return of capital to our shareholders.  \n \n And with that, Holly, let me turn it back to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investo r Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n", "original_text": "This focus, combined \nwith our commitment to further evolve the portfolio, will drive significant value to our customers, shareholders and \npatients. ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e020cc71024ec1aa1212d4d56051a63f60094e760c0b5f06c81410275f9f2e38", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2636e969-eebc-4e5b-a1a2-a8c4c8e504c1", "node_type": "1", "metadata": {"window": "We remain focused on driving growth as we \ninvest again st the strategic high -growth opportunities in oncology and biopharma services.  This focus, combined \nwith our commitment to further evolve the portfolio, will drive significant value to our customers, shareholders and \npatients.  Our outlook for fiscal 2022 r eflects this focus and execution with healthy adjusted operating profit and \nadjusted earnings per share growth and return of capital to our shareholders.  \n \n And with that, Holly, let me turn it back to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investo r Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Britt.  I'll now turn the call over to the operator for your questions. ", "original_text": "And with that, Holly, let me turn it back to you for Q&A.  \n "}, "hash": "976d72c18d02f42ee91f5015e1140308c58e1ea12b0532ac422a71e019cfd789", "class_name": "RelatedNodeInfo"}}, "text": "Our outlook for fiscal 2022 r eflects this focus and execution with healthy adjusted operating profit and \nadjusted earnings per share growth and return of capital to our shareholders.  \n \n", "start_char_idx": 1203, "end_char_idx": 1392, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2636e969-eebc-4e5b-a1a2-a8c4c8e504c1": {"__data__": {"id_": "2636e969-eebc-4e5b-a1a2-a8c4c8e504c1", "embedding": null, "metadata": {"window": "We remain focused on driving growth as we \ninvest again st the strategic high -growth opportunities in oncology and biopharma services.  This focus, combined \nwith our commitment to further evolve the portfolio, will drive significant value to our customers, shareholders and \npatients.  Our outlook for fiscal 2022 r eflects this focus and execution with healthy adjusted operating profit and \nadjusted earnings per share growth and return of capital to our shareholders.  \n \n And with that, Holly, let me turn it back to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investo r Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Britt.  I'll now turn the call over to the operator for your questions. ", "original_text": "And with that, Holly, let me turn it back to you for Q&A.  \n ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e0b8dec75ff27983ca96d4af55e0aea224e2447bb3be43e6e44c8a7e7b83eb5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2288b7bf-e6a2-4263-9570-5ee9482101f3", "node_type": "1", "metadata": {"window": "In closing, we're pleased with the strong results of our first quarter.  We remain focused on driving growth as we \ninvest again st the strategic high -growth opportunities in oncology and biopharma services.  This focus, combined \nwith our commitment to further evolve the portfolio, will drive significant value to our customers, shareholders and \npatients.  Our outlook for fiscal 2022 r eflects this focus and execution with healthy adjusted operating profit and \nadjusted earnings per share growth and return of capital to our shareholders.  \n \n And with that, Holly, let me turn it back to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investo r Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Britt. ", "original_text": "Our outlook for fiscal 2022 r eflects this focus and execution with healthy adjusted operating profit and \nadjusted earnings per share growth and return of capital to our shareholders.  \n \n", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2cd5e64305a4cb60a72275ec4691d090db47a8d23c382d0f5c0ae9e6df8567c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "37e9e46c-2c49-4bc1-b3f7-f6ae4cee1e6b", "node_type": "1", "metadata": {"window": "This focus, combined \nwith our commitment to further evolve the portfolio, will drive significant value to our customers, shareholders and \npatients.  Our outlook for fiscal 2022 r eflects this focus and execution with healthy adjusted operating profit and \nadjusted earnings per share growth and return of capital to our shareholders.  \n \n And with that, Holly, let me turn it back to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investo r Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Britt.  I'll now turn the call over to the operator for your questions.  In the interest of time, I ask that you \nlimit yourself to just one question to allow others an opportunity to participate. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investo r Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n"}, "hash": "976ca8b2961504fe77ff0e1ffcec24a2c06ceb3af94eaf395781805e813549de", "class_name": "RelatedNodeInfo"}}, "text": "And with that, Holly, let me turn it back to you for Q&A.  \n ", "start_char_idx": 1392, "end_char_idx": 1453, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "37e9e46c-2c49-4bc1-b3f7-f6ae4cee1e6b": {"__data__": {"id_": "37e9e46c-2c49-4bc1-b3f7-f6ae4cee1e6b", "embedding": null, "metadata": {"window": "This focus, combined \nwith our commitment to further evolve the portfolio, will drive significant value to our customers, shareholders and \npatients.  Our outlook for fiscal 2022 r eflects this focus and execution with healthy adjusted operating profit and \nadjusted earnings per share growth and return of capital to our shareholders.  \n \n And with that, Holly, let me turn it back to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investo r Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Britt.  I'll now turn the call over to the operator for your questions.  In the interest of time, I ask that you \nlimit yourself to just one question to allow others an opportunity to participate. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investo r Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e0b8dec75ff27983ca96d4af55e0aea224e2447bb3be43e6e44c8a7e7b83eb5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2636e969-eebc-4e5b-a1a2-a8c4c8e504c1", "node_type": "1", "metadata": {"window": "We remain focused on driving growth as we \ninvest again st the strategic high -growth opportunities in oncology and biopharma services.  This focus, combined \nwith our commitment to further evolve the portfolio, will drive significant value to our customers, shareholders and \npatients.  Our outlook for fiscal 2022 r eflects this focus and execution with healthy adjusted operating profit and \nadjusted earnings per share growth and return of capital to our shareholders.  \n \n And with that, Holly, let me turn it back to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investo r Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Britt.  I'll now turn the call over to the operator for your questions. ", "original_text": "And with that, Holly, let me turn it back to you for Q&A.  \n ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "afbb505cd5418a694eb3da32cbd29542c7e4447b1b84fe10c512116eb192cdfc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e9126e70-1561-406a-b069-8ef9c86944aa", "node_type": "1", "metadata": {"window": "Our outlook for fiscal 2022 r eflects this focus and execution with healthy adjusted operating profit and \nadjusted earnings per share growth and return of capital to our shareholders.  \n \n And with that, Holly, let me turn it back to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investo r Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Britt.  I'll now turn the call over to the operator for your questions.  In the interest of time, I ask that you \nlimit yourself to just one question to allow others an opportunity to participate.  Operator?  \n ", "original_text": "Thank you, Britt. "}, "hash": "e7a8862890c3f616516737c3726fae59acb00d101438f5f383ffbc85db6579d5", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investo r Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n", "start_char_idx": 1453, "end_char_idx": 1829, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e9126e70-1561-406a-b069-8ef9c86944aa": {"__data__": {"id_": "e9126e70-1561-406a-b069-8ef9c86944aa", "embedding": null, "metadata": {"window": "Our outlook for fiscal 2022 r eflects this focus and execution with healthy adjusted operating profit and \nadjusted earnings per share growth and return of capital to our shareholders.  \n \n And with that, Holly, let me turn it back to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investo r Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Britt.  I'll now turn the call over to the operator for your questions.  In the interest of time, I ask that you \nlimit yourself to just one question to allow others an opportunity to participate.  Operator?  \n ", "original_text": "Thank you, Britt. ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e0b8dec75ff27983ca96d4af55e0aea224e2447bb3be43e6e44c8a7e7b83eb5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "37e9e46c-2c49-4bc1-b3f7-f6ae4cee1e6b", "node_type": "1", "metadata": {"window": "This focus, combined \nwith our commitment to further evolve the portfolio, will drive significant value to our customers, shareholders and \npatients.  Our outlook for fiscal 2022 r eflects this focus and execution with healthy adjusted operating profit and \nadjusted earnings per share growth and return of capital to our shareholders.  \n \n And with that, Holly, let me turn it back to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investo r Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Britt.  I'll now turn the call over to the operator for your questions.  In the interest of time, I ask that you \nlimit yourself to just one question to allow others an opportunity to participate. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investo r Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94b8ee0def5786a5fb2b59eabb6f8f93491f75acdeef590776f19ab63ca8f028", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c021e71-bd71-41ca-bc40-fbe1b2f7c3ac", "node_type": "1", "metadata": {"window": "And with that, Holly, let me turn it back to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investo r Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Britt.  I'll now turn the call over to the operator for your questions.  In the interest of time, I ask that you \nlimit yourself to just one question to allow others an opportunity to participate.  Operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....   \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "original_text": "I'll now turn the call over to the operator for your questions. "}, "hash": "261dc365b98142111dd87506703dbd4594c9e8ed0e9d8129ca4d294ebfc49da1", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, Britt. ", "start_char_idx": 1829, "end_char_idx": 1847, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4c021e71-bd71-41ca-bc40-fbe1b2f7c3ac": {"__data__": {"id_": "4c021e71-bd71-41ca-bc40-fbe1b2f7c3ac", "embedding": null, "metadata": {"window": "And with that, Holly, let me turn it back to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investo r Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Britt.  I'll now turn the call over to the operator for your questions.  In the interest of time, I ask that you \nlimit yourself to just one question to allow others an opportunity to participate.  Operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....   \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "original_text": "I'll now turn the call over to the operator for your questions. ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e0b8dec75ff27983ca96d4af55e0aea224e2447bb3be43e6e44c8a7e7b83eb5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e9126e70-1561-406a-b069-8ef9c86944aa", "node_type": "1", "metadata": {"window": "Our outlook for fiscal 2022 r eflects this focus and execution with healthy adjusted operating profit and \nadjusted earnings per share growth and return of capital to our shareholders.  \n \n And with that, Holly, let me turn it back to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investo r Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Britt.  I'll now turn the call over to the operator for your questions.  In the interest of time, I ask that you \nlimit yourself to just one question to allow others an opportunity to participate.  Operator?  \n ", "original_text": "Thank you, Britt. ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fcc0fc72bbaf3a88e88939e74c7f1e5d2cf82707a6b8963d5824e2ccde2ff9b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b6a4af3-ab75-44c6-93b1-fe98f40f91b3", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investo r Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Britt.  I'll now turn the call over to the operator for your questions.  In the interest of time, I ask that you \nlimit yourself to just one question to allow others an opportunity to participate.  Operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....   \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And we will go first to Brian Tanquilut of Jefferies.  \n ", "original_text": "In the interest of time, I ask that you \nlimit yourself to just one question to allow others an opportunity to participate. "}, "hash": "f479c5385fe577dc51b717a65a2868b374f1371c9ad195089ddd5e0507b92176", "class_name": "RelatedNodeInfo"}}, "text": "I'll now turn the call over to the operator for your questions. ", "start_char_idx": 1847, "end_char_idx": 1911, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b6a4af3-ab75-44c6-93b1-fe98f40f91b3": {"__data__": {"id_": "0b6a4af3-ab75-44c6-93b1-fe98f40f91b3", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investo r Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Britt.  I'll now turn the call over to the operator for your questions.  In the interest of time, I ask that you \nlimit yourself to just one question to allow others an opportunity to participate.  Operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....   \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And we will go first to Brian Tanquilut of Jefferies.  \n ", "original_text": "In the interest of time, I ask that you \nlimit yourself to just one question to allow others an opportunity to participate. ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e0b8dec75ff27983ca96d4af55e0aea224e2447bb3be43e6e44c8a7e7b83eb5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4c021e71-bd71-41ca-bc40-fbe1b2f7c3ac", "node_type": "1", "metadata": {"window": "And with that, Holly, let me turn it back to you for Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investo r Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Britt.  I'll now turn the call over to the operator for your questions.  In the interest of time, I ask that you \nlimit yourself to just one question to allow others an opportunity to participate.  Operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....   \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "original_text": "I'll now turn the call over to the operator for your questions. ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da4320b4c3577fd21e118252c245204750883b2169f1322170d0aac71230df8c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c3bb3c7-0aa3-49bc-8f1a-4a9a9f96b7de", "node_type": "1", "metadata": {"window": "Thank you, Britt.  I'll now turn the call over to the operator for your questions.  In the interest of time, I ask that you \nlimit yourself to just one question to allow others an opportunity to participate.  Operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....   \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And we will go first to Brian Tanquilut of Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey. ", "original_text": "Operator?  \n "}, "hash": "484aac785399b8d3bd80d9d313c5baec95f282ec3924d7fa79b3636c39455dc2", "class_name": "RelatedNodeInfo"}}, "text": "In the interest of time, I ask that you \nlimit yourself to just one question to allow others an opportunity to participate. ", "start_char_idx": 1911, "end_char_idx": 2035, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c3bb3c7-0aa3-49bc-8f1a-4a9a9f96b7de": {"__data__": {"id_": "0c3bb3c7-0aa3-49bc-8f1a-4a9a9f96b7de", "embedding": null, "metadata": {"window": "Thank you, Britt.  I'll now turn the call over to the operator for your questions.  In the interest of time, I ask that you \nlimit yourself to just one question to allow others an opportunity to participate.  Operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....   \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And we will go first to Brian Tanquilut of Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey. ", "original_text": "Operator?  \n ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e0b8dec75ff27983ca96d4af55e0aea224e2447bb3be43e6e44c8a7e7b83eb5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b6a4af3-ab75-44c6-93b1-fe98f40f91b3", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investo r Relations, Corporate FP&A, M&A Finance, McKesson Corp.  \n Thank you, Britt.  I'll now turn the call over to the operator for your questions.  In the interest of time, I ask that you \nlimit yourself to just one question to allow others an opportunity to participate.  Operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....   \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And we will go first to Brian Tanquilut of Jefferies.  \n ", "original_text": "In the interest of time, I ask that you \nlimit yourself to just one question to allow others an opportunity to participate. ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f90e7348fa4352b1f0348d405bf682bd68890c7396fefc0c29a4ee0ee11f21a1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f6331bd3-932a-4005-bed2-185cc5c192b0", "node_type": "1", "metadata": {"window": "I'll now turn the call over to the operator for your questions.  In the interest of time, I ask that you \nlimit yourself to just one question to allow others an opportunity to participate.  Operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....   \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And we will go first to Brian Tanquilut of Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....   \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. "}, "hash": "dd91c9a44b10df606d6f128f457d32cfc145ca458f51df73bcbf542d14ab65eb", "class_name": "RelatedNodeInfo"}}, "text": "Operator?  \n ", "start_char_idx": 2035, "end_char_idx": 2048, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f6331bd3-932a-4005-bed2-185cc5c192b0": {"__data__": {"id_": "f6331bd3-932a-4005-bed2-185cc5c192b0", "embedding": null, "metadata": {"window": "I'll now turn the call over to the operator for your questions.  In the interest of time, I ask that you \nlimit yourself to just one question to allow others an opportunity to participate.  Operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....   \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And we will go first to Brian Tanquilut of Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....   \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e0b8dec75ff27983ca96d4af55e0aea224e2447bb3be43e6e44c8a7e7b83eb5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c3bb3c7-0aa3-49bc-8f1a-4a9a9f96b7de", "node_type": "1", "metadata": {"window": "Thank you, Britt.  I'll now turn the call over to the operator for your questions.  In the interest of time, I ask that you \nlimit yourself to just one question to allow others an opportunity to participate.  Operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....   \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And we will go first to Brian Tanquilut of Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey. ", "original_text": "Operator?  \n ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8a7155c419a70f0d3be0f5e2df4f4493271ad85a19e10384c532cf1a1bbcb391", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "143aa5a0-df28-46b1-872e-fdee33a508dd", "node_type": "1", "metadata": {"window": "In the interest of time, I ask that you \nlimit yourself to just one question to allow others an opportunity to participate.  Operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....   \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And we will go first to Brian Tanquilut of Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Congrats on a very strong quarter. ", "original_text": "[Operator Instructions] And we will go first to Brian Tanquilut of Jefferies.  \n "}, "hash": "5b851733f6548d6b6b7ced62e66e3519d45ed14a157696dfa26b03a9fcff3cf3", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....   \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "start_char_idx": 2048, "end_char_idx": 2376, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "143aa5a0-df28-46b1-872e-fdee33a508dd": {"__data__": {"id_": "143aa5a0-df28-46b1-872e-fdee33a508dd", "embedding": null, "metadata": {"window": "In the interest of time, I ask that you \nlimit yourself to just one question to allow others an opportunity to participate.  Operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....   \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And we will go first to Brian Tanquilut of Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Congrats on a very strong quarter. ", "original_text": "[Operator Instructions] And we will go first to Brian Tanquilut of Jefferies.  \n ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e0b8dec75ff27983ca96d4af55e0aea224e2447bb3be43e6e44c8a7e7b83eb5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f6331bd3-932a-4005-bed2-185cc5c192b0", "node_type": "1", "metadata": {"window": "I'll now turn the call over to the operator for your questions.  In the interest of time, I ask that you \nlimit yourself to just one question to allow others an opportunity to participate.  Operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....   \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And we will go first to Brian Tanquilut of Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....   \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cbb8281724be060d01ca9b2230274c4ed0df91d86e7605a39f894179c0d91ce6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ba74fbb-c57e-4601-8ea2-155aa129bdfe", "node_type": "1", "metadata": {"window": "Operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....   \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And we will go first to Brian Tanquilut of Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Congrats on a very strong quarter.  I guess, Britt, as I think about the guidance, it \nlooks like it assumes a lower margin profile. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey. "}, "hash": "a37c9133277b828ecf3b428d58b0b6d05d882f66792058044e5c1a0fd33d6324", "class_name": "RelatedNodeInfo"}}, "text": "[Operator Instructions] And we will go first to Brian Tanquilut of Jefferies.  \n ", "start_char_idx": 2376, "end_char_idx": 2457, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ba74fbb-c57e-4601-8ea2-155aa129bdfe": {"__data__": {"id_": "1ba74fbb-c57e-4601-8ea2-155aa129bdfe", "embedding": null, "metadata": {"window": "Operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....   \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And we will go first to Brian Tanquilut of Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Congrats on a very strong quarter.  I guess, Britt, as I think about the guidance, it \nlooks like it assumes a lower margin profile. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey. ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e0b8dec75ff27983ca96d4af55e0aea224e2447bb3be43e6e44c8a7e7b83eb5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "143aa5a0-df28-46b1-872e-fdee33a508dd", "node_type": "1", "metadata": {"window": "In the interest of time, I ask that you \nlimit yourself to just one question to allow others an opportunity to participate.  Operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....   \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And we will go first to Brian Tanquilut of Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Congrats on a very strong quarter. ", "original_text": "[Operator Instructions] And we will go first to Brian Tanquilut of Jefferies.  \n ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c420fecbed09fcc974036b1d6a062b1b4cade949bccd446cb3f75471fbec2609", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c423ae50-c242-4415-99ac-64658b49f848", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....   \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And we will go first to Brian Tanquilut of Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Congrats on a very strong quarter.  I guess, Britt, as I think about the guidance, it \nlooks like it assumes a lower margin profile.  Just curious what you're thinking in terms of any \u2013 the puts and takes \nin the margins as we look forward to the next three quarters?  \n ", "original_text": "Good afternoon, guys. "}, "hash": "a4227d87bb04951d377576a950ea8574f84ca65f0eeb567f5c96322eee095532", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey. ", "start_char_idx": 2457, "end_char_idx": 2779, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c423ae50-c242-4415-99ac-64658b49f848": {"__data__": {"id_": "c423ae50-c242-4415-99ac-64658b49f848", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....   \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And we will go first to Brian Tanquilut of Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Congrats on a very strong quarter.  I guess, Britt, as I think about the guidance, it \nlooks like it assumes a lower margin profile.  Just curious what you're thinking in terms of any \u2013 the puts and takes \nin the margins as we look forward to the next three quarters?  \n ", "original_text": "Good afternoon, guys. ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e0b8dec75ff27983ca96d4af55e0aea224e2447bb3be43e6e44c8a7e7b83eb5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ba74fbb-c57e-4601-8ea2-155aa129bdfe", "node_type": "1", "metadata": {"window": "Operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....   \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And we will go first to Brian Tanquilut of Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Congrats on a very strong quarter.  I guess, Britt, as I think about the guidance, it \nlooks like it assumes a lower margin profile. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey. ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5efad60c82480ba7794c1a8f1f5b00ff620c5d9454572cd1dff90382df2f81a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "631d0015-2755-43f5-8a51-4d26bc27e167", "node_type": "1", "metadata": {"window": "[Operator Instructions] And we will go first to Brian Tanquilut of Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Congrats on a very strong quarter.  I guess, Britt, as I think about the guidance, it \nlooks like it assumes a lower margin profile.  Just curious what you're thinking in terms of any \u2013 the puts and takes \nin the margins as we look forward to the next three quarters?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "Congrats on a very strong quarter. "}, "hash": "3d00719136cf9d34697e9e630bf2cfca4df8eee09dc60a3b4af23246205eda0b", "class_name": "RelatedNodeInfo"}}, "text": "Good afternoon, guys. ", "start_char_idx": 2779, "end_char_idx": 2801, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "631d0015-2755-43f5-8a51-4d26bc27e167": {"__data__": {"id_": "631d0015-2755-43f5-8a51-4d26bc27e167", "embedding": null, "metadata": {"window": "[Operator Instructions] And we will go first to Brian Tanquilut of Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Congrats on a very strong quarter.  I guess, Britt, as I think about the guidance, it \nlooks like it assumes a lower margin profile.  Just curious what you're thinking in terms of any \u2013 the puts and takes \nin the margins as we look forward to the next three quarters?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "Congrats on a very strong quarter. ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e0b8dec75ff27983ca96d4af55e0aea224e2447bb3be43e6e44c8a7e7b83eb5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c423ae50-c242-4415-99ac-64658b49f848", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....   \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And we will go first to Brian Tanquilut of Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Congrats on a very strong quarter.  I guess, Britt, as I think about the guidance, it \nlooks like it assumes a lower margin profile.  Just curious what you're thinking in terms of any \u2013 the puts and takes \nin the margins as we look forward to the next three quarters?  \n ", "original_text": "Good afternoon, guys. ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c05c6383d34aa5c4b106321ff3ee219b73a1586a0e6f947f5424d4a9b6773b1a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac7f7f5b-58c5-47d2-8aad-ad811ea1b3c5", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Congrats on a very strong quarter.  I guess, Britt, as I think about the guidance, it \nlooks like it assumes a lower margin profile.  Just curious what you're thinking in terms of any \u2013 the puts and takes \nin the margins as we look forward to the next three quarters?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes, Brian, thanks for that question. ", "original_text": "I guess, Britt, as I think about the guidance, it \nlooks like it assumes a lower margin profile. "}, "hash": "52e6b5d1df6e79e7baa1077810c0d0732fc547924225cbf7b4cfcd97b73ade7f", "class_name": "RelatedNodeInfo"}}, "text": "Congrats on a very strong quarter. ", "start_char_idx": 2801, "end_char_idx": 2836, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac7f7f5b-58c5-47d2-8aad-ad811ea1b3c5": {"__data__": {"id_": "ac7f7f5b-58c5-47d2-8aad-ad811ea1b3c5", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Congrats on a very strong quarter.  I guess, Britt, as I think about the guidance, it \nlooks like it assumes a lower margin profile.  Just curious what you're thinking in terms of any \u2013 the puts and takes \nin the margins as we look forward to the next three quarters?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes, Brian, thanks for that question. ", "original_text": "I guess, Britt, as I think about the guidance, it \nlooks like it assumes a lower margin profile. ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e0b8dec75ff27983ca96d4af55e0aea224e2447bb3be43e6e44c8a7e7b83eb5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "631d0015-2755-43f5-8a51-4d26bc27e167", "node_type": "1", "metadata": {"window": "[Operator Instructions] And we will go first to Brian Tanquilut of Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Congrats on a very strong quarter.  I guess, Britt, as I think about the guidance, it \nlooks like it assumes a lower margin profile.  Just curious what you're thinking in terms of any \u2013 the puts and takes \nin the margins as we look forward to the next three quarters?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "Congrats on a very strong quarter. ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c3a3dc82bcfe551b3734a6c5aadcc5ba35974c002eb63b099a468a723490a331", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de0b1c8b-3631-4ba0-bd85-a2c2974a2df5", "node_type": "1", "metadata": {"window": "Good afternoon, guys.  Congrats on a very strong quarter.  I guess, Britt, as I think about the guidance, it \nlooks like it assumes a lower margin profile.  Just curious what you're thinking in terms of any \u2013 the puts and takes \nin the margins as we look forward to the next three quarters?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes, Brian, thanks for that question.  I'd remind you that this is our first quarter, and we had a very strong first \nquarter. ", "original_text": "Just curious what you're thinking in terms of any \u2013 the puts and takes \nin the margins as we look forward to the next three quarters?  \n "}, "hash": "120b564c0f796f6ed49296e9f7eacf35563055c37384fab96869cd9250dc72a9", "class_name": "RelatedNodeInfo"}}, "text": "I guess, Britt, as I think about the guidance, it \nlooks like it assumes a lower margin profile. ", "start_char_idx": 2836, "end_char_idx": 2933, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de0b1c8b-3631-4ba0-bd85-a2c2974a2df5": {"__data__": {"id_": "de0b1c8b-3631-4ba0-bd85-a2c2974a2df5", "embedding": null, "metadata": {"window": "Good afternoon, guys.  Congrats on a very strong quarter.  I guess, Britt, as I think about the guidance, it \nlooks like it assumes a lower margin profile.  Just curious what you're thinking in terms of any \u2013 the puts and takes \nin the margins as we look forward to the next three quarters?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes, Brian, thanks for that question.  I'd remind you that this is our first quarter, and we had a very strong first \nquarter. ", "original_text": "Just curious what you're thinking in terms of any \u2013 the puts and takes \nin the margins as we look forward to the next three quarters?  \n ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e0b8dec75ff27983ca96d4af55e0aea224e2447bb3be43e6e44c8a7e7b83eb5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac7f7f5b-58c5-47d2-8aad-ad811ea1b3c5", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Congrats on a very strong quarter.  I guess, Britt, as I think about the guidance, it \nlooks like it assumes a lower margin profile.  Just curious what you're thinking in terms of any \u2013 the puts and takes \nin the margins as we look forward to the next three quarters?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes, Brian, thanks for that question. ", "original_text": "I guess, Britt, as I think about the guidance, it \nlooks like it assumes a lower margin profile. ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0e38109b92d89992eb37f0cd7c6055e8f818c6c02f8ff31bcc21e1674f5efc40", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da5cb730-f75a-4b14-97b5-051be51ff3c1", "node_type": "1", "metadata": {"window": "Congrats on a very strong quarter.  I guess, Britt, as I think about the guidance, it \nlooks like it assumes a lower margin profile.  Just curious what you're thinking in terms of any \u2013 the puts and takes \nin the margins as we look forward to the next three quarters?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes, Brian, thanks for that question.  I'd remind you that this is our first quarter, and we had a very strong first \nquarter.  We're still in an evolving environment. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "b3ebb34536b7aaa74520af379e2517f4d044bd50c236ece3ed1fb82de37c637a", "class_name": "RelatedNodeInfo"}}, "text": "Just curious what you're thinking in terms of any \u2013 the puts and takes \nin the margins as we look forward to the next three quarters?  \n ", "start_char_idx": 2933, "end_char_idx": 3070, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da5cb730-f75a-4b14-97b5-051be51ff3c1": {"__data__": {"id_": "da5cb730-f75a-4b14-97b5-051be51ff3c1", "embedding": null, "metadata": {"window": "Congrats on a very strong quarter.  I guess, Britt, as I think about the guidance, it \nlooks like it assumes a lower margin profile.  Just curious what you're thinking in terms of any \u2013 the puts and takes \nin the margins as we look forward to the next three quarters?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes, Brian, thanks for that question.  I'd remind you that this is our first quarter, and we had a very strong first \nquarter.  We're still in an evolving environment. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e0b8dec75ff27983ca96d4af55e0aea224e2447bb3be43e6e44c8a7e7b83eb5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de0b1c8b-3631-4ba0-bd85-a2c2974a2df5", "node_type": "1", "metadata": {"window": "Good afternoon, guys.  Congrats on a very strong quarter.  I guess, Britt, as I think about the guidance, it \nlooks like it assumes a lower margin profile.  Just curious what you're thinking in terms of any \u2013 the puts and takes \nin the margins as we look forward to the next three quarters?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes, Brian, thanks for that question.  I'd remind you that this is our first quarter, and we had a very strong first \nquarter. ", "original_text": "Just curious what you're thinking in terms of any \u2013 the puts and takes \nin the margins as we look forward to the next three quarters?  \n ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b2758be332ea718fd690153bcd233184251ab5220c6e03098125dbf9ed19d15a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "90c61411-b935-4d66-89d0-c113f577147c", "node_type": "1", "metadata": {"window": "I guess, Britt, as I think about the guidance, it \nlooks like it assumes a lower margin profile.  Just curious what you're thinking in terms of any \u2013 the puts and takes \nin the margins as we look forward to the next three quarters?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes, Brian, thanks for that question.  I'd remind you that this is our first quarter, and we had a very strong first \nquarter.  We're still in an evolving environment.  We're very encouraged by the utilization trends and the \nimprovement that we're seeing. ", "original_text": "A \nYes, Brian, thanks for that question. "}, "hash": "b47039bfac24df25794ffb4abd80455b60ccfafe69922591362b0a1cde9fa38c", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 3070, "end_char_idx": 3427, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "90c61411-b935-4d66-89d0-c113f577147c": {"__data__": {"id_": "90c61411-b935-4d66-89d0-c113f577147c", "embedding": null, "metadata": {"window": "I guess, Britt, as I think about the guidance, it \nlooks like it assumes a lower margin profile.  Just curious what you're thinking in terms of any \u2013 the puts and takes \nin the margins as we look forward to the next three quarters?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes, Brian, thanks for that question.  I'd remind you that this is our first quarter, and we had a very strong first \nquarter.  We're still in an evolving environment.  We're very encouraged by the utilization trends and the \nimprovement that we're seeing. ", "original_text": "A \nYes, Brian, thanks for that question. ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e0b8dec75ff27983ca96d4af55e0aea224e2447bb3be43e6e44c8a7e7b83eb5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da5cb730-f75a-4b14-97b5-051be51ff3c1", "node_type": "1", "metadata": {"window": "Congrats on a very strong quarter.  I guess, Britt, as I think about the guidance, it \nlooks like it assumes a lower margin profile.  Just curious what you're thinking in terms of any \u2013 the puts and takes \nin the margins as we look forward to the next three quarters?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes, Brian, thanks for that question.  I'd remind you that this is our first quarter, and we had a very strong first \nquarter.  We're still in an evolving environment. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05554b84bac7e94713b9b1f6884b32ea15a01da38fbaf0b4d637bff609bbd864", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4be811f-78a1-47bf-9228-75519f672a0c", "node_type": "1", "metadata": {"window": "Just curious what you're thinking in terms of any \u2013 the puts and takes \nin the margins as we look forward to the next three quarters?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes, Brian, thanks for that question.  I'd remind you that this is our first quarter, and we had a very strong first \nquarter.  We're still in an evolving environment.  We're very encouraged by the utilization trends and the \nimprovement that we're seeing.  As we think about our US Pharmaceutical business, our growth, as I mentioned in \nmy remarks, was driven in large part by the growth of our largest customers. ", "original_text": "I'd remind you that this is our first quarter, and we had a very strong first \nquarter. "}, "hash": "a0e1be15bf1e668dcaf8103c24e6f6f31bbc642bef18302ff0592f1aaee188c5", "class_name": "RelatedNodeInfo"}}, "text": "A \nYes, Brian, thanks for that question. ", "start_char_idx": 3427, "end_char_idx": 3468, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4be811f-78a1-47bf-9228-75519f672a0c": {"__data__": {"id_": "d4be811f-78a1-47bf-9228-75519f672a0c", "embedding": null, "metadata": {"window": "Just curious what you're thinking in terms of any \u2013 the puts and takes \nin the margins as we look forward to the next three quarters?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes, Brian, thanks for that question.  I'd remind you that this is our first quarter, and we had a very strong first \nquarter.  We're still in an evolving environment.  We're very encouraged by the utilization trends and the \nimprovement that we're seeing.  As we think about our US Pharmaceutical business, our growth, as I mentioned in \nmy remarks, was driven in large part by the growth of our largest customers. ", "original_text": "I'd remind you that this is our first quarter, and we had a very strong first \nquarter. ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e0b8dec75ff27983ca96d4af55e0aea224e2447bb3be43e6e44c8a7e7b83eb5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "90c61411-b935-4d66-89d0-c113f577147c", "node_type": "1", "metadata": {"window": "I guess, Britt, as I think about the guidance, it \nlooks like it assumes a lower margin profile.  Just curious what you're thinking in terms of any \u2013 the puts and takes \nin the margins as we look forward to the next three quarters?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes, Brian, thanks for that question.  I'd remind you that this is our first quarter, and we had a very strong first \nquarter.  We're still in an evolving environment.  We're very encouraged by the utilization trends and the \nimprovement that we're seeing. ", "original_text": "A \nYes, Brian, thanks for that question. ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "32438e2f23433e98f59bcbba8862ec1ddf86e2f33cd9432f9f7422bbedb90754", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "37025b6e-078e-4d59-962c-5efa0cd1acdd", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes, Brian, thanks for that question.  I'd remind you that this is our first quarter, and we had a very strong first \nquarter.  We're still in an evolving environment.  We're very encouraged by the utilization trends and the \nimprovement that we're seeing.  As we think about our US Pharmaceutical business, our growth, as I mentioned in \nmy remarks, was driven in large part by the growth of our largest customers.  So, that does impact the mix and i t \ncertainly impacted the mix in the first quarter. ", "original_text": "We're still in an evolving environment. "}, "hash": "bcd94d04d2121924f6e84ddb5fcca89bf376cf4e0cc70b73794b379183aebc0e", "class_name": "RelatedNodeInfo"}}, "text": "I'd remind you that this is our first quarter, and we had a very strong first \nquarter. ", "start_char_idx": 3468, "end_char_idx": 3556, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "37025b6e-078e-4d59-962c-5efa0cd1acdd": {"__data__": {"id_": "37025b6e-078e-4d59-962c-5efa0cd1acdd", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes, Brian, thanks for that question.  I'd remind you that this is our first quarter, and we had a very strong first \nquarter.  We're still in an evolving environment.  We're very encouraged by the utilization trends and the \nimprovement that we're seeing.  As we think about our US Pharmaceutical business, our growth, as I mentioned in \nmy remarks, was driven in large part by the growth of our largest customers.  So, that does impact the mix and i t \ncertainly impacted the mix in the first quarter. ", "original_text": "We're still in an evolving environment. ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e0b8dec75ff27983ca96d4af55e0aea224e2447bb3be43e6e44c8a7e7b83eb5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4be811f-78a1-47bf-9228-75519f672a0c", "node_type": "1", "metadata": {"window": "Just curious what you're thinking in terms of any \u2013 the puts and takes \nin the margins as we look forward to the next three quarters?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes, Brian, thanks for that question.  I'd remind you that this is our first quarter, and we had a very strong first \nquarter.  We're still in an evolving environment.  We're very encouraged by the utilization trends and the \nimprovement that we're seeing.  As we think about our US Pharmaceutical business, our growth, as I mentioned in \nmy remarks, was driven in large part by the growth of our largest customers. ", "original_text": "I'd remind you that this is our first quarter, and we had a very strong first \nquarter. ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e5115c52808ef7b855c2bda8b7f01052a7aeb2033ddd1c9509fd27d8fbe771a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e9fa9b7b-5d5d-4623-8479-2e50292d902a", "node_type": "1", "metadata": {"window": "A \nYes, Brian, thanks for that question.  I'd remind you that this is our first quarter, and we had a very strong first \nquarter.  We're still in an evolving environment.  We're very encouraged by the utilization trends and the \nimprovement that we're seeing.  As we think about our US Pharmaceutical business, our growth, as I mentioned in \nmy remarks, was driven in large part by the growth of our largest customers.  So, that does impact the mix and i t \ncertainly impacted the mix in the first quarter.  And in our RxTS business, we have very healthy growth, as I \nmentioned, across all of our different capabilities. ", "original_text": "We're very encouraged by the utilization trends and the \nimprovement that we're seeing. "}, "hash": "139e305f912ca16889d8fa58075293b14bc53721cb7811709fdc49b577d2e735", "class_name": "RelatedNodeInfo"}}, "text": "We're still in an evolving environment. ", "start_char_idx": 3556, "end_char_idx": 3596, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e9fa9b7b-5d5d-4623-8479-2e50292d902a": {"__data__": {"id_": "e9fa9b7b-5d5d-4623-8479-2e50292d902a", "embedding": null, "metadata": {"window": "A \nYes, Brian, thanks for that question.  I'd remind you that this is our first quarter, and we had a very strong first \nquarter.  We're still in an evolving environment.  We're very encouraged by the utilization trends and the \nimprovement that we're seeing.  As we think about our US Pharmaceutical business, our growth, as I mentioned in \nmy remarks, was driven in large part by the growth of our largest customers.  So, that does impact the mix and i t \ncertainly impacted the mix in the first quarter.  And in our RxTS business, we have very healthy growth, as I \nmentioned, across all of our different capabilities. ", "original_text": "We're very encouraged by the utilization trends and the \nimprovement that we're seeing. ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e0b8dec75ff27983ca96d4af55e0aea224e2447bb3be43e6e44c8a7e7b83eb5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "37025b6e-078e-4d59-962c-5efa0cd1acdd", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes, Brian, thanks for that question.  I'd remind you that this is our first quarter, and we had a very strong first \nquarter.  We're still in an evolving environment.  We're very encouraged by the utilization trends and the \nimprovement that we're seeing.  As we think about our US Pharmaceutical business, our growth, as I mentioned in \nmy remarks, was driven in large part by the growth of our largest customers.  So, that does impact the mix and i t \ncertainly impacted the mix in the first quarter. ", "original_text": "We're still in an evolving environment. ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "253a5f3ec3030d5921174e523199000e9bb4331a9c328a4e1a7d17f6c9d707a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8baaad5b-1eb3-47a8-b551-77290a7fc9b9", "node_type": "1", "metadata": {"window": "I'd remind you that this is our first quarter, and we had a very strong first \nquarter.  We're still in an evolving environment.  We're very encouraged by the utilization trends and the \nimprovement that we're seeing.  As we think about our US Pharmaceutical business, our growth, as I mentioned in \nmy remarks, was driven in large part by the growth of our largest customers.  So, that does impact the mix and i t \ncertainly impacted the mix in the first quarter.  And in our RxTS business, we have very healthy growth, as I \nmentioned, across all of our different capabilities.  And some of the growth that we're seeing in that business, \nthey're again mix impacted by som e of our 3PL growth. ", "original_text": "As we think about our US Pharmaceutical business, our growth, as I mentioned in \nmy remarks, was driven in large part by the growth of our largest customers. "}, "hash": "a2c31032086ba211d775a9374aa1d673f020a2d763bc6824304dfc4ce17e44d0", "class_name": "RelatedNodeInfo"}}, "text": "We're very encouraged by the utilization trends and the \nimprovement that we're seeing. ", "start_char_idx": 3596, "end_char_idx": 3684, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8baaad5b-1eb3-47a8-b551-77290a7fc9b9": {"__data__": {"id_": "8baaad5b-1eb3-47a8-b551-77290a7fc9b9", "embedding": null, "metadata": {"window": "I'd remind you that this is our first quarter, and we had a very strong first \nquarter.  We're still in an evolving environment.  We're very encouraged by the utilization trends and the \nimprovement that we're seeing.  As we think about our US Pharmaceutical business, our growth, as I mentioned in \nmy remarks, was driven in large part by the growth of our largest customers.  So, that does impact the mix and i t \ncertainly impacted the mix in the first quarter.  And in our RxTS business, we have very healthy growth, as I \nmentioned, across all of our different capabilities.  And some of the growth that we're seeing in that business, \nthey're again mix impacted by som e of our 3PL growth. ", "original_text": "As we think about our US Pharmaceutical business, our growth, as I mentioned in \nmy remarks, was driven in large part by the growth of our largest customers. ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e0b8dec75ff27983ca96d4af55e0aea224e2447bb3be43e6e44c8a7e7b83eb5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e9fa9b7b-5d5d-4623-8479-2e50292d902a", "node_type": "1", "metadata": {"window": "A \nYes, Brian, thanks for that question.  I'd remind you that this is our first quarter, and we had a very strong first \nquarter.  We're still in an evolving environment.  We're very encouraged by the utilization trends and the \nimprovement that we're seeing.  As we think about our US Pharmaceutical business, our growth, as I mentioned in \nmy remarks, was driven in large part by the growth of our largest customers.  So, that does impact the mix and i t \ncertainly impacted the mix in the first quarter.  And in our RxTS business, we have very healthy growth, as I \nmentioned, across all of our different capabilities. ", "original_text": "We're very encouraged by the utilization trends and the \nimprovement that we're seeing. ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b789e3c1e4d2429ecde20db4d71f2b618833aed8b45a454dea8984e69407c15", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b417c3e-ebe8-4394-8570-4a3ac281a510", "node_type": "1", "metadata": {"window": "We're still in an evolving environment.  We're very encouraged by the utilization trends and the \nimprovement that we're seeing.  As we think about our US Pharmaceutical business, our growth, as I mentioned in \nmy remarks, was driven in large part by the growth of our largest customers.  So, that does impact the mix and i t \ncertainly impacted the mix in the first quarter.  And in our RxTS business, we have very healthy growth, as I \nmentioned, across all of our different capabilities.  And some of the growth that we're seeing in that business, \nthey're again mix impacted by som e of our 3PL growth.  We're very encouraged by the growth of our access and \nadherence solutions, particularly our AMP product. ", "original_text": "So, that does impact the mix and i t \ncertainly impacted the mix in the first quarter. "}, "hash": "0a4c330e8beb2b7422bcc628ca2f6d3b79ffc3bebb713168c81f70fce4018fb5", "class_name": "RelatedNodeInfo"}}, "text": "As we think about our US Pharmaceutical business, our growth, as I mentioned in \nmy remarks, was driven in large part by the growth of our largest customers. ", "start_char_idx": 3684, "end_char_idx": 3842, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b417c3e-ebe8-4394-8570-4a3ac281a510": {"__data__": {"id_": "7b417c3e-ebe8-4394-8570-4a3ac281a510", "embedding": null, "metadata": {"window": "We're still in an evolving environment.  We're very encouraged by the utilization trends and the \nimprovement that we're seeing.  As we think about our US Pharmaceutical business, our growth, as I mentioned in \nmy remarks, was driven in large part by the growth of our largest customers.  So, that does impact the mix and i t \ncertainly impacted the mix in the first quarter.  And in our RxTS business, we have very healthy growth, as I \nmentioned, across all of our different capabilities.  And some of the growth that we're seeing in that business, \nthey're again mix impacted by som e of our 3PL growth.  We're very encouraged by the growth of our access and \nadherence solutions, particularly our AMP product. ", "original_text": "So, that does impact the mix and i t \ncertainly impacted the mix in the first quarter. ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e0b8dec75ff27983ca96d4af55e0aea224e2447bb3be43e6e44c8a7e7b83eb5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8baaad5b-1eb3-47a8-b551-77290a7fc9b9", "node_type": "1", "metadata": {"window": "I'd remind you that this is our first quarter, and we had a very strong first \nquarter.  We're still in an evolving environment.  We're very encouraged by the utilization trends and the \nimprovement that we're seeing.  As we think about our US Pharmaceutical business, our growth, as I mentioned in \nmy remarks, was driven in large part by the growth of our largest customers.  So, that does impact the mix and i t \ncertainly impacted the mix in the first quarter.  And in our RxTS business, we have very healthy growth, as I \nmentioned, across all of our different capabilities.  And some of the growth that we're seeing in that business, \nthey're again mix impacted by som e of our 3PL growth. ", "original_text": "As we think about our US Pharmaceutical business, our growth, as I mentioned in \nmy remarks, was driven in large part by the growth of our largest customers. ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "60fd83f15100b255db1d0d31a6d7ac0f7b725c2ef912008f88bd69489dfb25b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ca81ea8-3915-4e54-95e7-870266e370a6", "node_type": "1", "metadata": {"window": "We're very encouraged by the utilization trends and the \nimprovement that we're seeing.  As we think about our US Pharmaceutical business, our growth, as I mentioned in \nmy remarks, was driven in large part by the growth of our largest customers.  So, that does impact the mix and i t \ncertainly impacted the mix in the first quarter.  And in our RxTS business, we have very healthy growth, as I \nmentioned, across all of our different capabilities.  And some of the growth that we're seeing in that business, \nthey're again mix impacted by som e of our 3PL growth.  We're very encouraged by the growth of our access and \nadherence solutions, particularly our AMP product.  But I think, as you think about this, it is really a reflection of the \nfirst quarter. ", "original_text": "And in our RxTS business, we have very healthy growth, as I \nmentioned, across all of our different capabilities. "}, "hash": "d1dbf4ef5b3989dff99103d68c53398e0ffa2fe6b45e708ab9c5ae0f6de19b2e", "class_name": "RelatedNodeInfo"}}, "text": "So, that does impact the mix and i t \ncertainly impacted the mix in the first quarter. ", "start_char_idx": 3842, "end_char_idx": 3929, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ca81ea8-3915-4e54-95e7-870266e370a6": {"__data__": {"id_": "6ca81ea8-3915-4e54-95e7-870266e370a6", "embedding": null, "metadata": {"window": "We're very encouraged by the utilization trends and the \nimprovement that we're seeing.  As we think about our US Pharmaceutical business, our growth, as I mentioned in \nmy remarks, was driven in large part by the growth of our largest customers.  So, that does impact the mix and i t \ncertainly impacted the mix in the first quarter.  And in our RxTS business, we have very healthy growth, as I \nmentioned, across all of our different capabilities.  And some of the growth that we're seeing in that business, \nthey're again mix impacted by som e of our 3PL growth.  We're very encouraged by the growth of our access and \nadherence solutions, particularly our AMP product.  But I think, as you think about this, it is really a reflection of the \nfirst quarter. ", "original_text": "And in our RxTS business, we have very healthy growth, as I \nmentioned, across all of our different capabilities. ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e0b8dec75ff27983ca96d4af55e0aea224e2447bb3be43e6e44c8a7e7b83eb5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b417c3e-ebe8-4394-8570-4a3ac281a510", "node_type": "1", "metadata": {"window": "We're still in an evolving environment.  We're very encouraged by the utilization trends and the \nimprovement that we're seeing.  As we think about our US Pharmaceutical business, our growth, as I mentioned in \nmy remarks, was driven in large part by the growth of our largest customers.  So, that does impact the mix and i t \ncertainly impacted the mix in the first quarter.  And in our RxTS business, we have very healthy growth, as I \nmentioned, across all of our different capabilities.  And some of the growth that we're seeing in that business, \nthey're again mix impacted by som e of our 3PL growth.  We're very encouraged by the growth of our access and \nadherence solutions, particularly our AMP product. ", "original_text": "So, that does impact the mix and i t \ncertainly impacted the mix in the first quarter. ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a8c1d61a05eff0aa96ef1507614c4063f0d7614e6f1f8e7b779ae69b8fb58e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71530429-5427-4f82-9895-26ad9f52b315", "node_type": "1", "metadata": {"window": "As we think about our US Pharmaceutical business, our growth, as I mentioned in \nmy remarks, was driven in large part by the growth of our largest customers.  So, that does impact the mix and i t \ncertainly impacted the mix in the first quarter.  And in our RxTS business, we have very healthy growth, as I \nmentioned, across all of our different capabilities.  And some of the growth that we're seeing in that business, \nthey're again mix impacted by som e of our 3PL growth.  We're very encouraged by the growth of our access and \nadherence solutions, particularly our AMP product.  But I think, as you think about this, it is really a reflection of the \nfirst quarter.  It's a reflection of the continued improveme nt in utilization and it's a reflection of some mix within \nsome of our segments.  \n ", "original_text": "And some of the growth that we're seeing in that business, \nthey're again mix impacted by som e of our 3PL growth. "}, "hash": "f05d89afb21da75da95bed1a9b266fe3a77d9aa23e535a6014ae4c58b5ef803d", "class_name": "RelatedNodeInfo"}}, "text": "And in our RxTS business, we have very healthy growth, as I \nmentioned, across all of our different capabilities. ", "start_char_idx": 3929, "end_char_idx": 4043, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71530429-5427-4f82-9895-26ad9f52b315": {"__data__": {"id_": "71530429-5427-4f82-9895-26ad9f52b315", "embedding": null, "metadata": {"window": "As we think about our US Pharmaceutical business, our growth, as I mentioned in \nmy remarks, was driven in large part by the growth of our largest customers.  So, that does impact the mix and i t \ncertainly impacted the mix in the first quarter.  And in our RxTS business, we have very healthy growth, as I \nmentioned, across all of our different capabilities.  And some of the growth that we're seeing in that business, \nthey're again mix impacted by som e of our 3PL growth.  We're very encouraged by the growth of our access and \nadherence solutions, particularly our AMP product.  But I think, as you think about this, it is really a reflection of the \nfirst quarter.  It's a reflection of the continued improveme nt in utilization and it's a reflection of some mix within \nsome of our segments.  \n ", "original_text": "And some of the growth that we're seeing in that business, \nthey're again mix impacted by som e of our 3PL growth. ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e0b8dec75ff27983ca96d4af55e0aea224e2447bb3be43e6e44c8a7e7b83eb5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ca81ea8-3915-4e54-95e7-870266e370a6", "node_type": "1", "metadata": {"window": "We're very encouraged by the utilization trends and the \nimprovement that we're seeing.  As we think about our US Pharmaceutical business, our growth, as I mentioned in \nmy remarks, was driven in large part by the growth of our largest customers.  So, that does impact the mix and i t \ncertainly impacted the mix in the first quarter.  And in our RxTS business, we have very healthy growth, as I \nmentioned, across all of our different capabilities.  And some of the growth that we're seeing in that business, \nthey're again mix impacted by som e of our 3PL growth.  We're very encouraged by the growth of our access and \nadherence solutions, particularly our AMP product.  But I think, as you think about this, it is really a reflection of the \nfirst quarter. ", "original_text": "And in our RxTS business, we have very healthy growth, as I \nmentioned, across all of our different capabilities. ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7ecb8b337de9f39900bb41c8a5009d92823450dd66655b2b27ce1bba3b7f20d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "197a3d0b-916d-4bb7-b4c5-c2e8180ad2a1", "node_type": "1", "metadata": {"window": "So, that does impact the mix and i t \ncertainly impacted the mix in the first quarter.  And in our RxTS business, we have very healthy growth, as I \nmentioned, across all of our different capabilities.  And some of the growth that we're seeing in that business, \nthey're again mix impacted by som e of our 3PL growth.  We're very encouraged by the growth of our access and \nadherence solutions, particularly our AMP product.  But I think, as you think about this, it is really a reflection of the \nfirst quarter.  It's a reflection of the continued improveme nt in utilization and it's a reflection of some mix within \nsome of our segments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "We're very encouraged by the growth of our access and \nadherence solutions, particularly our AMP product. "}, "hash": "7d360b6e7339e71197289199ac3c8f8e995114a5dfa2c6fb34b8cf7fc868306e", "class_name": "RelatedNodeInfo"}}, "text": "And some of the growth that we're seeing in that business, \nthey're again mix impacted by som e of our 3PL growth. ", "start_char_idx": 4043, "end_char_idx": 4158, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "197a3d0b-916d-4bb7-b4c5-c2e8180ad2a1": {"__data__": {"id_": "197a3d0b-916d-4bb7-b4c5-c2e8180ad2a1", "embedding": null, "metadata": {"window": "So, that does impact the mix and i t \ncertainly impacted the mix in the first quarter.  And in our RxTS business, we have very healthy growth, as I \nmentioned, across all of our different capabilities.  And some of the growth that we're seeing in that business, \nthey're again mix impacted by som e of our 3PL growth.  We're very encouraged by the growth of our access and \nadherence solutions, particularly our AMP product.  But I think, as you think about this, it is really a reflection of the \nfirst quarter.  It's a reflection of the continued improveme nt in utilization and it's a reflection of some mix within \nsome of our segments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "We're very encouraged by the growth of our access and \nadherence solutions, particularly our AMP product. ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e0b8dec75ff27983ca96d4af55e0aea224e2447bb3be43e6e44c8a7e7b83eb5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71530429-5427-4f82-9895-26ad9f52b315", "node_type": "1", "metadata": {"window": "As we think about our US Pharmaceutical business, our growth, as I mentioned in \nmy remarks, was driven in large part by the growth of our largest customers.  So, that does impact the mix and i t \ncertainly impacted the mix in the first quarter.  And in our RxTS business, we have very healthy growth, as I \nmentioned, across all of our different capabilities.  And some of the growth that we're seeing in that business, \nthey're again mix impacted by som e of our 3PL growth.  We're very encouraged by the growth of our access and \nadherence solutions, particularly our AMP product.  But I think, as you think about this, it is really a reflection of the \nfirst quarter.  It's a reflection of the continued improveme nt in utilization and it's a reflection of some mix within \nsome of our segments.  \n ", "original_text": "And some of the growth that we're seeing in that business, \nthey're again mix impacted by som e of our 3PL growth. ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "404eef794ddb9bc53c3f5291015bf33b180055dff93cb64f0302795fa09cf279", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "07e31e3b-f5c2-4fd8-b843-5f9a23160bf7", "node_type": "1", "metadata": {"window": "And in our RxTS business, we have very healthy growth, as I \nmentioned, across all of our different capabilities.  And some of the growth that we're seeing in that business, \nthey're again mix impacted by som e of our 3PL growth.  We're very encouraged by the growth of our access and \nadherence solutions, particularly our AMP product.  But I think, as you think about this, it is really a reflection of the \nfirst quarter.  It's a reflection of the continued improveme nt in utilization and it's a reflection of some mix within \nsome of our segments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "But I think, as you think about this, it is really a reflection of the \nfirst quarter. "}, "hash": "00b321ccb051b89ce510f6188fe285b4cb161577bb83e7c5e4ec855991bf9720", "class_name": "RelatedNodeInfo"}}, "text": "We're very encouraged by the growth of our access and \nadherence solutions, particularly our AMP product. ", "start_char_idx": 4158, "end_char_idx": 4264, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "07e31e3b-f5c2-4fd8-b843-5f9a23160bf7": {"__data__": {"id_": "07e31e3b-f5c2-4fd8-b843-5f9a23160bf7", "embedding": null, "metadata": {"window": "And in our RxTS business, we have very healthy growth, as I \nmentioned, across all of our different capabilities.  And some of the growth that we're seeing in that business, \nthey're again mix impacted by som e of our 3PL growth.  We're very encouraged by the growth of our access and \nadherence solutions, particularly our AMP product.  But I think, as you think about this, it is really a reflection of the \nfirst quarter.  It's a reflection of the continued improveme nt in utilization and it's a reflection of some mix within \nsome of our segments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "But I think, as you think about this, it is really a reflection of the \nfirst quarter. ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e0b8dec75ff27983ca96d4af55e0aea224e2447bb3be43e6e44c8a7e7b83eb5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "197a3d0b-916d-4bb7-b4c5-c2e8180ad2a1", "node_type": "1", "metadata": {"window": "So, that does impact the mix and i t \ncertainly impacted the mix in the first quarter.  And in our RxTS business, we have very healthy growth, as I \nmentioned, across all of our different capabilities.  And some of the growth that we're seeing in that business, \nthey're again mix impacted by som e of our 3PL growth.  We're very encouraged by the growth of our access and \nadherence solutions, particularly our AMP product.  But I think, as you think about this, it is really a reflection of the \nfirst quarter.  It's a reflection of the continued improveme nt in utilization and it's a reflection of some mix within \nsome of our segments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "We're very encouraged by the growth of our access and \nadherence solutions, particularly our AMP product. ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6043f84a10b61bbcb2f8ee19183854ed88c1cd41e041cb08070163e1f9ed183f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11a819b8-d2de-4f79-ba18-87bb3da02a80", "node_type": "1", "metadata": {"window": "And some of the growth that we're seeing in that business, \nthey're again mix impacted by som e of our 3PL growth.  We're very encouraged by the growth of our access and \nadherence solutions, particularly our AMP product.  But I think, as you think about this, it is really a reflection of the \nfirst quarter.  It's a reflection of the continued improveme nt in utilization and it's a reflection of some mix within \nsome of our segments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "It's a reflection of the continued improveme nt in utilization and it's a reflection of some mix within \nsome of our segments.  \n "}, "hash": "7c567bdd27fc755a506709b13d0749e11025bd901e017ae10e4c7ac0a7187e8a", "class_name": "RelatedNodeInfo"}}, "text": "But I think, as you think about this, it is really a reflection of the \nfirst quarter. ", "start_char_idx": 4264, "end_char_idx": 4351, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "11a819b8-d2de-4f79-ba18-87bb3da02a80": {"__data__": {"id_": "11a819b8-d2de-4f79-ba18-87bb3da02a80", "embedding": null, "metadata": {"window": "And some of the growth that we're seeing in that business, \nthey're again mix impacted by som e of our 3PL growth.  We're very encouraged by the growth of our access and \nadherence solutions, particularly our AMP product.  But I think, as you think about this, it is really a reflection of the \nfirst quarter.  It's a reflection of the continued improveme nt in utilization and it's a reflection of some mix within \nsome of our segments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "It's a reflection of the continued improveme nt in utilization and it's a reflection of some mix within \nsome of our segments.  \n ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e0b8dec75ff27983ca96d4af55e0aea224e2447bb3be43e6e44c8a7e7b83eb5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "07e31e3b-f5c2-4fd8-b843-5f9a23160bf7", "node_type": "1", "metadata": {"window": "And in our RxTS business, we have very healthy growth, as I \nmentioned, across all of our different capabilities.  And some of the growth that we're seeing in that business, \nthey're again mix impacted by som e of our 3PL growth.  We're very encouraged by the growth of our access and \nadherence solutions, particularly our AMP product.  But I think, as you think about this, it is really a reflection of the \nfirst quarter.  It's a reflection of the continued improveme nt in utilization and it's a reflection of some mix within \nsome of our segments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "But I think, as you think about this, it is really a reflection of the \nfirst quarter. ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "110701bb76aafbbf6d4e9a22f083ac8c711e29b055e53e153b44eb3e46517801", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "823137a0-b4b5-4ca1-ad3c-c94e0a806217", "node_type": "1", "metadata": {"window": "We're very encouraged by the growth of our access and \nadherence solutions, particularly our AMP product.  But I think, as you think about this, it is really a reflection of the \nfirst quarter.  It's a reflection of the continued improveme nt in utilization and it's a reflection of some mix within \nsome of our segments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  "}, "hash": "6e83b6e138669e26c64801b0ac6bd51736ed9f4e6f61c2fc4049221fe775ff54", "class_name": "RelatedNodeInfo"}}, "text": "It's a reflection of the continued improveme nt in utilization and it's a reflection of some mix within \nsome of our segments.  \n ", "start_char_idx": 4351, "end_char_idx": 4481, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "823137a0-b4b5-4ca1-ad3c-c94e0a806217": {"__data__": {"id_": "823137a0-b4b5-4ca1-ad3c-c94e0a806217", "embedding": null, "metadata": {"window": "We're very encouraged by the growth of our access and \nadherence solutions, particularly our AMP product.  But I think, as you think about this, it is really a reflection of the \nfirst quarter.  It's a reflection of the continued improveme nt in utilization and it's a reflection of some mix within \nsome of our segments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e0b8dec75ff27983ca96d4af55e0aea224e2447bb3be43e6e44c8a7e7b83eb5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "11a819b8-d2de-4f79-ba18-87bb3da02a80", "node_type": "1", "metadata": {"window": "And some of the growth that we're seeing in that business, \nthey're again mix impacted by som e of our 3PL growth.  We're very encouraged by the growth of our access and \nadherence solutions, particularly our AMP product.  But I think, as you think about this, it is really a reflection of the \nfirst quarter.  It's a reflection of the continued improveme nt in utilization and it's a reflection of some mix within \nsome of our segments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "It's a reflection of the continued improveme nt in utilization and it's a reflection of some mix within \nsome of our segments.  \n ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0819e2992bb28ef47de04df6f1fb6b3a4df7301273f4b7fa8bfc638224b552d4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bab42afd-3bef-446e-9f44-0a65112c306d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, we can go to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And thank you. ", "original_text": "McKesson Corp.  "}, "hash": "fe3ffd4d3c0792b76c7322066ca85def77902273373f5389f5950115d0bba260", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "start_char_idx": 1453, "end_char_idx": 1724, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bab42afd-3bef-446e-9f44-0a65112c306d": {"__data__": {"id_": "bab42afd-3bef-446e-9f44-0a65112c306d", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, we can go to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And thank you. ", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d8820044a651357ed8a686d0dd56bd471f4344aae1542225ed269dd25e75035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "823137a0-b4b5-4ca1-ad3c-c94e0a806217", "node_type": "1", "metadata": {"window": "We're very encouraged by the growth of our access and \nadherence solutions, particularly our AMP product.  But I think, as you think about this, it is really a reflection of the \nfirst quarter.  It's a reflection of the continued improveme nt in utilization and it's a reflection of some mix within \nsome of our segments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b84e47c648d928ebe53a43b99625aed94913119dac349bf69b1c776fe3d14e56", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8e087ca-56ed-46b1-9c2c-cccce6ef744f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, we can go to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And thank you.  We  will go next to Steven Valiquette of Barclays.  \n ", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  "}, "hash": "b241557d714369ed93756e7bc553dd90608b2bd75bf0f1b9d3a01346aef1ed2a", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8e087ca-56ed-46b1-9c2c-cccce6ef744f": {"__data__": {"id_": "f8e087ca-56ed-46b1-9c2c-cccce6ef744f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, we can go to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And thank you.  We  will go next to Steven Valiquette of Barclays.  \n ", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d8820044a651357ed8a686d0dd56bd471f4344aae1542225ed269dd25e75035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bab42afd-3bef-446e-9f44-0a65112c306d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, we can go to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And thank you. ", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da7808b70b5640c39f094117f57ca2c28f491ac3fe5bf17d36b2e78732972b5e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "08f9263f-8a90-461d-bbee-4ca01a427ca2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, we can go to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And thank you.  We  will go next to Steven Valiquette of Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "original_text": "A \nOperator, we can go to the next question.  \n "}, "hash": "039cb80493aa8411e6cf6e60bbf0e820ebcba8c288c22279a3ad38b6ec07f8ae", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "start_char_idx": 16, "end_char_idx": 283, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "08f9263f-8a90-461d-bbee-4ca01a427ca2": {"__data__": {"id_": "08f9263f-8a90-461d-bbee-4ca01a427ca2", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, we can go to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And thank you.  We  will go next to Steven Valiquette of Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "original_text": "A \nOperator, we can go to the next question.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d8820044a651357ed8a686d0dd56bd471f4344aae1542225ed269dd25e75035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8e087ca-56ed-46b1-9c2c-cccce6ef744f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, we can go to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And thank you.  We  will go next to Steven Valiquette of Barclays.  \n ", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "36b1a05cacd0ca500fff38805076a738a82140230542e36978a31b1862fa1341", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7f7bf429-619f-41c0-8f40-5e0a7b936c8c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, we can go to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And thank you.  We  will go next to Steven Valiquette of Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And thank you. "}, "hash": "52a0fc8c686596a3fbaf15c0f2c5597993aa8f7fa952ca7580f0a7b133c855fe", "class_name": "RelatedNodeInfo"}}, "text": "A \nOperator, we can go to the next question.  \n ", "start_char_idx": 283, "end_char_idx": 331, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7f7bf429-619f-41c0-8f40-5e0a7b936c8c": {"__data__": {"id_": "7f7bf429-619f-41c0-8f40-5e0a7b936c8c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, we can go to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And thank you.  We  will go next to Steven Valiquette of Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And thank you. ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d8820044a651357ed8a686d0dd56bd471f4344aae1542225ed269dd25e75035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "08f9263f-8a90-461d-bbee-4ca01a427ca2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, we can go to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And thank you.  We  will go next to Steven Valiquette of Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "original_text": "A \nOperator, we can go to the next question.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7092411c4bb514e5f799552980007ec6df811c468352ee151d01593a6f41b348", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d75e04f3-9696-46e0-ba59-c0b32f90c776", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, we can go to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And thank you.  We  will go next to Steven Valiquette of Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks. ", "original_text": "We  will go next to Steven Valiquette of Barclays.  \n "}, "hash": "1d15caa95b27b397d75b2761b0675aec63e8c312b694d500184f6ed3b19c33ad", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And thank you. ", "start_char_idx": 331, "end_char_idx": 631, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d75e04f3-9696-46e0-ba59-c0b32f90c776": {"__data__": {"id_": "d75e04f3-9696-46e0-ba59-c0b32f90c776", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, we can go to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And thank you.  We  will go next to Steven Valiquette of Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks. ", "original_text": "We  will go next to Steven Valiquette of Barclays.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d8820044a651357ed8a686d0dd56bd471f4344aae1542225ed269dd25e75035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7f7bf429-619f-41c0-8f40-5e0a7b936c8c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, we can go to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And thank you.  We  will go next to Steven Valiquette of Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And thank you. ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad316e91352e1888203f279f20cfb93f4746c49c135e8ebe67e9a537a6195e1b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "230eca0c-1d24-436f-870f-cca1fbe79e37", "node_type": "1", "metadata": {"window": "A \nOperator, we can go to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And thank you.  We  will go next to Steven Valiquette of Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good afternoon, everyone. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  "}, "hash": "dc98a6939cd090d0d18307e5c1dbb8924d9a964e74751bb2a2120bd4c8c6f28a", "class_name": "RelatedNodeInfo"}}, "text": "We  will go next to Steven Valiquette of Barclays.  \n ", "start_char_idx": 631, "end_char_idx": 685, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "230eca0c-1d24-436f-870f-cca1fbe79e37": {"__data__": {"id_": "230eca0c-1d24-436f-870f-cca1fbe79e37", "embedding": null, "metadata": {"window": "A \nOperator, we can go to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And thank you.  We  will go next to Steven Valiquette of Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good afternoon, everyone. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d8820044a651357ed8a686d0dd56bd471f4344aae1542225ed269dd25e75035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d75e04f3-9696-46e0-ba59-c0b32f90c776", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, we can go to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And thank you.  We  will go next to Steven Valiquette of Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks. ", "original_text": "We  will go next to Steven Valiquette of Barclays.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "86193a518506a55c46a1bf9d4fdf34278749762862091d465243adf6faf78252", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "12a7bce2-dc91-4bbc-ae43-2a1c8dc4f118", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And thank you.  We  will go next to Steven Valiquette of Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good afternoon, everyone.  Thanks for taking the question. ", "original_text": "Q \nGreat. "}, "hash": "4ba8af5f3a201849042bc0b1e480da217fde6093f8b266428b982417d7721271", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "start_char_idx": 685, "end_char_idx": 1010, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "12a7bce2-dc91-4bbc-ae43-2a1c8dc4f118": {"__data__": {"id_": "12a7bce2-dc91-4bbc-ae43-2a1c8dc4f118", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And thank you.  We  will go next to Steven Valiquette of Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good afternoon, everyone.  Thanks for taking the question. ", "original_text": "Q \nGreat. ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d8820044a651357ed8a686d0dd56bd471f4344aae1542225ed269dd25e75035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "230eca0c-1d24-436f-870f-cca1fbe79e37", "node_type": "1", "metadata": {"window": "A \nOperator, we can go to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And thank you.  We  will go next to Steven Valiquette of Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good afternoon, everyone. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "91be1ca3c1a69bc3322bcac45783c8770495dc49d1ad582c3039739cac5fba93", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b5a66ff8-e6b3-447d-b683-21623b948b06", "node_type": "1", "metadata": {"window": "We  will go next to Steven Valiquette of Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good afternoon, everyone.  Thanks for taking the question.  I guess if we go back to when \nMcKesson acquired the European assets seven, eight  years ago, one of the drivers of the deal was to increase \nMcKesson's generic drug purchasing power. ", "original_text": "Thanks. "}, "hash": "323e7826d104386db9915e0c1f6b7374f6b46b2ce7a9795152318a7811095b99", "class_name": "RelatedNodeInfo"}}, "text": "Q \nGreat. ", "start_char_idx": 1010, "end_char_idx": 1020, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b5a66ff8-e6b3-447d-b683-21623b948b06": {"__data__": {"id_": "b5a66ff8-e6b3-447d-b683-21623b948b06", "embedding": null, "metadata": {"window": "We  will go next to Steven Valiquette of Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good afternoon, everyone.  Thanks for taking the question.  I guess if we go back to when \nMcKesson acquired the European assets seven, eight  years ago, one of the drivers of the deal was to increase \nMcKesson's generic drug purchasing power. ", "original_text": "Thanks. ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d8820044a651357ed8a686d0dd56bd471f4344aae1542225ed269dd25e75035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "12a7bce2-dc91-4bbc-ae43-2a1c8dc4f118", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And thank you.  We  will go next to Steven Valiquette of Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good afternoon, everyone.  Thanks for taking the question. ", "original_text": "Q \nGreat. ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c44db06e9e6f7b1749f84f2fe9243358c414351e4ef8ab0a19b79b7400f2383", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "315ebb76-7b06-412e-afaf-b3a2c2c27d23", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good afternoon, everyone.  Thanks for taking the question.  I guess if we go back to when \nMcKesson acquired the European assets seven, eight  years ago, one of the drivers of the deal was to increase \nMcKesson's generic drug purchasing power.  I guess, by announcing the sale to PHOENIX, my sense is you're \nprobably not too worried about any dissynergies related to less generic purchasing power you  went [ph] and did \n(00:38:32) the transaction.  \n \n", "original_text": "Good afternoon, everyone. "}, "hash": "30d8c8d5c9f0c2bf27ba8ea2bd57140782ba37dbcf23f14d191cb7edc7d0c64b", "class_name": "RelatedNodeInfo"}}, "text": "Thanks. ", "start_char_idx": 1020, "end_char_idx": 1028, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "315ebb76-7b06-412e-afaf-b3a2c2c27d23": {"__data__": {"id_": "315ebb76-7b06-412e-afaf-b3a2c2c27d23", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good afternoon, everyone.  Thanks for taking the question.  I guess if we go back to when \nMcKesson acquired the European assets seven, eight  years ago, one of the drivers of the deal was to increase \nMcKesson's generic drug purchasing power.  I guess, by announcing the sale to PHOENIX, my sense is you're \nprobably not too worried about any dissynergies related to less generic purchasing power you  went [ph] and did \n(00:38:32) the transaction.  \n \n", "original_text": "Good afternoon, everyone. ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d8820044a651357ed8a686d0dd56bd471f4344aae1542225ed269dd25e75035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b5a66ff8-e6b3-447d-b683-21623b948b06", "node_type": "1", "metadata": {"window": "We  will go next to Steven Valiquette of Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good afternoon, everyone.  Thanks for taking the question.  I guess if we go back to when \nMcKesson acquired the European assets seven, eight  years ago, one of the drivers of the deal was to increase \nMcKesson's generic drug purchasing power. ", "original_text": "Thanks. ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3c7f6bf09065cebe9cbc8bbbd5ca7286bfca55b80a44421623a26f9b7e44262f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4041f63d-ec98-42d7-a8af-df1830364314", "node_type": "1", "metadata": {"window": "Q \nGreat.  Thanks.  Good afternoon, everyone.  Thanks for taking the question.  I guess if we go back to when \nMcKesson acquired the European assets seven, eight  years ago, one of the drivers of the deal was to increase \nMcKesson's generic drug purchasing power.  I guess, by announcing the sale to PHOENIX, my sense is you're \nprobably not too worried about any dissynergies related to less generic purchasing power you  went [ph] and did \n(00:38:32) the transaction.  \n \n So, I guess, I'm just curious to hear a little more about McKesson's purchasing power today, whether it's \nClarusONE or other factors, such that the additional European purchasing power is less critical. ", "original_text": "Thanks for taking the question. "}, "hash": "a892c7ec980e71ae0257f42c180ece2accba3300787b346a4535f2ab786b6762", "class_name": "RelatedNodeInfo"}}, "text": "Good afternoon, everyone. ", "start_char_idx": 1028, "end_char_idx": 1054, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4041f63d-ec98-42d7-a8af-df1830364314": {"__data__": {"id_": "4041f63d-ec98-42d7-a8af-df1830364314", "embedding": null, "metadata": {"window": "Q \nGreat.  Thanks.  Good afternoon, everyone.  Thanks for taking the question.  I guess if we go back to when \nMcKesson acquired the European assets seven, eight  years ago, one of the drivers of the deal was to increase \nMcKesson's generic drug purchasing power.  I guess, by announcing the sale to PHOENIX, my sense is you're \nprobably not too worried about any dissynergies related to less generic purchasing power you  went [ph] and did \n(00:38:32) the transaction.  \n \n So, I guess, I'm just curious to hear a little more about McKesson's purchasing power today, whether it's \nClarusONE or other factors, such that the additional European purchasing power is less critical. ", "original_text": "Thanks for taking the question. ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d8820044a651357ed8a686d0dd56bd471f4344aae1542225ed269dd25e75035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "315ebb76-7b06-412e-afaf-b3a2c2c27d23", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteven Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nGreat.  Thanks.  Good afternoon, everyone.  Thanks for taking the question.  I guess if we go back to when \nMcKesson acquired the European assets seven, eight  years ago, one of the drivers of the deal was to increase \nMcKesson's generic drug purchasing power.  I guess, by announcing the sale to PHOENIX, my sense is you're \nprobably not too worried about any dissynergies related to less generic purchasing power you  went [ph] and did \n(00:38:32) the transaction.  \n \n", "original_text": "Good afternoon, everyone. ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc5694c3204aabe0f56cffc136448fcace23249927d18269798d1adcf7be6101", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8785d3a1-2b62-42cc-860c-bbdf88c2f04d", "node_type": "1", "metadata": {"window": "Thanks.  Good afternoon, everyone.  Thanks for taking the question.  I guess if we go back to when \nMcKesson acquired the European assets seven, eight  years ago, one of the drivers of the deal was to increase \nMcKesson's generic drug purchasing power.  I guess, by announcing the sale to PHOENIX, my sense is you're \nprobably not too worried about any dissynergies related to less generic purchasing power you  went [ph] and did \n(00:38:32) the transaction.  \n \n So, I guess, I'm just curious to hear a little more about McKesson's purchasing power today, whether it's \nClarusONE or other factors, such that the additional European purchasing power is less critical.  And j ust to make \nsure we're not missing anything around this too, hopefully, well, I guess, is there any post -deal agreement \nbetween McKesson and PHOENIX on generic purchasing collaboration, or was that even explored? ", "original_text": "I guess if we go back to when \nMcKesson acquired the European assets seven, eight  years ago, one of the drivers of the deal was to increase \nMcKesson's generic drug purchasing power. "}, "hash": "67f39dfd23f863673bf5016721a09d6b17abf28e93979ffee3814abf16705932", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking the question. ", "start_char_idx": 1054, "end_char_idx": 1086, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8785d3a1-2b62-42cc-860c-bbdf88c2f04d": {"__data__": {"id_": "8785d3a1-2b62-42cc-860c-bbdf88c2f04d", "embedding": null, "metadata": {"window": "Thanks.  Good afternoon, everyone.  Thanks for taking the question.  I guess if we go back to when \nMcKesson acquired the European assets seven, eight  years ago, one of the drivers of the deal was to increase \nMcKesson's generic drug purchasing power.  I guess, by announcing the sale to PHOENIX, my sense is you're \nprobably not too worried about any dissynergies related to less generic purchasing power you  went [ph] and did \n(00:38:32) the transaction.  \n \n So, I guess, I'm just curious to hear a little more about McKesson's purchasing power today, whether it's \nClarusONE or other factors, such that the additional European purchasing power is less critical.  And j ust to make \nsure we're not missing anything around this too, hopefully, well, I guess, is there any post -deal agreement \nbetween McKesson and PHOENIX on generic purchasing collaboration, or was that even explored? ", "original_text": "I guess if we go back to when \nMcKesson acquired the European assets seven, eight  years ago, one of the drivers of the deal was to increase \nMcKesson's generic drug purchasing power. ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d8820044a651357ed8a686d0dd56bd471f4344aae1542225ed269dd25e75035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4041f63d-ec98-42d7-a8af-df1830364314", "node_type": "1", "metadata": {"window": "Q \nGreat.  Thanks.  Good afternoon, everyone.  Thanks for taking the question.  I guess if we go back to when \nMcKesson acquired the European assets seven, eight  years ago, one of the drivers of the deal was to increase \nMcKesson's generic drug purchasing power.  I guess, by announcing the sale to PHOENIX, my sense is you're \nprobably not too worried about any dissynergies related to less generic purchasing power you  went [ph] and did \n(00:38:32) the transaction.  \n \n So, I guess, I'm just curious to hear a little more about McKesson's purchasing power today, whether it's \nClarusONE or other factors, such that the additional European purchasing power is less critical. ", "original_text": "Thanks for taking the question. ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2052f508b94280559026356cab15fc36b52f414b67e97b59aa11ecba6bf5732e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a2ef531-5d01-4aa0-b0f6-5bf5d105c782", "node_type": "1", "metadata": {"window": "Good afternoon, everyone.  Thanks for taking the question.  I guess if we go back to when \nMcKesson acquired the European assets seven, eight  years ago, one of the drivers of the deal was to increase \nMcKesson's generic drug purchasing power.  I guess, by announcing the sale to PHOENIX, my sense is you're \nprobably not too worried about any dissynergies related to less generic purchasing power you  went [ph] and did \n(00:38:32) the transaction.  \n \n So, I guess, I'm just curious to hear a little more about McKesson's purchasing power today, whether it's \nClarusONE or other factors, such that the additional European purchasing power is less critical.  And j ust to make \nsure we're not missing anything around this too, hopefully, well, I guess, is there any post -deal agreement \nbetween McKesson and PHOENIX on generic purchasing collaboration, or was that even explored?  Thanks.  \n ", "original_text": "I guess, by announcing the sale to PHOENIX, my sense is you're \nprobably not too worried about any dissynergies related to less generic purchasing power you  went [ph] and did \n(00:38:32) the transaction.  \n \n"}, "hash": "15fc7380a4d7b1bd6b0ba544a6668724c165821019412974b1ad65a81be67cce", "class_name": "RelatedNodeInfo"}}, "text": "I guess if we go back to when \nMcKesson acquired the European assets seven, eight  years ago, one of the drivers of the deal was to increase \nMcKesson's generic drug purchasing power. ", "start_char_idx": 1086, "end_char_idx": 1270, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a2ef531-5d01-4aa0-b0f6-5bf5d105c782": {"__data__": {"id_": "5a2ef531-5d01-4aa0-b0f6-5bf5d105c782", "embedding": null, "metadata": {"window": "Good afternoon, everyone.  Thanks for taking the question.  I guess if we go back to when \nMcKesson acquired the European assets seven, eight  years ago, one of the drivers of the deal was to increase \nMcKesson's generic drug purchasing power.  I guess, by announcing the sale to PHOENIX, my sense is you're \nprobably not too worried about any dissynergies related to less generic purchasing power you  went [ph] and did \n(00:38:32) the transaction.  \n \n So, I guess, I'm just curious to hear a little more about McKesson's purchasing power today, whether it's \nClarusONE or other factors, such that the additional European purchasing power is less critical.  And j ust to make \nsure we're not missing anything around this too, hopefully, well, I guess, is there any post -deal agreement \nbetween McKesson and PHOENIX on generic purchasing collaboration, or was that even explored?  Thanks.  \n ", "original_text": "I guess, by announcing the sale to PHOENIX, my sense is you're \nprobably not too worried about any dissynergies related to less generic purchasing power you  went [ph] and did \n(00:38:32) the transaction.  \n \n", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d8820044a651357ed8a686d0dd56bd471f4344aae1542225ed269dd25e75035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8785d3a1-2b62-42cc-860c-bbdf88c2f04d", "node_type": "1", "metadata": {"window": "Thanks.  Good afternoon, everyone.  Thanks for taking the question.  I guess if we go back to when \nMcKesson acquired the European assets seven, eight  years ago, one of the drivers of the deal was to increase \nMcKesson's generic drug purchasing power.  I guess, by announcing the sale to PHOENIX, my sense is you're \nprobably not too worried about any dissynergies related to less generic purchasing power you  went [ph] and did \n(00:38:32) the transaction.  \n \n So, I guess, I'm just curious to hear a little more about McKesson's purchasing power today, whether it's \nClarusONE or other factors, such that the additional European purchasing power is less critical.  And j ust to make \nsure we're not missing anything around this too, hopefully, well, I guess, is there any post -deal agreement \nbetween McKesson and PHOENIX on generic purchasing collaboration, or was that even explored? ", "original_text": "I guess if we go back to when \nMcKesson acquired the European assets seven, eight  years ago, one of the drivers of the deal was to increase \nMcKesson's generic drug purchasing power. ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c68750225bba81fc603ef89cac890fbbc374b1aea98f3292432b9b0cedea5a3a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3388c6d0-84af-4c49-827a-a0d85bdc5d61", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  I guess if we go back to when \nMcKesson acquired the European assets seven, eight  years ago, one of the drivers of the deal was to increase \nMcKesson's generic drug purchasing power.  I guess, by announcing the sale to PHOENIX, my sense is you're \nprobably not too worried about any dissynergies related to less generic purchasing power you  went [ph] and did \n(00:38:32) the transaction.  \n \n So, I guess, I'm just curious to hear a little more about McKesson's purchasing power today, whether it's \nClarusONE or other factors, such that the additional European purchasing power is less critical.  And j ust to make \nsure we're not missing anything around this too, hopefully, well, I guess, is there any post -deal agreement \nbetween McKesson and PHOENIX on generic purchasing collaboration, or was that even explored?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive  Officer & Director, McKesson Corp.  ", "original_text": "So, I guess, I'm just curious to hear a little more about McKesson's purchasing power today, whether it's \nClarusONE or other factors, such that the additional European purchasing power is less critical. "}, "hash": "1ee86ceec72f8259a992dce6c2743dcaace55e86a5bf48e856bab6034315f3d0", "class_name": "RelatedNodeInfo"}}, "text": "I guess, by announcing the sale to PHOENIX, my sense is you're \nprobably not too worried about any dissynergies related to less generic purchasing power you  went [ph] and did \n(00:38:32) the transaction.  \n \n", "start_char_idx": 1270, "end_char_idx": 1479, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3388c6d0-84af-4c49-827a-a0d85bdc5d61": {"__data__": {"id_": "3388c6d0-84af-4c49-827a-a0d85bdc5d61", "embedding": null, "metadata": {"window": "Thanks for taking the question.  I guess if we go back to when \nMcKesson acquired the European assets seven, eight  years ago, one of the drivers of the deal was to increase \nMcKesson's generic drug purchasing power.  I guess, by announcing the sale to PHOENIX, my sense is you're \nprobably not too worried about any dissynergies related to less generic purchasing power you  went [ph] and did \n(00:38:32) the transaction.  \n \n So, I guess, I'm just curious to hear a little more about McKesson's purchasing power today, whether it's \nClarusONE or other factors, such that the additional European purchasing power is less critical.  And j ust to make \nsure we're not missing anything around this too, hopefully, well, I guess, is there any post -deal agreement \nbetween McKesson and PHOENIX on generic purchasing collaboration, or was that even explored?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive  Officer & Director, McKesson Corp.  ", "original_text": "So, I guess, I'm just curious to hear a little more about McKesson's purchasing power today, whether it's \nClarusONE or other factors, such that the additional European purchasing power is less critical. ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d8820044a651357ed8a686d0dd56bd471f4344aae1542225ed269dd25e75035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a2ef531-5d01-4aa0-b0f6-5bf5d105c782", "node_type": "1", "metadata": {"window": "Good afternoon, everyone.  Thanks for taking the question.  I guess if we go back to when \nMcKesson acquired the European assets seven, eight  years ago, one of the drivers of the deal was to increase \nMcKesson's generic drug purchasing power.  I guess, by announcing the sale to PHOENIX, my sense is you're \nprobably not too worried about any dissynergies related to less generic purchasing power you  went [ph] and did \n(00:38:32) the transaction.  \n \n So, I guess, I'm just curious to hear a little more about McKesson's purchasing power today, whether it's \nClarusONE or other factors, such that the additional European purchasing power is less critical.  And j ust to make \nsure we're not missing anything around this too, hopefully, well, I guess, is there any post -deal agreement \nbetween McKesson and PHOENIX on generic purchasing collaboration, or was that even explored?  Thanks.  \n ", "original_text": "I guess, by announcing the sale to PHOENIX, my sense is you're \nprobably not too worried about any dissynergies related to less generic purchasing power you  went [ph] and did \n(00:38:32) the transaction.  \n \n", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "03847a4d6912cde9601e4c3bdc21b10100a6602ea8737bef25780274d449d7de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1ec5cc6-3e86-4653-a270-915a41515cfa", "node_type": "1", "metadata": {"window": "I guess if we go back to when \nMcKesson acquired the European assets seven, eight  years ago, one of the drivers of the deal was to increase \nMcKesson's generic drug purchasing power.  I guess, by announcing the sale to PHOENIX, my sense is you're \nprobably not too worried about any dissynergies related to less generic purchasing power you  went [ph] and did \n(00:38:32) the transaction.  \n \n So, I guess, I'm just curious to hear a little more about McKesson's purchasing power today, whether it's \nClarusONE or other factors, such that the additional European purchasing power is less critical.  And j ust to make \nsure we're not missing anything around this too, hopefully, well, I guess, is there any post -deal agreement \nbetween McKesson and PHOENIX on generic purchasing collaboration, or was that even explored?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive  Officer & Director, McKesson Corp.   A \nThank you for the questions. ", "original_text": "And j ust to make \nsure we're not missing anything around this too, hopefully, well, I guess, is there any post -deal agreement \nbetween McKesson and PHOENIX on generic purchasing collaboration, or was that even explored? "}, "hash": "8b8ef9b8cec3658c7b1b3269e056c9ecbd1e1157512bfabf90c70d944be0387c", "class_name": "RelatedNodeInfo"}}, "text": "So, I guess, I'm just curious to hear a little more about McKesson's purchasing power today, whether it's \nClarusONE or other factors, such that the additional European purchasing power is less critical. ", "start_char_idx": 1479, "end_char_idx": 1683, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1ec5cc6-3e86-4653-a270-915a41515cfa": {"__data__": {"id_": "b1ec5cc6-3e86-4653-a270-915a41515cfa", "embedding": null, "metadata": {"window": "I guess if we go back to when \nMcKesson acquired the European assets seven, eight  years ago, one of the drivers of the deal was to increase \nMcKesson's generic drug purchasing power.  I guess, by announcing the sale to PHOENIX, my sense is you're \nprobably not too worried about any dissynergies related to less generic purchasing power you  went [ph] and did \n(00:38:32) the transaction.  \n \n So, I guess, I'm just curious to hear a little more about McKesson's purchasing power today, whether it's \nClarusONE or other factors, such that the additional European purchasing power is less critical.  And j ust to make \nsure we're not missing anything around this too, hopefully, well, I guess, is there any post -deal agreement \nbetween McKesson and PHOENIX on generic purchasing collaboration, or was that even explored?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive  Officer & Director, McKesson Corp.   A \nThank you for the questions. ", "original_text": "And j ust to make \nsure we're not missing anything around this too, hopefully, well, I guess, is there any post -deal agreement \nbetween McKesson and PHOENIX on generic purchasing collaboration, or was that even explored? ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d8820044a651357ed8a686d0dd56bd471f4344aae1542225ed269dd25e75035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3388c6d0-84af-4c49-827a-a0d85bdc5d61", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  I guess if we go back to when \nMcKesson acquired the European assets seven, eight  years ago, one of the drivers of the deal was to increase \nMcKesson's generic drug purchasing power.  I guess, by announcing the sale to PHOENIX, my sense is you're \nprobably not too worried about any dissynergies related to less generic purchasing power you  went [ph] and did \n(00:38:32) the transaction.  \n \n So, I guess, I'm just curious to hear a little more about McKesson's purchasing power today, whether it's \nClarusONE or other factors, such that the additional European purchasing power is less critical.  And j ust to make \nsure we're not missing anything around this too, hopefully, well, I guess, is there any post -deal agreement \nbetween McKesson and PHOENIX on generic purchasing collaboration, or was that even explored?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive  Officer & Director, McKesson Corp.  ", "original_text": "So, I guess, I'm just curious to hear a little more about McKesson's purchasing power today, whether it's \nClarusONE or other factors, such that the additional European purchasing power is less critical. ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "723dcb60af15b7beebf5bded915e639a4fa86d9b9b2df3a6317ab0c642dc2e02", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af420427-c12c-447b-b60a-b91396676e1a", "node_type": "1", "metadata": {"window": "I guess, by announcing the sale to PHOENIX, my sense is you're \nprobably not too worried about any dissynergies related to less generic purchasing power you  went [ph] and did \n(00:38:32) the transaction.  \n \n So, I guess, I'm just curious to hear a little more about McKesson's purchasing power today, whether it's \nClarusONE or other factors, such that the additional European purchasing power is less critical.  And j ust to make \nsure we're not missing anything around this too, hopefully, well, I guess, is there any post -deal agreement \nbetween McKesson and PHOENIX on generic purchasing collaboration, or was that even explored?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive  Officer & Director, McKesson Corp.   A \nThank you for the questions.  Maybe I'll start. ", "original_text": "Thanks.  \n "}, "hash": "a18679cbcb6a8688a8032c38229175d2d02145a857ab5b971d9e4600a0f140a6", "class_name": "RelatedNodeInfo"}}, "text": "And j ust to make \nsure we're not missing anything around this too, hopefully, well, I guess, is there any post -deal agreement \nbetween McKesson and PHOENIX on generic purchasing collaboration, or was that even explored? ", "start_char_idx": 1683, "end_char_idx": 1905, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af420427-c12c-447b-b60a-b91396676e1a": {"__data__": {"id_": "af420427-c12c-447b-b60a-b91396676e1a", "embedding": null, "metadata": {"window": "I guess, by announcing the sale to PHOENIX, my sense is you're \nprobably not too worried about any dissynergies related to less generic purchasing power you  went [ph] and did \n(00:38:32) the transaction.  \n \n So, I guess, I'm just curious to hear a little more about McKesson's purchasing power today, whether it's \nClarusONE or other factors, such that the additional European purchasing power is less critical.  And j ust to make \nsure we're not missing anything around this too, hopefully, well, I guess, is there any post -deal agreement \nbetween McKesson and PHOENIX on generic purchasing collaboration, or was that even explored?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive  Officer & Director, McKesson Corp.   A \nThank you for the questions.  Maybe I'll start. ", "original_text": "Thanks.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d8820044a651357ed8a686d0dd56bd471f4344aae1542225ed269dd25e75035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1ec5cc6-3e86-4653-a270-915a41515cfa", "node_type": "1", "metadata": {"window": "I guess if we go back to when \nMcKesson acquired the European assets seven, eight  years ago, one of the drivers of the deal was to increase \nMcKesson's generic drug purchasing power.  I guess, by announcing the sale to PHOENIX, my sense is you're \nprobably not too worried about any dissynergies related to less generic purchasing power you  went [ph] and did \n(00:38:32) the transaction.  \n \n So, I guess, I'm just curious to hear a little more about McKesson's purchasing power today, whether it's \nClarusONE or other factors, such that the additional European purchasing power is less critical.  And j ust to make \nsure we're not missing anything around this too, hopefully, well, I guess, is there any post -deal agreement \nbetween McKesson and PHOENIX on generic purchasing collaboration, or was that even explored?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive  Officer & Director, McKesson Corp.   A \nThank you for the questions. ", "original_text": "And j ust to make \nsure we're not missing anything around this too, hopefully, well, I guess, is there any post -deal agreement \nbetween McKesson and PHOENIX on generic purchasing collaboration, or was that even explored? ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d984224421dbd6c35598bdf0cbd2c4e83729fd7fbbd842630236f5ba153e06b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8b066aa5-60f4-4bad-b699-9da45c5fcfd2", "node_type": "1", "metadata": {"window": "So, I guess, I'm just curious to hear a little more about McKesson's purchasing power today, whether it's \nClarusONE or other factors, such that the additional European purchasing power is less critical.  And j ust to make \nsure we're not missing anything around this too, hopefully, well, I guess, is there any post -deal agreement \nbetween McKesson and PHOENIX on generic purchasing collaboration, or was that even explored?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive  Officer & Director, McKesson Corp.   A \nThank you for the questions.  Maybe I'll start.  I mean if you wind the clock back to almost a decade ago when we \nexpanded into Europe, I think there were multiple elements for the company to strategically go to Europe.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive  Officer & Director, McKesson Corp.  "}, "hash": "36ce600b31a6e4ecf034c615e3ffd80bee81c4fc8427c7c2b224eed24339f44d", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 1905, "end_char_idx": 1916, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8b066aa5-60f4-4bad-b699-9da45c5fcfd2": {"__data__": {"id_": "8b066aa5-60f4-4bad-b699-9da45c5fcfd2", "embedding": null, "metadata": {"window": "So, I guess, I'm just curious to hear a little more about McKesson's purchasing power today, whether it's \nClarusONE or other factors, such that the additional European purchasing power is less critical.  And j ust to make \nsure we're not missing anything around this too, hopefully, well, I guess, is there any post -deal agreement \nbetween McKesson and PHOENIX on generic purchasing collaboration, or was that even explored?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive  Officer & Director, McKesson Corp.   A \nThank you for the questions.  Maybe I'll start.  I mean if you wind the clock back to almost a decade ago when we \nexpanded into Europe, I think there were multiple elements for the company to strategically go to Europe.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive  Officer & Director, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d8820044a651357ed8a686d0dd56bd471f4344aae1542225ed269dd25e75035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af420427-c12c-447b-b60a-b91396676e1a", "node_type": "1", "metadata": {"window": "I guess, by announcing the sale to PHOENIX, my sense is you're \nprobably not too worried about any dissynergies related to less generic purchasing power you  went [ph] and did \n(00:38:32) the transaction.  \n \n So, I guess, I'm just curious to hear a little more about McKesson's purchasing power today, whether it's \nClarusONE or other factors, such that the additional European purchasing power is less critical.  And j ust to make \nsure we're not missing anything around this too, hopefully, well, I guess, is there any post -deal agreement \nbetween McKesson and PHOENIX on generic purchasing collaboration, or was that even explored?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive  Officer & Director, McKesson Corp.   A \nThank you for the questions.  Maybe I'll start. ", "original_text": "Thanks.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6eb81388298df4f596c8c5cac48b36a25685d7e76917aba819adcb5288d8ddb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ecb1bc0-79cc-4754-be64-402875c2059e", "node_type": "1", "metadata": {"window": "And j ust to make \nsure we're not missing anything around this too, hopefully, well, I guess, is there any post -deal agreement \nbetween McKesson and PHOENIX on generic purchasing collaboration, or was that even explored?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive  Officer & Director, McKesson Corp.   A \nThank you for the questions.  Maybe I'll start.  I mean if you wind the clock back to almost a decade ago when we \nexpanded into Europe, I think there were multiple elements for the company to strategically go to Europe.   One of \nthem \u2013 one of many was the opportunity to make sure we stay leading in our generics procurement capabilities \nand scale. ", "original_text": "A \nThank you for the questions. "}, "hash": "e573f63a2f8f7dab8bccfe81025cfde12fd2cbee412ab7b1f2ab7249ca701945", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive  Officer & Director, McKesson Corp.  ", "start_char_idx": 1916, "end_char_idx": 2261, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ecb1bc0-79cc-4754-be64-402875c2059e": {"__data__": {"id_": "3ecb1bc0-79cc-4754-be64-402875c2059e", "embedding": null, "metadata": {"window": "And j ust to make \nsure we're not missing anything around this too, hopefully, well, I guess, is there any post -deal agreement \nbetween McKesson and PHOENIX on generic purchasing collaboration, or was that even explored?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive  Officer & Director, McKesson Corp.   A \nThank you for the questions.  Maybe I'll start.  I mean if you wind the clock back to almost a decade ago when we \nexpanded into Europe, I think there were multiple elements for the company to strategically go to Europe.   One of \nthem \u2013 one of many was the opportunity to make sure we stay leading in our generics procurement capabilities \nand scale. ", "original_text": "A \nThank you for the questions. ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d8820044a651357ed8a686d0dd56bd471f4344aae1542225ed269dd25e75035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8b066aa5-60f4-4bad-b699-9da45c5fcfd2", "node_type": "1", "metadata": {"window": "So, I guess, I'm just curious to hear a little more about McKesson's purchasing power today, whether it's \nClarusONE or other factors, such that the additional European purchasing power is less critical.  And j ust to make \nsure we're not missing anything around this too, hopefully, well, I guess, is there any post -deal agreement \nbetween McKesson and PHOENIX on generic purchasing collaboration, or was that even explored?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive  Officer & Director, McKesson Corp.   A \nThank you for the questions.  Maybe I'll start.  I mean if you wind the clock back to almost a decade ago when we \nexpanded into Europe, I think there were multiple elements for the company to strategically go to Europe.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive  Officer & Director, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c7ae0ea730213924dd46944c6e9d159bed362930509b6514dfac1141e8158861", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd4befdd-30f1-4260-a6b4-ee8f9ca386d7", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive  Officer & Director, McKesson Corp.   A \nThank you for the questions.  Maybe I'll start.  I mean if you wind the clock back to almost a decade ago when we \nexpanded into Europe, I think there were multiple elements for the company to strategically go to Europe.   One of \nthem \u2013 one of many was the opportunity to make sure we stay leading in our generics procurement capabilities \nand scale.  I think over the last years, we continued to invest in that capability. ", "original_text": "Maybe I'll start. "}, "hash": "3c4a1c1d198cf7d304aba353a9a10a9b8abcece2d0a71122a2e9fdb3cabf5d34", "class_name": "RelatedNodeInfo"}}, "text": "A \nThank you for the questions. ", "start_char_idx": 2261, "end_char_idx": 2293, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd4befdd-30f1-4260-a6b4-ee8f9ca386d7": {"__data__": {"id_": "dd4befdd-30f1-4260-a6b4-ee8f9ca386d7", "embedding": null, "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive  Officer & Director, McKesson Corp.   A \nThank you for the questions.  Maybe I'll start.  I mean if you wind the clock back to almost a decade ago when we \nexpanded into Europe, I think there were multiple elements for the company to strategically go to Europe.   One of \nthem \u2013 one of many was the opportunity to make sure we stay leading in our generics procurement capabilities \nand scale.  I think over the last years, we continued to invest in that capability. ", "original_text": "Maybe I'll start. ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d8820044a651357ed8a686d0dd56bd471f4344aae1542225ed269dd25e75035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ecb1bc0-79cc-4754-be64-402875c2059e", "node_type": "1", "metadata": {"window": "And j ust to make \nsure we're not missing anything around this too, hopefully, well, I guess, is there any post -deal agreement \nbetween McKesson and PHOENIX on generic purchasing collaboration, or was that even explored?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive  Officer & Director, McKesson Corp.   A \nThank you for the questions.  Maybe I'll start.  I mean if you wind the clock back to almost a decade ago when we \nexpanded into Europe, I think there were multiple elements for the company to strategically go to Europe.   One of \nthem \u2013 one of many was the opportunity to make sure we stay leading in our generics procurement capabilities \nand scale. ", "original_text": "A \nThank you for the questions. ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffe8d512bbcff4c93d7def9d304dd8668b1806fbccb10505cd030388de4b2328", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c4d3724-49a2-4320-ba7d-795ec1da20a4", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive  Officer & Director, McKesson Corp.   A \nThank you for the questions.  Maybe I'll start.  I mean if you wind the clock back to almost a decade ago when we \nexpanded into Europe, I think there were multiple elements for the company to strategically go to Europe.   One of \nthem \u2013 one of many was the opportunity to make sure we stay leading in our generics procurement capabilities \nand scale.  I think over the last years, we continued to invest in that capability.  We have a very successful \npartnership in ClarusONE, and we're very confident that we have not just the scale, but also the procurement \nexpertise, that we have a very contemporary generics procurement operation that will continue to be a leading \ngeneric operation after the divestiture of the European assets that  we've discussed. ", "original_text": "I mean if you wind the clock back to almost a decade ago when we \nexpanded into Europe, I think there were multiple elements for the company to strategically go to Europe.  "}, "hash": "0fe122c196bb2269d653875bdf46d776b33b0a62dd4530f33cd389f28ca9e9be", "class_name": "RelatedNodeInfo"}}, "text": "Maybe I'll start. ", "start_char_idx": 2293, "end_char_idx": 2311, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c4d3724-49a2-4320-ba7d-795ec1da20a4": {"__data__": {"id_": "2c4d3724-49a2-4320-ba7d-795ec1da20a4", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive  Officer & Director, McKesson Corp.   A \nThank you for the questions.  Maybe I'll start.  I mean if you wind the clock back to almost a decade ago when we \nexpanded into Europe, I think there were multiple elements for the company to strategically go to Europe.   One of \nthem \u2013 one of many was the opportunity to make sure we stay leading in our generics procurement capabilities \nand scale.  I think over the last years, we continued to invest in that capability.  We have a very successful \npartnership in ClarusONE, and we're very confident that we have not just the scale, but also the procurement \nexpertise, that we have a very contemporary generics procurement operation that will continue to be a leading \ngeneric operation after the divestiture of the European assets that  we've discussed. ", "original_text": "I mean if you wind the clock back to almost a decade ago when we \nexpanded into Europe, I think there were multiple elements for the company to strategically go to Europe.  ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d8820044a651357ed8a686d0dd56bd471f4344aae1542225ed269dd25e75035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd4befdd-30f1-4260-a6b4-ee8f9ca386d7", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive  Officer & Director, McKesson Corp.   A \nThank you for the questions.  Maybe I'll start.  I mean if you wind the clock back to almost a decade ago when we \nexpanded into Europe, I think there were multiple elements for the company to strategically go to Europe.   One of \nthem \u2013 one of many was the opportunity to make sure we stay leading in our generics procurement capabilities \nand scale.  I think over the last years, we continued to invest in that capability. ", "original_text": "Maybe I'll start. ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "75c4f597a90b481bd4ea038505d164ea803dc1059e76ff9ee670ef88f021a34e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff4fecb4-a224-4bd9-b09d-96a625ade4b7", "node_type": "1", "metadata": {"window": "A \nThank you for the questions.  Maybe I'll start.  I mean if you wind the clock back to almost a decade ago when we \nexpanded into Europe, I think there were multiple elements for the company to strategically go to Europe.   One of \nthem \u2013 one of many was the opportunity to make sure we stay leading in our generics procurement capabilities \nand scale.  I think over the last years, we continued to invest in that capability.  We have a very successful \npartnership in ClarusONE, and we're very confident that we have not just the scale, but also the procurement \nexpertise, that we have a very contemporary generics procurement operation that will continue to be a leading \ngeneric operation after the divestiture of the European assets that  we've discussed.  So, we're quite confident in \nthe productivity and the yield and results we see from ClarusONE, and we believe that will continue to be the case \ninto the future.  \n ", "original_text": "One of \nthem \u2013 one of many was the opportunity to make sure we stay leading in our generics procurement capabilities \nand scale. "}, "hash": "694ba753bd823cb5b00abaf919e2d36ff61a65a32e238ae22ab909b28e3ca6f1", "class_name": "RelatedNodeInfo"}}, "text": "I mean if you wind the clock back to almost a decade ago when we \nexpanded into Europe, I think there were multiple elements for the company to strategically go to Europe.  ", "start_char_idx": 2311, "end_char_idx": 2484, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff4fecb4-a224-4bd9-b09d-96a625ade4b7": {"__data__": {"id_": "ff4fecb4-a224-4bd9-b09d-96a625ade4b7", "embedding": null, "metadata": {"window": "A \nThank you for the questions.  Maybe I'll start.  I mean if you wind the clock back to almost a decade ago when we \nexpanded into Europe, I think there were multiple elements for the company to strategically go to Europe.   One of \nthem \u2013 one of many was the opportunity to make sure we stay leading in our generics procurement capabilities \nand scale.  I think over the last years, we continued to invest in that capability.  We have a very successful \npartnership in ClarusONE, and we're very confident that we have not just the scale, but also the procurement \nexpertise, that we have a very contemporary generics procurement operation that will continue to be a leading \ngeneric operation after the divestiture of the European assets that  we've discussed.  So, we're quite confident in \nthe productivity and the yield and results we see from ClarusONE, and we believe that will continue to be the case \ninto the future.  \n ", "original_text": "One of \nthem \u2013 one of many was the opportunity to make sure we stay leading in our generics procurement capabilities \nand scale. ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d8820044a651357ed8a686d0dd56bd471f4344aae1542225ed269dd25e75035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c4d3724-49a2-4320-ba7d-795ec1da20a4", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive  Officer & Director, McKesson Corp.   A \nThank you for the questions.  Maybe I'll start.  I mean if you wind the clock back to almost a decade ago when we \nexpanded into Europe, I think there were multiple elements for the company to strategically go to Europe.   One of \nthem \u2013 one of many was the opportunity to make sure we stay leading in our generics procurement capabilities \nand scale.  I think over the last years, we continued to invest in that capability.  We have a very successful \npartnership in ClarusONE, and we're very confident that we have not just the scale, but also the procurement \nexpertise, that we have a very contemporary generics procurement operation that will continue to be a leading \ngeneric operation after the divestiture of the European assets that  we've discussed. ", "original_text": "I mean if you wind the clock back to almost a decade ago when we \nexpanded into Europe, I think there were multiple elements for the company to strategically go to Europe.  ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b5ece36012c6d87ba9b816fba84868d41e71c82cec3ff87f4aca9f833efccc9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "60988d50-8788-4d1c-9425-fe2fc8882561", "node_type": "1", "metadata": {"window": "Maybe I'll start.  I mean if you wind the clock back to almost a decade ago when we \nexpanded into Europe, I think there were multiple elements for the company to strategically go to Europe.   One of \nthem \u2013 one of many was the opportunity to make sure we stay leading in our generics procurement capabilities \nand scale.  I think over the last years, we continued to invest in that capability.  We have a very successful \npartnership in ClarusONE, and we're very confident that we have not just the scale, but also the procurement \nexpertise, that we have a very contemporary generics procurement operation that will continue to be a leading \ngeneric operation after the divestiture of the European assets that  we've discussed.  So, we're quite confident in \nthe productivity and the yield and results we see from ClarusONE, and we believe that will continue to be the case \ninto the future.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A F inance, McKesson Corp.  ", "original_text": "I think over the last years, we continued to invest in that capability. "}, "hash": "c23a19c6b402aad2e67b3dc44ed735e140f7f267184cc1d63d6670d7e29d7a0f", "class_name": "RelatedNodeInfo"}}, "text": "One of \nthem \u2013 one of many was the opportunity to make sure we stay leading in our generics procurement capabilities \nand scale. ", "start_char_idx": 2484, "end_char_idx": 2613, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "60988d50-8788-4d1c-9425-fe2fc8882561": {"__data__": {"id_": "60988d50-8788-4d1c-9425-fe2fc8882561", "embedding": null, "metadata": {"window": "Maybe I'll start.  I mean if you wind the clock back to almost a decade ago when we \nexpanded into Europe, I think there were multiple elements for the company to strategically go to Europe.   One of \nthem \u2013 one of many was the opportunity to make sure we stay leading in our generics procurement capabilities \nand scale.  I think over the last years, we continued to invest in that capability.  We have a very successful \npartnership in ClarusONE, and we're very confident that we have not just the scale, but also the procurement \nexpertise, that we have a very contemporary generics procurement operation that will continue to be a leading \ngeneric operation after the divestiture of the European assets that  we've discussed.  So, we're quite confident in \nthe productivity and the yield and results we see from ClarusONE, and we believe that will continue to be the case \ninto the future.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A F inance, McKesson Corp.  ", "original_text": "I think over the last years, we continued to invest in that capability. ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d8820044a651357ed8a686d0dd56bd471f4344aae1542225ed269dd25e75035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff4fecb4-a224-4bd9-b09d-96a625ade4b7", "node_type": "1", "metadata": {"window": "A \nThank you for the questions.  Maybe I'll start.  I mean if you wind the clock back to almost a decade ago when we \nexpanded into Europe, I think there were multiple elements for the company to strategically go to Europe.   One of \nthem \u2013 one of many was the opportunity to make sure we stay leading in our generics procurement capabilities \nand scale.  I think over the last years, we continued to invest in that capability.  We have a very successful \npartnership in ClarusONE, and we're very confident that we have not just the scale, but also the procurement \nexpertise, that we have a very contemporary generics procurement operation that will continue to be a leading \ngeneric operation after the divestiture of the European assets that  we've discussed.  So, we're quite confident in \nthe productivity and the yield and results we see from ClarusONE, and we believe that will continue to be the case \ninto the future.  \n ", "original_text": "One of \nthem \u2013 one of many was the opportunity to make sure we stay leading in our generics procurement capabilities \nand scale. ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f0efe3d8ebf81f4d371b60da64199439c2512e912a2a03b1be35ff4a6761c546", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "df2bdb01-1ac9-45d6-ac07-42369a932102", "node_type": "1", "metadata": {"window": "I mean if you wind the clock back to almost a decade ago when we \nexpanded into Europe, I think there were multiple elements for the company to strategically go to Europe.   One of \nthem \u2013 one of many was the opportunity to make sure we stay leading in our generics procurement capabilities \nand scale.  I think over the last years, we continued to invest in that capability.  We have a very successful \npartnership in ClarusONE, and we're very confident that we have not just the scale, but also the procurement \nexpertise, that we have a very contemporary generics procurement operation that will continue to be a leading \ngeneric operation after the divestiture of the European assets that  we've discussed.  So, we're quite confident in \nthe productivity and the yield and results we see from ClarusONE, and we believe that will continue to be the case \ninto the future.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A F inance, McKesson Corp.   A \nWe'll go to the next question.  \n ", "original_text": "We have a very successful \npartnership in ClarusONE, and we're very confident that we have not just the scale, but also the procurement \nexpertise, that we have a very contemporary generics procurement operation that will continue to be a leading \ngeneric operation after the divestiture of the European assets that  we've discussed. "}, "hash": "7b130745fa41e3f960955cd556cb0b5320e4bd02a1ba53e4da346b08eb3d5582", "class_name": "RelatedNodeInfo"}}, "text": "I think over the last years, we continued to invest in that capability. ", "start_char_idx": 2613, "end_char_idx": 2685, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "df2bdb01-1ac9-45d6-ac07-42369a932102": {"__data__": {"id_": "df2bdb01-1ac9-45d6-ac07-42369a932102", "embedding": null, "metadata": {"window": "I mean if you wind the clock back to almost a decade ago when we \nexpanded into Europe, I think there were multiple elements for the company to strategically go to Europe.   One of \nthem \u2013 one of many was the opportunity to make sure we stay leading in our generics procurement capabilities \nand scale.  I think over the last years, we continued to invest in that capability.  We have a very successful \npartnership in ClarusONE, and we're very confident that we have not just the scale, but also the procurement \nexpertise, that we have a very contemporary generics procurement operation that will continue to be a leading \ngeneric operation after the divestiture of the European assets that  we've discussed.  So, we're quite confident in \nthe productivity and the yield and results we see from ClarusONE, and we believe that will continue to be the case \ninto the future.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A F inance, McKesson Corp.   A \nWe'll go to the next question.  \n ", "original_text": "We have a very successful \npartnership in ClarusONE, and we're very confident that we have not just the scale, but also the procurement \nexpertise, that we have a very contemporary generics procurement operation that will continue to be a leading \ngeneric operation after the divestiture of the European assets that  we've discussed. ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d8820044a651357ed8a686d0dd56bd471f4344aae1542225ed269dd25e75035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "60988d50-8788-4d1c-9425-fe2fc8882561", "node_type": "1", "metadata": {"window": "Maybe I'll start.  I mean if you wind the clock back to almost a decade ago when we \nexpanded into Europe, I think there were multiple elements for the company to strategically go to Europe.   One of \nthem \u2013 one of many was the opportunity to make sure we stay leading in our generics procurement capabilities \nand scale.  I think over the last years, we continued to invest in that capability.  We have a very successful \npartnership in ClarusONE, and we're very confident that we have not just the scale, but also the procurement \nexpertise, that we have a very contemporary generics procurement operation that will continue to be a leading \ngeneric operation after the divestiture of the European assets that  we've discussed.  So, we're quite confident in \nthe productivity and the yield and results we see from ClarusONE, and we believe that will continue to be the case \ninto the future.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A F inance, McKesson Corp.  ", "original_text": "I think over the last years, we continued to invest in that capability. ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "acc5d17e0790e01c2d0984e221cad373310dac36b048949a22c1f0ba33b9d2af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be4e766e-d515-49f0-913b-1f21b6fdbd5f", "node_type": "1", "metadata": {"window": "One of \nthem \u2013 one of many was the opportunity to make sure we stay leading in our generics procurement capabilities \nand scale.  I think over the last years, we continued to invest in that capability.  We have a very successful \npartnership in ClarusONE, and we're very confident that we have not just the scale, but also the procurement \nexpertise, that we have a very contemporary generics procurement operation that will continue to be a leading \ngeneric operation after the divestiture of the European assets that  we've discussed.  So, we're quite confident in \nthe productivity and the yield and results we see from ClarusONE, and we believe that will continue to be the case \ninto the future.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A F inance, McKesson Corp.   A \nWe'll go to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next, we will go to Michael Cherny of Bank of America.  \n ", "original_text": "So, we're quite confident in \nthe productivity and the yield and results we see from ClarusONE, and we believe that will continue to be the case \ninto the future.  \n "}, "hash": "2b4240a544ee58574e692dc2ba456f65011cd61103765a4eee1299e5211835c5", "class_name": "RelatedNodeInfo"}}, "text": "We have a very successful \npartnership in ClarusONE, and we're very confident that we have not just the scale, but also the procurement \nexpertise, that we have a very contemporary generics procurement operation that will continue to be a leading \ngeneric operation after the divestiture of the European assets that  we've discussed. ", "start_char_idx": 2685, "end_char_idx": 3019, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be4e766e-d515-49f0-913b-1f21b6fdbd5f": {"__data__": {"id_": "be4e766e-d515-49f0-913b-1f21b6fdbd5f", "embedding": null, "metadata": {"window": "One of \nthem \u2013 one of many was the opportunity to make sure we stay leading in our generics procurement capabilities \nand scale.  I think over the last years, we continued to invest in that capability.  We have a very successful \npartnership in ClarusONE, and we're very confident that we have not just the scale, but also the procurement \nexpertise, that we have a very contemporary generics procurement operation that will continue to be a leading \ngeneric operation after the divestiture of the European assets that  we've discussed.  So, we're quite confident in \nthe productivity and the yield and results we see from ClarusONE, and we believe that will continue to be the case \ninto the future.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A F inance, McKesson Corp.   A \nWe'll go to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next, we will go to Michael Cherny of Bank of America.  \n ", "original_text": "So, we're quite confident in \nthe productivity and the yield and results we see from ClarusONE, and we believe that will continue to be the case \ninto the future.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d8820044a651357ed8a686d0dd56bd471f4344aae1542225ed269dd25e75035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "df2bdb01-1ac9-45d6-ac07-42369a932102", "node_type": "1", "metadata": {"window": "I mean if you wind the clock back to almost a decade ago when we \nexpanded into Europe, I think there were multiple elements for the company to strategically go to Europe.   One of \nthem \u2013 one of many was the opportunity to make sure we stay leading in our generics procurement capabilities \nand scale.  I think over the last years, we continued to invest in that capability.  We have a very successful \npartnership in ClarusONE, and we're very confident that we have not just the scale, but also the procurement \nexpertise, that we have a very contemporary generics procurement operation that will continue to be a leading \ngeneric operation after the divestiture of the European assets that  we've discussed.  So, we're quite confident in \nthe productivity and the yield and results we see from ClarusONE, and we believe that will continue to be the case \ninto the future.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A F inance, McKesson Corp.   A \nWe'll go to the next question.  \n ", "original_text": "We have a very successful \npartnership in ClarusONE, and we're very confident that we have not just the scale, but also the procurement \nexpertise, that we have a very contemporary generics procurement operation that will continue to be a leading \ngeneric operation after the divestiture of the European assets that  we've discussed. ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f9e852a0242d6d1041bebb4899a172c89e74ee4384febda92856d7c4e9874087", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7dd8c65b-5370-4a59-8e52-6b67ce532a7c", "node_type": "1", "metadata": {"window": "I think over the last years, we continued to invest in that capability.  We have a very successful \npartnership in ClarusONE, and we're very confident that we have not just the scale, but also the procurement \nexpertise, that we have a very contemporary generics procurement operation that will continue to be a leading \ngeneric operation after the divestiture of the European assets that  we've discussed.  So, we're quite confident in \nthe productivity and the yield and results we see from ClarusONE, and we believe that will continue to be the case \ninto the future.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A F inance, McKesson Corp.   A \nWe'll go to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next, we will go to Michael Cherny of Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A F inance, McKesson Corp.  "}, "hash": "25fedc5f821ef61e37c4abd83af36f6912b7e9dc3c87dfef6ecf2914f57c6f19", "class_name": "RelatedNodeInfo"}}, "text": "So, we're quite confident in \nthe productivity and the yield and results we see from ClarusONE, and we believe that will continue to be the case \ninto the future.  \n ", "start_char_idx": 3019, "end_char_idx": 3185, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7dd8c65b-5370-4a59-8e52-6b67ce532a7c": {"__data__": {"id_": "7dd8c65b-5370-4a59-8e52-6b67ce532a7c", "embedding": null, "metadata": {"window": "I think over the last years, we continued to invest in that capability.  We have a very successful \npartnership in ClarusONE, and we're very confident that we have not just the scale, but also the procurement \nexpertise, that we have a very contemporary generics procurement operation that will continue to be a leading \ngeneric operation after the divestiture of the European assets that  we've discussed.  So, we're quite confident in \nthe productivity and the yield and results we see from ClarusONE, and we believe that will continue to be the case \ninto the future.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A F inance, McKesson Corp.   A \nWe'll go to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next, we will go to Michael Cherny of Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A F inance, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d8820044a651357ed8a686d0dd56bd471f4344aae1542225ed269dd25e75035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be4e766e-d515-49f0-913b-1f21b6fdbd5f", "node_type": "1", "metadata": {"window": "One of \nthem \u2013 one of many was the opportunity to make sure we stay leading in our generics procurement capabilities \nand scale.  I think over the last years, we continued to invest in that capability.  We have a very successful \npartnership in ClarusONE, and we're very confident that we have not just the scale, but also the procurement \nexpertise, that we have a very contemporary generics procurement operation that will continue to be a leading \ngeneric operation after the divestiture of the European assets that  we've discussed.  So, we're quite confident in \nthe productivity and the yield and results we see from ClarusONE, and we believe that will continue to be the case \ninto the future.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A F inance, McKesson Corp.   A \nWe'll go to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next, we will go to Michael Cherny of Bank of America.  \n ", "original_text": "So, we're quite confident in \nthe productivity and the yield and results we see from ClarusONE, and we believe that will continue to be the case \ninto the future.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25364a3fb5bef3455934b55e5e9addcfa0804d8e21355d1949575672b9d76d8b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "79266eac-e25d-4668-9af2-417d94bfe32a", "node_type": "1", "metadata": {"window": "We have a very successful \npartnership in ClarusONE, and we're very confident that we have not just the scale, but also the procurement \nexpertise, that we have a very contemporary generics procurement operation that will continue to be a leading \ngeneric operation after the divestiture of the European assets that  we've discussed.  So, we're quite confident in \nthe productivity and the yield and results we see from ClarusONE, and we believe that will continue to be the case \ninto the future.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A F inance, McKesson Corp.   A \nWe'll go to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next, we will go to Michael Cherny of Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon. ", "original_text": "A \nWe'll go to the next question.  \n "}, "hash": "c89945c9dea4e832c6abd89b71c81a4eef175f0fd2507bb8c7c69fc64d3df53c", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A F inance, McKesson Corp.  ", "start_char_idx": 3185, "end_char_idx": 3560, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "79266eac-e25d-4668-9af2-417d94bfe32a": {"__data__": {"id_": "79266eac-e25d-4668-9af2-417d94bfe32a", "embedding": null, "metadata": {"window": "We have a very successful \npartnership in ClarusONE, and we're very confident that we have not just the scale, but also the procurement \nexpertise, that we have a very contemporary generics procurement operation that will continue to be a leading \ngeneric operation after the divestiture of the European assets that  we've discussed.  So, we're quite confident in \nthe productivity and the yield and results we see from ClarusONE, and we believe that will continue to be the case \ninto the future.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A F inance, McKesson Corp.   A \nWe'll go to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next, we will go to Michael Cherny of Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon. ", "original_text": "A \nWe'll go to the next question.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d8820044a651357ed8a686d0dd56bd471f4344aae1542225ed269dd25e75035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7dd8c65b-5370-4a59-8e52-6b67ce532a7c", "node_type": "1", "metadata": {"window": "I think over the last years, we continued to invest in that capability.  We have a very successful \npartnership in ClarusONE, and we're very confident that we have not just the scale, but also the procurement \nexpertise, that we have a very contemporary generics procurement operation that will continue to be a leading \ngeneric operation after the divestiture of the European assets that  we've discussed.  So, we're quite confident in \nthe productivity and the yield and results we see from ClarusONE, and we believe that will continue to be the case \ninto the future.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A F inance, McKesson Corp.   A \nWe'll go to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next, we will go to Michael Cherny of Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A F inance, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "028bd3df0cfb09636d77b58d0fa5dcc9ec5e8ec00918e84cc5a6391f686fca03", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b882f3f-6752-4099-8112-ee031f06d06a", "node_type": "1", "metadata": {"window": "So, we're quite confident in \nthe productivity and the yield and results we see from ClarusONE, and we believe that will continue to be the case \ninto the future.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A F inance, McKesson Corp.   A \nWe'll go to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next, we will go to Michael Cherny of Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Congratulations on the quarter. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next, we will go to Michael Cherny of Bank of America.  \n "}, "hash": "bb19d92d479c5e97a2ad24f0a45cb5202c9f898a681e3d25b8d9371bbda22119", "class_name": "RelatedNodeInfo"}}, "text": "A \nWe'll go to the next question.  \n ", "start_char_idx": 3560, "end_char_idx": 3597, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b882f3f-6752-4099-8112-ee031f06d06a": {"__data__": {"id_": "5b882f3f-6752-4099-8112-ee031f06d06a", "embedding": null, "metadata": {"window": "So, we're quite confident in \nthe productivity and the yield and results we see from ClarusONE, and we believe that will continue to be the case \ninto the future.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A F inance, McKesson Corp.   A \nWe'll go to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next, we will go to Michael Cherny of Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Congratulations on the quarter. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next, we will go to Michael Cherny of Bank of America.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d8820044a651357ed8a686d0dd56bd471f4344aae1542225ed269dd25e75035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "79266eac-e25d-4668-9af2-417d94bfe32a", "node_type": "1", "metadata": {"window": "We have a very successful \npartnership in ClarusONE, and we're very confident that we have not just the scale, but also the procurement \nexpertise, that we have a very contemporary generics procurement operation that will continue to be a leading \ngeneric operation after the divestiture of the European assets that  we've discussed.  So, we're quite confident in \nthe productivity and the yield and results we see from ClarusONE, and we believe that will continue to be the case \ninto the future.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A F inance, McKesson Corp.   A \nWe'll go to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next, we will go to Michael Cherny of Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon. ", "original_text": "A \nWe'll go to the next question.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "24c79732f539da6ef3949a2f16fa708b2afbe5497730d707e337eeb42cb65116", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0606721a-d486-4f4e-b412-0953ba1e8f84", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A F inance, McKesson Corp.   A \nWe'll go to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next, we will go to Michael Cherny of Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Congratulations on the quarter.  I just want to dive in, I guess, a little bit more on the pharma \ndistribution outlook. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  "}, "hash": "fa58396d6587cb049d2f04b5af3becd21cb2bbe4cc46ede59f5484bba5ce60c8", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next, we will go to Michael Cherny of Bank of America.  \n ", "start_char_idx": 3597, "end_char_idx": 3944, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0606721a-d486-4f4e-b412-0953ba1e8f84": {"__data__": {"id_": "0606721a-d486-4f4e-b412-0953ba1e8f84", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A F inance, McKesson Corp.   A \nWe'll go to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next, we will go to Michael Cherny of Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Congratulations on the quarter.  I just want to dive in, I guess, a little bit more on the pharma \ndistribution outlook. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d8820044a651357ed8a686d0dd56bd471f4344aae1542225ed269dd25e75035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b882f3f-6752-4099-8112-ee031f06d06a", "node_type": "1", "metadata": {"window": "So, we're quite confident in \nthe productivity and the yield and results we see from ClarusONE, and we believe that will continue to be the case \ninto the future.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A F inance, McKesson Corp.   A \nWe'll go to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next, we will go to Michael Cherny of Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Congratulations on the quarter. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next, we will go to Michael Cherny of Bank of America.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7210796459d62d1f1c20dcc2d4a5377d3e5dd0bb07cdd2e277f1db378d601865", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36544304-b1c2-4e67-91bb-db6cb61ed455", "node_type": "1", "metadata": {"window": "A \nWe'll go to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next, we will go to Michael Cherny of Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Congratulations on the quarter.  I just want to dive in, I guess, a little bit more on the pharma \ndistribution outlook.  Clearly, the results were strong in the quarter. ", "original_text": "Q \nGood afternoon. "}, "hash": "9bf3dac457750fc56e25a4f76710adb377c6e4ae68a2a299a03a977dbab3d304", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "start_char_idx": 3944, "end_char_idx": 4265, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36544304-b1c2-4e67-91bb-db6cb61ed455": {"__data__": {"id_": "36544304-b1c2-4e67-91bb-db6cb61ed455", "embedding": null, "metadata": {"window": "A \nWe'll go to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next, we will go to Michael Cherny of Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Congratulations on the quarter.  I just want to dive in, I guess, a little bit more on the pharma \ndistribution outlook.  Clearly, the results were strong in the quarter. ", "original_text": "Q \nGood afternoon. ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d8820044a651357ed8a686d0dd56bd471f4344aae1542225ed269dd25e75035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0606721a-d486-4f4e-b412-0953ba1e8f84", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A F inance, McKesson Corp.   A \nWe'll go to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next, we will go to Michael Cherny of Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Congratulations on the quarter.  I just want to dive in, I guess, a little bit more on the pharma \ndistribution outlook. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c899c0b104a7a03bda18eb90cd2cb841b23f6f74a16fbdf98e3dd309016b988b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee890f70-d3e3-49ff-8e4b-062d6c3465b8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next, we will go to Michael Cherny of Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Congratulations on the quarter.  I just want to dive in, I guess, a little bit more on the pharma \ndistribution outlook.  Clearly, the results were strong in the quarter.  You're pointing towards higher [ph] reported \n(00:40:30) growth on a go -forward basis. ", "original_text": "Congratulations on the quarter. "}, "hash": "b519474f09899689a244ad1842bf0d6e8da2f83606d2a284b71fbba4c8748798", "class_name": "RelatedNodeInfo"}}, "text": "Q \nGood afternoon. ", "start_char_idx": 4265, "end_char_idx": 4284, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee890f70-d3e3-49ff-8e4b-062d6c3465b8": {"__data__": {"id_": "ee890f70-d3e3-49ff-8e4b-062d6c3465b8", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next, we will go to Michael Cherny of Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Congratulations on the quarter.  I just want to dive in, I guess, a little bit more on the pharma \ndistribution outlook.  Clearly, the results were strong in the quarter.  You're pointing towards higher [ph] reported \n(00:40:30) growth on a go -forward basis. ", "original_text": "Congratulations on the quarter. ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d8820044a651357ed8a686d0dd56bd471f4344aae1542225ed269dd25e75035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36544304-b1c2-4e67-91bb-db6cb61ed455", "node_type": "1", "metadata": {"window": "A \nWe'll go to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next, we will go to Michael Cherny of Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Congratulations on the quarter.  I just want to dive in, I guess, a little bit more on the pharma \ndistribution outlook.  Clearly, the results were strong in the quarter. ", "original_text": "Q \nGood afternoon. ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c2e793e801ac0de62b6816197db312d433c89bb8575003d301f88b4151d7c4e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f5e56e78-b406-43f7-a549-6f6b0217cc0d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Congratulations on the quarter.  I just want to dive in, I guess, a little bit more on the pharma \ndistribution outlook.  Clearly, the results were strong in the quarter.  You're pointing towards higher [ph] reported \n(00:40:30) growth on a go -forward basis.  As you think about the dynamics in the market maybe aside fr om the \nClarusONE question, but what has been the pace and health of recovery of your non -large national chain \ncustomers? ", "original_text": "I just want to dive in, I guess, a little bit more on the pharma \ndistribution outlook. "}, "hash": "e9507f64d55bb1f52a57e86fbc32af49c272577067203642db11c59e0727e4f5", "class_name": "RelatedNodeInfo"}}, "text": "Congratulations on the quarter. ", "start_char_idx": 4284, "end_char_idx": 4316, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f5e56e78-b406-43f7-a549-6f6b0217cc0d": {"__data__": {"id_": "f5e56e78-b406-43f7-a549-6f6b0217cc0d", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Congratulations on the quarter.  I just want to dive in, I guess, a little bit more on the pharma \ndistribution outlook.  Clearly, the results were strong in the quarter.  You're pointing towards higher [ph] reported \n(00:40:30) growth on a go -forward basis.  As you think about the dynamics in the market maybe aside fr om the \nClarusONE question, but what has been the pace and health of recovery of your non -large national chain \ncustomers? ", "original_text": "I just want to dive in, I guess, a little bit more on the pharma \ndistribution outlook. ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d8820044a651357ed8a686d0dd56bd471f4344aae1542225ed269dd25e75035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee890f70-d3e3-49ff-8e4b-062d6c3465b8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next, we will go to Michael Cherny of Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Congratulations on the quarter.  I just want to dive in, I guess, a little bit more on the pharma \ndistribution outlook.  Clearly, the results were strong in the quarter.  You're pointing towards higher [ph] reported \n(00:40:30) growth on a go -forward basis. ", "original_text": "Congratulations on the quarter. ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9747aa94080ad982118908d0f8a1e925fe1c14a3fa715bdf780344ad5f078d99", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "21b9c532-d38c-40a9-acda-390e66602011", "node_type": "1", "metadata": {"window": "Q \nGood afternoon.  Congratulations on the quarter.  I just want to dive in, I guess, a little bit more on the pharma \ndistribution outlook.  Clearly, the results were strong in the quarter.  You're pointing towards higher [ph] reported \n(00:40:30) growth on a go -forward basis.  As you think about the dynamics in the market maybe aside fr om the \nClarusONE question, but what has been the pace and health of recovery of your non -large national chain \ncustomers?  You called them out as specific contributors to the quarter. ", "original_text": "Clearly, the results were strong in the quarter. "}, "hash": "f07f30d201fecdfeb5f0f9b5ba22f7b736c2ac9ee4ffc46071569d1c4068e4b9", "class_name": "RelatedNodeInfo"}}, "text": "I just want to dive in, I guess, a little bit more on the pharma \ndistribution outlook. ", "start_char_idx": 4316, "end_char_idx": 4404, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "21b9c532-d38c-40a9-acda-390e66602011": {"__data__": {"id_": "21b9c532-d38c-40a9-acda-390e66602011", "embedding": null, "metadata": {"window": "Q \nGood afternoon.  Congratulations on the quarter.  I just want to dive in, I guess, a little bit more on the pharma \ndistribution outlook.  Clearly, the results were strong in the quarter.  You're pointing towards higher [ph] reported \n(00:40:30) growth on a go -forward basis.  As you think about the dynamics in the market maybe aside fr om the \nClarusONE question, but what has been the pace and health of recovery of your non -large national chain \ncustomers?  You called them out as specific contributors to the quarter. ", "original_text": "Clearly, the results were strong in the quarter. ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d8820044a651357ed8a686d0dd56bd471f4344aae1542225ed269dd25e75035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f5e56e78-b406-43f7-a549-6f6b0217cc0d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  Congratulations on the quarter.  I just want to dive in, I guess, a little bit more on the pharma \ndistribution outlook.  Clearly, the results were strong in the quarter.  You're pointing towards higher [ph] reported \n(00:40:30) growth on a go -forward basis.  As you think about the dynamics in the market maybe aside fr om the \nClarusONE question, but what has been the pace and health of recovery of your non -large national chain \ncustomers? ", "original_text": "I just want to dive in, I guess, a little bit more on the pharma \ndistribution outlook. ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0f3ff95645f8e7d69106ec7017e7a9032d057b0feb782290aa7c646b927d6cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "26358e0a-f65d-4409-a824-ea58ce1a5f20", "node_type": "1", "metadata": {"window": "Congratulations on the quarter.  I just want to dive in, I guess, a little bit more on the pharma \ndistribution outlook.  Clearly, the results were strong in the quarter.  You're pointing towards higher [ph] reported \n(00:40:30) growth on a go -forward basis.  As you think about the dynamics in the market maybe aside fr om the \nClarusONE question, but what has been the pace and health of recovery of your non -large national chain \ncustomers?  You called them out as specific contributors to the quarter.  Can you give us a sense about how the \nrest of your book of business, the r est of your customers are handling the potential or, hopefully, recovery in \nutilization across their platforms and where that factors in, in terms of your outlook for rest of the year?  ", "original_text": "You're pointing towards higher [ph] reported \n(00:40:30) growth on a go -forward basis. "}, "hash": "c1499fc7558f753d90ab8a883fe740d27e7d74aa24fe046fa49905afdd21c56e", "class_name": "RelatedNodeInfo"}}, "text": "Clearly, the results were strong in the quarter. ", "start_char_idx": 4404, "end_char_idx": 4453, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "26358e0a-f65d-4409-a824-ea58ce1a5f20": {"__data__": {"id_": "26358e0a-f65d-4409-a824-ea58ce1a5f20", "embedding": null, "metadata": {"window": "Congratulations on the quarter.  I just want to dive in, I guess, a little bit more on the pharma \ndistribution outlook.  Clearly, the results were strong in the quarter.  You're pointing towards higher [ph] reported \n(00:40:30) growth on a go -forward basis.  As you think about the dynamics in the market maybe aside fr om the \nClarusONE question, but what has been the pace and health of recovery of your non -large national chain \ncustomers?  You called them out as specific contributors to the quarter.  Can you give us a sense about how the \nrest of your book of business, the r est of your customers are handling the potential or, hopefully, recovery in \nutilization across their platforms and where that factors in, in terms of your outlook for rest of the year?  ", "original_text": "You're pointing towards higher [ph] reported \n(00:40:30) growth on a go -forward basis. ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d8820044a651357ed8a686d0dd56bd471f4344aae1542225ed269dd25e75035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "21b9c532-d38c-40a9-acda-390e66602011", "node_type": "1", "metadata": {"window": "Q \nGood afternoon.  Congratulations on the quarter.  I just want to dive in, I guess, a little bit more on the pharma \ndistribution outlook.  Clearly, the results were strong in the quarter.  You're pointing towards higher [ph] reported \n(00:40:30) growth on a go -forward basis.  As you think about the dynamics in the market maybe aside fr om the \nClarusONE question, but what has been the pace and health of recovery of your non -large national chain \ncustomers?  You called them out as specific contributors to the quarter. ", "original_text": "Clearly, the results were strong in the quarter. ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d77d81e308c22307e5a760d498328e35c8bd6afe27a09953a4a320276e835d2b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1f8ed5e-c950-48aa-8a7b-645e06530280", "node_type": "1", "metadata": {"window": "I just want to dive in, I guess, a little bit more on the pharma \ndistribution outlook.  Clearly, the results were strong in the quarter.  You're pointing towards higher [ph] reported \n(00:40:30) growth on a go -forward basis.  As you think about the dynamics in the market maybe aside fr om the \nClarusONE question, but what has been the pace and health of recovery of your non -large national chain \ncustomers?  You called them out as specific contributors to the quarter.  Can you give us a sense about how the \nrest of your book of business, the r est of your customers are handling the potential or, hopefully, recovery in \nutilization across their platforms and where that factors in, in terms of your outlook for rest of the year?  ", "original_text": "As you think about the dynamics in the market maybe aside fr om the \nClarusONE question, but what has been the pace and health of recovery of your non -large national chain \ncustomers? "}, "hash": "d11c8733596794990a79be986fadb990fed8a44fafdd9ba60649184e63e088dd", "class_name": "RelatedNodeInfo"}}, "text": "You're pointing towards higher [ph] reported \n(00:40:30) growth on a go -forward basis. ", "start_char_idx": 4453, "end_char_idx": 4541, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1f8ed5e-c950-48aa-8a7b-645e06530280": {"__data__": {"id_": "b1f8ed5e-c950-48aa-8a7b-645e06530280", "embedding": null, "metadata": {"window": "I just want to dive in, I guess, a little bit more on the pharma \ndistribution outlook.  Clearly, the results were strong in the quarter.  You're pointing towards higher [ph] reported \n(00:40:30) growth on a go -forward basis.  As you think about the dynamics in the market maybe aside fr om the \nClarusONE question, but what has been the pace and health of recovery of your non -large national chain \ncustomers?  You called them out as specific contributors to the quarter.  Can you give us a sense about how the \nrest of your book of business, the r est of your customers are handling the potential or, hopefully, recovery in \nutilization across their platforms and where that factors in, in terms of your outlook for rest of the year?  ", "original_text": "As you think about the dynamics in the market maybe aside fr om the \nClarusONE question, but what has been the pace and health of recovery of your non -large national chain \ncustomers? ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d8820044a651357ed8a686d0dd56bd471f4344aae1542225ed269dd25e75035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "26358e0a-f65d-4409-a824-ea58ce1a5f20", "node_type": "1", "metadata": {"window": "Congratulations on the quarter.  I just want to dive in, I guess, a little bit more on the pharma \ndistribution outlook.  Clearly, the results were strong in the quarter.  You're pointing towards higher [ph] reported \n(00:40:30) growth on a go -forward basis.  As you think about the dynamics in the market maybe aside fr om the \nClarusONE question, but what has been the pace and health of recovery of your non -large national chain \ncustomers?  You called them out as specific contributors to the quarter.  Can you give us a sense about how the \nrest of your book of business, the r est of your customers are handling the potential or, hopefully, recovery in \nutilization across their platforms and where that factors in, in terms of your outlook for rest of the year?  ", "original_text": "You're pointing towards higher [ph] reported \n(00:40:30) growth on a go -forward basis. ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b75e6c86410addc6c73c670039b2ee7a7341dd4a570b230a8710d1ed3e799b70", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "794fd2c4-4202-4f6f-a7ae-c474eb796918", "node_type": "1", "metadata": {"window": "Clearly, the results were strong in the quarter.  You're pointing towards higher [ph] reported \n(00:40:30) growth on a go -forward basis.  As you think about the dynamics in the market maybe aside fr om the \nClarusONE question, but what has been the pace and health of recovery of your non -large national chain \ncustomers?  You called them out as specific contributors to the quarter.  Can you give us a sense about how the \nrest of your book of business, the r est of your customers are handling the potential or, hopefully, recovery in \nutilization across their platforms and where that factors in, in terms of your outlook for rest of the year?  ", "original_text": "You called them out as specific contributors to the quarter. "}, "hash": "dc2aa869e4366c81daffb7541d45728a5e1580d8f2616e682c232f012475362b", "class_name": "RelatedNodeInfo"}}, "text": "As you think about the dynamics in the market maybe aside fr om the \nClarusONE question, but what has been the pace and health of recovery of your non -large national chain \ncustomers? ", "start_char_idx": 4541, "end_char_idx": 4726, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "794fd2c4-4202-4f6f-a7ae-c474eb796918": {"__data__": {"id_": "794fd2c4-4202-4f6f-a7ae-c474eb796918", "embedding": null, "metadata": {"window": "Clearly, the results were strong in the quarter.  You're pointing towards higher [ph] reported \n(00:40:30) growth on a go -forward basis.  As you think about the dynamics in the market maybe aside fr om the \nClarusONE question, but what has been the pace and health of recovery of your non -large national chain \ncustomers?  You called them out as specific contributors to the quarter.  Can you give us a sense about how the \nrest of your book of business, the r est of your customers are handling the potential or, hopefully, recovery in \nutilization across their platforms and where that factors in, in terms of your outlook for rest of the year?  ", "original_text": "You called them out as specific contributors to the quarter. ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d8820044a651357ed8a686d0dd56bd471f4344aae1542225ed269dd25e75035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1f8ed5e-c950-48aa-8a7b-645e06530280", "node_type": "1", "metadata": {"window": "I just want to dive in, I guess, a little bit more on the pharma \ndistribution outlook.  Clearly, the results were strong in the quarter.  You're pointing towards higher [ph] reported \n(00:40:30) growth on a go -forward basis.  As you think about the dynamics in the market maybe aside fr om the \nClarusONE question, but what has been the pace and health of recovery of your non -large national chain \ncustomers?  You called them out as specific contributors to the quarter.  Can you give us a sense about how the \nrest of your book of business, the r est of your customers are handling the potential or, hopefully, recovery in \nutilization across their platforms and where that factors in, in terms of your outlook for rest of the year?  ", "original_text": "As you think about the dynamics in the market maybe aside fr om the \nClarusONE question, but what has been the pace and health of recovery of your non -large national chain \ncustomers? ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b1b0229d6ee0bc7c4236a40c31a344a1730e4ed99e785b0ea9aeb28bcdfe963e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "676ab13a-6aca-4daf-90d1-93502fb82e19", "node_type": "1", "metadata": {"window": "You're pointing towards higher [ph] reported \n(00:40:30) growth on a go -forward basis.  As you think about the dynamics in the market maybe aside fr om the \nClarusONE question, but what has been the pace and health of recovery of your non -large national chain \ncustomers?  You called them out as specific contributors to the quarter.  Can you give us a sense about how the \nrest of your book of business, the r est of your customers are handling the potential or, hopefully, recovery in \nutilization across their platforms and where that factors in, in terms of your outlook for rest of the year?  ", "original_text": "Can you give us a sense about how the \nrest of your book of business, the r est of your customers are handling the potential or, hopefully, recovery in \nutilization across their platforms and where that factors in, in terms of your outlook for rest of the year?  "}, "hash": "ef292fde54f2e70402e48e6c83d8ad7b7c231d103ee31622482634eb258ade23", "class_name": "RelatedNodeInfo"}}, "text": "You called them out as specific contributors to the quarter. ", "start_char_idx": 4726, "end_char_idx": 4787, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "676ab13a-6aca-4daf-90d1-93502fb82e19": {"__data__": {"id_": "676ab13a-6aca-4daf-90d1-93502fb82e19", "embedding": null, "metadata": {"window": "You're pointing towards higher [ph] reported \n(00:40:30) growth on a go -forward basis.  As you think about the dynamics in the market maybe aside fr om the \nClarusONE question, but what has been the pace and health of recovery of your non -large national chain \ncustomers?  You called them out as specific contributors to the quarter.  Can you give us a sense about how the \nrest of your book of business, the r est of your customers are handling the potential or, hopefully, recovery in \nutilization across their platforms and where that factors in, in terms of your outlook for rest of the year?  ", "original_text": "Can you give us a sense about how the \nrest of your book of business, the r est of your customers are handling the potential or, hopefully, recovery in \nutilization across their platforms and where that factors in, in terms of your outlook for rest of the year?  ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d8820044a651357ed8a686d0dd56bd471f4344aae1542225ed269dd25e75035", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "794fd2c4-4202-4f6f-a7ae-c474eb796918", "node_type": "1", "metadata": {"window": "Clearly, the results were strong in the quarter.  You're pointing towards higher [ph] reported \n(00:40:30) growth on a go -forward basis.  As you think about the dynamics in the market maybe aside fr om the \nClarusONE question, but what has been the pace and health of recovery of your non -large national chain \ncustomers?  You called them out as specific contributors to the quarter.  Can you give us a sense about how the \nrest of your book of business, the r est of your customers are handling the potential or, hopefully, recovery in \nutilization across their platforms and where that factors in, in terms of your outlook for rest of the year?  ", "original_text": "You called them out as specific contributors to the quarter. ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "44e2941e34ba3f15be1de74d17225e401521f7f84cdf0c3e185111e6768a6de3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b7dc9b5-18b5-4354-a442-ac3768aa6255", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure, Michael.  I'll start with a couple of comments. ", "original_text": "McKesson Corp.  "}, "hash": "61fcf00c18a1c765db8542c52552c3e9938a1edb26a606134d8645530685a328", "class_name": "RelatedNodeInfo"}}, "text": "Can you give us a sense about how the \nrest of your book of business, the r est of your customers are handling the potential or, hopefully, recovery in \nutilization across their platforms and where that factors in, in terms of your outlook for rest of the year?  ", "start_char_idx": 4787, "end_char_idx": 5050, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b7dc9b5-18b5-4354-a442-ac3768aa6255": {"__data__": {"id_": "5b7dc9b5-18b5-4354-a442-ac3768aa6255", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure, Michael.  I'll start with a couple of comments. ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f909d867-900f-4080-b21d-623d7f441f91", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48c78109aaaa8e0a7f880420e0ba169dca753d5625f4df3ce84ea839ec0c7538", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "676ab13a-6aca-4daf-90d1-93502fb82e19", "node_type": "1", "metadata": {"window": "You're pointing towards higher [ph] reported \n(00:40:30) growth on a go -forward basis.  As you think about the dynamics in the market maybe aside fr om the \nClarusONE question, but what has been the pace and health of recovery of your non -large national chain \ncustomers?  You called them out as specific contributors to the quarter.  Can you give us a sense about how the \nrest of your book of business, the r est of your customers are handling the potential or, hopefully, recovery in \nutilization across their platforms and where that factors in, in terms of your outlook for rest of the year?  ", "original_text": "Can you give us a sense about how the \nrest of your book of business, the r est of your customers are handling the potential or, hopefully, recovery in \nutilization across their platforms and where that factors in, in terms of your outlook for rest of the year?  ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41d82726a5260c8387148b465ff527acca13c8e305ef719681bb949f2ce9f8ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7507ce9e-0382-4a6a-8c0b-0bc290310015", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure, Michael.  I'll start with a couple of comments.  So, first off, we are pleased at the trajectory of the recovery \nthat we have seen. ", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "5156c7f3f446b08490c38bdddbd8eb118204f1944b7e5ce243d7acd78ad55807", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7507ce9e-0382-4a6a-8c0b-0bc290310015": {"__data__": {"id_": "7507ce9e-0382-4a6a-8c0b-0bc290310015", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure, Michael.  I'll start with a couple of comments.  So, first off, we are pleased at the trajectory of the recovery \nthat we have seen. ", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f909d867-900f-4080-b21d-623d7f441f91", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48c78109aaaa8e0a7f880420e0ba169dca753d5625f4df3ce84ea839ec0c7538", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b7dc9b5-18b5-4354-a442-ac3768aa6255", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure, Michael.  I'll start with a couple of comments. ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f9d939d40484fe1a0d00326b867732bf6327b4243cdb869c9c774750b6fad9e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8fdd8a1d-0e56-4fb4-ab4e-cc9afc1733cb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure, Michael.  I'll start with a couple of comments.  So, first off, we are pleased at the trajectory of the recovery \nthat we have seen.  And it's been more or less in alignment with the expectations we set out at the beginning of \nthe year. ", "original_text": "A \nSure, Michael. "}, "hash": "c88d663678cb9e2a749877ef749c164e2a65516631e85e31d21745f538b0a8f4", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 16, "end_char_idx": 253, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8fdd8a1d-0e56-4fb4-ab4e-cc9afc1733cb": {"__data__": {"id_": "8fdd8a1d-0e56-4fb4-ab4e-cc9afc1733cb", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure, Michael.  I'll start with a couple of comments.  So, first off, we are pleased at the trajectory of the recovery \nthat we have seen.  And it's been more or less in alignment with the expectations we set out at the beginning of \nthe year. ", "original_text": "A \nSure, Michael. ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f909d867-900f-4080-b21d-623d7f441f91", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48c78109aaaa8e0a7f880420e0ba169dca753d5625f4df3ce84ea839ec0c7538", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7507ce9e-0382-4a6a-8c0b-0bc290310015", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure, Michael.  I'll start with a couple of comments.  So, first off, we are pleased at the trajectory of the recovery \nthat we have seen. ", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c87c4751b466d3b9fbe0801c04152310c221f16684bc17ba0f47266077af7748", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e4b9ea8-afe2-4d0e-b504-72a2de3eabab", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure, Michael.  I'll start with a couple of comments.  So, first off, we are pleased at the trajectory of the recovery \nthat we have seen.  And it's been more or less in alignment with the expectations we set out at the beginning of \nthe year.  And I think it's  not just isolated to a particular segment. ", "original_text": "I'll start with a couple of comments. "}, "hash": "18a84cbcc912955eabf8915efe0bbee21fe156dbf552e229aea41743a1eaf60b", "class_name": "RelatedNodeInfo"}}, "text": "A \nSure, Michael. ", "start_char_idx": 253, "end_char_idx": 271, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e4b9ea8-afe2-4d0e-b504-72a2de3eabab": {"__data__": {"id_": "9e4b9ea8-afe2-4d0e-b504-72a2de3eabab", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure, Michael.  I'll start with a couple of comments.  So, first off, we are pleased at the trajectory of the recovery \nthat we have seen.  And it's been more or less in alignment with the expectations we set out at the beginning of \nthe year.  And I think it's  not just isolated to a particular segment. ", "original_text": "I'll start with a couple of comments. ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f909d867-900f-4080-b21d-623d7f441f91", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48c78109aaaa8e0a7f880420e0ba169dca753d5625f4df3ce84ea839ec0c7538", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8fdd8a1d-0e56-4fb4-ab4e-cc9afc1733cb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure, Michael.  I'll start with a couple of comments.  So, first off, we are pleased at the trajectory of the recovery \nthat we have seen.  And it's been more or less in alignment with the expectations we set out at the beginning of \nthe year. ", "original_text": "A \nSure, Michael. ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73e11459359e3cb9f9bb2b3a29e0c566298b659e3ef78585b9a14abe3d54f228", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac313379-a460-472b-9230-00de94422b46", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure, Michael.  I'll start with a couple of comments.  So, first off, we are pleased at the trajectory of the recovery \nthat we have seen.  And it's been more or less in alignment with the expectations we set out at the beginning of \nthe year.  And I think it's  not just isolated to a particular segment.  I think if you look at the market overall, we \ncontinue to see, really through the first quarter, steady progression along the trend line that we signaled we \nthought would be the case.  \n \n", "original_text": "So, first off, we are pleased at the trajectory of the recovery \nthat we have seen. "}, "hash": "d5afe953ee7689c8a6dfc1521be9e05578454665fb0811eb52de69153f180226", "class_name": "RelatedNodeInfo"}}, "text": "I'll start with a couple of comments. ", "start_char_idx": 271, "end_char_idx": 309, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac313379-a460-472b-9230-00de94422b46": {"__data__": {"id_": "ac313379-a460-472b-9230-00de94422b46", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure, Michael.  I'll start with a couple of comments.  So, first off, we are pleased at the trajectory of the recovery \nthat we have seen.  And it's been more or less in alignment with the expectations we set out at the beginning of \nthe year.  And I think it's  not just isolated to a particular segment.  I think if you look at the market overall, we \ncontinue to see, really through the first quarter, steady progression along the trend line that we signaled we \nthought would be the case.  \n \n", "original_text": "So, first off, we are pleased at the trajectory of the recovery \nthat we have seen. ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f909d867-900f-4080-b21d-623d7f441f91", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48c78109aaaa8e0a7f880420e0ba169dca753d5625f4df3ce84ea839ec0c7538", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e4b9ea8-afe2-4d0e-b504-72a2de3eabab", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure, Michael.  I'll start with a couple of comments.  So, first off, we are pleased at the trajectory of the recovery \nthat we have seen.  And it's been more or less in alignment with the expectations we set out at the beginning of \nthe year.  And I think it's  not just isolated to a particular segment. ", "original_text": "I'll start with a couple of comments. ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20a1c21cd6a8152116fde2aa869ea1d6adb691a8cbc81fb2e640a747525a37cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32b5df39-e423-4110-b260-246cb73bdc00", "node_type": "1", "metadata": {"window": "A \nSure, Michael.  I'll start with a couple of comments.  So, first off, we are pleased at the trajectory of the recovery \nthat we have seen.  And it's been more or less in alignment with the expectations we set out at the beginning of \nthe year.  And I think it's  not just isolated to a particular segment.  I think if you look at the market overall, we \ncontinue to see, really through the first quarter, steady progression along the trend line that we signaled we \nthought would be the case.  \n \n So, we continue to be encouraged by that. ", "original_text": "And it's been more or less in alignment with the expectations we set out at the beginning of \nthe year. "}, "hash": "ca8075e7fb28f6e64e60f400c6f65adcee08220477b0332bf7d2e0b51873c684", "class_name": "RelatedNodeInfo"}}, "text": "So, first off, we are pleased at the trajectory of the recovery \nthat we have seen. ", "start_char_idx": 309, "end_char_idx": 393, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "32b5df39-e423-4110-b260-246cb73bdc00": {"__data__": {"id_": "32b5df39-e423-4110-b260-246cb73bdc00", "embedding": null, "metadata": {"window": "A \nSure, Michael.  I'll start with a couple of comments.  So, first off, we are pleased at the trajectory of the recovery \nthat we have seen.  And it's been more or less in alignment with the expectations we set out at the beginning of \nthe year.  And I think it's  not just isolated to a particular segment.  I think if you look at the market overall, we \ncontinue to see, really through the first quarter, steady progression along the trend line that we signaled we \nthought would be the case.  \n \n So, we continue to be encouraged by that. ", "original_text": "And it's been more or less in alignment with the expectations we set out at the beginning of \nthe year. ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f909d867-900f-4080-b21d-623d7f441f91", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48c78109aaaa8e0a7f880420e0ba169dca753d5625f4df3ce84ea839ec0c7538", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac313379-a460-472b-9230-00de94422b46", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure, Michael.  I'll start with a couple of comments.  So, first off, we are pleased at the trajectory of the recovery \nthat we have seen.  And it's been more or less in alignment with the expectations we set out at the beginning of \nthe year.  And I think it's  not just isolated to a particular segment.  I think if you look at the market overall, we \ncontinue to see, really through the first quarter, steady progression along the trend line that we signaled we \nthought would be the case.  \n \n", "original_text": "So, first off, we are pleased at the trajectory of the recovery \nthat we have seen. ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f9eef4e03fe332469780f6609bd71756f18f694bf5919b95eee2c80d031d9774", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9f40766-8cca-4612-ad3e-60f705cf16b0", "node_type": "1", "metadata": {"window": "I'll start with a couple of comments.  So, first off, we are pleased at the trajectory of the recovery \nthat we have seen.  And it's been more or less in alignment with the expectations we set out at the beginning of \nthe year.  And I think it's  not just isolated to a particular segment.  I think if you look at the market overall, we \ncontinue to see, really through the first quarter, steady progression along the trend line that we signaled we \nthought would be the case.  \n \n So, we continue to be encouraged by that.  We continue to think that we will reach a full recovery, meaning pre -\nCOVID levels in the second half of our fiscal year. ", "original_text": "And I think it's  not just isolated to a particular segment. "}, "hash": "3dbd3cf493e89d13b5f0147cc7cf5a0246f8a4a07451c9fd178bdd94da60882b", "class_name": "RelatedNodeInfo"}}, "text": "And it's been more or less in alignment with the expectations we set out at the beginning of \nthe year. ", "start_char_idx": 393, "end_char_idx": 497, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c9f40766-8cca-4612-ad3e-60f705cf16b0": {"__data__": {"id_": "c9f40766-8cca-4612-ad3e-60f705cf16b0", "embedding": null, "metadata": {"window": "I'll start with a couple of comments.  So, first off, we are pleased at the trajectory of the recovery \nthat we have seen.  And it's been more or less in alignment with the expectations we set out at the beginning of \nthe year.  And I think it's  not just isolated to a particular segment.  I think if you look at the market overall, we \ncontinue to see, really through the first quarter, steady progression along the trend line that we signaled we \nthought would be the case.  \n \n So, we continue to be encouraged by that.  We continue to think that we will reach a full recovery, meaning pre -\nCOVID levels in the second half of our fiscal year. ", "original_text": "And I think it's  not just isolated to a particular segment. ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f909d867-900f-4080-b21d-623d7f441f91", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48c78109aaaa8e0a7f880420e0ba169dca753d5625f4df3ce84ea839ec0c7538", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32b5df39-e423-4110-b260-246cb73bdc00", "node_type": "1", "metadata": {"window": "A \nSure, Michael.  I'll start with a couple of comments.  So, first off, we are pleased at the trajectory of the recovery \nthat we have seen.  And it's been more or less in alignment with the expectations we set out at the beginning of \nthe year.  And I think it's  not just isolated to a particular segment.  I think if you look at the market overall, we \ncontinue to see, really through the first quarter, steady progression along the trend line that we signaled we \nthought would be the case.  \n \n So, we continue to be encouraged by that. ", "original_text": "And it's been more or less in alignment with the expectations we set out at the beginning of \nthe year. ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e29e41a7b6990f162eca236369c0f48a4cd68ffb8d1c61aa7ae2edc5cdf76a3f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20085371-3c8b-4642-94d4-e486b12e5017", "node_type": "1", "metadata": {"window": "So, first off, we are pleased at the trajectory of the recovery \nthat we have seen.  And it's been more or less in alignment with the expectations we set out at the beginning of \nthe year.  And I think it's  not just isolated to a particular segment.  I think if you look at the market overall, we \ncontinue to see, really through the first quarter, steady progression along the trend line that we signaled we \nthought would be the case.  \n \n So, we continue to be encouraged by that.  We continue to think that we will reach a full recovery, meaning pre -\nCOVID levels in the second half of our fiscal year.  Obviously, we track the trends regularly. ", "original_text": "I think if you look at the market overall, we \ncontinue to see, really through the first quarter, steady progression along the trend line that we signaled we \nthought would be the case.  \n \n"}, "hash": "c761282ad0b42f380e5fe54f3529f758eefcebd6178575e08d806927177b6eed", "class_name": "RelatedNodeInfo"}}, "text": "And I think it's  not just isolated to a particular segment. ", "start_char_idx": 497, "end_char_idx": 558, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20085371-3c8b-4642-94d4-e486b12e5017": {"__data__": {"id_": "20085371-3c8b-4642-94d4-e486b12e5017", "embedding": null, "metadata": {"window": "So, first off, we are pleased at the trajectory of the recovery \nthat we have seen.  And it's been more or less in alignment with the expectations we set out at the beginning of \nthe year.  And I think it's  not just isolated to a particular segment.  I think if you look at the market overall, we \ncontinue to see, really through the first quarter, steady progression along the trend line that we signaled we \nthought would be the case.  \n \n So, we continue to be encouraged by that.  We continue to think that we will reach a full recovery, meaning pre -\nCOVID levels in the second half of our fiscal year.  Obviously, we track the trends regularly. ", "original_text": "I think if you look at the market overall, we \ncontinue to see, really through the first quarter, steady progression along the trend line that we signaled we \nthought would be the case.  \n \n", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f909d867-900f-4080-b21d-623d7f441f91", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48c78109aaaa8e0a7f880420e0ba169dca753d5625f4df3ce84ea839ec0c7538", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9f40766-8cca-4612-ad3e-60f705cf16b0", "node_type": "1", "metadata": {"window": "I'll start with a couple of comments.  So, first off, we are pleased at the trajectory of the recovery \nthat we have seen.  And it's been more or less in alignment with the expectations we set out at the beginning of \nthe year.  And I think it's  not just isolated to a particular segment.  I think if you look at the market overall, we \ncontinue to see, really through the first quarter, steady progression along the trend line that we signaled we \nthought would be the case.  \n \n So, we continue to be encouraged by that.  We continue to think that we will reach a full recovery, meaning pre -\nCOVID levels in the second half of our fiscal year. ", "original_text": "And I think it's  not just isolated to a particular segment. ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8db419a55df768b586af53d3e30b86f5abcedd61d7e551d271df6cc74439b68f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e6800d2-a29f-48d8-9a99-0dc4afbbe0d8", "node_type": "1", "metadata": {"window": "And it's been more or less in alignment with the expectations we set out at the beginning of \nthe year.  And I think it's  not just isolated to a particular segment.  I think if you look at the market overall, we \ncontinue to see, really through the first quarter, steady progression along the trend line that we signaled we \nthought would be the case.  \n \n So, we continue to be encouraged by that.  We continue to think that we will reach a full recovery, meaning pre -\nCOVID levels in the second half of our fiscal year.  Obviously, we track the trends regularly.  If we saw something \nthat would cause us to deviate from that, we would be  sure to share it with you. ", "original_text": "So, we continue to be encouraged by that. "}, "hash": "282a966205522e91f09ead9a4b9a6626945cf27c780343f47285617e9ccd1d41", "class_name": "RelatedNodeInfo"}}, "text": "I think if you look at the market overall, we \ncontinue to see, really through the first quarter, steady progression along the trend line that we signaled we \nthought would be the case.  \n \n", "start_char_idx": 558, "end_char_idx": 748, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e6800d2-a29f-48d8-9a99-0dc4afbbe0d8": {"__data__": {"id_": "2e6800d2-a29f-48d8-9a99-0dc4afbbe0d8", "embedding": null, "metadata": {"window": "And it's been more or less in alignment with the expectations we set out at the beginning of \nthe year.  And I think it's  not just isolated to a particular segment.  I think if you look at the market overall, we \ncontinue to see, really through the first quarter, steady progression along the trend line that we signaled we \nthought would be the case.  \n \n So, we continue to be encouraged by that.  We continue to think that we will reach a full recovery, meaning pre -\nCOVID levels in the second half of our fiscal year.  Obviously, we track the trends regularly.  If we saw something \nthat would cause us to deviate from that, we would be  sure to share it with you. ", "original_text": "So, we continue to be encouraged by that. ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f909d867-900f-4080-b21d-623d7f441f91", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48c78109aaaa8e0a7f880420e0ba169dca753d5625f4df3ce84ea839ec0c7538", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20085371-3c8b-4642-94d4-e486b12e5017", "node_type": "1", "metadata": {"window": "So, first off, we are pleased at the trajectory of the recovery \nthat we have seen.  And it's been more or less in alignment with the expectations we set out at the beginning of \nthe year.  And I think it's  not just isolated to a particular segment.  I think if you look at the market overall, we \ncontinue to see, really through the first quarter, steady progression along the trend line that we signaled we \nthought would be the case.  \n \n So, we continue to be encouraged by that.  We continue to think that we will reach a full recovery, meaning pre -\nCOVID levels in the second half of our fiscal year.  Obviously, we track the trends regularly. ", "original_text": "I think if you look at the market overall, we \ncontinue to see, really through the first quarter, steady progression along the trend line that we signaled we \nthought would be the case.  \n \n", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "81bfa88acb4a2ff965f4efbbf4f47c3bb4ebcabc27213c055c14fbb7844d281e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4cdbb22-9271-4e03-9bc9-03eab1092c87", "node_type": "1", "metadata": {"window": "And I think it's  not just isolated to a particular segment.  I think if you look at the market overall, we \ncontinue to see, really through the first quarter, steady progression along the trend line that we signaled we \nthought would be the case.  \n \n So, we continue to be encouraged by that.  We continue to think that we will reach a full recovery, meaning pre -\nCOVID levels in the second half of our fiscal year.  Obviously, we track the trends regularly.  If we saw something \nthat would cause us to deviate from that, we would be  sure to share it with you.  But right at this point in time, the \nrecovery has been more or less in line with how we thought. ", "original_text": "We continue to think that we will reach a full recovery, meaning pre -\nCOVID levels in the second half of our fiscal year. "}, "hash": "80ffec32801fd6b0e1733a442d035e8ae91f721d1bd7e1e4e8743c87e44e1133", "class_name": "RelatedNodeInfo"}}, "text": "So, we continue to be encouraged by that. ", "start_char_idx": 748, "end_char_idx": 790, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4cdbb22-9271-4e03-9bc9-03eab1092c87": {"__data__": {"id_": "a4cdbb22-9271-4e03-9bc9-03eab1092c87", "embedding": null, "metadata": {"window": "And I think it's  not just isolated to a particular segment.  I think if you look at the market overall, we \ncontinue to see, really through the first quarter, steady progression along the trend line that we signaled we \nthought would be the case.  \n \n So, we continue to be encouraged by that.  We continue to think that we will reach a full recovery, meaning pre -\nCOVID levels in the second half of our fiscal year.  Obviously, we track the trends regularly.  If we saw something \nthat would cause us to deviate from that, we would be  sure to share it with you.  But right at this point in time, the \nrecovery has been more or less in line with how we thought. ", "original_text": "We continue to think that we will reach a full recovery, meaning pre -\nCOVID levels in the second half of our fiscal year. ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f909d867-900f-4080-b21d-623d7f441f91", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48c78109aaaa8e0a7f880420e0ba169dca753d5625f4df3ce84ea839ec0c7538", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e6800d2-a29f-48d8-9a99-0dc4afbbe0d8", "node_type": "1", "metadata": {"window": "And it's been more or less in alignment with the expectations we set out at the beginning of \nthe year.  And I think it's  not just isolated to a particular segment.  I think if you look at the market overall, we \ncontinue to see, really through the first quarter, steady progression along the trend line that we signaled we \nthought would be the case.  \n \n So, we continue to be encouraged by that.  We continue to think that we will reach a full recovery, meaning pre -\nCOVID levels in the second half of our fiscal year.  Obviously, we track the trends regularly.  If we saw something \nthat would cause us to deviate from that, we would be  sure to share it with you. ", "original_text": "So, we continue to be encouraged by that. ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f817a7174cc1751ea6068f8572ee1ffa1129c28ef850aef60255fd30db6e8b51", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a98eadc-95a6-4f26-9f79-071b71c37811", "node_type": "1", "metadata": {"window": "I think if you look at the market overall, we \ncontinue to see, really through the first quarter, steady progression along the trend line that we signaled we \nthought would be the case.  \n \n So, we continue to be encouraged by that.  We continue to think that we will reach a full recovery, meaning pre -\nCOVID levels in the second half of our fiscal year.  Obviously, we track the trends regularly.  If we saw something \nthat would cause us to deviate from that, we would be  sure to share it with you.  But right at this point in time, the \nrecovery has been more or less in line with how we thought.  We're very pleased about that, and we expect that \nwe will get to the full recovery in the second half of this fiscal year.  \n ", "original_text": "Obviously, we track the trends regularly. "}, "hash": "3d4f7a61d5b3084c507b323800af0881724aa17325062cb4c98b0192db6316e1", "class_name": "RelatedNodeInfo"}}, "text": "We continue to think that we will reach a full recovery, meaning pre -\nCOVID levels in the second half of our fiscal year. ", "start_char_idx": 790, "end_char_idx": 913, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a98eadc-95a6-4f26-9f79-071b71c37811": {"__data__": {"id_": "5a98eadc-95a6-4f26-9f79-071b71c37811", "embedding": null, "metadata": {"window": "I think if you look at the market overall, we \ncontinue to see, really through the first quarter, steady progression along the trend line that we signaled we \nthought would be the case.  \n \n So, we continue to be encouraged by that.  We continue to think that we will reach a full recovery, meaning pre -\nCOVID levels in the second half of our fiscal year.  Obviously, we track the trends regularly.  If we saw something \nthat would cause us to deviate from that, we would be  sure to share it with you.  But right at this point in time, the \nrecovery has been more or less in line with how we thought.  We're very pleased about that, and we expect that \nwe will get to the full recovery in the second half of this fiscal year.  \n ", "original_text": "Obviously, we track the trends regularly. ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f909d867-900f-4080-b21d-623d7f441f91", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48c78109aaaa8e0a7f880420e0ba169dca753d5625f4df3ce84ea839ec0c7538", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4cdbb22-9271-4e03-9bc9-03eab1092c87", "node_type": "1", "metadata": {"window": "And I think it's  not just isolated to a particular segment.  I think if you look at the market overall, we \ncontinue to see, really through the first quarter, steady progression along the trend line that we signaled we \nthought would be the case.  \n \n So, we continue to be encouraged by that.  We continue to think that we will reach a full recovery, meaning pre -\nCOVID levels in the second half of our fiscal year.  Obviously, we track the trends regularly.  If we saw something \nthat would cause us to deviate from that, we would be  sure to share it with you.  But right at this point in time, the \nrecovery has been more or less in line with how we thought. ", "original_text": "We continue to think that we will reach a full recovery, meaning pre -\nCOVID levels in the second half of our fiscal year. ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5fbdf39fde8f39058c35c0f03c11c793c94773f59478380ff23cda45e5a5c0a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e0ce657-22c6-4fdf-873f-161fd9f60abc", "node_type": "1", "metadata": {"window": "So, we continue to be encouraged by that.  We continue to think that we will reach a full recovery, meaning pre -\nCOVID levels in the second half of our fiscal year.  Obviously, we track the trends regularly.  If we saw something \nthat would cause us to deviate from that, we would be  sure to share it with you.  But right at this point in time, the \nrecovery has been more or less in line with how we thought.  We're very pleased about that, and we expect that \nwe will get to the full recovery in the second half of this fiscal year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "If we saw something \nthat would cause us to deviate from that, we would be  sure to share it with you. "}, "hash": "98481404f0dd6260d007cd302a9989854108c4288fa0fdb6878df0e17033f86b", "class_name": "RelatedNodeInfo"}}, "text": "Obviously, we track the trends regularly. ", "start_char_idx": 913, "end_char_idx": 955, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e0ce657-22c6-4fdf-873f-161fd9f60abc": {"__data__": {"id_": "3e0ce657-22c6-4fdf-873f-161fd9f60abc", "embedding": null, "metadata": {"window": "So, we continue to be encouraged by that.  We continue to think that we will reach a full recovery, meaning pre -\nCOVID levels in the second half of our fiscal year.  Obviously, we track the trends regularly.  If we saw something \nthat would cause us to deviate from that, we would be  sure to share it with you.  But right at this point in time, the \nrecovery has been more or less in line with how we thought.  We're very pleased about that, and we expect that \nwe will get to the full recovery in the second half of this fiscal year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "If we saw something \nthat would cause us to deviate from that, we would be  sure to share it with you. ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f909d867-900f-4080-b21d-623d7f441f91", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48c78109aaaa8e0a7f880420e0ba169dca753d5625f4df3ce84ea839ec0c7538", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a98eadc-95a6-4f26-9f79-071b71c37811", "node_type": "1", "metadata": {"window": "I think if you look at the market overall, we \ncontinue to see, really through the first quarter, steady progression along the trend line that we signaled we \nthought would be the case.  \n \n So, we continue to be encouraged by that.  We continue to think that we will reach a full recovery, meaning pre -\nCOVID levels in the second half of our fiscal year.  Obviously, we track the trends regularly.  If we saw something \nthat would cause us to deviate from that, we would be  sure to share it with you.  But right at this point in time, the \nrecovery has been more or less in line with how we thought.  We're very pleased about that, and we expect that \nwe will get to the full recovery in the second half of this fiscal year.  \n ", "original_text": "Obviously, we track the trends regularly. ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7e29979a30b330b432733b201f2fa8a3c0a8334b7d4d360a1f5182fa4bbe012", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b8635137-f51e-4cfc-851c-d794754eb925", "node_type": "1", "metadata": {"window": "We continue to think that we will reach a full recovery, meaning pre -\nCOVID levels in the second half of our fiscal year.  Obviously, we track the trends regularly.  If we saw something \nthat would cause us to deviate from that, we would be  sure to share it with you.  But right at this point in time, the \nrecovery has been more or less in line with how we thought.  We're very pleased about that, and we expect that \nwe will get to the full recovery in the second half of this fiscal year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, maybe I would just add that I think the balance of our customers and the channels that we serve, and what \nwe're seeing in those various channels is reflected in the guidan ce that we gave you, 5% to 8% operating profit \ngrowth. ", "original_text": "But right at this point in time, the \nrecovery has been more or less in line with how we thought. "}, "hash": "d4df70aa6b705c56ebb7ef16f3ef90e658db2e0a8583f38c741d68b01a511c96", "class_name": "RelatedNodeInfo"}}, "text": "If we saw something \nthat would cause us to deviate from that, we would be  sure to share it with you. ", "start_char_idx": 955, "end_char_idx": 1058, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b8635137-f51e-4cfc-851c-d794754eb925": {"__data__": {"id_": "b8635137-f51e-4cfc-851c-d794754eb925", "embedding": null, "metadata": {"window": "We continue to think that we will reach a full recovery, meaning pre -\nCOVID levels in the second half of our fiscal year.  Obviously, we track the trends regularly.  If we saw something \nthat would cause us to deviate from that, we would be  sure to share it with you.  But right at this point in time, the \nrecovery has been more or less in line with how we thought.  We're very pleased about that, and we expect that \nwe will get to the full recovery in the second half of this fiscal year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, maybe I would just add that I think the balance of our customers and the channels that we serve, and what \nwe're seeing in those various channels is reflected in the guidan ce that we gave you, 5% to 8% operating profit \ngrowth. ", "original_text": "But right at this point in time, the \nrecovery has been more or less in line with how we thought. ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f909d867-900f-4080-b21d-623d7f441f91", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48c78109aaaa8e0a7f880420e0ba169dca753d5625f4df3ce84ea839ec0c7538", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e0ce657-22c6-4fdf-873f-161fd9f60abc", "node_type": "1", "metadata": {"window": "So, we continue to be encouraged by that.  We continue to think that we will reach a full recovery, meaning pre -\nCOVID levels in the second half of our fiscal year.  Obviously, we track the trends regularly.  If we saw something \nthat would cause us to deviate from that, we would be  sure to share it with you.  But right at this point in time, the \nrecovery has been more or less in line with how we thought.  We're very pleased about that, and we expect that \nwe will get to the full recovery in the second half of this fiscal year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "If we saw something \nthat would cause us to deviate from that, we would be  sure to share it with you. ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b7fe3edd3d4906d3a6a7732885a270deabbc1fde6f58942330d1527a91804c6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5da433f-6fbc-4dbf-b42f-5dbefe0aa582", "node_type": "1", "metadata": {"window": "Obviously, we track the trends regularly.  If we saw something \nthat would cause us to deviate from that, we would be  sure to share it with you.  But right at this point in time, the \nrecovery has been more or less in line with how we thought.  We're very pleased about that, and we expect that \nwe will get to the full recovery in the second half of this fiscal year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, maybe I would just add that I think the balance of our customers and the channels that we serve, and what \nwe're seeing in those various channels is reflected in the guidan ce that we gave you, 5% to 8% operating profit \ngrowth.  So, all of the channels are recovering, and they're recovering, as Brian mentioned, in line with our \nexpectations. ", "original_text": "We're very pleased about that, and we expect that \nwe will get to the full recovery in the second half of this fiscal year.  \n "}, "hash": "b44ad6001f2c7dd259a0999d3b0b7bae32a304b62ca87a48ce4fc7b2e825ae80", "class_name": "RelatedNodeInfo"}}, "text": "But right at this point in time, the \nrecovery has been more or less in line with how we thought. ", "start_char_idx": 1058, "end_char_idx": 1156, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5da433f-6fbc-4dbf-b42f-5dbefe0aa582": {"__data__": {"id_": "d5da433f-6fbc-4dbf-b42f-5dbefe0aa582", "embedding": null, "metadata": {"window": "Obviously, we track the trends regularly.  If we saw something \nthat would cause us to deviate from that, we would be  sure to share it with you.  But right at this point in time, the \nrecovery has been more or less in line with how we thought.  We're very pleased about that, and we expect that \nwe will get to the full recovery in the second half of this fiscal year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, maybe I would just add that I think the balance of our customers and the channels that we serve, and what \nwe're seeing in those various channels is reflected in the guidan ce that we gave you, 5% to 8% operating profit \ngrowth.  So, all of the channels are recovering, and they're recovering, as Brian mentioned, in line with our \nexpectations. ", "original_text": "We're very pleased about that, and we expect that \nwe will get to the full recovery in the second half of this fiscal year.  \n ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f909d867-900f-4080-b21d-623d7f441f91", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48c78109aaaa8e0a7f880420e0ba169dca753d5625f4df3ce84ea839ec0c7538", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b8635137-f51e-4cfc-851c-d794754eb925", "node_type": "1", "metadata": {"window": "We continue to think that we will reach a full recovery, meaning pre -\nCOVID levels in the second half of our fiscal year.  Obviously, we track the trends regularly.  If we saw something \nthat would cause us to deviate from that, we would be  sure to share it with you.  But right at this point in time, the \nrecovery has been more or less in line with how we thought.  We're very pleased about that, and we expect that \nwe will get to the full recovery in the second half of this fiscal year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, maybe I would just add that I think the balance of our customers and the channels that we serve, and what \nwe're seeing in those various channels is reflected in the guidan ce that we gave you, 5% to 8% operating profit \ngrowth. ", "original_text": "But right at this point in time, the \nrecovery has been more or less in line with how we thought. ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9cf7dbe7f4e93addfc5e1e55f39faaac1b38d97c68cf92eaa7bdc1a85200035a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8796b2bb-8aa7-4101-8ef4-75faa9975acd", "node_type": "1", "metadata": {"window": "If we saw something \nthat would cause us to deviate from that, we would be  sure to share it with you.  But right at this point in time, the \nrecovery has been more or less in line with how we thought.  We're very pleased about that, and we expect that \nwe will get to the full recovery in the second half of this fiscal year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, maybe I would just add that I think the balance of our customers and the channels that we serve, and what \nwe're seeing in those various channels is reflected in the guidan ce that we gave you, 5% to 8% operating profit \ngrowth.  So, all of the channels are recovering, and they're recovering, as Brian mentioned, in line with our \nexpectations.  And they're all contributing to that overall core operating profit growth.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "4ae7ede680c3dbaa662f31f1312cef243ef687a1bfa10caf8ec8ffc4316c6fa5", "class_name": "RelatedNodeInfo"}}, "text": "We're very pleased about that, and we expect that \nwe will get to the full recovery in the second half of this fiscal year.  \n ", "start_char_idx": 1156, "end_char_idx": 1283, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8796b2bb-8aa7-4101-8ef4-75faa9975acd": {"__data__": {"id_": "8796b2bb-8aa7-4101-8ef4-75faa9975acd", "embedding": null, "metadata": {"window": "If we saw something \nthat would cause us to deviate from that, we would be  sure to share it with you.  But right at this point in time, the \nrecovery has been more or less in line with how we thought.  We're very pleased about that, and we expect that \nwe will get to the full recovery in the second half of this fiscal year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, maybe I would just add that I think the balance of our customers and the channels that we serve, and what \nwe're seeing in those various channels is reflected in the guidan ce that we gave you, 5% to 8% operating profit \ngrowth.  So, all of the channels are recovering, and they're recovering, as Brian mentioned, in line with our \nexpectations.  And they're all contributing to that overall core operating profit growth.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f909d867-900f-4080-b21d-623d7f441f91", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48c78109aaaa8e0a7f880420e0ba169dca753d5625f4df3ce84ea839ec0c7538", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5da433f-6fbc-4dbf-b42f-5dbefe0aa582", "node_type": "1", "metadata": {"window": "Obviously, we track the trends regularly.  If we saw something \nthat would cause us to deviate from that, we would be  sure to share it with you.  But right at this point in time, the \nrecovery has been more or less in line with how we thought.  We're very pleased about that, and we expect that \nwe will get to the full recovery in the second half of this fiscal year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, maybe I would just add that I think the balance of our customers and the channels that we serve, and what \nwe're seeing in those various channels is reflected in the guidan ce that we gave you, 5% to 8% operating profit \ngrowth.  So, all of the channels are recovering, and they're recovering, as Brian mentioned, in line with our \nexpectations. ", "original_text": "We're very pleased about that, and we expect that \nwe will get to the full recovery in the second half of this fiscal year.  \n ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c35fa0444bf85688e7865d786c84d636473e9c752c59516563642b22f70b9fbf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b13a0888-129d-4fe6-a52d-eca05015a78c", "node_type": "1", "metadata": {"window": "But right at this point in time, the \nrecovery has been more or less in line with how we thought.  We're very pleased about that, and we expect that \nwe will get to the full recovery in the second half of this fiscal year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, maybe I would just add that I think the balance of our customers and the channels that we serve, and what \nwe're seeing in those various channels is reflected in the guidan ce that we gave you, 5% to 8% operating profit \ngrowth.  So, all of the channels are recovering, and they're recovering, as Brian mentioned, in line with our \nexpectations.  And they're all contributing to that overall core operating profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Wei ss \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "original_text": "A \nYeah, maybe I would just add that I think the balance of our customers and the channels that we serve, and what \nwe're seeing in those various channels is reflected in the guidan ce that we gave you, 5% to 8% operating profit \ngrowth. "}, "hash": "048e60b1976d044f5daef9a76005404c8254899de6533f96c5218392f87fa237", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 1283, "end_char_idx": 1640, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b13a0888-129d-4fe6-a52d-eca05015a78c": {"__data__": {"id_": "b13a0888-129d-4fe6-a52d-eca05015a78c", "embedding": null, "metadata": {"window": "But right at this point in time, the \nrecovery has been more or less in line with how we thought.  We're very pleased about that, and we expect that \nwe will get to the full recovery in the second half of this fiscal year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, maybe I would just add that I think the balance of our customers and the channels that we serve, and what \nwe're seeing in those various channels is reflected in the guidan ce that we gave you, 5% to 8% operating profit \ngrowth.  So, all of the channels are recovering, and they're recovering, as Brian mentioned, in line with our \nexpectations.  And they're all contributing to that overall core operating profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Wei ss \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "original_text": "A \nYeah, maybe I would just add that I think the balance of our customers and the channels that we serve, and what \nwe're seeing in those various channels is reflected in the guidan ce that we gave you, 5% to 8% operating profit \ngrowth. ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f909d867-900f-4080-b21d-623d7f441f91", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48c78109aaaa8e0a7f880420e0ba169dca753d5625f4df3ce84ea839ec0c7538", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8796b2bb-8aa7-4101-8ef4-75faa9975acd", "node_type": "1", "metadata": {"window": "If we saw something \nthat would cause us to deviate from that, we would be  sure to share it with you.  But right at this point in time, the \nrecovery has been more or less in line with how we thought.  We're very pleased about that, and we expect that \nwe will get to the full recovery in the second half of this fiscal year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, maybe I would just add that I think the balance of our customers and the channels that we serve, and what \nwe're seeing in those various channels is reflected in the guidan ce that we gave you, 5% to 8% operating profit \ngrowth.  So, all of the channels are recovering, and they're recovering, as Brian mentioned, in line with our \nexpectations.  And they're all contributing to that overall core operating profit growth.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cddba1db5c134617aecc1e31c1275cd3519351b1caa19a52742a1ab518f1bc1f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "79ef2bb9-2801-437a-8811-986258cc28a3", "node_type": "1", "metadata": {"window": "We're very pleased about that, and we expect that \nwe will get to the full recovery in the second half of this fiscal year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, maybe I would just add that I think the balance of our customers and the channels that we serve, and what \nwe're seeing in those various channels is reflected in the guidan ce that we gave you, 5% to 8% operating profit \ngrowth.  So, all of the channels are recovering, and they're recovering, as Brian mentioned, in line with our \nexpectations.  And they're all contributing to that overall core operating profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Wei ss \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nWe'll move to the next question.  \n ", "original_text": "So, all of the channels are recovering, and they're recovering, as Brian mentioned, in line with our \nexpectations. "}, "hash": "097c68c556f8346e8c0bf09ba237312d92c70f812743b4dcea80306cb6be25ce", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah, maybe I would just add that I think the balance of our customers and the channels that we serve, and what \nwe're seeing in those various channels is reflected in the guidan ce that we gave you, 5% to 8% operating profit \ngrowth. ", "start_char_idx": 1640, "end_char_idx": 1878, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "79ef2bb9-2801-437a-8811-986258cc28a3": {"__data__": {"id_": "79ef2bb9-2801-437a-8811-986258cc28a3", "embedding": null, "metadata": {"window": "We're very pleased about that, and we expect that \nwe will get to the full recovery in the second half of this fiscal year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, maybe I would just add that I think the balance of our customers and the channels that we serve, and what \nwe're seeing in those various channels is reflected in the guidan ce that we gave you, 5% to 8% operating profit \ngrowth.  So, all of the channels are recovering, and they're recovering, as Brian mentioned, in line with our \nexpectations.  And they're all contributing to that overall core operating profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Wei ss \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nWe'll move to the next question.  \n ", "original_text": "So, all of the channels are recovering, and they're recovering, as Brian mentioned, in line with our \nexpectations. ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f909d867-900f-4080-b21d-623d7f441f91", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48c78109aaaa8e0a7f880420e0ba169dca753d5625f4df3ce84ea839ec0c7538", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b13a0888-129d-4fe6-a52d-eca05015a78c", "node_type": "1", "metadata": {"window": "But right at this point in time, the \nrecovery has been more or less in line with how we thought.  We're very pleased about that, and we expect that \nwe will get to the full recovery in the second half of this fiscal year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, maybe I would just add that I think the balance of our customers and the channels that we serve, and what \nwe're seeing in those various channels is reflected in the guidan ce that we gave you, 5% to 8% operating profit \ngrowth.  So, all of the channels are recovering, and they're recovering, as Brian mentioned, in line with our \nexpectations.  And they're all contributing to that overall core operating profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Wei ss \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "original_text": "A \nYeah, maybe I would just add that I think the balance of our customers and the channels that we serve, and what \nwe're seeing in those various channels is reflected in the guidan ce that we gave you, 5% to 8% operating profit \ngrowth. ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1ba0ef3800efb86663bc794af5b68488ce628e184fc02d22ed9cb949b592acde", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "371b8c79-65b5-49eb-a70d-6519f4515dca", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, maybe I would just add that I think the balance of our customers and the channels that we serve, and what \nwe're seeing in those various channels is reflected in the guidan ce that we gave you, 5% to 8% operating profit \ngrowth.  So, all of the channels are recovering, and they're recovering, as Brian mentioned, in line with our \nexpectations.  And they're all contributing to that overall core operating profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Wei ss \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nWe'll move to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And we will go next to Lisa Gill of JPMorgan.  \n ", "original_text": "And they're all contributing to that overall core operating profit growth.  \n "}, "hash": "9f0f833760ea9ddeeca2a74ae04b33d7ad31388dff7135712def96f9c5402a5c", "class_name": "RelatedNodeInfo"}}, "text": "So, all of the channels are recovering, and they're recovering, as Brian mentioned, in line with our \nexpectations. ", "start_char_idx": 1878, "end_char_idx": 1994, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "371b8c79-65b5-49eb-a70d-6519f4515dca": {"__data__": {"id_": "371b8c79-65b5-49eb-a70d-6519f4515dca", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, maybe I would just add that I think the balance of our customers and the channels that we serve, and what \nwe're seeing in those various channels is reflected in the guidan ce that we gave you, 5% to 8% operating profit \ngrowth.  So, all of the channels are recovering, and they're recovering, as Brian mentioned, in line with our \nexpectations.  And they're all contributing to that overall core operating profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Wei ss \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nWe'll move to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And we will go next to Lisa Gill of JPMorgan.  \n ", "original_text": "And they're all contributing to that overall core operating profit growth.  \n ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f909d867-900f-4080-b21d-623d7f441f91", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48c78109aaaa8e0a7f880420e0ba169dca753d5625f4df3ce84ea839ec0c7538", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "79ef2bb9-2801-437a-8811-986258cc28a3", "node_type": "1", "metadata": {"window": "We're very pleased about that, and we expect that \nwe will get to the full recovery in the second half of this fiscal year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, maybe I would just add that I think the balance of our customers and the channels that we serve, and what \nwe're seeing in those various channels is reflected in the guidan ce that we gave you, 5% to 8% operating profit \ngrowth.  So, all of the channels are recovering, and they're recovering, as Brian mentioned, in line with our \nexpectations.  And they're all contributing to that overall core operating profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Wei ss \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nWe'll move to the next question.  \n ", "original_text": "So, all of the channels are recovering, and they're recovering, as Brian mentioned, in line with our \nexpectations. ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9dcbd20259b85e3f549e93e87cd97d4e2cf615af823c4a83e4489618cf64b41d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "83cb3516-dea5-414c-9bde-3c254dfbb007", "node_type": "1", "metadata": {"window": "A \nYeah, maybe I would just add that I think the balance of our customers and the channels that we serve, and what \nwe're seeing in those various channels is reflected in the guidan ce that we gave you, 5% to 8% operating profit \ngrowth.  So, all of the channels are recovering, and they're recovering, as Brian mentioned, in line with our \nexpectations.  And they're all contributing to that overall core operating profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Wei ss \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nWe'll move to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And we will go next to Lisa Gill of JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThank you. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Wei ss \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  "}, "hash": "d45dfc5d7af154ad6bc770ef3e04020d76137ebc2ce707de81ded3215e751dd1", "class_name": "RelatedNodeInfo"}}, "text": "And they're all contributing to that overall core operating profit growth.  \n ", "start_char_idx": 1994, "end_char_idx": 2072, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "83cb3516-dea5-414c-9bde-3c254dfbb007": {"__data__": {"id_": "83cb3516-dea5-414c-9bde-3c254dfbb007", "embedding": null, "metadata": {"window": "A \nYeah, maybe I would just add that I think the balance of our customers and the channels that we serve, and what \nwe're seeing in those various channels is reflected in the guidan ce that we gave you, 5% to 8% operating profit \ngrowth.  So, all of the channels are recovering, and they're recovering, as Brian mentioned, in line with our \nexpectations.  And they're all contributing to that overall core operating profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Wei ss \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nWe'll move to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And we will go next to Lisa Gill of JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThank you. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Wei ss \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f909d867-900f-4080-b21d-623d7f441f91", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48c78109aaaa8e0a7f880420e0ba169dca753d5625f4df3ce84ea839ec0c7538", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "371b8c79-65b5-49eb-a70d-6519f4515dca", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah, maybe I would just add that I think the balance of our customers and the channels that we serve, and what \nwe're seeing in those various channels is reflected in the guidan ce that we gave you, 5% to 8% operating profit \ngrowth.  So, all of the channels are recovering, and they're recovering, as Brian mentioned, in line with our \nexpectations.  And they're all contributing to that overall core operating profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Wei ss \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nWe'll move to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And we will go next to Lisa Gill of JPMorgan.  \n ", "original_text": "And they're all contributing to that overall core operating profit growth.  \n ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72a2fe309c97e12902a3897cfd411326a87dc503f66fd6e3f5b81add9ce3ff2a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4dc92c51-9b3e-4611-9124-7404be3ef34d", "node_type": "1", "metadata": {"window": "So, all of the channels are recovering, and they're recovering, as Brian mentioned, in line with our \nexpectations.  And they're all contributing to that overall core operating profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Wei ss \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nWe'll move to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And we will go next to Lisa Gill of JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThank you.  And let me  add my congratulations as well. ", "original_text": "A \nWe'll move to the next question.  \n "}, "hash": "800e80a955b1a62b9a4e39ac1359260e4e67d744611716d27b833ef7db6d8d27", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Wei ss \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "start_char_idx": 2072, "end_char_idx": 2446, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4dc92c51-9b3e-4611-9124-7404be3ef34d": {"__data__": {"id_": "4dc92c51-9b3e-4611-9124-7404be3ef34d", "embedding": null, "metadata": {"window": "So, all of the channels are recovering, and they're recovering, as Brian mentioned, in line with our \nexpectations.  And they're all contributing to that overall core operating profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Wei ss \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nWe'll move to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And we will go next to Lisa Gill of JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThank you.  And let me  add my congratulations as well. ", "original_text": "A \nWe'll move to the next question.  \n ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f909d867-900f-4080-b21d-623d7f441f91", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48c78109aaaa8e0a7f880420e0ba169dca753d5625f4df3ce84ea839ec0c7538", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "83cb3516-dea5-414c-9bde-3c254dfbb007", "node_type": "1", "metadata": {"window": "A \nYeah, maybe I would just add that I think the balance of our customers and the channels that we serve, and what \nwe're seeing in those various channels is reflected in the guidan ce that we gave you, 5% to 8% operating profit \ngrowth.  So, all of the channels are recovering, and they're recovering, as Brian mentioned, in line with our \nexpectations.  And they're all contributing to that overall core operating profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Wei ss \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nWe'll move to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And we will go next to Lisa Gill of JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThank you. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Wei ss \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3443d9014d124ab5f8260826428753a1dc7b7227a9e1f55953fc3b09e99412cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43eb72ef-28b8-4a66-8773-6607a83c0cc8", "node_type": "1", "metadata": {"window": "And they're all contributing to that overall core operating profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Wei ss \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nWe'll move to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And we will go next to Lisa Gill of JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThank you.  And let me  add my congratulations as well.  Brian and Britt, I just want to understand biosimilars. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And we will go next to Lisa Gill of JPMorgan.  \n "}, "hash": "4862f5daa82b0409ecf38fd76355131115293eb9266cf7c7fe93e94d53867201", "class_name": "RelatedNodeInfo"}}, "text": "A \nWe'll move to the next question.  \n ", "start_char_idx": 2446, "end_char_idx": 2485, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43eb72ef-28b8-4a66-8773-6607a83c0cc8": {"__data__": {"id_": "43eb72ef-28b8-4a66-8773-6607a83c0cc8", "embedding": null, "metadata": {"window": "And they're all contributing to that overall core operating profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Wei ss \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nWe'll move to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And we will go next to Lisa Gill of JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThank you.  And let me  add my congratulations as well.  Brian and Britt, I just want to understand biosimilars. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And we will go next to Lisa Gill of JPMorgan.  \n ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f909d867-900f-4080-b21d-623d7f441f91", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48c78109aaaa8e0a7f880420e0ba169dca753d5625f4df3ce84ea839ec0c7538", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4dc92c51-9b3e-4611-9124-7404be3ef34d", "node_type": "1", "metadata": {"window": "So, all of the channels are recovering, and they're recovering, as Brian mentioned, in line with our \nexpectations.  And they're all contributing to that overall core operating profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Wei ss \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nWe'll move to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And we will go next to Lisa Gill of JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThank you.  And let me  add my congratulations as well. ", "original_text": "A \nWe'll move to the next question.  \n ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "02b13f074a64529cf62ac351d09f2206ce639c2477139cadc817537265ec5648", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "977e90f2-1a7c-4698-9570-841798759cf8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Wei ss \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nWe'll move to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And we will go next to Lisa Gill of JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThank you.  And let me  add my congratulations as well.  Brian and Britt, I just want to understand biosimilars.  So, \nyou talked just now about operating profit. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThank you. "}, "hash": "b9d280f2ad7f7794afb14c907ec3dd91b15045f9d3d60ecf9ffdf527b612f449", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And we will go next to Lisa Gill of JPMorgan.  \n ", "start_char_idx": 2485, "end_char_idx": 2819, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "977e90f2-1a7c-4698-9570-841798759cf8": {"__data__": {"id_": "977e90f2-1a7c-4698-9570-841798759cf8", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Wei ss \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nWe'll move to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And we will go next to Lisa Gill of JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThank you.  And let me  add my congratulations as well.  Brian and Britt, I just want to understand biosimilars.  So, \nyou talked just now about operating profit. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThank you. ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f909d867-900f-4080-b21d-623d7f441f91", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48c78109aaaa8e0a7f880420e0ba169dca753d5625f4df3ce84ea839ec0c7538", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43eb72ef-28b8-4a66-8773-6607a83c0cc8", "node_type": "1", "metadata": {"window": "And they're all contributing to that overall core operating profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Wei ss \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nWe'll move to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And we will go next to Lisa Gill of JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThank you.  And let me  add my congratulations as well.  Brian and Britt, I just want to understand biosimilars. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And we will go next to Lisa Gill of JPMorgan.  \n ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8a7a978286f54829269a41dc26a7a5cab7fab2e48795410cca84bebcd810bc1e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e5d890f2-8354-4b09-9794-4b5926a618e5", "node_type": "1", "metadata": {"window": "A \nWe'll move to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And we will go next to Lisa Gill of JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThank you.  And let me  add my congratulations as well.  Brian and Britt, I just want to understand biosimilars.  So, \nyou talked just now about operating profit.  How much of an impact are biosimilars having? ", "original_text": "And let me  add my congratulations as well. "}, "hash": "bcb3f7f3e095c169d418c668ba0834bab7ba62c8cb3d97edaa78260c0bcc60c3", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThank you. ", "start_char_idx": 2819, "end_char_idx": 3154, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e5d890f2-8354-4b09-9794-4b5926a618e5": {"__data__": {"id_": "e5d890f2-8354-4b09-9794-4b5926a618e5", "embedding": null, "metadata": {"window": "A \nWe'll move to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And we will go next to Lisa Gill of JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThank you.  And let me  add my congratulations as well.  Brian and Britt, I just want to understand biosimilars.  So, \nyou talked just now about operating profit.  How much of an impact are biosimilars having? ", "original_text": "And let me  add my congratulations as well. ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f909d867-900f-4080-b21d-623d7f441f91", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48c78109aaaa8e0a7f880420e0ba169dca753d5625f4df3ce84ea839ec0c7538", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "977e90f2-1a7c-4698-9570-841798759cf8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Wei ss \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nWe'll move to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And we will go next to Lisa Gill of JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThank you.  And let me  add my congratulations as well.  Brian and Britt, I just want to understand biosimilars.  So, \nyou talked just now about operating profit. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThank you. ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5dcca3f1697d5120f2682774add9b5ebcc83c0fbeb887ec381b828f46d54585a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1582b25d-fc27-4c20-8450-eb61979a4312", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And we will go next to Lisa Gill of JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThank you.  And let me  add my congratulations as well.  Brian and Britt, I just want to understand biosimilars.  So, \nyou talked just now about operating profit.  How much of an impact are biosimilars having?  And then, as we think \nabout the comments, Brian, that you made both aroun d oncology and bio services, how do we think about that \ngoing forward, especially on the oncology side? ", "original_text": "Brian and Britt, I just want to understand biosimilars. "}, "hash": "768c35377adc56bf39e1be3524b379ad100efbd912236d070dc7ec6498d89e53", "class_name": "RelatedNodeInfo"}}, "text": "And let me  add my congratulations as well. ", "start_char_idx": 3154, "end_char_idx": 3198, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1582b25d-fc27-4c20-8450-eb61979a4312": {"__data__": {"id_": "1582b25d-fc27-4c20-8450-eb61979a4312", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And we will go next to Lisa Gill of JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThank you.  And let me  add my congratulations as well.  Brian and Britt, I just want to understand biosimilars.  So, \nyou talked just now about operating profit.  How much of an impact are biosimilars having?  And then, as we think \nabout the comments, Brian, that you made both aroun d oncology and bio services, how do we think about that \ngoing forward, especially on the oncology side? ", "original_text": "Brian and Britt, I just want to understand biosimilars. ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f909d867-900f-4080-b21d-623d7f441f91", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48c78109aaaa8e0a7f880420e0ba169dca753d5625f4df3ce84ea839ec0c7538", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e5d890f2-8354-4b09-9794-4b5926a618e5", "node_type": "1", "metadata": {"window": "A \nWe'll move to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And we will go next to Lisa Gill of JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThank you.  And let me  add my congratulations as well.  Brian and Britt, I just want to understand biosimilars.  So, \nyou talked just now about operating profit.  How much of an impact are biosimilars having? ", "original_text": "And let me  add my congratulations as well. ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "09a03830beae5e6f8c66b657ecf7eae7cb9ffa44fbbb9b951faf67a2694719cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "101256c4-ce56-43fe-96a2-43973b5852ac", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThank you.  And let me  add my congratulations as well.  Brian and Britt, I just want to understand biosimilars.  So, \nyou talked just now about operating profit.  How much of an impact are biosimilars having?  And then, as we think \nabout the comments, Brian, that you made both aroun d oncology and bio services, how do we think about that \ngoing forward, especially on the oncology side?  What type of investments are you making? ", "original_text": "So, \nyou talked just now about operating profit. "}, "hash": "0165b70731de80f7bd590aacd036ab6fac8fdfde5e62679322c68549081156e5", "class_name": "RelatedNodeInfo"}}, "text": "Brian and Britt, I just want to understand biosimilars. ", "start_char_idx": 3198, "end_char_idx": 3254, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "101256c4-ce56-43fe-96a2-43973b5852ac": {"__data__": {"id_": "101256c4-ce56-43fe-96a2-43973b5852ac", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThank you.  And let me  add my congratulations as well.  Brian and Britt, I just want to understand biosimilars.  So, \nyou talked just now about operating profit.  How much of an impact are biosimilars having?  And then, as we think \nabout the comments, Brian, that you made both aroun d oncology and bio services, how do we think about that \ngoing forward, especially on the oncology side?  What type of investments are you making? ", "original_text": "So, \nyou talked just now about operating profit. ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f909d867-900f-4080-b21d-623d7f441f91", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48c78109aaaa8e0a7f880420e0ba169dca753d5625f4df3ce84ea839ec0c7538", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1582b25d-fc27-4c20-8450-eb61979a4312", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And we will go next to Lisa Gill of JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThank you.  And let me  add my congratulations as well.  Brian and Britt, I just want to understand biosimilars.  So, \nyou talked just now about operating profit.  How much of an impact are biosimilars having?  And then, as we think \nabout the comments, Brian, that you made both aroun d oncology and bio services, how do we think about that \ngoing forward, especially on the oncology side? ", "original_text": "Brian and Britt, I just want to understand biosimilars. ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cdba1ec7cedf962f0e5af7843d89ee19f54795d7ae4972fb64423f4a20f7ef6b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "92579bf1-adca-43e9-baa6-a82007870b9f", "node_type": "1", "metadata": {"window": "And let me  add my congratulations as well.  Brian and Britt, I just want to understand biosimilars.  So, \nyou talked just now about operating profit.  How much of an impact are biosimilars having?  And then, as we think \nabout the comments, Brian, that you made both aroun d oncology and bio services, how do we think about that \ngoing forward, especially on the oncology side?  What type of investments are you making?  How important are \nbiosimilars? ", "original_text": "How much of an impact are biosimilars having? "}, "hash": "66d9563b28e894e66f56c6c89d9c8a8d410ebe66799413f054bb31ed548d11d2", "class_name": "RelatedNodeInfo"}}, "text": "So, \nyou talked just now about operating profit. ", "start_char_idx": 3254, "end_char_idx": 3303, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "92579bf1-adca-43e9-baa6-a82007870b9f": {"__data__": {"id_": "92579bf1-adca-43e9-baa6-a82007870b9f", "embedding": null, "metadata": {"window": "And let me  add my congratulations as well.  Brian and Britt, I just want to understand biosimilars.  So, \nyou talked just now about operating profit.  How much of an impact are biosimilars having?  And then, as we think \nabout the comments, Brian, that you made both aroun d oncology and bio services, how do we think about that \ngoing forward, especially on the oncology side?  What type of investments are you making?  How important are \nbiosimilars? ", "original_text": "How much of an impact are biosimilars having? ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f909d867-900f-4080-b21d-623d7f441f91", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48c78109aaaa8e0a7f880420e0ba169dca753d5625f4df3ce84ea839ec0c7538", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "101256c4-ce56-43fe-96a2-43973b5852ac", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThank you.  And let me  add my congratulations as well.  Brian and Britt, I just want to understand biosimilars.  So, \nyou talked just now about operating profit.  How much of an impact are biosimilars having?  And then, as we think \nabout the comments, Brian, that you made both aroun d oncology and bio services, how do we think about that \ngoing forward, especially on the oncology side?  What type of investments are you making? ", "original_text": "So, \nyou talked just now about operating profit. ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c219fd514164a304f68ed28e6230acd4162e6a5032ad04e57395af97fee98c0a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "372f5503-49b5-4846-9755-ac5f8b606f6a", "node_type": "1", "metadata": {"window": "Brian and Britt, I just want to understand biosimilars.  So, \nyou talked just now about operating profit.  How much of an impact are biosimilars having?  And then, as we think \nabout the comments, Brian, that you made both aroun d oncology and bio services, how do we think about that \ngoing forward, especially on the oncology side?  What type of investments are you making?  How important are \nbiosimilars?  Is this program \u2013 are you going to make acquisitions? ", "original_text": "And then, as we think \nabout the comments, Brian, that you made both aroun d oncology and bio services, how do we think about that \ngoing forward, especially on the oncology side? "}, "hash": "3905dfbdaf7f9300f051ba3a2573c821f4a8dfc2d662df4c1be5be9cdf92e25b", "class_name": "RelatedNodeInfo"}}, "text": "How much of an impact are biosimilars having? ", "start_char_idx": 3303, "end_char_idx": 3349, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "372f5503-49b5-4846-9755-ac5f8b606f6a": {"__data__": {"id_": "372f5503-49b5-4846-9755-ac5f8b606f6a", "embedding": null, "metadata": {"window": "Brian and Britt, I just want to understand biosimilars.  So, \nyou talked just now about operating profit.  How much of an impact are biosimilars having?  And then, as we think \nabout the comments, Brian, that you made both aroun d oncology and bio services, how do we think about that \ngoing forward, especially on the oncology side?  What type of investments are you making?  How important are \nbiosimilars?  Is this program \u2013 are you going to make acquisitions? ", "original_text": "And then, as we think \nabout the comments, Brian, that you made both aroun d oncology and bio services, how do we think about that \ngoing forward, especially on the oncology side? ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f909d867-900f-4080-b21d-623d7f441f91", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48c78109aaaa8e0a7f880420e0ba169dca753d5625f4df3ce84ea839ec0c7538", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "92579bf1-adca-43e9-baa6-a82007870b9f", "node_type": "1", "metadata": {"window": "And let me  add my congratulations as well.  Brian and Britt, I just want to understand biosimilars.  So, \nyou talked just now about operating profit.  How much of an impact are biosimilars having?  And then, as we think \nabout the comments, Brian, that you made both aroun d oncology and bio services, how do we think about that \ngoing forward, especially on the oncology side?  What type of investments are you making?  How important are \nbiosimilars? ", "original_text": "How much of an impact are biosimilars having? ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b9bb77c1022a96e669777914487af1fd68217fd86c61f41e2dbe412699501919", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "236bd445-e33f-4175-862c-eccbd6b51250", "node_type": "1", "metadata": {"window": "So, \nyou talked just now about operating profit.  How much of an impact are biosimilars having?  And then, as we think \nabout the comments, Brian, that you made both aroun d oncology and bio services, how do we think about that \ngoing forward, especially on the oncology side?  What type of investments are you making?  How important are \nbiosimilars?  Is this program \u2013 are you going to make acquisitions?  How do we think about that ? \n ", "original_text": "What type of investments are you making? "}, "hash": "0a48bd98e3399db00ee67ba399f3cb924c4da5d7317ae9c9edefacfacc35d06f", "class_name": "RelatedNodeInfo"}}, "text": "And then, as we think \nabout the comments, Brian, that you made both aroun d oncology and bio services, how do we think about that \ngoing forward, especially on the oncology side? ", "start_char_idx": 3349, "end_char_idx": 3529, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "236bd445-e33f-4175-862c-eccbd6b51250": {"__data__": {"id_": "236bd445-e33f-4175-862c-eccbd6b51250", "embedding": null, "metadata": {"window": "So, \nyou talked just now about operating profit.  How much of an impact are biosimilars having?  And then, as we think \nabout the comments, Brian, that you made both aroun d oncology and bio services, how do we think about that \ngoing forward, especially on the oncology side?  What type of investments are you making?  How important are \nbiosimilars?  Is this program \u2013 are you going to make acquisitions?  How do we think about that ? \n ", "original_text": "What type of investments are you making? ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f909d867-900f-4080-b21d-623d7f441f91", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48c78109aaaa8e0a7f880420e0ba169dca753d5625f4df3ce84ea839ec0c7538", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "372f5503-49b5-4846-9755-ac5f8b606f6a", "node_type": "1", "metadata": {"window": "Brian and Britt, I just want to understand biosimilars.  So, \nyou talked just now about operating profit.  How much of an impact are biosimilars having?  And then, as we think \nabout the comments, Brian, that you made both aroun d oncology and bio services, how do we think about that \ngoing forward, especially on the oncology side?  What type of investments are you making?  How important are \nbiosimilars?  Is this program \u2013 are you going to make acquisitions? ", "original_text": "And then, as we think \nabout the comments, Brian, that you made both aroun d oncology and bio services, how do we think about that \ngoing forward, especially on the oncology side? ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "10ad07ad845e252f201516813f765aa9b3df3b1102879f2e99d69ba992fc6aa2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75e1d83b-c1f3-4c9c-b486-c5282095f96a", "node_type": "1", "metadata": {"window": "How much of an impact are biosimilars having?  And then, as we think \nabout the comments, Brian, that you made both aroun d oncology and bio services, how do we think about that \ngoing forward, especially on the oncology side?  What type of investments are you making?  How important are \nbiosimilars?  Is this program \u2013 are you going to make acquisitions?  How do we think about that ? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "How important are \nbiosimilars? "}, "hash": "be38f7d7ae4bb3440e778a6bbd3ca8e1eff595c0b659779a4da927deb3f49a21", "class_name": "RelatedNodeInfo"}}, "text": "What type of investments are you making? ", "start_char_idx": 3529, "end_char_idx": 3570, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75e1d83b-c1f3-4c9c-b486-c5282095f96a": {"__data__": {"id_": "75e1d83b-c1f3-4c9c-b486-c5282095f96a", "embedding": null, "metadata": {"window": "How much of an impact are biosimilars having?  And then, as we think \nabout the comments, Brian, that you made both aroun d oncology and bio services, how do we think about that \ngoing forward, especially on the oncology side?  What type of investments are you making?  How important are \nbiosimilars?  Is this program \u2013 are you going to make acquisitions?  How do we think about that ? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "How important are \nbiosimilars? ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f909d867-900f-4080-b21d-623d7f441f91", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48c78109aaaa8e0a7f880420e0ba169dca753d5625f4df3ce84ea839ec0c7538", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "236bd445-e33f-4175-862c-eccbd6b51250", "node_type": "1", "metadata": {"window": "So, \nyou talked just now about operating profit.  How much of an impact are biosimilars having?  And then, as we think \nabout the comments, Brian, that you made both aroun d oncology and bio services, how do we think about that \ngoing forward, especially on the oncology side?  What type of investments are you making?  How important are \nbiosimilars?  Is this program \u2013 are you going to make acquisitions?  How do we think about that ? \n ", "original_text": "What type of investments are you making? ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94ba0d8df03e7a62629f8e86c6703f002b6302ca1eba1218daac2f63b92701a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a50a0dd-fc5f-457f-a490-6b7b072770da", "node_type": "1", "metadata": {"window": "And then, as we think \nabout the comments, Brian, that you made both aroun d oncology and bio services, how do we think about that \ngoing forward, especially on the oncology side?  What type of investments are you making?  How important are \nbiosimilars?  Is this program \u2013 are you going to make acquisitions?  How do we think about that ? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you. ", "original_text": "Is this program \u2013 are you going to make acquisitions? "}, "hash": "bf2af6db0395084a5875ad774adcb54c16114a9719fbfd45a7a8f2633b0c1bd3", "class_name": "RelatedNodeInfo"}}, "text": "How important are \nbiosimilars? ", "start_char_idx": 3570, "end_char_idx": 3602, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a50a0dd-fc5f-457f-a490-6b7b072770da": {"__data__": {"id_": "4a50a0dd-fc5f-457f-a490-6b7b072770da", "embedding": null, "metadata": {"window": "And then, as we think \nabout the comments, Brian, that you made both aroun d oncology and bio services, how do we think about that \ngoing forward, especially on the oncology side?  What type of investments are you making?  How important are \nbiosimilars?  Is this program \u2013 are you going to make acquisitions?  How do we think about that ? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you. ", "original_text": "Is this program \u2013 are you going to make acquisitions? ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f909d867-900f-4080-b21d-623d7f441f91", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48c78109aaaa8e0a7f880420e0ba169dca753d5625f4df3ce84ea839ec0c7538", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75e1d83b-c1f3-4c9c-b486-c5282095f96a", "node_type": "1", "metadata": {"window": "How much of an impact are biosimilars having?  And then, as we think \nabout the comments, Brian, that you made both aroun d oncology and bio services, how do we think about that \ngoing forward, especially on the oncology side?  What type of investments are you making?  How important are \nbiosimilars?  Is this program \u2013 are you going to make acquisitions?  How do we think about that ? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "How important are \nbiosimilars? ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "44f1a810e08fae767cf361b693c2d12d251755bafb734ebbcf5b2334c8441996", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "449650c6-d04f-45c0-ac89-12277f641a73", "node_type": "1", "metadata": {"window": "What type of investments are you making?  How important are \nbiosimilars?  Is this program \u2013 are you going to make acquisitions?  How do we think about that ? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you.  Thank you for the question, Lisa. ", "original_text": "How do we think about that ? \n "}, "hash": "c510f4651a5cd02421c7fe4c9725f53088feb57534c1a67f1c996adc6a3cab9f", "class_name": "RelatedNodeInfo"}}, "text": "Is this program \u2013 are you going to make acquisitions? ", "start_char_idx": 3602, "end_char_idx": 3656, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "449650c6-d04f-45c0-ac89-12277f641a73": {"__data__": {"id_": "449650c6-d04f-45c0-ac89-12277f641a73", "embedding": null, "metadata": {"window": "What type of investments are you making?  How important are \nbiosimilars?  Is this program \u2013 are you going to make acquisitions?  How do we think about that ? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you.  Thank you for the question, Lisa. ", "original_text": "How do we think about that ? \n ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f909d867-900f-4080-b21d-623d7f441f91", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48c78109aaaa8e0a7f880420e0ba169dca753d5625f4df3ce84ea839ec0c7538", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a50a0dd-fc5f-457f-a490-6b7b072770da", "node_type": "1", "metadata": {"window": "And then, as we think \nabout the comments, Brian, that you made both aroun d oncology and bio services, how do we think about that \ngoing forward, especially on the oncology side?  What type of investments are you making?  How important are \nbiosimilars?  Is this program \u2013 are you going to make acquisitions?  How do we think about that ? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you. ", "original_text": "Is this program \u2013 are you going to make acquisitions? ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46c4ba6dd419bdca4d83dc50e7afe3a9f6f244ae26a207ff484a497129451ffa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2420823c-c080-4154-aefa-37aabc15287f", "node_type": "1", "metadata": {"window": "How important are \nbiosimilars?  Is this program \u2013 are you going to make acquisitions?  How do we think about that ? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you.  Thank you for the question, Lisa.  I'll maybe start with biosimilars and then round into the oncology \nquestion. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "a1763bb3813c9661568bfd17323f0c2cc3e7e7cdcf20979850f09304355b271c", "class_name": "RelatedNodeInfo"}}, "text": "How do we think about that ? \n ", "start_char_idx": 3656, "end_char_idx": 3687, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2420823c-c080-4154-aefa-37aabc15287f": {"__data__": {"id_": "2420823c-c080-4154-aefa-37aabc15287f", "embedding": null, "metadata": {"window": "How important are \nbiosimilars?  Is this program \u2013 are you going to make acquisitions?  How do we think about that ? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you.  Thank you for the question, Lisa.  I'll maybe start with biosimilars and then round into the oncology \nquestion. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f909d867-900f-4080-b21d-623d7f441f91", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48c78109aaaa8e0a7f880420e0ba169dca753d5625f4df3ce84ea839ec0c7538", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "449650c6-d04f-45c0-ac89-12277f641a73", "node_type": "1", "metadata": {"window": "What type of investments are you making?  How important are \nbiosimilars?  Is this program \u2013 are you going to make acquisitions?  How do we think about that ? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you.  Thank you for the question, Lisa. ", "original_text": "How do we think about that ? \n ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2181bfb2fc945b54148c19ef49ab54f34b8f37f4a9c6f1706e0d7695d07e740b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f3e692a9-1482-4381-9b69-77063ee31307", "node_type": "1", "metadata": {"window": "Is this program \u2013 are you going to make acquisitions?  How do we think about that ? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you.  Thank you for the question, Lisa.  I'll maybe start with biosimilars and then round into the oncology \nquestion.  I mean, biosimilars, we think we are very well positioned given our strength in the specialty business \nand including the oncology elements of that. ", "original_text": "A \nThank you. "}, "hash": "bc356410b18059d3cabbf13ee591c28987c38589c964a269d2877f1227b78fd9", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 3687, "end_char_idx": 4031, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f3e692a9-1482-4381-9b69-77063ee31307": {"__data__": {"id_": "f3e692a9-1482-4381-9b69-77063ee31307", "embedding": null, "metadata": {"window": "Is this program \u2013 are you going to make acquisitions?  How do we think about that ? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you.  Thank you for the question, Lisa.  I'll maybe start with biosimilars and then round into the oncology \nquestion.  I mean, biosimilars, we think we are very well positioned given our strength in the specialty business \nand including the oncology elements of that. ", "original_text": "A \nThank you. ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f909d867-900f-4080-b21d-623d7f441f91", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48c78109aaaa8e0a7f880420e0ba169dca753d5625f4df3ce84ea839ec0c7538", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2420823c-c080-4154-aefa-37aabc15287f", "node_type": "1", "metadata": {"window": "How important are \nbiosimilars?  Is this program \u2013 are you going to make acquisitions?  How do we think about that ? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you.  Thank you for the question, Lisa.  I'll maybe start with biosimilars and then round into the oncology \nquestion. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0c4c4de422d910890e20243ede77eaa7e92ab17ef2d88ef8346c2e923dd57e29", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09eab0b4-923e-4961-a5c6-7e5b001a550d", "node_type": "1", "metadata": {"window": "How do we think about that ? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you.  Thank you for the question, Lisa.  I'll maybe start with biosimilars and then round into the oncology \nquestion.  I mean, biosimilars, we think we are very well positioned given our strength in the specialty business \nand including the oncology elements of that.  It still, from our perspective, is fairly early days. ", "original_text": "Thank you for the question, Lisa. "}, "hash": "9a9b83736de7e98f00dad9834ecddc66ae2f21b83e2e67f7ec30e480d0c20058", "class_name": "RelatedNodeInfo"}}, "text": "A \nThank you. ", "start_char_idx": 4031, "end_char_idx": 4045, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09eab0b4-923e-4961-a5c6-7e5b001a550d": {"__data__": {"id_": "09eab0b4-923e-4961-a5c6-7e5b001a550d", "embedding": null, "metadata": {"window": "How do we think about that ? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you.  Thank you for the question, Lisa.  I'll maybe start with biosimilars and then round into the oncology \nquestion.  I mean, biosimilars, we think we are very well positioned given our strength in the specialty business \nand including the oncology elements of that.  It still, from our perspective, is fairly early days. ", "original_text": "Thank you for the question, Lisa. ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f909d867-900f-4080-b21d-623d7f441f91", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48c78109aaaa8e0a7f880420e0ba169dca753d5625f4df3ce84ea839ec0c7538", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f3e692a9-1482-4381-9b69-77063ee31307", "node_type": "1", "metadata": {"window": "Is this program \u2013 are you going to make acquisitions?  How do we think about that ? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you.  Thank you for the question, Lisa.  I'll maybe start with biosimilars and then round into the oncology \nquestion.  I mean, biosimilars, we think we are very well positioned given our strength in the specialty business \nand including the oncology elements of that. ", "original_text": "A \nThank you. ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "02f50f232a29a2ea11908c0c7fd62ccb815bdfbd0bfa1669ca99ccebed5a1b4a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03deea13-2ab1-41af-9afa-9c8a6a07ed9c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you.  Thank you for the question, Lisa.  I'll maybe start with biosimilars and then round into the oncology \nquestion.  I mean, biosimilars, we think we are very well positioned given our strength in the specialty business \nand including the oncology elements of that.  It still, from our perspective, is fairly early days.  There is just under a \ndozen in the marketplace today. ", "original_text": "I'll maybe start with biosimilars and then round into the oncology \nquestion. "}, "hash": "da63710305be313316bfa559b602661ede9a8d991ea064a7389a9591ba3915a7", "class_name": "RelatedNodeInfo"}}, "text": "Thank you for the question, Lisa. ", "start_char_idx": 4045, "end_char_idx": 4079, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03deea13-2ab1-41af-9afa-9c8a6a07ed9c": {"__data__": {"id_": "03deea13-2ab1-41af-9afa-9c8a6a07ed9c", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you.  Thank you for the question, Lisa.  I'll maybe start with biosimilars and then round into the oncology \nquestion.  I mean, biosimilars, we think we are very well positioned given our strength in the specialty business \nand including the oncology elements of that.  It still, from our perspective, is fairly early days.  There is just under a \ndozen in the marketplace today. ", "original_text": "I'll maybe start with biosimilars and then round into the oncology \nquestion. ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f909d867-900f-4080-b21d-623d7f441f91", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48c78109aaaa8e0a7f880420e0ba169dca753d5625f4df3ce84ea839ec0c7538", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09eab0b4-923e-4961-a5c6-7e5b001a550d", "node_type": "1", "metadata": {"window": "How do we think about that ? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you.  Thank you for the question, Lisa.  I'll maybe start with biosimilars and then round into the oncology \nquestion.  I mean, biosimilars, we think we are very well positioned given our strength in the specialty business \nand including the oncology elements of that.  It still, from our perspective, is fairly early days. ", "original_text": "Thank you for the question, Lisa. ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c265a7419393f4d4fc97b93c8419c30cc062e0e17f6b5edab0e8b7a2eabfd680", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "126706c5-90ac-47c0-a422-e764e8b09d56", "node_type": "1", "metadata": {"window": "A \nThank you.  Thank you for the question, Lisa.  I'll maybe start with biosimilars and then round into the oncology \nquestion.  I mean, biosimilars, we think we are very well positioned given our strength in the specialty business \nand including the oncology elements of that.  It still, from our perspective, is fairly early days.  There is just under a \ndozen in the marketplace today.  We think the pipeline does look good. ", "original_text": "I mean, biosimilars, we think we are very well positioned given our strength in the specialty business \nand including the oncology elements of that. "}, "hash": "23eae5b960b26828a02e68aa5e0aa76b6e2ffca85c7814a7b13db912a470e0e7", "class_name": "RelatedNodeInfo"}}, "text": "I'll maybe start with biosimilars and then round into the oncology \nquestion. ", "start_char_idx": 4079, "end_char_idx": 4157, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "126706c5-90ac-47c0-a422-e764e8b09d56": {"__data__": {"id_": "126706c5-90ac-47c0-a422-e764e8b09d56", "embedding": null, "metadata": {"window": "A \nThank you.  Thank you for the question, Lisa.  I'll maybe start with biosimilars and then round into the oncology \nquestion.  I mean, biosimilars, we think we are very well positioned given our strength in the specialty business \nand including the oncology elements of that.  It still, from our perspective, is fairly early days.  There is just under a \ndozen in the marketplace today.  We think the pipeline does look good. ", "original_text": "I mean, biosimilars, we think we are very well positioned given our strength in the specialty business \nand including the oncology elements of that. ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f909d867-900f-4080-b21d-623d7f441f91", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48c78109aaaa8e0a7f880420e0ba169dca753d5625f4df3ce84ea839ec0c7538", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03deea13-2ab1-41af-9afa-9c8a6a07ed9c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you.  Thank you for the question, Lisa.  I'll maybe start with biosimilars and then round into the oncology \nquestion.  I mean, biosimilars, we think we are very well positioned given our strength in the specialty business \nand including the oncology elements of that.  It still, from our perspective, is fairly early days.  There is just under a \ndozen in the marketplace today. ", "original_text": "I'll maybe start with biosimilars and then round into the oncology \nquestion. ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f6c99b0651b7529603637d7b2d2d1e47a65bf07f5bcb849113ef841243fd58e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3684376a-cbf9-4fdf-8ec1-6b838972a489", "node_type": "1", "metadata": {"window": "Thank you for the question, Lisa.  I'll maybe start with biosimilars and then round into the oncology \nquestion.  I mean, biosimilars, we think we are very well positioned given our strength in the specialty business \nand including the oncology elements of that.  It still, from our perspective, is fairly early days.  There is just under a \ndozen in the marketplace today.  We think the pipeline does look good.  And that given the a ssets we have in \noncology and biopharma and our footprint in the specialty space, we will benefit from that. ", "original_text": "It still, from our perspective, is fairly early days. "}, "hash": "0d1502994e5001f610dc0f91e3607a5a3f45d7ebc4a1265ef033ecb4e34cdce1", "class_name": "RelatedNodeInfo"}}, "text": "I mean, biosimilars, we think we are very well positioned given our strength in the specialty business \nand including the oncology elements of that. ", "start_char_idx": 4157, "end_char_idx": 4306, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3684376a-cbf9-4fdf-8ec1-6b838972a489": {"__data__": {"id_": "3684376a-cbf9-4fdf-8ec1-6b838972a489", "embedding": null, "metadata": {"window": "Thank you for the question, Lisa.  I'll maybe start with biosimilars and then round into the oncology \nquestion.  I mean, biosimilars, we think we are very well positioned given our strength in the specialty business \nand including the oncology elements of that.  It still, from our perspective, is fairly early days.  There is just under a \ndozen in the marketplace today.  We think the pipeline does look good.  And that given the a ssets we have in \noncology and biopharma and our footprint in the specialty space, we will benefit from that. ", "original_text": "It still, from our perspective, is fairly early days. ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f909d867-900f-4080-b21d-623d7f441f91", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48c78109aaaa8e0a7f880420e0ba169dca753d5625f4df3ce84ea839ec0c7538", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "126706c5-90ac-47c0-a422-e764e8b09d56", "node_type": "1", "metadata": {"window": "A \nThank you.  Thank you for the question, Lisa.  I'll maybe start with biosimilars and then round into the oncology \nquestion.  I mean, biosimilars, we think we are very well positioned given our strength in the specialty business \nand including the oncology elements of that.  It still, from our perspective, is fairly early days.  There is just under a \ndozen in the marketplace today.  We think the pipeline does look good. ", "original_text": "I mean, biosimilars, we think we are very well positioned given our strength in the specialty business \nand including the oncology elements of that. ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "421f4c87b97e48b0094760374c13d6f6a1fcec7e943e0572361412fdbff735d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "190fe8de-621f-42d6-8e68-dc108bb53cee", "node_type": "1", "metadata": {"window": "I'll maybe start with biosimilars and then round into the oncology \nquestion.  I mean, biosimilars, we think we are very well positioned given our strength in the specialty business \nand including the oncology elements of that.  It still, from our perspective, is fairly early days.  There is just under a \ndozen in the marketplace today.  We think the pipeline does look good.  And that given the a ssets we have in \noncology and biopharma and our footprint in the specialty space, we will benefit from that.  And we have seen a \ngrowing impact of biosimilars over the last several quarters.  \n \n", "original_text": "There is just under a \ndozen in the marketplace today. "}, "hash": "e9ef74a69d77caff20dbc1c41fb1243690ff8448308841213f063eadbc179a52", "class_name": "RelatedNodeInfo"}}, "text": "It still, from our perspective, is fairly early days. ", "start_char_idx": 4306, "end_char_idx": 4360, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "190fe8de-621f-42d6-8e68-dc108bb53cee": {"__data__": {"id_": "190fe8de-621f-42d6-8e68-dc108bb53cee", "embedding": null, "metadata": {"window": "I'll maybe start with biosimilars and then round into the oncology \nquestion.  I mean, biosimilars, we think we are very well positioned given our strength in the specialty business \nand including the oncology elements of that.  It still, from our perspective, is fairly early days.  There is just under a \ndozen in the marketplace today.  We think the pipeline does look good.  And that given the a ssets we have in \noncology and biopharma and our footprint in the specialty space, we will benefit from that.  And we have seen a \ngrowing impact of biosimilars over the last several quarters.  \n \n", "original_text": "There is just under a \ndozen in the marketplace today. ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f909d867-900f-4080-b21d-623d7f441f91", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48c78109aaaa8e0a7f880420e0ba169dca753d5625f4df3ce84ea839ec0c7538", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3684376a-cbf9-4fdf-8ec1-6b838972a489", "node_type": "1", "metadata": {"window": "Thank you for the question, Lisa.  I'll maybe start with biosimilars and then round into the oncology \nquestion.  I mean, biosimilars, we think we are very well positioned given our strength in the specialty business \nand including the oncology elements of that.  It still, from our perspective, is fairly early days.  There is just under a \ndozen in the marketplace today.  We think the pipeline does look good.  And that given the a ssets we have in \noncology and biopharma and our footprint in the specialty space, we will benefit from that. ", "original_text": "It still, from our perspective, is fairly early days. ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b1e6429506a237ef0fa34e5df2bfd6be25b60c9a03850699d664e6cba4818198", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4109baee-9437-4daf-a89d-a49c620f1fba", "node_type": "1", "metadata": {"window": "I mean, biosimilars, we think we are very well positioned given our strength in the specialty business \nand including the oncology elements of that.  It still, from our perspective, is fairly early days.  There is just under a \ndozen in the marketplace today.  We think the pipeline does look good.  And that given the a ssets we have in \noncology and biopharma and our footprint in the specialty space, we will benefit from that.  And we have seen a \ngrowing impact of biosimilars over the last several quarters.  \n \n As it relates to oncology, we use the word ecosystem, and that's really just to try to introduce this notion that there \nare many assets that McKesson has that relate to our oncology businesses, whether it's distribution, specialty ", "original_text": "We think the pipeline does look good. "}, "hash": "df7e9dbf3be15f7f6beea28c0b45389b018ce3e38932710ad5982696350c3f43", "class_name": "RelatedNodeInfo"}}, "text": "There is just under a \ndozen in the marketplace today. ", "start_char_idx": 4360, "end_char_idx": 4415, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4109baee-9437-4daf-a89d-a49c620f1fba": {"__data__": {"id_": "4109baee-9437-4daf-a89d-a49c620f1fba", "embedding": null, "metadata": {"window": "I mean, biosimilars, we think we are very well positioned given our strength in the specialty business \nand including the oncology elements of that.  It still, from our perspective, is fairly early days.  There is just under a \ndozen in the marketplace today.  We think the pipeline does look good.  And that given the a ssets we have in \noncology and biopharma and our footprint in the specialty space, we will benefit from that.  And we have seen a \ngrowing impact of biosimilars over the last several quarters.  \n \n As it relates to oncology, we use the word ecosystem, and that's really just to try to introduce this notion that there \nare many assets that McKesson has that relate to our oncology businesses, whether it's distribution, specialty ", "original_text": "We think the pipeline does look good. ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f909d867-900f-4080-b21d-623d7f441f91", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48c78109aaaa8e0a7f880420e0ba169dca753d5625f4df3ce84ea839ec0c7538", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "190fe8de-621f-42d6-8e68-dc108bb53cee", "node_type": "1", "metadata": {"window": "I'll maybe start with biosimilars and then round into the oncology \nquestion.  I mean, biosimilars, we think we are very well positioned given our strength in the specialty business \nand including the oncology elements of that.  It still, from our perspective, is fairly early days.  There is just under a \ndozen in the marketplace today.  We think the pipeline does look good.  And that given the a ssets we have in \noncology and biopharma and our footprint in the specialty space, we will benefit from that.  And we have seen a \ngrowing impact of biosimilars over the last several quarters.  \n \n", "original_text": "There is just under a \ndozen in the marketplace today. ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "11aba4d4a8a0a126e8a41cebda289e1a0bfcd213da451886796ce94879341ad0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9e8e9c8-6ef5-4bd5-b4a7-f676670a31ec", "node_type": "1", "metadata": {"window": "It still, from our perspective, is fairly early days.  There is just under a \ndozen in the marketplace today.  We think the pipeline does look good.  And that given the a ssets we have in \noncology and biopharma and our footprint in the specialty space, we will benefit from that.  And we have seen a \ngrowing impact of biosimilars over the last several quarters.  \n \n As it relates to oncology, we use the word ecosystem, and that's really just to try to introduce this notion that there \nare many assets that McKesson has that relate to our oncology businesses, whether it's distribution, specialty ", "original_text": "And that given the a ssets we have in \noncology and biopharma and our footprint in the specialty space, we will benefit from that. "}, "hash": "f3c46f367323d307ed88630b01c6f82c576ab8defdfac634cf3d0b43b864cdbb", "class_name": "RelatedNodeInfo"}}, "text": "We think the pipeline does look good. ", "start_char_idx": 4415, "end_char_idx": 4453, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9e8e9c8-6ef5-4bd5-b4a7-f676670a31ec": {"__data__": {"id_": "a9e8e9c8-6ef5-4bd5-b4a7-f676670a31ec", "embedding": null, "metadata": {"window": "It still, from our perspective, is fairly early days.  There is just under a \ndozen in the marketplace today.  We think the pipeline does look good.  And that given the a ssets we have in \noncology and biopharma and our footprint in the specialty space, we will benefit from that.  And we have seen a \ngrowing impact of biosimilars over the last several quarters.  \n \n As it relates to oncology, we use the word ecosystem, and that's really just to try to introduce this notion that there \nare many assets that McKesson has that relate to our oncology businesses, whether it's distribution, specialty ", "original_text": "And that given the a ssets we have in \noncology and biopharma and our footprint in the specialty space, we will benefit from that. ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f909d867-900f-4080-b21d-623d7f441f91", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48c78109aaaa8e0a7f880420e0ba169dca753d5625f4df3ce84ea839ec0c7538", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4109baee-9437-4daf-a89d-a49c620f1fba", "node_type": "1", "metadata": {"window": "I mean, biosimilars, we think we are very well positioned given our strength in the specialty business \nand including the oncology elements of that.  It still, from our perspective, is fairly early days.  There is just under a \ndozen in the marketplace today.  We think the pipeline does look good.  And that given the a ssets we have in \noncology and biopharma and our footprint in the specialty space, we will benefit from that.  And we have seen a \ngrowing impact of biosimilars over the last several quarters.  \n \n As it relates to oncology, we use the word ecosystem, and that's really just to try to introduce this notion that there \nare many assets that McKesson has that relate to our oncology businesses, whether it's distribution, specialty ", "original_text": "We think the pipeline does look good. ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00e11e112b4da45ba70bf0c48c2279cc3c09cc63f530d36178156f36bed6011f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f7718fe3-cc93-49d6-a346-fdc08543dfaf", "node_type": "1", "metadata": {"window": "There is just under a \ndozen in the marketplace today.  We think the pipeline does look good.  And that given the a ssets we have in \noncology and biopharma and our footprint in the specialty space, we will benefit from that.  And we have seen a \ngrowing impact of biosimilars over the last several quarters.  \n \n As it relates to oncology, we use the word ecosystem, and that's really just to try to introduce this notion that there \nare many assets that McKesson has that relate to our oncology businesses, whether it's distribution, specialty ", "original_text": "And we have seen a \ngrowing impact of biosimilars over the last several quarters.  \n \n"}, "hash": "386ded8f1680cf404e96f9a987f6c712f9951f65c659cbf92fa76c81bfea0cd7", "class_name": "RelatedNodeInfo"}}, "text": "And that given the a ssets we have in \noncology and biopharma and our footprint in the specialty space, we will benefit from that. ", "start_char_idx": 4453, "end_char_idx": 4584, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f7718fe3-cc93-49d6-a346-fdc08543dfaf": {"__data__": {"id_": "f7718fe3-cc93-49d6-a346-fdc08543dfaf", "embedding": null, "metadata": {"window": "There is just under a \ndozen in the marketplace today.  We think the pipeline does look good.  And that given the a ssets we have in \noncology and biopharma and our footprint in the specialty space, we will benefit from that.  And we have seen a \ngrowing impact of biosimilars over the last several quarters.  \n \n As it relates to oncology, we use the word ecosystem, and that's really just to try to introduce this notion that there \nare many assets that McKesson has that relate to our oncology businesses, whether it's distribution, specialty ", "original_text": "And we have seen a \ngrowing impact of biosimilars over the last several quarters.  \n \n", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f909d867-900f-4080-b21d-623d7f441f91", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48c78109aaaa8e0a7f880420e0ba169dca753d5625f4df3ce84ea839ec0c7538", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9e8e9c8-6ef5-4bd5-b4a7-f676670a31ec", "node_type": "1", "metadata": {"window": "It still, from our perspective, is fairly early days.  There is just under a \ndozen in the marketplace today.  We think the pipeline does look good.  And that given the a ssets we have in \noncology and biopharma and our footprint in the specialty space, we will benefit from that.  And we have seen a \ngrowing impact of biosimilars over the last several quarters.  \n \n As it relates to oncology, we use the word ecosystem, and that's really just to try to introduce this notion that there \nare many assets that McKesson has that relate to our oncology businesses, whether it's distribution, specialty ", "original_text": "And that given the a ssets we have in \noncology and biopharma and our footprint in the specialty space, we will benefit from that. ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "de07d8149364df4fe01a33e152ba721d4861dd0bf4442313a133e8810e44af97", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8973c7b3-43ee-4145-9d28-131ab0e827ed", "node_type": "1", "metadata": {"window": "We think the pipeline does look good.  And that given the a ssets we have in \noncology and biopharma and our footprint in the specialty space, we will benefit from that.  And we have seen a \ngrowing impact of biosimilars over the last several quarters.  \n \n As it relates to oncology, we use the word ecosystem, and that's really just to try to introduce this notion that there \nare many assets that McKesson has that relate to our oncology businesses, whether it's distribution, specialty ", "original_text": "As it relates to oncology, we use the word ecosystem, and that's really just to try to introduce this notion that there \nare many assets that McKesson has that relate to our oncology businesses, whether it's distribution, specialty "}, "hash": "968b2954dd7d8b1ef5c0a20bd8dc5d538a4d1fc70f873bfa6bc2549ed90d51f8", "class_name": "RelatedNodeInfo"}}, "text": "And we have seen a \ngrowing impact of biosimilars over the last several quarters.  \n \n", "start_char_idx": 4584, "end_char_idx": 4670, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8973c7b3-43ee-4145-9d28-131ab0e827ed": {"__data__": {"id_": "8973c7b3-43ee-4145-9d28-131ab0e827ed", "embedding": null, "metadata": {"window": "We think the pipeline does look good.  And that given the a ssets we have in \noncology and biopharma and our footprint in the specialty space, we will benefit from that.  And we have seen a \ngrowing impact of biosimilars over the last several quarters.  \n \n As it relates to oncology, we use the word ecosystem, and that's really just to try to introduce this notion that there \nare many assets that McKesson has that relate to our oncology businesses, whether it's distribution, specialty ", "original_text": "As it relates to oncology, we use the word ecosystem, and that's really just to try to introduce this notion that there \nare many assets that McKesson has that relate to our oncology businesses, whether it's distribution, specialty ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f909d867-900f-4080-b21d-623d7f441f91", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48c78109aaaa8e0a7f880420e0ba169dca753d5625f4df3ce84ea839ec0c7538", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f7718fe3-cc93-49d6-a346-fdc08543dfaf", "node_type": "1", "metadata": {"window": "There is just under a \ndozen in the marketplace today.  We think the pipeline does look good.  And that given the a ssets we have in \noncology and biopharma and our footprint in the specialty space, we will benefit from that.  And we have seen a \ngrowing impact of biosimilars over the last several quarters.  \n \n As it relates to oncology, we use the word ecosystem, and that's really just to try to introduce this notion that there \nare many assets that McKesson has that relate to our oncology businesses, whether it's distribution, specialty ", "original_text": "And we have seen a \ngrowing impact of biosimilars over the last several quarters.  \n \n", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c1814c117ff17c9652e89aab45f63492329ef1d41a249a74c6b2bc1f61728541", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "96a649f6-81e4-4729-a0f0-d578cd6d9531", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ndistribution, GPOs, health economic outcome, research.  The latest addition to that portfol io of assets is the data \nand insights business that we call Ontada.  \n \n And when we think of the oncology ecosystem, we think of these as all kind of self -reinforcing and adding \nmomentum to each other. ", "original_text": "McKesson Corp.  "}, "hash": "40ffa76ce94af9cfb735494e9c99a62bcc4af40c02ff958fd019ad263a27685e", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to oncology, we use the word ecosystem, and that's really just to try to introduce this notion that there \nare many assets that McKesson has that relate to our oncology businesses, whether it's distribution, specialty ", "start_char_idx": 4670, "end_char_idx": 4902, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "96a649f6-81e4-4729-a0f0-d578cd6d9531": {"__data__": {"id_": "96a649f6-81e4-4729-a0f0-d578cd6d9531", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ndistribution, GPOs, health economic outcome, research.  The latest addition to that portfol io of assets is the data \nand insights business that we call Ontada.  \n \n And when we think of the oncology ecosystem, we think of these as all kind of self -reinforcing and adding \nmomentum to each other. ", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7c86e1438adf8e697caee39b47ea8dbb10d71fa08f6a27738752a5bac88f2df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8973c7b3-43ee-4145-9d28-131ab0e827ed", "node_type": "1", "metadata": {"window": "We think the pipeline does look good.  And that given the a ssets we have in \noncology and biopharma and our footprint in the specialty space, we will benefit from that.  And we have seen a \ngrowing impact of biosimilars over the last several quarters.  \n \n As it relates to oncology, we use the word ecosystem, and that's really just to try to introduce this notion that there \nare many assets that McKesson has that relate to our oncology businesses, whether it's distribution, specialty ", "original_text": "As it relates to oncology, we use the word ecosystem, and that's really just to try to introduce this notion that there \nare many assets that McKesson has that relate to our oncology businesses, whether it's distribution, specialty ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0405f78d30ced6d689b74d7a5477fcb2924c61d1e3384d91271f0af0ca9955b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4030a1b9-1ac4-4c4e-b4a7-f7dc523eea81", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ndistribution, GPOs, health economic outcome, research.  The latest addition to that portfol io of assets is the data \nand insights business that we call Ontada.  \n \n And when we think of the oncology ecosystem, we think of these as all kind of self -reinforcing and adding \nmomentum to each other.  We add providers that add scale to GPO, that adds more cu stomers and data to \nOntada. ", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ndistribution, GPOs, health economic outcome, research. "}, "hash": "b760f1d9a25bbc4644e5bb885f876c7d57912a14e420af21045bd921a021cc2b", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4030a1b9-1ac4-4c4e-b4a7-f7dc523eea81": {"__data__": {"id_": "4030a1b9-1ac4-4c4e-b4a7-f7dc523eea81", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ndistribution, GPOs, health economic outcome, research.  The latest addition to that portfol io of assets is the data \nand insights business that we call Ontada.  \n \n And when we think of the oncology ecosystem, we think of these as all kind of self -reinforcing and adding \nmomentum to each other.  We add providers that add scale to GPO, that adds more cu stomers and data to \nOntada. ", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ndistribution, GPOs, health economic outcome, research. ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7c86e1438adf8e697caee39b47ea8dbb10d71fa08f6a27738752a5bac88f2df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "96a649f6-81e4-4729-a0f0-d578cd6d9531", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ndistribution, GPOs, health economic outcome, research.  The latest addition to that portfol io of assets is the data \nand insights business that we call Ontada.  \n \n And when we think of the oncology ecosystem, we think of these as all kind of self -reinforcing and adding \nmomentum to each other. ", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef8a170cb5c1e4deb83c0ca3d78f51330b0174287f2cd02a862774d49e8aecc3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b735c43-f0a9-48b3-9970-e8fe0cd30353", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ndistribution, GPOs, health economic outcome, research.  The latest addition to that portfol io of assets is the data \nand insights business that we call Ontada.  \n \n And when we think of the oncology ecosystem, we think of these as all kind of self -reinforcing and adding \nmomentum to each other.  We add providers that add scale to GPO, that adds more cu stomers and data to \nOntada.  As Ontada matures, as partnerships expand, we get more insights. ", "original_text": "The latest addition to that portfol io of assets is the data \nand insights business that we call Ontada.  \n \n"}, "hash": "ffe499aa5de3ea485d5b3767054d8908fa8431c627fab47b84ecd5bc8f641192", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ndistribution, GPOs, health economic outcome, research. ", "start_char_idx": 16, "end_char_idx": 236, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b735c43-f0a9-48b3-9970-e8fe0cd30353": {"__data__": {"id_": "4b735c43-f0a9-48b3-9970-e8fe0cd30353", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ndistribution, GPOs, health economic outcome, research.  The latest addition to that portfol io of assets is the data \nand insights business that we call Ontada.  \n \n And when we think of the oncology ecosystem, we think of these as all kind of self -reinforcing and adding \nmomentum to each other.  We add providers that add scale to GPO, that adds more cu stomers and data to \nOntada.  As Ontada matures, as partnerships expand, we get more insights. ", "original_text": "The latest addition to that portfol io of assets is the data \nand insights business that we call Ontada.  \n \n", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7c86e1438adf8e697caee39b47ea8dbb10d71fa08f6a27738752a5bac88f2df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4030a1b9-1ac4-4c4e-b4a7-f7dc523eea81", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ndistribution, GPOs, health economic outcome, research.  The latest addition to that portfol io of assets is the data \nand insights business that we call Ontada.  \n \n And when we think of the oncology ecosystem, we think of these as all kind of self -reinforcing and adding \nmomentum to each other.  We add providers that add scale to GPO, that adds more cu stomers and data to \nOntada. ", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ndistribution, GPOs, health economic outcome, research. ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73d8716f8ba276846ac7f8193baf4b6a3b2c8c159c90792217b40fc461c5fb3f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5dd8c5f5-d46d-4212-8038-d2b9333c4502", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ndistribution, GPOs, health economic outcome, research.  The latest addition to that portfol io of assets is the data \nand insights business that we call Ontada.  \n \n And when we think of the oncology ecosystem, we think of these as all kind of self -reinforcing and adding \nmomentum to each other.  We add providers that add scale to GPO, that adds more cu stomers and data to \nOntada.  As Ontada matures, as partnerships expand, we get more insights.  We funnel that back to providers \nwhich makes us a more attractive solution provider to them. ", "original_text": "And when we think of the oncology ecosystem, we think of these as all kind of self -reinforcing and adding \nmomentum to each other. "}, "hash": "c716046ee92b08822dace41d6ff2fc88413383ed6b984426c061f952628f2210", "class_name": "RelatedNodeInfo"}}, "text": "The latest addition to that portfol io of assets is the data \nand insights business that we call Ontada.  \n \n", "start_char_idx": 236, "end_char_idx": 345, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5dd8c5f5-d46d-4212-8038-d2b9333c4502": {"__data__": {"id_": "5dd8c5f5-d46d-4212-8038-d2b9333c4502", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ndistribution, GPOs, health economic outcome, research.  The latest addition to that portfol io of assets is the data \nand insights business that we call Ontada.  \n \n And when we think of the oncology ecosystem, we think of these as all kind of self -reinforcing and adding \nmomentum to each other.  We add providers that add scale to GPO, that adds more cu stomers and data to \nOntada.  As Ontada matures, as partnerships expand, we get more insights.  We funnel that back to providers \nwhich makes us a more attractive solution provider to them. ", "original_text": "And when we think of the oncology ecosystem, we think of these as all kind of self -reinforcing and adding \nmomentum to each other. ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7c86e1438adf8e697caee39b47ea8dbb10d71fa08f6a27738752a5bac88f2df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b735c43-f0a9-48b3-9970-e8fe0cd30353", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ndistribution, GPOs, health economic outcome, research.  The latest addition to that portfol io of assets is the data \nand insights business that we call Ontada.  \n \n And when we think of the oncology ecosystem, we think of these as all kind of self -reinforcing and adding \nmomentum to each other.  We add providers that add scale to GPO, that adds more cu stomers and data to \nOntada.  As Ontada matures, as partnerships expand, we get more insights. ", "original_text": "The latest addition to that portfol io of assets is the data \nand insights business that we call Ontada.  \n \n", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4f15141d8fcacd49cd988592d28efc1b8ae42a9143d6d6da21317e1302c18ad3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d0dc986-fbf8-4525-a767-9e31c565a221", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ndistribution, GPOs, health economic outcome, research.  The latest addition to that portfol io of assets is the data \nand insights business that we call Ontada.  \n \n And when we think of the oncology ecosystem, we think of these as all kind of self -reinforcing and adding \nmomentum to each other.  We add providers that add scale to GPO, that adds more cu stomers and data to \nOntada.  As Ontada matures, as partnerships expand, we get more insights.  We funnel that back to providers \nwhich makes us a more attractive solution provider to them.  So, that's really how we're thinking about it. ", "original_text": "We add providers that add scale to GPO, that adds more cu stomers and data to \nOntada. "}, "hash": "cb96f58fb057b4c1b14bd06fd16242c8b1ee19a821fd9cff80c7a7186ea05b64", "class_name": "RelatedNodeInfo"}}, "text": "And when we think of the oncology ecosystem, we think of these as all kind of self -reinforcing and adding \nmomentum to each other. ", "start_char_idx": 345, "end_char_idx": 477, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d0dc986-fbf8-4525-a767-9e31c565a221": {"__data__": {"id_": "7d0dc986-fbf8-4525-a767-9e31c565a221", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ndistribution, GPOs, health economic outcome, research.  The latest addition to that portfol io of assets is the data \nand insights business that we call Ontada.  \n \n And when we think of the oncology ecosystem, we think of these as all kind of self -reinforcing and adding \nmomentum to each other.  We add providers that add scale to GPO, that adds more cu stomers and data to \nOntada.  As Ontada matures, as partnerships expand, we get more insights.  We funnel that back to providers \nwhich makes us a more attractive solution provider to them.  So, that's really how we're thinking about it. ", "original_text": "We add providers that add scale to GPO, that adds more cu stomers and data to \nOntada. ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7c86e1438adf8e697caee39b47ea8dbb10d71fa08f6a27738752a5bac88f2df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5dd8c5f5-d46d-4212-8038-d2b9333c4502", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ndistribution, GPOs, health economic outcome, research.  The latest addition to that portfol io of assets is the data \nand insights business that we call Ontada.  \n \n And when we think of the oncology ecosystem, we think of these as all kind of self -reinforcing and adding \nmomentum to each other.  We add providers that add scale to GPO, that adds more cu stomers and data to \nOntada.  As Ontada matures, as partnerships expand, we get more insights.  We funnel that back to providers \nwhich makes us a more attractive solution provider to them. ", "original_text": "And when we think of the oncology ecosystem, we think of these as all kind of self -reinforcing and adding \nmomentum to each other. ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c422317dbb89191bc4848c12ef20718f7c3e88584606d8425a4fc509f2a9666e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4a4153c-1183-4083-b772-c0520ad24e88", "node_type": "1", "metadata": {"window": "The latest addition to that portfol io of assets is the data \nand insights business that we call Ontada.  \n \n And when we think of the oncology ecosystem, we think of these as all kind of self -reinforcing and adding \nmomentum to each other.  We add providers that add scale to GPO, that adds more cu stomers and data to \nOntada.  As Ontada matures, as partnerships expand, we get more insights.  We funnel that back to providers \nwhich makes us a more attractive solution provider to them.  So, that's really how we're thinking about it.  Each into \nthemselves is  a good business we think. ", "original_text": "As Ontada matures, as partnerships expand, we get more insights. "}, "hash": "101a98bb5a9f77198208d8632818c4e613f993c17fd0c276469806458686ae20", "class_name": "RelatedNodeInfo"}}, "text": "We add providers that add scale to GPO, that adds more cu stomers and data to \nOntada. ", "start_char_idx": 477, "end_char_idx": 564, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4a4153c-1183-4083-b772-c0520ad24e88": {"__data__": {"id_": "a4a4153c-1183-4083-b772-c0520ad24e88", "embedding": null, "metadata": {"window": "The latest addition to that portfol io of assets is the data \nand insights business that we call Ontada.  \n \n And when we think of the oncology ecosystem, we think of these as all kind of self -reinforcing and adding \nmomentum to each other.  We add providers that add scale to GPO, that adds more cu stomers and data to \nOntada.  As Ontada matures, as partnerships expand, we get more insights.  We funnel that back to providers \nwhich makes us a more attractive solution provider to them.  So, that's really how we're thinking about it.  Each into \nthemselves is  a good business we think. ", "original_text": "As Ontada matures, as partnerships expand, we get more insights. ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7c86e1438adf8e697caee39b47ea8dbb10d71fa08f6a27738752a5bac88f2df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d0dc986-fbf8-4525-a767-9e31c565a221", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ndistribution, GPOs, health economic outcome, research.  The latest addition to that portfol io of assets is the data \nand insights business that we call Ontada.  \n \n And when we think of the oncology ecosystem, we think of these as all kind of self -reinforcing and adding \nmomentum to each other.  We add providers that add scale to GPO, that adds more cu stomers and data to \nOntada.  As Ontada matures, as partnerships expand, we get more insights.  We funnel that back to providers \nwhich makes us a more attractive solution provider to them.  So, that's really how we're thinking about it. ", "original_text": "We add providers that add scale to GPO, that adds more cu stomers and data to \nOntada. ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5cd116b722b6d42da88e5074373ac7024ecf47262072f854d38ed195b569687d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76484694-a622-471e-b021-41f497eacef2", "node_type": "1", "metadata": {"window": "And when we think of the oncology ecosystem, we think of these as all kind of self -reinforcing and adding \nmomentum to each other.  We add providers that add scale to GPO, that adds more cu stomers and data to \nOntada.  As Ontada matures, as partnerships expand, we get more insights.  We funnel that back to providers \nwhich makes us a more attractive solution provider to them.  So, that's really how we're thinking about it.  Each into \nthemselves is  a good business we think.  But together, we think there's real differentiation and strength.  \n ", "original_text": "We funnel that back to providers \nwhich makes us a more attractive solution provider to them. "}, "hash": "f91b81e27f7c06502c421384cbd5954aebf1c204883c2c7c55fc5dd2fa633a9f", "class_name": "RelatedNodeInfo"}}, "text": "As Ontada matures, as partnerships expand, we get more insights. ", "start_char_idx": 564, "end_char_idx": 629, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "76484694-a622-471e-b021-41f497eacef2": {"__data__": {"id_": "76484694-a622-471e-b021-41f497eacef2", "embedding": null, "metadata": {"window": "And when we think of the oncology ecosystem, we think of these as all kind of self -reinforcing and adding \nmomentum to each other.  We add providers that add scale to GPO, that adds more cu stomers and data to \nOntada.  As Ontada matures, as partnerships expand, we get more insights.  We funnel that back to providers \nwhich makes us a more attractive solution provider to them.  So, that's really how we're thinking about it.  Each into \nthemselves is  a good business we think.  But together, we think there's real differentiation and strength.  \n ", "original_text": "We funnel that back to providers \nwhich makes us a more attractive solution provider to them. ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7c86e1438adf8e697caee39b47ea8dbb10d71fa08f6a27738752a5bac88f2df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4a4153c-1183-4083-b772-c0520ad24e88", "node_type": "1", "metadata": {"window": "The latest addition to that portfol io of assets is the data \nand insights business that we call Ontada.  \n \n And when we think of the oncology ecosystem, we think of these as all kind of self -reinforcing and adding \nmomentum to each other.  We add providers that add scale to GPO, that adds more cu stomers and data to \nOntada.  As Ontada matures, as partnerships expand, we get more insights.  We funnel that back to providers \nwhich makes us a more attractive solution provider to them.  So, that's really how we're thinking about it.  Each into \nthemselves is  a good business we think. ", "original_text": "As Ontada matures, as partnerships expand, we get more insights. ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50ec8f938cfcadb59f26b7f67061b1e6f10facae766f61c513dc595b84df4a61", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dbe47897-d936-415d-aba1-0dcd1e44666e", "node_type": "1", "metadata": {"window": "We add providers that add scale to GPO, that adds more cu stomers and data to \nOntada.  As Ontada matures, as partnerships expand, we get more insights.  We funnel that back to providers \nwhich makes us a more attractive solution provider to them.  So, that's really how we're thinking about it.  Each into \nthemselves is  a good business we think.  But together, we think there's real differentiation and strength.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "So, that's really how we're thinking about it. "}, "hash": "410f42ca883d87298e96e979e395dac69aee91d49fa70f9fa7e7f96f8453b112", "class_name": "RelatedNodeInfo"}}, "text": "We funnel that back to providers \nwhich makes us a more attractive solution provider to them. ", "start_char_idx": 629, "end_char_idx": 723, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dbe47897-d936-415d-aba1-0dcd1e44666e": {"__data__": {"id_": "dbe47897-d936-415d-aba1-0dcd1e44666e", "embedding": null, "metadata": {"window": "We add providers that add scale to GPO, that adds more cu stomers and data to \nOntada.  As Ontada matures, as partnerships expand, we get more insights.  We funnel that back to providers \nwhich makes us a more attractive solution provider to them.  So, that's really how we're thinking about it.  Each into \nthemselves is  a good business we think.  But together, we think there's real differentiation and strength.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "So, that's really how we're thinking about it. ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7c86e1438adf8e697caee39b47ea8dbb10d71fa08f6a27738752a5bac88f2df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76484694-a622-471e-b021-41f497eacef2", "node_type": "1", "metadata": {"window": "And when we think of the oncology ecosystem, we think of these as all kind of self -reinforcing and adding \nmomentum to each other.  We add providers that add scale to GPO, that adds more cu stomers and data to \nOntada.  As Ontada matures, as partnerships expand, we get more insights.  We funnel that back to providers \nwhich makes us a more attractive solution provider to them.  So, that's really how we're thinking about it.  Each into \nthemselves is  a good business we think.  But together, we think there's real differentiation and strength.  \n ", "original_text": "We funnel that back to providers \nwhich makes us a more attractive solution provider to them. ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df2a5f4ce634b0a0ecded9a3c117f02fa0def5ceff49ff16aeb8cb0f0d133361", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "12f615b0-51ca-4f90-929e-9cb9d3ee8899", "node_type": "1", "metadata": {"window": "As Ontada matures, as partnerships expand, we get more insights.  We funnel that back to providers \nwhich makes us a more attractive solution provider to them.  So, that's really how we're thinking about it.  Each into \nthemselves is  a good business we think.  But together, we think there's real differentiation and strength.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd, Lisa, I'd just add on that we're really pleased that the development of  biosimilars are really adding to the \noperating profit growth in the segment. ", "original_text": "Each into \nthemselves is  a good business we think. "}, "hash": "791b21f2d90eae6b22c7934c489d8c8d089deb7169b551be8f89517625d7ba32", "class_name": "RelatedNodeInfo"}}, "text": "So, that's really how we're thinking about it. ", "start_char_idx": 723, "end_char_idx": 770, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "12f615b0-51ca-4f90-929e-9cb9d3ee8899": {"__data__": {"id_": "12f615b0-51ca-4f90-929e-9cb9d3ee8899", "embedding": null, "metadata": {"window": "As Ontada matures, as partnerships expand, we get more insights.  We funnel that back to providers \nwhich makes us a more attractive solution provider to them.  So, that's really how we're thinking about it.  Each into \nthemselves is  a good business we think.  But together, we think there's real differentiation and strength.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd, Lisa, I'd just add on that we're really pleased that the development of  biosimilars are really adding to the \noperating profit growth in the segment. ", "original_text": "Each into \nthemselves is  a good business we think. ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7c86e1438adf8e697caee39b47ea8dbb10d71fa08f6a27738752a5bac88f2df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dbe47897-d936-415d-aba1-0dcd1e44666e", "node_type": "1", "metadata": {"window": "We add providers that add scale to GPO, that adds more cu stomers and data to \nOntada.  As Ontada matures, as partnerships expand, we get more insights.  We funnel that back to providers \nwhich makes us a more attractive solution provider to them.  So, that's really how we're thinking about it.  Each into \nthemselves is  a good business we think.  But together, we think there's real differentiation and strength.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "So, that's really how we're thinking about it. ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "95d80b9edf3d9b7fbdd9660a37981e89cc9d41242dffc9d06cbd752ba25d83a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bbcf528c-9a5d-4d71-855a-7ff850fb62a3", "node_type": "1", "metadata": {"window": "We funnel that back to providers \nwhich makes us a more attractive solution provider to them.  So, that's really how we're thinking about it.  Each into \nthemselves is  a good business we think.  But together, we think there's real differentiation and strength.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd, Lisa, I'd just add on that we're really pleased that the development of  biosimilars are really adding to the \noperating profit growth in the segment.  It's growing over time. ", "original_text": "But together, we think there's real differentiation and strength.  \n "}, "hash": "ec581319b91ed417bcaec1449c3a2eea78eabc324cf1157b2799d8d5cd837a86", "class_name": "RelatedNodeInfo"}}, "text": "Each into \nthemselves is  a good business we think. ", "start_char_idx": 770, "end_char_idx": 822, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bbcf528c-9a5d-4d71-855a-7ff850fb62a3": {"__data__": {"id_": "bbcf528c-9a5d-4d71-855a-7ff850fb62a3", "embedding": null, "metadata": {"window": "We funnel that back to providers \nwhich makes us a more attractive solution provider to them.  So, that's really how we're thinking about it.  Each into \nthemselves is  a good business we think.  But together, we think there's real differentiation and strength.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd, Lisa, I'd just add on that we're really pleased that the development of  biosimilars are really adding to the \noperating profit growth in the segment.  It's growing over time. ", "original_text": "But together, we think there's real differentiation and strength.  \n ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7c86e1438adf8e697caee39b47ea8dbb10d71fa08f6a27738752a5bac88f2df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "12f615b0-51ca-4f90-929e-9cb9d3ee8899", "node_type": "1", "metadata": {"window": "As Ontada matures, as partnerships expand, we get more insights.  We funnel that back to providers \nwhich makes us a more attractive solution provider to them.  So, that's really how we're thinking about it.  Each into \nthemselves is  a good business we think.  But together, we think there's real differentiation and strength.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd, Lisa, I'd just add on that we're really pleased that the development of  biosimilars are really adding to the \noperating profit growth in the segment. ", "original_text": "Each into \nthemselves is  a good business we think. ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a3e93911e5eebc8e5aca59fd8d58fd9b34fd55e0512b2a434f0438376fdbe98", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9253bbc5-ae7f-4bd3-b5ce-d2bd1524ac31", "node_type": "1", "metadata": {"window": "So, that's really how we're thinking about it.  Each into \nthemselves is  a good business we think.  But together, we think there's real differentiation and strength.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd, Lisa, I'd just add on that we're really pleased that the development of  biosimilars are really adding to the \noperating profit growth in the segment.  It's growing over time.  We think that it will continue to grow. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "0a427ce4058e0d5645994654bbcf0d6c0f1aec5b52760926aff260f5756ab348", "class_name": "RelatedNodeInfo"}}, "text": "But together, we think there's real differentiation and strength.  \n ", "start_char_idx": 822, "end_char_idx": 891, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9253bbc5-ae7f-4bd3-b5ce-d2bd1524ac31": {"__data__": {"id_": "9253bbc5-ae7f-4bd3-b5ce-d2bd1524ac31", "embedding": null, "metadata": {"window": "So, that's really how we're thinking about it.  Each into \nthemselves is  a good business we think.  But together, we think there's real differentiation and strength.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd, Lisa, I'd just add on that we're really pleased that the development of  biosimilars are really adding to the \noperating profit growth in the segment.  It's growing over time.  We think that it will continue to grow. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7c86e1438adf8e697caee39b47ea8dbb10d71fa08f6a27738752a5bac88f2df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bbcf528c-9a5d-4d71-855a-7ff850fb62a3", "node_type": "1", "metadata": {"window": "We funnel that back to providers \nwhich makes us a more attractive solution provider to them.  So, that's really how we're thinking about it.  Each into \nthemselves is  a good business we think.  But together, we think there's real differentiation and strength.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd, Lisa, I'd just add on that we're really pleased that the development of  biosimilars are really adding to the \noperating profit growth in the segment.  It's growing over time. ", "original_text": "But together, we think there's real differentiation and strength.  \n ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b1f2de1b36650d1c90575ebd037fc17da400285be6967519b92edf093aed47c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b4c2dab-ed35-4a52-8311-322096dc384f", "node_type": "1", "metadata": {"window": "Each into \nthemselves is  a good business we think.  But together, we think there's real differentiation and strength.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd, Lisa, I'd just add on that we're really pleased that the development of  biosimilars are really adding to the \noperating profit growth in the segment.  It's growing over time.  We think that it will continue to grow.  And the \nchannel matters, where we have more services to provide. ", "original_text": "A \nAnd, Lisa, I'd just add on that we're really pleased that the development of  biosimilars are really adding to the \noperating profit growth in the segment. "}, "hash": "e1715fcb72b6c7e93d0beba08deb2aa043289357341d05bf3bcde65be0768903", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 891, "end_char_idx": 1248, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b4c2dab-ed35-4a52-8311-322096dc384f": {"__data__": {"id_": "4b4c2dab-ed35-4a52-8311-322096dc384f", "embedding": null, "metadata": {"window": "Each into \nthemselves is  a good business we think.  But together, we think there's real differentiation and strength.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd, Lisa, I'd just add on that we're really pleased that the development of  biosimilars are really adding to the \noperating profit growth in the segment.  It's growing over time.  We think that it will continue to grow.  And the \nchannel matters, where we have more services to provide. ", "original_text": "A \nAnd, Lisa, I'd just add on that we're really pleased that the development of  biosimilars are really adding to the \noperating profit growth in the segment. ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7c86e1438adf8e697caee39b47ea8dbb10d71fa08f6a27738752a5bac88f2df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9253bbc5-ae7f-4bd3-b5ce-d2bd1524ac31", "node_type": "1", "metadata": {"window": "So, that's really how we're thinking about it.  Each into \nthemselves is  a good business we think.  But together, we think there's real differentiation and strength.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd, Lisa, I'd just add on that we're really pleased that the development of  biosimilars are really adding to the \noperating profit growth in the segment.  It's growing over time.  We think that it will continue to grow. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d156b4114b7e1738690bf65026e951fdf3824a90582082a3d477612b02706ef5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc12d7a6-5b66-406d-a68e-2b8ce6c61fc1", "node_type": "1", "metadata": {"window": "But together, we think there's real differentiation and strength.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd, Lisa, I'd just add on that we're really pleased that the development of  biosimilars are really adding to the \noperating profit growth in the segment.  It's growing over time.  We think that it will continue to grow.  And the \nchannel matters, where we have more services to provide.  As Brian mentioned, GPO services is a good exampl e \nof that.  \n \n", "original_text": "It's growing over time. "}, "hash": "abf99810c2ef5579a5f2543a13d7585064b872dc422a92c9767a67a34fa5a77d", "class_name": "RelatedNodeInfo"}}, "text": "A \nAnd, Lisa, I'd just add on that we're really pleased that the development of  biosimilars are really adding to the \noperating profit growth in the segment. ", "start_char_idx": 1248, "end_char_idx": 1407, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc12d7a6-5b66-406d-a68e-2b8ce6c61fc1": {"__data__": {"id_": "bc12d7a6-5b66-406d-a68e-2b8ce6c61fc1", "embedding": null, "metadata": {"window": "But together, we think there's real differentiation and strength.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd, Lisa, I'd just add on that we're really pleased that the development of  biosimilars are really adding to the \noperating profit growth in the segment.  It's growing over time.  We think that it will continue to grow.  And the \nchannel matters, where we have more services to provide.  As Brian mentioned, GPO services is a good exampl e \nof that.  \n \n", "original_text": "It's growing over time. ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7c86e1438adf8e697caee39b47ea8dbb10d71fa08f6a27738752a5bac88f2df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b4c2dab-ed35-4a52-8311-322096dc384f", "node_type": "1", "metadata": {"window": "Each into \nthemselves is  a good business we think.  But together, we think there's real differentiation and strength.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd, Lisa, I'd just add on that we're really pleased that the development of  biosimilars are really adding to the \noperating profit growth in the segment.  It's growing over time.  We think that it will continue to grow.  And the \nchannel matters, where we have more services to provide. ", "original_text": "A \nAnd, Lisa, I'd just add on that we're really pleased that the development of  biosimilars are really adding to the \noperating profit growth in the segment. ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f48e27b9416158c0aa83472024d59610ee2865a65bbcf5ed141275cbc9349c9b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5fe1c900-43ed-4a0a-810a-fe7554b9cb1a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd, Lisa, I'd just add on that we're really pleased that the development of  biosimilars are really adding to the \noperating profit growth in the segment.  It's growing over time.  We think that it will continue to grow.  And the \nchannel matters, where we have more services to provide.  As Brian mentioned, GPO services is a good exampl e \nof that.  \n \n Certainly, it's more profitable for us and we'll see higher adoption rates. ", "original_text": "We think that it will continue to grow. "}, "hash": "cdf6cef273d108610fce1a94646b7a96308d891a2f4884078ba4198862c560bd", "class_name": "RelatedNodeInfo"}}, "text": "It's growing over time. ", "start_char_idx": 1407, "end_char_idx": 1431, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5fe1c900-43ed-4a0a-810a-fe7554b9cb1a": {"__data__": {"id_": "5fe1c900-43ed-4a0a-810a-fe7554b9cb1a", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd, Lisa, I'd just add on that we're really pleased that the development of  biosimilars are really adding to the \noperating profit growth in the segment.  It's growing over time.  We think that it will continue to grow.  And the \nchannel matters, where we have more services to provide.  As Brian mentioned, GPO services is a good exampl e \nof that.  \n \n Certainly, it's more profitable for us and we'll see higher adoption rates. ", "original_text": "We think that it will continue to grow. ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7c86e1438adf8e697caee39b47ea8dbb10d71fa08f6a27738752a5bac88f2df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc12d7a6-5b66-406d-a68e-2b8ce6c61fc1", "node_type": "1", "metadata": {"window": "But together, we think there's real differentiation and strength.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd, Lisa, I'd just add on that we're really pleased that the development of  biosimilars are really adding to the \noperating profit growth in the segment.  It's growing over time.  We think that it will continue to grow.  And the \nchannel matters, where we have more services to provide.  As Brian mentioned, GPO services is a good exampl e \nof that.  \n \n", "original_text": "It's growing over time. ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a3c2ca5b426b99354739dfa8535bb1f03130b417d11e38f04615014ea0d0e37", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "21ff7094-4220-43ce-9f26-57bb408b4fd7", "node_type": "1", "metadata": {"window": "A \nAnd, Lisa, I'd just add on that we're really pleased that the development of  biosimilars are really adding to the \noperating profit growth in the segment.  It's growing over time.  We think that it will continue to grow.  And the \nchannel matters, where we have more services to provide.  As Brian mentioned, GPO services is a good exampl e \nof that.  \n \n Certainly, it's more profitable for us and we'll see higher adoption rates.  The adoption rates continue to build. ", "original_text": "And the \nchannel matters, where we have more services to provide. "}, "hash": "bed43d4bce247a2bb2131384b8978469e735c0c19d6a75161a9c1285a26da1e5", "class_name": "RelatedNodeInfo"}}, "text": "We think that it will continue to grow. ", "start_char_idx": 1431, "end_char_idx": 1471, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "21ff7094-4220-43ce-9f26-57bb408b4fd7": {"__data__": {"id_": "21ff7094-4220-43ce-9f26-57bb408b4fd7", "embedding": null, "metadata": {"window": "A \nAnd, Lisa, I'd just add on that we're really pleased that the development of  biosimilars are really adding to the \noperating profit growth in the segment.  It's growing over time.  We think that it will continue to grow.  And the \nchannel matters, where we have more services to provide.  As Brian mentioned, GPO services is a good exampl e \nof that.  \n \n Certainly, it's more profitable for us and we'll see higher adoption rates.  The adoption rates continue to build. ", "original_text": "And the \nchannel matters, where we have more services to provide. ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7c86e1438adf8e697caee39b47ea8dbb10d71fa08f6a27738752a5bac88f2df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5fe1c900-43ed-4a0a-810a-fe7554b9cb1a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd, Lisa, I'd just add on that we're really pleased that the development of  biosimilars are really adding to the \noperating profit growth in the segment.  It's growing over time.  We think that it will continue to grow.  And the \nchannel matters, where we have more services to provide.  As Brian mentioned, GPO services is a good exampl e \nof that.  \n \n Certainly, it's more profitable for us and we'll see higher adoption rates. ", "original_text": "We think that it will continue to grow. ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9d704b7cd16886ac84c88fa9a64e0312c2fa351b781bbb16a42ce2e6f0d2001f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94c4717e-7ea7-4352-8d3c-d3943d9a1ca0", "node_type": "1", "metadata": {"window": "It's growing over time.  We think that it will continue to grow.  And the \nchannel matters, where we have more services to provide.  As Brian mentioned, GPO services is a good exampl e \nof that.  \n \n Certainly, it's more profitable for us and we'll see higher adoption rates.  The adoption rates continue to build.  And \nthat, I think, is reflective of the growing operating profit contribution that we're seeing from biosimilars. ", "original_text": "As Brian mentioned, GPO services is a good exampl e \nof that.  \n \n"}, "hash": "4ba1f0ee6bc78c2e1d2350b888667bbf7aaaac6815ad9644599cb6a4e8f1f209", "class_name": "RelatedNodeInfo"}}, "text": "And the \nchannel matters, where we have more services to provide. ", "start_char_idx": 1471, "end_char_idx": 1537, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94c4717e-7ea7-4352-8d3c-d3943d9a1ca0": {"__data__": {"id_": "94c4717e-7ea7-4352-8d3c-d3943d9a1ca0", "embedding": null, "metadata": {"window": "It's growing over time.  We think that it will continue to grow.  And the \nchannel matters, where we have more services to provide.  As Brian mentioned, GPO services is a good exampl e \nof that.  \n \n Certainly, it's more profitable for us and we'll see higher adoption rates.  The adoption rates continue to build.  And \nthat, I think, is reflective of the growing operating profit contribution that we're seeing from biosimilars. ", "original_text": "As Brian mentioned, GPO services is a good exampl e \nof that.  \n \n", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7c86e1438adf8e697caee39b47ea8dbb10d71fa08f6a27738752a5bac88f2df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "21ff7094-4220-43ce-9f26-57bb408b4fd7", "node_type": "1", "metadata": {"window": "A \nAnd, Lisa, I'd just add on that we're really pleased that the development of  biosimilars are really adding to the \noperating profit growth in the segment.  It's growing over time.  We think that it will continue to grow.  And the \nchannel matters, where we have more services to provide.  As Brian mentioned, GPO services is a good exampl e \nof that.  \n \n Certainly, it's more profitable for us and we'll see higher adoption rates.  The adoption rates continue to build. ", "original_text": "And the \nchannel matters, where we have more services to provide. ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3f177ccc28726222c0a7576ac46f96a0983c644d6f2c935a43c774b66e96ba57", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b0cc8c3-ebf0-44cd-ae02-4100193706af", "node_type": "1", "metadata": {"window": "We think that it will continue to grow.  And the \nchannel matters, where we have more services to provide.  As Brian mentioned, GPO services is a good exampl e \nof that.  \n \n Certainly, it's more profitable for us and we'll see higher adoption rates.  The adoption rates continue to build.  And \nthat, I think, is reflective of the growing operating profit contribution that we're seeing from biosimilars.  But we do \nthink,  longer term, there is a larger opportunity.  \n ", "original_text": "Certainly, it's more profitable for us and we'll see higher adoption rates. "}, "hash": "ea166440fff82e29c22a657c8a3583dbe18bb78a6cbb45286c9d5d0053a5fe59", "class_name": "RelatedNodeInfo"}}, "text": "As Brian mentioned, GPO services is a good exampl e \nof that.  \n \n", "start_char_idx": 1537, "end_char_idx": 1603, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b0cc8c3-ebf0-44cd-ae02-4100193706af": {"__data__": {"id_": "0b0cc8c3-ebf0-44cd-ae02-4100193706af", "embedding": null, "metadata": {"window": "We think that it will continue to grow.  And the \nchannel matters, where we have more services to provide.  As Brian mentioned, GPO services is a good exampl e \nof that.  \n \n Certainly, it's more profitable for us and we'll see higher adoption rates.  The adoption rates continue to build.  And \nthat, I think, is reflective of the growing operating profit contribution that we're seeing from biosimilars.  But we do \nthink,  longer term, there is a larger opportunity.  \n ", "original_text": "Certainly, it's more profitable for us and we'll see higher adoption rates. ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7c86e1438adf8e697caee39b47ea8dbb10d71fa08f6a27738752a5bac88f2df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94c4717e-7ea7-4352-8d3c-d3943d9a1ca0", "node_type": "1", "metadata": {"window": "It's growing over time.  We think that it will continue to grow.  And the \nchannel matters, where we have more services to provide.  As Brian mentioned, GPO services is a good exampl e \nof that.  \n \n Certainly, it's more profitable for us and we'll see higher adoption rates.  The adoption rates continue to build.  And \nthat, I think, is reflective of the growing operating profit contribution that we're seeing from biosimilars. ", "original_text": "As Brian mentioned, GPO services is a good exampl e \nof that.  \n \n", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "60cd62fe525c73d24d4e63a2d673e3656abbe98ef7127ace09e28001e188109f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb38692d-9345-43c3-9ced-bb3c682743e7", "node_type": "1", "metadata": {"window": "And the \nchannel matters, where we have more services to provide.  As Brian mentioned, GPO services is a good exampl e \nof that.  \n \n Certainly, it's more profitable for us and we'll see higher adoption rates.  The adoption rates continue to build.  And \nthat, I think, is reflective of the growing operating profit contribution that we're seeing from biosimilars.  But we do \nthink,  longer term, there is a larger opportunity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "original_text": "The adoption rates continue to build. "}, "hash": "9376c67cb3f49d6f8d3ca995336d42da1da8c966e5ee69bd9896f21eab34074b", "class_name": "RelatedNodeInfo"}}, "text": "Certainly, it's more profitable for us and we'll see higher adoption rates. ", "start_char_idx": 1603, "end_char_idx": 1679, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb38692d-9345-43c3-9ced-bb3c682743e7": {"__data__": {"id_": "fb38692d-9345-43c3-9ced-bb3c682743e7", "embedding": null, "metadata": {"window": "And the \nchannel matters, where we have more services to provide.  As Brian mentioned, GPO services is a good exampl e \nof that.  \n \n Certainly, it's more profitable for us and we'll see higher adoption rates.  The adoption rates continue to build.  And \nthat, I think, is reflective of the growing operating profit contribution that we're seeing from biosimilars.  But we do \nthink,  longer term, there is a larger opportunity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "original_text": "The adoption rates continue to build. ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7c86e1438adf8e697caee39b47ea8dbb10d71fa08f6a27738752a5bac88f2df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b0cc8c3-ebf0-44cd-ae02-4100193706af", "node_type": "1", "metadata": {"window": "We think that it will continue to grow.  And the \nchannel matters, where we have more services to provide.  As Brian mentioned, GPO services is a good exampl e \nof that.  \n \n Certainly, it's more profitable for us and we'll see higher adoption rates.  The adoption rates continue to build.  And \nthat, I think, is reflective of the growing operating profit contribution that we're seeing from biosimilars.  But we do \nthink,  longer term, there is a larger opportunity.  \n ", "original_text": "Certainly, it's more profitable for us and we'll see higher adoption rates. ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a57ad1dcd3798b1fa5e9487d1323838ec02c6c9de417037a08697bedc3d494f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e46d2bd1-c08b-4ad1-9ca8-30c29ce6ee9d", "node_type": "1", "metadata": {"window": "As Brian mentioned, GPO services is a good exampl e \nof that.  \n \n Certainly, it's more profitable for us and we'll see higher adoption rates.  The adoption rates continue to build.  And \nthat, I think, is reflective of the growing operating profit contribution that we're seeing from biosimilars.  But we do \nthink,  longer term, there is a larger opportunity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question.  \n ", "original_text": "And \nthat, I think, is reflective of the growing operating profit contribution that we're seeing from biosimilars. "}, "hash": "65f186fab29f5f6a29b80d7f7b87659d9b2fb67efde903a48e002b2c54794579", "class_name": "RelatedNodeInfo"}}, "text": "The adoption rates continue to build. ", "start_char_idx": 1679, "end_char_idx": 1717, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e46d2bd1-c08b-4ad1-9ca8-30c29ce6ee9d": {"__data__": {"id_": "e46d2bd1-c08b-4ad1-9ca8-30c29ce6ee9d", "embedding": null, "metadata": {"window": "As Brian mentioned, GPO services is a good exampl e \nof that.  \n \n Certainly, it's more profitable for us and we'll see higher adoption rates.  The adoption rates continue to build.  And \nthat, I think, is reflective of the growing operating profit contribution that we're seeing from biosimilars.  But we do \nthink,  longer term, there is a larger opportunity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question.  \n ", "original_text": "And \nthat, I think, is reflective of the growing operating profit contribution that we're seeing from biosimilars. ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7c86e1438adf8e697caee39b47ea8dbb10d71fa08f6a27738752a5bac88f2df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb38692d-9345-43c3-9ced-bb3c682743e7", "node_type": "1", "metadata": {"window": "And the \nchannel matters, where we have more services to provide.  As Brian mentioned, GPO services is a good exampl e \nof that.  \n \n Certainly, it's more profitable for us and we'll see higher adoption rates.  The adoption rates continue to build.  And \nthat, I think, is reflective of the growing operating profit contribution that we're seeing from biosimilars.  But we do \nthink,  longer term, there is a larger opportunity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "original_text": "The adoption rates continue to build. ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "21b8281ee0393cb02351b50015586d9771326e8d92f246c375b20f70083e8bc4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0e82fdcc-7966-48b6-af4b-571522d1a054", "node_type": "1", "metadata": {"window": "Certainly, it's more profitable for us and we'll see higher adoption rates.  The adoption rates continue to build.  And \nthat, I think, is reflective of the growing operating profit contribution that we're seeing from biosimilars.  But we do \nthink,  longer term, there is a larger opportunity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Eric Percher of Nephron Research.  \n ", "original_text": "But we do \nthink,  longer term, there is a larger opportunity.  \n "}, "hash": "832731a32b6cc1246b93b99702dffd4db0098a057395b9166fde0002dcbe5345", "class_name": "RelatedNodeInfo"}}, "text": "And \nthat, I think, is reflective of the growing operating profit contribution that we're seeing from biosimilars. ", "start_char_idx": 1717, "end_char_idx": 1832, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0e82fdcc-7966-48b6-af4b-571522d1a054": {"__data__": {"id_": "0e82fdcc-7966-48b6-af4b-571522d1a054", "embedding": null, "metadata": {"window": "Certainly, it's more profitable for us and we'll see higher adoption rates.  The adoption rates continue to build.  And \nthat, I think, is reflective of the growing operating profit contribution that we're seeing from biosimilars.  But we do \nthink,  longer term, there is a larger opportunity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Eric Percher of Nephron Research.  \n ", "original_text": "But we do \nthink,  longer term, there is a larger opportunity.  \n ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7c86e1438adf8e697caee39b47ea8dbb10d71fa08f6a27738752a5bac88f2df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e46d2bd1-c08b-4ad1-9ca8-30c29ce6ee9d", "node_type": "1", "metadata": {"window": "As Brian mentioned, GPO services is a good exampl e \nof that.  \n \n Certainly, it's more profitable for us and we'll see higher adoption rates.  The adoption rates continue to build.  And \nthat, I think, is reflective of the growing operating profit contribution that we're seeing from biosimilars.  But we do \nthink,  longer term, there is a larger opportunity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question.  \n ", "original_text": "And \nthat, I think, is reflective of the growing operating profit contribution that we're seeing from biosimilars. ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eedd1b0c6222e9744e770944a1264505a8874457aca70ad2991b1fb83e2d3490", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd801f24-c20b-43e8-984f-fa54a49c5a26", "node_type": "1", "metadata": {"window": "The adoption rates continue to build.  And \nthat, I think, is reflective of the growing operating profit contribution that we're seeing from biosimilars.  But we do \nthink,  longer term, there is a larger opportunity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Eric Percher of Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst,  Nephron Research LLC  Q \nThank you. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  "}, "hash": "68288b7956edb4ba8d12cca2d412c41aebf9ad04daa5737bc9a2ab644a01a69c", "class_name": "RelatedNodeInfo"}}, "text": "But we do \nthink,  longer term, there is a larger opportunity.  \n ", "start_char_idx": 1832, "end_char_idx": 1898, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd801f24-c20b-43e8-984f-fa54a49c5a26": {"__data__": {"id_": "dd801f24-c20b-43e8-984f-fa54a49c5a26", "embedding": null, "metadata": {"window": "The adoption rates continue to build.  And \nthat, I think, is reflective of the growing operating profit contribution that we're seeing from biosimilars.  But we do \nthink,  longer term, there is a larger opportunity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Eric Percher of Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst,  Nephron Research LLC  Q \nThank you. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7c86e1438adf8e697caee39b47ea8dbb10d71fa08f6a27738752a5bac88f2df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0e82fdcc-7966-48b6-af4b-571522d1a054", "node_type": "1", "metadata": {"window": "Certainly, it's more profitable for us and we'll see higher adoption rates.  The adoption rates continue to build.  And \nthat, I think, is reflective of the growing operating profit contribution that we're seeing from biosimilars.  But we do \nthink,  longer term, there is a larger opportunity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Eric Percher of Nephron Research.  \n ", "original_text": "But we do \nthink,  longer term, there is a larger opportunity.  \n ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c9ef6c424401635d30a19d3d622b807f05bd40b5f1737f5ecaa88a9a71840ab5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d7c4b49a-791e-44cc-b3cb-5d68012b580a", "node_type": "1", "metadata": {"window": "And \nthat, I think, is reflective of the growing operating profit contribution that we're seeing from biosimilars.  But we do \nthink,  longer term, there is a larger opportunity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Eric Percher of Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst,  Nephron Research LLC  Q \nThank you.  The international D&A dynamics are interesting. ", "original_text": "A \nOperator, next question.  \n "}, "hash": "b86ed0972067950da85a73481a2196df91748f6a562e514f286a2ae8cd5b0d6b", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "start_char_idx": 1898, "end_char_idx": 2272, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d7c4b49a-791e-44cc-b3cb-5d68012b580a": {"__data__": {"id_": "d7c4b49a-791e-44cc-b3cb-5d68012b580a", "embedding": null, "metadata": {"window": "And \nthat, I think, is reflective of the growing operating profit contribution that we're seeing from biosimilars.  But we do \nthink,  longer term, there is a larger opportunity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Eric Percher of Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst,  Nephron Research LLC  Q \nThank you.  The international D&A dynamics are interesting. ", "original_text": "A \nOperator, next question.  \n ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7c86e1438adf8e697caee39b47ea8dbb10d71fa08f6a27738752a5bac88f2df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd801f24-c20b-43e8-984f-fa54a49c5a26", "node_type": "1", "metadata": {"window": "The adoption rates continue to build.  And \nthat, I think, is reflective of the growing operating profit contribution that we're seeing from biosimilars.  But we do \nthink,  longer term, there is a larger opportunity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Eric Percher of Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst,  Nephron Research LLC  Q \nThank you. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0792d060fab3ea3ff6b9371e347146e23e9114538e6f9b61a78e241c6481e2ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62e0b336-868d-4fff-88ad-3fa3f7e26b18", "node_type": "1", "metadata": {"window": "But we do \nthink,  longer term, there is a larger opportunity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Eric Percher of Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst,  Nephron Research LLC  Q \nThank you.  The international D&A dynamics are interesting.  Thank you for that detail. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Eric Percher of Nephron Research.  \n "}, "hash": "ab253a6c1269e6474ef2388c2541fd09d657a83b71353c6429b947350f3a9467", "class_name": "RelatedNodeInfo"}}, "text": "A \nOperator, next question.  \n ", "start_char_idx": 2272, "end_char_idx": 2303, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62e0b336-868d-4fff-88ad-3fa3f7e26b18": {"__data__": {"id_": "62e0b336-868d-4fff-88ad-3fa3f7e26b18", "embedding": null, "metadata": {"window": "But we do \nthink,  longer term, there is a larger opportunity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Eric Percher of Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst,  Nephron Research LLC  Q \nThank you.  The international D&A dynamics are interesting.  Thank you for that detail. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Eric Percher of Nephron Research.  \n ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7c86e1438adf8e697caee39b47ea8dbb10d71fa08f6a27738752a5bac88f2df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d7c4b49a-791e-44cc-b3cb-5d68012b580a", "node_type": "1", "metadata": {"window": "And \nthat, I think, is reflective of the growing operating profit contribution that we're seeing from biosimilars.  But we do \nthink,  longer term, there is a larger opportunity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Eric Percher of Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst,  Nephron Research LLC  Q \nThank you.  The international D&A dynamics are interesting. ", "original_text": "A \nOperator, next question.  \n ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1315add186d0e140b1b6dc7e5e1b4b160c3616cbca08fcae9baad12a8aa32295", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fbb122e5-87dc-41c6-a03e-896c32a6343a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Eric Percher of Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst,  Nephron Research LLC  Q \nThank you.  The international D&A dynamics are interesting.  Thank you for that detail.  Maybe a two -parter, Britt. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst,  Nephron Research LLC  Q \nThank you. "}, "hash": "be64e06ff2ccf4d39ded4c592fccac5f7ddbcd0ac7021ab0210dfd39655d7d7a", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Eric Percher of Nephron Research.  \n ", "start_char_idx": 2303, "end_char_idx": 2638, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fbb122e5-87dc-41c6-a03e-896c32a6343a": {"__data__": {"id_": "fbb122e5-87dc-41c6-a03e-896c32a6343a", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Eric Percher of Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst,  Nephron Research LLC  Q \nThank you.  The international D&A dynamics are interesting.  Thank you for that detail.  Maybe a two -parter, Britt. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst,  Nephron Research LLC  Q \nThank you. ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7c86e1438adf8e697caee39b47ea8dbb10d71fa08f6a27738752a5bac88f2df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62e0b336-868d-4fff-88ad-3fa3f7e26b18", "node_type": "1", "metadata": {"window": "But we do \nthink,  longer term, there is a larger opportunity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Eric Percher of Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst,  Nephron Research LLC  Q \nThank you.  The international D&A dynamics are interesting.  Thank you for that detail. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Eric Percher of Nephron Research.  \n ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5c7b9b582cca1be04e9c8a954c62e3b44366c16cc1d779a238c70de039b4d9d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ebbf5fe-42a0-4c19-8653-9338f11d8c81", "node_type": "1", "metadata": {"window": "A \nOperator, next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Eric Percher of Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst,  Nephron Research LLC  Q \nThank you.  The international D&A dynamics are interesting.  Thank you for that detail.  Maybe a two -parter, Britt. \n One is when we think about the remaining European business, can you provide us some sense of scale? ", "original_text": "The international D&A dynamics are interesting. "}, "hash": "9e4eabd03c862c575c40a809d984b84c9db1630e4d284198d6903bd8454c9cca", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst,  Nephron Research LLC  Q \nThank you. ", "start_char_idx": 2638, "end_char_idx": 2971, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ebbf5fe-42a0-4c19-8653-9338f11d8c81": {"__data__": {"id_": "0ebbf5fe-42a0-4c19-8653-9338f11d8c81", "embedding": null, "metadata": {"window": "A \nOperator, next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Eric Percher of Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst,  Nephron Research LLC  Q \nThank you.  The international D&A dynamics are interesting.  Thank you for that detail.  Maybe a two -parter, Britt. \n One is when we think about the remaining European business, can you provide us some sense of scale? ", "original_text": "The international D&A dynamics are interesting. ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7c86e1438adf8e697caee39b47ea8dbb10d71fa08f6a27738752a5bac88f2df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fbb122e5-87dc-41c6-a03e-896c32a6343a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Eric Percher of Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst,  Nephron Research LLC  Q \nThank you.  The international D&A dynamics are interesting.  Thank you for that detail.  Maybe a two -parter, Britt. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst,  Nephron Research LLC  Q \nThank you. ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "21cd9827c4dfc1d218f4de847e7e5d406505d0638dfcc1c034c80a9513bee418", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "816830c4-ef62-4376-b137-b09e064d5d61", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Eric Percher of Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst,  Nephron Research LLC  Q \nThank you.  The international D&A dynamics are interesting.  Thank you for that detail.  Maybe a two -parter, Britt. \n One is when we think about the remaining European business, can you provide us some sense of scale?  I think \nthe last t ime we got a Celesio number without Canada was around $230 million of op profit. ", "original_text": "Thank you for that detail. "}, "hash": "b07e515c2f418a4240727bd22d595e28b037105047540ec8d5e60ef411ed331a", "class_name": "RelatedNodeInfo"}}, "text": "The international D&A dynamics are interesting. ", "start_char_idx": 2971, "end_char_idx": 3019, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "816830c4-ef62-4376-b137-b09e064d5d61": {"__data__": {"id_": "816830c4-ef62-4376-b137-b09e064d5d61", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Eric Percher of Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst,  Nephron Research LLC  Q \nThank you.  The international D&A dynamics are interesting.  Thank you for that detail.  Maybe a two -parter, Britt. \n One is when we think about the remaining European business, can you provide us some sense of scale?  I think \nthe last t ime we got a Celesio number without Canada was around $230 million of op profit. ", "original_text": "Thank you for that detail. ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7c86e1438adf8e697caee39b47ea8dbb10d71fa08f6a27738752a5bac88f2df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ebbf5fe-42a0-4c19-8653-9338f11d8c81", "node_type": "1", "metadata": {"window": "A \nOperator, next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Eric Percher of Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst,  Nephron Research LLC  Q \nThank you.  The international D&A dynamics are interesting.  Thank you for that detail.  Maybe a two -parter, Britt. \n One is when we think about the remaining European business, can you provide us some sense of scale? ", "original_text": "The international D&A dynamics are interesting. ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df7caafb9ff20caa41eebbea05ecfab63f3840de7123fe40e1ac76f77354774c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d4a9ecf-b96b-41fc-a7c3-56a294e18319", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst,  Nephron Research LLC  Q \nThank you.  The international D&A dynamics are interesting.  Thank you for that detail.  Maybe a two -parter, Britt. \n One is when we think about the remaining European business, can you provide us some sense of scale?  I think \nthe last t ime we got a Celesio number without Canada was around $230 million of op profit.  And then, on the \nD&A, could the same circumstances exist for the remaining EU business, should you get to a sale?  \n ", "original_text": "Maybe a two -parter, Britt. \n"}, "hash": "0d19418716400e3fc6c14cd9ca16b860f8b18d0749dd5952b22ab06b0a83ac8b", "class_name": "RelatedNodeInfo"}}, "text": "Thank you for that detail. ", "start_char_idx": 3019, "end_char_idx": 3046, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d4a9ecf-b96b-41fc-a7c3-56a294e18319": {"__data__": {"id_": "6d4a9ecf-b96b-41fc-a7c3-56a294e18319", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst,  Nephron Research LLC  Q \nThank you.  The international D&A dynamics are interesting.  Thank you for that detail.  Maybe a two -parter, Britt. \n One is when we think about the remaining European business, can you provide us some sense of scale?  I think \nthe last t ime we got a Celesio number without Canada was around $230 million of op profit.  And then, on the \nD&A, could the same circumstances exist for the remaining EU business, should you get to a sale?  \n ", "original_text": "Maybe a two -parter, Britt. \n", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7c86e1438adf8e697caee39b47ea8dbb10d71fa08f6a27738752a5bac88f2df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "816830c4-ef62-4376-b137-b09e064d5d61", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Next will be Eric Percher of Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst,  Nephron Research LLC  Q \nThank you.  The international D&A dynamics are interesting.  Thank you for that detail.  Maybe a two -parter, Britt. \n One is when we think about the remaining European business, can you provide us some sense of scale?  I think \nthe last t ime we got a Celesio number without Canada was around $230 million of op profit. ", "original_text": "Thank you for that detail. ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ae18fee54c0ba1cd36cadda37abdc9416b92c30ab7e00ad52cd8281ac9587ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4cc809cb-633f-4f0a-95b8-a7fd4b758095", "node_type": "1", "metadata": {"window": "The international D&A dynamics are interesting.  Thank you for that detail.  Maybe a two -parter, Britt. \n One is when we think about the remaining European business, can you provide us some sense of scale?  I think \nthe last t ime we got a Celesio number without Canada was around $230 million of op profit.  And then, on the \nD&A, could the same circumstances exist for the remaining EU business, should you get to a sale?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKes son Corp.  ", "original_text": "One is when we think about the remaining European business, can you provide us some sense of scale? "}, "hash": "2627a246ab7a68d0c5ba9752ad5597cffc658e69d3213935d391293509944e23", "class_name": "RelatedNodeInfo"}}, "text": "Maybe a two -parter, Britt. \n", "start_char_idx": 3046, "end_char_idx": 3075, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4cc809cb-633f-4f0a-95b8-a7fd4b758095": {"__data__": {"id_": "4cc809cb-633f-4f0a-95b8-a7fd4b758095", "embedding": null, "metadata": {"window": "The international D&A dynamics are interesting.  Thank you for that detail.  Maybe a two -parter, Britt. \n One is when we think about the remaining European business, can you provide us some sense of scale?  I think \nthe last t ime we got a Celesio number without Canada was around $230 million of op profit.  And then, on the \nD&A, could the same circumstances exist for the remaining EU business, should you get to a sale?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKes son Corp.  ", "original_text": "One is when we think about the remaining European business, can you provide us some sense of scale? ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7c86e1438adf8e697caee39b47ea8dbb10d71fa08f6a27738752a5bac88f2df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d4a9ecf-b96b-41fc-a7c3-56a294e18319", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst,  Nephron Research LLC  Q \nThank you.  The international D&A dynamics are interesting.  Thank you for that detail.  Maybe a two -parter, Britt. \n One is when we think about the remaining European business, can you provide us some sense of scale?  I think \nthe last t ime we got a Celesio number without Canada was around $230 million of op profit.  And then, on the \nD&A, could the same circumstances exist for the remaining EU business, should you get to a sale?  \n ", "original_text": "Maybe a two -parter, Britt. \n", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "17053904d183e23bbf79ff87fcf71e8cd45e9f087c36545ef37e8b1e6d51086d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17414686-4c78-4852-84be-7494ac0e127e", "node_type": "1", "metadata": {"window": "Thank you for that detail.  Maybe a two -parter, Britt. \n One is when we think about the remaining European business, can you provide us some sense of scale?  I think \nthe last t ime we got a Celesio number without Canada was around $230 million of op profit.  And then, on the \nD&A, could the same circumstances exist for the remaining EU business, should you get to a sale?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKes son Corp.   A \nYeah. ", "original_text": "I think \nthe last t ime we got a Celesio number without Canada was around $230 million of op profit. "}, "hash": "f761a2906ccc4b2e8ff6f6a311e12e87d83c34638fd029ba87569386ca89f136", "class_name": "RelatedNodeInfo"}}, "text": "One is when we think about the remaining European business, can you provide us some sense of scale? ", "start_char_idx": 3075, "end_char_idx": 3175, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17414686-4c78-4852-84be-7494ac0e127e": {"__data__": {"id_": "17414686-4c78-4852-84be-7494ac0e127e", "embedding": null, "metadata": {"window": "Thank you for that detail.  Maybe a two -parter, Britt. \n One is when we think about the remaining European business, can you provide us some sense of scale?  I think \nthe last t ime we got a Celesio number without Canada was around $230 million of op profit.  And then, on the \nD&A, could the same circumstances exist for the remaining EU business, should you get to a sale?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKes son Corp.   A \nYeah. ", "original_text": "I think \nthe last t ime we got a Celesio number without Canada was around $230 million of op profit. ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7c86e1438adf8e697caee39b47ea8dbb10d71fa08f6a27738752a5bac88f2df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4cc809cb-633f-4f0a-95b8-a7fd4b758095", "node_type": "1", "metadata": {"window": "The international D&A dynamics are interesting.  Thank you for that detail.  Maybe a two -parter, Britt. \n One is when we think about the remaining European business, can you provide us some sense of scale?  I think \nthe last t ime we got a Celesio number without Canada was around $230 million of op profit.  And then, on the \nD&A, could the same circumstances exist for the remaining EU business, should you get to a sale?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKes son Corp.  ", "original_text": "One is when we think about the remaining European business, can you provide us some sense of scale? ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "55fd714810e836d2eb72b2cf9a70cddb25250e4f5ddd4e0a47e51d326393eb46", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de80aa3a-a1ed-43d1-b214-bc9a31b9fce2", "node_type": "1", "metadata": {"window": "Maybe a two -parter, Britt. \n One is when we think about the remaining European business, can you provide us some sense of scale?  I think \nthe last t ime we got a Celesio number without Canada was around $230 million of op profit.  And then, on the \nD&A, could the same circumstances exist for the remaining EU business, should you get to a sale?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKes son Corp.   A \nYeah.  Great questions, Eric, and thank you for those questions. ", "original_text": "And then, on the \nD&A, could the same circumstances exist for the remaining EU business, should you get to a sale?  \n "}, "hash": "b55c00bef63869691d7f11cd4783a87ac9b3ed8dc557cf2114aaa8e190f59531", "class_name": "RelatedNodeInfo"}}, "text": "I think \nthe last t ime we got a Celesio number without Canada was around $230 million of op profit. ", "start_char_idx": 3175, "end_char_idx": 3276, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de80aa3a-a1ed-43d1-b214-bc9a31b9fce2": {"__data__": {"id_": "de80aa3a-a1ed-43d1-b214-bc9a31b9fce2", "embedding": null, "metadata": {"window": "Maybe a two -parter, Britt. \n One is when we think about the remaining European business, can you provide us some sense of scale?  I think \nthe last t ime we got a Celesio number without Canada was around $230 million of op profit.  And then, on the \nD&A, could the same circumstances exist for the remaining EU business, should you get to a sale?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKes son Corp.   A \nYeah.  Great questions, Eric, and thank you for those questions. ", "original_text": "And then, on the \nD&A, could the same circumstances exist for the remaining EU business, should you get to a sale?  \n ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7c86e1438adf8e697caee39b47ea8dbb10d71fa08f6a27738752a5bac88f2df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17414686-4c78-4852-84be-7494ac0e127e", "node_type": "1", "metadata": {"window": "Thank you for that detail.  Maybe a two -parter, Britt. \n One is when we think about the remaining European business, can you provide us some sense of scale?  I think \nthe last t ime we got a Celesio number without Canada was around $230 million of op profit.  And then, on the \nD&A, could the same circumstances exist for the remaining EU business, should you get to a sale?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKes son Corp.   A \nYeah. ", "original_text": "I think \nthe last t ime we got a Celesio number without Canada was around $230 million of op profit. ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7221a4131a7a8cd30d2ef6ff2250db94263cc3d238d3b619e558b057d74a02ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc2a3621-b807-49d9-8503-7bc6c7a2b8ef", "node_type": "1", "metadata": {"window": "One is when we think about the remaining European business, can you provide us some sense of scale?  I think \nthe last t ime we got a Celesio number without Canada was around $230 million of op profit.  And then, on the \nD&A, could the same circumstances exist for the remaining EU business, should you get to a sale?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKes son Corp.   A \nYeah.  Great questions, Eric, and thank you for those questions.  I mean we're not going to break out the \ninternational business into its piece parts. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKes son Corp.  "}, "hash": "68fb1e0e13a2f2e2d22fc80a170ff0a1f7e1a7a61a7cc2ea150bd8a2bd9d498f", "class_name": "RelatedNodeInfo"}}, "text": "And then, on the \nD&A, could the same circumstances exist for the remaining EU business, should you get to a sale?  \n ", "start_char_idx": 3276, "end_char_idx": 3394, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc2a3621-b807-49d9-8503-7bc6c7a2b8ef": {"__data__": {"id_": "bc2a3621-b807-49d9-8503-7bc6c7a2b8ef", "embedding": null, "metadata": {"window": "One is when we think about the remaining European business, can you provide us some sense of scale?  I think \nthe last t ime we got a Celesio number without Canada was around $230 million of op profit.  And then, on the \nD&A, could the same circumstances exist for the remaining EU business, should you get to a sale?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKes son Corp.   A \nYeah.  Great questions, Eric, and thank you for those questions.  I mean we're not going to break out the \ninternational business into its piece parts. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKes son Corp.  ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7c86e1438adf8e697caee39b47ea8dbb10d71fa08f6a27738752a5bac88f2df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de80aa3a-a1ed-43d1-b214-bc9a31b9fce2", "node_type": "1", "metadata": {"window": "Maybe a two -parter, Britt. \n One is when we think about the remaining European business, can you provide us some sense of scale?  I think \nthe last t ime we got a Celesio number without Canada was around $230 million of op profit.  And then, on the \nD&A, could the same circumstances exist for the remaining EU business, should you get to a sale?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKes son Corp.   A \nYeah.  Great questions, Eric, and thank you for those questions. ", "original_text": "And then, on the \nD&A, could the same circumstances exist for the remaining EU business, should you get to a sale?  \n ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0c96f294c080b066e2270906c2ea252146e585c89fbf0fde054399b5492452d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "adc253a6-b16c-47f2-989c-926d3bb12c33", "node_type": "1", "metadata": {"window": "I think \nthe last t ime we got a Celesio number without Canada was around $230 million of op profit.  And then, on the \nD&A, could the same circumstances exist for the remaining EU business, should you get to a sale?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKes son Corp.   A \nYeah.  Great questions, Eric, and thank you for those questions.  I mean we're not going to break out the \ninternational business into its piece parts.  We just don't think that that's something that we're ready to do at this \npoint in time. ", "original_text": "A \nYeah. "}, "hash": "6a95faf71ca7bf1dc9c018e5a4e1b271bd347fbed2bd1a519c966f76032731ba", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKes son Corp.  ", "start_char_idx": 3394, "end_char_idx": 3739, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "adc253a6-b16c-47f2-989c-926d3bb12c33": {"__data__": {"id_": "adc253a6-b16c-47f2-989c-926d3bb12c33", "embedding": null, "metadata": {"window": "I think \nthe last t ime we got a Celesio number without Canada was around $230 million of op profit.  And then, on the \nD&A, could the same circumstances exist for the remaining EU business, should you get to a sale?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKes son Corp.   A \nYeah.  Great questions, Eric, and thank you for those questions.  I mean we're not going to break out the \ninternational business into its piece parts.  We just don't think that that's something that we're ready to do at this \npoint in time. ", "original_text": "A \nYeah. ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7c86e1438adf8e697caee39b47ea8dbb10d71fa08f6a27738752a5bac88f2df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc2a3621-b807-49d9-8503-7bc6c7a2b8ef", "node_type": "1", "metadata": {"window": "One is when we think about the remaining European business, can you provide us some sense of scale?  I think \nthe last t ime we got a Celesio number without Canada was around $230 million of op profit.  And then, on the \nD&A, could the same circumstances exist for the remaining EU business, should you get to a sale?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKes son Corp.   A \nYeah.  Great questions, Eric, and thank you for those questions.  I mean we're not going to break out the \ninternational business into its piece parts. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKes son Corp.  ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3c39e1f91fc621de9050c6c3fa20104b041b0ed39117468407efc961b7b5e4f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6704cf25-4686-4008-8090-7f47ff054125", "node_type": "1", "metadata": {"window": "And then, on the \nD&A, could the same circumstances exist for the remaining EU business, should you get to a sale?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKes son Corp.   A \nYeah.  Great questions, Eric, and thank you for those questions.  I mean we're not going to break out the \ninternational business into its piece parts.  We just don't think that that's something that we're ready to do at this \npoint in time.  And I would just say that every transaction that could happen in the future, we will evaluate that \nbased on the facts of the transaction. ", "original_text": "Great questions, Eric, and thank you for those questions. "}, "hash": "6ef2c17de91bc9f2087162f064aafbe90f8e5143252969ad09c813904ac77790", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 3739, "end_char_idx": 3748, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6704cf25-4686-4008-8090-7f47ff054125": {"__data__": {"id_": "6704cf25-4686-4008-8090-7f47ff054125", "embedding": null, "metadata": {"window": "And then, on the \nD&A, could the same circumstances exist for the remaining EU business, should you get to a sale?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKes son Corp.   A \nYeah.  Great questions, Eric, and thank you for those questions.  I mean we're not going to break out the \ninternational business into its piece parts.  We just don't think that that's something that we're ready to do at this \npoint in time.  And I would just say that every transaction that could happen in the future, we will evaluate that \nbased on the facts of the transaction. ", "original_text": "Great questions, Eric, and thank you for those questions. ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7c86e1438adf8e697caee39b47ea8dbb10d71fa08f6a27738752a5bac88f2df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "adc253a6-b16c-47f2-989c-926d3bb12c33", "node_type": "1", "metadata": {"window": "I think \nthe last t ime we got a Celesio number without Canada was around $230 million of op profit.  And then, on the \nD&A, could the same circumstances exist for the remaining EU business, should you get to a sale?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKes son Corp.   A \nYeah.  Great questions, Eric, and thank you for those questions.  I mean we're not going to break out the \ninternational business into its piece parts.  We just don't think that that's something that we're ready to do at this \npoint in time. ", "original_text": "A \nYeah. ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dd266dac0fad211d574c30d7c2740f591d3546d3a1fdb6481677a476c5c337db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4164cdd9-4867-4285-ac1b-2423f6da85b1", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKes son Corp.   A \nYeah.  Great questions, Eric, and thank you for those questions.  I mean we're not going to break out the \ninternational business into its piece parts.  We just don't think that that's something that we're ready to do at this \npoint in time.  And I would just say that every transaction that could happen in the future, we will evaluate that \nbased on the facts of the transaction.  For this particular transaction, we deemed that these assets would be in a \nheld-for-sale perspective. ", "original_text": "I mean we're not going to break out the \ninternational business into its piece parts. "}, "hash": "0e6ddef388c923a783e4552b6ff4ee0bce3399a6ba8464d00d9e4499becc05c2", "class_name": "RelatedNodeInfo"}}, "text": "Great questions, Eric, and thank you for those questions. ", "start_char_idx": 3748, "end_char_idx": 3806, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4164cdd9-4867-4285-ac1b-2423f6da85b1": {"__data__": {"id_": "4164cdd9-4867-4285-ac1b-2423f6da85b1", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKes son Corp.   A \nYeah.  Great questions, Eric, and thank you for those questions.  I mean we're not going to break out the \ninternational business into its piece parts.  We just don't think that that's something that we're ready to do at this \npoint in time.  And I would just say that every transaction that could happen in the future, we will evaluate that \nbased on the facts of the transaction.  For this particular transaction, we deemed that these assets would be in a \nheld-for-sale perspective. ", "original_text": "I mean we're not going to break out the \ninternational business into its piece parts. ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7c86e1438adf8e697caee39b47ea8dbb10d71fa08f6a27738752a5bac88f2df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6704cf25-4686-4008-8090-7f47ff054125", "node_type": "1", "metadata": {"window": "And then, on the \nD&A, could the same circumstances exist for the remaining EU business, should you get to a sale?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKes son Corp.   A \nYeah.  Great questions, Eric, and thank you for those questions.  I mean we're not going to break out the \ninternational business into its piece parts.  We just don't think that that's something that we're ready to do at this \npoint in time.  And I would just say that every transaction that could happen in the future, we will evaluate that \nbased on the facts of the transaction. ", "original_text": "Great questions, Eric, and thank you for those questions. ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9bea251ce2f1f0bf19527d194abd95f42640a12ecfbc44f5bd0a82cfcc0b618b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7fd9c80f-17ae-4c1b-8f04-84077bf2d8e8", "node_type": "1", "metadata": {"window": "A \nYeah.  Great questions, Eric, and thank you for those questions.  I mean we're not going to break out the \ninternational business into its piece parts.  We just don't think that that's something that we're ready to do at this \npoint in time.  And I would just say that every transaction that could happen in the future, we will evaluate that \nbased on the facts of the transaction.  For this particular transaction, we deemed that these assets would be in a \nheld-for-sale perspective.  But I can't really com ment on what future transactions might look like. ", "original_text": "We just don't think that that's something that we're ready to do at this \npoint in time. "}, "hash": "ea2982a29c04fc5de325316ac5771564414e9d687b7c55953e2eb208e73153aa", "class_name": "RelatedNodeInfo"}}, "text": "I mean we're not going to break out the \ninternational business into its piece parts. ", "start_char_idx": 3806, "end_char_idx": 3892, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7fd9c80f-17ae-4c1b-8f04-84077bf2d8e8": {"__data__": {"id_": "7fd9c80f-17ae-4c1b-8f04-84077bf2d8e8", "embedding": null, "metadata": {"window": "A \nYeah.  Great questions, Eric, and thank you for those questions.  I mean we're not going to break out the \ninternational business into its piece parts.  We just don't think that that's something that we're ready to do at this \npoint in time.  And I would just say that every transaction that could happen in the future, we will evaluate that \nbased on the facts of the transaction.  For this particular transaction, we deemed that these assets would be in a \nheld-for-sale perspective.  But I can't really com ment on what future transactions might look like. ", "original_text": "We just don't think that that's something that we're ready to do at this \npoint in time. ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7c86e1438adf8e697caee39b47ea8dbb10d71fa08f6a27738752a5bac88f2df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4164cdd9-4867-4285-ac1b-2423f6da85b1", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKes son Corp.   A \nYeah.  Great questions, Eric, and thank you for those questions.  I mean we're not going to break out the \ninternational business into its piece parts.  We just don't think that that's something that we're ready to do at this \npoint in time.  And I would just say that every transaction that could happen in the future, we will evaluate that \nbased on the facts of the transaction.  For this particular transaction, we deemed that these assets would be in a \nheld-for-sale perspective. ", "original_text": "I mean we're not going to break out the \ninternational business into its piece parts. ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "29bc9f1d589dfcdbdf99f417ee2e29690202c4e062412748738273f2bcf0b6ca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ab620af-1c8b-4700-98f1-5f92d9a6a050", "node_type": "1", "metadata": {"window": "Great questions, Eric, and thank you for those questions.  I mean we're not going to break out the \ninternational business into its piece parts.  We just don't think that that's something that we're ready to do at this \npoint in time.  And I would just say that every transaction that could happen in the future, we will evaluate that \nbased on the facts of the transaction.  For this particular transaction, we deemed that these assets would be in a \nheld-for-sale perspective.  But I can't really com ment on what future transactions might look like.  It's difficult to \nknow how those transactions may or may not come together and what the specific details would be.  \n \n", "original_text": "And I would just say that every transaction that could happen in the future, we will evaluate that \nbased on the facts of the transaction. "}, "hash": "2455d8ef853a739e9202c1d644026772edadb087f5dab7d0a6cac41d36ba435d", "class_name": "RelatedNodeInfo"}}, "text": "We just don't think that that's something that we're ready to do at this \npoint in time. ", "start_char_idx": 3892, "end_char_idx": 3981, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ab620af-1c8b-4700-98f1-5f92d9a6a050": {"__data__": {"id_": "5ab620af-1c8b-4700-98f1-5f92d9a6a050", "embedding": null, "metadata": {"window": "Great questions, Eric, and thank you for those questions.  I mean we're not going to break out the \ninternational business into its piece parts.  We just don't think that that's something that we're ready to do at this \npoint in time.  And I would just say that every transaction that could happen in the future, we will evaluate that \nbased on the facts of the transaction.  For this particular transaction, we deemed that these assets would be in a \nheld-for-sale perspective.  But I can't really com ment on what future transactions might look like.  It's difficult to \nknow how those transactions may or may not come together and what the specific details would be.  \n \n", "original_text": "And I would just say that every transaction that could happen in the future, we will evaluate that \nbased on the facts of the transaction. ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7c86e1438adf8e697caee39b47ea8dbb10d71fa08f6a27738752a5bac88f2df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7fd9c80f-17ae-4c1b-8f04-84077bf2d8e8", "node_type": "1", "metadata": {"window": "A \nYeah.  Great questions, Eric, and thank you for those questions.  I mean we're not going to break out the \ninternational business into its piece parts.  We just don't think that that's something that we're ready to do at this \npoint in time.  And I would just say that every transaction that could happen in the future, we will evaluate that \nbased on the facts of the transaction.  For this particular transaction, we deemed that these assets would be in a \nheld-for-sale perspective.  But I can't really com ment on what future transactions might look like. ", "original_text": "We just don't think that that's something that we're ready to do at this \npoint in time. ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "35c7067932c110e30b9d5347b434f93805291cdff39175d75f34a9a7f2cddd5e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "800cab7d-b17c-4bc3-a845-00f2d19ebe16", "node_type": "1", "metadata": {"window": "I mean we're not going to break out the \ninternational business into its piece parts.  We just don't think that that's something that we're ready to do at this \npoint in time.  And I would just say that every transaction that could happen in the future, we will evaluate that \nbased on the facts of the transaction.  For this particular transaction, we deemed that these assets would be in a \nheld-for-sale perspective.  But I can't really com ment on what future transactions might look like.  It's difficult to \nknow how those transactions may or may not come together and what the specific details would be.  \n \n Next question, operator.  \n ", "original_text": "For this particular transaction, we deemed that these assets would be in a \nheld-for-sale perspective. "}, "hash": "5123ef7aeb81e5c654b174ee0292deb036ea0ea95eaf1bdb982fc4caf304cb78", "class_name": "RelatedNodeInfo"}}, "text": "And I would just say that every transaction that could happen in the future, we will evaluate that \nbased on the facts of the transaction. ", "start_char_idx": 3981, "end_char_idx": 4120, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "800cab7d-b17c-4bc3-a845-00f2d19ebe16": {"__data__": {"id_": "800cab7d-b17c-4bc3-a845-00f2d19ebe16", "embedding": null, "metadata": {"window": "I mean we're not going to break out the \ninternational business into its piece parts.  We just don't think that that's something that we're ready to do at this \npoint in time.  And I would just say that every transaction that could happen in the future, we will evaluate that \nbased on the facts of the transaction.  For this particular transaction, we deemed that these assets would be in a \nheld-for-sale perspective.  But I can't really com ment on what future transactions might look like.  It's difficult to \nknow how those transactions may or may not come together and what the specific details would be.  \n \n Next question, operator.  \n ", "original_text": "For this particular transaction, we deemed that these assets would be in a \nheld-for-sale perspective. ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7c86e1438adf8e697caee39b47ea8dbb10d71fa08f6a27738752a5bac88f2df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ab620af-1c8b-4700-98f1-5f92d9a6a050", "node_type": "1", "metadata": {"window": "Great questions, Eric, and thank you for those questions.  I mean we're not going to break out the \ninternational business into its piece parts.  We just don't think that that's something that we're ready to do at this \npoint in time.  And I would just say that every transaction that could happen in the future, we will evaluate that \nbased on the facts of the transaction.  For this particular transaction, we deemed that these assets would be in a \nheld-for-sale perspective.  But I can't really com ment on what future transactions might look like.  It's difficult to \nknow how those transactions may or may not come together and what the specific details would be.  \n \n", "original_text": "And I would just say that every transaction that could happen in the future, we will evaluate that \nbased on the facts of the transaction. ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72bee6e86ef371ef61369918816e1729a62ae7147979d84ef024660fca82e2cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9cd1cd37-0121-4b93-a0df-e7aae0a236ea", "node_type": "1", "metadata": {"window": "We just don't think that that's something that we're ready to do at this \npoint in time.  And I would just say that every transaction that could happen in the future, we will evaluate that \nbased on the facts of the transaction.  For this particular transaction, we deemed that these assets would be in a \nheld-for-sale perspective.  But I can't really com ment on what future transactions might look like.  It's difficult to \nknow how those transactions may or may not come together and what the specific details would be.  \n \n Next question, operator.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee of Cowen.  \n ", "original_text": "But I can't really com ment on what future transactions might look like. "}, "hash": "e495afb172238a6d12bfc185c90572e433f3e12b221570d1c96300638d78da0b", "class_name": "RelatedNodeInfo"}}, "text": "For this particular transaction, we deemed that these assets would be in a \nheld-for-sale perspective. ", "start_char_idx": 4120, "end_char_idx": 4223, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9cd1cd37-0121-4b93-a0df-e7aae0a236ea": {"__data__": {"id_": "9cd1cd37-0121-4b93-a0df-e7aae0a236ea", "embedding": null, "metadata": {"window": "We just don't think that that's something that we're ready to do at this \npoint in time.  And I would just say that every transaction that could happen in the future, we will evaluate that \nbased on the facts of the transaction.  For this particular transaction, we deemed that these assets would be in a \nheld-for-sale perspective.  But I can't really com ment on what future transactions might look like.  It's difficult to \nknow how those transactions may or may not come together and what the specific details would be.  \n \n Next question, operator.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee of Cowen.  \n ", "original_text": "But I can't really com ment on what future transactions might look like. ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7c86e1438adf8e697caee39b47ea8dbb10d71fa08f6a27738752a5bac88f2df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "800cab7d-b17c-4bc3-a845-00f2d19ebe16", "node_type": "1", "metadata": {"window": "I mean we're not going to break out the \ninternational business into its piece parts.  We just don't think that that's something that we're ready to do at this \npoint in time.  And I would just say that every transaction that could happen in the future, we will evaluate that \nbased on the facts of the transaction.  For this particular transaction, we deemed that these assets would be in a \nheld-for-sale perspective.  But I can't really com ment on what future transactions might look like.  It's difficult to \nknow how those transactions may or may not come together and what the specific details would be.  \n \n Next question, operator.  \n ", "original_text": "For this particular transaction, we deemed that these assets would be in a \nheld-for-sale perspective. ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3813a5a9a72cfdf64688b2a88bdad6264379e3a296b4c0bf234c831b73c4eee7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31aecf5b-2bc3-49df-9a28-326f27eb9d6f", "node_type": "1", "metadata": {"window": "And I would just say that every transaction that could happen in the future, we will evaluate that \nbased on the facts of the transaction.  For this particular transaction, we deemed that these assets would be in a \nheld-for-sale perspective.  But I can't really com ment on what future transactions might look like.  It's difficult to \nknow how those transactions may or may not come together and what the specific details would be.  \n \n Next question, operator.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee of Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "It's difficult to \nknow how those transactions may or may not come together and what the specific details would be.  \n \n"}, "hash": "adf89237b6f542d0f6099167338baf79255af868898799a3e254e658d245891a", "class_name": "RelatedNodeInfo"}}, "text": "But I can't really com ment on what future transactions might look like. ", "start_char_idx": 4223, "end_char_idx": 4296, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31aecf5b-2bc3-49df-9a28-326f27eb9d6f": {"__data__": {"id_": "31aecf5b-2bc3-49df-9a28-326f27eb9d6f", "embedding": null, "metadata": {"window": "And I would just say that every transaction that could happen in the future, we will evaluate that \nbased on the facts of the transaction.  For this particular transaction, we deemed that these assets would be in a \nheld-for-sale perspective.  But I can't really com ment on what future transactions might look like.  It's difficult to \nknow how those transactions may or may not come together and what the specific details would be.  \n \n Next question, operator.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee of Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "It's difficult to \nknow how those transactions may or may not come together and what the specific details would be.  \n \n", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7c86e1438adf8e697caee39b47ea8dbb10d71fa08f6a27738752a5bac88f2df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9cd1cd37-0121-4b93-a0df-e7aae0a236ea", "node_type": "1", "metadata": {"window": "We just don't think that that's something that we're ready to do at this \npoint in time.  And I would just say that every transaction that could happen in the future, we will evaluate that \nbased on the facts of the transaction.  For this particular transaction, we deemed that these assets would be in a \nheld-for-sale perspective.  But I can't really com ment on what future transactions might look like.  It's difficult to \nknow how those transactions may or may not come together and what the specific details would be.  \n \n Next question, operator.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee of Cowen.  \n ", "original_text": "But I can't really com ment on what future transactions might look like. ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3ce858ac5bc804cb678b50f73e258ce8c8850da7ca923f37a19aec3240dddf3b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc124232-1489-46ed-8ed0-12cd5d75bd56", "node_type": "1", "metadata": {"window": "For this particular transaction, we deemed that these assets would be in a \nheld-for-sale perspective.  But I can't really com ment on what future transactions might look like.  It's difficult to \nknow how those transactions may or may not come together and what the specific details would be.  \n \n Next question, operator.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee of Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Next question, operator.  \n "}, "hash": "e6a696725807a0c3092b1a3c890bbedab932c0e813d5452e9bab3117c76f3184", "class_name": "RelatedNodeInfo"}}, "text": "It's difficult to \nknow how those transactions may or may not come together and what the specific details would be.  \n \n", "start_char_idx": 4296, "end_char_idx": 4416, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc124232-1489-46ed-8ed0-12cd5d75bd56": {"__data__": {"id_": "fc124232-1489-46ed-8ed0-12cd5d75bd56", "embedding": null, "metadata": {"window": "For this particular transaction, we deemed that these assets would be in a \nheld-for-sale perspective.  But I can't really com ment on what future transactions might look like.  It's difficult to \nknow how those transactions may or may not come together and what the specific details would be.  \n \n Next question, operator.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee of Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Next question, operator.  \n ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7c86e1438adf8e697caee39b47ea8dbb10d71fa08f6a27738752a5bac88f2df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31aecf5b-2bc3-49df-9a28-326f27eb9d6f", "node_type": "1", "metadata": {"window": "And I would just say that every transaction that could happen in the future, we will evaluate that \nbased on the facts of the transaction.  For this particular transaction, we deemed that these assets would be in a \nheld-for-sale perspective.  But I can't really com ment on what future transactions might look like.  It's difficult to \nknow how those transactions may or may not come together and what the specific details would be.  \n \n Next question, operator.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee of Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "It's difficult to \nknow how those transactions may or may not come together and what the specific details would be.  \n \n", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80b51d04bd98ce61fa0aada45915d0a5b7a7be5ad969b3a3a2d26d2858a9c3e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "516bbaf7-2c84-4aa2-a31b-c3b9f56ecf15", "node_type": "1", "metadata": {"window": "But I can't really com ment on what future transactions might look like.  It's difficult to \nknow how those transactions may or may not come together and what the specific details would be.  \n \n Next question, operator.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee of Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee of Cowen.  \n "}, "hash": "1504825cdbe3c66a1189772830d67382d79bd361c812a9cd48261300efaf96b8", "class_name": "RelatedNodeInfo"}}, "text": "Next question, operator.  \n ", "start_char_idx": 4416, "end_char_idx": 4444, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "516bbaf7-2c84-4aa2-a31b-c3b9f56ecf15": {"__data__": {"id_": "516bbaf7-2c84-4aa2-a31b-c3b9f56ecf15", "embedding": null, "metadata": {"window": "But I can't really com ment on what future transactions might look like.  It's difficult to \nknow how those transactions may or may not come together and what the specific details would be.  \n \n Next question, operator.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee of Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee of Cowen.  \n ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7c86e1438adf8e697caee39b47ea8dbb10d71fa08f6a27738752a5bac88f2df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc124232-1489-46ed-8ed0-12cd5d75bd56", "node_type": "1", "metadata": {"window": "For this particular transaction, we deemed that these assets would be in a \nheld-for-sale perspective.  But I can't really com ment on what future transactions might look like.  It's difficult to \nknow how those transactions may or may not come together and what the specific details would be.  \n \n Next question, operator.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee of Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Next question, operator.  \n ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a1be31338196a4f9ddacda46b4644302250a32ad2ec525da7b065d4b34a32810", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a644bd2a-977d-48d7-9f6b-b774bba667da", "node_type": "1", "metadata": {"window": "It's difficult to \nknow how those transactions may or may not come together and what the specific details would be.  \n \n Next question, operator.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee of Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  "}, "hash": "3818bdbeaad9eb55d64fa50142ed845bd5c45a3fd4630fae5e555ad4c6314119", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee of Cowen.  \n ", "start_char_idx": 4444, "end_char_idx": 4773, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a644bd2a-977d-48d7-9f6b-b774bba667da": {"__data__": {"id_": "a644bd2a-977d-48d7-9f6b-b774bba667da", "embedding": null, "metadata": {"window": "It's difficult to \nknow how those transactions may or may not come together and what the specific details would be.  \n \n Next question, operator.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee of Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7c86e1438adf8e697caee39b47ea8dbb10d71fa08f6a27738752a5bac88f2df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "516bbaf7-2c84-4aa2-a31b-c3b9f56ecf15", "node_type": "1", "metadata": {"window": "But I can't really com ment on what future transactions might look like.  It's difficult to \nknow how those transactions may or may not come together and what the specific details would be.  \n \n Next question, operator.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee of Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee of Cowen.  \n ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "32be2a6058f60eab1e148f22059fe18ba78c386486bd71b413c45e7f21da32bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f67647d4-bca2-4d34-bf9e-fbfa2e1dea9a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nCharles Rhyee  \nAnalyst, Cowen and Company  Q \nYeah.  Thanks for taking the question.  Just wanted to, Britt, just talk about the guidance here for the remainder of \nthe year. ", "original_text": "McKesson Corp.  "}, "hash": "de64fe77ab3db5bb2085064e9dde2e0fbc54a433ca5bb7a9b0b708e853e91807", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "start_char_idx": 891, "end_char_idx": 1162, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f67647d4-bca2-4d34-bf9e-fbfa2e1dea9a": {"__data__": {"id_": "f67647d4-bca2-4d34-bf9e-fbfa2e1dea9a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nCharles Rhyee  \nAnalyst, Cowen and Company  Q \nYeah.  Thanks for taking the question.  Just wanted to, Britt, just talk about the guidance here for the remainder of \nthe year. ", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a976dbf98a9c7ca6e0f2c96b598e037e7b2bd8c548cd866a1c876b2affb94ad3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a644bd2a-977d-48d7-9f6b-b774bba667da", "node_type": "1", "metadata": {"window": "It's difficult to \nknow how those transactions may or may not come together and what the specific details would be.  \n \n Next question, operator.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee of Cowen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "81b3f09e756689668b3a299da0af1c19fba0a04e7df45c82989ca89f67320d21", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "436d2139-1097-4c38-8a3b-74dfded9c73e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nCharles Rhyee  \nAnalyst, Cowen and Company  Q \nYeah.  Thanks for taking the question.  Just wanted to, Britt, just talk about the guidance here for the remainder of \nthe year.  Obviously, a large outsized performance in the quarter, at least relative to what I think consensus was \nexpecting. ", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nCharles Rhyee  \nAnalyst, Cowen and Company  Q \nYeah. "}, "hash": "2cced23f8cfb60d79147fa05d52e42c91d39de79bd2ee1ff2c4d0ab5659e2da8", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "436d2139-1097-4c38-8a3b-74dfded9c73e": {"__data__": {"id_": "436d2139-1097-4c38-8a3b-74dfded9c73e", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nCharles Rhyee  \nAnalyst, Cowen and Company  Q \nYeah.  Thanks for taking the question.  Just wanted to, Britt, just talk about the guidance here for the remainder of \nthe year.  Obviously, a large outsized performance in the quarter, at least relative to what I think consensus was \nexpecting. ", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nCharles Rhyee  \nAnalyst, Cowen and Company  Q \nYeah. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a976dbf98a9c7ca6e0f2c96b598e037e7b2bd8c548cd866a1c876b2affb94ad3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f67647d4-bca2-4d34-bf9e-fbfa2e1dea9a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nCharles Rhyee  \nAnalyst, Cowen and Company  Q \nYeah.  Thanks for taking the question.  Just wanted to, Britt, just talk about the guidance here for the remainder of \nthe year. ", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b3326e740dd05b1140c951167634eb86706802bfcf1b0e7dfb095b63b21c001d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "401f2e5f-898d-42df-9d93-c959d0a058a8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nCharles Rhyee  \nAnalyst, Cowen and Company  Q \nYeah.  Thanks for taking the question.  Just wanted to, Britt, just talk about the guidance here for the remainder of \nthe year.  Obviously, a large outsized performance in the quarter, at least relative to what I think consensus was \nexpecting.  Maybe if you could talk about how this came in at least relative to what you were expecting coming into \nthis quarter. ", "original_text": "Thanks for taking the question. "}, "hash": "1123a6b0cb2df4078e0c692f384beb00a0f48aa980250ba74a98fac2992e04b7", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nCharles Rhyee  \nAnalyst, Cowen and Company  Q \nYeah. ", "start_char_idx": 16, "end_char_idx": 234, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "401f2e5f-898d-42df-9d93-c959d0a058a8": {"__data__": {"id_": "401f2e5f-898d-42df-9d93-c959d0a058a8", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nCharles Rhyee  \nAnalyst, Cowen and Company  Q \nYeah.  Thanks for taking the question.  Just wanted to, Britt, just talk about the guidance here for the remainder of \nthe year.  Obviously, a large outsized performance in the quarter, at least relative to what I think consensus was \nexpecting.  Maybe if you could talk about how this came in at least relative to what you were expecting coming into \nthis quarter. ", "original_text": "Thanks for taking the question. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a976dbf98a9c7ca6e0f2c96b598e037e7b2bd8c548cd866a1c876b2affb94ad3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "436d2139-1097-4c38-8a3b-74dfded9c73e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nCharles Rhyee  \nAnalyst, Cowen and Company  Q \nYeah.  Thanks for taking the question.  Just wanted to, Britt, just talk about the guidance here for the remainder of \nthe year.  Obviously, a large outsized performance in the quarter, at least relative to what I think consensus was \nexpecting. ", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nCharles Rhyee  \nAnalyst, Cowen and Company  Q \nYeah. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "836f1dbadbc59e266d34c4c60dda0bac8d2d54a6232e6b65f29fac438764e4b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13729ea3-9522-45d3-9b0b-c9085019269d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nCharles Rhyee  \nAnalyst, Cowen and Company  Q \nYeah.  Thanks for taking the question.  Just wanted to, Britt, just talk about the guidance here for the remainder of \nthe year.  Obviously, a large outsized performance in the quarter, at least relative to what I think consensus was \nexpecting.  Maybe if you could talk about how this came in at least relative to what you were expecting coming into \nthis quarter.  And as we think about the rest of the year, if I look at the pieces, it seems like we're getting a benefit \nfrom t he D&A, also a tax benefit. ", "original_text": "Just wanted to, Britt, just talk about the guidance here for the remainder of \nthe year. "}, "hash": "20cc94c3fdee0e47b94f3a873a925bba893ed6e476900607394fc857483714f3", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking the question. ", "start_char_idx": 234, "end_char_idx": 266, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "13729ea3-9522-45d3-9b0b-c9085019269d": {"__data__": {"id_": "13729ea3-9522-45d3-9b0b-c9085019269d", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nCharles Rhyee  \nAnalyst, Cowen and Company  Q \nYeah.  Thanks for taking the question.  Just wanted to, Britt, just talk about the guidance here for the remainder of \nthe year.  Obviously, a large outsized performance in the quarter, at least relative to what I think consensus was \nexpecting.  Maybe if you could talk about how this came in at least relative to what you were expecting coming into \nthis quarter.  And as we think about the rest of the year, if I look at the pieces, it seems like we're getting a benefit \nfrom t he D&A, also a tax benefit. ", "original_text": "Just wanted to, Britt, just talk about the guidance here for the remainder of \nthe year. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a976dbf98a9c7ca6e0f2c96b598e037e7b2bd8c548cd866a1c876b2affb94ad3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "401f2e5f-898d-42df-9d93-c959d0a058a8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nCharles Rhyee  \nAnalyst, Cowen and Company  Q \nYeah.  Thanks for taking the question.  Just wanted to, Britt, just talk about the guidance here for the remainder of \nthe year.  Obviously, a large outsized performance in the quarter, at least relative to what I think consensus was \nexpecting.  Maybe if you could talk about how this came in at least relative to what you were expecting coming into \nthis quarter. ", "original_text": "Thanks for taking the question. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "707e663f97ab6bad9b49f083982966bb5e13b815f769a0680f5d162caaef8ea7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b426762f-bd32-4b36-bac8-9a050737207a", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nCharles Rhyee  \nAnalyst, Cowen and Company  Q \nYeah.  Thanks for taking the question.  Just wanted to, Britt, just talk about the guidance here for the remainder of \nthe year.  Obviously, a large outsized performance in the quarter, at least relative to what I think consensus was \nexpecting.  Maybe if you could talk about how this came in at least relative to what you were expecting coming into \nthis quarter.  And as we think about the rest of the year, if I look at the pieces, it seems like we're getting a benefit \nfrom t he D&A, also a tax benefit.  Is that really the big drivers here relative to your expectations coming in? ", "original_text": "Obviously, a large outsized performance in the quarter, at least relative to what I think consensus was \nexpecting. "}, "hash": "baf039630c11769eef7ffcdd4cc0d91784f110dd26d2e0a0557b6168787d1237", "class_name": "RelatedNodeInfo"}}, "text": "Just wanted to, Britt, just talk about the guidance here for the remainder of \nthe year. ", "start_char_idx": 266, "end_char_idx": 355, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b426762f-bd32-4b36-bac8-9a050737207a": {"__data__": {"id_": "b426762f-bd32-4b36-bac8-9a050737207a", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nCharles Rhyee  \nAnalyst, Cowen and Company  Q \nYeah.  Thanks for taking the question.  Just wanted to, Britt, just talk about the guidance here for the remainder of \nthe year.  Obviously, a large outsized performance in the quarter, at least relative to what I think consensus was \nexpecting.  Maybe if you could talk about how this came in at least relative to what you were expecting coming into \nthis quarter.  And as we think about the rest of the year, if I look at the pieces, it seems like we're getting a benefit \nfrom t he D&A, also a tax benefit.  Is that really the big drivers here relative to your expectations coming in? ", "original_text": "Obviously, a large outsized performance in the quarter, at least relative to what I think consensus was \nexpecting. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a976dbf98a9c7ca6e0f2c96b598e037e7b2bd8c548cd866a1c876b2affb94ad3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13729ea3-9522-45d3-9b0b-c9085019269d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nCharles Rhyee  \nAnalyst, Cowen and Company  Q \nYeah.  Thanks for taking the question.  Just wanted to, Britt, just talk about the guidance here for the remainder of \nthe year.  Obviously, a large outsized performance in the quarter, at least relative to what I think consensus was \nexpecting.  Maybe if you could talk about how this came in at least relative to what you were expecting coming into \nthis quarter.  And as we think about the rest of the year, if I look at the pieces, it seems like we're getting a benefit \nfrom t he D&A, also a tax benefit. ", "original_text": "Just wanted to, Britt, just talk about the guidance here for the remainder of \nthe year. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a031f0fd149d24c7f5fd5d79d4ef976a78a0454d7993cc7c3654339853808609", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "14cb1736-1c54-420b-a250-095b9a0c293c", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  Just wanted to, Britt, just talk about the guidance here for the remainder of \nthe year.  Obviously, a large outsized performance in the quarter, at least relative to what I think consensus was \nexpecting.  Maybe if you could talk about how this came in at least relative to what you were expecting coming into \nthis quarter.  And as we think about the rest of the year, if I look at the pieces, it seems like we're getting a benefit \nfrom t he D&A, also a tax benefit.  Is that really the big drivers here relative to your expectations coming in?  And \nmaybe any kind of thoughts around that as we think about the remainder of the year relative to how you guys \nwere \u2013 your plan came in. ", "original_text": "Maybe if you could talk about how this came in at least relative to what you were expecting coming into \nthis quarter. "}, "hash": "a396812691154e5e93e547baa5f8109c81e97977f9bfbea9aaa30533af86f674", "class_name": "RelatedNodeInfo"}}, "text": "Obviously, a large outsized performance in the quarter, at least relative to what I think consensus was \nexpecting. ", "start_char_idx": 355, "end_char_idx": 471, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "14cb1736-1c54-420b-a250-095b9a0c293c": {"__data__": {"id_": "14cb1736-1c54-420b-a250-095b9a0c293c", "embedding": null, "metadata": {"window": "Thanks for taking the question.  Just wanted to, Britt, just talk about the guidance here for the remainder of \nthe year.  Obviously, a large outsized performance in the quarter, at least relative to what I think consensus was \nexpecting.  Maybe if you could talk about how this came in at least relative to what you were expecting coming into \nthis quarter.  And as we think about the rest of the year, if I look at the pieces, it seems like we're getting a benefit \nfrom t he D&A, also a tax benefit.  Is that really the big drivers here relative to your expectations coming in?  And \nmaybe any kind of thoughts around that as we think about the remainder of the year relative to how you guys \nwere \u2013 your plan came in. ", "original_text": "Maybe if you could talk about how this came in at least relative to what you were expecting coming into \nthis quarter. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a976dbf98a9c7ca6e0f2c96b598e037e7b2bd8c548cd866a1c876b2affb94ad3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b426762f-bd32-4b36-bac8-9a050737207a", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nCharles Rhyee  \nAnalyst, Cowen and Company  Q \nYeah.  Thanks for taking the question.  Just wanted to, Britt, just talk about the guidance here for the remainder of \nthe year.  Obviously, a large outsized performance in the quarter, at least relative to what I think consensus was \nexpecting.  Maybe if you could talk about how this came in at least relative to what you were expecting coming into \nthis quarter.  And as we think about the rest of the year, if I look at the pieces, it seems like we're getting a benefit \nfrom t he D&A, also a tax benefit.  Is that really the big drivers here relative to your expectations coming in? ", "original_text": "Obviously, a large outsized performance in the quarter, at least relative to what I think consensus was \nexpecting. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "053c4e2f9080b8c9b6e00a17ee0a23b0693b3abd51af47a802de5af20744e661", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d6003e3e-40d1-49f0-af5e-8bd55e3ddf20", "node_type": "1", "metadata": {"window": "Just wanted to, Britt, just talk about the guidance here for the remainder of \nthe year.  Obviously, a large outsized performance in the quarter, at least relative to what I think consensus was \nexpecting.  Maybe if you could talk about how this came in at least relative to what you were expecting coming into \nthis quarter.  And as we think about the rest of the year, if I look at the pieces, it seems like we're getting a benefit \nfrom t he D&A, also a tax benefit.  Is that really the big drivers here relative to your expectations coming in?  And \nmaybe any kind of thoughts around that as we think about the remainder of the year relative to how you guys \nwere \u2013 your plan came in.  Thanks.  \n ", "original_text": "And as we think about the rest of the year, if I look at the pieces, it seems like we're getting a benefit \nfrom t he D&A, also a tax benefit. "}, "hash": "8c4c18e6cdc4dcbf9edb6743b36aa6e7e080b5755fd606754f13c7385f93f8a9", "class_name": "RelatedNodeInfo"}}, "text": "Maybe if you could talk about how this came in at least relative to what you were expecting coming into \nthis quarter. ", "start_char_idx": 471, "end_char_idx": 590, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d6003e3e-40d1-49f0-af5e-8bd55e3ddf20": {"__data__": {"id_": "d6003e3e-40d1-49f0-af5e-8bd55e3ddf20", "embedding": null, "metadata": {"window": "Just wanted to, Britt, just talk about the guidance here for the remainder of \nthe year.  Obviously, a large outsized performance in the quarter, at least relative to what I think consensus was \nexpecting.  Maybe if you could talk about how this came in at least relative to what you were expecting coming into \nthis quarter.  And as we think about the rest of the year, if I look at the pieces, it seems like we're getting a benefit \nfrom t he D&A, also a tax benefit.  Is that really the big drivers here relative to your expectations coming in?  And \nmaybe any kind of thoughts around that as we think about the remainder of the year relative to how you guys \nwere \u2013 your plan came in.  Thanks.  \n ", "original_text": "And as we think about the rest of the year, if I look at the pieces, it seems like we're getting a benefit \nfrom t he D&A, also a tax benefit. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a976dbf98a9c7ca6e0f2c96b598e037e7b2bd8c548cd866a1c876b2affb94ad3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "14cb1736-1c54-420b-a250-095b9a0c293c", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  Just wanted to, Britt, just talk about the guidance here for the remainder of \nthe year.  Obviously, a large outsized performance in the quarter, at least relative to what I think consensus was \nexpecting.  Maybe if you could talk about how this came in at least relative to what you were expecting coming into \nthis quarter.  And as we think about the rest of the year, if I look at the pieces, it seems like we're getting a benefit \nfrom t he D&A, also a tax benefit.  Is that really the big drivers here relative to your expectations coming in?  And \nmaybe any kind of thoughts around that as we think about the remainder of the year relative to how you guys \nwere \u2013 your plan came in. ", "original_text": "Maybe if you could talk about how this came in at least relative to what you were expecting coming into \nthis quarter. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "70daf92a950b44b2a639854d46faeb4533f3caf9f6a6bdfde2f1c97692ffe2c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f2930220-c519-4143-a953-e83b1d72545e", "node_type": "1", "metadata": {"window": "Obviously, a large outsized performance in the quarter, at least relative to what I think consensus was \nexpecting.  Maybe if you could talk about how this came in at least relative to what you were expecting coming into \nthis quarter.  And as we think about the rest of the year, if I look at the pieces, it seems like we're getting a benefit \nfrom t he D&A, also a tax benefit.  Is that really the big drivers here relative to your expectations coming in?  And \nmaybe any kind of thoughts around that as we think about the remainder of the year relative to how you guys \nwere \u2013 your plan came in.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Is that really the big drivers here relative to your expectations coming in? "}, "hash": "5893055978d2cb0dc05f41e3de14a865ca04fcb41d7100dc1bf5b636a78fc2df", "class_name": "RelatedNodeInfo"}}, "text": "And as we think about the rest of the year, if I look at the pieces, it seems like we're getting a benefit \nfrom t he D&A, also a tax benefit. ", "start_char_idx": 590, "end_char_idx": 733, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f2930220-c519-4143-a953-e83b1d72545e": {"__data__": {"id_": "f2930220-c519-4143-a953-e83b1d72545e", "embedding": null, "metadata": {"window": "Obviously, a large outsized performance in the quarter, at least relative to what I think consensus was \nexpecting.  Maybe if you could talk about how this came in at least relative to what you were expecting coming into \nthis quarter.  And as we think about the rest of the year, if I look at the pieces, it seems like we're getting a benefit \nfrom t he D&A, also a tax benefit.  Is that really the big drivers here relative to your expectations coming in?  And \nmaybe any kind of thoughts around that as we think about the remainder of the year relative to how you guys \nwere \u2013 your plan came in.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Is that really the big drivers here relative to your expectations coming in? ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a976dbf98a9c7ca6e0f2c96b598e037e7b2bd8c548cd866a1c876b2affb94ad3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d6003e3e-40d1-49f0-af5e-8bd55e3ddf20", "node_type": "1", "metadata": {"window": "Just wanted to, Britt, just talk about the guidance here for the remainder of \nthe year.  Obviously, a large outsized performance in the quarter, at least relative to what I think consensus was \nexpecting.  Maybe if you could talk about how this came in at least relative to what you were expecting coming into \nthis quarter.  And as we think about the rest of the year, if I look at the pieces, it seems like we're getting a benefit \nfrom t he D&A, also a tax benefit.  Is that really the big drivers here relative to your expectations coming in?  And \nmaybe any kind of thoughts around that as we think about the remainder of the year relative to how you guys \nwere \u2013 your plan came in.  Thanks.  \n ", "original_text": "And as we think about the rest of the year, if I look at the pieces, it seems like we're getting a benefit \nfrom t he D&A, also a tax benefit. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b4bb3b283fdf917d729ab959cbcdb52f8af1895cca29df82fa53ba856000fef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ecbc28c-8125-4995-b847-f1d8ed740192", "node_type": "1", "metadata": {"window": "Maybe if you could talk about how this came in at least relative to what you were expecting coming into \nthis quarter.  And as we think about the rest of the year, if I look at the pieces, it seems like we're getting a benefit \nfrom t he D&A, also a tax benefit.  Is that really the big drivers here relative to your expectations coming in?  And \nmaybe any kind of thoughts around that as we think about the remainder of the year relative to how you guys \nwere \u2013 your plan came in.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "And \nmaybe any kind of thoughts around that as we think about the remainder of the year relative to how you guys \nwere \u2013 your plan came in. "}, "hash": "c67a4a133f5fa11a5f9e29392f763979756cdb1d5cda1d1c542f5e16a4370138", "class_name": "RelatedNodeInfo"}}, "text": "Is that really the big drivers here relative to your expectations coming in? ", "start_char_idx": 733, "end_char_idx": 810, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ecbc28c-8125-4995-b847-f1d8ed740192": {"__data__": {"id_": "9ecbc28c-8125-4995-b847-f1d8ed740192", "embedding": null, "metadata": {"window": "Maybe if you could talk about how this came in at least relative to what you were expecting coming into \nthis quarter.  And as we think about the rest of the year, if I look at the pieces, it seems like we're getting a benefit \nfrom t he D&A, also a tax benefit.  Is that really the big drivers here relative to your expectations coming in?  And \nmaybe any kind of thoughts around that as we think about the remainder of the year relative to how you guys \nwere \u2013 your plan came in.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "And \nmaybe any kind of thoughts around that as we think about the remainder of the year relative to how you guys \nwere \u2013 your plan came in. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a976dbf98a9c7ca6e0f2c96b598e037e7b2bd8c548cd866a1c876b2affb94ad3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f2930220-c519-4143-a953-e83b1d72545e", "node_type": "1", "metadata": {"window": "Obviously, a large outsized performance in the quarter, at least relative to what I think consensus was \nexpecting.  Maybe if you could talk about how this came in at least relative to what you were expecting coming into \nthis quarter.  And as we think about the rest of the year, if I look at the pieces, it seems like we're getting a benefit \nfrom t he D&A, also a tax benefit.  Is that really the big drivers here relative to your expectations coming in?  And \nmaybe any kind of thoughts around that as we think about the remainder of the year relative to how you guys \nwere \u2013 your plan came in.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Is that really the big drivers here relative to your expectations coming in? ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "baf698971e4b28ece362a0dfddda7f329480d30f898488d4b380a303311432f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d6b7376-c3a1-472e-9494-726a19e71afa", "node_type": "1", "metadata": {"window": "And as we think about the rest of the year, if I look at the pieces, it seems like we're getting a benefit \nfrom t he D&A, also a tax benefit.  Is that really the big drivers here relative to your expectations coming in?  And \nmaybe any kind of thoughts around that as we think about the remainder of the year relative to how you guys \nwere \u2013 your plan came in.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thank you for that question. ", "original_text": "Thanks.  \n "}, "hash": "62f7d673a7f7ba86c90fb8103ae21c162e92591d8b945430333a079a82d435b3", "class_name": "RelatedNodeInfo"}}, "text": "And \nmaybe any kind of thoughts around that as we think about the remainder of the year relative to how you guys \nwere \u2013 your plan came in. ", "start_char_idx": 810, "end_char_idx": 950, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d6b7376-c3a1-472e-9494-726a19e71afa": {"__data__": {"id_": "4d6b7376-c3a1-472e-9494-726a19e71afa", "embedding": null, "metadata": {"window": "And as we think about the rest of the year, if I look at the pieces, it seems like we're getting a benefit \nfrom t he D&A, also a tax benefit.  Is that really the big drivers here relative to your expectations coming in?  And \nmaybe any kind of thoughts around that as we think about the remainder of the year relative to how you guys \nwere \u2013 your plan came in.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thank you for that question. ", "original_text": "Thanks.  \n ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a976dbf98a9c7ca6e0f2c96b598e037e7b2bd8c548cd866a1c876b2affb94ad3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ecbc28c-8125-4995-b847-f1d8ed740192", "node_type": "1", "metadata": {"window": "Maybe if you could talk about how this came in at least relative to what you were expecting coming into \nthis quarter.  And as we think about the rest of the year, if I look at the pieces, it seems like we're getting a benefit \nfrom t he D&A, also a tax benefit.  Is that really the big drivers here relative to your expectations coming in?  And \nmaybe any kind of thoughts around that as we think about the remainder of the year relative to how you guys \nwere \u2013 your plan came in.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "And \nmaybe any kind of thoughts around that as we think about the remainder of the year relative to how you guys \nwere \u2013 your plan came in. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1dccc0d60030374c42baeadcb17dd29b5575329e9094c64a7ffca4e150f778ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "760631ce-7b40-453f-8695-ffc1da725a0b", "node_type": "1", "metadata": {"window": "Is that really the big drivers here relative to your expectations coming in?  And \nmaybe any kind of thoughts around that as we think about the remainder of the year relative to how you guys \nwere \u2013 your plan came in.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thank you for that question.  Maybe I'll just start with, as you look at some of our macro assumptions, we \ntalked about these in May that we assume that we would continue to see grow ing patient activity and prescription \nvolumes. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "92517decb232471e0d17d7106d88e863c553491330c73dcf45e1d819d9751f77", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 950, "end_char_idx": 961, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "760631ce-7b40-453f-8695-ffc1da725a0b": {"__data__": {"id_": "760631ce-7b40-453f-8695-ffc1da725a0b", "embedding": null, "metadata": {"window": "Is that really the big drivers here relative to your expectations coming in?  And \nmaybe any kind of thoughts around that as we think about the remainder of the year relative to how you guys \nwere \u2013 your plan came in.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thank you for that question.  Maybe I'll just start with, as you look at some of our macro assumptions, we \ntalked about these in May that we assume that we would continue to see grow ing patient activity and prescription \nvolumes. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a976dbf98a9c7ca6e0f2c96b598e037e7b2bd8c548cd866a1c876b2affb94ad3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d6b7376-c3a1-472e-9494-726a19e71afa", "node_type": "1", "metadata": {"window": "And as we think about the rest of the year, if I look at the pieces, it seems like we're getting a benefit \nfrom t he D&A, also a tax benefit.  Is that really the big drivers here relative to your expectations coming in?  And \nmaybe any kind of thoughts around that as we think about the remainder of the year relative to how you guys \nwere \u2013 your plan came in.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thank you for that question. ", "original_text": "Thanks.  \n ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d8d3ca00c3ebb35e043077ff811e3771c000de99af5a73a48915dddb8c07535", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "817a8a2c-e61a-46c8-b436-b251bd74a842", "node_type": "1", "metadata": {"window": "And \nmaybe any kind of thoughts around that as we think about the remainder of the year relative to how you guys \nwere \u2013 your plan came in.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thank you for that question.  Maybe I'll just start with, as you look at some of our macro assumptions, we \ntalked about these in May that we assume that we would continue to see grow ing patient activity and prescription \nvolumes.  We saw that. ", "original_text": "A \nYeah. "}, "hash": "1009a8a0b91948e5d7b688360a0d0d1f0ec1b1d721c7ed6cc01738b643faa38f", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 961, "end_char_idx": 1305, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "817a8a2c-e61a-46c8-b436-b251bd74a842": {"__data__": {"id_": "817a8a2c-e61a-46c8-b436-b251bd74a842", "embedding": null, "metadata": {"window": "And \nmaybe any kind of thoughts around that as we think about the remainder of the year relative to how you guys \nwere \u2013 your plan came in.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thank you for that question.  Maybe I'll just start with, as you look at some of our macro assumptions, we \ntalked about these in May that we assume that we would continue to see grow ing patient activity and prescription \nvolumes.  We saw that. ", "original_text": "A \nYeah. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a976dbf98a9c7ca6e0f2c96b598e037e7b2bd8c548cd866a1c876b2affb94ad3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "760631ce-7b40-453f-8695-ffc1da725a0b", "node_type": "1", "metadata": {"window": "Is that really the big drivers here relative to your expectations coming in?  And \nmaybe any kind of thoughts around that as we think about the remainder of the year relative to how you guys \nwere \u2013 your plan came in.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thank you for that question.  Maybe I'll just start with, as you look at some of our macro assumptions, we \ntalked about these in May that we assume that we would continue to see grow ing patient activity and prescription \nvolumes. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fba1604f9b7077eb242a5af5971fa09e73963837305d00f019c913052a554d3e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b6b9f3d-6ed1-4fe1-a32e-78f06cad4eda", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thank you for that question.  Maybe I'll just start with, as you look at some of our macro assumptions, we \ntalked about these in May that we assume that we would continue to see grow ing patient activity and prescription \nvolumes.  We saw that.  We saw that in the first quarter. ", "original_text": "Thank you for that question. "}, "hash": "06d6789685cd1d3f4a4ba59259d637869fd839fb3e6361508a39fcf8837d730b", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 1305, "end_char_idx": 1314, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b6b9f3d-6ed1-4fe1-a32e-78f06cad4eda": {"__data__": {"id_": "4b6b9f3d-6ed1-4fe1-a32e-78f06cad4eda", "embedding": null, "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thank you for that question.  Maybe I'll just start with, as you look at some of our macro assumptions, we \ntalked about these in May that we assume that we would continue to see grow ing patient activity and prescription \nvolumes.  We saw that.  We saw that in the first quarter. ", "original_text": "Thank you for that question. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a976dbf98a9c7ca6e0f2c96b598e037e7b2bd8c548cd866a1c876b2affb94ad3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "817a8a2c-e61a-46c8-b436-b251bd74a842", "node_type": "1", "metadata": {"window": "And \nmaybe any kind of thoughts around that as we think about the remainder of the year relative to how you guys \nwere \u2013 your plan came in.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thank you for that question.  Maybe I'll just start with, as you look at some of our macro assumptions, we \ntalked about these in May that we assume that we would continue to see grow ing patient activity and prescription \nvolumes.  We saw that. ", "original_text": "A \nYeah. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "140203563dd9dd0012543cfa86e3c5ab47cb8fa7f13323eaa17f525ded6bad3a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "07d2b955-3b87-42a2-aea9-b305a4a70714", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thank you for that question.  Maybe I'll just start with, as you look at some of our macro assumptions, we \ntalked about these in May that we assume that we would continue to see grow ing patient activity and prescription \nvolumes.  We saw that.  We saw that in the first quarter.  And so, that was in line with our expectations. ", "original_text": "Maybe I'll just start with, as you look at some of our macro assumptions, we \ntalked about these in May that we assume that we would continue to see grow ing patient activity and prescription \nvolumes. "}, "hash": "eabe4f8532fbac4dda8171c5583f2f4043579fbf82ee7ede5b4401d6bcc74935", "class_name": "RelatedNodeInfo"}}, "text": "Thank you for that question. ", "start_char_idx": 1314, "end_char_idx": 1343, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "07d2b955-3b87-42a2-aea9-b305a4a70714": {"__data__": {"id_": "07d2b955-3b87-42a2-aea9-b305a4a70714", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thank you for that question.  Maybe I'll just start with, as you look at some of our macro assumptions, we \ntalked about these in May that we assume that we would continue to see grow ing patient activity and prescription \nvolumes.  We saw that.  We saw that in the first quarter.  And so, that was in line with our expectations. ", "original_text": "Maybe I'll just start with, as you look at some of our macro assumptions, we \ntalked about these in May that we assume that we would continue to see grow ing patient activity and prescription \nvolumes. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a976dbf98a9c7ca6e0f2c96b598e037e7b2bd8c548cd866a1c876b2affb94ad3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b6b9f3d-6ed1-4fe1-a32e-78f06cad4eda", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thank you for that question.  Maybe I'll just start with, as you look at some of our macro assumptions, we \ntalked about these in May that we assume that we would continue to see grow ing patient activity and prescription \nvolumes.  We saw that.  We saw that in the first quarter. ", "original_text": "Thank you for that question. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1bafb2ee2d5d8c60f7592f6769dbe962c6c4a428753717f5ce9abde4a4222ca7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a32bb471-1a79-4ae3-9f48-d5a960db822b", "node_type": "1", "metadata": {"window": "A \nYeah.  Thank you for that question.  Maybe I'll just start with, as you look at some of our macro assumptions, we \ntalked about these in May that we assume that we would continue to see grow ing patient activity and prescription \nvolumes.  We saw that.  We saw that in the first quarter.  And so, that was in line with our expectations.  We see that \ncontinuing to build and continuing to improve. ", "original_text": "We saw that. "}, "hash": "893658f8b98d7c60caf8927ca6b51c6925bf369326cf9002a2c36bcd5a9f17ef", "class_name": "RelatedNodeInfo"}}, "text": "Maybe I'll just start with, as you look at some of our macro assumptions, we \ntalked about these in May that we assume that we would continue to see grow ing patient activity and prescription \nvolumes. ", "start_char_idx": 1343, "end_char_idx": 1545, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a32bb471-1a79-4ae3-9f48-d5a960db822b": {"__data__": {"id_": "a32bb471-1a79-4ae3-9f48-d5a960db822b", "embedding": null, "metadata": {"window": "A \nYeah.  Thank you for that question.  Maybe I'll just start with, as you look at some of our macro assumptions, we \ntalked about these in May that we assume that we would continue to see grow ing patient activity and prescription \nvolumes.  We saw that.  We saw that in the first quarter.  And so, that was in line with our expectations.  We see that \ncontinuing to build and continuing to improve. ", "original_text": "We saw that. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a976dbf98a9c7ca6e0f2c96b598e037e7b2bd8c548cd866a1c876b2affb94ad3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "07d2b955-3b87-42a2-aea9-b305a4a70714", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thank you for that question.  Maybe I'll just start with, as you look at some of our macro assumptions, we \ntalked about these in May that we assume that we would continue to see grow ing patient activity and prescription \nvolumes.  We saw that.  We saw that in the first quarter.  And so, that was in line with our expectations. ", "original_text": "Maybe I'll just start with, as you look at some of our macro assumptions, we \ntalked about these in May that we assume that we would continue to see grow ing patient activity and prescription \nvolumes. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53dd7a257d362282034414ea4434ec1e18ef2e4a75f6aa13036f84d8986c9e97", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b00ff72d-413d-4364-936c-ceb74ff59874", "node_type": "1", "metadata": {"window": "Thank you for that question.  Maybe I'll just start with, as you look at some of our macro assumptions, we \ntalked about these in May that we assume that we would continue to see grow ing patient activity and prescription \nvolumes.  We saw that.  We saw that in the first quarter.  And so, that was in line with our expectations.  We see that \ncontinuing to build and continuing to improve.  And so, just from a very macro utilization perspective,  we're seeing \nthe improvement that we expected to see. ", "original_text": "We saw that in the first quarter. "}, "hash": "b9e517c0f5ff345bba5acd269d732810faa49b0b741b0484c80abce89d534c53", "class_name": "RelatedNodeInfo"}}, "text": "We saw that. ", "start_char_idx": 1545, "end_char_idx": 1558, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b00ff72d-413d-4364-936c-ceb74ff59874": {"__data__": {"id_": "b00ff72d-413d-4364-936c-ceb74ff59874", "embedding": null, "metadata": {"window": "Thank you for that question.  Maybe I'll just start with, as you look at some of our macro assumptions, we \ntalked about these in May that we assume that we would continue to see grow ing patient activity and prescription \nvolumes.  We saw that.  We saw that in the first quarter.  And so, that was in line with our expectations.  We see that \ncontinuing to build and continuing to improve.  And so, just from a very macro utilization perspective,  we're seeing \nthe improvement that we expected to see. ", "original_text": "We saw that in the first quarter. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a976dbf98a9c7ca6e0f2c96b598e037e7b2bd8c548cd866a1c876b2affb94ad3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a32bb471-1a79-4ae3-9f48-d5a960db822b", "node_type": "1", "metadata": {"window": "A \nYeah.  Thank you for that question.  Maybe I'll just start with, as you look at some of our macro assumptions, we \ntalked about these in May that we assume that we would continue to see grow ing patient activity and prescription \nvolumes.  We saw that.  We saw that in the first quarter.  And so, that was in line with our expectations.  We see that \ncontinuing to build and continuing to improve. ", "original_text": "We saw that. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98f2800b8aa555891d8009ad4556798ca0230a692601adc35bd3d6d37493719d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4aefc882-3c0a-4abd-9aec-509df9d94789", "node_type": "1", "metadata": {"window": "Maybe I'll just start with, as you look at some of our macro assumptions, we \ntalked about these in May that we assume that we would continue to see grow ing patient activity and prescription \nvolumes.  We saw that.  We saw that in the first quarter.  And so, that was in line with our expectations.  We see that \ncontinuing to build and continuing to improve.  And so, just from a very macro utilization perspective,  we're seeing \nthe improvement that we expected to see.  We're seeing it on the trajectory that we expected to see. ", "original_text": "And so, that was in line with our expectations. "}, "hash": "461467d5f2ff6cb87974baed386cd1176a2f55350b0cc926c634a6ebb698a838", "class_name": "RelatedNodeInfo"}}, "text": "We saw that in the first quarter. ", "start_char_idx": 1558, "end_char_idx": 1592, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4aefc882-3c0a-4abd-9aec-509df9d94789": {"__data__": {"id_": "4aefc882-3c0a-4abd-9aec-509df9d94789", "embedding": null, "metadata": {"window": "Maybe I'll just start with, as you look at some of our macro assumptions, we \ntalked about these in May that we assume that we would continue to see grow ing patient activity and prescription \nvolumes.  We saw that.  We saw that in the first quarter.  And so, that was in line with our expectations.  We see that \ncontinuing to build and continuing to improve.  And so, just from a very macro utilization perspective,  we're seeing \nthe improvement that we expected to see.  We're seeing it on the trajectory that we expected to see. ", "original_text": "And so, that was in line with our expectations. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a976dbf98a9c7ca6e0f2c96b598e037e7b2bd8c548cd866a1c876b2affb94ad3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b00ff72d-413d-4364-936c-ceb74ff59874", "node_type": "1", "metadata": {"window": "Thank you for that question.  Maybe I'll just start with, as you look at some of our macro assumptions, we \ntalked about these in May that we assume that we would continue to see grow ing patient activity and prescription \nvolumes.  We saw that.  We saw that in the first quarter.  And so, that was in line with our expectations.  We see that \ncontinuing to build and continuing to improve.  And so, just from a very macro utilization perspective,  we're seeing \nthe improvement that we expected to see. ", "original_text": "We saw that in the first quarter. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7fa76591be846bd37a7db57c6594838d668662c61d1c827b92d64bc84fe22806", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "398d98cf-ab51-4ebe-a46b-be28725c38b9", "node_type": "1", "metadata": {"window": "We saw that.  We saw that in the first quarter.  And so, that was in line with our expectations.  We see that \ncontinuing to build and continuing to improve.  And so, just from a very macro utilization perspective,  we're seeing \nthe improvement that we expected to see.  We're seeing it on the trajectory that we expected to see.  And so, we're \nvery encouraged by that.  \n \n", "original_text": "We see that \ncontinuing to build and continuing to improve. "}, "hash": "6d58892cb7445d3b6e37b670234df8418f95d9c5da7c786947cedc248c9144cd", "class_name": "RelatedNodeInfo"}}, "text": "And so, that was in line with our expectations. ", "start_char_idx": 1592, "end_char_idx": 1640, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "398d98cf-ab51-4ebe-a46b-be28725c38b9": {"__data__": {"id_": "398d98cf-ab51-4ebe-a46b-be28725c38b9", "embedding": null, "metadata": {"window": "We saw that.  We saw that in the first quarter.  And so, that was in line with our expectations.  We see that \ncontinuing to build and continuing to improve.  And so, just from a very macro utilization perspective,  we're seeing \nthe improvement that we expected to see.  We're seeing it on the trajectory that we expected to see.  And so, we're \nvery encouraged by that.  \n \n", "original_text": "We see that \ncontinuing to build and continuing to improve. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a976dbf98a9c7ca6e0f2c96b598e037e7b2bd8c548cd866a1c876b2affb94ad3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4aefc882-3c0a-4abd-9aec-509df9d94789", "node_type": "1", "metadata": {"window": "Maybe I'll just start with, as you look at some of our macro assumptions, we \ntalked about these in May that we assume that we would continue to see grow ing patient activity and prescription \nvolumes.  We saw that.  We saw that in the first quarter.  And so, that was in line with our expectations.  We see that \ncontinuing to build and continuing to improve.  And so, just from a very macro utilization perspective,  we're seeing \nthe improvement that we expected to see.  We're seeing it on the trajectory that we expected to see. ", "original_text": "And so, that was in line with our expectations. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28de043e0a0688765df1481b811876aa099a1236b5ffb07c1586acc0c08e63a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4239ef0-44f1-492e-b3ed-c2763069b106", "node_type": "1", "metadata": {"window": "We saw that in the first quarter.  And so, that was in line with our expectations.  We see that \ncontinuing to build and continuing to improve.  And so, just from a very macro utilization perspective,  we're seeing \nthe improvement that we expected to see.  We're seeing it on the trajectory that we expected to see.  And so, we're \nvery encouraged by that.  \n \n Our businesses, each of our segments had very strong performance. ", "original_text": "And so, just from a very macro utilization perspective,  we're seeing \nthe improvement that we expected to see. "}, "hash": "64d37a6ac05059e46e5a83988ed344085816391d506c1f844574e38657e11b5e", "class_name": "RelatedNodeInfo"}}, "text": "We see that \ncontinuing to build and continuing to improve. ", "start_char_idx": 1640, "end_char_idx": 1700, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4239ef0-44f1-492e-b3ed-c2763069b106": {"__data__": {"id_": "a4239ef0-44f1-492e-b3ed-c2763069b106", "embedding": null, "metadata": {"window": "We saw that in the first quarter.  And so, that was in line with our expectations.  We see that \ncontinuing to build and continuing to improve.  And so, just from a very macro utilization perspective,  we're seeing \nthe improvement that we expected to see.  We're seeing it on the trajectory that we expected to see.  And so, we're \nvery encouraged by that.  \n \n Our businesses, each of our segments had very strong performance. ", "original_text": "And so, just from a very macro utilization perspective,  we're seeing \nthe improvement that we expected to see. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a976dbf98a9c7ca6e0f2c96b598e037e7b2bd8c548cd866a1c876b2affb94ad3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "398d98cf-ab51-4ebe-a46b-be28725c38b9", "node_type": "1", "metadata": {"window": "We saw that.  We saw that in the first quarter.  And so, that was in line with our expectations.  We see that \ncontinuing to build and continuing to improve.  And so, just from a very macro utilization perspective,  we're seeing \nthe improvement that we expected to see.  We're seeing it on the trajectory that we expected to see.  And so, we're \nvery encouraged by that.  \n \n", "original_text": "We see that \ncontinuing to build and continuing to improve. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7549c80e66979fe2d8e249b0d25bae9ad85555420006d3303cef623a4944f5c7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "074a9070-c029-45e6-9966-54ff9e83475a", "node_type": "1", "metadata": {"window": "And so, that was in line with our expectations.  We see that \ncontinuing to build and continuing to improve.  And so, just from a very macro utilization perspective,  we're seeing \nthe improvement that we expected to see.  We're seeing it on the trajectory that we expected to see.  And so, we're \nvery encouraged by that.  \n \n Our businesses, each of our segments had very strong performance.  And so, we're very encouraged by tha t. It is \nour first quarter. ", "original_text": "We're seeing it on the trajectory that we expected to see. "}, "hash": "bd5090ada68328372df0b701e72897b2127ff23bc65079646b6ce52b5e733c20", "class_name": "RelatedNodeInfo"}}, "text": "And so, just from a very macro utilization perspective,  we're seeing \nthe improvement that we expected to see. ", "start_char_idx": 1700, "end_char_idx": 1812, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "074a9070-c029-45e6-9966-54ff9e83475a": {"__data__": {"id_": "074a9070-c029-45e6-9966-54ff9e83475a", "embedding": null, "metadata": {"window": "And so, that was in line with our expectations.  We see that \ncontinuing to build and continuing to improve.  And so, just from a very macro utilization perspective,  we're seeing \nthe improvement that we expected to see.  We're seeing it on the trajectory that we expected to see.  And so, we're \nvery encouraged by that.  \n \n Our businesses, each of our segments had very strong performance.  And so, we're very encouraged by tha t. It is \nour first quarter. ", "original_text": "We're seeing it on the trajectory that we expected to see. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a976dbf98a9c7ca6e0f2c96b598e037e7b2bd8c548cd866a1c876b2affb94ad3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4239ef0-44f1-492e-b3ed-c2763069b106", "node_type": "1", "metadata": {"window": "We saw that in the first quarter.  And so, that was in line with our expectations.  We see that \ncontinuing to build and continuing to improve.  And so, just from a very macro utilization perspective,  we're seeing \nthe improvement that we expected to see.  We're seeing it on the trajectory that we expected to see.  And so, we're \nvery encouraged by that.  \n \n Our businesses, each of our segments had very strong performance. ", "original_text": "And so, just from a very macro utilization perspective,  we're seeing \nthe improvement that we expected to see. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0dc1f7adf30f3289cfff680ed5a92a071771b8bfdec17f99488cd24d42d15dc3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "620b21c9-7b60-410e-b578-8232c8fbbe34", "node_type": "1", "metadata": {"window": "We see that \ncontinuing to build and continuing to improve.  And so, just from a very macro utilization perspective,  we're seeing \nthe improvement that we expected to see.  We're seeing it on the trajectory that we expected to see.  And so, we're \nvery encouraged by that.  \n \n Our businesses, each of our segments had very strong performance.  And so, we're very encouraged by tha t. It is \nour first quarter.  Certainly, utilization will continue to evolve over the rest of the year. ", "original_text": "And so, we're \nvery encouraged by that.  \n \n"}, "hash": "ababa4a8ee8cebd7f21a632e851004979972470a84fd09786333fade7ef68960", "class_name": "RelatedNodeInfo"}}, "text": "We're seeing it on the trajectory that we expected to see. ", "start_char_idx": 1812, "end_char_idx": 1871, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "620b21c9-7b60-410e-b578-8232c8fbbe34": {"__data__": {"id_": "620b21c9-7b60-410e-b578-8232c8fbbe34", "embedding": null, "metadata": {"window": "We see that \ncontinuing to build and continuing to improve.  And so, just from a very macro utilization perspective,  we're seeing \nthe improvement that we expected to see.  We're seeing it on the trajectory that we expected to see.  And so, we're \nvery encouraged by that.  \n \n Our businesses, each of our segments had very strong performance.  And so, we're very encouraged by tha t. It is \nour first quarter.  Certainly, utilization will continue to evolve over the rest of the year. ", "original_text": "And so, we're \nvery encouraged by that.  \n \n", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a976dbf98a9c7ca6e0f2c96b598e037e7b2bd8c548cd866a1c876b2affb94ad3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "074a9070-c029-45e6-9966-54ff9e83475a", "node_type": "1", "metadata": {"window": "And so, that was in line with our expectations.  We see that \ncontinuing to build and continuing to improve.  And so, just from a very macro utilization perspective,  we're seeing \nthe improvement that we expected to see.  We're seeing it on the trajectory that we expected to see.  And so, we're \nvery encouraged by that.  \n \n Our businesses, each of our segments had very strong performance.  And so, we're very encouraged by tha t. It is \nour first quarter. ", "original_text": "We're seeing it on the trajectory that we expected to see. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e0e0e75d625b19fa07934ff8cf51a6ca781ae94a2f88d57e2d8fee435656cc4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73314e49-61ae-4c03-91ce-7506285b6bac", "node_type": "1", "metadata": {"window": "And so, just from a very macro utilization perspective,  we're seeing \nthe improvement that we expected to see.  We're seeing it on the trajectory that we expected to see.  And so, we're \nvery encouraged by that.  \n \n Our businesses, each of our segments had very strong performance.  And so, we're very encouraged by tha t. It is \nour first quarter.  Certainly, utilization will continue to evolve over the rest of the year.  But we're very encouraged \nby that. ", "original_text": "Our businesses, each of our segments had very strong performance. "}, "hash": "e85897e4b14b1979da76ab3bfc585c5588b579a5419db4a22bcfed49c47ca241", "class_name": "RelatedNodeInfo"}}, "text": "And so, we're \nvery encouraged by that.  \n \n", "start_char_idx": 1871, "end_char_idx": 1915, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73314e49-61ae-4c03-91ce-7506285b6bac": {"__data__": {"id_": "73314e49-61ae-4c03-91ce-7506285b6bac", "embedding": null, "metadata": {"window": "And so, just from a very macro utilization perspective,  we're seeing \nthe improvement that we expected to see.  We're seeing it on the trajectory that we expected to see.  And so, we're \nvery encouraged by that.  \n \n Our businesses, each of our segments had very strong performance.  And so, we're very encouraged by tha t. It is \nour first quarter.  Certainly, utilization will continue to evolve over the rest of the year.  But we're very encouraged \nby that. ", "original_text": "Our businesses, each of our segments had very strong performance. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a976dbf98a9c7ca6e0f2c96b598e037e7b2bd8c548cd866a1c876b2affb94ad3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "620b21c9-7b60-410e-b578-8232c8fbbe34", "node_type": "1", "metadata": {"window": "We see that \ncontinuing to build and continuing to improve.  And so, just from a very macro utilization perspective,  we're seeing \nthe improvement that we expected to see.  We're seeing it on the trajectory that we expected to see.  And so, we're \nvery encouraged by that.  \n \n Our businesses, each of our segments had very strong performance.  And so, we're very encouraged by tha t. It is \nour first quarter.  Certainly, utilization will continue to evolve over the rest of the year. ", "original_text": "And so, we're \nvery encouraged by that.  \n \n", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1f14c3596ccc2b3805c0caf5dbb9881f0ebfdc5e71daa571c92283394ce4b1a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c3b5871-3a00-4591-8bec-dfc948a49179", "node_type": "1", "metadata": {"window": "We're seeing it on the trajectory that we expected to see.  And so, we're \nvery encouraged by that.  \n \n Our businesses, each of our segments had very strong performance.  And so, we're very encouraged by tha t. It is \nour first quarter.  Certainly, utilization will continue to evolve over the rest of the year.  But we're very encouraged \nby that.  The strong operating performance, the utilization that we're seeing, the patient activity that we're seeing, \nwe expect that will continue, along the lines that we thought it would.  \n \n", "original_text": "And so, we're very encouraged by tha t. It is \nour first quarter. "}, "hash": "d24aa97567dab1e0e7b2ca8c74f0b6fcf9ab733b93642974cc423f61c6333185", "class_name": "RelatedNodeInfo"}}, "text": "Our businesses, each of our segments had very strong performance. ", "start_char_idx": 1915, "end_char_idx": 1981, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c3b5871-3a00-4591-8bec-dfc948a49179": {"__data__": {"id_": "8c3b5871-3a00-4591-8bec-dfc948a49179", "embedding": null, "metadata": {"window": "We're seeing it on the trajectory that we expected to see.  And so, we're \nvery encouraged by that.  \n \n Our businesses, each of our segments had very strong performance.  And so, we're very encouraged by tha t. It is \nour first quarter.  Certainly, utilization will continue to evolve over the rest of the year.  But we're very encouraged \nby that.  The strong operating performance, the utilization that we're seeing, the patient activity that we're seeing, \nwe expect that will continue, along the lines that we thought it would.  \n \n", "original_text": "And so, we're very encouraged by tha t. It is \nour first quarter. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a976dbf98a9c7ca6e0f2c96b598e037e7b2bd8c548cd866a1c876b2affb94ad3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73314e49-61ae-4c03-91ce-7506285b6bac", "node_type": "1", "metadata": {"window": "And so, just from a very macro utilization perspective,  we're seeing \nthe improvement that we expected to see.  We're seeing it on the trajectory that we expected to see.  And so, we're \nvery encouraged by that.  \n \n Our businesses, each of our segments had very strong performance.  And so, we're very encouraged by tha t. It is \nour first quarter.  Certainly, utilization will continue to evolve over the rest of the year.  But we're very encouraged \nby that. ", "original_text": "Our businesses, each of our segments had very strong performance. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "afe134fc8ea2f2a8f0a3062fa5efc151c3b5b0f5bc0f3099f308ac72f398d6cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "56ea7d30-1847-4586-8dd0-29f5f573b962", "node_type": "1", "metadata": {"window": "And so, we're \nvery encouraged by that.  \n \n Our businesses, each of our segments had very strong performance.  And so, we're very encouraged by tha t. It is \nour first quarter.  Certainly, utilization will continue to evolve over the rest of the year.  But we're very encouraged \nby that.  The strong operating performance, the utilization that we're seeing, the patient activity that we're seeing, \nwe expect that will continue, along the lines that we thought it would.  \n \n Certainly, the vaccine distribution and kitting program continues to evolve and it was a little bit higher than we had \nanticipated and we've increased the guide for that. ", "original_text": "Certainly, utilization will continue to evolve over the rest of the year. "}, "hash": "324ee6019cb4a6a0d5600fa65569bac1eeb0e5657ddc65aa9f25c32d3aae3e7f", "class_name": "RelatedNodeInfo"}}, "text": "And so, we're very encouraged by tha t. It is \nour first quarter. ", "start_char_idx": 1981, "end_char_idx": 2047, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "56ea7d30-1847-4586-8dd0-29f5f573b962": {"__data__": {"id_": "56ea7d30-1847-4586-8dd0-29f5f573b962", "embedding": null, "metadata": {"window": "And so, we're \nvery encouraged by that.  \n \n Our businesses, each of our segments had very strong performance.  And so, we're very encouraged by tha t. It is \nour first quarter.  Certainly, utilization will continue to evolve over the rest of the year.  But we're very encouraged \nby that.  The strong operating performance, the utilization that we're seeing, the patient activity that we're seeing, \nwe expect that will continue, along the lines that we thought it would.  \n \n Certainly, the vaccine distribution and kitting program continues to evolve and it was a little bit higher than we had \nanticipated and we've increased the guide for that. ", "original_text": "Certainly, utilization will continue to evolve over the rest of the year. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a976dbf98a9c7ca6e0f2c96b598e037e7b2bd8c548cd866a1c876b2affb94ad3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c3b5871-3a00-4591-8bec-dfc948a49179", "node_type": "1", "metadata": {"window": "We're seeing it on the trajectory that we expected to see.  And so, we're \nvery encouraged by that.  \n \n Our businesses, each of our segments had very strong performance.  And so, we're very encouraged by tha t. It is \nour first quarter.  Certainly, utilization will continue to evolve over the rest of the year.  But we're very encouraged \nby that.  The strong operating performance, the utilization that we're seeing, the patient activity that we're seeing, \nwe expect that will continue, along the lines that we thought it would.  \n \n", "original_text": "And so, we're very encouraged by tha t. It is \nour first quarter. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8ddc8cfedb4bae717d8030c2a041bfc0c7a881a4e59aa5d437a4cd6f04332316", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "847be36a-8dea-42d7-88ae-fad809f076db", "node_type": "1", "metadata": {"window": "Our businesses, each of our segments had very strong performance.  And so, we're very encouraged by tha t. It is \nour first quarter.  Certainly, utilization will continue to evolve over the rest of the year.  But we're very encouraged \nby that.  The strong operating performance, the utilization that we're seeing, the patient activity that we're seeing, \nwe expect that will continue, along the lines that we thought it would.  \n \n Certainly, the vaccine distribution and kitting program continues to evolve and it was a little bit higher than we had \nanticipated and we've increased the guide for that.  Generally speaking, ut ilization is strong. ", "original_text": "But we're very encouraged \nby that. "}, "hash": "b294d859bea8555b7a710a4ce09078ee320d721bdac90a6ed236476a587dc108", "class_name": "RelatedNodeInfo"}}, "text": "Certainly, utilization will continue to evolve over the rest of the year. ", "start_char_idx": 2047, "end_char_idx": 2121, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "847be36a-8dea-42d7-88ae-fad809f076db": {"__data__": {"id_": "847be36a-8dea-42d7-88ae-fad809f076db", "embedding": null, "metadata": {"window": "Our businesses, each of our segments had very strong performance.  And so, we're very encouraged by tha t. It is \nour first quarter.  Certainly, utilization will continue to evolve over the rest of the year.  But we're very encouraged \nby that.  The strong operating performance, the utilization that we're seeing, the patient activity that we're seeing, \nwe expect that will continue, along the lines that we thought it would.  \n \n Certainly, the vaccine distribution and kitting program continues to evolve and it was a little bit higher than we had \nanticipated and we've increased the guide for that.  Generally speaking, ut ilization is strong. ", "original_text": "But we're very encouraged \nby that. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a976dbf98a9c7ca6e0f2c96b598e037e7b2bd8c548cd866a1c876b2affb94ad3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "56ea7d30-1847-4586-8dd0-29f5f573b962", "node_type": "1", "metadata": {"window": "And so, we're \nvery encouraged by that.  \n \n Our businesses, each of our segments had very strong performance.  And so, we're very encouraged by tha t. It is \nour first quarter.  Certainly, utilization will continue to evolve over the rest of the year.  But we're very encouraged \nby that.  The strong operating performance, the utilization that we're seeing, the patient activity that we're seeing, \nwe expect that will continue, along the lines that we thought it would.  \n \n Certainly, the vaccine distribution and kitting program continues to evolve and it was a little bit higher than we had \nanticipated and we've increased the guide for that. ", "original_text": "Certainly, utilization will continue to evolve over the rest of the year. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "36d31558d5e5837a991b6b5a5bef2d40bebd56f5ecc85054aacf01ac3ed5dc32", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ba6b5bb-4968-44f6-be18-32176a6ad54a", "node_type": "1", "metadata": {"window": "And so, we're very encouraged by tha t. It is \nour first quarter.  Certainly, utilization will continue to evolve over the rest of the year.  But we're very encouraged \nby that.  The strong operating performance, the utilization that we're seeing, the patient activity that we're seeing, \nwe expect that will continue, along the lines that we thought it would.  \n \n Certainly, the vaccine distribution and kitting program continues to evolve and it was a little bit higher than we had \nanticipated and we've increased the guide for that.  Generally speaking, ut ilization is strong.  It's in line with what \nour expectations were and we expect that will continue through the remainder of the year.  \n \n", "original_text": "The strong operating performance, the utilization that we're seeing, the patient activity that we're seeing, \nwe expect that will continue, along the lines that we thought it would.  \n \n"}, "hash": "155116ccf1d615e115fa05da45ca26dcd3b5ff5abfec666ae14dabbae131aa86", "class_name": "RelatedNodeInfo"}}, "text": "But we're very encouraged \nby that. ", "start_char_idx": 2121, "end_char_idx": 2157, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ba6b5bb-4968-44f6-be18-32176a6ad54a": {"__data__": {"id_": "6ba6b5bb-4968-44f6-be18-32176a6ad54a", "embedding": null, "metadata": {"window": "And so, we're very encouraged by tha t. It is \nour first quarter.  Certainly, utilization will continue to evolve over the rest of the year.  But we're very encouraged \nby that.  The strong operating performance, the utilization that we're seeing, the patient activity that we're seeing, \nwe expect that will continue, along the lines that we thought it would.  \n \n Certainly, the vaccine distribution and kitting program continues to evolve and it was a little bit higher than we had \nanticipated and we've increased the guide for that.  Generally speaking, ut ilization is strong.  It's in line with what \nour expectations were and we expect that will continue through the remainder of the year.  \n \n", "original_text": "The strong operating performance, the utilization that we're seeing, the patient activity that we're seeing, \nwe expect that will continue, along the lines that we thought it would.  \n \n", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a976dbf98a9c7ca6e0f2c96b598e037e7b2bd8c548cd866a1c876b2affb94ad3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "847be36a-8dea-42d7-88ae-fad809f076db", "node_type": "1", "metadata": {"window": "Our businesses, each of our segments had very strong performance.  And so, we're very encouraged by tha t. It is \nour first quarter.  Certainly, utilization will continue to evolve over the rest of the year.  But we're very encouraged \nby that.  The strong operating performance, the utilization that we're seeing, the patient activity that we're seeing, \nwe expect that will continue, along the lines that we thought it would.  \n \n Certainly, the vaccine distribution and kitting program continues to evolve and it was a little bit higher than we had \nanticipated and we've increased the guide for that.  Generally speaking, ut ilization is strong. ", "original_text": "But we're very encouraged \nby that. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c00ef4e95014bcfefd2bd1a42b84ca085ea69f6c73423e937a712a64fd039fb9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d8012de-c6bd-48f2-9b77-928f32a6eb5a", "node_type": "1", "metadata": {"window": "Certainly, utilization will continue to evolve over the rest of the year.  But we're very encouraged \nby that.  The strong operating performance, the utilization that we're seeing, the patient activity that we're seeing, \nwe expect that will continue, along the lines that we thought it would.  \n \n Certainly, the vaccine distribution and kitting program continues to evolve and it was a little bit higher than we had \nanticipated and we've increased the guide for that.  Generally speaking, ut ilization is strong.  It's in line with what \nour expectations were and we expect that will continue through the remainder of the year.  \n \n And you had asked a question on tax. ", "original_text": "Certainly, the vaccine distribution and kitting program continues to evolve and it was a little bit higher than we had \nanticipated and we've increased the guide for that. "}, "hash": "4d8b07154cf00d205082941bd3fc0b51a14604250a1af142e602dc495e292b62", "class_name": "RelatedNodeInfo"}}, "text": "The strong operating performance, the utilization that we're seeing, the patient activity that we're seeing, \nwe expect that will continue, along the lines that we thought it would.  \n \n", "start_char_idx": 2157, "end_char_idx": 2343, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d8012de-c6bd-48f2-9b77-928f32a6eb5a": {"__data__": {"id_": "1d8012de-c6bd-48f2-9b77-928f32a6eb5a", "embedding": null, "metadata": {"window": "Certainly, utilization will continue to evolve over the rest of the year.  But we're very encouraged \nby that.  The strong operating performance, the utilization that we're seeing, the patient activity that we're seeing, \nwe expect that will continue, along the lines that we thought it would.  \n \n Certainly, the vaccine distribution and kitting program continues to evolve and it was a little bit higher than we had \nanticipated and we've increased the guide for that.  Generally speaking, ut ilization is strong.  It's in line with what \nour expectations were and we expect that will continue through the remainder of the year.  \n \n And you had asked a question on tax. ", "original_text": "Certainly, the vaccine distribution and kitting program continues to evolve and it was a little bit higher than we had \nanticipated and we've increased the guide for that. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a976dbf98a9c7ca6e0f2c96b598e037e7b2bd8c548cd866a1c876b2affb94ad3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ba6b5bb-4968-44f6-be18-32176a6ad54a", "node_type": "1", "metadata": {"window": "And so, we're very encouraged by tha t. It is \nour first quarter.  Certainly, utilization will continue to evolve over the rest of the year.  But we're very encouraged \nby that.  The strong operating performance, the utilization that we're seeing, the patient activity that we're seeing, \nwe expect that will continue, along the lines that we thought it would.  \n \n Certainly, the vaccine distribution and kitting program continues to evolve and it was a little bit higher than we had \nanticipated and we've increased the guide for that.  Generally speaking, ut ilization is strong.  It's in line with what \nour expectations were and we expect that will continue through the remainder of the year.  \n \n", "original_text": "The strong operating performance, the utilization that we're seeing, the patient activity that we're seeing, \nwe expect that will continue, along the lines that we thought it would.  \n \n", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bb08159b28067f76229c690169ad43f10724eb3077ef5504fe2c5be0a415edd9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb1b7cdb-379f-4164-84b3-2e20ff30a228", "node_type": "1", "metadata": {"window": "But we're very encouraged \nby that.  The strong operating performance, the utilization that we're seeing, the patient activity that we're seeing, \nwe expect that will continue, along the lines that we thought it would.  \n \n Certainly, the vaccine distribution and kitting program continues to evolve and it was a little bit higher than we had \nanticipated and we've increased the guide for that.  Generally speaking, ut ilization is strong.  It's in line with what \nour expectations were and we expect that will continue through the remainder of the year.  \n \n And you had asked a question on tax.  The one thing that I would remind you on tax is we don't guide tax by \nquarter. ", "original_text": "Generally speaking, ut ilization is strong. "}, "hash": "351f59bcff9daaff86322d546f995a6b5f8de271672c134007357053c6c8059b", "class_name": "RelatedNodeInfo"}}, "text": "Certainly, the vaccine distribution and kitting program continues to evolve and it was a little bit higher than we had \nanticipated and we've increased the guide for that. ", "start_char_idx": 2343, "end_char_idx": 2515, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb1b7cdb-379f-4164-84b3-2e20ff30a228": {"__data__": {"id_": "eb1b7cdb-379f-4164-84b3-2e20ff30a228", "embedding": null, "metadata": {"window": "But we're very encouraged \nby that.  The strong operating performance, the utilization that we're seeing, the patient activity that we're seeing, \nwe expect that will continue, along the lines that we thought it would.  \n \n Certainly, the vaccine distribution and kitting program continues to evolve and it was a little bit higher than we had \nanticipated and we've increased the guide for that.  Generally speaking, ut ilization is strong.  It's in line with what \nour expectations were and we expect that will continue through the remainder of the year.  \n \n And you had asked a question on tax.  The one thing that I would remind you on tax is we don't guide tax by \nquarter. ", "original_text": "Generally speaking, ut ilization is strong. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a976dbf98a9c7ca6e0f2c96b598e037e7b2bd8c548cd866a1c876b2affb94ad3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d8012de-c6bd-48f2-9b77-928f32a6eb5a", "node_type": "1", "metadata": {"window": "Certainly, utilization will continue to evolve over the rest of the year.  But we're very encouraged \nby that.  The strong operating performance, the utilization that we're seeing, the patient activity that we're seeing, \nwe expect that will continue, along the lines that we thought it would.  \n \n Certainly, the vaccine distribution and kitting program continues to evolve and it was a little bit higher than we had \nanticipated and we've increased the guide for that.  Generally speaking, ut ilization is strong.  It's in line with what \nour expectations were and we expect that will continue through the remainder of the year.  \n \n And you had asked a question on tax. ", "original_text": "Certainly, the vaccine distribution and kitting program continues to evolve and it was a little bit higher than we had \nanticipated and we've increased the guide for that. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3550d7829b4165fcf7a19083befed553a8d1e1085109627d8faf58b9daf8c945", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "88f2af39-4a9b-483d-8ba3-e9965fc2d960", "node_type": "1", "metadata": {"window": "The strong operating performance, the utilization that we're seeing, the patient activity that we're seeing, \nwe expect that will continue, along the lines that we thought it would.  \n \n Certainly, the vaccine distribution and kitting program continues to evolve and it was a little bit higher than we had \nanticipated and we've increased the guide for that.  Generally speaking, ut ilization is strong.  It's in line with what \nour expectations were and we expect that will continue through the remainder of the year.  \n \n And you had asked a question on tax.  The one thing that I would remind you on tax is we don't guide tax by \nquarter.  We gu ide you on an annual basis. ", "original_text": "It's in line with what \nour expectations were and we expect that will continue through the remainder of the year.  \n \n"}, "hash": "d8ed97a85ff3ecf5eca3a3c59bf05d07917816385bf58aa6b98755f0d5b6c843", "class_name": "RelatedNodeInfo"}}, "text": "Generally speaking, ut ilization is strong. ", "start_char_idx": 2515, "end_char_idx": 2559, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "88f2af39-4a9b-483d-8ba3-e9965fc2d960": {"__data__": {"id_": "88f2af39-4a9b-483d-8ba3-e9965fc2d960", "embedding": null, "metadata": {"window": "The strong operating performance, the utilization that we're seeing, the patient activity that we're seeing, \nwe expect that will continue, along the lines that we thought it would.  \n \n Certainly, the vaccine distribution and kitting program continues to evolve and it was a little bit higher than we had \nanticipated and we've increased the guide for that.  Generally speaking, ut ilization is strong.  It's in line with what \nour expectations were and we expect that will continue through the remainder of the year.  \n \n And you had asked a question on tax.  The one thing that I would remind you on tax is we don't guide tax by \nquarter.  We gu ide you on an annual basis. ", "original_text": "It's in line with what \nour expectations were and we expect that will continue through the remainder of the year.  \n \n", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a976dbf98a9c7ca6e0f2c96b598e037e7b2bd8c548cd866a1c876b2affb94ad3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb1b7cdb-379f-4164-84b3-2e20ff30a228", "node_type": "1", "metadata": {"window": "But we're very encouraged \nby that.  The strong operating performance, the utilization that we're seeing, the patient activity that we're seeing, \nwe expect that will continue, along the lines that we thought it would.  \n \n Certainly, the vaccine distribution and kitting program continues to evolve and it was a little bit higher than we had \nanticipated and we've increased the guide for that.  Generally speaking, ut ilization is strong.  It's in line with what \nour expectations were and we expect that will continue through the remainder of the year.  \n \n And you had asked a question on tax.  The one thing that I would remind you on tax is we don't guide tax by \nquarter. ", "original_text": "Generally speaking, ut ilization is strong. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4dea7a3363a7922e43f916112b8d1e9e098f9a7b37add5ec031fbe06a5cde847", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "277b6875-dc10-430c-8470-221382d41aec", "node_type": "1", "metadata": {"window": "Certainly, the vaccine distribution and kitting program continues to evolve and it was a little bit higher than we had \nanticipated and we've increased the guide for that.  Generally speaking, ut ilization is strong.  It's in line with what \nour expectations were and we expect that will continue through the remainder of the year.  \n \n And you had asked a question on tax.  The one thing that I would remind you on tax is we don't guide tax by \nquarter.  We gu ide you on an annual basis.  We did not change our guidance for the full year effective tax rate. ", "original_text": "And you had asked a question on tax. "}, "hash": "bfe688afbbf414829291b7f74ad07660f112f073efc8986395a655ec6b6461d5", "class_name": "RelatedNodeInfo"}}, "text": "It's in line with what \nour expectations were and we expect that will continue through the remainder of the year.  \n \n", "start_char_idx": 2559, "end_char_idx": 2677, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "277b6875-dc10-430c-8470-221382d41aec": {"__data__": {"id_": "277b6875-dc10-430c-8470-221382d41aec", "embedding": null, "metadata": {"window": "Certainly, the vaccine distribution and kitting program continues to evolve and it was a little bit higher than we had \nanticipated and we've increased the guide for that.  Generally speaking, ut ilization is strong.  It's in line with what \nour expectations were and we expect that will continue through the remainder of the year.  \n \n And you had asked a question on tax.  The one thing that I would remind you on tax is we don't guide tax by \nquarter.  We gu ide you on an annual basis.  We did not change our guidance for the full year effective tax rate. ", "original_text": "And you had asked a question on tax. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a976dbf98a9c7ca6e0f2c96b598e037e7b2bd8c548cd866a1c876b2affb94ad3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "88f2af39-4a9b-483d-8ba3-e9965fc2d960", "node_type": "1", "metadata": {"window": "The strong operating performance, the utilization that we're seeing, the patient activity that we're seeing, \nwe expect that will continue, along the lines that we thought it would.  \n \n Certainly, the vaccine distribution and kitting program continues to evolve and it was a little bit higher than we had \nanticipated and we've increased the guide for that.  Generally speaking, ut ilization is strong.  It's in line with what \nour expectations were and we expect that will continue through the remainder of the year.  \n \n And you had asked a question on tax.  The one thing that I would remind you on tax is we don't guide tax by \nquarter.  We gu ide you on an annual basis. ", "original_text": "It's in line with what \nour expectations were and we expect that will continue through the remainder of the year.  \n \n", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea0dadc6a9354512fda6a504e76b41632e9d1aeb22d2f7ed54bdd02622d2c566", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "df8e8850-11a3-448a-9678-d667b917279b", "node_type": "1", "metadata": {"window": "Generally speaking, ut ilization is strong.  It's in line with what \nour expectations were and we expect that will continue through the remainder of the year.  \n \n And you had asked a question on tax.  The one thing that I would remind you on tax is we don't guide tax by \nquarter.  We gu ide you on an annual basis.  We did not change our guidance for the full year effective tax rate.  And \nI think if you look over the last few years, the annual guidance around the tax rate that we've given has pretty \nmuch been in line with the original guide.  \n ", "original_text": "The one thing that I would remind you on tax is we don't guide tax by \nquarter. "}, "hash": "61756a2d9889e49a2a1b0e37ebfb28dac798103573d2f90b12dad76f0761d896", "class_name": "RelatedNodeInfo"}}, "text": "And you had asked a question on tax. ", "start_char_idx": 2677, "end_char_idx": 2714, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "df8e8850-11a3-448a-9678-d667b917279b": {"__data__": {"id_": "df8e8850-11a3-448a-9678-d667b917279b", "embedding": null, "metadata": {"window": "Generally speaking, ut ilization is strong.  It's in line with what \nour expectations were and we expect that will continue through the remainder of the year.  \n \n And you had asked a question on tax.  The one thing that I would remind you on tax is we don't guide tax by \nquarter.  We gu ide you on an annual basis.  We did not change our guidance for the full year effective tax rate.  And \nI think if you look over the last few years, the annual guidance around the tax rate that we've given has pretty \nmuch been in line with the original guide.  \n ", "original_text": "The one thing that I would remind you on tax is we don't guide tax by \nquarter. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a976dbf98a9c7ca6e0f2c96b598e037e7b2bd8c548cd866a1c876b2affb94ad3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "277b6875-dc10-430c-8470-221382d41aec", "node_type": "1", "metadata": {"window": "Certainly, the vaccine distribution and kitting program continues to evolve and it was a little bit higher than we had \nanticipated and we've increased the guide for that.  Generally speaking, ut ilization is strong.  It's in line with what \nour expectations were and we expect that will continue through the remainder of the year.  \n \n And you had asked a question on tax.  The one thing that I would remind you on tax is we don't guide tax by \nquarter.  We gu ide you on an annual basis.  We did not change our guidance for the full year effective tax rate. ", "original_text": "And you had asked a question on tax. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64207c762f48d158a67adfdd7b4e56edb6833e55818091486b14e2e64b039b12", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca7d37cc-5b9e-4279-8a3c-c27ffa950c9c", "node_type": "1", "metadata": {"window": "It's in line with what \nour expectations were and we expect that will continue through the remainder of the year.  \n \n And you had asked a question on tax.  The one thing that I would remind you on tax is we don't guide tax by \nquarter.  We gu ide you on an annual basis.  We did not change our guidance for the full year effective tax rate.  And \nI think if you look over the last few years, the annual guidance around the tax rate that we've given has pretty \nmuch been in line with the original guide.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "original_text": "We gu ide you on an annual basis. "}, "hash": "0e48d8c18992054a8b2cf03ef56315d9f748a65ebd9af915b353c08c35781a8f", "class_name": "RelatedNodeInfo"}}, "text": "The one thing that I would remind you on tax is we don't guide tax by \nquarter. ", "start_char_idx": 2714, "end_char_idx": 2794, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca7d37cc-5b9e-4279-8a3c-c27ffa950c9c": {"__data__": {"id_": "ca7d37cc-5b9e-4279-8a3c-c27ffa950c9c", "embedding": null, "metadata": {"window": "It's in line with what \nour expectations were and we expect that will continue through the remainder of the year.  \n \n And you had asked a question on tax.  The one thing that I would remind you on tax is we don't guide tax by \nquarter.  We gu ide you on an annual basis.  We did not change our guidance for the full year effective tax rate.  And \nI think if you look over the last few years, the annual guidance around the tax rate that we've given has pretty \nmuch been in line with the original guide.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "original_text": "We gu ide you on an annual basis. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a976dbf98a9c7ca6e0f2c96b598e037e7b2bd8c548cd866a1c876b2affb94ad3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "df8e8850-11a3-448a-9678-d667b917279b", "node_type": "1", "metadata": {"window": "Generally speaking, ut ilization is strong.  It's in line with what \nour expectations were and we expect that will continue through the remainder of the year.  \n \n And you had asked a question on tax.  The one thing that I would remind you on tax is we don't guide tax by \nquarter.  We gu ide you on an annual basis.  We did not change our guidance for the full year effective tax rate.  And \nI think if you look over the last few years, the annual guidance around the tax rate that we've given has pretty \nmuch been in line with the original guide.  \n ", "original_text": "The one thing that I would remind you on tax is we don't guide tax by \nquarter. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4b189dcae03cea9ce36dea281c3a1ecff251b06653a6645554da85c022a4dc0d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "37d1b0f4-52b0-460c-a657-c6bd00c54fef", "node_type": "1", "metadata": {"window": "And you had asked a question on tax.  The one thing that I would remind you on tax is we don't guide tax by \nquarter.  We gu ide you on an annual basis.  We did not change our guidance for the full year effective tax rate.  And \nI think if you look over the last few years, the annual guidance around the tax rate that we've given has pretty \nmuch been in line with the original guide.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nNext question.  \n ", "original_text": "We did not change our guidance for the full year effective tax rate. "}, "hash": "24a71c9a8cf5951b25f207fb6b56f3a3903c34c51001ff3c6b8ad9f9d9f08c97", "class_name": "RelatedNodeInfo"}}, "text": "We gu ide you on an annual basis. ", "start_char_idx": 2794, "end_char_idx": 2828, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "37d1b0f4-52b0-460c-a657-c6bd00c54fef": {"__data__": {"id_": "37d1b0f4-52b0-460c-a657-c6bd00c54fef", "embedding": null, "metadata": {"window": "And you had asked a question on tax.  The one thing that I would remind you on tax is we don't guide tax by \nquarter.  We gu ide you on an annual basis.  We did not change our guidance for the full year effective tax rate.  And \nI think if you look over the last few years, the annual guidance around the tax rate that we've given has pretty \nmuch been in line with the original guide.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nNext question.  \n ", "original_text": "We did not change our guidance for the full year effective tax rate. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a976dbf98a9c7ca6e0f2c96b598e037e7b2bd8c548cd866a1c876b2affb94ad3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca7d37cc-5b9e-4279-8a3c-c27ffa950c9c", "node_type": "1", "metadata": {"window": "It's in line with what \nour expectations were and we expect that will continue through the remainder of the year.  \n \n And you had asked a question on tax.  The one thing that I would remind you on tax is we don't guide tax by \nquarter.  We gu ide you on an annual basis.  We did not change our guidance for the full year effective tax rate.  And \nI think if you look over the last few years, the annual guidance around the tax rate that we've given has pretty \nmuch been in line with the original guide.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "original_text": "We gu ide you on an annual basis. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3aa04de9367b8451c3f36b640df5e6fe15bb81ec6828e32bed5ee61f505d4212", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09b3bcff-d13b-45a3-a0a2-449483e437c9", "node_type": "1", "metadata": {"window": "The one thing that I would remind you on tax is we don't guide tax by \nquarter.  We gu ide you on an annual basis.  We did not change our guidance for the full year effective tax rate.  And \nI think if you look over the last few years, the annual guidance around the tax rate that we've given has pretty \nmuch been in line with the original guide.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And we'll go to Kevin Caliendo of UBS.  \n ", "original_text": "And \nI think if you look over the last few years, the annual guidance around the tax rate that we've given has pretty \nmuch been in line with the original guide.  \n "}, "hash": "ea0743e70b2e5aefd92dc459fb80a5435d2be62c054304d6039077198d66d767", "class_name": "RelatedNodeInfo"}}, "text": "We did not change our guidance for the full year effective tax rate. ", "start_char_idx": 2828, "end_char_idx": 2897, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09b3bcff-d13b-45a3-a0a2-449483e437c9": {"__data__": {"id_": "09b3bcff-d13b-45a3-a0a2-449483e437c9", "embedding": null, "metadata": {"window": "The one thing that I would remind you on tax is we don't guide tax by \nquarter.  We gu ide you on an annual basis.  We did not change our guidance for the full year effective tax rate.  And \nI think if you look over the last few years, the annual guidance around the tax rate that we've given has pretty \nmuch been in line with the original guide.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And we'll go to Kevin Caliendo of UBS.  \n ", "original_text": "And \nI think if you look over the last few years, the annual guidance around the tax rate that we've given has pretty \nmuch been in line with the original guide.  \n ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a976dbf98a9c7ca6e0f2c96b598e037e7b2bd8c548cd866a1c876b2affb94ad3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "37d1b0f4-52b0-460c-a657-c6bd00c54fef", "node_type": "1", "metadata": {"window": "And you had asked a question on tax.  The one thing that I would remind you on tax is we don't guide tax by \nquarter.  We gu ide you on an annual basis.  We did not change our guidance for the full year effective tax rate.  And \nI think if you look over the last few years, the annual guidance around the tax rate that we've given has pretty \nmuch been in line with the original guide.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nNext question.  \n ", "original_text": "We did not change our guidance for the full year effective tax rate. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a42e8aba83f2d8e34cec68240235a42b689437f5de26650b8a09188c451de28b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c1e5c3f5-104a-4de7-b165-2b840d74b5c6", "node_type": "1", "metadata": {"window": "We gu ide you on an annual basis.  We did not change our guidance for the full year effective tax rate.  And \nI think if you look over the last few years, the annual guidance around the tax rate that we've given has pretty \nmuch been in line with the original guide.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And we'll go to Kevin Caliendo of UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks for taking my call. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  "}, "hash": "66bf7e5de4e4366eef1148e65e87077b3c9a10675d750b5f202f6df66bc7e5eb", "class_name": "RelatedNodeInfo"}}, "text": "And \nI think if you look over the last few years, the annual guidance around the tax rate that we've given has pretty \nmuch been in line with the original guide.  \n ", "start_char_idx": 2897, "end_char_idx": 3062, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c1e5c3f5-104a-4de7-b165-2b840d74b5c6": {"__data__": {"id_": "c1e5c3f5-104a-4de7-b165-2b840d74b5c6", "embedding": null, "metadata": {"window": "We gu ide you on an annual basis.  We did not change our guidance for the full year effective tax rate.  And \nI think if you look over the last few years, the annual guidance around the tax rate that we've given has pretty \nmuch been in line with the original guide.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And we'll go to Kevin Caliendo of UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks for taking my call. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a976dbf98a9c7ca6e0f2c96b598e037e7b2bd8c548cd866a1c876b2affb94ad3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09b3bcff-d13b-45a3-a0a2-449483e437c9", "node_type": "1", "metadata": {"window": "The one thing that I would remind you on tax is we don't guide tax by \nquarter.  We gu ide you on an annual basis.  We did not change our guidance for the full year effective tax rate.  And \nI think if you look over the last few years, the annual guidance around the tax rate that we've given has pretty \nmuch been in line with the original guide.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And we'll go to Kevin Caliendo of UBS.  \n ", "original_text": "And \nI think if you look over the last few years, the annual guidance around the tax rate that we've given has pretty \nmuch been in line with the original guide.  \n ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45fd866a4ecfcef9def5fafd9cac6fcaa68329249745e9fc5504e34db56eeb78", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b618a7e6-21cf-4100-b2b4-7dfeadb35bf3", "node_type": "1", "metadata": {"window": "We did not change our guidance for the full year effective tax rate.  And \nI think if you look over the last few years, the annual guidance around the tax rate that we've given has pretty \nmuch been in line with the original guide.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And we'll go to Kevin Caliendo of UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks for taking my call.  So, I want  to ask the guidance question a little bit differently, because it is unusual for \nMcKesson to sort of raise guidance for all the segments right after the first quarter. ", "original_text": "A \nNext question.  \n "}, "hash": "7dd915f2a023c987775df0d439d0ff0fcc958d48dca0aca0e0b3d377c3758f69", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "start_char_idx": 3062, "end_char_idx": 3436, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b618a7e6-21cf-4100-b2b4-7dfeadb35bf3": {"__data__": {"id_": "b618a7e6-21cf-4100-b2b4-7dfeadb35bf3", "embedding": null, "metadata": {"window": "We did not change our guidance for the full year effective tax rate.  And \nI think if you look over the last few years, the annual guidance around the tax rate that we've given has pretty \nmuch been in line with the original guide.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And we'll go to Kevin Caliendo of UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks for taking my call.  So, I want  to ask the guidance question a little bit differently, because it is unusual for \nMcKesson to sort of raise guidance for all the segments right after the first quarter. ", "original_text": "A \nNext question.  \n ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a976dbf98a9c7ca6e0f2c96b598e037e7b2bd8c548cd866a1c876b2affb94ad3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c1e5c3f5-104a-4de7-b165-2b840d74b5c6", "node_type": "1", "metadata": {"window": "We gu ide you on an annual basis.  We did not change our guidance for the full year effective tax rate.  And \nI think if you look over the last few years, the annual guidance around the tax rate that we've given has pretty \nmuch been in line with the original guide.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And we'll go to Kevin Caliendo of UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks for taking my call. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4f2ca83c75a428cb5011ad93cb4a05697cc23d834473bf1fa0209eafffbc5ea0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5cf8c82e-8c37-4e95-abda-6f0c248bde74", "node_type": "1", "metadata": {"window": "And \nI think if you look over the last few years, the annual guidance around the tax rate that we've given has pretty \nmuch been in line with the original guide.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And we'll go to Kevin Caliendo of UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks for taking my call.  So, I want  to ask the guidance question a little bit differently, because it is unusual for \nMcKesson to sort of raise guidance for all the segments right after the first quarter.  And I'm wondering if it's just \nsomething about the way \u2013 if it's COVID -related or not. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And we'll go to Kevin Caliendo of UBS.  \n "}, "hash": "826689072737743b3cd52b504b7c7112140e7bf397f8f4085faddffa3f49925d", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question.  \n ", "start_char_idx": 3436, "end_char_idx": 3457, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5cf8c82e-8c37-4e95-abda-6f0c248bde74": {"__data__": {"id_": "5cf8c82e-8c37-4e95-abda-6f0c248bde74", "embedding": null, "metadata": {"window": "And \nI think if you look over the last few years, the annual guidance around the tax rate that we've given has pretty \nmuch been in line with the original guide.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And we'll go to Kevin Caliendo of UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks for taking my call.  So, I want  to ask the guidance question a little bit differently, because it is unusual for \nMcKesson to sort of raise guidance for all the segments right after the first quarter.  And I'm wondering if it's just \nsomething about the way \u2013 if it's COVID -related or not. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And we'll go to Kevin Caliendo of UBS.  \n ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a976dbf98a9c7ca6e0f2c96b598e037e7b2bd8c548cd866a1c876b2affb94ad3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b618a7e6-21cf-4100-b2b4-7dfeadb35bf3", "node_type": "1", "metadata": {"window": "We did not change our guidance for the full year effective tax rate.  And \nI think if you look over the last few years, the annual guidance around the tax rate that we've given has pretty \nmuch been in line with the original guide.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And we'll go to Kevin Caliendo of UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks for taking my call.  So, I want  to ask the guidance question a little bit differently, because it is unusual for \nMcKesson to sort of raise guidance for all the segments right after the first quarter. ", "original_text": "A \nNext question.  \n ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "33632764822be7626b18ab83aa53a8133f43eb4520b9612817bdce1e8074646c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e8b133c-d838-4372-a291-617d518be231", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And we'll go to Kevin Caliendo of UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks for taking my call.  So, I want  to ask the guidance question a little bit differently, because it is unusual for \nMcKesson to sort of raise guidance for all the segments right after the first quarter.  And I'm wondering if it's just \nsomething about the way \u2013 if it's COVID -related or not.  But I mean, to raise your revenue expectations for all of \nyour segments versus what you guided to just a couple months ago, is there anything else specific? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks for taking my call. "}, "hash": "aaacdf86dfca8df67a2201fa9b84c7c0bd4df00f51c08a1f754a349262ef7f00", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And we'll go to Kevin Caliendo of UBS.  \n ", "start_char_idx": 3457, "end_char_idx": 3784, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e8b133c-d838-4372-a291-617d518be231": {"__data__": {"id_": "7e8b133c-d838-4372-a291-617d518be231", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And we'll go to Kevin Caliendo of UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks for taking my call.  So, I want  to ask the guidance question a little bit differently, because it is unusual for \nMcKesson to sort of raise guidance for all the segments right after the first quarter.  And I'm wondering if it's just \nsomething about the way \u2013 if it's COVID -related or not.  But I mean, to raise your revenue expectations for all of \nyour segments versus what you guided to just a couple months ago, is there anything else specific? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks for taking my call. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a976dbf98a9c7ca6e0f2c96b598e037e7b2bd8c548cd866a1c876b2affb94ad3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5cf8c82e-8c37-4e95-abda-6f0c248bde74", "node_type": "1", "metadata": {"window": "And \nI think if you look over the last few years, the annual guidance around the tax rate that we've given has pretty \nmuch been in line with the original guide.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And we'll go to Kevin Caliendo of UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks for taking my call.  So, I want  to ask the guidance question a little bit differently, because it is unusual for \nMcKesson to sort of raise guidance for all the segments right after the first quarter.  And I'm wondering if it's just \nsomething about the way \u2013 if it's COVID -related or not. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And we'll go to Kevin Caliendo of UBS.  \n ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "92e58c44c2ace4ea560ce6ddf616c899aec8146fccaf5a1f56fa8c88604578c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc25a6ad-c887-4a1e-90d6-3906a03307ab", "node_type": "1", "metadata": {"window": "A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And we'll go to Kevin Caliendo of UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks for taking my call.  So, I want  to ask the guidance question a little bit differently, because it is unusual for \nMcKesson to sort of raise guidance for all the segments right after the first quarter.  And I'm wondering if it's just \nsomething about the way \u2013 if it's COVID -related or not.  But I mean, to raise your revenue expectations for all of \nyour segments versus what you guided to just a couple months ago, is there anything else specific?  I mean, was \nit just conservatism on your part? ", "original_text": "So, I want  to ask the guidance question a little bit differently, because it is unusual for \nMcKesson to sort of raise guidance for all the segments right after the first quarter. "}, "hash": "23288e748e38a54498e7d3fab33178779b81f1ea743ee92005a6a69686f3f3bb", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks for taking my call. ", "start_char_idx": 3784, "end_char_idx": 4132, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc25a6ad-c887-4a1e-90d6-3906a03307ab": {"__data__": {"id_": "fc25a6ad-c887-4a1e-90d6-3906a03307ab", "embedding": null, "metadata": {"window": "A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And we'll go to Kevin Caliendo of UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks for taking my call.  So, I want  to ask the guidance question a little bit differently, because it is unusual for \nMcKesson to sort of raise guidance for all the segments right after the first quarter.  And I'm wondering if it's just \nsomething about the way \u2013 if it's COVID -related or not.  But I mean, to raise your revenue expectations for all of \nyour segments versus what you guided to just a couple months ago, is there anything else specific?  I mean, was \nit just conservatism on your part? ", "original_text": "So, I want  to ask the guidance question a little bit differently, because it is unusual for \nMcKesson to sort of raise guidance for all the segments right after the first quarter. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a976dbf98a9c7ca6e0f2c96b598e037e7b2bd8c548cd866a1c876b2affb94ad3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e8b133c-d838-4372-a291-617d518be231", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And we'll go to Kevin Caliendo of UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks for taking my call.  So, I want  to ask the guidance question a little bit differently, because it is unusual for \nMcKesson to sort of raise guidance for all the segments right after the first quarter.  And I'm wondering if it's just \nsomething about the way \u2013 if it's COVID -related or not.  But I mean, to raise your revenue expectations for all of \nyour segments versus what you guided to just a couple months ago, is there anything else specific? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks for taking my call. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4e0669279764e87257ed2ab8a969401a5e73ff03dc05d0ae9f981efc5d36677a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68b490f4-00ba-41e6-ab80-43f3f735994f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And we'll go to Kevin Caliendo of UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks for taking my call.  So, I want  to ask the guidance question a little bit differently, because it is unusual for \nMcKesson to sort of raise guidance for all the segments right after the first quarter.  And I'm wondering if it's just \nsomething about the way \u2013 if it's COVID -related or not.  But I mean, to raise your revenue expectations for all of \nyour segments versus what you guided to just a couple months ago, is there anything else specific?  I mean, was \nit just conservatism on your part?  Because we can't just point to script growth or pati ent volume, there's got to be ", "original_text": "And I'm wondering if it's just \nsomething about the way \u2013 if it's COVID -related or not. "}, "hash": "4851e1bf54eecb91d7b75746cfa6b9e69953860434b79f49bc083ad5436c3c37", "class_name": "RelatedNodeInfo"}}, "text": "So, I want  to ask the guidance question a little bit differently, because it is unusual for \nMcKesson to sort of raise guidance for all the segments right after the first quarter. ", "start_char_idx": 4132, "end_char_idx": 4313, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68b490f4-00ba-41e6-ab80-43f3f735994f": {"__data__": {"id_": "68b490f4-00ba-41e6-ab80-43f3f735994f", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And we'll go to Kevin Caliendo of UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks for taking my call.  So, I want  to ask the guidance question a little bit differently, because it is unusual for \nMcKesson to sort of raise guidance for all the segments right after the first quarter.  And I'm wondering if it's just \nsomething about the way \u2013 if it's COVID -related or not.  But I mean, to raise your revenue expectations for all of \nyour segments versus what you guided to just a couple months ago, is there anything else specific?  I mean, was \nit just conservatism on your part?  Because we can't just point to script growth or pati ent volume, there's got to be ", "original_text": "And I'm wondering if it's just \nsomething about the way \u2013 if it's COVID -related or not. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a976dbf98a9c7ca6e0f2c96b598e037e7b2bd8c548cd866a1c876b2affb94ad3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc25a6ad-c887-4a1e-90d6-3906a03307ab", "node_type": "1", "metadata": {"window": "A \nNext question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And we'll go to Kevin Caliendo of UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks for taking my call.  So, I want  to ask the guidance question a little bit differently, because it is unusual for \nMcKesson to sort of raise guidance for all the segments right after the first quarter.  And I'm wondering if it's just \nsomething about the way \u2013 if it's COVID -related or not.  But I mean, to raise your revenue expectations for all of \nyour segments versus what you guided to just a couple months ago, is there anything else specific?  I mean, was \nit just conservatism on your part? ", "original_text": "So, I want  to ask the guidance question a little bit differently, because it is unusual for \nMcKesson to sort of raise guidance for all the segments right after the first quarter. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a1866b7f8b3be0c7ffd0c898d05094bdd164088e8a507f0cb3b277d867b4b19c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c8763c96-9224-4974-9b8a-c4e74c17ad08", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks for taking my call.  So, I want  to ask the guidance question a little bit differently, because it is unusual for \nMcKesson to sort of raise guidance for all the segments right after the first quarter.  And I'm wondering if it's just \nsomething about the way \u2013 if it's COVID -related or not.  But I mean, to raise your revenue expectations for all of \nyour segments versus what you guided to just a couple months ago, is there anything else specific?  I mean, was \nit just conservatism on your part?  Because we can't just point to script growth or pati ent volume, there's got to be ", "original_text": "But I mean, to raise your revenue expectations for all of \nyour segments versus what you guided to just a couple months ago, is there anything else specific? "}, "hash": "b262d9e123fee44d0a211fa8df5c5f9faccb4507771c9d3c1f4ac127157517b8", "class_name": "RelatedNodeInfo"}}, "text": "And I'm wondering if it's just \nsomething about the way \u2013 if it's COVID -related or not. ", "start_char_idx": 4313, "end_char_idx": 4402, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c8763c96-9224-4974-9b8a-c4e74c17ad08": {"__data__": {"id_": "c8763c96-9224-4974-9b8a-c4e74c17ad08", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks for taking my call.  So, I want  to ask the guidance question a little bit differently, because it is unusual for \nMcKesson to sort of raise guidance for all the segments right after the first quarter.  And I'm wondering if it's just \nsomething about the way \u2013 if it's COVID -related or not.  But I mean, to raise your revenue expectations for all of \nyour segments versus what you guided to just a couple months ago, is there anything else specific?  I mean, was \nit just conservatism on your part?  Because we can't just point to script growth or pati ent volume, there's got to be ", "original_text": "But I mean, to raise your revenue expectations for all of \nyour segments versus what you guided to just a couple months ago, is there anything else specific? ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a976dbf98a9c7ca6e0f2c96b598e037e7b2bd8c548cd866a1c876b2affb94ad3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68b490f4-00ba-41e6-ab80-43f3f735994f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And we'll go to Kevin Caliendo of UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks for taking my call.  So, I want  to ask the guidance question a little bit differently, because it is unusual for \nMcKesson to sort of raise guidance for all the segments right after the first quarter.  And I'm wondering if it's just \nsomething about the way \u2013 if it's COVID -related or not.  But I mean, to raise your revenue expectations for all of \nyour segments versus what you guided to just a couple months ago, is there anything else specific?  I mean, was \nit just conservatism on your part?  Because we can't just point to script growth or pati ent volume, there's got to be ", "original_text": "And I'm wondering if it's just \nsomething about the way \u2013 if it's COVID -related or not. ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5ed7d5276c0ee213e7f0a91eb817017417a059ad238e6a21f829bb9a79c9e62", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "508e1cd7-d6f8-4593-8c08-fd8446b2935a", "node_type": "1", "metadata": {"window": "So, I want  to ask the guidance question a little bit differently, because it is unusual for \nMcKesson to sort of raise guidance for all the segments right after the first quarter.  And I'm wondering if it's just \nsomething about the way \u2013 if it's COVID -related or not.  But I mean, to raise your revenue expectations for all of \nyour segments versus what you guided to just a couple months ago, is there anything else specific?  I mean, was \nit just conservatism on your part?  Because we can't just point to script growth or pati ent volume, there's got to be ", "original_text": "I mean, was \nit just conservatism on your part? "}, "hash": "0c1c2ad1778c4a8e03291c1c8712fe15c9a9799cbcb88f3e719f9bf9f879d353", "class_name": "RelatedNodeInfo"}}, "text": "But I mean, to raise your revenue expectations for all of \nyour segments versus what you guided to just a couple months ago, is there anything else specific? ", "start_char_idx": 4402, "end_char_idx": 4560, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "508e1cd7-d6f8-4593-8c08-fd8446b2935a": {"__data__": {"id_": "508e1cd7-d6f8-4593-8c08-fd8446b2935a", "embedding": null, "metadata": {"window": "So, I want  to ask the guidance question a little bit differently, because it is unusual for \nMcKesson to sort of raise guidance for all the segments right after the first quarter.  And I'm wondering if it's just \nsomething about the way \u2013 if it's COVID -related or not.  But I mean, to raise your revenue expectations for all of \nyour segments versus what you guided to just a couple months ago, is there anything else specific?  I mean, was \nit just conservatism on your part?  Because we can't just point to script growth or pati ent volume, there's got to be ", "original_text": "I mean, was \nit just conservatism on your part? ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a976dbf98a9c7ca6e0f2c96b598e037e7b2bd8c548cd866a1c876b2affb94ad3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c8763c96-9224-4974-9b8a-c4e74c17ad08", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks for taking my call.  So, I want  to ask the guidance question a little bit differently, because it is unusual for \nMcKesson to sort of raise guidance for all the segments right after the first quarter.  And I'm wondering if it's just \nsomething about the way \u2013 if it's COVID -related or not.  But I mean, to raise your revenue expectations for all of \nyour segments versus what you guided to just a couple months ago, is there anything else specific?  I mean, was \nit just conservatism on your part?  Because we can't just point to script growth or pati ent volume, there's got to be ", "original_text": "But I mean, to raise your revenue expectations for all of \nyour segments versus what you guided to just a couple months ago, is there anything else specific? ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7066356794075c5e4542351d9307961f9a394fbac29b74900788c560cd5ce03b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f886668e-b648-490d-bd57-fa0c18f21982", "node_type": "1", "metadata": {"window": "And I'm wondering if it's just \nsomething about the way \u2013 if it's COVID -related or not.  But I mean, to raise your revenue expectations for all of \nyour segments versus what you guided to just a couple months ago, is there anything else specific?  I mean, was \nit just conservatism on your part?  Because we can't just point to script growth or pati ent volume, there's got to be ", "original_text": "Because we can't just point to script growth or pati ent volume, there's got to be "}, "hash": "ca838469b7f2cad2a7c540f93ca568b60c23cde46bbd6b4dc809aca5f095f34d", "class_name": "RelatedNodeInfo"}}, "text": "I mean, was \nit just conservatism on your part? ", "start_char_idx": 4560, "end_char_idx": 4608, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f886668e-b648-490d-bd57-fa0c18f21982": {"__data__": {"id_": "f886668e-b648-490d-bd57-fa0c18f21982", "embedding": null, "metadata": {"window": "And I'm wondering if it's just \nsomething about the way \u2013 if it's COVID -related or not.  But I mean, to raise your revenue expectations for all of \nyour segments versus what you guided to just a couple months ago, is there anything else specific?  I mean, was \nit just conservatism on your part?  Because we can't just point to script growth or pati ent volume, there's got to be ", "original_text": "Because we can't just point to script growth or pati ent volume, there's got to be ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a976dbf98a9c7ca6e0f2c96b598e037e7b2bd8c548cd866a1c876b2affb94ad3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "508e1cd7-d6f8-4593-8c08-fd8446b2935a", "node_type": "1", "metadata": {"window": "So, I want  to ask the guidance question a little bit differently, because it is unusual for \nMcKesson to sort of raise guidance for all the segments right after the first quarter.  And I'm wondering if it's just \nsomething about the way \u2013 if it's COVID -related or not.  But I mean, to raise your revenue expectations for all of \nyour segments versus what you guided to just a couple months ago, is there anything else specific?  I mean, was \nit just conservatism on your part?  Because we can't just point to script growth or pati ent volume, there's got to be ", "original_text": "I mean, was \nit just conservatism on your part? ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df5073722300f885920f0998dc0f4f9466ca80dbcb9187d3dd3bcde04f3dc582", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e9e683d0-8072-4fc1-a6c0-213b094d8c97", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsome sort of larger macro thing happening here that's driving this.  And I know you kind of addressed it, but maybe \ntalk specifically about the conservatism, or when you went into the year, what were the overhangs that possibly  \nlifted that are allowing you to do this across the board?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "McKesson Corp.  "}, "hash": "3958cdbc26471ad01fc198b9b5754266560798b6e33e201624f2ada558f90d13", "class_name": "RelatedNodeInfo"}}, "text": "Because we can't just point to script growth or pati ent volume, there's got to be ", "start_char_idx": 4608, "end_char_idx": 4691, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e9e683d0-8072-4fc1-a6c0-213b094d8c97": {"__data__": {"id_": "e9e683d0-8072-4fc1-a6c0-213b094d8c97", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsome sort of larger macro thing happening here that's driving this.  And I know you kind of addressed it, but maybe \ntalk specifically about the conservatism, or when you went into the year, what were the overhangs that possibly  \nlifted that are allowing you to do this across the board?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d4bb324-d13b-491a-9b23-44037291468e", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20cbda6bfd56661affb59a6962656da50d7ceb4c07b85f8b3cc6c6cf537c4cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f886668e-b648-490d-bd57-fa0c18f21982", "node_type": "1", "metadata": {"window": "And I'm wondering if it's just \nsomething about the way \u2013 if it's COVID -related or not.  But I mean, to raise your revenue expectations for all of \nyour segments versus what you guided to just a couple months ago, is there anything else specific?  I mean, was \nit just conservatism on your part?  Because we can't just point to script growth or pati ent volume, there's got to be ", "original_text": "Because we can't just point to script growth or pati ent volume, there's got to be ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5eb292a1b80a64de4035a9fad926af17df66d7636c68b48139ceea097b91956d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9321c5f9-b05b-4fa6-a265-f22d99f82a58", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsome sort of larger macro thing happening here that's driving this.  And I know you kind of addressed it, but maybe \ntalk specifically about the conservatism, or when you went into the year, what were the overhangs that possibly  \nlifted that are allowing you to do this across the board?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWell, let me start. ", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsome sort of larger macro thing happening here that's driving this. "}, "hash": "5073d62ec9d0ef7c1e4b544f6a851a039e51e932ec1235570596dea0a3ec22a6", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9321c5f9-b05b-4fa6-a265-f22d99f82a58": {"__data__": {"id_": "9321c5f9-b05b-4fa6-a265-f22d99f82a58", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsome sort of larger macro thing happening here that's driving this.  And I know you kind of addressed it, but maybe \ntalk specifically about the conservatism, or when you went into the year, what were the overhangs that possibly  \nlifted that are allowing you to do this across the board?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWell, let me start. ", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsome sort of larger macro thing happening here that's driving this. ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d4bb324-d13b-491a-9b23-44037291468e", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20cbda6bfd56661affb59a6962656da50d7ceb4c07b85f8b3cc6c6cf537c4cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e9e683d0-8072-4fc1-a6c0-213b094d8c97", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsome sort of larger macro thing happening here that's driving this.  And I know you kind of addressed it, but maybe \ntalk specifically about the conservatism, or when you went into the year, what were the overhangs that possibly  \nlifted that are allowing you to do this across the board?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c545cd6ff1abe391aa291795cd06ea0a40e4e5526f1c0f0bc1bb6d447f3564dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fcca8f67-c668-41de-a04f-073ed01ef5b2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsome sort of larger macro thing happening here that's driving this.  And I know you kind of addressed it, but maybe \ntalk specifically about the conservatism, or when you went into the year, what were the overhangs that possibly  \nlifted that are allowing you to do this across the board?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWell, let me start.  I appreciate the question, and let me phrase it a little bit differently. ", "original_text": "And I know you kind of addressed it, but maybe \ntalk specifically about the conservatism, or when you went into the year, what were the overhangs that possibly  \nlifted that are allowing you to do this across the board?  \n "}, "hash": "0d993e8f18faccb9d28d1b1d322c47cef9991e2adfede3b324e41b3be33811ea", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsome sort of larger macro thing happening here that's driving this. ", "start_char_idx": 16, "end_char_idx": 249, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fcca8f67-c668-41de-a04f-073ed01ef5b2": {"__data__": {"id_": "fcca8f67-c668-41de-a04f-073ed01ef5b2", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsome sort of larger macro thing happening here that's driving this.  And I know you kind of addressed it, but maybe \ntalk specifically about the conservatism, or when you went into the year, what were the overhangs that possibly  \nlifted that are allowing you to do this across the board?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWell, let me start.  I appreciate the question, and let me phrase it a little bit differently. ", "original_text": "And I know you kind of addressed it, but maybe \ntalk specifically about the conservatism, or when you went into the year, what were the overhangs that possibly  \nlifted that are allowing you to do this across the board?  \n ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d4bb324-d13b-491a-9b23-44037291468e", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20cbda6bfd56661affb59a6962656da50d7ceb4c07b85f8b3cc6c6cf537c4cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9321c5f9-b05b-4fa6-a265-f22d99f82a58", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsome sort of larger macro thing happening here that's driving this.  And I know you kind of addressed it, but maybe \ntalk specifically about the conservatism, or when you went into the year, what were the overhangs that possibly  \nlifted that are allowing you to do this across the board?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWell, let me start. ", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsome sort of larger macro thing happening here that's driving this. ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "528a630a3fe81fb12de3dd4e72369dd41cc4a3558c484866a4edf60b23fdc2a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23abc526-bde2-4677-aec6-e4a3738a265c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsome sort of larger macro thing happening here that's driving this.  And I know you kind of addressed it, but maybe \ntalk specifically about the conservatism, or when you went into the year, what were the overhangs that possibly  \nlifted that are allowing you to do this across the board?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWell, let me start.  I appreciate the question, and let me phrase it a little bit differently.  We don't provide  \nconservative guidances. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "7dad7c527964c05df9e1c97d17ae2d431a20aa522aabef4c325dc1f2a8849819", "class_name": "RelatedNodeInfo"}}, "text": "And I know you kind of addressed it, but maybe \ntalk specifically about the conservatism, or when you went into the year, what were the overhangs that possibly  \nlifted that are allowing you to do this across the board?  \n ", "start_char_idx": 249, "end_char_idx": 472, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "23abc526-bde2-4677-aec6-e4a3738a265c": {"__data__": {"id_": "23abc526-bde2-4677-aec6-e4a3738a265c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsome sort of larger macro thing happening here that's driving this.  And I know you kind of addressed it, but maybe \ntalk specifically about the conservatism, or when you went into the year, what were the overhangs that possibly  \nlifted that are allowing you to do this across the board?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWell, let me start.  I appreciate the question, and let me phrase it a little bit differently.  We don't provide  \nconservative guidances. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d4bb324-d13b-491a-9b23-44037291468e", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20cbda6bfd56661affb59a6962656da50d7ceb4c07b85f8b3cc6c6cf537c4cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fcca8f67-c668-41de-a04f-073ed01ef5b2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsome sort of larger macro thing happening here that's driving this.  And I know you kind of addressed it, but maybe \ntalk specifically about the conservatism, or when you went into the year, what were the overhangs that possibly  \nlifted that are allowing you to do this across the board?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWell, let me start.  I appreciate the question, and let me phrase it a little bit differently. ", "original_text": "And I know you kind of addressed it, but maybe \ntalk specifically about the conservatism, or when you went into the year, what were the overhangs that possibly  \nlifted that are allowing you to do this across the board?  \n ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "89b9a61bdf3afde8d0bba0545efc900165c900230e10a5fe9c0dd91ede9d859e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e32a4671-c530-4c70-8950-8ab3071eac62", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsome sort of larger macro thing happening here that's driving this.  And I know you kind of addressed it, but maybe \ntalk specifically about the conservatism, or when you went into the year, what were the overhangs that possibly  \nlifted that are allowing you to do this across the board?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWell, let me start.  I appreciate the question, and let me phrase it a little bit differently.  We don't provide  \nconservative guidances.  We provide guidances based on what we see in our markets and what we're seeing \nwithin our businesses. ", "original_text": "A \nWell, let me start. "}, "hash": "287defe818a75c614630ea98ec9735d6b5d93aeb97461c91d20a5c407a494645", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 472, "end_char_idx": 829, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e32a4671-c530-4c70-8950-8ab3071eac62": {"__data__": {"id_": "e32a4671-c530-4c70-8950-8ab3071eac62", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsome sort of larger macro thing happening here that's driving this.  And I know you kind of addressed it, but maybe \ntalk specifically about the conservatism, or when you went into the year, what were the overhangs that possibly  \nlifted that are allowing you to do this across the board?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWell, let me start.  I appreciate the question, and let me phrase it a little bit differently.  We don't provide  \nconservative guidances.  We provide guidances based on what we see in our markets and what we're seeing \nwithin our businesses. ", "original_text": "A \nWell, let me start. ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d4bb324-d13b-491a-9b23-44037291468e", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20cbda6bfd56661affb59a6962656da50d7ceb4c07b85f8b3cc6c6cf537c4cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23abc526-bde2-4677-aec6-e4a3738a265c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsome sort of larger macro thing happening here that's driving this.  And I know you kind of addressed it, but maybe \ntalk specifically about the conservatism, or when you went into the year, what were the overhangs that possibly  \nlifted that are allowing you to do this across the board?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWell, let me start.  I appreciate the question, and let me phrase it a little bit differently.  We don't provide  \nconservative guidances. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5cdbc24fd289509080c1e944f91ce203837371d204f8f041560dfb9d7ce3ffe5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "330b7c94-153b-4213-a4cc-c436992632dd", "node_type": "1", "metadata": {"window": "And I know you kind of addressed it, but maybe \ntalk specifically about the conservatism, or when you went into the year, what were the overhangs that possibly  \nlifted that are allowing you to do this across the board?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWell, let me start.  I appreciate the question, and let me phrase it a little bit differently.  We don't provide  \nconservative guidances.  We provide guidances based on what we see in our markets and what we're seeing \nwithin our businesses.  I would remind you that when we gave you our guidance, one of the things that we talked \nabout is that the markets that we operate  in had not fully recovered. ", "original_text": "I appreciate the question, and let me phrase it a little bit differently. "}, "hash": "ae4e4bc872ec18213f01b346e013435a0698f507c2b936b91c2cac22ce7864a5", "class_name": "RelatedNodeInfo"}}, "text": "A \nWell, let me start. ", "start_char_idx": 829, "end_char_idx": 852, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "330b7c94-153b-4213-a4cc-c436992632dd": {"__data__": {"id_": "330b7c94-153b-4213-a4cc-c436992632dd", "embedding": null, "metadata": {"window": "And I know you kind of addressed it, but maybe \ntalk specifically about the conservatism, or when you went into the year, what were the overhangs that possibly  \nlifted that are allowing you to do this across the board?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWell, let me start.  I appreciate the question, and let me phrase it a little bit differently.  We don't provide  \nconservative guidances.  We provide guidances based on what we see in our markets and what we're seeing \nwithin our businesses.  I would remind you that when we gave you our guidance, one of the things that we talked \nabout is that the markets that we operate  in had not fully recovered. ", "original_text": "I appreciate the question, and let me phrase it a little bit differently. ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d4bb324-d13b-491a-9b23-44037291468e", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20cbda6bfd56661affb59a6962656da50d7ceb4c07b85f8b3cc6c6cf537c4cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e32a4671-c530-4c70-8950-8ab3071eac62", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsome sort of larger macro thing happening here that's driving this.  And I know you kind of addressed it, but maybe \ntalk specifically about the conservatism, or when you went into the year, what were the overhangs that possibly  \nlifted that are allowing you to do this across the board?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWell, let me start.  I appreciate the question, and let me phrase it a little bit differently.  We don't provide  \nconservative guidances.  We provide guidances based on what we see in our markets and what we're seeing \nwithin our businesses. ", "original_text": "A \nWell, let me start. ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a7e3ba76885162c9a2406a39ab24db8c421514acb93380666adf4bbb2dc3d43", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8dd3ce96-f85f-483b-8f40-6f5bbb80b27c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWell, let me start.  I appreciate the question, and let me phrase it a little bit differently.  We don't provide  \nconservative guidances.  We provide guidances based on what we see in our markets and what we're seeing \nwithin our businesses.  I would remind you that when we gave you our guidance, one of the things that we talked \nabout is that the markets that we operate  in had not fully recovered.  And so, we're coming off a year of one of the \nmost dynamic environments that we've ever operated in. ", "original_text": "We don't provide  \nconservative guidances. "}, "hash": "4353dbbcfd0aab35357a361fd573b3db73a91ac4a4e751d4bc0079403f8cbab1", "class_name": "RelatedNodeInfo"}}, "text": "I appreciate the question, and let me phrase it a little bit differently. ", "start_char_idx": 852, "end_char_idx": 926, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8dd3ce96-f85f-483b-8f40-6f5bbb80b27c": {"__data__": {"id_": "8dd3ce96-f85f-483b-8f40-6f5bbb80b27c", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWell, let me start.  I appreciate the question, and let me phrase it a little bit differently.  We don't provide  \nconservative guidances.  We provide guidances based on what we see in our markets and what we're seeing \nwithin our businesses.  I would remind you that when we gave you our guidance, one of the things that we talked \nabout is that the markets that we operate  in had not fully recovered.  And so, we're coming off a year of one of the \nmost dynamic environments that we've ever operated in. ", "original_text": "We don't provide  \nconservative guidances. ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d4bb324-d13b-491a-9b23-44037291468e", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20cbda6bfd56661affb59a6962656da50d7ceb4c07b85f8b3cc6c6cf537c4cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "330b7c94-153b-4213-a4cc-c436992632dd", "node_type": "1", "metadata": {"window": "And I know you kind of addressed it, but maybe \ntalk specifically about the conservatism, or when you went into the year, what were the overhangs that possibly  \nlifted that are allowing you to do this across the board?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWell, let me start.  I appreciate the question, and let me phrase it a little bit differently.  We don't provide  \nconservative guidances.  We provide guidances based on what we see in our markets and what we're seeing \nwithin our businesses.  I would remind you that when we gave you our guidance, one of the things that we talked \nabout is that the markets that we operate  in had not fully recovered. ", "original_text": "I appreciate the question, and let me phrase it a little bit differently. ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5295ca4d6da98b2a39f9f34e2f0617ed24956f9fe8037167030b30bb2f61c44", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "afe19e15-c5a8-4913-bc3b-7003cafb577c", "node_type": "1", "metadata": {"window": "A \nWell, let me start.  I appreciate the question, and let me phrase it a little bit differently.  We don't provide  \nconservative guidances.  We provide guidances based on what we see in our markets and what we're seeing \nwithin our businesses.  I would remind you that when we gave you our guidance, one of the things that we talked \nabout is that the markets that we operate  in had not fully recovered.  And so, we're coming off a year of one of the \nmost dynamic environments that we've ever operated in.  And when we provided that guidance, we're very clear \nthat our markets had not fully recovered. ", "original_text": "We provide guidances based on what we see in our markets and what we're seeing \nwithin our businesses. "}, "hash": "5f167445a0880df07e441fe344dbc4d3c03c3405667b42cf4520dd5f1e79d1b6", "class_name": "RelatedNodeInfo"}}, "text": "We don't provide  \nconservative guidances. ", "start_char_idx": 926, "end_char_idx": 969, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "afe19e15-c5a8-4913-bc3b-7003cafb577c": {"__data__": {"id_": "afe19e15-c5a8-4913-bc3b-7003cafb577c", "embedding": null, "metadata": {"window": "A \nWell, let me start.  I appreciate the question, and let me phrase it a little bit differently.  We don't provide  \nconservative guidances.  We provide guidances based on what we see in our markets and what we're seeing \nwithin our businesses.  I would remind you that when we gave you our guidance, one of the things that we talked \nabout is that the markets that we operate  in had not fully recovered.  And so, we're coming off a year of one of the \nmost dynamic environments that we've ever operated in.  And when we provided that guidance, we're very clear \nthat our markets had not fully recovered. ", "original_text": "We provide guidances based on what we see in our markets and what we're seeing \nwithin our businesses. ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d4bb324-d13b-491a-9b23-44037291468e", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20cbda6bfd56661affb59a6962656da50d7ceb4c07b85f8b3cc6c6cf537c4cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8dd3ce96-f85f-483b-8f40-6f5bbb80b27c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nWell, let me start.  I appreciate the question, and let me phrase it a little bit differently.  We don't provide  \nconservative guidances.  We provide guidances based on what we see in our markets and what we're seeing \nwithin our businesses.  I would remind you that when we gave you our guidance, one of the things that we talked \nabout is that the markets that we operate  in had not fully recovered.  And so, we're coming off a year of one of the \nmost dynamic environments that we've ever operated in. ", "original_text": "We don't provide  \nconservative guidances. ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1b06f5c58c006a1b7170bb05bb5c5ed0ae23241464997832a85bfeae6c6dea9d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a457555a-fe31-4216-a01d-55985dc3ddfa", "node_type": "1", "metadata": {"window": "I appreciate the question, and let me phrase it a little bit differently.  We don't provide  \nconservative guidances.  We provide guidances based on what we see in our markets and what we're seeing \nwithin our businesses.  I would remind you that when we gave you our guidance, one of the things that we talked \nabout is that the markets that we operate  in had not fully recovered.  And so, we're coming off a year of one of the \nmost dynamic environments that we've ever operated in.  And when we provided that guidance, we're very clear \nthat our markets had not fully recovered.  We expected that they would. ", "original_text": "I would remind you that when we gave you our guidance, one of the things that we talked \nabout is that the markets that we operate  in had not fully recovered. "}, "hash": "41df0d48eca3b8df0d8418d194bc5ccd467573a29b998813e8239f22738717f0", "class_name": "RelatedNodeInfo"}}, "text": "We provide guidances based on what we see in our markets and what we're seeing \nwithin our businesses. ", "start_char_idx": 969, "end_char_idx": 1072, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a457555a-fe31-4216-a01d-55985dc3ddfa": {"__data__": {"id_": "a457555a-fe31-4216-a01d-55985dc3ddfa", "embedding": null, "metadata": {"window": "I appreciate the question, and let me phrase it a little bit differently.  We don't provide  \nconservative guidances.  We provide guidances based on what we see in our markets and what we're seeing \nwithin our businesses.  I would remind you that when we gave you our guidance, one of the things that we talked \nabout is that the markets that we operate  in had not fully recovered.  And so, we're coming off a year of one of the \nmost dynamic environments that we've ever operated in.  And when we provided that guidance, we're very clear \nthat our markets had not fully recovered.  We expected that they would. ", "original_text": "I would remind you that when we gave you our guidance, one of the things that we talked \nabout is that the markets that we operate  in had not fully recovered. ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d4bb324-d13b-491a-9b23-44037291468e", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20cbda6bfd56661affb59a6962656da50d7ceb4c07b85f8b3cc6c6cf537c4cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "afe19e15-c5a8-4913-bc3b-7003cafb577c", "node_type": "1", "metadata": {"window": "A \nWell, let me start.  I appreciate the question, and let me phrase it a little bit differently.  We don't provide  \nconservative guidances.  We provide guidances based on what we see in our markets and what we're seeing \nwithin our businesses.  I would remind you that when we gave you our guidance, one of the things that we talked \nabout is that the markets that we operate  in had not fully recovered.  And so, we're coming off a year of one of the \nmost dynamic environments that we've ever operated in.  And when we provided that guidance, we're very clear \nthat our markets had not fully recovered. ", "original_text": "We provide guidances based on what we see in our markets and what we're seeing \nwithin our businesses. ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d4d212ae432381d577796c79a453847a3b50fd16b334ac8bd11912acfa38dce3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35f2c2b8-4c63-4e1e-9e2e-e76c8e84af3b", "node_type": "1", "metadata": {"window": "We don't provide  \nconservative guidances.  We provide guidances based on what we see in our markets and what we're seeing \nwithin our businesses.  I would remind you that when we gave you our guidance, one of the things that we talked \nabout is that the markets that we operate  in had not fully recovered.  And so, we're coming off a year of one of the \nmost dynamic environments that we've ever operated in.  And when we provided that guidance, we're very clear \nthat our markets had not fully recovered.  We expected that they would.  Bu t certainly, it was going to evolve over \ntime.  \n \n", "original_text": "And so, we're coming off a year of one of the \nmost dynamic environments that we've ever operated in. "}, "hash": "13714744786e8284adc4cbfa227c745bc458aa58cb78706cb7cdb5c5413e9c93", "class_name": "RelatedNodeInfo"}}, "text": "I would remind you that when we gave you our guidance, one of the things that we talked \nabout is that the markets that we operate  in had not fully recovered. ", "start_char_idx": 1072, "end_char_idx": 1232, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35f2c2b8-4c63-4e1e-9e2e-e76c8e84af3b": {"__data__": {"id_": "35f2c2b8-4c63-4e1e-9e2e-e76c8e84af3b", "embedding": null, "metadata": {"window": "We don't provide  \nconservative guidances.  We provide guidances based on what we see in our markets and what we're seeing \nwithin our businesses.  I would remind you that when we gave you our guidance, one of the things that we talked \nabout is that the markets that we operate  in had not fully recovered.  And so, we're coming off a year of one of the \nmost dynamic environments that we've ever operated in.  And when we provided that guidance, we're very clear \nthat our markets had not fully recovered.  We expected that they would.  Bu t certainly, it was going to evolve over \ntime.  \n \n", "original_text": "And so, we're coming off a year of one of the \nmost dynamic environments that we've ever operated in. ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d4bb324-d13b-491a-9b23-44037291468e", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20cbda6bfd56661affb59a6962656da50d7ceb4c07b85f8b3cc6c6cf537c4cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a457555a-fe31-4216-a01d-55985dc3ddfa", "node_type": "1", "metadata": {"window": "I appreciate the question, and let me phrase it a little bit differently.  We don't provide  \nconservative guidances.  We provide guidances based on what we see in our markets and what we're seeing \nwithin our businesses.  I would remind you that when we gave you our guidance, one of the things that we talked \nabout is that the markets that we operate  in had not fully recovered.  And so, we're coming off a year of one of the \nmost dynamic environments that we've ever operated in.  And when we provided that guidance, we're very clear \nthat our markets had not fully recovered.  We expected that they would. ", "original_text": "I would remind you that when we gave you our guidance, one of the things that we talked \nabout is that the markets that we operate  in had not fully recovered. ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "de1597f1bb05b73ef4b47662f48a51e5f9017c54c14723c7e6c7f74b4be28e97", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "21b2d1b5-41e7-4092-9aea-65cf744c6160", "node_type": "1", "metadata": {"window": "We provide guidances based on what we see in our markets and what we're seeing \nwithin our businesses.  I would remind you that when we gave you our guidance, one of the things that we talked \nabout is that the markets that we operate  in had not fully recovered.  And so, we're coming off a year of one of the \nmost dynamic environments that we've ever operated in.  And when we provided that guidance, we're very clear \nthat our markets had not fully recovered.  We expected that they would.  Bu t certainly, it was going to evolve over \ntime.  \n \n Our businesses continue to operate at a very high level. ", "original_text": "And when we provided that guidance, we're very clear \nthat our markets had not fully recovered. "}, "hash": "6b22980b9ad303c5a3f3eadf1d168370a2de1a208fb390607c065bc6fe80f70f", "class_name": "RelatedNodeInfo"}}, "text": "And so, we're coming off a year of one of the \nmost dynamic environments that we've ever operated in. ", "start_char_idx": 1232, "end_char_idx": 1334, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "21b2d1b5-41e7-4092-9aea-65cf744c6160": {"__data__": {"id_": "21b2d1b5-41e7-4092-9aea-65cf744c6160", "embedding": null, "metadata": {"window": "We provide guidances based on what we see in our markets and what we're seeing \nwithin our businesses.  I would remind you that when we gave you our guidance, one of the things that we talked \nabout is that the markets that we operate  in had not fully recovered.  And so, we're coming off a year of one of the \nmost dynamic environments that we've ever operated in.  And when we provided that guidance, we're very clear \nthat our markets had not fully recovered.  We expected that they would.  Bu t certainly, it was going to evolve over \ntime.  \n \n Our businesses continue to operate at a very high level. ", "original_text": "And when we provided that guidance, we're very clear \nthat our markets had not fully recovered. ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d4bb324-d13b-491a-9b23-44037291468e", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20cbda6bfd56661affb59a6962656da50d7ceb4c07b85f8b3cc6c6cf537c4cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35f2c2b8-4c63-4e1e-9e2e-e76c8e84af3b", "node_type": "1", "metadata": {"window": "We don't provide  \nconservative guidances.  We provide guidances based on what we see in our markets and what we're seeing \nwithin our businesses.  I would remind you that when we gave you our guidance, one of the things that we talked \nabout is that the markets that we operate  in had not fully recovered.  And so, we're coming off a year of one of the \nmost dynamic environments that we've ever operated in.  And when we provided that guidance, we're very clear \nthat our markets had not fully recovered.  We expected that they would.  Bu t certainly, it was going to evolve over \ntime.  \n \n", "original_text": "And so, we're coming off a year of one of the \nmost dynamic environments that we've ever operated in. ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7d3f9753a62a5557aafa63ec1e90f4af01428147e6b4ea619834fcc0f92c3942", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e919b8f9-1e99-46a7-afc9-d5372f147fe0", "node_type": "1", "metadata": {"window": "I would remind you that when we gave you our guidance, one of the things that we talked \nabout is that the markets that we operate  in had not fully recovered.  And so, we're coming off a year of one of the \nmost dynamic environments that we've ever operated in.  And when we provided that guidance, we're very clear \nthat our markets had not fully recovered.  We expected that they would.  Bu t certainly, it was going to evolve over \ntime.  \n \n Our businesses continue to operate at a very high level.  And I think you saw that in the performance this quarter. \n", "original_text": "We expected that they would. "}, "hash": "d35d7e3d79877fba2a5bd7b298cd941152a741f2bc9e664e4870db6bffed82dc", "class_name": "RelatedNodeInfo"}}, "text": "And when we provided that guidance, we're very clear \nthat our markets had not fully recovered. ", "start_char_idx": 1334, "end_char_idx": 1430, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e919b8f9-1e99-46a7-afc9-d5372f147fe0": {"__data__": {"id_": "e919b8f9-1e99-46a7-afc9-d5372f147fe0", "embedding": null, "metadata": {"window": "I would remind you that when we gave you our guidance, one of the things that we talked \nabout is that the markets that we operate  in had not fully recovered.  And so, we're coming off a year of one of the \nmost dynamic environments that we've ever operated in.  And when we provided that guidance, we're very clear \nthat our markets had not fully recovered.  We expected that they would.  Bu t certainly, it was going to evolve over \ntime.  \n \n Our businesses continue to operate at a very high level.  And I think you saw that in the performance this quarter. \n", "original_text": "We expected that they would. ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d4bb324-d13b-491a-9b23-44037291468e", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20cbda6bfd56661affb59a6962656da50d7ceb4c07b85f8b3cc6c6cf537c4cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "21b2d1b5-41e7-4092-9aea-65cf744c6160", "node_type": "1", "metadata": {"window": "We provide guidances based on what we see in our markets and what we're seeing \nwithin our businesses.  I would remind you that when we gave you our guidance, one of the things that we talked \nabout is that the markets that we operate  in had not fully recovered.  And so, we're coming off a year of one of the \nmost dynamic environments that we've ever operated in.  And when we provided that guidance, we're very clear \nthat our markets had not fully recovered.  We expected that they would.  Bu t certainly, it was going to evolve over \ntime.  \n \n Our businesses continue to operate at a very high level. ", "original_text": "And when we provided that guidance, we're very clear \nthat our markets had not fully recovered. ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c150e1991cfb6e63cbe1c7256d9059df7f71ffe50e6a68fdc61d5e7f647d294a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9946ddd4-f170-488c-85e1-d423ff7f08e2", "node_type": "1", "metadata": {"window": "And so, we're coming off a year of one of the \nmost dynamic environments that we've ever operated in.  And when we provided that guidance, we're very clear \nthat our markets had not fully recovered.  We expected that they would.  Bu t certainly, it was going to evolve over \ntime.  \n \n Our businesses continue to operate at a very high level.  And I think you saw that in the performance this quarter. \n We're very encouraged by the utilization trends that we see. ", "original_text": "Bu t certainly, it was going to evolve over \ntime.  \n \n"}, "hash": "be0e292f886ef087e8ac1ee4ba80e313661078f4c140cf31d75e0b7e91a6f790", "class_name": "RelatedNodeInfo"}}, "text": "We expected that they would. ", "start_char_idx": 1430, "end_char_idx": 1459, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9946ddd4-f170-488c-85e1-d423ff7f08e2": {"__data__": {"id_": "9946ddd4-f170-488c-85e1-d423ff7f08e2", "embedding": null, "metadata": {"window": "And so, we're coming off a year of one of the \nmost dynamic environments that we've ever operated in.  And when we provided that guidance, we're very clear \nthat our markets had not fully recovered.  We expected that they would.  Bu t certainly, it was going to evolve over \ntime.  \n \n Our businesses continue to operate at a very high level.  And I think you saw that in the performance this quarter. \n We're very encouraged by the utilization trends that we see. ", "original_text": "Bu t certainly, it was going to evolve over \ntime.  \n \n", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d4bb324-d13b-491a-9b23-44037291468e", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20cbda6bfd56661affb59a6962656da50d7ceb4c07b85f8b3cc6c6cf537c4cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e919b8f9-1e99-46a7-afc9-d5372f147fe0", "node_type": "1", "metadata": {"window": "I would remind you that when we gave you our guidance, one of the things that we talked \nabout is that the markets that we operate  in had not fully recovered.  And so, we're coming off a year of one of the \nmost dynamic environments that we've ever operated in.  And when we provided that guidance, we're very clear \nthat our markets had not fully recovered.  We expected that they would.  Bu t certainly, it was going to evolve over \ntime.  \n \n Our businesses continue to operate at a very high level.  And I think you saw that in the performance this quarter. \n", "original_text": "We expected that they would. ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77e9d2fcd5a04b7879ce058e89f10d4a1bfb9d2f6f541deba619d5666acc6bb7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6088d1b4-b225-4078-9bb0-1ee63b8dae52", "node_type": "1", "metadata": {"window": "And when we provided that guidance, we're very clear \nthat our markets had not fully recovered.  We expected that they would.  Bu t certainly, it was going to evolve over \ntime.  \n \n Our businesses continue to operate at a very high level.  And I think you saw that in the performance this quarter. \n We're very encouraged by the utilization trends that we see.  We're very encouraged by the per formance that each \nof the businesses has shown. ", "original_text": "Our businesses continue to operate at a very high level. "}, "hash": "290deefc2909fee1bd0cd0eb2fe8fb239aecfa900c1803f95157ef161db69696", "class_name": "RelatedNodeInfo"}}, "text": "Bu t certainly, it was going to evolve over \ntime.  \n \n", "start_char_idx": 1459, "end_char_idx": 1514, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6088d1b4-b225-4078-9bb0-1ee63b8dae52": {"__data__": {"id_": "6088d1b4-b225-4078-9bb0-1ee63b8dae52", "embedding": null, "metadata": {"window": "And when we provided that guidance, we're very clear \nthat our markets had not fully recovered.  We expected that they would.  Bu t certainly, it was going to evolve over \ntime.  \n \n Our businesses continue to operate at a very high level.  And I think you saw that in the performance this quarter. \n We're very encouraged by the utilization trends that we see.  We're very encouraged by the per formance that each \nof the businesses has shown. ", "original_text": "Our businesses continue to operate at a very high level. ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d4bb324-d13b-491a-9b23-44037291468e", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20cbda6bfd56661affb59a6962656da50d7ceb4c07b85f8b3cc6c6cf537c4cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9946ddd4-f170-488c-85e1-d423ff7f08e2", "node_type": "1", "metadata": {"window": "And so, we're coming off a year of one of the \nmost dynamic environments that we've ever operated in.  And when we provided that guidance, we're very clear \nthat our markets had not fully recovered.  We expected that they would.  Bu t certainly, it was going to evolve over \ntime.  \n \n Our businesses continue to operate at a very high level.  And I think you saw that in the performance this quarter. \n We're very encouraged by the utilization trends that we see. ", "original_text": "Bu t certainly, it was going to evolve over \ntime.  \n \n", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8217b7932bd16bf1c1ed8523cad5b67d8d1be238af1806f4b713edf72919b79d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7efb492d-cbe4-454c-a042-7f76dc1c7bf1", "node_type": "1", "metadata": {"window": "We expected that they would.  Bu t certainly, it was going to evolve over \ntime.  \n \n Our businesses continue to operate at a very high level.  And I think you saw that in the performance this quarter. \n We're very encouraged by the utilization trends that we see.  We're very encouraged by the per formance that each \nof the businesses has shown.  And we're seeing really good reaction and response to a lot of the products that we \nhave, specifically in the RxTS business, as an example. ", "original_text": "And I think you saw that in the performance this quarter. \n"}, "hash": "979ff0798d679d4fa5262e88ce30208cbacf418bc84b2f2fb13d5c3aa3b39b90", "class_name": "RelatedNodeInfo"}}, "text": "Our businesses continue to operate at a very high level. ", "start_char_idx": 1514, "end_char_idx": 1571, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7efb492d-cbe4-454c-a042-7f76dc1c7bf1": {"__data__": {"id_": "7efb492d-cbe4-454c-a042-7f76dc1c7bf1", "embedding": null, "metadata": {"window": "We expected that they would.  Bu t certainly, it was going to evolve over \ntime.  \n \n Our businesses continue to operate at a very high level.  And I think you saw that in the performance this quarter. \n We're very encouraged by the utilization trends that we see.  We're very encouraged by the per formance that each \nof the businesses has shown.  And we're seeing really good reaction and response to a lot of the products that we \nhave, specifically in the RxTS business, as an example. ", "original_text": "And I think you saw that in the performance this quarter. \n", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d4bb324-d13b-491a-9b23-44037291468e", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20cbda6bfd56661affb59a6962656da50d7ceb4c07b85f8b3cc6c6cf537c4cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6088d1b4-b225-4078-9bb0-1ee63b8dae52", "node_type": "1", "metadata": {"window": "And when we provided that guidance, we're very clear \nthat our markets had not fully recovered.  We expected that they would.  Bu t certainly, it was going to evolve over \ntime.  \n \n Our businesses continue to operate at a very high level.  And I think you saw that in the performance this quarter. \n We're very encouraged by the utilization trends that we see.  We're very encouraged by the per formance that each \nof the businesses has shown. ", "original_text": "Our businesses continue to operate at a very high level. ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "62cf452c043208c6e84a4f4a5f7664a50eeacd25e4f7e9dab80cbd01259b5a36", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7434c9fd-cb77-4959-b889-adf54799c680", "node_type": "1", "metadata": {"window": "Bu t certainly, it was going to evolve over \ntime.  \n \n Our businesses continue to operate at a very high level.  And I think you saw that in the performance this quarter. \n We're very encouraged by the utilization trends that we see.  We're very encouraged by the per formance that each \nof the businesses has shown.  And we're seeing really good reaction and response to a lot of the products that we \nhave, specifically in the RxTS business, as an example.  So, I think what you're seeing is an environment that is \ncontinuing to recover, not necessarily on an even basis over the last year and a half, and a business that is \nperforming very well in those situations.  \n ", "original_text": "We're very encouraged by the utilization trends that we see. "}, "hash": "903ab92f4166f61994f9df7ced76f9a60c332143cd333698b8f23b33efd282b9", "class_name": "RelatedNodeInfo"}}, "text": "And I think you saw that in the performance this quarter. \n", "start_char_idx": 1571, "end_char_idx": 1630, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7434c9fd-cb77-4959-b889-adf54799c680": {"__data__": {"id_": "7434c9fd-cb77-4959-b889-adf54799c680", "embedding": null, "metadata": {"window": "Bu t certainly, it was going to evolve over \ntime.  \n \n Our businesses continue to operate at a very high level.  And I think you saw that in the performance this quarter. \n We're very encouraged by the utilization trends that we see.  We're very encouraged by the per formance that each \nof the businesses has shown.  And we're seeing really good reaction and response to a lot of the products that we \nhave, specifically in the RxTS business, as an example.  So, I think what you're seeing is an environment that is \ncontinuing to recover, not necessarily on an even basis over the last year and a half, and a business that is \nperforming very well in those situations.  \n ", "original_text": "We're very encouraged by the utilization trends that we see. ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d4bb324-d13b-491a-9b23-44037291468e", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20cbda6bfd56661affb59a6962656da50d7ceb4c07b85f8b3cc6c6cf537c4cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7efb492d-cbe4-454c-a042-7f76dc1c7bf1", "node_type": "1", "metadata": {"window": "We expected that they would.  Bu t certainly, it was going to evolve over \ntime.  \n \n Our businesses continue to operate at a very high level.  And I think you saw that in the performance this quarter. \n We're very encouraged by the utilization trends that we see.  We're very encouraged by the per formance that each \nof the businesses has shown.  And we're seeing really good reaction and response to a lot of the products that we \nhave, specifically in the RxTS business, as an example. ", "original_text": "And I think you saw that in the performance this quarter. \n", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7d16ba777c149e00b89c540adf420ac8cfc8fd63c17b7ec0b224949096a0da0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29739d60-b2d3-4131-9cae-259aa28b081f", "node_type": "1", "metadata": {"window": "Our businesses continue to operate at a very high level.  And I think you saw that in the performance this quarter. \n We're very encouraged by the utilization trends that we see.  We're very encouraged by the per formance that each \nof the businesses has shown.  And we're seeing really good reaction and response to a lot of the products that we \nhave, specifically in the RxTS business, as an example.  So, I think what you're seeing is an environment that is \ncontinuing to recover, not necessarily on an even basis over the last year and a half, and a business that is \nperforming very well in those situations.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "original_text": "We're very encouraged by the per formance that each \nof the businesses has shown. "}, "hash": "a750620312d2edb1bc0b86bcc61e1b0a3dd77af264f63ea853ebc920f0579b3d", "class_name": "RelatedNodeInfo"}}, "text": "We're very encouraged by the utilization trends that we see. ", "start_char_idx": 1630, "end_char_idx": 1691, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29739d60-b2d3-4131-9cae-259aa28b081f": {"__data__": {"id_": "29739d60-b2d3-4131-9cae-259aa28b081f", "embedding": null, "metadata": {"window": "Our businesses continue to operate at a very high level.  And I think you saw that in the performance this quarter. \n We're very encouraged by the utilization trends that we see.  We're very encouraged by the per formance that each \nof the businesses has shown.  And we're seeing really good reaction and response to a lot of the products that we \nhave, specifically in the RxTS business, as an example.  So, I think what you're seeing is an environment that is \ncontinuing to recover, not necessarily on an even basis over the last year and a half, and a business that is \nperforming very well in those situations.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "original_text": "We're very encouraged by the per formance that each \nof the businesses has shown. ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d4bb324-d13b-491a-9b23-44037291468e", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20cbda6bfd56661affb59a6962656da50d7ceb4c07b85f8b3cc6c6cf537c4cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7434c9fd-cb77-4959-b889-adf54799c680", "node_type": "1", "metadata": {"window": "Bu t certainly, it was going to evolve over \ntime.  \n \n Our businesses continue to operate at a very high level.  And I think you saw that in the performance this quarter. \n We're very encouraged by the utilization trends that we see.  We're very encouraged by the per formance that each \nof the businesses has shown.  And we're seeing really good reaction and response to a lot of the products that we \nhave, specifically in the RxTS business, as an example.  So, I think what you're seeing is an environment that is \ncontinuing to recover, not necessarily on an even basis over the last year and a half, and a business that is \nperforming very well in those situations.  \n ", "original_text": "We're very encouraged by the utilization trends that we see. ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "01f09f4a26d2ec88744d30dd2087eeb21ec30d382a0d69fee2ffd07359953a8b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae4a5e21-f5f2-413f-9cae-acef6106293e", "node_type": "1", "metadata": {"window": "And I think you saw that in the performance this quarter. \n We're very encouraged by the utilization trends that we see.  We're very encouraged by the per formance that each \nof the businesses has shown.  And we're seeing really good reaction and response to a lot of the products that we \nhave, specifically in the RxTS business, as an example.  So, I think what you're seeing is an environment that is \ncontinuing to recover, not necessarily on an even basis over the last year and a half, and a business that is \nperforming very well in those situations.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nNext questio n. \n ", "original_text": "And we're seeing really good reaction and response to a lot of the products that we \nhave, specifically in the RxTS business, as an example. "}, "hash": "32c677be174af3a5e258c92e0082221c483728344e69fe8651542217a85dd5c7", "class_name": "RelatedNodeInfo"}}, "text": "We're very encouraged by the per formance that each \nof the businesses has shown. ", "start_char_idx": 1691, "end_char_idx": 1773, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae4a5e21-f5f2-413f-9cae-acef6106293e": {"__data__": {"id_": "ae4a5e21-f5f2-413f-9cae-acef6106293e", "embedding": null, "metadata": {"window": "And I think you saw that in the performance this quarter. \n We're very encouraged by the utilization trends that we see.  We're very encouraged by the per formance that each \nof the businesses has shown.  And we're seeing really good reaction and response to a lot of the products that we \nhave, specifically in the RxTS business, as an example.  So, I think what you're seeing is an environment that is \ncontinuing to recover, not necessarily on an even basis over the last year and a half, and a business that is \nperforming very well in those situations.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nNext questio n. \n ", "original_text": "And we're seeing really good reaction and response to a lot of the products that we \nhave, specifically in the RxTS business, as an example. ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d4bb324-d13b-491a-9b23-44037291468e", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20cbda6bfd56661affb59a6962656da50d7ceb4c07b85f8b3cc6c6cf537c4cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29739d60-b2d3-4131-9cae-259aa28b081f", "node_type": "1", "metadata": {"window": "Our businesses continue to operate at a very high level.  And I think you saw that in the performance this quarter. \n We're very encouraged by the utilization trends that we see.  We're very encouraged by the per formance that each \nof the businesses has shown.  And we're seeing really good reaction and response to a lot of the products that we \nhave, specifically in the RxTS business, as an example.  So, I think what you're seeing is an environment that is \ncontinuing to recover, not necessarily on an even basis over the last year and a half, and a business that is \nperforming very well in those situations.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "original_text": "We're very encouraged by the per formance that each \nof the businesses has shown. ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4f9e1f742bdff81090598cffbdf3b65fd2c44f98db7875f604bdeb608e55b147", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b750984-9836-47dc-9317-a46a2ec79b4a", "node_type": "1", "metadata": {"window": "We're very encouraged by the utilization trends that we see.  We're very encouraged by the per formance that each \nof the businesses has shown.  And we're seeing really good reaction and response to a lot of the products that we \nhave, specifically in the RxTS business, as an example.  So, I think what you're seeing is an environment that is \ncontinuing to recover, not necessarily on an even basis over the last year and a half, and a business that is \nperforming very well in those situations.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nNext questio n. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldwasser of Morgan Stanley.  \n ", "original_text": "So, I think what you're seeing is an environment that is \ncontinuing to recover, not necessarily on an even basis over the last year and a half, and a business that is \nperforming very well in those situations.  \n "}, "hash": "ed2e096fa19454e6cadda48c06655c1df55eff738a2548b35b54aca8364c3428", "class_name": "RelatedNodeInfo"}}, "text": "And we're seeing really good reaction and response to a lot of the products that we \nhave, specifically in the RxTS business, as an example. ", "start_char_idx": 1773, "end_char_idx": 1914, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b750984-9836-47dc-9317-a46a2ec79b4a": {"__data__": {"id_": "4b750984-9836-47dc-9317-a46a2ec79b4a", "embedding": null, "metadata": {"window": "We're very encouraged by the utilization trends that we see.  We're very encouraged by the per formance that each \nof the businesses has shown.  And we're seeing really good reaction and response to a lot of the products that we \nhave, specifically in the RxTS business, as an example.  So, I think what you're seeing is an environment that is \ncontinuing to recover, not necessarily on an even basis over the last year and a half, and a business that is \nperforming very well in those situations.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nNext questio n. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldwasser of Morgan Stanley.  \n ", "original_text": "So, I think what you're seeing is an environment that is \ncontinuing to recover, not necessarily on an even basis over the last year and a half, and a business that is \nperforming very well in those situations.  \n ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d4bb324-d13b-491a-9b23-44037291468e", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20cbda6bfd56661affb59a6962656da50d7ceb4c07b85f8b3cc6c6cf537c4cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae4a5e21-f5f2-413f-9cae-acef6106293e", "node_type": "1", "metadata": {"window": "And I think you saw that in the performance this quarter. \n We're very encouraged by the utilization trends that we see.  We're very encouraged by the per formance that each \nof the businesses has shown.  And we're seeing really good reaction and response to a lot of the products that we \nhave, specifically in the RxTS business, as an example.  So, I think what you're seeing is an environment that is \ncontinuing to recover, not necessarily on an even basis over the last year and a half, and a business that is \nperforming very well in those situations.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nNext questio n. \n ", "original_text": "And we're seeing really good reaction and response to a lot of the products that we \nhave, specifically in the RxTS business, as an example. ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b16919bf4bbf57e0ec03e8dbae7db102e54b2055c4c5031f5e30ce1806805bc2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc803359-3400-46a0-ac76-6a4b68c3fbe0", "node_type": "1", "metadata": {"window": "We're very encouraged by the per formance that each \nof the businesses has shown.  And we're seeing really good reaction and response to a lot of the products that we \nhave, specifically in the RxTS business, as an example.  So, I think what you're seeing is an environment that is \ncontinuing to recover, not necessarily on an even basis over the last year and a half, and a business that is \nperforming very well in those situations.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nNext questio n. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldwasser of Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  "}, "hash": "a8490293091a38157b750570d942236bc09355e828226bc2d75fe90a6813cd8a", "class_name": "RelatedNodeInfo"}}, "text": "So, I think what you're seeing is an environment that is \ncontinuing to recover, not necessarily on an even basis over the last year and a half, and a business that is \nperforming very well in those situations.  \n ", "start_char_idx": 1914, "end_char_idx": 2128, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc803359-3400-46a0-ac76-6a4b68c3fbe0": {"__data__": {"id_": "cc803359-3400-46a0-ac76-6a4b68c3fbe0", "embedding": null, "metadata": {"window": "We're very encouraged by the per formance that each \nof the businesses has shown.  And we're seeing really good reaction and response to a lot of the products that we \nhave, specifically in the RxTS business, as an example.  So, I think what you're seeing is an environment that is \ncontinuing to recover, not necessarily on an even basis over the last year and a half, and a business that is \nperforming very well in those situations.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nNext questio n. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldwasser of Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d4bb324-d13b-491a-9b23-44037291468e", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20cbda6bfd56661affb59a6962656da50d7ceb4c07b85f8b3cc6c6cf537c4cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b750984-9836-47dc-9317-a46a2ec79b4a", "node_type": "1", "metadata": {"window": "We're very encouraged by the utilization trends that we see.  We're very encouraged by the per formance that each \nof the businesses has shown.  And we're seeing really good reaction and response to a lot of the products that we \nhave, specifically in the RxTS business, as an example.  So, I think what you're seeing is an environment that is \ncontinuing to recover, not necessarily on an even basis over the last year and a half, and a business that is \nperforming very well in those situations.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nNext questio n. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldwasser of Morgan Stanley.  \n ", "original_text": "So, I think what you're seeing is an environment that is \ncontinuing to recover, not necessarily on an even basis over the last year and a half, and a business that is \nperforming very well in those situations.  \n ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f532540a7e41cfdd6d2b1845a2e2a986bf4456c5e4349cd7dee9bc1dd3e44b5b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c478cd76-4303-4ca7-808b-cb7502645bff", "node_type": "1", "metadata": {"window": "And we're seeing really good reaction and response to a lot of the products that we \nhave, specifically in the RxTS business, as an example.  So, I think what you're seeing is an environment that is \ncontinuing to recover, not necessarily on an even basis over the last year and a half, and a business that is \nperforming very well in those situations.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nNext questio n. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldwasser of Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah. ", "original_text": "A \nNext questio n. \n "}, "hash": "dc7de5194e09ab67b0982b54d3c7ab84fb59e6560587fd1544b71fab02118678", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "start_char_idx": 2128, "end_char_idx": 2502, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c478cd76-4303-4ca7-808b-cb7502645bff": {"__data__": {"id_": "c478cd76-4303-4ca7-808b-cb7502645bff", "embedding": null, "metadata": {"window": "And we're seeing really good reaction and response to a lot of the products that we \nhave, specifically in the RxTS business, as an example.  So, I think what you're seeing is an environment that is \ncontinuing to recover, not necessarily on an even basis over the last year and a half, and a business that is \nperforming very well in those situations.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nNext questio n. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldwasser of Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah. ", "original_text": "A \nNext questio n. \n ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d4bb324-d13b-491a-9b23-44037291468e", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20cbda6bfd56661affb59a6962656da50d7ceb4c07b85f8b3cc6c6cf537c4cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc803359-3400-46a0-ac76-6a4b68c3fbe0", "node_type": "1", "metadata": {"window": "We're very encouraged by the per formance that each \nof the businesses has shown.  And we're seeing really good reaction and response to a lot of the products that we \nhave, specifically in the RxTS business, as an example.  So, I think what you're seeing is an environment that is \ncontinuing to recover, not necessarily on an even basis over the last year and a half, and a business that is \nperforming very well in those situations.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nNext questio n. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldwasser of Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bccd42c9285b29ea0f53c922de5df13b9dc9096ff1bfcbfb281a3e7dc075230d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5cd6e6d2-aedf-4fe7-90dc-bcca0f346030", "node_type": "1", "metadata": {"window": "So, I think what you're seeing is an environment that is \ncontinuing to recover, not necessarily on an even basis over the last year and a half, and a business that is \nperforming very well in those situations.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nNext questio n. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldwasser of Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldwasser of Morgan Stanley.  \n "}, "hash": "4629ec5bca5bb96285074734a020daa61a6e5d8f4ea3e12a7785efd38ce1150e", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext questio n. \n ", "start_char_idx": 2502, "end_char_idx": 2523, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5cd6e6d2-aedf-4fe7-90dc-bcca0f346030": {"__data__": {"id_": "5cd6e6d2-aedf-4fe7-90dc-bcca0f346030", "embedding": null, "metadata": {"window": "So, I think what you're seeing is an environment that is \ncontinuing to recover, not necessarily on an even basis over the last year and a half, and a business that is \nperforming very well in those situations.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nNext questio n. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldwasser of Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldwasser of Morgan Stanley.  \n ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d4bb324-d13b-491a-9b23-44037291468e", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20cbda6bfd56661affb59a6962656da50d7ceb4c07b85f8b3cc6c6cf537c4cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c478cd76-4303-4ca7-808b-cb7502645bff", "node_type": "1", "metadata": {"window": "And we're seeing really good reaction and response to a lot of the products that we \nhave, specifically in the RxTS business, as an example.  So, I think what you're seeing is an environment that is \ncontinuing to recover, not necessarily on an even basis over the last year and a half, and a business that is \nperforming very well in those situations.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nNext questio n. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldwasser of Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah. ", "original_text": "A \nNext questio n. \n ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "440ff238eb9c838b02981c5106820c32fd961f6a62eb294ad3cf9d84a412196c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc7ddfd4-79ce-4c88-a5eb-7bbec8b5a16a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nNext questio n. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldwasser of Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good afternoon. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. "}, "hash": "887cad79d4f7a619cf05564855aaa8a4e139d868be95095a4529a3395a3ad795", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldwasser of Morgan Stanley.  \n ", "start_char_idx": 2523, "end_char_idx": 2864, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc7ddfd4-79ce-4c88-a5eb-7bbec8b5a16a": {"__data__": {"id_": "fc7ddfd4-79ce-4c88-a5eb-7bbec8b5a16a", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nNext questio n. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldwasser of Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good afternoon. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d4bb324-d13b-491a-9b23-44037291468e", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20cbda6bfd56661affb59a6962656da50d7ceb4c07b85f8b3cc6c6cf537c4cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5cd6e6d2-aedf-4fe7-90dc-bcca0f346030", "node_type": "1", "metadata": {"window": "So, I think what you're seeing is an environment that is \ncontinuing to recover, not necessarily on an even basis over the last year and a half, and a business that is \nperforming very well in those situations.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nNext questio n. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldwasser of Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldwasser of Morgan Stanley.  \n ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "510b68714483ebe28556b7fa5757fc499f3a5c69a65e74f002fd07eebbee7f7f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd4b655d-110b-4f5b-8bfd-2c05e0ae9212", "node_type": "1", "metadata": {"window": "A \nNext questio n. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldwasser of Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good afternoon.  I want to go back to kind of especially Ontada. ", "original_text": "LLC  Q \nYeah. "}, "hash": "499df1b4797df24379a1b5ee1cff9aba98c1c516f5ccead536d3ee73ad59a410", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "start_char_idx": 2864, "end_char_idx": 3188, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd4b655d-110b-4f5b-8bfd-2c05e0ae9212": {"__data__": {"id_": "fd4b655d-110b-4f5b-8bfd-2c05e0ae9212", "embedding": null, "metadata": {"window": "A \nNext questio n. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldwasser of Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good afternoon.  I want to go back to kind of especially Ontada. ", "original_text": "LLC  Q \nYeah. ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d4bb324-d13b-491a-9b23-44037291468e", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20cbda6bfd56661affb59a6962656da50d7ceb4c07b85f8b3cc6c6cf537c4cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc7ddfd4-79ce-4c88-a5eb-7bbec8b5a16a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nNext questio n. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldwasser of Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good afternoon. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "186dfd9a3329fc7f574a442252a180d03ae6ebba2c3398e4f0cd7e76357536e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ca3d230-9882-43cd-9e8e-5a2e8d8e6542", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldwasser of Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good afternoon.  I want to go back to kind of especially Ontada.  You talked, Brian, about sort of [ph] \ncontactor (00:52:08) relationship and sort of that cycle between providers and biopharma, et cetera. ", "original_text": "Hi. "}, "hash": "17ae202e09433aeb29e87a67a73b2bbfff4f2d3e8381a2ac547e74214ce107b3", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Q \nYeah. ", "start_char_idx": 3188, "end_char_idx": 3202, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ca3d230-9882-43cd-9e8e-5a2e8d8e6542": {"__data__": {"id_": "9ca3d230-9882-43cd-9e8e-5a2e8d8e6542", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldwasser of Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good afternoon.  I want to go back to kind of especially Ontada.  You talked, Brian, about sort of [ph] \ncontactor (00:52:08) relationship and sort of that cycle between providers and biopharma, et cetera. ", "original_text": "Hi. ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d4bb324-d13b-491a-9b23-44037291468e", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20cbda6bfd56661affb59a6962656da50d7ceb4c07b85f8b3cc6c6cf537c4cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd4b655d-110b-4f5b-8bfd-2c05e0ae9212", "node_type": "1", "metadata": {"window": "A \nNext questio n. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldwasser of Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good afternoon.  I want to go back to kind of especially Ontada. ", "original_text": "LLC  Q \nYeah. ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37eb4c5502b139a71206de0b79f54ee00e89733835e41c4caba329d65492cb65", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24d76ffc-e815-4db5-b6f0-48c1d9a2f448", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good afternoon.  I want to go back to kind of especially Ontada.  You talked, Brian, about sort of [ph] \ncontactor (00:52:08) relationship and sort of that cycle between providers and biopharma, et cetera.  So, for \nOntada, are payers customers as well? ", "original_text": "Good afternoon. "}, "hash": "842130f43d023d987b8daa80d8cf84b11ef547ab06d4a7edef295fd0d33598dc", "class_name": "RelatedNodeInfo"}}, "text": "Hi. ", "start_char_idx": 3202, "end_char_idx": 3206, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24d76ffc-e815-4db5-b6f0-48c1d9a2f448": {"__data__": {"id_": "24d76ffc-e815-4db5-b6f0-48c1d9a2f448", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good afternoon.  I want to go back to kind of especially Ontada.  You talked, Brian, about sort of [ph] \ncontactor (00:52:08) relationship and sort of that cycle between providers and biopharma, et cetera.  So, for \nOntada, are payers customers as well? ", "original_text": "Good afternoon. ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d4bb324-d13b-491a-9b23-44037291468e", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20cbda6bfd56661affb59a6962656da50d7ceb4c07b85f8b3cc6c6cf537c4cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ca3d230-9882-43cd-9e8e-5a2e8d8e6542", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldwasser of Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good afternoon.  I want to go back to kind of especially Ontada.  You talked, Brian, about sort of [ph] \ncontactor (00:52:08) relationship and sort of that cycle between providers and biopharma, et cetera. ", "original_text": "Hi. ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8553290ef1105166b6684e21b2b6a58c6c8ca6b2ae4c93f02e14ea365fd2c8bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e8b7018a-e1cd-4742-8742-c945281efee6", "node_type": "1", "metadata": {"window": "LLC  Q \nYeah.  Hi.  Good afternoon.  I want to go back to kind of especially Ontada.  You talked, Brian, about sort of [ph] \ncontactor (00:52:08) relationship and sort of that cycle between providers and biopharma, et cetera.  So, for \nOntada, are payers customers as well?  And is that sort of kind of like \u2013 and if not, is that sort of a growth \nopportunity that you're looking at? ", "original_text": "I want to go back to kind of especially Ontada. "}, "hash": "c003cee8f35c99c43f4abc02f9fd0fa1e3a73b129904f86126ec74f3b24374ed", "class_name": "RelatedNodeInfo"}}, "text": "Good afternoon. ", "start_char_idx": 3206, "end_char_idx": 3222, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e8b7018a-e1cd-4742-8742-c945281efee6": {"__data__": {"id_": "e8b7018a-e1cd-4742-8742-c945281efee6", "embedding": null, "metadata": {"window": "LLC  Q \nYeah.  Hi.  Good afternoon.  I want to go back to kind of especially Ontada.  You talked, Brian, about sort of [ph] \ncontactor (00:52:08) relationship and sort of that cycle between providers and biopharma, et cetera.  So, for \nOntada, are payers customers as well?  And is that sort of kind of like \u2013 and if not, is that sort of a growth \nopportunity that you're looking at? ", "original_text": "I want to go back to kind of especially Ontada. ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d4bb324-d13b-491a-9b23-44037291468e", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20cbda6bfd56661affb59a6962656da50d7ceb4c07b85f8b3cc6c6cf537c4cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24d76ffc-e815-4db5-b6f0-48c1d9a2f448", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good afternoon.  I want to go back to kind of especially Ontada.  You talked, Brian, about sort of [ph] \ncontactor (00:52:08) relationship and sort of that cycle between providers and biopharma, et cetera.  So, for \nOntada, are payers customers as well? ", "original_text": "Good afternoon. ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "801f8531670bf602a4d17cfaa4ad6d8cb21177570de33ff9857edb5e71dc6bfb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7641711e-8500-4f84-a3f3-165de428d36d", "node_type": "1", "metadata": {"window": "Hi.  Good afternoon.  I want to go back to kind of especially Ontada.  You talked, Brian, about sort of [ph] \ncontactor (00:52:08) relationship and sort of that cycle between providers and biopharma, et cetera.  So, for \nOntada, are payers customers as well?  And is that sort of kind of like \u2013 and if not, is that sort of a growth \nopportunity that you're looking at?  Just kind o f like interested in kind of like opportunities to grow that oncology \nbusiness beyond just the pipeline of drugs.  \n ", "original_text": "You talked, Brian, about sort of [ph] \ncontactor (00:52:08) relationship and sort of that cycle between providers and biopharma, et cetera. "}, "hash": "c742856587e26ac8a10af270fac7c7af597313e45f463a47f74387a9d0ee72e3", "class_name": "RelatedNodeInfo"}}, "text": "I want to go back to kind of especially Ontada. ", "start_char_idx": 3222, "end_char_idx": 3270, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7641711e-8500-4f84-a3f3-165de428d36d": {"__data__": {"id_": "7641711e-8500-4f84-a3f3-165de428d36d", "embedding": null, "metadata": {"window": "Hi.  Good afternoon.  I want to go back to kind of especially Ontada.  You talked, Brian, about sort of [ph] \ncontactor (00:52:08) relationship and sort of that cycle between providers and biopharma, et cetera.  So, for \nOntada, are payers customers as well?  And is that sort of kind of like \u2013 and if not, is that sort of a growth \nopportunity that you're looking at?  Just kind o f like interested in kind of like opportunities to grow that oncology \nbusiness beyond just the pipeline of drugs.  \n ", "original_text": "You talked, Brian, about sort of [ph] \ncontactor (00:52:08) relationship and sort of that cycle between providers and biopharma, et cetera. ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d4bb324-d13b-491a-9b23-44037291468e", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20cbda6bfd56661affb59a6962656da50d7ceb4c07b85f8b3cc6c6cf537c4cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e8b7018a-e1cd-4742-8742-c945281efee6", "node_type": "1", "metadata": {"window": "LLC  Q \nYeah.  Hi.  Good afternoon.  I want to go back to kind of especially Ontada.  You talked, Brian, about sort of [ph] \ncontactor (00:52:08) relationship and sort of that cycle between providers and biopharma, et cetera.  So, for \nOntada, are payers customers as well?  And is that sort of kind of like \u2013 and if not, is that sort of a growth \nopportunity that you're looking at? ", "original_text": "I want to go back to kind of especially Ontada. ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "273dbc812e7c45b77c039095feaf20630db3749c19f4158f587c47f1fdd66b66", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5bcca6a0-b8fd-4c99-8a41-c1f86652a085", "node_type": "1", "metadata": {"window": "Good afternoon.  I want to go back to kind of especially Ontada.  You talked, Brian, about sort of [ph] \ncontactor (00:52:08) relationship and sort of that cycle between providers and biopharma, et cetera.  So, for \nOntada, are payers customers as well?  And is that sort of kind of like \u2013 and if not, is that sort of a growth \nopportunity that you're looking at?  Just kind o f like interested in kind of like opportunities to grow that oncology \nbusiness beyond just the pipeline of drugs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "So, for \nOntada, are payers customers as well? "}, "hash": "bbd39ec9743b91124ad58a5afce83fc4687bf8ff356bd42e505d08ae73d59ae6", "class_name": "RelatedNodeInfo"}}, "text": "You talked, Brian, about sort of [ph] \ncontactor (00:52:08) relationship and sort of that cycle between providers and biopharma, et cetera. ", "start_char_idx": 3270, "end_char_idx": 3410, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5bcca6a0-b8fd-4c99-8a41-c1f86652a085": {"__data__": {"id_": "5bcca6a0-b8fd-4c99-8a41-c1f86652a085", "embedding": null, "metadata": {"window": "Good afternoon.  I want to go back to kind of especially Ontada.  You talked, Brian, about sort of [ph] \ncontactor (00:52:08) relationship and sort of that cycle between providers and biopharma, et cetera.  So, for \nOntada, are payers customers as well?  And is that sort of kind of like \u2013 and if not, is that sort of a growth \nopportunity that you're looking at?  Just kind o f like interested in kind of like opportunities to grow that oncology \nbusiness beyond just the pipeline of drugs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "So, for \nOntada, are payers customers as well? ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d4bb324-d13b-491a-9b23-44037291468e", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20cbda6bfd56661affb59a6962656da50d7ceb4c07b85f8b3cc6c6cf537c4cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7641711e-8500-4f84-a3f3-165de428d36d", "node_type": "1", "metadata": {"window": "Hi.  Good afternoon.  I want to go back to kind of especially Ontada.  You talked, Brian, about sort of [ph] \ncontactor (00:52:08) relationship and sort of that cycle between providers and biopharma, et cetera.  So, for \nOntada, are payers customers as well?  And is that sort of kind of like \u2013 and if not, is that sort of a growth \nopportunity that you're looking at?  Just kind o f like interested in kind of like opportunities to grow that oncology \nbusiness beyond just the pipeline of drugs.  \n ", "original_text": "You talked, Brian, about sort of [ph] \ncontactor (00:52:08) relationship and sort of that cycle between providers and biopharma, et cetera. ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2590494b73278baf1e134bfdbcd0e406ffe7ba146227692e4fa915fb2b70bf83", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf1eda71-9c95-4383-9847-8b58c73673c6", "node_type": "1", "metadata": {"window": "I want to go back to kind of especially Ontada.  You talked, Brian, about sort of [ph] \ncontactor (00:52:08) relationship and sort of that cycle between providers and biopharma, et cetera.  So, for \nOntada, are payers customers as well?  And is that sort of kind of like \u2013 and if not, is that sort of a growth \nopportunity that you're looking at?  Just kind o f like interested in kind of like opportunities to grow that oncology \nbusiness beyond just the pipeline of drugs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Ricky. ", "original_text": "And is that sort of kind of like \u2013 and if not, is that sort of a growth \nopportunity that you're looking at? "}, "hash": "b464f4cafd8173072b1b251579e3aedfc2a95c7b3f80b21e0c02ade313feefcc", "class_name": "RelatedNodeInfo"}}, "text": "So, for \nOntada, are payers customers as well? ", "start_char_idx": 3410, "end_char_idx": 3457, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf1eda71-9c95-4383-9847-8b58c73673c6": {"__data__": {"id_": "cf1eda71-9c95-4383-9847-8b58c73673c6", "embedding": null, "metadata": {"window": "I want to go back to kind of especially Ontada.  You talked, Brian, about sort of [ph] \ncontactor (00:52:08) relationship and sort of that cycle between providers and biopharma, et cetera.  So, for \nOntada, are payers customers as well?  And is that sort of kind of like \u2013 and if not, is that sort of a growth \nopportunity that you're looking at?  Just kind o f like interested in kind of like opportunities to grow that oncology \nbusiness beyond just the pipeline of drugs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Ricky. ", "original_text": "And is that sort of kind of like \u2013 and if not, is that sort of a growth \nopportunity that you're looking at? ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d4bb324-d13b-491a-9b23-44037291468e", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20cbda6bfd56661affb59a6962656da50d7ceb4c07b85f8b3cc6c6cf537c4cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5bcca6a0-b8fd-4c99-8a41-c1f86652a085", "node_type": "1", "metadata": {"window": "Good afternoon.  I want to go back to kind of especially Ontada.  You talked, Brian, about sort of [ph] \ncontactor (00:52:08) relationship and sort of that cycle between providers and biopharma, et cetera.  So, for \nOntada, are payers customers as well?  And is that sort of kind of like \u2013 and if not, is that sort of a growth \nopportunity that you're looking at?  Just kind o f like interested in kind of like opportunities to grow that oncology \nbusiness beyond just the pipeline of drugs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "So, for \nOntada, are payers customers as well? ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "904a99f796914d01e8e7f7bc13355b30c1ebf460ce610d790f6eeef1165e77d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81ab7d28-649e-47d6-bde6-80627ad6696d", "node_type": "1", "metadata": {"window": "You talked, Brian, about sort of [ph] \ncontactor (00:52:08) relationship and sort of that cycle between providers and biopharma, et cetera.  So, for \nOntada, are payers customers as well?  And is that sort of kind of like \u2013 and if not, is that sort of a growth \nopportunity that you're looking at?  Just kind o f like interested in kind of like opportunities to grow that oncology \nbusiness beyond just the pipeline of drugs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Ricky.  I think there is lots of interest in data and insi ghts and understanding patients and provider \nbehavior as it relates to these oncolytics. ", "original_text": "Just kind o f like interested in kind of like opportunities to grow that oncology \nbusiness beyond just the pipeline of drugs.  \n "}, "hash": "2a086c3caf1c2a5de95c67df29782bfc9192f5be9676e3e73190365501b1a100", "class_name": "RelatedNodeInfo"}}, "text": "And is that sort of kind of like \u2013 and if not, is that sort of a growth \nopportunity that you're looking at? ", "start_char_idx": 3457, "end_char_idx": 3566, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81ab7d28-649e-47d6-bde6-80627ad6696d": {"__data__": {"id_": "81ab7d28-649e-47d6-bde6-80627ad6696d", "embedding": null, "metadata": {"window": "You talked, Brian, about sort of [ph] \ncontactor (00:52:08) relationship and sort of that cycle between providers and biopharma, et cetera.  So, for \nOntada, are payers customers as well?  And is that sort of kind of like \u2013 and if not, is that sort of a growth \nopportunity that you're looking at?  Just kind o f like interested in kind of like opportunities to grow that oncology \nbusiness beyond just the pipeline of drugs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Ricky.  I think there is lots of interest in data and insi ghts and understanding patients and provider \nbehavior as it relates to these oncolytics. ", "original_text": "Just kind o f like interested in kind of like opportunities to grow that oncology \nbusiness beyond just the pipeline of drugs.  \n ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d4bb324-d13b-491a-9b23-44037291468e", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20cbda6bfd56661affb59a6962656da50d7ceb4c07b85f8b3cc6c6cf537c4cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf1eda71-9c95-4383-9847-8b58c73673c6", "node_type": "1", "metadata": {"window": "I want to go back to kind of especially Ontada.  You talked, Brian, about sort of [ph] \ncontactor (00:52:08) relationship and sort of that cycle between providers and biopharma, et cetera.  So, for \nOntada, are payers customers as well?  And is that sort of kind of like \u2013 and if not, is that sort of a growth \nopportunity that you're looking at?  Just kind o f like interested in kind of like opportunities to grow that oncology \nbusiness beyond just the pipeline of drugs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Ricky. ", "original_text": "And is that sort of kind of like \u2013 and if not, is that sort of a growth \nopportunity that you're looking at? ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "840c23ec0392f12ed932b4b61669d5c8bd4f68e05196e17baabf5d973200cb4f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a069db4d-88a9-4815-a945-dd015ddb1d94", "node_type": "1", "metadata": {"window": "So, for \nOntada, are payers customers as well?  And is that sort of kind of like \u2013 and if not, is that sort of a growth \nopportunity that you're looking at?  Just kind o f like interested in kind of like opportunities to grow that oncology \nbusiness beyond just the pipeline of drugs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Ricky.  I think there is lots of interest in data and insi ghts and understanding patients and provider \nbehavior as it relates to these oncolytics.  Our primary focus in Ontada is really to leverage the data, the working \nrelationships and the scale of our physician relationships to generate insights that help the d evelopment, the \ndiscovery and, ultimately, the launch and adoption of oncology products.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "8c4cc5a4211c3a32e5a69f4e3204769fb91991688ffd076275f04bac4b201b4d", "class_name": "RelatedNodeInfo"}}, "text": "Just kind o f like interested in kind of like opportunities to grow that oncology \nbusiness beyond just the pipeline of drugs.  \n ", "start_char_idx": 3566, "end_char_idx": 3696, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a069db4d-88a9-4815-a945-dd015ddb1d94": {"__data__": {"id_": "a069db4d-88a9-4815-a945-dd015ddb1d94", "embedding": null, "metadata": {"window": "So, for \nOntada, are payers customers as well?  And is that sort of kind of like \u2013 and if not, is that sort of a growth \nopportunity that you're looking at?  Just kind o f like interested in kind of like opportunities to grow that oncology \nbusiness beyond just the pipeline of drugs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Ricky.  I think there is lots of interest in data and insi ghts and understanding patients and provider \nbehavior as it relates to these oncolytics.  Our primary focus in Ontada is really to leverage the data, the working \nrelationships and the scale of our physician relationships to generate insights that help the d evelopment, the \ndiscovery and, ultimately, the launch and adoption of oncology products.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d4bb324-d13b-491a-9b23-44037291468e", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20cbda6bfd56661affb59a6962656da50d7ceb4c07b85f8b3cc6c6cf537c4cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81ab7d28-649e-47d6-bde6-80627ad6696d", "node_type": "1", "metadata": {"window": "You talked, Brian, about sort of [ph] \ncontactor (00:52:08) relationship and sort of that cycle between providers and biopharma, et cetera.  So, for \nOntada, are payers customers as well?  And is that sort of kind of like \u2013 and if not, is that sort of a growth \nopportunity that you're looking at?  Just kind o f like interested in kind of like opportunities to grow that oncology \nbusiness beyond just the pipeline of drugs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Ricky.  I think there is lots of interest in data and insi ghts and understanding patients and provider \nbehavior as it relates to these oncolytics. ", "original_text": "Just kind o f like interested in kind of like opportunities to grow that oncology \nbusiness beyond just the pipeline of drugs.  \n ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "33aab9ceeb087542cb642bd290487fefb125e4eac5ca71705e9817ecd5b39045", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2138c191-d192-447a-a8aa-55d3e0225a57", "node_type": "1", "metadata": {"window": "And is that sort of kind of like \u2013 and if not, is that sort of a growth \nopportunity that you're looking at?  Just kind o f like interested in kind of like opportunities to grow that oncology \nbusiness beyond just the pipeline of drugs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Ricky.  I think there is lots of interest in data and insi ghts and understanding patients and provider \nbehavior as it relates to these oncolytics.  Our primary focus in Ontada is really to leverage the data, the working \nrelationships and the scale of our physician relationships to generate insights that help the d evelopment, the \ndiscovery and, ultimately, the launch and adoption of oncology products.  \n \n And likewise, to take the early lessons we get in the research and the development and launch planning around \nthese products, to ensure that providers are most able t o react, adopt and get great patient outcomes from that. \n", "original_text": "A \nThank you, Ricky. "}, "hash": "d2b66043ef6149c7ef468094fefcf6db650fb915f340b95249fdf7469e9a4023", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 3696, "end_char_idx": 4040, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2138c191-d192-447a-a8aa-55d3e0225a57": {"__data__": {"id_": "2138c191-d192-447a-a8aa-55d3e0225a57", "embedding": null, "metadata": {"window": "And is that sort of kind of like \u2013 and if not, is that sort of a growth \nopportunity that you're looking at?  Just kind o f like interested in kind of like opportunities to grow that oncology \nbusiness beyond just the pipeline of drugs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Ricky.  I think there is lots of interest in data and insi ghts and understanding patients and provider \nbehavior as it relates to these oncolytics.  Our primary focus in Ontada is really to leverage the data, the working \nrelationships and the scale of our physician relationships to generate insights that help the d evelopment, the \ndiscovery and, ultimately, the launch and adoption of oncology products.  \n \n And likewise, to take the early lessons we get in the research and the development and launch planning around \nthese products, to ensure that providers are most able t o react, adopt and get great patient outcomes from that. \n", "original_text": "A \nThank you, Ricky. ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d4bb324-d13b-491a-9b23-44037291468e", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20cbda6bfd56661affb59a6962656da50d7ceb4c07b85f8b3cc6c6cf537c4cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a069db4d-88a9-4815-a945-dd015ddb1d94", "node_type": "1", "metadata": {"window": "So, for \nOntada, are payers customers as well?  And is that sort of kind of like \u2013 and if not, is that sort of a growth \nopportunity that you're looking at?  Just kind o f like interested in kind of like opportunities to grow that oncology \nbusiness beyond just the pipeline of drugs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Ricky.  I think there is lots of interest in data and insi ghts and understanding patients and provider \nbehavior as it relates to these oncolytics.  Our primary focus in Ontada is really to leverage the data, the working \nrelationships and the scale of our physician relationships to generate insights that help the d evelopment, the \ndiscovery and, ultimately, the launch and adoption of oncology products.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "24b18ae2d16447f1252ee9151d8b45513924790c36218c43ed350c71261da854", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "816eb37b-11fe-4ab2-a7e7-7b87f9191d7f", "node_type": "1", "metadata": {"window": "Just kind o f like interested in kind of like opportunities to grow that oncology \nbusiness beyond just the pipeline of drugs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Ricky.  I think there is lots of interest in data and insi ghts and understanding patients and provider \nbehavior as it relates to these oncolytics.  Our primary focus in Ontada is really to leverage the data, the working \nrelationships and the scale of our physician relationships to generate insights that help the d evelopment, the \ndiscovery and, ultimately, the launch and adoption of oncology products.  \n \n And likewise, to take the early lessons we get in the research and the development and launch planning around \nthese products, to ensure that providers are most able t o react, adopt and get great patient outcomes from that. \n So, we see it as a very virtuous cycle, really anchored in provider and in the biopharma companies. ", "original_text": "I think there is lots of interest in data and insi ghts and understanding patients and provider \nbehavior as it relates to these oncolytics. "}, "hash": "967b669f5eb519af006fff3178ba4819b16b2bcabe709823f8ec0332ab79ea1b", "class_name": "RelatedNodeInfo"}}, "text": "A \nThank you, Ricky. ", "start_char_idx": 4040, "end_char_idx": 4061, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "816eb37b-11fe-4ab2-a7e7-7b87f9191d7f": {"__data__": {"id_": "816eb37b-11fe-4ab2-a7e7-7b87f9191d7f", "embedding": null, "metadata": {"window": "Just kind o f like interested in kind of like opportunities to grow that oncology \nbusiness beyond just the pipeline of drugs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Ricky.  I think there is lots of interest in data and insi ghts and understanding patients and provider \nbehavior as it relates to these oncolytics.  Our primary focus in Ontada is really to leverage the data, the working \nrelationships and the scale of our physician relationships to generate insights that help the d evelopment, the \ndiscovery and, ultimately, the launch and adoption of oncology products.  \n \n And likewise, to take the early lessons we get in the research and the development and launch planning around \nthese products, to ensure that providers are most able t o react, adopt and get great patient outcomes from that. \n So, we see it as a very virtuous cycle, really anchored in provider and in the biopharma companies. ", "original_text": "I think there is lots of interest in data and insi ghts and understanding patients and provider \nbehavior as it relates to these oncolytics. ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d4bb324-d13b-491a-9b23-44037291468e", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20cbda6bfd56661affb59a6962656da50d7ceb4c07b85f8b3cc6c6cf537c4cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2138c191-d192-447a-a8aa-55d3e0225a57", "node_type": "1", "metadata": {"window": "And is that sort of kind of like \u2013 and if not, is that sort of a growth \nopportunity that you're looking at?  Just kind o f like interested in kind of like opportunities to grow that oncology \nbusiness beyond just the pipeline of drugs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Ricky.  I think there is lots of interest in data and insi ghts and understanding patients and provider \nbehavior as it relates to these oncolytics.  Our primary focus in Ontada is really to leverage the data, the working \nrelationships and the scale of our physician relationships to generate insights that help the d evelopment, the \ndiscovery and, ultimately, the launch and adoption of oncology products.  \n \n And likewise, to take the early lessons we get in the research and the development and launch planning around \nthese products, to ensure that providers are most able t o react, adopt and get great patient outcomes from that. \n", "original_text": "A \nThank you, Ricky. ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c7e5fb9e5305212c203b196a79924482b7ee03bd7df143fd31d481c97ec54f0b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7533a5bd-c356-4c06-89ce-d6851e6a871c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Ricky.  I think there is lots of interest in data and insi ghts and understanding patients and provider \nbehavior as it relates to these oncolytics.  Our primary focus in Ontada is really to leverage the data, the working \nrelationships and the scale of our physician relationships to generate insights that help the d evelopment, the \ndiscovery and, ultimately, the launch and adoption of oncology products.  \n \n And likewise, to take the early lessons we get in the research and the development and launch planning around \nthese products, to ensure that providers are most able t o react, adopt and get great patient outcomes from that. \n So, we see it as a very virtuous cycle, really anchored in provider and in the biopharma companies.  But there may \nbe several other interested parties in the data, insights that we can generate, and t hat's something that we'd \ncertainly consider as the business matures.  ", "original_text": "Our primary focus in Ontada is really to leverage the data, the working \nrelationships and the scale of our physician relationships to generate insights that help the d evelopment, the \ndiscovery and, ultimately, the launch and adoption of oncology products.  \n \n"}, "hash": "7a66cc31ac4c7b36323f7f12f5e979ca88a97cf9c8868b73636eea15b51cc0f7", "class_name": "RelatedNodeInfo"}}, "text": "I think there is lots of interest in data and insi ghts and understanding patients and provider \nbehavior as it relates to these oncolytics. ", "start_char_idx": 4061, "end_char_idx": 4202, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7533a5bd-c356-4c06-89ce-d6851e6a871c": {"__data__": {"id_": "7533a5bd-c356-4c06-89ce-d6851e6a871c", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Ricky.  I think there is lots of interest in data and insi ghts and understanding patients and provider \nbehavior as it relates to these oncolytics.  Our primary focus in Ontada is really to leverage the data, the working \nrelationships and the scale of our physician relationships to generate insights that help the d evelopment, the \ndiscovery and, ultimately, the launch and adoption of oncology products.  \n \n And likewise, to take the early lessons we get in the research and the development and launch planning around \nthese products, to ensure that providers are most able t o react, adopt and get great patient outcomes from that. \n So, we see it as a very virtuous cycle, really anchored in provider and in the biopharma companies.  But there may \nbe several other interested parties in the data, insights that we can generate, and t hat's something that we'd \ncertainly consider as the business matures.  ", "original_text": "Our primary focus in Ontada is really to leverage the data, the working \nrelationships and the scale of our physician relationships to generate insights that help the d evelopment, the \ndiscovery and, ultimately, the launch and adoption of oncology products.  \n \n", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d4bb324-d13b-491a-9b23-44037291468e", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20cbda6bfd56661affb59a6962656da50d7ceb4c07b85f8b3cc6c6cf537c4cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "816eb37b-11fe-4ab2-a7e7-7b87f9191d7f", "node_type": "1", "metadata": {"window": "Just kind o f like interested in kind of like opportunities to grow that oncology \nbusiness beyond just the pipeline of drugs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Ricky.  I think there is lots of interest in data and insi ghts and understanding patients and provider \nbehavior as it relates to these oncolytics.  Our primary focus in Ontada is really to leverage the data, the working \nrelationships and the scale of our physician relationships to generate insights that help the d evelopment, the \ndiscovery and, ultimately, the launch and adoption of oncology products.  \n \n And likewise, to take the early lessons we get in the research and the development and launch planning around \nthese products, to ensure that providers are most able t o react, adopt and get great patient outcomes from that. \n So, we see it as a very virtuous cycle, really anchored in provider and in the biopharma companies. ", "original_text": "I think there is lots of interest in data and insi ghts and understanding patients and provider \nbehavior as it relates to these oncolytics. ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "847efd1a1466338517609b80c76f3308a6a13b050e7f519cb12af0252804d7b6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2be9c89-a25d-45c8-a33e-e7064907b612", "node_type": "1", "metadata": {"window": "A \nThank you, Ricky.  I think there is lots of interest in data and insi ghts and understanding patients and provider \nbehavior as it relates to these oncolytics.  Our primary focus in Ontada is really to leverage the data, the working \nrelationships and the scale of our physician relationships to generate insights that help the d evelopment, the \ndiscovery and, ultimately, the launch and adoption of oncology products.  \n \n And likewise, to take the early lessons we get in the research and the development and launch planning around \nthese products, to ensure that providers are most able t o react, adopt and get great patient outcomes from that. \n So, we see it as a very virtuous cycle, really anchored in provider and in the biopharma companies.  But there may \nbe several other interested parties in the data, insights that we can generate, and t hat's something that we'd \ncertainly consider as the business matures.  ", "original_text": "And likewise, to take the early lessons we get in the research and the development and launch planning around \nthese products, to ensure that providers are most able t o react, adopt and get great patient outcomes from that. \n"}, "hash": "3c3c65e46f971db69b8116823fcdb250758b8638f816da0d3cfcec3c40700fc8", "class_name": "RelatedNodeInfo"}}, "text": "Our primary focus in Ontada is really to leverage the data, the working \nrelationships and the scale of our physician relationships to generate insights that help the d evelopment, the \ndiscovery and, ultimately, the launch and adoption of oncology products.  \n \n", "start_char_idx": 4202, "end_char_idx": 4465, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2be9c89-a25d-45c8-a33e-e7064907b612": {"__data__": {"id_": "d2be9c89-a25d-45c8-a33e-e7064907b612", "embedding": null, "metadata": {"window": "A \nThank you, Ricky.  I think there is lots of interest in data and insi ghts and understanding patients and provider \nbehavior as it relates to these oncolytics.  Our primary focus in Ontada is really to leverage the data, the working \nrelationships and the scale of our physician relationships to generate insights that help the d evelopment, the \ndiscovery and, ultimately, the launch and adoption of oncology products.  \n \n And likewise, to take the early lessons we get in the research and the development and launch planning around \nthese products, to ensure that providers are most able t o react, adopt and get great patient outcomes from that. \n So, we see it as a very virtuous cycle, really anchored in provider and in the biopharma companies.  But there may \nbe several other interested parties in the data, insights that we can generate, and t hat's something that we'd \ncertainly consider as the business matures.  ", "original_text": "And likewise, to take the early lessons we get in the research and the development and launch planning around \nthese products, to ensure that providers are most able t o react, adopt and get great patient outcomes from that. \n", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d4bb324-d13b-491a-9b23-44037291468e", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20cbda6bfd56661affb59a6962656da50d7ceb4c07b85f8b3cc6c6cf537c4cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7533a5bd-c356-4c06-89ce-d6851e6a871c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Ricky.  I think there is lots of interest in data and insi ghts and understanding patients and provider \nbehavior as it relates to these oncolytics.  Our primary focus in Ontada is really to leverage the data, the working \nrelationships and the scale of our physician relationships to generate insights that help the d evelopment, the \ndiscovery and, ultimately, the launch and adoption of oncology products.  \n \n And likewise, to take the early lessons we get in the research and the development and launch planning around \nthese products, to ensure that providers are most able t o react, adopt and get great patient outcomes from that. \n So, we see it as a very virtuous cycle, really anchored in provider and in the biopharma companies.  But there may \nbe several other interested parties in the data, insights that we can generate, and t hat's something that we'd \ncertainly consider as the business matures.  ", "original_text": "Our primary focus in Ontada is really to leverage the data, the working \nrelationships and the scale of our physician relationships to generate insights that help the d evelopment, the \ndiscovery and, ultimately, the launch and adoption of oncology products.  \n \n", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a76f319b22c3571f9d32a322d6b608dfa95f01804f240ac08ce0dc62ec6602c7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c1cf53e-4f99-49de-8280-7f0e9226ce80", "node_type": "1", "metadata": {"window": "I think there is lots of interest in data and insi ghts and understanding patients and provider \nbehavior as it relates to these oncolytics.  Our primary focus in Ontada is really to leverage the data, the working \nrelationships and the scale of our physician relationships to generate insights that help the d evelopment, the \ndiscovery and, ultimately, the launch and adoption of oncology products.  \n \n And likewise, to take the early lessons we get in the research and the development and launch planning around \nthese products, to ensure that providers are most able t o react, adopt and get great patient outcomes from that. \n So, we see it as a very virtuous cycle, really anchored in provider and in the biopharma companies.  But there may \nbe several other interested parties in the data, insights that we can generate, and t hat's something that we'd \ncertainly consider as the business matures.  ", "original_text": "So, we see it as a very virtuous cycle, really anchored in provider and in the biopharma companies. "}, "hash": "fc8fa80c049f204944708618973b9ec065ede2649c705c26a8f0fd5600af676b", "class_name": "RelatedNodeInfo"}}, "text": "And likewise, to take the early lessons we get in the research and the development and launch planning around \nthese products, to ensure that providers are most able t o react, adopt and get great patient outcomes from that. \n", "start_char_idx": 4465, "end_char_idx": 4691, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c1cf53e-4f99-49de-8280-7f0e9226ce80": {"__data__": {"id_": "3c1cf53e-4f99-49de-8280-7f0e9226ce80", "embedding": null, "metadata": {"window": "I think there is lots of interest in data and insi ghts and understanding patients and provider \nbehavior as it relates to these oncolytics.  Our primary focus in Ontada is really to leverage the data, the working \nrelationships and the scale of our physician relationships to generate insights that help the d evelopment, the \ndiscovery and, ultimately, the launch and adoption of oncology products.  \n \n And likewise, to take the early lessons we get in the research and the development and launch planning around \nthese products, to ensure that providers are most able t o react, adopt and get great patient outcomes from that. \n So, we see it as a very virtuous cycle, really anchored in provider and in the biopharma companies.  But there may \nbe several other interested parties in the data, insights that we can generate, and t hat's something that we'd \ncertainly consider as the business matures.  ", "original_text": "So, we see it as a very virtuous cycle, really anchored in provider and in the biopharma companies. ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d4bb324-d13b-491a-9b23-44037291468e", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20cbda6bfd56661affb59a6962656da50d7ceb4c07b85f8b3cc6c6cf537c4cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2be9c89-a25d-45c8-a33e-e7064907b612", "node_type": "1", "metadata": {"window": "A \nThank you, Ricky.  I think there is lots of interest in data and insi ghts and understanding patients and provider \nbehavior as it relates to these oncolytics.  Our primary focus in Ontada is really to leverage the data, the working \nrelationships and the scale of our physician relationships to generate insights that help the d evelopment, the \ndiscovery and, ultimately, the launch and adoption of oncology products.  \n \n And likewise, to take the early lessons we get in the research and the development and launch planning around \nthese products, to ensure that providers are most able t o react, adopt and get great patient outcomes from that. \n So, we see it as a very virtuous cycle, really anchored in provider and in the biopharma companies.  But there may \nbe several other interested parties in the data, insights that we can generate, and t hat's something that we'd \ncertainly consider as the business matures.  ", "original_text": "And likewise, to take the early lessons we get in the research and the development and launch planning around \nthese products, to ensure that providers are most able t o react, adopt and get great patient outcomes from that. \n", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a1e51feadf315568f278fa6c48b6298c3b1c2adc76271dc4505e16bfa3f23b9d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0e3accd-cc39-467b-8ca9-a9beb9a0867e", "node_type": "1", "metadata": {"window": "Our primary focus in Ontada is really to leverage the data, the working \nrelationships and the scale of our physician relationships to generate insights that help the d evelopment, the \ndiscovery and, ultimately, the launch and adoption of oncology products.  \n \n And likewise, to take the early lessons we get in the research and the development and launch planning around \nthese products, to ensure that providers are most able t o react, adopt and get great patient outcomes from that. \n So, we see it as a very virtuous cycle, really anchored in provider and in the biopharma companies.  But there may \nbe several other interested parties in the data, insights that we can generate, and t hat's something that we'd \ncertainly consider as the business matures.  ", "original_text": "But there may \nbe several other interested parties in the data, insights that we can generate, and t hat's something that we'd \ncertainly consider as the business matures.  "}, "hash": "b069ae2b9584e9ce5b4fd8b696db480c422d24e4dc2a6ac89ae2179233dd3345", "class_name": "RelatedNodeInfo"}}, "text": "So, we see it as a very virtuous cycle, really anchored in provider and in the biopharma companies. ", "start_char_idx": 4691, "end_char_idx": 4791, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0e3accd-cc39-467b-8ca9-a9beb9a0867e": {"__data__": {"id_": "d0e3accd-cc39-467b-8ca9-a9beb9a0867e", "embedding": null, "metadata": {"window": "Our primary focus in Ontada is really to leverage the data, the working \nrelationships and the scale of our physician relationships to generate insights that help the d evelopment, the \ndiscovery and, ultimately, the launch and adoption of oncology products.  \n \n And likewise, to take the early lessons we get in the research and the development and launch planning around \nthese products, to ensure that providers are most able t o react, adopt and get great patient outcomes from that. \n So, we see it as a very virtuous cycle, really anchored in provider and in the biopharma companies.  But there may \nbe several other interested parties in the data, insights that we can generate, and t hat's something that we'd \ncertainly consider as the business matures.  ", "original_text": "But there may \nbe several other interested parties in the data, insights that we can generate, and t hat's something that we'd \ncertainly consider as the business matures.  ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d4bb324-d13b-491a-9b23-44037291468e", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20cbda6bfd56661affb59a6962656da50d7ceb4c07b85f8b3cc6c6cf537c4cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c1cf53e-4f99-49de-8280-7f0e9226ce80", "node_type": "1", "metadata": {"window": "I think there is lots of interest in data and insi ghts and understanding patients and provider \nbehavior as it relates to these oncolytics.  Our primary focus in Ontada is really to leverage the data, the working \nrelationships and the scale of our physician relationships to generate insights that help the d evelopment, the \ndiscovery and, ultimately, the launch and adoption of oncology products.  \n \n And likewise, to take the early lessons we get in the research and the development and launch planning around \nthese products, to ensure that providers are most able t o react, adopt and get great patient outcomes from that. \n So, we see it as a very virtuous cycle, really anchored in provider and in the biopharma companies.  But there may \nbe several other interested parties in the data, insights that we can generate, and t hat's something that we'd \ncertainly consider as the business matures.  ", "original_text": "So, we see it as a very virtuous cycle, really anchored in provider and in the biopharma companies. ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cb39e03d8ed7742e481250bbd07574e77d9fef1c5c8122b6f4bb7fd8a45a5e3d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ae976db-a92b-479a-95b3-b954da19991e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "original_text": "McKesson Corp.  "}, "hash": "faa2b418a2bdb630d01b2aa12def9b4f655fbdcd3bb655f06bed2379fe77a624", "class_name": "RelatedNodeInfo"}}, "text": "But there may \nbe several other interested parties in the data, insights that we can generate, and t hat's something that we'd \ncertainly consider as the business matures.  ", "start_char_idx": 4791, "end_char_idx": 4964, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ae976db-a92b-479a-95b3-b954da19991e": {"__data__": {"id_": "1ae976db-a92b-479a-95b3-b954da19991e", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03733b2e-50cf-454d-ad00-c59834e71dbe", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05c3c367d9d46d218a59e914d0733d7e37ccaa9d4a611b35f16820b8aba05ff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0e3accd-cc39-467b-8ca9-a9beb9a0867e", "node_type": "1", "metadata": {"window": "Our primary focus in Ontada is really to leverage the data, the working \nrelationships and the scale of our physician relationships to generate insights that help the d evelopment, the \ndiscovery and, ultimately, the launch and adoption of oncology products.  \n \n And likewise, to take the early lessons we get in the research and the development and launch planning around \nthese products, to ensure that providers are most able t o react, adopt and get great patient outcomes from that. \n So, we see it as a very virtuous cycle, really anchored in provider and in the biopharma companies.  But there may \nbe several other interested parties in the data, insights that we can generate, and t hat's something that we'd \ncertainly consider as the business matures.  ", "original_text": "But there may \nbe several other interested parties in the data, insights that we can generate, and t hat's something that we'd \ncertainly consider as the business matures.  ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7d659ace7438b3e9686aac72d1b11214001fd72974b0bd3407aaf61fc56e3c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fbe2dc6c-7dd1-4acf-9dea-fb7b981b274d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Jailendra Singh of Credit Suisse.  \n ", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  "}, "hash": "b097a54996811257e35b2b31fadc8f6932dc2e9a771e81cc79c73cd48bef8330", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fbe2dc6c-7dd1-4acf-9dea-fb7b981b274d": {"__data__": {"id_": "fbe2dc6c-7dd1-4acf-9dea-fb7b981b274d", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Jailendra Singh of Credit Suisse.  \n ", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03733b2e-50cf-454d-ad00-c59834e71dbe", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05c3c367d9d46d218a59e914d0733d7e37ccaa9d4a611b35f16820b8aba05ff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ae976db-a92b-479a-95b3-b954da19991e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d72a266b8601d1c5f2ffbf0e4677b5e794e36d2b67f8a157404c681c41a1bc7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d7d4d3a6-884f-4f04-8d1e-7855ed050df3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Jailendra Singh of Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAdam Heussner  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nHi. ", "original_text": "A \nOperator, we have time for one more question.  \n "}, "hash": "1131924b3a79488c38f99df68b0614fc6fee71f182f4bd94a9d934882e03dfc9", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "start_char_idx": 16, "end_char_idx": 283, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d7d4d3a6-884f-4f04-8d1e-7855ed050df3": {"__data__": {"id_": "d7d4d3a6-884f-4f04-8d1e-7855ed050df3", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Jailendra Singh of Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAdam Heussner  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nHi. ", "original_text": "A \nOperator, we have time for one more question.  \n ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03733b2e-50cf-454d-ad00-c59834e71dbe", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05c3c367d9d46d218a59e914d0733d7e37ccaa9d4a611b35f16820b8aba05ff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fbe2dc6c-7dd1-4acf-9dea-fb7b981b274d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Jailendra Singh of Credit Suisse.  \n ", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "95000bb74f7d84aaf9c5b4f5cc58bd7c5a9bf314fd3d328b4cc74c933cdfa123", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c69de311-f58d-4755-a083-8a8623c02954", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Jailendra Singh of Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAdam Heussner  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nHi.  This is Adam on for Jailendra today. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. "}, "hash": "ef8ac64c9cbba3e5f9bf1983b50784f16d73e9dc62558de497b427a7149023c8", "class_name": "RelatedNodeInfo"}}, "text": "A \nOperator, we have time for one more question.  \n ", "start_char_idx": 283, "end_char_idx": 335, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c69de311-f58d-4755-a083-8a8623c02954": {"__data__": {"id_": "c69de311-f58d-4755-a083-8a8623c02954", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Jailendra Singh of Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAdam Heussner  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nHi.  This is Adam on for Jailendra today. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03733b2e-50cf-454d-ad00-c59834e71dbe", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05c3c367d9d46d218a59e914d0733d7e37ccaa9d4a611b35f16820b8aba05ff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d7d4d3a6-884f-4f04-8d1e-7855ed050df3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Jailendra Singh of Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAdam Heussner  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nHi. ", "original_text": "A \nOperator, we have time for one more question.  \n ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfa0ea80ff60f917cbd4331e6f3e07b98f0dd8a322c154512b9dba8e5df09428", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "14cec6d0-3587-4d1e-9994-126d5424878f", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Jailendra Singh of Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAdam Heussner  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nHi.  This is Adam on for Jailendra today.  Thanks for taking the question. ", "original_text": "That question will come from Jailendra Singh of Credit Suisse.  \n "}, "hash": "39476c4f468152dcd99c15e13f1974b882eff3516e5457d8ea2444e3d1ad75e8", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "start_char_idx": 335, "end_char_idx": 631, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "14cec6d0-3587-4d1e-9994-126d5424878f": {"__data__": {"id_": "14cec6d0-3587-4d1e-9994-126d5424878f", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Jailendra Singh of Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAdam Heussner  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nHi.  This is Adam on for Jailendra today.  Thanks for taking the question. ", "original_text": "That question will come from Jailendra Singh of Credit Suisse.  \n ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03733b2e-50cf-454d-ad00-c59834e71dbe", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05c3c367d9d46d218a59e914d0733d7e37ccaa9d4a611b35f16820b8aba05ff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c69de311-f58d-4755-a083-8a8623c02954", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Jailendra Singh of Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAdam Heussner  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nHi.  This is Adam on for Jailendra today. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "07cf1b32b18659d066f64b3dc407b23c2a2fdf01f85925c09526c3b4e023b430", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b0ff3fe-584a-4211-8826-988e09b050b9", "node_type": "1", "metadata": {"window": "A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Jailendra Singh of Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAdam Heussner  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nHi.  This is Adam on for Jailendra today.  Thanks for taking the question.  Just wanted to follow -up on the \nassumption of a return to pre -COVID uti lization in the second half of your fiscal year. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAdam Heussner  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nHi. "}, "hash": "1af41d6ebc398937b1b33bfd31c7199e10a90f11967109f6b2166bf166405d4d", "class_name": "RelatedNodeInfo"}}, "text": "That question will come from Jailendra Singh of Credit Suisse.  \n ", "start_char_idx": 631, "end_char_idx": 697, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b0ff3fe-584a-4211-8826-988e09b050b9": {"__data__": {"id_": "7b0ff3fe-584a-4211-8826-988e09b050b9", "embedding": null, "metadata": {"window": "A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Jailendra Singh of Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAdam Heussner  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nHi.  This is Adam on for Jailendra today.  Thanks for taking the question.  Just wanted to follow -up on the \nassumption of a return to pre -COVID uti lization in the second half of your fiscal year. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAdam Heussner  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nHi. ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03733b2e-50cf-454d-ad00-c59834e71dbe", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05c3c367d9d46d218a59e914d0733d7e37ccaa9d4a611b35f16820b8aba05ff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "14cec6d0-3587-4d1e-9994-126d5424878f", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Jailendra Singh of Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAdam Heussner  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nHi.  This is Adam on for Jailendra today.  Thanks for taking the question. ", "original_text": "That question will come from Jailendra Singh of Credit Suisse.  \n ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b987db5740e3f7fa834d9ff9f0d31d33024c200888f6f5364b1a6273f5bd9fbe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81f1d316-73ad-4f99-8b38-8b9d6882f6a0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Jailendra Singh of Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAdam Heussner  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nHi.  This is Adam on for Jailendra today.  Thanks for taking the question.  Just wanted to follow -up on the \nassumption of a return to pre -COVID uti lization in the second half of your fiscal year.  One of your competitors, this \nmorning, think it is \u2013 they saw a return to pre -COVID prescription utilization in the June quarter. ", "original_text": "This is Adam on for Jailendra today. "}, "hash": "d3826aba3df2fd02d43eafd690d1b3947d965789dea839bcfee330b47c6f4938", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAdam Heussner  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nHi. ", "start_char_idx": 697, "end_char_idx": 1037, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81f1d316-73ad-4f99-8b38-8b9d6882f6a0": {"__data__": {"id_": "81f1d316-73ad-4f99-8b38-8b9d6882f6a0", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Jailendra Singh of Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAdam Heussner  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nHi.  This is Adam on for Jailendra today.  Thanks for taking the question.  Just wanted to follow -up on the \nassumption of a return to pre -COVID uti lization in the second half of your fiscal year.  One of your competitors, this \nmorning, think it is \u2013 they saw a return to pre -COVID prescription utilization in the June quarter. ", "original_text": "This is Adam on for Jailendra today. ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03733b2e-50cf-454d-ad00-c59834e71dbe", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05c3c367d9d46d218a59e914d0733d7e37ccaa9d4a611b35f16820b8aba05ff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b0ff3fe-584a-4211-8826-988e09b050b9", "node_type": "1", "metadata": {"window": "A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Jailendra Singh of Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAdam Heussner  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nHi.  This is Adam on for Jailendra today.  Thanks for taking the question.  Just wanted to follow -up on the \nassumption of a return to pre -COVID uti lization in the second half of your fiscal year. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAdam Heussner  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nHi. ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "42a6260795d0452f388aa460f3ead8452cd9c9857e6c1c7f90af6d8ffb936c74", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2a2edb3-0053-4205-b0df-c4b745ca628d", "node_type": "1", "metadata": {"window": "That question will come from Jailendra Singh of Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAdam Heussner  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nHi.  This is Adam on for Jailendra today.  Thanks for taking the question.  Just wanted to follow -up on the \nassumption of a return to pre -COVID uti lization in the second half of your fiscal year.  One of your competitors, this \nmorning, think it is \u2013 they saw a return to pre -COVID prescription utilization in the June quarter.  So, I mean, is the \ndifference in comments just a function of customer or chan nel mix or, I guess, the way pre -COVID is being \nmeasured? ", "original_text": "Thanks for taking the question. "}, "hash": "7f2406162e6de0f9633af57886d9c8eefe0bdfd37eb9154ee7d3273b3b52a122", "class_name": "RelatedNodeInfo"}}, "text": "This is Adam on for Jailendra today. ", "start_char_idx": 1037, "end_char_idx": 1074, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2a2edb3-0053-4205-b0df-c4b745ca628d": {"__data__": {"id_": "c2a2edb3-0053-4205-b0df-c4b745ca628d", "embedding": null, "metadata": {"window": "That question will come from Jailendra Singh of Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAdam Heussner  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nHi.  This is Adam on for Jailendra today.  Thanks for taking the question.  Just wanted to follow -up on the \nassumption of a return to pre -COVID uti lization in the second half of your fiscal year.  One of your competitors, this \nmorning, think it is \u2013 they saw a return to pre -COVID prescription utilization in the June quarter.  So, I mean, is the \ndifference in comments just a function of customer or chan nel mix or, I guess, the way pre -COVID is being \nmeasured? ", "original_text": "Thanks for taking the question. ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03733b2e-50cf-454d-ad00-c59834e71dbe", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05c3c367d9d46d218a59e914d0733d7e37ccaa9d4a611b35f16820b8aba05ff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81f1d316-73ad-4f99-8b38-8b9d6882f6a0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Jailendra Singh of Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAdam Heussner  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nHi.  This is Adam on for Jailendra today.  Thanks for taking the question.  Just wanted to follow -up on the \nassumption of a return to pre -COVID uti lization in the second half of your fiscal year.  One of your competitors, this \nmorning, think it is \u2013 they saw a return to pre -COVID prescription utilization in the June quarter. ", "original_text": "This is Adam on for Jailendra today. ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "584f21b4960f9dad484f2452495abf4b8b4ead5722339b69e92b0f1e21201cb9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0dc30ff-098a-42b3-b3a8-73a2201b815d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAdam Heussner  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nHi.  This is Adam on for Jailendra today.  Thanks for taking the question.  Just wanted to follow -up on the \nassumption of a return to pre -COVID uti lization in the second half of your fiscal year.  One of your competitors, this \nmorning, think it is \u2013 they saw a return to pre -COVID prescription utilization in the June quarter.  So, I mean, is the \ndifference in comments just a function of customer or chan nel mix or, I guess, the way pre -COVID is being \nmeasured?  Or what else should we be thinking about when attempting to bridge those comments? ", "original_text": "Just wanted to follow -up on the \nassumption of a return to pre -COVID uti lization in the second half of your fiscal year. "}, "hash": "c39d02d342d5e5233b6da581d92c5c9cb710876c2fbe0d75aaa9f54ed417c3af", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking the question. ", "start_char_idx": 1074, "end_char_idx": 1106, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0dc30ff-098a-42b3-b3a8-73a2201b815d": {"__data__": {"id_": "f0dc30ff-098a-42b3-b3a8-73a2201b815d", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAdam Heussner  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nHi.  This is Adam on for Jailendra today.  Thanks for taking the question.  Just wanted to follow -up on the \nassumption of a return to pre -COVID uti lization in the second half of your fiscal year.  One of your competitors, this \nmorning, think it is \u2013 they saw a return to pre -COVID prescription utilization in the June quarter.  So, I mean, is the \ndifference in comments just a function of customer or chan nel mix or, I guess, the way pre -COVID is being \nmeasured?  Or what else should we be thinking about when attempting to bridge those comments? ", "original_text": "Just wanted to follow -up on the \nassumption of a return to pre -COVID uti lization in the second half of your fiscal year. ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03733b2e-50cf-454d-ad00-c59834e71dbe", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05c3c367d9d46d218a59e914d0733d7e37ccaa9d4a611b35f16820b8aba05ff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2a2edb3-0053-4205-b0df-c4b745ca628d", "node_type": "1", "metadata": {"window": "That question will come from Jailendra Singh of Credit Suisse.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAdam Heussner  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nHi.  This is Adam on for Jailendra today.  Thanks for taking the question.  Just wanted to follow -up on the \nassumption of a return to pre -COVID uti lization in the second half of your fiscal year.  One of your competitors, this \nmorning, think it is \u2013 they saw a return to pre -COVID prescription utilization in the June quarter.  So, I mean, is the \ndifference in comments just a function of customer or chan nel mix or, I guess, the way pre -COVID is being \nmeasured? ", "original_text": "Thanks for taking the question. ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b9bed6322549ff62ce2044230e6e08ccad3d281047ff841c19760bf9a402abf2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca4361d5-04cd-43ab-a62b-f670d6b07cbe", "node_type": "1", "metadata": {"window": "This is Adam on for Jailendra today.  Thanks for taking the question.  Just wanted to follow -up on the \nassumption of a return to pre -COVID uti lization in the second half of your fiscal year.  One of your competitors, this \nmorning, think it is \u2013 they saw a return to pre -COVID prescription utilization in the June quarter.  So, I mean, is the \ndifference in comments just a function of customer or chan nel mix or, I guess, the way pre -COVID is being \nmeasured?  Or what else should we be thinking about when attempting to bridge those comments?  Thanks.  \n ", "original_text": "One of your competitors, this \nmorning, think it is \u2013 they saw a return to pre -COVID prescription utilization in the June quarter. "}, "hash": "8983cd3a98bebc80d2b9785d9bf8f8832abaf251aac44b686d5c00dc90abfc27", "class_name": "RelatedNodeInfo"}}, "text": "Just wanted to follow -up on the \nassumption of a return to pre -COVID uti lization in the second half of your fiscal year. ", "start_char_idx": 1106, "end_char_idx": 1230, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca4361d5-04cd-43ab-a62b-f670d6b07cbe": {"__data__": {"id_": "ca4361d5-04cd-43ab-a62b-f670d6b07cbe", "embedding": null, "metadata": {"window": "This is Adam on for Jailendra today.  Thanks for taking the question.  Just wanted to follow -up on the \nassumption of a return to pre -COVID uti lization in the second half of your fiscal year.  One of your competitors, this \nmorning, think it is \u2013 they saw a return to pre -COVID prescription utilization in the June quarter.  So, I mean, is the \ndifference in comments just a function of customer or chan nel mix or, I guess, the way pre -COVID is being \nmeasured?  Or what else should we be thinking about when attempting to bridge those comments?  Thanks.  \n ", "original_text": "One of your competitors, this \nmorning, think it is \u2013 they saw a return to pre -COVID prescription utilization in the June quarter. ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03733b2e-50cf-454d-ad00-c59834e71dbe", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05c3c367d9d46d218a59e914d0733d7e37ccaa9d4a611b35f16820b8aba05ff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0dc30ff-098a-42b3-b3a8-73a2201b815d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAdam Heussner  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nHi.  This is Adam on for Jailendra today.  Thanks for taking the question.  Just wanted to follow -up on the \nassumption of a return to pre -COVID uti lization in the second half of your fiscal year.  One of your competitors, this \nmorning, think it is \u2013 they saw a return to pre -COVID prescription utilization in the June quarter.  So, I mean, is the \ndifference in comments just a function of customer or chan nel mix or, I guess, the way pre -COVID is being \nmeasured?  Or what else should we be thinking about when attempting to bridge those comments? ", "original_text": "Just wanted to follow -up on the \nassumption of a return to pre -COVID uti lization in the second half of your fiscal year. ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "34316a4205212b057c4e94a207d12df5aeabd1df7542033063b18c06ea1ab139", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24c6a7f2-699b-49e5-8a32-f8fc4607d218", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  Just wanted to follow -up on the \nassumption of a return to pre -COVID uti lization in the second half of your fiscal year.  One of your competitors, this \nmorning, think it is \u2013 they saw a return to pre -COVID prescription utilization in the June quarter.  So, I mean, is the \ndifference in comments just a function of customer or chan nel mix or, I guess, the way pre -COVID is being \nmeasured?  Or what else should we be thinking about when attempting to bridge those comments?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "So, I mean, is the \ndifference in comments just a function of customer or chan nel mix or, I guess, the way pre -COVID is being \nmeasured? "}, "hash": "b2fd90b7ff92439f5de2e823ead6176b44e096d81219501b8c098d15588791a2", "class_name": "RelatedNodeInfo"}}, "text": "One of your competitors, this \nmorning, think it is \u2013 they saw a return to pre -COVID prescription utilization in the June quarter. ", "start_char_idx": 1230, "end_char_idx": 1362, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24c6a7f2-699b-49e5-8a32-f8fc4607d218": {"__data__": {"id_": "24c6a7f2-699b-49e5-8a32-f8fc4607d218", "embedding": null, "metadata": {"window": "Thanks for taking the question.  Just wanted to follow -up on the \nassumption of a return to pre -COVID uti lization in the second half of your fiscal year.  One of your competitors, this \nmorning, think it is \u2013 they saw a return to pre -COVID prescription utilization in the June quarter.  So, I mean, is the \ndifference in comments just a function of customer or chan nel mix or, I guess, the way pre -COVID is being \nmeasured?  Or what else should we be thinking about when attempting to bridge those comments?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "So, I mean, is the \ndifference in comments just a function of customer or chan nel mix or, I guess, the way pre -COVID is being \nmeasured? ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03733b2e-50cf-454d-ad00-c59834e71dbe", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05c3c367d9d46d218a59e914d0733d7e37ccaa9d4a611b35f16820b8aba05ff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca4361d5-04cd-43ab-a62b-f670d6b07cbe", "node_type": "1", "metadata": {"window": "This is Adam on for Jailendra today.  Thanks for taking the question.  Just wanted to follow -up on the \nassumption of a return to pre -COVID uti lization in the second half of your fiscal year.  One of your competitors, this \nmorning, think it is \u2013 they saw a return to pre -COVID prescription utilization in the June quarter.  So, I mean, is the \ndifference in comments just a function of customer or chan nel mix or, I guess, the way pre -COVID is being \nmeasured?  Or what else should we be thinking about when attempting to bridge those comments?  Thanks.  \n ", "original_text": "One of your competitors, this \nmorning, think it is \u2013 they saw a return to pre -COVID prescription utilization in the June quarter. ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "23f4c877bef9873bce57b99f8e8a92669bd732a2b4252ebd9c449e26f8577ce9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "78a4fa3b-e189-447b-a47f-fe53da30df68", "node_type": "1", "metadata": {"window": "Just wanted to follow -up on the \nassumption of a return to pre -COVID uti lization in the second half of your fiscal year.  One of your competitors, this \nmorning, think it is \u2013 they saw a return to pre -COVID prescription utilization in the June quarter.  So, I mean, is the \ndifference in comments just a function of customer or chan nel mix or, I guess, the way pre -COVID is being \nmeasured?  Or what else should we be thinking about when attempting to bridge those comments?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThank you for your question. ", "original_text": "Or what else should we be thinking about when attempting to bridge those comments? "}, "hash": "de8b9bfc144fd5321481c90df02cc8007dbf474eeb545b56562f89e819b28405", "class_name": "RelatedNodeInfo"}}, "text": "So, I mean, is the \ndifference in comments just a function of customer or chan nel mix or, I guess, the way pre -COVID is being \nmeasured? ", "start_char_idx": 1362, "end_char_idx": 1501, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "78a4fa3b-e189-447b-a47f-fe53da30df68": {"__data__": {"id_": "78a4fa3b-e189-447b-a47f-fe53da30df68", "embedding": null, "metadata": {"window": "Just wanted to follow -up on the \nassumption of a return to pre -COVID uti lization in the second half of your fiscal year.  One of your competitors, this \nmorning, think it is \u2013 they saw a return to pre -COVID prescription utilization in the June quarter.  So, I mean, is the \ndifference in comments just a function of customer or chan nel mix or, I guess, the way pre -COVID is being \nmeasured?  Or what else should we be thinking about when attempting to bridge those comments?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThank you for your question. ", "original_text": "Or what else should we be thinking about when attempting to bridge those comments? ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03733b2e-50cf-454d-ad00-c59834e71dbe", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05c3c367d9d46d218a59e914d0733d7e37ccaa9d4a611b35f16820b8aba05ff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24c6a7f2-699b-49e5-8a32-f8fc4607d218", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  Just wanted to follow -up on the \nassumption of a return to pre -COVID uti lization in the second half of your fiscal year.  One of your competitors, this \nmorning, think it is \u2013 they saw a return to pre -COVID prescription utilization in the June quarter.  So, I mean, is the \ndifference in comments just a function of customer or chan nel mix or, I guess, the way pre -COVID is being \nmeasured?  Or what else should we be thinking about when attempting to bridge those comments?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "So, I mean, is the \ndifference in comments just a function of customer or chan nel mix or, I guess, the way pre -COVID is being \nmeasured? ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "60a91817a3f420fbc6a1cbb97406329e385fb20cb4a241ba9ea6fe77555f059c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36ac3b2b-b296-4029-8fdf-713d043f7476", "node_type": "1", "metadata": {"window": "One of your competitors, this \nmorning, think it is \u2013 they saw a return to pre -COVID prescription utilization in the June quarter.  So, I mean, is the \ndifference in comments just a function of customer or chan nel mix or, I guess, the way pre -COVID is being \nmeasured?  Or what else should we be thinking about when attempting to bridge those comments?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThank you for your question.  I'll give you one example in our medical business, as an example. ", "original_text": "Thanks.  \n "}, "hash": "ef257c3c15cfcef0813765b06f396651c8f71dccf9d25b3fe4f45cb8ca5863df", "class_name": "RelatedNodeInfo"}}, "text": "Or what else should we be thinking about when attempting to bridge those comments? ", "start_char_idx": 1501, "end_char_idx": 1584, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36ac3b2b-b296-4029-8fdf-713d043f7476": {"__data__": {"id_": "36ac3b2b-b296-4029-8fdf-713d043f7476", "embedding": null, "metadata": {"window": "One of your competitors, this \nmorning, think it is \u2013 they saw a return to pre -COVID prescription utilization in the June quarter.  So, I mean, is the \ndifference in comments just a function of customer or chan nel mix or, I guess, the way pre -COVID is being \nmeasured?  Or what else should we be thinking about when attempting to bridge those comments?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThank you for your question.  I'll give you one example in our medical business, as an example. ", "original_text": "Thanks.  \n ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03733b2e-50cf-454d-ad00-c59834e71dbe", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05c3c367d9d46d218a59e914d0733d7e37ccaa9d4a611b35f16820b8aba05ff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "78a4fa3b-e189-447b-a47f-fe53da30df68", "node_type": "1", "metadata": {"window": "Just wanted to follow -up on the \nassumption of a return to pre -COVID uti lization in the second half of your fiscal year.  One of your competitors, this \nmorning, think it is \u2013 they saw a return to pre -COVID prescription utilization in the June quarter.  So, I mean, is the \ndifference in comments just a function of customer or chan nel mix or, I guess, the way pre -COVID is being \nmeasured?  Or what else should we be thinking about when attempting to bridge those comments?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThank you for your question. ", "original_text": "Or what else should we be thinking about when attempting to bridge those comments? ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "783c57a58f3f939cd0e3e16b3187665a6b8804a7eecae78e08d768c4e1cd1989", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e02cb768-c4a7-4299-92ae-15e2b62a85b1", "node_type": "1", "metadata": {"window": "So, I mean, is the \ndifference in comments just a function of customer or chan nel mix or, I guess, the way pre -COVID is being \nmeasured?  Or what else should we be thinking about when attempting to bridge those comments?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThank you for your question.  I'll give you one example in our medical business, as an example.  What we saw in \nthe June quarter was that primary care patient visits improved from the fourth quarter back to about 95% of pre -\nCOVID levels. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "41539a8b49430bd8be6c88d0c58076faeee8aeb5836cc900f518e9bc2594f6b1", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 1584, "end_char_idx": 1595, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e02cb768-c4a7-4299-92ae-15e2b62a85b1": {"__data__": {"id_": "e02cb768-c4a7-4299-92ae-15e2b62a85b1", "embedding": null, "metadata": {"window": "So, I mean, is the \ndifference in comments just a function of customer or chan nel mix or, I guess, the way pre -COVID is being \nmeasured?  Or what else should we be thinking about when attempting to bridge those comments?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThank you for your question.  I'll give you one example in our medical business, as an example.  What we saw in \nthe June quarter was that primary care patient visits improved from the fourth quarter back to about 95% of pre -\nCOVID levels. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03733b2e-50cf-454d-ad00-c59834e71dbe", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05c3c367d9d46d218a59e914d0733d7e37ccaa9d4a611b35f16820b8aba05ff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36ac3b2b-b296-4029-8fdf-713d043f7476", "node_type": "1", "metadata": {"window": "One of your competitors, this \nmorning, think it is \u2013 they saw a return to pre -COVID prescription utilization in the June quarter.  So, I mean, is the \ndifference in comments just a function of customer or chan nel mix or, I guess, the way pre -COVID is being \nmeasured?  Or what else should we be thinking about when attempting to bridge those comments?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThank you for your question.  I'll give you one example in our medical business, as an example. ", "original_text": "Thanks.  \n ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3ed751c5a085358b5be6c6b2bfc22319503bd66af533e007fb034f77edc0dfd8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84ed0c8f-d886-439b-9181-632e5bd6830a", "node_type": "1", "metadata": {"window": "Or what else should we be thinking about when attempting to bridge those comments?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThank you for your question.  I'll give you one example in our medical business, as an example.  What we saw in \nthe June quarter was that primary care patient visits improved from the fourth quarter back to about 95% of pre -\nCOVID levels.  So, continuing to see the improvement, but not back at pre -COVID levels. ", "original_text": "A \nThank you for your question. "}, "hash": "a87bea032588dffe86fa20df92eed157ad413847f99a62f11ed8a6b208b06bdb", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 1595, "end_char_idx": 1952, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "84ed0c8f-d886-439b-9181-632e5bd6830a": {"__data__": {"id_": "84ed0c8f-d886-439b-9181-632e5bd6830a", "embedding": null, "metadata": {"window": "Or what else should we be thinking about when attempting to bridge those comments?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThank you for your question.  I'll give you one example in our medical business, as an example.  What we saw in \nthe June quarter was that primary care patient visits improved from the fourth quarter back to about 95% of pre -\nCOVID levels.  So, continuing to see the improvement, but not back at pre -COVID levels. ", "original_text": "A \nThank you for your question. ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03733b2e-50cf-454d-ad00-c59834e71dbe", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05c3c367d9d46d218a59e914d0733d7e37ccaa9d4a611b35f16820b8aba05ff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e02cb768-c4a7-4299-92ae-15e2b62a85b1", "node_type": "1", "metadata": {"window": "So, I mean, is the \ndifference in comments just a function of customer or chan nel mix or, I guess, the way pre -COVID is being \nmeasured?  Or what else should we be thinking about when attempting to bridge those comments?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThank you for your question.  I'll give you one example in our medical business, as an example.  What we saw in \nthe June quarter was that primary care patient visits improved from the fourth quarter back to about 95% of pre -\nCOVID levels. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "112ef9f5f2c40e5f065547acca9b7613be88f715d594d143c7c1058a7cf71aa0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "407e014d-ccb9-4f95-a303-d03e56bb811b", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThank you for your question.  I'll give you one example in our medical business, as an example.  What we saw in \nthe June quarter was that primary care patient visits improved from the fourth quarter back to about 95% of pre -\nCOVID levels.  So, continuing to see the improvement, but not back at pre -COVID levels.  So when we speak \nabout utilization, we are seeing pre -COVID levels for oncology and for specialty, but we're not seeing that quite \nyet for primary care patients, as an example, continuing to improve on the trajectory that we laid out in our \nearnings call and that we had expected. ", "original_text": "I'll give you one example in our medical business, as an example. "}, "hash": "52d6ad0bb39369648bda45bd30a4fa964f53c693b13b3d20cfcfeacf38286f90", "class_name": "RelatedNodeInfo"}}, "text": "A \nThank you for your question. ", "start_char_idx": 1952, "end_char_idx": 1984, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "407e014d-ccb9-4f95-a303-d03e56bb811b": {"__data__": {"id_": "407e014d-ccb9-4f95-a303-d03e56bb811b", "embedding": null, "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThank you for your question.  I'll give you one example in our medical business, as an example.  What we saw in \nthe June quarter was that primary care patient visits improved from the fourth quarter back to about 95% of pre -\nCOVID levels.  So, continuing to see the improvement, but not back at pre -COVID levels.  So when we speak \nabout utilization, we are seeing pre -COVID levels for oncology and for specialty, but we're not seeing that quite \nyet for primary care patients, as an example, continuing to improve on the trajectory that we laid out in our \nearnings call and that we had expected. ", "original_text": "I'll give you one example in our medical business, as an example. ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03733b2e-50cf-454d-ad00-c59834e71dbe", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05c3c367d9d46d218a59e914d0733d7e37ccaa9d4a611b35f16820b8aba05ff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "84ed0c8f-d886-439b-9181-632e5bd6830a", "node_type": "1", "metadata": {"window": "Or what else should we be thinking about when attempting to bridge those comments?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThank you for your question.  I'll give you one example in our medical business, as an example.  What we saw in \nthe June quarter was that primary care patient visits improved from the fourth quarter back to about 95% of pre -\nCOVID levels.  So, continuing to see the improvement, but not back at pre -COVID levels. ", "original_text": "A \nThank you for your question. ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80d12144d177cfebb228f3748afc696faab5bcf0defc7a313d6859b8e8b06c90", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7a385f73-6995-4e0f-9f11-276b0923034a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThank you for your question.  I'll give you one example in our medical business, as an example.  What we saw in \nthe June quarter was that primary care patient visits improved from the fourth quarter back to about 95% of pre -\nCOVID levels.  So, continuing to see the improvement, but not back at pre -COVID levels.  So when we speak \nabout utilization, we are seeing pre -COVID levels for oncology and for specialty, but we're not seeing that quite \nyet for primary care patients, as an example, continuing to improve on the trajectory that we laid out in our \nearnings call and that we had expected.  But that's one example for our business that is perhaps a little bit \ndifferent.  \n ", "original_text": "What we saw in \nthe June quarter was that primary care patient visits improved from the fourth quarter back to about 95% of pre -\nCOVID levels. "}, "hash": "7620c08a8fe09d48e6dec8bf80efb512a5b97bf1007ca82ba3ffd4b7ffacd6b2", "class_name": "RelatedNodeInfo"}}, "text": "I'll give you one example in our medical business, as an example. ", "start_char_idx": 1984, "end_char_idx": 2050, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7a385f73-6995-4e0f-9f11-276b0923034a": {"__data__": {"id_": "7a385f73-6995-4e0f-9f11-276b0923034a", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThank you for your question.  I'll give you one example in our medical business, as an example.  What we saw in \nthe June quarter was that primary care patient visits improved from the fourth quarter back to about 95% of pre -\nCOVID levels.  So, continuing to see the improvement, but not back at pre -COVID levels.  So when we speak \nabout utilization, we are seeing pre -COVID levels for oncology and for specialty, but we're not seeing that quite \nyet for primary care patients, as an example, continuing to improve on the trajectory that we laid out in our \nearnings call and that we had expected.  But that's one example for our business that is perhaps a little bit \ndifferent.  \n ", "original_text": "What we saw in \nthe June quarter was that primary care patient visits improved from the fourth quarter back to about 95% of pre -\nCOVID levels. ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03733b2e-50cf-454d-ad00-c59834e71dbe", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05c3c367d9d46d218a59e914d0733d7e37ccaa9d4a611b35f16820b8aba05ff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "407e014d-ccb9-4f95-a303-d03e56bb811b", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThank you for your question.  I'll give you one example in our medical business, as an example.  What we saw in \nthe June quarter was that primary care patient visits improved from the fourth quarter back to about 95% of pre -\nCOVID levels.  So, continuing to see the improvement, but not back at pre -COVID levels.  So when we speak \nabout utilization, we are seeing pre -COVID levels for oncology and for specialty, but we're not seeing that quite \nyet for primary care patients, as an example, continuing to improve on the trajectory that we laid out in our \nearnings call and that we had expected. ", "original_text": "I'll give you one example in our medical business, as an example. ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e9b12716c8818616ada209978dde335be49a55cda3112be6537dd3ac0519fe71", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20dc8f7c-6405-4ae2-a70a-e83f431ba9f2", "node_type": "1", "metadata": {"window": "A \nThank you for your question.  I'll give you one example in our medical business, as an example.  What we saw in \nthe June quarter was that primary care patient visits improved from the fourth quarter back to about 95% of pre -\nCOVID levels.  So, continuing to see the improvement, but not back at pre -COVID levels.  So when we speak \nabout utilization, we are seeing pre -COVID levels for oncology and for specialty, but we're not seeing that quite \nyet for primary care patients, as an example, continuing to improve on the trajectory that we laid out in our \nearnings call and that we had expected.  But that's one example for our business that is perhaps a little bit \ndifferent.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "So, continuing to see the improvement, but not back at pre -COVID levels. "}, "hash": "ad5d70a8f21642e193f5728eea544630410df10bdb44db291cec18948026287b", "class_name": "RelatedNodeInfo"}}, "text": "What we saw in \nthe June quarter was that primary care patient visits improved from the fourth quarter back to about 95% of pre -\nCOVID levels. ", "start_char_idx": 2050, "end_char_idx": 2194, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20dc8f7c-6405-4ae2-a70a-e83f431ba9f2": {"__data__": {"id_": "20dc8f7c-6405-4ae2-a70a-e83f431ba9f2", "embedding": null, "metadata": {"window": "A \nThank you for your question.  I'll give you one example in our medical business, as an example.  What we saw in \nthe June quarter was that primary care patient visits improved from the fourth quarter back to about 95% of pre -\nCOVID levels.  So, continuing to see the improvement, but not back at pre -COVID levels.  So when we speak \nabout utilization, we are seeing pre -COVID levels for oncology and for specialty, but we're not seeing that quite \nyet for primary care patients, as an example, continuing to improve on the trajectory that we laid out in our \nearnings call and that we had expected.  But that's one example for our business that is perhaps a little bit \ndifferent.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "So, continuing to see the improvement, but not back at pre -COVID levels. ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03733b2e-50cf-454d-ad00-c59834e71dbe", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05c3c367d9d46d218a59e914d0733d7e37ccaa9d4a611b35f16820b8aba05ff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7a385f73-6995-4e0f-9f11-276b0923034a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThank you for your question.  I'll give you one example in our medical business, as an example.  What we saw in \nthe June quarter was that primary care patient visits improved from the fourth quarter back to about 95% of pre -\nCOVID levels.  So, continuing to see the improvement, but not back at pre -COVID levels.  So when we speak \nabout utilization, we are seeing pre -COVID levels for oncology and for specialty, but we're not seeing that quite \nyet for primary care patients, as an example, continuing to improve on the trajectory that we laid out in our \nearnings call and that we had expected.  But that's one example for our business that is perhaps a little bit \ndifferent.  \n ", "original_text": "What we saw in \nthe June quarter was that primary care patient visits improved from the fourth quarter back to about 95% of pre -\nCOVID levels. ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b8178f9a22338a31947ebf0a712f6c63eb53ce9816d1957b0117afa47915c3f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9764b223-9732-4375-a2c7-8ce092a0e44f", "node_type": "1", "metadata": {"window": "I'll give you one example in our medical business, as an example.  What we saw in \nthe June quarter was that primary care patient visits improved from the fourth quarter back to about 95% of pre -\nCOVID levels.  So, continuing to see the improvement, but not back at pre -COVID levels.  So when we speak \nabout utilization, we are seeing pre -COVID levels for oncology and for specialty, but we're not seeing that quite \nyet for primary care patients, as an example, continuing to improve on the trajectory that we laid out in our \nearnings call and that we had expected.  But that's one example for our business that is perhaps a little bit \ndifferent.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great. ", "original_text": "So when we speak \nabout utilization, we are seeing pre -COVID levels for oncology and for specialty, but we're not seeing that quite \nyet for primary care patients, as an example, continuing to improve on the trajectory that we laid out in our \nearnings call and that we had expected. "}, "hash": "e797285ef746228376df7c05d4da488f55d94d7460c8602799866287651cad99", "class_name": "RelatedNodeInfo"}}, "text": "So, continuing to see the improvement, but not back at pre -COVID levels. ", "start_char_idx": 2194, "end_char_idx": 2268, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9764b223-9732-4375-a2c7-8ce092a0e44f": {"__data__": {"id_": "9764b223-9732-4375-a2c7-8ce092a0e44f", "embedding": null, "metadata": {"window": "I'll give you one example in our medical business, as an example.  What we saw in \nthe June quarter was that primary care patient visits improved from the fourth quarter back to about 95% of pre -\nCOVID levels.  So, continuing to see the improvement, but not back at pre -COVID levels.  So when we speak \nabout utilization, we are seeing pre -COVID levels for oncology and for specialty, but we're not seeing that quite \nyet for primary care patients, as an example, continuing to improve on the trajectory that we laid out in our \nearnings call and that we had expected.  But that's one example for our business that is perhaps a little bit \ndifferent.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great. ", "original_text": "So when we speak \nabout utilization, we are seeing pre -COVID levels for oncology and for specialty, but we're not seeing that quite \nyet for primary care patients, as an example, continuing to improve on the trajectory that we laid out in our \nearnings call and that we had expected. ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03733b2e-50cf-454d-ad00-c59834e71dbe", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05c3c367d9d46d218a59e914d0733d7e37ccaa9d4a611b35f16820b8aba05ff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20dc8f7c-6405-4ae2-a70a-e83f431ba9f2", "node_type": "1", "metadata": {"window": "A \nThank you for your question.  I'll give you one example in our medical business, as an example.  What we saw in \nthe June quarter was that primary care patient visits improved from the fourth quarter back to about 95% of pre -\nCOVID levels.  So, continuing to see the improvement, but not back at pre -COVID levels.  So when we speak \nabout utilization, we are seeing pre -COVID levels for oncology and for specialty, but we're not seeing that quite \nyet for primary care patients, as an example, continuing to improve on the trajectory that we laid out in our \nearnings call and that we had expected.  But that's one example for our business that is perhaps a little bit \ndifferent.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "So, continuing to see the improvement, but not back at pre -COVID levels. ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ee014add98f031c6f636f93e58af98dcaf67dc9f79da803f5d33d79617f5fa9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "210504be-97d5-407c-84a8-bfe280fb22b7", "node_type": "1", "metadata": {"window": "What we saw in \nthe June quarter was that primary care patient visits improved from the fourth quarter back to about 95% of pre -\nCOVID levels.  So, continuing to see the improvement, but not back at pre -COVID levels.  So when we speak \nabout utilization, we are seeing pre -COVID levels for oncology and for specialty, but we're not seeing that quite \nyet for primary care patients, as an example, continuing to improve on the trajectory that we laid out in our \nearnings call and that we had expected.  But that's one example for our business that is perhaps a little bit \ndifferent.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thank you, everyone. ", "original_text": "But that's one example for our business that is perhaps a little bit \ndifferent.  \n "}, "hash": "27ce151cae27b21dd93f7d329faa256590531de48061bd08beb820d17c59f65b", "class_name": "RelatedNodeInfo"}}, "text": "So when we speak \nabout utilization, we are seeing pre -COVID levels for oncology and for specialty, but we're not seeing that quite \nyet for primary care patients, as an example, continuing to improve on the trajectory that we laid out in our \nearnings call and that we had expected. ", "start_char_idx": 2268, "end_char_idx": 2553, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "210504be-97d5-407c-84a8-bfe280fb22b7": {"__data__": {"id_": "210504be-97d5-407c-84a8-bfe280fb22b7", "embedding": null, "metadata": {"window": "What we saw in \nthe June quarter was that primary care patient visits improved from the fourth quarter back to about 95% of pre -\nCOVID levels.  So, continuing to see the improvement, but not back at pre -COVID levels.  So when we speak \nabout utilization, we are seeing pre -COVID levels for oncology and for specialty, but we're not seeing that quite \nyet for primary care patients, as an example, continuing to improve on the trajectory that we laid out in our \nearnings call and that we had expected.  But that's one example for our business that is perhaps a little bit \ndifferent.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thank you, everyone. ", "original_text": "But that's one example for our business that is perhaps a little bit \ndifferent.  \n ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03733b2e-50cf-454d-ad00-c59834e71dbe", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05c3c367d9d46d218a59e914d0733d7e37ccaa9d4a611b35f16820b8aba05ff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9764b223-9732-4375-a2c7-8ce092a0e44f", "node_type": "1", "metadata": {"window": "I'll give you one example in our medical business, as an example.  What we saw in \nthe June quarter was that primary care patient visits improved from the fourth quarter back to about 95% of pre -\nCOVID levels.  So, continuing to see the improvement, but not back at pre -COVID levels.  So when we speak \nabout utilization, we are seeing pre -COVID levels for oncology and for specialty, but we're not seeing that quite \nyet for primary care patients, as an example, continuing to improve on the trajectory that we laid out in our \nearnings call and that we had expected.  But that's one example for our business that is perhaps a little bit \ndifferent.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great. ", "original_text": "So when we speak \nabout utilization, we are seeing pre -COVID levels for oncology and for specialty, but we're not seeing that quite \nyet for primary care patients, as an example, continuing to improve on the trajectory that we laid out in our \nearnings call and that we had expected. ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80580322a380d2db94c4fcf2e8fe445b3051dfc03fd7652a4f1d6393721853b6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad6893e0-091d-4c43-8d1d-fe6b389ba3fc", "node_type": "1", "metadata": {"window": "So, continuing to see the improvement, but not back at pre -COVID levels.  So when we speak \nabout utilization, we are seeing pre -COVID levels for oncology and for specialty, but we're not seeing that quite \nyet for primary care patients, as an example, continuing to improve on the trajectory that we laid out in our \nearnings call and that we had expected.  But that's one example for our business that is perhaps a little bit \ndifferent.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thank you, everyone.  Thank you f or your insightful questions. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n"}, "hash": "9bc22b424ce842053e1780bcd65cf36e6dde190c256908718bf1474d41891317", "class_name": "RelatedNodeInfo"}}, "text": "But that's one example for our business that is perhaps a little bit \ndifferent.  \n ", "start_char_idx": 2553, "end_char_idx": 2637, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad6893e0-091d-4c43-8d1d-fe6b389ba3fc": {"__data__": {"id_": "ad6893e0-091d-4c43-8d1d-fe6b389ba3fc", "embedding": null, "metadata": {"window": "So, continuing to see the improvement, but not back at pre -COVID levels.  So when we speak \nabout utilization, we are seeing pre -COVID levels for oncology and for specialty, but we're not seeing that quite \nyet for primary care patients, as an example, continuing to improve on the trajectory that we laid out in our \nearnings call and that we had expected.  But that's one example for our business that is perhaps a little bit \ndifferent.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thank you, everyone.  Thank you f or your insightful questions. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03733b2e-50cf-454d-ad00-c59834e71dbe", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05c3c367d9d46d218a59e914d0733d7e37ccaa9d4a611b35f16820b8aba05ff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "210504be-97d5-407c-84a8-bfe280fb22b7", "node_type": "1", "metadata": {"window": "What we saw in \nthe June quarter was that primary care patient visits improved from the fourth quarter back to about 95% of pre -\nCOVID levels.  So, continuing to see the improvement, but not back at pre -COVID levels.  So when we speak \nabout utilization, we are seeing pre -COVID levels for oncology and for specialty, but we're not seeing that quite \nyet for primary care patients, as an example, continuing to improve on the trajectory that we laid out in our \nearnings call and that we had expected.  But that's one example for our business that is perhaps a little bit \ndifferent.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thank you, everyone. ", "original_text": "But that's one example for our business that is perhaps a little bit \ndifferent.  \n ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e5f24140d228dcabc72a3420f6cdaf2a13f8ab5877440826f99d709f0c3ab32d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe362cda-5722-43c6-a6c5-d0e86d13cf7b", "node_type": "1", "metadata": {"window": "So when we speak \nabout utilization, we are seeing pre -COVID levels for oncology and for specialty, but we're not seeing that quite \nyet for primary care patients, as an example, continuing to improve on the trajectory that we laid out in our \nearnings call and that we had expected.  But that's one example for our business that is perhaps a little bit \ndifferent.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thank you, everyone.  Thank you f or your insightful questions.  Thank you for joining on this call. ", "original_text": "Great. "}, "hash": "193123479d898e3b89680eb386c2027affe9cf3d499f99025677a7aa9893e3ae", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "start_char_idx": 2637, "end_char_idx": 2982, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe362cda-5722-43c6-a6c5-d0e86d13cf7b": {"__data__": {"id_": "fe362cda-5722-43c6-a6c5-d0e86d13cf7b", "embedding": null, "metadata": {"window": "So when we speak \nabout utilization, we are seeing pre -COVID levels for oncology and for specialty, but we're not seeing that quite \nyet for primary care patients, as an example, continuing to improve on the trajectory that we laid out in our \nearnings call and that we had expected.  But that's one example for our business that is perhaps a little bit \ndifferent.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thank you, everyone.  Thank you f or your insightful questions.  Thank you for joining on this call. ", "original_text": "Great. ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03733b2e-50cf-454d-ad00-c59834e71dbe", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05c3c367d9d46d218a59e914d0733d7e37ccaa9d4a611b35f16820b8aba05ff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad6893e0-091d-4c43-8d1d-fe6b389ba3fc", "node_type": "1", "metadata": {"window": "So, continuing to see the improvement, but not back at pre -COVID levels.  So when we speak \nabout utilization, we are seeing pre -COVID levels for oncology and for specialty, but we're not seeing that quite \nyet for primary care patients, as an example, continuing to improve on the trajectory that we laid out in our \nearnings call and that we had expected.  But that's one example for our business that is perhaps a little bit \ndifferent.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thank you, everyone.  Thank you f or your insightful questions. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2a74c9750044003b7f2f5ce49bed23ede891b66b86818216c1849847e0911922", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80a35f00-f6c2-4d7a-849d-9d19e5dc059d", "node_type": "1", "metadata": {"window": "But that's one example for our business that is perhaps a little bit \ndifferent.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thank you, everyone.  Thank you f or your insightful questions.  Thank you for joining on this call.  And \nthank you, Jenny, for helping facilitate the call. ", "original_text": "Well, thank you, everyone. "}, "hash": "0403987093230ed363eafdcb264238985a0fa567c3dd9a6e42ce85dac51cda98", "class_name": "RelatedNodeInfo"}}, "text": "Great. ", "start_char_idx": 2982, "end_char_idx": 2989, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80a35f00-f6c2-4d7a-849d-9d19e5dc059d": {"__data__": {"id_": "80a35f00-f6c2-4d7a-849d-9d19e5dc059d", "embedding": null, "metadata": {"window": "But that's one example for our business that is perhaps a little bit \ndifferent.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thank you, everyone.  Thank you f or your insightful questions.  Thank you for joining on this call.  And \nthank you, Jenny, for helping facilitate the call. ", "original_text": "Well, thank you, everyone. ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03733b2e-50cf-454d-ad00-c59834e71dbe", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05c3c367d9d46d218a59e914d0733d7e37ccaa9d4a611b35f16820b8aba05ff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe362cda-5722-43c6-a6c5-d0e86d13cf7b", "node_type": "1", "metadata": {"window": "So when we speak \nabout utilization, we are seeing pre -COVID levels for oncology and for specialty, but we're not seeing that quite \nyet for primary care patients, as an example, continuing to improve on the trajectory that we laid out in our \nearnings call and that we had expected.  But that's one example for our business that is perhaps a little bit \ndifferent.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thank you, everyone.  Thank you f or your insightful questions.  Thank you for joining on this call. ", "original_text": "Great. ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2eee1ad05da273c3e7e948d68ff6313ca3ff10b6ea7878efbc93a1d3037cabc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "67216b12-9817-4256-bf29-ddbd6fbdd52f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thank you, everyone.  Thank you f or your insightful questions.  Thank you for joining on this call.  And \nthank you, Jenny, for helping facilitate the call.  McKesson is off to a very strong start in our fiscal 2022. ", "original_text": "Thank you f or your insightful questions. "}, "hash": "d9524bfa8780c487a0a5a6663aaae638f976536dcfb8c2471042b2484a436610", "class_name": "RelatedNodeInfo"}}, "text": "Well, thank you, everyone. ", "start_char_idx": 2989, "end_char_idx": 3016, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "67216b12-9817-4256-bf29-ddbd6fbdd52f": {"__data__": {"id_": "67216b12-9817-4256-bf29-ddbd6fbdd52f", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thank you, everyone.  Thank you f or your insightful questions.  Thank you for joining on this call.  And \nthank you, Jenny, for helping facilitate the call.  McKesson is off to a very strong start in our fiscal 2022. ", "original_text": "Thank you f or your insightful questions. ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03733b2e-50cf-454d-ad00-c59834e71dbe", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05c3c367d9d46d218a59e914d0733d7e37ccaa9d4a611b35f16820b8aba05ff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80a35f00-f6c2-4d7a-849d-9d19e5dc059d", "node_type": "1", "metadata": {"window": "But that's one example for our business that is perhaps a little bit \ndifferent.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thank you, everyone.  Thank you f or your insightful questions.  Thank you for joining on this call.  And \nthank you, Jenny, for helping facilitate the call. ", "original_text": "Well, thank you, everyone. ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7aa8b08cc0f48e349af52ad5fa8ef6825fcc0da03d18b8c04d14ecca0304ba2d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b402dacf-e727-464a-b881-6e4f4bfc3108", "node_type": "1", "metadata": {"window": "Great.  Well, thank you, everyone.  Thank you f or your insightful questions.  Thank you for joining on this call.  And \nthank you, Jenny, for helping facilitate the call.  McKesson is off to a very strong start in our fiscal 2022.  I'm \nincredibly excited not just about the recovery of the markets, but frank ly, the execution by our teams, which is \ngenerating this performance in the business.  \n \n", "original_text": "Thank you for joining on this call. "}, "hash": "63d4b969e36fcc083c6682537ce21bf6ac2383440e34992cefcb2ecd6f060fab", "class_name": "RelatedNodeInfo"}}, "text": "Thank you f or your insightful questions. ", "start_char_idx": 3016, "end_char_idx": 3058, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b402dacf-e727-464a-b881-6e4f4bfc3108": {"__data__": {"id_": "b402dacf-e727-464a-b881-6e4f4bfc3108", "embedding": null, "metadata": {"window": "Great.  Well, thank you, everyone.  Thank you f or your insightful questions.  Thank you for joining on this call.  And \nthank you, Jenny, for helping facilitate the call.  McKesson is off to a very strong start in our fiscal 2022.  I'm \nincredibly excited not just about the recovery of the markets, but frank ly, the execution by our teams, which is \ngenerating this performance in the business.  \n \n", "original_text": "Thank you for joining on this call. ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03733b2e-50cf-454d-ad00-c59834e71dbe", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05c3c367d9d46d218a59e914d0733d7e37ccaa9d4a611b35f16820b8aba05ff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "67216b12-9817-4256-bf29-ddbd6fbdd52f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thank you, everyone.  Thank you f or your insightful questions.  Thank you for joining on this call.  And \nthank you, Jenny, for helping facilitate the call.  McKesson is off to a very strong start in our fiscal 2022. ", "original_text": "Thank you f or your insightful questions. ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "acff7d3925a942c9ffb3b461c8aa540100868be881f42baf88465a548e949bf6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a44e9f8-97fc-4ceb-bc3c-110a87877191", "node_type": "1", "metadata": {"window": "Well, thank you, everyone.  Thank you f or your insightful questions.  Thank you for joining on this call.  And \nthank you, Jenny, for helping facilitate the call.  McKesson is off to a very strong start in our fiscal 2022.  I'm \nincredibly excited not just about the recovery of the markets, but frank ly, the execution by our teams, which is \ngenerating this performance in the business.  \n \n So, I want to be sure to thank our more than 75,000 employees for their commitment to be together, to be a team, \nto focus on doing good for our company, for our customer s and for the health care industry. ", "original_text": "And \nthank you, Jenny, for helping facilitate the call. "}, "hash": "72cf8ab94cda32905a39b44707b8dcc7cd7e981c31c043218050295ecf60c1c8", "class_name": "RelatedNodeInfo"}}, "text": "Thank you for joining on this call. ", "start_char_idx": 3058, "end_char_idx": 3094, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a44e9f8-97fc-4ceb-bc3c-110a87877191": {"__data__": {"id_": "1a44e9f8-97fc-4ceb-bc3c-110a87877191", "embedding": null, "metadata": {"window": "Well, thank you, everyone.  Thank you f or your insightful questions.  Thank you for joining on this call.  And \nthank you, Jenny, for helping facilitate the call.  McKesson is off to a very strong start in our fiscal 2022.  I'm \nincredibly excited not just about the recovery of the markets, but frank ly, the execution by our teams, which is \ngenerating this performance in the business.  \n \n So, I want to be sure to thank our more than 75,000 employees for their commitment to be together, to be a team, \nto focus on doing good for our company, for our customer s and for the health care industry. ", "original_text": "And \nthank you, Jenny, for helping facilitate the call. ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03733b2e-50cf-454d-ad00-c59834e71dbe", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05c3c367d9d46d218a59e914d0733d7e37ccaa9d4a611b35f16820b8aba05ff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b402dacf-e727-464a-b881-6e4f4bfc3108", "node_type": "1", "metadata": {"window": "Great.  Well, thank you, everyone.  Thank you f or your insightful questions.  Thank you for joining on this call.  And \nthank you, Jenny, for helping facilitate the call.  McKesson is off to a very strong start in our fiscal 2022.  I'm \nincredibly excited not just about the recovery of the markets, but frank ly, the execution by our teams, which is \ngenerating this performance in the business.  \n \n", "original_text": "Thank you for joining on this call. ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d4c920fd8aeddcb00db41ca63220d38f29b9f9302754c80eb9161398a9bfb6a1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a8fd421-4a89-438f-b96e-305083f0b4fa", "node_type": "1", "metadata": {"window": "Thank you f or your insightful questions.  Thank you for joining on this call.  And \nthank you, Jenny, for helping facilitate the call.  McKesson is off to a very strong start in our fiscal 2022.  I'm \nincredibly excited not just about the recovery of the markets, but frank ly, the execution by our teams, which is \ngenerating this performance in the business.  \n \n So, I want to be sure to thank our more than 75,000 employees for their commitment to be together, to be a team, \nto focus on doing good for our company, for our customer s and for the health care industry.  As a global leader in \nhealth care, we are committed to doing our part to serve our employees, our customers, our partners and our \ncommunities as they continue the pandemic response efforts.  \n \n", "original_text": "McKesson is off to a very strong start in our fiscal 2022. "}, "hash": "cde207e5c01fa04300a04efdbf5e57f4bbf0a807e5bfce489df338e056208572", "class_name": "RelatedNodeInfo"}}, "text": "And \nthank you, Jenny, for helping facilitate the call. ", "start_char_idx": 3094, "end_char_idx": 3150, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a8fd421-4a89-438f-b96e-305083f0b4fa": {"__data__": {"id_": "2a8fd421-4a89-438f-b96e-305083f0b4fa", "embedding": null, "metadata": {"window": "Thank you f or your insightful questions.  Thank you for joining on this call.  And \nthank you, Jenny, for helping facilitate the call.  McKesson is off to a very strong start in our fiscal 2022.  I'm \nincredibly excited not just about the recovery of the markets, but frank ly, the execution by our teams, which is \ngenerating this performance in the business.  \n \n So, I want to be sure to thank our more than 75,000 employees for their commitment to be together, to be a team, \nto focus on doing good for our company, for our customer s and for the health care industry.  As a global leader in \nhealth care, we are committed to doing our part to serve our employees, our customers, our partners and our \ncommunities as they continue the pandemic response efforts.  \n \n", "original_text": "McKesson is off to a very strong start in our fiscal 2022. ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03733b2e-50cf-454d-ad00-c59834e71dbe", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05c3c367d9d46d218a59e914d0733d7e37ccaa9d4a611b35f16820b8aba05ff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a44e9f8-97fc-4ceb-bc3c-110a87877191", "node_type": "1", "metadata": {"window": "Well, thank you, everyone.  Thank you f or your insightful questions.  Thank you for joining on this call.  And \nthank you, Jenny, for helping facilitate the call.  McKesson is off to a very strong start in our fiscal 2022.  I'm \nincredibly excited not just about the recovery of the markets, but frank ly, the execution by our teams, which is \ngenerating this performance in the business.  \n \n So, I want to be sure to thank our more than 75,000 employees for their commitment to be together, to be a team, \nto focus on doing good for our company, for our customer s and for the health care industry. ", "original_text": "And \nthank you, Jenny, for helping facilitate the call. ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "513a1c302bae9cdef404dedd5eb634d0b437d1387a91fe5243394af96780b5a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a76ab28-d248-47aa-838e-46b2ee839180", "node_type": "1", "metadata": {"window": "Thank you for joining on this call.  And \nthank you, Jenny, for helping facilitate the call.  McKesson is off to a very strong start in our fiscal 2022.  I'm \nincredibly excited not just about the recovery of the markets, but frank ly, the execution by our teams, which is \ngenerating this performance in the business.  \n \n So, I want to be sure to thank our more than 75,000 employees for their commitment to be together, to be a team, \nto focus on doing good for our company, for our customer s and for the health care industry.  As a global leader in \nhealth care, we are committed to doing our part to serve our employees, our customers, our partners and our \ncommunities as they continue the pandemic response efforts.  \n \n So in closing, I just want to  wish you all and your family's good health and wellness. ", "original_text": "I'm \nincredibly excited not just about the recovery of the markets, but frank ly, the execution by our teams, which is \ngenerating this performance in the business.  \n \n"}, "hash": "47d7cbd8a622beefa8579d3652bf9780da1b535a8539fcf7e5b0e308dee64912", "class_name": "RelatedNodeInfo"}}, "text": "McKesson is off to a very strong start in our fiscal 2022. ", "start_char_idx": 3150, "end_char_idx": 3209, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a76ab28-d248-47aa-838e-46b2ee839180": {"__data__": {"id_": "4a76ab28-d248-47aa-838e-46b2ee839180", "embedding": null, "metadata": {"window": "Thank you for joining on this call.  And \nthank you, Jenny, for helping facilitate the call.  McKesson is off to a very strong start in our fiscal 2022.  I'm \nincredibly excited not just about the recovery of the markets, but frank ly, the execution by our teams, which is \ngenerating this performance in the business.  \n \n So, I want to be sure to thank our more than 75,000 employees for their commitment to be together, to be a team, \nto focus on doing good for our company, for our customer s and for the health care industry.  As a global leader in \nhealth care, we are committed to doing our part to serve our employees, our customers, our partners and our \ncommunities as they continue the pandemic response efforts.  \n \n So in closing, I just want to  wish you all and your family's good health and wellness. ", "original_text": "I'm \nincredibly excited not just about the recovery of the markets, but frank ly, the execution by our teams, which is \ngenerating this performance in the business.  \n \n", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03733b2e-50cf-454d-ad00-c59834e71dbe", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05c3c367d9d46d218a59e914d0733d7e37ccaa9d4a611b35f16820b8aba05ff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a8fd421-4a89-438f-b96e-305083f0b4fa", "node_type": "1", "metadata": {"window": "Thank you f or your insightful questions.  Thank you for joining on this call.  And \nthank you, Jenny, for helping facilitate the call.  McKesson is off to a very strong start in our fiscal 2022.  I'm \nincredibly excited not just about the recovery of the markets, but frank ly, the execution by our teams, which is \ngenerating this performance in the business.  \n \n So, I want to be sure to thank our more than 75,000 employees for their commitment to be together, to be a team, \nto focus on doing good for our company, for our customer s and for the health care industry.  As a global leader in \nhealth care, we are committed to doing our part to serve our employees, our customers, our partners and our \ncommunities as they continue the pandemic response efforts.  \n \n", "original_text": "McKesson is off to a very strong start in our fiscal 2022. ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3c0134513abf2a7e81030da6f23394f41b57c45a353ffe11fb85a51b6287338", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7a25391b-923c-4cb2-8b2d-88cd4b33ac9f", "node_type": "1", "metadata": {"window": "And \nthank you, Jenny, for helping facilitate the call.  McKesson is off to a very strong start in our fiscal 2022.  I'm \nincredibly excited not just about the recovery of the markets, but frank ly, the execution by our teams, which is \ngenerating this performance in the business.  \n \n So, I want to be sure to thank our more than 75,000 employees for their commitment to be together, to be a team, \nto focus on doing good for our company, for our customer s and for the health care industry.  As a global leader in \nhealth care, we are committed to doing our part to serve our employees, our customers, our partners and our \ncommunities as they continue the pandemic response efforts.  \n \n So in closing, I just want to  wish you all and your family's good health and wellness.  Have a great evening. ", "original_text": "So, I want to be sure to thank our more than 75,000 employees for their commitment to be together, to be a team, \nto focus on doing good for our company, for our customer s and for the health care industry. "}, "hash": "c9f34616469856e3ec0c9a7de75f749b8f9063aaed899aa2caa65735aa8f2eeb", "class_name": "RelatedNodeInfo"}}, "text": "I'm \nincredibly excited not just about the recovery of the markets, but frank ly, the execution by our teams, which is \ngenerating this performance in the business.  \n \n", "start_char_idx": 3209, "end_char_idx": 3378, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7a25391b-923c-4cb2-8b2d-88cd4b33ac9f": {"__data__": {"id_": "7a25391b-923c-4cb2-8b2d-88cd4b33ac9f", "embedding": null, "metadata": {"window": "And \nthank you, Jenny, for helping facilitate the call.  McKesson is off to a very strong start in our fiscal 2022.  I'm \nincredibly excited not just about the recovery of the markets, but frank ly, the execution by our teams, which is \ngenerating this performance in the business.  \n \n So, I want to be sure to thank our more than 75,000 employees for their commitment to be together, to be a team, \nto focus on doing good for our company, for our customer s and for the health care industry.  As a global leader in \nhealth care, we are committed to doing our part to serve our employees, our customers, our partners and our \ncommunities as they continue the pandemic response efforts.  \n \n So in closing, I just want to  wish you all and your family's good health and wellness.  Have a great evening. ", "original_text": "So, I want to be sure to thank our more than 75,000 employees for their commitment to be together, to be a team, \nto focus on doing good for our company, for our customer s and for the health care industry. ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03733b2e-50cf-454d-ad00-c59834e71dbe", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05c3c367d9d46d218a59e914d0733d7e37ccaa9d4a611b35f16820b8aba05ff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a76ab28-d248-47aa-838e-46b2ee839180", "node_type": "1", "metadata": {"window": "Thank you for joining on this call.  And \nthank you, Jenny, for helping facilitate the call.  McKesson is off to a very strong start in our fiscal 2022.  I'm \nincredibly excited not just about the recovery of the markets, but frank ly, the execution by our teams, which is \ngenerating this performance in the business.  \n \n So, I want to be sure to thank our more than 75,000 employees for their commitment to be together, to be a team, \nto focus on doing good for our company, for our customer s and for the health care industry.  As a global leader in \nhealth care, we are committed to doing our part to serve our employees, our customers, our partners and our \ncommunities as they continue the pandemic response efforts.  \n \n So in closing, I just want to  wish you all and your family's good health and wellness. ", "original_text": "I'm \nincredibly excited not just about the recovery of the markets, but frank ly, the execution by our teams, which is \ngenerating this performance in the business.  \n \n", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "feea904da2b40a521e159179f89ced861c7bd7bbf9b9641baffa47d66a89eb3b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6110ef7-ec23-4b73-b74b-f4740002a68a", "node_type": "1", "metadata": {"window": "McKesson is off to a very strong start in our fiscal 2022.  I'm \nincredibly excited not just about the recovery of the markets, but frank ly, the execution by our teams, which is \ngenerating this performance in the business.  \n \n So, I want to be sure to thank our more than 75,000 employees for their commitment to be together, to be a team, \nto focus on doing good for our company, for our customer s and for the health care industry.  As a global leader in \nhealth care, we are committed to doing our part to serve our employees, our customers, our partners and our \ncommunities as they continue the pandemic response efforts.  \n \n So in closing, I just want to  wish you all and your family's good health and wellness.  Have a great evening.  Thank \nyou. \n ", "original_text": "As a global leader in \nhealth care, we are committed to doing our part to serve our employees, our customers, our partners and our \ncommunities as they continue the pandemic response efforts.  \n \n"}, "hash": "3d4ffee961438784d72288696fe6e020074efbd168ee987b8502a168cfba5646", "class_name": "RelatedNodeInfo"}}, "text": "So, I want to be sure to thank our more than 75,000 employees for their commitment to be together, to be a team, \nto focus on doing good for our company, for our customer s and for the health care industry. ", "start_char_idx": 3378, "end_char_idx": 3585, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6110ef7-ec23-4b73-b74b-f4740002a68a": {"__data__": {"id_": "b6110ef7-ec23-4b73-b74b-f4740002a68a", "embedding": null, "metadata": {"window": "McKesson is off to a very strong start in our fiscal 2022.  I'm \nincredibly excited not just about the recovery of the markets, but frank ly, the execution by our teams, which is \ngenerating this performance in the business.  \n \n So, I want to be sure to thank our more than 75,000 employees for their commitment to be together, to be a team, \nto focus on doing good for our company, for our customer s and for the health care industry.  As a global leader in \nhealth care, we are committed to doing our part to serve our employees, our customers, our partners and our \ncommunities as they continue the pandemic response efforts.  \n \n So in closing, I just want to  wish you all and your family's good health and wellness.  Have a great evening.  Thank \nyou. \n ", "original_text": "As a global leader in \nhealth care, we are committed to doing our part to serve our employees, our customers, our partners and our \ncommunities as they continue the pandemic response efforts.  \n \n", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03733b2e-50cf-454d-ad00-c59834e71dbe", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05c3c367d9d46d218a59e914d0733d7e37ccaa9d4a611b35f16820b8aba05ff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7a25391b-923c-4cb2-8b2d-88cd4b33ac9f", "node_type": "1", "metadata": {"window": "And \nthank you, Jenny, for helping facilitate the call.  McKesson is off to a very strong start in our fiscal 2022.  I'm \nincredibly excited not just about the recovery of the markets, but frank ly, the execution by our teams, which is \ngenerating this performance in the business.  \n \n So, I want to be sure to thank our more than 75,000 employees for their commitment to be together, to be a team, \nto focus on doing good for our company, for our customer s and for the health care industry.  As a global leader in \nhealth care, we are committed to doing our part to serve our employees, our customers, our partners and our \ncommunities as they continue the pandemic response efforts.  \n \n So in closing, I just want to  wish you all and your family's good health and wellness.  Have a great evening. ", "original_text": "So, I want to be sure to thank our more than 75,000 employees for their commitment to be together, to be a team, \nto focus on doing good for our company, for our customer s and for the health care industry. ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "582de9a6e166711e18c55e11694c36be08c288e6042261d11292dec492b3a767", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22cfee2b-dfca-4ab4-9059-e88d636aa4c4", "node_type": "1", "metadata": {"window": "I'm \nincredibly excited not just about the recovery of the markets, but frank ly, the execution by our teams, which is \ngenerating this performance in the business.  \n \n So, I want to be sure to thank our more than 75,000 employees for their commitment to be together, to be a team, \nto focus on doing good for our company, for our customer s and for the health care industry.  As a global leader in \nhealth care, we are committed to doing our part to serve our employees, our customers, our partners and our \ncommunities as they continue the pandemic response efforts.  \n \n So in closing, I just want to  wish you all and your family's good health and wellness.  Have a great evening.  Thank \nyou. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And thank you for joining today's conference call. ", "original_text": "So in closing, I just want to  wish you all and your family's good health and wellness. "}, "hash": "1ced9ab9f40776a8393978e55d1b8ae3366b78d4eff8c8f193cb2defeb39779a", "class_name": "RelatedNodeInfo"}}, "text": "As a global leader in \nhealth care, we are committed to doing our part to serve our employees, our customers, our partners and our \ncommunities as they continue the pandemic response efforts.  \n \n", "start_char_idx": 3585, "end_char_idx": 3781, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22cfee2b-dfca-4ab4-9059-e88d636aa4c4": {"__data__": {"id_": "22cfee2b-dfca-4ab4-9059-e88d636aa4c4", "embedding": null, "metadata": {"window": "I'm \nincredibly excited not just about the recovery of the markets, but frank ly, the execution by our teams, which is \ngenerating this performance in the business.  \n \n So, I want to be sure to thank our more than 75,000 employees for their commitment to be together, to be a team, \nto focus on doing good for our company, for our customer s and for the health care industry.  As a global leader in \nhealth care, we are committed to doing our part to serve our employees, our customers, our partners and our \ncommunities as they continue the pandemic response efforts.  \n \n So in closing, I just want to  wish you all and your family's good health and wellness.  Have a great evening.  Thank \nyou. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And thank you for joining today's conference call. ", "original_text": "So in closing, I just want to  wish you all and your family's good health and wellness. ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03733b2e-50cf-454d-ad00-c59834e71dbe", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05c3c367d9d46d218a59e914d0733d7e37ccaa9d4a611b35f16820b8aba05ff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6110ef7-ec23-4b73-b74b-f4740002a68a", "node_type": "1", "metadata": {"window": "McKesson is off to a very strong start in our fiscal 2022.  I'm \nincredibly excited not just about the recovery of the markets, but frank ly, the execution by our teams, which is \ngenerating this performance in the business.  \n \n So, I want to be sure to thank our more than 75,000 employees for their commitment to be together, to be a team, \nto focus on doing good for our company, for our customer s and for the health care industry.  As a global leader in \nhealth care, we are committed to doing our part to serve our employees, our customers, our partners and our \ncommunities as they continue the pandemic response efforts.  \n \n So in closing, I just want to  wish you all and your family's good health and wellness.  Have a great evening.  Thank \nyou. \n ", "original_text": "As a global leader in \nhealth care, we are committed to doing our part to serve our employees, our customers, our partners and our \ncommunities as they continue the pandemic response efforts.  \n \n", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88fde477edd08a2a2d2fe944a5d9dbbcc9bd9416eb43980e9d63db312002b031", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a5b920b-8ed9-4b3d-a802-ce8b4f65bbc7", "node_type": "1", "metadata": {"window": "So, I want to be sure to thank our more than 75,000 employees for their commitment to be together, to be a team, \nto focus on doing good for our company, for our customer s and for the health care industry.  As a global leader in \nhealth care, we are committed to doing our part to serve our employees, our customers, our partners and our \ncommunities as they continue the pandemic response efforts.  \n \n So in closing, I just want to  wish you all and your family's good health and wellness.  Have a great evening.  Thank \nyou. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n ", "original_text": "Have a great evening. "}, "hash": "5bbd13342a633d77ed714ef6dbdd205b0b415f3b80262faa8382ca3d53114b2b", "class_name": "RelatedNodeInfo"}}, "text": "So in closing, I just want to  wish you all and your family's good health and wellness. ", "start_char_idx": 3781, "end_char_idx": 3869, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a5b920b-8ed9-4b3d-a802-ce8b4f65bbc7": {"__data__": {"id_": "0a5b920b-8ed9-4b3d-a802-ce8b4f65bbc7", "embedding": null, "metadata": {"window": "So, I want to be sure to thank our more than 75,000 employees for their commitment to be together, to be a team, \nto focus on doing good for our company, for our customer s and for the health care industry.  As a global leader in \nhealth care, we are committed to doing our part to serve our employees, our customers, our partners and our \ncommunities as they continue the pandemic response efforts.  \n \n So in closing, I just want to  wish you all and your family's good health and wellness.  Have a great evening.  Thank \nyou. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n ", "original_text": "Have a great evening. ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03733b2e-50cf-454d-ad00-c59834e71dbe", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05c3c367d9d46d218a59e914d0733d7e37ccaa9d4a611b35f16820b8aba05ff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22cfee2b-dfca-4ab4-9059-e88d636aa4c4", "node_type": "1", "metadata": {"window": "I'm \nincredibly excited not just about the recovery of the markets, but frank ly, the execution by our teams, which is \ngenerating this performance in the business.  \n \n So, I want to be sure to thank our more than 75,000 employees for their commitment to be together, to be a team, \nto focus on doing good for our company, for our customer s and for the health care industry.  As a global leader in \nhealth care, we are committed to doing our part to serve our employees, our customers, our partners and our \ncommunities as they continue the pandemic response efforts.  \n \n So in closing, I just want to  wish you all and your family's good health and wellness.  Have a great evening.  Thank \nyou. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And thank you for joining today's conference call. ", "original_text": "So in closing, I just want to  wish you all and your family's good health and wellness. ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "265841f67694e345458d4c9d11938c2fcb9fd698988ce9573b8b20d41fc0764b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "86af7ae7-464a-4610-9a4e-cd49d1263391", "node_type": "1", "metadata": {"window": "As a global leader in \nhealth care, we are committed to doing our part to serve our employees, our customers, our partners and our \ncommunities as they continue the pandemic response efforts.  \n \n So in closing, I just want to  wish you all and your family's good health and wellness.  Have a great evening.  Thank \nyou. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n ", "original_text": "Thank \nyou. \n "}, "hash": "d538973e5cac9d108cfbfa1afe57166a328046a5c0486cd288eb7895ad16589e", "class_name": "RelatedNodeInfo"}}, "text": "Have a great evening. ", "start_char_idx": 3869, "end_char_idx": 3891, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "86af7ae7-464a-4610-9a4e-cd49d1263391": {"__data__": {"id_": "86af7ae7-464a-4610-9a4e-cd49d1263391", "embedding": null, "metadata": {"window": "As a global leader in \nhealth care, we are committed to doing our part to serve our employees, our customers, our partners and our \ncommunities as they continue the pandemic response efforts.  \n \n So in closing, I just want to  wish you all and your family's good health and wellness.  Have a great evening.  Thank \nyou. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n ", "original_text": "Thank \nyou. \n ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03733b2e-50cf-454d-ad00-c59834e71dbe", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05c3c367d9d46d218a59e914d0733d7e37ccaa9d4a611b35f16820b8aba05ff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a5b920b-8ed9-4b3d-a802-ce8b4f65bbc7", "node_type": "1", "metadata": {"window": "So, I want to be sure to thank our more than 75,000 employees for their commitment to be together, to be a team, \nto focus on doing good for our company, for our customer s and for the health care industry.  As a global leader in \nhealth care, we are committed to doing our part to serve our employees, our customers, our partners and our \ncommunities as they continue the pandemic response efforts.  \n \n So in closing, I just want to  wish you all and your family's good health and wellness.  Have a great evening.  Thank \nyou. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n ", "original_text": "Have a great evening. ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "766741a714ff1ca7d8abbad291cdc02ff7dcfdbc02fc73b128e033dc41124072", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68323828-d849-41cf-9b24-7b37caec19f2", "node_type": "1", "metadata": {"window": "So in closing, I just want to  wish you all and your family's good health and wellness.  Have a great evening.  Thank \nyou. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And thank you for joining today's conference call. "}, "hash": "2fe1ae0615e5b6264c999c86e76952e35f26f3615a0a555768ce1af6081aa3d4", "class_name": "RelatedNodeInfo"}}, "text": "Thank \nyou. \n ", "start_char_idx": 3891, "end_char_idx": 3905, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68323828-d849-41cf-9b24-7b37caec19f2": {"__data__": {"id_": "68323828-d849-41cf-9b24-7b37caec19f2", "embedding": null, "metadata": {"window": "So in closing, I just want to  wish you all and your family's good health and wellness.  Have a great evening.  Thank \nyou. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And thank you for joining today's conference call. ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03733b2e-50cf-454d-ad00-c59834e71dbe", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05c3c367d9d46d218a59e914d0733d7e37ccaa9d4a611b35f16820b8aba05ff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "86af7ae7-464a-4610-9a4e-cd49d1263391", "node_type": "1", "metadata": {"window": "As a global leader in \nhealth care, we are committed to doing our part to serve our employees, our customers, our partners and our \ncommunities as they continue the pandemic response efforts.  \n \n So in closing, I just want to  wish you all and your family's good health and wellness.  Have a great evening.  Thank \nyou. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n ", "original_text": "Thank \nyou. \n ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d64fa8a85f98c03d46fee58eeca2c052dc46885aaf938eb8190f72b977e25e48", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce8d8bbf-dbbd-405f-a668-51f9ae36b247", "node_type": "1", "metadata": {"window": "Have a great evening.  Thank \nyou. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n ", "original_text": "You may now disconnect, and have a great day.  \n \n \n \n "}, "hash": "eec7f683f217c9e5150a64d2236704a19f1220703365a72b6cd317fd21e4139c", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And thank you for joining today's conference call. ", "start_char_idx": 3905, "end_char_idx": 4241, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce8d8bbf-dbbd-405f-a668-51f9ae36b247": {"__data__": {"id_": "ce8d8bbf-dbbd-405f-a668-51f9ae36b247", "embedding": null, "metadata": {"window": "Have a great evening.  Thank \nyou. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n ", "original_text": "You may now disconnect, and have a great day.  \n \n \n \n ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "03733b2e-50cf-454d-ad00-c59834e71dbe", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05c3c367d9d46d218a59e914d0733d7e37ccaa9d4a611b35f16820b8aba05ff1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68323828-d849-41cf-9b24-7b37caec19f2", "node_type": "1", "metadata": {"window": "So in closing, I just want to  wish you all and your family's good health and wellness.  Have a great evening.  Thank \nyou. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And thank you for joining today's conference call. ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f59b58bc53a8ff1bdb96c7ca1b0d5b98a29e84b8bec7207749389078c587a19a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6387056-da82-4129-951f-067d08f69f1c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based  on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or tim eliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intend ed to be used as the primary basis \nof investment decisions. ", "original_text": "McKesson Corp.  "}, "hash": "8d1ee9cfb74fc0e2c8d72c0dc5d9d55d01f6deeac78433949d50020b6139163e", "class_name": "RelatedNodeInfo"}}, "text": "You may now disconnect, and have a great day.  \n \n \n \n ", "start_char_idx": 4241, "end_char_idx": 4296, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6387056-da82-4129-951f-067d08f69f1c": {"__data__": {"id_": "c6387056-da82-4129-951f-067d08f69f1c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based  on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or tim eliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intend ed to be used as the primary basis \nof investment decisions. ", "original_text": "McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "22a2c3bc-f5a9-4e9d-9fec-881d6056ae02", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cb7562e4cee9284d80cde223227002be318f20241a0d5667d4c739826593f41c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce8d8bbf-dbbd-405f-a668-51f9ae36b247", "node_type": "1", "metadata": {"window": "Have a great evening.  Thank \nyou. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And thank you for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n ", "original_text": "You may now disconnect, and have a great day.  \n \n \n \n ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9dea4726c7ddeab382dcee391d34aaee2fe66c46bfad6ce787df2f96b9365204", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "926a5899-a150-4884-b82c-3e1287d1832d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based  on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or tim eliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intend ed to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as finan cial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an of fer or solicitation would be illegal. ", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based  on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n"}, "hash": "8ce6b8e4fa42edaccd61c9077163d282686ada69cfb057102beaa4629d916cd8", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "926a5899-a150-4884-b82c-3e1287d1832d": {"__data__": {"id_": "926a5899-a150-4884-b82c-3e1287d1832d", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based  on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or tim eliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intend ed to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as finan cial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an of fer or solicitation would be illegal. ", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based  on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n", "page_label": "19", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "22a2c3bc-f5a9-4e9d-9fec-881d6056ae02", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cb7562e4cee9284d80cde223227002be318f20241a0d5667d4c739826593f41c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6387056-da82-4129-951f-067d08f69f1c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based  on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or tim eliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intend ed to be used as the primary basis \nof investment decisions. ", "original_text": "McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b3057ce2c404a7e5a3442188d3035e0e574f882ab07d29a2243bd49aa9ee062b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "462fc660-c57d-4a4d-93d9-567d4cfea8bc", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based  on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or tim eliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intend ed to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as finan cial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an of fer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice. ", "original_text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or tim eliness of the information. "}, "hash": "bfe1b9a699bd8baf1af25d6b38ccf1206daf8c6974dfd060de6f9586513dfcfc", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based  on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n", "start_char_idx": 16, "end_char_idx": 404, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "462fc660-c57d-4a4d-93d9-567d4cfea8bc": {"__data__": {"id_": "462fc660-c57d-4a4d-93d9-567d4cfea8bc", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based  on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or tim eliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intend ed to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as finan cial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an of fer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice. ", "original_text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or tim eliness of the information. ", "page_label": "19", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "22a2c3bc-f5a9-4e9d-9fec-881d6056ae02", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cb7562e4cee9284d80cde223227002be318f20241a0d5667d4c739826593f41c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "926a5899-a150-4884-b82c-3e1287d1832d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based  on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or tim eliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intend ed to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as finan cial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an of fer or solicitation would be illegal. ", "original_text": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based  on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n", "page_label": "19", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8268e744107aa1e4c684a1453d9b350bb1fffed9186b0d65c4c1a1d49d04ed9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f7e021ac-8ac6-44e3-83ca-bddd47e9d45a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based  on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or tim eliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intend ed to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as finan cial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an of fer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinio ns or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "original_text": "You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intend ed to be used as the primary basis \nof investment decisions. "}, "hash": "d4619487dc086a11d029e4cf0556ede92db981ac545b7c076a26b6d9c381a1cd", "class_name": "RelatedNodeInfo"}}, "text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or tim eliness of the information. ", "start_char_idx": 404, "end_char_idx": 527, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f7e021ac-8ac6-44e3-83ca-bddd47e9d45a": {"__data__": {"id_": "f7e021ac-8ac6-44e3-83ca-bddd47e9d45a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based  on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or tim eliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intend ed to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as finan cial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an of fer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinio ns or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "original_text": "You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intend ed to be used as the primary basis \nof investment decisions. ", "page_label": "19", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "22a2c3bc-f5a9-4e9d-9fec-881d6056ae02", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cb7562e4cee9284d80cde223227002be318f20241a0d5667d4c739826593f41c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "462fc660-c57d-4a4d-93d9-567d4cfea8bc", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based  on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or tim eliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intend ed to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as finan cial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an of fer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice. ", "original_text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or tim eliness of the information. ", "page_label": "19", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0baeded25193cd43fdd51f273b61a8bddb98ccbd6d8fe111b9662915cff42c2c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e261ad7e-917e-4468-a72e-dae359c44f2a", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based  on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or tim eliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intend ed to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as finan cial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an of fer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinio ns or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "original_text": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as finan cial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an of fer or solicitation would be illegal. "}, "hash": "6f0b5e663be3fee8eaf9fbf3f7431f189eb14b3670ccb4e501bac670fbd54d1e", "class_name": "RelatedNodeInfo"}}, "text": "You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intend ed to be used as the primary basis \nof investment decisions. ", "start_char_idx": 527, "end_char_idx": 819, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e261ad7e-917e-4468-a72e-dae359c44f2a": {"__data__": {"id_": "e261ad7e-917e-4468-a72e-dae359c44f2a", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based  on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or tim eliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intend ed to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as finan cial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an of fer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinio ns or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "original_text": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as finan cial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an of fer or solicitation would be illegal. ", "page_label": "19", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "22a2c3bc-f5a9-4e9d-9fec-881d6056ae02", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cb7562e4cee9284d80cde223227002be318f20241a0d5667d4c739826593f41c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f7e021ac-8ac6-44e3-83ca-bddd47e9d45a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based  on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or tim eliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intend ed to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as finan cial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an of fer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinio ns or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "original_text": "You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intend ed to be used as the primary basis \nof investment decisions. ", "page_label": "19", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f4a876f4fa10102804ec23c88d7dc0b3ba3280bda7468a926671cc2f03a691ca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4d8d46f-d1a3-4eb9-8933-74fe573567ae", "node_type": "1", "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or tim eliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intend ed to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as finan cial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an of fer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinio ns or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO TH E SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "original_text": "Any \ninformation expressed herein on this date is subject to change without notice. "}, "hash": "1da11265daad8b3adeefc95c0e5605c1443dd7e4738fb96725c6a4f073b877cf", "class_name": "RelatedNodeInfo"}}, "text": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as finan cial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an of fer or solicitation would be illegal. ", "start_char_idx": 819, "end_char_idx": 1182, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4d8d46f-d1a3-4eb9-8933-74fe573567ae": {"__data__": {"id_": "c4d8d46f-d1a3-4eb9-8933-74fe573567ae", "embedding": null, "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or tim eliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intend ed to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as finan cial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an of fer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinio ns or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO TH E SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "original_text": "Any \ninformation expressed herein on this date is subject to change without notice. ", "page_label": "19", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "22a2c3bc-f5a9-4e9d-9fec-881d6056ae02", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cb7562e4cee9284d80cde223227002be318f20241a0d5667d4c739826593f41c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e261ad7e-917e-4468-a72e-dae359c44f2a", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based  on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or tim eliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intend ed to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as finan cial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an of fer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinio ns or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "original_text": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as finan cial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an of fer or solicitation would be illegal. ", "page_label": "19", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1f99f56211d0501ccb03835404d0115da7fab0b9cbe557a4f99c4a8f1f3545d9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13bc8c0d-96a2-434f-af98-bbcf299b5f66", "node_type": "1", "metadata": {"window": "You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intend ed to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as finan cial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an of fer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinio ns or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO TH E SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTS ET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WI LL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOS T PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER  OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n", "original_text": "Any opinio ns or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC. "}, "hash": "38059dff839d35efed0c12e868b880e8db63975348b93b7add87fc45d2d03bf3", "class_name": "RelatedNodeInfo"}}, "text": "Any \ninformation expressed herein on this date is subject to change without notice. ", "start_char_idx": 1182, "end_char_idx": 1266, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "13bc8c0d-96a2-434f-af98-bbcf299b5f66": {"__data__": {"id_": "13bc8c0d-96a2-434f-af98-bbcf299b5f66", "embedding": null, "metadata": {"window": "You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intend ed to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as finan cial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an of fer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinio ns or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO TH E SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTS ET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WI LL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOS T PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER  OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n", "original_text": "Any opinio ns or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "page_label": "19", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "22a2c3bc-f5a9-4e9d-9fec-881d6056ae02", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cb7562e4cee9284d80cde223227002be318f20241a0d5667d4c739826593f41c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4d8d46f-d1a3-4eb9-8933-74fe573567ae", "node_type": "1", "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or tim eliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intend ed to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as finan cial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an of fer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinio ns or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO TH E SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "original_text": "Any \ninformation expressed herein on this date is subject to change without notice. ", "page_label": "19", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "14e668eeb5a5a6a5d31691385886c8a5abc89760a4f3aaa77de0b0427c4ebaf2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "990e26a6-9665-491e-a4f7-149fe1859ca9", "node_type": "1", "metadata": {"window": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as finan cial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an of fer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinio ns or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO TH E SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTS ET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WI LL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOS T PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER  OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "original_text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n"}, "hash": "40aa937b0666e4eff67abd35d7da43d21edefc85d0e11a2831f7a8bb96e33ef4", "class_name": "RelatedNodeInfo"}}, "text": "Any opinio ns or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "start_char_idx": 1266, "end_char_idx": 1394, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "990e26a6-9665-491e-a4f7-149fe1859ca9": {"__data__": {"id_": "990e26a6-9665-491e-a4f7-149fe1859ca9", "embedding": null, "metadata": {"window": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as finan cial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an of fer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinio ns or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO TH E SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTS ET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WI LL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOS T PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER  OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "original_text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "page_label": "19", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "22a2c3bc-f5a9-4e9d-9fec-881d6056ae02", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cb7562e4cee9284d80cde223227002be318f20241a0d5667d4c739826593f41c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13bc8c0d-96a2-434f-af98-bbcf299b5f66", "node_type": "1", "metadata": {"window": "You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intend ed to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as finan cial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an of fer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinio ns or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO TH E SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTS ET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WI LL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOS T PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER  OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n", "original_text": "Any opinio ns or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "page_label": "19", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cf094ef21f7806d7970d0c9ffc763a5e0772b808abb4a4de439b666204f43e3e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "851fd01c-5be6-4b6b-8874-3f329a13e52f", "node_type": "1", "metadata": {"window": "Any \ninformation expressed herein on this date is subject to change without notice.  Any opinio ns or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO TH E SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTS ET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WI LL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOS T PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER  OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO TH E SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. "}, "hash": "29d05ab594cf9170bd0ac73e2b34555ac3b21928f83dbcab86b09cbebcabfc73", "class_name": "RelatedNodeInfo"}}, "text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "start_char_idx": 1394, "end_char_idx": 1557, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "851fd01c-5be6-4b6b-8874-3f329a13e52f": {"__data__": {"id_": "851fd01c-5be6-4b6b-8874-3f329a13e52f", "embedding": null, "metadata": {"window": "Any \ninformation expressed herein on this date is subject to change without notice.  Any opinio ns or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO TH E SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTS ET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WI LL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOS T PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER  OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO TH E SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "page_label": "19", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "22a2c3bc-f5a9-4e9d-9fec-881d6056ae02", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cb7562e4cee9284d80cde223227002be318f20241a0d5667d4c739826593f41c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "990e26a6-9665-491e-a4f7-149fe1859ca9", "node_type": "1", "metadata": {"window": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as finan cial or other advice or as an offer to sell or the solicitation of an offer to buy any security in any state where such an of fer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinio ns or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO TH E SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTS ET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WI LL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOS T PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER  OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "original_text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "page_label": "19", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1f33e8ae1d0a498b49970069389f52770ea7018b6ee03ac2c38ebfa19b2be4cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f1d1419-9857-4039-9cc9-35ca3e020a8c", "node_type": "1", "metadata": {"window": "Any opinio ns or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO TH E SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTS ET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WI LL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOS T PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER  OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTS ET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WI LL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOS T PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER  OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n"}, "hash": "6587a69a56627366442a898a668a9644df2f872583f77833dd6339232ee30223", "class_name": "RelatedNodeInfo"}}, "text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO TH E SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "start_char_idx": 1557, "end_char_idx": 1991, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f1d1419-9857-4039-9cc9-35ca3e020a8c": {"__data__": {"id_": "3f1d1419-9857-4039-9cc9-35ca3e020a8c", "embedding": null, "metadata": {"window": "Any opinio ns or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO TH E SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTS ET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WI LL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOS T PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER  OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTS ET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WI LL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOS T PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER  OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n", "page_label": "19", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "22a2c3bc-f5a9-4e9d-9fec-881d6056ae02", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cb7562e4cee9284d80cde223227002be318f20241a0d5667d4c739826593f41c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "851fd01c-5be6-4b6b-8874-3f329a13e52f", "node_type": "1", "metadata": {"window": "Any \ninformation expressed herein on this date is subject to change without notice.  Any opinio ns or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO TH E SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTS ET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WI LL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOS T PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER  OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO TH E SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "page_label": "19", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9d86bd6d677108a0da90234ef4ad253e8c8ac4671940a4f015468e1404fa13a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "46cd4c97-ceb3-4f28-ba3f-e5eeccdd69f0", "node_type": "1", "metadata": {"window": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO TH E SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTS ET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WI LL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOS T PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER  OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. "}, "hash": "f32446f663b870cdecd093146b7fff5a9ab59484a117a683b04e53ee6d43eb6d", "class_name": "RelatedNodeInfo"}}, "text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTS ET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WI LL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOS T PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER  OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n", "start_char_idx": 1991, "end_char_idx": 2671, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "46cd4c97-ceb3-4f28-ba3f-e5eeccdd69f0": {"__data__": {"id_": "46cd4c97-ceb3-4f28-ba3f-e5eeccdd69f0", "embedding": null, "metadata": {"window": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO TH E SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTS ET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WI LL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOS T PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER  OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "page_label": "19", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "22a2c3bc-f5a9-4e9d-9fec-881d6056ae02", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cb7562e4cee9284d80cde223227002be318f20241a0d5667d4c739826593f41c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f1d1419-9857-4039-9cc9-35ca3e020a8c", "node_type": "1", "metadata": {"window": "Any opinio ns or assertions contained in this information do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO TH E SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTS ET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WI LL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOS T PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER  OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTS ET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WI LL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOS T PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER  OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n", "page_label": "19", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5422c1fee122e5fbd2cac6a490288a6d9a48ac973b64a33509c7615255434b63", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b8d23bf1-e297-44d6-b411-68028cb5313f", "node_type": "1", "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO TH E SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTS ET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WI LL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOS T PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER  OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All \nother trademarks mentioned are trademarks of their respective companies. "}, "hash": "14e5606b04b4313bf458f20cd5d2d15e79cdd42be2fa2742343c5dfde032fd43", "class_name": "RelatedNodeInfo"}}, "text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "start_char_idx": 2671, "end_char_idx": 2860, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b8d23bf1-e297-44d6-b411-68028cb5313f": {"__data__": {"id_": "b8d23bf1-e297-44d6-b411-68028cb5313f", "embedding": null, "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO TH E SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTS ET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WI LL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOS T PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER  OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All \nother trademarks mentioned are trademarks of their respective companies. ", "page_label": "19", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "22a2c3bc-f5a9-4e9d-9fec-881d6056ae02", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cb7562e4cee9284d80cde223227002be318f20241a0d5667d4c739826593f41c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "46cd4c97-ceb3-4f28-ba3f-e5eeccdd69f0", "node_type": "1", "metadata": {"window": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO TH E SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTS ET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WI LL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOS T PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER  OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "page_label": "19", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73b911ece18014fe3561fb4dcbc84162c39084670ba6890041093c1c90e87206", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab34ee79-3f40-4278-856d-13a1f715de37", "node_type": "1", "metadata": {"window": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTS ET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WI LL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOS T PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER  OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All rights reserved.  "}, "hash": "61c7bb971812a12b3f9286cdd0c2e6c57dd38bc2396b79d7b41e3d84057b41af", "class_name": "RelatedNodeInfo"}}, "text": "All \nother trademarks mentioned are trademarks of their respective companies. ", "start_char_idx": 2860, "end_char_idx": 2938, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab34ee79-3f40-4278-856d-13a1f715de37": {"__data__": {"id_": "ab34ee79-3f40-4278-856d-13a1f715de37", "embedding": null, "metadata": {"window": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTS ET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WI LL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOS T PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER  OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All rights reserved.  ", "page_label": "19", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "22a2c3bc-f5a9-4e9d-9fec-881d6056ae02", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cb7562e4cee9284d80cde223227002be318f20241a0d5667d4c739826593f41c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b8d23bf1-e297-44d6-b411-68028cb5313f", "node_type": "1", "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO TH E SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTS ET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSORS OR SUPPLIERS WI LL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOS T PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER  OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2021  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All \nother trademarks mentioned are trademarks of their respective companies. ", "page_label": "19", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fba8f11c0e8ac0743661713498b80e9662a5b25423269bab39949a8c3d1c93a8", "class_name": "RelatedNodeInfo"}}, "text": "All rights reserved.  ", "start_char_idx": 2938, "end_char_idx": 2960, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"f83e9682-a495-4a36-a4a8-4e014dbd92c8": {"doc_hash": "3895a6612842a1670cd2ef8ca6ac7e8f5dd57c5e8bb79fccf2e16841c5ebdf22", "ref_doc_id": "d722b2c6-7573-48d7-9a60-f4b19a5e6cb3"}, "ec128aed-3c4f-4f95-8b2f-d785c52e4ebb": {"doc_hash": "1f7b0b3621ffed0e7a505efb83c1cf05380684d50f6b37ef63d72ae22be5bd39", "ref_doc_id": "d722b2c6-7573-48d7-9a60-f4b19a5e6cb3"}, "6582eba8-2152-47f3-8923-e4a7cc436a98": {"doc_hash": "a26b733d1547c45d9bc0fe598fdf2a982bdc78acc8ee8768c09806da021ca829", "ref_doc_id": "6464c30c-9944-4870-b7fd-30474d3e4691"}, "c16b6ac7-9fb5-44b6-897c-c8bbbc105df6": {"doc_hash": "8956bdb755d6e8f162795e0c8dd0f4ac7f0cb0f6a0baf9bd6f7cab7408463cd8", "ref_doc_id": "6464c30c-9944-4870-b7fd-30474d3e4691"}, "31fdebb4-7161-4aa7-939a-87c79c7d7d8d": {"doc_hash": "4edd43f3b8d29e2908eb6e2f9cf2468265d56c36c624abed9a37504253b30aa1", "ref_doc_id": "6464c30c-9944-4870-b7fd-30474d3e4691"}, "77750ec6-480d-4325-8aca-1cdeddb3ed3e": {"doc_hash": "86e1bdbd851c15efb52ed1231a3150a0779136d6604a477c3788e2042c202f38", "ref_doc_id": "6464c30c-9944-4870-b7fd-30474d3e4691"}, "3b869698-0365-4461-8a32-c7c76314708c": {"doc_hash": "f76c54d84305151459de70b5bbf871b385b133e2e05919c15b64b8ec7a3dc1e6", "ref_doc_id": "6464c30c-9944-4870-b7fd-30474d3e4691"}, "f696633f-3170-428f-a177-b1bc588b35c7": {"doc_hash": "b110762a8de5a1c6c817ebf8b8d72047368f5667f4d60134dbacb23533ceae9c", "ref_doc_id": "6464c30c-9944-4870-b7fd-30474d3e4691"}, "b2893e45-a589-4373-8848-d928f97a1cf8": {"doc_hash": "131debb9a4b4a0a32012a2925c4c94ec99fd1441435c634e0d558da605ab061e", "ref_doc_id": "6464c30c-9944-4870-b7fd-30474d3e4691"}, "edda169b-9d02-4c3a-81a0-81ed150dd0fc": {"doc_hash": "70e5d8125af2a47f0fa73ce89ea178da7eea0593cdca6eb3d2dbc688dfd32dc9", "ref_doc_id": "6464c30c-9944-4870-b7fd-30474d3e4691"}, "99a8d6da-fe84-401a-8a6a-d044775aeef1": {"doc_hash": "329489d5b17f6cbc73786a61a2e6908cf04b98119130fe33687c409306d180ea", "ref_doc_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8"}, "d1d1419e-2bbb-4c5d-a5ed-9215f9c73a02": {"doc_hash": "04dacb8632f6f5d31a1544857fc2e4a060f0dbd24e8e62008a94a610aea95eba", "ref_doc_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8"}, "457cf053-83a7-48a5-a713-b2f43607afea": {"doc_hash": "7b881101e795d2569f8fc48898885ce808309f7e46dd676cea5d88b5d682d70e", "ref_doc_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8"}, "b98e6ce4-63ae-4c9e-946a-4b1ba6ae1e0b": {"doc_hash": "af47ce42db44b2e72ba4c99bd32fe3398d472b396ea2217bdf1dcb8b4af5eaaa", "ref_doc_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8"}, "f523c120-2c37-4cc5-a00e-d79ecb49ec38": {"doc_hash": "48230a0fac0122ab49b529da870a2a413ba62022d597476d5ad6de8b5a74d667", "ref_doc_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8"}, "6f41daaa-f10a-48c8-9db0-a62861abacf2": {"doc_hash": "50ef7ed2cbf29d093722139ad5ee81ba9295fa9ef5b048b800394712b6d9f5bb", "ref_doc_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8"}, "2cd79074-27cf-4109-80a0-8836a74cbd67": {"doc_hash": "ba3e9530aec875a0ae07c15c421203899ed8facf2392a2fb4f561dfa12aca34c", "ref_doc_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8"}, "ecf906c3-b20c-418a-94dd-244b93fba816": {"doc_hash": "a2b57f04e03a48f66f06fdad57762aa5d52eabba046c253ae127b41d5852a89d", "ref_doc_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8"}, "ed2c0c07-5989-4f5c-b9b7-d3614c03ec97": {"doc_hash": "a95fa6712ac9b64976107996ce85c76cc25120a1a599e15b3cb759eb2cfad9b7", "ref_doc_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8"}, "3dad2a05-56c1-4b3d-ae8a-2d117e128145": {"doc_hash": "bdc474dd3fe51c05f4be293fb8981d325b0e1f184c65b774e0b38d9b476d2c0f", "ref_doc_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8"}, "de00f2ab-9af6-4fdc-9f32-3b3629b82c5b": {"doc_hash": "28957515021da0bd8c0fc6e313043d8082cce141e072cd0e569a5be693ad9166", "ref_doc_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8"}, "ba88020a-3774-4150-95c0-eadbd35d6e34": {"doc_hash": "9e7a236bdaf1ba77170f1fc22f92826bcc88a22cae7a0cc5dbd8d526ebf44723", "ref_doc_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8"}, "c0e8da74-71f3-4579-bb60-b4e2d22724dd": {"doc_hash": "da0f0dc47885b76149ebddd415259ce5b3dabe8b858dd83b4fbe2b9e690f9f8c", "ref_doc_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8"}, "7e3fb905-c808-4c72-9988-092173fc332e": {"doc_hash": "ce70de6f852ba88f7f9a81fbee03423afb677069da96309ae8cfab81e83b8a46", "ref_doc_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8"}, "075a7369-29b1-425f-9266-4eb3823cc4f3": {"doc_hash": "16ffe8cc0070c506f8b75a4ea4002777546a37f653bb5825cd62f1afeada98d4", "ref_doc_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8"}, "762aa045-09df-4d7f-a3a2-746bcb0aa253": {"doc_hash": "f20444353b9a05ee26b9f21604f863f4535aed97eadc4b3b9470398ff8b658f8", "ref_doc_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8"}, "9e5a43be-5022-4053-b87e-1b7101db70da": {"doc_hash": "b2a10b2d2a0519e94e763c371d3b804c9ba282618532e32dcf3500b88c9bc856", "ref_doc_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8"}, "788f3d9c-5f38-4fd4-9f1e-d710ab04a3c2": {"doc_hash": "16caeda25459d2060fd765dffd605711833d491ef3855d2e1b29062b8439f6e1", "ref_doc_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8"}, "a2a7d591-0172-4bea-b6bc-500673f85b8e": {"doc_hash": "f50f8123263895d1c1cd9d6ef3139327a1f4ea3c4831a5c75146b1330478f2ab", "ref_doc_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8"}, "476329e1-aff9-4a14-b432-9980aab58668": {"doc_hash": "2e3a2b4f41692412e780e0eaa91c2e74f58adef64a2644f6b787afa70dbdc52a", "ref_doc_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8"}, "db397d6e-e0d5-4b2e-a6f9-aa9bfd9c1da9": {"doc_hash": "f87444f70347e125b997cf7af587d8fd45f0f917270ef821f28c71bcbf0d5b7f", "ref_doc_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8"}, "700990cd-a583-49ec-a912-21367bdc88f2": {"doc_hash": "3ede0850d644444ab61dda1a7a4b6785803a389a92157d5bf9144ebd6994d313", "ref_doc_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8"}, "8d0d3edd-552b-489e-b875-74220e3d1196": {"doc_hash": "a30a5d377a7304ef15c3bbf8512964de4eadd36c580cbd3ebf9ed16ba8f14bd1", "ref_doc_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8"}, "d62f0f69-44e8-4529-bf6d-ba12c52478f0": {"doc_hash": "5c06c8e026c92a4b4a2fa16d8829094655b8800c019b12d475bf8f653b1f7719", "ref_doc_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8"}, "684b5ed1-0fbd-42d2-b92b-f5e9518be79b": {"doc_hash": "e59648fe0a9871c77af447119ee7bb0e824b7a893c9035bfa3c1e0cc64652e84", "ref_doc_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8"}, "7365827a-e44a-46fd-b8e0-51db5c52ef6c": {"doc_hash": "9d3b4cec457baf48b87c5cb428f0342f670ba853f22669ffa672bbe847999c84", "ref_doc_id": "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8"}, "ce7ee229-8083-4fe9-82d3-a147aa02706c": {"doc_hash": "d332bbcfbacb329f9c9f27818df9ea1543a818f1993315785109adc6cfb33b73", "ref_doc_id": "aab73de7-ebef-4918-a603-d86999a6bb6b"}, "40738c12-5fb4-4b89-9afe-171b5bf4e61f": {"doc_hash": "65caac9018d3d0a371ae0af92c768078e30fbeeacb799b0bf32f7768bfb7e6bb", "ref_doc_id": "aab73de7-ebef-4918-a603-d86999a6bb6b"}, "8dbfb1e4-9b0c-4486-81d0-c72af5a1de1a": {"doc_hash": "06d65caa869fd4f69a41ad1878cddd39ec7b7fe9f71b1cd50e594af9611c6983", "ref_doc_id": "aab73de7-ebef-4918-a603-d86999a6bb6b"}, "b73a2fb4-dd1c-4380-a8c1-c0e82a86ba0e": {"doc_hash": "7e865673486f497e4f2a33c33683a760e997fb43902aee81ca5f00d55df39170", "ref_doc_id": "aab73de7-ebef-4918-a603-d86999a6bb6b"}, "287a00fc-2062-4d04-9545-f3a31d0fe8da": {"doc_hash": "a3adb48207736a0cd6c9bf94908be05e0a1fc9449065c0080973e6dd21d026c4", "ref_doc_id": "aab73de7-ebef-4918-a603-d86999a6bb6b"}, "60879f82-860d-40cc-8e6e-7646a7f4c04f": {"doc_hash": "4ef5f38595bada2e84f4fcd74a0977433ceeff5144104749f24295c014870d82", "ref_doc_id": "aab73de7-ebef-4918-a603-d86999a6bb6b"}, "b6617c27-4688-48c7-addb-fbd8d2495fc1": {"doc_hash": "55897c33584e6f4f534fd68cf86e3348b3139084b698c735c81705ac60cc35a5", "ref_doc_id": "aab73de7-ebef-4918-a603-d86999a6bb6b"}, "d38de659-b006-4b2b-925c-f77785825da3": {"doc_hash": "4bb5f29c88b4b5cf62d8f4215390bac6c701dde81bb34b6a7fa5980030b7e1f5", "ref_doc_id": "aab73de7-ebef-4918-a603-d86999a6bb6b"}, "3348ed2d-9eba-42fd-90d8-39141be3c4cd": {"doc_hash": "9d95a7099f59392f78e9b6f1ac7b34dd22954adfc2b01b6a63469a26805c5530", "ref_doc_id": "aab73de7-ebef-4918-a603-d86999a6bb6b"}, "21e0f154-4ae3-452f-9f66-7559709e042e": {"doc_hash": "6469f8644cd021294e4424945a2baa842c53d521225d4e6cd0b73fd1133a4758", "ref_doc_id": "aab73de7-ebef-4918-a603-d86999a6bb6b"}, "b02d88aa-a561-4588-be76-7f2bad2be6cf": {"doc_hash": "35248b335f764cbc39ca9b48463f8682fbf50aea91059ce7bae363686aac1d81", "ref_doc_id": "aab73de7-ebef-4918-a603-d86999a6bb6b"}, "5a41e7c1-daf3-4602-b03e-372d076995bc": {"doc_hash": "05774308bb812ed1c1ea65ba2d68bbdf2cb70458aee77d71cd5c51396d7bd8bd", "ref_doc_id": "aab73de7-ebef-4918-a603-d86999a6bb6b"}, "c70e5224-e48b-4b44-9788-932c86458571": {"doc_hash": "2055de93657d9a18dde840dbe3fa4bfd5c25819bf74097e430e77cf509839e87", "ref_doc_id": "aab73de7-ebef-4918-a603-d86999a6bb6b"}, "d2d48526-221e-4a5b-8e21-baf48fc1d8d9": {"doc_hash": "99e4c32a6db47ef4581000966d99447667c6f4b4333677dc6a48056cfbca8208", "ref_doc_id": "aab73de7-ebef-4918-a603-d86999a6bb6b"}, "4e702d4d-32a8-4918-8e7c-bf688c2c495d": {"doc_hash": "50415b9e2acbe49126949ce04028ced6de003809002c7637dd489018928ab5f9", "ref_doc_id": "aab73de7-ebef-4918-a603-d86999a6bb6b"}, "1dafb4f4-86c7-4132-9ef3-99abf227b352": {"doc_hash": "66783dc267c1323888718a796f78d01a43c64eb9b549d91e7651837eb5f15590", "ref_doc_id": "aab73de7-ebef-4918-a603-d86999a6bb6b"}, "94888eb3-2fd3-4d1f-afa9-13c4b8f347af": {"doc_hash": "c72ccc5c5826f11383b4bed10dd01ab0dfcbfc2073d0399e0c16bf5e84804c40", "ref_doc_id": "aab73de7-ebef-4918-a603-d86999a6bb6b"}, "0eaa8fcd-51d6-4be5-b020-9c2b79628dd1": {"doc_hash": "74d43c9aae2f8750ce14c9d3f168f56716129b2487e21724a264f9e1068c7b25", "ref_doc_id": "aab73de7-ebef-4918-a603-d86999a6bb6b"}, "fb840545-f360-43c1-b029-4b461c5cae8d": {"doc_hash": "af17f0a794b5ff37f39eef2ce69c8bf386182b8f7fa9c3f1c74b56314c225819", "ref_doc_id": "aab73de7-ebef-4918-a603-d86999a6bb6b"}, "43a700a0-c926-4ecc-aacf-00f3716eb136": {"doc_hash": "5eb13665ebad59237cfee5a1c45465a9031eb7cc8aadec911dcf2317222383be", "ref_doc_id": "aab73de7-ebef-4918-a603-d86999a6bb6b"}, "4ca7e15f-fdbc-491d-9d1b-74b999eadee9": {"doc_hash": "cced6323b571f59c248f9373f8bb109c4f077f610bbed95e988369664aeb8d74", "ref_doc_id": "aab73de7-ebef-4918-a603-d86999a6bb6b"}, "221fece3-216c-487e-8de4-c703341d76c5": {"doc_hash": "9437f24e3fd4618123754357fdbe1b7f1e42777d6fbeb390e0d134e6ba942ab6", "ref_doc_id": "aab73de7-ebef-4918-a603-d86999a6bb6b"}, "cc6e4c4d-ea59-4a1b-a600-56c8905f7595": {"doc_hash": "39d497c6d05129acb8595d2e2c811e70f48ad186bfd216928b20c3bf4c630263", "ref_doc_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325"}, "543244ed-7423-4dab-90f7-26279a703bdb": {"doc_hash": "499f9e42978eb4879097c6aa28523bed92db4a1cd7aa64bbbd4aca821851875a", "ref_doc_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325"}, "1caf4599-4614-4f81-98aa-d6565c103aa5": {"doc_hash": "d92ab0e7226bfb25e6fc063a1c9c970795117472e8667b54a45201e94c4a3636", "ref_doc_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325"}, "1b3f95cd-3f93-4837-b699-889e2a4bed89": {"doc_hash": "3ea2b46e865017583dc39eab538c09fa396ca3f2bda2fa808ea1abd6d3f84598", "ref_doc_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325"}, "089b2f5e-8390-4126-8c94-1975296141f3": {"doc_hash": "1facf78615c344e17310e5e000264769c42f62b02f888cd53f59c6ac8ebb4828", "ref_doc_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325"}, "fd91253e-bdfc-4188-9b2d-8683ccfd507d": {"doc_hash": "bf7fb17e929ff8089e22dc10c3969fc9f7b12191092cf72b813543a04ecbc48f", "ref_doc_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325"}, "4448a8bc-4bd5-44f4-8519-7c4afc2ae657": {"doc_hash": "4ba35071b9a8700efd20cfb944b0f3234b7d55453ec2bfefa8380a59d312852e", "ref_doc_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325"}, "7bd764bb-a95a-455c-b9b0-afa598f3bc9d": {"doc_hash": "8bfb8daf0b4ba7ddc8ec0b529030be73c78eeef92b19e3549e787a22ff514c55", "ref_doc_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325"}, "fd48613f-d7c9-4b69-8d0e-3f3a788d9423": {"doc_hash": "86b1711ce8e13a3b68b9aa7e40ab13ec60d1b01a70460fd854094f720f49bdc1", "ref_doc_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325"}, "3ba3b3a7-0fe1-47c4-88e8-3e59534d9359": {"doc_hash": "957bf98d1a3d64f6170ad9bf4aaeb7cc948456704cd297f03355491506db009f", "ref_doc_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325"}, "7ddf13f7-f253-4cd3-b214-bcd58b0c96a3": {"doc_hash": "ad333c5463b32f2c3d0403b8cadfb0b1543eac5e9bae52f0a70ec08fc282a810", "ref_doc_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325"}, "2da63bf2-277a-4caf-b6d1-f3b6475f4e11": {"doc_hash": "3dd3caf0e43621ebdfc824d00d3b4e65fe83190818efe993fa4017615193a04f", "ref_doc_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325"}, "352a3560-d200-48d5-8ae8-294c72d1705b": {"doc_hash": "e97d0d1848233826f676cfdba058e5d4a2661040690f198d510bb91db28b8423", "ref_doc_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325"}, "22d5cec0-b9d0-4421-9f09-1595c2ae18c4": {"doc_hash": "6e73111d6c04a1922cc3a29bf9a4aaff10512b99f3cfa80a276a6ab730953004", "ref_doc_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325"}, "2d078137-0358-4985-b56d-8a07fe6a6e67": {"doc_hash": "b45bb7d4381e936dc23ff013a40bf115eacc4f440e4d212aa5c662a705bb23fa", "ref_doc_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325"}, "2b128367-34bf-4c37-b189-e2894cffad08": {"doc_hash": "ead60cd4cf44543db6804479c399171b54d699e678efb2d24e84c1eb5905c91e", "ref_doc_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325"}, "eefa3a66-b993-40e7-9efe-b5e9b6b76646": {"doc_hash": "420d22b015085e7c50fc4d81dc3b8829c91312a0f1f7de79191c87d3cfcd338a", "ref_doc_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325"}, "c27b8da1-4023-4672-a2eb-acdb504063fa": {"doc_hash": "70446851155f5d8181861ec442609fb86b82378c7fb08b655655592261c31901", "ref_doc_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325"}, "b2a816ea-df61-4499-bae7-07ad21468024": {"doc_hash": "fb164a433916a41f43caa31b3bbc95d2ffba153891608c1ad7fd309f2a5be161", "ref_doc_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325"}, "caa2eb17-98b5-4f91-b9b0-30fc4331c39a": {"doc_hash": "6fdf1502b56fb88d2621cd388876d13b9779045e0db4868cd668da39b3c64916", "ref_doc_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325"}, "1b10b331-afd2-4b23-9764-08ded3d37185": {"doc_hash": "4aa39e77720d25e9a9a0e793fded32d54c5fdf8b89be73c89ecc39aa2f03066a", "ref_doc_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325"}, "f7887e28-9c21-4773-b285-7627117ce47f": {"doc_hash": "0664a0531af43c67da14950ff86dea0f71d13cdc0bcddb04ca887ef280a23dcb", "ref_doc_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325"}, "9f930f83-4729-407d-8c0a-8ef339a66b43": {"doc_hash": "6bf90d05755d41d96eb1e1518bab1bc7da83fd4987809dedb0c92dc8f661486d", "ref_doc_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325"}, "57a66c74-fecd-4fe9-80b0-6031c910a757": {"doc_hash": "16868f0d562d2ba37b2577b526021705dc77132e820b4d4f2534138dc6e01c1f", "ref_doc_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325"}, "2dc66ff7-a240-466f-a074-82012c59058f": {"doc_hash": "94a2f63b444f6324d5ad23982787c03430ca1b637cd595de1a33d480a481fdf2", "ref_doc_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325"}, "de598687-e2df-469d-8641-513b680ff796": {"doc_hash": "6e84c3d041142363b88b7f2d9fc3da49aa6fbf96a74924546c76e9d7b57e6317", "ref_doc_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325"}, "ca93a3be-8929-4588-9164-bf9165a43d6d": {"doc_hash": "725d5ba5788786cfc761795684b10efc5c36dd9d0af17761fb6cff011805c758", "ref_doc_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325"}, "fb9d3cfd-d7a4-4991-b9ce-96ec3fff4858": {"doc_hash": "c1e73c5778c2134463507b251da0b3e54d6aa1a823a43f427d6e2b439ef4c2ad", "ref_doc_id": "f365cd4e-b668-4c4a-9f08-b63a33cd9325"}, "2d160a25-bc44-4383-ac1b-0cf8af5c699d": {"doc_hash": "e6438a6b5a82210ebf9e4d7f59f6e4ac2d352886da0ce04449733682566be0b9", "ref_doc_id": "5a8a9216-8deb-4e14-80bf-7ca55ba8e1b3"}, "bada9e6c-5064-49af-9b8a-2b492140a369": {"doc_hash": "d6a2dbca703f8cbd9845b8f89e6fc6406d9cdaaee8754c6c2d9b1a3e52262963", "ref_doc_id": "5a8a9216-8deb-4e14-80bf-7ca55ba8e1b3"}, "8657a3d5-161c-4370-a5e0-5626426b9a9e": {"doc_hash": "2bdd5bb6014853e633ad84bb9c47894ba86a8c7a9a747026d9e9f8799373e23a", "ref_doc_id": "5a8a9216-8deb-4e14-80bf-7ca55ba8e1b3"}, "51e2f6e5-9386-4a0c-a3b7-63671cea186c": {"doc_hash": "ab0d5f508bbcd97f131552954c5e99139307f6906b36e0c6bee8cf4a7733bb07", "ref_doc_id": "5a8a9216-8deb-4e14-80bf-7ca55ba8e1b3"}, "95a1e65c-fc0e-4a06-afd2-c02a2d496a14": {"doc_hash": "e623d42be68fb283b78a321582c229abc7df3099808da675a44f497be2dd1ebf", "ref_doc_id": "5a8a9216-8deb-4e14-80bf-7ca55ba8e1b3"}, "38f7b1f1-6365-44a8-aab5-b59c4cb65b7e": {"doc_hash": "fde225e15bd97e38283f165030598aa9a50f1d3e49860e9423cf7ebe412618df", "ref_doc_id": "5a8a9216-8deb-4e14-80bf-7ca55ba8e1b3"}, "0f9d3cd1-3c01-4c9c-b614-861dab1fd871": {"doc_hash": "9d706f0e73d59a7d0c86d963960724519508ce7f89f4065c8deb19a57ccf7b95", "ref_doc_id": "5a8a9216-8deb-4e14-80bf-7ca55ba8e1b3"}, "4001fd35-e2f0-4aaa-ac87-264600899c43": {"doc_hash": "2d6fd3014c3cf2b25d7d5ba9242bcef14902e7602127fa6563be6a6370bf5b71", "ref_doc_id": "5a8a9216-8deb-4e14-80bf-7ca55ba8e1b3"}, "21d36668-ce01-4fda-b10c-6aada7e8db93": {"doc_hash": "60c5f817d35b359711d8f0099cfc0ce2314dcbd78faffbe86c3817e289537a74", "ref_doc_id": "5a8a9216-8deb-4e14-80bf-7ca55ba8e1b3"}, "964226ba-ff1a-4103-a704-8bc624ea1e3a": {"doc_hash": "09f23300682d1163c8c93aa313377da83473acfc730b9bdb700b71a769f71387", "ref_doc_id": "5a8a9216-8deb-4e14-80bf-7ca55ba8e1b3"}, "b5381bcc-f224-4128-a1e1-8fdf7c4ddd26": {"doc_hash": "effb6d664de7a7e1e8d62c5ac1eefc785ca61d729663bcb90322d262180b1723", "ref_doc_id": "5a8a9216-8deb-4e14-80bf-7ca55ba8e1b3"}, "c80097b2-1e43-40c6-8e5d-3583c33167c7": {"doc_hash": "a8e9c0f2229474c106c18511dc51146b6d929ece9d221829419eae2b0bd00bce", "ref_doc_id": "5a8a9216-8deb-4e14-80bf-7ca55ba8e1b3"}, "bbff9dfb-5a22-4188-b5ae-c4e0fd77c695": {"doc_hash": "c1312990bb53927c9a0aed6156742e8e4c3599903996cf1a404de98f2083442b", "ref_doc_id": "5a8a9216-8deb-4e14-80bf-7ca55ba8e1b3"}, "f846f458-8638-4a22-aef0-138ba1cf2c30": {"doc_hash": "62157c7562b4839dc0b6f66978baa12eaa0829b42834761155d3ff0223f9bd83", "ref_doc_id": "5a8a9216-8deb-4e14-80bf-7ca55ba8e1b3"}, "3d467cb1-15e7-417b-8119-d204f425b266": {"doc_hash": "c5d2610b69703bf6c3bf4879c63e55a828c101db90d251c30660cb6b647670dd", "ref_doc_id": "5a8a9216-8deb-4e14-80bf-7ca55ba8e1b3"}, "3b51c955-0d17-4316-91e8-75b0a700d21d": {"doc_hash": "339c6dca400f414a38df30b446dc8ecce445931b00daa96fe2dce403e1184f02", "ref_doc_id": "5a8a9216-8deb-4e14-80bf-7ca55ba8e1b3"}, "bda6271b-2ebe-4f41-8a68-eb6d43a87a3b": {"doc_hash": "bc5142cda15dc16002cb20114ea82f7fc534f439a33330353dec3dc0d466f735", "ref_doc_id": "5a8a9216-8deb-4e14-80bf-7ca55ba8e1b3"}, "76b30c8c-481a-4e93-a72d-8b2beaf7c138": {"doc_hash": "d95f989058e8038ac9a7d0dd5aba1efd06c0a3996e2af24fd893a05d2fba40f3", "ref_doc_id": "5a8a9216-8deb-4e14-80bf-7ca55ba8e1b3"}, "9ad863a7-ba66-4131-b0c6-ecdf9e8dc175": {"doc_hash": "45555f4a066f57255c2505c67c290343de5a7c6d9ac32e8be50da24e6fe9e942", "ref_doc_id": "5a8a9216-8deb-4e14-80bf-7ca55ba8e1b3"}, "67c33a4a-a5e7-4ce6-b6b1-5832565b8945": {"doc_hash": "5ed09f62a4e79cf268a9459b368076d11a1326ad998073b2d4a2a338740966ad", "ref_doc_id": "5a8a9216-8deb-4e14-80bf-7ca55ba8e1b3"}, "0a2a34d8-231a-4c63-adb9-c0a3dbff2693": {"doc_hash": "9abd8630d51fd370a8edbed00f8c978e99ef03f3359fcf4b07ee84a2ab2ae73b", "ref_doc_id": "5a8a9216-8deb-4e14-80bf-7ca55ba8e1b3"}, "3b1c75a6-e455-4acb-8d86-cc1e6d8cbf12": {"doc_hash": "c4fce2e4b3b873d598733f62f58ab71c598920bd6be2bb4fdc82223f905725c6", "ref_doc_id": "c73484e1-29f7-4a39-9410-ade1661a5493"}, "11235ed8-81e7-4e6a-b0b7-46dbb2e45934": {"doc_hash": "58e3b76c95705138543cce1bf86edcd26626c9adf4f26409968055dec9463306", "ref_doc_id": "c73484e1-29f7-4a39-9410-ade1661a5493"}, "6ea4d31c-ac5f-48b9-a0d0-cd928e8e4852": {"doc_hash": "9f6e5b8009b788fa83e11516a4c7246befb492bc79709de1bfdbe512846bf909", "ref_doc_id": "c73484e1-29f7-4a39-9410-ade1661a5493"}, "f57362bb-e9da-44b4-9ea7-45dc118ed78f": {"doc_hash": "e67eb19a79511005421477f4d1de2cecb2a9ff97bb2c8b3921dab5e3fe6beee2", "ref_doc_id": "c73484e1-29f7-4a39-9410-ade1661a5493"}, "d74b1fd4-9f27-4ea3-b33e-d67b4a8da2dc": {"doc_hash": "65aaebf4bb3bed83288ee3674c5f832657fc73862fd8d4978dbbf3b23325ecfe", "ref_doc_id": "c73484e1-29f7-4a39-9410-ade1661a5493"}, "b762a92a-1fd7-4fc5-bfc3-b0558bba8e83": {"doc_hash": "390892e3a2d3c917c72d484155444c7554547bd72d39aa41ad30ade81f8c228e", "ref_doc_id": "c73484e1-29f7-4a39-9410-ade1661a5493"}, "d7a845d7-b00c-4a62-8085-ebacf58be99a": {"doc_hash": "e344447e1723c8815f2ec899df207bb15a3b9d67239a544bddaec1a8329807c0", "ref_doc_id": "c73484e1-29f7-4a39-9410-ade1661a5493"}, "e63e32ae-6671-47db-9ea8-25eff69ebc10": {"doc_hash": "6696058af25b1cd9ad7e3a16f4a09030c23b4eb4ebf0d05df82cb2453a8279f0", "ref_doc_id": "c73484e1-29f7-4a39-9410-ade1661a5493"}, "74474007-e75e-41f1-87cb-72d693461369": {"doc_hash": "fc2f739a06ace558e63daa5817a20ce792ee4347a58d2ae2ccb300e66da76aa0", "ref_doc_id": "c73484e1-29f7-4a39-9410-ade1661a5493"}, "29e97fdc-769c-4074-b2ec-ab82326ac8ee": {"doc_hash": "01949af6fc50f1c532a46ea4fa9071ea82b5a53188ed5f8ee955d96f5812567d", "ref_doc_id": "c73484e1-29f7-4a39-9410-ade1661a5493"}, "c49c284b-892a-489d-a78c-edcabd441a3e": {"doc_hash": "c39a9e5e99f70c1b6111d55ba432276dd8029221769981fa36981c13afad43ac", "ref_doc_id": "c73484e1-29f7-4a39-9410-ade1661a5493"}, "fbc8833c-9f50-4b42-9162-234f8eff4809": {"doc_hash": "123e68f91eb013f2372d0381887eb066f5dd5c6049f9b6816a0287ce885c6159", "ref_doc_id": "c73484e1-29f7-4a39-9410-ade1661a5493"}, "7e7ebb4a-23cf-488e-96a9-b51104f3dc14": {"doc_hash": "304f72ef3e0b9d6a1838c3a0e55d9668c59833fc80548230d4dc703a55d53bfe", "ref_doc_id": "c73484e1-29f7-4a39-9410-ade1661a5493"}, "97d296fb-c5a7-4ecb-9bba-e6c8ef339995": {"doc_hash": "9f843d069dca8783ebe1bacb249f140ac865482472b6404bacc7f0f323ab886f", "ref_doc_id": "c73484e1-29f7-4a39-9410-ade1661a5493"}, "6968186c-3690-4b61-a640-38113eddee23": {"doc_hash": "917122f9d858645e88b233eb8217d9cc85696cd183668f176f3aaba687e26dbd", "ref_doc_id": "c73484e1-29f7-4a39-9410-ade1661a5493"}, "116cbcdc-4bee-44d4-8041-afe9be4e1272": {"doc_hash": "b4c443bdbb2fcb9cb772d25dfe9d64098d6a8243fd4fc5c12cf7a8a0d6e71d41", "ref_doc_id": "c73484e1-29f7-4a39-9410-ade1661a5493"}, "e2c87cc3-9b9c-4f73-b1d0-aff1e10807c4": {"doc_hash": "76a7adc65908b0c8c4b0688f2a11002649068fe6a9a8b5e0c7f16c08d788118b", "ref_doc_id": "c73484e1-29f7-4a39-9410-ade1661a5493"}, "71502514-5dd9-478f-97f0-41468b22eb06": {"doc_hash": "0d67d4c82964f573086317c00e212c54695059f419e3caa148326defbbf1ed09", "ref_doc_id": "c73484e1-29f7-4a39-9410-ade1661a5493"}, "bcd066fa-aecd-434f-a73c-e50f98492cfa": {"doc_hash": "57d581b1a0957aac49d46af284498ec4908529a67ffae586874f28b99d0cb2de", "ref_doc_id": "c73484e1-29f7-4a39-9410-ade1661a5493"}, "5d951b41-9c17-42f8-9a9f-16d8774cc151": {"doc_hash": "157690d0576e52ca786148c7e66068c6b8843fa581b0d80154906c91eb2e890a", "ref_doc_id": "c73484e1-29f7-4a39-9410-ade1661a5493"}, "669e40df-56a7-406e-bdb6-78911d59393d": {"doc_hash": "1540419341f1efb32b4bdffd7e8761c09a1765e5b20b0bf6c67bb22c4395e99c", "ref_doc_id": "c73484e1-29f7-4a39-9410-ade1661a5493"}, "a4a3ccbd-9dd1-4171-82d3-2646896a0e56": {"doc_hash": "cfe91232b94253231a223b0d1b21b444b4e476fd0bf548982bdd313362fda5a9", "ref_doc_id": "c73484e1-29f7-4a39-9410-ade1661a5493"}, "52a70626-1056-4609-87cb-0b2648aa166e": {"doc_hash": "d491518b97dbe3d6a9fe3ea5a674be662eefa98cfdad600f24072a575aa5083c", "ref_doc_id": "c73484e1-29f7-4a39-9410-ade1661a5493"}, "e798b718-8dc1-4e3a-a001-c3458b9f0809": {"doc_hash": "b398f2045f84f92ce2ef2124c2e67ac1177c6ac754e1af9a0aed6576ce1eb195", "ref_doc_id": "c73484e1-29f7-4a39-9410-ade1661a5493"}, "cb502cf6-9c2d-4506-9e91-20b68970e9d4": {"doc_hash": "babe94ec85f79fcafbc54040d304c6a6f09a79df49558f65c2077511a81482d1", "ref_doc_id": "c73484e1-29f7-4a39-9410-ade1661a5493"}, "443ebb30-f426-4b10-8cda-a17a945f0421": {"doc_hash": "7d58d82853ec80651c8cfe76e1f3cb5993529fd3c03fb9b3dbacfeabdbd9230d", "ref_doc_id": "c73484e1-29f7-4a39-9410-ade1661a5493"}, "ec8581dc-743f-432b-b4b1-17e57d47661c": {"doc_hash": "42bc30750566841903b8f1114cbc755f5bd375690b835401abfe6ce96f654750", "ref_doc_id": "c73484e1-29f7-4a39-9410-ade1661a5493"}, "e7c870c4-92cd-4ce5-8190-5a61dc744bed": {"doc_hash": "2c3f5abb6225567272481d3be2f0608be1cba6db4197f28486912354b18c59b4", "ref_doc_id": "c73484e1-29f7-4a39-9410-ade1661a5493"}, "f01b621c-8781-4678-9567-44f6e6f9a89d": {"doc_hash": "108473a018275ef0285acd40bc2042ea21b45a6e652efa09abd36c5e3f17003c", "ref_doc_id": "c73484e1-29f7-4a39-9410-ade1661a5493"}, "4c2931d9-3cf4-4efe-97b8-583682dedfe5": {"doc_hash": "816e1227d4bce79abbd2147cfbd224b5b58f4fb065d3d4e0bf12fff84651178a", "ref_doc_id": "f814064c-e4e4-4a0c-a559-30de71f2b69b"}, "52d0dbe8-ff4d-4fa6-b0b3-33702bc0805d": {"doc_hash": "71177b4984324ab76b37f083b17f59952ef97fc5f68e9afa57e6f7c10f2039ff", "ref_doc_id": "f814064c-e4e4-4a0c-a559-30de71f2b69b"}, "45a50a94-d594-4356-90eb-c05ad720b1c2": {"doc_hash": "5fb7651ab7093acde8d4aca46db0f09cc8abc6723f8ae85037d8d81b0578d358", "ref_doc_id": "f814064c-e4e4-4a0c-a559-30de71f2b69b"}, "0116716d-2282-4700-ac1f-86230ff9c21e": {"doc_hash": "0241893377e4edd15c6302e3a3d15efb26ce06c60253cb073f75bd817392b755", "ref_doc_id": "f814064c-e4e4-4a0c-a559-30de71f2b69b"}, "597f608c-38e6-4583-9e05-882aa761432a": {"doc_hash": "8c976d48b51fda4fcfc8d8ba3dfa10a91fc0f6a763c273cb0829e8a8a22291ea", "ref_doc_id": "f814064c-e4e4-4a0c-a559-30de71f2b69b"}, "5e25868c-67ef-4e9c-affa-cd2e590021f6": {"doc_hash": "994a2376c8ee9951441cb97f7e4584b70593f4dbf73cc0e27a61812511039498", "ref_doc_id": "f814064c-e4e4-4a0c-a559-30de71f2b69b"}, "ef39308c-9ff4-4fa6-8d8b-7f34e656556c": {"doc_hash": "d755b9a26f7ecabae1482f4b0ede0ecb4092e48923bab5c55439b1fdba1a9fbb", "ref_doc_id": "f814064c-e4e4-4a0c-a559-30de71f2b69b"}, "5d0d8edf-12da-4f67-a7dd-9fb5126558a3": {"doc_hash": "541c0d96ede9cbdcfcc6a3520cba171f4c1417922567c30abfd9003e78eb9497", "ref_doc_id": "f814064c-e4e4-4a0c-a559-30de71f2b69b"}, "36b4135b-069b-434d-aca5-dc6d397e8928": {"doc_hash": "5635247efbed88d4d6afa574f6a2b1b2144a6fbe591e47d8dd54f72144eba266", "ref_doc_id": "f814064c-e4e4-4a0c-a559-30de71f2b69b"}, "f1dc62f2-bad7-4809-b510-aaf9d5715f1c": {"doc_hash": "c021005163e64384352bd6e0c8ba4e8c4fc9f231fc3db2149671e0b2e77763e0", "ref_doc_id": "f814064c-e4e4-4a0c-a559-30de71f2b69b"}, "8d751b42-3569-4fbf-ac88-4025dd074770": {"doc_hash": "a111e75f10c90cce4ab67292a9384eda0dbb8123f1c923d465b428472ac496fe", "ref_doc_id": "f814064c-e4e4-4a0c-a559-30de71f2b69b"}, "712ed9c8-cc23-4712-bb19-0963a9341340": {"doc_hash": "26de1221b9207a8c2b3bd5e6bcca30fc3013a650d8dc3c8f6f56e6e6f15f64f2", "ref_doc_id": "f814064c-e4e4-4a0c-a559-30de71f2b69b"}, "fdcdf3c8-7100-47e6-a0eb-b575ef16f355": {"doc_hash": "7d59b7e1a7a39e00388b5b64afa1172868cdf7fb59f1d9518498509d85181f73", "ref_doc_id": "f814064c-e4e4-4a0c-a559-30de71f2b69b"}, "7457408c-9af1-49d5-acdf-08e8c9fd1f38": {"doc_hash": "15e8c48453b1f85e7cf7f63c4d3a2a62598801cddb018a04ccd588786f835b3c", "ref_doc_id": "f814064c-e4e4-4a0c-a559-30de71f2b69b"}, "93126888-687d-45e6-a1b0-b1aa390e640b": {"doc_hash": "b7834924f6eed9b34ed28efb07af7d8d9be16a4f2f5bd4704c3dac9651e1ad3e", "ref_doc_id": "f814064c-e4e4-4a0c-a559-30de71f2b69b"}, "38da15b6-9a60-4634-83b4-55ef267e4f15": {"doc_hash": "3da685e365ff6d78b2e8b277fe0bd8af9fc4ac44173e3f214d46938fada65057", "ref_doc_id": "f814064c-e4e4-4a0c-a559-30de71f2b69b"}, "e98bf018-66b5-4995-8749-b0d96ab85252": {"doc_hash": "28b43de5aa63a1895f4b444acdbff72ad9e207fd1990f8a725990d8f3ac7c675", "ref_doc_id": "f814064c-e4e4-4a0c-a559-30de71f2b69b"}, "a86b5497-f5ba-40b4-b33e-ea586b11cee7": {"doc_hash": "7bf566a122b57d8fba6e8a9bd11d46fdc85aaaefa103ee16a27768a75348385a", "ref_doc_id": "f814064c-e4e4-4a0c-a559-30de71f2b69b"}, "698e1d7d-cd12-43e2-a5c0-4c9a01158a41": {"doc_hash": "2eb7aaca262523d95f6d8745d8666a8f62fc097eb6b89326b7346f2b78d96c29", "ref_doc_id": "f814064c-e4e4-4a0c-a559-30de71f2b69b"}, "ba756eba-0b19-4a36-a4a1-c4d9105ffba6": {"doc_hash": "1c3e838f67f1e6b940dd8387b2868f44f4a189dbdd865018cdf0554b9f27ecc5", "ref_doc_id": "f814064c-e4e4-4a0c-a559-30de71f2b69b"}, "6633cdd7-1e1c-47af-8a7d-136e6b475dfe": {"doc_hash": "cef43d76c9cfb87abacffedaaa4523a41effaaa1f564b9beb2cbfe7103b09a26", "ref_doc_id": "f814064c-e4e4-4a0c-a559-30de71f2b69b"}, "8f093c09-42b6-4a5a-8b8d-cc0a3901fe00": {"doc_hash": "901a6ca259557f7bdf40c3af8d870f79d7c266934c202b4cb719868c2d31ba0c", "ref_doc_id": "f814064c-e4e4-4a0c-a559-30de71f2b69b"}, "db21c0dd-2673-403e-9089-f127cfb23285": {"doc_hash": "d7019fcfc34320346bd0dc94ef66b2e9aa8c4fd6915f49cd53036b875a14fff9", "ref_doc_id": "f814064c-e4e4-4a0c-a559-30de71f2b69b"}, "a90312b1-5ff9-4ef0-ae6a-5c8796ea43f6": {"doc_hash": "e949d2ffd8a45e44d72fe9047f8ec9e53fdd05bbb390e74e055b57b7ca0f966f", "ref_doc_id": "538e5af4-2c9f-4709-9ba0-f8be11c81f27"}, "f566e4cc-3fad-49a4-899d-7a65ab8d5ab7": {"doc_hash": "ff845eaf535f8882f679261c561475d81e1f1136ce2c91040644ce5d41a2a512", "ref_doc_id": "538e5af4-2c9f-4709-9ba0-f8be11c81f27"}, "f32526a7-936e-4ff0-a791-9324a6177977": {"doc_hash": "fc9ca1047b5511d0222f9d69d5bcda477638b0c4e13e6bca18b9a60ea933c55d", "ref_doc_id": "538e5af4-2c9f-4709-9ba0-f8be11c81f27"}, "8d382a1e-6038-4aeb-83f9-2454c8408fe6": {"doc_hash": "73ae10e461db349c6487ab39dbdf67d74b0aa94909a3610675f00db429541b17", "ref_doc_id": "538e5af4-2c9f-4709-9ba0-f8be11c81f27"}, "49e135f0-05c0-4100-97f2-505cb130e0cb": {"doc_hash": "affea92873fda93f9ce9b0fc760394d1345c8cadb53817a508a7aaee07beb19a", "ref_doc_id": "538e5af4-2c9f-4709-9ba0-f8be11c81f27"}, "ae865361-eca3-4b03-8fde-163603c226b6": {"doc_hash": "28ef84c75bc9dd3326147e958679511aec3e212b95b6f73e54aae1f36a5514fd", "ref_doc_id": "538e5af4-2c9f-4709-9ba0-f8be11c81f27"}, "ab6a8c2e-6ea9-4a48-9d0b-74cc3454b4f9": {"doc_hash": "2199a6073348afad2e928f8c6f9ea6e6b233a2d8bc211ec625ff09749b76e727", "ref_doc_id": "538e5af4-2c9f-4709-9ba0-f8be11c81f27"}, "ebf078f5-b2d7-483b-ac2d-0176db9b45b6": {"doc_hash": "27d9016eee2951eb88dda2dec0d78f2e5acbd9982fc2488023f53b5d9ddc3ee5", "ref_doc_id": "538e5af4-2c9f-4709-9ba0-f8be11c81f27"}, "aa80c09d-22e5-41b8-9fe2-368efcc71eeb": {"doc_hash": "24320e8add7626ec1969b0e15316291af62b2fb5edf983fe5a18d24e8e312841", "ref_doc_id": "538e5af4-2c9f-4709-9ba0-f8be11c81f27"}, "e9bdfdb4-41a6-472a-9c5b-15bc6758ca01": {"doc_hash": "5e6f47dfcc9d65c31f20c2439fc091208ab0103614bc053e793189cd16b97720", "ref_doc_id": "538e5af4-2c9f-4709-9ba0-f8be11c81f27"}, "adfbc5c6-dbec-434e-b607-3781ca9b0e3d": {"doc_hash": "e227e4f735ecccc405e228d46d56c1a1f1278364a6614fc4a77cd655d878089c", "ref_doc_id": "538e5af4-2c9f-4709-9ba0-f8be11c81f27"}, "b868dc91-776d-413c-b5ef-2a69250b4110": {"doc_hash": "31fb79e2cd8dccf004f65a22c106277de398aafcfc796331ba20a2b9289a24f7", "ref_doc_id": "538e5af4-2c9f-4709-9ba0-f8be11c81f27"}, "f455dcc5-044c-4b2d-8b19-e3e2b1298a25": {"doc_hash": "3faa73755279c27701152003935425c615cf6aa929d7e0886611c57c53327368", "ref_doc_id": "538e5af4-2c9f-4709-9ba0-f8be11c81f27"}, "2a94bbe6-a393-4f47-a964-15c6c06f066f": {"doc_hash": "94e1559d694517223f725ae14f4112900cd35fdc7fb4dd9a28e8b1941ce7940f", "ref_doc_id": "538e5af4-2c9f-4709-9ba0-f8be11c81f27"}, "33605712-7f2e-4f96-a16c-c9b734cee2ee": {"doc_hash": "d21aeb3f37ad0ffa7858a052b7269abd765b98ad2cd280df45a73d4013646337", "ref_doc_id": "538e5af4-2c9f-4709-9ba0-f8be11c81f27"}, "bb245d20-4b69-4b34-8665-f263cfbdabdf": {"doc_hash": "f73756e63777f7aa4ecfc49829cc4be4552fa712fe1755c09f4fd0cbd26b9348", "ref_doc_id": "538e5af4-2c9f-4709-9ba0-f8be11c81f27"}, "2f2b8289-1be7-4d70-ae36-6a127ab3cb8f": {"doc_hash": "57d1333f9bc0c259d5dc0a2f6dba5f3b498654b29bf0a2f9e4980742fcdc5785", "ref_doc_id": "538e5af4-2c9f-4709-9ba0-f8be11c81f27"}, "fc543d3d-679d-40f2-aade-bfc909a38cd0": {"doc_hash": "9ddcbfb29ccf76481d8c4dcd2701aeac390d82bc04702eaf6d662590e671f344", "ref_doc_id": "538e5af4-2c9f-4709-9ba0-f8be11c81f27"}, "5c672f9e-cde1-4448-9341-4167c1fa9644": {"doc_hash": "f2c6ce4c1b5ef22a1ee0f5e6aa13a3dcccd906798b3e1602b3f041e7659f87df", "ref_doc_id": "538e5af4-2c9f-4709-9ba0-f8be11c81f27"}, "bd68e987-f384-44aa-9b8c-c406714340bf": {"doc_hash": "6c40defe75c11e0243cd699715353ee5fca941fa2ea9588108e94a49300da326", "ref_doc_id": "538e5af4-2c9f-4709-9ba0-f8be11c81f27"}, "a4aa2dd7-7928-4ced-8b15-461867784303": {"doc_hash": "b59a9d3a9d20e9708ec17e48495adc0bb6a168f17a8e3ff4c111be6fa4aba23b", "ref_doc_id": "538e5af4-2c9f-4709-9ba0-f8be11c81f27"}, "ce896aa3-9b23-46fb-a57b-566f587f7376": {"doc_hash": "92203ea608ca41cb2147dcfea9401b8e4752a3420e0b78e3a156324d6e7af841", "ref_doc_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de"}, "c1f172f1-849d-4980-83a0-8c58864b2ab3": {"doc_hash": "d910651d30d3c8e0a960aa1723c693426c0edf5bf8c2d04a25ca2e0b76384a97", "ref_doc_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de"}, "779bb085-8bbf-4741-9f5a-ee58a195a3ee": {"doc_hash": "0108a353840da437b9ced95bde59df19eddcfbfbb619e7fa9e7dc92856755390", "ref_doc_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de"}, "025d43a6-8a49-4858-864d-46bf7e71044b": {"doc_hash": "eadd6a309611c98905ddaf53fa87f379775b5f4ae6f7dcdfdffdfd3f670f7209", "ref_doc_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de"}, "a6a0b1ae-9c8a-4a19-b917-8318e1763e9b": {"doc_hash": "beda519c340149aa76858e6f7a01ea15012090677b23d549c2e11f413b75d1ef", "ref_doc_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de"}, "d2a2ffae-0a6a-443a-b2f9-f0769c2eb74c": {"doc_hash": "08cde3fca78bfe3270c75154efba5aa3a57a98bae9d7069a6696b00a5c300fd0", "ref_doc_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de"}, "e7969e38-6897-4eed-ac3c-bbfd6d365bc0": {"doc_hash": "1fce1147b0bd79ecfdb62c6c2bbaadf7b026859870bb9b21dfa21cd96820ae2b", "ref_doc_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de"}, "b902883b-949b-4192-a66e-5cc6f058d548": {"doc_hash": "3569f669f2e6b53c328f616210e81b240af083a5de4576881432e724fa4e0f16", "ref_doc_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de"}, "03bd78a2-2916-4196-a725-8a2f53984deb": {"doc_hash": "9446add60e237ec71d1e99743c3655b64a732e6314b263dabad5cf5497d390af", "ref_doc_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de"}, "c2113b4e-48dc-445a-81fb-6b2d550eaa9b": {"doc_hash": "f8b60d16b355ec336d7b10ee3d4c865b798d729c4d6c29cedb37b18062391a37", "ref_doc_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de"}, "06a3276a-9792-4e8f-b620-f4a2e6d0a49f": {"doc_hash": "bad9d8298a73d5e105053e2ba06cc0d697cc4db49ea47b3102a8024d6ab41f65", "ref_doc_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de"}, "992ffcc9-8f04-4da0-8b9a-4714540a8873": {"doc_hash": "39db7750dc5929dd1a6c01a8a2b34469eba3dc6c87694cd3554cc52d0c033208", "ref_doc_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de"}, "f45aeb1f-690b-4c44-b3aa-4116fd82a479": {"doc_hash": "effbab2ea2faecad7a3b7433943061b350457b20b7d2b9e1d34d53a79e11dc81", "ref_doc_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de"}, "6dd44dac-b214-4bd3-923c-d5fea3d07c50": {"doc_hash": "f24fa802b39ca742918df5fab194e0494bc44e2aa4e6833cee0a131d8216e257", "ref_doc_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de"}, "55783554-8357-4aee-8b99-0ec801ae2e52": {"doc_hash": "c291bb2803f97fa1b00ba6c2d4434c5647166f4bb74332fa8d9a8386f633330e", "ref_doc_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de"}, "087fe09a-eca9-47b8-8932-76d49386680e": {"doc_hash": "20c2e406e0fa4acaa5fe7ad11f64e02b440f94dd3ff5ca562ac4bf57ac3e314e", "ref_doc_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de"}, "9102f105-2ebe-42a7-8f78-c941fb5a431b": {"doc_hash": "173af5dcefbcbc06a4a2b41eb9447ffca1de0da903a3b0c871055eabcfdeee3b", "ref_doc_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de"}, "cd34f446-3c0a-4c5a-b182-8353067c7ae4": {"doc_hash": "b598f429e9cdb4a186bec8dcf8464790640543e369a0265a88fda536d39d5ab9", "ref_doc_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de"}, "36902320-6767-4852-a8fc-d5d87bb374a0": {"doc_hash": "bdfbfce6ab2555c7335058bd8ca73681885574d110b3af7b6e009a8c53fedcb0", "ref_doc_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de"}, "b0874b41-fb24-4091-8550-9ca33823a115": {"doc_hash": "dd9c6beb4318eac96c963d954a1483baac579076109382fdb00af1862ec80f08", "ref_doc_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de"}, "8b09b061-8d45-419b-8557-eaffb6eb7b0a": {"doc_hash": "c4d40b9787b2ea2854668b147e900e584433815f8ee62372d49565b0eb36787b", "ref_doc_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de"}, "b6e28386-1eea-4693-82c6-b814edc05b35": {"doc_hash": "20e48b24db9567f2abf7d0c366a129caa0791889d8e05dfd3e87cd71ec8c0219", "ref_doc_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de"}, "172134b3-14e5-4af0-a415-d6950b22407b": {"doc_hash": "48f110e684a3db34208aab29b63ff98cfefcf6d4942a335f829f2161832ee9da", "ref_doc_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de"}, "cd6bcc59-a4d9-445e-b645-c1e5ee85e6ab": {"doc_hash": "db8e72fee13d23dd78b07e6599fd87ab5a6f3521b05f2057191486511a8c457a", "ref_doc_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de"}, "54e1d588-7cb2-4f29-85ba-fb959a796e8b": {"doc_hash": "010a32f533dd1df8b3777d2032904739296a03c730575a25d4c41cfeaf1fe76c", "ref_doc_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de"}, "a68a17a3-fd8c-44e5-b790-ca16f9609a3f": {"doc_hash": "c03ab6ae563a50f7ed10a238d09ac7c464d15103ef7a4739a9ebf17d6480ae3b", "ref_doc_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de"}, "bfb56051-6816-483f-8451-ec0dac69e7e1": {"doc_hash": "15e39569b9e7504f695203c78ade358ca8d50783dbe517bf87c41db4ab59bf1a", "ref_doc_id": "c7483f50-b0ff-416b-b034-bb525fd2d0de"}, "32583cc3-92c0-47ba-a5fb-7988407ecf89": {"doc_hash": "780307fdbe61db4e7943bb4d3037fda3274b5d055900617969a037c0c92ec9f6", "ref_doc_id": "5627115a-c77a-423f-83db-5f873b473ef8"}, "8e94e47a-8c6e-4b5b-8958-39d384676f79": {"doc_hash": "7aa1c0fb17444430c65de1dc0fbcd57bdb888a85a2a647e85555f6592f8f6fa0", "ref_doc_id": "5627115a-c77a-423f-83db-5f873b473ef8"}, "1c7c31d7-67b0-4635-b0d8-a0a2c8887652": {"doc_hash": "025c26cbc69ec784732c93ed921cdfc5daf36253e78d0008bc145be0a4275e37", "ref_doc_id": "5627115a-c77a-423f-83db-5f873b473ef8"}, "a53ab538-2f74-4fd7-b6cf-d96e6396f066": {"doc_hash": "d6ad8a071411afad2c5ae98690ba90af60e0ba867085e70c1f3476cbf5bc936c", "ref_doc_id": "5627115a-c77a-423f-83db-5f873b473ef8"}, "9eeb541e-feca-4edd-b8d1-f6e0a6cb7e4e": {"doc_hash": "efe9ffa2a5e32a712ba3d52371ea9b0f56993b2ce902861f77cfd01cc5d72c78", "ref_doc_id": "5627115a-c77a-423f-83db-5f873b473ef8"}, "e5d6a8ed-1ff8-43ab-8e1a-a046db7be58d": {"doc_hash": "5a8b3377b8123212f529fde864ca4ea72d703b9e49ee0f4452ba64ed7a3374e9", "ref_doc_id": "5627115a-c77a-423f-83db-5f873b473ef8"}, "e941ba15-f36d-49f7-9b05-f9b4df94518e": {"doc_hash": "291c65ef7e15be3d64babf1ea18a319a681bffd49c54d43a90985c527d29c6ee", "ref_doc_id": "5627115a-c77a-423f-83db-5f873b473ef8"}, "86bf8546-84d1-4e52-9226-00ea87b2cf09": {"doc_hash": "940789060b61ad8dfb7aac805e28187e05d50ff18d345ad564cba3ca6fc0bfab", "ref_doc_id": "5627115a-c77a-423f-83db-5f873b473ef8"}, "35eb249b-1d1d-41d9-b36a-9c25285b60b1": {"doc_hash": "fa845830428a7a1114824cc08bcc9c830530e7cf9b6114a3a58bd3a02b3cb10b", "ref_doc_id": "5627115a-c77a-423f-83db-5f873b473ef8"}, "3372fc1c-a3e7-4fc4-9d50-48514c50151e": {"doc_hash": "c44ba55eaa9d84ed77bd9f07540bb1251f0568a419d088d4f74a0b0cd2ca449b", "ref_doc_id": "5627115a-c77a-423f-83db-5f873b473ef8"}, "dcfc7fd5-6d53-4c03-b02f-7cdcc9d5abc9": {"doc_hash": "549a485284822c02e309d04e74923812ef6d6591a579caa8b0936a80f81965a4", "ref_doc_id": "5627115a-c77a-423f-83db-5f873b473ef8"}, "3a55486f-ef77-42ad-938a-53d8ed8499c7": {"doc_hash": "41c281b6fc369c2fce913b85c4ddbb092a1cdeb3c6306571f22288f3c6339d61", "ref_doc_id": "5627115a-c77a-423f-83db-5f873b473ef8"}, "005ed327-fe91-453a-b49e-b6074fe6487b": {"doc_hash": "da5141e5e7165d32493392d47c4ee82238bec5cb08509ae3f9ed9fee0952f4bc", "ref_doc_id": "5627115a-c77a-423f-83db-5f873b473ef8"}, "b642ea10-a4ca-47ff-8638-f51ef9585db9": {"doc_hash": "8d23b0ddf4e5136e863ad1ced90afaba4ac02c252e67c7aa4cf0b93efee238fe", "ref_doc_id": "5627115a-c77a-423f-83db-5f873b473ef8"}, "76268bb7-6aac-472d-b8e9-9eeef8acead7": {"doc_hash": "471b1f5545081f99cd4f7169562cdbc57d9dd0bcf0c9556448e3448ac45a6ac9", "ref_doc_id": "5627115a-c77a-423f-83db-5f873b473ef8"}, "e7c7f9f2-999b-415e-bf5e-4772a9809177": {"doc_hash": "22b40905833b103934e5d27432dff1490c017bb62457c28b8c3f1ffb423af39f", "ref_doc_id": "5627115a-c77a-423f-83db-5f873b473ef8"}, "8a5df632-896d-41e8-89f4-6e3c1efe2c3e": {"doc_hash": "46033012c932777583ce91ab576b732820df2341aa60b3a56ed31a8a55f8058f", "ref_doc_id": "5627115a-c77a-423f-83db-5f873b473ef8"}, "b19518e1-b58c-47aa-9b26-c14e5cf6193a": {"doc_hash": "b52f50d88c12c3dcb743bb06f30863db9f529827f8e8552c4de05a728510f98c", "ref_doc_id": "5627115a-c77a-423f-83db-5f873b473ef8"}, "711bb4cf-c33b-4a13-b3be-b9b89d7a485c": {"doc_hash": "ed1bbd80784d77c9ff526606414e72e5bc4dfd80f53e5c5f1115b3b707887a63", "ref_doc_id": "5627115a-c77a-423f-83db-5f873b473ef8"}, "d7233c4c-58e9-42bf-9819-0968bfaf78e9": {"doc_hash": "d3b5e70fc4bf72e1e899bdbe739abd6733de4dfd409a5ae2c5acb1095a569e42", "ref_doc_id": "5627115a-c77a-423f-83db-5f873b473ef8"}, "9b456253-5279-40d1-b8a8-569c6b8da2b9": {"doc_hash": "ba36bc8de1eb5a66fbbea6baec5ed2be3fdeabad75007cfeff43085100cc5c37", "ref_doc_id": "5627115a-c77a-423f-83db-5f873b473ef8"}, "e528031a-1144-44c2-851e-c4b0dbd99b26": {"doc_hash": "66b327e58bf1d4ca593e4a78242c3006352bf965e2dcfc7b8e0cf2daf5be20d4", "ref_doc_id": "5627115a-c77a-423f-83db-5f873b473ef8"}, "ea6b1d55-c9cb-43d3-936d-136deaab3615": {"doc_hash": "7bc3b067422a77275332c620e6c455f0c0c744c7a75b1abfd0cbadf83859acb4", "ref_doc_id": "5627115a-c77a-423f-83db-5f873b473ef8"}, "df49c8fb-a556-4bbb-b302-c0276d016f32": {"doc_hash": "24d85f1b27b18bf11e76749649812173cd982f5cc5d3a3b81d1b41cd970988fb", "ref_doc_id": "5627115a-c77a-423f-83db-5f873b473ef8"}, "1a8c55e7-8e5e-4d38-b242-e803471cd938": {"doc_hash": "eae39dc8711188d073e583b38c3820d0169e49cdd19ac9004795808b1274e2c3", "ref_doc_id": "5627115a-c77a-423f-83db-5f873b473ef8"}, "dbea9e38-8459-4ba4-8244-f328aba1bb3a": {"doc_hash": "5813f9dbf7702999cbba49fda5bd8dfc83fcecf6edf5d95346f4517e15d58380", "ref_doc_id": "5627115a-c77a-423f-83db-5f873b473ef8"}, "de566afb-e48f-432f-b50a-f7e263280ff8": {"doc_hash": "5c4472bf1fbc787f20f94bac47ac20925d48b0d984a79a860f7da8327b0883c2", "ref_doc_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded"}, "ce96a2df-1e87-42cc-9805-873f31eca61c": {"doc_hash": "ef06e3f744a2913883679b659156df1c96bd1735fed5cf2fab5360d69754a040", "ref_doc_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded"}, "7e08ae9b-3a34-4d84-a2d0-7192a116c0eb": {"doc_hash": "8756a9492be30fa7b8a2b7299a6b4d4d65c27a2b6114edcc406ca27fe84acda0", "ref_doc_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded"}, "fcd76f21-729d-4bb4-a4b2-36e02e9c58da": {"doc_hash": "c71ad75f888ce7f075946cd0db2ea80683978b3e191c0f216a385f8f2642652c", "ref_doc_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded"}, "771f0825-9ede-447e-b427-a72336ab8db6": {"doc_hash": "c2e0b86c410973444a5993e9572d7f7c241cb8ef448bc40b29dba3f0fd54c5fc", "ref_doc_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded"}, "d0e92bf9-c418-45e4-b477-6f7a015ad158": {"doc_hash": "6f7d63a53fbe7bb83e4130398ca6e05468ac0f69b05b20be547d1389725ca73f", "ref_doc_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded"}, "4c6506e4-3e3e-4640-91c9-2038d6b0d05b": {"doc_hash": "bba964d76ea78800585253df84c4cc79ee16ce176dfc04b3e5d3dec0003f348e", "ref_doc_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded"}, "fc8a2e9f-40e5-40b0-9903-2e573b4380f2": {"doc_hash": "4f744248a85068e3d54e38c2caf91161102e3347eb1574e7d78ba147b76bb33a", "ref_doc_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded"}, "3cf5e5fb-d0c1-4ed4-9f0a-ee62cc1b2bdf": {"doc_hash": "e020cc71024ec1aa1212d4d56051a63f60094e760c0b5f06c81410275f9f2e38", "ref_doc_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded"}, "2288b7bf-e6a2-4263-9570-5ee9482101f3": {"doc_hash": "c2cd5e64305a4cb60a72275ec4691d090db47a8d23c382d0f5c0ae9e6df8567c", "ref_doc_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded"}, "2636e969-eebc-4e5b-a1a2-a8c4c8e504c1": {"doc_hash": "afbb505cd5418a694eb3da32cbd29542c7e4447b1b84fe10c512116eb192cdfc", "ref_doc_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded"}, "37e9e46c-2c49-4bc1-b3f7-f6ae4cee1e6b": {"doc_hash": "94b8ee0def5786a5fb2b59eabb6f8f93491f75acdeef590776f19ab63ca8f028", "ref_doc_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded"}, "e9126e70-1561-406a-b069-8ef9c86944aa": {"doc_hash": "fcc0fc72bbaf3a88e88939e74c7f1e5d2cf82707a6b8963d5824e2ccde2ff9b3", "ref_doc_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded"}, "4c021e71-bd71-41ca-bc40-fbe1b2f7c3ac": {"doc_hash": "da4320b4c3577fd21e118252c245204750883b2169f1322170d0aac71230df8c", "ref_doc_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded"}, "0b6a4af3-ab75-44c6-93b1-fe98f40f91b3": {"doc_hash": "f90e7348fa4352b1f0348d405bf682bd68890c7396fefc0c29a4ee0ee11f21a1", "ref_doc_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded"}, "0c3bb3c7-0aa3-49bc-8f1a-4a9a9f96b7de": {"doc_hash": "8a7155c419a70f0d3be0f5e2df4f4493271ad85a19e10384c532cf1a1bbcb391", "ref_doc_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded"}, "f6331bd3-932a-4005-bed2-185cc5c192b0": {"doc_hash": "cbb8281724be060d01ca9b2230274c4ed0df91d86e7605a39f894179c0d91ce6", "ref_doc_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded"}, "143aa5a0-df28-46b1-872e-fdee33a508dd": {"doc_hash": "c420fecbed09fcc974036b1d6a062b1b4cade949bccd446cb3f75471fbec2609", "ref_doc_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded"}, "1ba74fbb-c57e-4601-8ea2-155aa129bdfe": {"doc_hash": "5efad60c82480ba7794c1a8f1f5b00ff620c5d9454572cd1dff90382df2f81a3", "ref_doc_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded"}, "c423ae50-c242-4415-99ac-64658b49f848": {"doc_hash": "c05c6383d34aa5c4b106321ff3ee219b73a1586a0e6f947f5424d4a9b6773b1a", "ref_doc_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded"}, "631d0015-2755-43f5-8a51-4d26bc27e167": {"doc_hash": "c3a3dc82bcfe551b3734a6c5aadcc5ba35974c002eb63b099a468a723490a331", "ref_doc_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded"}, "ac7f7f5b-58c5-47d2-8aad-ad811ea1b3c5": {"doc_hash": "0e38109b92d89992eb37f0cd7c6055e8f818c6c02f8ff31bcc21e1674f5efc40", "ref_doc_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded"}, "de0b1c8b-3631-4ba0-bd85-a2c2974a2df5": {"doc_hash": "b2758be332ea718fd690153bcd233184251ab5220c6e03098125dbf9ed19d15a", "ref_doc_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded"}, "da5cb730-f75a-4b14-97b5-051be51ff3c1": {"doc_hash": "05554b84bac7e94713b9b1f6884b32ea15a01da38fbaf0b4d637bff609bbd864", "ref_doc_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded"}, "90c61411-b935-4d66-89d0-c113f577147c": {"doc_hash": "32438e2f23433e98f59bcbba8862ec1ddf86e2f33cd9432f9f7422bbedb90754", "ref_doc_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded"}, "d4be811f-78a1-47bf-9228-75519f672a0c": {"doc_hash": "e5115c52808ef7b855c2bda8b7f01052a7aeb2033ddd1c9509fd27d8fbe771a3", "ref_doc_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded"}, "37025b6e-078e-4d59-962c-5efa0cd1acdd": {"doc_hash": "253a5f3ec3030d5921174e523199000e9bb4331a9c328a4e1a7d17f6c9d707a3", "ref_doc_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded"}, "e9fa9b7b-5d5d-4623-8479-2e50292d902a": {"doc_hash": "7b789e3c1e4d2429ecde20db4d71f2b618833aed8b45a454dea8984e69407c15", "ref_doc_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded"}, "8baaad5b-1eb3-47a8-b551-77290a7fc9b9": {"doc_hash": "60fd83f15100b255db1d0d31a6d7ac0f7b725c2ef912008f88bd69489dfb25b4", "ref_doc_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded"}, "7b417c3e-ebe8-4394-8570-4a3ac281a510": {"doc_hash": "6a8c1d61a05eff0aa96ef1507614c4063f0d7614e6f1f8e7b779ae69b8fb58e5", "ref_doc_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded"}, "6ca81ea8-3915-4e54-95e7-870266e370a6": {"doc_hash": "e7ecb8b337de9f39900bb41c8a5009d92823450dd66655b2b27ce1bba3b7f20d", "ref_doc_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded"}, "71530429-5427-4f82-9895-26ad9f52b315": {"doc_hash": "404eef794ddb9bc53c3f5291015bf33b180055dff93cb64f0302795fa09cf279", "ref_doc_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded"}, "197a3d0b-916d-4bb7-b4c5-c2e8180ad2a1": {"doc_hash": "6043f84a10b61bbcb2f8ee19183854ed88c1cd41e041cb08070163e1f9ed183f", "ref_doc_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded"}, "07e31e3b-f5c2-4fd8-b843-5f9a23160bf7": {"doc_hash": "110701bb76aafbbf6d4e9a22f083ac8c711e29b055e53e153b44eb3e46517801", "ref_doc_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded"}, "11a819b8-d2de-4f79-ba18-87bb3da02a80": {"doc_hash": "0819e2992bb28ef47de04df6f1fb6b3a4df7301273f4b7fa8bfc638224b552d4", "ref_doc_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded"}, "823137a0-b4b5-4ca1-ad3c-c94e0a806217": {"doc_hash": "b84e47c648d928ebe53a43b99625aed94913119dac349bf69b1c776fe3d14e56", "ref_doc_id": "479b31b8-dce0-491b-b9a4-e8a875be4ded"}, "bab42afd-3bef-446e-9f44-0a65112c306d": {"doc_hash": "da7808b70b5640c39f094117f57ca2c28f491ac3fe5bf17d36b2e78732972b5e", "ref_doc_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1"}, "f8e087ca-56ed-46b1-9c2c-cccce6ef744f": {"doc_hash": "36b1a05cacd0ca500fff38805076a738a82140230542e36978a31b1862fa1341", "ref_doc_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1"}, "08f9263f-8a90-461d-bbee-4ca01a427ca2": {"doc_hash": "7092411c4bb514e5f799552980007ec6df811c468352ee151d01593a6f41b348", "ref_doc_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1"}, "7f7bf429-619f-41c0-8f40-5e0a7b936c8c": {"doc_hash": "ad316e91352e1888203f279f20cfb93f4746c49c135e8ebe67e9a537a6195e1b", "ref_doc_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1"}, "d75e04f3-9696-46e0-ba59-c0b32f90c776": {"doc_hash": "86193a518506a55c46a1bf9d4fdf34278749762862091d465243adf6faf78252", "ref_doc_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1"}, "230eca0c-1d24-436f-870f-cca1fbe79e37": {"doc_hash": "91be1ca3c1a69bc3322bcac45783c8770495dc49d1ad582c3039739cac5fba93", "ref_doc_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1"}, "12a7bce2-dc91-4bbc-ae43-2a1c8dc4f118": {"doc_hash": "2c44db06e9e6f7b1749f84f2fe9243358c414351e4ef8ab0a19b79b7400f2383", "ref_doc_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1"}, "b5a66ff8-e6b3-447d-b683-21623b948b06": {"doc_hash": "3c7f6bf09065cebe9cbc8bbbd5ca7286bfca55b80a44421623a26f9b7e44262f", "ref_doc_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1"}, "315ebb76-7b06-412e-afaf-b3a2c2c27d23": {"doc_hash": "bc5694c3204aabe0f56cffc136448fcace23249927d18269798d1adcf7be6101", "ref_doc_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1"}, "4041f63d-ec98-42d7-a8af-df1830364314": {"doc_hash": "2052f508b94280559026356cab15fc36b52f414b67e97b59aa11ecba6bf5732e", "ref_doc_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1"}, "8785d3a1-2b62-42cc-860c-bbdf88c2f04d": {"doc_hash": "c68750225bba81fc603ef89cac890fbbc374b1aea98f3292432b9b0cedea5a3a", "ref_doc_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1"}, "5a2ef531-5d01-4aa0-b0f6-5bf5d105c782": {"doc_hash": "03847a4d6912cde9601e4c3bdc21b10100a6602ea8737bef25780274d449d7de", "ref_doc_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1"}, "3388c6d0-84af-4c49-827a-a0d85bdc5d61": {"doc_hash": "723dcb60af15b7beebf5bded915e639a4fa86d9b9b2df3a6317ab0c642dc2e02", "ref_doc_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1"}, "b1ec5cc6-3e86-4653-a270-915a41515cfa": {"doc_hash": "1d984224421dbd6c35598bdf0cbd2c4e83729fd7fbbd842630236f5ba153e06b", "ref_doc_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1"}, "af420427-c12c-447b-b60a-b91396676e1a": {"doc_hash": "a6eb81388298df4f596c8c5cac48b36a25685d7e76917aba819adcb5288d8ddb", "ref_doc_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1"}, "8b066aa5-60f4-4bad-b699-9da45c5fcfd2": {"doc_hash": "c7ae0ea730213924dd46944c6e9d159bed362930509b6514dfac1141e8158861", "ref_doc_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1"}, "3ecb1bc0-79cc-4754-be64-402875c2059e": {"doc_hash": "ffe8d512bbcff4c93d7def9d304dd8668b1806fbccb10505cd030388de4b2328", "ref_doc_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1"}, "dd4befdd-30f1-4260-a6b4-ee8f9ca386d7": {"doc_hash": "75c4f597a90b481bd4ea038505d164ea803dc1059e76ff9ee670ef88f021a34e", "ref_doc_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1"}, "2c4d3724-49a2-4320-ba7d-795ec1da20a4": {"doc_hash": "0b5ece36012c6d87ba9b816fba84868d41e71c82cec3ff87f4aca9f833efccc9", "ref_doc_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1"}, "ff4fecb4-a224-4bd9-b09d-96a625ade4b7": {"doc_hash": "f0efe3d8ebf81f4d371b60da64199439c2512e912a2a03b1be35ff4a6761c546", "ref_doc_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1"}, "60988d50-8788-4d1c-9425-fe2fc8882561": {"doc_hash": "acc5d17e0790e01c2d0984e221cad373310dac36b048949a22c1f0ba33b9d2af", "ref_doc_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1"}, "df2bdb01-1ac9-45d6-ac07-42369a932102": {"doc_hash": "f9e852a0242d6d1041bebb4899a172c89e74ee4384febda92856d7c4e9874087", "ref_doc_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1"}, "be4e766e-d515-49f0-913b-1f21b6fdbd5f": {"doc_hash": "25364a3fb5bef3455934b55e5e9addcfa0804d8e21355d1949575672b9d76d8b", "ref_doc_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1"}, "7dd8c65b-5370-4a59-8e52-6b67ce532a7c": {"doc_hash": "028bd3df0cfb09636d77b58d0fa5dcc9ec5e8ec00918e84cc5a6391f686fca03", "ref_doc_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1"}, "79266eac-e25d-4668-9af2-417d94bfe32a": {"doc_hash": "24c79732f539da6ef3949a2f16fa708b2afbe5497730d707e337eeb42cb65116", "ref_doc_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1"}, "5b882f3f-6752-4099-8112-ee031f06d06a": {"doc_hash": "7210796459d62d1f1c20dcc2d4a5377d3e5dd0bb07cdd2e277f1db378d601865", "ref_doc_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1"}, "0606721a-d486-4f4e-b412-0953ba1e8f84": {"doc_hash": "c899c0b104a7a03bda18eb90cd2cb841b23f6f74a16fbdf98e3dd309016b988b", "ref_doc_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1"}, "36544304-b1c2-4e67-91bb-db6cb61ed455": {"doc_hash": "6c2e793e801ac0de62b6816197db312d433c89bb8575003d301f88b4151d7c4e", "ref_doc_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1"}, "ee890f70-d3e3-49ff-8e4b-062d6c3465b8": {"doc_hash": "9747aa94080ad982118908d0f8a1e925fe1c14a3fa715bdf780344ad5f078d99", "ref_doc_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1"}, "f5e56e78-b406-43f7-a549-6f6b0217cc0d": {"doc_hash": "d0f3ff95645f8e7d69106ec7017e7a9032d057b0feb782290aa7c646b927d6cf", "ref_doc_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1"}, "21b9c532-d38c-40a9-acda-390e66602011": {"doc_hash": "d77d81e308c22307e5a760d498328e35c8bd6afe27a09953a4a320276e835d2b", "ref_doc_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1"}, "26358e0a-f65d-4409-a824-ea58ce1a5f20": {"doc_hash": "b75e6c86410addc6c73c670039b2ee7a7341dd4a570b230a8710d1ed3e799b70", "ref_doc_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1"}, "b1f8ed5e-c950-48aa-8a7b-645e06530280": {"doc_hash": "b1b0229d6ee0bc7c4236a40c31a344a1730e4ed99e785b0ea9aeb28bcdfe963e", "ref_doc_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1"}, "794fd2c4-4202-4f6f-a7ae-c474eb796918": {"doc_hash": "44e2941e34ba3f15be1de74d17225e401521f7f84cdf0c3e185111e6768a6de3", "ref_doc_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1"}, "676ab13a-6aca-4daf-90d1-93502fb82e19": {"doc_hash": "41d82726a5260c8387148b465ff527acca13c8e305ef719681bb949f2ce9f8ea", "ref_doc_id": "c9244e4d-ed3c-492b-9103-569b52d1b9e1"}, "5b7dc9b5-18b5-4354-a442-ac3768aa6255": {"doc_hash": "f9d939d40484fe1a0d00326b867732bf6327b4243cdb869c9c774750b6fad9e5", "ref_doc_id": "f909d867-900f-4080-b21d-623d7f441f91"}, "7507ce9e-0382-4a6a-8c0b-0bc290310015": {"doc_hash": "c87c4751b466d3b9fbe0801c04152310c221f16684bc17ba0f47266077af7748", "ref_doc_id": "f909d867-900f-4080-b21d-623d7f441f91"}, "8fdd8a1d-0e56-4fb4-ab4e-cc9afc1733cb": {"doc_hash": "73e11459359e3cb9f9bb2b3a29e0c566298b659e3ef78585b9a14abe3d54f228", "ref_doc_id": "f909d867-900f-4080-b21d-623d7f441f91"}, "9e4b9ea8-afe2-4d0e-b504-72a2de3eabab": {"doc_hash": "20a1c21cd6a8152116fde2aa869ea1d6adb691a8cbc81fb2e640a747525a37cf", "ref_doc_id": "f909d867-900f-4080-b21d-623d7f441f91"}, "ac313379-a460-472b-9230-00de94422b46": {"doc_hash": "f9eef4e03fe332469780f6609bd71756f18f694bf5919b95eee2c80d031d9774", "ref_doc_id": "f909d867-900f-4080-b21d-623d7f441f91"}, "32b5df39-e423-4110-b260-246cb73bdc00": {"doc_hash": "e29e41a7b6990f162eca236369c0f48a4cd68ffb8d1c61aa7ae2edc5cdf76a3f", "ref_doc_id": "f909d867-900f-4080-b21d-623d7f441f91"}, "c9f40766-8cca-4612-ad3e-60f705cf16b0": {"doc_hash": "8db419a55df768b586af53d3e30b86f5abcedd61d7e551d271df6cc74439b68f", "ref_doc_id": "f909d867-900f-4080-b21d-623d7f441f91"}, "20085371-3c8b-4642-94d4-e486b12e5017": {"doc_hash": "81bfa88acb4a2ff965f4efbbf4f47c3bb4ebcabc27213c055c14fbb7844d281e", "ref_doc_id": "f909d867-900f-4080-b21d-623d7f441f91"}, "2e6800d2-a29f-48d8-9a99-0dc4afbbe0d8": {"doc_hash": "f817a7174cc1751ea6068f8572ee1ffa1129c28ef850aef60255fd30db6e8b51", "ref_doc_id": "f909d867-900f-4080-b21d-623d7f441f91"}, "a4cdbb22-9271-4e03-9bc9-03eab1092c87": {"doc_hash": "a5fbdf39fde8f39058c35c0f03c11c793c94773f59478380ff23cda45e5a5c0a", "ref_doc_id": "f909d867-900f-4080-b21d-623d7f441f91"}, "5a98eadc-95a6-4f26-9f79-071b71c37811": {"doc_hash": "e7e29979a30b330b432733b201f2fa8a3c0a8334b7d4d360a1f5182fa4bbe012", "ref_doc_id": "f909d867-900f-4080-b21d-623d7f441f91"}, "3e0ce657-22c6-4fdf-873f-161fd9f60abc": {"doc_hash": "2b7fe3edd3d4906d3a6a7732885a270deabbc1fde6f58942330d1527a91804c6", "ref_doc_id": "f909d867-900f-4080-b21d-623d7f441f91"}, "b8635137-f51e-4cfc-851c-d794754eb925": {"doc_hash": "9cf7dbe7f4e93addfc5e1e55f39faaac1b38d97c68cf92eaa7bdc1a85200035a", "ref_doc_id": "f909d867-900f-4080-b21d-623d7f441f91"}, "d5da433f-6fbc-4dbf-b42f-5dbefe0aa582": {"doc_hash": "c35fa0444bf85688e7865d786c84d636473e9c752c59516563642b22f70b9fbf", "ref_doc_id": "f909d867-900f-4080-b21d-623d7f441f91"}, "8796b2bb-8aa7-4101-8ef4-75faa9975acd": {"doc_hash": "cddba1db5c134617aecc1e31c1275cd3519351b1caa19a52742a1ab518f1bc1f", "ref_doc_id": "f909d867-900f-4080-b21d-623d7f441f91"}, "b13a0888-129d-4fe6-a52d-eca05015a78c": {"doc_hash": "1ba0ef3800efb86663bc794af5b68488ce628e184fc02d22ed9cb949b592acde", "ref_doc_id": "f909d867-900f-4080-b21d-623d7f441f91"}, "79ef2bb9-2801-437a-8811-986258cc28a3": {"doc_hash": "9dcbd20259b85e3f549e93e87cd97d4e2cf615af823c4a83e4489618cf64b41d", "ref_doc_id": "f909d867-900f-4080-b21d-623d7f441f91"}, "371b8c79-65b5-49eb-a70d-6519f4515dca": {"doc_hash": "72a2fe309c97e12902a3897cfd411326a87dc503f66fd6e3f5b81add9ce3ff2a", "ref_doc_id": "f909d867-900f-4080-b21d-623d7f441f91"}, "83cb3516-dea5-414c-9bde-3c254dfbb007": {"doc_hash": "3443d9014d124ab5f8260826428753a1dc7b7227a9e1f55953fc3b09e99412cf", "ref_doc_id": "f909d867-900f-4080-b21d-623d7f441f91"}, "4dc92c51-9b3e-4611-9124-7404be3ef34d": {"doc_hash": "02b13f074a64529cf62ac351d09f2206ce639c2477139cadc817537265ec5648", "ref_doc_id": "f909d867-900f-4080-b21d-623d7f441f91"}, "43eb72ef-28b8-4a66-8773-6607a83c0cc8": {"doc_hash": "8a7a978286f54829269a41dc26a7a5cab7fab2e48795410cca84bebcd810bc1e", "ref_doc_id": "f909d867-900f-4080-b21d-623d7f441f91"}, "977e90f2-1a7c-4698-9570-841798759cf8": {"doc_hash": "5dcca3f1697d5120f2682774add9b5ebcc83c0fbeb887ec381b828f46d54585a", "ref_doc_id": "f909d867-900f-4080-b21d-623d7f441f91"}, "e5d890f2-8354-4b09-9794-4b5926a618e5": {"doc_hash": "09a03830beae5e6f8c66b657ecf7eae7cb9ffa44fbbb9b951faf67a2694719cf", "ref_doc_id": "f909d867-900f-4080-b21d-623d7f441f91"}, "1582b25d-fc27-4c20-8450-eb61979a4312": {"doc_hash": "cdba1ec7cedf962f0e5af7843d89ee19f54795d7ae4972fb64423f4a20f7ef6b", "ref_doc_id": "f909d867-900f-4080-b21d-623d7f441f91"}, "101256c4-ce56-43fe-96a2-43973b5852ac": {"doc_hash": "c219fd514164a304f68ed28e6230acd4162e6a5032ad04e57395af97fee98c0a", "ref_doc_id": "f909d867-900f-4080-b21d-623d7f441f91"}, "92579bf1-adca-43e9-baa6-a82007870b9f": {"doc_hash": "b9bb77c1022a96e669777914487af1fd68217fd86c61f41e2dbe412699501919", "ref_doc_id": "f909d867-900f-4080-b21d-623d7f441f91"}, "372f5503-49b5-4846-9755-ac5f8b606f6a": {"doc_hash": "10ad07ad845e252f201516813f765aa9b3df3b1102879f2e99d69ba992fc6aa2", "ref_doc_id": "f909d867-900f-4080-b21d-623d7f441f91"}, "236bd445-e33f-4175-862c-eccbd6b51250": {"doc_hash": "94ba0d8df03e7a62629f8e86c6703f002b6302ca1eba1218daac2f63b92701a4", "ref_doc_id": "f909d867-900f-4080-b21d-623d7f441f91"}, "75e1d83b-c1f3-4c9c-b486-c5282095f96a": {"doc_hash": "44f1a810e08fae767cf361b693c2d12d251755bafb734ebbcf5b2334c8441996", "ref_doc_id": "f909d867-900f-4080-b21d-623d7f441f91"}, "4a50a0dd-fc5f-457f-a490-6b7b072770da": {"doc_hash": "46c4ba6dd419bdca4d83dc50e7afe3a9f6f244ae26a207ff484a497129451ffa", "ref_doc_id": "f909d867-900f-4080-b21d-623d7f441f91"}, "449650c6-d04f-45c0-ac89-12277f641a73": {"doc_hash": "2181bfb2fc945b54148c19ef49ab54f34b8f37f4a9c6f1706e0d7695d07e740b", "ref_doc_id": "f909d867-900f-4080-b21d-623d7f441f91"}, "2420823c-c080-4154-aefa-37aabc15287f": {"doc_hash": "0c4c4de422d910890e20243ede77eaa7e92ab17ef2d88ef8346c2e923dd57e29", "ref_doc_id": "f909d867-900f-4080-b21d-623d7f441f91"}, "f3e692a9-1482-4381-9b69-77063ee31307": {"doc_hash": "02f50f232a29a2ea11908c0c7fd62ccb815bdfbd0bfa1669ca99ccebed5a1b4a", "ref_doc_id": "f909d867-900f-4080-b21d-623d7f441f91"}, "09eab0b4-923e-4961-a5c6-7e5b001a550d": {"doc_hash": "c265a7419393f4d4fc97b93c8419c30cc062e0e17f6b5edab0e8b7a2eabfd680", "ref_doc_id": "f909d867-900f-4080-b21d-623d7f441f91"}, "03deea13-2ab1-41af-9afa-9c8a6a07ed9c": {"doc_hash": "f6c99b0651b7529603637d7b2d2d1e47a65bf07f5bcb849113ef841243fd58e0", "ref_doc_id": "f909d867-900f-4080-b21d-623d7f441f91"}, "126706c5-90ac-47c0-a422-e764e8b09d56": {"doc_hash": "421f4c87b97e48b0094760374c13d6f6a1fcec7e943e0572361412fdbff735d5", "ref_doc_id": "f909d867-900f-4080-b21d-623d7f441f91"}, "3684376a-cbf9-4fdf-8ec1-6b838972a489": {"doc_hash": "b1e6429506a237ef0fa34e5df2bfd6be25b60c9a03850699d664e6cba4818198", "ref_doc_id": "f909d867-900f-4080-b21d-623d7f441f91"}, "190fe8de-621f-42d6-8e68-dc108bb53cee": {"doc_hash": "11aba4d4a8a0a126e8a41cebda289e1a0bfcd213da451886796ce94879341ad0", "ref_doc_id": "f909d867-900f-4080-b21d-623d7f441f91"}, "4109baee-9437-4daf-a89d-a49c620f1fba": {"doc_hash": "00e11e112b4da45ba70bf0c48c2279cc3c09cc63f530d36178156f36bed6011f", "ref_doc_id": "f909d867-900f-4080-b21d-623d7f441f91"}, "a9e8e9c8-6ef5-4bd5-b4a7-f676670a31ec": {"doc_hash": "de07d8149364df4fe01a33e152ba721d4861dd0bf4442313a133e8810e44af97", "ref_doc_id": "f909d867-900f-4080-b21d-623d7f441f91"}, "f7718fe3-cc93-49d6-a346-fdc08543dfaf": {"doc_hash": "c1814c117ff17c9652e89aab45f63492329ef1d41a249a74c6b2bc1f61728541", "ref_doc_id": "f909d867-900f-4080-b21d-623d7f441f91"}, "8973c7b3-43ee-4145-9d28-131ab0e827ed": {"doc_hash": "d0405f78d30ced6d689b74d7a5477fcb2924c61d1e3384d91271f0af0ca9955b", "ref_doc_id": "f909d867-900f-4080-b21d-623d7f441f91"}, "96a649f6-81e4-4729-a0f0-d578cd6d9531": {"doc_hash": "ef8a170cb5c1e4deb83c0ca3d78f51330b0174287f2cd02a862774d49e8aecc3", "ref_doc_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee"}, "4030a1b9-1ac4-4c4e-b4a7-f7dc523eea81": {"doc_hash": "73d8716f8ba276846ac7f8193baf4b6a3b2c8c159c90792217b40fc461c5fb3f", "ref_doc_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee"}, "4b735c43-f0a9-48b3-9970-e8fe0cd30353": {"doc_hash": "4f15141d8fcacd49cd988592d28efc1b8ae42a9143d6d6da21317e1302c18ad3", "ref_doc_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee"}, "5dd8c5f5-d46d-4212-8038-d2b9333c4502": {"doc_hash": "c422317dbb89191bc4848c12ef20718f7c3e88584606d8425a4fc509f2a9666e", "ref_doc_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee"}, "7d0dc986-fbf8-4525-a767-9e31c565a221": {"doc_hash": "5cd116b722b6d42da88e5074373ac7024ecf47262072f854d38ed195b569687d", "ref_doc_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee"}, "a4a4153c-1183-4083-b772-c0520ad24e88": {"doc_hash": "50ec8f938cfcadb59f26b7f67061b1e6f10facae766f61c513dc595b84df4a61", "ref_doc_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee"}, "76484694-a622-471e-b021-41f497eacef2": {"doc_hash": "df2a5f4ce634b0a0ecded9a3c117f02fa0def5ceff49ff16aeb8cb0f0d133361", "ref_doc_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee"}, "dbe47897-d936-415d-aba1-0dcd1e44666e": {"doc_hash": "95d80b9edf3d9b7fbdd9660a37981e89cc9d41242dffc9d06cbd752ba25d83a6", "ref_doc_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee"}, "12f615b0-51ca-4f90-929e-9cb9d3ee8899": {"doc_hash": "6a3e93911e5eebc8e5aca59fd8d58fd9b34fd55e0512b2a434f0438376fdbe98", "ref_doc_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee"}, "bbcf528c-9a5d-4d71-855a-7ff850fb62a3": {"doc_hash": "8b1f2de1b36650d1c90575ebd037fc17da400285be6967519b92edf093aed47c", "ref_doc_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee"}, "9253bbc5-ae7f-4bd3-b5ce-d2bd1524ac31": {"doc_hash": "d156b4114b7e1738690bf65026e951fdf3824a90582082a3d477612b02706ef5", "ref_doc_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee"}, "4b4c2dab-ed35-4a52-8311-322096dc384f": {"doc_hash": "f48e27b9416158c0aa83472024d59610ee2865a65bbcf5ed141275cbc9349c9b", "ref_doc_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee"}, "bc12d7a6-5b66-406d-a68e-2b8ce6c61fc1": {"doc_hash": "3a3c2ca5b426b99354739dfa8535bb1f03130b417d11e38f04615014ea0d0e37", "ref_doc_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee"}, "5fe1c900-43ed-4a0a-810a-fe7554b9cb1a": {"doc_hash": "9d704b7cd16886ac84c88fa9a64e0312c2fa351b781bbb16a42ce2e6f0d2001f", "ref_doc_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee"}, "21ff7094-4220-43ce-9f26-57bb408b4fd7": {"doc_hash": "3f177ccc28726222c0a7576ac46f96a0983c644d6f2c935a43c774b66e96ba57", "ref_doc_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee"}, "94c4717e-7ea7-4352-8d3c-d3943d9a1ca0": {"doc_hash": "60cd62fe525c73d24d4e63a2d673e3656abbe98ef7127ace09e28001e188109f", "ref_doc_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee"}, "0b0cc8c3-ebf0-44cd-ae02-4100193706af": {"doc_hash": "3a57ad1dcd3798b1fa5e9487d1323838ec02c6c9de417037a08697bedc3d494f", "ref_doc_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee"}, "fb38692d-9345-43c3-9ced-bb3c682743e7": {"doc_hash": "21b8281ee0393cb02351b50015586d9771326e8d92f246c375b20f70083e8bc4", "ref_doc_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee"}, "e46d2bd1-c08b-4ad1-9ca8-30c29ce6ee9d": {"doc_hash": "eedd1b0c6222e9744e770944a1264505a8874457aca70ad2991b1fb83e2d3490", "ref_doc_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee"}, "0e82fdcc-7966-48b6-af4b-571522d1a054": {"doc_hash": "c9ef6c424401635d30a19d3d622b807f05bd40b5f1737f5ecaa88a9a71840ab5", "ref_doc_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee"}, "dd801f24-c20b-43e8-984f-fa54a49c5a26": {"doc_hash": "0792d060fab3ea3ff6b9371e347146e23e9114538e6f9b61a78e241c6481e2ed", "ref_doc_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee"}, "d7c4b49a-791e-44cc-b3cb-5d68012b580a": {"doc_hash": "1315add186d0e140b1b6dc7e5e1b4b160c3616cbca08fcae9baad12a8aa32295", "ref_doc_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee"}, "62e0b336-868d-4fff-88ad-3fa3f7e26b18": {"doc_hash": "5c7b9b582cca1be04e9c8a954c62e3b44366c16cc1d779a238c70de039b4d9d5", "ref_doc_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee"}, "fbb122e5-87dc-41c6-a03e-896c32a6343a": {"doc_hash": "21cd9827c4dfc1d218f4de847e7e5d406505d0638dfcc1c034c80a9513bee418", "ref_doc_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee"}, "0ebbf5fe-42a0-4c19-8653-9338f11d8c81": {"doc_hash": "df7caafb9ff20caa41eebbea05ecfab63f3840de7123fe40e1ac76f77354774c", "ref_doc_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee"}, "816830c4-ef62-4376-b137-b09e064d5d61": {"doc_hash": "6ae18fee54c0ba1cd36cadda37abdc9416b92c30ab7e00ad52cd8281ac9587ec", "ref_doc_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee"}, "6d4a9ecf-b96b-41fc-a7c3-56a294e18319": {"doc_hash": "17053904d183e23bbf79ff87fcf71e8cd45e9f087c36545ef37e8b1e6d51086d", "ref_doc_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee"}, "4cc809cb-633f-4f0a-95b8-a7fd4b758095": {"doc_hash": "55fd714810e836d2eb72b2cf9a70cddb25250e4f5ddd4e0a47e51d326393eb46", "ref_doc_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee"}, "17414686-4c78-4852-84be-7494ac0e127e": {"doc_hash": "7221a4131a7a8cd30d2ef6ff2250db94263cc3d238d3b619e558b057d74a02ee", "ref_doc_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee"}, "de80aa3a-a1ed-43d1-b214-bc9a31b9fce2": {"doc_hash": "0c96f294c080b066e2270906c2ea252146e585c89fbf0fde054399b5492452d3", "ref_doc_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee"}, "bc2a3621-b807-49d9-8503-7bc6c7a2b8ef": {"doc_hash": "3c39e1f91fc621de9050c6c3fa20104b041b0ed39117468407efc961b7b5e4f0", "ref_doc_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee"}, "adc253a6-b16c-47f2-989c-926d3bb12c33": {"doc_hash": "dd266dac0fad211d574c30d7c2740f591d3546d3a1fdb6481677a476c5c337db", "ref_doc_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee"}, "6704cf25-4686-4008-8090-7f47ff054125": {"doc_hash": "9bea251ce2f1f0bf19527d194abd95f42640a12ecfbc44f5bd0a82cfcc0b618b", "ref_doc_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee"}, "4164cdd9-4867-4285-ac1b-2423f6da85b1": {"doc_hash": "29bc9f1d589dfcdbdf99f417ee2e29690202c4e062412748738273f2bcf0b6ca", "ref_doc_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee"}, "7fd9c80f-17ae-4c1b-8f04-84077bf2d8e8": {"doc_hash": "35c7067932c110e30b9d5347b434f93805291cdff39175d75f34a9a7f2cddd5e", "ref_doc_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee"}, "5ab620af-1c8b-4700-98f1-5f92d9a6a050": {"doc_hash": "72bee6e86ef371ef61369918816e1729a62ae7147979d84ef024660fca82e2cc", "ref_doc_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee"}, "800cab7d-b17c-4bc3-a845-00f2d19ebe16": {"doc_hash": "3813a5a9a72cfdf64688b2a88bdad6264379e3a296b4c0bf234c831b73c4eee7", "ref_doc_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee"}, "9cd1cd37-0121-4b93-a0df-e7aae0a236ea": {"doc_hash": "3ce858ac5bc804cb678b50f73e258ce8c8850da7ca923f37a19aec3240dddf3b", "ref_doc_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee"}, "31aecf5b-2bc3-49df-9a28-326f27eb9d6f": {"doc_hash": "80b51d04bd98ce61fa0aada45915d0a5b7a7be5ad969b3a3a2d26d2858a9c3e1", "ref_doc_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee"}, "fc124232-1489-46ed-8ed0-12cd5d75bd56": {"doc_hash": "a1be31338196a4f9ddacda46b4644302250a32ad2ec525da7b065d4b34a32810", "ref_doc_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee"}, "516bbaf7-2c84-4aa2-a31b-c3b9f56ecf15": {"doc_hash": "32be2a6058f60eab1e148f22059fe18ba78c386486bd71b413c45e7f21da32bb", "ref_doc_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee"}, "a644bd2a-977d-48d7-9f6b-b774bba667da": {"doc_hash": "81b3f09e756689668b3a299da0af1c19fba0a04e7df45c82989ca89f67320d21", "ref_doc_id": "f8067737-6869-4df7-ab67-d2d29cf9e8ee"}, "f67647d4-bca2-4d34-bf9e-fbfa2e1dea9a": {"doc_hash": "b3326e740dd05b1140c951167634eb86706802bfcf1b0e7dfb095b63b21c001d", "ref_doc_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297"}, "436d2139-1097-4c38-8a3b-74dfded9c73e": {"doc_hash": "836f1dbadbc59e266d34c4c60dda0bac8d2d54a6232e6b65f29fac438764e4b4", "ref_doc_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297"}, "401f2e5f-898d-42df-9d93-c959d0a058a8": {"doc_hash": "707e663f97ab6bad9b49f083982966bb5e13b815f769a0680f5d162caaef8ea7", "ref_doc_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297"}, "13729ea3-9522-45d3-9b0b-c9085019269d": {"doc_hash": "a031f0fd149d24c7f5fd5d79d4ef976a78a0454d7993cc7c3654339853808609", "ref_doc_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297"}, "b426762f-bd32-4b36-bac8-9a050737207a": {"doc_hash": "053c4e2f9080b8c9b6e00a17ee0a23b0693b3abd51af47a802de5af20744e661", "ref_doc_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297"}, "14cb1736-1c54-420b-a250-095b9a0c293c": {"doc_hash": "70daf92a950b44b2a639854d46faeb4533f3caf9f6a6bdfde2f1c97692ffe2c8", "ref_doc_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297"}, "d6003e3e-40d1-49f0-af5e-8bd55e3ddf20": {"doc_hash": "8b4bb3b283fdf917d729ab959cbcdb52f8af1895cca29df82fa53ba856000fef", "ref_doc_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297"}, "f2930220-c519-4143-a953-e83b1d72545e": {"doc_hash": "baf698971e4b28ece362a0dfddda7f329480d30f898488d4b380a303311432f3", "ref_doc_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297"}, "9ecbc28c-8125-4995-b847-f1d8ed740192": {"doc_hash": "1dccc0d60030374c42baeadcb17dd29b5575329e9094c64a7ffca4e150f778ed", "ref_doc_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297"}, "4d6b7376-c3a1-472e-9494-726a19e71afa": {"doc_hash": "4d8d3ca00c3ebb35e043077ff811e3771c000de99af5a73a48915dddb8c07535", "ref_doc_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297"}, "760631ce-7b40-453f-8695-ffc1da725a0b": {"doc_hash": "fba1604f9b7077eb242a5af5971fa09e73963837305d00f019c913052a554d3e", "ref_doc_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297"}, "817a8a2c-e61a-46c8-b436-b251bd74a842": {"doc_hash": "140203563dd9dd0012543cfa86e3c5ab47cb8fa7f13323eaa17f525ded6bad3a", "ref_doc_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297"}, "4b6b9f3d-6ed1-4fe1-a32e-78f06cad4eda": {"doc_hash": "1bafb2ee2d5d8c60f7592f6769dbe962c6c4a428753717f5ce9abde4a4222ca7", "ref_doc_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297"}, "07d2b955-3b87-42a2-aea9-b305a4a70714": {"doc_hash": "53dd7a257d362282034414ea4434ec1e18ef2e4a75f6aa13036f84d8986c9e97", "ref_doc_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297"}, "a32bb471-1a79-4ae3-9f48-d5a960db822b": {"doc_hash": "98f2800b8aa555891d8009ad4556798ca0230a692601adc35bd3d6d37493719d", "ref_doc_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297"}, "b00ff72d-413d-4364-936c-ceb74ff59874": {"doc_hash": "7fa76591be846bd37a7db57c6594838d668662c61d1c827b92d64bc84fe22806", "ref_doc_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297"}, "4aefc882-3c0a-4abd-9aec-509df9d94789": {"doc_hash": "28de043e0a0688765df1481b811876aa099a1236b5ffb07c1586acc0c08e63a9", "ref_doc_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297"}, "398d98cf-ab51-4ebe-a46b-be28725c38b9": {"doc_hash": "7549c80e66979fe2d8e249b0d25bae9ad85555420006d3303cef623a4944f5c7", "ref_doc_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297"}, "a4239ef0-44f1-492e-b3ed-c2763069b106": {"doc_hash": "0dc1f7adf30f3289cfff680ed5a92a071771b8bfdec17f99488cd24d42d15dc3", "ref_doc_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297"}, "074a9070-c029-45e6-9966-54ff9e83475a": {"doc_hash": "1e0e0e75d625b19fa07934ff8cf51a6ca781ae94a2f88d57e2d8fee435656cc4", "ref_doc_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297"}, "620b21c9-7b60-410e-b578-8232c8fbbe34": {"doc_hash": "1f14c3596ccc2b3805c0caf5dbb9881f0ebfdc5e71daa571c92283394ce4b1a4", "ref_doc_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297"}, "73314e49-61ae-4c03-91ce-7506285b6bac": {"doc_hash": "afe134fc8ea2f2a8f0a3062fa5efc151c3b5b0f5bc0f3099f308ac72f398d6cf", "ref_doc_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297"}, "8c3b5871-3a00-4591-8bec-dfc948a49179": {"doc_hash": "8ddc8cfedb4bae717d8030c2a041bfc0c7a881a4e59aa5d437a4cd6f04332316", "ref_doc_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297"}, "56ea7d30-1847-4586-8dd0-29f5f573b962": {"doc_hash": "36d31558d5e5837a991b6b5a5bef2d40bebd56f5ecc85054aacf01ac3ed5dc32", "ref_doc_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297"}, "847be36a-8dea-42d7-88ae-fad809f076db": {"doc_hash": "c00ef4e95014bcfefd2bd1a42b84ca085ea69f6c73423e937a712a64fd039fb9", "ref_doc_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297"}, "6ba6b5bb-4968-44f6-be18-32176a6ad54a": {"doc_hash": "bb08159b28067f76229c690169ad43f10724eb3077ef5504fe2c5be0a415edd9", "ref_doc_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297"}, "1d8012de-c6bd-48f2-9b77-928f32a6eb5a": {"doc_hash": "3550d7829b4165fcf7a19083befed553a8d1e1085109627d8faf58b9daf8c945", "ref_doc_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297"}, "eb1b7cdb-379f-4164-84b3-2e20ff30a228": {"doc_hash": "4dea7a3363a7922e43f916112b8d1e9e098f9a7b37add5ec031fbe06a5cde847", "ref_doc_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297"}, "88f2af39-4a9b-483d-8ba3-e9965fc2d960": {"doc_hash": "ea0dadc6a9354512fda6a504e76b41632e9d1aeb22d2f7ed54bdd02622d2c566", "ref_doc_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297"}, "277b6875-dc10-430c-8470-221382d41aec": {"doc_hash": "64207c762f48d158a67adfdd7b4e56edb6833e55818091486b14e2e64b039b12", "ref_doc_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297"}, "df8e8850-11a3-448a-9678-d667b917279b": {"doc_hash": "4b189dcae03cea9ce36dea281c3a1ecff251b06653a6645554da85c022a4dc0d", "ref_doc_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297"}, "ca7d37cc-5b9e-4279-8a3c-c27ffa950c9c": {"doc_hash": "3aa04de9367b8451c3f36b640df5e6fe15bb81ec6828e32bed5ee61f505d4212", "ref_doc_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297"}, "37d1b0f4-52b0-460c-a657-c6bd00c54fef": {"doc_hash": "a42e8aba83f2d8e34cec68240235a42b689437f5de26650b8a09188c451de28b", "ref_doc_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297"}, "09b3bcff-d13b-45a3-a0a2-449483e437c9": {"doc_hash": "45fd866a4ecfcef9def5fafd9cac6fcaa68329249745e9fc5504e34db56eeb78", "ref_doc_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297"}, "c1e5c3f5-104a-4de7-b165-2b840d74b5c6": {"doc_hash": "4f2ca83c75a428cb5011ad93cb4a05697cc23d834473bf1fa0209eafffbc5ea0", "ref_doc_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297"}, "b618a7e6-21cf-4100-b2b4-7dfeadb35bf3": {"doc_hash": "33632764822be7626b18ab83aa53a8133f43eb4520b9612817bdce1e8074646c", "ref_doc_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297"}, "5cf8c82e-8c37-4e95-abda-6f0c248bde74": {"doc_hash": "92e58c44c2ace4ea560ce6ddf616c899aec8146fccaf5a1f56fa8c88604578c5", "ref_doc_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297"}, "7e8b133c-d838-4372-a291-617d518be231": {"doc_hash": "4e0669279764e87257ed2ab8a969401a5e73ff03dc05d0ae9f981efc5d36677a", "ref_doc_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297"}, "fc25a6ad-c887-4a1e-90d6-3906a03307ab": {"doc_hash": "a1866b7f8b3be0c7ffd0c898d05094bdd164088e8a507f0cb3b277d867b4b19c", "ref_doc_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297"}, "68b490f4-00ba-41e6-ab80-43f3f735994f": {"doc_hash": "d5ed7d5276c0ee213e7f0a91eb817017417a059ad238e6a21f829bb9a79c9e62", "ref_doc_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297"}, "c8763c96-9224-4974-9b8a-c4e74c17ad08": {"doc_hash": "7066356794075c5e4542351d9307961f9a394fbac29b74900788c560cd5ce03b", "ref_doc_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297"}, "508e1cd7-d6f8-4593-8c08-fd8446b2935a": {"doc_hash": "df5073722300f885920f0998dc0f4f9466ca80dbcb9187d3dd3bcde04f3dc582", "ref_doc_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297"}, "f886668e-b648-490d-bd57-fa0c18f21982": {"doc_hash": "5eb292a1b80a64de4035a9fad926af17df66d7636c68b48139ceea097b91956d", "ref_doc_id": "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297"}, "e9e683d0-8072-4fc1-a6c0-213b094d8c97": {"doc_hash": "c545cd6ff1abe391aa291795cd06ea0a40e4e5526f1c0f0bc1bb6d447f3564dc", "ref_doc_id": "7d4bb324-d13b-491a-9b23-44037291468e"}, "9321c5f9-b05b-4fa6-a265-f22d99f82a58": {"doc_hash": "528a630a3fe81fb12de3dd4e72369dd41cc4a3558c484866a4edf60b23fdc2a3", "ref_doc_id": "7d4bb324-d13b-491a-9b23-44037291468e"}, "fcca8f67-c668-41de-a04f-073ed01ef5b2": {"doc_hash": "89b9a61bdf3afde8d0bba0545efc900165c900230e10a5fe9c0dd91ede9d859e", "ref_doc_id": "7d4bb324-d13b-491a-9b23-44037291468e"}, "23abc526-bde2-4677-aec6-e4a3738a265c": {"doc_hash": "5cdbc24fd289509080c1e944f91ce203837371d204f8f041560dfb9d7ce3ffe5", "ref_doc_id": "7d4bb324-d13b-491a-9b23-44037291468e"}, "e32a4671-c530-4c70-8950-8ab3071eac62": {"doc_hash": "6a7e3ba76885162c9a2406a39ab24db8c421514acb93380666adf4bbb2dc3d43", "ref_doc_id": "7d4bb324-d13b-491a-9b23-44037291468e"}, "330b7c94-153b-4213-a4cc-c436992632dd": {"doc_hash": "f5295ca4d6da98b2a39f9f34e2f0617ed24956f9fe8037167030b30bb2f61c44", "ref_doc_id": "7d4bb324-d13b-491a-9b23-44037291468e"}, "8dd3ce96-f85f-483b-8f40-6f5bbb80b27c": {"doc_hash": "1b06f5c58c006a1b7170bb05bb5c5ed0ae23241464997832a85bfeae6c6dea9d", "ref_doc_id": "7d4bb324-d13b-491a-9b23-44037291468e"}, "afe19e15-c5a8-4913-bc3b-7003cafb577c": {"doc_hash": "d4d212ae432381d577796c79a453847a3b50fd16b334ac8bd11912acfa38dce3", "ref_doc_id": "7d4bb324-d13b-491a-9b23-44037291468e"}, "a457555a-fe31-4216-a01d-55985dc3ddfa": {"doc_hash": "de1597f1bb05b73ef4b47662f48a51e5f9017c54c14723c7e6c7f74b4be28e97", "ref_doc_id": "7d4bb324-d13b-491a-9b23-44037291468e"}, "35f2c2b8-4c63-4e1e-9e2e-e76c8e84af3b": {"doc_hash": "7d3f9753a62a5557aafa63ec1e90f4af01428147e6b4ea619834fcc0f92c3942", "ref_doc_id": "7d4bb324-d13b-491a-9b23-44037291468e"}, "21b2d1b5-41e7-4092-9aea-65cf744c6160": {"doc_hash": "c150e1991cfb6e63cbe1c7256d9059df7f71ffe50e6a68fdc61d5e7f647d294a", "ref_doc_id": "7d4bb324-d13b-491a-9b23-44037291468e"}, "e919b8f9-1e99-46a7-afc9-d5372f147fe0": {"doc_hash": "77e9d2fcd5a04b7879ce058e89f10d4a1bfb9d2f6f541deba619d5666acc6bb7", "ref_doc_id": "7d4bb324-d13b-491a-9b23-44037291468e"}, "9946ddd4-f170-488c-85e1-d423ff7f08e2": {"doc_hash": "8217b7932bd16bf1c1ed8523cad5b67d8d1be238af1806f4b713edf72919b79d", "ref_doc_id": "7d4bb324-d13b-491a-9b23-44037291468e"}, "6088d1b4-b225-4078-9bb0-1ee63b8dae52": {"doc_hash": "62cf452c043208c6e84a4f4a5f7664a50eeacd25e4f7e9dab80cbd01259b5a36", "ref_doc_id": "7d4bb324-d13b-491a-9b23-44037291468e"}, "7efb492d-cbe4-454c-a042-7f76dc1c7bf1": {"doc_hash": "e7d16ba777c149e00b89c540adf420ac8cfc8fd63c17b7ec0b224949096a0da0", "ref_doc_id": "7d4bb324-d13b-491a-9b23-44037291468e"}, "7434c9fd-cb77-4959-b889-adf54799c680": {"doc_hash": "01f09f4a26d2ec88744d30dd2087eeb21ec30d382a0d69fee2ffd07359953a8b", "ref_doc_id": "7d4bb324-d13b-491a-9b23-44037291468e"}, "29739d60-b2d3-4131-9cae-259aa28b081f": {"doc_hash": "4f9e1f742bdff81090598cffbdf3b65fd2c44f98db7875f604bdeb608e55b147", "ref_doc_id": "7d4bb324-d13b-491a-9b23-44037291468e"}, "ae4a5e21-f5f2-413f-9cae-acef6106293e": {"doc_hash": "b16919bf4bbf57e0ec03e8dbae7db102e54b2055c4c5031f5e30ce1806805bc2", "ref_doc_id": "7d4bb324-d13b-491a-9b23-44037291468e"}, "4b750984-9836-47dc-9317-a46a2ec79b4a": {"doc_hash": "f532540a7e41cfdd6d2b1845a2e2a986bf4456c5e4349cd7dee9bc1dd3e44b5b", "ref_doc_id": "7d4bb324-d13b-491a-9b23-44037291468e"}, "cc803359-3400-46a0-ac76-6a4b68c3fbe0": {"doc_hash": "bccd42c9285b29ea0f53c922de5df13b9dc9096ff1bfcbfb281a3e7dc075230d", "ref_doc_id": "7d4bb324-d13b-491a-9b23-44037291468e"}, "c478cd76-4303-4ca7-808b-cb7502645bff": {"doc_hash": "440ff238eb9c838b02981c5106820c32fd961f6a62eb294ad3cf9d84a412196c", "ref_doc_id": "7d4bb324-d13b-491a-9b23-44037291468e"}, "5cd6e6d2-aedf-4fe7-90dc-bcca0f346030": {"doc_hash": "510b68714483ebe28556b7fa5757fc499f3a5c69a65e74f002fd07eebbee7f7f", "ref_doc_id": "7d4bb324-d13b-491a-9b23-44037291468e"}, "fc7ddfd4-79ce-4c88-a5eb-7bbec8b5a16a": {"doc_hash": "186dfd9a3329fc7f574a442252a180d03ae6ebba2c3398e4f0cd7e76357536e5", "ref_doc_id": "7d4bb324-d13b-491a-9b23-44037291468e"}, "fd4b655d-110b-4f5b-8bfd-2c05e0ae9212": {"doc_hash": "37eb4c5502b139a71206de0b79f54ee00e89733835e41c4caba329d65492cb65", "ref_doc_id": "7d4bb324-d13b-491a-9b23-44037291468e"}, "9ca3d230-9882-43cd-9e8e-5a2e8d8e6542": {"doc_hash": "8553290ef1105166b6684e21b2b6a58c6c8ca6b2ae4c93f02e14ea365fd2c8bb", "ref_doc_id": "7d4bb324-d13b-491a-9b23-44037291468e"}, "24d76ffc-e815-4db5-b6f0-48c1d9a2f448": {"doc_hash": "801f8531670bf602a4d17cfaa4ad6d8cb21177570de33ff9857edb5e71dc6bfb", "ref_doc_id": "7d4bb324-d13b-491a-9b23-44037291468e"}, "e8b7018a-e1cd-4742-8742-c945281efee6": {"doc_hash": "273dbc812e7c45b77c039095feaf20630db3749c19f4158f587c47f1fdd66b66", "ref_doc_id": "7d4bb324-d13b-491a-9b23-44037291468e"}, "7641711e-8500-4f84-a3f3-165de428d36d": {"doc_hash": "2590494b73278baf1e134bfdbcd0e406ffe7ba146227692e4fa915fb2b70bf83", "ref_doc_id": "7d4bb324-d13b-491a-9b23-44037291468e"}, "5bcca6a0-b8fd-4c99-8a41-c1f86652a085": {"doc_hash": "904a99f796914d01e8e7f7bc13355b30c1ebf460ce610d790f6eeef1165e77d7", "ref_doc_id": "7d4bb324-d13b-491a-9b23-44037291468e"}, "cf1eda71-9c95-4383-9847-8b58c73673c6": {"doc_hash": "840c23ec0392f12ed932b4b61669d5c8bd4f68e05196e17baabf5d973200cb4f", "ref_doc_id": "7d4bb324-d13b-491a-9b23-44037291468e"}, "81ab7d28-649e-47d6-bde6-80627ad6696d": {"doc_hash": "33aab9ceeb087542cb642bd290487fefb125e4eac5ca71705e9817ecd5b39045", "ref_doc_id": "7d4bb324-d13b-491a-9b23-44037291468e"}, "a069db4d-88a9-4815-a945-dd015ddb1d94": {"doc_hash": "24b18ae2d16447f1252ee9151d8b45513924790c36218c43ed350c71261da854", "ref_doc_id": "7d4bb324-d13b-491a-9b23-44037291468e"}, "2138c191-d192-447a-a8aa-55d3e0225a57": {"doc_hash": "c7e5fb9e5305212c203b196a79924482b7ee03bd7df143fd31d481c97ec54f0b", "ref_doc_id": "7d4bb324-d13b-491a-9b23-44037291468e"}, "816eb37b-11fe-4ab2-a7e7-7b87f9191d7f": {"doc_hash": "847efd1a1466338517609b80c76f3308a6a13b050e7f519cb12af0252804d7b6", "ref_doc_id": "7d4bb324-d13b-491a-9b23-44037291468e"}, "7533a5bd-c356-4c06-89ce-d6851e6a871c": {"doc_hash": "a76f319b22c3571f9d32a322d6b608dfa95f01804f240ac08ce0dc62ec6602c7", "ref_doc_id": "7d4bb324-d13b-491a-9b23-44037291468e"}, "d2be9c89-a25d-45c8-a33e-e7064907b612": {"doc_hash": "a1e51feadf315568f278fa6c48b6298c3b1c2adc76271dc4505e16bfa3f23b9d", "ref_doc_id": "7d4bb324-d13b-491a-9b23-44037291468e"}, "3c1cf53e-4f99-49de-8280-7f0e9226ce80": {"doc_hash": "cb39e03d8ed7742e481250bbd07574e77d9fef1c5c8122b6f4bb7fd8a45a5e3d", "ref_doc_id": "7d4bb324-d13b-491a-9b23-44037291468e"}, "d0e3accd-cc39-467b-8ca9-a9beb9a0867e": {"doc_hash": "a7d659ace7438b3e9686aac72d1b11214001fd72974b0bd3407aaf61fc56e3c1", "ref_doc_id": "7d4bb324-d13b-491a-9b23-44037291468e"}, "1ae976db-a92b-479a-95b3-b954da19991e": {"doc_hash": "1d72a266b8601d1c5f2ffbf0e4677b5e794e36d2b67f8a157404c681c41a1bc7", "ref_doc_id": "03733b2e-50cf-454d-ad00-c59834e71dbe"}, "fbe2dc6c-7dd1-4acf-9dea-fb7b981b274d": {"doc_hash": "95000bb74f7d84aaf9c5b4f5cc58bd7c5a9bf314fd3d328b4cc74c933cdfa123", "ref_doc_id": "03733b2e-50cf-454d-ad00-c59834e71dbe"}, "d7d4d3a6-884f-4f04-8d1e-7855ed050df3": {"doc_hash": "dfa0ea80ff60f917cbd4331e6f3e07b98f0dd8a322c154512b9dba8e5df09428", "ref_doc_id": "03733b2e-50cf-454d-ad00-c59834e71dbe"}, "c69de311-f58d-4755-a083-8a8623c02954": {"doc_hash": "07cf1b32b18659d066f64b3dc407b23c2a2fdf01f85925c09526c3b4e023b430", "ref_doc_id": "03733b2e-50cf-454d-ad00-c59834e71dbe"}, "14cec6d0-3587-4d1e-9994-126d5424878f": {"doc_hash": "b987db5740e3f7fa834d9ff9f0d31d33024c200888f6f5364b1a6273f5bd9fbe", "ref_doc_id": "03733b2e-50cf-454d-ad00-c59834e71dbe"}, "7b0ff3fe-584a-4211-8826-988e09b050b9": {"doc_hash": "42a6260795d0452f388aa460f3ead8452cd9c9857e6c1c7f90af6d8ffb936c74", "ref_doc_id": "03733b2e-50cf-454d-ad00-c59834e71dbe"}, "81f1d316-73ad-4f99-8b38-8b9d6882f6a0": {"doc_hash": "584f21b4960f9dad484f2452495abf4b8b4ead5722339b69e92b0f1e21201cb9", "ref_doc_id": "03733b2e-50cf-454d-ad00-c59834e71dbe"}, "c2a2edb3-0053-4205-b0df-c4b745ca628d": {"doc_hash": "b9bed6322549ff62ce2044230e6e08ccad3d281047ff841c19760bf9a402abf2", "ref_doc_id": "03733b2e-50cf-454d-ad00-c59834e71dbe"}, "f0dc30ff-098a-42b3-b3a8-73a2201b815d": {"doc_hash": "34316a4205212b057c4e94a207d12df5aeabd1df7542033063b18c06ea1ab139", "ref_doc_id": "03733b2e-50cf-454d-ad00-c59834e71dbe"}, "ca4361d5-04cd-43ab-a62b-f670d6b07cbe": {"doc_hash": "23f4c877bef9873bce57b99f8e8a92669bd732a2b4252ebd9c449e26f8577ce9", "ref_doc_id": "03733b2e-50cf-454d-ad00-c59834e71dbe"}, "24c6a7f2-699b-49e5-8a32-f8fc4607d218": {"doc_hash": "60a91817a3f420fbc6a1cbb97406329e385fb20cb4a241ba9ea6fe77555f059c", "ref_doc_id": "03733b2e-50cf-454d-ad00-c59834e71dbe"}, "78a4fa3b-e189-447b-a47f-fe53da30df68": {"doc_hash": "783c57a58f3f939cd0e3e16b3187665a6b8804a7eecae78e08d768c4e1cd1989", "ref_doc_id": "03733b2e-50cf-454d-ad00-c59834e71dbe"}, "36ac3b2b-b296-4029-8fdf-713d043f7476": {"doc_hash": "3ed751c5a085358b5be6c6b2bfc22319503bd66af533e007fb034f77edc0dfd8", "ref_doc_id": "03733b2e-50cf-454d-ad00-c59834e71dbe"}, "e02cb768-c4a7-4299-92ae-15e2b62a85b1": {"doc_hash": "112ef9f5f2c40e5f065547acca9b7613be88f715d594d143c7c1058a7cf71aa0", "ref_doc_id": "03733b2e-50cf-454d-ad00-c59834e71dbe"}, "84ed0c8f-d886-439b-9181-632e5bd6830a": {"doc_hash": "80d12144d177cfebb228f3748afc696faab5bcf0defc7a313d6859b8e8b06c90", "ref_doc_id": "03733b2e-50cf-454d-ad00-c59834e71dbe"}, "407e014d-ccb9-4f95-a303-d03e56bb811b": {"doc_hash": "e9b12716c8818616ada209978dde335be49a55cda3112be6537dd3ac0519fe71", "ref_doc_id": "03733b2e-50cf-454d-ad00-c59834e71dbe"}, "7a385f73-6995-4e0f-9f11-276b0923034a": {"doc_hash": "8b8178f9a22338a31947ebf0a712f6c63eb53ce9816d1957b0117afa47915c3f", "ref_doc_id": "03733b2e-50cf-454d-ad00-c59834e71dbe"}, "20dc8f7c-6405-4ae2-a70a-e83f431ba9f2": {"doc_hash": "5ee014add98f031c6f636f93e58af98dcaf67dc9f79da803f5d33d79617f5fa9", "ref_doc_id": "03733b2e-50cf-454d-ad00-c59834e71dbe"}, "9764b223-9732-4375-a2c7-8ce092a0e44f": {"doc_hash": "80580322a380d2db94c4fcf2e8fe445b3051dfc03fd7652a4f1d6393721853b6", "ref_doc_id": "03733b2e-50cf-454d-ad00-c59834e71dbe"}, "210504be-97d5-407c-84a8-bfe280fb22b7": {"doc_hash": "e5f24140d228dcabc72a3420f6cdaf2a13f8ab5877440826f99d709f0c3ab32d", "ref_doc_id": "03733b2e-50cf-454d-ad00-c59834e71dbe"}, "ad6893e0-091d-4c43-8d1d-fe6b389ba3fc": {"doc_hash": "2a74c9750044003b7f2f5ce49bed23ede891b66b86818216c1849847e0911922", "ref_doc_id": "03733b2e-50cf-454d-ad00-c59834e71dbe"}, "fe362cda-5722-43c6-a6c5-d0e86d13cf7b": {"doc_hash": "c2eee1ad05da273c3e7e948d68ff6313ca3ff10b6ea7878efbc93a1d3037cabc", "ref_doc_id": "03733b2e-50cf-454d-ad00-c59834e71dbe"}, "80a35f00-f6c2-4d7a-849d-9d19e5dc059d": {"doc_hash": "7aa8b08cc0f48e349af52ad5fa8ef6825fcc0da03d18b8c04d14ecca0304ba2d", "ref_doc_id": "03733b2e-50cf-454d-ad00-c59834e71dbe"}, "67216b12-9817-4256-bf29-ddbd6fbdd52f": {"doc_hash": "acff7d3925a942c9ffb3b461c8aa540100868be881f42baf88465a548e949bf6", "ref_doc_id": "03733b2e-50cf-454d-ad00-c59834e71dbe"}, "b402dacf-e727-464a-b881-6e4f4bfc3108": {"doc_hash": "d4c920fd8aeddcb00db41ca63220d38f29b9f9302754c80eb9161398a9bfb6a1", "ref_doc_id": "03733b2e-50cf-454d-ad00-c59834e71dbe"}, "1a44e9f8-97fc-4ceb-bc3c-110a87877191": {"doc_hash": "513a1c302bae9cdef404dedd5eb634d0b437d1387a91fe5243394af96780b5a2", "ref_doc_id": "03733b2e-50cf-454d-ad00-c59834e71dbe"}, "2a8fd421-4a89-438f-b96e-305083f0b4fa": {"doc_hash": "d3c0134513abf2a7e81030da6f23394f41b57c45a353ffe11fb85a51b6287338", "ref_doc_id": "03733b2e-50cf-454d-ad00-c59834e71dbe"}, "4a76ab28-d248-47aa-838e-46b2ee839180": {"doc_hash": "feea904da2b40a521e159179f89ced861c7bd7bbf9b9641baffa47d66a89eb3b", "ref_doc_id": "03733b2e-50cf-454d-ad00-c59834e71dbe"}, "7a25391b-923c-4cb2-8b2d-88cd4b33ac9f": {"doc_hash": "582de9a6e166711e18c55e11694c36be08c288e6042261d11292dec492b3a767", "ref_doc_id": "03733b2e-50cf-454d-ad00-c59834e71dbe"}, "b6110ef7-ec23-4b73-b74b-f4740002a68a": {"doc_hash": "88fde477edd08a2a2d2fe944a5d9dbbcc9bd9416eb43980e9d63db312002b031", "ref_doc_id": "03733b2e-50cf-454d-ad00-c59834e71dbe"}, "22cfee2b-dfca-4ab4-9059-e88d636aa4c4": {"doc_hash": "265841f67694e345458d4c9d11938c2fcb9fd698988ce9573b8b20d41fc0764b", "ref_doc_id": "03733b2e-50cf-454d-ad00-c59834e71dbe"}, "0a5b920b-8ed9-4b3d-a802-ce8b4f65bbc7": {"doc_hash": "766741a714ff1ca7d8abbad291cdc02ff7dcfdbc02fc73b128e033dc41124072", "ref_doc_id": "03733b2e-50cf-454d-ad00-c59834e71dbe"}, "86af7ae7-464a-4610-9a4e-cd49d1263391": {"doc_hash": "d64fa8a85f98c03d46fee58eeca2c052dc46885aaf938eb8190f72b977e25e48", "ref_doc_id": "03733b2e-50cf-454d-ad00-c59834e71dbe"}, "68323828-d849-41cf-9b24-7b37caec19f2": {"doc_hash": "f59b58bc53a8ff1bdb96c7ca1b0d5b98a29e84b8bec7207749389078c587a19a", "ref_doc_id": "03733b2e-50cf-454d-ad00-c59834e71dbe"}, "ce8d8bbf-dbbd-405f-a668-51f9ae36b247": {"doc_hash": "9dea4726c7ddeab382dcee391d34aaee2fe66c46bfad6ce787df2f96b9365204", "ref_doc_id": "03733b2e-50cf-454d-ad00-c59834e71dbe"}, "c6387056-da82-4129-951f-067d08f69f1c": {"doc_hash": "b3057ce2c404a7e5a3442188d3035e0e574f882ab07d29a2243bd49aa9ee062b", "ref_doc_id": "22a2c3bc-f5a9-4e9d-9fec-881d6056ae02"}, "926a5899-a150-4884-b82c-3e1287d1832d": {"doc_hash": "a8268e744107aa1e4c684a1453d9b350bb1fffed9186b0d65c4c1a1d49d04ed9", "ref_doc_id": "22a2c3bc-f5a9-4e9d-9fec-881d6056ae02"}, "462fc660-c57d-4a4d-93d9-567d4cfea8bc": {"doc_hash": "0baeded25193cd43fdd51f273b61a8bddb98ccbd6d8fe111b9662915cff42c2c", "ref_doc_id": "22a2c3bc-f5a9-4e9d-9fec-881d6056ae02"}, "f7e021ac-8ac6-44e3-83ca-bddd47e9d45a": {"doc_hash": "f4a876f4fa10102804ec23c88d7dc0b3ba3280bda7468a926671cc2f03a691ca", "ref_doc_id": "22a2c3bc-f5a9-4e9d-9fec-881d6056ae02"}, "e261ad7e-917e-4468-a72e-dae359c44f2a": {"doc_hash": "1f99f56211d0501ccb03835404d0115da7fab0b9cbe557a4f99c4a8f1f3545d9", "ref_doc_id": "22a2c3bc-f5a9-4e9d-9fec-881d6056ae02"}, "c4d8d46f-d1a3-4eb9-8933-74fe573567ae": {"doc_hash": "14e668eeb5a5a6a5d31691385886c8a5abc89760a4f3aaa77de0b0427c4ebaf2", "ref_doc_id": "22a2c3bc-f5a9-4e9d-9fec-881d6056ae02"}, "13bc8c0d-96a2-434f-af98-bbcf299b5f66": {"doc_hash": "cf094ef21f7806d7970d0c9ffc763a5e0772b808abb4a4de439b666204f43e3e", "ref_doc_id": "22a2c3bc-f5a9-4e9d-9fec-881d6056ae02"}, "990e26a6-9665-491e-a4f7-149fe1859ca9": {"doc_hash": "1f33e8ae1d0a498b49970069389f52770ea7018b6ee03ac2c38ebfa19b2be4cf", "ref_doc_id": "22a2c3bc-f5a9-4e9d-9fec-881d6056ae02"}, "851fd01c-5be6-4b6b-8874-3f329a13e52f": {"doc_hash": "9d86bd6d677108a0da90234ef4ad253e8c8ac4671940a4f015468e1404fa13a7", "ref_doc_id": "22a2c3bc-f5a9-4e9d-9fec-881d6056ae02"}, "3f1d1419-9857-4039-9cc9-35ca3e020a8c": {"doc_hash": "5422c1fee122e5fbd2cac6a490288a6d9a48ac973b64a33509c7615255434b63", "ref_doc_id": "22a2c3bc-f5a9-4e9d-9fec-881d6056ae02"}, "46cd4c97-ceb3-4f28-ba3f-e5eeccdd69f0": {"doc_hash": "73b911ece18014fe3561fb4dcbc84162c39084670ba6890041093c1c90e87206", "ref_doc_id": "22a2c3bc-f5a9-4e9d-9fec-881d6056ae02"}, "b8d23bf1-e297-44d6-b411-68028cb5313f": {"doc_hash": "fba8f11c0e8ac0743661713498b80e9662a5b25423269bab39949a8c3d1c93a8", "ref_doc_id": "22a2c3bc-f5a9-4e9d-9fec-881d6056ae02"}, "ab34ee79-3f40-4278-856d-13a1f715de37": {"doc_hash": "cc6e7a88aed1d4d7d1bf1e7aebbec01c06e806803d03fb0ef14c11bc9343dd68", "ref_doc_id": "22a2c3bc-f5a9-4e9d-9fec-881d6056ae02"}}, "docstore/ref_doc_info": {"d722b2c6-7573-48d7-9a60-f4b19a5e6cb3": {"node_ids": ["f83e9682-a495-4a36-a4a8-4e014dbd92c8", "ec128aed-3c4f-4f95-8b2f-d785c52e4ebb"], "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n04-Aug-2021  \nMcKesson Corp.   (MCK ) \nQ1 2022 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n04-Aug-2021  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "6464c30c-9944-4870-b7fd-30474d3e4691": {"node_ids": ["6582eba8-2152-47f3-8923-e4a7cc436a98", "c16b6ac7-9fb5-44b6-897c-c8bbbc105df6", "31fdebb4-7161-4aa7-939a-87c79c7d7d8d", "77750ec6-480d-4325-8aca-1cdeddb3ed3e", "3b869698-0365-4461-8a32-c7c76314708c", "f696633f-3170-428f-a177-b1bc588b35c7", "b2893e45-a589-4373-8848-d928f97a1cf8", "edda169b-9d02-4c3a-81a0-81ed150dd0fc"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A \nFinance, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "d4b1ac0c-75a8-46ad-bd31-cf116cdb55e8": {"node_ids": ["99a8d6da-fe84-401a-8a6a-d044775aeef1", "d1d1419e-2bbb-4c5d-a5ed-9215f9c73a02", "457cf053-83a7-48a5-a713-b2f43607afea", "b98e6ce4-63ae-4c9e-946a-4b1ba6ae1e0b", "f523c120-2c37-4cc5-a00e-d79ecb49ec38", "6f41daaa-f10a-48c8-9db0-a62861abacf2", "2cd79074-27cf-4109-80a0-8836a74cbd67", "ecf906c3-b20c-418a-94dd-244b93fba816", "ed2c0c07-5989-4f5c-b9b7-d3614c03ec97", "3dad2a05-56c1-4b3d-ae8a-2d117e128145", "de00f2ab-9af6-4fdc-9f32-3b3629b82c5b", "ba88020a-3774-4150-95c0-eadbd35d6e34", "c0e8da74-71f3-4579-bb60-b4e2d22724dd", "7e3fb905-c808-4c72-9988-092173fc332e", "075a7369-29b1-425f-9266-4eb3823cc4f3", "762aa045-09df-4d7f-a3a2-746bcb0aa253", "9e5a43be-5022-4053-b87e-1b7101db70da", "788f3d9c-5f38-4fd4-9f1e-d710ab04a3c2", "a2a7d591-0172-4bea-b6bc-500673f85b8e", "476329e1-aff9-4a14-b432-9980aab58668", "db397d6e-e0d5-4b2e-a6f9-aa9bfd9c1da9", "700990cd-a583-49ec-a912-21367bdc88f2", "8d0d3edd-552b-489e-b875-74220e3d1196", "d62f0f69-44e8-4529-bf6d-ba12c52478f0", "684b5ed1-0fbd-42d2-b92b-f5e9518be79b", "7365827a-e44a-46fd-b8e0-51db5c52ef6c"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to the McKesson's Q1 Earnings Call.  Today's conference is being recorded.  At this time, I \nwould like to turn the call over to Holly Weiss. ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "aab73de7-ebef-4918-a603-d86999a6bb6b": {"node_ids": ["ce7ee229-8083-4fe9-82d3-a147aa02706c", "40738c12-5fb4-4b89-9afe-171b5bf4e61f", "8dbfb1e4-9b0c-4486-81d0-c72af5a1de1a", "b73a2fb4-dd1c-4380-a8c1-c0e82a86ba0e", "287a00fc-2062-4d04-9545-f3a31d0fe8da", "60879f82-860d-40cc-8e6e-7646a7f4c04f", "b6617c27-4688-48c7-addb-fbd8d2495fc1", "d38de659-b006-4b2b-925c-f77785825da3", "3348ed2d-9eba-42fd-90d8-39141be3c4cd", "21e0f154-4ae3-452f-9f66-7559709e042e", "b02d88aa-a561-4588-be76-7f2bad2be6cf", "5a41e7c1-daf3-4602-b03e-372d076995bc", "c70e5224-e48b-4b44-9788-932c86458571", "d2d48526-221e-4a5b-8e21-baf48fc1d8d9", "4e702d4d-32a8-4918-8e7c-bf688c2c495d", "1dafb4f4-86c7-4132-9ef3-99abf227b352", "94888eb3-2fd3-4d1f-afa9-13c4b8f347af", "0eaa8fcd-51d6-4be5-b020-9c2b79628dd1", "fb840545-f360-43c1-b029-4b461c5cae8d", "43a700a0-c926-4ecc-aacf-00f3716eb136", "4ca7e15f-fdbc-491d-9d1b-74b999eadee9", "221fece3-216c-487e-8de4-c703341d76c5"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nIf we're able to reach a final settlement, it would provide immediate relief to thousands of communities across the \nUnited States that have been impac ted by this public health crisis.  While we strongly dispute the allegations made \nin these lawsuits, we believe that bringing resolution to these outstanding claims is in the best interest of those \nimpacted by this crisis.  We also believe resolution is in t he best interest of our shareholders, and will allow us to \nfurther focus on the business and our role in protecting the safety and the integrity of the pharmaceutical supply \nchain.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "f365cd4e-b668-4c4a-9f08-b63a33cd9325": {"node_ids": ["cc6e4c4d-ea59-4a1b-a600-56c8905f7595", "543244ed-7423-4dab-90f7-26279a703bdb", "1caf4599-4614-4f81-98aa-d6565c103aa5", "1b3f95cd-3f93-4837-b699-889e2a4bed89", "089b2f5e-8390-4126-8c94-1975296141f3", "fd91253e-bdfc-4188-9b2d-8683ccfd507d", "4448a8bc-4bd5-44f4-8519-7c4afc2ae657", "7bd764bb-a95a-455c-b9b0-afa598f3bc9d", "fd48613f-d7c9-4b69-8d0e-3f3a788d9423", "3ba3b3a7-0fe1-47c4-88e8-3e59534d9359", "7ddf13f7-f253-4cd3-b214-bcd58b0c96a3", "2da63bf2-277a-4caf-b6d1-f3b6475f4e11", "352a3560-d200-48d5-8ae8-294c72d1705b", "22d5cec0-b9d0-4421-9f09-1595c2ae18c4", "2d078137-0358-4985-b56d-8a07fe6a6e67", "2b128367-34bf-4c37-b189-e2894cffad08", "eefa3a66-b993-40e7-9efe-b5e9b6b76646", "c27b8da1-4023-4672-a2eb-acdb504063fa", "b2a816ea-df61-4499-bae7-07ad21468024", "caa2eb17-98b5-4f91-b9b0-30fc4331c39a", "1b10b331-afd2-4b23-9764-08ded3d37185", "f7887e28-9c21-4773-b285-7627117ce47f", "9f930f83-4729-407d-8c0a-8ef339a66b43", "57a66c74-fecd-4fe9-80b0-6031c910a757", "2dc66ff7-a240-466f-a074-82012c59058f", "de598687-e2df-469d-8641-513b680ff796", "ca93a3be-8929-4588-9164-bf9165a43d6d", "fb9d3cfd-d7a4-4991-b9ce-96ec3fff4858"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nOur roles in Europe and Canada are also continuing to evolve, and we're partnering with local governments to \ndistribute and administer COVID -19 vaccines there as well.  Through July, we've distributed over 45 million \nvaccines to adminis tration sites in select markets across these geographies.  \n \n Based on our first quarter results, our evolving roles in the COVID -19 response efforts and our confidence in our \noutlook for the remainder of our fiscal 2022, we are raising our adjusted earnings per diluted share guidance to \n$19.80 to $20.40 from a previous range of $18.85 to $19.45.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "5a8a9216-8deb-4e14-80bf-7ca55ba8e1b3": {"node_ids": ["2d160a25-bc44-4383-ac1b-0cf8af5c699d", "bada9e6c-5064-49af-9b8a-2b492140a369", "8657a3d5-161c-4370-a5e0-5626426b9a9e", "51e2f6e5-9386-4a0c-a3b7-63671cea186c", "95a1e65c-fc0e-4a06-afd2-c02a2d496a14", "38f7b1f1-6365-44a8-aab5-b59c4cb65b7e", "0f9d3cd1-3c01-4c9c-b614-861dab1fd871", "4001fd35-e2f0-4aaa-ac87-264600899c43", "21d36668-ce01-4fda-b10c-6aada7e8db93", "964226ba-ff1a-4103-a704-8bc624ea1e3a", "b5381bcc-f224-4128-a1e1-8fdf7c4ddd26", "c80097b2-1e43-40c6-8e5d-3583c33167c7", "bbff9dfb-5a22-4188-b5ae-c4e0fd77c695", "f846f458-8638-4a22-aef0-138ba1cf2c30", "3d467cb1-15e7-417b-8119-d204f425b266", "3b51c955-0d17-4316-91e8-75b0a700d21d", "bda6271b-2ebe-4f41-8a68-eb6d43a87a3b", "76b30c8c-481a-4e93-a72d-8b2beaf7c138", "9ad863a7-ba66-4131-b0c6-ecdf9e8dc175", "67c33a4a-a5e7-4ce6-b6b1-5832565b8945", "0a2a34d8-231a-4c63-adb9-c0a3dbff2693"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nOver the past several years, we've committed to transforming our operati ng model.  We've centralized back -office \nfunctions across North America and Europe to further rationalize costs through a reduction of our own retail \npharmacy footprint and a commitment to lower spend across the organization.  Throughout our enterprise, ther e's \nan initiative we call Spend Smart, which helped us achieve our three -year cost reduction target of $400 million to \n$500 million of annual cost savings by the end of our fiscal 2021.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "c73484e1-29f7-4a39-9410-ade1661a5493": {"node_ids": ["3b1c75a6-e455-4acb-8d86-cc1e6d8cbf12", "11235ed8-81e7-4e6a-b0b7-46dbb2e45934", "6ea4d31c-ac5f-48b9-a0d0-cd928e8e4852", "f57362bb-e9da-44b4-9ea7-45dc118ed78f", "d74b1fd4-9f27-4ea3-b33e-d67b4a8da2dc", "b762a92a-1fd7-4fc5-bfc3-b0558bba8e83", "d7a845d7-b00c-4a62-8085-ebacf58be99a", "e63e32ae-6671-47db-9ea8-25eff69ebc10", "74474007-e75e-41f1-87cb-72d693461369", "29e97fdc-769c-4074-b2ec-ab82326ac8ee", "c49c284b-892a-489d-a78c-edcabd441a3e", "fbc8833c-9f50-4b42-9162-234f8eff4809", "7e7ebb4a-23cf-488e-96a9-b51104f3dc14", "97d296fb-c5a7-4ecb-9bba-e6c8ef339995", "6968186c-3690-4b61-a640-38113eddee23", "116cbcdc-4bee-44d4-8041-afe9be4e1272", "e2c87cc3-9b9c-4f73-b1d0-aff1e10807c4", "71502514-5dd9-478f-97f0-41468b22eb06", "bcd066fa-aecd-434f-a73c-e50f98492cfa", "5d951b41-9c17-42f8-9a9f-16d8774cc151", "669e40df-56a7-406e-bdb6-78911d59393d", "a4a3ccbd-9dd1-4171-82d3-2646896a0e56", "52a70626-1056-4609-87cb-0b2648aa166e", "e798b718-8dc1-4e3a-a001-c3458b9f0809", "cb502cf6-9c2d-4506-9e91-20b68970e9d4", "443ebb30-f426-4b10-8cda-a17a945f0421", "ec8581dc-743f-432b-b4b1-17e57d47661c", "e7c870c4-92cd-4ce5-8190-5a61dc744bed", "f01b621c-8781-4678-9567-44f6e6f9a89d"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \nIn closing, we believe that we've made significant strides against our strategic priorities of strengthening the core, \nsimplifying the bu siness and investing in our growth areas of oncology and biopharma services.  Announcing the \nproposed opioid settlement agreement is an important development.  In addition, our strategic intent to exit the \nEuropean region positions us to become a more focuse d and agile company. ", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "f814064c-e4e4-4a0c-a559-30de71f2b69b": {"node_ids": ["4c2931d9-3cf4-4efe-97b8-583682dedfe5", "52d0dbe8-ff4d-4fa6-b0b3-33702bc0805d", "45a50a94-d594-4356-90eb-c05ad720b1c2", "0116716d-2282-4700-ac1f-86230ff9c21e", "597f608c-38e6-4583-9e05-882aa761432a", "5e25868c-67ef-4e9c-affa-cd2e590021f6", "ef39308c-9ff4-4fa6-8d8b-7f34e656556c", "5d0d8edf-12da-4f67-a7dd-9fb5126558a3", "36b4135b-069b-434d-aca5-dc6d397e8928", "f1dc62f2-bad7-4809-b510-aaf9d5715f1c", "8d751b42-3569-4fbf-ac88-4025dd074770", "712ed9c8-cc23-4712-bb19-0963a9341340", "fdcdf3c8-7100-47e6-a0eb-b575ef16f355", "7457408c-9af1-49d5-acdf-08e8c9fd1f38", "93126888-687d-45e6-a1b0-b1aa390e640b", "38da15b6-9a60-4634-83b4-55ef267e4f15", "e98bf018-66b5-4995-8749-b0d96ab85252", "a86b5497-f5ba-40b4-b33e-ea586b11cee7", "698e1d7d-cd12-43e2-a5c0-4c9a01158a41", "ba756eba-0b19-4a36-a4a1-c4d9105ffba6", "6633cdd7-1e1c-47af-8a7d-136e6b475dfe", "8f093c09-42b6-4a5a-8b8d-cc0a3901fe00", "db21c0dd-2673-403e-9089-f127cfb23285"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nExiting Europe at this time is the right course of action for McKesson and our shareholders, and it will sharpen the \nfocus on our growth strategies of oncology and biopharma services as we develop and grow a connected \necosystem.  \n \n Let me now turn to our first quarter results.  Before I provide more details on our first quarter adjusted results, I \nwant to point out two items that impacted our GAAP -only results in the quarter. ", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "538e5af4-2c9f-4709-9ba0-f8be11c81f27": {"node_ids": ["a90312b1-5ff9-4ef0-ae6a-5c8796ea43f6", "f566e4cc-3fad-49a4-899d-7a65ab8d5ab7", "f32526a7-936e-4ff0-a791-9324a6177977", "8d382a1e-6038-4aeb-83f9-2454c8408fe6", "49e135f0-05c0-4100-97f2-505cb130e0cb", "ae865361-eca3-4b03-8fde-163603c226b6", "ab6a8c2e-6ea9-4a48-9d0b-74cc3454b4f9", "ebf078f5-b2d7-483b-ac2d-0176db9b45b6", "aa80c09d-22e5-41b8-9fe2-368efcc71eeb", "e9bdfdb4-41a6-472a-9c5b-15bc6758ca01", "adfbc5c6-dbec-434e-b607-3781ca9b0e3d", "b868dc91-776d-413c-b5ef-2a69250b4110", "f455dcc5-044c-4b2d-8b19-e3e2b1298a25", "2a94bbe6-a393-4f47-a964-15c6c06f066f", "33605712-7f2e-4f96-a16c-c9b734cee2ee", "bb245d20-4b69-4b34-8665-f263cfbdabdf", "2f2b8289-1be7-4d70-ae36-6a127ab3cb8f", "fc543d3d-679d-40f2-aade-bfc909a38cd0", "5c672f9e-cde1-4448-9341-4167c1fa9644", "bd68e987-f384-44aa-9b8c-c406714340bf", "a4aa2dd7-7928-4ced-8b15-461867784303"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAdjusted operating profit in the quarter increased 16% to $682 million, driven by the contribution from COVID -19 \nvaccine distribution and growth in specialt y products distribution to our providers and health care systems, which \nwas partially offset by higher operating costs in support of the company's oncology growth initiative.  \n \n Turning to Prescription Technology Solutions, we're very pleased with the strong  growth and scale that we're \nbuilding in this higher -margin segment.  The drivers for our Prescription Technology Solutions businesses continue \nto move in the right direction. ", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "c7483f50-b0ff-416b-b034-bb525fd2d0de": {"node_ids": ["ce896aa3-9b23-46fb-a57b-566f587f7376", "c1f172f1-849d-4980-83a0-8c58864b2ab3", "779bb085-8bbf-4741-9f5a-ee58a195a3ee", "025d43a6-8a49-4858-864d-46bf7e71044b", "a6a0b1ae-9c8a-4a19-b917-8318e1763e9b", "d2a2ffae-0a6a-443a-b2f9-f0769c2eb74c", "e7969e38-6897-4eed-ac3c-bbfd6d365bc0", "b902883b-949b-4192-a66e-5cc6f058d548", "03bd78a2-2916-4196-a725-8a2f53984deb", "c2113b4e-48dc-445a-81fb-6b2d550eaa9b", "06a3276a-9792-4e8f-b620-f4a2e6d0a49f", "992ffcc9-8f04-4da0-8b9a-4714540a8873", "f45aeb1f-690b-4c44-b3aa-4116fd82a479", "6dd44dac-b214-4bd3-923c-d5fea3d07c50", "55783554-8357-4aee-8b99-0ec801ae2e52", "087fe09a-eca9-47b8-8932-76d49386680e", "9102f105-2ebe-42a7-8f78-c941fb5a431b", "cd34f446-3c0a-4c5a-b182-8353067c7ae4", "36902320-6767-4852-a8fc-d5d87bb374a0", "b0874b41-fb24-4091-8550-9ca33823a115", "8b09b061-8d45-419b-8557-eaffb6eb7b0a", "b6e28386-1eea-4693-82c6-b814edc05b35", "172134b3-14e5-4af0-a415-d6950b22407b", "cd6bcc59-a4d9-445e-b645-c1e5ee85e6ab", "54e1d588-7cb2-4f29-85ba-fb959a796e8b", "a68a17a3-fd8c-44e5-b790-ca16f9609a3f", "bfb56051-6816-483f-8451-ec0dac69e7e1"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nMoving on to Corporate, for the quarter, adjusted corporate expenses were $154 million, a decrease of 7% year -\nover-year, driven by decreased opioid lit igation expenses.  We reported opioid -related litigation expenses of $35 \nmillion for the first quarter.  We continue to estimate fiscal 2022 opioid -related litigation expenses to approximate \n$155 million.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "5627115a-c77a-423f-83db-5f873b473ef8": {"node_ids": ["32583cc3-92c0-47ba-a5fb-7988407ecf89", "8e94e47a-8c6e-4b5b-8958-39d384676f79", "1c7c31d7-67b0-4635-b0d8-a0a2c8887652", "a53ab538-2f74-4fd7-b6cf-d96e6396f066", "9eeb541e-feca-4edd-b8d1-f6e0a6cb7e4e", "e5d6a8ed-1ff8-43ab-8e1a-a046db7be58d", "e941ba15-f36d-49f7-9b05-f9b4df94518e", "86bf8546-84d1-4e52-9226-00ea87b2cf09", "35eb249b-1d1d-41d9-b36a-9c25285b60b1", "3372fc1c-a3e7-4fc4-9d50-48514c50151e", "dcfc7fd5-6d53-4c03-b02f-7cdcc9d5abc9", "3a55486f-ef77-42ad-938a-53d8ed8499c7", "005ed327-fe91-453a-b49e-b6074fe6487b", "b642ea10-a4ca-47ff-8638-f51ef9585db9", "76268bb7-6aac-472d-b8e9-9eeef8acead7", "e7c7f9f2-999b-415e-bf5e-4772a9809177", "8a5df632-896d-41e8-89f4-6e3c1efe2c3e", "b19518e1-b58c-47aa-9b26-c14e5cf6193a", "711bb4cf-c33b-4a13-b3be-b9b89d7a485c", "d7233c4c-58e9-42bf-9819-0968bfaf78e9", "9b456253-5279-40d1-b8a8-569c6b8da2b9", "e528031a-1144-44c2-851e-c4b0dbd99b26", "ea6b1d55-c9cb-43d3-936d-136deaab3615", "df49c8fb-a556-4bbb-b302-c0276d016f32", "1a8c55e7-8e5e-4d38-b242-e803471cd938", "dbea9e38-8459-4ba4-8244-f328aba1bb3a"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nOur current outlook remains aligned t o the volume distribution schedule provided by the CDC and the US \ngovernment, which excludes booster shots and vaccines for pediatrics, which have not been approved by the \nFDA.  We will continue to invest in our leading and differentiated position in oncolo gy.  These investments will \nrepresent an approximate $0.20 headwind in fiscal 2022. ", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "479b31b8-dce0-491b-b9a4-e8a875be4ded": {"node_ids": ["de566afb-e48f-432f-b50a-f7e263280ff8", "ce96a2df-1e87-42cc-9805-873f31eca61c", "7e08ae9b-3a34-4d84-a2d0-7192a116c0eb", "fcd76f21-729d-4bb4-a4b2-36e02e9c58da", "771f0825-9ede-447e-b427-a72336ab8db6", "d0e92bf9-c418-45e4-b477-6f7a015ad158", "4c6506e4-3e3e-4640-91c9-2038d6b0d05b", "fc8a2e9f-40e5-40b0-9903-2e573b4380f2", "3cf5e5fb-d0c1-4ed4-9f0a-ee62cc1b2bdf", "2288b7bf-e6a2-4263-9570-5ee9482101f3", "2636e969-eebc-4e5b-a1a2-a8c4c8e504c1", "37e9e46c-2c49-4bc1-b3f7-f6ae4cee1e6b", "e9126e70-1561-406a-b069-8ef9c86944aa", "4c021e71-bd71-41ca-bc40-fbe1b2f7c3ac", "0b6a4af3-ab75-44c6-93b1-fe98f40f91b3", "0c3bb3c7-0aa3-49bc-8f1a-4a9a9f96b7de", "f6331bd3-932a-4005-bed2-185cc5c192b0", "143aa5a0-df28-46b1-872e-fdee33a508dd", "1ba74fbb-c57e-4601-8ea2-155aa129bdfe", "c423ae50-c242-4415-99ac-64658b49f848", "631d0015-2755-43f5-8a51-4d26bc27e167", "ac7f7f5b-58c5-47d2-8aad-ad811ea1b3c5", "de0b1c8b-3631-4ba0-bd85-a2c2974a2df5", "da5cb730-f75a-4b14-97b5-051be51ff3c1", "90c61411-b935-4d66-89d0-c113f577147c", "d4be811f-78a1-47bf-9228-75519f672a0c", "37025b6e-078e-4d59-962c-5efa0cd1acdd", "e9fa9b7b-5d5d-4623-8479-2e50292d902a", "8baaad5b-1eb3-47a8-b551-77290a7fc9b9", "7b417c3e-ebe8-4394-8570-4a3ac281a510", "6ca81ea8-3915-4e54-95e7-870266e370a6", "71530429-5427-4f82-9895-26ad9f52b315", "197a3d0b-916d-4bb7-b4c5-c2e8180ad2a1", "07e31e3b-f5c2-4fd8-b843-5f9a23160bf7", "11a819b8-d2de-4f79-ba18-87bb3da02a80", "823137a0-b4b5-4ca1-ad3c-c94e0a806217"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nAs a rem inder, this is reflected in the financing activities section of our cash flow statement.  As a result of this \nactivity, McKesson holds approximately 95% of McKesson Europe's outstanding common shares, and we \nanticipate income attributable to non -controlling  interest in the range of $175 million to $195 million in fiscal 2022.  \n \n Our commitment to return cash to shareholders through dividend and share repurchases was recently highlighted \nby our Board's approval of a 12% increase to our quarterly dividend to $0. ", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "c9244e4d-ed3c-492b-9103-569b52d1b9e1": {"node_ids": ["bab42afd-3bef-446e-9f44-0a65112c306d", "f8e087ca-56ed-46b1-9c2c-cccce6ef744f", "08f9263f-8a90-461d-bbee-4ca01a427ca2", "7f7bf429-619f-41c0-8f40-5e0a7b936c8c", "d75e04f3-9696-46e0-ba59-c0b32f90c776", "230eca0c-1d24-436f-870f-cca1fbe79e37", "12a7bce2-dc91-4bbc-ae43-2a1c8dc4f118", "b5a66ff8-e6b3-447d-b683-21623b948b06", "315ebb76-7b06-412e-afaf-b3a2c2c27d23", "4041f63d-ec98-42d7-a8af-df1830364314", "8785d3a1-2b62-42cc-860c-bbdf88c2f04d", "5a2ef531-5d01-4aa0-b0f6-5bf5d105c782", "3388c6d0-84af-4c49-827a-a0d85bdc5d61", "b1ec5cc6-3e86-4653-a270-915a41515cfa", "af420427-c12c-447b-b60a-b91396676e1a", "8b066aa5-60f4-4bad-b699-9da45c5fcfd2", "3ecb1bc0-79cc-4754-be64-402875c2059e", "dd4befdd-30f1-4260-a6b4-ee8f9ca386d7", "2c4d3724-49a2-4320-ba7d-795ec1da20a4", "ff4fecb4-a224-4bd9-b09d-96a625ade4b7", "60988d50-8788-4d1c-9425-fe2fc8882561", "df2bdb01-1ac9-45d6-ac07-42369a932102", "be4e766e-d515-49f0-913b-1f21b6fdbd5f", "7dd8c65b-5370-4a59-8e52-6b67ce532a7c", "79266eac-e25d-4668-9af2-417d94bfe32a", "5b882f3f-6752-4099-8112-ee031f06d06a", "0606721a-d486-4f4e-b412-0953ba1e8f84", "36544304-b1c2-4e67-91bb-db6cb61ed455", "ee890f70-d3e3-49ff-8e4b-062d6c3465b8", "f5e56e78-b406-43f7-a549-6f6b0217cc0d", "21b9c532-d38c-40a9-acda-390e66602011", "26358e0a-f65d-4409-a824-ea58ce1a5f20", "b1f8ed5e-c950-48aa-8a7b-645e06530280", "794fd2c4-4202-4f6f-a7ae-c474eb796918", "676ab13a-6aca-4daf-90d1-93502fb82e19"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, we can go to the next question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And thank you. ", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "f909d867-900f-4080-b21d-623d7f441f91": {"node_ids": ["5b7dc9b5-18b5-4354-a442-ac3768aa6255", "7507ce9e-0382-4a6a-8c0b-0bc290310015", "8fdd8a1d-0e56-4fb4-ab4e-cc9afc1733cb", "9e4b9ea8-afe2-4d0e-b504-72a2de3eabab", "ac313379-a460-472b-9230-00de94422b46", "32b5df39-e423-4110-b260-246cb73bdc00", "c9f40766-8cca-4612-ad3e-60f705cf16b0", "20085371-3c8b-4642-94d4-e486b12e5017", "2e6800d2-a29f-48d8-9a99-0dc4afbbe0d8", "a4cdbb22-9271-4e03-9bc9-03eab1092c87", "5a98eadc-95a6-4f26-9f79-071b71c37811", "3e0ce657-22c6-4fdf-873f-161fd9f60abc", "b8635137-f51e-4cfc-851c-d794754eb925", "d5da433f-6fbc-4dbf-b42f-5dbefe0aa582", "8796b2bb-8aa7-4101-8ef4-75faa9975acd", "b13a0888-129d-4fe6-a52d-eca05015a78c", "79ef2bb9-2801-437a-8811-986258cc28a3", "371b8c79-65b5-49eb-a70d-6519f4515dca", "83cb3516-dea5-414c-9bde-3c254dfbb007", "4dc92c51-9b3e-4611-9124-7404be3ef34d", "43eb72ef-28b8-4a66-8773-6607a83c0cc8", "977e90f2-1a7c-4698-9570-841798759cf8", "e5d890f2-8354-4b09-9794-4b5926a618e5", "1582b25d-fc27-4c20-8450-eb61979a4312", "101256c4-ce56-43fe-96a2-43973b5852ac", "92579bf1-adca-43e9-baa6-a82007870b9f", "372f5503-49b5-4846-9755-ac5f8b606f6a", "236bd445-e33f-4175-862c-eccbd6b51250", "75e1d83b-c1f3-4c9c-b486-c5282095f96a", "4a50a0dd-fc5f-457f-a490-6b7b072770da", "449650c6-d04f-45c0-ac89-12277f641a73", "2420823c-c080-4154-aefa-37aabc15287f", "f3e692a9-1482-4381-9b69-77063ee31307", "09eab0b4-923e-4961-a5c6-7e5b001a550d", "03deea13-2ab1-41af-9afa-9c8a6a07ed9c", "126706c5-90ac-47c0-a422-e764e8b09d56", "3684376a-cbf9-4fdf-8ec1-6b838972a489", "190fe8de-621f-42d6-8e68-dc108bb53cee", "4109baee-9437-4daf-a89d-a49c620f1fba", "a9e8e9c8-6ef5-4bd5-b4a7-f676670a31ec", "f7718fe3-cc93-49d6-a346-fdc08543dfaf", "8973c7b3-43ee-4145-9d28-131ab0e827ed"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure, Michael.  I'll start with a couple of comments. ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "f8067737-6869-4df7-ab67-d2d29cf9e8ee": {"node_ids": ["96a649f6-81e4-4729-a0f0-d578cd6d9531", "4030a1b9-1ac4-4c4e-b4a7-f7dc523eea81", "4b735c43-f0a9-48b3-9970-e8fe0cd30353", "5dd8c5f5-d46d-4212-8038-d2b9333c4502", "7d0dc986-fbf8-4525-a767-9e31c565a221", "a4a4153c-1183-4083-b772-c0520ad24e88", "76484694-a622-471e-b021-41f497eacef2", "dbe47897-d936-415d-aba1-0dcd1e44666e", "12f615b0-51ca-4f90-929e-9cb9d3ee8899", "bbcf528c-9a5d-4d71-855a-7ff850fb62a3", "9253bbc5-ae7f-4bd3-b5ce-d2bd1524ac31", "4b4c2dab-ed35-4a52-8311-322096dc384f", "bc12d7a6-5b66-406d-a68e-2b8ce6c61fc1", "5fe1c900-43ed-4a0a-810a-fe7554b9cb1a", "21ff7094-4220-43ce-9f26-57bb408b4fd7", "94c4717e-7ea7-4352-8d3c-d3943d9a1ca0", "0b0cc8c3-ebf0-44cd-ae02-4100193706af", "fb38692d-9345-43c3-9ced-bb3c682743e7", "e46d2bd1-c08b-4ad1-9ca8-30c29ce6ee9d", "0e82fdcc-7966-48b6-af4b-571522d1a054", "dd801f24-c20b-43e8-984f-fa54a49c5a26", "d7c4b49a-791e-44cc-b3cb-5d68012b580a", "62e0b336-868d-4fff-88ad-3fa3f7e26b18", "fbb122e5-87dc-41c6-a03e-896c32a6343a", "0ebbf5fe-42a0-4c19-8653-9338f11d8c81", "816830c4-ef62-4376-b137-b09e064d5d61", "6d4a9ecf-b96b-41fc-a7c3-56a294e18319", "4cc809cb-633f-4f0a-95b8-a7fd4b758095", "17414686-4c78-4852-84be-7494ac0e127e", "de80aa3a-a1ed-43d1-b214-bc9a31b9fce2", "bc2a3621-b807-49d9-8503-7bc6c7a2b8ef", "adc253a6-b16c-47f2-989c-926d3bb12c33", "6704cf25-4686-4008-8090-7f47ff054125", "4164cdd9-4867-4285-ac1b-2423f6da85b1", "7fd9c80f-17ae-4c1b-8f04-84077bf2d8e8", "5ab620af-1c8b-4700-98f1-5f92d9a6a050", "800cab7d-b17c-4bc3-a845-00f2d19ebe16", "9cd1cd37-0121-4b93-a0df-e7aae0a236ea", "31aecf5b-2bc3-49df-9a28-326f27eb9d6f", "fc124232-1489-46ed-8ed0-12cd5d75bd56", "516bbaf7-2c84-4aa2-a31b-c3b9f56ecf15", "a644bd2a-977d-48d7-9f6b-b774bba667da"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \ndistribution, GPOs, health economic outcome, research.  The latest addition to that portfol io of assets is the data \nand insights business that we call Ontada.  \n \n And when we think of the oncology ecosystem, we think of these as all kind of self -reinforcing and adding \nmomentum to each other. ", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "dd9c08c9-16b1-4d28-87ca-ce1f75fb0297": {"node_ids": ["f67647d4-bca2-4d34-bf9e-fbfa2e1dea9a", "436d2139-1097-4c38-8a3b-74dfded9c73e", "401f2e5f-898d-42df-9d93-c959d0a058a8", "13729ea3-9522-45d3-9b0b-c9085019269d", "b426762f-bd32-4b36-bac8-9a050737207a", "14cb1736-1c54-420b-a250-095b9a0c293c", "d6003e3e-40d1-49f0-af5e-8bd55e3ddf20", "f2930220-c519-4143-a953-e83b1d72545e", "9ecbc28c-8125-4995-b847-f1d8ed740192", "4d6b7376-c3a1-472e-9494-726a19e71afa", "760631ce-7b40-453f-8695-ffc1da725a0b", "817a8a2c-e61a-46c8-b436-b251bd74a842", "4b6b9f3d-6ed1-4fe1-a32e-78f06cad4eda", "07d2b955-3b87-42a2-aea9-b305a4a70714", "a32bb471-1a79-4ae3-9f48-d5a960db822b", "b00ff72d-413d-4364-936c-ceb74ff59874", "4aefc882-3c0a-4abd-9aec-509df9d94789", "398d98cf-ab51-4ebe-a46b-be28725c38b9", "a4239ef0-44f1-492e-b3ed-c2763069b106", "074a9070-c029-45e6-9966-54ff9e83475a", "620b21c9-7b60-410e-b578-8232c8fbbe34", "73314e49-61ae-4c03-91ce-7506285b6bac", "8c3b5871-3a00-4591-8bec-dfc948a49179", "56ea7d30-1847-4586-8dd0-29f5f573b962", "847be36a-8dea-42d7-88ae-fad809f076db", "6ba6b5bb-4968-44f6-be18-32176a6ad54a", "1d8012de-c6bd-48f2-9b77-928f32a6eb5a", "eb1b7cdb-379f-4164-84b3-2e20ff30a228", "88f2af39-4a9b-483d-8ba3-e9965fc2d960", "277b6875-dc10-430c-8470-221382d41aec", "df8e8850-11a3-448a-9678-d667b917279b", "ca7d37cc-5b9e-4279-8a3c-c27ffa950c9c", "37d1b0f4-52b0-460c-a657-c6bd00c54fef", "09b3bcff-d13b-45a3-a0a2-449483e437c9", "c1e5c3f5-104a-4de7-b165-2b840d74b5c6", "b618a7e6-21cf-4100-b2b4-7dfeadb35bf3", "5cf8c82e-8c37-4e95-abda-6f0c248bde74", "7e8b133c-d838-4372-a291-617d518be231", "fc25a6ad-c887-4a1e-90d6-3906a03307ab", "68b490f4-00ba-41e6-ab80-43f3f735994f", "c8763c96-9224-4974-9b8a-c4e74c17ad08", "508e1cd7-d6f8-4593-8c08-fd8446b2935a", "f886668e-b648-490d-bd57-fa0c18f21982"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nCharles Rhyee  \nAnalyst, Cowen and Company  Q \nYeah.  Thanks for taking the question.  Just wanted to, Britt, just talk about the guidance here for the remainder of \nthe year. ", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "7d4bb324-d13b-491a-9b23-44037291468e": {"node_ids": ["e9e683d0-8072-4fc1-a6c0-213b094d8c97", "9321c5f9-b05b-4fa6-a265-f22d99f82a58", "fcca8f67-c668-41de-a04f-073ed01ef5b2", "23abc526-bde2-4677-aec6-e4a3738a265c", "e32a4671-c530-4c70-8950-8ab3071eac62", "330b7c94-153b-4213-a4cc-c436992632dd", "8dd3ce96-f85f-483b-8f40-6f5bbb80b27c", "afe19e15-c5a8-4913-bc3b-7003cafb577c", "a457555a-fe31-4216-a01d-55985dc3ddfa", "35f2c2b8-4c63-4e1e-9e2e-e76c8e84af3b", "21b2d1b5-41e7-4092-9aea-65cf744c6160", "e919b8f9-1e99-46a7-afc9-d5372f147fe0", "9946ddd4-f170-488c-85e1-d423ff7f08e2", "6088d1b4-b225-4078-9bb0-1ee63b8dae52", "7efb492d-cbe4-454c-a042-7f76dc1c7bf1", "7434c9fd-cb77-4959-b889-adf54799c680", "29739d60-b2d3-4131-9cae-259aa28b081f", "ae4a5e21-f5f2-413f-9cae-acef6106293e", "4b750984-9836-47dc-9317-a46a2ec79b4a", "cc803359-3400-46a0-ac76-6a4b68c3fbe0", "c478cd76-4303-4ca7-808b-cb7502645bff", "5cd6e6d2-aedf-4fe7-90dc-bcca0f346030", "fc7ddfd4-79ce-4c88-a5eb-7bbec8b5a16a", "fd4b655d-110b-4f5b-8bfd-2c05e0ae9212", "9ca3d230-9882-43cd-9e8e-5a2e8d8e6542", "24d76ffc-e815-4db5-b6f0-48c1d9a2f448", "e8b7018a-e1cd-4742-8742-c945281efee6", "7641711e-8500-4f84-a3f3-165de428d36d", "5bcca6a0-b8fd-4c99-8a41-c1f86652a085", "cf1eda71-9c95-4383-9847-8b58c73673c6", "81ab7d28-649e-47d6-bde6-80627ad6696d", "a069db4d-88a9-4815-a945-dd015ddb1d94", "2138c191-d192-447a-a8aa-55d3e0225a57", "816eb37b-11fe-4ab2-a7e7-7b87f9191d7f", "7533a5bd-c356-4c06-89ce-d6851e6a871c", "d2be9c89-a25d-45c8-a33e-e7064907b612", "3c1cf53e-4f99-49de-8280-7f0e9226ce80", "d0e3accd-cc39-467b-8ca9-a9beb9a0867e"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nsome sort of larger macro thing happening here that's driving this.  And I know you kind of addressed it, but maybe \ntalk specifically about the conservatism, or when you went into the year, what were the overhangs that possibly  \nlifted that are allowing you to do this across the board?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "03733b2e-50cf-454d-ad00-c59834e71dbe": {"node_ids": ["1ae976db-a92b-479a-95b3-b954da19991e", "fbe2dc6c-7dd1-4acf-9dea-fb7b981b274d", "d7d4d3a6-884f-4f04-8d1e-7855ed050df3", "c69de311-f58d-4755-a083-8a8623c02954", "14cec6d0-3587-4d1e-9994-126d5424878f", "7b0ff3fe-584a-4211-8826-988e09b050b9", "81f1d316-73ad-4f99-8b38-8b9d6882f6a0", "c2a2edb3-0053-4205-b0df-c4b745ca628d", "f0dc30ff-098a-42b3-b3a8-73a2201b815d", "ca4361d5-04cd-43ab-a62b-f670d6b07cbe", "24c6a7f2-699b-49e5-8a32-f8fc4607d218", "78a4fa3b-e189-447b-a47f-fe53da30df68", "36ac3b2b-b296-4029-8fdf-713d043f7476", "e02cb768-c4a7-4299-92ae-15e2b62a85b1", "84ed0c8f-d886-439b-9181-632e5bd6830a", "407e014d-ccb9-4f95-a303-d03e56bb811b", "7a385f73-6995-4e0f-9f11-276b0923034a", "20dc8f7c-6405-4ae2-a70a-e83f431ba9f2", "9764b223-9732-4375-a2c7-8ce092a0e44f", "210504be-97d5-407c-84a8-bfe280fb22b7", "ad6893e0-091d-4c43-8d1d-fe6b389ba3fc", "fe362cda-5722-43c6-a6c5-d0e86d13cf7b", "80a35f00-f6c2-4d7a-849d-9d19e5dc059d", "67216b12-9817-4256-bf29-ddbd6fbdd52f", "b402dacf-e727-464a-b881-6e4f4bfc3108", "1a44e9f8-97fc-4ceb-bc3c-110a87877191", "2a8fd421-4a89-438f-b96e-305083f0b4fa", "4a76ab28-d248-47aa-838e-46b2ee839180", "7a25391b-923c-4cb2-8b2d-88cd4b33ac9f", "b6110ef7-ec23-4b73-b74b-f4740002a68a", "22cfee2b-dfca-4ab4-9059-e88d636aa4c4", "0a5b920b-8ed9-4b3d-a802-ce8b4f65bbc7", "86af7ae7-464a-4610-9a4e-cd49d1263391", "68323828-d849-41cf-9b24-7b37caec19f2", "ce8d8bbf-dbbd-405f-a668-51f9ae36b247"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, Corporate FP&A, M&A Finance, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "22a2c3bc-f5a9-4e9d-9fec-881d6056ae02": {"node_ids": ["c6387056-da82-4129-951f-067d08f69f1c", "926a5899-a150-4884-b82c-3e1287d1832d", "462fc660-c57d-4a4d-93d9-567d4cfea8bc", "f7e021ac-8ac6-44e3-83ca-bddd47e9d45a", "e261ad7e-917e-4468-a72e-dae359c44f2a", "c4d8d46f-d1a3-4eb9-8933-74fe573567ae", "13bc8c0d-96a2-434f-af98-bbcf299b5f66", "990e26a6-9665-491e-a4f7-149fe1859ca9", "851fd01c-5be6-4b6b-8874-3f329a13e52f", "3f1d1419-9857-4039-9cc9-35ca3e020a8c", "46cd4c97-ceb3-4f28-ba3f-e5eeccdd69f0", "b8d23bf1-e297-44d6-b411-68028cb5313f", "ab34ee79-3f40-4278-856d-13a1f715de37"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2022 Earnings Call  Corrected Transcript  \n04-Aug-2021   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2021  FactSet  CallStreet, LLC  \n \n \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based  on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or tim eliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. This information is not intend ed to be used as the primary basis \nof investment decisions. ", "original_text": "McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q1-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 355424, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}}}